#name	canonical_name	mimid
AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 1; AAA1	AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 1; AAA1	100070
ANEURYSM, ABDOMINAL AORTIC; AAA	AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 1; AAA1	100070
ABDOMINAL AORTIC ANEURYSM	AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 1; AAA1	100070
PRUNE BELLY SYNDROME; PBS	PRUNE BELLY SYNDROME; PBS	100100
ABDOMINAL MUSCLES, ABSENCE OF, WITH URINARY TRACT ABNORMALITY ANDCRYPTORCHIDISM	PRUNE BELLY SYNDROME; PBS	100100
EAGLE-BARRETT SYNDROME; EGBRS	PRUNE BELLY SYNDROME; PBS	100100
ADAMS-OLIVER SYNDROME 1; AOS1	ADAMS-OLIVER SYNDROME 1; AOS1	100300
AOS	ADAMS-OLIVER SYNDROME 1; AOS1	100300
ABSENCE DEFECT OF LIMBS, SCALP, AND SKULL	ADAMS-OLIVER SYNDROME 1; AOS1	100300
CONGENITAL SCALP DEFECTS WITH DISTAL LIMB REDUCTION ANOMALIES	ADAMS-OLIVER SYNDROME 1; AOS1	100300
APLASIA CUTIS CONGENITA WITH TERMINAL TRANSVERSE LIMB DEFECTSAPLASIA CUTIS CONGENITA, CONGENITAL HEART DEFECT, AND FRONTONASALCYSTS, INCLUDED	ADAMS-OLIVER SYNDROME 1; AOS1	100300
ACANTHOSIS NIGRICANS	ACANTHOSIS NIGRICANS	100600
ALDEHYDE DEHYDROGENASE 2 FAMILY; ALDH2	ALDEHYDE DEHYDROGENASE 2 FAMILY; ALDH2	100650
ALDEHYDE DEHYDROGENASE 2	ALDEHYDE DEHYDROGENASE 2 FAMILY; ALDH2	100650
ALDH, LIVER MITOCHONDRIAL	ALDEHYDE DEHYDROGENASE 2 FAMILY; ALDH2	100650
ACETALDEHYDE DEHYDROGENASE 2SUBLINGUAL NITROGLYCERIN, SUSCEPTIBILITY TO POOR RESPONSE TO, INCLUDED	ALDEHYDE DEHYDROGENASE 2 FAMILY; ALDH2	100650
ALDH2/HMGIC FUSION GENE, INCLUDED	ALDEHYDE DEHYDROGENASE 2 FAMILY; ALDH2	100650
ESOPHAGEAL CANCER, ALCOHOL-RELATED, SUSCEPTIBILITY TO, INCLUDED	ALDEHYDE DEHYDROGENASE 2 FAMILY; ALDH2	100650
ACHONDROPLASIA; ACH	ACHONDROPLASIA; ACH	100800
ACHOO SYNDROME	ACHOO SYNDROME	100820
AUTOSOMAL DOMINANT COMPELLING HELIOOPHTHALMIC OUTBURST SYNDROME	ACHOO SYNDROME	100820
PHOTIC SNEEZE REFLEX	ACHOO SYNDROME	100820
SNEEZING FROM LIGHT EXPOSURE	ACHOO SYNDROME	100820
PEROUTKA SNEEZE	ACHOO SYNDROME	100820
NEUROFIBROMATOSIS, TYPE II; NF2	NEUROFIBROMATOSIS, TYPE II; NF2	101000
NEUROFIBROMATOSIS, CENTRAL TYPE	NEUROFIBROMATOSIS, TYPE II; NF2	101000
ACOUSTIC SCHWANNOMAS, BILATERAL	NEUROFIBROMATOSIS, TYPE II; NF2	101000
BILATERAL ACOUSTIC NEUROFIBROMATOSIS; BANF	NEUROFIBROMATOSIS, TYPE II; NF2	101000
ACOUSTIC NEURINOMA, BILATERAL; ACN	NEUROFIBROMATOSIS, TYPE II; NF2	101000
APERT SYNDROME	APERT SYNDROME	101200
ACROCEPHALOSYNDACTYLY, TYPE I; ACS1	APERT SYNDROME	101200
ACS IAPERT-CROUZON DISEASE, INCLUDED	APERT SYNDROME	101200
ACROCEPHALOSYNDACTYLY, TYPE II, INCLUDED	APERT SYNDROME	101200
ACS II, INCLUDED	APERT SYNDROME	101200
VOGT CEPHALODACTYLY, INCLUDED	APERT SYNDROME	101200
SAETHRE-CHOTZEN SYNDROME; SCS	SAETHRE-CHOTZEN SYNDROME; SCS	101400
ACROCEPHALOSYNDACTYLY, TYPE III; ACS3	SAETHRE-CHOTZEN SYNDROME; SCS	101400
ACS III	SAETHRE-CHOTZEN SYNDROME; SCS	101400
CHOTZEN SYNDROME	SAETHRE-CHOTZEN SYNDROME; SCS	101400
ACROCEPHALY, SKULL ASYMMETRY, AND MILD SYNDACTYLYSAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, INCLUDED	SAETHRE-CHOTZEN SYNDROME; SCS	101400
BLEPHAROPHIMOSIS, EPICANTHUS INVERSUS, AND PTOSIS 3, FORMERLY, INCLUDED;BPES3, FORMERLY, INCLUDED	SAETHRE-CHOTZEN SYNDROME; SCS	101400
PFEIFFER SYNDROME	PFEIFFER SYNDROME	101600
ACROCEPHALOSYNDACTYLY, TYPE V; ACS5	PFEIFFER SYNDROME	101600
ACS V	PFEIFFER SYNDROME	101600
NOACK SYNDROMECRANIOFACIAL-SKELETAL-DERMATOLOGIC DYSPLASIA, INCLUDED	PFEIFFER SYNDROME	101600
ACRODYSOSTOSIS 1 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS1	ACRODYSOSTOSIS 1 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS1	101800
ADOHR	ACRODYSOSTOSIS 1 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS1	101800
PALMOPLANTAR KERATODERMA, PUNCTATE TYPE III; PPKP3	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE III; PPKP3	101850
ACROKERATOELASTOIDOSIS; AKE	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE III; PPKP3	101850
COLLAGENOUS PLAQUES OF HANDS AND FEET	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE III; PPKP3	101850
ACROKERATOSIS VERRUCIFORMIS; AKV	ACROKERATOSIS VERRUCIFORMIS; AKV	101900
HOPF DISEASE	ACROKERATOSIS VERRUCIFORMIS; AKV	101900
ACROMEGALOID CHANGES, CUTIS VERTICIS GYRATA, AND CORNEAL LEUKOMA	ACROMEGALOID CHANGES, CUTIS VERTICIS GYRATA, AND CORNEAL LEUKOMA	102100
ROSENTHAL-KLOEPFER SYNDROME	ACROMEGALOID CHANGES, CUTIS VERTICIS GYRATA, AND CORNEAL LEUKOMA	102100
ACROMEGALOID FACIAL APPEARANCE SYNDROME	ACROMEGALOID FACIAL APPEARANCE SYNDROME	102150
AFA SYNDROME	ACROMEGALOID FACIAL APPEARANCE SYNDROME	102150
THICK LIPS AND ORAL MUCOSA	ACROMEGALOID FACIAL APPEARANCE SYNDROME	102150
PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 1; PAGH1	PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 1; PAGH1	102200
SOMATOTROPINOMA, FAMILIAL ISOLATED; FIS	PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 1; PAGH1	102200
ISOLATED FAMILIAL SOMATOTROPINOMA; IFS	PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 1; PAGH1	102200
SOMATOTROPHINOMA, FAMILIAL	PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 1; PAGH1	102200
ACROMEGALY DUE TO PITUITARY ADENOMA 1PITUITARY ADENOMA PREDISPOSITION, INCLUDED; PAP, INCLUDED	PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 1; PAGH1	102200
PITUITARY ADENOMA, FAMILIAL ISOLATED, INCLUDED; FIPA, INCLUDED	PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 1; PAGH1	102200
RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 1; RLS1	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 1; RLS1	102300
ACROMELALGIA, HEREDITARY	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 1; RLS1	102300
EKBOM SYNDROME	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 1; RLS1	102300
ACROMIAL DIMPLES	ACROMIAL DIMPLES	102350
SUPRASPINOUS FOSSAE, CONGENITAL	ACROMIAL DIMPLES	102350
ACROMICRIC DYSPLASIA; ACMICD	ACROMICRIC DYSPLASIA; ACMICD	102370
HAJDU-CHENEY SYNDROME; HJCYS	HAJDU-CHENEY SYNDROME; HJCYS	102500
ACROOSTEOLYSIS WITH OSTEOPOROSIS AND CHANGES IN SKULL AND MANDIBLE	HAJDU-CHENEY SYNDROME; HJCYS	102500
CHENEY SYNDROME	HAJDU-CHENEY SYNDROME; HJCYS	102500
ARTHRODENTOOSTEODYSPLASIA	HAJDU-CHENEY SYNDROME; HJCYS	102500
SERPENTINE FIBULA-POLYCYSTIC KIDNEY SYNDROME; SFPKS	HAJDU-CHENEY SYNDROME; HJCYS	102500
ACROPECTOROVERTEBRAL DYSPLASIA; ACRPV	ACROPECTOROVERTEBRAL DYSPLASIA; ACRPV	102510
F SYNDROME	ACROPECTOROVERTEBRAL DYSPLASIA; ACRPV	102510
SPERMATOGENIC FAILURE 6; SPGF6	SPERMATOGENIC FAILURE 6; SPGF6	102530
GLOBOZOOSPERMIA	SPERMATOGENIC FAILURE 6; SPGF6	102530
ROUND-HEADED SPERMATOZOA	SPERMATOGENIC FAILURE 6; SPGF6	102530
SPERMATOZOA, ROUND-HEADED	SPERMATOGENIC FAILURE 6; SPGF6	102530
ACROSOME MALFORMATION OF SPERMATOZOA	SPERMATOGENIC FAILURE 6; SPGF6	102530
ACTININ, ALPHA-3; ACTN3ACTN3 DEFICIENCY, INCLUDED	ACTININ, ALPHA-3; ACTN3ACTN3 DEFICIENCY, INCLUDED	102574
SPRINTING PERFORMANCE, INCLUDED	ACTININ, ALPHA-3; ACTN3ACTN3 DEFICIENCY, INCLUDED	102574
SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY	102700
SCID DUE TO ADA DEFICIENCY	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY	102700
ADA-SCID	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY	102700
SCID DUE TO ADA DEFICIENCY, EARLY-ONSETSCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY	102700
SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY	102700
ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY	102700
PARTIAL ADA DEFICIENCY, INCLUDED	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY	102700
ADENOSINE TRIPHOSPHATASE DEFICIENCY, ANEMIA DUE TO	ADENOSINE TRIPHOSPHATASE DEFICIENCY, ANEMIA DUE TO	102800
ADENOSINE TRIPHOSPHATE, ELEVATED, OF ERYTHROCYTES	ADENOSINE TRIPHOSPHATE, ELEVATED, OF ERYTHROCYTES	102900
PYRUVATE KINASE HYPERACTIVITY	ADENOSINE TRIPHOSPHATE, ELEVATED, OF ERYTHROCYTES	102900
ADENYLOSUCCINASE DEFICIENCY	ADENYLOSUCCINASE DEFICIENCY	103050
ADENYLOSUCCINATE LYASE DEFICIENCY; ADSLD	ADENYLOSUCCINASE DEFICIENCY	103050
ADSL DEFICIENCY	ADENYLOSUCCINASE DEFICIENCY	103050
ADIE PUPIL	ADIE PUPIL	103100
ADIE SYNDROME	ADIE PUPIL	103100
POORLY REACTING PUPILSHOLMES-ADIE SYNDROME, INCLUDED	ADIE PUPIL	103100
ADIPOSIS DOLOROSA	ADIPOSIS DOLOROSA	103200
DERCUM DISEASE	ADIPOSIS DOLOROSA	103200
ADULT SYNDROME	ADULT SYNDROME	103285
ACRO-DERMATO-UNGUAL-LACRIMAL-TOOTH SYNDROME	ADULT SYNDROME	103285
HYPOGLOSSIA-HYPODACTYLIA	HYPOGLOSSIA-HYPODACTYLIA	103300
PEROMELIA WITH MICROGNATHISM	HYPOGLOSSIA-HYPODACTYLIA	103300
OROMANDIBULAR LIMB HYPOPLASIA	HYPOGLOSSIA-HYPODACTYLIA	103300
AGLOSSIA-ADACTYLIAHANHART SYNDROME, INCLUDED	HYPOGLOSSIA-HYPODACTYLIA	103300
ALACRIMA, CONGENITAL	ALACRIMA, CONGENITAL	103420
ALACRIMIA CONGENITA	ALACRIMA, CONGENITAL	103420
ALBINISM, OCULAR, WITH SENSORINEURAL DEAFNESS	ALBINISM, OCULAR, WITH SENSORINEURAL DEAFNESS	103470
WAARDENBURG SYNDROME, TYPE 2, WITH OCULAR ALBINISM, AUTOSOMAL RECESSIVE;WS2-OA	ALBINISM, OCULAR, WITH SENSORINEURAL DEAFNESS	103470
TIETZ SYNDROME	TIETZ SYNDROME	103500
ALBINISM-DEAFNESS OF TIETZ	TIETZ SYNDROME	103500
HYPOPIGMENTATION/DEAFNESS OF TIETZ	TIETZ SYNDROME	103500
TIETZ ALBINISM-DEAFNESS SYNDROME	TIETZ SYNDROME	103500
PSEUDOHYPOPARATHYROIDISM, TYPE IA; PHP1A	PSEUDOHYPOPARATHYROIDISM, TYPE IA; PHP1A	103580
PHP IA	PSEUDOHYPOPARATHYROIDISM, TYPE IA; PHP1A	103580
ALBRIGHT HEREDITARY OSTEODYSTROPHY WITH MULTIPLE HORMONE RESISTANCE	PSEUDOHYPOPARATHYROIDISM, TYPE IA; PHP1A	103580
ALCOHOL DEHYDROGENASE 1B, CLASS I, BETA POLYPEPTIDE; ADH1B	ALCOHOL DEHYDROGENASE 1B, CLASS I, BETA POLYPEPTIDE; ADH1B	103720
ALCOHOL DEHYDROGENASE 2; ADH2	ALCOHOL DEHYDROGENASE 1B, CLASS I, BETA POLYPEPTIDE; ADH1B	103720
ADH, BETA SUBUNITAERODIGESTIVE TRACT CANCER, SQUAMOUS CELL, ALCOHOL-RELATED, PROTECTIONAGAINST, INCLUDED	ALCOHOL DEHYDROGENASE 1B, CLASS I, BETA POLYPEPTIDE; ADH1B	103720
ALCOHOL DEPENDENCE	ALCOHOL DEPENDENCE	103780
ALCOHOLISM	ALCOHOL DEPENDENCE	103780
GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; GRA	GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; GRA	103900
HYPERALDOSTERONISM, FAMILIAL, TYPE I	GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; GRA	103900
FH I	GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; GRA	103900
GLUCOCORTICOID-SUPPRESSIBLE HYPERALDOSTERONISM; GSH	GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; GRA	103900
ALDOSTERONISM, SENSITIVE TO DEXAMETHASONE	GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; GRA	103900
ACTH-DEPENDENT HYPERALDOSTERONISM SYNDROME	GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; GRA	103900
ALOPECIA AREATA 1; AA1ALOPECIA UNIVERSALIS, INCLUDED; AU, INCLUDED	ALOPECIA AREATA 1; AA1ALOPECIA UNIVERSALIS, INCLUDED; AU, INCLUDED	104000
PALMOPLANTAR KERATODERMA AND CONGENITAL ALOPECIA 1; PPKCA1	PALMOPLANTAR KERATODERMA AND CONGENITAL ALOPECIA 1; PPKCA1	104100
PPKCA, STEVANOVIC TYPE	PALMOPLANTAR KERATODERMA AND CONGENITAL ALOPECIA 1; PPKCA1	104100
KERATODERMA-HYPOTRICHOSIS-LEUKONYCHIA TOTALIS SYNDROME	PALMOPLANTAR KERATODERMA AND CONGENITAL ALOPECIA 1; PPKCA1	104100
ALOPECIA, PSYCHOMOTOR EPILEPSY, PYORRHEA, AND MENTAL SUBNORMALITY	ALOPECIA, PSYCHOMOTOR EPILEPSY, PYORRHEA, AND MENTAL SUBNORMALITY	104130
SHOKEIR SYNDROME	ALOPECIA, PSYCHOMOTOR EPILEPSY, PYORRHEA, AND MENTAL SUBNORMALITY	104130
ALPORT SYNDROME, AUTOSOMAL DOMINANT	ALPORT SYNDROME, AUTOSOMAL DOMINANT	104200
ALPHA-2C-ADRENERGIC RECEPTOR; ADRA2C	ALPHA-2C-ADRENERGIC RECEPTOR; ADRA2C	104250
ALPHA-2-ADRENERGIC RECEPTOR, RENAL TYPECONGESTIVE HEART FAILURE AND BETA-BLOCKER RESPONSE, MODIFIER OF, INCLUDED	ALPHA-2C-ADRENERGIC RECEPTOR; ADRA2C	104250
ALTERNATING HEMIPLEGIA OF CHILDHOOD 1; AHC1	ALTERNATING HEMIPLEGIA OF CHILDHOOD 1; AHC1	104290
ALZHEIMER DISEASE; AD	ALZHEIMER DISEASE; AD	104300
PRESENILE AND SENILE DEMENTIAALZHEIMER DISEASE, FAMILIAL, 1, INCLUDED; AD1, INCLUDED	ALZHEIMER DISEASE; AD	104300
ALZHEIMER DISEASE, EARLY-ONSET, WITH CEREBRAL AMYLOID ANGIOPATHY,INCLUDED	ALZHEIMER DISEASE; AD	104300
ALZHEIMER DISEASE, PROTECTION AGAINST, INCLUDED	ALZHEIMER DISEASE; AD	104300
ALZHEIMER DISEASE 2	ALZHEIMER DISEASE 2	104310
AD2	ALZHEIMER DISEASE 2	104310
ALZHEIMER DISEASE 2, LATE-ONSET	ALZHEIMER DISEASE 2	104310
ALZHEIMER DISEASE ASSOCIATED WITH APOE4	ALZHEIMER DISEASE 2	104310
AMELOGENESIS IMPERFECTA, TYPE IB; AI1B	AMELOGENESIS IMPERFECTA, TYPE IB; AI1B	104500
AMELOGENESIS IMPERFECTA, HYPOPLASTIC LOCAL, AUTOSOMAL DOMINANT	AMELOGENESIS IMPERFECTA, TYPE IB; AI1B	104500
AIH2	AMELOGENESIS IMPERFECTA, TYPE IB; AI1B	104500
ENAMEL HYPOPLASIA, HEREDITARY LOCALIZED	AMELOGENESIS IMPERFECTA, TYPE IB; AI1B	104500
AMELOGENESIS IMPERFECTA, TYPE IV; AI4	AMELOGENESIS IMPERFECTA, TYPE IV; AI4	104510
AMELOGENESIS IMPERFECTA, HYPOMATURATION-HYPOPLASTIC TYPE, WITH TAURODONTISM;AIHHT	AMELOGENESIS IMPERFECTA, TYPE IV; AI4	104510
AMELOGENESIS IMPERFECTA, TYPE IA; AI1AAMELOGENESIS IMPERFECTA, HYPOPLASTIC TYPE IA	AMELOGENESIS IMPERFECTA, TYPE IA; AI1AAMELOGENESIS IMPERFECTA, HYPOPLASTIC TYPE IA	104530
AMELOONYCHOHYPOHIDROTIC SYNDROME	AMELOONYCHOHYPOHIDROTIC SYNDROME	104570
AMYLOIDOSIS, FINNISH TYPE	AMYLOIDOSIS, FINNISH TYPE	105120
AMYLOIDOSIS V	AMYLOIDOSIS, FINNISH TYPE	105120
AMYLOIDOSIS, MERETOJA TYPE	AMYLOIDOSIS, FINNISH TYPE	105120
AMYLOID CRANIAL NEUROPATHY WITH LATTICE CORNEAL DYSTROPHY	AMYLOIDOSIS, FINNISH TYPE	105120
AMYLOIDOSIS DUE TO MUTANT GELSOLINCEREBRAL AMYLOID ANGIOPATHY, GSN-RELATED, INCLUDED	AMYLOIDOSIS, FINNISH TYPE	105120
CORNEAL DYSTROPHY, LATTICE TYPE II, INCLUDED; LCD2, INCLUDED	AMYLOIDOSIS, FINNISH TYPE	105120
LATTICE CORNEAL DYSTROPHY, TYPE II, INCLUDED	AMYLOIDOSIS, FINNISH TYPE	105120
CEREBRAL AMYLOID ANGIOPATHY, CST3-RELATED	CEREBRAL AMYLOID ANGIOPATHY, CST3-RELATED	105150
AMYLOIDOSIS, CEREBROARTERIAL, ICELANDIC TYPE	CEREBRAL AMYLOID ANGIOPATHY, CST3-RELATED	105150
AMYLOIDOSIS VI	CEREBRAL AMYLOID ANGIOPATHY, CST3-RELATED	105150
HEREDITARY CEREBRAL HEMORRHAGE WITH AMYLOIDOSIS; HCHWA	CEREBRAL AMYLOID ANGIOPATHY, CST3-RELATED	105150
CEREBRAL HEMORRHAGE, HEREDITARY, WITH AMYLOIDOSIS	CEREBRAL AMYLOID ANGIOPATHY, CST3-RELATED	105150
AMYLOIDOSIS, FAMILIAL VISCERAL	AMYLOIDOSIS, FAMILIAL VISCERAL	105200
AMYLOIDOSIS VIII	AMYLOIDOSIS, FAMILIAL VISCERAL	105200
OSTERTAG TYPE AMYLOIDOSIS	AMYLOIDOSIS, FAMILIAL VISCERAL	105200
GERMAN TYPE AMYLOIDOSIS	AMYLOIDOSIS, FAMILIAL VISCERAL	105200
AMYLOIDOSIS, FAMILIAL RENAL	AMYLOIDOSIS, FAMILIAL VISCERAL	105200
AMYLOIDOSIS, SYSTEMIC NONNEUROPATHIC	AMYLOIDOSIS, FAMILIAL VISCERAL	105200
AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED	AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED	105210
HEREDITARY AMYLOIDOSIS, TRANSTHYRETIN-RELATED	AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED	105210
TRANSTHYRETIN AMYLOIDOSIS	AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED	105210
AMYLOID POLYNEUROPATHY, FAMILIAL; FAPAMYLOIDOSIS, LEPTOMENINGEAL, TRANSTHYRETIN-RELATED, INCLUDED	AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED	105210
AMYLOID CARDIOMYOPATHY, TRANSTHYRETIN-RELATED, INCLUDED	AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED	105210
AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1	AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1	105250
AMYLOIDOSIS, PRIMARY CUTANEOUS, 1; PCA1	AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1	105250
PCA	AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1	105250
LICHEN AMYLOIDOSIS, FAMILIAL	AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1	105250
AMYLOIDOSIS IX	AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1	105250
AMYLOIDOSIS, FAMILIAL CUTANEOUS LICHEN	AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1	105250
AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1	AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1	105400
AMYOTROPHIC LATERAL SCLEROSIS 1, FAMILIAL; FALS	AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1	105400
AMYOTROPHIC LATERAL SCLEROSIS 1, AUTOSOMAL DOMINANTAMYOTROPHIC LATERAL SCLEROSIS 1, AUTOSOMAL RECESSIVE, INCLUDED	AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1	105400
AMYOTROPHIC LATERAL SCLEROSIS, SPORADIC, INCLUDED	AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1	105400
AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1	AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1	105500
AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX OF GUAM	AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1	105500
GUAM DISEASE	AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1	105500
ALS-PDC	AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1	105500
FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 1; FTDALS1	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 1; FTDALS1	105550
FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS; FTDALS	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 1; FTDALS1	105550
FRONTOTEMPORAL DEMENTIA AND/OR MOTOR NEURON DISEASE; FTDMND	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 1; FTDALS1	105550
AMYOTROPHIC LATERAL SCLEROSIS AND/OR FRONTOTEMPORAL DEMENTIA; ALSFTD	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 1; FTDALS1	105550
ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE III; CDAN3	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE III; CDAN3	105600
DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE III	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE III; CDAN3	105600
CDA III	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE III; CDAN3	105600
ANEMIA WITH MULTINUCLEATED ERYTHROBLASTS	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE III; CDAN3	105600
ERYTHRORETICULOSIS, HEREDITARY BENIGN	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE III; CDAN3	105600
DIAMOND-BLACKFAN ANEMIA 1; DBA1	DIAMOND-BLACKFAN ANEMIA 1; DBA1	105650
DBA	DIAMOND-BLACKFAN ANEMIA 1; DBA1	105650
BLACKFAN-DIAMOND SYNDROME; BDS	DIAMOND-BLACKFAN ANEMIA 1; DBA1	105650
ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND	DIAMOND-BLACKFAN ANEMIA 1; DBA1	105650
ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC	DIAMOND-BLACKFAN ANEMIA 1; DBA1	105650
RED CELL APLASIA, PURE, HEREDITARY	DIAMOND-BLACKFAN ANEMIA 1; DBA1	105650
AREGENERATIVE ANEMIA, CHRONIC CONGENITAL	DIAMOND-BLACKFAN ANEMIA 1; DBA1	105650
ERYTHROGENESIS IMPERFECTA	DIAMOND-BLACKFAN ANEMIA 1; DBA1	105650
AASE-SMITH SYNDROME II	DIAMOND-BLACKFAN ANEMIA 1; DBA1	105650
AASE SYNDROME	DIAMOND-BLACKFAN ANEMIA 1; DBA1	105650
ANEURYSM, INTRACRANIAL BERRY, 1; ANIB1	ANEURYSM, INTRACRANIAL BERRY, 1; ANIB1	105800
ANEURYSMAL SUBARACHNOID HEMORRHAGE, FAMILIAL	ANEURYSM, INTRACRANIAL BERRY, 1; ANIB1	105800
ANGELMAN SYNDROME; AS	ANGELMAN SYNDROME; AS	105830
HAPPY PUPPET SYNDROME, FORMERLYANGELMAN SYNDROME CHROMOSOME REGION, INCLUDED; ANCR, INCLUDED	ANGELMAN SYNDROME; AS	105830
ANGIOMA, HEREDITARY NEUROCUTANEOUSSPINAL ARTERIAL VENOUS MALFORMATIONS WITH CUTANEOUS HEMANGIOMAS, INCLUDED	ANGIOMA, HEREDITARY NEUROCUTANEOUSSPINAL ARTERIAL VENOUS MALFORMATIONS WITH CUTANEOUS HEMANGIOMAS, INCLUDED	106070
HEMANGIOMATOSIS, DISSEMINATED, INCLUDED	ANGIOMA, HEREDITARY NEUROCUTANEOUSSPINAL ARTERIAL VENOUS MALFORMATIONS WITH CUTANEOUS HEMANGIOMAS, INCLUDED	106070
ANGIOEDEMA, HEREDITARY, TYPE I; HAE1	ANGIOEDEMA, HEREDITARY, TYPE I; HAE1	106100
ANGIONEUROTIC EDEMA, HEREDITARY; HANE	ANGIOEDEMA, HEREDITARY, TYPE I; HAE1	106100
C1 ESTERASE INHIBITOR, DEFICIENCY OFANGIOEDEMA, HEREDITARY, TYPE II, INCLUDED; HAE2, INCLUDED	ANGIOEDEMA, HEREDITARY, TYPE I; HAE1	106100
ANGIOTENSINOGEN; AGT	ANGIOTENSINOGEN; AGT	106150
SERPINA8IgA NEPHROPATHY, PROGRESSION TO RENAL FAILURE IN, SUSCEPTIBILITY TO,INCLUDED	ANGIOTENSINOGEN; AGT	106150
ANGIOTENSIN I, INCLUDED	ANGIOTENSINOGEN; AGT	106150
ANGIOTENSIN II, INCLUDED	ANGIOTENSINOGEN; AGT	106150
ANGIOTENSIN I-CONVERTING ENZYME; ACE	ANGIOTENSIN I-CONVERTING ENZYME; ACE	106180
ACE1	ANGIOTENSIN I-CONVERTING ENZYME; ACE	106180
DIPEPTIDYL CARBOXYPEPTIDASE 1; DCP1	ANGIOTENSIN I-CONVERTING ENZYME; ACE	106180
KININASE IIANGIOTENSIN I-CONVERTING ENZYME, PLASMA LEVEL OF, INCLUDED	ANGIOTENSIN I-CONVERTING ENZYME; ACE	106180
ANGIOTENSIN I-CONVERTING ENZYME, BENIGN SERUM INCREASE, INCLUDED	ANGIOTENSIN I-CONVERTING ENZYME; ACE	106180
IgA NEPHROPATHY, PROGRESSION TO RENAL FAILURE IN, SUSCEPTIBILITY TO,INCLUDED	ANGIOTENSIN I-CONVERTING ENZYME; ACE	106180
ANGIOTENSIN I-CONVERTING ENZYME, TESTICULAR, INCLUDED	ANGIOTENSIN I-CONVERTING ENZYME; ACE	106180
ANHIDROSIS, ISOLATED, WITH NORMAL SWEAT GLANDS; ANHD	ANHIDROSIS, ISOLATED, WITH NORMAL SWEAT GLANDS; ANHD	106190
DANN-EPSTEIN-SOHAR SYNDROME	ANHIDROSIS, ISOLATED, WITH NORMAL SWEAT GLANDS; ANHD	106190
ANIRIDIA; AN	ANIRIDIA; AN	106210
ANIRIDIA II, FORMERLY; AN2, FORMERLYCATARACT, CONGENITAL, WITH LATE-ONSET CORNEAL DYSTROPHY, INCLUDED	ANIRIDIA; AN	106210
ANKYLOBLEPHARON-ECTODERMAL DEFECTS-CLEFT LIP/PALATE	ANKYLOBLEPHARON-ECTODERMAL DEFECTS-CLEFT LIP/PALATE	106260
AEC SYNDROME	ANKYLOBLEPHARON-ECTODERMAL DEFECTS-CLEFT LIP/PALATE	106260
HAY-WELLS SYNDROME	ANKYLOBLEPHARON-ECTODERMAL DEFECTS-CLEFT LIP/PALATE	106260
SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 1; SPDA1	SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 1; SPDA1	106300
ANKYLOSING SPONDYLITIS, SUSCEPTIBILITY TO	SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 1; SPDA1	106300
MARIE-STRUMPELL SPONDYLITIS	SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 1; SPDA1	106300
BECHTEREW SYNDROME	SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 1; SPDA1	106300
TOOTH AGENESIS, SELECTIVE, 1; STHAG1	TOOTH AGENESIS, SELECTIVE, 1; STHAG1	106600
HYPODONTIA/OLIGODONTIA 1; HYD1	TOOTH AGENESIS, SELECTIVE, 1; STHAG1	106600
SECOND PREMOLARS AND THIRD MOLARS, ABSENCE OF	TOOTH AGENESIS, SELECTIVE, 1; STHAG1	106600
TOOTH AGENESIS, FAMILIALTOOTH AGENESIS, SELECTIVE, WITH OROFACIAL CLEFT, INCLUDED	TOOTH AGENESIS, SELECTIVE, 1; STHAG1	106600
HYPODONTIA/OLIGODONTIA WITH OROFACIAL CLEFT, INCLUDED	TOOTH AGENESIS, SELECTIVE, 1; STHAG1	106600
TOTAL ANOMALOUS PULMONARY VENOUS RETURN 1; TAPVR1	TOTAL ANOMALOUS PULMONARY VENOUS RETURN 1; TAPVR1	106700
ANOMALOUS PULMONARY VENOUS RETURN; APVR	TOTAL ANOMALOUS PULMONARY VENOUS RETURN 1; TAPVR1	106700
SCIMITAR SYNDROME	TOTAL ANOMALOUS PULMONARY VENOUS RETURN 1; TAPVR1	106700
SCIMITAR ANOMALY	TOTAL ANOMALOUS PULMONARY VENOUS RETURN 1; TAPVR1	106700
ANONYCHIA-ONYCHODYSTROPHY WITH HYPOPLASIA OR ABSENCE OF DISTAL PHALANGES	ANONYCHIA-ONYCHODYSTROPHY WITH HYPOPLASIA OR ABSENCE OF DISTAL PHALANGES	106995
COOKS SYNDROME	ANONYCHIA-ONYCHODYSTROPHY WITH HYPOPLASIA OR ABSENCE OF DISTAL PHALANGES	106995
NAIL DISORDER, NONSYNDROMIC CONGENITAL, 6; NDNC6	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 6; NDNC6	107000
ANONYCHIA/HYPONYCHIA AND ONYCHODYSTROPHY	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 6; NDNC6	107000
ANONYCHIA, PARTIAL	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 6; NDNC6	107000
ANORECTAL ANOMALIES	ANORECTAL ANOMALIES	107100
ANOSMIA, ISOLATED CONGENITAL; ANIC	ANOSMIA, ISOLATED CONGENITAL; ANIC	107200
ANOSMIA, CONGENITAL	ANOSMIA, ISOLATED CONGENITAL; ANIC	107200
ANTERIOR SEGMENT MESENCHYMAL DYSGENESIS; ASMD	ANTERIOR SEGMENT MESENCHYMAL DYSGENESIS; ASMD	107250
ANTERIOR SEGMENT OCULAR DYSGENESIS; ASOD	ANTERIOR SEGMENT MESENCHYMAL DYSGENESIS; ASMD	107250
ANTIPYRINE METABOLISM	ANTIPYRINE METABOLISM	107290
TOWNES-BROCKS SYNDROME; TBS	TOWNES-BROCKS SYNDROME; TBS	107480
RENAL-EAR-ANAL-RADIAL SYNDROME	TOWNES-BROCKS SYNDROME; TBS	107480
REAR SYNDROME	TOWNES-BROCKS SYNDROME; TBS	107480
ANUS, IMPERFORATE, WITH HAND, FOOT, AND EAR ANOMALIES	TOWNES-BROCKS SYNDROME; TBS	107480
DEAFNESS, SENSORINEURAL, WITH IMPERFORATE ANUS AND THUMB ANOMALIESTOWNES-BROCKS-BRANCHIOOTORENAL-LIKE SYNDROME, INCLUDED	TOWNES-BROCKS SYNDROME; TBS	107480
APLASIA CUTIS CONGENITA, NONSYNDROMIC; ACC	APLASIA CUTIS CONGENITA, NONSYNDROMIC; ACC	107600
CONGENITAL DEFECT OF SKULL AND SCALP	APLASIA CUTIS CONGENITA, NONSYNDROMIC; ACC	107600
SCALP DEFECT, CONGENITAL	APLASIA CUTIS CONGENITA, NONSYNDROMIC; ACC	107600
APNEA, OBSTRUCTIVE SLEEP	APNEA, OBSTRUCTIVE SLEEP	107650
OSA	APNEA, OBSTRUCTIVE SLEEP	107650
OBSTRUCTIVE SLEEP APNEA SYNDROME; OSAS	APNEA, OBSTRUCTIVE SLEEP	107650
SLEEP APNEA/HYPOPNEA SYNDROME; SAHS; OSAHS	APNEA, OBSTRUCTIVE SLEEP	107650
APOLIPOPROTEIN A-II; APOA2APOLIPOPROTEIN A-II DEFICIENCY, INCLUDED	APOLIPOPROTEIN A-II; APOA2APOLIPOPROTEIN A-II DEFICIENCY, INCLUDED	107670
APOLIPOPROTEIN A-I; APOA1	APOLIPOPROTEIN A-I; APOA1	107680
APOLIPOPROTEIN OF HIGH DENSITY LIPOPROTEINAPOA1 DEFICIENCY, INCLUDED	APOLIPOPROTEIN A-I; APOA1	107680
APOA1/APOC3 FUSION GENE, INCLUDED	APOLIPOPROTEIN A-I; APOA1	107680
APOLIPOPROTEIN B; APOBAPOB100, INCLUDED	APOLIPOPROTEIN B; APOBAPOB100, INCLUDED	107730
APOB48, INCLUDED	APOLIPOPROTEIN B; APOBAPOB100, INCLUDED	107730
APOLIPOPROTEIN B ALLOTYPES, INCLUDED	APOLIPOPROTEIN B; APOBAPOB100, INCLUDED	107730
Ag LIPOPROTEIN TYPES, INCLUDED	APOLIPOPROTEIN B; APOBAPOB100, INCLUDED	107730
LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS4, INCLUDED; LDLCQ4, INCLUDED	APOLIPOPROTEIN B; APOBAPOB100, INCLUDED	107730
APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	107741
HYPERLIPOPROTEINEMIA, TYPE III, INCLUDED	APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	107741
DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d, INCLUDED	APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	107741
FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA, INCLUDED	APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	107741
FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA, INCLUDED	APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	107741
HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS, INCLUDED	APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	107741
BROAD-BETALIPOPROTEINEMIA, INCLUDED	APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	107741
FLOATING-BETALIPOPROTEINEMIA, INCLUDED	APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	107741
CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED	APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	107741
LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS5, INCLUDED; LDLCQ5, INCLUDED	APOLIPOPROTEIN E; APOEAPOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF, INCLUDED	107741
ARBITRARY RESTRICTION POLYMORPHISM 1	ARBITRARY RESTRICTION POLYMORPHISM 1	107750
ANONYMOUS RESTRICTION POLYMORPHISM 1; ARP1	ARBITRARY RESTRICTION POLYMORPHISM 1	107750
RESTRICTION FRAGMENT LENGTH POLYMORPHISM 14A	ARBITRARY RESTRICTION POLYMORPHISM 1	107750
RFLP-14A	ARBITRARY RESTRICTION POLYMORPHISM 1	107750
ARP-14A; D14S1	ARBITRARY RESTRICTION POLYMORPHISM 1	107750
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 1; ARVD1	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 1; ARVD1	107970
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 1; ARVC1UHL ANOMALY, INCLUDED	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 1; ARVD1	107970
CARDIOMYOPATHY, RIGHT VENTRICULAR DILATED, INCLUDED	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 1; ARVD1	107970
ARTERIOVENOUS MALFORMATIONS OF THE BRAIN	ARTERIOVENOUS MALFORMATIONS OF THE BRAIN	108010
BAVM	ARTERIOVENOUS MALFORMATIONS OF THE BRAIN	108010
CEREBRAL ARTERIOVENOUS MALFORMATIONSINTRACRANIAL HEMORRHAGE IN BRAIN ARTERIOVENOUS MALFORMATIONS, SUSCEPTIBILITYTO, INCLUDED	ARTERIOVENOUS MALFORMATIONS OF THE BRAIN	108010
ARTHROGRYPOSIS, DISTAL, TYPE 1A; DA1A	ARTHROGRYPOSIS, DISTAL, TYPE 1A; DA1A	108120
ARTHROGRYPOSIS, DISTAL, TYPE 1; DA1	ARTHROGRYPOSIS, DISTAL, TYPE 1A; DA1A	108120
ARTHROGRYPOSIS MULTIPLEX CONGENITA, DISTAL, TYPE I; AMCD1	ARTHROGRYPOSIS, DISTAL, TYPE 1A; DA1A	108120
ARTHROGRYPOSIS, DISTAL, TYPE 5; DA5	ARTHROGRYPOSIS, DISTAL, TYPE 5; DA5	108145
ARTHROGRYPOSIS WITH OCULOMOTOR LIMITATION AND ELECTRORETINAL ABNORMALITIES	ARTHROGRYPOSIS, DISTAL, TYPE 5; DA5	108145
OCULOMELIC AMYOPLASIA	ARTHROGRYPOSIS, DISTAL, TYPE 5; DA5	108145
ARTHROGRYPOSIS, DISTAL, TYPE IIB; DAIIB	ARTHROGRYPOSIS, DISTAL, TYPE 5; DA5	108145
STICKLER SYNDROME, TYPE I; STL1	STICKLER SYNDROME, TYPE I; STL1	108300
STICKLER SYNDROME, VITREOUS TYPE 1	STICKLER SYNDROME, TYPE I; STL1	108300
STICKLER SYNDROME, MEMBRANOUS VITREOUS TYPE	STICKLER SYNDROME, TYPE I; STL1	108300
ARTHROOPHTHALMOPATHY, HEREDITARY PROGRESSIVE; AOM	STICKLER SYNDROME, TYPE I; STL1	108300
ARYL HYDROCARBON HYDROXYLASE INDUCIBILITY	ARYL HYDROCARBON HYDROXYLASE INDUCIBILITY	108340
AHH INDUCIBILITY; AHHI	ARYL HYDROCARBON HYDROXYLASE INDUCIBILITY	108340
ASPARAGUS, SPECIFIC SMELL HYPERSENSITIVITY	ASPARAGUS, SPECIFIC SMELL HYPERSENSITIVITY	108390
SPERMATOGENIC FAILURE 2; SPGF2	SPERMATOGENIC FAILURE 2; SPGF2	108420
ASPERMIOGENESIS FACTOR; ASG	SPERMATOGENIC FAILURE 2; SPGF2	108420
EPISODIC ATAXIA, TYPE 2; EA2	EPISODIC ATAXIA, TYPE 2; EA2	108500
ATAXIA, EPISODIC, WITH NYSTAGMUS	EPISODIC ATAXIA, TYPE 2; EA2	108500
EPISODIC ATAXIA, NYSTAGMUS-ASSOCIATED	EPISODIC ATAXIA, TYPE 2; EA2	108500
CEREBELLOPATHY, HEREDITARY PAROXYSMAL	EPISODIC ATAXIA, TYPE 2; EA2	108500
ATAXIA, FAMILIAL PAROXYSMAL	EPISODIC ATAXIA, TYPE 2; EA2	108500
ACETAZOLAMIDE-RESPONSIVE HEREDITARY PAROXYSMAL CEREBELLAR ATAXIA;APCA	EPISODIC ATAXIA, TYPE 2; EA2	108500
CEREBELLAR ATAXIA, PAROXYSMAL, ACETAZOLAMIDE-RESPONSIVE; CAPA	EPISODIC ATAXIA, TYPE 2; EA2	108500
SPASTIC ATAXIA 1, AUTOSOMAL DOMINANT; SPAX1	SPASTIC ATAXIA 1, AUTOSOMAL DOMINANT; SPAX1	108600
SPASTIC ATAXIA 7, AUTOSOMAL DOMINANT; SPAX7	SPASTIC ATAXIA 7, AUTOSOMAL DOMINANT; SPAX7	108650
SPASTIC ATAXIA WITH CONGENITAL MIOSIS	SPASTIC ATAXIA 7, AUTOSOMAL DOMINANT; SPAX7	108650
MIOSIS, CONGENITAL, WITH SPASTIC ATAXIA	SPASTIC ATAXIA 7, AUTOSOMAL DOMINANT; SPAX7	108650
ATELOSTEOGENESIS, TYPE I; AO1	ATELOSTEOGENESIS, TYPE I; AO1	108720
AOI	ATELOSTEOGENESIS, TYPE I; AO1	108720
GIANT CELL CHONDRODYSPLASIA	ATELOSTEOGENESIS, TYPE I; AO1	108720
SPONDYLOHUMEROFEMORAL HYPOPLASIA	ATELOSTEOGENESIS, TYPE I; AO1	108720
ATELOSTEOGENESIS, TYPE III; AO3	ATELOSTEOGENESIS, TYPE III; AO3	108721
AOIII	ATELOSTEOGENESIS, TYPE III; AO3	108721
ATHEROSCLEROSIS SUSCEPTIBILITY; ATHS	ATHEROSCLEROSIS SUSCEPTIBILITY; ATHS	108725
ATHEROGENIC LIPOPROTEIN PHENOTYPE; ALP	ATHEROSCLEROSIS SUSCEPTIBILITY; ATHS	108725
ATRESIA OF EXTERNAL AUDITORY CANAL AND CONDUCTIVE DEAFNESS	ATRESIA OF EXTERNAL AUDITORY CANAL AND CONDUCTIVE DEAFNESS	108760
ATRIAL STANDSTILL 1; ATRST1	ATRIAL STANDSTILL 1; ATRST1	108770
ATRIAL CARDIOMYOPATHY WITH HEART BLOCK	ATRIAL STANDSTILL 1; ATRST1	108770
CARDIOMYOPATHY, FAMILIAL, WITH CONDUCTION DISTURBANCE	ATRIAL STANDSTILL 1; ATRST1	108770
ATRIAL SEPTAL DEFECT 1; ASD1ATRIAL SEPTAL DEFECT, PRIMUM TYPE, INCLUDED	ATRIAL SEPTAL DEFECT 1; ASD1ATRIAL SEPTAL DEFECT, PRIMUM TYPE, INCLUDED	108800
ASD I, INCLUDED	ATRIAL SEPTAL DEFECT 1; ASD1ATRIAL SEPTAL DEFECT, PRIMUM TYPE, INCLUDED	108800
ATRIAL SEPTAL DEFECT, SECUNDUM TYPE, INCLUDED	ATRIAL SEPTAL DEFECT 1; ASD1ATRIAL SEPTAL DEFECT, PRIMUM TYPE, INCLUDED	108800
ASD II, INCLUDED	ATRIAL SEPTAL DEFECT 1; ASD1ATRIAL SEPTAL DEFECT, PRIMUM TYPE, INCLUDED	108800
ATRIAL SEPTAL DEFECT 7 WITH OR WITHOUT ATRIOVENTRICULAR CONDUCTIONDEFECTS; ASD7	ATRIAL SEPTAL DEFECT 7 WITH OR WITHOUT ATRIOVENTRICULAR CONDUCTIONDEFECTS; ASD7	108900
ASD WITH OR WITHOUT ATRIOVENTRICULAR CONDUCTION DEFECTS	ATRIAL SEPTAL DEFECT 7 WITH OR WITHOUT ATRIOVENTRICULAR CONDUCTIONDEFECTS; ASD7	108900
PR INTERVAL, VARIATION IN	PR INTERVAL, VARIATION IN	108980
ATRIOVENTRICULAR CONDUCTION TIME, VARIATION IN	PR INTERVAL, VARIATION IN	108980
SVEINSSON CHORIORETINAL ATROPHY; SCRA	SVEINSSON CHORIORETINAL ATROPHY; SCRA	108985
ATROPHIA AREATA; AA	SVEINSSON CHORIORETINAL ATROPHY; SCRA	108985
PERIPAPILLARY CHORIORETINAL DEGENERATION, ICELANDIC TYPE	SVEINSSON CHORIORETINAL ATROPHY; SCRA	108985
HELICOIDAL PERIPAPILLARY CHORIORETINAL DEGENERATION; HPCD	SVEINSSON CHORIORETINAL ATROPHY; SCRA	108985
AURICULOOSTEODYSPLASIA	AURICULOOSTEODYSPLASIA	109000
AUTOIMMUNE DISEASE	AUTOIMMUNE DISEASE	109100
MACHADO-JOSEPH DISEASE; MJD	MACHADO-JOSEPH DISEASE; MJD	109150
SPINOCEREBELLAR ATAXIA 3; SCA3	MACHADO-JOSEPH DISEASE; MJD	109150
SPINOCEREBELLAR ATROPHY III	MACHADO-JOSEPH DISEASE; MJD	109150
AZOREAN NEUROLOGIC DISEASE	MACHADO-JOSEPH DISEASE; MJD	109150
SPINOPONTINE ATROPHY	MACHADO-JOSEPH DISEASE; MJD	109150
NIGROSPINODENTATAL DEGENERATION	MACHADO-JOSEPH DISEASE; MJD	109150
AZOTEMIA, FAMILIAL	AZOTEMIA, FAMILIAL	109160
ALOPECIA, ANDROGENETIC, 1; AGA1	ALOPECIA, ANDROGENETIC, 1; AGA1	109200
ANDROGENETIC ALOPECIA; AGABALDNESS, MALE PATTERN, INCLUDED; MPB, INCLUDED	ALOPECIA, ANDROGENETIC, 1; AGA1	109200
SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1; SLC4A1	SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1; SLC4A1	109270
BAND 3 OF RED CELL MEMBRANE; BND3	SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1; SLC4A1	109270
ERYTHROCYTE MEMBRANE PROTEIN BAND 3; EMPB3	SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1; SLC4A1	109270
ERYTHROID PROTEIN BAND 3; EPB3	SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1; SLC4A1	109270
ANION EXCHANGE PROTEIN 1; AE1ACANTHOCYTOSIS, ONE FORM OF, INCLUDED	SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1; SLC4A1	109270
GASTROESOPHAGEAL REFLUX; GER	GASTROESOPHAGEAL REFLUX; GER	109350
GASTROESOPHAGEAL REFLUX DISEASE; GERD	GASTROESOPHAGEAL REFLUX; GER	109350
GASTROESOPHAGEAL REFLUX, PEDIATRIC	GASTROESOPHAGEAL REFLUX; GER	109350
BASAL CELL NEVUS SYNDROME; BCNS	BASAL CELL NEVUS SYNDROME; BCNS	109400
GORLIN SYNDROME	BASAL CELL NEVUS SYNDROME; BCNS	109400
GORLIN-GOLTZ SYNDROME	BASAL CELL NEVUS SYNDROME; BCNS	109400
NEVOID BASAL CELL CARCINOMA SYNDROME; NBCCS	BASAL CELL NEVUS SYNDROME; BCNS	109400
MULTIPLE BASAL CELL NEVI, ODONTOGENIC KERATOCYSTS, AND SKELETAL ANOMALIES	BASAL CELL NEVUS SYNDROME; BCNS	109400
BASILAR IMPRESSION, PRIMARY	BASILAR IMPRESSION, PRIMARY	109500
LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 2	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 2	109543
CLLS2	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 2	109543
B-CELL MALIGNANCY, LOW-GRADE	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 2	109543
DISRUPTED IN B-CELL MALIGNANCY; DBM	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 2	109543
LEUKEMIA, CHRONIC LYMPHOCYTIC, B-CELL; BCLL	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 2	109543
BETA-1-ADRENERGIC RECEPTOR; ADRB1	BETA-1-ADRENERGIC RECEPTOR; ADRB1	109630
ADRB1R	BETA-1-ADRENERGIC RECEPTOR; ADRB1	109630
B1ARCONGESTIVE HEART FAILURE AND BETA-BLOCKER RESPONSE, MODIFIER OF, INCLUDED	BETA-1-ADRENERGIC RECEPTOR; ADRB1	109630
BEHCET SYNDROME	BEHCET SYNDROME	109650
BEHCET DISEASE; BD	BEHCET SYNDROME	109650
BETA-AMINO ACIDS, RENAL TRANSPORT OF; AABT	BETA-AMINO ACIDS, RENAL TRANSPORT OF; AABT	109660
TAURINE RENAL REABSORPTION	BETA-AMINO ACIDS, RENAL TRANSPORT OF; AABT	109660
BETA-2-ADRENERGIC RECEPTOR; ADRB2	BETA-2-ADRENERGIC RECEPTOR; ADRB2	109690
BETA-ADRENERGIC RECEPTOR; ADRBR	BETA-2-ADRENERGIC RECEPTOR; ADRB2	109690
BETA-2-ADRENOCEPTOR; BAR; B2AR	BETA-2-ADRENERGIC RECEPTOR; ADRB2	109690
ADRB2RBETA-2-ADRENORECEPTOR AGONIST, REDUCED RESPONSE TO, INCLUDED	BETA-2-ADRENERGIC RECEPTOR; ADRB2	109690
BILIARY CIRRHOSIS, PRIMARY, 1; PBC1	BILIARY CIRRHOSIS, PRIMARY, 1; PBC1	109720
PBC	BILIARY CIRRHOSIS, PRIMARY, 1; PBC1	109720
AORTIC VALVE DISEASE 1; AOVD1	AORTIC VALVE DISEASE 1; AOVD1	109730
AORTIC VALVE DISEASE	AORTIC VALVE DISEASE 1; AOVD1	109730
BICUSPID AORTIC VALVE; BAV	AORTIC VALVE DISEASE 1; AOVD1	109730
AORTIC VALVE, BICUSPID	AORTIC VALVE DISEASE 1; AOVD1	109730
AORTIC VALVE, CALCIFICATION OF	AORTIC VALVE DISEASE 1; AOVD1	109730
AORTIC STENOSIS, CALCIFIC	AORTIC VALVE DISEASE 1; AOVD1	109730
BLADDER CANCER	BLADDER CANCER	109800
BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPESBPES, TYPE I, INCLUDED	BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPESBPES, TYPE I, INCLUDED	110100
BPES, TYPE II, INCLUDED	BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPESBPES, TYPE I, INCLUDED	110100
BPES WITH OVARIAN FAILURE, INCLUDED	BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPESBPES, TYPE I, INCLUDED	110100
BPES WITHOUT OVARIAN FAILURE, INCLUDED	BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPESBPES, TYPE I, INCLUDED	110100
BPES WITH DUANE RETRACTION SYNDROME, INCLUDED	BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPESBPES, TYPE I, INCLUDED	110100
BPES, TYPE I, AUTOSOMAL RECESSIVE, INCLUDED	BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPESBPES, TYPE I, INCLUDED	110100
BLOOD GROUP--AHONEN; AN	BLOOD GROUP--AHONEN; AN	110350
BLOOD GROUP--COLTON; CO	BLOOD GROUP--COLTON; CO	110450
BLOOD GROUP--DIEGO SYSTEM; DI	BLOOD GROUP--DIEGO SYSTEM; DI	110500
DIEGO BLOOD GROUP	BLOOD GROUP--DIEGO SYSTEM; DI	110500
BLOOD GROUP, DUFFY SYSTEM; FY	BLOOD GROUP, DUFFY SYSTEM; FY	110700
DUFFY BLOOD GROUP SYSTEMPLASMODIUM VIVAX, RESISTANCE TO, INCLUDED	BLOOD GROUP, DUFFY SYSTEM; FY	110700
BLOOD GROUP, I SYSTEM; Ii	BLOOD GROUP, I SYSTEM; Ii	110800
I BLOOD GROUP SYSTEM	BLOOD GROUP, I SYSTEM; Ii	110800
Ii BLOOD GROUP SYSTEMADULT i PHENOTYPE, INCLUDED	BLOOD GROUP, I SYSTEM; Ii	110800
BLOOD GROUP--KELL SYSTEM; KEL	BLOOD GROUP--KELL SYSTEM; KEL	110900
BLOOD GROUP--KELL-CELLANO SYSTEMKELL-NULL, INCLUDED	BLOOD GROUP--KELL SYSTEM; KEL	110900
K(0), INCLUDED	BLOOD GROUP--KELL SYSTEM; KEL	110900
Ko, INCLUDED	BLOOD GROUP--KELL SYSTEM; KEL	110900
BLOOD GROUP--KIDD SYSTEM; JK	BLOOD GROUP--KIDD SYSTEM; JK	111000
FUCOSYLTRANSFERASE 3; FUT3	FUCOSYLTRANSFERASE 3; FUT3	111100
LEWIS ENZYMEBLOOD GROUP--LEWIS SYSTEM; Le	FUCOSYLTRANSFERASE 3; FUT3	111100
Les	FUCOSYLTRANSFERASE 3; FUT3	111100
BLOOD GROUP--LKE; LKE	BLOOD GROUP--LKE; LKE	111130
BLOOD GROUP--LUKE, FORMERLY	BLOOD GROUP--LKE; LKE	111130
BLOOD GROUP--LUTHERAN INHIBITOR; INLU	BLOOD GROUP--LUTHERAN INHIBITOR; INLU	111150
DOMINANT LU (a-b-) PHENOTYPE	BLOOD GROUP--LUTHERAN INHIBITOR; INLU	111150
BLOOD GROUP--LUTHERAN SYSTEM; LUAUBERGER SYSTEM, INCLUDED; AU, INCLUDED	BLOOD GROUP--LUTHERAN SYSTEM; LUAUBERGER SYSTEM, INCLUDED; AU, INCLUDED	111200
BLOOD GROUP SYSTEM, LANDSTEINER-WIENER; LW	BLOOD GROUP SYSTEM, LANDSTEINER-WIENER; LW	111250
LANDSTEINER-WIENER BLOOD GROUP SYSTEM	BLOOD GROUP SYSTEM, LANDSTEINER-WIENER; LW	111250
BLOOD GROUP--MN LOCUS; MNGLYCOPHORIN A, INCLUDED; GPA, INCLUDED	BLOOD GROUP--MN LOCUS; MNGLYCOPHORIN A, INCLUDED; GPA, INCLUDED	111300
GYPA, INCLUDED	BLOOD GROUP--MN LOCUS; MNGLYCOPHORIN A, INCLUDED; GPA, INCLUDED	111300
BLOOD GROUP--OK; OK	BLOOD GROUP--OK; OK	111380
BLOOD GROUP, P1PK SYSTEMP(1) PHENOTYPE, INCLUDED	BLOOD GROUP, P1PK SYSTEMP(1) PHENOTYPE, INCLUDED	111400
P(2) PHENOTYPE, INCLUDED	BLOOD GROUP, P1PK SYSTEMP(1) PHENOTYPE, INCLUDED	111400
P1(k) PHENOTYPE, INCLUDED	BLOOD GROUP, P1PK SYSTEMP(1) PHENOTYPE, INCLUDED	111400
P2(k) PHENOTYPE, INCLUDED	BLOOD GROUP, P1PK SYSTEMP(1) PHENOTYPE, INCLUDED	111400
p PHENOTYPE, INCLUDED	BLOOD GROUP, P1PK SYSTEMP(1) PHENOTYPE, INCLUDED	111400
NOR POLYAGGLUTINATION SYNDROME, INCLUDED	BLOOD GROUP, P1PK SYSTEMP(1) PHENOTYPE, INCLUDED	111400
BLOOD GROUP--PRIVATE SYSTEMS	BLOOD GROUP--PRIVATE SYSTEMS	111500
ANTIGENIC DETERMINANTS OF LOW FREQUENCY IN THE POPULATION	BLOOD GROUP--PRIVATE SYSTEMS	111500
BLOOD GROUP, LANGEREIS SYSTEM; LAN	BLOOD GROUP, LANGEREIS SYSTEM; LAN	111600
RADIN BLOOD GROUP ANTIGEN; RD	RADIN BLOOD GROUP ANTIGEN; RD	111620
BLOOD GROUP--RADIN ANTIGEN	RADIN BLOOD GROUP ANTIGEN; RD	111620
BLOOD GROUP--RHESUS SYSTEM E POLYPEPTIDE; RHE	BLOOD GROUP--RHESUS SYSTEM E POLYPEPTIDE; RHE	111690
RHESUS BLOOD GROUP, CcEe ANTIGENS; RHCE	RHESUS BLOOD GROUP, CcEe ANTIGENS; RHCE	111700
BLOOD GROUP--RHESUS SYSTEM Cc/Ee POLYPEPTIDE	RHESUS BLOOD GROUP, CcEe ANTIGENS; RHCE	111700
RHC	RHESUS BLOOD GROUP, CcEe ANTIGENS; RHCE	111700
RHERH-NULL DISEASE, AMORPH TYPE, INCLUDED	RHESUS BLOOD GROUP, CcEe ANTIGENS; RHCE	111700
BLOOD GROUP--Ss LOCUS; SsGLYCOPHORIN B, INCLUDED; GPB, INCLUDED	BLOOD GROUP--Ss LOCUS; SsGLYCOPHORIN B, INCLUDED; GPB, INCLUDED	111740
GYPB, INCLUDED	BLOOD GROUP--Ss LOCUS; SsGLYCOPHORIN B, INCLUDED; GPB, INCLUDED	111740
BLOOD GROUP--SCIANNA SYSTEM; SC	BLOOD GROUP--SCIANNA SYSTEM; SC	111750
SCIANNA BLOOD GROUP	BLOOD GROUP--SCIANNA SYSTEM; SC	111750
BLOOD GROUP--STOLTZFUS SYSTEM; Sf	BLOOD GROUP--STOLTZFUS SYSTEM; Sf	111800
BLOOD GROUP--Ul SYSTEM; UL	BLOOD GROUP--Ul SYSTEM; UL	112000
BLOOD GROUP--WALDNER TYPE; WD	BLOOD GROUP--WALDNER TYPE; WD	112010
WALDNER BLOOD GROUP ANTIGEN	BLOOD GROUP--WALDNER TYPE; WD	112010
BLOOD GROUP--WRIGHT ANTIGEN; WR	BLOOD GROUP--WRIGHT ANTIGEN; WR	112050
WRIGHT BLOOD GROUP ANTIGEN	BLOOD GROUP--WRIGHT ANTIGEN; WR	112050
YT BLOOD GROUP ANTIGEN	YT BLOOD GROUP ANTIGEN	112100
CARTWRIGHT ANTIGEN	YT BLOOD GROUP ANTIGEN	112100
BLUE RUBBER BLEB NEVUS	BLUE RUBBER BLEB NEVUS	112200
BEAN SYNDROME	BLUE RUBBER BLEB NEVUS	112200
COLE-CARPENTER SYNDROME 1; CLCRP1	COLE-CARPENTER SYNDROME 1; CLCRP1	112240
BONE FRAGILITY WITH CRANIOSYNOSTOSIS, OCULAR PROPTOSIS, HYDROCEPHALUS,AND DISTINCTIVE FACIAL FEATURES	COLE-CARPENTER SYNDROME 1; CLCRP1	112240
DIAPHYSEAL MEDULLARY STENOSIS WITH MALIGNANT FIBROUS HISTIOCYTOMA;DMSMFH	DIAPHYSEAL MEDULLARY STENOSIS WITH MALIGNANT FIBROUS HISTIOCYTOMA;DMSMFH	112250
BONE DYSPLASIA WITH MEDULLARY FIBROSARCOMA; BDMF	DIAPHYSEAL MEDULLARY STENOSIS WITH MALIGNANT FIBROUS HISTIOCYTOMA;DMSMFH	112250
BONE DYSPLASIA WITH MALIGNANT FIBROUS HISTIOCYTOMA	DIAPHYSEAL MEDULLARY STENOSIS WITH MALIGNANT FIBROUS HISTIOCYTOMA;DMSMFH	112250
MYOPATHY, LIMB-GIRDLE, WITH BONE FRAGILITY	DIAPHYSEAL MEDULLARY STENOSIS WITH MALIGNANT FIBROUS HISTIOCYTOMA;DMSMFH	112250
BOOK SYNDROME	BOOK SYNDROME	112300
PHC SYNDROME	BOOK SYNDROME	112300
BOOMERANG DYSPLASIA	BOOMERANG DYSPLASIA	112310
WEISMANN-NETTER SYNDROME; WNS	WEISMANN-NETTER SYNDROME; WNS	112350
BOWING OF LEGS, ANTERIOR, WITH DWARFISM	WEISMANN-NETTER SYNDROME; WNS	112350
TOXOPACHYOSTEOSE DIAPHYSAIRE TIBIO-PERONIERE	WEISMANN-NETTER SYNDROME; WNS	112350
HYPERTENSION AND BRACHYDACTYLY SYNDROME; HTNB	HYPERTENSION AND BRACHYDACTYLY SYNDROME; HTNB	112410
BRACHYDACTYLY WITH HYPERTENSION	HYPERTENSION AND BRACHYDACTYLY SYNDROME; HTNB	112410
BRACHYDACTYLY, TYPE E, WITH SHORT STATURE AND HYPERTENSION	HYPERTENSION AND BRACHYDACTYLY SYNDROME; HTNB	112410
BILGINTURAN SYNDROME	HYPERTENSION AND BRACHYDACTYLY SYNDROME; HTNB	112410
BRACHYDACTYLY, COMBINED B AND E TYPES	BRACHYDACTYLY, COMBINED B AND E TYPES	112440
PITT-WILLIAMS BRACHYDACTYLY	BRACHYDACTYLY, COMBINED B AND E TYPES	112440
BRACHYDACTYLY, BALLARD TYPE	BRACHYDACTYLY, COMBINED B AND E TYPES	112440
BRACHYDACTYLY, TYPE A1; BDA1	BRACHYDACTYLY, TYPE A1; BDA1	112500
FARABEE-TYPE BRACHYDACTYLY	BRACHYDACTYLY, TYPE A1; BDA1	112500
BRACHYDACTYLY, TYPE A2; BDA2	BRACHYDACTYLY, TYPE A2; BDA2	112600
BRACHYMESOPHALANGY II	BRACHYDACTYLY, TYPE A2; BDA2	112600
MOHR-WRIEDT TYPE BRACHYDACTYLY	BRACHYDACTYLY, TYPE A2; BDA2	112600
BRACHYDACTYLY, TYPE A3; BDA3	BRACHYDACTYLY, TYPE A3; BDA3	112700
BRACHYMESOPHALANGY V	BRACHYDACTYLY, TYPE A3; BDA3	112700
BRACHYDACTYLY-CLINODACTYLY	BRACHYDACTYLY, TYPE A3; BDA3	112700
BRACHYDACTYLY, TYPE A4; BDA4	BRACHYDACTYLY, TYPE A4; BDA4	112800
BRACHYMESOPHALANGY II AND V	BRACHYDACTYLY, TYPE A4; BDA4	112800
TEMTAMY TYPE BRACHYDACTYLY	BRACHYDACTYLY, TYPE A4; BDA4	112800
BRACHYDACTYLY, TYPE B1; BDB1	BRACHYDACTYLY, TYPE B1; BDB1	113000
BRACHYDACTYLY, TYPE B; BDB	BRACHYDACTYLY, TYPE B1; BDB1	113000
BRACHYDACTYLY, TYPE C; BDC	BRACHYDACTYLY, TYPE C; BDC	113100
BRACHYDACTYLY, HAWS TYPE	BRACHYDACTYLY, TYPE C; BDC	113100
BRACHYDACTYLY, TYPE D; BDD	BRACHYDACTYLY, TYPE D; BDD	113200
STUB THUMB	BRACHYDACTYLY, TYPE D; BDD	113200
BRACHYDACTYLY, TYPE E1; BDE1	BRACHYDACTYLY, TYPE E1; BDE1	113300
BRACHYDACTYLY, TYPE E; BDE	BRACHYDACTYLY, TYPE E1; BDE1	113300
BRACHYOLMIA TYPE 3; BCYM3	BRACHYOLMIA TYPE 3; BCYM3	113500
BRACHYOLMIA, AUTOSOMAL DOMINANT	BRACHYOLMIA TYPE 3; BCYM3	113500
BRACHYRACHIA	BRACHYOLMIA TYPE 3; BCYM3	113500
BRANCHIOOCULOFACIAL SYNDROME; BOFS	BRANCHIOOCULOFACIAL SYNDROME; BOFS	113620
BOF SYNDROME	BRANCHIOOCULOFACIAL SYNDROME; BOFS	113620
BRANCHIAL CLEFTS WITH CHARACTERISTIC FACIES, GROWTH RETARDATION, IMPERFORATENASOLACRIMAL DUCT, AND PREMATURE AGING	BRANCHIOOCULOFACIAL SYNDROME; BOFS	113620
HEMANGIOMATOUS BRANCHIAL CLEFTS-LIP PSEUDOCLEFT SYNDROME	BRANCHIOOCULOFACIAL SYNDROME; BOFS	113620
LIP PSEUDOCLEFT-HEMANGIOMATOUS BRANCHIAL CYST SYNDROME	BRANCHIOOCULOFACIAL SYNDROME; BOFS	113620
BRANCHIOOTORENAL SYNDROME 1; BOR1	BRANCHIOOTORENAL SYNDROME 1; BOR1	113650
BRANCHIOOTORENAL DYSPLASIA	BRANCHIOOTORENAL SYNDROME 1; BOR1	113650
MELNICK-FRASER SYNDROME	BRANCHIOOTORENAL SYNDROME 1; BOR1	113650
HYPERTROPHY OF THE BREAST, JUVENILE; JHB	HYPERTROPHY OF THE BREAST, JUVENILE; JHB	113670
GIGANTOMASTIA, JUVENILE	HYPERTROPHY OF THE BREAST, JUVENILE; JHB	113670
BREASTS AND/OR NIPPLES, APLASIA OR HYPOPLASIA OF, 1; BNAH1	BREASTS AND/OR NIPPLES, APLASIA OR HYPOPLASIA OF, 1; BNAH1	113700
AMASTIA	BREASTS AND/OR NIPPLES, APLASIA OR HYPOPLASIA OF, 1; BNAH1	113700
ATHELIA	BREASTS AND/OR NIPPLES, APLASIA OR HYPOPLASIA OF, 1; BNAH1	113700
AMAZIA	BREASTS AND/OR NIPPLES, APLASIA OR HYPOPLASIA OF, 1; BNAH1	113700
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 4; SHEP4	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 4; SHEP4	113750
SKIN/HAIR/EYE PIGMENTATION 4, FAIR/DARK SKINALBINISM, OCULOCUTANEOUS, TYPE VI, INCLUDED; OCA6, INCLUDED	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 4; SHEP4	113750
EPIDERMOLYTIC HYPERKERATOSIS; EHK	EPIDERMOLYTIC HYPERKERATOSIS; EHK	113800
BULLOUS ERYTHRODERMA ICHTHYOSIFORMIS CONGENITA OF BROCQ	EPIDERMOLYTIC HYPERKERATOSIS; EHK	113800
BULLOUS CONGENITAL ICHTHYOSIFORM ERYTHRODERMA; BCIE	EPIDERMOLYTIC HYPERKERATOSIS; EHK	113800
BULLOUS ICHTHYOSIFORM ERYTHRODERMA; BIE	EPIDERMOLYTIC HYPERKERATOSIS; EHK	113800
EPIDERMOLYTIC ICHTHYOSISEPIDERMOLYTIC HYPERKERATOSIS, LATE-ONSET, INCLUDED	EPIDERMOLYTIC HYPERKERATOSIS; EHK	113800
PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A	113900
PFHBIA	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A	113900
HEART BLOCK, PROGRESSIVE FAMILIAL, TYPE I; PFHBI	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A	113900
LENEGRE-LEV DISEASE	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A	113900
CARDIAC CONDUCTION DEFECT, PROGRESSIVE; PCCD	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A	113900
BUNDLE BRANCH BLOCK	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A	113900
HEREDITARY BUNDLE BRANCH SYSTEM DEFECT; HBBDHEART BLOCK, NONPROGRESSIVE, INCLUDED	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A	113900
CARDIAC CONDUCTION DEFECT, NONPROGRESSIVE, INCLUDED	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A	113900
BUNDLE BRANCH BLOCK, FAMILIAL ISOLATED COMPLETE RIGHT	BUNDLE BRANCH BLOCK, FAMILIAL ISOLATED COMPLETE RIGHT	113950
BURKITT LYMPHOMA; BL	BURKITT LYMPHOMA; BL	113970
CAFFEY DISEASE	CAFFEY DISEASE	114000
INFANTILE CORTICAL HYPEROSTOSIS	CAFFEY DISEASE	114000
BASAL GANGLIA CALCIFICATION, IDIOPATHIC, CHILDHOOD-ONSET	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, CHILDHOOD-ONSET	114100
IBGC, CHILDHOOD-ONSET	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, CHILDHOOD-ONSET	114100
STRIOPALLIDODENTATE CALCINOSIS, BILATERAL, CHILDHOOD-ONSET	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, CHILDHOOD-ONSET	114100
CEREBRAL CALCIFICATION, NONARTERIOSCLEROTIC, IDIOPATHIC, CHILDHOOD-ONSET	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, CHILDHOOD-ONSET	114100
CALLOSITIES, HEREDITARY PAINFUL	CALLOSITIES, HEREDITARY PAINFUL	114140
CALLOSITIES, PAINFUL PLANTAR	CALLOSITIES, HEREDITARY PAINFUL	114140
CAMPTOBRACHYDACTYLY	CAMPTOBRACHYDACTYLY	114150
CAMPTODACTYLY 1; CAMPD1	CAMPTODACTYLY 1; CAMPD1	114200
CAMPTODACTYLY AND KNUCKLE PADSSTREBLODACTYLY, INCLUDED	CAMPTODACTYLY 1; CAMPD1	114200
CAMPOMELIC DYSPLASIA	CAMPOMELIC DYSPLASIA	114290
CMPD	CAMPOMELIC DYSPLASIA	114290
CMD1; CMPD1	CAMPOMELIC DYSPLASIA	114290
CMPD1/SRA1CAMPOMELIC DYSPLASIA WITH AUTOSOMAL SEX REVERSAL, INCLUDED	CAMPOMELIC DYSPLASIA	114290
ACAMPOMELIC CAMPOMELIC DYSPLASIA, INCLUDED	CAMPOMELIC DYSPLASIA	114290
ACAMPOMELIC CAMPOMELIC DYSPLASIA WITH AUTOSOMAL SEX REVERSAL, INCLUDED	CAMPOMELIC DYSPLASIA	114290
CAMPTOMELIC DYSPLASIA, INCLUDED	CAMPOMELIC DYSPLASIA	114290
ARTHROGRYPOSIS, DISTAL, TYPE 3; DA3	ARTHROGRYPOSIS, DISTAL, TYPE 3; DA3	114300
GORDON SYNDROME	ARTHROGRYPOSIS, DISTAL, TYPE 3; DA3	114300
ARTHROGRYPOSIS MULTIPLEX CONGENITA, DISTAL, TYPE IIA	ARTHROGRYPOSIS, DISTAL, TYPE 3; DA3	114300
CAMPTODACTYLY, CLEFT PALATE, AND CLUBFOOT	ARTHROGRYPOSIS, DISTAL, TYPE 3; DA3	114300
BREAST CANCER	BREAST CANCER	114480
BREAST CANCER, FAMILIALBREAST CANCER, FAMILIAL MALE, INCLUDED	BREAST CANCER	114480
COLORECTAL CANCER; CRC	COLORECTAL CANCER; CRC	114500
COLON CANCER	COLORECTAL CANCER; CRC	114500
HEPATOCELLULAR CARCINOMA	HEPATOCELLULAR CARCINOMA	114550
HCC	HEPATOCELLULAR CARCINOMA	114550
CANCER, HEPATOCELLULAR	HEPATOCELLULAR CARCINOMA	114550
LIVER CANCER	HEPATOCELLULAR CARCINOMA	114550
LIVER CELL CARCINOMA; LCC	HEPATOCELLULAR CARCINOMA	114550
HEPATOMAHEPATOBLASTOMA, INCLUDED	HEPATOCELLULAR CARCINOMA	114550
HEPATOBLASTOMA CAUSED BY SOMATIC MUTATION, INCLUDED	HEPATOCELLULAR CARCINOMA	114550
CANDIDIASIS, FAMILIAL, 1; CANDF1	CANDIDIASIS, FAMILIAL, 1; CANDF1	114580
CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL DOMINANT, WITHOR WITHOUT THYROID DISEASE	CANDIDIASIS, FAMILIAL, 1; CANDF1	114580
CMCT	CANDIDIASIS, FAMILIAL, 1; CANDF1	114580
CANINE TEETH, ABSENCE OF UPPER PERMANENT	CANINE TEETH, ABSENCE OF UPPER PERMANENT	114600
CARBOXYLESTERASE 1; CES1	CARBOXYLESTERASE 1; CES1	114835
SERINE ESTERASE 1; SES1	CARBOXYLESTERASE 1; CES1	114835
CARBOXYLESTERASE, LIVER	CARBOXYLESTERASE 1; CES1	114835
TRIACYLGLYCEROL HYDROLASE; TGH	CARBOXYLESTERASE 1; CES1	114835
CARBOXYLESTERASE 2, FORMERLY; CES2, FORMERLY	CARBOXYLESTERASE 1; CES1	114835
CHOLESTEROL ESTER HYDROLASE, NEUTRAL, MACROPHAGE-DERIVED; CEHMONOCYTE ESTERASE DEFICIENCY, INCLUDED	CARBOXYLESTERASE 1; CES1	114835
MONOCYTE CARBOXYLESTERASE DEFICIENCY, INCLUDED	CARBOXYLESTERASE 1; CES1	114835
CARBOXYLESTERASE 1 DEFICIENCY, INCLUDED	CARBOXYLESTERASE 1; CES1	114835
CARCINOID TUMORS, INTESTINAL	CARCINOID TUMORS, INTESTINAL	114900
CARDIAC CONDUCTION DEFECTSUDDEN CARDIAC DEATH, INCLUDED; SCD, INCLUDED	CARDIAC CONDUCTION DEFECTSUDDEN CARDIAC DEATH, INCLUDED; SCD, INCLUDED	115080
FAMILIAL SUDDEN DEATH, INCLUDED	CARDIAC CONDUCTION DEFECTSUDDEN CARDIAC DEATH, INCLUDED; SCD, INCLUDED	115080
CARDIOFACIOCUTANEOUS SYNDROME 1; CFC1	CARDIOFACIOCUTANEOUS SYNDROME 1; CFC1	115150
CFC SYNDROME	CARDIOFACIOCUTANEOUS SYNDROME 1; CFC1	115150
CFCS	CARDIOFACIOCUTANEOUS SYNDROME 1; CFC1	115150
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 2; CMH2	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 2; CMH2	115195
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 3; CMH3	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 3; CMH3	115196
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 4; CMH4CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 4, SUSCEPTIBILITY TO, INCLUDED	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 4; CMH4CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 4, SUSCEPTIBILITY TO, INCLUDED	115197
CARDIOMYOPATHY, DILATED, 1A; CMD1A	CARDIOMYOPATHY, DILATED, 1A; CMD1A	115200
CARDIOMYOPATHY, DILATED, WITH CONDUCTION DEFECT 1; CDCD1	CARDIOMYOPATHY, DILATED, 1A; CMD1A	115200
CARDIOMYOPATHY, IDIOPATHIC DILATED	CARDIOMYOPATHY, DILATED, 1A; CMD1A	115200
CARDIOMYOPATHY, FAMILIAL IDIOPATHIC	CARDIOMYOPATHY, DILATED, 1A; CMD1A	115200
CARDIOMYOPATHY, CONGESTIVE	CARDIOMYOPATHY, DILATED, 1A; CMD1A	115200
CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 1; RCM1	CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 1; RCM1	115210
RCM	CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 1; RCM1	115210
HYPERCAROTENEMIA AND VITAMIN A DEFICIENCY, AUTOSOMAL DOMINANTCAROTENOIDS, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1, INCLUDED	HYPERCAROTENEMIA AND VITAMIN A DEFICIENCY, AUTOSOMAL DOMINANTCAROTENOIDS, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1, INCLUDED	115300
PARAGANGLIOMAS 4; PGL4	PARAGANGLIOMAS 4; PGL4	115310
CAROTID BODY TUMORS AND MULTIPLE EXTRAADRENAL PHEOCHROMOCYTOMAS	PARAGANGLIOMAS 4; PGL4	115310
PHEOCHROMOCYTOMA, EXTRAADRENAL, AND CERVICAL PARAGANGLIOMA	PARAGANGLIOMAS 4; PGL4	115310
PARAGANGLIOMAS, HEREDITARY EXTRAADRENAL	PARAGANGLIOMAS 4; PGL4	115310
PHEOCHROMOCYTOMA, FAMILIAL EXTRAADRENAL	PARAGANGLIOMAS 4; PGL4	115310
PARAGANGLIOMA, FAMILIAL MALIGNANT	PARAGANGLIOMAS 4; PGL4	115310
CARPAL TUNNEL SYNDROME; CTS1	CARPAL TUNNEL SYNDROME; CTS1	115430
CTS	CARPAL TUNNEL SYNDROME; CTS1	115430
AMYOTROPHY, THENAR, OF CARPAL ORIGIN	CARPAL TUNNEL SYNDROME; CTS1	115430
CAT EYE SYNDROME; CES	CAT EYE SYNDROME; CES	115470
SCHMID-FRACCARO SYNDROME	CAT EYE SYNDROME; CES	115470
CHROMOSOME 22 PARTIAL TETRASOMY	CAT EYE SYNDROME; CES	115470
INV DUP(22)(q11)	CAT EYE SYNDROME; CES	115470
CATARACT 32, MULTIPLE TYPES; CTRCT32	CATARACT 32, MULTIPLE TYPES; CTRCT32	115650
CATARACT, ANTERIOR POLAR, 1; CTAA1	CATARACT 32, MULTIPLE TYPES; CTRCT32	115650
CATARACT, ANTERIOR POLAR; CAP	CATARACT 32, MULTIPLE TYPES; CTRCT32	115650
CATARACT, POSTERIOR POLAR, 5; CTPP5	CATARACT 32, MULTIPLE TYPES; CTRCT32	115650
CATARACT 7; CTRCT7	CATARACT 7; CTRCT7	115660
CATARACT 7, CERULEAN TYPE	CATARACT 7; CTRCT7	115660
CATARACT, CONGENITAL, CERULEAN TYPE, 1; CCA1	CATARACT 7; CTRCT7	115660
CATARACT 8, MULTIPLE TYPES; CTRCT8	CATARACT 8, MULTIPLE TYPES; CTRCT8	115665
CATARACT, CONGENITAL, VOLKMANN TYPE; CCV	CATARACT 8, MULTIPLE TYPES; CTRCT8	115665
CATARACT 4, MULTIPLE TYPES; CTRCT4	CATARACT 4, MULTIPLE TYPES; CTRCT4	115700
CATARACT 4, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA	CATARACT 4, MULTIPLE TYPES; CTRCT4	115700
CATARACT, CRYSTALLINE ACULEIFORM; CACA	CATARACT 4, MULTIPLE TYPES; CTRCT4	115700
CATARACT, CONGENITAL, CERULEAN TYPE, 3; CCA3	CATARACT 4, MULTIPLE TYPES; CTRCT4	115700
CATARACT, NONNUCLEAR POLYMORPHIC CONGENITAL; PCC	CATARACT 4, MULTIPLE TYPES; CTRCT4	115700
CATARACT, PUNCTATE, PROGRESSIVE JUVENILE-ONSET	CATARACT 4, MULTIPLE TYPES; CTRCT4	115700
CATARACT 29; CTRCT29	CATARACT 29; CTRCT29	115800
CATARACT 29, CORALLIFORM	CATARACT 29; CTRCT29	115800
CATARACT 42; CTRCT42	CATARACT 42; CTRCT42	115900
CATARACT 20, MULTIPLE TYPES; CTRCT20	CATARACT 20, MULTIPLE TYPES; CTRCT20	116100
CATARACT 1, MULTIPLE TYPES; CTRCT1	CATARACT 1, MULTIPLE TYPES; CTRCT1	116200
CATARACT 1, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA	CATARACT 1, MULTIPLE TYPES; CTRCT1	116200
CATARACT, DUFFY-LINKED	CATARACT 1, MULTIPLE TYPES; CTRCT1	116200
CATARACT, ZONULAR PULVERULENT, 1; CZP1; CZP; CAE1	CATARACT 1, MULTIPLE TYPES; CTRCT1	116200
CATARACT 30; CTRCT30	CATARACT 30; CTRCT30	116300
CATARACT 30, PULVERULENT	CATARACT 30; CTRCT30	116300
CATARACT 41; CTRCT41	CATARACT 41; CTRCT41	116400
CATARACT 41, CONGENITAL NUCLEAR TYPE	CATARACT 41; CTRCT41	116400
CATARACT 6, MULTIPLE TYPES; CTRCT6	CATARACT 6, MULTIPLE TYPES; CTRCT6	116600
CATARACT, POSTERIOR POLAR, 1; CTPP1	CATARACT 6, MULTIPLE TYPES; CTRCT6	116600
CATARACT, AGE-RELATED CORTICAL, 2; ARCC2	CATARACT 6, MULTIPLE TYPES; CTRCT6	116600
CATARACT 13 WITH ADULT i PHENOTYPE; CTRCT13	CATARACT 13 WITH ADULT i PHENOTYPE; CTRCT13	116700
CATECHOL-O-METHYLTRANSFERASE; COMTCATECHOL-O-METHYLTRANSFERASE ACTIVITY, LOW, IN RED CELLS, INCLUDED	CATECHOL-O-METHYLTRANSFERASE; COMTCATECHOL-O-METHYLTRANSFERASE ACTIVITY, LOW, IN RED CELLS, INCLUDED	116790
CATARACT 5, MULTIPLE TYPES; CTRCT5	CATARACT 5, MULTIPLE TYPES; CTRCT5	116800
CATARACT, LAMELLAR	CATARACT 5, MULTIPLE TYPES; CTRCT5	116800
CATARACT, MARNER TYPE; CAM; CTM	CATARACT 5, MULTIPLE TYPES; CTRCT5	116800
CEREBRAL CAVERNOUS MALFORMATIONS; CCM	CEREBRAL CAVERNOUS MALFORMATIONS; CCM	116860
CAVERNOUS ANGIOMA, FAMILIAL	CEREBRAL CAVERNOUS MALFORMATIONS; CCM	116860
CAVERNOUS ANGIOMATOUS MALFORMATIONS; CAM	CEREBRAL CAVERNOUS MALFORMATIONS; CCM	116860
CEREBRAL CAPILLARY MALFORMATIONSCEREBRAL CAVERNOUS MALFORMATIONS 1, INCLUDED; CCM1, INCLUDED	CEREBRAL CAVERNOUS MALFORMATIONS; CCM	116860
CAVERNOUS MALFORMATIONS OF CNS AND RETINA, INCLUDED	CEREBRAL CAVERNOUS MALFORMATIONS; CCM	116860
HYPERKERATOTIC CUTANEOUS CAPILLARY-VENOUS MALFORMATIONS ASSOCIATEDWITH CEREBRAL CAPILLARY MALFORMATIONS, INCLUDED	CEREBRAL CAVERNOUS MALFORMATIONS; CCM	116860
LEUKOCYTE ADHESION DEFICIENCY, TYPE I; LAD	LEUKOCYTE ADHESION DEFICIENCY, TYPE I; LAD	116920
LAD1	LEUKOCYTE ADHESION DEFICIENCY, TYPE I; LAD	116920
LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 1 IMMUNODEFICIENCY	LEUKOCYTE ADHESION DEFICIENCY, TYPE I; LAD	116920
LFA1 IMMUNODEFICIENCY	LEUKOCYTE ADHESION DEFICIENCY, TYPE I; LAD	116920
CENTRAL CORE DISEASE OF MUSCLE; CCD	CENTRAL CORE DISEASE OF MUSCLE; CCD	117000
CCOMINICORE MYOPATHY, MODERATE, WITH HAND INVOLVEMENT, INCLUDED	CENTRAL CORE DISEASE OF MUSCLE; CCD	117000
MULTICORE MYOPATHY, MODERATE, WITH HAND INVOLVEMENT, INCLUDED	CENTRAL CORE DISEASE OF MUSCLE; CCD	117000
MULTIMINICORE DISEASE, MODERATE, WITH HAND INVOLVEMENT, INCLUDED	CENTRAL CORE DISEASE OF MUSCLE; CCD	117000
NEUROMUSCULAR DISEASE, CONGENITAL, WITH UNIFORM TYPE 1 FIBER, INCLUDED;CNMDU1, INCLUDED	CENTRAL CORE DISEASE OF MUSCLE; CCD	117000
CENTRALOPATHIC EPILEPSY	CENTRALOPATHIC EPILEPSY	117100
CENTROTEMPORAL EPILEPSY; ECT	CENTRALOPATHIC EPILEPSY	117100
TEMPORAL-CENTRAL FOCAL EPILEPSY	CENTRALOPATHIC EPILEPSY	117100
BENIGN ROLANDIC EPILEPSY	CENTRALOPATHIC EPILEPSY	117100
BENIGN EPILEPSY OF CHILDHOOD WITH CENTROTEMPORAL SPIKES; BECTS	CENTRALOPATHIC EPILEPSY	117100
SPINOCEREBELLAR ATAXIA 31; SCA31	SPINOCEREBELLAR ATAXIA 31; SCA31	117210
SPINOCEREBELLAR ATAXIA, 16q22-LINKED	SPINOCEREBELLAR ATAXIA 31; SCA31	117210
CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 2	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 2	117300
DEMENTIA, FAMILIAL DANISH; FDD	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 2	117300
FAMILIAL DANISH DEMENTIA	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 2	117300
CEREBELLAR ATAXIA, CATARACT, DEAFNESS, AND DEMENTIA OR PSYCHOSIS	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 2	117300
HEREDOPATHIA OPHTHALMOOTOENCEPHALICA; HOOE	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 2	117300
SPINOCEREBELLAR ATAXIA 29; SCA29	SPINOCEREBELLAR ATAXIA 29; SCA29	117360
CEREBELLAR ATAXIA, CONGENITAL NONPROGRESSIVE, AUTOSOMAL DOMINANT;CNPCA	SPINOCEREBELLAR ATAXIA 29; SCA29	117360
CEREBELLAR VERMIS APLASIA	SPINOCEREBELLAR ATAXIA 29; SCA29	117360
APLASIA OF CEREBELLAR VERMIS; ACV	SPINOCEREBELLAR ATAXIA 29; SCA29	117360
SOTOS SYNDROME 1; SOTOS1	SOTOS SYNDROME 1; SOTOS1	117550
SOTOS SYNDROME	SOTOS SYNDROME 1; SOTOS1	117550
CEREBRAL GIGANTISM	SOTOS SYNDROME 1; SOTOS1	117550
CHROMOSOME 5q35 DELETION SYNDROME	SOTOS SYNDROME 1; SOTOS1	117550
CEREBROCOSTOMANDIBULAR SYNDROME; CCMS	CEREBROCOSTOMANDIBULAR SYNDROME; CCMS	117650
RIB GAP DEFECTS WITH MICROGNATHIA	CEREBROCOSTOMANDIBULAR SYNDROME; CCMS	117650
APOCRINE GLAND SECRETION, VARIATION IN	APOCRINE GLAND SECRETION, VARIATION IN	117800
EAR WAX, WET/DRY; EWWD	APOCRINE GLAND SECRETION, VARIATION IN	117800
WET WAX; WW	APOCRINE GLAND SECRETION, VARIATION IN	117800
CERUMEN, VARIATION IN	APOCRINE GLAND SECRETION, VARIATION IN	117800
AXILLARY ODOR, VARIATION IN	APOCRINE GLAND SECRETION, VARIATION IN	117800
COLOSTRUM SECRETION, VARIATION IN	APOCRINE GLAND SECRETION, VARIATION IN	117800
KLIPPEL-FEIL SYNDROME 1, AUTOSOMAL DOMINANT; KFS1	KLIPPEL-FEIL SYNDROME 1, AUTOSOMAL DOMINANT; KFS1	118100
KFS	KLIPPEL-FEIL SYNDROME 1, AUTOSOMAL DOMINANT; KFS1	118100
CERVICAL VERTEBRAL FUSION, AUTOSOMAL DOMINANT	KLIPPEL-FEIL SYNDROME 1, AUTOSOMAL DOMINANT; KFS1	118100
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	118200
HEREDITARY MOTOR AND SENSORY NEUROPATHY I; HMSN I	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	118200
HEREDITARY MOTOR AND SENSORY NEUROPATHY IB; HMSN IB	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	118200
HMSN1	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	118200
HMSN1B	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	118200
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1B	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	118200
CHARCOT-MARIE-TOOTH DISEASE, SLOW NERVE CONDUCTION TYPE, LINKED TODUFFY	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	118200
PERONEAL MUSCULAR ATROPHY	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	118200
CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, WITH FOCALLY FOLDEDMYELIN SHEATHS, TYPE 1B	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	118200
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A1; CMT2A1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A1; CMT2A1	118210
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2A1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A1; CMT2A1	118210
CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2A1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A1; CMT2A1	118210
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2A1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A1; CMT2A1	118210
HEREDITARY MOTOR AND SENSORY NEUROPATHY IIA1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A1; CMT2A1	118210
HMSN IIA1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A1; CMT2A1	118210
HMSN2A1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A1; CMT2A1	118210
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1A; CMT1A	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1A; CMT1A	118220
HEREDITARY MOTOR AND SENSORY NEUROPATHY IA; HMSN IA	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1A; CMT1A	118220
HMSN1A	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1A; CMT1A	118220
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1A	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1A; CMT1A	118220
CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, WITH FOCALLY FOLDEDMYELIN SHEATHS, TYPE 1A	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1A; CMT1A	118220
CHARCOT-MARIE-TOOTH DISEASE AND DEAFNESS	CHARCOT-MARIE-TOOTH DISEASE AND DEAFNESS	118300
CHARCOT-MARIE-TOOTH NEUROPATHY AND DEAFNESS, AUTOSOMAL DOMINANT	CHARCOT-MARIE-TOOTH DISEASE AND DEAFNESS	118300
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1E; CMT1E	CHARCOT-MARIE-TOOTH DISEASE AND DEAFNESS	118300
CHERUBISM	CHERUBISM	118400
CRBM	CHERUBISM	118400
CHIARI MALFORMATION TYPE I	CHIARI MALFORMATION TYPE I	118420
CM1CHIARI MALFORMATION TYPE I WITH SYRINGOMYELIA, INCLUDED	CHIARI MALFORMATION TYPE I	118420
CM1 WITH SYRINGOMYELIA, INCLUDED	CHIARI MALFORMATION TYPE I	118420
ALAGILLE SYNDROME 1; ALGS1	ALAGILLE SYNDROME 1; ALGS1	118450
ALAGILLE SYNDROME; ALGS	ALAGILLE SYNDROME 1; ALGS1	118450
ALAGILLE-WATSON SYNDROME; AWS	ALAGILLE SYNDROME 1; ALGS1	118450
CHOLESTASIS WITH PERIPHERAL PULMONARY STENOSIS	ALAGILLE SYNDROME 1; ALGS1	118450
ARTERIOHEPATIC DYSPLASIA; AHD	ALAGILLE SYNDROME 1; ALGS1	118450
HEPATIC DUCTULAR HYPOPLASIA, SYNDROMATIC	ALAGILLE SYNDROME 1; ALGS1	118450
CHONDROCALCINOSIS 2; CCAL2	CHONDROCALCINOSIS 2; CCAL2	118600
CHONDROCALCINOSIS, FAMILIAL ARTICULAR	CHONDROCALCINOSIS 2; CCAL2	118600
CALCIUM GOUT	CHONDROCALCINOSIS 2; CCAL2	118600
CALCIUM PYROPHOSPHATE ARTHROPATHY	CHONDROCALCINOSIS 2; CCAL2	118600
CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD	CHONDROCALCINOSIS 2; CCAL2	118600
CHONDRODYSPLASIA PUNCTATA, TIBIA-METACARPAL TYPE	CHONDRODYSPLASIA PUNCTATA, TIBIA-METACARPAL TYPE	118651
CHONDRODYSPLASIA PUNCTATA, MT TYPE	CHONDRODYSPLASIA PUNCTATA, TIBIA-METACARPAL TYPE	118651
CHOREA, BENIGN HEREDITARY; BHC	CHOREA, BENIGN HEREDITARY; BHC	118700
BCH	CHOREA, BENIGN HEREDITARY; BHC	118700
HEREDITARY PROGRESSIVE CHOREA WITHOUT DEMENTIA	CHOREA, BENIGN HEREDITARY; BHC	118700
PAROXYSMAL NONKINESIGENIC DYSKINESIA 1; PNKD1	PAROXYSMAL NONKINESIGENIC DYSKINESIA 1; PNKD1	118800
PAROXYSMAL DYSTONIC CHOREOATHETOSIS; PDC	PAROXYSMAL NONKINESIGENIC DYSKINESIA 1; PNKD1	118800
CHOREOATHETOSIS, FAMILIAL PAROXYSMAL; FPD1	PAROXYSMAL NONKINESIGENIC DYSKINESIA 1; PNKD1	118800
MOUNT-REBACK SYNDROME	PAROXYSMAL NONKINESIGENIC DYSKINESIA 1; PNKD1	118800
CHOREOATHETOSIS, NONKINESIGENIC	PAROXYSMAL NONKINESIGENIC DYSKINESIA 1; PNKD1	118800
DYSTONIA 8; DYT8	PAROXYSMAL NONKINESIGENIC DYSKINESIA 1; PNKD1	118800
CHYLOMICRONEMIA, FAMILIAL, DUE TO CIRCULATING INHIBITOR OF LIPOPROTEINLIPASE	CHYLOMICRONEMIA, FAMILIAL, DUE TO CIRCULATING INHIBITOR OF LIPOPROTEINLIPASE	118830
HYPERLIPOPROTEINEMIA, TYPE IC	CHYLOMICRONEMIA, FAMILIAL, DUE TO CIRCULATING INHIBITOR OF LIPOPROTEINLIPASE	118830
CHROMATE RESISTANCE; CHR	CHROMATE RESISTANCE; CHR	118840
CLEFT CHIN	CLEFT CHIN	119000
CHIN DIMPLE	CLEFT CHIN	119000
SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 1; SHFLD1	SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 1; SHFLD1	119100
SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY; SHFLD	SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 1; SHFLD1	119100
CLEFT HAND AND ABSENT TIBIA	SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 1; SHFLD1	119100
APLASIA OF TIBIA WITH ECTRODACTYLY	SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 1; SHFLD1	119100
TIBIAL APLASIA WITH SPLIT-HAND/SPLIT-FOOT DEFORMITY	SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 1; SHFLD1	119100
ECTRODACTYLY WITH APLASIA OF LONG BONES	SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 1; SHFLD1	119100
VAN DER WOUDE SYNDROME 1; VWS1	VAN DER WOUDE SYNDROME 1; VWS1	119300
VDWS	VAN DER WOUDE SYNDROME 1; VWS1	119300
LIP-PIT SYNDROME; LPS; PIT	VAN DER WOUDE SYNDROME 1; VWS1	119300
CLEFT LIP AND/OR PALATE WITH MUCOUS CYSTS OF LOWER LIP	VAN DER WOUDE SYNDROME 1; VWS1	119300
POPLITEAL PTERYGIUM SYNDROME; PPS	POPLITEAL PTERYGIUM SYNDROME; PPS	119500
CLEFT LIP/PALATE, PARAMEDIAN MUCOUS CYSTS OF THE LOWER LIP, POPLITEALPTERYGIUM, DIGITAL AND GENITAL ANOMALIES	POPLITEAL PTERYGIUM SYNDROME; PPS	119500
FACIOGENITOPOPLITEAL SYNDROME	POPLITEAL PTERYGIUM SYNDROME; PPS	119500
OROFACIAL CLEFT 1; OFC1	OROFACIAL CLEFT 1; OFC1	119530
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 1	OROFACIAL CLEFT 1; OFC1	119530
OROFACIAL CLEFT, NONSYNDROMIC; OFC	OROFACIAL CLEFT 1; OFC1	119530
CLEFT LIP/PALATE, NONSYNDROMIC	OROFACIAL CLEFT 1; OFC1	119530
CLEFT PALATE, ISOLATED; CPI	CLEFT PALATE, ISOLATED; CPI	119540
CLEFT PALATE; CP	CLEFT PALATE, ISOLATED; CPI	119540
SYNGNATHIA	SYNGNATHIA	119550
CLEFT PALATE-LATERAL SYNECHIA SYNDROME	SYNGNATHIA	119550
CPLS SYNDROME	SYNGNATHIA	119550
BLEPHAROCHEILODONTIC SYNDROME; BCDS	BLEPHAROCHEILODONTIC SYNDROME; BCDS	119580
BCD SYNDROME	BLEPHAROCHEILODONTIC SYNDROME; BCDS	119580
CLEFTING, ECTROPION, AND CONICAL TEETH	BLEPHAROCHEILODONTIC SYNDROME; BCDS	119580
ECTROPION, INFERIOR, WITH CLEFT LIP AND/OR PALATE	BLEPHAROCHEILODONTIC SYNDROME; BCDS	119580
ELSCHNIG SYNDROME	BLEPHAROCHEILODONTIC SYNDROME; BCDS	119580
LAGOPHTHALMIA WITH BILATERAL CLEFT LIP AND PALATE	BLEPHAROCHEILODONTIC SYNDROME; BCDS	119580
CLEIDOCRANIAL DYSPLASIA; CCD	CLEIDOCRANIAL DYSPLASIA; CCD	119600
CLEIDOCRANIAL DYSOSTOSIS; CLCDCLEIDOCRANIAL DYSPLASIA, FORME FRUSTE, WITH BRACHYDACTYLY, INCLUDED	CLEIDOCRANIAL DYSPLASIA; CCD	119600
CLEIDOCRANIAL DYSPLASIA, FORME FRUSTE, DENTAL ANOMALIES ONLY, INCLUDED	CLEIDOCRANIAL DYSPLASIA; CCD	119600
CLUBFOOT, CONGENITAL, WITH OR WITHOUT DEFICIENCY OF LONG BONES AND/ORMIRROR-IMAGE POLYDACTYLY; CCF	CLUBFOOT, CONGENITAL, WITH OR WITHOUT DEFICIENCY OF LONG BONES AND/ORMIRROR-IMAGE POLYDACTYLY; CCF	119800
DIGITAL CLUBBING, ISOLATED CONGENITAL	DIGITAL CLUBBING, ISOLATED CONGENITAL	119900
CLUBBING OF DIGITS	DIGITAL CLUBBING, ISOLATED CONGENITAL	119900
ACROPACHY, HEREDITARY	DIGITAL CLUBBING, ISOLATED CONGENITAL	119900
CLUSTER HEADACHE, FAMILIAL	CLUSTER HEADACHE, FAMILIAL	119915
COXSACKIEVIRUS B3 SUSCEPTIBILITY; CXB3S	COXSACKIEVIRUS B3 SUSCEPTIBILITY; CXB3S	120050
CB3S	COXSACKIEVIRUS B3 SUSCEPTIBILITY; CXB3S	120050
COLCHICINE RESISTANCE	COLCHICINE RESISTANCE	120080
COLCHICINE SENSITIVITY; CLCS	COLCHICINE RESISTANCE	120080
FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 1; FCAS1	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 1; FCAS1	120100
FCAS	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 1; FCAS1	120100
COLD HYPERSENSITIVITY	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 1; FCAS1	120100
COLD-INDUCED AUTOINFLAMMATORY SYNDROME, FAMILIAL	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 1; FCAS1	120100
COLD URTICARIA, FAMILIAL; FCU	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 1; FCAS1	120100
CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME 1; CAPS1	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 1; FCAS1	120100
COLLAGEN, TYPE II, ALPHA-1; COL2A1	COLLAGEN, TYPE II, ALPHA-1; COL2A1	120140
COLLAGEN, TYPE II	COLLAGEN, TYPE II, ALPHA-1; COL2A1	120140
COLLAGEN OF CARTILAGECHONDROCALCIN, INCLUDED	COLLAGEN, TYPE II, ALPHA-1; COL2A1	120140
VITREORETINOPATHY WITH PHALANGEAL EPIPHYSEAL DYSPLASIA, INCLUDED	COLLAGEN, TYPE II, ALPHA-1; COL2A1	120140
COLLAGEN, TYPE I, ALPHA-1; COL1A1	COLLAGEN, TYPE I, ALPHA-1; COL1A1	120150
COLLAGEN OF SKIN, TENDON, AND BONE, ALPHA-1 CHAINCOL1A1/PDGFB FUSION GENE, INCLUDED	COLLAGEN, TYPE I, ALPHA-1; COL1A1	120150
OI/EDS COMBINED SYNDROME, INCLUDED	COLLAGEN, TYPE I, ALPHA-1; COL1A1	120150
COLOBOMA, OCULAR, AUTOSOMAL DOMINANT	COLOBOMA, OCULAR, AUTOSOMAL DOMINANT	120200
COLOBOMA, UVEORETINAL	COLOBOMA, OCULAR, AUTOSOMAL DOMINANT	120200
COLOBOMA OF IRIS, CHOROID, AND RETINA; COI	COLOBOMA, OCULAR, AUTOSOMAL DOMINANT	120200
COLOBOMA OF MACULA	COLOBOMA OF MACULA	120300
AGENESIS OF MACULA	COLOBOMA OF MACULA	120300
PAPILLORENAL SYNDROME; PAPRS	PAPILLORENAL SYNDROME; PAPRS	120330
RENAL-COLOBOMA SYNDROME	PAPILLORENAL SYNDROME; PAPRS	120330
OPTIC NERVE COLOBOMA WITH RENAL DISEASE	PAPILLORENAL SYNDROME; PAPRS	120330
COLOBOMA OF OPTIC NERVE WITH RENAL DISEASE	PAPILLORENAL SYNDROME; PAPRS	120330
OPTIC COLOBOMA, VESICOURETERAL REFLUX, AND RENAL ANOMALIES	PAPILLORENAL SYNDROME; PAPRS	120330
RENAL-COLOBOMA SYNDROME WITH MACULAR ABNORMALITIES	PAPILLORENAL SYNDROME; PAPRS	120330
CONGENITAL ANOMALIES OF THE KIDNEY AND URINARY TRACT WITH OR WITHOUTOCULAR ABNORMALITIES	PAPILLORENAL SYNDROME; PAPRS	120330
CAKUT WITH OR WITHOUT OCULAR ABNORMALITIES	PAPILLORENAL SYNDROME; PAPRS	120330
COLOBOMA OF OPTIC NERVEOPTIC NERVE HEAD PITS, BILATERAL CONGENITAL, INCLUDED	COLOBOMA OF OPTIC NERVEOPTIC NERVE HEAD PITS, BILATERAL CONGENITAL, INCLUDED	120430
MORNING GLORY DISC ANOMALY, INCLUDED	COLOBOMA OF OPTIC NERVEOPTIC NERVE HEAD PITS, BILATERAL CONGENITAL, INCLUDED	120430
COLOBOMA, OCULAR, WITH OR WITHOUT HEARING IMPAIRMENT, CLEFT LIP/PALATE,AND/OR MENTAL RETARDATION; COB1	COLOBOMA, OCULAR, WITH OR WITHOUT HEARING IMPAIRMENT, CLEFT LIP/PALATE,AND/OR MENTAL RETARDATION; COB1	120433
LYNCH SYNDROME I	LYNCH SYNDROME I	120435
COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 1; HNPCC1	LYNCH SYNDROME I	120435
COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 1; FCC1	LYNCH SYNDROME I	120435
COCA1LYNCH SYNDROME II, INCLUDED	LYNCH SYNDROME I	120435
COMEDONES, FAMILIAL DYSKERATOTIC	COMEDONES, FAMILIAL DYSKERATOTIC	120450
BRANCHIOOTIC SYNDROME 2	BRANCHIOOTIC SYNDROME 2	120502
BO SYNDROME 2; BOS2	BRANCHIOOTIC SYNDROME 2	120502
COMPLEMENT COMPONENT 4, PARTIAL DEFICIENCY OF	COMPLEMENT COMPONENT 4, PARTIAL DEFICIENCY OF	120790
CONE-ROD DYSTROPHY 2; CORD2	CONE-ROD DYSTROPHY 2; CORD2	120970
CONE-ROD DYSTROPHY; CORD	CONE-ROD DYSTROPHY 2; CORD2	120970
CONE-ROD RETINAL DYSTROPHY; CRD; CRD2	CONE-ROD DYSTROPHY 2; CORD2	120970
RETINAL CONE-ROD DYSTROPHY; RCRD2	CONE-ROD DYSTROPHY 2; CORD2	120970
ARTHROGRYPOSIS, DISTAL, TYPE 9; DA9	ARTHROGRYPOSIS, DISTAL, TYPE 9; DA9	121050
BEALS SYNDROME	ARTHROGRYPOSIS, DISTAL, TYPE 9; DA9	121050
CONTRACTURAL ARACHNODACTYLY, CONGENITAL; CCA	ARTHROGRYPOSIS, DISTAL, TYPE 9; DA9	121050
SEIZURES, BENIGN FAMILIAL NEONATAL, 1; BFNS1EPILEPSY, BENIGN NEONATAL, 1, AND/OR MYOKYMIA, INCLUDED	SEIZURES, BENIGN FAMILIAL NEONATAL, 1; BFNS1EPILEPSY, BENIGN NEONATAL, 1, AND/OR MYOKYMIA, INCLUDED	121200
SEIZURES, BENIGN FAMILIAL NEONATAL, 1, AND/OR MYOKYMIA, INCLUDED	SEIZURES, BENIGN FAMILIAL NEONATAL, 1; BFNS1EPILEPSY, BENIGN NEONATAL, 1, AND/OR MYOKYMIA, INCLUDED	121200
SEIZURES, BENIGN FAMILIAL NEONATAL, 2; BFNS2	SEIZURES, BENIGN FAMILIAL NEONATAL, 2; BFNS2	121201
CONVULSIONS, BENIGN FAMILIAL NEONATAL, 2; BFNC2	SEIZURES, BENIGN FAMILIAL NEONATAL, 2; BFNS2	121201
FEBRILE SEIZURES, FAMILIAL, 1; FEB1	FEBRILE SEIZURES, FAMILIAL, 1; FEB1	121210
CONVULSIONS, FAMILIAL FEBRILE;  1	FEBRILE SEIZURES, FAMILIAL, 1; FEB1	121210
COPROPORPHYRIA, HEREDITARY; HCP	COPROPORPHYRIA, HEREDITARY; HCP	121300
COPROPORPHYRINOGEN OXIDASE DEFICIENCY	COPROPORPHYRIA, HEREDITARY; HCP	121300
CPOX DEFICIENCY	COPROPORPHYRIA, HEREDITARY; HCP	121300
CPO DEFICIENCY	COPROPORPHYRIA, HEREDITARY; HCP	121300
CPX DEFICIENCYHARDEROPORPHYRIA, INCLUDED	COPROPORPHYRIA, HEREDITARY; HCP	121300
CORNEA GUTTATA WITH ANTERIOR POLAR CATARACTS	CORNEA GUTTATA WITH ANTERIOR POLAR CATARACTS	121390
CORNEA PLANA 1; CNA1	CORNEA PLANA 1; CNA1	121400
CORNEAL ENDOTHELIAL DYSTROPHY 1, AUTOSOMAL DOMINANT; CHED1	CORNEAL ENDOTHELIAL DYSTROPHY 1, AUTOSOMAL DOMINANT; CHED1	121700
CORNEAL DYSTROPHY, CONGENITAL HEREDITARY ENDOTHELIAL; CHED	CORNEAL ENDOTHELIAL DYSTROPHY 1, AUTOSOMAL DOMINANT; CHED1	121700
CONGENITAL HEREDITARY ENDOTHELIAL DYSTROPHY OF CORNEA	CORNEAL ENDOTHELIAL DYSTROPHY 1, AUTOSOMAL DOMINANT; CHED1	121700
MAUMENEE CORNEAL DYSTROPHY	CORNEAL ENDOTHELIAL DYSTROPHY 1, AUTOSOMAL DOMINANT; CHED1	121700
SCHNYDER CORNEAL DYSTROPHY; SCCD	SCHNYDER CORNEAL DYSTROPHY; SCCD	121800
CORNEAL DYSTROPHY, SCHNYDER	SCHNYDER CORNEAL DYSTROPHY; SCCD	121800
SCHNYDER CRYSTALLINE CORNEAL DYSTROPHY	SCHNYDER CORNEAL DYSTROPHY; SCCD	121800
CORNEAL DYSTROPHY, CRYSTALLINE, OF SCHNYDER	SCHNYDER CORNEAL DYSTROPHY; SCCD	121800
CORNEAL DYSTROPHY, EPITHELIAL BASEMENT MEMBRANE; EBMD	CORNEAL DYSTROPHY, EPITHELIAL BASEMENT MEMBRANE; EBMD	121820
CORNEAL DYSTROPHY, ANTERIOR BASEMENT MEMBRANE	CORNEAL DYSTROPHY, EPITHELIAL BASEMENT MEMBRANE; EBMD	121820
COGAN CORNEAL DYSTROPHY	CORNEAL DYSTROPHY, EPITHELIAL BASEMENT MEMBRANE; EBMD	121820
CORNEAL DYSTROPHY, MAP-DOT-FINGERPRINT TYPE	CORNEAL DYSTROPHY, EPITHELIAL BASEMENT MEMBRANE; EBMD	121820
CORNEAL DYSTROPHY, MICROCYSTIC	CORNEAL DYSTROPHY, EPITHELIAL BASEMENT MEMBRANE; EBMD	121820
CORNEAL DYSTROPHY, FLECK	CORNEAL DYSTROPHY, FLECK	121850
CFD	CORNEAL DYSTROPHY, FLECK	121850
FLECK CORNEAL DYSTROPHY; FCD	CORNEAL DYSTROPHY, FLECK	121850
CORNEAL DYSTROPHY, FRANCOIS-NEETENS SPECKLED OR FLECKED	CORNEAL DYSTROPHY, FLECK	121850
CORNEAL DYSTROPHY, GROENOUW TYPE I; CDGG1	CORNEAL DYSTROPHY, GROENOUW TYPE I; CDGG1	121900
GRANULAR CORNEAL DYSTROPHY, TYPE I; GCD1	CORNEAL DYSTROPHY, GROENOUW TYPE I; CDGG1	121900
CORNEAL DYSTROPHY, PUNCTATE OR NODULAR	CORNEAL DYSTROPHY, GROENOUW TYPE I; CDGG1	121900
CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 1; PPCD1	CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 1; PPCD1	122000
POSTERIOR POLYMORPHOUS CORNEAL DYSTROPHY; PPCD	CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 1; PPCD1	122000
CORNEAL DYSTROPHY, HEREDITARY POLYMORPHOUS POSTERIOR	CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 1; PPCD1	122000
CORNEAL DYSTROPHY, MEESMANN; MECD	CORNEAL DYSTROPHY, MEESMANN; MECD	122100
CORNEAL DYSTROPHY, MEESMANN EPITHELIAL	CORNEAL DYSTROPHY, MEESMANN; MECD	122100
MEESMANN CORNEAL DYSTROPHY	CORNEAL DYSTROPHY, MEESMANN; MECD	122100
CORNEAL DYSTROPHY, JUVENILE EPITHELIAL, OF MEESMANN	CORNEAL DYSTROPHY, MEESMANN; MECD	122100
CORNEAL DYSTROPHY, LATTICE TYPE I; LCD1	CORNEAL DYSTROPHY, LATTICE TYPE I; LCD1	122200
LCD	CORNEAL DYSTROPHY, LATTICE TYPE I; LCD1	122200
LATTICE CORNEAL DYSTROPHY, TYPE I	CORNEAL DYSTROPHY, LATTICE TYPE I; LCD1	122200
CDL1	CORNEAL DYSTROPHY, LATTICE TYPE I; LCD1	122200
EPITHELIAL RECURRENT EROSION DYSTROPHY; ERED	EPITHELIAL RECURRENT EROSION DYSTROPHY; ERED	122400
CORNEAL EROSIONS, RECURRING HEREDITARY	EPITHELIAL RECURRENT EROSION DYSTROPHY; ERED	122400
CORNEAL HYPESTHESIA, FAMILIAL	CORNEAL HYPESTHESIA, FAMILIAL	122450
TRIGEMINAL ANESTHESIA, FAMILIAL	CORNEAL HYPESTHESIA, FAMILIAL	122450
HUMAN CORONAVIRUS SENSITIVITY; HCVS	HUMAN CORONAVIRUS SENSITIVITY; HCVS	122460
CORONAVIRUS 229E SUSCEPTIBILITY; CVS	HUMAN CORONAVIRUS SENSITIVITY; HCVS	122460
CORNELIA DE LANGE SYNDROME 1; CDLS1	CORNELIA DE LANGE SYNDROME 1; CDLS1	122470
CDL; CDLS	CORNELIA DE LANGE SYNDROME 1; CDLS1	122470
TYPUS DEGENERATIVUS AMSTELODAMENSIS	CORNELIA DE LANGE SYNDROME 1; CDLS1	122470
DE LANGE SYNDROME	CORNELIA DE LANGE SYNDROME 1; CDLS1	122470
BRACHMANN-DE LANGE SYNDROME; BDLS	CORNELIA DE LANGE SYNDROME 1; CDLS1	122470
SPONDYLOCOSTAL DYSOSTOSIS 5; SCDO5	SPONDYLOCOSTAL DYSOSTOSIS 5; SCDO5	122600
SPONDYLOCOSTAL DYSPLASIA	SPONDYLOCOSTAL DYSOSTOSIS 5; SCDO5	122600
SPONDYLOTHORACIC DYSOSTOSIS	SPONDYLOCOSTAL DYSOSTOSIS 5; SCDO5	122600
COSTOVERTEBRAL SEGMENTATION ANOMALIESPOLYDYSSPONDYLY, INCLUDED	SPONDYLOCOSTAL DYSOSTOSIS 5; SCDO5	122600
COUMARIN RESISTANCE	COUMARIN RESISTANCE	122700
COUMARIN, POOR METABOLISM OF	COUMARIN RESISTANCE	122700
WARFARIN RESISTANCECOUMARIN SENSITIVITY, INCLUDED	COUMARIN RESISTANCE	122700
WARFARIN SENSITIVITY, INCLUDED	COUMARIN RESISTANCE	122700
CYTOCHROME P450, SUBFAMILY IIA, POLYPEPTIDE 6; CYP2A6	CYTOCHROME P450, SUBFAMILY IIA, POLYPEPTIDE 6; CYP2A6	122720
COUMARIN 7-HYDROXYLASE	CYTOCHROME P450, SUBFAMILY IIA, POLYPEPTIDE 6; CYP2A6	122720
CYTOCHROME P450, PHENOBARBITAL-INDUCIBLE; P450PB	CYTOCHROME P450, SUBFAMILY IIA, POLYPEPTIDE 6; CYP2A6	122720
CYP2A3, FORMERLYTEGAFUR, POOR METABOLISM OF, INCLUDED	CYTOCHROME P450, SUBFAMILY IIA, POLYPEPTIDE 6; CYP2A6	122720
COXA VARA	COXA VARA	122750
CRANIODIAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CDD	CRANIODIAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CDD	122860
CRANIOFACIAL-DEAFNESS-HAND SYNDROME; CDHS	CRANIOFACIAL-DEAFNESS-HAND SYNDROME; CDHS	122880
CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CMDD	CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CMDD	123000
CMD	CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CMDD	123000
CRANIOMETAPHYSEAL DYSPLASIA, JACKSON TYPE; CMDJ	CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CMDD	123000
CRANIOSYNOSTOSIS 1; CRS1	CRANIOSYNOSTOSIS 1; CRS1	123100
CRS	CRANIOSYNOSTOSIS 1; CRS1	123100
CRANIOSTENOSIS	CRANIOSYNOSTOSIS 1; CRS1	123100
JACKSON-WEISS SYNDROME; JWS	JACKSON-WEISS SYNDROME; JWS	123150
CRANIOSYNOSTOSIS, MIDFACIAL HYPOPLASIA, AND FOOT ABNORMALITIES	JACKSON-WEISS SYNDROME; JWS	123150
HYDROCEPHALUS, AUTOSOMAL DOMINANT; HDCPH1	HYDROCEPHALUS, AUTOSOMAL DOMINANT; HDCPH1	123155
CREATINE PHOSPHOKINASE, ELEVATED SERUM	CREATINE PHOSPHOKINASE, ELEVATED SERUM	123320
CPK, ELEVATED SERUM	CREATINE PHOSPHOKINASE, ELEVATED SERUM	123320
HYPERCKEMIA, IDIOPATHIC	CREATINE PHOSPHOKINASE, ELEVATED SERUM	123320
CREUTZFELDT-JAKOB DISEASE; CJD	CREUTZFELDT-JAKOB DISEASE; CJD	123400
CREUTZFELDT-JAKOB DISEASE, FAMILIALCREUTZFELDT-JAKOB DISEASE, SPORADIC, INCLUDED; sCJD, INCLUDED	CREUTZFELDT-JAKOB DISEASE; CJD	123400
CREUTZFELDT-JAKOB DISEASE, VARIANT, INCLUDED; vCJD, INCLUDED	CREUTZFELDT-JAKOB DISEASE; CJD	123400
CREUTZFELDT-JAKOB DISEASE, HEIDENHAIN VARIANT, INCLUDED	CREUTZFELDT-JAKOB DISEASE; CJD	123400
CRI-DU-CHAT SYNDROME	CRI-DU-CHAT SYNDROME	123450
CAT CRY SYNDROME	CRI-DU-CHAT SYNDROME	123450
CHROMOSOME 5p DELETION SYNDROME	CRI-DU-CHAT SYNDROME	123450
CROUZON SYNDROME	CROUZON SYNDROME	123500
CRANIOFACIAL DYSOSTOSIS, TYPE I; CFD1	CROUZON SYNDROME	123500
CROUZON CRANIOFACIAL DYSOSTOSIS	CROUZON SYNDROME	123500
CRYOGLOBULINEMIA, FAMILIAL MIXED	CRYOGLOBULINEMIA, FAMILIAL MIXED	123550
MELTZER SYNDROME	CRYOGLOBULINEMIA, FAMILIAL MIXED	123550
CRYPTOPHTHALMOS, UNILATERAL OR BILATERAL, ISOLATED	CRYPTOPHTHALMOS, UNILATERAL OR BILATERAL, ISOLATED	123570
ANKYLOBLEPHARON, SIMPLE	CRYPTOPHTHALMOS, UNILATERAL OR BILATERAL, ISOLATED	123570
CRYPTOPHTHALMOS WITH MICROPHTHALMIA AND PETERS ANOMALY	CRYPTOPHTHALMOS, UNILATERAL OR BILATERAL, ISOLATED	123570
CUTIS LAXA, AUTOSOMAL DOMINANT 1; ADCL1	CUTIS LAXA, AUTOSOMAL DOMINANT 1; ADCL1	123700
BEARE-STEVENSON CUTIS GYRATA SYNDROME; BSTVS	BEARE-STEVENSON CUTIS GYRATA SYNDROME; BSTVS	123790
BEARE-STEVENSON SYNDROME	BEARE-STEVENSON CUTIS GYRATA SYNDROME; BSTVS	123790
CUTIS GYRATA SYNDROME OF BEARE AND STEVENSON	BEARE-STEVENSON CUTIS GYRATA SYNDROME; BSTVS	123790
MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 1; MC3DN1	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 1; MC3DN1	124000
CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 2; CYP1A2	CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 2; CYP1A2	124060
CYTOCHROME P-450, AROMATIC COMPOUND-INDUCIBLE	CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 2; CYP1A2	124060
DIOXIN-INDUCIBLE P3-450PHENACETIN METABOLISM, DEFECT IN, INCLUDED	CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 2; CYP1A2	124060
PHENACETIN O-DEETHYLASE, DEFICIENCY OF, INCLUDED	CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 2; CYP1A2	124060
DARIER-WHITE DISEASE; DAR	DARIER-WHITE DISEASE; DAR	124200
KERATOSIS FOLLICULARIS	DARIER-WHITE DISEASE; DAR	124200
DARIER DISEASE; DDDARIER DISEASE, ACRAL HEMORRHAGIC TYPE, INCLUDED	DARIER-WHITE DISEASE; DAR	124200
DARIER DISEASE, SEGMENTAL, INCLUDED	DARIER-WHITE DISEASE; DAR	124200
DARWINIAN TUBERCLE OF PINNA	DARWINIAN TUBERCLE OF PINNA	124300
DARWINIAN POINT OF PINNADARWINIAN NOTCH, INCLUDED	DARWINIAN TUBERCLE OF PINNA	124300
DEAFNESS, CONGENITAL, AND ONYCHODYSTROPHY, AUTOSOMAL DOMINANT; DDOD	DEAFNESS, CONGENITAL, AND ONYCHODYSTROPHY, AUTOSOMAL DOMINANT; DDOD	124480
DDOD SYNDROME	DEAFNESS, CONGENITAL, AND ONYCHODYSTROPHY, AUTOSOMAL DOMINANT; DDOD	124480
DEAFNESS, CONGENITAL, WITH KERATOPACHYDERMIA AND CONSTRICTIONS OFFINGERS AND TOES	DEAFNESS, CONGENITAL, WITH KERATOPACHYDERMIA AND CONSTRICTIONS OFFINGERS AND TOES	124500
VOHWINKEL SYNDROME	DEAFNESS, CONGENITAL, WITH KERATOPACHYDERMIA AND CONSTRICTIONS OFFINGERS AND TOES	124500
MUTILATING KERATODERMA	DEAFNESS, CONGENITAL, WITH KERATOPACHYDERMIA AND CONSTRICTIONS OFFINGERS AND TOES	124500
KERATODERMA HEREDITARIUM MUTILANS; KHM	DEAFNESS, CONGENITAL, WITH KERATOPACHYDERMIA AND CONSTRICTIONS OFFINGERS AND TOES	124500
DEAFNESS, MID-TONE NEURAL	DEAFNESS, MID-TONE NEURAL	124700
DEAFNESS, AUTOSOMAL DOMINANT 1; DFNA1	DEAFNESS, AUTOSOMAL DOMINANT 1; DFNA1	124900
HEREDITARY LOW FREQUENCY HEARING LOSS; LFHL1	DEAFNESS, AUTOSOMAL DOMINANT 1; DFNA1	124900
DEAFNESS, PROGRESSIVE LOW TONE	DEAFNESS, AUTOSOMAL DOMINANT 1; DFNA1	124900
KONIGSMARK SYNDROME	DEAFNESS, AUTOSOMAL DOMINANT 1; DFNA1	124900
OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY,ATAXIA, AND NEUROPATHY	OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY,ATAXIA, AND NEUROPATHY	125250
DOMINANT OPTIC ATROPHY PLUS SYNDROME; DOA+	OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY,ATAXIA, AND NEUROPATHY	125250
DEFECTIVE INTERFERING PARTICLE INDUCTION, CONTROL OF	DEFECTIVE INTERFERING PARTICLE INDUCTION, CONTROL OF	125260
DIPI, CONTROL OF	DEFECTIVE INTERFERING PARTICLE INDUCTION, CONTROL OF	125260
HOMOLOGOUS VIRAL INTERFERENCE	DEFECTIVE INTERFERING PARTICLE INDUCTION, CONTROL OF	125260
VESICULAR STOMATITIS VIRUS DEFECTIVE INTERFERING PARTICLE REPRESSOR;VDI	DEFECTIVE INTERFERING PARTICLE INDUCTION, CONTROL OF	125260
CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL INFARCTSAND LEUKOENCEPHALOPATHY; CADASIL	CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL INFARCTSAND LEUKOENCEPHALOPATHY; CADASIL	125310
DEMENTIA, HEREDITARY MULTI-INFARCT TYPE	CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL INFARCTSAND LEUKOENCEPHALOPATHY; CADASIL	125310
CASIL	CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL INFARCTSAND LEUKOENCEPHALOPATHY; CADASIL	125310
FAILURE OF TOOTH ERUPTION, PRIMARY; PFE	FAILURE OF TOOTH ERUPTION, PRIMARY; PFE	125350
PRIMARY FAILURE OF ERUPTION, NONSYNDROMIC	FAILURE OF TOOTH ERUPTION, PRIMARY; PFE	125350
PRIMARY RETENTION OF TEETH	FAILURE OF TOOTH ERUPTION, PRIMARY; PFE	125350
UNERUPTED SECOND PRIMARY MOLAR	FAILURE OF TOOTH ERUPTION, PRIMARY; PFE	125350
POSTERIOR OPENBITE MALOCCLUSION, FAMILIAL	FAILURE OF TOOTH ERUPTION, PRIMARY; PFE	125350
DENTAL NONERUPTION	FAILURE OF TOOTH ERUPTION, PRIMARY; PFE	125350
DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA	DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA	125370
MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS	DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA	125370
NAITO-OYANAGI DISEASE; NOD	DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA	125370
HAW RIVER SYNDROME; HRS	DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA	125370
ATAXIA, CHOREA, SEIZURES, AND DEMENTIA	DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA	125370
DENTIN DYSPLASIA, TYPE I; DTDP1	DENTIN DYSPLASIA, TYPE I; DTDP1	125400
DENTIN DYSPLASIA, SHIELDS TYPE I	DENTIN DYSPLASIA, TYPE I; DTDP1	125400
ROOTLESS TEETH	DENTIN DYSPLASIA, TYPE I; DTDP1	125400
RADICULAR DENTIN DYSPLASIADENTIN DYSPLASIA, TYPE I, WITH EXTREME MICRODONTIA AND MISSHAPEN TEETH,INCLUDED	DENTIN DYSPLASIA, TYPE I; DTDP1	125400
DENTIN DYSPLASIA, TYPE II	DENTIN DYSPLASIA, TYPE II	125420
DTDP2	DENTIN DYSPLASIA, TYPE II	125420
DENTIN DYSPLASIA, SHIELDS TYPE II	DENTIN DYSPLASIA, TYPE II	125420
CORONAL DENTIN DYSPLASIA	DENTIN DYSPLASIA, TYPE II	125420
ANOMALOUS DYSPLASIA OF DENTIN	DENTIN DYSPLASIA, TYPE II	125420
PULPAL DYSPLASIA	DENTIN DYSPLASIA, TYPE II	125420
PULP STONES	DENTIN DYSPLASIA, TYPE II	125420
DENTIN DYSPLASIA WITH SCLEROTIC BONES	DENTIN DYSPLASIA WITH SCLEROTIC BONES	125440
MAJOR AFFECTIVE DISORDER 1; MAFD1	MAJOR AFFECTIVE DISORDER 1; MAFD1	125480
MANIC-DEPRESSIVE PSYCHOSIS; MD1	MAJOR AFFECTIVE DISORDER 1; MAFD1	125480
BIPOLAR AFFECTIVE DISORDER; BPAD	MAJOR AFFECTIVE DISORDER 1; MAFD1	125480
MANIC-DEPRESSIVE PSYCHOSIS, AUTOSOMAL	MAJOR AFFECTIVE DISORDER 1; MAFD1	125480
DENTINOGENESIS IMPERFECTA 1; DGI1	DENTINOGENESIS IMPERFECTA 1; DGI1	125490
OPALESCENT DENTIN	DENTINOGENESIS IMPERFECTA 1; DGI1	125490
DENTINOGENESIS IMPERFECTA WITHOUT OSTEOGENESIS IMPERFECTA	DENTINOGENESIS IMPERFECTA 1; DGI1	125490
OPALESCENT TEETH WITHOUT OSTEOGENESIS IMPERFECTA	DENTINOGENESIS IMPERFECTA 1; DGI1	125490
DENTINOGENESIS IMPERFECTA, SHIELDS TYPE II	DENTINOGENESIS IMPERFECTA 1; DGI1	125490
DGI-II	DENTINOGENESIS IMPERFECTA 1; DGI1	125490
CAPDEPONT TEETH	DENTINOGENESIS IMPERFECTA 1; DGI1	125490
DENTINOGENESIS IMPERFECTA, SHIELDS TYPE III	DENTINOGENESIS IMPERFECTA, SHIELDS TYPE III	125500
DGI-III	DENTINOGENESIS IMPERFECTA, SHIELDS TYPE III	125500
BRANDYWINE TYPE DENTINOGENESIS IMPERFECTA	DENTINOGENESIS IMPERFECTA, SHIELDS TYPE III	125500
CAYLER CARDIOFACIAL SYNDROME	CAYLER CARDIOFACIAL SYNDROME	125520
DEPRESSOR ANGULI ORIS MUSCLE, HYPOPLASIA OF	CAYLER CARDIOFACIAL SYNDROME	125520
ASYMMETRIC CRYING FACIES; ACF	CAYLER CARDIOFACIAL SYNDROME	125520
FACIAL PARESIS, PARTIAL, UNILATERAL	CAYLER CARDIOFACIAL SYNDROME	125520
DERMAL RIDGES, PATTERNLESS	DERMAL RIDGES, PATTERNLESS	125540
DERMAL RIDGES-OFF-THE-END; ROES	DERMAL RIDGES-OFF-THE-END; ROES	125550
RIDGES-OFF-THE-END SYNDROME	DERMAL RIDGES-OFF-THE-END; ROES	125550
DERMATOGLYPHICS--FINGERPRINT PATTERN	DERMATOGLYPHICS--FINGERPRINT PATTERN	125590
DERMATOPATHIA PIGMENTOSA RETICULARIS; DPR	DERMATOPATHIA PIGMENTOSA RETICULARIS; DPR	125595
DIABETES INSIPIDUS, NEUROHYPOPHYSEAL	DIABETES INSIPIDUS, NEUROHYPOPHYSEAL	125700
DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI	DIABETES INSIPIDUS, NEUROHYPOPHYSEAL	125700
DIABETES INSIPIDUS, CRANIAL TYPE	DIABETES INSIPIDUS, NEUROHYPOPHYSEAL	125700
DIABETES INSIPIDUS, NEPHROGENIC, AUTOSOMAL	DIABETES INSIPIDUS, NEPHROGENIC, AUTOSOMAL	125800
DIABETES INSIPIDUS, NEPHROGENIC, TYPE II	DIABETES INSIPIDUS, NEPHROGENIC, AUTOSOMAL	125800
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 1; MODY1	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 1; MODY1	125850
MODY, TYPE 1	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 1; MODY1	125850
MILD JUVENILE DIABETES MELLITUS	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 1; MODY1	125850
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 2; MODY2	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 2; MODY2	125851
MODY, TYPE 2	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 2; MODY2	125851
MODY, GLUCOKINASE-RELATED	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 2; MODY2	125851
DIABETES MELLITUS, INSULIN-DEPENDENT, 2	DIABETES MELLITUS, INSULIN-DEPENDENT, 2	125852
INSULIN-DEPENDENT DIABETES MELLITUS 2; IDDM2	DIABETES MELLITUS, INSULIN-DEPENDENT, 2	125852
DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM	DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM	125853
DIABETES MELLITUS, TYPE II; T2D	DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM	125853
NONINSULIN-DEPENDENT DIABETES MELLITUS	DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM	125853
MATURITY-ONSET DIABETESINSULIN RESISTANCE, SUSCEPTIBILITY TO, INCLUDED	DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM	125853
DIABETES MELLITUS, TYPE 2, PROTECTION AGAINST, INCLUDED	DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM	125853
NAD(P)H DEHYDROGENASE, QUINONE 1; NQO1	NAD(P)H DEHYDROGENASE, QUINONE 1; NQO1	125860
NAD(P)H:MENADIONE OXIDOREDUCTASE 1, DIOXIN-INDUCIBLE 1; NMOR1	NAD(P)H DEHYDROGENASE, QUINONE 1; NQO1	125860
DIAPHORASE 4; DIA4	NAD(P)H DEHYDROGENASE, QUINONE 1; NQO1	125860
DT DIAPHORASE; DTDBENZENE TOXICITY, SUSCEPTIBILITY TO, INCLUDED	NAD(P)H DEHYDROGENASE, QUINONE 1; NQO1	125860
LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED	NAD(P)H DEHYDROGENASE, QUINONE 1; NQO1	125860
BREAST CANCER, POST-CHEMOTHERAPY SURVIVAL IN, INCLUDED	NAD(P)H DEHYDROGENASE, QUINONE 1; NQO1	125860
DIGITOTALAR DYSMORPHISM	DIGITOTALAR DYSMORPHISM	126050
ULNAR DRIFT, HEREDITARY	DIGITOTALAR DYSMORPHISM	126050
DILUTION, PIGMENTARY	DILUTION, PIGMENTARY	126070
ALBINOIDISM, OCULOCUTANEOUS, AUTOSOMAL DOMINANT	DILUTION, PIGMENTARY	126070
ALBINISM, PARTIAL	DILUTION, PIGMENTARY	126070
HYPOPIGMENTATION	DILUTION, PIGMENTARY	126070
MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO; MS	MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO; MS	126200
DISSEMINATED SCLEROSISMULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 1, INCLUDED; MS1, INCLUDED	MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO; MS	126200
DISTICHIASIS	DISTICHIASIS	126300
EYELASHES, TWO ROWS OF	DISTICHIASIS	126300
DOPAMINE RECEPTOR D5; DRD5	DOPAMINE RECEPTOR D5; DRD5	126453
DOPAMINE RECEPTOR D1B; DRD1BDYSTONIA, PRIMARY CERVICAL, INCLUDED	DOPAMINE RECEPTOR D5; DRD5	126453
DOUGHNUT LESIONS OF SKULL, FAMILIAL	DOUGHNUT LESIONS OF SKULL, FAMILIAL	126550
DOYNE HONEYCOMB RETINAL DYSTROPHY; DHRD	DOYNE HONEYCOMB RETINAL DYSTROPHY; DHRD	126600
DOYNE HONEYCOMB DEGENERATION OF RETINA; DHDMALATTIA LEVENTINESE, INCLUDED; MLVT, INCLUDED	DOYNE HONEYCOMB RETINAL DYSTROPHY; DHRD	126600
DRUSEN, RADIAL, AUTOSOMAL DOMINANT, INCLUDED	DOYNE HONEYCOMB RETINAL DYSTROPHY; DHRD	126600
BASAL LAMINAR DRUSEN	BASAL LAMINAR DRUSEN	126700
DRUSEN OF BRUCH MEMBRANE	BASAL LAMINAR DRUSEN	126700
DRUSEN, CUTICULAR	BASAL LAMINAR DRUSEN	126700
DRUSEN, EARLY ADULT-ONSET, GROUPED	BASAL LAMINAR DRUSEN	126700
DUANE RETRACTION SYNDROME 1; DURS1	DUANE RETRACTION SYNDROME 1; DURS1	126800
DRS	DUANE RETRACTION SYNDROME 1; DURS1	126800
DUANE SYNDROME; DUS	DUANE RETRACTION SYNDROME 1; DURS1	126800
DUANE ANOMALY	DUANE RETRACTION SYNDROME 1; DURS1	126800
RETRACTION SYNDROME	DUANE RETRACTION SYNDROME 1; DURS1	126800
DUODENAL ULCER, HYPERPEPSINOGENEMIC I	DUODENAL ULCER, HYPERPEPSINOGENEMIC I	126850
DUPUYTREN CONTRACTUREDUPUYTREN CONTRACTURE 1, INCLUDED; DUPC1, INCLUDED	DUPUYTREN CONTRACTUREDUPUYTREN CONTRACTURE 1, INCLUDED; DUPC1, INCLUDED	126900
PLANTAR FIBROMAS, INCLUDED	DUPUYTREN CONTRACTUREDUPUYTREN CONTRACTURE 1, INCLUDED; DUPC1, INCLUDED	126900
PLANTAR FIBROMATOSIS, FAMILIAL, INCLUDED	DUPUYTREN CONTRACTUREDUPUYTREN CONTRACTURE 1, INCLUDED; DUPC1, INCLUDED	126900
KENNY-CAFFEY SYNDROME, TYPE 2; KCS2	KENNY-CAFFEY SYNDROME, TYPE 2; KCS2	127000
DWARFISM, CORTICAL THICKENING OF TUBULAR BONES, AND TRANSIENT HYPOCALCEMIA	KENNY-CAFFEY SYNDROME, TYPE 2; KCS2	127000
KENNY SYNDROME	KENNY-CAFFEY SYNDROME, TYPE 2; KCS2	127000
LERI-WEILL DYSCHONDROSTEOSIS; LWD	LERI-WEILL DYSCHONDROSTEOSIS; LWD	127300
DYSCHONDROSTEOSIS; DCOMADELUNG DEFORMITY, INCLUDED	LERI-WEILL DYSCHONDROSTEOSIS; LWD	127300
DYSCHROMATOSIS SYMMETRICA HEREDITARIA; DSH	DYSCHROMATOSIS SYMMETRICA HEREDITARIA; DSH	127400
DYSCHROMATOSIS SYMMETRICA HEREDITARIA 1; DSH1	DYSCHROMATOSIS SYMMETRICA HEREDITARIA; DSH	127400
RETICULATE ACROPIGMENTATION OF DOHI; RAD	DYSCHROMATOSIS SYMMETRICA HEREDITARIA; DSH	127400
SYMMETRIC DYSCHROMATOSIS OF THE EXTREMITIES	DYSCHROMATOSIS SYMMETRICA HEREDITARIA; DSH	127400
DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 1; DUH1	DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 1; DUH1	127500
DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1; DKCA1	DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1; DKCA1	127550
DYSKERATOSIS CONGENITA, SCOGGINS TYPE	DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1; DKCA1	127550
DYSKERATOSIS, HEREDITARY BENIGN INTRAEPITHELIAL; HBID	DYSKERATOSIS, HEREDITARY BENIGN INTRAEPITHELIAL; HBID	127600
DKBI	DYSKERATOSIS, HEREDITARY BENIGN INTRAEPITHELIAL; HBID	127600
DYSLEXIA, SUSCEPTIBILITY TO, 1; DYX1	DYSLEXIA, SUSCEPTIBILITY TO, 1; DYX1	127700
WORD-BLINDNESS, CONGENITAL	DYSLEXIA, SUSCEPTIBILITY TO, 1; DYX1	127700
READING DISABILITY, SPECIFIC, 1DYSLEXIA, SUSCEPTIBILITY TO, 4, INCLUDED; DYX4, INCLUDED	DYSLEXIA, SUSCEPTIBILITY TO, 1; DYX1	127700
DYSLEXIA, SUSCEPTIBILITY TO, 7, INCLUDED; DYX7, INCLUDED	DYSLEXIA, SUSCEPTIBILITY TO, 1; DYX1	127700
DEMENTIA, LEWY BODY; DLB	DEMENTIA, LEWY BODY; DLB	127750
LEWY BODY DEMENTIA	DEMENTIA, LEWY BODY; DLB	127750
DIFFUSE LEWY BODY DISEASEDIFFUSE LEWY BODY DISEASE WITH GAZE PALSY, INCLUDED	DEMENTIA, LEWY BODY; DLB	127750
LEWY BODY VARIANT OF ALZHEIMER DISEASE, INCLUDED	DEMENTIA, LEWY BODY; DLB	127750
DYSTELEPHALANGY	DYSTELEPHALANGY	128000
KIRNER DEFORMITY	DYSTELEPHALANGY	128000
DYSTONIA 1, TORSION, AUTOSOMAL DOMINANT; DYT1	DYSTONIA 1, TORSION, AUTOSOMAL DOMINANT; DYT1	128100
DYSTONIA MUSCULORUM DEFORMANS 1	DYSTONIA 1, TORSION, AUTOSOMAL DOMINANT; DYT1	128100
EARLY-ONSET TORSION DYSTONIA; EOTD	DYSTONIA 1, TORSION, AUTOSOMAL DOMINANT; DYT1	128100
DYSTONIA 4, TORSION, AUTOSOMAL DOMINANT; DYT4	DYSTONIA 4, TORSION, AUTOSOMAL DOMINANT; DYT4	128101
WHISPERING DYSPHONIA, HEREDITARY	DYSTONIA 4, TORSION, AUTOSOMAL DOMINANT; DYT4	128101
DYSTONIA MUSCULORUM DEFORMANS 4	DYSTONIA 4, TORSION, AUTOSOMAL DOMINANT; DYT4	128101
EPISODIC KINESIGENIC DYSKINESIA 1; EKD1	EPISODIC KINESIGENIC DYSKINESIA 1; EKD1	128200
PAROXYSMAL KINESIGENIC CHOREOATHETOSIS; PKC	EPISODIC KINESIGENIC DYSKINESIA 1; EKD1	128200
PAROXYSMAL KINESIGENIC DYSKINESIA; PKD	EPISODIC KINESIGENIC DYSKINESIA 1; EKD1	128200
DYSTONIA, FAMILIAL PAROXYSMAL	EPISODIC KINESIGENIC DYSKINESIA 1; EKD1	128200
DYSTONIA 10; DYT10	EPISODIC KINESIGENIC DYSKINESIA 1; EKD1	128200
DYSTONIA, DOPA-RESPONSIVE; DRD	DYSTONIA, DOPA-RESPONSIVE; DRD	128230
DYSTONIA 5; DYT5	DYSTONIA, DOPA-RESPONSIVE; DRD	128230
DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION	DYSTONIA, DOPA-RESPONSIVE; DRD	128230
DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION	DYSTONIA, DOPA-RESPONSIVE; DRD	128230
SEGAWA SYNDROME, AUTOSOMAL DOMINANT	DYSTONIA, DOPA-RESPONSIVE; DRD	128230
DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT	DYSTONIA, DOPA-RESPONSIVE; DRD	128230
DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT	DYSTONIA, DOPA-RESPONSIVE; DRD	128230
DYSTONIA 12; DYT12	DYSTONIA 12; DYT12	128235
DYSTONIA-PARKINSONISM, RAPID-ONSET; RDP	DYSTONIA 12; DYT12	128235
EAR MALFORMATION	EAR MALFORMATION	128600
CUP EAR	EAR MALFORMATION	128600
PREAURICULAR FISTULAE, CONGENITAL	PREAURICULAR FISTULAE, CONGENITAL	128700
PAFC	PREAURICULAR FISTULAE, CONGENITAL	128700
EAR PITS	PREAURICULAR FISTULAE, CONGENITAL	128700
EARLOBES, THICKENED, WITH CONDUCTIVE DEAFNESS FROM INCUDOSTAPEDIALABNORMALITIES	EARLOBES, THICKENED, WITH CONDUCTIVE DEAFNESS FROM INCUDOSTAPEDIALABNORMALITIES	128980
ECHO VIRUS 11 SENSITIVITY; E11S	ECHO VIRUS 11 SENSITIVITY; E11S	129150
ADERMATOGLYPHIA WITH CONGENITAL FACIAL MILIA AND ACRAL BLISTERS, DIGITALCONTRACTURES, AND NAIL ABNORMALITIES	ADERMATOGLYPHIA WITH CONGENITAL FACIAL MILIA AND ACRAL BLISTERS, DIGITALCONTRACTURES, AND NAIL ABNORMALITIES	129200
ECTODERMAL DYSPLASIA, ABSENT DERMATOGLYPHIC PATTERN, CHANGES IN NAILS,AND SIMIAN CREASE	ADERMATOGLYPHIA WITH CONGENITAL FACIAL MILIA AND ACRAL BLISTERS, DIGITALCONTRACTURES, AND NAIL ABNORMALITIES	129200
BASAN SYNDROME	ADERMATOGLYPHIA WITH CONGENITAL FACIAL MILIA AND ACRAL BLISTERS, DIGITALCONTRACTURES, AND NAIL ABNORMALITIES	129200
RAPP-HODGKIN SYNDROME; RHS	RAPP-HODGKIN SYNDROME; RHS	129400
ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH CLEFT LIP/PALATEOROFACIAL CLEFT 8, INCLUDED; OFC8, INCLUDED	RAPP-HODGKIN SYNDROME; RHS	129400
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 8, INCLUDED	RAPP-HODGKIN SYNDROME; RHS	129400
ECTODERMAL DYSPLASIA 10A, HYPOHIDROTIC/HAIR/NAIL TYPE, AUTOSOMAL DOMINANT;ECTD10A	ECTODERMAL DYSPLASIA 10A, HYPOHIDROTIC/HAIR/NAIL TYPE, AUTOSOMAL DOMINANT;ECTD10A	129490
ECTODERMAL DYSPLASIA, HYPOHIDROTIC, AUTOSOMAL DOMINANT; HED	ECTODERMAL DYSPLASIA 10A, HYPOHIDROTIC/HAIR/NAIL TYPE, AUTOSOMAL DOMINANT;ECTD10A	129490
CLOUSTON SYNDROME	CLOUSTON SYNDROME	129500
ECTODERMAL DYSPLASIA 2, CLOUSTON TYPE; ECTD2	CLOUSTON SYNDROME	129500
ECTODERMAL DYSPLASIA, HIDROTIC, AUTOSOMAL DOMINANT	CLOUSTON SYNDROME	129500
CLOUSTON HIDROTIC ECTODERMAL DYSPLASIA	CLOUSTON SYNDROME	129500
ECTODERMAL DYSPLASIA, HIDROTIC, 2, FORMERLY; HED2, FORMERLY	CLOUSTON SYNDROME	129500
ECTOPIA LENTIS 1, ISOLATED, AUTOSOMAL DOMINANT; ECTOL1	ECTOPIA LENTIS 1, ISOLATED, AUTOSOMAL DOMINANT; ECTOL1	129600
EDINBURGH MALFORMATION SYNDROME	EDINBURGH MALFORMATION SYNDROME	129850
ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME1; EEC1	ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME1; EEC1	129900
EEC	ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME1; EEC1	129900
EEC SYNDROME 1	ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME1; EEC1	129900
EHLERS-DANLOS SYNDROME, CLASSIC TYPE	EHLERS-DANLOS SYNDROME, CLASSIC TYPE	130000
EHLERS-DANLOS SYNDROME, TYPE I, FORMERLY; EDS1, FORMERLY	EHLERS-DANLOS SYNDROME, CLASSIC TYPE	130000
EHLERS-DANLOS SYNDROME, SEVERE CLASSIC TYPE, FORMERLY	EHLERS-DANLOS SYNDROME, CLASSIC TYPE	130000
EDS I, FORMERLY	EHLERS-DANLOS SYNDROME, CLASSIC TYPE	130000
EHLERS-DANLOS SYNDROME, GRAVIS TYPE, FORMERLY	EHLERS-DANLOS SYNDROME, CLASSIC TYPE	130000
EHLERS-DANLOS SYNDROME, TYPE II, FORMERLY; EDS2, FORMERLY	EHLERS-DANLOS SYNDROME, CLASSIC TYPE	130000
EHLERS DANLOS SYNDROME, MILD CLASSIC TYPE, FORMERLY	EHLERS-DANLOS SYNDROME, CLASSIC TYPE	130000
EDS II, FORMERLY	EHLERS-DANLOS SYNDROME, CLASSIC TYPE	130000
EHLERS DANLOS SYNDROME, MITIS TYPE, FORMERLY	EHLERS-DANLOS SYNDROME, CLASSIC TYPE	130000
EHLERS-DANLOS SYNDROME, HYPERMOBILITY TYPE	EHLERS-DANLOS SYNDROME, HYPERMOBILITY TYPE	130020
EHLERS-DANLOS SYNDROME, TYPE III; EDS3	EHLERS-DANLOS SYNDROME, HYPERMOBILITY TYPE	130020
EDS III	EHLERS-DANLOS SYNDROME, HYPERMOBILITY TYPE	130020
BENIGN HYPERMOBILITY SYNDROME	EHLERS-DANLOS SYNDROME, HYPERMOBILITY TYPE	130020
EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT	EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT	130050
EHLERS-DANLOS SYNDROME, VASCULAR TYPE	EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT	130050
EDS IV; EDS4	EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT	130050
EHLERS-DANLOS SYNDROME, ARTERIAL TYPE	EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT	130050
EHLERS-DANLOS SYNDROME, ECCHYMOTIC TYPE	EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT	130050
EHLERS-DANLOS SYNDROME, SACK-BARABAS TYPE	EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT	130050
EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL DOMINANT	EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL DOMINANT	130060
EHLERS-DANLOS SYNDROME, ARTHROCHALASIA TYPE	EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL DOMINANT	130060
EDS VIIA; EDS7A	EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL DOMINANT	130060
ARTHROCHALASIS MULTIPLEX CONGENITA	EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL DOMINANT	130060
EDS VII, MUTANT PROCOLLAGEN TYPEEDS VIIB, INCLUDED; EDS7B, INCLUDED	EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL DOMINANT	130060
EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 1; EDSP1	EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 1; EDSP1	130070
PROTEODERMATAN SULFATE, DEFECTIVE BIOSYNTHESIS OF	EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 1; EDSP1	130070
PDS, DEFECTIVE BIOSYNTHESIS OF	EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 1; EDSP1	130070
DERMATAN SULFATE PROTEOGLYCAN	EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 1; EDSP1	130070
XYLOSYLPROTEIN 4-BETA-GALACTOSYLTRANSFERASE DEFICIENCY	EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 1; EDSP1	130070
XGPT DEFICIENCY	EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 1; EDSP1	130070
GALACTOSYLTRANSFERASE I DEFICIENCY	EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 1; EDSP1	130070
EHLERS-DANLOS SYNDROME, TYPE VIII	EHLERS-DANLOS SYNDROME, TYPE VIII	130080
EHLERS-DANLOS SYNDROME, PERIODONTITIS TYPE	EHLERS-DANLOS SYNDROME, TYPE VIII	130080
EHLERS-DANLOS SYNDROME, PERIODONTOSIS TYPE	EHLERS-DANLOS SYNDROME, TYPE VIII	130080
EDS VIII	EHLERS-DANLOS SYNDROME, TYPE VIII	130080
EDS8	EHLERS-DANLOS SYNDROME, TYPE VIII	130080
ELECTROENCEPHALOGRAM, LOW-VOLTAGE	ELECTROENCEPHALOGRAM, LOW-VOLTAGE	130180
EEG, LOW-VOLTAGE; EEGL	ELECTROENCEPHALOGRAM, LOW-VOLTAGE	130180
ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1; EEGV1	ELECTROENCEPHALOGRAM, LOW-VOLTAGE	130180
ELECTROENCEPHALOGRAPHIC PATTERN, BETA FREQUENCY, QUANTITATIVE TRAITLOCUS; EEGBQTL	ELECTROENCEPHALOGRAPHIC PATTERN, BETA FREQUENCY, QUANTITATIVE TRAITLOCUS; EEGBQTL	130190
ELLIPTOCYTOSIS 2; EL2	ELLIPTOCYTOSIS 2; EL2	130600
ELLIPTOCYTOSIS, RHESUS-UNLINKED TYPE	ELLIPTOCYTOSIS 2; EL2	130600
BECKWITH-WIEDEMANN SYNDROME; BWS	BECKWITH-WIEDEMANN SYNDROME; BWS	130650
EXOMPHALOS-MACROGLOSSIA-GIGANTISM SYNDROME	BECKWITH-WIEDEMANN SYNDROME; BWS	130650
EMG SYNDROME	BECKWITH-WIEDEMANN SYNDROME; BWS	130650
WIEDEMANN-BECKWITH SYNDROME; WBSBECKWITH-WIEDEMANN SYNDROME CHROMOSOME REGION, INCLUDED; BWCR, INCLUDED	BECKWITH-WIEDEMANN SYNDROME; BWS	130650
LATERAL MENINGOCELE SYNDROME; LMNS	LATERAL MENINGOCELE SYNDROME; LMNS	130720
LMS	LATERAL MENINGOCELE SYNDROME; LMNS	130720
LEHMAN SYNDROME	LATERAL MENINGOCELE SYNDROME; LMNS	130720
AMELOGENESIS IMPERFECTA, TYPE III; AI3	AMELOGENESIS IMPERFECTA, TYPE III; AI3	130900
AMELOGENESIS IMPERFECTA, HYPOCALCIFICATION TYPE, AUTOSOMAL DOMINANT;ADHCAI	AMELOGENESIS IMPERFECTA, TYPE III; AI3	130900
AMELOGENESIS IMPERFECTA, HYPOMINERALIZATION TYPE	AMELOGENESIS IMPERFECTA, TYPE III; AI3	130900
MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1	MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1	131100
MEN I	MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1	131100
ENDOCRINE ADENOMATOSIS, MULTIPLE	MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1	131100
MEA I	MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1	131100
WERMER SYNDROMEMEN1 SOMATIC MUTATIONS, INCLUDED	MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1	131100
ENDOMETRIOSIS, SUSCEPTIBILITY TO, 1	ENDOMETRIOSIS, SUSCEPTIBILITY TO, 1	131200
ENDO1	ENDOMETRIOSIS, SUSCEPTIBILITY TO, 1	131200
ENDOTHELIN 1; EDN1	ENDOTHELIN 1; EDN1	131240
ET1HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS7, INCLUDED; HDLCQ7, INCLUDED	ENDOTHELIN 1; EDN1	131240
PREPROENDOTHELIN 1, INCLUDED	ENDOTHELIN 1; EDN1	131240
CAMURATI-ENGELMANN DISEASE; CAEND	CAMURATI-ENGELMANN DISEASE; CAEND	131300
CED	CAMURATI-ENGELMANN DISEASE; CAEND	131300
ENGELMANN DISEASE	CAMURATI-ENGELMANN DISEASE; CAEND	131300
DIAPHYSEAL DYSPLASIA 1, PROGRESSIVE; DPD1	CAMURATI-ENGELMANN DISEASE; CAEND	131300
PROGRESSIVE DIAPHYSEAL DYSPLASIA; PDD	CAMURATI-ENGELMANN DISEASE; CAEND	131300
EOSINOPHILIA, FAMILIAL	EOSINOPHILIA, FAMILIAL	131400
EOS	EOSINOPHILIA, FAMILIAL	131400
MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA	MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA	131440
MPE; EMP	MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA	131440
EOSINOPHILS, MALIGNANT PROLIFERATION OF	MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA	131440
EPICANTHUS	EPICANTHUS	131500
TRANSIENT BULLOUS DERMOLYSIS OF THE NEWBORN; TBDN	TRANSIENT BULLOUS DERMOLYSIS OF THE NEWBORN; TBDN	131705
EPIDERMOLYSIS BULLOSA DYSTROPHICA, NEONATAL FORM	TRANSIENT BULLOUS DERMOLYSIS OF THE NEWBORN; TBDN	131705
DYSTROPHIC EPIDERMOLYSIS BULLOSA, NEONATAL	TRANSIENT BULLOUS DERMOLYSIS OF THE NEWBORN; TBDN	131705
EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT; DDEB	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT; DDEB	131750
DYSTROPHIC EPIDERMOLYSIS BULLOSA, AUTOSOMAL DOMINANT	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT; DDEB	131750
EPIDERMOLYSIS BULLOSA DYSTROPHICA, COCKAYNE-TOURAINE TYPE; EBDCT	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT; DDEB	131750
EPIDERMOLYSIS BULLOSA DYSTROPHICA, PASINI TYPE	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT; DDEB	131750
ALBOPAPULOID DOMINANT DYSTROPHIC EPIDERMOLYSIS BULLOSA; EBDDEPIDERMOLYSIS BULLOSA DYSTROPHICA WITH SUBCORNEAL CLEAVAGE, INCLUDED;EBDSC, INCLUDED	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT; DDEB	131750
EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA TYPE; EBSDM	EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA TYPE; EBSDM	131760
EPIDERMOLYSIS BULLOSA HERPETIFORMIS, DOWLING-MEARA TYPE	EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA TYPE; EBSDM	131760
EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED SEVERE	EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA TYPE; EBSDM	131760
EPIDERMOLYSIS BULLOSA SIMPLEX, LOCALIZED	EPIDERMOLYSIS BULLOSA SIMPLEX, LOCALIZED	131800
EPIDERMOLYSIS BULLOSA SIMPLEX, WEBER-COCKAYNE TYPE	EPIDERMOLYSIS BULLOSA SIMPLEX, LOCALIZED	131800
EPIDERMOLYSIS BULLOSA OF HANDS AND FEET	EPIDERMOLYSIS BULLOSA SIMPLEX, LOCALIZED	131800
EBS, ACRAL FORM	EPIDERMOLYSIS BULLOSA SIMPLEX, LOCALIZED	131800
EPIDERMOLYSIS BULLOSA DYSTROPHICA, PRETIBIAL	EPIDERMOLYSIS BULLOSA DYSTROPHICA, PRETIBIAL	131850
DYSTROPHIC EPIDERMOLYSIS BULLOSA, PRETIBIAL	EPIDERMOLYSIS BULLOSA DYSTROPHICA, PRETIBIAL	131850
DEB, PRETIBIAL	EPIDERMOLYSIS BULLOSA DYSTROPHICA, PRETIBIAL	131850
EPIDERMOLYSIS BULLOSA, PRETIBIAL	EPIDERMOLYSIS BULLOSA DYSTROPHICA, PRETIBIAL	131850
EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED	EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED	131900
EBS, GENERALIZED	EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED	131900
EPIDERMOLYSIS BULLOSA SIMPLEX, KOEBNER TYPE	EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED	131900
EPIDERMOLYSIS BULLOSA SIMPLEX, OGNA TYPE; EBSOG	EPIDERMOLYSIS BULLOSA SIMPLEX, OGNA TYPE; EBSOG	131950
EPIDERMOLYSIS BULLOSA SIMPLEX WITH MOTTLED PIGMENTATION; EBSMP	EPIDERMOLYSIS BULLOSA SIMPLEX WITH MOTTLED PIGMENTATION; EBSMP	131960
SPECKLED HYPERPIGMENTATION WITH PUNCTATE PALMOPLANTAR KERATOSES ANDCHILDHOOD BLISTERING	EPIDERMOLYSIS BULLOSA SIMPLEX WITH MOTTLED PIGMENTATION; EBSMP	131960
EPIDERMOLYSIS BULLOSA WITH CONGENITAL LOCALIZED ABSENCE OF SKIN ANDDEFORMITY OF NAILS	EPIDERMOLYSIS BULLOSA WITH CONGENITAL LOCALIZED ABSENCE OF SKIN ANDDEFORMITY OF NAILS	132000
EPIDERMOLYSIS BULLOSA DYSTROPHICA, BART TYPE	EPIDERMOLYSIS BULLOSA WITH CONGENITAL LOCALIZED ABSENCE OF SKIN ANDDEFORMITY OF NAILS	132000
PHOTOPAROXYSMAL RESPONSE 1; PPR1	PHOTOPAROXYSMAL RESPONSE 1; PPR1	132100
PPR	PHOTOPAROXYSMAL RESPONSE 1; PPR1	132100
PHOTOSENSITIVITY	PHOTOPAROXYSMAL RESPONSE 1; PPR1	132100
PHOTOCONVULSIVE REACTION	PHOTOPAROXYSMAL RESPONSE 1; PPR1	132100
EPILEPSY, PHOTOGENIC	PHOTOPAROXYSMAL RESPONSE 1; PPR1	132100
EPIPHYSEAL DYSPLASIA, MULTIPLE, 1; EDM1	EPIPHYSEAL DYSPLASIA, MULTIPLE, 1; EDM1	132400
MULTIPLE EPIPHYSEAL DYSPLASIA, COMP-RELATEDEPIPHYSEAL DYSPLASIA, FAIRBANK TYPE, INCLUDED	EPIPHYSEAL DYSPLASIA, MULTIPLE, 1; EDM1	132400
EPIPHYSEAL DYSPLASIA, RIBBING TYPE, INCLUDED	EPIPHYSEAL DYSPLASIA, MULTIPLE, 1; EDM1	132400
EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH MYOPIA AND CONDUCTIVE DEAFNESS;EDMMD	EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH MYOPIA AND CONDUCTIVE DEAFNESS;EDMMD	132450
PILOMATRIXOMA	PILOMATRIXOMA	132600
PILOMATRICOMA; PTR	PILOMATRIXOMA	132600
EPITHELIOMA CALCIFICANS OF MALHERBE	PILOMATRIXOMA	132600
CYLINDROMATOSIS, FAMILIAL	CYLINDROMATOSIS, FAMILIAL	132700
ANCELL-SPIEGLER CYLINDROMAS	CYLINDROMATOSIS, FAMILIAL	132700
'TURBAN TUMOR' SYNDROME	CYLINDROMATOSIS, FAMILIAL	132700
CYLINDROMAS, DERMAL ECCRINE	CYLINDROMATOSIS, FAMILIAL	132700
MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO; MSSE	MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO; MSSE	132800
FERGUSON-SMITH TYPE EPITHELIOMA	MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO; MSSE	132800
ESS1, FORMERLY	MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO; MSSE	132800
EPOXIDE HYDROLASE 1, MICROSOMAL; EPHX1	EPOXIDE HYDROLASE 1, MICROSOMAL; EPHX1	132810
EPOXIDE HYDROLASE; EPHX	EPOXIDE HYDROLASE 1, MICROSOMAL; EPHX1	132810
EPOXIDE HYDROLASE, MICROSOMAL XENOBIOTIC; EPOXPHENYTOIN TOXICITY, INCLUDED	EPOXIDE HYDROLASE 1, MICROSOMAL; EPHX1	132810
ARENE OXIDE DETOXIFICATION DEFECT, INCLUDED	EPOXIDE HYDROLASE 1, MICROSOMAL; EPHX1	132810
FETAL HYDANTOIN SYNDROME, INCLUDED; FHS, INCLUDED	EPOXIDE HYDROLASE 1, MICROSOMAL; EPHX1	132810
DIPHENYLHYDANTOIN, DEFECT IN HYDROXYLATION OF, INCLUDED	EPOXIDE HYDROLASE 1, MICROSOMAL; EPHX1	132810
LYMPHOPROLIFERATIVE DISORDERS, SUSCEPTIBILITY TO, INCLUDED	EPOXIDE HYDROLASE 1, MICROSOMAL; EPHX1	132810
AORTIC ANEURYSM, FAMILIAL THORACIC 4; AAT4	AORTIC ANEURYSM, FAMILIAL THORACIC 4; AAT4	132900
FAA4	AORTIC ANEURYSM, FAMILIAL THORACIC 4; AAT4	132900
AORTIC ANEURYSM/AORTIC DISSECTION AND PATENT DUCTUS ARTERIOSUS	AORTIC ANEURYSM, FAMILIAL THORACIC 4; AAT4	132900
ERYTHEMA PALMARE HEREDITARIUM	ERYTHEMA PALMARE HEREDITARIUM	133000
ERYTHERMALGIA, PRIMARY	ERYTHERMALGIA, PRIMARY	133020
ERYTHROMELALGIA, PRIMARY	ERYTHERMALGIA, PRIMARY	133020
ERYTHROMELALGIA, FAMILIALNEUROPATHY, SMALL FIBER, INCLUDED; SFNP, INCLUDED	ERYTHERMALGIA, PRIMARY	133020
ERYTHROCYTOSIS, FAMILIAL, 1; ECYT1	ERYTHROCYTOSIS, FAMILIAL, 1; ECYT1	133100
POLYCYTHEMIA, PRIMARY FAMILIAL AND CONGENITAL; PFCP	ERYTHROCYTOSIS, FAMILIAL, 1; ECYT1	133100
ERYTHROCYTOSIS, AUTOSOMAL DOMINANT BENIGN	ERYTHROCYTOSIS, FAMILIAL, 1; ECYT1	133100
SPINOCEREBELLAR ATAXIA 34; SCA34	SPINOCEREBELLAR ATAXIA 34; SCA34	133190
ERYTHROKERATODERMIA WITH ATAXIA	SPINOCEREBELLAR ATAXIA 34; SCA34	133190
ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA; EKVP	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA; EKVP	133200
ERYTHROKERATODERMIA VARIABILIS; EKV	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA; EKVP	133200
ERYTHROKERATODERMIA, PROGRESSIVE SYMMETRIC; PSEK	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA; EKVP	133200
ERYTHROKERATODERMIA FIGURATA, CONGENITAL FAMILIAL, IN PLAQUES	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA; EKVP	133200
ERYTHROKERATODERMIA VARIABILIS WITH ERYTHEMA GYRATUM REPENSGREITHER DISEASE, INCLUDED	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA; EKVP	133200
KERATOSIS PALMOPLANTARIS TRANSGREDIENS ET PROGREDIENS, INCLUDED	ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA; EKVP	133200
ESOPHAGEAL CANCERESOPHAGEAL SQUAMOUS CELL CARCINOMA, SUSCEPTIBILITY TO, INCLUDED	ESOPHAGEAL CANCERESOPHAGEAL SQUAMOUS CELL CARCINOMA, SUSCEPTIBILITY TO, INCLUDED	133239
ESCC, SUSCEPTIBILITY TO, INCLUDED	ESOPHAGEAL CANCERESOPHAGEAL SQUAMOUS CELL CARCINOMA, SUSCEPTIBILITY TO, INCLUDED	133239
AERODIGESTIVE TRACT CANCER, SUSCEPTIBILITY TO, INCLUDED	ESOPHAGEAL CANCERESOPHAGEAL SQUAMOUS CELL CARCINOMA, SUSCEPTIBILITY TO, INCLUDED	133239
GASTRIC CARDIA ADENOCARCINOMA, SUSCEPTIBILITY TO, INCLUDED	ESOPHAGEAL CANCERESOPHAGEAL SQUAMOUS CELL CARCINOMA, SUSCEPTIBILITY TO, INCLUDED	133239
ESTROGEN RECEPTOR 1; ESR1	ESTROGEN RECEPTOR 1; ESR1	133430
ESTROGEN RECEPTOR; ESR; ER	ESTROGEN RECEPTOR 1; ESR1	133430
ESTROGEN RECEPTOR, ALPHA; ESRAHDL CHOLESTEROL, AUGMENTED RESPONSE OF, TO HORMONE REPLACEMENT, INCLUDED	ESTROGEN RECEPTOR 1; ESR1	133430
ATHEROSCLEROSIS, SUSCEPTIBILITY TO, INCLUDED	ESTROGEN RECEPTOR 1; ESR1	133430
EXCHONDROSIS OF PINNA, POSTERIOR	EXCHONDROSIS OF PINNA, POSTERIOR	133500
EAR BUMP	EXCHONDROSIS OF PINNA, POSTERIOR	133500
COCKAYNE SYNDROME B; CSB	COCKAYNE SYNDROME B; CSB	133540
EXOSTOSES, MULTIPLE, TYPE I	EXOSTOSES, MULTIPLE, TYPE I	133700
EXT; EXT1	EXOSTOSES, MULTIPLE, TYPE I	133700
MULTIPLE CARTILAGINOUS EXOSTOSES	EXOSTOSES, MULTIPLE, TYPE I	133700
DIAPHYSEAL ACLASIS	EXOSTOSES, MULTIPLE, TYPE I	133700
MULTIPLE OSTEOCHONDROMAS	EXOSTOSES, MULTIPLE, TYPE I	133700
OSTEOCHONDROMATOSIS	EXOSTOSES, MULTIPLE, TYPE I	133700
EXOSTOSES, MULTIPLE, TYPE II	EXOSTOSES, MULTIPLE, TYPE II	133701
EXT2	EXOSTOSES, MULTIPLE, TYPE II	133701
EXUDATIVE VITREORETINOPATHY 1; EVR1	EXUDATIVE VITREORETINOPATHY 1; EVR1	133780
EXUDATIVE VITREORETINOPATHY, FAMILIAL, AUTOSOMAL DOMINANT	EXUDATIVE VITREORETINOPATHY 1; EVR1	133780
FEVR, AUTOSOMAL DOMINANT	EXUDATIVE VITREORETINOPATHY 1; EVR1	133780
CRISWICK-SCHEPENS SYNDROMERETINOPATHY OF PREMATURITY, INCLUDED; ROP, INCLUDED	EXUDATIVE VITREORETINOPATHY 1; EVR1	133780
FACIAL PALSY, FAMILIAL RECURRENT PERIPHERAL	FACIAL PALSY, FAMILIAL RECURRENT PERIPHERAL	134200
FANCONI RENOTUBULAR SYNDROME 1; FRTS1	FANCONI RENOTUBULAR SYNDROME 1; FRTS1	134600
FANCONI RENOTUBULAR SYNDROME; FRTS	FANCONI RENOTUBULAR SYNDROME 1; FRTS1	134600
RENAL FANCONI SYNDROME; RFS	FANCONI RENOTUBULAR SYNDROME 1; FRTS1	134600
ADULT FANCONI SYNDROME	FANCONI RENOTUBULAR SYNDROME 1; FRTS1	134600
FANCONI SYNDROME WITHOUT CYSTINOSIS	FANCONI RENOTUBULAR SYNDROME 1; FRTS1	134600
LUDER-SHELDON SYNDROME	FANCONI RENOTUBULAR SYNDROME 1; FRTS1	134600
FAMILIAL MEDITERRANEAN FEVER, AUTOSOMAL DOMINANT	FAMILIAL MEDITERRANEAN FEVER, AUTOSOMAL DOMINANT	134610
FMF, AUTOSOMAL DOMINANT	FAMILIAL MEDITERRANEAN FEVER, AUTOSOMAL DOMINANT	134610
FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FOP	FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FOP	135100
BIRT-HOGG-DUBE SYNDROME; BHD	BIRT-HOGG-DUBE SYNDROME; BHD	135150
HORNSTEIN-KNICKENBERG SYNDROME	BIRT-HOGG-DUBE SYNDROME; BHD	135150
FIBROFOLLICULOMAS WITH TRICHODISCOMAS AND ACROCHORDONS	BIRT-HOGG-DUBE SYNDROME; BHD	135150
DESMOID DISEASE, HEREDITARY	DESMOID DISEASE, HEREDITARY	135290
FIBROMATOSIS, FAMILIAL INFILTRATIVE; FIFDESMOID TUMOR CAUSED BY SOMATIC MUTATION, INCLUDED	DESMOID DISEASE, HEREDITARY	135290
FIBROMATOSIS, GINGIVAL, 1; GINGF1	FIBROMATOSIS, GINGIVAL, 1; GINGF1	135300
GINGF	FIBROMATOSIS, GINGIVAL, 1; GINGF1	135300
GGF1	FIBROMATOSIS, GINGIVAL, 1; GINGF1	135300
FIBROMATOSIS, GINGIVAL, HEREDITARY; HGF	FIBROMATOSIS, GINGIVAL, 1; GINGF1	135300
HYPERTRICHOSIS, CONGENITAL GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA;HTC3	HYPERTRICHOSIS, CONGENITAL GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA;HTC3	135400
FIBROMATOSIS, GINGIVAL, WITH HYPERTRICHOSIS	HYPERTRICHOSIS, CONGENITAL GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA;HTC3	135400
CHROMOSOME 17q24.2-q24.3 DELETION SYNDROME	HYPERTRICHOSIS, CONGENITAL GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA;HTC3	135400
CHROMOSOME 17q24.2-q24.3 DUPLICATION SYNDROME	HYPERTRICHOSIS, CONGENITAL GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA;HTC3	135400
MICRODELETION 17q24.2-q24.3 SYNDROME	HYPERTRICHOSIS, CONGENITAL GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA;HTC3	135400
MICRODUPLICATION 17q24.2-q24.3 SYNDROME	HYPERTRICHOSIS, CONGENITAL GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA;HTC3	135400
HYPERTRICHOSIS TERMINALIS, GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA	HYPERTRICHOSIS, CONGENITAL GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA;HTC3	135400
ZIMMERMANN-LABAND SYNDROME 1; ZLS1	ZIMMERMANN-LABAND SYNDROME 1; ZLS1	135500
LABAND SYNDROME	ZIMMERMANN-LABAND SYNDROME 1; ZLS1	135500
FIBROMATOSIS, GINGIVAL, WITH ABNORMAL FINGERS, FINGERNAILS, NOSE,AND EARS, AND SPLENOMEGALY	ZIMMERMANN-LABAND SYNDROME 1; ZLS1	135500
FIBROMATOSIS, GINGIVAL, WITH PROGRESSIVE DEAFNESS	FIBROMATOSIS, GINGIVAL, WITH PROGRESSIVE DEAFNESS	135550
GINGIVAL FIBROMATOSIS WITH SENSORINEURAL HEARING LOSS; GFD	FIBROMATOSIS, GINGIVAL, WITH PROGRESSIVE DEAFNESS	135550
JONES SYNDROME	FIBROMATOSIS, GINGIVAL, WITH PROGRESSIVE DEAFNESS	135550
FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 1; CFEOM1	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 1; CFEOM1	135700
OPHTHALMOPLEGIA, CONGENITAL	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 1; CFEOM1	135700
BLEPHAROPTOSIS WITH ABSENT EYE MOVEMENTS	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 1; CFEOM1	135700
FEOM1 LOCUSFIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3B, INCLUDED; CFEOM3B,INCLUDED	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 1; CFEOM1	135700
LAURIN-SANDROW SYNDROME; LSS	LAURIN-SANDROW SYNDROME; LSS	135750
SANDROW SYNDROME	LAURIN-SANDROW SYNDROME; LSS	135750
MIRROR HANDS AND FEET WITH NASAL DEFECTS	LAURIN-SANDROW SYNDROME; LSS	135750
TETRAMELIC MIRROR-IMAGE POLYDACTYLY; TMIP	LAURIN-SANDROW SYNDROME; LSS	135750
MIRROR-IMAGE POLYDACTYLY; MIP	LAURIN-SANDROW SYNDROME; LSS	135750
FIBULA AND ULNA, DUPLICATION OF, WITH ABSENCE OF TIBIA AND RADIUSLAURIN-SANDROW SYNDROME, SEGMENTAL, INCLUDED	LAURIN-SANDROW SYNDROME; LSS	135750
COFFIN-SIRIS SYNDROME; CSS	COFFIN-SIRIS SYNDROME; CSS	135900
FIFTH DIGIT SYNDROME	COFFIN-SIRIS SYNDROME; CSS	135900
ADERMATOGLYPHIA; ADERM	ADERMATOGLYPHIA; ADERM	136000
FINGERPRINTS, ABSENCE OF	ADERMATOGLYPHIA; ADERM	136000
FISH-EYE DISEASE; FED	FISH-EYE DISEASE; FED	136120
DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY	FISH-EYE DISEASE; FED	136120
ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY	FISH-EYE DISEASE; FED	136120
ALPHA-LCAT DEFICIENCY	FISH-EYE DISEASE; FED	136120
LCATA DEFICIENCY	FISH-EYE DISEASE; FED	136120
FLOATING-HARBOR SYNDROME; FLHS	FLOATING-HARBOR SYNDROME; FLHS	136140
FLYNN-AIRD SYNDROME	FLYNN-AIRD SYNDROME	136300
FOCAL FACIAL DERMAL DYSPLASIA 1, BRAUER TYPE; FFDD1	FOCAL FACIAL DERMAL DYSPLASIA 1, BRAUER TYPE; FFDD1	136500
BRAUER SYNDROME	FOCAL FACIAL DERMAL DYSPLASIA 1, BRAUER TYPE; FFDD1	136500
HEREDITARY SYMMETRICAL APLASTIC NEVI OF TEMPLES	FOCAL FACIAL DERMAL DYSPLASIA 1, BRAUER TYPE; FFDD1	136500
BITEMPORAL APLASIA CUTIS CONGENITA	FOCAL FACIAL DERMAL DYSPLASIA 1, BRAUER TYPE; FFDD1	136500
FOVEAL HYPOPLASIA 1; FVH1	FOVEAL HYPOPLASIA 1; FVH1	136520
FOVEAL HYPOPLASIA 1 WITH OR WITHOUT ANTERIOR SEGMENT ANOMALIES AND/ORCATARACT	FOVEAL HYPOPLASIA 1; FVH1	136520
FRAGILE SITE 10q23	FRAGILE SITE 10q23	136540
MACULAR DYSTROPHY, RETINAL, 1, NORTH CAROLINA TYPE; MCDR1	MACULAR DYSTROPHY, RETINAL, 1, NORTH CAROLINA TYPE; MCDR1	136550
NORTH CAROLINA MACULAR DYSTROPHY; NCMD	MACULAR DYSTROPHY, RETINAL, 1, NORTH CAROLINA TYPE; MCDR1	136550
CENTRAL AREOLAR PIGMENT EPITHELIAL DYSTROPHY; CAPED	MACULAR DYSTROPHY, RETINAL, 1, NORTH CAROLINA TYPE; MCDR1	136550
RETINAL PIGMENT EPITHELIAL DYSTROPHY, CENTRAL	MACULAR DYSTROPHY, RETINAL, 1, NORTH CAROLINA TYPE; MCDR1	136550
FOVEAL DYSTROPHY, PROGRESSIVE	MACULAR DYSTROPHY, RETINAL, 1, NORTH CAROLINA TYPE; MCDR1	136550
CHROMOSOME 16p12.1 DELETION SYNDROME, 520-KBFRAGILE SITE, DISTAMYCIN A TYPE, RARE, FRA(16)(p12.1), INCLUDED; FRA16E,INCLUDED	CHROMOSOME 16p12.1 DELETION SYNDROME, 520-KBFRAGILE SITE, DISTAMYCIN A TYPE, RARE, FRA(16)(p12.1), INCLUDED; FRA16E,INCLUDED	136570
FRAGILE SITE 16p12, INCLUDED	CHROMOSOME 16p12.1 DELETION SYNDROME, 520-KBFRAGILE SITE, DISTAMYCIN A TYPE, RARE, FRA(16)(p12.1), INCLUDED; FRA16E,INCLUDED	136570
FRAGILE SITE, DISTAMYCIN A TYPE, RARE, FRA(16)(q22.1); FRA16B	FRAGILE SITE, DISTAMYCIN A TYPE, RARE, FRA(16)(q22.1); FRA16B	136580
FRAGILE SITE 16q22	FRAGILE SITE, DISTAMYCIN A TYPE, RARE, FRA(16)(q22.1); FRA16B	136580
FRAGILE SITE 20p11	FRAGILE SITE 20p11	136590
FRAGILE SITE 10q25; FRA10B	FRAGILE SITE 10q25; FRA10B	136620
BrdU-DEPENDENT FRAGILE SITE	FRAGILE SITE 10q25; FRA10B	136620
MENTAL RETARDATION, FRA12A TYPE	MENTAL RETARDATION, FRA12A TYPE	136630
FRAGILE SITE 9q32	FRAGILE SITE 9q32	136640
FRAGILE SITE 17p12	FRAGILE SITE 17p12	136660
FRASIER SYNDROME	FRASIER SYNDROME	136680
FRONTONASAL DYSPLASIA 1; FND1	FRONTONASAL DYSPLASIA 1; FND1	136760
FRONTORHINY	FRONTONASAL DYSPLASIA 1; FND1	136760
FRONTONASAL DYSPLASIA; FND	FRONTONASAL DYSPLASIA 1; FND1	136760
FRONTONASAL MALFORMATION; FNM	FRONTONASAL DYSPLASIA 1; FND1	136760
MEDIAN FACIAL CLEFT SYNDROME	FRONTONASAL DYSPLASIA 1; FND1	136760
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 1; FECD1	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 1; FECD1	136800
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, EARLY-ONSET	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 1; FECD1	136800
FUNDUS ALBIPUNCTATUSRETINITIS PUNCTATA ALBESCENS, INCLUDED	FUNDUS ALBIPUNCTATUSRETINITIS PUNCTATA ALBESCENS, INCLUDED	136880
SORSBY FUNDUS DYSTROPHY; SFD	SORSBY FUNDUS DYSTROPHY; SFD	136900
FUNDUS DYSTROPHY, PSEUDOINFLAMMATORY, OF SORSBY	SORSBY FUNDUS DYSTROPHY; SFD	136900
MACULAR DYSTROPHY, HEMORRHAGIC	SORSBY FUNDUS DYSTROPHY; SFD	136900
IMMUNOGLOBULIN A DEFICIENCY 1; IGAD1	IMMUNOGLOBULIN A DEFICIENCY 1; IGAD1	137100
IMMUNOGLOBULIN A, SELECTIVE DEFICIENCY OF	IMMUNOGLOBULIN A DEFICIENCY 1; IGAD1	137100
IgA, SELECTIVE DEFICIENCY OF	IMMUNOGLOBULIN A DEFICIENCY 1; IGAD1	137100
GAMMA-A-GLOBULIN, SELECTIVE DEFICIENCY OF	IMMUNOGLOBULIN A DEFICIENCY 1; IGAD1	137100
NEUROMYOTONIA AND AXONAL NEUROPATHY, AUTOSOMAL RECESSIVE; NMAN	NEUROMYOTONIA AND AXONAL NEUROPATHY, AUTOSOMAL RECESSIVE; NMAN	137200
GAMSTORP-WOHLFART SYNDROME	NEUROMYOTONIA AND AXONAL NEUROPATHY, AUTOSOMAL RECESSIVE; NMAN	137200
MYOKYMIA, MYOTONIA, AND MUSCLE WASTING	NEUROMYOTONIA AND AXONAL NEUROPATHY, AUTOSOMAL RECESSIVE; NMAN	137200
GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC	GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC	137215
GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC	GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC	137215
GASTRIC CANCER, FAMILIAL DIFFUSEBREAST CANCER, LOBULAR, INCLUDED; LBC, INCLUDED	GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC	137215
GASTRIC CANCER, FAMILIAL DIFFUSE, AND CLEFT LIP WITH OR WITHOUT CLEFTPALATE, INCLUDED	GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC	137215
GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GIPR	GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GIPR	137241
INSULINOTROPIC POLYPEPTIDE RECEPTOR, GLUCOSE-DEPENDENTPLASMA GLUCOSE, 2-HOUR, QUANTITATIVE TRAIT LOCUS 2, INCLUDED; PGQTL2,INCLUDED	GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GIPR	137241
GENOCHONDROMATOSIS	GENOCHONDROMATOSIS	137360
GERSTMANN-STRAUSSLER DISEASE; GSD	GERSTMANN-STRAUSSLER DISEASE; GSD	137440
ENCEPHALOPATHY, SUBACUTE SPONGIFORM, GERSTMANN-STRAUSSLER TYPE	GERSTMANN-STRAUSSLER DISEASE; GSD	137440
GERSTMANN-STRAUSSLER-SCHEINKER DISEASE; GSS	GERSTMANN-STRAUSSLER DISEASE; GSD	137440
CEREBELLAR ATAXIA, PROGRESSIVE DEMENTIA, AND AMYLOID DEPOSITS IN CNS	GERSTMANN-STRAUSSLER DISEASE; GSD	137440
AMYLOIDOSIS, CEREBRAL, WITH SPONGIFORM ENCEPHALOPATHY	GERSTMANN-STRAUSSLER DISEASE; GSD	137440
PRION DEMENTIACEREBRAL AMYLOID ANGIOPATHY, PRNP-RELATED, INCLUDED	GERSTMANN-STRAUSSLER DISEASE; GSD	137440
GIANT NEUTROPHIL LEUKOCYTES	GIANT NEUTROPHIL LEUKOCYTES	137500
MELANOCYTIC NEVUS SYNDROME, CONGENITAL; CMNS	MELANOCYTIC NEVUS SYNDROME, CONGENITAL; CMNS	137550
GIANT PIGMENTED HAIRY NEVUS; GPHN	MELANOCYTIC NEVUS SYNDROME, CONGENITAL; CMNS	137550
GIANT CONGENITAL PIGMENTED NEVUS	MELANOCYTIC NEVUS SYNDROME, CONGENITAL; CMNS	137550
PIGMENTED MOLESNEVUS SPILUS, INCLUDED	MELANOCYTIC NEVUS SYNDROME, CONGENITAL; CMNS	137550
SPITZ NEVUS, INCLUDED	MELANOCYTIC NEVUS SYNDROME, CONGENITAL; CMNS	137550
GIGANTIFORM CEMENTOMA, FAMILIAL	GIGANTIFORM CEMENTOMA, FAMILIAL	137575
CEMENTOMAS, FAMILIAL MULTIPLE	GIGANTIFORM CEMENTOMA, FAMILIAL	137575
CEMENTAL DYSPLASIA, PERIAPICAL	GIGANTIFORM CEMENTOMA, FAMILIAL	137575
GILLES DE LA TOURETTE SYNDROME; GTS	GILLES DE LA TOURETTE SYNDROME; GTS	137580
TOURETTE SYNDROME; TS	GILLES DE LA TOURETTE SYNDROME; GTS	137580
TOURETTE DISORDERCHRONIC MOTOR TICS, INCLUDED	GILLES DE LA TOURETTE SYNDROME; GTS	137580
IRIDOGONIODYSGENESIS, TYPE 2; IRID2	IRIDOGONIODYSGENESIS, TYPE 2; IRID2	137600
IRIDOGONIODYSGENESIS SYNDROME; IGDS	IRIDOGONIODYSGENESIS, TYPE 2; IRID2	137600
IRIS HYPOPLASIA WITH EARLY-ONSET GLAUCOMA, AUTOSOMAL DOMINANT; IHGA	IRIDOGONIODYSGENESIS, TYPE 2; IRID2	137600
GLAUCOMA 1, OPEN ANGLE, A; GLC1A	GLAUCOMA 1, OPEN ANGLE, A; GLC1A	137750
GLAUCOMA, PRIMARY OPEN ANGLE, JUVENILE-ONSET, 1; JOAG1GLAUCOMA 1, OPEN ANGLE, L, INCLUDED; GLC1L, INCLUDED	GLAUCOMA 1, OPEN ANGLE, A; GLC1A	137750
GLAUCOMA, PRIMARY OPEN ANGLE; POAGGLAUCOMA 1, OPEN ANGLE, E, INCLUDED; GLC1E, INCLUDED	GLAUCOMA, PRIMARY OPEN ANGLE; POAGGLAUCOMA 1, OPEN ANGLE, E, INCLUDED; GLC1E, INCLUDED	137760
GLAUCOMA, PRIMARY OPEN ANGLE, ADULT-ONSET, INCLUDED	GLAUCOMA, PRIMARY OPEN ANGLE; POAGGLAUCOMA 1, OPEN ANGLE, E, INCLUDED; GLC1E, INCLUDED	137760
GLIOMA SUSCEPTIBILITY 1; GLM1GLIOMA OF BRAIN, FAMILIAL, INCLUDED; GLM, INCLUDED	GLIOMA SUSCEPTIBILITY 1; GLM1GLIOMA OF BRAIN, FAMILIAL, INCLUDED; GLM, INCLUDED	137800
GLIOBLASTOMA MULTIFORME, INCLUDED; GBM, INCLUDED	GLIOMA SUSCEPTIBILITY 1; GLM1GLIOMA OF BRAIN, FAMILIAL, INCLUDED; GLM, INCLUDED	137800
ASTROCYTOMA, INCLUDED	GLIOMA SUSCEPTIBILITY 1; GLM1GLIOMA OF BRAIN, FAMILIAL, INCLUDED; GLM, INCLUDED	137800
OLIGODENDROGLIOMA, INCLUDED	GLIOMA SUSCEPTIBILITY 1; GLM1GLIOMA OF BRAIN, FAMILIAL, INCLUDED; GLM, INCLUDED	137800
EPENDYMOMA, INCLUDED	GLIOMA SUSCEPTIBILITY 1; GLM1GLIOMA OF BRAIN, FAMILIAL, INCLUDED; GLM, INCLUDED	137800
SUBEPENDYMOMA, INCLUDED	GLIOMA SUSCEPTIBILITY 1; GLM1GLIOMA OF BRAIN, FAMILIAL, INCLUDED; GLM, INCLUDED	137800
RENAL CYSTS AND DIABETES SYNDROME; RCAD	RENAL CYSTS AND DIABETES SYNDROME; RCAD	137920
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 5; MODY5	RENAL CYSTS AND DIABETES SYNDROME; RCAD	137920
HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, ATYPICAL	RENAL CYSTS AND DIABETES SYNDROME; RCAD	137920
FJHN, ATYPICAL	RENAL CYSTS AND DIABETES SYNDROME; RCAD	137920
GLOMERULOCYSTIC KIDNEY DISEASE, HYPOPLASTIC TYPE	RENAL CYSTS AND DIABETES SYNDROME; RCAD	137920
GLOMERULOCYSTIC KIDNEY, FAMILIAL HYPOPLASTIC	RENAL CYSTS AND DIABETES SYNDROME; RCAD	137920
CONGENITAL ANOMALIES OF THE KIDNEY AND URINARY TRACT WITH DIABETES	RENAL CYSTS AND DIABETES SYNDROME; RCAD	137920
CAKUT WITH DIABETES	RENAL CYSTS AND DIABETES SYNDROME; RCAD	137920
HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA-RENAL DEFECT SYNDROME; HLTRS	HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA-RENAL DEFECT SYNDROME; HLTRS	137940
GLOMERULONEPHRITIS WITH SPARSE HAIR AND TELANGIECTASES	HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA-RENAL DEFECT SYNDROME; HLTRS	137940
TELANGIECTATIC MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS	HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA-RENAL DEFECT SYNDROME; HLTRS	137940
GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 1; GFND1	GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 1; GFND1	137950
GLOMERULOPATHY WITH GIANT FIBRILLAR DEPOSITS	GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 1; GFND1	137950
LOBULAR GLOMERULOPATHY, FAMILIAL	GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 1; GFND1	137950
GLOMUVENOUS MALFORMATIONS; GVM	GLOMUVENOUS MALFORMATIONS; GVM	138000
VENOUS MALFORMATIONS WITH GLOMUS CELLS; VMGLOM	GLOMUVENOUS MALFORMATIONS; GVM	138000
GLOMUS TUMORS, MULTIPLE	GLOMUVENOUS MALFORMATIONS; GVM	138000
GLOMANGIOMAS, MULTIPLE	GLOMUVENOUS MALFORMATIONS; GVM	138000
GLUTATHIONE REDUCTASE; GSRGLUTATHIONE REDUCTASE, HEMOLYTIC ANEMIA DUE TO DEFICIENCY OF, IN REDCELLS, INCLUDED	GLUTATHIONE REDUCTASE; GSRGLUTATHIONE REDUCTASE, HEMOLYTIC ANEMIA DUE TO DEFICIENCY OF, IN REDCELLS, INCLUDED	138300
HYPERGLYCINURIA	HYPERGLYCINURIA	138500
GLYCINURIA WITH OR WITHOUT OXALATE UROLITHIASIS	HYPERGLYCINURIA	138500
GLYCINURIA WITH OR WITHOUT OXALATE NEPHROLITHIASIS	HYPERGLYCINURIA	138500
IMINOGLYCINURIA TYPE II	HYPERGLYCINURIA	138500
GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS;MNG1	GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS;MNG1	138800
GOITER, NONTOXIC, WITH INTRATHYROIDAL CALCIFICATION	GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS;MNG1	138800
MULTINODULAR GOITER, ADOLESCENT	GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS;MNG1	138800
EUTHYROID GOITER	GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS;MNG1	138800
SIMPLE GOITER	GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS;MNG1	138800
URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 1; UAQTL1	URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 1; UAQTL1	138900
GOUT SUSCEPTIBILITY 1; GOUT1	URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 1; UAQTL1	138900
GRAY PLATELET SYNDROME; GPS	GRAY PLATELET SYNDROME; GPS	139090
BLEEDING DISORDER, PLATELET-TYPE, 4; BDPLT4	GRAY PLATELET SYNDROME; GPS	139090
PLATELET ALPHA-GRANULE DEFICIENCY	GRAY PLATELET SYNDROME; GPS	139090
GRAYING OF HAIR, PRECOCIOUS	GRAYING OF HAIR, PRECOCIOUS	139100
WHITE HAIR, PREMATURE	GRAYING OF HAIR, PRECOCIOUS	139100
MYHRE SYNDROME; MYHRS	MYHRE SYNDROME; MYHRS	139210
GROWTH-MENTAL DEFICIENCY SYNDROME OF MYHRE	MYHRE SYNDROME; MYHRS	139210
LARYNGOTRACHEAL STENOSIS, ARTHROPATHY, PROGNATHISM, AND SHORT STATURE;LAPS SYNDROME	MYHRE SYNDROME; MYHRS	139210
AROMATASE EXCESS SYNDROME; AEXS	AROMATASE EXCESS SYNDROME; AEXS	139300
AROMATASE ACTIVITY, INCREASEDGYNECOMASTIA, FAMILIAL, DUE TO INCREASED AROMATASE ACTIVITY, INCLUDED	AROMATASE EXCESS SYNDROME; AEXS	139300
GYNECOMASTIA, HEREDITARY, INCLUDED	AROMATASE EXCESS SYNDROME; AEXS	139300
GUILLAIN-BARRE SYNDROME, FAMILIAL; GBS	GUILLAIN-BARRE SYNDROME, FAMILIAL; GBS	139393
POLYNEUROPATHY, INFLAMMATORY DEMYELINATING, ACUTE; AIDPPOLYNEUROPATHY, INFLAMMATORY DEMYELINATING, CHRONIC, INCLUDED; CIDP,INCLUDED	GUILLAIN-BARRE SYNDROME, FAMILIAL; GBS	139393
HAIR MORPHOLOGY 2; HRM2	HAIR MORPHOLOGY 2; HRM2	139450
CURLY HAIR	HAIR MORPHOLOGY 2; HRM2	139450
HAIR CURVATURE, VARIATION IN	HAIR MORPHOLOGY 2; HRM2	139450
HAIRY ELBOWS	HAIRY ELBOWS	139600
HYPERTRICHOSIS CUBITI	HAIRY ELBOWS	139600
HAIRY PALMS AND SOLES	HAIRY PALMS AND SOLES	139650
CIRCUMSCRIBED HAIRY DYSEMBRYOPLASIA OF PALMS	HAIRY PALMS AND SOLES	139650
HAND SKILL, RELATIVE; HSR	HAND SKILL, RELATIVE; HSR	139900
HANDEDNESS	HAND SKILL, RELATIVE; HSR	139900
HAND-FOOT-GENITAL SYNDROME; HFG	HAND-FOOT-GENITAL SYNDROME; HFG	140000
HAND-FOOT-UTERUS SYNDROME; HFU	HAND-FOOT-GENITAL SYNDROME; HFG	140000
HASHIMOTO THYROIDITIS	HASHIMOTO THYROIDITIS	140300
HT	HASHIMOTO THYROIDITIS	140300
HASHIMOTO STRUMA	HASHIMOTO THYROIDITIS	140300
HYPOTHYROIDISM, AUTOIMMUNETHYROID AUTOANTIBODIES, INCLUDED	HASHIMOTO THYROIDITIS	140300
HAWKINSINURIA	HAWKINSINURIA	140350
PROGRESSIVE FAMILIAL HEART BLOCK, TYPE II; PFHB2	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE II; PFHB2	140400
PFHBII	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE II; PFHB2	140400
OSTEOARTHRITIS SUSCEPTIBILITY 2; OS2	OSTEOARTHRITIS SUSCEPTIBILITY 2; OS2	140600
OSTEOARTHRITIS OF DISTAL INTERPHALANGEAL JOINTS	OSTEOARTHRITIS SUSCEPTIBILITY 2; OS2	140600
OADIP	OSTEOARTHRITIS SUSCEPTIBILITY 2; OS2	140600
DIPOA	OSTEOARTHRITIS SUSCEPTIBILITY 2; OS2	140600
HAND OSTEOARTHRITIS; HOAHEBERDEN NODES, INCLUDED	OSTEOARTHRITIS SUSCEPTIBILITY 2; OS2	140600
HEINZ BODY ANEMIAS	HEINZ BODY ANEMIAS	140700
HEMATURIA, BENIGN FAMILIAL; BFH	HEMATURIA, BENIGN FAMILIAL; BFH	141200
THIN-BASEMENT-MEMBRANE NEPHROPATHY	HEMATURIA, BENIGN FAMILIAL; BFH	141200
THIN MEMBRANE NEPHROPATHY; TMN	HEMATURIA, BENIGN FAMILIAL; BFH	141200
HEMIFACIAL ATROPHY, PROGRESSIVE; HFA	HEMIFACIAL ATROPHY, PROGRESSIVE; HFA	141300
PARRY-ROMBERG SYNDROME	HEMIFACIAL ATROPHY, PROGRESSIVE; HFA	141300
HEMIFACIAL HYPERPLASIA WITH STRABISMUS	HEMIFACIAL HYPERPLASIA WITH STRABISMUS	141350
BENCZE SYNDROME	HEMIFACIAL HYPERPLASIA WITH STRABISMUS	141350
HEMIFACIAL MICROSOMIA WITH RADIAL DEFECTS	HEMIFACIAL MICROSOMIA WITH RADIAL DEFECTS	141400
GOLDENHAR SYNDROME WITH IPSILATERAL RADIAL DEFECT	HEMIFACIAL MICROSOMIA WITH RADIAL DEFECTS	141400
OCULOAURICULOVERTEBRAL SPECTRUM WITH RADIAL DEFECT	HEMIFACIAL MICROSOMIA WITH RADIAL DEFECTS	141400
OAVS WITH RADIAL DEFECT	HEMIFACIAL MICROSOMIA WITH RADIAL DEFECTS	141400
MIGRAINE, FAMILIAL HEMIPLEGIC, 1; FHM1	MIGRAINE, FAMILIAL HEMIPLEGIC, 1; FHM1	141500
FHM	MIGRAINE, FAMILIAL HEMIPLEGIC, 1; FHM1	141500
MHP1MIGRAINE, FAMILIAL HEMIPLEGIC 1, WITH PROGRESSIVE CEREBELLAR ATAXIA,INCLUDED	MIGRAINE, FAMILIAL HEMIPLEGIC, 1; FHM1	141500
MIGRAINE, SPORADIC HEMIPLEGIC, INCLUDED	MIGRAINE, FAMILIAL HEMIPLEGIC, 1; FHM1	141500
FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HBFQTL1	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HBFQTL1	141749
HEMOGLOBIN F, HEREDITARY PERSISTENCE OF; HPFH	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HBFQTL1	141749
HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN, HB GENE CLUSTER-RELATEDDELTA-BETA THALASSEMIA, INCLUDED	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HBFQTL1	141749
ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, CHROMOSOME 16-RELATED	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, CHROMOSOME 16-RELATED	141750
ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, DELETION-TYPE	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, CHROMOSOME 16-RELATED	141750
ATR-16 SYNDROME	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, CHROMOSOME 16-RELATED	141750
ATR, DELETION-TYPE	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, CHROMOSOME 16-RELATED	141750
HEMOGLOBIN H-RELATED MENTAL RETARDATION; HBHR	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, CHROMOSOME 16-RELATED	141750
MENTAL RETARDATION WITH HEMOGLOBIN H	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, CHROMOSOME 16-RELATED	141750
CHROMOSOME 16p DELETION SYNDROME	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, CHROMOSOME 16-RELATED	141750
HEMOGLOBIN--ALPHA LOCUS 1; HBA1	HEMOGLOBIN--ALPHA LOCUS 1; HBA1	141800
3-PRIME @ALPHA-GLOBIN GENE	HEMOGLOBIN--ALPHA LOCUS 1; HBA1	141800
MINOR ALPHA-GLOBIN LOCUSMETHEMOGLOBINEMIA, ALPHA-GLOBIN TYPE, INCLUDED	HEMOGLOBIN--ALPHA LOCUS 1; HBA1	141800
ERYTHREMIA, ALPHA-GLOBIN TYPE, INCLUDED	HEMOGLOBIN--ALPHA LOCUS 1; HBA1	141800
HEMOGLOBIN--BETA LOCUS; HBBMETHEMOGLOBINEMIA, BETA-GLOBIN TYPE, INCLUDED	HEMOGLOBIN--BETA LOCUS; HBBMETHEMOGLOBINEMIA, BETA-GLOBIN TYPE, INCLUDED	141900
ERYTHREMIA, BETA-GLOBIN TYPE, INCLUDED	HEMOGLOBIN--BETA LOCUS; HBBMETHEMOGLOBINEMIA, BETA-GLOBIN TYPE, INCLUDED	141900
HEMOGLOBIN--VARIANTS FOR WHICH THE CHAIN CARRYING THE MUTATION ISUNKNOWN OR UNCERTAIN	HEMOGLOBIN--VARIANTS FOR WHICH THE CHAIN CARRYING THE MUTATION ISUNKNOWN OR UNCERTAIN	142309
HEPATIC ADENOMAS, FAMILIAL	HEPATIC ADENOMAS, FAMILIAL	142330
LIVER CELL ADENOMAS, FAMILIAL	HEPATIC ADENOMAS, FAMILIAL	142330
FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 5; HBFQTL5	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 5; HBFQTL5	142335
DIAPHRAGMATIC HERNIA, CONGENITAL	DIAPHRAGMATIC HERNIA, CONGENITAL	142340
DIH	DIAPHRAGMATIC HERNIA, CONGENITAL	142340
HERNIA, CONGENITAL DIAPHRAGMATIC; HCD; CDH	DIAPHRAGMATIC HERNIA, CONGENITAL	142340
DIAPHRAGMATIC DEFECT, CONGENITAL	DIAPHRAGMATIC HERNIA, CONGENITAL	142340
DIAPHRAGM, UNILATERAL AGENESIS OF	DIAPHRAGMATIC HERNIA, CONGENITAL	142340
HEMIDIAPHRAGM, AGENESIS OFDIAPHRAGMATIC HERNIA 1, INCLUDED; DIH1, INCLUDED	DIAPHRAGMATIC HERNIA, CONGENITAL	142340
DIAPHRAGM, COMPLETE AGENESIS OF, INCLUDED	DIAPHRAGMATIC HERNIA, CONGENITAL	142340
HEPATITIS B VACCINE, RESPONSE TO	HEPATITIS B VACCINE, RESPONSE TO	142395
HBV VACCINE, RESPONSE TO	HEPATITIS B VACCINE, RESPONSE TO	142395
HERNIA, HIATUS	HERNIA, HIATUS	142400
HIATAL HERNIA	HERNIA, HIATUS	142400
FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 2; HBFQTL2	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 2; HBFQTL2	142470
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1	142623
HIRSCHSPRUNG DISEASE; HSCR	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1	142623
AGANGLIONIC MEGACOLON	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1	142623
MEGACOLON, AGANGLIONIC; MGC	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1	142623
BEUKES HIP DYSPLASIA; BHD	BEUKES HIP DYSPLASIA; BHD	142669
HIP DYSPLASIA, BEUKES TYPE	BEUKES HIP DYSPLASIA; BHD	142669
BEUKES FAMILIAL HIP DYSPLASIA; BFHD	BEUKES HIP DYSPLASIA; BHD	142669
OSTEOARTHROPATHY, PREMATURE DEGENERATIVE, OF HIP	BEUKES HIP DYSPLASIA; BHD	142669
PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT	PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT	142680
FPF	PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT	142680
HIBERNIAN FEVER, FAMILIAL; FHF	PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT	142680
FAMILIAL HIBERNIAN FEVER	PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT	142680
TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME; TRAPS	PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT	142680
TNF RECEPTOR-ASSOCIATED PERIODIC SYNDROME	PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT	142680
ACNE INVERSA, FAMILIAL, 1; ACNINV1	ACNE INVERSA, FAMILIAL, 1; ACNINV1	142690
ACNE INVERSA, FAMILIAL	ACNE INVERSA, FAMILIAL, 1; ACNINV1	142690
HIDRADENITIS SUPPURATIVA, FAMILIAL	ACNE INVERSA, FAMILIAL, 1; ACNINV1	142690
DEVELOPMENTAL DYSPLASIA OF THE HIP 1; DDH1HIP DYSPLASIA, DEVELOPMENTAL; DDH	DEVELOPMENTAL DYSPLASIA OF THE HIP 1; DDH1HIP DYSPLASIA, DEVELOPMENTAL; DDH	142700
HIP DYSPLASIA, CONGENITAL; CDH	DEVELOPMENTAL DYSPLASIA OF THE HIP 1; DDH1HIP DYSPLASIA, DEVELOPMENTAL; DDH	142700
ACETABULAR DYSPLASIA	DEVELOPMENTAL DYSPLASIA OF THE HIP 1; DDH1HIP DYSPLASIA, DEVELOPMENTAL; DDH	142700
MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, B; HLA-B	MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, B; HLA-B	142830
HLA-B HISTOCOMPATIBILITY TYPEABACAVIR HYPERSENSITIVITY, SUSCEPTIBILITY TO, INCLUDED	MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, B; HLA-B	142830
SYNOVITIS, CHRONIC, SUSCEPTIBILITY TO, INCLUDED	MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, B; HLA-B	142830
DRUG-INDUCED LIVER INJURY DUE TO FLUCLOXACILLIN, INCLUDED	MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, B; HLA-B	142830
HOLT-ORAM SYNDROME; HOS	HOLT-ORAM SYNDROME; HOS	142900
HOS1	HOLT-ORAM SYNDROME; HOS	142900
HEART-HAND SYNDROME	HOLT-ORAM SYNDROME; HOS	142900
ATRIODIGITAL DYSPLASIA	HOLT-ORAM SYNDROME; HOS	142900
3-@HYDROXY-3-METHYLGLUTARYL-CoA REDUCTASE; HMGCR	3-@HYDROXY-3-METHYLGLUTARYL-CoA REDUCTASE; HMGCR	142910
HMG-CoA REDUCTASELOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS3, INCLUDED; LDLCQ3, INCLUDED	3-@HYDROXY-3-METHYLGLUTARYL-CoA REDUCTASE; HMGCR	142910
STATINS, ATTENUATED CHOLESTEROL LOWERING BY, INCLUDED	3-@HYDROXY-3-METHYLGLUTARYL-CoA REDUCTASE; HMGCR	142910
HOLOPROSENCEPHALY 3; HPE3	HOLOPROSENCEPHALY 3; HPE3	142945
HLP3	HOLOPROSENCEPHALY 3; HPE3	142945
HOLOPROSENCEPHALY 4; HPE4	HOLOPROSENCEPHALY 4; HPE4	142946
HORNER SYNDROME, CONGENITAL	HORNER SYNDROME, CONGENITAL	143000
SPONDYLOEPIPHYSEAL DYSPLASIA WITH CONGENITAL JOINT DISLOCATIONS	SPONDYLOEPIPHYSEAL DYSPLASIA WITH CONGENITAL JOINT DISLOCATIONS	143095
HUMEROSPINAL DYSOSTOSIS; HSD	SPONDYLOEPIPHYSEAL DYSPLASIA WITH CONGENITAL JOINT DISLOCATIONS	143095
SPONDYLOEPIPHYSEAL DYSPLASIA, OMANI TYPE	SPONDYLOEPIPHYSEAL DYSPLASIA WITH CONGENITAL JOINT DISLOCATIONS	143095
CHONDRODYSPLASIA WITH MULTIPLE DISLOCATIONS; CDMD	SPONDYLOEPIPHYSEAL DYSPLASIA WITH CONGENITAL JOINT DISLOCATIONS	143095
HUNTINGTON DISEASE; HD	HUNTINGTON DISEASE; HD	143100
HUNTINGTON CHOREA	HUNTINGTON DISEASE; HD	143100
WAGNER VITREORETINOPATHY; WGVRP	WAGNER VITREORETINOPATHY; WGVRP	143200
EROSIVE VITREORETINOPATHY; ERVR	WAGNER VITREORETINOPATHY; WGVRP	143200
WAGNER VITREORETINAL DEGENERATION	WAGNER VITREORETINOPATHY; WGVRP	143200
HYALOIDEORETINAL DEGENERATION OF WAGNER	WAGNER VITREORETINOPATHY; WGVRP	143200
WAGNER SYNDROME 1; WGN1	WAGNER VITREORETINOPATHY; WGVRP	143200
CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 2	CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 2	143400
URETEROPELVIC JUNCTION OBSTRUCTION; UPJO	CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 2	143400
PELVIURETERIC JUNCTION OBSTRUCTION; PUJO	CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 2	143400
HYDRONEPHROSIS DUE TO PUJO	CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 2	143400
MULTICYSTIC RENAL DYSPLASIA, BILATERAL; MCRD	CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 2	143400
ATTENTION DEFICIT-HYPERACTIVITY DISORDER; ADHD	ATTENTION DEFICIT-HYPERACTIVITY DISORDER; ADHD	143465
HYPERACTIVITY OF CHILDHOOD	ATTENTION DEFICIT-HYPERACTIVITY DISORDER; ADHD	143465
HYPERALPHALIPOPROTEINEMIA 1; HALP1	HYPERALPHALIPOPROTEINEMIA 1; HALP1	143470
CHOLESTEROL ESTER TRANSFER PROTEIN DEFICIENCY	HYPERALPHALIPOPROTEINEMIA 1; HALP1	143470
CETP DEFICIENCYHIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS10, INCLUDED	HYPERALPHALIPOPROTEINEMIA 1; HALP1	143470
HDLCQ10, INCLUDED	HYPERALPHALIPOPROTEINEMIA 1; HALP1	143470
GILBERT SYNDROME	GILBERT SYNDROME	143500
HYPERBILIRUBINEMIA, GILBERT TYPE; HBLRG	GILBERT SYNDROME	143500
HYPERBILIRUBINEMIA, ARIAS TYPE	GILBERT SYNDROME	143500
HYPERBILIRUBINEMIA I	GILBERT SYNDROME	143500
ORTHOSTATIC HYPOTENSIVE DISORDER, STREETEN TYPE	ORTHOSTATIC HYPOTENSIVE DISORDER, STREETEN TYPE	143850
OHDS	ORTHOSTATIC HYPOTENSIVE DISORDER, STREETEN TYPE	143850
ORTHOSTATIC HYPOTENSIVE DISORDER	ORTHOSTATIC HYPOTENSIVE DISORDER, STREETEN TYPE	143850
HYPERBRADYKININISM	ORTHOSTATIC HYPOTENSIVE DISORDER, STREETEN TYPE	143850
HYPERCHLORHIDROSIS, ISOLATED	HYPERCHLORHIDROSIS, ISOLATED	143860
HYPERCALCIURIA, ABSORPTIVE, 2; HCA2	HYPERCALCIURIA, ABSORPTIVE, 2; HCA2	143870
HYPERCALCIURIA, FAMILIAL IDIOPATHIC	HYPERCALCIURIA, ABSORPTIVE, 2; HCA2	143870
HYPERCALCEMIA, INFANTILE	HYPERCALCEMIA, INFANTILE	143880
HYPERCALCEMIA, IDIOPATHIC, OF INFANCY	HYPERCALCEMIA, INFANTILE	143880
HYPERCHOLESTEROLEMIA, FAMILIAL	HYPERCHOLESTEROLEMIA, FAMILIAL	143890
FHC; FH	HYPERCHOLESTEROLEMIA, FAMILIAL	143890
HYPERLIPOPROTEINEMIA, TYPE II	HYPERCHOLESTEROLEMIA, FAMILIAL	143890
HYPERLIPOPROTEINEMIA, TYPE IIA	HYPERCHOLESTEROLEMIA, FAMILIAL	143890
HYPER-LOW-DENSITY-LIPOPROTEINEMIA	HYPERCHOLESTEROLEMIA, FAMILIAL	143890
HYPERCHOLESTEROLEMIC XANTHOMATOSIS, FAMILIAL	HYPERCHOLESTEROLEMIA, FAMILIAL	143890
LDL RECEPTOR DISORDERLOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS2, INCLUDED; LDLCQ2, INCLUDED	HYPERCHOLESTEROLEMIA, FAMILIAL	143890
HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, TYPE B	HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, TYPE B	144010
APOLIPOPROTEIN B-100, FAMILIAL LIGAND-DEFECTIVE	HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, TYPE B	144010
HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LIGAND-DEFECTIVE APOLIPOPROTEINB	HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, TYPE B	144010
APOLIPOPROTEIN B-100, FAMILIAL DEFECTIVE	HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, TYPE B	144010
HYPERHIDROSIS PALMARIS ET PLANTARIS; HYPRPP	HYPERHIDROSIS PALMARIS ET PLANTARIS; HYPRPP	144110
HYPERHIDROSIS, PRIMARY PALMAR	HYPERHIDROSIS PALMARIS ET PLANTARIS; HYPRPP	144110
HYPERKERATOSIS LENTICULARIS PERSTANS; HLP	HYPERKERATOSIS LENTICULARIS PERSTANS; HLP	144150
FLEGEL DISEASE	HYPERKERATOSIS LENTICULARIS PERSTANS; HLP	144150
PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK	PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK	144200
PPKE	PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK	144200
KERATODERMA, EPIDERMOLYTIC PALMOPLANTAR	PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK	144200
PALMOPLANTAR KERATODERMA, VORNER TYPE	PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK	144200
HYPERKERATOSIS, LOCALIZED EPIDERMOLYTIC	PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK	144200
KERATOSIS PALMARIS ET PLANTARIS FAMILIARIS	PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK	144200
TYLOSIS	PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK	144200
KERATOSIS OF GREITHERPALMOPLANTAR KERATODERMA, EPIDERMOLYTIC, WITH KNUCKLE PADS, INCLUDED	PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK	144200
HYPERLIPIDEMIA, FAMILIAL COMBINED; FCHL	HYPERLIPIDEMIA, FAMILIAL COMBINED; FCHL	144250
FAMILIAL COMBINED HYPERLIPIDEMIA	HYPERLIPIDEMIA, FAMILIAL COMBINED; FCHL	144250
HYPERLIPOPROTEINEMIA, TYPE V	HYPERLIPOPROTEINEMIA, TYPE V	144650
HYPERLIPIDEMIA, TYPE V	HYPERLIPOPROTEINEMIA, TYPE V	144650
HYPERCHYLOMICRONEMIA, LATE-ONSET	HYPERLIPOPROTEINEMIA, TYPE V	144650
HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL	HYPERLIPOPROTEINEMIA, TYPE V	144650
HYPERLIPEMIA, MIXED	HYPERLIPOPROTEINEMIA, TYPE V	144650
HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED	HYPERLIPOPROTEINEMIA, TYPE V	144650
RENAL CELL CARCINOMA, NONPAPILLARY; RCC	RENAL CELL CARCINOMA, NONPAPILLARY; RCC	144700
HYPERNEPHROMA	RENAL CELL CARCINOMA, NONPAPILLARY; RCC	144700
ADENOCARCINOMA OF KIDNEYNONPAPILLARY RENAL CARCINOMA 1 LOCUS, INCLUDED; NRC1, INCLUDED	RENAL CELL CARCINOMA, NONPAPILLARY; RCC	144700
ENDOSTEAL HYPEROSTOSIS, AUTOSOMAL DOMINANT	ENDOSTEAL HYPEROSTOSIS, AUTOSOMAL DOMINANT	144750
HYPEROSTOSIS CORTICALIS GENERALISATA, BENIGN FORM OF WORTH, WITH TORUSPALATINUS	ENDOSTEAL HYPEROSTOSIS, AUTOSOMAL DOMINANT	144750
OSTEOSCLEROSIS, AUTOSOMAL DOMINANT	ENDOSTEAL HYPEROSTOSIS, AUTOSOMAL DOMINANT	144750
HYPEROSTOSIS CRANIALIS INTERNA	HYPEROSTOSIS CRANIALIS INTERNA	144755
HYPERPARATHYROIDISM 1; HRPT1	HYPERPARATHYROIDISM 1; HRPT1	145000
HYPERPARATHYROIDISM, FAMILIAL ISOLATED PRIMARY; FIHPPARATHYROID ADENOMA, FAMILIAL, INCLUDED	HYPERPARATHYROIDISM 1; HRPT1	145000
HYPERPARATHYROIDISM 2; HRPT2	HYPERPARATHYROIDISM 2; HRPT2	145001
HYPERPARATHYROIDISM, FAMILIAL PRIMARY, WITH MULTIPLE OSSIFYING JAWFIBROMAS	HYPERPARATHYROIDISM 2; HRPT2	145001
HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, HEREDITARY; HPT-JTPARATHYROID ADENOMATOSIS, FAMILIAL CYSTIC, INCLUDED	HYPERPARATHYROIDISM 2; HRPT2	145001
HYPERPIGMENTATION OF EYELIDS	HYPERPIGMENTATION OF EYELIDS	145100
HYPERPIGMENTATION WITH OR WITHOUT HYPOPIGMENTATION, FAMILIAL PROGRESSIVE;FPHH	HYPERPIGMENTATION WITH OR WITHOUT HYPOPIGMENTATION, FAMILIAL PROGRESSIVE;FPHH	145250
MELANOSIS UNIVERSALIS HEREDITARIA; MUH	HYPERPIGMENTATION WITH OR WITHOUT HYPOPIGMENTATION, FAMILIAL PROGRESSIVE;FPHH	145250
HYPERPIGMENTATION, FAMILIAL PROGRESSIVE, 2, FORMERLY; FPH2, FORMERLY	HYPERPIGMENTATION WITH OR WITHOUT HYPOPIGMENTATION, FAMILIAL PROGRESSIVE;FPHH	145250
PSEUDOHYPOALDOSTERONISM, TYPE IIA; PHA2A	PSEUDOHYPOALDOSTERONISM, TYPE IIA; PHA2A	145260
HYPERPOTASSEMIA AND HYPERTENSION, FAMILIAL	PSEUDOHYPOALDOSTERONISM, TYPE IIA; PHA2A	145260
HYPERTENSIVE HYPERKALEMIA, FAMILIAL	PSEUDOHYPOALDOSTERONISM, TYPE IIA; PHA2A	145260
GORDON HYPERKALEMIA-HYPERTENSION SYNDROME	PSEUDOHYPOALDOSTERONISM, TYPE IIA; PHA2A	145260
HYPERTELORISM	HYPERTELORISM	145400
OPITZ GBBB SYNDROME, TYPE II; GBBB2	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
OPITZ GBBB SYNDROME, AUTOSOMAL DOMINANT	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
HYPERTELORISM WITH ESOPHAGEAL ABNORMALITY AND HYPOSPADIAS	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
G SYNDROME	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
HYPOSPADIAS-DYSPHAGIA SYNDROME	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
OPITZ-FRIAS SYNDROME	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
OPITZ-G SYNDROME, TYPE II; OGS2	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
TELECANTHUS WITH ASSOCIATED ABNORMALITIES	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
BBB SYNDROME	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
HYPERTELORISM-HYPOSPADIAS SYNDROME	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
TELECANTHUS-HYPOSPADIAS SYNDROME	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
OPITZ BBBG SYNDROME	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
GBBB SYNDROME	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
OPITZ OCULOGENITOLARYNGEAL SYNDROME, TYPE II	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
CHROMOSOME 22q11.2 DELETION SYNDROME, OPITZ PHENOTYPE	OPITZ GBBB SYNDROME, TYPE II; GBBB2	145410
HYPERTELORISM, TEEBI TYPE	HYPERTELORISM, TEEBI TYPE	145420
BRACHYCEPHALOFRONTONASAL DYSPLASIA	HYPERTELORISM, TEEBI TYPE	145420
HYPERTENSION, ESSENTIAL	HYPERTENSION, ESSENTIAL	145500
EHT	HYPERTENSION, ESSENTIAL	145500
MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1; MHS1	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1; MHS1	145600
MHS	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1; MHS1	145600
HYPERTHERMIA OF ANESTHESIA	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1; MHS1	145600
HYPERPYREXIA, MALIGNANT; MHKING SYNDROME, INCLUDED	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1; MHS1	145600
KING-DENBOROUGH SYNDROME, INCLUDED	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1; MHS1	145600
THYROID HORMONE RESISTANCE, SELECTIVE PITUITARY; PRTH	THYROID HORMONE RESISTANCE, SELECTIVE PITUITARY; PRTH	145650
HYPERTHYROIDISM, FAMILIAL, DUE TO INAPPROPRIATE THYROTROPIN SECRETION	THYROID HORMONE RESISTANCE, SELECTIVE PITUITARY; PRTH	145650
HYPERTHYROXINEMIA, DYSTRANSTHYRETINEMIC; DTTRH	HYPERTHYROXINEMIA, DYSTRANSTHYRETINEMIC; DTTRH	145680
HYPERTHYROXINEMIA, DYSPREALBUMINEMIC	HYPERTHYROXINEMIA, DYSTRANSTHYRETINEMIC; DTTRH	145680
DYSTRANSTHYRETINEMIC EUTHYROIDAL HYPERTHYROXINEMIA	HYPERTHYROXINEMIA, DYSTRANSTHYRETINEMIC; DTTRH	145680
EUTHRYROIDAL HYPERTHYROXINEMIA 2	HYPERTHYROXINEMIA, DYSTRANSTHYRETINEMIC; DTTRH	145680
HYPERTRICHOSIS LANUGINOSA CONGENITA	HYPERTRICHOSIS LANUGINOSA CONGENITA	145700
HYPERTRICHOSIS UNIVERSALIS	HYPERTRICHOSIS LANUGINOSA CONGENITA	145700
HYPERTRICHOSIS UNIVERSALIS CONGENITA, AMBRAS TYPE; HTC1	HYPERTRICHOSIS UNIVERSALIS CONGENITA, AMBRAS TYPE; HTC1	145701
AMBRAS SYNDROME	HYPERTRICHOSIS UNIVERSALIS CONGENITA, AMBRAS TYPE; HTC1	145701
HYPERTRICHOSIS, CONGENITAL GENERALIZED	HYPERTRICHOSIS UNIVERSALIS CONGENITA, AMBRAS TYPE; HTC1	145701
HYPERTRIGLYCERIDEMIA, FAMILIAL	HYPERTRIGLYCERIDEMIA, FAMILIAL	145750
HYPERTROPHIA MUSCULORUM VERA	HYPERTROPHIA MUSCULORUM VERA	145800
HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS	HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS	145900
DEJERINE-SOTTAS SYNDROME; DSS	HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS	145900
CHARCOT-MARIE-TOOTH DISEASE, TYPE 3; CMT3	HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS	145900
HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE III; HMSN3	HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS	145900
DEJERINE-SOTTAS NEUROPATHY; DSN	HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS	145900
HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1	145980
FHH1	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1	145980
FAMILIAL BENIGN HYPERCALCEMIA 1; FBH1	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1	145980
HYPERCALCEMIA, FAMILIAL BENIGNHYPOCALCIURIC HYPERCALCEMIA, ACQUIRED, INCLUDED	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1	145980
HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2	145981
FAMILIAL BENIGN HYPERCALCEMIA, TYPE II; FBH2	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2	145981
HYPERCALCEMIA, FAMILIAL BENIGN, TYPE II	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2	145981
HYPOCHONDROPLASIA; HCH	HYPOCHONDROPLASIA; HCH	146000
HYPOGONADOTROPIC HYPOGONADISM 7 WITH OR WITHOUT ANOSMIA; HH7	HYPOGONADOTROPIC HYPOGONADISM 7 WITH OR WITHOUT ANOSMIA; HH7	146110
HYPOGONADISM, ISOLATED HYPOGONADOTROPIC	HYPOGONADOTROPIC HYPOGONADISM 7 WITH OR WITHOUT ANOSMIA; HH7	146110
IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; IHH	HYPOGONADOTROPIC HYPOGONADISM 7 WITH OR WITHOUT ANOSMIA; HH7	146110
HYPOPARATHYROIDISM, FAMILIAL ISOLATED; FIH	HYPOPARATHYROIDISM, FAMILIAL ISOLATED; FIH	146200
HYPOPARATHYROIDISM, AUTOSOMAL DOMINANTHYPOPARATHYROIDISM, AUTOSOMAL RECESSIVE, INCLUDED	HYPOPARATHYROIDISM, FAMILIAL ISOLATED; FIH	146200
HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DISEASE; HDR	HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DISEASE; HDR	146255
HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DYSPLASIA SYNDROME;HDRS	HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DISEASE; HDR	146255
BARAKAT SYNDROME	HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DISEASE; HDR	146255
NEPHROSIS, NERVE DEAFNESS, AND HYPOPARATHYROIDISM	HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DISEASE; HDR	146255
HYPOPHOSPHATASIA, ADULT	HYPOPHOSPHATASIA, ADULT	146300
HYPOPHOSPHATASIA, MILDODONTOHYPOPHOSPHATASIA, INCLUDED	HYPOPHOSPHATASIA, ADULT	146300
HYPOPHOSPHATEMIC BONE DISEASE; HBD	HYPOPHOSPHATEMIC BONE DISEASE; HBD	146350
CHROMOSOME 18p DELETION SYNDROME	CHROMOSOME 18p DELETION SYNDROME	146390
18p- SYNDROME	CHROMOSOME 18p DELETION SYNDROME	146390
HYPOSPADIAS 3, AUTOSOMAL; HYSP3	HYPOSPADIAS 3, AUTOSOMAL; HYSP3	146450
MULTIPLE SYSTEM ATROPHY 1, SUSCEPTIBILITY TO; MSA1	MULTIPLE SYSTEM ATROPHY 1, SUSCEPTIBILITY TO; MSA1	146500
MSA1, SUSCEPTIBILITY TOAUTONOMIC FAILURE, PURE, INCLUDED	MULTIPLE SYSTEM ATROPHY 1, SUSCEPTIBILITY TO; MSA1	146500
HYPOTENSION, ORTHOSTATIC, INCLUDED	MULTIPLE SYSTEM ATROPHY 1, SUSCEPTIBILITY TO; MSA1	146500
PALLISTER-HALL SYNDROME; PHS	PALLISTER-HALL SYNDROME; PHS	146510
HYPOTHALAMIC HAMARTOBLASTOMA, HYPOPITUITARISM, IMPERFORATE ANUS, ANDPOSTAXIAL POLYDACTYLY	PALLISTER-HALL SYNDROME; PHS	146510
HYPOTRICHOSIS 2; HYPT2	HYPOTRICHOSIS 2; HYPT2	146520
HYPOTRICHOSIS SIMPLEX OF THE SCALP 1; HTSS1	HYPOTRICHOSIS 2; HYPT2	146520
HTSS	HYPOTRICHOSIS 2; HYPT2	146520
HYPOTRICHOSIS, SPANISH TYPE	HYPOTRICHOSIS 2; HYPT2	146520
HYPOTRICHOSIS 4; HYPT4	HYPOTRICHOSIS 4; HYPT4	146550
MARIE UNNA HEREDITARY HYPOTRICHOSIS 1; MUHH1	HYPOTRICHOSIS 4; HYPT4	146550
HYPOTRICHOSIS, MARIE UNNA TYPE, 1	HYPOTRICHOSIS 4; HYPT4	146550
ICHTHYOSIS HYSTRIX, CURTH-MACKLIN TYPE; IHCM	ICHTHYOSIS HYSTRIX, CURTH-MACKLIN TYPE; IHCM	146590
IMP DEHYDROGENASE 2; IMPDH2	IMP DEHYDROGENASE 2; IMPDH2	146691
INOSINE-5-PRIME-MONOPHOSPHATE DEHYDROGENASE, TYPE II; IMPD2; IMPDHIIIMPDH2 ENZYME ACTIVITY, VARIATION IN, INCLUDED	IMP DEHYDROGENASE 2; IMPDH2	146691
ICHTHYOSIS VULGARIS	ICHTHYOSIS VULGARIS	146700
ICHTHYOSIS SIMPLEX	ICHTHYOSIS VULGARIS	146700
ICHTHYOSIS BULLOSA OF SIEMENS; IBS	ICHTHYOSIS BULLOSA OF SIEMENS; IBS	146800
ICHTHYOSIS, BULLOUS TYPEICHTHYOSIS EXFOLIATIVA, INCLUDED	ICHTHYOSIS BULLOSA OF SIEMENS; IBS	146800
IgE RESPONSIVENESS, ATOPIC; IGER	IgE RESPONSIVENESS, ATOPIC; IGER	147050
IMMUNOGLOBULIN E, BASIC LEVEL OF, IN SERUM	IgE RESPONSIVENESS, ATOPIC; IGER	147050
IgE, LEVEL OF; IGEL	IgE RESPONSIVENESS, ATOPIC; IGER	147050
IgE RESPONSE UNDERLYING ALLERGIC ASTHMA AND RHINITISIgE, ELEVATED LEVEL OF, INCLUDED	IgE RESPONSIVENESS, ATOPIC; IGER	147050
ATOPY, SUSCEPTIBILITY TO, INCLUDED	IgE RESPONSIVENESS, ATOPIC; IGER	147050
ATOPIC HYPERSENSITIVITY, INCLUDED	IgE RESPONSIVENESS, ATOPIC; IGER	147050
HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL DOMINANT	HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL DOMINANT	147060
HYPER-IgE SYNDROME, AUTOSOMAL DOMINANT	HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL DOMINANT	147060
HIES, AUTOSOMAL DOMINANT	HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL DOMINANT	147060
JOB SYNDROME	HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL DOMINANT	147060
IMMUNOGLOBULIN E CONCENTRATION, SERUM; IGES	IMMUNOGLOBULIN E CONCENTRATION, SERUM; IGES	147061
SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; SMMCI	SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; SMMCI	147250
INCISORS, FUSED	SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; SMMCI	147250
FUSED INCISORS	SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; SMMCI	147250
SINGLE UPPER CENTRAL INCISOR	SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; SMMCI	147250
SINGLE CENTRAL MAXILLARY INCISORSOLITARY MEDIAN MAXILLARY CENTRAL INCISOR SYNDROME, INCLUDED	SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; SMMCI	147250
SMMCI SYNDROME, INCLUDED	SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; SMMCI	147250
INCISORS, SHOVEL-SHAPED	INCISORS, SHOVEL-SHAPED	147400
SINODONTY	INCISORS, SHOVEL-SHAPED	147400
INCLUSION BODY MYOSITIS	INCLUSION BODY MYOSITIS	147421
IBM	INCLUSION BODY MYOSITIS	147421
INDIFFERENCE TO PAIN, CONGENITAL, AUTOSOMAL DOMINANT	INDIFFERENCE TO PAIN, CONGENITAL, AUTOSOMAL DOMINANT	147430
CONGENITAL ANALGESIA, AUTOSOMAL DOMINANT	INDIFFERENCE TO PAIN, CONGENITAL, AUTOSOMAL DOMINANT	147430
CHOLESTASIS, INTRAHEPATIC, OF PREGNANCY, 1; ICP1	CHOLESTASIS, INTRAHEPATIC, OF PREGNANCY, 1; ICP1	147480
CHOLESTASIS, PREGNANCY-RELATED, 1	CHOLESTASIS, INTRAHEPATIC, OF PREGNANCY, 1; ICP1	147480
INSULIN RECEPTOR SUBSTRATE 1; IRS1CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED	INSULIN RECEPTOR SUBSTRATE 1; IRS1CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED	147545
IVIC SYNDROME	IVIC SYNDROME	147750
RADIAL RAY DEFECTS, HEARING IMPAIRMENT, EXTERNAL OPHTHALMOPLEGIA,AND THROMBOCYTOPENIA	IVIC SYNDROME	147750
OCULOOTORADIAL SYNDROME; OORS	IVIC SYNDROME	147750
JOHNSON NEUROECTODERMAL SYNDROME	JOHNSON NEUROECTODERMAL SYNDROME	147770
JOHNSON-MCMILLIN SYNDROME; JMS	JOHNSON NEUROECTODERMAL SYNDROME	147770
ALOPECIA-ANOSMIA-DEAFNESS-HYPOGONADISM SYNDROME	JOHNSON NEUROECTODERMAL SYNDROME	147770
AADH SYNDROME	JOHNSON NEUROECTODERMAL SYNDROME	147770
JACOBSEN SYNDROME; JBS	JACOBSEN SYNDROME; JBS	147791
CHROMOSOME 11q DELETION SYNDROME	JACOBSEN SYNDROME; JBS	147791
PARTIAL 11q MONOSOMY SYNDROME	JACOBSEN SYNDROME; JBS	147791
AASE-SMITH SYNDROME I	AASE-SMITH SYNDROME I	147800
AASE-SMITH SYNDROME	AASE-SMITH SYNDROME I	147800
JOINT CONTRACTURES WITH OTHER ABNORMALITIES	AASE-SMITH SYNDROME I	147800
SMALL PATELLA SYNDROME; SPS	SMALL PATELLA SYNDROME; SPS	147891
ISCHIOPATELLAR DYSPLASIA	SMALL PATELLA SYNDROME; SPS	147891
COXOPODOPATELLAR SYNDROME	SMALL PATELLA SYNDROME; SPS	147891
SCOTT-TAOR SYNDROME	SMALL PATELLA SYNDROME; SPS	147891
DEIODINASE, IODOTHYRONINE, TYPE I; DIO1	DEIODINASE, IODOTHYRONINE, TYPE I; DIO1	147892
THYROXINE DEIODINASE, TYPE I; TXDI1HYPERTHYROXINEMIA DUE TO DECREASED PERIPHERAL CONVERSION OF T4, INCLUDED	DEIODINASE, IODOTHYRONINE, TYPE I; DIO1	147892
5-PRIME-@DEIODINASE DEFICIENCY, GENERALIZED, CAUSING EUTHYROID HYPERTHYROXINEMIA,INCLUDED	DEIODINASE, IODOTHYRONINE, TYPE I; DIO1	147892
JOINT LAXITY, FAMILIAL	JOINT LAXITY, FAMILIAL	147900
FAMILIAL JOINT INSTABILITY SYNDROME	JOINT LAXITY, FAMILIAL	147900
ARTICULAR HYPERMOBILITY SYNDROME	JOINT LAXITY, FAMILIAL	147900
EHLERS-DANLOS SYNDROME, TYPE XI, FORMERLY	JOINT LAXITY, FAMILIAL	147900
EDS XI, FORMERLY	JOINT LAXITY, FAMILIAL	147900
EDS11, FORMERLY	JOINT LAXITY, FAMILIAL	147900
KABUKI SYNDROME 1; KABUK1	KABUKI SYNDROME 1; KABUK1	147920
KABUKI SYNDROME	KABUKI SYNDROME 1; KABUK1	147920
KABUKI MAKE-UP SYNDROME; KMS	KABUKI SYNDROME 1; KABUK1	147920
NIIKAWA-KUROKI SYNDROME	KABUKI SYNDROME 1; KABUK1	147920
HYPOGONADOTROPIC HYPOGONADISM 2 WITH OR WITHOUT ANOSMIA; HH2	HYPOGONADOTROPIC HYPOGONADISM 2 WITH OR WITHOUT ANOSMIA; HH2	147950
KALLMANN SYNDROME 2; KAL2	HYPOGONADOTROPIC HYPOGONADISM 2 WITH OR WITHOUT ANOSMIA; HH2	147950
KAPOSI SARCOMA, SUSCEPTIBILITY TO	KAPOSI SARCOMA, SUSCEPTIBILITY TO	148000
MULTIPLE IDIOPATHIC PIGMENTED HEMANGIOSARCOMA, SUSCEPTIBILITY TOMULTICENTRIC CASTLEMAN DISEASE, SUSCEPTIBILITY TO, INCLUDED; MCD,INCLUDED	KAPOSI SARCOMA, SUSCEPTIBILITY TO	148000
KBG SYNDROME; KBGS	KBG SYNDROME; KBGS	148050
MACRODONTIA, MENTAL RETARDATION, CHARACTERISTIC FACIES, SHORT STATURE,AND SKELETAL ANOMALIES	KBG SYNDROME; KBGS	148050
KELOID FORMATION	KELOID FORMATION	148100
KERATITIS, HEREDITARY	KERATITIS, HEREDITARY	148190
KERATITIS FUGAX HEREDITARIA	KERATITIS FUGAX HEREDITARIA	148200
KERATOENDOTHELIITIS FUGAX HEREDITARIA	KERATITIS FUGAX HEREDITARIA	148200
KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME, AUTOSOMAL DOMINANT	KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME, AUTOSOMAL DOMINANT	148210
KID SYNDROME, AUTOSOMAL DOMINANT	KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME, AUTOSOMAL DOMINANT	148210
KERATOCONUS 1; KTCN1	KERATOCONUS 1; KTCN1	148300
KERATODERMA, PALMOPLANTAR, WITH DEAFNESS	KERATODERMA, PALMOPLANTAR, WITH DEAFNESS	148350
KERATOLYTIC WINTER ERYTHEMA; KWE	KERATOLYTIC WINTER ERYTHEMA; KWE	148370
OUDTSHOORN SKIN DISEASE	KERATOLYTIC WINTER ERYTHEMA; KWE	148370
TYLOSIS WITH ESOPHAGEAL CANCER; TOC	TYLOSIS WITH ESOPHAGEAL CANCER; TOC	148500
PALMOPLANTAR KERATODERMA WITH ESOPHAGEAL CANCER	TYLOSIS WITH ESOPHAGEAL CANCER; TOC	148500
KERATOSIS PALMARIS ET PLANTARIS WITH ESOPHAGEAL CANCER	TYLOSIS WITH ESOPHAGEAL CANCER; TOC	148500
PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IA; PPKP1A	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IA; PPKP1A	148600
PALMOPLANTAR KERATODERMA, PUNCTATE TYPE I; PPKP1	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IA; PPKP1A	148600
KPPP1	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IA; PPKP1A	148600
KERATODERMIA PALMOPLANTARIS PAPULOSA, BUSCHKE-FISCHER-BRAUER TYPE	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IA; PPKP1A	148600
KERATOSIS PALMOPLANTARIS PAPULOSA	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IA; PPKP1A	148600
PALMOPLANTAR KERATODERMA I, STRIATE, FOCAL, OR DIFFUSE; PPKS1	PALMOPLANTAR KERATODERMA I, STRIATE, FOCAL, OR DIFFUSE; PPKS1	148700
KERATOSIS PALMOPLANTARIS STRIATA I	PALMOPLANTAR KERATODERMA I, STRIATE, FOCAL, OR DIFFUSE; PPKS1	148700
STRIATE PALMOPLANTAR KERATODERMA I; SPPK1	PALMOPLANTAR KERATODERMA I, STRIATE, FOCAL, OR DIFFUSE; PPKS1	148700
KERATODERMA, PALMOPLANTAR, STRIATE FORM I; KPPS1	PALMOPLANTAR KERATODERMA I, STRIATE, FOCAL, OR DIFFUSE; PPKS1	148700
KERATOSIS, FOCAL PALMOPLANTAR AND GINGIVAL	KERATOSIS, FOCAL PALMOPLANTAR AND GINGIVAL	148730
FOCAL PALMOPLANTAR AND GINGIVAL HYPERKERATOSIS SYNDROME	KERATOSIS, FOCAL PALMOPLANTAR AND GINGIVAL	148730
WAARDENBURG SYNDROME, TYPE 3; WS3	WAARDENBURG SYNDROME, TYPE 3; WS3	148820
WAARDENBURG SYNDROME WITH UPPER LIMB ANOMALIES	WAARDENBURG SYNDROME, TYPE 3; WS3	148820
WAARDENBURG SYNDROME, TYPE III	WAARDENBURG SYNDROME, TYPE 3; WS3	148820
KLEIN-WAARDENBURG SYNDROME	WAARDENBURG SYNDROME, TYPE 3; WS3	148820
KLEINE-LEVIN HIBERNATION SYNDROME	KLEINE-LEVIN HIBERNATION SYNDROME	148840
KLEINE-LEVIN SYNDROME	KLEINE-LEVIN HIBERNATION SYNDROME	148840
KLIPPEL-TRENAUNAY-WEBER SYNDROME	KLIPPEL-TRENAUNAY-WEBER SYNDROME	149000
KTW SYNDROME	KLIPPEL-TRENAUNAY-WEBER SYNDROME	149000
KLIPPEL-TRENAUNAY SYNDROME; KTS	KLIPPEL-TRENAUNAY-WEBER SYNDROME	149000
ANGIOOSTEOHYPERTROPHY SYNDROME	KLIPPEL-TRENAUNAY-WEBER SYNDROME	149000
KNUCKLE PADS	KNUCKLE PADS	149100
KNUCKLE PADS, LEUKONYCHIA, AND SENSORINEURAL DEAFNESS	KNUCKLE PADS, LEUKONYCHIA, AND SENSORINEURAL DEAFNESS	149200
BART-PUMPHREY SYNDROME	KNUCKLE PADS, LEUKONYCHIA, AND SENSORINEURAL DEAFNESS	149200
NAIL DISORDER, NONSYNDROMIC CONGENITAL, 2; NDNC2	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 2; NDNC2	149300
KOILONYCHIA, HEREDITARY	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 2; NDNC2	149300
SPOON NAILSKOILONYCHIA WITH LEUKONYCHIA, INCLUDED	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 2; NDNC2	149300
HYPEREKPLEXIA, HEREDITARY 1; HKPX1	HYPEREKPLEXIA, HEREDITARY 1; HKPX1	149400
STARTLE DISEASE, FAMILIAL	HYPEREKPLEXIA, HEREDITARY 1; HKPX1	149400
STARTLE REACTION, EXAGGERATED	HYPEREKPLEXIA, HEREDITARY 1; HKPX1	149400
EXAGGERATED STARTLE REACTION	HYPEREKPLEXIA, HEREDITARY 1; HKPX1	149400
STHE	HYPEREKPLEXIA, HEREDITARY 1; HKPX1	149400
STIFF-BABY SYNDROME	HYPEREKPLEXIA, HEREDITARY 1; HKPX1	149400
STIFF-MAN SYNDROME, CONGENITAL	HYPEREKPLEXIA, HEREDITARY 1; HKPX1	149400
STIFF-PERSON SYNDROME, CONGENITAL	HYPEREKPLEXIA, HEREDITARY 1; HKPX1	149400
KOK DISEASE	HYPEREKPLEXIA, HEREDITARY 1; HKPX1	149400
LACRIMAL DUCT DEFECT; LCDD	LACRIMAL DUCT DEFECT; LCDD	149700
NASOLACRIMAL DUCT OBSTRUCTION	LACRIMAL DUCT DEFECT; LCDD	149700
LACRIMAL PUNCTA, ABSENCE OF	LACRIMAL DUCT DEFECT; LCDD	149700
LACRIMOAURICULODENTODIGITAL SYNDROME; LADD	LACRIMOAURICULODENTODIGITAL SYNDROME; LADD	149730
LEVY-HOLLISTER SYNDROME	LACRIMOAURICULODENTODIGITAL SYNDROME; LADD	149730
TRICHORHINOPHALANGEAL SYNDROME, TYPE II; TRPS2	TRICHORHINOPHALANGEAL SYNDROME, TYPE II; TRPS2	150230
LANGER-GIEDION SYNDROME; LGS	TRICHORHINOPHALANGEAL SYNDROME, TYPE II; TRPS2	150230
CHROMOSOME 8q24.1 DELETION SYNDROME	TRICHORHINOPHALANGEAL SYNDROME, TYPE II; TRPS2	150230
LARSEN SYNDROME; LRS	LARSEN SYNDROME; LRS	150250
LARYNGEAL ABDUCTOR PARALYSIS	LARYNGEAL ABDUCTOR PARALYSIS	150260
LABD	LARYNGEAL ABDUCTOR PARALYSIS	150260
GERHARDT SYNDROME	LARYNGEAL ABDUCTOR PARALYSIS	150260
VOCAL CORD DYSFUNCTION, FAMILIAL	LARYNGEAL ABDUCTOR PARALYSIS	150260
LARYNGEAL ADDUCTOR PARALYSIS; LAP	LARYNGEAL ADDUCTOR PARALYSIS; LAP	150270
VOCAL CORD DYSFUNCTION, ADDUCTOR TYPE	LARYNGEAL ADDUCTOR PARALYSIS; LAP	150270
TOOTH AGENESIS, SELECTIVE, 4; STHAG4	TOOTH AGENESIS, SELECTIVE, 4; STHAG4	150400
LATERAL INCISORS, ABSENCE OF	TOOTH AGENESIS, SELECTIVE, 4; STHAG4	150400
LATERAL INCISORS, PEGGED OR MISSINGSUCCEDANEOUS TEETH, AGENESIS OF, INCLUDED	TOOTH AGENESIS, SELECTIVE, 4; STHAG4	150400
LEGG-CALVE-PERTHES DISEASE; LCPD	LEGG-CALVE-PERTHES DISEASE; LCPD	150600
LCP	LEGG-CALVE-PERTHES DISEASE; LCPD	150600
LEGG-PERTHES DISEASE	LEGG-CALVE-PERTHES DISEASE; LCPD	150600
PERTHES DISEASE	LEGG-CALVE-PERTHES DISEASE; LCPD	150600
LEIOMYOMA, UTERINE; UL	LEIOMYOMA, UTERINE; UL	150699
HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER; HLRCC	HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER; HLRCC	150800
MULTIPLE CUTANEOUS AND UTERINE LEIOMYOMATA 1, WITH OR WITHOUT RENALCELL CARCINOMA; MCUL1	HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER; HLRCC	150800
LEIOMYOMATOSIS AND RENAL CELL CANCER, HEREDITARY; LRCC	HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER; HLRCC	150800
LEIOMYOMA, MULTIPLE CUTANEOUS; MCL	HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER; HLRCC	150800
LENTIGINOSIS, INHERITED PATTERNED	LENTIGINOSIS, INHERITED PATTERNED	151001
LENTIGINOSIS, GENERALIZED	LENTIGINOSIS, INHERITED PATTERNED	151001
LENTIGINOSIS PROFUSA	LENTIGINOSIS, INHERITED PATTERNED	151001
LENTIGINOSIS, DIFFUSE	LENTIGINOSIS, INHERITED PATTERNED	151001
LENZ-MAJEWSKI HYPEROSTOTIC DWARFISM; LMHD	LENZ-MAJEWSKI HYPEROSTOTIC DWARFISM; LMHD	151050
LENZ-MAJEWSKI SYNDROME	LENZ-MAJEWSKI HYPEROSTOTIC DWARFISM; LMHD	151050
LEOPARD SYNDROME 1; LPRD1	LEOPARD SYNDROME 1; LPRD1	151100
LENTIGINOSIS, CARDIOMYOPATHIC	LEOPARD SYNDROME 1; LPRD1	151100
MULTIPLE LENTIGINES SYNDROME	LEOPARD SYNDROME 1; LPRD1	151100
CHROMOSOME 8q22.1 DUPLICATION SYNDROME	CHROMOSOME 8q22.1 DUPLICATION SYNDROME	151200
LERI PLEONOSTEOSIS	CHROMOSOME 8q22.1 DUPLICATION SYNDROME	151200
PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, TORRANCE TYPE; PLSDT	PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, TORRANCE TYPE; PLSDT	151210
LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, TORRANCE TYPE	PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, TORRANCE TYPE; PLSDT	151210
THANATOPHORIC DYSPLASIA, TORRANCE VARIANTPLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, LUTON TYPE, INCLUDED; PLSDL,INCLUDED	PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, TORRANCE TYPE; PLSDT	151210
THANATOPHORIC DYSPLASIA, LUTON VARIANT, INCLUDED	PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, TORRANCE TYPE; PLSDT	151210
LEUKEMIA, CHRONIC LYMPHOCYTIC; CLL	LEUKEMIA, CHRONIC LYMPHOCYTIC; CLL	151400
LEUKEMIA, CHRONIC LYMPHATIC	LEUKEMIA, CHRONIC LYMPHOCYTIC; CLL	151400
B-CELL CLL/LYMPHOMA 2; BCL2	B-CELL CLL/LYMPHOMA 2; BCL2	151430
ONCOGENE B-CELL LEUKEMIA 2LEUKEMIA/LYMPHOMA, B-CELL, 2, INCLUDED	B-CELL CLL/LYMPHOMA 2; BCL2	151430
NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3; NDNC3	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3; NDNC3	151600
LEUKONYCHIA TOTALIS AND/OR PARTIALIS	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3; NDNC3	151600
PORCELAIN NAILSLEUKONYCHIA STRIATUS, INCLUDED	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3; NDNC3	151600
LEUKONYCHIA PUNCTATA, INCLUDED	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3; NDNC3	151600
LI-FRAUMENI SYNDROME 1; LFS1	LI-FRAUMENI SYNDROME 1; LFS1	151623
SARCOMA FAMILY SYNDROME OF LI AND FRAUMENI	LI-FRAUMENI SYNDROME 1; LFS1	151623
SBLA SYNDROMELI-FRAUMENI-LIKE SYNDROME, INCLUDED; LFL, INCLUDED	LI-FRAUMENI SYNDROME 1; LFS1	151623
LIP, MEDIAN NODULE OF UPPER	LIP, MEDIAN NODULE OF UPPER	151630
LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2	151660
FPL2	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2	151660
LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2	151660
LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2	151660
LIPODYSTROPHY, REVERSE PARTIAL	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2	151660
LIPOATROPHIC DIABETES	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2	151660
LIPOMATOSIS, MULTIPLE	LIPOMATOSIS, MULTIPLE	151900
LIPOMATOSIS, FAMILIAL MULTIPLE; FML	LIPOMATOSIS, MULTIPLE	151900
LIPOMA; LIPO	LIPOMATOSIS, MULTIPLE	151900
LIPOPROTEIN TYPES--Ld SYSTEM	LIPOPROTEIN TYPES--Ld SYSTEM	152100
APOLIPOPROTEIN(a); LPALIPOPROTEIN(a), INCLUDED; Lp(a), INCLUDED	APOLIPOPROTEIN(a); LPALIPOPROTEIN(a), INCLUDED; Lp(a), INCLUDED	152200
LIPOPROTEIN TYPES--Lp SYSTEM Lp(a) HYPERLIPOPROTEINEMIA, INCLUDED	APOLIPOPROTEIN(a); LPALIPOPROTEIN(a), INCLUDED; Lp(a), INCLUDED	152200
SINKING PRE-BETA-LIPOPROTEIN, INCLUDED; SPB, INCLUDED	APOLIPOPROTEIN(a); LPALIPOPROTEIN(a), INCLUDED; Lp(a), INCLUDED	152200
LIPOPROTEIN(a) DEFICIENCY, CONGENITAL, INCLUDED	APOLIPOPROTEIN(a); LPALIPOPROTEIN(a), INCLUDED; Lp(a), INCLUDED	152200
Lp(a) DEFICIENCY, CONGENITAL, INCLUDED	APOLIPOPROTEIN(a); LPALIPOPROTEIN(a), INCLUDED; Lp(a), INCLUDED	152200
CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED	APOLIPOPROTEIN(a); LPALIPOPROTEIN(a), INCLUDED; Lp(a), INCLUDED	152200
LONGEVITY 1	LONGEVITY 1	152430
SYSTEMIC LUPUS ERYTHEMATOSUS; SLEEXCESS LYMPHOCYTE LOW MOLECULAR WEIGHT DNA, INCLUDED	SYSTEMIC LUPUS ERYTHEMATOSUS; SLEEXCESS LYMPHOCYTE LOW MOLECULAR WEIGHT DNA, INCLUDED	152700
EXCESS LMW-DNA, INCLUDED	SYSTEMIC LUPUS ERYTHEMATOSUS; SLEEXCESS LYMPHOCYTE LOW MOLECULAR WEIGHT DNA, INCLUDED	152700
LYMPHANGIECTASIA, INTESTINAL	LYMPHANGIECTASIA, INTESTINAL	152800
MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, LYMPHEDEMA, OR MENTALRETARDATION; MCLMR	MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, LYMPHEDEMA, OR MENTALRETARDATION; MCLMR	152950
MICROCEPHALY, LYMPHEDEMA, CHORIORETINAL DYSPLASIA SYNDROME	MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, LYMPHEDEMA, OR MENTALRETARDATION; MCLMR	152950
MLCRD SYNDROME	MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, LYMPHEDEMA, OR MENTALRETARDATION; MCLMR	152950
MICROCEPHALY AND CHORIORETINOPATHY WITH OR WITHOUT MENTAL RETARDATION,AUTOSOMAL DOMINANT	MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, LYMPHEDEMA, OR MENTALRETARDATION; MCLMR	152950
CDMMR SYNDROME	MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, LYMPHEDEMA, OR MENTALRETARDATION; MCLMR	152950
LYMPHEDEMA, MICROCEPHALY, CHORIORETINOPATHY SYNDROME	MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, LYMPHEDEMA, OR MENTALRETARDATION; MCLMR	152950
LYMPHEDEMA AND RETINAL FOLDS WITH MICROCEPHALY AND MICROPHTHALMOS	MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, LYMPHEDEMA, OR MENTALRETARDATION; MCLMR	152950
LYMPHEDEMA, HEREDITARY, IA; LMPH1A	LYMPHEDEMA, HEREDITARY, IA; LMPH1A	153100
NONNE-MILROY LYMPHEDEMA	LYMPHEDEMA, HEREDITARY, IA; LMPH1A	153100
MILROY DISEASE	LYMPHEDEMA, HEREDITARY, IA; LMPH1A	153100
LYMPHEDEMA, EARLY-ONSET	LYMPHEDEMA, HEREDITARY, IA; LMPH1A	153100
PRIMARY CONGENITAL LYMPHEDEMA; PCL	LYMPHEDEMA, HEREDITARY, IA; LMPH1A	153100
LYMPHEDEMA, HEREDITARY, II; LMPH2	LYMPHEDEMA, HEREDITARY, II; LMPH2	153200
MEIGE DISEASE	LYMPHEDEMA, HEREDITARY, II; LMPH2	153200
MEIGE LYMPHEDEMA	LYMPHEDEMA, HEREDITARY, II; LMPH2	153200
LYMPHEDEMA, LATE-ONSET	LYMPHEDEMA, HEREDITARY, II; LMPH2	153200
LYMPHEDEMA PRAECOX	LYMPHEDEMA, HEREDITARY, II; LMPH2	153200
LYMPHOID ENHANCER-BINDING FACTOR 1; LEF1	LYMPHOID ENHANCER-BINDING FACTOR 1; LEF1	153245
TRANSCRIPTION FACTOR, T CELL-SPECIFIC, 1, ALPHA	LYMPHOID ENHANCER-BINDING FACTOR 1; LEF1	153245
TCF1-ALPHASEBACEOUS TUMORS, SOMATIC, INCLUDED	LYMPHOID ENHANCER-BINDING FACTOR 1; LEF1	153245
YELLOW NAIL SYNDROME	YELLOW NAIL SYNDROME	153300
YNS	YELLOW NAIL SYNDROME	153300
LYMPHEDEMA AND YELLOW NAILS	YELLOW NAIL SYNDROME	153300
LYMPHEDEMA-DISTICHIASIS SYNDROME	LYMPHEDEMA-DISTICHIASIS SYNDROME	153400
LYMPHEDEMA WITH DISTICHIASISLYMPHEDEMA-DISTICHIASIS SYNDROME WITH RENAL DISEASE AND DIABETES MELLITUS,INCLUDED	LYMPHEDEMA-DISTICHIASIS SYNDROME	153400
BANNAYAN-RILEY-RUVALCABA SYNDROME; BRRS	BANNAYAN-RILEY-RUVALCABA SYNDROME; BRRS	153480
BANNAYAN-ZONANA SYNDROME; BZS	BANNAYAN-RILEY-RUVALCABA SYNDROME; BRRS	153480
RILEY-SMITH SYNDROME	BANNAYAN-RILEY-RUVALCABA SYNDROME; BRRS	153480
RUVALCABA-MYHRE-SMITH SYNDROME; RMSS	BANNAYAN-RILEY-RUVALCABA SYNDROME; BRRS	153480
MACROCEPHALY, PSEUDOPAPILLEDEMA, AND MULTIPLE HEMANGIOMATA	BANNAYAN-RILEY-RUVALCABA SYNDROME; BRRS	153480
MACROCEPHALY, MULTIPLE LIPOMAS, AND HEMANGIOMATA	BANNAYAN-RILEY-RUVALCABA SYNDROME; BRRS	153480
CHROMOSOME 5q DELETION SYNDROME	CHROMOSOME 5q DELETION SYNDROME	153550
5q- SYNDROME	CHROMOSOME 5q DELETION SYNDROME	153550
MACROCYTIC ANEMIA, REFRACTORY, DUE TO 5q DELETION; MARMEGAKARYOCYTES, UNILOBULAR NUCLEATED, INCLUDED	CHROMOSOME 5q DELETION SYNDROME	153550
MACROGLOBULINEMIA, WALDENSTROM, SUSCEPTIBILITY TO, 1; WM1MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, INCLUDED	MACROGLOBULINEMIA, WALDENSTROM, SUSCEPTIBILITY TO, 1; WM1MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, INCLUDED	153600
MACROGLOSSIA	MACROGLOSSIA	153630
FECHTNER SYNDROME; FTNS	FECHTNER SYNDROME; FTNS	153640
MACROTHROMBOCYTOPENIA, NEPHRITIS, DEAFNESS, AND LEUKOCYTE INCLUSIONS	FECHTNER SYNDROME; FTNS	153640
ALPORT SYNDROME WITH MACROTHROMBOCYTOPENIA, FORMERLY; APSM, FORMERLY	FECHTNER SYNDROME; FTNS	153640
EPSTEIN SYNDROME	EPSTEIN SYNDROME	153650
MACROTHROMBOCYTOPENIA, NEPHRITIS, AND DEAFNESS	EPSTEIN SYNDROME	153650
BERNARD-SOULIER SYNDROME, TYPE A2, AUTOSOMAL DOMINANT; BSSA2	BERNARD-SOULIER SYNDROME, TYPE A2, AUTOSOMAL DOMINANT; BSSA2	153670
MACULAR DYSTROPHY, VITELLIFORM, 2; VMD2	MACULAR DYSTROPHY, VITELLIFORM, 2; VMD2	153700
VITELLIFORM MACULAR DYSTROPHY, EARLY-ONSET	MACULAR DYSTROPHY, VITELLIFORM, 2; VMD2	153700
VITELLIFORM MACULAR DYSTROPHY, JUVENILE-ONSET	MACULAR DYSTROPHY, VITELLIFORM, 2; VMD2	153700
BEST MACULAR DYSTROPHY; BMD	MACULAR DYSTROPHY, VITELLIFORM, 2; VMD2	153700
MACULAR DEGENERATION, POLYMORPHIC VITELLINE	MACULAR DYSTROPHY, VITELLIFORM, 2; VMD2	153700
BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL	MACULAR DYSTROPHY, VITELLIFORM, 2; VMD2	153700
MACULAR DEGENERATION, AGE-RELATED, 2; ARMD2	MACULAR DEGENERATION, AGE-RELATED, 2; ARMD2	153800
MACULOPATHY, AGE-RELATED, 2	MACULAR DEGENERATION, AGE-RELATED, 2; ARMD2	153800
MACULAR DEGENERATION, SENILE	MACULAR DEGENERATION, AGE-RELATED, 2; ARMD2	153800
MACULAR DYSTROPHY, VITELLIFORM, 1; VMD1	MACULAR DYSTROPHY, VITELLIFORM, 1; VMD1	153840
MACULAR DYSTROPHY, ATYPICAL VITELLIFORM	MACULAR DYSTROPHY, VITELLIFORM, 1; VMD1	153840
MACULAR DYSTROPHY, CONCENTRIC ANNULAR	MACULAR DYSTROPHY, CONCENTRIC ANNULAR	153870
MCDCA	MACULAR DYSTROPHY, CONCENTRIC ANNULAR	153870
MACULAR DYSTROPHY, BENIGN CONCENTRIC ANNULAR; BCAMD	MACULAR DYSTROPHY, CONCENTRIC ANNULAR	153870
MACULAR DYSTROPHY, DOMINANT CYSTOID; DCMD	MACULAR DYSTROPHY, DOMINANT CYSTOID; DCMD	153880
CYSTOID MACULAR DYSTROPHY; CYMD	MACULAR DYSTROPHY, DOMINANT CYSTOID; DCMD	153880
MACULAR EDEMA, CYSTOID	MACULAR DYSTROPHY, DOMINANT CYSTOID; DCMD	153880
MDDC	MACULAR DYSTROPHY, DOMINANT CYSTOID; DCMD	153880
HYPOMAGNESEMIA 2, RENAL; HOMG2	HYPOMAGNESEMIA 2, RENAL; HOMG2	154020
MAGNESIUM WASTING, RENAL	HYPOMAGNESEMIA 2, RENAL; HOMG2	154020
MAGNESIUM LOSS, ISOLATED RENAL	HYPOMAGNESEMIA 2, RENAL; HOMG2	154020
46,XY SEX REVERSAL 4; SRXY4	46,XY SEX REVERSAL 4; SRXY4	154230
46,XY GONADAL DYSGENESIS, PARTIAL OR COMPLETE, WITH 9p24.3 DELETION	46,XY SEX REVERSAL 4; SRXY4	154230
CHROMOSOME 9p24.3 DELETION SYNDROME	46,XY SEX REVERSAL 4; SRXY4	154230
MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 2	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 2	154275
MHS2	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 2	154275
MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 3	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 3	154276
MHS3	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 3	154276
ACROFACIAL DYSOSTOSIS 1, NAGER TYPE; AFD1	ACROFACIAL DYSOSTOSIS 1, NAGER TYPE; AFD1	154400
MANDIBULOFACIAL DYSOSTOSIS, TREACHER COLLINS TYPE, WITH LIMB ANOMALIES	ACROFACIAL DYSOSTOSIS 1, NAGER TYPE; AFD1	154400
NAGER ACROFACIAL DYSOSTOSIS	ACROFACIAL DYSOSTOSIS 1, NAGER TYPE; AFD1	154400
AFD, NAGER TYPE	ACROFACIAL DYSOSTOSIS 1, NAGER TYPE; AFD1	154400
NAGER SYNDROME	ACROFACIAL DYSOSTOSIS 1, NAGER TYPE; AFD1	154400
TREACHER COLLINS SYNDROME 1; TCS1	TREACHER COLLINS SYNDROME 1; TCS1	154500
TREACHER COLLINS-FRANCESCHETTI SYNDROME; TCOF	TREACHER COLLINS SYNDROME 1; TCS1	154500
TREACHER COLLINS SYNDROME; TCS	TREACHER COLLINS SYNDROME 1; TCS1	154500
MANDIBULOFACIAL DYSOSTOSIS; MFD1	TREACHER COLLINS SYNDROME 1; TCS1	154500
MANNOSE 6-PHOSPHATE RECEPTOR RECOGNITION DEFECT, LEBANESE TYPE	MANNOSE 6-PHOSPHATE RECEPTOR RECOGNITION DEFECT, LEBANESE TYPE	154570
PHOSPHODIESTER GLYCOSIDE DEFICIENCY	MANNOSE 6-PHOSPHATE RECEPTOR RECOGNITION DEFECT, LEBANESE TYPE	154570
MARFAN SYNDROME; MFS	MARFAN SYNDROME; MFS	154700
MARFAN SYNDROME, TYPE I; MFS1	MARFAN SYNDROME; MFS	154700
MARSHALL SYNDROME; MRSHS	MARSHALL SYNDROME; MRSHS	154780
MAXILLOFACIAL DYSOSTOSIS	MAXILLOFACIAL DYSOSTOSIS	155000
MAXILLONASAL DYSPLASIA, BINDER TYPE	MAXILLONASAL DYSPLASIA, BINDER TYPE	155050
BINDER SYNDROME	MAXILLONASAL DYSPLASIA, BINDER TYPE	155050
MAY-HEGGLIN ANOMALY; MHA	MAY-HEGGLIN ANOMALY; MHA	155100
BLEEDING DISORDER, PLATELET-TYPE, 6; BDPLT6	MAY-HEGGLIN ANOMALY; MHA	155100
DOHLE LEUKOCYTE INCLUSIONS WITH GIANT PLATELETS	MAY-HEGGLIN ANOMALY; MHA	155100
MACROTHROMBOCYTOPENIA WITH LEUKOCYTE INCLUSIONS	MAY-HEGGLIN ANOMALY; MHA	155100
CLEFT, MEDIAN, OF UPPER LIP WITH POLYPS OF FACIAL SKIN AND NASAL MUCOSA	CLEFT, MEDIAN, OF UPPER LIP WITH POLYPS OF FACIAL SKIN AND NASAL MUCOSA	155145
PAI SYNDROME	CLEFT, MEDIAN, OF UPPER LIP WITH POLYPS OF FACIAL SKIN AND NASAL MUCOSA	155145
THYROID CARCINOMA, FAMILIAL MEDULLARY; MTC	THYROID CARCINOMA, FAMILIAL MEDULLARY; MTC	155240
FMTC	THYROID CARCINOMA, FAMILIAL MEDULLARY; MTC	155240
MTC1	THYROID CARCINOMA, FAMILIAL MEDULLARY; MTC	155240
MEDULLOBLASTOMA; MDBMEDULLOBLASTOMA, DESMOPLASTIC, INCLUDED	MEDULLOBLASTOMA; MDBMEDULLOBLASTOMA, DESMOPLASTIC, INCLUDED	155255
MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY, INCLUDED; MBEN, INCLUDED	MEDULLOBLASTOMA; MDBMEDULLOBLASTOMA, DESMOPLASTIC, INCLUDED	155255
VISCERAL MYOPATHY; VSCM	VISCERAL MYOPATHY; VSCM	155310
MEGACYSTIS-MICROCOLON-INTESTINAL HYPOPERISTALSIS SYNDROME; MMIH	VISCERAL MYOPATHY; VSCM	155310
INFANTILE VISCERAL MYOPATHY	VISCERAL MYOPATHY; VSCM	155310
MEGADUODENUM AND/OR MEGACYSTIS	VISCERAL MYOPATHY; VSCM	155310
BERDON SYNDROME	VISCERAL MYOPATHY; VSCM	155310
PSEUDOOBSTRUCTION, IDIOPATHIC INTESTINAL	VISCERAL MYOPATHY; VSCM	155310
MEGALENCEPHALY, AUTOSOMAL DOMINANT	MEGALENCEPHALY, AUTOSOMAL DOMINANT	155350
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1	155600
MELANOMA, CUTANEOUS MALIGNANT; CMM	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1	155600
MELANOMA, MALIGNANT	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1	155600
FAMILIAL ATYPICAL MOLE-MALIGNANT MELANOMA SYNDROME; FAMMM	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1	155600
MELANOMA, FAMILIAL; MLM	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1	155600
DYSPLASTIC NEVUS SYNDROME, HEREDITARY; DNS	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1	155600
B-K MOLE SYNDROME	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1	155600
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 2; CMM2	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 2; CMM2	155601
MELANOMA, UVEAL	MELANOMA, UVEAL	155720
MELANOMA-ASTROCYTOMA SYNDROME	MELANOMA-ASTROCYTOMA SYNDROME	155755
MELANOMA AND NEURAL SYSTEM TUMOR SYNDROME	MELANOMA-ASTROCYTOMA SYNDROME	155755
MELKERSSON-ROSENTHAL SYNDROME	MELKERSSON-ROSENTHAL SYNDROME	155900
MROS; MRS	MELKERSSON-ROSENTHAL SYNDROME	155900
MELKERSSON SYNDROME	MELKERSSON-ROSENTHAL SYNDROME	155900
MELORHEOSTOSIS, ISOLATED	MELORHEOSTOSIS, ISOLATED	155950
MEL	MELORHEOSTOSIS, ISOLATED	155950
MEMBRANOUS CRANIAL OSSIFICATION, DELAYED	MEMBRANOUS CRANIAL OSSIFICATION, DELAYED	155980
MENTAL RETARDATION, AUTOSOMAL DOMINANT 1; MRD1CHROMOSOME 2q23.1 DELETION SYNDROME, INCLUDED	MENTAL RETARDATION, AUTOSOMAL DOMINANT 1; MRD1CHROMOSOME 2q23.1 DELETION SYNDROME, INCLUDED	156200
MESOMELIC DWARFISM OF HYPOPLASTIC TIBIA AND RADIUS TYPE	MESOMELIC DWARFISM OF HYPOPLASTIC TIBIA AND RADIUS TYPE	156230
MESOMELIC DYSPLASIA, KANTAPUTRA TYPE; MMDK	MESOMELIC DYSPLASIA, KANTAPUTRA TYPE; MMDK	156232
MDK	MESOMELIC DYSPLASIA, KANTAPUTRA TYPE; MMDK	156232
MESOMELIC DYSPLASIA WITH ANKLE, CARPAL, AND TARSAL SYNOSTOSIS	MESOMELIC DYSPLASIA, KANTAPUTRA TYPE; MMDK	156232
MESOMELIC DYSPLASIA, THAI TYPE	MESOMELIC DYSPLASIA, KANTAPUTRA TYPE; MMDK	156232
MESOTHELIOMA, MALIGNANT; MESOM	MESOTHELIOMA, MALIGNANT; MESOM	156240
METACHONDROMATOSIS; METCDS	METACHONDROMATOSIS; METCDS	156250
METAPHYSEAL CHONDRODYSPLASIA, JANSEN TYPE	METAPHYSEAL CHONDRODYSPLASIA, JANSEN TYPE	156400
METAPHYSEAL CHONDRODYSPLASIA, MURK JANSEN TYPE	METAPHYSEAL CHONDRODYSPLASIA, JANSEN TYPE	156400
METAPHYSEAL CHONDRODYSPLASIA, SCHMID TYPE; MCDS	METAPHYSEAL CHONDRODYSPLASIA, SCHMID TYPE; MCDS	156500
SPONDYLOMETAPHYSEAL DYSPLASIA, JAPANESE TYPE	METAPHYSEAL CHONDRODYSPLASIA, SCHMID TYPE; MCDS	156500
METAPHYSEAL DYSPLASIA WITH MAXILLARY HYPOPLASIA WITH OR WITHOUT BRACHYDACTYLY;MDMHB	METAPHYSEAL DYSPLASIA WITH MAXILLARY HYPOPLASIA WITH OR WITHOUT BRACHYDACTYLY;MDMHB	156510
METATARSUS VARUS, TYPE I	METATARSUS VARUS, TYPE I	156520
METATROPIC DYSPLASIA	METATROPIC DYSPLASIA	156530
METATROPIC DWARFISM	METATROPIC DYSPLASIA	156530
KNIEST DYSPLASIA	KNIEST DYSPLASIA	156550
MICROCEPHALY, AUTOSOMAL DOMINANT	MICROCEPHALY, AUTOSOMAL DOMINANT	156580
MICROCORIA, CONGENITAL	MICROCORIA, CONGENITAL	156600
CHROMOSOME 13q32 DELETION SYNDROME	MICROCORIA, CONGENITAL	156600
MCOR	MICROCORIA, CONGENITAL	156600
MIOSIS, CONGENITAL	MICROCORIA, CONGENITAL	156600
SKIN CREASES, MULTIPLE BENIGN RING-SHAPED, OF LIMBS	SKIN CREASES, MULTIPLE BENIGN RING-SHAPED, OF LIMBS	156610
MICHELIN TIRE BABY SYNDROME	SKIN CREASES, MULTIPLE BENIGN RING-SHAPED, OF LIMBS	156610
MICROPHTHALMIA, ISOLATED, WITH CATARACT 1; MCOPCT1	MICROPHTHALMIA, ISOLATED, WITH CATARACT 1; MCOPCT1	156850
CATARACT, CONGENITAL, WITH MICROPHTHALMIA; CATM	MICROPHTHALMIA, ISOLATED, WITH CATARACT 1; MCOPCT1	156850
HOLOPROSENCEPHALY 2; HPE2	HOLOPROSENCEPHALY 2; HPE2	157170
MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	157300
MGR1	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	157300
MGAU; MA	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	157300
MIGRAINE	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	157300
MILIA, MULTIPLE ERUPTIVE	MILIA, MULTIPLE ERUPTIVE	157400
MIRROR MOVEMENTS 1; MRMV1	MIRROR MOVEMENTS 1; MRMV1	157600
MIRROR MOVEMENTS, CONGENITAL	MIRROR MOVEMENTS 1; MRMV1	157600
BIMANUAL SYNERGIA	MIRROR MOVEMENTS 1; MRMV1	157600
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 1; PEOA1	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 1; PEOA1	157640
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 1; PEOA1	157640
MITRAL VALVE PROLAPSE 1; MVP1	MITRAL VALVE PROLAPSE 1; MVP1	157700
MITRAL VALVE PROLAPSE, MYXOMATOUS 1; MMVP1	MITRAL VALVE PROLAPSE 1; MVP1	157700
MYXOMATOUS MITRAL VALVE PROLAPSE 1	MITRAL VALVE PROLAPSE 1; MVP1	157700
MITRAL VALVE PROLAPSE, FAMILIAL; MVP PROLAPSED MITRAL VALVE; PMV	MITRAL VALVE PROLAPSE 1; MVP1	157700
MITRAL REGURGITATION, FAMILIAL	MITRAL VALVE PROLAPSE 1; MVP1	157700
FLOPPY MITRAL VALVE	MITRAL VALVE PROLAPSE 1; MVP1	157700
BARLOW SYNDROME	MITRAL VALVE PROLAPSE 1; MVP1	157700
MYXOMATOUS VALVULAR DISEASE, FAMILIAL	MITRAL VALVE PROLAPSE 1; MVP1	157700
CLICK-MURMUR SYNDROME	MITRAL VALVE PROLAPSE 1; MVP1	157700
MOEBIUS SYNDROME; MBS	MOEBIUS SYNDROME; MBS	157900
MOBIUS SYNDROME; MBS	MOEBIUS SYNDROME; MBS	157900
MOEBIUS SEQUENCE	MOEBIUS SYNDROME; MBS	157900
PERMANENT MOLARS, SECONDARY RETENTION OF	PERMANENT MOLARS, SECONDARY RETENTION OF	157950
ANKYLOSIS OF TEETH	PERMANENT MOLARS, SECONDARY RETENTION OF	157950
DENTAL ANKYLOSIS	PERMANENT MOLARS, SECONDARY RETENTION OF	157950
MOLAR I REINCLUSION	PERMANENT MOLARS, SECONDARY RETENTION OF	157950
MONILETHRIX; MNLIX	MONILETHRIX; MNLIX	158000
CHEMOKINE, CC MOTIF, LIGAND 2; CCL2	CHEMOKINE, CC MOTIF, LIGAND 2; CCL2	158105
SMALL INDUCIBLE CYTOKINE A2; SCYA2	CHEMOKINE, CC MOTIF, LIGAND 2; CCL2	158105
MONOCYTE CHEMOTACTIC PROTEIN 1; MCP1	CHEMOKINE, CC MOTIF, LIGAND 2; CCL2	158105
MONOCYTE CHEMOTACTIC AND ACTIVATING FACTOR; MCAFCORONARY ARTERY DISEASE, MODIFIER OF, INCLUDED	CHEMOKINE, CC MOTIF, LIGAND 2; CCL2	158105
CORONARY ARTERY DISEASE, DEVELOPMENT OF, IN HIV, INCLUDED	CHEMOKINE, CC MOTIF, LIGAND 2; CCL2	158105
CHROMOSOME 9p DELETION SYNDROME	CHROMOSOME 9p DELETION SYNDROME	158170
MONOSOMY 9p SYNDROME	CHROMOSOME 9p DELETION SYNDROME	158170
ARTHROGRYPOSIS, DISTAL, TYPE 7; DA7	ARTHROGRYPOSIS, DISTAL, TYPE 7; DA7	158300
TRISMUS-PSEUDOCAMPTODACTYLY SYNDROME	ARTHROGRYPOSIS, DISTAL, TYPE 7; DA7	158300
MOUTH, INABILITY TO OPEN COMPLETELY, AND SHORT FINGER-FLEXOR TENDONS	ARTHROGRYPOSIS, DISTAL, TYPE 7; DA7	158300
HECHT SYNDROME	ARTHROGRYPOSIS, DISTAL, TYPE 7; DA7	158300
MUCOEPITHELIAL DYSPLASIA, HEREDITARY	MUCOEPITHELIAL DYSPLASIA, HEREDITARY	158310
HMD	MUCOEPITHELIAL DYSPLASIA, HEREDITARY	158310
MUIR-TORRE SYNDROME; MRTES	MUIR-TORRE SYNDROME; MRTES	158320
CUTANEOUS SEBACEOUS NEOPLASMS AND KERATOACANTHOMAS, MULTIPLE, WITHGASTROINTESTINAL AND OTHER CARCINOMAS	MUIR-TORRE SYNDROME; MRTES	158320
MULLERIAN APLASIA AND HYPERANDROGENISM	MULLERIAN APLASIA AND HYPERANDROGENISM	158330
MULLERIAN DUCT FAILURE AND HYPERANDROGENISM	MULLERIAN APLASIA AND HYPERANDROGENISM	158330
COWDEN SYNDROME 1; CWS1	COWDEN SYNDROME 1; CWS1	158350
CS; CD	COWDEN SYNDROME 1; CWS1	158350
MULTIPLE HAMARTOMA SYNDROME; MHAMDYSPLASTIC GANGLIOCYTOMA OF THE CEREBELLUM, INCLUDED	COWDEN SYNDROME 1; CWS1	158350
CEREBELLOPARENCHYMAL DISORDER VI, INCLUDED; CPD6, INCLUDED	COWDEN SYNDROME 1; CWS1	158350
CEREBELLAR GRANULE CELL HYPERTROPHY AND MEGALENCEPHALY, INCLUDED	COWDEN SYNDROME 1; CWS1	158350
LHERMITTE-DUCLOS DISEASE, INCLUDED; LDD, INCLUDED	COWDEN SYNDROME 1; CWS1	158350
PROTEUS-LIKE SYNDROME, INCLUDED	COWDEN SYNDROME 1; CWS1	158350
MUSCLE CRAMPS, FAMILIAL	MUSCLE CRAMPS, FAMILIAL	158400
MUSCULAR ATROPHY, ATAXIA, RETINITIS PIGMENTOSA, AND DIABETES MELLITUS	MUSCULAR ATROPHY, ATAXIA, RETINITIS PIGMENTOSA, AND DIABETES MELLITUS	158500
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA; HMN7A	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA; HMN7A	158580
HMN VIIA	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA; HMN7A	158580
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA; HMN7A	158580
DHMN7A	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA; HMN7A	158580
DHMNVP	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA; HMN7A	158580
SPINAL MUSCULAR ATROPHY, DISTAL, WITH VOCAL CORD PARALYSIS	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA; HMN7A	158580
HARPER-YOUNG MYOPATHY	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA; HMN7A	158580
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIA; HMN2A	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIA; HMN2A	158590
HMN IIA	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIA; HMN2A	158590
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IIA; DHMN2A	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIA; HMN2A	158590
SPINAL MUSCULAR ATROPHY, DISTAL, ADULT, AUTOSOMAL DOMINANT, IIA	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIA; HMN2A	158590
CHARCOT-MARIE-TOOTH DISEASE, SPINAL, IIA	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIA; HMN2A	158590
SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 1, AUTOSOMALDOMINANT; SMALED1	SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 1, AUTOSOMALDOMINANT; SMALED1	158600
SMA-LED	SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 1, AUTOSOMALDOMINANT; SMALED1	158600
SPINAL MUSCULAR ATROPHY, CHILDHOOD, PROXIMAL, AUTOSOMAL DOMINANT	SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 1, AUTOSOMALDOMINANT; SMALED1	158600
SPINAL MUSCULAR ATROPHY, JUVENILE, PROXIMAL, AUTOSOMAL DOMINANT	SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 1, AUTOSOMALDOMINANT; SMALED1	158600
KUGELBERG-WELANDER SYNDROME, AUTOSOMAL DOMINANT	SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 1, AUTOSOMALDOMINANT; SMALED1	158600
BETHLEM MYOPATHY 1; BTHLM1	BETHLEM MYOPATHY 1; BTHLM1	158810
BETHLEM MYOPATHY	BETHLEM MYOPATHY 1; BTHLM1	158810
MYOPATHY, BENIGN CONGENITAL, WITH CONTRACTURES	BETHLEM MYOPATHY 1; BTHLM1	158810
MUSCULAR DYSTROPHY, BENIGN CONGENITAL	BETHLEM MYOPATHY 1; BTHLM1	158810
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1	158900
MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL, TYPE 1	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1	158900
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FSHD; FMD	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1	158900
MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL, TYPE 1A; FSHD1A	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1	158900
LANDOUZY-DEJERINE MUSCULAR DYSTROPHYFACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY, INFANTILE, INCLUDED	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1	158900
FACIOSCAPULOHUMERAL DYSTROPHY WITH SENSORINEURAL HEARING LOSS ANDTORTUOSITY OF RETINAL ARTERIOLES, INCLUDED	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1	158900
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2; FSHD2	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2; FSHD2	158901
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2, DIGENIC	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2; FSHD2	158901
FSHD2, DIGENIC	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2; FSHD2	158901
MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL, TYPE 2	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2; FSHD2	158901
MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL, TYPE 1B; FSHD1B	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2; FSHD2	158901
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1A; LGMD1A	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1A; LGMD1A	159000
LGMD1	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1A; LGMD1A	159000
MUSCULAR DYSTROPHY, PROXIMAL, TYPE 1A	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1A; LGMD1A	159000
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1B; LGMD1B	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1B; LGMD1B	159001
MUSCULAR DYSTROPHY, PROXIMAL, TYPE 1B	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1B; LGMD1B	159001
MUSCULAR DYSTROPHY, PSEUDOHYPERTROPHIC, WITH INTERNALIZED CAPILLARIES	MUSCULAR DYSTROPHY, PSEUDOHYPERTROPHIC, WITH INTERNALIZED CAPILLARIES	159050
MUSICAL PERFECT PITCH	MUSICAL PERFECT PITCH	159300
ABSOLUTE PITCH; AP	MUSICAL PERFECT PITCH	159300
LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA GENE; MLL; MLL1	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
TRITHORAX, DROSOPHILA, HOMOLOG OF; TRX1	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
HRX	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MYELOID/LYMPHOID LEUKEMIA GENE	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MIXED LINEAGE LEUKEMIA GENE	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
ALL1 GENE; ALL1	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
CXXC FINGER PROTEIN 7; CXXC7MIXED LINEAGE LEUKEMIA, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/AF4 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/ENL FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/AF9 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/GMPS FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/FBP17 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/LPP FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/GPH FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/PNUTL1 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/CDK6 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/LASP1 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/GRAF FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/ABI1 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/LAF4 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/CBL FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/LARG FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/AF10 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/AF15q14 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/AF6 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/CIP29 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/SEPT6 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/MAML2 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MLL/KIAA1524 FUSION GENE, INCLUDED	LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A	159555
MYELOPROLIFERATIVE SYNDROME, TRANSIENT	MYELOPROLIFERATIVE SYNDROME, TRANSIENT	159595
MST	MYELOPROLIFERATIVE SYNDROME, TRANSIENT	159595
LEUKEMIA, TRANSIENT	MYELOPROLIFERATIVE SYNDROME, TRANSIENT	159595
TRANSIENT ABNORMAL MYELOPOIESIS; TAM	MYELOPROLIFERATIVE SYNDROME, TRANSIENT	159595
MYOCLONIC EPILEPSY, HARTUNG TYPE	MYOCLONIC EPILEPSY, HARTUNG TYPE	159600
DYSTONIA 11, MYOCLONIC; DYT11	DYSTONIA 11, MYOCLONIC; DYT11	159900
MYOCLONUS-DYSTONIA SYNDROME	DYSTONIA 11, MYOCLONIC; DYT11	159900
MYOCLONIC DYSTONIA	DYSTONIA 11, MYOCLONIC; DYT11	159900
DYSTONIA, ALCOHOL-RESPONSIVE	DYSTONIA 11, MYOCLONIC; DYT11	159900
MYOCLONUS, HEREDITARY ESSENTIAL	DYSTONIA 11, MYOCLONIC; DYT11	159900
SPINAL MUSCULAR ATROPHY WITH PROGRESSIVE MYOCLONIC EPILEPSY; SMAPME	SPINAL MUSCULAR ATROPHY WITH PROGRESSIVE MYOCLONIC EPILEPSY; SMAPME	159950
MYOCLONUS, HEREDITARY, WITH PROGRESSIVE DISTAL MUSCULAR ATROPHY	SPINAL MUSCULAR ATROPHY WITH PROGRESSIVE MYOCLONIC EPILEPSY; SMAPME	159950
MYOGLOBINURIA, AUTOSOMAL DOMINANT	MYOGLOBINURIA, AUTOSOMAL DOMINANT	160010
EPISODIC ATAXIA, TYPE 1; EA1	EPISODIC ATAXIA, TYPE 1; EA1	160120
EPISODIC ATAXIA WITH MYOKYMIA; EAM	EPISODIC ATAXIA, TYPE 1; EA1	160120
ATAXIA, EPISODIC, WITH MYOKYMIA; AEM; AEMK	EPISODIC ATAXIA, TYPE 1; EA1	160120
PAROXYSMAL ATAXIA WITH NEUROMYOTONIA, HEREDITARY	EPISODIC ATAXIA, TYPE 1; EA1	160120
MYOKYMIA WITH PERIODIC ATAXIAMYOKYMIA 1, INCLUDED	EPISODIC ATAXIA, TYPE 1; EA1	160120
CONTINUOUS MUSCLE FIBER ACTIVITY, HEREDITARY, INCLUDED	EPISODIC ATAXIA, TYPE 1; EA1	160120
ISAACS-MERTENS SYNDROME, INCLUDED	EPISODIC ATAXIA, TYPE 1; EA1	160120
MYOKYMIA 1 WITH OR WITHOUT HYPOMAGNESEMIA, INCLUDED	EPISODIC ATAXIA, TYPE 1; EA1	160120
MYOPATHY, CENTRONUCLEAR, 1; CNM1	MYOPATHY, CENTRONUCLEAR, 1; CNM1	160150
MYOPATHY, CENTRONUCLEAR, AUTOSOMAL DOMINANT	MYOPATHY, CENTRONUCLEAR, 1; CNM1	160150
MYOTUBULAR MYOPATHY, AUTOSOMAL DOMINANT	MYOPATHY, CENTRONUCLEAR, 1; CNM1	160150
MYOPATHY, DISTAL, INFANTILE-ONSET	MYOPATHY, DISTAL, INFANTILE-ONSET	160300
MYOPATHY, DISTAL, 1; MPD1	MYOPATHY, DISTAL, 1; MPD1	160500
MYOPATHY, LATE DISTAL HEREDITARY	MYOPATHY, DISTAL, 1; MPD1	160500
LAING DISTAL MYOPATHY	MYOPATHY, DISTAL, 1; MPD1	160500
MYOPATHY, DISTAL, EARLY-ONSET, AUTOSOMAL DOMINANT	MYOPATHY, DISTAL, 1; MPD1	160500
MYOPATHY, TUBULAR AGGREGATE, 1; TAM1	MYOPATHY, TUBULAR AGGREGATE, 1; TAM1	160565
MYOPATHY, TUBULAR AGGREGATE; TAM	MYOPATHY, TUBULAR AGGREGATE, 1; TAM1	160565
TUBULAR AGGREGATE MYOPATHY	MYOPATHY, TUBULAR AGGREGATE, 1; TAM1	160565
MYOPIA 2, AUTOSOMAL DOMINANT; MYP2	MYOPIA 2, AUTOSOMAL DOMINANT; MYP2	160700
MYOSITIS	MYOSITIS	160750
MYOPATHY, FAMILIAL IDIOPATHIC INFLAMMATORY; IIM	MYOSITIS	160750
MYOTONIA CONGENITA, AUTOSOMAL DOMINANT	MYOTONIA CONGENITA, AUTOSOMAL DOMINANT	160800
THOMSEN DISEASE; THDMYOTONIA LEVIOR, INCLUDED	MYOTONIA CONGENITA, AUTOSOMAL DOMINANT	160800
MYOTONIC DYSTROPHY 1; DM1	MYOTONIC DYSTROPHY 1; DM1	160900
DYSTROPHIA MYOTONICA 1	MYOTONIC DYSTROPHY 1; DM1	160900
DYSTROPHIA MYOTONICA; DM	MYOTONIC DYSTROPHY 1; DM1	160900
STEINERT DISEASE	MYOTONIC DYSTROPHY 1; DM1	160900
CARNEY COMPLEX, TYPE 1; CNC1	CARNEY COMPLEX, TYPE 1; CNC1	160980
CARNEY MYXOMA-ENDOCRINE COMPLEX	CARNEY COMPLEX, TYPE 1; CNC1	160980
CARNEY SYNDROME; CAR	CARNEY COMPLEX, TYPE 1; CNC1	160980
MYXOMA, SPOTTY PIGMENTATION, AND ENDOCRINE OVERACTIVITY	CARNEY COMPLEX, TYPE 1; CNC1	160980
NAME SYNDROME	CARNEY COMPLEX, TYPE 1; CNC1	160980
LAMB SYNDROME	CARNEY COMPLEX, TYPE 1; CNC1	160980
NAEGELI SYNDROME	NAEGELI SYNDROME	161000
NAEGELI-FRANCESCHETTI-JADASSOHN SYNDROME	NAEGELI SYNDROME	161000
NFJ SYNDROME; NFJS	NAEGELI SYNDROME	161000
NAIL DISORDER, NONSYNDROMIC CONGENITAL, 1; NDNC1	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 1; NDNC1	161050
TWENTY-NAIL DYSTROPHY	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 1; NDNC1	161050
ONYCHODYSTROPHY TOTALIS, ISOLATEDNAIL GROWTH, INCLUDED	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 1; NDNC1	161050
NAIL-PATELLA SYNDROME; NPS	NAIL-PATELLA SYNDROME; NPS	161200
NPS1	NAIL-PATELLA SYNDROME; NPS	161200
ONYCHOOSTEODYSPLASIA	NAIL-PATELLA SYNDROME; NPS	161200
TURNER-KIESER SYNDROME	NAIL-PATELLA SYNDROME; NPS	161200
FONG DISEASE	NAIL-PATELLA SYNDROME; NPS	161200
NARCOLEPSY 1; NRCLP1	NARCOLEPSY 1; NRCLP1	161400
NARCOLEPTIC SYNDROME 1CATAPLEXY, INCLUDED	NARCOLEPSY 1; NRCLP1	161400
NASAL GROOVE, FAMILIAL TRANSVERSE	NASAL GROOVE, FAMILIAL TRANSVERSE	161500
NASOPHARYNGEAL CARCINOMA, SUSCEPTIBILITY TO, 2	NASOPHARYNGEAL CARCINOMA, SUSCEPTIBILITY TO, 2	161550
NPCA2	NASOPHARYNGEAL CARCINOMA, SUSCEPTIBILITY TO, 2	161550
NEMALINE MYOPATHY 3; NEM3MYOPATHY, ACTIN, CONGENITAL, WITH EXCESS OF THIN MYOFILAMENTS, INCLUDED	NEMALINE MYOPATHY 3; NEM3MYOPATHY, ACTIN, CONGENITAL, WITH EXCESS OF THIN MYOFILAMENTS, INCLUDED	161800
NEMALINE MYOPATHY 3, WITH INTRANUCLEAR RODS, INCLUDED	NEMALINE MYOPATHY 3; NEM3MYOPATHY, ACTIN, CONGENITAL, WITH EXCESS OF THIN MYOFILAMENTS, INCLUDED	161800
MYOPATHY, ACTIN, CONGENITAL, WITH CORES, INCLUDED	NEMALINE MYOPATHY 3; NEM3MYOPATHY, ACTIN, CONGENITAL, WITH EXCESS OF THIN MYOFILAMENTS, INCLUDED	161800
RENAL FAILURE, PROGRESSIVE, WITH HYPERTENSION; RFH1	RENAL FAILURE, PROGRESSIVE, WITH HYPERTENSION; RFH1	161900
NEPHROPATHY, FAMILIAL	RENAL FAILURE, PROGRESSIVE, WITH HYPERTENSION; RFH1	161900
NEPHRITIS, FAMILIAL, WITHOUT DEAFNESS OR OCULAR DEFECT	RENAL FAILURE, PROGRESSIVE, WITH HYPERTENSION; RFH1	161900
RENAL FAILURE, ADULT-ONSET; AORF	RENAL FAILURE, PROGRESSIVE, WITH HYPERTENSION; RFH1	161900
IgA NEPHROPATHY, SUSCEPTIBILITY TO, 1; IGAN1	IgA NEPHROPATHY, SUSCEPTIBILITY TO, 1; IGAN1	161950
IGAN	IgA NEPHROPATHY, SUSCEPTIBILITY TO, 1; IGAN1	161950
NEPHRITIS, IgA TYPE	IgA NEPHROPATHY, SUSCEPTIBILITY TO, 1; IGAN1	161950
BERGER DISEASE	IgA NEPHROPATHY, SUSCEPTIBILITY TO, 1; IGAN1	161950
HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1	162000
HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1	162000
FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1	162000
NEPHROPATHY, FAMILIAL, WITH GOUT	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1	162000
GOUTY NEPHROPATHY, FAMILIAL JUVENILE	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1	162000
NEURAL RETINA LEUCINE ZIPPER; NRL	NEURAL RETINA LEUCINE ZIPPER; NRL	162080
NEURAL RETINA-SPECIFIC GENE	NEURAL RETINA LEUCINE ZIPPER; NRL	162080
D14S46ERETINAL DEGENERATION, AUTOSOMAL RECESSIVE, CLUMPED PIGMENT TYPE, INCLUDED	NEURAL RETINA LEUCINE ZIPPER; NRL	162080
SCHWANNOMATOSIS 1; SWNTS1	SCHWANNOMATOSIS 1; SWNTS1	162091
NEURILEMMOMATOSIS, CONGENITAL CUTANEOUS	SCHWANNOMATOSIS 1; SWNTS1	162091
AMYOTROPHY, HEREDITARY NEURALGIC; HNA	AMYOTROPHY, HEREDITARY NEURALGIC; HNA	162100
NEURITIS WITH BRACHIAL PREDILECTION; NAPB	AMYOTROPHY, HEREDITARY NEURALGIC; HNA	162100
BRACHIAL PLEXUS NEUROPATHY, HEREDITARY	AMYOTROPHY, HEREDITARY NEURALGIC; HNA	162100
AMYOTROPHY, HEREDITARY NEURALGIC, WITH PREDILECTION FOR BRACHIAL PLEXUS	AMYOTROPHY, HEREDITARY NEURALGIC; HNA	162100
NEUROFIBROMATOSIS, TYPE I; NF1	NEUROFIBROMATOSIS, TYPE I; NF1	162200
NEUROFIBROMATOSIS, PERIPHERAL TYPE	NEUROFIBROMATOSIS, TYPE I; NF1	162200
VON RECKLINGHAUSEN DISEASE	NEUROFIBROMATOSIS, TYPE I; NF1	162200
NEUROFIBROMATOSIS, FAMILIAL SPINAL	NEUROFIBROMATOSIS, FAMILIAL SPINAL	162210
FSNF	NEUROFIBROMATOSIS, FAMILIAL SPINAL	162210
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B	162300
MEN IIB	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B	162300
NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B	162300
WAGENMANN-FROBOESE SYNDROME	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B	162300
MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLYMUCOSAL NEUROMA SYNDROME, INCLUDED	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B	162300
CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B	CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B	162350
KUFS DISEASE, AUTOSOMAL DOMINANT	CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B	162350
CEROID LIPOFUSCINOSIS, NEURONAL, PARRY TYPE	CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B	162350
NEUROPATHY, CONGENITAL, WITH ARTHROGRYPOSIS MULTIPLEX	NEUROPATHY, CONGENITAL, WITH ARTHROGRYPOSIS MULTIPLEX	162370
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IA; HSAN1A	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IA; HSAN1A	162400
HSAN IA	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IA; HSAN1A	162400
NEUROPATHY, HEREDITARY SENSORY, TYPE IA; HSN1A	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IA; HSAN1A	162400
HSN IA	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IA; HSAN1A	162400
NEUROPATHY, HEREDITARY SENSORY RADICULAR, AUTOSOMAL DOMINANT, TYPE1A	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IA; HSAN1A	162400
NEUROPATHY, HEREDITARY, WITH LIABILITY TO PRESSURE PALSIES; HNPP	NEUROPATHY, HEREDITARY, WITH LIABILITY TO PRESSURE PALSIES; HNPP	162500
POLYNEUROPATHY, FAMILIAL RECURRENT	NEUROPATHY, HEREDITARY, WITH LIABILITY TO PRESSURE PALSIES; HNPP	162500
TOMACULOUS NEUROPATHY	NEUROPATHY, HEREDITARY, WITH LIABILITY TO PRESSURE PALSIES; HNPP	162500
NEUTROPENIA, CHRONIC FAMILIAL	NEUTROPENIA, CHRONIC FAMILIAL	162700
LEUKOPENIA, BENIGN FAMILIAL	NEUTROPENIA, CHRONIC FAMILIAL	162700
CYCLIC NEUTROPENIA	CYCLIC NEUTROPENIA	162800
CYCLIC HEMATOPOIESIS	CYCLIC NEUTROPENIA	162800
NEUTROPHIL MIGRATION; NM	NEUTROPHIL MIGRATION; NM	162820
NEUTROPHIL CHEMOTACTIC RESPONSE; NCR	NEUTROPHIL MIGRATION; NM	162820
NEUTROPHILIA, HEREDITARY	NEUTROPHILIA, HEREDITARY	162830
NEVUS, EPIDERMAL	NEVUS, EPIDERMAL	162900
NEVUS, KERATINOCYTIC, NONEPIDERMOLYTICNEVUS SEBACEOUS, INCLUDED	NEVUS, EPIDERMAL	162900
NEVUS, WOOLLY HAIR, INCLUDED	NEVUS, EPIDERMAL	162900
CAPILLARY MALFORMATIONS, CONGENITAL; CMC	CAPILLARY MALFORMATIONS, CONGENITAL; CMC	163000
NEVI FLAMMEI, FAMILIAL MULTIPLE	CAPILLARY MALFORMATIONS, CONGENITAL; CMC	163000
PORT-WINE STAIN	CAPILLARY MALFORMATIONS, CONGENITAL; CMC	163000
CAPILLARY MALFORMATIONS; CMAL	CAPILLARY MALFORMATIONS, CONGENITAL; CMC	163000
NEVUS FLAMMEUS OF NAPE OF NECK	NEVUS FLAMMEUS OF NAPE OF NECK	163100
UNNA NEVUS	NEVUS FLAMMEUS OF NAPE OF NECK	163100
ERYTHEMA NUCHAE	NEVUS FLAMMEUS OF NAPE OF NECK	163100
SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM	SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM	163200
SFM SYNDROME	SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM	163200
LINEAR SEBACEOUS NEVUS SYNDROME	SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM	163200
SEBACEOUS NEVUS SYNDROME, LINEAR	SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM	163200
JADASSOHN NEVUS PHAKOMATOSIS; JNP	SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM	163200
NEVUS SEBACEUS OF JADASSOHN	SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM	163200
ORGANOID NEVUS PHAKOMATOSIS	SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM	163200
EPIDERMAL NEVUS SYNDROME, FORMERLY	SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM	163200
NIEVERGELT SYNDROME	NIEVERGELT SYNDROME	163400
MESOMELIC DYSPLASIA, NIEVERGELT TYPE	NIEVERGELT SYNDROME	163400
NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 2; CSNBAD2	NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 2; CSNBAD2	163500
NIGHT BLINDNESS, CONGENITAL STATIONARY, RAMBUSCH TYPE	NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 2; CSNBAD2	163500
NIPPLES, SUPERNUMERARY	NIPPLES, SUPERNUMERARY	163700
ACCESSORY NIPPLES	NIPPLES, SUPERNUMERARY	163700
POLYMASTIA	NIPPLES, SUPERNUMERARY	163700
POLYTHELIA, FAMILIAL	NIPPLES, SUPERNUMERARY	163700
NITRIC OXIDE SYNTHASE 3; NOS3	NITRIC OXIDE SYNTHASE 3; NOS3	163729
NITRIC OXIDE SYNTHASE, ENDOTHELIAL; ENOSCORONARY ARTERY SPASM 1, SUSCEPTIBILITY TO, INCLUDED	NITRIC OXIDE SYNTHASE 3; NOS3	163729
ALZHEIMER DISEASE, LATE-ONSET, SUSCEPTIBILITY TO, INCLUDED	NITRIC OXIDE SYNTHASE 3; NOS3	163729
HYPERTENSION, PREGNANCY-INDUCED, SUSCEPTIBILITY TO, INCLUDED	NITRIC OXIDE SYNTHASE 3; NOS3	163729
HYPERTENSION RESISTANT TO CONVENTIONAL THERAPY, INCLUDED	NITRIC OXIDE SYNTHASE 3; NOS3	163729
SICK SINUS SYNDROME 2, AUTOSOMAL DOMINANT; SSS2	SICK SINUS SYNDROME 2, AUTOSOMAL DOMINANT; SSS2	163800
SSS, AUTOSOMAL DOMINANT	SICK SINUS SYNDROME 2, AUTOSOMAL DOMINANT; SSS2	163800
ATRIAL FIBRILLATION WITH BRADYARRHYTHMIA	SICK SINUS SYNDROME 2, AUTOSOMAL DOMINANT; SSS2	163800
SINUS NODE DISEASE, FAMILIAL, AUTOSOMAL DOMINANT	SICK SINUS SYNDROME 2, AUTOSOMAL DOMINANT; SSS2	163800
SINUS BRADYCARDIA SYNDROME, FAMILIAL, AUTOSOMAL DOMINANT	SICK SINUS SYNDROME 2, AUTOSOMAL DOMINANT; SSS2	163800
NOONAN SYNDROME 1; NS1	NOONAN SYNDROME 1; NS1	163950
NOONAN SYNDROME	NOONAN SYNDROME 1; NS1	163950
MALE TURNER SYNDROME	NOONAN SYNDROME 1; NS1	163950
FEMALE PSEUDO-TURNER SYNDROME	NOONAN SYNDROME 1; NS1	163950
TURNER PHENOTYPE WITH NORMAL KARYOTYPEPTERYGIUM COLLI SYNDROME, INCLUDED	NOONAN SYNDROME 1; NS1	163950
NYSTAGMUS 2, CONGENITAL, AUTOSOMAL DOMINANT; NYS2	NYSTAGMUS 2, CONGENITAL, AUTOSOMAL DOMINANT; NYS2	164100
NYSTAGMUS, CONGENITAL MOTOR, 2	NYSTAGMUS 2, CONGENITAL, AUTOSOMAL DOMINANT; NYS2	164100
NYSTAGMUS, HEREDITARY VERTICAL	NYSTAGMUS, HEREDITARY VERTICAL	164150
NYSTAGMUS, VOLUNTARY	NYSTAGMUS, VOLUNTARY	164170
OCULODENTODIGITAL DYSPLASIA; ODDD	OCULODENTODIGITAL DYSPLASIA; ODDD	164200
ODD SYNDROME	OCULODENTODIGITAL DYSPLASIA; ODDD	164200
OCULODENTOOSSEOUS DYSPLASIA; ODOD	OCULODENTODIGITAL DYSPLASIA; ODDD	164200
HEMIFACIAL MICROSOMIA; HFM	HEMIFACIAL MICROSOMIA; HFM	164210
OCULOAURICULOVERTEBRAL SPECTRUM; OAVS	HEMIFACIAL MICROSOMIA; HFM	164210
GOLDENHAR SYNDROME	HEMIFACIAL MICROSOMIA; HFM	164210
OCULOAURICULOVERTEBRAL DYSPLASIA	HEMIFACIAL MICROSOMIA; HFM	164210
OAV DYSPLASIA	HEMIFACIAL MICROSOMIA; HFM	164210
FACIOAURICULOVERTEBRAL SEQUENCE	HEMIFACIAL MICROSOMIA; HFM	164210
FAV SEQUENCE	HEMIFACIAL MICROSOMIA; HFM	164210
SCHILBACH-ROTT SYNDROME	SCHILBACH-ROTT SYNDROME	164220
OCULAR HYPOTELORISM, SUBMUCOSAL CLEFT PALATE, AND HYPOSPADIAS	SCHILBACH-ROTT SYNDROME	164220
CLEFT PALATE, HYPOTELORISM, AND HYPOSPADIAS	SCHILBACH-ROTT SYNDROME	164220
BLEPHAROFACIOSKELETAL SYNDROME; BRSS	SCHILBACH-ROTT SYNDROME	164220
OBSESSIVE-COMPULSIVE DISORDER; OCD	OBSESSIVE-COMPULSIVE DISORDER; OCD	164230
FEINGOLD SYNDROME 1; FGLDS1	FEINGOLD SYNDROME 1; FGLDS1	164280
FEINGOLD SYNDROME	FEINGOLD SYNDROME 1; FGLDS1	164280
OCULODIGITOESOPHAGODUODENAL SYNDROME; ODED	FEINGOLD SYNDROME 1; FGLDS1	164280
ODED SYNDROME	FEINGOLD SYNDROME 1; FGLDS1	164280
MICROCEPHALY-OCULO-DIGITO-ESOPHAGEAL-DUODENAL SYNDROME; MODED	FEINGOLD SYNDROME 1; FGLDS1	164280
DIGITAL ANOMALIES WITH SHORT PALPEBRAL FISSURES AND ATRESIA OF ESOPHAGUSOR DUODENUM	FEINGOLD SYNDROME 1; FGLDS1	164280
MICROCEPHALY, MENTAL RETARDATION, AND TRACHEOESOPHAGEAL FISTULA SYNDROME	FEINGOLD SYNDROME 1; FGLDS1	164280
MMT SYNDROME	FEINGOLD SYNDROME 1; FGLDS1	164280
MICROCEPHALY AND DIGITAL ABNORMALITIES WITH NORMAL INTELLIGENCE	FEINGOLD SYNDROME 1; FGLDS1	164280
OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPMD	OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPMD	164300
MUSCULAR DYSTROPHY, OCULOPHARYNGEAL	OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPMD	164300
OCULOPHARYNGODISTAL MYOPATHY; OPDM	OCULOPHARYNGODISTAL MYOPATHY; OPDM	164310
FACIOOCULOLARYNGOPHARYNGEAL MYOPATHY WITH DISTAL AND RESPIRATORY INVOLVEMENT;FOLP-DR	OCULOPHARYNGODISTAL MYOPATHY; OPDM	164310
SPINOCEREBELLAR ATAXIA 1; SCA1	SPINOCEREBELLAR ATAXIA 1; SCA1	164400
SPINOCEREBELLAR ATROPHY I	SPINOCEREBELLAR ATAXIA 1; SCA1	164400
OLIVOPONTOCEREBELLAR ATROPHY I; OPCA1	SPINOCEREBELLAR ATAXIA 1; SCA1	164400
OPCA I	SPINOCEREBELLAR ATAXIA 1; SCA1	164400
CEREBELLOPARENCHYMAL DISORDER I; CPD1	SPINOCEREBELLAR ATAXIA 1; SCA1	164400
MENZEL TYPE OPCA	SPINOCEREBELLAR ATAXIA 1; SCA1	164400
OLIVOPONTOCEREBELLAR ATROPHY IV; OPCA4	SPINOCEREBELLAR ATAXIA 1; SCA1	164400
OPCA IV	SPINOCEREBELLAR ATAXIA 1; SCA1	164400
SCHUT-HAYMAKER TYPE OPCA	SPINOCEREBELLAR ATAXIA 1; SCA1	164400
SPINOCEREBELLAR ATAXIA 7; SCA7	SPINOCEREBELLAR ATAXIA 7; SCA7	164500
OLIVOPONTOCEREBELLAR ATROPHY III; OPCA3	SPINOCEREBELLAR ATAXIA 7; SCA7	164500
OPCA III	SPINOCEREBELLAR ATAXIA 7; SCA7	164500
OPCA WITH RETINAL DEGENERATION	SPINOCEREBELLAR ATAXIA 7; SCA7	164500
OPCA WITH MACULAR DEGENERATION AND EXTERNAL OPHTHALMOPLEGIA	SPINOCEREBELLAR ATAXIA 7; SCA7	164500
AUTOSOMAL DOMINANT CEREBELLAR ATAXIA, TYPE II	SPINOCEREBELLAR ATAXIA 7; SCA7	164500
ADCA, TYPE II	SPINOCEREBELLAR ATAXIA 7; SCA7	164500
OMODYSPLASIA 2; OMOD2	OMODYSPLASIA 2; OMOD2	164745
OMODYSPLASIA, AUTOSOMAL DOMINANT	OMODYSPLASIA 2; OMOD2	164745
OMPHALOCELE, AUTOSOMAL	OMPHALOCELE, AUTOSOMAL	164750
CHROMOSOME 1p31 DUPLICATION SYNDROME	OMPHALOCELE, AUTOSOMAL	164750
REARRANGED DURING TRANSFECTION PROTOONCOGENE; RET	REARRANGED DURING TRANSFECTION PROTOONCOGENE; RET	164761
RET PROTOONCOGENERET/ELKS FUSION GENE, INCLUDED	REARRANGED DURING TRANSFECTION PROTOONCOGENE; RET	164761
HIRSCHSPRUNG DISEASE, PROTECTION AGAINST, INCLUDED	REARRANGED DURING TRANSFECTION PROTOONCOGENE; RET	164761
NAIL DISORDER, NONSYNDROMIC CONGENITAL, 5; NDNC5	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 5; NDNC5	164800
ONYCHOLYSIS, PARTIAL, WITH SCLERONYCHIA	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 5; NDNC5	164800
ONYCHOLYSIS, HEREDITARY DISTAL	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 5; NDNC5	164800
OPHTHALMOMANDIBULOMELIC DYSPLASIA	OPHTHALMOMANDIBULOMELIC DYSPLASIA	164900
OMM SYNDROME	OPHTHALMOMANDIBULOMELIC DYSPLASIA	164900
OPHTHALMOPLEGIA, FAMILIAL STATIC	OPHTHALMOPLEGIA, FAMILIAL STATIC	165000
EXTERNAL OPHTHALMOPLEGIA, NONPROGRESSIVE, CONGENITAL HEREDITARY	OPHTHALMOPLEGIA, FAMILIAL STATIC	165000
OPTIC ATROPHY 3, AUTOSOMAL DOMINANT; OPA3	OPTIC ATROPHY 3, AUTOSOMAL DOMINANT; OPA3	165300
OPTIC ATROPHY AND CATARACT, AUTOSOMAL DOMINANT	OPTIC ATROPHY 3, AUTOSOMAL DOMINANT; OPA3	165300
OPTIC ATROPHY 1; OPA1	OPTIC ATROPHY 1; OPA1	165500
OPTIC ATROPHY, JUVENILE	OPTIC ATROPHY 1; OPA1	165500
KJER-TYPE OPTIC ATROPHY	OPTIC ATROPHY 1; OPA1	165500
OPTIC ATROPHY, KJER TYPE; OAK	OPTIC ATROPHY 1; OPA1	165500
OPTIC NERVE HYPOPLASIA, BILATERALOPTIC NERVE APLASIA, BILATERAL, INCLUDED	OPTIC NERVE HYPOPLASIA, BILATERALOPTIC NERVE APLASIA, BILATERAL, INCLUDED	165550
OSLAM SYNDROME	OSLAM SYNDROME	165660
OSTEOSARCOMA, LIMB ANOMALIES, AND MACROCYTOSIS	OSLAM SYNDROME	165660
OSTEOSARCOMA, LIMB ANOMALIES, AND ERYTHROID MACROCYTOSIS WITH MEGALOBLASTICMARROW	OSLAM SYNDROME	165660
THIEMANN DISEASE	THIEMANN DISEASE	165700
THIEMANN EPIPHYSEAL DISEASE	THIEMANN DISEASE	165700
OSTEOARTHROPATHY OF FINGERS, FAMILIAL	THIEMANN DISEASE	165700
OSTEOARTHRITIS SUSCEPTIBILITY 1; OS1	OSTEOARTHRITIS SUSCEPTIBILITY 1; OS1	165720
OA	OSTEOARTHRITIS SUSCEPTIBILITY 1; OS1	165720
OSTEOARTHROSIS	OSTEOARTHRITIS SUSCEPTIBILITY 1; OS1	165720
OSTEOARTHRITIS OF HIP, FEMALE-SPECIFIC, SUSCEPTIBILITY TO	OSTEOARTHRITIS SUSCEPTIBILITY 1; OS1	165720
OSTEOCHONDRITIS DISSECANS, SHORT STATURE, AND EARLY-ONSET OSTEOARTHRITIS;OD	OSTEOCHONDRITIS DISSECANS, SHORT STATURE, AND EARLY-ONSET OSTEOARTHRITIS;OD	165800
ENCHONDROMATOSIS, MULTIPLE, OLLIER TYPE	ENCHONDROMATOSIS, MULTIPLE, OLLIER TYPE	166000
OLLIER DISEASE	ENCHONDROMATOSIS, MULTIPLE, OLLIER TYPE	166000
OSTEOCHONDROMATOSIS	ENCHONDROMATOSIS, MULTIPLE, OLLIER TYPE	166000
DYSCHONDROPLASIA	ENCHONDROMATOSIS, MULTIPLE, OLLIER TYPE	166000
OSTEOGENESIS IMPERFECTA, TYPE I; OI1	OSTEOGENESIS IMPERFECTA, TYPE I; OI1	166200
OI, TYPE I	OSTEOGENESIS IMPERFECTA, TYPE I; OI1	166200
OSTEOGENESIS IMPERFECTA TARDA	OSTEOGENESIS IMPERFECTA, TYPE I; OI1	166200
OSTEOGENESIS IMPERFECTA WITH BLUE SCLERAE	OSTEOGENESIS IMPERFECTA, TYPE I; OI1	166200
OSTEOGENESIS IMPERFECTA, TYPE II; OI2	OSTEOGENESIS IMPERFECTA, TYPE II; OI2	166210
OI, TYPE II	OSTEOGENESIS IMPERFECTA, TYPE II; OI2	166210
OSTEOGENESIS IMPERFECTA CONGENITA, PERINATAL LETHAL FORM	OSTEOGENESIS IMPERFECTA, TYPE II; OI2	166210
OSTEOGENESIS IMPERFECTA CONGENITA; OIC	OSTEOGENESIS IMPERFECTA, TYPE II; OI2	166210
VROLIK TYPE OF OSTEOGENESIS IMPERFECTA	OSTEOGENESIS IMPERFECTA, TYPE II; OI2	166210
OSTEOGENESIS IMPERFECTA, TYPE IV; OI4	OSTEOGENESIS IMPERFECTA, TYPE IV; OI4	166220
OI, TYPE IV	OSTEOGENESIS IMPERFECTA, TYPE IV; OI4	166220
OSTEOGENESIS IMPERFECTA WITH NORMAL SCLERAE	OSTEOGENESIS IMPERFECTA, TYPE IV; OI4	166220
OSTEOGLOPHONIC DYSPLASIA; OGD	OSTEOGLOPHONIC DYSPLASIA; OGD	166250
OSTEOGLOPHONIC DWARFISM	OSTEOGLOPHONIC DYSPLASIA; OGD	166250
GNATHODIAPHYSEAL DYSPLASIA; GDD	GNATHODIAPHYSEAL DYSPLASIA; GDD	166260
OSTEOGENESIS IMPERFECTA WITH UNUSUAL SKELETAL LESIONS	GNATHODIAPHYSEAL DYSPLASIA; GDD	166260
GNATHODIAPHYSEAL SCLEROSIS	GNATHODIAPHYSEAL DYSPLASIA; GDD	166260
MULTICENTRIC CARPOTARSAL OSTEOLYSIS SYNDROME; MCTO	MULTICENTRIC CARPOTARSAL OSTEOLYSIS SYNDROME; MCTO	166300
OSTEOLYSIS, HEREDITARY, OF CARPAL BONES WITH OR WITHOUT NEPHROPATHY	MULTICENTRIC CARPOTARSAL OSTEOLYSIS SYNDROME; MCTO	166300
MULTICENTRIC OSTEOLYSIS, AUTOSOMAL DOMINANT	MULTICENTRIC CARPOTARSAL OSTEOLYSIS SYNDROME; MCTO	166300
OSSEOUS HETEROPLASIA, PROGRESSIVE; POH	OSSEOUS HETEROPLASIA, PROGRESSIVE; POH	166350
ECTOPIC OSSIFICATION, FAMILIAL	OSSEOUS HETEROPLASIA, PROGRESSIVE; POH	166350
OSTEOMA CUTIS	OSSEOUS HETEROPLASIA, PROGRESSIVE; POH	166350
OSTEOPETROSIS, AUTOSOMAL DOMINANT 2; OPTA2	OSTEOPETROSIS, AUTOSOMAL DOMINANT 2; OPTA2	166600
OSTEOPETROSIS, AUTOSOMAL DOMINANT, TYPE II	OSTEOPETROSIS, AUTOSOMAL DOMINANT 2; OPTA2	166600
MARBLE BONES, AUTOSOMAL DOMINANT	OSTEOPETROSIS, AUTOSOMAL DOMINANT 2; OPTA2	166600
OSTEOSCLEROSIS FRAGILIS GENERALISATA	OSTEOPETROSIS, AUTOSOMAL DOMINANT 2; OPTA2	166600
ALBERS-SCHONBERG DISEASE, AUTOSOMAL DOMINANT	OSTEOPETROSIS, AUTOSOMAL DOMINANT 2; OPTA2	166600
BUSCHKE-OLLENDORFF SYNDROME; BOS	BUSCHKE-OLLENDORFF SYNDROME; BOS	166700
DERMATOOSTEOPOIKILOSIS	BUSCHKE-OLLENDORFF SYNDROME; BOS	166700
DERMATOFIBROSIS, DISSEMINATED, WITH OSTEOPOIKILOSIS	BUSCHKE-OLLENDORFF SYNDROME; BOS	166700
DERMATOFIBROSIS LENTICULARIS DISSEMINATA WITH OSTEOPOIKILOSIS	BUSCHKE-OLLENDORFF SYNDROME; BOS	166700
OSTEOPATHIA CONDENSANS DISSEMINATAOSTEOPOIKILOSIS, ISOLATED, INCLUDED	BUSCHKE-OLLENDORFF SYNDROME; BOS	166700
DERMATOFIBROSIS LENTICULARIS DISSEMINATA, ISOLATED, INCLUDED	BUSCHKE-OLLENDORFF SYNDROME; BOS	166700
OSTEOPOIKILOSIS WITH MELORHEOSTOSIS, INCLUDED	BUSCHKE-OLLENDORFF SYNDROME; BOS	166700
OSTEOPOROSIS	OSTEOPOROSIS	166710
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS; BMND	OSTEOPOROSIS	166710
OSTEOPOROSIS, POSTMENOPAUSAL	OSTEOPOROSIS	166710
OSTEOPOROSIS, INVOLUTIONALFRACTURE, HIP, SUSCEPTIBILITY TO, INCLUDED	OSTEOPOROSIS	166710
OTODENTAL DYSPLASIA	OTODENTAL DYSPLASIA	166750
CHROMOSOME 11q13 DELETION SYNDROME	OTODENTAL DYSPLASIA	166750
OTODENTAL SYNDROMEOTODENTAL SYNDROME WITH COLOBOMA, INCLUDED	OTODENTAL DYSPLASIA	166750
OCULOOTODENTAL SYNDROME, INCLUDED	OTODENTAL DYSPLASIA	166750
OTITIS MEDIA, SUSCEPTIBILITY TO	OTITIS MEDIA, SUSCEPTIBILITY TO	166760
OMS	OTITIS MEDIA, SUSCEPTIBILITY TO	166760
OTITIS MEDIA, CHRONIC/RECURRENT	OTITIS MEDIA, SUSCEPTIBILITY TO	166760
COME/ROM	OTITIS MEDIA, SUSCEPTIBILITY TO	166760
OTOFACIOCERVICAL SYNDROME 1; OFC1	OTOFACIOCERVICAL SYNDROME 1; OFC1	166780
OFC	OTOFACIOCERVICAL SYNDROME 1; OFC1	166780
OTOSCLEROSIS 1; OTSC1	OTOSCLEROSIS 1; OTSC1	166800
OTS	OTOSCLEROSIS 1; OTSC1	166800
OVALOCYTOSIS, SOUTHEAST ASIAN; SAO	OVALOCYTOSIS, SOUTHEAST ASIAN; SAO	166900
OVALOCYTOSIS, MALAYSIAN-MELANESIAN-FILIPINO TYPE	OVALOCYTOSIS, SOUTHEAST ASIAN; SAO	166900
ELLIPTOCYTOSIS 4; EL4	OVALOCYTOSIS, SOUTHEAST ASIAN; SAO	166900
ELLIPTOCYTOSIS, STOMATOCYTIC HEREDITARY	OVALOCYTOSIS, SOUTHEAST ASIAN; SAO	166900
HE, STOMATOCYTIC	OVALOCYTOSIS, SOUTHEAST ASIAN; SAO	166900
OVARIAN CANCEROVARIAN CANCER, EPITHELIAL, INCLUDED	OVARIAN CANCEROVARIAN CANCER, EPITHELIAL, INCLUDED	167000
NEPHROLITHIASIS, CALCIUM OXALATE	NEPHROLITHIASIS, CALCIUM OXALATE	167030
KIDNEY STONES	NEPHROLITHIASIS, CALCIUM OXALATE	167030
UROLITHIASIS, CALCIUM OXALATE	NEPHROLITHIASIS, CALCIUM OXALATE	167030
HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL DOMINANT; PHOAD	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL DOMINANT; PHOAD	167100
PHO, AUTOSOMAL DOMINANT	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL DOMINANT; PHOAD	167100
PACHYDERMOPERIOSTOSIS, AUTOSOMAL DOMINANT	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL DOMINANT; PHOAD	167100
PDP, AUTOSOMAL DOMINANT	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL DOMINANT; PHOAD	167100
PACHYONYCHIA CONGENITA 1; PC1	PACHYONYCHIA CONGENITA 1; PC1	167200
PACHYONYCHIA CONGENITA, JADASSOHN-LEWANDOWSKY TYPE, FORMERLY	PACHYONYCHIA CONGENITA 1; PC1	167200
JADASSOHN-LEWANDOWSKY SYNDROME, FORMERLY	PACHYONYCHIA CONGENITA 1; PC1	167200
PACHYONYCHIA CONGENITA 2; PC2	PACHYONYCHIA CONGENITA 2; PC2	167210
PACHYONYCHIA CONGENITA, JACKSON-LAWLER TYPE, FORMERLY	PACHYONYCHIA CONGENITA 2; PC2	167210
PAGET DISEASE OF BONE 3; PDB3	PAGET DISEASE OF BONE 3; PDB3	167250
INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 1; IBMPFD1	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 1; IBMPFD1	167320
MULTISYSTEM PROTEINOPATHY 1; MSP1	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 1; IBMPFD1	167320
MUSCULAR DYSTROPHY, LIMB-GIRDLE, WITH PAGET DISEASE OF BONE	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 1; IBMPFD1	167320
PAGETOID AMYOTROPHIC LATERAL SCLEROSIS	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 1; IBMPFD1	167320
PAGETOID NEUROSKELETAL SYNDROME	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 1; IBMPFD1	167320
LOWER MOTOR NEURON DEGENERATION WITH PAGET-LIKE BONE DISEASE	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 1; IBMPFD1	167320
PAROXYSMAL EXTREME PAIN DISORDER	PAROXYSMAL EXTREME PAIN DISORDER	167400
PEXPD; PEPD	PAROXYSMAL EXTREME PAIN DISORDER	167400
PAIN, SUBMANDIBULAR, OCULAR, AND RECTAL, WITH FLUSHING	PAROXYSMAL EXTREME PAIN DISORDER	167400
RECTAL PAIN, FAMILIAL	PAROXYSMAL EXTREME PAIN DISORDER	167400
PALATOPHARYNGEAL INCOMPETENCE	PALATOPHARYNGEAL INCOMPETENCE	167500
VELOPHARYNGEAL INCOMPETENCE; VPI	PALATOPHARYNGEAL INCOMPETENCE	167500
VELOPHARYNGEAL INSUFFICIENCY	PALATOPHARYNGEAL INCOMPETENCE	167500
PALPEBRAL COLOBOMA-LIPOMA SYNDROME	PALPEBRAL COLOBOMA-LIPOMA SYNDROME	167730
NASOPALPEBRAL LIPOMA-COLOBOMA SYNDROME	PALPEBRAL COLOBOMA-LIPOMA SYNDROME	167730
PANCREATITIS, HEREDITARY; PCTT	PANCREATITIS, HEREDITARY; PCTT	167800
HPC	PANCREATITIS, HEREDITARY; PCTT	167800
HP	PANCREATITIS, HEREDITARY; PCTT	167800
PANCREATITIS, CHRONICPANCREATITIS, CHRONIC, SUSCEPTIBILITY TO, INCLUDED	PANCREATITIS, HEREDITARY; PCTT	167800
PANCREATITIS, CALCIFIC, INCLUDED	PANCREATITIS, HEREDITARY; PCTT	167800
PANCREATITIS, CHRONIC, PROTECTION AGAINST, INCLUDED	PANCREATITIS, HEREDITARY; PCTT	167800
PANIC DISORDER 1; PAND1	PANIC DISORDER 1; PAND1	167870
PANIC DISORDER SUSCEPTIBILITY LOCUS, CHROMOSOME 13q-RELATED	PANIC DISORDER 1; PAND1	167870
PANIC DISORDERPANIC DISORDER WITH BLADDER CONDITIONS, INCLUDED	PANIC DISORDER 1; PAND1	167870
PANIC DISORDER WITH JOINT LAXITY, INCLUDED	PANIC DISORDER 1; PAND1	167870
PAPILLOMATOSIS, CONFLUENT AND RETICULATED; CARP	PAPILLOMATOSIS, CONFLUENT AND RETICULATED; CARP	167900
PAPILLOMATOSIS, RETICULATED AND CONFLUENT, OF GOUGEROT AND CARTEAUD	PAPILLOMATOSIS, CONFLUENT AND RETICULATED; CARP	167900
PAPILLOMATOSIS, FAMILIAL CUTANEOUS	PAPILLOMATOSIS, CONFLUENT AND RETICULATED; CARP	167900
PARAGANGLIOMAS 1; PGL1	PARAGANGLIOMAS 1; PGL1	168000
PARAGANGLIOMAS, FAMILIAL, 1	PARAGANGLIOMAS 1; PGL1	168000
PARAGANGLIOMATA; PGL	PARAGANGLIOMAS 1; PGL1	168000
GLOMUS TUMORS, FAMILIAL, 1	PARAGANGLIOMAS 1; PGL1	168000
CHEMODECTOMAS	PARAGANGLIOMAS 1; PGL1	168000
CAROTID BODY TUMORS; CBT1	PARAGANGLIOMAS 1; PGL1	168000
GLOMUS JUGULARE TUMORS	PARAGANGLIOMAS 1; PGL1	168000
PARAGANGLIOMA, CAROTID BODY	PARAGANGLIOMAS 1; PGL1	168000
PARAGANGLIOMAS, FAMILIAL NONCHROMAFFIN, 1PARAGANGLIOMAS WITH SENSORINEURAL HEARING LOSS, INCLUDED	PARAGANGLIOMAS 1; PGL1	168000
PARAMYOTONIA CONGENITA OF VON EULENBURG; PMC	PARAMYOTONIA CONGENITA OF VON EULENBURG; PMC	168300
PARALYSIS PERIODICA PARAMYOTONICAPARAMYOTONIA CONGENITA WITHOUT COLD PARALYSIS, INCLUDED	PARAMYOTONIA CONGENITA OF VON EULENBURG; PMC	168300
PARASTREMMATIC DWARFISM	PARASTREMMATIC DWARFISM	168400
PARATHYROID HORMONE-LIKE HORMONE; PTHLH	PARATHYROID HORMONE-LIKE HORMONE; PTHLH	168470
PARATHYROID HORMONE-RELATED PROTEIN; PTHRP	PARATHYROID HORMONE-LIKE HORMONE; PTHLH	168470
PTH-RELATED PROTEIN	PARATHYROID HORMONE-LIKE HORMONE; PTHLH	168470
PTHR, FORMERLYHUMORAL HYPERCALCEMIA OF MALIGNANCY, INCLUDED; HHM, INCLUDED	PARATHYROID HORMONE-LIKE HORMONE; PTHLH	168470
PARIETAL FORAMINA; PFM	PARIETAL FORAMINA; PFM	168500
PARIETAL FORAMINA, SYMMETRIC	PARIETAL FORAMINA; PFM	168500
FORAMINA PARIETALIA PERMAGNA; FPP	PARIETAL FORAMINA; PFM	168500
CATLIN MARKS	PARIETAL FORAMINA; PFM	168500
CRANIUM BIFIDUM OCCULTUM	PARIETAL FORAMINA; PFM	168500
CRANIUM BIFIDUM, HEREDITARYPARIETAL FORAMINA 1, INCLUDED; PFM1, INCLUDED	PARIETAL FORAMINA; PFM	168500
PARIETAL FORAMINA WITH CLEIDOCRANIAL DYSPLASIA; PFMCCD	PARIETAL FORAMINA WITH CLEIDOCRANIAL DYSPLASIA; PFMCCD	168550
CLEIDOCRANIAL DYSPLASIA WITH PARIETAL FORAMINA	PARIETAL FORAMINA WITH CLEIDOCRANIAL DYSPLASIA; PFMCCD	168550
PARKINSON DISEASE, LATE-ONSET; PD	PARKINSON DISEASE, LATE-ONSET; PD	168600
PARK	PARKINSON DISEASE, LATE-ONSET; PD	168600
PARKINSON DISEASE 1, AUTOSOMAL DOMINANT; PARK1PARKINSON DISEASE 1, AUTOSOMAL DOMINANT LEWY BODY	PARKINSON DISEASE 1, AUTOSOMAL DOMINANT; PARK1PARKINSON DISEASE 1, AUTOSOMAL DOMINANT LEWY BODY	168601
ATYPICAL PARKINSON DISEASE, INCLUDED	PARKINSON DISEASE 1, AUTOSOMAL DOMINANT; PARK1PARKINSON DISEASE 1, AUTOSOMAL DOMINANT LEWY BODY	168601
PERRY SYNDROME	PERRY SYNDROME	168605
PARKINSONISM WITH ALVEOLAR HYPOVENTILATION AND MENTAL DEPRESSION	PERRY SYNDROME	168605
PARAOXONASE 1; PON1	PARAOXONASE 1; PON1	168820
PON	PARAOXONASE 1; PON1	168820
PARAOXONASE, PLASMA	PARAOXONASE 1; PON1	168820
ARYLESTERASE	PARAOXONASE 1; PON1	168820
ESTERASE A; ESAPON1 ENZYME ACTIVITY, VARIATION IN, INCLUDED	PARAOXONASE 1; PON1	168820
ORGANOPHOSPHATE POISONING, SUSCEPTIBILITY TO, INCLUDED	PARAOXONASE 1; PON1	168820
CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED	PARAOXONASE 1; PON1	168820
CORONARY ARTERY SPASM 2, SUSCEPTIBILITY TO, INCLUDED	PARAOXONASE 1; PON1	168820
PATELLA APLASIA-HYPOPLASIA; PTLAH	PATELLA APLASIA-HYPOPLASIA; PTLAH	168860
PATELLA, CHONDROMALACIA OF	PATELLA, CHONDROMALACIA OF	168900
PATELLA, FAMILIAL RECURRENT DISLOCATION OF	PATELLA, FAMILIAL RECURRENT DISLOCATION OF	169000
CHAR SYNDROME	CHAR SYNDROME	169100
CHAR	CHAR SYNDROME	169100
PATENT DUCTUS ARTERIOSUS WITH FACIAL DYSMORPHISM AND ABNORMAL FIFTHDIGITS	CHAR SYNDROME	169100
MACULAR DYSTROPHY, PATTERNED, 1; MDPT1	MACULAR DYSTROPHY, PATTERNED, 1; MDPT1	169150
PATTERNED DYSTROPHY OF RETINAL PIGMENT EPITHELIUM	MACULAR DYSTROPHY, PATTERNED, 1; MDPT1	169150
MACULAR DYSTROPHY, BUTTERFLY-SHAPED PIGMENTARY	MACULAR DYSTROPHY, PATTERNED, 1; MDPT1	169150
BUTTERFLY DYSTROPHY OF RETINAL PIGMENT EPITHELIUM	MACULAR DYSTROPHY, PATTERNED, 1; MDPT1	169150
PELGER-HUET ANOMALY; PHA	PELGER-HUET ANOMALY; PHA	169400
LEUKODYSTROPHY, DEMYELINATING, ADULT-ONSET, AUTOSOMAL DOMINANT; ADLD	LEUKODYSTROPHY, DEMYELINATING, ADULT-ONSET, AUTOSOMAL DOMINANT; ADLD	169500
PELIZAEUS-MERZBACHER DISEASE, AUTOSOMAL DOMINANT OR LATE-ONSET TYPE,FORMERLY	LEUKODYSTROPHY, DEMYELINATING, ADULT-ONSET, AUTOSOMAL DOMINANT; ADLD	169500
PELVIC LIPOMATOSIS WITH CROSSED RENAL ECTOPIA	PELVIC LIPOMATOSIS WITH CROSSED RENAL ECTOPIA	169545
BENIGN CHRONIC PEMPHIGUS; BCPM	BENIGN CHRONIC PEMPHIGUS; BCPM	169600
PEMPHIGUS, BENIGN FAMILIAL	BENIGN CHRONIC PEMPHIGUS; BCPM	169600
HAILEY-HAILEY DISEASE; HHD	BENIGN CHRONIC PEMPHIGUS; BCPM	169600
PROLIDASE DEFICIENCY	PROLIDASE DEFICIENCY	170100
ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS	ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS	170390
ANDERSEN SYNDROME	ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS	170390
LONG QT SYNDROME 7; LQT7	ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS	170390
ANDERSEN-TAWIL SYNDROME; ATS	ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS	170390
PERIODIC PARALYSIS, POTASSIUM-SENSITIVE CARDIODYSRHYTHMIC TYPE	ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS	170390
HYPOKALEMIC PERIODIC PARALYSIS, TYPE 1; HOKPP1	HYPOKALEMIC PERIODIC PARALYSIS, TYPE 1; HOKPP1	170400
HYPOKALEMIC PERIODIC PARALYSIS; HOKPP	HYPOKALEMIC PERIODIC PARALYSIS, TYPE 1; HOKPP1	170400
HYPERKALEMIC PERIODIC PARALYSIS; HYPP	HYPERKALEMIC PERIODIC PARALYSIS; HYPP	170500
ADYNAMIA EPISODICA HEREDITARIA WITH OR WITHOUT MYOTONIA	HYPERKALEMIC PERIODIC PARALYSIS; HYPP	170500
GAMSTORP DISEASENORMOKALEMIC PERIODIC PARALYSIS, POTASSIUM-SENSITIVE, INCLUDED	HYPERKALEMIC PERIODIC PARALYSIS; HYPP	170500
PERIODONTITIS, AGGRESSIVE, 1	PERIODONTITIS, AGGRESSIVE, 1	170650
PERIODONTITIS, JUVENILE; JPD; JP	PERIODONTITIS, AGGRESSIVE, 1	170650
PERIODONTITIS, PREPUBERTAL; PPP	PERIODONTITIS, AGGRESSIVE, 1	170650
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA; PPARA	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA; PPARA	170998
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PPARHYPERAPOBETALIPOPROTEINEMIA, SUSCEPTIBILITY TO, INCLUDED	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA; PPARA	170998
PEYRONIE DISEASE	PEYRONIE DISEASE	171000
THIOUREA TASTINGPHENYLTHIOCARBAMIDE TASTING, INCLUDED	THIOUREA TASTINGPHENYLTHIOCARBAMIDE TASTING, INCLUDED	171200
PTC TASTING, INCLUDED	THIOUREA TASTINGPHENYLTHIOCARBAMIDE TASTING, INCLUDED	171200
PROPYLTHIOURACIL TASTING, INCLUDED	THIOUREA TASTINGPHENYLTHIOCARBAMIDE TASTING, INCLUDED	171200
PROP TASTING, INCLUDED	THIOUREA TASTINGPHENYLTHIOCARBAMIDE TASTING, INCLUDED	171200
PHEOCHROMOCYTOMAPHEOCHROMOCYTOMA, SUSCEPTIBILITY TO	PHEOCHROMOCYTOMAPHEOCHROMOCYTOMA, SUSCEPTIBILITY TO	171300
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA; MEN2A	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA; MEN2A	171400
PHEOCHROMOCYTOMA AND AMYLOID-PRODUCING MEDULLARY THYROID CARCINOMA	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA; MEN2A	171400
PTC SYNDROME	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA; MEN2A	171400
SIPPLE SYNDROMETHYROID CARCINOMA, FAMILIAL MEDULLARY, INCLUDED	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA; MEN2A	171400
ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1	171720
ALPQTL1	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1	171720
ALKALINE PHOSPHATASE, ELEVATED SERUM	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1	171720
HYPERPHOSPHATASEMIA, BENIGN FAMILIAL	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1	171720
6-@PHOSPHOGLUCONOLACTONASE DEFICIENCY	6-@PHOSPHOGLUCONOLACTONASE DEFICIENCY	172150
PGLS DEFICIENCY	6-@PHOSPHOGLUCONOLACTONASE DEFICIENCY	172150
6PGL DEFICIENCY	6-@PHOSPHOGLUCONOLACTONASE DEFICIENCY	172150
PHOSPHOLIPID TRANSFER PROTEIN; PLTP	PHOSPHOLIPID TRANSFER PROTEIN; PLTP	172425
LIPID TRANSFER PROTEIN IIHIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS9, INCLUDED; HDLCQ9, INCLUDED	PHOSPHOLIPID TRANSFER PROTEIN; PLTP	172425
PICK DISEASE OF BRAIN	PICK DISEASE OF BRAIN	172700
LOBAR ATROPHY OF BRAIN	PICK DISEASE OF BRAIN	172700
DEMENTIA WITH LOBAR ATROPHY AND NEURONAL CYTOPLASMIC INCLUSIONS	PICK DISEASE OF BRAIN	172700
PIEBALD TRAIT; PBT	PIEBALD TRAIT; PBT	172800
PIEBALDISM	PIEBALD TRAIT; PBT	172800
PIGMENTED PARAVENOUS CHORIORETINAL ATROPHY; PPCRA	PIGMENTED PARAVENOUS CHORIORETINAL ATROPHY; PPCRA	172870
PIGMENTED PURPURIC ERUPTION	PIGMENTED PURPURIC ERUPTION	172900
ISOLATED GROWTH HORMONE DEFICIENCY, TYPE II; IGHD2	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE II; IGHD2	173100
IGHD II	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE II; IGHD2	173100
GROWTH HORMONE DEFICIENCY, ISOLATED, AUTOSOMAL DOMINANT	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE II; IGHD2	173100
PITUITARY DWARFISM DUE TO ISOLATED GROWTH HORMONE DEFICIENCY, AUTOSOMALDOMINANT	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE II; IGHD2	173100
PITYRIASIS RUBRA PILARIS; PRP	PITYRIASIS RUBRA PILARIS; PRP	173200
INTEGRIN, BETA-3; ITGB3	INTEGRIN, BETA-3; ITGB3	173470
PLATELET GLYCOPROTEIN IIIa; GP3A	INTEGRIN, BETA-3; ITGB3	173470
GP IIIa	INTEGRIN, BETA-3; ITGB3	173470
PLATELET FIBRINOGEN RECEPTOR, BETA SUBUNIT	INTEGRIN, BETA-3; ITGB3	173470
CD61THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE, INCLUDED; NAIT, INCLUDED	INTEGRIN, BETA-3; ITGB3	173470
POSTTRANSFUSION PURPURA, INCLUDED; PTP, INCLUDED	INTEGRIN, BETA-3; ITGB3	173470
PLATELET GROUPS--Pl(E) SYSTEM	PLATELET GROUPS--Pl(E) SYSTEM	173540
PNEUMOTHORAX, PRIMARY SPONTANEOUS	PNEUMOTHORAX, PRIMARY SPONTANEOUS	173600
PSP	PNEUMOTHORAX, PRIMARY SPONTANEOUS	173600
KINDLER SYNDROME	KINDLER SYNDROME	173650
POIKILODERMA, HEREDITARY ACROKERATOTIC	KINDLER SYNDROME	173650
BULLOUS ACROKERATOTIC POIKILODERMA OF KINDLER AND WEARY	KINDLER SYNDROME	173650
POIKILODERMA, CONGENITAL, WITH BULLAE, WEARY TYPE	KINDLER SYNDROME	173650
POLAND SYNDROME	POLAND SYNDROME	173800
POLAND SYNDACTYLY	POLAND SYNDROME	173800
POLAND ANOMALY	POLAND SYNDROME	173800
POLAND SEQUENCEPECTORALIS MUSCLE, ABSENCE OF, INCLUDED	POLAND SYNDROME	173800
POLYCYSTIC KIDNEY DISEASE 1; PKD1	POLYCYSTIC KIDNEY DISEASE 1; PKD1	173900
POLYCYSTIC KIDNEY DISEASE, ADULT, TYPE I; APKD1POLYCYSTIC KIDNEY DISEASE, ADULT, INCLUDED; APKD, INCLUDED	POLYCYSTIC KIDNEY DISEASE 1; PKD1	173900
POTTER TYPE III POLYCYSTIC KIDNEY DISEASE, INCLUDED	POLYCYSTIC KIDNEY DISEASE 1; PKD1	173900
MEDULLARY CYSTIC KIDNEY DISEASE 1; MCKD1	MEDULLARY CYSTIC KIDNEY DISEASE 1; MCKD1	174000
MCKD	MEDULLARY CYSTIC KIDNEY DISEASE 1; MCKD1	174000
MEDULLARY CYSTIC KIDNEY DISEASE, AUTOSOMAL DOMINANT; ADMCKD1	MEDULLARY CYSTIC KIDNEY DISEASE 1; MCKD1	174000
POLYCYSTIC KIDNEYS, MEDULLARY TYPE	MEDULLARY CYSTIC KIDNEY DISEASE 1; MCKD1	174000
POLYCYSTIC LIVER DISEASE; PCLD	POLYCYSTIC LIVER DISEASE; PCLD	174050
POLYDACTYLY, POSTAXIAL, TYPE A1; PAPA1	POLYDACTYLY, POSTAXIAL, TYPE A1; PAPA1	174200
POSTAXIAL POLYDACTYLY, TYPE A; PAPA	POLYDACTYLY, POSTAXIAL, TYPE A1; PAPA1	174200
POLYDACTYLY, POSTAXIALPOSTAXIAL POLYDACTYLY, TYPE B, INCLUDED; PAPB, INCLUDED	POLYDACTYLY, POSTAXIAL, TYPE A1; PAPA1	174200
OROFACIODIGITAL SYNDROME V; OFD5	OROFACIODIGITAL SYNDROME V; OFD5	174300
OFDS V	OROFACIODIGITAL SYNDROME V; OFD5	174300
ORAL-FACIAL-DIGITAL SYNDROME, TYPE V	OROFACIODIGITAL SYNDROME V; OFD5	174300
OROFACIODIGITAL SYNDROME, THURSTON TYPE	OROFACIODIGITAL SYNDROME V; OFD5	174300
THURSTON SYNDROME	OROFACIODIGITAL SYNDROME V; OFD5	174300
POLYDACTYLY, POSTAXIAL, WITH MEDIAN CLEFT OF UPPER LIP	OROFACIODIGITAL SYNDROME V; OFD5	174300
POLYDACTYLY, PREAXIAL I	POLYDACTYLY, PREAXIAL I	174400
THUMB POLYDACTYLYTHENAR HYPOPLASIA, INCLUDED	POLYDACTYLY, PREAXIAL I	174400
FROMONT ANOMALY, INCLUDED	POLYDACTYLY, PREAXIAL I	174400
POLYDACTYLY, PREAXIAL II; PPD2	POLYDACTYLY, PREAXIAL II; PPD2	174500
POLYDACTYLY OF TRIPHALANGEAL THUMB	POLYDACTYLY, PREAXIAL II; PPD2	174500
TRIPHALANGEAL THUMB-POLYDACTYLY SYNDROMETRIPHALANGEAL THUMB WITH POLYSYNDACTYLY, INCLUDED	POLYDACTYLY, PREAXIAL II; PPD2	174500
TRIPHALANGEAL THUMB-POLYSYNDACTYLY SYNDROME, INCLUDED	POLYDACTYLY, PREAXIAL II; PPD2	174500
TPT-PS SYNDROME, INCLUDED	POLYDACTYLY, PREAXIAL II; PPD2	174500
TRIPHALANGEAL THUMB, INCLUDED; TPT, INCLUDED	POLYDACTYLY, PREAXIAL II; PPD2	174500
POLYDACTYLY, PREAXIAL III	POLYDACTYLY, PREAXIAL III	174600
INDEX FINGER POLYDACTYLY	POLYDACTYLY, PREAXIAL III	174600
POLYDACTYLY, PREAXIAL IV	POLYDACTYLY, PREAXIAL IV	174700
POLYSYNDACTYLY, UNCOMPLICATEDCROSSED POLYDACTYLY, TYPE I, INCLUDED; CP1, INCLUDED	POLYDACTYLY, PREAXIAL IV	174700
ACTINIC PRURIGOPOLYMORPHIC LIGHT ERUPTION, HEREDITARY; HPLE	ACTINIC PRURIGOPOLYMORPHIC LIGHT ERUPTION, HEREDITARY; HPLE	174770
JUVENILE SPRING ERUPTION OF EARS, INCLUDED	ACTINIC PRURIGOPOLYMORPHIC LIGHT ERUPTION, HEREDITARY; HPLE	174770
MCCUNE-ALBRIGHT SYNDROME; MAS	MCCUNE-ALBRIGHT SYNDROME; MAS	174800
ALBRIGHT SYNDROMEPOLYOSTOTIC FIBROUS DYSPLASIA, INCLUDED; PFD, INCLUDED; POFD, INCLUDED	MCCUNE-ALBRIGHT SYNDROME; MAS	174800
FAMILIAL EXPANSILE OSTEOLYSIS; FEO	FAMILIAL EXPANSILE OSTEOLYSIS; FEO	174810
POLYOSTOTIC OSTEOLYTIC DYSPLASIA, HEREDITARY EXPANSILE; HEPOD	FAMILIAL EXPANSILE OSTEOLYSIS; FEO	174810
MCCABE DISEASE	FAMILIAL EXPANSILE OSTEOLYSIS; FEO	174810
EXPANSILE OSTEOLYSIS, FAMILIAL; EOF	FAMILIAL EXPANSILE OSTEOLYSIS; FEO	174810
JUVENILE POLYPOSIS SYNDROME; JPS	JUVENILE POLYPOSIS SYNDROME; JPS	174900
POLYPOSIS, JUVENILE INTESTINAL; PJI	JUVENILE POLYPOSIS SYNDROME; JPS	174900
JUVENILE INTESTINAL POLYPOSIS; JIP	JUVENILE POLYPOSIS SYNDROME; JPS	174900
POLYPOSIS, FAMILIAL, OF ENTIRE GASTROINTESTINAL TRACTJUVENILE POLYPOSIS OF STOMACH, INCLUDED	JUVENILE POLYPOSIS SYNDROME; JPS	174900
JUVENILE POLYPOSIS COLI, INCLUDED	JUVENILE POLYPOSIS SYNDROME; JPS	174900
POLYPOSIS, GASTRIC	POLYPOSIS, GASTRIC	175020
JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME;JPHT	JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME;JPHT	175050
JP/HHT SYNDROME	JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME;JPHT	175050
JUVENILE POLYPOSIS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA	JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME;JPHT	175050
JPS/HHT	JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME;JPHT	175050
TELANGIECTASIA, HEREDITARY HEMORRHAGIC, WITH JUVENILE POLYPOSIS COLI	JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME;JPHT	175050
POLYPOSIS, GENERALIZED JUVENILE, WITH PULMONARY ARTERIOVENOUS MALFORMATION	JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME;JPHT	175050
FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1	FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1	175100
ADENOMATOUS POLYPOSIS OF THE COLON; APC	FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1	175100
FAMILIAL POLYPOSIS OF THE COLON; FPC	FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1	175100
POLYPOSIS, ADENOMATOUS INTESTINALGARDNER SYNDROME, INCLUDED; GS, INCLUDED	FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1	175100
BRAIN TUMOR-POLYPOSIS SYNDROME 2, INCLUDED; BTPS2, INCLUDED	FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1	175100
FAMILIAL ADENOMATOUS POLYPOSIS, ATTENUATED, INCLUDED; AFAP, INCLUDED	FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1	175100
ADENOMATOUS POLYPOSIS COLI, ATTENUATED, INCLUDED; AAPC, INCLUDED	FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1	175100
PEUTZ-JEGHERS SYNDROME; PJS	PEUTZ-JEGHERS SYNDROME; PJS	175200
POLYPOSIS, HAMARTOMATOUS INTESTINAL	PEUTZ-JEGHERS SYNDROME; PJS	175200
POLYPS-AND-SPOTS SYNDROME	PEUTZ-JEGHERS SYNDROME; PJS	175200
POLYSYNDACTYLY, CROSSED	POLYSYNDACTYLY, CROSSED	175690
GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; GCPS	GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; GCPS	175700
POLYSYNDACTYLY WITH PECULIAR SKULL SHAPE	GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; GCPS	175700
PORENCEPHALY 1; POREN1	PORENCEPHALY 1; POREN1	175780
HEMIPLEGIA, INFANTILE, WITH PORENCEPHALY PORENCEPHALY, TYPE 1; T1P	PORENCEPHALY 1; POREN1	175780
PORENCEPHALY, TYPE 1, AUTOSOMAL DOMINANT; ADT1P	PORENCEPHALY 1; POREN1	175780
POROKERATOSIS 1, MULTIPLE TYPES; POROK1	POROKERATOSIS 1, MULTIPLE TYPES; POROK1	175800
POROKERATOSIS OF MIBELLI	POROKERATOSIS 1, MULTIPLE TYPES; POROK1	175800
POROKERATOSIS 2, PALMAR, PLANTAR, AND DISSEMINATED TYPE; POROK2	POROKERATOSIS 2, PALMAR, PLANTAR, AND DISSEMINATED TYPE; POROK2	175850
POROKERATOSIS, PALMAR, PLANTAR, AND DISSEMINATED; PPPD	POROKERATOSIS 2, PALMAR, PLANTAR, AND DISSEMINATED TYPE; POROK2	175850
POROKERATOSIS, PALMAR, PLANTAR, AND DISSEMINATED, 1; PPPD1	POROKERATOSIS 2, PALMAR, PLANTAR, AND DISSEMINATED TYPE; POROK2	175850
POROKERATOSIS PLANTARIS PALMARIS ET DISSEMINATA	POROKERATOSIS 2, PALMAR, PLANTAR, AND DISSEMINATED TYPE; POROK2	175850
POROKERATOSIS PALMARIS ET PLANTARIS DISSEMINATA	POROKERATOSIS 2, PALMAR, PLANTAR, AND DISSEMINATED TYPE; POROK2	175850
PALMOPLANTAR KERATODERMA, PUNCTATE TYPE II; PPKP2	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE II; PPKP2	175860
POROKERATOSIS PUNCTATA PALMARIS ET PLANTARIS; PPPP	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE II; PPKP2	175860
POROKERATOSIS 3, MULTIPLE TYPES; POROK3	POROKERATOSIS 3, MULTIPLE TYPES; POROK3	175900
POROKERATOSIS, DISSEMINATED SUPERFICIAL ACTINIC, 1; DSAP1	POROKERATOSIS 3, MULTIPLE TYPES; POROK3	175900
PORPHYRIA, ACUTE INTERMITTENT; AIP	PORPHYRIA, ACUTE INTERMITTENT; AIP	176000
PORPHYRIA, SWEDISH TYPE	PORPHYRIA, ACUTE INTERMITTENT; AIP	176000
PORPHOBILINOGEN DEAMINASE DEFICIENCY	PORPHYRIA, ACUTE INTERMITTENT; AIP	176000
PBGD DEFICIENCY	PORPHYRIA, ACUTE INTERMITTENT; AIP	176000
UROPORPHYRINOGEN SYNTHASE DEFICIENCY	PORPHYRIA, ACUTE INTERMITTENT; AIP	176000
UPS DEFICIENCYPORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED	PORPHYRIA, ACUTE INTERMITTENT; AIP	176000
PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED	PORPHYRIA, ACUTE INTERMITTENT; AIP	176000
PORPHYRIA CUTANEA TARDA	PORPHYRIA CUTANEA TARDA	176100
PCT	PORPHYRIA CUTANEA TARDA	176100
PORPHYRIA CUTANEA TARDA, TYPE II	PORPHYRIA CUTANEA TARDA	176100
PCT, TYPE II	PORPHYRIA CUTANEA TARDA	176100
PCT, 'FAMILIAL' TYPE	PORPHYRIA CUTANEA TARDA	176100
PORPHYRIA, HEPATOCUTANEOUS TYPE	PORPHYRIA CUTANEA TARDA	176100
UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY	PORPHYRIA CUTANEA TARDA	176100
UROD DEFICIENCYPORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED	PORPHYRIA CUTANEA TARDA	176100
PORPHYRIA VARIEGATA	PORPHYRIA VARIEGATA	176200
VARIEGATE PORPHYRIA; VP	PORPHYRIA VARIEGATA	176200
PORPHYRIA, SOUTH AFRICAN TYPE	PORPHYRIA VARIEGATA	176200
PROTOPORPHYRINOGEN OXIDASE DEFICIENCY	PORPHYRIA VARIEGATA	176200
PPOX DEFICIENCYVARIEGATE PORPHYRIA, HOMOZYGOUS VARIANT	PORPHYRIA VARIEGATA	176200
PRADER-WILLI SYNDROME; PWS	PRADER-WILLI SYNDROME; PWS	176270
PRADER-LABHART-WILLI SYNDROMEPRADER-WILLI SYNDROME CHROMOSOME REGION, INCLUDED; PWCR, INCLUDED	PRADER-WILLI SYNDROME; PWS	176270
PRADER-WILLI-LIKE SYNDROME ASSOCIATED WITH CHROMOSOME 6, INCLUDED	PRADER-WILLI SYNDROME; PWS	176270
PREAXIAL DEFICIENCY, POSTAXIAL POLYDACTYLY, AND HYPOSPADIAS	PREAXIAL DEFICIENCY, POSTAXIAL POLYDACTYLY, AND HYPOSPADIAS	176305
GUTTMACHER SYNDROME	PREAXIAL DEFICIENCY, POSTAXIAL POLYDACTYLY, AND HYPOSPADIAS	176305
PRECOCIOUS PUBERTY, CENTRAL, 1; CPPB1	PRECOCIOUS PUBERTY, CENTRAL, 1; CPPB1	176400
PRECOCIOUS PUBERTY, MALE-LIMITED	PRECOCIOUS PUBERTY, MALE-LIMITED	176410
SEXUAL PRECOCITY, FAMILIAL, GONADOTROPIN-INDEPENDENT	PRECOCIOUS PUBERTY, MALE-LIMITED	176410
TESTOTOXICOSIS, FAMILIALLEYDIG CELL ADENOMA, SOMATIC, WITH MALE-LIMITED PRECOCIOUS PUBERTY,INCLUDED	PRECOCIOUS PUBERTY, MALE-LIMITED	176410
PREMATURE CHROMATID SEPARATION TRAIT; PCS	PREMATURE CHROMATID SEPARATION TRAIT; PCS	176430
TOTAL PREMATURE CHROMATID SEPARATION TRAIT	PREMATURE CHROMATID SEPARATION TRAIT; PCS	176430
CURRARINO SYNDROME	CURRARINO SYNDROME	176450
CURRARINO TRIADSACRAL AGENESIS SYNDROME, INCLUDED	CURRARINO SYNDROME	176450
SACRAL AGENESIS, HEREDITARY, WITH PRESACRAL MASS, ANTERIOR MENINGOCELE,AND/OR TERATOMA, AND ANORECTAL MALFORMATION, INCLUDED	CURRARINO SYNDROME	176450
SCRA1, INCLUDED	CURRARINO SYNDROME	176450
CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 1	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 1	176500
DEMENTIA, FAMILIAL BRITISH; FBD	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 1	176500
PRESENILE DEMENTIA WITH SPASTIC ATAXIA	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 1	176500
CEREBRAL AMYLOID ANGIOPATHY, BRITISH TYPE	CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 1	176500
HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS	HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS	176670
PROGERIAPROGERIA SYNDROME, CHILDHOOD-ONSET, INCLUDED	HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS	176670
PROGNATHISM, MANDIBULAR	PROGNATHISM, MANDIBULAR	176700
'HABSBURG JAW'	PROGNATHISM, MANDIBULAR	176700
'HAPSBURG JAW'	PROGNATHISM, MANDIBULAR	176700
PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO	PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO	176780
PROLAPSE OF VAGINA AND RECTUM	PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO	176780
RECTAL PROLAPSE	PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO	176780
VAGINAL PROLAPSEPELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO, 1, INCLUDED; PVOP1, INCLUDED	PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO	176780
PROSTATE CANCER	PROSTATE CANCER	176807
THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL DOMINANT; THPH3	THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL DOMINANT; THPH3	176860
PROTEIN C DEFICIENCY, AUTOSOMAL DOMINANT	THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL DOMINANT; THPH3	176860
PROC DEFICIENCY, AUTOSOMAL DOMINANTPROTEIN C DEFICIENCY, ACQUIRED, INCLUDED	THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL DOMINANT; THPH3	176860
PROTEUS SYNDROME	PROTEUS SYNDROME	176920
GIGANTISM, PARTIAL, OF HANDS AND FEET, NEVI, HEMIHYPERTROPHY, ANDMACROCEPHALYELATTOPROTEUS SYNDROME, INCLUDED	PROTEUS SYNDROME	176920
PROTOPORPHYRIA, ERYTHROPOIETIC; EPP	PROTOPORPHYRIA, ERYTHROPOIETIC; EPP	177000
ERYTHROHEPATIC PROTOPORPHYRIA	PROTOPORPHYRIA, ERYTHROPOIETIC; EPP	177000
HEME SYNTHETASE DEFICIENCY	PROTOPORPHYRIA, ERYTHROPOIETIC; EPP	177000
FERROCHELATASE DEFICIENCY	PROTOPORPHYRIA, ERYTHROPOIETIC; EPP	177000
PROTRUSIO ACETABULI	PROTRUSIO ACETABULI	177050
PSEUDOACHONDROPLASIA; PSACH	PSEUDOACHONDROPLASIA; PSACH	177170
PSEUDOACHONDROPLASTIC DYSPLASIA	PSEUDOACHONDROPLASIA; PSACH	177170
SPONDYLOEPIPHYSEAL DYSPLASIA, PSEUDOACHONDROPLASTIC	PSEUDOACHONDROPLASIA; PSACH	177170
LIDDLE SYNDROME; LIDLS	LIDDLE SYNDROME; LIDLS	177200
PSEUDOALDOSTERONISM	LIDDLE SYNDROME; LIDLS	177200
BUTYRYLCHOLINESTERASE; BCHE	BUTYRYLCHOLINESTERASE; BCHE	177400
PSEUDOCHOLINESTERASE E1; CHE1	BUTYRYLCHOLINESTERASE; BCHE	177400
ACYLCHOLINE ACYLHYDROLASEBUTYRYLCHOLINESTERASE DEFICIENCY, INCLUDED	BUTYRYLCHOLINESTERASE; BCHE	177400
ACHOLINESTERASEMIA, INCLUDED	BUTYRYLCHOLINESTERASE; BCHE	177400
SUXAMETHONIUM SENSITIVITY, INCLUDED	BUTYRYLCHOLINESTERASE; BCHE	177400
PSEUDOCHOLINESTERASE DEFICIENCY, INCLUDED	BUTYRYLCHOLINESTERASE; BCHE	177400
APNEA, POSTANESTHETIC, INCLUDED	BUTYRYLCHOLINESTERASE; BCHE	177400
BUTYRYLCHOLINESTERASE DEFICIENCY, FLUORIDE-RESISTANT, JAPANESE TYPE,INCLUDED	BUTYRYLCHOLINESTERASE; BCHE	177400
HYPOCHOLINESTERASEMIA, FLUORIDE-RESISTANT, JAPANESE TYPE, INCLUDED	BUTYRYLCHOLINESTERASE; BCHE	177400
EXFOLIATION SYNDROME; XFS	EXFOLIATION SYNDROME; XFS	177650
EXFOLIATION GLAUCOMA; XFG	EXFOLIATION SYNDROME; XFS	177650
PSEUDOEXFOLIATION GLAUCOMA; PEXG	EXFOLIATION SYNDROME; XFS	177650
PSEUDOEXFOLIATION OF THE LENS	EXFOLIATION SYNDROME; XFS	177650
PSEUDOEXFOLIATION SYNDROME; PEXS	EXFOLIATION SYNDROME; XFS	177650
GLAUCOMA 1, OPEN ANGLE, P; GLC1P	GLAUCOMA 1, OPEN ANGLE, P; GLC1P	177700
PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL DOMINANT; PHA1A	PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL DOMINANT; PHA1A	177735
PHA I, AUTOSOMAL DOMINANT	PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL DOMINANT; PHA1A	177735
PSEUDOMONILETHRIX	PSEUDOMONILETHRIX	177750
PSEUDO-VON WILLEBRAND DISEASE; VWDP	PSEUDO-VON WILLEBRAND DISEASE; VWDP	177820
BLEEDING DISORDER, PLATELET-TYPE, 3; BDPLT3	PSEUDO-VON WILLEBRAND DISEASE; VWDP	177820
VON WILLEBRAND DISEASE, PLATELET-TYPE	PSEUDO-VON WILLEBRAND DISEASE; VWDP	177820
PSEUDOXANTHOMA ELASTICUM, FORME FRUSTEPSEUDOXANTHOMA ELASTICUM, HETEROZYGOUS, INCLUDED	PSEUDOXANTHOMA ELASTICUM, FORME FRUSTEPSEUDOXANTHOMA ELASTICUM, HETEROZYGOUS, INCLUDED	177850
PSORIASIS 1, SUSCEPTIBILITY TO; PSORS1	PSORIASIS 1, SUSCEPTIBILITY TO; PSORS1	177900
PTERYGIA, MENTAL RETARDATION, AND DISTINCTIVE CRANIOFACIAL FEATURES	PTERYGIA, MENTAL RETARDATION, AND DISTINCTIVE CRANIOFACIAL FEATURES	177980
HASPESLAGH SYNDROME	PTERYGIA, MENTAL RETARDATION, AND DISTINCTIVE CRANIOFACIAL FEATURES	177980
ARTHROGRYPOSIS, DISTAL, TYPE 8; DA8	ARTHROGRYPOSIS, DISTAL, TYPE 8; DA8	178110
MULTIPLE PTERYGIUM SYNDROME, AUTOSOMAL DOMINANT	ARTHROGRYPOSIS, DISTAL, TYPE 8; DA8	178110
PTERYGIUM SYNDROME, MULTIPLE, AUTOSOMAL DOMINANT	ARTHROGRYPOSIS, DISTAL, TYPE 8; DA8	178110
PTERYGIUM, ANTECUBITAL	PTERYGIUM, ANTECUBITAL	178200
PTOSIS, HEREDITARY CONGENITAL 1; PTOS1	PTOSIS, HEREDITARY CONGENITAL 1; PTOS1	178300
PUBIC BONE DYSPLASIA	PUBIC BONE DYSPLASIA	178350
PULMONARY FIBROSIS, IDIOPATHIC; IPF	PULMONARY FIBROSIS, IDIOPATHIC; IPF	178500
IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL	PULMONARY FIBROSIS, IDIOPATHIC; IPF	178500
FIBROSING ALVEOLITIS, CRYPTOGENIC	PULMONARY FIBROSIS, IDIOPATHIC; IPF	178500
FIBROCYSTIC PULMONARY DYSPLASIA	PULMONARY FIBROSIS, IDIOPATHIC; IPF	178500
INTERSTITIAL PNEUMONITIS, USUAL; UIPHAMMAN-RICH DISEASE, INCLUDED	PULMONARY FIBROSIS, IDIOPATHIC; IPF	178500
PULMONARY HYPERTENSION, PRIMARY, 1; PPH1	PULMONARY HYPERTENSION, PRIMARY, 1; PPH1	178600
PHT	PULMONARY HYPERTENSION, PRIMARY, 1; PPH1	178600
PULMONARY ARTERIAL HYPERTENSION; PAHPULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-ASSOCIATED, INCLUDED	PULMONARY HYPERTENSION, PRIMARY, 1; PPH1	178600
PULMONARY HYPERTENSION, PRIMARY, FENFLURAMINE-ASSOCIATED, INCLUDED	PULMONARY HYPERTENSION, PRIMARY, 1; PPH1	178600
PULMONARY HYPERTENSION, PRIMARY, 1, WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA,INCLUDED	PULMONARY HYPERTENSION, PRIMARY, 1; PPH1	178600
PPH1 WITH HHT, INCLUDED	PULMONARY HYPERTENSION, PRIMARY, 1; PPH1	178600
PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 1; IHPS1	PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 1; IHPS1	179010
PYLORIC STENOSIS, INFANTILE	PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 1; IHPS1	179010
PYLORIC STENOSIS, INFANTILE HYPERTROPHIC; IHPS	PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 1; IHPS1	179010
RADIAL HEADS, POSTERIOR DISLOCATION OF	RADIAL HEADS, POSTERIOR DISLOCATION OF	179200
RAYNAUD DISEASE	RAYNAUD DISEASE	179600
COLD FINGERS, HEREDITARY	RAYNAUD DISEASE	179600
RECOMBINANT CHROMOSOME 8 SYNDROME	RECOMBINANT CHROMOSOME 8 SYNDROME	179613
REC8 SYNDROME	RECOMBINANT CHROMOSOME 8 SYNDROME	179613
CHROMOSOME 8q22.1-qter DUPLICATION AND 8pter-p23.1 DELETION	RECOMBINANT CHROMOSOME 8 SYNDROME	179613
SAN LUIS VALLEY SYNDROME	RECOMBINANT CHROMOSOME 8 SYNDROME	179613
RAPH BLOOD GROUP SYSTEM	RAPH BLOOD GROUP SYSTEM	179620
MER2 BLOOD CELL ANTIGEN EXPRESSION; MER2	RAPH BLOOD GROUP SYSTEM	179620
RED CELL PERMEABILITY DEFECT	RED CELL PERMEABILITY DEFECT	179650
ELLIPTOCYTOSIS WITH TRANSVERSE SLITLIKE CHANGES	RED CELL PERMEABILITY DEFECT	179650
RED CELL PHOSPHOLIPID DEFECT WITH HEMOLYSIS	RED CELL PHOSPHOLIPID DEFECT WITH HEMOLYSIS	179700
HIGH RED CELL PHOSPHATIDYLCHOLINE HEMOLYTIC ANEMIA; HPCHA	RED CELL PHOSPHOLIPID DEFECT WITH HEMOLYSIS	179700
PHOSPHATIDYLCHOLINE RED CELL MEMBRANE DISORDER	RED CELL PHOSPHOLIPID DEFECT WITH HEMOLYSIS	179700
LEAKY RED CELL SYNDROME	RED CELL PHOSPHOLIPID DEFECT WITH HEMOLYSIS	179700
RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL DOMINANT	RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL DOMINANT	179800
RTA, DISTAL TYPE, AUTOSOMAL DOMINANT	RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL DOMINANT	179800
RENAL TUBULAR ACIDOSIS I	RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL DOMINANT	179800
RTA, CLASSIC TYPE	RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL DOMINANT	179800
RTA, GRADIENT TYPE	RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL DOMINANT	179800
DOWLING-DEGOS DISEASE 1; DDD1	DOWLING-DEGOS DISEASE 1; DDD1	179850
DDD	DOWLING-DEGOS DISEASE 1; DDD1	179850
RETICULAR PIGMENT ANOMALY OF FLEXURES	DOWLING-DEGOS DISEASE 1; DDD1	179850
RETINAL APLASIA	RETINAL APLASIA	179900
AMAUROSIS CONGENITA	RETINAL APLASIA	179900
RETINAL ARTERIES, TORTUOSITY OF; RATOR	RETINAL ARTERIES, TORTUOSITY OF; RATOR	180000
RETINAL HEMORRHAGE WITH VASCULAR TORTUOSITY	RETINAL ARTERIES, TORTUOSITY OF; RATOR	180000
RETINAL CONE DYSTROPHY 1; RCD1	RETINAL CONE DYSTROPHY 1; RCD1	180020
RETINAL CONE DEGENERATION	RETINAL CONE DYSTROPHY 1; RCD1	180020
CONE DYSTROPHY, AUTOSOMAL DOMINANT	RETINAL CONE DYSTROPHY 1; RCD1	180020
RETINAL DETACHMENT	RETINAL DETACHMENT	180050
RETINITIS PIGMENTOSA 1; RP1	RETINITIS PIGMENTOSA 1; RP1	180100
RETINITIS PIGMENTOSA 9; RP9	RETINITIS PIGMENTOSA 9; RP9	180104
RETINITIS PIGMENTOSA 10; RP10	RETINITIS PIGMENTOSA 10; RP10	180105
RETINOBLASTOMA; RB1	RETINOBLASTOMA; RB1	180200
RB	RETINOBLASTOMA; RB1	180200
RHABDOMYOSARCOMA, EMBRYONAL, 2; RMSE2	RHABDOMYOSARCOMA, EMBRYONAL, 2; RMSE2	180295
RHEUMATOID ARTHRITIS; RA	RHEUMATOID ARTHRITIS; RA	180300
RHEUMATOID ARTHRITIS, SUSCEPTIBILITY TO	RHEUMATOID ARTHRITIS; RA	180300
AXENFELD-RIEGER SYNDROME, TYPE 1; RIEG1	AXENFELD-RIEGER SYNDROME, TYPE 1; RIEG1	180500
RIEGER SYNDROME, TYPE 1	AXENFELD-RIEGER SYNDROME, TYPE 1; RIEG1	180500
RIEG	AXENFELD-RIEGER SYNDROME, TYPE 1; RIEG1	180500
RGS	AXENFELD-RIEGER SYNDROME, TYPE 1; RIEG1	180500
RING DERMOID OF CORNEA; RDC	RING DERMOID OF CORNEA; RDC	180550
RINGED HAIR	RINGED HAIR	180600
PILI ANNULATI	RINGED HAIR	180600
ROBINOW SYNDROME, AUTOSOMAL DOMINANT 1; DRS1	ROBINOW SYNDROME, AUTOSOMAL DOMINANT 1; DRS1	180700
ROBINOW DWARFISM	ROBINOW SYNDROME, AUTOSOMAL DOMINANT 1; DRS1	180700
FETAL FACE SYNDROME	ROBINOW SYNDROME, AUTOSOMAL DOMINANT 1; DRS1	180700
ACRAL DYSOSTOSIS WITH FACIAL AND GENITAL ABNORMALITIES	ROBINOW SYNDROME, AUTOSOMAL DOMINANT 1; DRS1	180700
ROBINOW-SORAUF SYNDROME	ROBINOW-SORAUF SYNDROME	180750
CRANIOSYNOSTOSIS-BIFID HALLUX SYNDROME	ROBINOW-SORAUF SYNDROME	180750
ACROCEPHALOSYNDACTYLY, ROBINOW-SORAUF TYPE	ROBINOW-SORAUF SYNDROME	180750
ROUSSY-LEVY HEREDITARY AREFLEXIC DYSTASIA	ROUSSY-LEVY HEREDITARY AREFLEXIC DYSTASIA	180800
ROUSSY-LEVY SYNDROME	ROUSSY-LEVY HEREDITARY AREFLEXIC DYSTASIA	180800
RUBINSTEIN-TAYBI SYNDROME 1; RSTS1	RUBINSTEIN-TAYBI SYNDROME 1; RSTS1	180849
RUBINSTEIN SYNDROME	RUBINSTEIN-TAYBI SYNDROME 1; RSTS1	180849
BROAD THUMBS AND GREAT TOES, CHARACTERISTIC FACIES, AND MENTAL RETARDATION	RUBINSTEIN-TAYBI SYNDROME 1; RSTS1	180849
BROAD THUMB-HALLUX SYNDROME	RUBINSTEIN-TAYBI SYNDROME 1; RSTS1	180849
SILVER-RUSSELL SYNDROME; SRS	SILVER-RUSSELL SYNDROME; SRS	180860
RUSSELL-SILVER SYNDROME; RSS	SILVER-RUSSELL SYNDROME; SRS	180860
SILVER-RUSSELL DWARFISM	SILVER-RUSSELL SYNDROME; SRS	180860
RUTHERFURD SYNDROME	RUTHERFURD SYNDROME	180900
CORNEAL DYSTROPHY WITH GUM HYPERTROPHY	RUTHERFURD SYNDROME	180900
GINGIVAL HYPERTROPHY WITH CORNEAL DYSTROPHY	RUTHERFURD SYNDROME	180900
APLASIA OF LACRIMAL AND SALIVARY GLANDS; ALSGSALIVARY GLANDS, ABSENCE OF, INCLUDE, INCLUDED	APLASIA OF LACRIMAL AND SALIVARY GLANDS; ALSGSALIVARY GLANDS, ABSENCE OF, INCLUDE, INCLUDED	180920
PAROTID APLASIA OR HYPOPLASIA, INCLUDED	APLASIA OF LACRIMAL AND SALIVARY GLANDS; ALSGSALIVARY GLANDS, ABSENCE OF, INCLUDE, INCLUDED	180920
SALIVARY SUBSTANCE, CLOSTRIDIUM BOTULINUM TYPE	SALIVARY SUBSTANCE, CLOSTRIDIUM BOTULINUM TYPE	180950
SARCOIDOSIS, SUSCEPTIBILITY TO, 1; SS1	SARCOIDOSIS, SUSCEPTIBILITY TO, 1; SS1	181000
SARCOIDOSIS	SARCOIDOSIS, SUSCEPTIBILITY TO, 1; SS1	181000
BOECK SARCOID	SARCOIDOSIS, SUSCEPTIBILITY TO, 1; SS1	181000
SALIVARY GLAND ADENOMA, PLEOMORPHIC	SALIVARY GLAND ADENOMA, PLEOMORPHIC	181030
SGPA	SALIVARY GLAND ADENOMA, PLEOMORPHIC	181030
PSA	SALIVARY GLAND ADENOMA, PLEOMORPHIC	181030
SCALP-EAR-NIPPLE SYNDROME; SENS	SCALP-EAR-NIPPLE SYNDROME; SENS	181270
FINLAY-MARKS SYNDROME	SCALP-EAR-NIPPLE SYNDROME; SENS	181270
SEN SYNDROME	SCALP-EAR-NIPPLE SYNDROME; SENS	181270
EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT; EDMD2	EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT; EDMD2	181350
EMD2	EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT; EDMD2	181350
EMERY-DREIFUSS MUSCULAR DYSTROPHY, AUTOSOMAL DOMINANT	EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT; EDMD2	181350
SCAPULOILIOPERONEAL ATROPHY WITH CARDIOPATHY	EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT; EDMD2	181350
MUSCULAR DYSTROPHY WITH EARLY CONTRACTURES AND CARDIOMYOPATHY, AUTOSOMALDOMINANT	EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT; EDMD2	181350
HAUPTMANN-THANNHAUSER MUSCULAR DYSTROPHY	EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT; EDMD2	181350
SCAPULOPERONEAL SYNDROME, NEUROGENIC, KAESER TYPE; SCPNK	SCAPULOPERONEAL SYNDROME, NEUROGENIC, KAESER TYPE; SCPNK	181400
KAESER SYNDROME	SCAPULOPERONEAL SYNDROME, NEUROGENIC, KAESER TYPE; SCPNK	181400
STARK-KAESER SYNDROME	SCAPULOPERONEAL SYNDROME, NEUROGENIC, KAESER TYPE; SCPNK	181400
SCAPULOPERONEAL SYNDROME, NEUROGENIC TYPE, OF KAESER	SCAPULOPERONEAL SYNDROME, NEUROGENIC, KAESER TYPE; SCPNK	181400
SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY; SPSMA	SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY; SPSMA	181405
AMYOTROPHY, NEUROGENIC SCAPULOPERONEAL, NEW ENGLAND TYPE	SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY; SPSMA	181405
SCAPULOPERONEAL MYOPATHY, MYH7-RELATED; SPMM	SCAPULOPERONEAL MYOPATHY, MYH7-RELATED; SPMM	181430
SCAPULOPERONEAL MUSCULAR DYSTROPHY; SPMD	SCAPULOPERONEAL MYOPATHY, MYH7-RELATED; SPMM	181430
SCAPULOPERONEAL SYNDROME, MYOPATHIC TYPE	SCAPULOPERONEAL MYOPATHY, MYH7-RELATED; SPMM	181430
SCHEUERMANN DISEASE	SCHEUERMANN DISEASE	181440
SCHEUERMANN JUVENILE KYPHOSIS	SCHEUERMANN DISEASE	181440
SPINAL OSTEOCHONDROSIS	SCHEUERMANN DISEASE	181440
ULNAR-MAMMARY SYNDROME; UMS	ULNAR-MAMMARY SYNDROME; UMS	181450
PALLISTER ULNAR-MAMMARY SYNDROME	ULNAR-MAMMARY SYNDROME; UMS	181450
SCHINZEL SYNDROME	ULNAR-MAMMARY SYNDROME; UMS	181450
SCHISTOSOMA MANSONI INFECTION, SUSCEPTIBILITY/RESISTANCE TO	SCHISTOSOMA MANSONI INFECTION, SUSCEPTIBILITY/RESISTANCE TO	181460
SCHISTOSOMA MANSONI, INTENSITY OF INFECTION BY; SM1	SCHISTOSOMA MANSONI INFECTION, SUSCEPTIBILITY/RESISTANCE TO	181460
SCHIZOPHRENIA; SCZD	SCHIZOPHRENIA; SCZD	181500
SCHIZOAFFECTIVE DISORDER, INCLUDED	SCHIZOPHRENIA; SCZD	181500
SCHIZOPHRENIA 1; SCZD1	SCHIZOPHRENIA 1; SCZD1	181510
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 5-RELATED	SCHIZOPHRENIA 1; SCZD1	181510
SCHOLTE SYNDROME	SCHOLTE SYNDROME	181515
EARLY BALDING, PATELLA LUXATION, ACROMICRIA, AND HYPOGONADISM	SCHOLTE SYNDROME	181515
SCLEROTYLOSIS	SCLEROTYLOSIS	181600
TYS	SCLEROTYLOSIS	181600
SCLEROATROPHIC AND KERATOTIC DERMATOSIS OF LIMBS	SCLEROTYLOSIS	181600
HURIEZ SYNDROME; HRZ	SCLEROTYLOSIS	181600
SCLERODERMA, FAMILIAL PROGRESSIVE	SCLERODERMA, FAMILIAL PROGRESSIVE	181750
SYSTEMIC SCLEROSIS, SUSCEPTIBILITY TOCREST SYNDROME, INCLUDED	SCLERODERMA, FAMILIAL PROGRESSIVE	181750
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 1; IS1	SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 1; IS1	181800
ADOLESCENT ISOLATED SCOLIOSIS; AIS	SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 1; IS1	181800
ADOLESCENT IDIOPATHIC SCOLIOSIS	SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 1; IS1	181800
KERATOSIS, SEBORRHEIC	KERATOSIS, SEBORRHEIC	182000
FUCOSYLTRANSFERASE 2; FUT2	FUCOSYLTRANSFERASE 2; FUT2	182100
SECRETOR FACTOR; SeNORWALK VIRUS INFECTION, RESISTANCE TO, INCLUDED	FUCOSYLTRANSFERASE 2; FUT2	182100
SHPRINTZEN-GOLDBERG CRANIOSYNOSTOSIS SYNDROME; SGS	SHPRINTZEN-GOLDBERG CRANIOSYNOSTOSIS SYNDROME; SGS	182212
CRANIOSYNOSTOSIS WITH ARACHNODACTYLY AND ABDOMINAL HERNIAS	SHPRINTZEN-GOLDBERG CRANIOSYNOSTOSIS SYNDROME; SGS	182212
MARFANOID DISORDER WITH CRANIOSYNOSTOSIS, TYPE I	SHPRINTZEN-GOLDBERG CRANIOSYNOSTOSIS SYNDROME; SGS	182212
MARFANOID CRANIOSYNOSTOSIS SYNDROME	SHPRINTZEN-GOLDBERG CRANIOSYNOSTOSIS SYNDROME; SGS	182212
SEPTOOPTIC DYSPLASIA	SEPTOOPTIC DYSPLASIA	182230
DE MORSIER SYNDROMEPITUITARY HORMONE DEFICIENCY, COMBINED, 5, INCLUDED; CPHD5, INCLUDED	SEPTOOPTIC DYSPLASIA	182230
GROWTH HORMONE DEFICIENCY WITH PITUITARY ANOMALIES, INCLUDED	SEPTOOPTIC DYSPLASIA	182230
SINGLETON-MERTEN SYNDROME 1; SGMRT1	SINGLETON-MERTEN SYNDROME 1; SGMRT1	182250
SMALL CELL CANCER OF THE LUNG	SMALL CELL CANCER OF THE LUNG	182280
SCLC1	SMALL CELL CANCER OF THE LUNG	182280
SCLC; SCCL	SMALL CELL CANCER OF THE LUNG	182280
SMITH-MAGENIS SYNDROME; SMS	SMITH-MAGENIS SYNDROME; SMS	182290
CHROMOSOME 17p11.2 DELETION SYNDROMESMITH-MAGENIS CHROMOSOME REGION, INCLUDED; SMCR, INCLUDED	SMITH-MAGENIS SYNDROME; SMS	182290
SNEDDON SYNDROME	SNEDDON SYNDROME	182410
LIVEDO RETICULARIS AND CEREBROVASCULAR ACCIDENTS	SNEDDON SYNDROME	182410
SOMATOSTATIN RECEPTOR 5; SSTR5SOMATOSTATIN ANALOG, RESISTANCE TO, INCLUDED	SOMATOSTATIN RECEPTOR 5; SSTR5SOMATOSTATIN ANALOG, RESISTANCE TO, INCLUDED	182455
SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT; SPG3A	SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT; SPG3A	182600
SPG3	SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT; SPG3A	182600
STRUMPELL DISEASE	SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT; SPG3A	182600
FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 1; FSP1	SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT; SPG3A	182600
SPASTIC PARAPLEGIA 4, AUTOSOMAL DOMINANT; SPG4	SPASTIC PARAPLEGIA 4, AUTOSOMAL DOMINANT; SPG4	182601
FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 2; FSP2	SPASTIC PARAPLEGIA 4, AUTOSOMAL DOMINANT; SPG4	182601
SPECTRIN, BETA, ERYTHROCYTIC; SPTB	SPECTRIN, BETA, ERYTHROCYTIC; SPTB	182870
SPECTRIN, BETA-IELLIPTOCYTOSIS 3, INCLUDED; EL3, INCLUDED	SPECTRIN, BETA, ERYTHROCYTIC; SPTB	182870
SPHEROCYTOSIS, TYPE 1; SPH1	SPHEROCYTOSIS, TYPE 1; SPH1	182900
SPHEROCYTOSIS, HEREDITARY, 1; HS1	SPHEROCYTOSIS, TYPE 1; SPH1	182900
SPH; HS	SPHEROCYTOSIS, TYPE 1; SPH1	182900
MYOPATHY, SPHEROID BODY	MYOPATHY, SPHEROID BODY	182920
NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO; NTDSPINA BIFIDA, INCLUDED	NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO; NTDSPINA BIFIDA, INCLUDED	182940
SPINAL ARACHNOIDITIS	SPINAL ARACHNOIDITIS	182950
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE I; HMN1	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE I; HMN1	182960
HMN I	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE I; HMN1	182960
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE I; DHMN1	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE I; HMN1	182960
SPINAL MUSCULAR ATROPHY, DISTAL, JUVENILE, AUTOSOMAL DOMINANT, I	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE I; HMN1	182960
CHARCOT-MARIE-TOOTH DISEASE, SPINAL, I	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE I; HMN1	182960
SPINAL MUSCULAR ATROPHY, FACIOSCAPULOHUMERAL TYPE	SPINAL MUSCULAR ATROPHY, FACIOSCAPULOHUMERAL TYPE	182970
FSHSMA	SPINAL MUSCULAR ATROPHY, FACIOSCAPULOHUMERAL TYPE	182970
SPINAL MUSCULAR ATROPHY, LATE-ONSET, FINKEL TYPE; SMAFK	SPINAL MUSCULAR ATROPHY, LATE-ONSET, FINKEL TYPE; SMAFK	182980
FINKEL LATE-ADULT TYPE SMA	SPINAL MUSCULAR ATROPHY, LATE-ONSET, FINKEL TYPE; SMAFK	182980
SPINAL MUSCULAR ATROPHY, PROXIMAL, ADULT, AUTOSOMAL DOMINANT	SPINAL MUSCULAR ATROPHY, LATE-ONSET, FINKEL TYPE; SMAFK	182980
SPINOCEREBELLAR ATAXIA WITH RIGIDITY AND PERIPHERAL NEUROPATHY	SPINOCEREBELLAR ATAXIA WITH RIGIDITY AND PERIPHERAL NEUROPATHY	183050
SPINOCEREBELLAR ATAXIA 6; SCA6	SPINOCEREBELLAR ATAXIA 6; SCA6	183086
SPINOCEREBELLAR ATAXIA 2; SCA2	SPINOCEREBELLAR ATAXIA 2; SCA2	183090
SPINOCEREBELLAR ATROPHY II	SPINOCEREBELLAR ATAXIA 2; SCA2	183090
OLIVOPONTOCEREBELLAR ATROPHY, HOLGUIN TYPE	SPINOCEREBELLAR ATAXIA 2; SCA2	183090
OLIVOPONTOCEREBELLAR ATROPHY II; OPCA2	SPINOCEREBELLAR ATAXIA 2; SCA2	183090
SPINOCEREBELLAR ATAXIA, CUBAN TYPE	SPINOCEREBELLAR ATAXIA 2; SCA2	183090
CEREBELLAR DEGENERATION WITH SLOW EYE MOVEMENTS	SPINOCEREBELLAR ATAXIA 2; SCA2	183090
WADIA-SWAMI SYNDROME	SPINOCEREBELLAR ATAXIA 2; SCA2	183090
SPINOCEREBELLAR DEGENERATION WITH SLOW EYE MOVEMENTS; SDSEMAMYOTROPHIC LATERAL SCLEROSIS, SUSCEPTIBILITY TO, 13, INCLUDED; ALS13,INCLUDED	SPINOCEREBELLAR ATAXIA 2; SCA2	183090
SPLIT-HAND/FOOT MALFORMATION 1; SHFM1	SPLIT-HAND/FOOT MALFORMATION 1; SHFM1	183600
SPLIT-HAND/FOOT MALFORMATION 1 WITH OR WITHOUT DEAFNESS	SPLIT-HAND/FOOT MALFORMATION 1; SHFM1	183600
SPLIT-HAND/FOOT DEFORMITY 1; SHFD1; SHSF1	SPLIT-HAND/FOOT MALFORMATION 1; SHFM1	183600
SPLIT-HAND DEFORMITY	SPLIT-HAND/FOOT MALFORMATION 1; SHFM1	183600
ECTRODACTYLY; ECD	SPLIT-HAND/FOOT MALFORMATION 1; SHFM1	183600
SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 2; SPDA2	SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 2; SPDA2	183840
SPONDYLOEPIPHYSEAL DYSPLASIA CONGENITA; SEDC	SPONDYLOEPIPHYSEAL DYSPLASIA CONGENITA; SEDC	183900
SED CONGENITA	SPONDYLOEPIPHYSEAL DYSPLASIA CONGENITA; SEDC	183900
SPONDYLOEPIPHYSEAL DYSPLASIA, CONGENITAL TYPE	SPONDYLOEPIPHYSEAL DYSPLASIA CONGENITA; SEDC	183900
SPONDYLOEPIPHYSEAL DYSPLASIA, MAROTEAUX TYPE	SPONDYLOEPIPHYSEAL DYSPLASIA, MAROTEAUX TYPE	184095
SED, MAROTEAUX TYPE	SPONDYLOEPIPHYSEAL DYSPLASIA, MAROTEAUX TYPE	184095
PSEUDO-MORQUIO SYNDROME, TYPE 2	SPONDYLOEPIPHYSEAL DYSPLASIA, MAROTEAUX TYPE	184095
SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, AUTOSOMAL DOMINANT	SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, AUTOSOMAL DOMINANT	184100
SPONDYLOLISTHESIS	SPONDYLOLISTHESIS	184200
SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK	184250
SEMD, STRUDWICK TYPE	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK	184250
SPONDYLOMETAEPIPHYSEAL DYSPLASIA CONGENITA, STRUDWICK TYPE	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK	184250
SMED, STRUDWICK TYPE	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK	184250
SMED, TYPE I	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK	184250
STRUDWICK SYNDROME	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK	184250
DAPPLED METAPHYSIS SYNDROME	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK	184250
SPONDYLOMETAPHYSEAL DYSPLASIA; SMD	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK	184250
SEMDC	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK	184250
SPONDYLOMETAPHYSEAL DYSPLASIA, KOZLOWSKI TYPE; SMDK	SPONDYLOMETAPHYSEAL DYSPLASIA, KOZLOWSKI TYPE; SMDK	184252
SMD, KOZLOWSKI TYPE	SPONDYLOMETAPHYSEAL DYSPLASIA, KOZLOWSKI TYPE; SMDK	184252
SPONDYLOMETAPHYSEAL DYSPLASIA, CORNER FRACTURE TYPE	SPONDYLOMETAPHYSEAL DYSPLASIA, CORNER FRACTURE TYPE	184255
SPONDYLOMETAPHYSEAL DYSPLASIA, SUTCLIFFE TYPE	SPONDYLOMETAPHYSEAL DYSPLASIA, CORNER FRACTURE TYPE	184255
SPRENGEL DEFORMITY	SPRENGEL DEFORMITY	184400
HIGH SCAPULA	SPRENGEL DEFORMITY	184400
STUTTERING, FAMILIAL PERSISTENT, 1; STUT1	STUTTERING, FAMILIAL PERSISTENT, 1; STUT1	184450
STAMMERING	STUTTERING, FAMILIAL PERSISTENT, 1; STUT1	184450
STAPES ANKYLOSIS WITH BROAD THUMB AND TOES	STAPES ANKYLOSIS WITH BROAD THUMB AND TOES	184460
ANKYLOSIS OF STAPES, HYPEROPIA, BROAD THUMBS, BROAD FIRST TOES, ANDSYNDACTYLY	STAPES ANKYLOSIS WITH BROAD THUMB AND TOES	184460
TEUNISSEN-CREMERS SYNDROME	STAPES ANKYLOSIS WITH BROAD THUMB AND TOES	184460
STAPES ANKYLOSIS SYNDROME WITHOUT SYMPHALANGISM	STAPES ANKYLOSIS WITH BROAD THUMB AND TOES	184460
STEATOCYSTOMA MULTIPLEX	STEATOCYSTOMA MULTIPLEX	184500
SEBACEOUS CYSTS, MULTIPLE	STEATOCYSTOMA MULTIPLEX	184500
POLYCYSTIC OVARY SYNDROME 1; PCOS1	POLYCYSTIC OVARY SYNDROME 1; PCOS1	184700
PCO1; PCO	POLYCYSTIC OVARY SYNDROME 1; PCOS1	184700
PCOS	POLYCYSTIC OVARY SYNDROME 1; PCOS1	184700
STEIN-LEVENTHAL SYNDROME	POLYCYSTIC OVARY SYNDROME 1; PCOS1	184700
HYPERANDROGENEMIA	POLYCYSTIC OVARY SYNDROME 1; PCOS1	184700
NUCLEAR RECEPTOR SUBFAMILY 5, GROUP A, MEMBER 1; NR5A1	NUCLEAR RECEPTOR SUBFAMILY 5, GROUP A, MEMBER 1; NR5A1	184757
FUSHI TARAZU FACTOR, DROSOPHILA, HOMOLOG 1; FTZF1; FTZ1	NUCLEAR RECEPTOR SUBFAMILY 5, GROUP A, MEMBER 1; NR5A1	184757
STEROIDOGENIC FACTOR 1; SF1	NUCLEAR RECEPTOR SUBFAMILY 5, GROUP A, MEMBER 1; NR5A1	184757
ADRENAL 4 BINDING PROTEIN; AD4BPADRENOCORTICAL INSUFFICIENCY, INCLUDED	NUCLEAR RECEPTOR SUBFAMILY 5, GROUP A, MEMBER 1; NR5A1	184757
STICKLER SYNDROME, TYPE III; STL3	STICKLER SYNDROME, TYPE III; STL3	184840
STICKLER SYNDROME, NONOCULAR TYPE	STICKLER SYNDROME, TYPE III; STL3	184840
STIFF-PERSON SYNDROME; SPS	STIFF-PERSON SYNDROME; SPS	184850
STIFF-MAN SYNDROME	STIFF-PERSON SYNDROME; SPS	184850
STIFF-TRUNK SYNDROMEPROGRESSIVE ENCEPHALOMYELITIS WITH RIGIDITY, INCLUDED; PERM, INCLUDED;PER, INCLUDED	STIFF-PERSON SYNDROME; SPS	184850
STIFF SKIN SYNDROME; SSKS	STIFF SKIN SYNDROME; SSKS	184900
OVERHYDRATED HEREDITARY STOMATOCYTOSIS; OHS	OVERHYDRATED HEREDITARY STOMATOCYTOSIS; OHS	185000
POTASSIUM-SODIUM DISORDER OF ERYTHROCYTE	OVERHYDRATED HEREDITARY STOMATOCYTOSIS; OHS	185000
CRYOHYDROCYTOSIS; CHC	CRYOHYDROCYTOSIS; CHC	185020
STOMATOCYTOSIS, COLD-SENSITIVE	CRYOHYDROCYTOSIS; CHC	185020
STORAGE POOL PLATELET DISEASE	STORAGE POOL PLATELET DISEASE	185050
STORMORKEN SYNDROME; STRMK	STORMORKEN SYNDROME; STRMK	185070
THROMBOCYTOPATHY, ASPLENIA, AND MIOSIS	STORMORKEN SYNDROME; STRMK	185070
YORK PLATELET SYNDROME; YPS	STORMORKEN SYNDROME; STRMK	185070
STRABISMUS, SUSCEPTIBILITY TOSTRABISMUS, SUSCEPTIBILITY TO, 1, INCLUDED; STBMS1, INCLUDED	STRABISMUS, SUSCEPTIBILITY TOSTRABISMUS, SUSCEPTIBILITY TO, 1, INCLUDED; STBMS1, INCLUDED	185100
STRIAE DISTENSAE, FAMILIAL	STRIAE DISTENSAE, FAMILIAL	185200
STURGE-WEBER SYNDROME; SWS	STURGE-WEBER SYNDROME; SWS	185300
SUPRAVALVULAR AORTIC STENOSIS; SVAS	SUPRAVALVULAR AORTIC STENOSIS; SVAS	185500
SUPRAVALVAR AORTIC STENOSIS, EISENBERG TYPE	SUPRAVALVULAR AORTIC STENOSIS; SVAS	185500
SYMPHALANGISM, DISTAL	SYMPHALANGISM, DISTAL	185700
SYM2	SYMPHALANGISM, DISTAL	185700
SYMPHALANGISM, PROXIMAL, 1A; SYM1A	SYMPHALANGISM, PROXIMAL, 1A; SYM1A	185800
SYM1	SYMPHALANGISM, PROXIMAL, 1A; SYM1A	185800
CUSHING SYMPHALANGISM	SYMPHALANGISM, PROXIMAL, 1A; SYM1A	185800
HEREDITARY ABSENCE OF THE PROXIMAL INTERPHALANGEAL JOINTS	SYMPHALANGISM, PROXIMAL, 1A; SYM1A	185800
CHROMOSOME 2q35 DUPLICATION SYNDROME	CHROMOSOME 2q35 DUPLICATION SYNDROME	185900
SYNDACTYLY, TYPE I; SDTY1	CHROMOSOME 2q35 DUPLICATION SYNDROME	185900
SD1	CHROMOSOME 2q35 DUPLICATION SYNDROME	185900
ZYGODACTYLYCRANIOSYNOSTOSIS, PHILADELPHIA TYPE, INCLUDED	CHROMOSOME 2q35 DUPLICATION SYNDROME	185900
SYNPOLYDACTYLY 1; SPD1	SYNPOLYDACTYLY 1; SPD1	186000
SYNDACTYLY, TYPE IISYNPOLYDACTYLY WITH FOOT ANOMALIES, INCLUDED	SYNPOLYDACTYLY 1; SPD1	186000
SYNDACTYLY, TYPE III	SYNDACTYLY, TYPE III	186100
SDTY3	SYNDACTYLY, TYPE III	186100
RING AND LITTLE FINGER SYNDACTYLY	SYNDACTYLY, TYPE III	186100
SYNDACTYLY OF FINGERS IV AND V	SYNDACTYLY, TYPE III	186100
SYNDACTYLY, TYPE IV; SDTY4	SYNDACTYLY, TYPE IV; SDTY4	186200
HAAS TYPE SYNDACTYLY	SYNDACTYLY, TYPE IV; SDTY4	186200
POLYSYNDACTYLY, HAAS TYPE	SYNDACTYLY, TYPE IV; SDTY4	186200
SD4	SYNDACTYLY, TYPE IV; SDTY4	186200
SYNDACTYLY, TYPE V	SYNDACTYLY, TYPE V	186300
SYNDACTYLY WITH METACARPAL AND METATARSAL FUSION	SYNDACTYLY, TYPE V	186300
SYNDACTYLY-POLYDACTYLY-EARLOBE SYNDROME	SYNDACTYLY-POLYDACTYLY-EARLOBE SYNDROME	186350
SPEL SYNDROME	SYNDACTYLY-POLYDACTYLY-EARLOBE SYNDROME	186350
SYNOSTOSES, TARSAL, CARPAL, AND DIGITAL	SYNOSTOSES, TARSAL, CARPAL, AND DIGITAL	186400
CALCANEONAVICULAR COALITION	SYNOSTOSES, TARSAL, CARPAL, AND DIGITAL	186400
MULTIPLE SYNOSTOSES SYNDROME 1; SYNS1	MULTIPLE SYNOSTOSES SYNDROME 1; SYNS1	186500
SYNOSTOSES, MULTIPLE, WITH BRACHYDACTYLY	MULTIPLE SYNOSTOSES SYNDROME 1; SYNS1	186500
SYMPHALANGISM-BRACHYDACTYLY SYNDROME	MULTIPLE SYNOSTOSES SYNDROME 1; SYNS1	186500
WL SYNDROME	MULTIPLE SYNOSTOSES SYNDROME 1; SYNS1	186500
DEAFNESS-SYMPHALANGISM SYNDROME OF HERRMANN	MULTIPLE SYNOSTOSES SYNDROME 1; SYNS1	186500
FACIOAUDIOSYMPHALANGISM SYNDROME	MULTIPLE SYNOSTOSES SYNDROME 1; SYNS1	186500
LIEBENBERG SYNDROME; LBNBG	LIEBENBERG SYNDROME; LBNBG	186550
SYNOSTOSIS, CARPAL, WITH DYSPLASTIC ELBOW JOINTS AND BRACHYDACTYLY	LIEBENBERG SYNDROME; LBNBG	186550
BRACHYDACTYLY WITH JOINT DYSPLASIA	LIEBENBERG SYNDROME; LBNBG	186550
TARSAL-CARPAL COALITION SYNDROME; TCCSYNOSTOSIS OF TALUS AND CALCANEUS WITH SHORT STATURE, INCLUDED	TARSAL-CARPAL COALITION SYNDROME; TCCSYNOSTOSIS OF TALUS AND CALCANEUS WITH SHORT STATURE, INCLUDED	186570
BLAU SYNDROME; BLAUS	BLAU SYNDROME; BLAUS	186580
GRANULOMATOSIS, FAMILIAL JUVENILE SYSTEMIC	BLAU SYNDROME; BLAUS	186580
ARTHROCUTANEOUVEAL GRANULOMATOSIS; ACUG	BLAU SYNDROME; BLAUS	186580
JABS SYNDROME	BLAU SYNDROME; BLAUS	186580
GRANULOMATOUS INFLAMMATORY ARTHRITIS, DERMATITIS, AND UVEITIS, FAMILIAL	BLAU SYNDROME; BLAUS	186580
GRANULOMATOSIS, FAMILIAL, BLAU TYPESYNOVITIS, GRANULOMATOUS, WITH UVEITIS AND CRANIAL NEUROPATHIES, INCLUDED	BLAU SYNDROME; BLAUS	186580
SYRINGOMYELIA, ISOLATED	SYRINGOMYELIA, ISOLATED	186700
TARSAL COALITION	TARSAL COALITION	186850
TARSAL FUSION	TARSAL COALITION	186850
TEAR PROTEIN, ANODAL	TEAR PROTEIN, ANODAL	186890
TEETH, ODD SHAPES OFLOBODONTIA, INCLUDED	TEETH, ODD SHAPES OFLOBODONTIA, INCLUDED	187000
CONICAL TEETH, MULTIPLE, INCLUDED	TEETH, ODD SHAPES OFLOBODONTIA, INCLUDED	187000
TELANGIECTASIA, HEREDITARY BENIGN	TELANGIECTASIA, HEREDITARY BENIGN	187260
HBT	TELANGIECTASIA, HEREDITARY BENIGN	187260
TELANGIECTASIA, GENERALIZED ESSENTIAL	TELANGIECTASIA, HEREDITARY BENIGN	187260
TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER;HHT	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER;HHT	187300
OSLER-RENDU-WEBER DISEASE	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER;HHT	187300
ORW DISEASETELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 1, INCLUDED; HHT1, INCLUDED	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER;HHT	187300
ARTHROGRYPOSIS, DISTAL, TYPE 10; DA10	ARTHROGRYPOSIS, DISTAL, TYPE 10; DA10	187370
CONGENITAL PLANTAR CONTRACTURES	ARTHROGRYPOSIS, DISTAL, TYPE 10; DA10	187370
TENDO CALCANEUS, SHORT	ARTHROGRYPOSIS, DISTAL, TYPE 10; DA10	187370
TERATOCARCINOMA-DERIVED GROWTH FACTOR 1; TDGF1	TERATOCARCINOMA-DERIVED GROWTH FACTOR 1; TDGF1	187395
CRIPTO GROWTH FACTOR; CRGFFOREBRAIN DEFECTS, INCLUDED	TERATOCARCINOMA-DERIVED GROWTH FACTOR 1; TDGF1	187395
TETRALOGY OF FALLOT; TOF	TETRALOGY OF FALLOT; TOF	187500
THANATOPHORIC DYSPLASIA, TYPE I; TD1	THANATOPHORIC DYSPLASIA, TYPE I; TD1	187600
THANATOPHORIC DYSPLASIA; TD	THANATOPHORIC DYSPLASIA, TYPE I; TD1	187600
THANATOPHORIC DWARFISM	THANATOPHORIC DYSPLASIA, TYPE I; TD1	187600
PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, SAN DIEGO TYPE	THANATOPHORIC DYSPLASIA, TYPE I; TD1	187600
LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, SAN DIEGO TYPE	THANATOPHORIC DYSPLASIA, TYPE I; TD1	187600
THANATOPHORIC DYSPLASIA, TYPE II; TD2	THANATOPHORIC DYSPLASIA, TYPE II; TD2	187601
THANATOPHORIC DYSPLASIA WITH STRAIGHT FEMURS AND CLOVERLEAF SKULL	THANATOPHORIC DYSPLASIA, TYPE II; TD2	187601
THANATOPHORIC DYSPLASIA WITH KLEEBLATTSCHAEDEL	THANATOPHORIC DYSPLASIA, TYPE II; TD2	187601
CLOVERLEAF SKULL WITH THANATOPHORIC DWARFISM	THANATOPHORIC DYSPLASIA, TYPE II; TD2	187601
THEOPHYLLINE BIOTRANSFORMATION	THEOPHYLLINE BIOTRANSFORMATION	187650
BLEEDING DISORDER, PLATELET-TYPE, 16; BDPLT16	BLEEDING DISORDER, PLATELET-TYPE, 16; BDPLT16	187800
GLANZMANN THROMBASTHENIA, AUTOSOMAL DOMINANT	BLEEDING DISORDER, PLATELET-TYPE, 16; BDPLT16	187800
THROMBASTHENIA OF GLANZMANN AND NAEGELI, AUTOSOMAL DOMINANT	BLEEDING DISORDER, PLATELET-TYPE, 16; BDPLT16	187800
BLEEDING DISORDER, PLATELET-TYPE, 17; BDPLT17	BLEEDING DISORDER, PLATELET-TYPE, 17; BDPLT17	187900
THROMBASTHENIA-THROMBOCYTOPENIA, HEREDITARY	BLEEDING DISORDER, PLATELET-TYPE, 17; BDPLT17	187900
THROMBOCYTHEMIA 1; THCYT1	THROMBOCYTHEMIA 1; THCYT1	187950
THROMBOCYTOSIS 1	THROMBOCYTHEMIA 1; THCYT1	187950
THROMBOCYTOPENIA 2; THC2	THROMBOCYTOPENIA 2; THC2	188000
THROMBOCYTOPENIA, AUTOSOMAL DOMINANT, 2	THROMBOCYTOPENIA 2; THC2	188000
THROMBOCYTOPENIA, PARIS-TROUSSEAU TYPE; TCPT	THROMBOCYTOPENIA, PARIS-TROUSSEAU TYPE; TCPT	188025
CHROMOSOME 11q23 DELETION SYNDROME	THROMBOCYTOPENIA, PARIS-TROUSSEAU TYPE; TCPT	188025
THROMBOPHILIA DUE TO THROMBIN DEFECT; THPH1	THROMBOPHILIA DUE TO THROMBIN DEFECT; THPH1	188050
THROMBOPHILIA DUE TO FACTOR 2 DEFECT	THROMBOPHILIA DUE TO THROMBIN DEFECT; THPH1	188050
VENOUS THROMBOSIS	THROMBOPHILIA DUE TO THROMBIN DEFECT; THPH1	188050
VENOUS THROMBOEMBOLISMTHROMBOSIS, PROTECTION AGAINST, INCLUDED	THROMBOPHILIA DUE TO THROMBIN DEFECT; THPH1	188050
THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2	THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2	188055
ACTIVATED PROTEIN C RESISTANCE	THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2	188055
APC RESISTANCE	THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2	188055
THROMBOPHILIA DUE TO DEFICIENCY OF ACTIVATED PROTEIN C COFACTOR	THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2	188055
PROC COFACTOR DEFICIENCY	THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2	188055
PCCF DEFICIENCY	THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2	188055
THROMBOPHILIA VTHROMBOPHILIA DUE TO FACTOR V LEIDEN, INCLUDED	THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2	188055
DIGEORGE SYNDROME; DGS	DIGEORGE SYNDROME; DGS	188400
CHROMOSOME 22q11.2 DELETION SYNDROME	DIGEORGE SYNDROME; DGS	188400
HYPOPLASIA OF THYMUS AND PARATHYROIDS	DIGEORGE SYNDROME; DGS	188400
THIRD AND FOURTH PHARYNGEAL POUCH SYNDROMEDIGEORGE SYNDROME CHROMOSOME REGION, INCLUDED; DGCR, INCLUDED	DIGEORGE SYNDROME; DGS	188400
TAKAO VCF SYNDROME, INCLUDED	DIGEORGE SYNDROME; DGS	188400
CATCH22, INCLUDED	DIGEORGE SYNDROME; DGS	188400
THYROID CANCER, NONMEDULLARY, 2; NMTC2	THYROID CANCER, NONMEDULLARY, 2; NMTC2	188470
THYROTROPIN-RELEASING HORMONE RECEPTOR; TRHRTHYROTROPIN-RELEASING HORMONE RESISTANCE, GENERALIZED, INCLUDED	THYROTROPIN-RELEASING HORMONE RECEPTOR; TRHRTHYROTROPIN-RELEASING HORMONE RESISTANCE, GENERALIZED, INCLUDED	188545
THYROID CANCER, NONMEDULLARY, 1; NMTC1	THYROID CANCER, NONMEDULLARY, 1; NMTC1	188550
PAPILLARY CARCINOMA OF THYROID; PACT; PTC; TPC	THYROID CANCER, NONMEDULLARY, 1; NMTC1	188550
FAMILIAL NONMEDULLARY THYROID CANCER, PAPILLARY	THYROID CANCER, NONMEDULLARY, 1; NMTC1	188550
NONMEDULLARY THYROID CARCINOMA, PAPILLARY	THYROID CANCER, NONMEDULLARY, 1; NMTC1	188550
THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL DOMINANT; GRTH	THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL DOMINANT; GRTH	188570
GTHR	THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL DOMINANT; GRTH	188570
THYROID HORMONE UNRESPONSIVENESS	THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL DOMINANT; GRTH	188570
HYPERTHYROXINEMIA, FAMILIAL EUTHYROID, SECONDARY TO PITUITARY ANDPERIPHERAL RESISTANCE TO THYROID HORMONES	THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL DOMINANT; GRTH	188570
THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 1; TTPP1	THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 1; TTPP1	188580
TIBIA, HYPOPLASIA OR APLASIA OF, WITH POLYDACTYLY; THYP	TIBIA, HYPOPLASIA OR APLASIA OF, WITH POLYDACTYLY; THYP	188740
TIBIAL HEMIMELIA-POLYDACTYLY-TRIPHALANGEAL THUMBS WITH FIBULAR DIMELIA	TIBIA, HYPOPLASIA OR APLASIA OF, WITH POLYDACTYLY; THYP	188740
TIBIAL TORSION, BILATERAL MEDIAL	TIBIAL TORSION, BILATERAL MEDIAL	188800
TOBACCO ADDICTION, SUSCEPTIBILITY TO	TOBACCO ADDICTION, SUSCEPTIBILITY TO	188890
CIGARETTE HABITUATION, SUSCEPTIBILITY TO	TOBACCO ADDICTION, SUSCEPTIBILITY TO	188890
SMOKING HABIT, SUSCEPTIBILITY TO	TOBACCO ADDICTION, SUSCEPTIBILITY TO	188890
NICOTINE DEPENDENCE, SUSCEPTIBILITY TO	TOBACCO ADDICTION, SUSCEPTIBILITY TO	188890
NICOTINE ADDICTION, SUSCEPTIBILITY TO	TOBACCO ADDICTION, SUSCEPTIBILITY TO	188890
WITKOP SYNDROME	WITKOP SYNDROME	189500
ECTODERMAL DYSPLASIA 3, WITKOP TYPE; ECTD3	WITKOP SYNDROME	189500
ECTODERMAL DYSPLASIA 3, TOOTH/NAIL TYPE; ECTD3	WITKOP SYNDROME	189500
NAIL DYSPLASIA WITH HYPODONTIA	WITKOP SYNDROME	189500
TOOTH-AND-NAIL SYNDROME; TNS	WITKOP SYNDROME	189500
TORUS PALATINUS AND TORUS MANDIBULARIS	TORUS PALATINUS AND TORUS MANDIBULARIS	189700
PREECLAMPSIA/ECLAMPSIA 1; PEE1	PREECLAMPSIA/ECLAMPSIA 1; PEE1	189800
PREG1	PREECLAMPSIA/ECLAMPSIA 1; PEE1	189800
PEE	PREECLAMPSIA/ECLAMPSIA 1; PEE1	189800
TOXEMIA OF PREGNANCYHYPERTENSION, PREGNANCY-INDUCED, INCLUDED	PREECLAMPSIA/ECLAMPSIA 1; PEE1	189800
HEMOLYSIS, ELEVATED LIVER ENZYMES, AND LOW PLATELET COUNT, INCLUDED;HELLP, INCLUDED	PREECLAMPSIA/ECLAMPSIA 1; PEE1	189800
GENIOSPASM 1; GSM1	GENIOSPASM 1; GSM1	190100
TREMBLING CHIN	GENIOSPASM 1; GSM1	190100
TREMOR, HEREDITARY ESSENTIAL, 1; ETM1	TREMOR, HEREDITARY ESSENTIAL, 1; ETM1	190300
TREMOR, FAMILIAL ESSENTIAL, 1; FET1	TREMOR, HEREDITARY ESSENTIAL, 1; ETM1	190300
TREMOR, NYSTAGMUS, AND DUODENAL ULCER	TREMOR, NYSTAGMUS, AND DUODENAL ULCER	190310
TRICHODENTOOSSEOUS SYNDROME; TDO	TRICHODENTOOSSEOUS SYNDROME; TDO	190320
TDO SYNDROME	TRICHODENTOOSSEOUS SYNDROME; TDO	190320
TRICHOMEGALY; TCMGLY	TRICHOMEGALY; TCMGLY	190330
EYELASHES, LONG	TRICHOMEGALY; TCMGLY	190330
DISCOID FIBROMAS, FAMILIAL MULTIPLE; FMDF	DISCOID FIBROMAS, FAMILIAL MULTIPLE; FMDF	190340
TRICHODISCOMAS, FAMILIAL MULTIPLE	DISCOID FIBROMAS, FAMILIAL MULTIPLE; FMDF	190340
TRICHORHINOPHALANGEAL SYNDROME, TYPE I; TRPS1	TRICHORHINOPHALANGEAL SYNDROME, TYPE I; TRPS1	190350
TRPS I	TRICHORHINOPHALANGEAL SYNDROME, TYPE I; TRPS1	190350
TRICHORHINOPHALANGEAL SYNDROME, TYPE III; TRPS3	TRICHORHINOPHALANGEAL SYNDROME, TYPE III; TRPS3	190351
SUGIO-KAJII SYNDROME	TRICHORHINOPHALANGEAL SYNDROME, TYPE III; TRPS3	190351
TRIGONOCEPHALY 1; TRIGNO1	TRIGONOCEPHALY 1; TRIGNO1	190440
CRANIOSYNOSTOSIS, METOPIC	TRIGONOCEPHALY 1; TRIGNO1	190440
TRIPHALANGEAL THUMB, NONOPPOSABLE	TRIPHALANGEAL THUMB, NONOPPOSABLE	190600
TRIPHALANGEAL THUMBS WITH BRACHYECTRODACTYLY	TRIPHALANGEAL THUMBS WITH BRACHYECTRODACTYLY	190680
DOWN SYNDROME	DOWN SYNDROME	190685
TRISOMY 21DOWN SYNDROME CHROMOSOME REGION, INCLUDED; DCR, INCLUDED	DOWN SYNDROME	190685
DOWN SYNDROME CRITICAL REGION, INCLUDED; DSCR, INCLUDED	DOWN SYNDROME	190685
TRANSIENT MYELOPROLIFERATIVE DISORDER OF DOWN SYNDROME, INCLUDED	DOWN SYNDROME	190685
LEUKEMIA, MEGAKARYOBLASTIC, OF DOWN SYNDROME, INCLUDED	DOWN SYNDROME	190685
TRITANOPIA	TRITANOPIA	190900
COLORBLINDNESS, TRITANOPIC	TRITANOPIA	190900
BLUE COLORBLINDNESS	TRITANOPIA	190900
COLORBLINDNESS, TRITAN; CBT	TRITANOPIA	190900
TUBEROUS SCLEROSIS 1; TSC1	TUBEROUS SCLEROSIS 1; TSC1	191100
TUBEROUS SCLEROSIS COMPLEX; TSC	TUBEROUS SCLEROSIS 1; TSC1	191100
TUBEROSE SCLEROSIS; TS	TUBEROUS SCLEROSIS 1; TSC1	191100
SUPPRESSOR OF TUMORIGENICITY 3; ST3	SUPPRESSOR OF TUMORIGENICITY 3; ST3	191181
TUMOR-SUPPRESSOR GENE, HELA CELL TYPE; TSHL	SUPPRESSOR OF TUMORIGENICITY 3; ST3	191181
CERVICAL CARCINOMA, TUMOR-SUPPRESSOR GENE INVOLVED IN; CCTS	SUPPRESSOR OF TUMORIGENICITY 3; ST3	191181
TUNE DEAFNESS	TUNE DEAFNESS	191200
DYSMELODIA	TUNE DEAFNESS	191200
AMUSIA, CONGENITAL	TUNE DEAFNESS	191200
TONE DEAFNESS	TUNE DEAFNESS	191200
INFLAMMATORY BOWEL DISEASE 11; IBD11	INFLAMMATORY BOWEL DISEASE 11; IBD11	191390
ULNAR HYPOPLASIA	ULNAR HYPOPLASIA	191440
UPPER LIMB MESOMELIC DYSPLASIA	ULNAR HYPOPLASIA	191440
UNCOMBABLE HAIR SYNDROME	UNCOMBABLE HAIR SYNDROME	191480
PILI TRIANGULI ET CANALICULI	UNCOMBABLE HAIR SYNDROME	191480
UNDRITZ ANOMALY	UNDRITZ ANOMALY	191500
HYPERSEGMENTATION OF NUCLEI OF POLYMORPHONUCLEAR LEUKOCYTES	UNDRITZ ANOMALY	191500
UPINGTON DISEASE	UPINGTON DISEASE	191520
PERTHES-LIKE HIP DISEASE, ENCHONDROMATA, AND ECCHONDROMATA	UPINGTON DISEASE	191520
URATE-BINDING GLOBULIN, DECREASE IN	URATE-BINDING GLOBULIN, DECREASE IN	191530
URETER, BIFID OR DOUBLE	URETER, BIFID OR DOUBLE	191550
RENAL HYPODYSPLASIA/APLASIA 1; RHDA1	RENAL HYPODYSPLASIA/APLASIA 1; RHDA1	191830
RENAL ADYSPLASIA	RENAL HYPODYSPLASIA/APLASIA 1; RHDA1	191830
RENAL AGENESIS	RENAL HYPODYSPLASIA/APLASIA 1; RHDA1	191830
RENAL APLASIA	RENAL HYPODYSPLASIA/APLASIA 1; RHDA1	191830
HEREDITARY RENAL APLASIA; HRA	RENAL HYPODYSPLASIA/APLASIA 1; RHDA1	191830
MUCKLE-WELLS SYNDROME; MWS	MUCKLE-WELLS SYNDROME; MWS	191900
URTICARIA-DEAFNESS-AMYLOIDOSIS SYNDROME	MUCKLE-WELLS SYNDROME; MWS	191900
UDA SYNDROME	MUCKLE-WELLS SYNDROME; MWS	191900
CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME 2; CAPS2	MUCKLE-WELLS SYNDROME; MWS	191900
VASCULAR ENDOTHELIAL GROWTH FACTOR A; VEGFA	VASCULAR ENDOTHELIAL GROWTH FACTOR A; VEGFA	192240
VEGFATHEROSCLEROSIS, SUSCEPTIBILITY TO, INCLUDED	VASCULAR ENDOTHELIAL GROWTH FACTOR A; VEGFA	192240
VASCULOPATHY, RETINAL, WITH CEREBRAL LEUKODYSTROPHY; RVCL	VASCULOPATHY, RETINAL, WITH CEREBRAL LEUKODYSTROPHY; RVCL	192315
CEREBRORETINAL VASCULOPATHY, HEREDITARY; CRV	VASCULOPATHY, RETINAL, WITH CEREBRAL LEUKODYSTROPHY; RVCL	192315
RETINOPATHY, VASCULAR, WITH CEREBRAL AND RENAL INVOLVEMENT AND RAYNAUDAND MIGRAINE PHENOMENA	VASCULOPATHY, RETINAL, WITH CEREBRAL LEUKODYSTROPHY; RVCL	192315
VATER/VACTERL ASSOCIATION	VATER/VACTERL ASSOCIATION	192350
VELOCARDIOFACIAL SYNDROME	VELOCARDIOFACIAL SYNDROME	192430
CHROMOSOME 22q11.2 DELETION SYNDROME	VELOCARDIOFACIAL SYNDROME	192430
VCF SYNDROME; VCFS	VELOCARDIOFACIAL SYNDROME	192430
SHPRINTZEN VCF SYNDROME	VELOCARDIOFACIAL SYNDROME	192430
LONG QT SYNDROME 1; LQT1	LONG QT SYNDROME 1; LQT1	192500
WARD-ROMANO SYNDROME; WRS	LONG QT SYNDROME 1; LQT1	192500
ROMANO-WARD SYNDROME; RWS	LONG QT SYNDROME 1; LQT1	192500
VENTRICULAR FIBRILLATION WITH PROLONGED QT INTERVALLONG QT SYNDROME 1/2, DIGENIC, INCLUDED; LQT1/2, DIGENIC, INCLUDED	LONG QT SYNDROME 1; LQT1	192500
LONG QT SYNDROME 1, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	LONG QT SYNDROME 1; LQT1	192500
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 1; CMH1	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 1; CMH1	192600
CMH	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 1; CMH1	192600
VENTRICULAR HYPERTROPHY, HEREDITARY	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 1; CMH1	192600
ASYMMETRIC SEPTAL HYPERTROPHY; ASH	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 1; CMH1	192600
HYPERTROPHIC SUBAORTIC STENOSIS, IDIOPATHIC	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 1; CMH1	192600
VENTRICULAR TACHYCARDIA, FAMILIAL	VENTRICULAR TACHYCARDIA, FAMILIAL	192605
VENTRICULAR TACHYCARDIA, FAMILIAL POLYMORPHIC	VENTRICULAR TACHYCARDIA, FAMILIAL	192605
VERTEBRAL HYPOPLASIA WITH LUMBAR KYPHOSIS	VERTEBRAL HYPOPLASIA WITH LUMBAR KYPHOSIS	192900
VERTICAL TALUS, CONGENITAL; CVT	VERTICAL TALUS, CONGENITAL; CVT	192950
ROCKER-BOTTOM FOOT	VERTICAL TALUS, CONGENITAL; CVT	192950
PES VALGUS, CONGENITAL CONVEX	VERTICAL TALUS, CONGENITAL; CVT	192950
VESICOURETERAL REFLUX 1; VUR1	VESICOURETERAL REFLUX 1; VUR1	193000
VUR	VESICOURETERAL REFLUX 1; VUR1	193000
NYSTAGMUS 4, CONGENITAL, AUTOSOMAL DOMINANT; NYS4	NYSTAGMUS 4, CONGENITAL, AUTOSOMAL DOMINANT; NYS4	193003
VESTIBULOCEREBELLAR DISORDER WITH PREDOMINANT OCULAR SIGNS	NYSTAGMUS 4, CONGENITAL, AUTOSOMAL DOMINANT; NYS4	193003
VERTIGO, BENIGN RECURRENT; BRV	VERTIGO, BENIGN RECURRENT; BRV	193007
VERTIGO, BENIGN PAROXYSMAL POSITIONAL; BPPV	VERTIGO, BENIGN RECURRENT; BRV	193007
VESTIBULOPATHY, FAMILIALVERTIGO, BENIGN RECURRENT, 1, INCLUDED; BRV1, INCLUDED	VERTIGO, BENIGN RECURRENT; BRV	193007
TRANSCOBALAMIN I DEFICIENCY	TRANSCOBALAMIN I DEFICIENCY	193090
TCN1 DEFICIENCY	TRANSCOBALAMIN I DEFICIENCY	193090
COBALAMIN PSEUDODEFICIENCY DUE TO TRANSCOBALAMIN DEFICIENCY	TRANSCOBALAMIN I DEFICIENCY	193090
COBALAMIN R BINDER PROTEIN DEFICIENCYTRANSCOBALAMIN I DEFICIENCY WITH LACTOFERRIN DEFICIENCY, INCLUDED	TRANSCOBALAMIN I DEFICIENCY	193090
R BINDER DEFICIENCY WITH LACTOFERRIN DEFICIENCY, INCLUDED	TRANSCOBALAMIN I DEFICIENCY	193090
HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL DOMINANT; ADHR	HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL DOMINANT; ADHR	193100
VITAMIN D-RESISTANT RICKETS, AUTOSOMAL DOMINANT	HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL DOMINANT; ADHR	193100
HYPOPHOSPHATEMIA, AUTOSOMAL DOMINANT	HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL DOMINANT; ADHR	193100
VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 6;VAMAS6	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 6;VAMAS6	193200
VITREORETINOCHOROIDOPATHY; VRCP	VITREORETINOCHOROIDOPATHY; VRCP	193220
VITREORETINOCHOROIDOPATHY, AUTOSOMAL DOMINANT; ADVIRC	VITREORETINOCHOROIDOPATHY; VRCP	193220
VITREORETINOCHOROIDOPATHY WITH MICROCORNEA, GLAUCOMA, AND CATARACT	VITREORETINOCHOROIDOPATHY; VRCP	193220
VITREORETINOCHOROIDOPATHY, AUTOSOMAL DOMINANT, WITH NANOPHTHALMOSMICROCORNEA, ROD-CONE DYSTROPHY, CATARACT, AND POSTERIOR STAPHYLOMA,INCLUDED; MRCS, INCLUDED	VITREORETINOCHOROIDOPATHY; VRCP	193220
VITREORETINAL DEGENERATION, SNOWFLAKE TYPE; SVD	VITREORETINAL DEGENERATION, SNOWFLAKE TYPE; SVD	193230
SNOWFLAKE VITREORETINAL DEGENERATION	VITREORETINAL DEGENERATION, SNOWFLAKE TYPE; SVD	193230
VITREORETINOPATHY, NEOVASCULAR INFLAMMATORY; VRNI	VITREORETINOPATHY, NEOVASCULAR INFLAMMATORY; VRNI	193235
PROLIFERATIVE VITREORETINOPATHY; PVR	VITREORETINOPATHY, NEOVASCULAR INFLAMMATORY; VRNI	193235
VITREORETINOPATHY, NEOVASCULAR INFLAMMATORY, AUTOSOMAL DOMINANT; ADNIV	VITREORETINOPATHY, NEOVASCULAR INFLAMMATORY; VRNI	193235
VOLVULUS OF MIDGUT	VOLVULUS OF MIDGUT	193250
INTESTINAL MALROTATION, FAMILIAL	VOLVULUS OF MIDGUT	193250
VON HIPPEL-LINDAU SYNDROME; VHLVON HIPPEL-LINDAU SYNDROME, MODIFIERS OF, INCLUDED	VON HIPPEL-LINDAU SYNDROME; VHLVON HIPPEL-LINDAU SYNDROME, MODIFIERS OF, INCLUDED	193300
VON WILLEBRAND DISEASE, TYPE 1; VWD1	VON WILLEBRAND DISEASE, TYPE 1; VWD1	193400
VON WILLEBRAND DISEASE, TYPE I	VON WILLEBRAND DISEASE, TYPE 1; VWD1	193400
VWD, TYPE 1	VON WILLEBRAND DISEASE, TYPE 1; VWD1	193400
WAARDENBURG SYNDROME, TYPE 1; WS1	WAARDENBURG SYNDROME, TYPE 1; WS1	193500
WAARDENBURG SYNDROME WITH DYSTOPIA CANTHORUM	WAARDENBURG SYNDROME, TYPE 1; WS1	193500
WAARDENBURG SYNDROME, TYPE 2A; WS2A	WAARDENBURG SYNDROME, TYPE 2A; WS2A	193510
WAARDENBURG SYNDROME, TYPE IIA	WAARDENBURG SYNDROME, TYPE 2A; WS2A	193510
WAARDENBURG SYNDROME WITHOUT DYSTOPIA CANTHORUM	WAARDENBURG SYNDROME, TYPE 2A; WS2A	193510
WS2	WAARDENBURG SYNDROME, TYPE 2A; WS2A	193510
WATSON SYNDROME; WTSN	WATSON SYNDROME; WTSN	193520
PULMONIC STENOSIS WITH CAFE-AU-LAIT SPOTS	WATSON SYNDROME; WTSN	193520
CAFE-AU-LAIT SPOTS WITH PULMONIC STENOSIS	WATSON SYNDROME; WTSN	193520
WEYERS ACROFACIAL DYSOSTOSIS; WAD	WEYERS ACROFACIAL DYSOSTOSIS; WAD	193530
ACRODENTAL DYSOSTOSIS OF WEYERS	WEYERS ACROFACIAL DYSOSTOSIS; WAD	193530
CURRY-HALL SYNDROME	WEYERS ACROFACIAL DYSOSTOSIS; WAD	193530
WHIM SYNDROME; WHIMS	WHIM SYNDROME; WHIMS	193670
WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS, AND MYELOKATHEXIS SYNDROME	WHIM SYNDROME; WHIMS	193670
ARTHROGRYPOSIS, DISTAL, TYPE 2A; DA2A	ARTHROGRYPOSIS, DISTAL, TYPE 2A; DA2A	193700
FREEMAN-SHELDON SYNDROME; FSS	ARTHROGRYPOSIS, DISTAL, TYPE 2A; DA2A	193700
WHISTLING FACE-WINDMILL VANE HAND SYNDROME	ARTHROGRYPOSIS, DISTAL, TYPE 2A; DA2A	193700
CRANIOCARPOTARSAL DYSTROPHY	ARTHROGRYPOSIS, DISTAL, TYPE 2A; DA2A	193700
CRANIOCARPOTARSAL DYSPLASIA	ARTHROGRYPOSIS, DISTAL, TYPE 2A; DA2A	193700
WHITE SPONGE NEVUS 1; WSN1	WHITE SPONGE NEVUS 1; WSN1	193900
WHITE SPONGE NEVUS OF CANNON	WHITE SPONGE NEVUS 1; WSN1	193900
LEUKOKERATOSIS, HEREDITARY MUCOSAL	WHITE SPONGE NEVUS 1; WSN1	193900
WILLIAMS-BEUREN SYNDROME; WBS	WILLIAMS-BEUREN SYNDROME; WBS	194050
CHROMOSOME 7q11.23 DELETION SYNDROME, 1.5- TO 1.8-MB	WILLIAMS-BEUREN SYNDROME; WBS	194050
WILLIAMS SYNDROME; WMS; WS	WILLIAMS-BEUREN SYNDROME; WBS	194050
WILMS TUMOR 1; WT1	WILMS TUMOR 1; WT1	194070
NEPHROBLASTOMA	WILMS TUMOR 1; WT1	194070
WILMS TUMOR 2; WT2	WILMS TUMOR 2; WT2	194071
WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, AND MENTAL RETARDATIONSYNDROME; WAGR	WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, AND MENTAL RETARDATIONSYNDROME; WAGR	194072
WAGR SYNDROME	WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, AND MENTAL RETARDATIONSYNDROME; WAGR	194072
CHROMOSOME 11p13 DELETION SYNDROME	WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, AND MENTAL RETARDATIONSYNDROME; WAGR	194072
DENYS-DRASH SYNDROME; DDS	DENYS-DRASH SYNDROME; DDS	194080
DRASH SYNDROME	DENYS-DRASH SYNDROME; DDS	194080
WILMS TUMOR AND PSEUDO- OR TRUE HERMAPHRODITISM	DENYS-DRASH SYNDROME; DDS	194080
NEPHROPATHY, WILMS TUMOR, AND GENITAL ANOMALIES	DENYS-DRASH SYNDROME; DDS	194080
WILMS TUMOR 3; WT3	WILMS TUMOR 3; WT3	194090
WOLF-HIRSCHHORN SYNDROME; WHS	WOLF-HIRSCHHORN SYNDROME; WHS	194190
CHROMOSOME 4p16.3 DELETION SYNDROME	WOLF-HIRSCHHORN SYNDROME; WHS	194190
PITT-ROGERS-DANKS SYNDROME; PRDS	WOLF-HIRSCHHORN SYNDROME; WHS	194190
PITT SYNDROME	WOLF-HIRSCHHORN SYNDROME; WHS	194190
WITTWER SYNDROME	WOLF-HIRSCHHORN SYNDROME; WHS	194190
WOLFF-PARKINSON-WHITE SYNDROME	WOLFF-PARKINSON-WHITE SYNDROME	194200
WPW SYNDROMEPREEXCITATION SYNDROME, INCLUDED	WOLFF-PARKINSON-WHITE SYNDROME	194200
ACCESSORY ATRIOVENTRICULAR PATHWAYS, INCLUDED	WOLFF-PARKINSON-WHITE SYNDROME	194200
WOOLLY HAIR, AUTOSOMAL DOMINANT; ADWH	WOOLLY HAIR, AUTOSOMAL DOMINANT; ADWH	194300
WT LIMB-BLOOD SYNDROME	WT LIMB-BLOOD SYNDROME	194350
DEHYDRATED HEREDITARY STOMATOCYTOSIS 1 WITH OR WITHOUT PSEUDOHYPERKALEMIAAND/OR PERINATAL EDEMA; DHS1	DEHYDRATED HEREDITARY STOMATOCYTOSIS 1 WITH OR WITHOUT PSEUDOHYPERKALEMIAAND/OR PERINATAL EDEMA; DHS1	194380
DEHYDRATED HEREDITARY STOMATOCYTOSIS; DHS	DEHYDRATED HEREDITARY STOMATOCYTOSIS 1 WITH OR WITHOUT PSEUDOHYPERKALEMIAAND/OR PERINATAL EDEMA; DHS1	194380
XEROCYTOSIS, HEREDITARY	DEHYDRATED HEREDITARY STOMATOCYTOSIS 1 WITH OR WITHOUT PSEUDOHYPERKALEMIAAND/OR PERINATAL EDEMA; DHS1	194380
DESICCYTOSIS, HEREDITARY	DEHYDRATED HEREDITARY STOMATOCYTOSIS 1 WITH OR WITHOUT PSEUDOHYPERKALEMIAAND/OR PERINATAL EDEMA; DHS1	194380
PSEUDOHYPERKALEMIA, FAMILIAL, 1, DUE TO RED CELL LEAK; PSHK1	DEHYDRATED HEREDITARY STOMATOCYTOSIS 1 WITH OR WITHOUT PSEUDOHYPERKALEMIAAND/OR PERINATAL EDEMA; DHS1	194380
PSEUDOHYPERKALEMIA EDINBURGH	DEHYDRATED HEREDITARY STOMATOCYTOSIS 1 WITH OR WITHOUT PSEUDOHYPERKALEMIAAND/OR PERINATAL EDEMA; DHS1	194380
ZINC, ELEVATED PLASMA	ZINC, ELEVATED PLASMA	194470
ALBUMIN BINDING OF ZINC, ELEVATED	ZINC, ELEVATED PLASMA	194470
HYPERZINCEMIA, FAMILIAL DYSALBUMINEMICHYPERZINCEMIA AND HYPERCALPROTECTINEMIA, INCLUDED	ZINC, ELEVATED PLASMA	194470
ABETALIPOPROTEINEMIA; ABL	ABETALIPOPROTEINEMIA; ABL	200100
ACANTHOCYTOSIS	ABETALIPOPROTEINEMIA; ABL	200100
BASSEN-KORNZWEIG SYNDROME	ABETALIPOPROTEINEMIA; ABL	200100
MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY	ABETALIPOPROTEINEMIA; ABL	200100
MTP DEFICIENCY	ABETALIPOPROTEINEMIA; ABL	200100
ABLEPHARON-MACROSTOMIA SYNDROME; AMS	ABLEPHARON-MACROSTOMIA SYNDROME; AMS	200110
CHOREOACANTHOCYTOSIS; CHAC	CHOREOACANTHOCYTOSIS; CHAC	200150
LEVINE-CRITCHLEY SYNDROME	CHOREOACANTHOCYTOSIS; CHAC	200150
ACANTHOCYTOSIS WITH NEUROLOGIC DISORDER	CHOREOACANTHOCYTOSIS; CHAC	200150
NEUROACANTHOCYTOSIS	CHOREOACANTHOCYTOSIS; CHAC	200150
CHOREA-ACANTHOCYTOSIS	CHOREOACANTHOCYTOSIS; CHAC	200150
ACHALASIA, FAMILIAL ESOPHAGEAL	ACHALASIA, FAMILIAL ESOPHAGEAL	200400
ACHEIROPODY; ACHP	ACHEIROPODY; ACHP	200500
ACHEIROPODIA	ACHEIROPODY; ACHP	200500
ACHEIROPODY, BRAZILIAN TYPE	ACHEIROPODY; ACHP	200500
ACHONDROGENESIS, TYPE IA; ACG1A	ACHONDROGENESIS, TYPE IA; ACG1A	200600
ACHONDROGENESIS, HOUSTON-HARRIS TYPE	ACHONDROGENESIS, TYPE IA; ACG1A	200600
ACHONDROGENESIS, TYPE II; ACG2	ACHONDROGENESIS, TYPE II; ACG2	200610
ACHONDROGENESIS, LANGER-SALDINO TYPE	ACHONDROGENESIS, TYPE II; ACG2	200610
CHONDROGENESIS IMPERFECTA	ACHONDROGENESIS, TYPE II; ACG2	200610
ACHONDROGENESIS, TYPE IB, FORMERLYHYPOCHONDROGENESIS, INCLUDED	ACHONDROGENESIS, TYPE II; ACG2	200610
CHONDRODYSPLASIA, GREBE TYPE	CHONDRODYSPLASIA, GREBE TYPE	200700
ACHONDROGENESIS, BRAZILIAN	CHONDRODYSPLASIA, GREBE TYPE	200700
GREBE CHONDRODYSPLASIA	CHONDRODYSPLASIA, GREBE TYPE	200700
GREBE DYSPLASIA	CHONDRODYSPLASIA, GREBE TYPE	200700
ACROMESOMELIC DYSPLASIA, GREBE TYPE; AMDG	CHONDRODYSPLASIA, GREBE TYPE	200700
ACHONDROGENESIS, TYPE II, FORMERLY	CHONDRODYSPLASIA, GREBE TYPE	200700
ACROCALLOSAL SYNDROME; ACLS	ACROCALLOSAL SYNDROME; ACLS	200990
HALLUX DUPLICATION, POSTAXIAL POLYDACTYLY, AND ABSENCE OF CORPUS CALLOSUM	ACROCALLOSAL SYNDROME; ACLS	200990
SCHINZEL ACROCALLOSAL SYNDROMEJOUBERT SYNDROME 12, INCLUDED; JBTS12, INCLUDED	ACROCALLOSAL SYNDROME; ACLS	200990
JOUBERT SYNDROME 12/15, DIGENIC, INCLUDED	ACROCALLOSAL SYNDROME; ACLS	200990
CARPENTER SYNDROME 1; CRPT1	CARPENTER SYNDROME 1; CRPT1	201000
CARPENTER SYNDROME	CARPENTER SYNDROME 1; CRPT1	201000
ACROCEPHALOPOLYSYNDACTYLY TYPE II	CARPENTER SYNDROME 1; CRPT1	201000
ACPS II	CARPENTER SYNDROME 1; CRPT1	201000
ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ	ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ	201100
ACROFACIAL DYSOSTOSIS SYNDROME OF RODRIGUEZ	ACROFACIAL DYSOSTOSIS SYNDROME OF RODRIGUEZ	201170
RODRIGUEZ LETHAL ACROFACIAL DYSOSTOSIS SYNDROME	ACROFACIAL DYSOSTOSIS SYNDROME OF RODRIGUEZ	201170
ACROMESOMELIC DYSPLASIA, HUNTER-THOMPSON TYPE; AMDH	ACROMESOMELIC DYSPLASIA, HUNTER-THOMPSON TYPE; AMDH	201250
ACROMESOMELIC DWARFISM	ACROMESOMELIC DYSPLASIA, HUNTER-THOMPSON TYPE; AMDH	201250
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	201300
HSAN IIA	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	201300
NEUROPATHY, HEREDITARY SENSORY, TYPE IIA; HSN2A	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	201300
HSN IIA	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	201300
ACROOSTEOLYSIS, NEUROGENIC	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	201300
ACROOSTEOLYSIS, GIACCAI TYPE	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	201300
NEUROPATHY, HEREDITARY SENSORY RADICULAR, AUTOSOMAL RECESSIVE	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	201300
MORVAN DISEASE	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	201300
NEUROPATHY, PROGRESSIVE SENSORY, OF CHILDREN	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	201300
NEUROPATHY, CONGENITAL SENSORY	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A	201300
ACTH DEFICIENCY, ISOLATED; IAD	ACTH DEFICIENCY, ISOLATED; IAD	201400
ADRENOCORTICOTROPIC HORMONE DEFICIENCY	ACTH DEFICIENCY, ISOLATED; IAD	201400
ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF; ACADMD	ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF; ACADMD	201450
ACADM DEFICIENCY	ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF; ACADMD	201450
MCAD DEFICIENCY	ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF; ACADMD	201450
MCADH DEFICIENCY	ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF; ACADMD	201450
CARNITINE DEFICIENCY SECONDARY TO MEDIUM-CHAIN ACYL-CoA DEHYDROGENASEDEFICIENCY	ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF; ACADMD	201450
ACYL-CoA DEHYDROGENASE, SHORT-CHAIN, DEFICIENCY OF; ACADSD	ACYL-CoA DEHYDROGENASE, SHORT-CHAIN, DEFICIENCY OF; ACADSD	201470
ACADS DEFICIENCY	ACYL-CoA DEHYDROGENASE, SHORT-CHAIN, DEFICIENCY OF; ACADSD	201470
LIPID-STORAGE MYOPATHY SECONDARY TO SHORT-CHAIN ACYL-CoA DEHYDROGENASEDEFICIENCY	ACYL-CoA DEHYDROGENASE, SHORT-CHAIN, DEFICIENCY OF; ACADSD	201470
SCADH DEFICIENCY	ACYL-CoA DEHYDROGENASE, SHORT-CHAIN, DEFICIENCY OF; ACADSD	201470
SCAD DEFICIENCY	ACYL-CoA DEHYDROGENASE, SHORT-CHAIN, DEFICIENCY OF; ACADSD	201470
ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN, DEFICIENCY OF; ACADVLD	ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN, DEFICIENCY OF; ACADVLD	201475
VLCAD DEFICIENCY	ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN, DEFICIENCY OF; ACADVLD	201475
ADDUCTED THUMBS SYNDROME	ADDUCTED THUMBS SYNDROME	201550
LIPOID CONGENITAL ADRENAL HYPERPLASIA; LCAH	LIPOID CONGENITAL ADRENAL HYPERPLASIA; LCAH	201710
ADRENAL HYPERPLASIA I	LIPOID CONGENITAL ADRENAL HYPERPLASIA; LCAH	201710
LIPOID HYPERPLASIA, CONGENITAL, OF ADRENAL CORTEX WITH MALE PSEUDOHERMAPHRODITISM	LIPOID CONGENITAL ADRENAL HYPERPLASIA; LCAH	201710
ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS;ABS1	ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS;ABS1	201750
3-@BETA-HYDROXYSTEROID DEHYDROGENASE, TYPE II, DEFICIENCY OF	3-@BETA-HYDROXYSTEROID DEHYDROGENASE, TYPE II, DEFICIENCY OF	201810
3-@BETA-HYDROXYSTEROID DEHYDROGENASE DEFICIENCY	3-@BETA-HYDROXYSTEROID DEHYDROGENASE, TYPE II, DEFICIENCY OF	201810
3-@BETA-HSD DEFICIENCY; HSDB	3-@BETA-HYDROXYSTEROID DEHYDROGENASE, TYPE II, DEFICIENCY OF	201810
ADRENAL HYPERPLASIA II	3-@BETA-HYDROXYSTEROID DEHYDROGENASE, TYPE II, DEFICIENCY OF	201810
ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY	201910
ADRENAL HYPERPLASIA III	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY	201910
21-@HYDROXYLASE DEFICIENCY	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY	201910
CYP21 DEFICIENCY	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY	201910
CONGENITAL ADRENAL HYPERPLASIA 1; CAH1HYPERANDROGENISM, NONCLASSIC TYPE, DUE TO 21-HYDROXYLASE DEFICIENCY,INCLUDED	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY	201910
ADRENAL HYPERPLASIA, CONGENITAL, DUE TO STEROID 11-BETA-HYDROXYLASEDEFICIENCY	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO STEROID 11-BETA-HYDROXYLASEDEFICIENCY	202010
ADRENAL HYPERPLASIA IV	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO STEROID 11-BETA-HYDROXYLASEDEFICIENCY	202010
STEROID 11-BETA-HYDROXYLASE DEFICIENCY	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO STEROID 11-BETA-HYDROXYLASEDEFICIENCY	202010
11-@BETA-HYDROXYLASE DEFICIENCY	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO STEROID 11-BETA-HYDROXYLASEDEFICIENCY	202010
ADRENAL HYPERPLASIA, HYPERTENSIVE FORM	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO STEROID 11-BETA-HYDROXYLASEDEFICIENCY	202010
P450C11B1 DEFICIENCY	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO STEROID 11-BETA-HYDROXYLASEDEFICIENCY	202010
ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY	202110
ADRENAL HYPERPLASIA V	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY	202110
17-@ALPHA-HYDROXYLASE DEFICIENCY17,20-@LYASE DEFICIENCY, ISOLATED, INCLUDED	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY	202110
17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY	202110
17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED	ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY	202110
GLUCOCORTICOID DEFICIENCY 1; GCCD1	GLUCOCORTICOID DEFICIENCY 1; GCCD1	202200
FAMILIAL GLUCOCORTICOID DEFICIENCY 1; FGD1	GLUCOCORTICOID DEFICIENCY 1; GCCD1	202200
ADRENAL UNRESPONSIVENESS TO ACTH	GLUCOCORTICOID DEFICIENCY 1; GCCD1	202200
ACTH RESISTANCE	GLUCOCORTICOID DEFICIENCY 1; GCCD1	202200
ADRENOCORTICAL CARCINOMA, HEREDITARY; ADCCADRENOCORTICAL CARCINOMA, PEDIATRIC, INCLUDED	ADRENOCORTICAL CARCINOMA, HEREDITARY; ADCCADRENOCORTICAL CARCINOMA, PEDIATRIC, INCLUDED	202300
PEROXISOME BIOGENESIS DISORDER 2B; PBD2B	PEROXISOME BIOGENESIS DISORDER 2B; PBD2B	202370
AFIBRINOGENEMIA, CONGENITALHYPOFIBRINOGENEMIA, CONGENITAL, INCLUDED	AFIBRINOGENEMIA, CONGENITALHYPOFIBRINOGENEMIA, CONGENITAL, INCLUDED	202400
AGNATHIA-OTOCEPHALY COMPLEX; AGOTC	AGNATHIA-OTOCEPHALY COMPLEX; AGOTC	202650
DYSGNATHIA COMPLEX AGNATHIA-HOLOPROSENCEPHALY	AGNATHIA-OTOCEPHALY COMPLEX; AGOTC	202650
HOLOPROSENCEPHALY-AGNATHIA	AGNATHIA-OTOCEPHALY COMPLEX; AGOTC	202650
OTOCEPHALY	AGNATHIA-OTOCEPHALY COMPLEX; AGOTC	202650
NEUTROPENIA, SEVERE CONGENITAL, 1, AUTOSOMAL DOMINANT; SCN1	NEUTROPENIA, SEVERE CONGENITAL, 1, AUTOSOMAL DOMINANT; SCN1	202700
ALBINISM, OCULOCUTANEOUS, TYPE IA; OCA1A	ALBINISM, OCULOCUTANEOUS, TYPE IA; OCA1A	203100
OCULOCUTANEOUS ALBINISM, TYPE I; OCA1	ALBINISM, OCULOCUTANEOUS, TYPE IA; OCA1A	203100
ALBINISM I	ALBINISM, OCULOCUTANEOUS, TYPE IA; OCA1A	203100
OCULOCUTANEOUS ALBINISM, TYROSINASE-NEGATIVE; ATN	ALBINISM, OCULOCUTANEOUS, TYPE IA; OCA1A	203100
ALBINISM, OCULOCUTANEOUS, TYPE II; OCA2	ALBINISM, OCULOCUTANEOUS, TYPE II; OCA2	203200
OCULOCUTANEOUS ALBINISM, TYPE II	ALBINISM, OCULOCUTANEOUS, TYPE II; OCA2	203200
OCULOCUTANEOUS ALBINISM, TYROSINASE-POSITIVE	ALBINISM, OCULOCUTANEOUS, TYPE II; OCA2	203200
ALBINISM IIALBINISM, BROWN OCULOCUTANEOUS, INCLUDED; BOCA, INCLUDED	ALBINISM, OCULOCUTANEOUS, TYPE II; OCA2	203200
BROWN OCULOCUTANEOUS ALBINISM, INCLUDED	ALBINISM, OCULOCUTANEOUS, TYPE II; OCA2	203200
ALBINISM, OCULOCUTANEOUS, TYPE III; OCA3	ALBINISM, OCULOCUTANEOUS, TYPE III; OCA3	203290
OCULOCUTANEOUS ALBINISM, TYPE III	ALBINISM, OCULOCUTANEOUS, TYPE III; OCA3	203290
ALBINISM III	ALBINISM, OCULOCUTANEOUS, TYPE III; OCA3	203290
RUFOUS OCULOCUTANEOUS ALBINISM; ROCA	ALBINISM, OCULOCUTANEOUS, TYPE III; OCA3	203290
XANTHISM	ALBINISM, OCULOCUTANEOUS, TYPE III; OCA3	203290
HERMANSKY-PUDLAK SYNDROME 1; HPS1	HERMANSKY-PUDLAK SYNDROME 1; HPS1	203300
ALBINISM WITH HEMORRHAGIC DIATHESIS AND PIGMENTED RETICULOENDOTHELIALCELLS	HERMANSKY-PUDLAK SYNDROME 1; HPS1	203300
DELTA STORAGE POOL DISEASE	HERMANSKY-PUDLAK SYNDROME 1; HPS1	203300
PSEUDOHYPOPARATHYROIDISM, TYPE II; PHP2	PSEUDOHYPOPARATHYROIDISM, TYPE II; PHP2	203330
PHP II	PSEUDOHYPOPARATHYROIDISM, TYPE II; PHP2	203330
CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY	CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY	203400
CMO I DEFICIENCY	CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY	203400
ALDOSTERONE DEFICIENCY I	CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY	203400
HYPERRENINEMIC HYPOALDOSTERONISM, FAMILIAL, 1; FHHA1A	CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY	203400
ALDOSTERONE DEFICIENCY DUE TO DEFECT IN STEROID 18-HYDROXYLASE	CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY	203400
18-@HYDROXYLASE DEFICIENCY	CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY	203400
STEROID 18-@HYDROXYLASE DEFICIENCY	CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY	203400
ALEXANDER DISEASE; ALXDRD	ALEXANDER DISEASE; ALXDRD	203450
ALKAPTONURIA; AKU	ALKAPTONURIA; AKU	203500
HOMOGENTISIC ACID OXIDASE DEFICIENCY	ALKAPTONURIA; AKU	203500
ALOPECIA-MENTAL RETARDATION SYNDROME 1; APMR1	ALOPECIA-MENTAL RETARDATION SYNDROME 1; APMR1	203650
AMR SYNDROME	ALOPECIA-MENTAL RETARDATION SYNDROME 1; APMR1	203650
ALOPECIA UNIVERSALIS CONGENITA; ALUNC	ALOPECIA UNIVERSALIS CONGENITA; ALUNC	203655
ATRICHIA, GENERALIZED	ALOPECIA UNIVERSALIS CONGENITA; ALUNC	203655
MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A	MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A	203700
ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS	MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A	203700
ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY	MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A	203700
ALPERS SYNDROME	MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A	203700
ALPERS-HUTTENLOCHER SYNDROME	MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A	203700
NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE;PNDC	MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A	203700
ALPHA-KETOGLUTARATE DEHYDROGENASE DEFICIENCY	ALPHA-KETOGLUTARATE DEHYDROGENASE DEFICIENCY	203740
ALPHA-KGD DEFICIENCY	ALPHA-KETOGLUTARATE DEHYDROGENASE DEFICIENCY	203740
2-@KETOGLUTARATE DEHYDROGENASE DEFICIENCY	ALPHA-KETOGLUTARATE DEHYDROGENASE DEFICIENCY	203740
OXOGLUTARIC ACIDURIA	ALPHA-KETOGLUTARATE DEHYDROGENASE DEFICIENCY	203740
ALPHA-METHYLACETOACETIC ACIDURIA	ALPHA-METHYLACETOACETIC ACIDURIA	203750
2-@METHYL-3-HYDROXYBUTYRIC ACIDEMIA	ALPHA-METHYLACETOACETIC ACIDURIA	203750
BETA-KETOTHIOLASE DEFICIENCY	ALPHA-METHYLACETOACETIC ACIDURIA	203750
MITOCHONDRIAL ACETOACETYL-CoA THIOLASE DEFICIENCY	ALPHA-METHYLACETOACETIC ACIDURIA	203750
MAT DEFICIENCY	ALPHA-METHYLACETOACETIC ACIDURIA	203750
T2 DEFICIENCY	ALPHA-METHYLACETOACETIC ACIDURIA	203750
3-@OXOTHIOLASE DEFICIENCY	ALPHA-METHYLACETOACETIC ACIDURIA	203750
3-@KETOTHIOLASE DEFICIENCY	ALPHA-METHYLACETOACETIC ACIDURIA	203750
3-@KTD DEFICIENCY	ALPHA-METHYLACETOACETIC ACIDURIA	203750
ALPORT SYNDROME, AUTOSOMAL RECESSIVE	ALPORT SYNDROME, AUTOSOMAL RECESSIVE	203780
ALSTROM SYNDROME; ALMS	ALSTROM SYNDROME; ALMS	203800
ALSS	ALSTROM SYNDROME; ALMS	203800
LEBER CONGENITAL AMAUROSIS 1; LCA1	LEBER CONGENITAL AMAUROSIS 1; LCA1	204000
AMAUROSIS CONGENITA OF LEBER I	LEBER CONGENITAL AMAUROSIS 1; LCA1	204000
LCA	LEBER CONGENITAL AMAUROSIS 1; LCA1	204000
RETINAL BLINDNESS, CONGENITAL; CRB	LEBER CONGENITAL AMAUROSIS 1; LCA1	204000
LEBER CONGENITAL AMAUROSIS 2; LCA2	LEBER CONGENITAL AMAUROSIS 2; LCA2	204100
AMAUROSIS CONGENITA OF LEBER II	LEBER CONGENITAL AMAUROSIS 2; LCA2	204100
CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3	CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3	204200
NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL	CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3	204200
BATTEN DISEASE	CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3	204200
VOGT-SPIELMEYER DISEASE	CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3	204200
SPIELMEYER-SJOGREN DISEASE	CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3	204200
CEROID LIPOFUSCINOSIS, NEURONAL, 4A, AUTOSOMAL RECESSIVE; CLN4A	CEROID LIPOFUSCINOSIS, NEURONAL, 4A, AUTOSOMAL RECESSIVE; CLN4A	204300
CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2	CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2	204500
CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET	CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2	204500
JANSKY-BIELSCHOWSKY DISEASENEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED	CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2	204500
AMELOGENESIS IMPERFECTA, TYPE IC; AI1C	AMELOGENESIS IMPERFECTA, TYPE IC; AI1C	204650
AMELOGENESIS IMPERFECTA, LOCAL HYPOPLASTIC TYPE, AUTOSOMAL RECESSIVE	AMELOGENESIS IMPERFECTA, TYPE IC; AI1C	204650
AMELOGENESIS IMPERFECTA, HYPOPLASTIC, WITH OR WITHOUT OPENBITE MALOCCLUSION,AUTOSOMAL RECESSIVE	AMELOGENESIS IMPERFECTA, TYPE IC; AI1C	204650
AMELOGENESIS IMPERFECTA, TYPE IG; AI1G	AMELOGENESIS IMPERFECTA, TYPE IG; AI1G	204690
ENAMEL-RENAL SYNDROME; ERS	AMELOGENESIS IMPERFECTA, TYPE IG; AI1G	204690
ENAMEL-RENAL-GINGIVAL SYNDROME	AMELOGENESIS IMPERFECTA, TYPE IG; AI1G	204690
AMELOGENESIS IMPERFECTA, HYPOPLASTIC, WITH NEPHROCALCINOSIS	AMELOGENESIS IMPERFECTA, TYPE IG; AI1G	204690
AMELOGENESIS IMPERFECTA AND GINGIVAL FIBROMATOSIS SYNDROME; AIGFS	AMELOGENESIS IMPERFECTA, TYPE IG; AI1G	204690
AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA1; AI2A1	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA1; AI2A1	204700
AMELOGENESIS IMPERFECTA, PIGMENTED HYPOMATURATION TYPE, 1	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA1; AI2A1	204700
2-@AMINOADIPIC 2-OXOADIPIC ACIDURIA; AMOXAD	2-@AMINOADIPIC 2-OXOADIPIC ACIDURIA; AMOXAD	204750
AMOBARBITAL, DEFICIENT N-HYDROXYLATION OF	AMOBARBITAL, DEFICIENT N-HYDROXYLATION OF	204800
CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD	CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD	204870
CDGDL	CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD	204870
AMYLOIDOSIS, CORNEAL	CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD	204870
AMYLOID CORNEAL DYSTROPHY, JAPANESE TYPE	CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD	204870
CORNEAL DYSTROPHY, LATTICE TYPE III	CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD	204870
LATTICE CORNEAL DYSTROPHY, TYPE III	CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD	204870
AMYOTROPHIC LATERAL SCLEROSIS 2, JUVENILE; ALS2	AMYOTROPHIC LATERAL SCLEROSIS 2, JUVENILE; ALS2	205100
ALS, JUVENILE; ALSJ	AMYOTROPHIC LATERAL SCLEROSIS 2, JUVENILE; ALS2	205100
AMYOTROPHIC LATERAL SCLEROSIS, JUVENILE, WITH DEMENTIA	AMYOTROPHIC LATERAL SCLEROSIS, JUVENILE, WITH DEMENTIA	205200
ALS-DEMENTIA COMPLEX	AMYOTROPHIC LATERAL SCLEROSIS, JUVENILE, WITH DEMENTIA	205200
TANGIER DISEASE; TGD	TANGIER DISEASE; TGD	205400
HIGH DENSITY LIPOPROTEIN DEFICIENCY, TYPE 1; HDLDT1	TANGIER DISEASE; TGD	205400
HIGH DENSITY LIPOPROTEIN DEFICIENCY, TANGIER TYPE	TANGIER DISEASE; TGD	205400
ANALPHALIPOPROTEINEMIA	TANGIER DISEASE; TGD	205400
ANEMIA, SIDEROBLASTIC, PYRIDOXINE-REFRACTORY, AUTOSOMAL RECESSIVE	ANEMIA, SIDEROBLASTIC, PYRIDOXINE-REFRACTORY, AUTOSOMAL RECESSIVE	205950
ANEMIA, HYPOCHROMIC MICROCYTIC, WITH IRON OVERLOAD 1; AHMIO1	ANEMIA, HYPOCHROMIC MICROCYTIC, WITH IRON OVERLOAD 1; AHMIO1	206100
IRON-REFRACTORY IRON DEFICIENCY ANEMIA; IRIDA	IRON-REFRACTORY IRON DEFICIENCY ANEMIA; IRIDA	206200
ANEMIA, HYPOCHROMIC MICROCYTIC, WITH DEFECT IN IRON METABOLISM	IRON-REFRACTORY IRON DEFICIENCY ANEMIA; IRIDA	206200
IRON-HANDLING DISORDER, HEREDITARY	IRON-REFRACTORY IRON DEFICIENCY ANEMIA; IRIDA	206200
PSEUDO-IRON-DEFICIENCY ANEMIA	IRON-REFRACTORY IRON DEFICIENCY ANEMIA; IRIDA	206200
ANENCEPHALY	ANENCEPHALY	206500
ANGIOMATOSIS, DIFFUSE CORTICOMENINGEAL, OF DIVRY AND VAN BOGAERT	ANGIOMATOSIS, DIFFUSE CORTICOMENINGEAL, OF DIVRY AND VAN BOGAERT	206570
DIVRY-VAN BOGAERT SYNDROME	ANGIOMATOSIS, DIFFUSE CORTICOMENINGEAL, OF DIVRY AND VAN BOGAERT	206570
ANIRIDIA, CEREBELLAR ATAXIA, AND MENTAL RETARDATION	ANIRIDIA, CEREBELLAR ATAXIA, AND MENTAL RETARDATION	206700
GILLESPIE SYNDROME	ANIRIDIA, CEREBELLAR ATAXIA, AND MENTAL RETARDATION	206700
ANODONTIA OF PERMANENT DENTITION	ANODONTIA OF PERMANENT DENTITION	206780
TEETH, PERMANENT, ABSENCE OF	ANODONTIA OF PERMANENT DENTITION	206780
NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4; NDNC4	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4; NDNC4	206800
ANONYCHIA/HYPONYCHIA CONGENITA	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4; NDNC4	206800
ANONYCHIA TOTALIS	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4; NDNC4	206800
MICROPHTHALMIA, SYNDROMIC 3; MCOPS3	MICROPHTHALMIA, SYNDROMIC 3; MCOPS3	206900
MICROPHTHALMIA AND ESOPHAGEAL ATRESIA SYNDROME	MICROPHTHALMIA, SYNDROMIC 3; MCOPS3	206900
ANOPHTHALMIA, CLINICAL, WITH ASSOCIATED ANOMALIES	MICROPHTHALMIA, SYNDROMIC 3; MCOPS3	206900
ANOPHTHALMIA-ESOPHAGEAL-GENITAL SYNDROME	MICROPHTHALMIA, SYNDROMIC 3; MCOPS3	206900
AEG SYNDROMEOPTIC NERVE HYPOPLASIA AND ABNORMALITIES OF THE CENTRAL NERVOUS SYSTEM,INCLUDED	MICROPHTHALMIA, SYNDROMIC 3; MCOPS3	206900
MICROPHTHALMIA WITH LIMB ANOMALIES; MLA	MICROPHTHALMIA WITH LIMB ANOMALIES; MLA	206920
WAARDENBURG ANOPHTHALMIA SYNDROME	MICROPHTHALMIA WITH LIMB ANOMALIES; MLA	206920
ANOPHTHALMIA-SYNDACTYLY	MICROPHTHALMIA WITH LIMB ANOMALIES; MLA	206920
OPHTHALMOACROMELIC SYNDROME; OAS	MICROPHTHALMIA WITH LIMB ANOMALIES; MLA	206920
ANTLEY-BIXLER SYNDROME WITHOUT GENITAL ANOMALIES OR DISORDERED STEROIDOGENESIS;ABS2	ANTLEY-BIXLER SYNDROME WITHOUT GENITAL ANOMALIES OR DISORDERED STEROIDOGENESIS;ABS2	207410
TRAPEZOIDOCEPHALY-SYNOSTOSIS SYNDROME	ANTLEY-BIXLER SYNDROME WITHOUT GENITAL ANOMALIES OR DISORDERED STEROIDOGENESIS;ABS2	207410
MULTISYNOSTOTIC OSTEODYSGENESIS WITH LONG BONE FRACTURES	ANTLEY-BIXLER SYNDROME WITHOUT GENITAL ANOMALIES OR DISORDERED STEROIDOGENESIS;ABS2	207410
OSTEODYSGENESIS, MULTISYNOSTOTIC, WITH FRACTURES	ANTLEY-BIXLER SYNDROME WITHOUT GENITAL ANOMALIES OR DISORDERED STEROIDOGENESIS;ABS2	207410
APOLIPOPROTEIN C-II DEFICIENCY	APOLIPOPROTEIN C-II DEFICIENCY	207750
HYPERLIPOPROTEINEMIA, TYPE IB	APOLIPOPROTEIN C-II DEFICIENCY	207750
C-II ANAPOLIPOPROTEINEMIA	APOLIPOPROTEIN C-II DEFICIENCY	207750
APOC2 DEFICIENCY	APOLIPOPROTEIN C-II DEFICIENCY	207750
ARGININEMIA	ARGININEMIA	207800
ARGINASE DEFICIENCY	ARGININEMIA	207800
HYPERARGININEMIA	ARGININEMIA	207800
ARG1 DEFICIENCY	ARGININEMIA	207800
ARGININOSUCCINIC ACIDURIA	ARGININOSUCCINIC ACIDURIA	207900
ARGININOSUCCINASE DEFICIENCY	ARGININOSUCCINIC ACIDURIA	207900
ARGININOSUCCINATE LYASE DEFICIENCY	ARGININOSUCCINIC ACIDURIA	207900
ASL DEFICIENCY	ARGININOSUCCINIC ACIDURIA	207900
ARGININOSUCCINIC ACID LYASE DEFICIENCY	ARGININOSUCCINIC ACIDURIA	207900
CHIARI MALFORMATION TYPE II	CHIARI MALFORMATION TYPE II	207950
CM2	CHIARI MALFORMATION TYPE II	207950
ARNOLD-CHIARI MALFORMATION	CHIARI MALFORMATION TYPE II	207950
ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 1; GACI1	ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 1; GACI1	208000
GACI	ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 1; GACI1	208000
IDIOPATHIC INFANTILE ARTERIAL CALCIFICATION; IIAC	ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 1; GACI1	208000
ARTERIAL CALCIFICATION, IDIOPATHIC INFANTILE	ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 1; GACI1	208000
ARTERIOPATHY, OCCLUSIVE INFANTILECORONARY SCLEROSIS, MEDIAL, OF INFANCY, INCLUDED	ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 1; GACI1	208000
ARTERIAL TORTUOSITY SYNDROME; ATS	ARTERIAL TORTUOSITY SYNDROME; ATS	208050
ARTERIAL TORTUOSITY	ARTERIAL TORTUOSITY SYNDROME; ATS	208050
ARTERIOSCLEROSIS, SEVERE JUVENILE	ARTERIOSCLEROSIS, SEVERE JUVENILE	208060
ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS 1; ARCS1	ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS 1; ARCS1	208085
ARC SYNDROME; ARCS	ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS 1; ARCS1	208085
ARTHROGRYPOSIS MULTIPLEX CONGENITA, NEUROGENIC TYPE; AMCN	ARTHROGRYPOSIS MULTIPLEX CONGENITA, NEUROGENIC TYPE; AMCN	208100
AMC, NEUROGENIC TYPE	ARTHROGRYPOSIS MULTIPLEX CONGENITA, NEUROGENIC TYPE; AMCN	208100
FETAL AKINESIA DEFORMATION SEQUENCE; FADS	FETAL AKINESIA DEFORMATION SEQUENCE; FADS	208150
PENA-SHOKEIR SYNDROME, TYPE I	FETAL AKINESIA DEFORMATION SEQUENCE; FADS	208150
FETAL AKINESIA SEQUENCE	FETAL AKINESIA DEFORMATION SEQUENCE; FADS	208150
ARTHROGRYPOSIS MULTIPLEX CONGENITA WITH PULMONARY HYPOPLASIA	FETAL AKINESIA DEFORMATION SEQUENCE; FADS	208150
ARTHROPATHY, PROGRESSIVE PSEUDORHEUMATOID, OF CHILDHOOD; PPAC	ARTHROPATHY, PROGRESSIVE PSEUDORHEUMATOID, OF CHILDHOOD; PPAC	208230
PROGRESSIVE PSEUDORHEUMATOID ARTHROPATHY OF CHILDHOOD	ARTHROPATHY, PROGRESSIVE PSEUDORHEUMATOID, OF CHILDHOOD; PPAC	208230
SPONDYLOEPIPHYSEAL DYSPLASIA TARDA WITH PROGRESSIVE ARTHROPATHY; SEDT-PA	ARTHROPATHY, PROGRESSIVE PSEUDORHEUMATOID, OF CHILDHOOD; PPAC	208230
PROGRESSIVE PSEUDORHEUMATOID DYSPLASIA; PPD	ARTHROPATHY, PROGRESSIVE PSEUDORHEUMATOID, OF CHILDHOOD; PPAC	208230
CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP	CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP	208250
ARTHROPATHY-CAMPTODACTYLY SYNDROME	CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP	208250
HYPERTROPHIC SYNOVITIS, CONGENITAL FAMILIAL	CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP	208250
JACOBS SYNDROME	CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP	208250
FIBROSING SEROSITIS, FAMILIAL	CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP	208250
PERICARDITIS-ARTHROPATHY-CAMPTODACTYLY SYNDROME	CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP	208250
PAC SYNDROME	CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP	208250
CAMPTODACTYLY-ARTHROPATHY-PERICARDITIS SYNDROME	CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP	208250
CAP SYNDROME	CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP	208250
ASPARTYLGLUCOSAMINURIA; AGU	ASPARTYLGLUCOSAMINURIA; AGU	208400
GLYCOSYLASPARAGINASE DEFICIENCY	ASPARTYLGLUCOSAMINURIA; AGU	208400
ASPARTYLGLUCOSAMINIDASE DEFICIENCY	ASPARTYLGLUCOSAMINURIA; AGU	208400
AGA DEFICIENCY	ASPARTYLGLUCOSAMINURIA; AGU	208400
GLYCOASPARAGINASE	ASPARTYLGLUCOSAMINURIA; AGU	208400
ASPARTYLGLYCOSAMINURIA	ASPARTYLGLUCOSAMINURIA; AGU	208400
SHORT-RIB THORACIC DYSPLASIA 1 WITH OR WITHOUT POLYDACTYLY; SRTD1	SHORT-RIB THORACIC DYSPLASIA 1 WITH OR WITHOUT POLYDACTYLY; SRTD1	208500
ASPHYXIATING THORACIC DYSTROPHY 1; ATD1	SHORT-RIB THORACIC DYSPLASIA 1 WITH OR WITHOUT POLYDACTYLY; SRTD1	208500
JEUNE SYNDROME	SHORT-RIB THORACIC DYSPLASIA 1 WITH OR WITHOUT POLYDACTYLY; SRTD1	208500
THORACIC-PELVIC-PHALANGEAL DYSTROPHY	SHORT-RIB THORACIC DYSPLASIA 1 WITH OR WITHOUT POLYDACTYLY; SRTD1	208500
RIGHT ATRIAL ISOMERISM; RAI	RIGHT ATRIAL ISOMERISM; RAI	208530
ASPLENIA WITH CARDIOVASCULAR ANOMALIES	RIGHT ATRIAL ISOMERISM; RAI	208530
IVEMARK SYNDROMEPOLYSPLENIA SYNDROME, INCLUDED	RIGHT ATRIAL ISOMERISM; RAI	208530
POLYASPLENIA, INCLUDED	RIGHT ATRIAL ISOMERISM; RAI	208530
HETEROTAXY, VISCEROATRIAL, AUTOSOMAL RECESSIVE, INCLUDED	RIGHT ATRIAL ISOMERISM; RAI	208530
VAH, AUTOSOMAL RECESSIVE, INCLUDED	RIGHT ATRIAL ISOMERISM; RAI	208530
RENAL-HEPATIC-PANCREATIC DYSPLASIA 1; RHPD1	RENAL-HEPATIC-PANCREATIC DYSPLASIA 1; RHPD1	208540
RHPD	RENAL-HEPATIC-PANCREATIC DYSPLASIA 1; RHPD1	208540
ASTHMA, NASAL POLYPS, AND ASPIRIN INTOLERANCE	ASTHMA, NASAL POLYPS, AND ASPIRIN INTOLERANCE	208550
ASA TRIADASTHMA, ASPIRIN-INDUCED, SUSCEPTIBILITY TO, INCLUDED	ASTHMA, NASAL POLYPS, AND ASPIRIN INTOLERANCE	208550
ASTHMA AND NASAL POLYPS, INCLUDED	ASTHMA, NASAL POLYPS, AND ASPIRIN INTOLERANCE	208550
ATAXIA, DEAFNESS, AND CARDIOMYOPATHY	ATAXIA, DEAFNESS, AND CARDIOMYOPATHY	208750
ATAXIA-TELANGIECTASIA; AT	ATAXIA-TELANGIECTASIA; AT	208900
AT1	ATAXIA-TELANGIECTASIA; AT	208900
LOUIS-BAR SYNDROMEAT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED	ATAXIA-TELANGIECTASIA; AT	208900
AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED	ATAXIA-TELANGIECTASIA; AT	208900
AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED	ATAXIA-TELANGIECTASIA; AT	208900
AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED	ATAXIA-TELANGIECTASIA; AT	208900
ATAXIA-TELANGIECTASIA VARIANT, INCLUDED	ATAXIA-TELANGIECTASIA; AT	208900
ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA;EAOH	ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA;EAOH	208920
ATAXIA-OCULOMOTOR APRAXIA SYNDROME; AOA	ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA;EAOH	208920
ATAXIA-OCULOMOTOR APRAXIA 1; AOA1	ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA;EAOH	208920
ATAXIA-TELANGIECTASIA-LIKE SYNDROME	ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA;EAOH	208920
CEREBELLAR ATAXIA, EARLY-ONSET, WITH HYPOALBUMINEMIA; EOCA-HAATAXIA, ADULT-ONSET, WITH OCULOMOTOR APRAXIA, INCLUDED	ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA;EAOH	208920
ATONIC-ASTATIC SYNDROME OF FOERSTER	ATONIC-ASTATIC SYNDROME OF FOERSTER	209100
ATRANSFERRINEMIA	ATRANSFERRINEMIA	209300
HYPOTRANSFERRINEMIA, FAMILIALTRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; TFQTL1,INCLUDED	ATRANSFERRINEMIA	209300
ATRICHIA WITH PAPULAR LESIONS; APL	ATRICHIA WITH PAPULAR LESIONS; APL	209500
PAPULAR ATRICHIA	ATRICHIA WITH PAPULAR LESIONS; APL	209500
ATROPHODERMA VERMICULATA; AVA	ATROPHODERMA VERMICULATA; AVA	209700
FOLLICULITIS ULERYTHEMATOSA RETICULATA	ATROPHODERMA VERMICULATA; AVA	209700
ATROPHODERMIA VERMICULATA	ATROPHODERMA VERMICULATA; AVA	209700
HONEYCOMB ATROPHY	ATROPHODERMA VERMICULATA; AVA	209700
ATROPHODERMIA RETICULATA SYMMETRICA FACIEI	ATROPHODERMA VERMICULATA; AVA	209700
AUTISM	AUTISM	209850
AUTISTIC DISORDERAUTISM, SUSCEPTIBILITY TO, 1, INCLUDED; AUTS1, INCLUDED	AUTISM	209850
AUTISM SPECTRUM DISORDER, INCLUDED; ASD, INCLUDED	AUTISM	209850
CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS	CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS	209880
AUTONOMIC CONTROL, CONGENITAL FAILURE OF	CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS	209880
ONDINE CURSE, CONGENITALONDINE-HIRSCHSPRUNG DISEASE, INCLUDED; OHD, INCLUDED	CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS	209880
CCHS WITH HIRSCHSPRUNG DISEASE, INCLUDED	CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS	209880
HADDAD SYNDROME, INCLUDED	CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS	209880
BARBER-SAY SYNDROME; BBRSAY	BARBER-SAY SYNDROME; BBRSAY	209885
BSS	BARBER-SAY SYNDROME; BBRSAY	209885
HYPERTRICHOSIS, ATROPHIC SKIN, ECTROPION, AND MACROSTOMIA	BARBER-SAY SYNDROME; BBRSAY	209885
BARDET-BIEDL SYNDROME 1; BBS1	BARDET-BIEDL SYNDROME 1; BBS1	209900
BARE LYMPHOCYTE SYNDROME, TYPE II	BARE LYMPHOCYTE SYNDROME, TYPE II	209920
BLS, TYPE II	BARE LYMPHOCYTE SYNDROME, TYPE II	209920
BARE LYMPHOCYTE SYNDROME; BLS	BARE LYMPHOCYTE SYNDROME, TYPE II	209920
SEVERE COMBINED IMMUNODEFICIENCY, HLA CLASS II-NEGATIVE	BARE LYMPHOCYTE SYNDROME, TYPE II	209920
SCID, HLA CLASS II-NEGATIVEBARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP A, INCLUDED	BARE LYMPHOCYTE SYNDROME, TYPE II	209920
BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP B, INCLUDED	BARE LYMPHOCYTE SYNDROME, TYPE II	209920
BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP C, INCLUDED	BARE LYMPHOCYTE SYNDROME, TYPE II	209920
BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP D, INCLUDED	BARE LYMPHOCYTE SYNDROME, TYPE II	209920
BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP E, INCLUDED	BARE LYMPHOCYTE SYNDROME, TYPE II	209920
IMMUNODEFICIENCY 27A; IMD27A	IMMUNODEFICIENCY 27A; IMD27A	209950
IMMUNODEFICIENCY 27A, MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE	IMMUNODEFICIENCY 27A; IMD27A	209950
IFNGR1 DEFICIENCY, AUTOSOMAL RECESSIVE	IMMUNODEFICIENCY 27A; IMD27A	209950
BEHR SYNDROME	BEHR SYNDROME	210000
OPTIC ATROPHY, INFANTILE HEREDITARY, WITH NEUROLOGIC ABNORMALITIES	BEHR SYNDROME	210000
BETA-AMINOISOBUTYRIC ACID, URINARY EXCRETION OF	BETA-AMINOISOBUTYRIC ACID, URINARY EXCRETION OF	210100
BAIB URINARY EXCRETION	BETA-AMINOISOBUTYRIC ACID, URINARY EXCRETION OF	210100
HYPER-BETA-AMINOISOBUTYRIC ACIDURIA	BETA-AMINOISOBUTYRIC ACID, URINARY EXCRETION OF	210100
3-@METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D	3-@METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D	210200
MCCD TYPE 1	3-@METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D	210200
MCC1 DEFICIENCY	3-@METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D	210200
3-@METHYLCROTONYLGLYCINURIA I	3-@METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D	210200
METHYLCROTONYLGLYCINURIA TYPE I	3-@METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D	210200
3-@METHYLCROTONYL-CoA CARBOXYLASE 2 DEFICIENCY; MCC2D	3-@METHYLCROTONYL-CoA CARBOXYLASE 2 DEFICIENCY; MCC2D	210210
MCC2 DEFICIENCY	3-@METHYLCROTONYL-CoA CARBOXYLASE 2 DEFICIENCY; MCC2D	210210
3-@METHYLCROTONYLGLYCINURIA II	3-@METHYLCROTONYL-CoA CARBOXYLASE 2 DEFICIENCY; MCC2D	210210
METHYLCROTONYLGLYCINURIA, TYPE II	3-@METHYLCROTONYL-CoA CARBOXYLASE 2 DEFICIENCY; MCC2D	210210
SITOSTEROLEMIA	SITOSTEROLEMIA	210250
STSL	SITOSTEROLEMIA	210250
PHYTOSTEROLEMIAMACROTHROMBOCYTOPENIA/STOMATOCYTOSIS, MEDITERRANEAN, INCLUDED	SITOSTEROLEMIA	210250
BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY; BCD	BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY; BCD	210370
BIETTI CRYSTALLINE DYSTROPHY	BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY; BCD	210370
BIETTI TAPETORETINAL DEGENERATION WITH MARGINAL CORNEAL DYSTROPHY	BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY; BCD	210370
BILIARY ATRESIA, EXTRAHEPATIC; EHBA	BILIARY ATRESIA, EXTRAHEPATIC; EHBA	210500
SECKEL SYNDROME 1; SCKL1	SECKEL SYNDROME 1; SCKL1	210600
SCKL	SECKEL SYNDROME 1; SCKL1	210600
SECKEL-TYPE DWARFISM	SECKEL SYNDROME 1; SCKL1	210600
NANOCEPHALIC DWARFISM	SECKEL SYNDROME 1; SCKL1	210600
MICROCEPHALIC PRIMORDIAL DWARFISM I	SECKEL SYNDROME 1; SCKL1	210600
BIRD-HEADED DWARFISM	SECKEL SYNDROME 1; SCKL1	210600
MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I; MOPD1	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I; MOPD1	210710
MOPD I; MOPD	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I; MOPD1	210710
OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I; MOPD1	210710
BRACHYMELIC PRIMORDIAL DWARFISM	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I; MOPD1	210710
TAYBI-LINDER SYNDROME; TALS	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I; MOPD1	210710
CEPHALOSKELETAL DYSPLASIA	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I; MOPD1	210710
LOW-BIRTH-WEIGHT DWARFISM WITH SKELETAL DYSPLASIA	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I; MOPD1	210710
MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE II; MOPD2	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE II; MOPD2	210720
MOPD II	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE II; MOPD2	210720
OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE II	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE II; MOPD2	210720
MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III	210730
MOPD III; MOPD3	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III	210730
OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III	210730
MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, CAROLINE CRACHAMITYPE	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III	210730
MOPD, CAROLINE CRACHAMI TYPE	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III	210730
MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, SICILIAN FAIRYTYPE	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III	210730
MOPD, SICILIAN FAIRY TYPE	MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III	210730
BLEPHAROPHIMOSIS WITH PTOSIS, SYNDACTYLY, AND SHORT STATURE	BLEPHAROPHIMOSIS WITH PTOSIS, SYNDACTYLY, AND SHORT STATURE	210745
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 6; SHEP6	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 6; SHEP6	210750
SKIN/HAIR/EYE PIGMENTATION 6, BLOND/BROWN HAIR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 6; SHEP6	210750
SKIN/HAIR/EYE PIGMENTATION 6, BLUE/GREEN EYES	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 6; SHEP6	210750
BLOOM SYNDROME; BLM	BLOOM SYNDROME; BLM	210900
BS; BLS	BLOOM SYNDROME; BLM	210900
FUCOSYLTRANSFERASE 1; FUT1	FUCOSYLTRANSFERASE 1; FUT1	211100
H ANTIGEN	FUCOSYLTRANSFERASE 1; FUT1	211100
HhBOMBAY PHENOTYPE, INCLUDED	FUCOSYLTRANSFERASE 1; FUT1	211100
H-DEFICIENT BLOOD GROUPS, INCLUDED	FUCOSYLTRANSFERASE 1; FUT1	211100
REUNION VARIANT, INCLUDED	FUCOSYLTRANSFERASE 1; FUT1	211100
PARA-BOMBAY PHENOTYPE, INCLUDED	FUCOSYLTRANSFERASE 1; FUT1	211100
BOWEN-CONRADI SYNDROME; BWCNS	BOWEN-CONRADI SYNDROME; BWCNS	211180
BOWEN HUTTERITE SYNDROME, FORMERLY	BOWEN-CONRADI SYNDROME; BWCNS	211180
KYPHOMELIC DYSPLASIA	KYPHOMELIC DYSPLASIA	211350
BOWING, CONGENITAL, WITH SHORT BONES	KYPHOMELIC DYSPLASIA	211350
SABINAS BRITTLE HAIR SYNDROME	SABINAS BRITTLE HAIR SYNDROME	211390
BRITTLE HAIR AND MENTAL DEFICIT	SABINAS BRITTLE HAIR SYNDROME	211390
BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 1; BESC1	BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 1; BESC1	211400
CYSTIC FIBROSIS-LIKE SYNDROME	BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 1; BESC1	211400
FAZIO-LONDE DISEASE	FAZIO-LONDE DISEASE	211500
BULBAR PALSY, PROGRESSIVE, OF CHILDHOOD	FAZIO-LONDE DISEASE	211500
BROWN-VIALETTO-VAN LAERE SYNDROME 1; BVVLS1	BROWN-VIALETTO-VAN LAERE SYNDROME 1; BVVLS1	211530
BULBAR PALSY, PROGRESSIVE, WITH SENSORINEURAL DEAFNESS	BROWN-VIALETTO-VAN LAERE SYNDROME 1; BVVLS1	211530
PONTOBULBAR PALSY WITH DEAFNESS	BROWN-VIALETTO-VAN LAERE SYNDROME 1; BVVLS1	211530
CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 1; PFIC1	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 1; PFIC1	211600
BYLER DISEASE	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 1; PFIC1	211600
C SYNDROME	C SYNDROME	211750
OPITZ TRIGONOCEPHALY SYNDROME	C SYNDROME	211750
TRIGONOCEPHALY SYNDROME	C SYNDROME	211750
CALCIFICATION OF JOINTS AND ARTERIES; CALJA	CALCIFICATION OF JOINTS AND ARTERIES; CALJA	211800
ARTERIAL CALCIFICATION DUE TO DEFICIENCY OF CD73; ACDC	CALCIFICATION OF JOINTS AND ARTERIES; CALJA	211800
CAMPOMELIA, CUMMING TYPE	CAMPOMELIA, CUMMING TYPE	211890
CERVICAL LYMPHOCELE WITH BOWED LONG BONES	CAMPOMELIA, CUMMING TYPE	211890
CUMMING SYNDROME	CAMPOMELIA, CUMMING TYPE	211890
TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC	211900
CALCINOSIS, TUMORAL, WITH HYPERPHOSPHATEMIA	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC	211900
TUMORAL CALCINOSIS, PRIMARY HYPERPHOSPHATEMIC; PHPTC	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC	211900
LIPOCALCINOGRANULOMATOSIS	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC	211900
TEUTSCHLAENDER DISEASE, FAMILIAL	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC	211900
MORBUS TEUTSCHLAENDER	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC	211900
HYPEROSTOSIS-HYPERPHOSPHATEMIA SYNDROME; HHS	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC	211900
HYPEROSTOSIS WITH HYPERPHOSPHATEMIA	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC	211900
CORTICAL HYPEROSTOSIS WITH HYPERPHOSPHATEMIA	TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC	211900
CAMPTODACTYLY WITH MUSCULAR HYPOPLASIA, SKELETAL DYSPLASIA, AND ABNORMALPALMAR CREASES	CAMPTODACTYLY WITH MUSCULAR HYPOPLASIA, SKELETAL DYSPLASIA, AND ABNORMALPALMAR CREASES	211960
TEL HASHOMER CAMPTODACTYLY SYNDROME	CAMPTODACTYLY WITH MUSCULAR HYPOPLASIA, SKELETAL DYSPLASIA, AND ABNORMALPALMAR CREASES	211960
LUNG CANCERALVEOLAR CELL CARCINOMA, INCLUDED	LUNG CANCERALVEOLAR CELL CARCINOMA, INCLUDED	211980
ADENOCARCINOMA OF LUNG, INCLUDED	LUNG CANCERALVEOLAR CELL CARCINOMA, INCLUDED	211980
NONSMALL CELL LUNG CANCER, INCLUDED	LUNG CANCERALVEOLAR CELL CARCINOMA, INCLUDED	211980
LUNG CANCER, PROTECTION AGAINST, INCLUDED	LUNG CANCERALVEOLAR CELL CARCINOMA, INCLUDED	211980
CANDIDIASIS, FAMILIAL, 2; CANDF2	CANDIDIASIS, FAMILIAL, 2; CANDF2	212050
CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL RECESSIVE	CANDIDIASIS, FAMILIAL, 2; CANDF2	212050
CARD9 IMMUNODEFICIENCY	CANDIDIASIS, FAMILIAL, 2; CANDF2	212050
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A	212065
CDG Ia; CDGIa	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A	212065
JAEKEN SYNDROME	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A	212065
PHOSPHOMANNOMUTASE 2 DEFICIENCY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A	212065
CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE Ia, FORMERLY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A	212065
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A	212066
CDG IIa; CDGIIa	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A	212066
ALKURAYA SYNDROME	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A	212066
MENTAL RETARDATION, GROWTH RETARDATION, PROMINENT COLUMELLA, AND OPENMOUTH	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A	212066
CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE II, FORMERLY; CDGS2,FORMERLY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A	212066
CARBOXYPEPTIDASE N DEFICIENCY	CARBOXYPEPTIDASE N DEFICIENCY	212070
CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM	CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM	212112
MALOUF SYNDROME	CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM	212112
CARDIOMYOPATHY, CONGESTIVE, WITH HYPERGONADOTROPIC HYPOGONADISM	CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM	212112
CARDIOMYOPATHY, DILATED, WITH PREMATURE OVARIAN FAILURE	CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM	212112
CARDIOMYOPATHY WITH PRIMARY TESTICULAR FAILURE	CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM	212112
NAJJAR SYNDROME	CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM	212112
GENITAL ANOMALY WITH CARDIOMYOPATHY	CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM	212112
CARDIOGENITAL SYNDROME	CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM	212112
CARDIOMYOPATHY ASSOCIATED WITH MYOPATHY AND SUDDEN DEATH	CARDIOMYOPATHY ASSOCIATED WITH MYOPATHY AND SUDDEN DEATH	212130
CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD	CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD	212138
CACT DEFICIENCY	CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD	212138
CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP	CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP	212140
SYSTEMIC CARNITINE DEFICIENCY; SCD	CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP	212140
CARNITINE DEFICIENCY, SYSTEMIC, DUE TO DEFECT IN RENAL REABSORPTIONOF CARNITINE	CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP	212140
CARNITINE DEFICIENCY, PRIMARY	CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP	212140
CARNITINE TRANSPORTER, PLASMA-MEMBRANE, DEFICIENCY OF	CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP	212140
CARNITINE UPTAKE DEFECT; CUD	CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP	212140
CARNITINE DEFICIENCY, MYOPATHIC	CARNITINE DEFICIENCY, MYOPATHIC	212160
CARNOSINEMIA	CARNOSINEMIA	212200
CARNOSINASE DEFICIENCY	CARNOSINEMIA	212200
SENGERS SYNDROME	SENGERS SYNDROME	212350
MITOCHONDRIAL DNA DEPLETION SYNDROME 10 (CARDIOMYOPATHIC TYPE); MTDPS10	SENGERS SYNDROME	212350
CARDIOMYOPATHY AND CATARACT	SENGERS SYNDROME	212350
CATARACT AND CONGENITAL ICHTHYOSIS	CATARACT AND CONGENITAL ICHTHYOSIS	212400
CATARACT, CONGENITAL OR JUVENILECATARACT, JUVENILE, HUTTERITE TYPE, INCLUDED	CATARACT, CONGENITAL OR JUVENILECATARACT, JUVENILE, HUTTERITE TYPE, INCLUDED	212500
OPTIC DISC ANOMALIES WITH RETINAL AND/OR MACULAR DYSTROPHY; ODRMD	OPTIC DISC ANOMALIES WITH RETINAL AND/OR MACULAR DYSTROPHY; ODRMD	212550
MARTSOLF SYNDROME	MARTSOLF SYNDROME	212720
CATARACT-MENTAL RETARDATION-HYPOGONADISM	MARTSOLF SYNDROME	212720
CELIAC DISEASE, SUSCEPTIBILITY TO, 1; CELIAC1	CELIAC DISEASE, SUSCEPTIBILITY TO, 1; CELIAC1	212750
CELIAC SPRUE, SUSCEPTIBILITY TO, 1	CELIAC DISEASE, SUSCEPTIBILITY TO, 1; CELIAC1	212750
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 1	CELIAC DISEASE, SUSCEPTIBILITY TO, 1; CELIAC1	212750
CENANI-LENZ SYNDACTYLY SYNDROME; CLSS	CENANI-LENZ SYNDACTYLY SYNDROME; CLSS	212780
CENANI SYNDACTYLISM	CENANI-LENZ SYNDACTYLY SYNDROME; CLSS	212780
CENANI-LENZ SYNDACTYLY	CENANI-LENZ SYNDACTYLY SYNDROME; CLSS	212780
SYNDACTYLY, TYPE VII	CENANI-LENZ SYNDACTYLY SYNDROME; CLSS	212780
PREMATURE CENTROMERE DIVISION; PCD	PREMATURE CENTROMERE DIVISION; PCD	212790
X-CHROMOSOME CENTROMERE PECULIARITY	PREMATURE CENTROMERE DIVISION; PCD	212790
GORDON HOLMES SYNDROME; GDHS	GORDON HOLMES SYNDROME; GDHS	212840
CEREBELLAR ATAXIA AND HYPOGONADOTROPIC HYPOGONADISM; CAHH	GORDON HOLMES SYNDROME; GDHS	212840
LUTEINIZING HORMONE-RELEASING HORMONE, DEFICIENCY OF, WITH ATAXIA	GORDON HOLMES SYNDROME; GDHS	212840
LHRH DEFICIENCY AND ATAXIA	GORDON HOLMES SYNDROME; GDHS	212840
CEREBELLAR ATAXIA, EARLY-ONSET, WITH RETAINED TENDON REFLEXES; EOCA	CEREBELLAR ATAXIA, EARLY-ONSET, WITH RETAINED TENDON REFLEXES; EOCA	212895
CEREBELLAR HYPOPLASIA	CEREBELLAR HYPOPLASIA	213000
CEREBELLOPARENCHYMAL DISORDER II; CPD2	CEREBELLOPARENCHYMAL DISORDER II; CPD2	213100
CPD, LATE-ONSET RECESSIVE TYPE	CEREBELLOPARENCHYMAL DISORDER II; CPD2	213100
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 2; SCAR2	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 2; SCAR2	213200
CEREBELLAR HYPOPLASIA, NONPROGRESSIVE NORMAN TYPE	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 2; SCAR2	213200
CEREBELLAR GRANULAR CELL HYPOPLASIA AND MENTAL RETARDATION, CONGENITAL	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 2; SCAR2	213200
CEREBELLOPARENCHYMAL DISORDER III	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 2; SCAR2	213200
CPD III; CPD3	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 2; SCAR2	213200
JOUBERT SYNDROME 1; JBTS1	JOUBERT SYNDROME 1; JBTS1	213300
JOUBERT SYNDROME; JBTS	JOUBERT SYNDROME 1; JBTS1	213300
JOUBERT-BOLTSHAUSER SYNDROME	JOUBERT SYNDROME 1; JBTS1	213300
CEREBELLOPARENCHYMAL DISORDER IV; CPD4	JOUBERT SYNDROME 1; JBTS1	213300
CEREBELLOOCULORENAL SYNDROME 1; CORS1	JOUBERT SYNDROME 1; JBTS1	213300
BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 1; IBGC1	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 1; IBGC1	213600
STRIOPALLIDODENTATE CALCINOSIS, BILATERAL; BSPDC	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 1; IBGC1	213600
STRIOPALLIDODENTATE CALCINOSIS, AUTOSOMAL DOMINANT, ADULT-ONSET	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 1; IBGC1	213600
CEREBRAL CALCIFICATION, NONARTERIOSCLEROTIC, IDIOPATHIC, ADULT-ONSET	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 1; IBGC1	213600
FERROCALCINOSIS, CEREBROVASCULAR	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 1; IBGC1	213600
FAHR DISEASE, FAMILIAL, FORMERLY	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 1; IBGC1	213600
BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 3, FORMERLY; IBGC3, FORMERLY	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 1; IBGC1	213600
CEREBROTENDINOUS XANTHOMATOSIS; CTX	CEREBROTENDINOUS XANTHOMATOSIS; CTX	213700
CEREBRAL CHOLESTERINOSIS	CEREBROTENDINOUS XANTHOMATOSIS; CTX	213700
CRANIOFACIAL DYSMORPHISM, SKELETAL ANOMALIES, AND MENTAL RETARDATIONSYNDROME; CFSMR	CRANIOFACIAL DYSMORPHISM, SKELETAL ANOMALIES, AND MENTAL RETARDATIONSYNDROME; CFSMR	213980
CEREBROFACIOTHORACIC DYSPLASIA	CRANIOFACIAL DYSMORPHISM, SKELETAL ANOMALIES, AND MENTAL RETARDATIONSYNDROME; CFSMR	213980
PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER); PBD1A	PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER); PBD1A	214100
ZS; ZWS	PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER); PBD1A	214100
CEREBROHEPATORENAL SYNDROME; CHRPEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 1, INCLUDED;CG1, INCLUDED	PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER); PBD1A	214100
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP E, INCLUDED;CGE, INCLUDED	PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER); PBD1A	214100
PEROXISOME BIOGENESIS DISORDER 2A (ZELLWEGER); PBD2APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 2, INCLUDED;CG2, INCLUDED	PEROXISOME BIOGENESIS DISORDER 2A (ZELLWEGER); PBD2APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 2, INCLUDED;CG2, INCLUDED	214110
CEREBROOCULOFACIOSKELETAL SYNDROME 1; COFS1	CEREBROOCULOFACIOSKELETAL SYNDROME 1; COFS1	214150
COFS SYNDROME; COFS	CEREBROOCULOFACIOSKELETAL SYNDROME 1; COFS1	214150
PENA-SHOKEIR SYNDROME, TYPE II	CEREBROOCULOFACIOSKELETAL SYNDROME 1; COFS1	214150
KLIPPEL-FEIL SYNDROME 2, AUTOSOMAL RECESSIVE; KFS2	KLIPPEL-FEIL SYNDROME 2, AUTOSOMAL RECESSIVE; KFS2	214300
KFS, AUTOSOMAL RECESSIVE	KLIPPEL-FEIL SYNDROME 2, AUTOSOMAL RECESSIVE; KFS2	214300
CERVICAL VERTEBRAL FUSION, AUTOSOMAL RECESSIVE	KLIPPEL-FEIL SYNDROME 2, AUTOSOMAL RECESSIVE; KFS2	214300
NEUROPATHY, HEREDITARY MOTOR AND SENSORY, WITH DEAFNESS, MENTAL RETARDATION,AND ABSENT SENSORY LARGE MYELINATED FIBERS	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, WITH DEAFNESS, MENTAL RETARDATION,AND ABSENT SENSORY LARGE MYELINATED FIBERS	214370
CHARCOT-MARIE-TOOTH DISEASE AND DEAFNESS	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, WITH DEAFNESS, MENTAL RETARDATION,AND ABSENT SENSORY LARGE MYELINATED FIBERS	214370
DEAFNESS WITH CHARCOT-MARIE-TOOTH DISEASE	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, WITH DEAFNESS, MENTAL RETARDATION,AND ABSENT SENSORY LARGE MYELINATED FIBERS	214370
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4A; CMT4A	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4A; CMT4A	214400
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE4A	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4A; CMT4A	214400
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4A	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4A; CMT4A	214400
GRISCELLI SYNDROME, TYPE 1; GS1	GRISCELLI SYNDROME, TYPE 1; GS1	214450
GRISCELLI SYNDROME WITH NEUROLOGIC IMPAIRMENT	GRISCELLI SYNDROME, TYPE 1; GS1	214450
PARTIAL ALBINISM AND PRIMARY NEUROLOGIC DISEASE WITHOUT HEMOPHAGOCYTICSYNDROME	GRISCELLI SYNDROME, TYPE 1; GS1	214450
GRISCELLI SYNDROME, CUTANEOUS AND NEUROLOGIC TYPE	GRISCELLI SYNDROME, TYPE 1; GS1	214450
CHEDIAK-HIGASHI SYNDROME; CHS	CHEDIAK-HIGASHI SYNDROME; CHS	214500
DIARRHEA 1, SECRETORY CHLORIDE, CONGENITAL; DIAR1	DIARRHEA 1, SECRETORY CHLORIDE, CONGENITAL; DIAR1	214700
CHLORIDE DIARRHEA, CONGENITAL, FINNISH TYPE	DIARRHEA 1, SECRETORY CHLORIDE, CONGENITAL; DIAR1	214700
CHLORIDORRHEA, CONGENITAL	DIARRHEA 1, SECRETORY CHLORIDE, CONGENITAL; DIAR1	214700
CHARGE SYNDROME	CHARGE SYNDROME	214800
CHARGE ASSOCIATION--COLOBOMA, HEART ANOMALY, CHOANAL ATRESIA, RETARDATION,GENITAL AND EAR ANOMALIES	CHARGE SYNDROME	214800
HALL-HITTNER SYNDROME; HHS	CHARGE SYNDROME	214800
CHOLESTASIS-LYMPHEDEMA SYNDROME	CHOLESTASIS-LYMPHEDEMA SYNDROME	214900
CHLS	CHOLESTASIS-LYMPHEDEMA SYNDROME	214900
AAGENAES SYNDROME	CHOLESTASIS-LYMPHEDEMA SYNDROME	214900
LYMPHEDEMA-CHOLESTASIS SYNDROME; LCS; LCS1	CHOLESTASIS-LYMPHEDEMA SYNDROME	214900
BILE ACID SYNTHESIS DEFECT, CONGENITAL, 4; CBAS4	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 4; CBAS4	214950
CHOLESTASIS, INTRAHEPATIC, WITH DEFECTIVE CONVERSION OF TRIHYDROXYCOPROSTANICACID TO CHOLIC ACID	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 4; CBAS4	214950
TRIHYDROXYCOPROSTANIC ACID IN BILE	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 4; CBAS4	214950
CHONDRODYSPLASIA, BLOMSTRAND TYPE; BOCD	CHONDRODYSPLASIA, BLOMSTRAND TYPE; BOCD	215045
RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1; RCDP1	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1; RCDP1	215100
PEROXISOME BIOGENESIS DISORDER 9; PBD9	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1; RCDP1	215100
CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC FORM; CDPR	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1; RCDP1	215100
CHONDRODYSTROPHIA CALCIFICANS PUNCTATA	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1; RCDP1	215100
GREENBERG DYSPLASIA; GRBGD	GREENBERG DYSPLASIA; GRBGD	215140
HYDROPS-ECTOPIC CALCIFICATION-MOTH-EATEN SKELETAL DYSPLASIA	GREENBERG DYSPLASIA; GRBGD	215140
HEM SKELETAL DYSPLASIA	GREENBERG DYSPLASIA; GRBGD	215140
MOTH-EATEN SKELETAL DYSPLASIA	GREENBERG DYSPLASIA; GRBGD	215140
CHONDRODYSTROPHY, HYDROPIC AND PRENATALLY LETHAL TYPE	GREENBERG DYSPLASIA; GRBGD	215140
OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA; OSMED	OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA; OSMED	215150
CHONDRODYSTROPHY WITH SENSORINEURAL DEAFNESS	OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA; OSMED	215150
NANCE-INSLEY SYNDROME	OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA; OSMED	215150
NANCE-SWEENEY CHONDRODYSPLASIA	OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA; OSMED	215150
CHONDROSARCOMA	CHONDROSARCOMA	215300
CHORDOMA, SUSCEPTIBILITY TO; CHDM	CHORDOMA, SUSCEPTIBILITY TO; CHDM	215400
BOUCHER-NEUHAUSER SYNDROME; BNHS	BOUCHER-NEUHAUSER SYNDROME; BNHS	215470
SPINOCEREBELLAR ATAXIA, HYPOGONADOTROPIC HYPOGONADISM, AND CHORIORETINALDYSTROPHY	BOUCHER-NEUHAUSER SYNDROME; BNHS	215470
CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, 1; CACD1	CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, 1; CACD1	215500
CHOROIDAL DYSTROPHY, CENTRAL AREOLAR; CACD	CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, 1; CACD1	215500
CHOROIDAL SCLEROSIS	CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, 1; CACD1	215500
CILIARY DYSKINESIA WITH TRANSPOSITION OF CILIARY MICROTUBULES	CILIARY DYSKINESIA WITH TRANSPOSITION OF CILIARY MICROTUBULES	215520
CIRRHOSIS, FAMILIALCIRRHOSIS, FAMILIAL, WITH PULMONARY HYPERTENSION, INCLUDED	CIRRHOSIS, FAMILIALCIRRHOSIS, FAMILIAL, WITH PULMONARY HYPERTENSION, INCLUDED	215600
INDIAN CHILDHOOD CIRRHOSIS, INCLUDED; ICC, INCLUDED	CIRRHOSIS, FAMILIALCIRRHOSIS, FAMILIAL, WITH PULMONARY HYPERTENSION, INCLUDED	215600
SEN SYNDROME, INCLUDED	CIRRHOSIS, FAMILIALCIRRHOSIS, FAMILIAL, WITH PULMONARY HYPERTENSION, INCLUDED	215600
COPPER-OVERLOAD CIRRHOSIS, INCLUDED	CIRRHOSIS, FAMILIALCIRRHOSIS, FAMILIAL, WITH PULMONARY HYPERTENSION, INCLUDED	215600
ENDEMIC TYROLEAN INFANTILE CIRRHOSIS, INCLUDED; ETIC, INCLUDED	CIRRHOSIS, FAMILIALCIRRHOSIS, FAMILIAL, WITH PULMONARY HYPERTENSION, INCLUDED	215600
COPPER TOXICOSIS, IDIOPATHIC, INCLUDED; ICT, INCLUDED	CIRRHOSIS, FAMILIALCIRRHOSIS, FAMILIAL, WITH PULMONARY HYPERTENSION, INCLUDED	215600
CIRRHOSIS, CRYPTOGENIC, INCLUDED	CIRRHOSIS, FAMILIALCIRRHOSIS, FAMILIAL, WITH PULMONARY HYPERTENSION, INCLUDED	215600
CIRRHOSIS, NONCRYPTOGENIC, SUSCEPTIBILITY TO, INCLUDED	CIRRHOSIS, FAMILIALCIRRHOSIS, FAMILIAL, WITH PULMONARY HYPERTENSION, INCLUDED	215600
CITRULLINEMIA, CLASSIC	CITRULLINEMIA, CLASSIC	215700
CITRULLINEMIA, TYPE I; CTLN1	CITRULLINEMIA, CLASSIC	215700
CITRULLINURIA	CITRULLINEMIA, CLASSIC	215700
ARGININOSUCCINATE SYNTHETASE DEFICIENCY	CITRULLINEMIA, CLASSIC	215700
ASS DEFICIENCY	CITRULLINEMIA, CLASSIC	215700
YUNIS-VARON SYNDROME; YVS	YUNIS-VARON SYNDROME; YVS	216340
CLEIDOCRANIAL DYSPLASIA WITH MICROGNATHIA, ABSENT THUMBS, AND DISTALAPHALANGIA	YUNIS-VARON SYNDROME; YVS	216340
COACH SYNDROME	COACH SYNDROME	216360
CEREBELLAR VERMIS HYPO/APLASIA, OLIGOPHRENIA, CONGENITAL ATAXIA, OCULARCOLOBOMA, AND HEPATIC FIBROSIS	COACH SYNDROME	216360
JOUBERT SYNDROME WITH CONGENITAL HEPATIC FIBROSIS	COACH SYNDROME	216360
COCKAYNE SYNDROME A; CSA	COCKAYNE SYNDROME A; CSA	216400
COHEN SYNDROME; COH1	COHEN SYNDROME; COH1	216550
COH	COHEN SYNDROME; COH1	216550
HYPOTONIA, OBESITY, AND PROMINENT INCISORS	COHEN SYNDROME; COH1	216550
PEPPER SYNDROME	COHEN SYNDROME; COH1	216550
CHS1, FORMERLY	COHEN SYNDROME; COH1	216550
COLLAGENOSIS, FAMILIAL REACTIVE PERFORATING; RPC	COLLAGENOSIS, FAMILIAL REACTIVE PERFORATING; RPC	216700
COLOBOMA, OCULAR, AUTOSOMAL RECESSIVE	COLOBOMA, OCULAR, AUTOSOMAL RECESSIVE	216820
ACHROMATOPSIA 2; ACHM2	ACHROMATOPSIA 2; ACHM2	216900
COLORBLINDNESS, TOTAL	ACHROMATOPSIA 2; ACHM2	216900
ROD MONOCHROMATISM 2	ACHROMATOPSIA 2; ACHM2	216900
ROD MONOCHROMACY 2; RMCH2	ACHROMATOPSIA 2; ACHM2	216900
COMPLEMENT COMPONENT C1r/C1s DEFICIENCY	COMPLEMENT COMPONENT C1r/C1s DEFICIENCY	216950
C1r/C1s DEFICIENCY	COMPLEMENT COMPONENT C1r/C1s DEFICIENCY	216950
COMPLEMENT COMPONENT 2 DEFICIENCY; C2D	COMPLEMENT COMPONENT 2 DEFICIENCY; C2D	217000
C2 DEFICIENCY	COMPLEMENT COMPONENT 2 DEFICIENCY; C2D	217000
JALILI SYNDROME	JALILI SYNDROME	217080
CONE-ROD DYSTROPHY AND AMELOGENESIS IMPERFECTA	JALILI SYNDROME	217080
CONGENITAL HEART DEFECTS, HAMARTOMAS OF TONGUE, AND POLYSYNDACTYLY;CHDTHP	CONGENITAL HEART DEFECTS, HAMARTOMAS OF TONGUE, AND POLYSYNDACTYLY;CHDTHP	217085
PLASMINOGEN DEFICIENCY, TYPE ILIGNEOUS CONJUNCTIVITIS, INCLUDED	PLASMINOGEN DEFICIENCY, TYPE ILIGNEOUS CONJUNCTIVITIS, INCLUDED	217090
DYSPLASMINOGENEMIA, INCLUDED	PLASMINOGEN DEFICIENCY, TYPE ILIGNEOUS CONJUNCTIVITIS, INCLUDED	217090
CONOTRUNCAL HEART MALFORMATIONS; CTHMTRUNCUS ARTERIOSUS COMMUNIS, INCLUDED	CONOTRUNCAL HEART MALFORMATIONS; CTHMTRUNCUS ARTERIOSUS COMMUNIS, INCLUDED	217095
CONOTRUNCAL ANOMALY FACE SYNDROME, INCLUDED; CAFS, INCLUDED	CONOTRUNCAL HEART MALFORMATIONS; CTHMTRUNCUS ARTERIOSUS COMMUNIS, INCLUDED	217095
DOUBLE-OUTLET RIGHT VENTRICLE, INCLUDED; DORV, INCLUDED	CONOTRUNCAL HEART MALFORMATIONS; CTHMTRUNCUS ARTERIOSUS COMMUNIS, INCLUDED	217095
PERSISTENT TRUNCUS ARTERIOSUS, INCLUDED; PTA, INCLUDED	CONOTRUNCAL HEART MALFORMATIONS; CTHMTRUNCUS ARTERIOSUS COMMUNIS, INCLUDED	217095
INTERRUPTED AORTIC ARCH, INCLUDED	CONOTRUNCAL HEART MALFORMATIONS; CTHMTRUNCUS ARTERIOSUS COMMUNIS, INCLUDED	217095
CONSTRICTING BANDS, CONGENITAL	CONSTRICTING BANDS, CONGENITAL	217100
AMNIOTIC BAND SEQUENCE; ABS	CONSTRICTING BANDS, CONGENITAL	217100
STREETER ANOMALYADAM COMPLEX, INCLUDED	CONSTRICTING BANDS, CONGENITAL	217100
TERMINAL TRANSVERSE DEFECTS OF ARM, INCLUDED	CONSTRICTING BANDS, CONGENITAL	217100
AMPUTATION, CONGENITAL, INCLUDED	CONSTRICTING BANDS, CONGENITAL	217100
CORNEA PLANA 2; CNA2	CORNEA PLANA 2; CNA2	217300
CORNEAL DYSTROPHY AND PERCEPTIVE DEAFNESS; CDPD	CORNEAL DYSTROPHY AND PERCEPTIVE DEAFNESS; CDPD	217400
CDPD1	CORNEAL DYSTROPHY AND PERCEPTIVE DEAFNESS; CDPD	217400
CORNEAL DYSTROPHY AND SENSORINEURAL DEAFNESS	CORNEAL DYSTROPHY AND PERCEPTIVE DEAFNESS; CDPD	217400
HARBOYAN SYNDROME	CORNEAL DYSTROPHY AND PERCEPTIVE DEAFNESS; CDPD	217400
CORNEAL DYSTROPHY, BAND-SHAPED	CORNEAL DYSTROPHY, BAND-SHAPED	217500
BAND KERATOPATHY	CORNEAL DYSTROPHY, BAND-SHAPED	217500
CORNEAL ENDOTHELIAL DYSTROPHY 2, AUTOSOMAL RECESSIVE; CHED2	CORNEAL ENDOTHELIAL DYSTROPHY 2, AUTOSOMAL RECESSIVE; CHED2	217700
CORNEAL DYSTROPHY, CONGENITAL HEREDITARY ENDOTHELIAL	CORNEAL ENDOTHELIAL DYSTROPHY 2, AUTOSOMAL RECESSIVE; CHED2	217700
CONGENITAL HEREDITARY ENDOTHELIAL DYSTROPHY OF CORNEA	CORNEAL ENDOTHELIAL DYSTROPHY 2, AUTOSOMAL RECESSIVE; CHED2	217700
MAUMENEE CORNEAL DYSTROPHY	CORNEAL ENDOTHELIAL DYSTROPHY 2, AUTOSOMAL RECESSIVE; CHED2	217700
MACULAR DYSTROPHY, CORNEAL; MCD	MACULAR DYSTROPHY, CORNEAL; MCD	217800
CORNEAL DYSTROPHY, MACULAR TYPE	MACULAR DYSTROPHY, CORNEAL; MCD	217800
GROENOUW TYPE II CORNEAL DYSTROPHY	MACULAR DYSTROPHY, CORNEAL; MCD	217800
MACULAR CORNEAL DYSTROPHY, TYPE I	MACULAR DYSTROPHY, CORNEAL; MCD	217800
MCDC1, FORMERLYMACULAR CORNEAL DYSTROPHY, TYPE II, INCLUDED	MACULAR DYSTROPHY, CORNEAL; MCD	217800
CORPUS CALLOSUM, AGENESIS OF, WITH FACIAL ANOMALIES AND ROBIN SEQUENCE	CORPUS CALLOSUM, AGENESIS OF, WITH FACIAL ANOMALIES AND ROBIN SEQUENCE	217980
TORIELLO-CAREY SYNDROME	CORPUS CALLOSUM, AGENESIS OF, WITH FACIAL ANOMALIES AND ROBIN SEQUENCE	217980
CORPUS CALLOSUM, AGENESIS OF	CORPUS CALLOSUM, AGENESIS OF	217990
ACC	CORPUS CALLOSUM, AGENESIS OF	217990
AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY; ACCPN	AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY; ACCPN	218000
CHARLEVOIX DISEASE	AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY; ACCPN	218000
ANDERMANN SYNDROME	AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY; ACCPN	218000
POLYNEUROPATHY, SENSORIMOTOR, WITH OR WITHOUT AGENESIS OF THE CORPUSCALLOSUM	AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY; ACCPN	218000
CORPUS CALLOSUM, AGENESIS OF, WITH NEURONOPATHY	AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY; ACCPN	218000
APPARENT MINERALOCORTICOID EXCESS; AME	APPARENT MINERALOCORTICOID EXCESS; AME	218030
AME1	APPARENT MINERALOCORTICOID EXCESS; AME	218030
CORTISOL 11-BETA-KETOREDUCTASE DEFICIENCY	APPARENT MINERALOCORTICOID EXCESS; AME	218030
COSTELLO SYNDROME; CSTLO	COSTELLO SYNDROME; CSTLO	218040
FACIOCUTANEOSKELETAL SYNDROME	COSTELLO SYNDROME; CSTLO	218040
FCS SYNDROMEMYOPATHY, CONGENITAL, WITH EXCESS OF MUSCLE SPINDLES, INCLUDED; CMEMS,INCLUDED	COSTELLO SYNDROME; CSTLO	218040
CRANIAL NERVES, CONGENITAL PARESIS OF	CRANIAL NERVES, CONGENITAL PARESIS OF	218100
CRANIOECTODERMAL DYSPLASIA 1; CED1	CRANIOECTODERMAL DYSPLASIA 1; CED1	218330
SENSENBRENNER SYNDROME	CRANIOECTODERMAL DYSPLASIA 1; CED1	218330
LEVIN SYNDROME I	CRANIOECTODERMAL DYSPLASIA 1; CED1	218330
TEMTAMY SYNDROME; TEMTYS	TEMTAMY SYNDROME; TEMTYS	218340
MENTAL RETARDATION WITH OR WITHOUT CRANIOFACIAL DYSMORPHISM, OCULARCOLOBOMA, OR ABNORMAL CORPUS CALLOSUM	TEMTAMY SYNDROME; TEMTYS	218340
CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL RECESSIVE; CMDR	CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL RECESSIVE; CMDR	218400
BALLER-GEROLD SYNDROME; BGS	BALLER-GEROLD SYNDROME; BGS	218600
CRANIOSYNOSTOSIS WITH RADIAL DEFECTS	BALLER-GEROLD SYNDROME; BGS	218600
CRANIOSYNOSTOSIS-RADIAL APLASIA SYNDROME	BALLER-GEROLD SYNDROME; BGS	218600
HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	218700
THYROID DYSGENESIS	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	218700
THYROID AGENESIS	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	218700
THYROID HYPOPLASIA	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	218700
THYROID, ECTOPIC	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	218700
HYPOTHYROIDISM, CONGENITAL, DUE TO THYROID DYSGENESIS	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	218700
HYPOTHYROIDISM, ATHYREOTIC	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	218700
ATHYREOTIC HYPOTHYROIDISM	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	218700
RESISTANCE TO THYROTROPIN; RTSH	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	218700
THYROTROPIN RESISTANCE	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2	218700
CRIGLER-NAJJAR SYNDROME, TYPE I	CRIGLER-NAJJAR SYNDROME, TYPE I	218800
HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1	CRIGLER-NAJJAR SYNDROME, TYPE I	218800
CRIGLER-NAJJAR SYNDROME	CRIGLER-NAJJAR SYNDROME, TYPE I	218800
CROME SYNDROME	CROME SYNDROME	218900
FRASER SYNDROME	FRASER SYNDROME	219000
CRYPTOPHTHALMOS WITH OTHER MALFORMATIONSCRYPTOPHTHALMOS-SYNDACTYLY SYNDROME, INCLUDED	FRASER SYNDROME	219000
CRYPTORCHIDISM, UNILATERAL OR BILATERAL	CRYPTORCHIDISM, UNILATERAL OR BILATERAL	219050
UNDESCENDED TESTIS	CRYPTORCHIDISM, UNILATERAL OR BILATERAL	219050
ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA; AIMAH1	ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA; AIMAH1	219080
ACTH-INDEPENDENT MACRONODULAR ADRENOCORTICAL HYPERPLASIA	ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA; AIMAH1	219080
ADRENOCORTICOTROPIC HORMONE-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA	ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA; AIMAH1	219080
CORTICOTROPIN-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA	ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA; AIMAH1	219080
CUSHING SYNDROME, ADRENAL, DUE TO AIMAH	ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA; AIMAH1	219080
PITUITARY ADENOMA, ACTH-SECRETING	PITUITARY ADENOMA, ACTH-SECRETING	219090
CUSHING DISEASE, PITUITARY	PITUITARY ADENOMA, ACTH-SECRETING	219090
CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IA; ARCL1A	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IA; ARCL1A	219100
ARCL1	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IA; ARCL1A	219100
CUTIS LAXA, AUTOSOMAL RECESSIVE	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IA; ARCL1A	219100
CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIA; ARCL3A	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIA; ARCL3A	219150
DE BARSY SYNDROME A	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIA; ARCL3A	219150
CUTIS LAXA, CORNEAL CLOUDING, AND MENTAL RETARDATION	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIA; ARCL3A	219150
PROGEROID SYNDROME OF DE BARSY	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIA; ARCL3A	219150
CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; ARCL2A	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; ARCL2A	219200
ARCL2	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; ARCL2A	219200
CUTIS LAXA WITH CONGENITAL DISORDER OF GLYCOSYLATION	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; ARCL2A	219200
CUTIS LAXA WITH GROWTH AND DEVELOPMENTAL DELAY	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; ARCL2A	219200
CUTIS LAXA, DEBRE TYPE	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; ARCL2A	219200
CUTIS LAXA WITH BONE DYSTROPHY	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; ARCL2A	219200
CUTIS LAXA WITH JOINT LAXITY AND RETARDED DEVELOPMENT	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; ARCL2A	219200
CYSTATHIONINURIA	CYSTATHIONINURIA	219500
CYSTATHIONASE DEFICIENCY	CYSTATHIONINURIA	219500
CYSTIC FIBROSIS; CF	CYSTIC FIBROSIS; CF	219700
MUCOVISCIDOSIS	CYSTIC FIBROSIS; CF	219700
VENTRICULOMEGALY WITH CYSTIC KIDNEY DISEASE; VMCKD	VENTRICULOMEGALY WITH CYSTIC KIDNEY DISEASE; VMCKD	219730
CYSTINOSIS, ADULT NONNEPHROPATHIC	CYSTINOSIS, ADULT NONNEPHROPATHIC	219750
CYSTINOSIS, OCULAR NONNEPHROPATHIC	CYSTINOSIS, ADULT NONNEPHROPATHIC	219750
CYSTINOSIS, BENIGN NONNEPHROPATHIC	CYSTINOSIS, ADULT NONNEPHROPATHIC	219750
CYSTINOSIS, NEPHROPATHIC; CTNS	CYSTINOSIS, NEPHROPATHIC; CTNS	219800
LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF	CYSTINOSIS, NEPHROPATHIC; CTNS	219800
CYSTINOSIN, DEFECT OFCYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED	CYSTINOSIS, NEPHROPATHIC; CTNS	219800
CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED	CYSTINOSIS, NEPHROPATHIC; CTNS	219800
CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE	CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE	219900
CYSTINOSIS, INTERMEDIATE	CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE	219900
CYSTINURIA	CYSTINURIA	220100
CSNU	CYSTINURIA	220100
CYSTINURIA, TYPE I, FORMERLY; CSNU1, FORMERLY	CYSTINURIA	220100
CYSTINURIA, TYPE II, FORMERLY	CYSTINURIA	220100
CYSTINURIA, TYPE III, FORMERLY; CSNU3, FORMERLY	CYSTINURIA	220100
CYSTINURIA, TYPE NON-I, FORMERLYCYSTINURIA, TYPE A, INCLUDED	CYSTINURIA	220100
CYSTINURIA, TYPE B, INCLUDED	CYSTINURIA	220100
CYSTINURIA, TYPE A/B, INCLUDED	CYSTINURIA	220100
MITOCHONDRIAL COMPLEX IV DEFICIENCY	MITOCHONDRIAL COMPLEX IV DEFICIENCY	220110
CYTOCHROME c OXIDASE DEFICIENCY	MITOCHONDRIAL COMPLEX IV DEFICIENCY	220110
COX DEFICIENCY	MITOCHONDRIAL COMPLEX IV DEFICIENCY	220110
LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC	LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC	220111
CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE	LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC	220111
COX DEFICIENCY, FRENCH CANADIAN TYPE	LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC	220111
COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE	LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC	220111
LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE	LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC	220111
D-GLYCERIC ACIDURIA	D-GLYCERIC ACIDURIA	220120
D-GLYCERIC ACIDEMIA	D-GLYCERIC ACIDURIA	220120
GLYCERATE KINASE DEFICIENCY	D-GLYCERIC ACIDURIA	220120
HYPOURICEMIA, RENAL, 1; RHUC1	HYPOURICEMIA, RENAL, 1; RHUC1	220150
DALMATIAN HYPOURICEMIA	HYPOURICEMIA, RENAL, 1; RHUC1	220150
RENAL HYPOURICEMIA	HYPOURICEMIA, RENAL, 1; RHUC1	220150
DANDY-WALKER SYNDROME; DWSDANDY-WALKER MALFORMATION, INCLUDED; DWM, INCLUDED	DANDY-WALKER SYNDROME; DWSDANDY-WALKER MALFORMATION, INCLUDED; DWM, INCLUDED	220200
RITSCHER-SCHINZEL SYNDROME 1; RTSC1	RITSCHER-SCHINZEL SYNDROME 1; RTSC1	220210
CRANIOCEREBELLOCARDIAC DYSPLASIA	RITSCHER-SCHINZEL SYNDROME 1; RTSC1	220210
3@C SYNDROME	RITSCHER-SCHINZEL SYNDROME 1; RTSC1	220210
DANDY-WALKER-LIKE MALFORMATION WITH ATRIOVENTRICULAR SEPTAL DEFECT	RITSCHER-SCHINZEL SYNDROME 1; RTSC1	220210
DEAFNESS, AUTOSOMAL RECESSIVE 1A; DFNB1ADEAFNESS, DIGENIC, GJB2/GJB6, INCLUDED	DEAFNESS, AUTOSOMAL RECESSIVE 1A; DFNB1ADEAFNESS, DIGENIC, GJB2/GJB6, INCLUDED	220290
DEAFNESS, DIGENIC, GJB2/GJB3, INCLUDED	DEAFNESS, AUTOSOMAL RECESSIVE 1A; DFNB1ADEAFNESS, DIGENIC, GJB2/GJB6, INCLUDED	220290
JERVELL AND LANGE-NIELSEN SYNDROME 1; JLNS1	JERVELL AND LANGE-NIELSEN SYNDROME 1; JLNS1	220400
DEAFNESS, CONGENITAL, AND FUNCTIONAL HEART DISEASE	JERVELL AND LANGE-NIELSEN SYNDROME 1; JLNS1	220400
PROLONGED QT INTERVAL IN EKG AND SUDDEN DEATH	JERVELL AND LANGE-NIELSEN SYNDROME 1; JLNS1	220400
CARDIOAUDITORY SYNDROME OF JERVELL AND LANGE-NIELSEN	JERVELL AND LANGE-NIELSEN SYNDROME 1; JLNS1	220400
SURDO-CARDIAC SYNDROME	JERVELL AND LANGE-NIELSEN SYNDROME 1; JLNS1	220400
DEAFNESS, ONYCHODYSTROPHY, OSTEODYSTROPHY, MENTAL RETARDATION, ANDSEIZURES SYNDROME; DOORS	DEAFNESS, ONYCHODYSTROPHY, OSTEODYSTROPHY, MENTAL RETARDATION, ANDSEIZURES SYNDROME; DOORS	220500
DOOR SYNDROME	DEAFNESS, ONYCHODYSTROPHY, OSTEODYSTROPHY, MENTAL RETARDATION, ANDSEIZURES SYNDROME; DOORS	220500
DIGITORENOCEREBRAL SYNDROME	DEAFNESS, ONYCHODYSTROPHY, OSTEODYSTROPHY, MENTAL RETARDATION, ANDSEIZURES SYNDROME; DOORS	220500
DRC SYNDROME	DEAFNESS, ONYCHODYSTROPHY, OSTEODYSTROPHY, MENTAL RETARDATION, ANDSEIZURES SYNDROME; DOORS	220500
BRACHYDACTYLY DUE TO ABSENCE OF DISTAL PHALANGES	DEAFNESS, ONYCHODYSTROPHY, OSTEODYSTROPHY, MENTAL RETARDATION, ANDSEIZURES SYNDROME; DOORS	220500
ERONEN SYNDROME	DEAFNESS, ONYCHODYSTROPHY, OSTEODYSTROPHY, MENTAL RETARDATION, ANDSEIZURES SYNDROME; DOORS	220500
SPLIT-HAND/FOOT MALFORMATION 1 WITH SENSORINEURAL HEARING LOSS, AUTOSOMALRECESSIVE; SHFM1D	SPLIT-HAND/FOOT MALFORMATION 1 WITH SENSORINEURAL HEARING LOSS, AUTOSOMALRECESSIVE; SHFM1D	220600
DEAFNESS, CONGENITAL, WITH SPLIT HANDS AND FEET	SPLIT-HAND/FOOT MALFORMATION 1 WITH SENSORINEURAL HEARING LOSS, AUTOSOMALRECESSIVE; SHFM1D	220600
DEAFNESS AND MYOPIA; DFNMYP	DEAFNESS AND MYOPIA; DFNMYP	221200
DEAFNESS, CONDUCTIVE, WITH MALFORMED EXTERNAL EAR	DEAFNESS, CONDUCTIVE, WITH MALFORMED EXTERNAL EAR	221300
DEAFNESS, CONGENITAL, WITH VITILIGO AND ACHALASIA	DEAFNESS, CONGENITAL, WITH VITILIGO AND ACHALASIA	221350
PITUITARY HORMONE DEFICIENCY, COMBINED, 3; CPHD3	PITUITARY HORMONE DEFICIENCY, COMBINED, 3; CPHD3	221750
PITUITARY HORMONE DEFICIENCY, COMBINED, WITH RIGID CERVICAL SPINE	PITUITARY HORMONE DEFICIENCY, COMBINED, 3; CPHD3	221750
DEAFNESS, SENSORINEURAL, WITH PITUITARY DWARFISM	PITUITARY HORMONE DEFICIENCY, COMBINED, 3; CPHD3	221750
POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY;PLOSL	POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY;PLOSL	221770
NASU-HAKOLA DISEASE; NHD	POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY;PLOSL	221770
PRESENILE DEMENTIA WITH BONE CYSTS	POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY;PLOSL	221770
DEMENTIA, PREFRONTAL, WITH BONE CYSTS	POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY;PLOSL	221770
DEMENTIA, PROGRESSIVE, WITH LIPOMEMBRANOUS POLYCYSTIC OSTEODYSPLASIA	POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY;PLOSL	221770
BRAIN-BONE-FAT DISEASE	POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY;PLOSL	221770
DERMOCHONDROCORNEAL DYSTROPHY	DERMOCHONDROCORNEAL DYSTROPHY	221800
FRANCOIS SYNDROME	DERMOCHONDROCORNEAL DYSTROPHY	221800
LEUKOENCEPHALOPATHY, DIFFUSE HEREDITARY, WITH SPHEROIDS; HDLS	LEUKOENCEPHALOPATHY, DIFFUSE HEREDITARY, WITH SPHEROIDS; HDLS	221820
LEUKOENCEPHALOPATHY WITH NEUROAXONAL SPHEROIDS, AUTOSOMAL DOMINANT	LEUKOENCEPHALOPATHY, DIFFUSE HEREDITARY, WITH SPHEROIDS; HDLS	221820
GLIOSIS, FAMILIAL PROGRESSIVE SUBCORTICAL; GPSC	LEUKOENCEPHALOPATHY, DIFFUSE HEREDITARY, WITH SPHEROIDS; HDLS	221820
DEMENTIA, FAMILIAL, NEUMANN TYPE	LEUKOENCEPHALOPATHY, DIFFUSE HEREDITARY, WITH SPHEROIDS; HDLS	221820
SUBCORTICAL GLIOSIS OF NEUMANN	LEUKOENCEPHALOPATHY, DIFFUSE HEREDITARY, WITH SPHEROIDS; HDLS	221820
PERSISTENT HYPERPLASTIC PRIMARY VITREOUS, AUTOSOMAL RECESSIVE; PHPVAR	PERSISTENT HYPERPLASTIC PRIMARY VITREOUS, AUTOSOMAL RECESSIVE; PHPVAR	221900
RETINAL NONATTACHMENT, NONSYNDROMIC CONGENITAL; RNANC; NCRNA	PERSISTENT HYPERPLASTIC PRIMARY VITREOUS, AUTOSOMAL RECESSIVE; PHPVAR	221900
RETINAL NONATTACHMENT AND FALCIFORM DETACHMENT	PERSISTENT HYPERPLASTIC PRIMARY VITREOUS, AUTOSOMAL RECESSIVE; PHPVAR	221900
PERSISTENT FETAL VASCULATURE	PERSISTENT HYPERPLASTIC PRIMARY VITREOUS, AUTOSOMAL RECESSIVE; PHPVAR	221900
DIABETES MELLITUS, INSULIN-DEPENDENT; IDDM	DIABETES MELLITUS, INSULIN-DEPENDENT; IDDM	222100
DIABETES MELLITUS, TYPE I	DIABETES MELLITUS, INSULIN-DEPENDENT; IDDM	222100
JUVENILE-ONSET DIABETES; JODDIABETES MELLITUS, INSULIN-DEPENDENT, 1, INCLUDED; IDDM1, INCLUDED	DIABETES MELLITUS, INSULIN-DEPENDENT; IDDM	222100
INSULIN-DEPENDENT DIABETES MELLITUS 1, INCLUDED	DIABETES MELLITUS, INSULIN-DEPENDENT; IDDM	222100
WOLFRAM SYNDROME 1; WFS1	WOLFRAM SYNDROME 1; WFS1	222300
WFS	WOLFRAM SYNDROME 1; WFS1	222300
DIABETES INSIPIDUS AND MELLITUS WITH OPTIC ATROPHY AND DEAFNESS; DIDMOAD	WOLFRAM SYNDROME 1; WFS1	222300
DIAPHRAGMATIC HERNIA 2; DIH2	DIAPHRAGMATIC HERNIA 2; DIH2	222400
DONNAI-BARROW SYNDROME	DONNAI-BARROW SYNDROME	222448
FACIOOCULOACOUSTICORENAL SYNDROME	DONNAI-BARROW SYNDROME	222448
DBS/FOAR SYNDROME	DONNAI-BARROW SYNDROME	222448
DIAPHRAGMATIC HERNIA, EXOMPHALOS, ABSENT CORPUS CALLOSUM, HYPERTELORISM,MYOPIA, SENSORINEURAL DEAFNESS, AND PROTEINURIA	DONNAI-BARROW SYNDROME	222448
TRICHOHEPATOENTERIC SYNDROME 1; THES1	TRICHOHEPATOENTERIC SYNDROME 1; THES1	222470
THE SYNDROME	TRICHOHEPATOENTERIC SYNDROME 1; THES1	222470
DIARRHEA, SYNDROMIC	TRICHOHEPATOENTERIC SYNDROME 1; THES1	222470
DIARRHEA, FATAL INFANTILE, WITH TRICHORRHEXIS NODOSA	TRICHOHEPATOENTERIC SYNDROME 1; THES1	222470
DIASTROPHIC DYSPLASIA; DTD	DIASTROPHIC DYSPLASIA; DTD	222600
DDDIASTROPHIC DYSPLASIA, BROAD BONE-PLATYSPONDYLIC VARIANT, INCLUDED	DIASTROPHIC DYSPLASIA; DTD	222600
DIBASIC AMINO ACIDURIA I	DIBASIC AMINO ACIDURIA I	222690
LYSINURIC PROTEIN INTOLERANCE; LPI	LYSINURIC PROTEIN INTOLERANCE; LPI	222700
DIBASIC AMINO ACIDURIA II	LYSINURIC PROTEIN INTOLERANCE; LPI	222700
DICARBOXYLIC AMINOACIDURIA; DCBXA	DICARBOXYLIC AMINOACIDURIA; DCBXA	222730
GLUTAMATE-ASPARTATE TRANSPORT DEFECT	DICARBOXYLIC AMINOACIDURIA; DCBXA	222730
DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD	DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD	222748
DIHYDROPYRIMIDINURIA	DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD	222748
DPYS DEFICIENCY	DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD	222748
DPH DEFICIENCY	DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD	222748
RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2	222765
DIHYDROXYACETONEPHOSPHATE ACYLTRANSFERASE DEFICIENCY	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2	222765
DHAPAT DEFICIENCY	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2	222765
GLYCERONEPHOSPHATE O-ACYLTRANSFERASE DEFICIENCY	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2	222765
GNPAT DEFICIENCY	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2	222765
PEROXISOMAL DIHYDROXYACETONEPHOSPHATE ACYLTRANSFERASE DEFICIENCY	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2	222765
CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC, DUE TO DIHYDROXYACETONEPHOSPHATEACYLTRANSFERASE DEFICIENCY	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2	222765
BISPHOSPHOGLYCERATE MUTASE DEFICIENCY	BISPHOSPHOGLYCERATE MUTASE DEFICIENCY	222800
BISPHOSPHOGLYCEROMUTASE DEFICIENCY	BISPHOSPHOGLYCERATE MUTASE DEFICIENCY	222800
BPGM DEFICIENCY	BISPHOSPHOGLYCERATE MUTASE DEFICIENCY	222800
DIPHOSPHOGLYCERATE MUTASE DEFICIENCY OF ERYTHROCYTE	BISPHOSPHOGLYCERATE MUTASE DEFICIENCY	222800
DPGM DEFICIENCY	BISPHOSPHOGLYCERATE MUTASE DEFICIENCY	222800
SUCRASE-ISOMALTASE DEFICIENCY, CONGENITAL; CSID	SUCRASE-ISOMALTASE DEFICIENCY, CONGENITAL; CSID	222900
DISACCHARIDE INTOLERANCE I	SUCRASE-ISOMALTASE DEFICIENCY, CONGENITAL; CSID	222900
SUCROSE-ISOMALTOSE MALABSORPTION, CONGENITAL	SUCRASE-ISOMALTASE DEFICIENCY, CONGENITAL; CSID	222900
SUCROSE INTOLERANCE, CONGENITAL	SUCRASE-ISOMALTASE DEFICIENCY, CONGENITAL; CSID	222900
SI DEFICIENCY	SUCRASE-ISOMALTASE DEFICIENCY, CONGENITAL; CSID	222900
LACTASE DEFICIENCY, CONGENITAL	LACTASE DEFICIENCY, CONGENITAL	223000
ALACTASIA, CONGENITAL	LACTASE DEFICIENCY, CONGENITAL	223000
DISACCHARIDE INTOLERANCE II	LACTASE DEFICIENCY, CONGENITAL	223000
LACTOSE INTOLERANCE, ADULT TYPE	LACTOSE INTOLERANCE, ADULT TYPE	223100
HYPOLACTASIA, ADULT TYPE	LACTOSE INTOLERANCE, ADULT TYPE	223100
ADULT LACTASE DEFICIENCY	LACTOSE INTOLERANCE, ADULT TYPE	223100
DISACCHARIDE INTOLERANCE IIILACTASE PERSISTENCE, INCLUDED	LACTOSE INTOLERANCE, ADULT TYPE	223100
DISORGANIZATION, MOUSE, HOMOLOG OF	DISORGANIZATION, MOUSE, HOMOLOG OF	223200
DS	DISORGANIZATION, MOUSE, HOMOLOG OF	223200
DOPAMINE BETA-HYDROXYLASE DEFICIENCY, CONGENITAL	DOPAMINE BETA-HYDROXYLASE DEFICIENCY, CONGENITAL	223360
NOREPINEPHRINE DEFICIENCY	DOPAMINE BETA-HYDROXYLASE DEFICIENCY, CONGENITAL	223360
NORADRENALINE DEFICIENCY	DOPAMINE BETA-HYDROXYLASE DEFICIENCY, CONGENITAL	223360
DUBOWITZ SYNDROME	DUBOWITZ SYNDROME	223370
DYGGVE-MELCHIOR-CLAUSEN DISEASE; DMC	DYGGVE-MELCHIOR-CLAUSEN DISEASE; DMC	223800
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE III; HSAN3	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE III; HSAN3	223900
HSAN III	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE III; HSAN3	223900
DYSAUTONOMIA, FAMILIAL; DYS; FD	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE III; HSAN3	223900
RILEY-DAY SYNDROME	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE III; HSAN3	223900
CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME1; CAMRQ1	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME1; CAMRQ1	224050
CEREBELLAR HYPOPLASIA, VLDLR-ASSOCIATED	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME1; CAMRQ1	224050
CEREBELLAR ATAXIA AND MENTAL RETARDATION WITH OR WITHOUT QUADRUPEDALLOCOMOTION 1	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME1; CAMRQ1	224050
CEREBELLAR ATAXIA, CONGENITAL, AND MENTAL RETARDATION, AUTOSOMAL RECESSIVE	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME1; CAMRQ1	224050
DYSEQUILIBRIUM SYNDROME; DES	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME1; CAMRQ1	224050
ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE II; CDAN2	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE II; CDAN2	224100
DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE II	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE II; CDAN2	224100
CDA II	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE II; CDAN2	224100
DYSERYTHROPOIETIC ANEMIA, HEMPAS TYPE	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE II; CDAN2	224100
HEREDITARY ERYTHROBLASTIC MULTINUCLEARITY WITH POSITIVE ACIDIFIED-SERUMTEST; HEMPAS	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE II; CDAN2	224100
ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A	224120
DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE Ia	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A	224120
CDA Ia	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A	224120
ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE I	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A	224120
DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1; DKCB1	DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1; DKCB1	224230
DYSOSTEOSCLEROSIS	DYSOSTEOSCLEROSIS	224300
DYSSEGMENTAL DYSPLASIA, ROLLAND-DESBUQUOIS TYPE	DYSSEGMENTAL DYSPLASIA, ROLLAND-DESBUQUOIS TYPE	224400
DDRD	DYSSEGMENTAL DYSPLASIA, ROLLAND-DESBUQUOIS TYPE	224400
DYSSEGMENTAL DWARFISM, ROLLAND-DESBUQUOIS TYPE	DYSSEGMENTAL DYSPLASIA, ROLLAND-DESBUQUOIS TYPE	224400
ANISOSPONDYLIC CAMPTOMICROMELIC DWARFISM, ROLLAND-DESBUQUOIS TYPE	DYSSEGMENTAL DYSPLASIA, ROLLAND-DESBUQUOIS TYPE	224400
DYSSEGMENTAL DYSPLASIA, SILVERMAN-HANDMAKER TYPE; DDSH	DYSSEGMENTAL DYSPLASIA, SILVERMAN-HANDMAKER TYPE; DDSH	224410
DYSSEGMENTAL DWARFISM, SILVERMAN-HANDMAKER TYPE	DYSSEGMENTAL DYSPLASIA, SILVERMAN-HANDMAKER TYPE; DDSH	224410
ANISOSPONDYLIC CAMPTOMICROMELIC DWARFISM, SILVERMAN-HANDMAKER TYPE	DYSSEGMENTAL DYSPLASIA, SILVERMAN-HANDMAKER TYPE; DDSH	224410
DYSTONIA 2, TORSION, AUTOSOMAL RECESSIVE; DYT2	DYSTONIA 2, TORSION, AUTOSOMAL RECESSIVE; DYT2	224500
DYSTONIA MUSCULORUM DEFORMANS 2	DYSTONIA 2, TORSION, AUTOSOMAL RECESSIVE; DYT2	224500
MEIER-GORLIN SYNDROME 1; MGORS1	MEIER-GORLIN SYNDROME 1; MGORS1	224690
EAR, PATELLA, SHORT STATURE SYNDROME; EPS	MEIER-GORLIN SYNDROME 1; MGORS1	224690
MICROTIA, ABSENT PATELLAE, MICROGNATHIA SYNDROME	MEIER-GORLIN SYNDROME 1; MGORS1	224690
MEIER-GORLIN SYNDROME	MEIER-GORLIN SYNDROME 1; MGORS1	224690
SCHOPF-SCHULZ-PASSARGE SYNDROME; SSPS	SCHOPF-SCHULZ-PASSARGE SYNDROME; SSPS	224750
KERATOSIS PALMOPLANTARIS WITH CYSTIC EYELIDS, HYPODONTIA, AND HYPOTRICHOSIS	SCHOPF-SCHULZ-PASSARGE SYNDROME; SSPS	224750
ECCRINE TUMORS WITH ECTODERMAL DYSPLASIA	SCHOPF-SCHULZ-PASSARGE SYNDROME; SSPS	224750
ECTODERMAL DYSPLASIA 10B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALRECESSIVE; ECTD10B	ECTODERMAL DYSPLASIA 10B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALRECESSIVE; ECTD10B	224900
ECTODERMAL DYSPLASIA, HYPOHIDROTIC; HED	ECTODERMAL DYSPLASIA 10B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALRECESSIVE; ECTD10B	224900
ECTODERMAL DYSPLASIA, ANHIDROTIC; EDA	ECTODERMAL DYSPLASIA 10B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALRECESSIVE; ECTD10B	224900
ROSSELLI-GULIENETTI SYNDROME	ROSSELLI-GULIENETTI SYNDROME	225000
CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1	CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1	225060
ZLOTOGORA-OGUR SYNDROME	CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1	225060
ECTODERMAL DYSPLASIA, MARGARITA ISLAND TYPE	CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1	225060
ECTODERMAL DYSPLASIA, TYPE 4; ED4	CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1	225060
ECTODERMAL DYSPLASIA, CLEFT LIP AND PALATE, MENTAL RETARDATION, ANDSYNDACTYLYOROFACIAL CLEFT 7, INCLUDED; OFC7, INCLUDED	CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1	225060
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 7, INCLUDED	CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1	225060
ECTOPIA LENTIS 2, ISOLATED, AUTOSOMAL RECESSIVE; ECTOL2	ECTOPIA LENTIS 2, ISOLATED, AUTOSOMAL RECESSIVE; ECTOL2	225100
ECTOPIA LENTIS ET PUPILLAE	ECTOPIA LENTIS ET PUPILLAE	225200
ECTOPIA LENTIS WITH ECTOPIA OF PUPIL	ECTOPIA LENTIS ET PUPILLAE	225200
HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 5; CHNG5	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 5; CHNG5	225250
ECTODERMAL DYSPLASIA, ECTRODACTYLY, AND MACULAR DYSTROPHY SYNDROME;EEMS	ECTODERMAL DYSPLASIA, ECTRODACTYLY, AND MACULAR DYSTROPHY SYNDROME;EEMS	225280
EEM SYNDROME	ECTODERMAL DYSPLASIA, ECTRODACTYLY, AND MACULAR DYSTROPHY SYNDROME;EEMS	225280
SPLIT-HAND/FOOT MALFORMATION 6; SHFM6	SPLIT-HAND/FOOT MALFORMATION 6; SHFM6	225300
ECTRODACTYLY, AUTOSOMAL RECESSIVE	SPLIT-HAND/FOOT MALFORMATION 6; SHFM6	225300
EHLERS-DANLOS SYNDROME, AUTOSOMAL RECESSIVE, CARDIAC VALVULAR FORM	EHLERS-DANLOS SYNDROME, AUTOSOMAL RECESSIVE, CARDIAC VALVULAR FORM	225320
EHLERS-DANLOS SYNDROME, TYPE VI; EDS6	EHLERS-DANLOS SYNDROME, TYPE VI; EDS6	225400
EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC TYPE	EHLERS-DANLOS SYNDROME, TYPE VI; EDS6	225400
EDS VI	EHLERS-DANLOS SYNDROME, TYPE VI; EDS6	225400
EHLERS-DANLOS SYNDROME, OCULAR-SCOLIOTIC TYPE	EHLERS-DANLOS SYNDROME, TYPE VI; EDS6	225400
NEVO SYNDROME	EHLERS-DANLOS SYNDROME, TYPE VI; EDS6	225400
EHLERS-DANLOS SYNDROME, TYPE VIA, FORMERLY; EDS6A, FORMERLY	EHLERS-DANLOS SYNDROME, TYPE VI; EDS6	225400
EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL RECESSIVE	EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL RECESSIVE	225410
EHLERS-DANLOS SYNDROME, DERMATOSPARAXIS TYPE	EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL RECESSIVE	225410
DERMATOSPARAXIS	EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL RECESSIVE	225410
EDS VIIC	EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL RECESSIVE	225410
EDS7C	EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL RECESSIVE	225410
ELLIS-VAN CREVELD SYNDROME; EVC	ELLIS-VAN CREVELD SYNDROME; EVC	225500
CHONDROECTODERMAL DYSPLASIA	ELLIS-VAN CREVELD SYNDROME; EVC	225500
MESOECTODERMAL DYSPLASIA	ELLIS-VAN CREVELD SYNDROME; EVC	225500
AICARDI-GOUTIERES SYNDROME 1; AGS1	AICARDI-GOUTIERES SYNDROME 1; AGS1	225750
AGS	AICARDI-GOUTIERES SYNDROME 1; AGS1	225750
ENCEPHALOPATHY, FAMILIAL INFANTILE, WITH INTRACRANIAL CALCIFICATIONAND CHRONIC CEREBROSPINAL FLUID LYMPHOCYTOSIS	AICARDI-GOUTIERES SYNDROME 1; AGS1	225750
CREE ENCEPHALITIS	AICARDI-GOUTIERES SYNDROME 1; AGS1	225750
PSEUDOTOXOPLASMOSIS SYNDROMEAICARDI-GOUTIERES SYNDROME 1, AUTOSOMAL DOMINANT, INCLUDED	AICARDI-GOUTIERES SYNDROME 1; AGS1	225750
PONTOCEREBELLAR HYPOPLASIA, TYPE 4; PCH4	PONTOCEREBELLAR HYPOPLASIA, TYPE 4; PCH4	225753
ENCEPHALOPATHY, FATAL INFANTILE, WITH OLIVOPONTOCEREBELLAR HYPOPLASIA	PONTOCEREBELLAR HYPOPLASIA, TYPE 4; PCH4	225753
PROLIFERATIVE VASCULOPATHY AND HYDRANENCEPHALY-HYDROCEPHALY SYNDROME;PVHH	PROLIFERATIVE VASCULOPATHY AND HYDRANENCEPHALY-HYDROCEPHALY SYNDROME;PVHH	225790
HYDRANENCEPHALY, FOWLER TYPE	PROLIFERATIVE VASCULOPATHY AND HYDRANENCEPHALY-HYDROCEPHALY SYNDROME;PVHH	225790
HYDROCEPHALY/HYDRANENCEPHALY DUE TO CEREBRAL VASCULOPATHY	PROLIFERATIVE VASCULOPATHY AND HYDRANENCEPHALY-HYDROCEPHALY SYNDROME;PVHH	225790
ENCEPHALOCLASTIC PROLIFERATIVE VASCULOPATHY; EPV	PROLIFERATIVE VASCULOPATHY AND HYDRANENCEPHALY-HYDROCEPHALY SYNDROME;PVHH	225790
ENTEROKINASE DEFICIENCY	ENTEROKINASE DEFICIENCY	226200
ENTEROPEPTIDASE DEFICIENCY	ENTEROKINASE DEFICIENCY	226200
ENTEROPATHY, PROTEIN-LOSING	ENTEROPATHY, PROTEIN-LOSING	226300
EPIDERMODYSPLASIA VERRUCIFORMIS; EV	EPIDERMODYSPLASIA VERRUCIFORMIS; EV	226400
EVER	EPIDERMODYSPLASIA VERRUCIFORMIS; EV	226400
EPIDERMOLYSIS BULLOSA DYSTROPHICA NEUROTROPHICA	EPIDERMOLYSIS BULLOSA DYSTROPHICA NEUROTROPHICA	226500
EPIDERMOLYSIS BULLOSA WITH CONGENITAL DEAFNESS	EPIDERMOLYSIS BULLOSA DYSTROPHICA NEUROTROPHICA	226500
EPIDERMOLYSIS BULLOSA PROGRESSIVA, RECESSIVE; EBR3	EPIDERMOLYSIS BULLOSA DYSTROPHICA NEUROTROPHICA	226500
EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE; RDEB	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE; RDEB	226600
DYSTROPHIC EPIDERMOLYSIS BULLOSA, AUTOSOMAL RECESSIVE	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE; RDEB	226600
EPIDERMOLYSIS BULLOSA DYSTROPHICA, HALLOPEAU-SIEMENS TYPE; EBR1	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE; RDEB	226600
EPIDERMOLYSIS BULLOSA DYSTROPHICA, GENERALIZED SEVERE, AUTOSOMAL RECESSIVEEPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, LOCALISATAVARIANT, INCLUDED	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE; RDEB	226600
EPIDERMOLYSIS BULLOSA DYSTROPHICA INVERSA, AUTOSOMAL RECESSIVE, INCLUDED	EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE; RDEB	226600
EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE	226650
EPIDERMOLYSIS BULLOSA JUNCTIONALIS, NON-HERLITZ TYPE	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE	226650
EPIDERMOLYSIS BULLOSA JUNCTIONALIS, PROGRESSIVE	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE	226650
EPIDERMOLYSIS BULLOSA JUNCTIONALIS, SEVERE NONLETHAL	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE	226650
EPIDERMOLYSIS BULLOSA JUNCTIONALIS, DISENTIS TYPE	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE	226650
EPIDERMOLYSIS BULLOSA, GENERALIZED ATROPHIC BENIGN; GABEBEPIDERMOLYSIS BULLOSA, JUNCTIONAL, LOCALISATA VARIANT, INCLUDED	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE	226650
JUNCTIONAL EPIDERMOLYSIS BULLOSA INVERSA, INCLUDED	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE	226650
JEB-I, INCLUDED	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE	226650
EPIDERMOLYSIS BULLOSA SIMPLEX WITH MUSCULAR DYSTROPHY; EBSMD	EPIDERMOLYSIS BULLOSA SIMPLEX WITH MUSCULAR DYSTROPHY; EBSMD	226670
EPIDERMOLYSIS BULLOSA SIMPLEX AND LIMB-GIRDLE MUSCULAR DYSTROPHY	EPIDERMOLYSIS BULLOSA SIMPLEX WITH MUSCULAR DYSTROPHY; EBSMD	226670
MD-EBS; MDEBS	EPIDERMOLYSIS BULLOSA SIMPLEX WITH MUSCULAR DYSTROPHY; EBSMD	226670
EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE	226700
EPIDERMOLYSIS BULLOSA JUNCTIONALIS, HERLITZ TYPE	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE	226700
JEB-HERLITZ TYPE	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE	226700
EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ-PEARSON TYPE	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE	226700
HERLITZ-PEARSON-TYPE EPIDERMOLYSIS BULLOSA	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE	226700
EPIDERMOLYSIS BULLOSA LETALIS	EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE	226700
EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA	EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA	226730
EPIDERMOLYSIS BULLOSA, JUNCTIONAL, WITH PYLORIC ATRESIA	EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA	226730
JUNCTIONAL EPIDERMOLYSIS BULLOSA WITH PYLORIC ATRESIA	EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA	226730
JEB-PA	EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA	226730
EPIDERMOLYSIS BULLOSA, JUNCTIONAL, WITH PYLORIC ATRESIA AND APLASIACUTIS CONGENITA	EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA	226730
EB-PA-ACC	EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA	226730
CARMI SYNDROME	EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA	226730
APLASIA CUTIS CONGENITA WITH GASTROINTESTINAL ATRESIA	EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA	226730
KOHLSCHUTTER-TONZ SYNDROME; KTZS	KOHLSCHUTTER-TONZ SYNDROME; KTZS	226750
EPILEPSY AND YELLOW TEETH	KOHLSCHUTTER-TONZ SYNDROME; KTZS	226750
EPILEPSY, DEMENTIA, AND AMELOGENESIS IMPERFECTA	KOHLSCHUTTER-TONZ SYNDROME; KTZS	226750
KOHLSCHUTTER SYNDROME	KOHLSCHUTTER-TONZ SYNDROME; KTZS	226750
EPIPHYSEAL DYSPLASIA, MULTIPLE, 4; EDM4	EPIPHYSEAL DYSPLASIA, MULTIPLE, 4; EDM4	226900
MULTIPLE EPIPHYSEAL DYSPLASIA, AUTOSOMAL RECESSIVE	EPIPHYSEAL DYSPLASIA, MULTIPLE, 4; EDM4	226900
MULTIPLE EPIPHYSEAL DYSPLASIA WITH CLUBFOOT	EPIPHYSEAL DYSPLASIA, MULTIPLE, 4; EDM4	226900
MULTIPLE EPIPHYSEAL DYSPLASIA WITH BILAYERED PATELLAE	EPIPHYSEAL DYSPLASIA, MULTIPLE, 4; EDM4	226900
EPIPHYSEAL DYSPLASIA, MICROCEPHALY, AND NYSTAGMUS	EPIPHYSEAL DYSPLASIA, MICROCEPHALY, AND NYSTAGMUS	226960
LOWRY-WOOD SYNDROME; LWS	EPIPHYSEAL DYSPLASIA, MICROCEPHALY, AND NYSTAGMUS	226960
EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS	EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS	226980
MED-IDDM SYNDROME	EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS	226980
IDDM-MED SYNDROME	EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS	226980
WOLCOTT-RALLISON SYNDROME	EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS	226980
TRANSIENT ERYTHROBLASTOPENIA OF CHILDHOOD; TEC	TRANSIENT ERYTHROBLASTOPENIA OF CHILDHOOD; TEC	227050
ERYTHROBLASTOPENIA, TRANSIENT	TRANSIENT ERYTHROBLASTOPENIA OF CHILDHOOD; TEC	227050
ERYTHRODERMA, LETHAL CONGENITAL	ERYTHRODERMA, LETHAL CONGENITAL	227090
ETHANOLAMINOSIS	ETHANOLAMINOSIS	227150
ETHANOLAMINE KINASE DEFICIENCY	ETHANOLAMINOSIS	227150
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1	227220
SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1	227220
SKIN/HAIR/EYE PIGMENTATION 1, BLUE/BROWN EYES	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1	227220
SKIN/HAIR/EYE PIGMENTATION 1, BLOND/BROWN HAIR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1	227220
EYE COLOR, BROWN/BLUE	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1	227220
EYE COLOR, BLUE/NONBLUE	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1	227220
EYE COLOR 3; EYCL3	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1	227220
BROWN EYE COLOR 2; BEY2	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1	227220
HAIR COLOR 3; HCL3	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1	227220
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 5; SHEP5	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 5; SHEP5	227240
SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 5; SHEP5	227240
SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 5; SHEP5	227240
SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 5; SHEP5	227240
FOCAL FACIAL DERMAL DYSPLASIA 3, SETLEIS TYPE; FFDD3	FOCAL FACIAL DERMAL DYSPLASIA 3, SETLEIS TYPE; FFDD3	227260
SETLEIS SYNDROME	FOCAL FACIAL DERMAL DYSPLASIA 3, SETLEIS TYPE; FFDD3	227260
BITEMPORAL FORCEPS MARKS SYNDROME	FOCAL FACIAL DERMAL DYSPLASIA 3, SETLEIS TYPE; FFDD3	227260
FACIAL ECTODERMAL DYSPLASIA	FOCAL FACIAL DERMAL DYSPLASIA 3, SETLEIS TYPE; FFDD3	227260
FOCAL FACIAL DERMAL DYSPLASIA, TYPE II, FORMERLY	FOCAL FACIAL DERMAL DYSPLASIA 3, SETLEIS TYPE; FFDD3	227260
FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 1; F5F8D1	FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 1; F5F8D1	227300
FAMILIAL MULTIPLE COAGULATION FACTOR DEFICIENCY I; FMFD1	FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 1; F5F8D1	227300
FMFD I	FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 1; F5F8D1	227300
MULTIPLE COAGULATION FACTOR DEFICIENCY I; MCFD1	FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 1; F5F8D1	227300
FACIODIGITOGENITAL SYNDROME, AUTOSOMAL RECESSIVE	FACIODIGITOGENITAL SYNDROME, AUTOSOMAL RECESSIVE	227330
AARSKOG-LIKE SYNDROME	FACIODIGITOGENITAL SYNDROME, AUTOSOMAL RECESSIVE	227330
KUWAIT TYPE FACIODIGITOGENITAL SYNDROME	FACIODIGITOGENITAL SYNDROME, AUTOSOMAL RECESSIVE	227330
FACTOR V DEFICIENCY	FACTOR V DEFICIENCY	227400
PARAHEMOPHILIA	FACTOR V DEFICIENCY	227400
OWREN PARAHEMOPHILIA	FACTOR V DEFICIENCY	227400
LABILE FACTOR DEFICIENCY	FACTOR V DEFICIENCY	227400
FACTOR VII DEFICIENCY	FACTOR VII DEFICIENCY	227500
F7 DEFICIENCY	FACTOR VII DEFICIENCY	227500
HYPOPROCONVERTINEMIA	FACTOR VII DEFICIENCY	227500
FACTOR X DEFICIENCY	FACTOR X DEFICIENCY	227600
F10 DEFICIENCY	FACTOR X DEFICIENCY	227600
STUART-PROWER FACTOR DEFICIENCY	FACTOR X DEFICIENCY	227600
FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC	FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC	227645
FACC; FAC	FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC	227645
FANCONI PANCYTOPENIA, TYPE 3; FA3	FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC	227645
FANCONI ANEMIA, COMPLEMENTATION GROUP D2; FANCD2	FANCONI ANEMIA, COMPLEMENTATION GROUP D2; FANCD2	227646
FAD2	FANCONI ANEMIA, COMPLEMENTATION GROUP D2; FANCD2	227646
FANCONI ANEMIA, COMPLEMENTATION GROUP D; FANCD; FACD	FANCONI ANEMIA, COMPLEMENTATION GROUP D2; FANCD2	227646
FANCONI PANCYTOPENIA, TYPE 4; FA4	FANCONI ANEMIA, COMPLEMENTATION GROUP D2; FANCD2	227646
FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA	FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA	227650
FANCONI ANEMIA; FAFANCONI ANEMIA, ESTREN-DAMESHEK VARIANT, INCLUDED	FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA	227650
ESTREN-DAMESHEK VARIANT OF FANCONI ANEMIA, INCLUDED	FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA	227650
ESTREN-DAMESHEK VARIANT OF FANCONI PANCYTOPENIA, INCLUDED	FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA	227650
FANCONI-BICKEL SYNDROME; FBS	FANCONI-BICKEL SYNDROME; FBS	227810
HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME	FANCONI-BICKEL SYNDROME; FBS	227810
HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY	FANCONI-BICKEL SYNDROME; FBS	227810
HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA	FANCONI-BICKEL SYNDROME; FBS	227810
FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE	FANCONI-BICKEL SYNDROME; FBS	227810
PSEUDO-PHLORIZIN DIABETES	FANCONI-BICKEL SYNDROME; FBS	227810
GLYCOGENOSIS, FANCONI TYPE	FANCONI-BICKEL SYNDROME; FBS	227810
GLYCOGEN STORAGE DISEASE XI	FANCONI-BICKEL SYNDROME; FBS	227810
FARBER LIPOGRANULOMATOSIS; FRBRL	FARBER LIPOGRANULOMATOSIS; FRBRL	228000
FARBER DISEASE	FARBER LIPOGRANULOMATOSIS; FRBRL	228000
CERAMIDASE DEFICIENCY	FARBER LIPOGRANULOMATOSIS; FRBRL	228000
ACID CERAMIDASE DEFICIENCY	FARBER LIPOGRANULOMATOSIS; FRBRL	228000
AC DEFICIENCY	FARBER LIPOGRANULOMATOSIS; FRBRL	228000
N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY	FARBER LIPOGRANULOMATOSIS; FRBRL	228000
VISCERAL STEATOSIS, CONGENITAL	VISCERAL STEATOSIS, CONGENITAL	228100
FATTY LIVER DISEASE, CONGENITAL	VISCERAL STEATOSIS, CONGENITAL	228100
FATTY METAMORPHOSIS OF VISCERA	VISCERAL STEATOSIS, CONGENITAL	228100
STEATOSIS OF LIVER	VISCERAL STEATOSIS, CONGENITAL	228100
WHITE LIVER DISEASE	VISCERAL STEATOSIS, CONGENITAL	228100
FEMUR, UNILATERAL BIFID, WITH MONODACTYLOUS ECTRODACTYLY	FEMUR, UNILATERAL BIFID, WITH MONODACTYLOUS ECTRODACTYLY	228250
GOLLOP-WOLFGANG COMPLEX; GWC	FEMUR, UNILATERAL BIFID, WITH MONODACTYLOUS ECTRODACTYLY	228250
HYPOGONADOTROPIC HYPOGONADISM 23 WITHOUT ANOSMIA; HH23	HYPOGONADOTROPIC HYPOGONADISM 23 WITHOUT ANOSMIA; HH23	228300
PASQUALINI SYNDROME	HYPOGONADOTROPIC HYPOGONADISM 23 WITHOUT ANOSMIA; HH23	228300
FERTILE EUNUCH SYNDROME	HYPOGONADOTROPIC HYPOGONADISM 23 WITHOUT ANOSMIA; HH23	228300
FIBROCHONDROGENESIS 1; FBCG1	FIBROCHONDROGENESIS 1; FBCG1	228520
MYOFIBROMATOSIS, INFANTILE, 1; IMF1	MYOFIBROMATOSIS, INFANTILE, 1; IMF1	228550
MYOFIBROMATOSIS, JUVENILE	MYOFIBROMATOSIS, INFANTILE, 1; IMF1	228550
FIBROMATOSIS, CONGENITAL GENERALIZED; CGF	MYOFIBROMATOSIS, INFANTILE, 1; IMF1	228550
HYALINE FIBROMATOSIS SYNDROME; HFS	HYALINE FIBROMATOSIS SYNDROME; HFS	228600
HYALINOSIS, SYSTEMIC	HYALINE FIBROMATOSIS SYNDROME; HFS	228600
FIBULAR HYPOPLASIA AND COMPLEX BRACHYDACTYLY	FIBULAR HYPOPLASIA AND COMPLEX BRACHYDACTYLY	228900
DU PAN SYNDROME	FIBULAR HYPOPLASIA AND COMPLEX BRACHYDACTYLY	228900
FIBULAR APLASIA OR HYPOPLASIA, FEMORAL BOWING AND POLY-, SYN-, ANDOLIGODACTYLY	FIBULAR APLASIA OR HYPOPLASIA, FEMORAL BOWING AND POLY-, SYN-, ANDOLIGODACTYLY	228930
FUHRMANN SYNDROME	FIBULAR APLASIA OR HYPOPLASIA, FEMORAL BOWING AND POLY-, SYN-, ANDOLIGODACTYLY	228930
HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY	HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY	228960
HMWK DEFICIENCY	HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY	228960
KININOGEN DEFICIENCY, HIGH MOLECULAR WEIGHT	HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY	228960
FITZGERALD TRAITKININOGEN DEFICIENCY, TOTAL, INCLUDED	HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY	228960
KININOGEN DEFICIENCY, HIGH MOLECULAR WEIGHT AND LOW MOLECULAR WEIGHT,INCLUDED	HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY	228960
FLAUJEAC TRAIT, INCLUDED	HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY	228960
WILLIAMS TRAIT, INCLUDED	HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY	228960
FLECK RETINA, FAMILIAL BENIGN; FRFB	FLECK RETINA, FAMILIAL BENIGN; FRFB	228980
FOLATE MALABSORPTION, HEREDITARY	FOLATE MALABSORPTION, HEREDITARY	229050
HYPOGONADOTROPIC HYPOGONADISM 24 WITHOUT ANOSMIA; HH24	HYPOGONADOTROPIC HYPOGONADISM 24 WITHOUT ANOSMIA; HH24	229070
FOLLICLE-STIMULATING HORMONE DEFICIENCY, ISOLATED	HYPOGONADOTROPIC HYPOGONADISM 24 WITHOUT ANOSMIA; HH24	229070
FORMIMINOTRANSFERASE DEFICIENCY	FORMIMINOTRANSFERASE DEFICIENCY	229100
GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY	FORMIMINOTRANSFERASE DEFICIENCY	229100
FORMIMINOGLUTAMIC ACIDURIA	FORMIMINOTRANSFERASE DEFICIENCY	229100
FIGLU-URIA	FORMIMINOTRANSFERASE DEFICIENCY	229100
FOUNTAIN SYNDROME	FOUNTAIN SYNDROME	229120
MENTAL RETARDATION, SENSORINEURAL DEAFNESS, SKELETAL ABNORMALITIES,AND COARSE FACE WITH FULL LIPS	FOUNTAIN SYNDROME	229120
BRITTLE CORNEA SYNDROME 1; BCS1	BRITTLE CORNEA SYNDROME 1; BCS1	229200
FRAGILITAS OCULI WITH JOINT HYPEREXTENSIBILITY	BRITTLE CORNEA SYNDROME 1; BCS1	229200
CORNEAL FRAGILITY, KERATOGLOBUS, BLUE SCLERAE, JOINT HYPEREXTENSIBILITY	BRITTLE CORNEA SYNDROME 1; BCS1	229200
DYSGENESIS MESODERMALIS CORNEAE ET SCLERAE	BRITTLE CORNEA SYNDROME 1; BCS1	229200
EHLERS-DANLOS SYNDROME, TYPE VIB, FORMERLY; EDS6B, FORMERLY	BRITTLE CORNEA SYNDROME 1; BCS1	229200
FRIEDREICH ATAXIA 1; FRDA	FRIEDREICH ATAXIA 1; FRDA	229300
FRDA1	FRIEDREICH ATAXIA 1; FRDA	229300
FAFRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED	FRIEDREICH ATAXIA 1; FRDA	229300
FRONTOFACIONASAL DYSPLASIA	FRONTOFACIONASAL DYSPLASIA	229400
FFND	FRONTOFACIONASAL DYSPLASIA	229400
FRONTOFACIONASAL DYSOSTOSIS	FRONTOFACIONASAL DYSPLASIA	229400
FRUCTOSE AND GALACTOSE INTOLERANCE	FRUCTOSE AND GALACTOSE INTOLERANCE	229500
FRUCTOSE INTOLERANCE, HEREDITARY	FRUCTOSE INTOLERANCE, HEREDITARY	229600
FRUCTOSEMIA	FRUCTOSE INTOLERANCE, HEREDITARY	229600
FRUCTOSE-1-PHOSPHATE ALDOLASE DEFICIENCY	FRUCTOSE INTOLERANCE, HEREDITARY	229600
FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE B DEFICIENCY	FRUCTOSE INTOLERANCE, HEREDITARY	229600
ALDOLASE B DEFICIENCY	FRUCTOSE INTOLERANCE, HEREDITARY	229600
ALDOB DEFICIENCY	FRUCTOSE INTOLERANCE, HEREDITARY	229600
FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D	FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D	229700
FRUCTOSURIA, ESSENTIAL	FRUCTOSURIA, ESSENTIAL	229800
HEPATIC FRUCTOKINASE DEFICIENCY	FRUCTOSURIA, ESSENTIAL	229800
KETOHEXOKINASE DEFICIENCY	FRUCTOSURIA, ESSENTIAL	229800
FRYNS SYNDROME; FRNS	FRYNS SYNDROME; FRNS	229850
DIAPHRAGMATIC HERNIA, ABNORMAL FACE, AND DISTAL LIMB ANOMALIES	FRYNS SYNDROME; FRNS	229850
FUCOSIDOSIS	FUCOSIDOSIS	230000
ALPHA-L-FUCOSIDASE DEFICIENCY	FUCOSIDOSIS	230000
GALACTOKINASE DEFICIENCY	GALACTOKINASE DEFICIENCY	230200
GALK DEFICIENCY	GALACTOKINASE DEFICIENCY	230200
GALACTOSEMIA II	GALACTOKINASE DEFICIENCY	230200
GALACTOSE EPIMERASE DEFICIENCY	GALACTOSE EPIMERASE DEFICIENCY	230350
GALE DEFICIENCY	GALACTOSE EPIMERASE DEFICIENCY	230350
GALACTOSEMIA III	GALACTOSE EPIMERASE DEFICIENCY	230350
UDP-GALACTOSE-4-EPIMERASE DEFICIENCY	GALACTOSE EPIMERASE DEFICIENCY	230350
GALACTOSEMIA	GALACTOSEMIA	230400
GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE DEFICIENCY	GALACTOSEMIA	230400
GALT DEFICIENCY	GALACTOSEMIA	230400
GALACTOSEMIA, CLASSICGALACTOSEMIA, DUARTE VARIANT	GALACTOSEMIA	230400
GAMMA-GLUTAMYLCYSTEINE SYNTHETASE DEFICIENCY, HEMOLYTIC ANEMIA DUETO	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE DEFICIENCY, HEMOLYTIC ANEMIA DUETO	230450
GM1-GANGLIOSIDOSIS, TYPE I	GM1-GANGLIOSIDOSIS, TYPE I	230500
GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I	GM1-GANGLIOSIDOSIS, TYPE I	230500
GANGLIOSIDOSIS, GENERALIZED GM1, INFANTILE FORM	GM1-GANGLIOSIDOSIS, TYPE I	230500
GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 1	GM1-GANGLIOSIDOSIS, TYPE I	230500
BETA-GALACTOSIDASE-1 DEFICIENCY	GM1-GANGLIOSIDOSIS, TYPE I	230500
GLB1 DEFICIENCYGM1-GANGLIOSIDOSIS, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED	GM1-GANGLIOSIDOSIS, TYPE I	230500
GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I, WITH CARDIAC INVOLVEMENT,INCLUDED	GM1-GANGLIOSIDOSIS, TYPE I	230500
GM1-GANGLIOSIDOSIS, TYPE II	GM1-GANGLIOSIDOSIS, TYPE II	230600
GANGLIOSIDOSIS, GENERALIZED GM1, JUVENILE TYPE	GM1-GANGLIOSIDOSIS, TYPE II	230600
GANGLIOSIDOSIS, GENERALIZED GM1, TYPE II	GM1-GANGLIOSIDOSIS, TYPE II	230600
GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 2GANGLIOSIDOSIS, GENERALIZED GM1, LATE-INFANTILE TYPE, INCLUDED	GM1-GANGLIOSIDOSIS, TYPE II	230600
GM1-GANGLIOSIDOSIS, TYPE III	GM1-GANGLIOSIDOSIS, TYPE III	230650
GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE	GM1-GANGLIOSIDOSIS, TYPE III	230650
GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE	GM1-GANGLIOSIDOSIS, TYPE III	230650
GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III	GM1-GANGLIOSIDOSIS, TYPE III	230650
GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3	GM1-GANGLIOSIDOSIS, TYPE III	230650
GAPO SYNDROME	GAPO SYNDROME	230740
GROWTH RETARDATION, ALOPECIA, PSEUDOANODONTIA, AND OPTIC ATROPHY	GAPO SYNDROME	230740
GAUCHER DISEASE, TYPE I	GAUCHER DISEASE, TYPE I	230800
GD I	GAUCHER DISEASE, TYPE I	230800
GAUCHER DISEASE, NONCEREBRAL JUVENILE	GAUCHER DISEASE, TYPE I	230800
GLUCOCEREBROSIDASE DEFICIENCY	GAUCHER DISEASE, TYPE I	230800
ACID BETA-GLUCOSIDASE DEFICIENCY	GAUCHER DISEASE, TYPE I	230800
GBA DEFICIENCY	GAUCHER DISEASE, TYPE I	230800
GAUCHER DISEASE, TYPE II	GAUCHER DISEASE, TYPE II	230900
GD II	GAUCHER DISEASE, TYPE II	230900
GAUCHER DISEASE, ACUTE NEURONOPATHIC TYPE	GAUCHER DISEASE, TYPE II	230900
GAUCHER DISEASE, TYPE III	GAUCHER DISEASE, TYPE III	231000
GD III	GAUCHER DISEASE, TYPE III	231000
GAUCHER DISEASE, SUBACUTE NEURONOPATHIC TYPE	GAUCHER DISEASE, TYPE III	231000
GAUCHER DISEASE, CHRONIC NEURONOPATHIC TYPE	GAUCHER DISEASE, TYPE III	231000
GAUCHER DISEASE, JUVENILE AND ADULT, CEREBRALGAUCHER DISEASE, TYPE IIIA, INCLUDED	GAUCHER DISEASE, TYPE III	231000
GAUCHER DISEASE, TYPE IIIB, INCLUDED	GAUCHER DISEASE, TYPE III	231000
GAUCHER DISEASE, NORRBOTTNIAN TYPE, INCLUDED	GAUCHER DISEASE, TYPE III	231000
GAUCHER DISEASE, TYPE IIIC	GAUCHER DISEASE, TYPE IIIC	231005
GELEOPHYSIC DYSPLASIA 1; GPHYSD1	GELEOPHYSIC DYSPLASIA 1; GPHYSD1	231050
GERODERMA OSTEODYSPLASTICUM; GO	GERODERMA OSTEODYSPLASTICUM; GO	231070
GERODERMIA OSTEODYSPLASTICA	GERODERMA OSTEODYSPLASTICUM; GO	231070
WALT DISNEY DWARFISM	GERODERMA OSTEODYSPLASTICUM; GO	231070
HYDATIDIFORM MOLE, RECURRENT, 1; HYDM1	HYDATIDIFORM MOLE, RECURRENT, 1; HYDM1	231090
HYDATIDIFORM MOLE; HYDM	HYDATIDIFORM MOLE, RECURRENT, 1; HYDM1	231090
HYDATIDIFORM MOLE, COMPLETE; CHM	HYDATIDIFORM MOLE, RECURRENT, 1; HYDM1	231090
GESTATIONAL TROPHOBLASTIC DISEASE	HYDATIDIFORM MOLE, RECURRENT, 1; HYDM1	231090
GHOSAL HEMATODIAPHYSEAL DYSPLASIA; GHDD	GHOSAL HEMATODIAPHYSEAL DYSPLASIA; GHDD	231095
GHOSAL SYNDROME	GHOSAL HEMATODIAPHYSEAL DYSPLASIA; GHDD	231095
BERNARD-SOULIER SYNDROME; BSS	BERNARD-SOULIER SYNDROME; BSS	231200
BLEEDING DISORDER, PLATELET-TYPE, 1; BDPLT1	BERNARD-SOULIER SYNDROME; BSS	231200
PLATELET GLYCOPROTEIN Ib DEFICIENCY	BERNARD-SOULIER SYNDROME; BSS	231200
GLYCOPROTEIN Ib, PLATELET, DEFICIENCY OF	BERNARD-SOULIER SYNDROME; BSS	231200
VON WILLEBRAND FACTOR RECEPTOR DEFICIENCYBERNARD-SOULIER SYNDROME, TYPE A1, INCLUDED	BERNARD-SOULIER SYNDROME; BSS	231200
BERNARD-SOULIER SYNDROME, TYPE B, INCLUDED	BERNARD-SOULIER SYNDROME; BSS	231200
BERNARD-SOULIER SYNDROME, TYPE C, INCLUDED	BERNARD-SOULIER SYNDROME; BSS	231200
GLAUCOMA 3, PRIMARY CONGENITAL, A; GLC3A	GLAUCOMA 3, PRIMARY CONGENITAL, A; GLC3A	231300
GLAUCOMA, CONGENITAL; GLC3	GLAUCOMA 3, PRIMARY CONGENITAL, A; GLC3A	231300
BUPHTHALMOSGLAUCOMA, PRIMARY OPEN ANGLE, ADULT-ONSET, INCLUDED	GLAUCOMA 3, PRIMARY CONGENITAL, A; GLC3A	231300
GLAUCOMA, PRIMARY OPEN ANGLE, JUVENILE-ONSET, INCLUDED	GLAUCOMA 3, PRIMARY CONGENITAL, A; GLC3A	231300
3-@HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY	3-@HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY	231530
HADH DEFICIENCY	3-@HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY	231530
SCHAD DEFICIENCY, FORMERLY	3-@HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY	231530
ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS	ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS	231550
TRIPLE-A SYNDROME	ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS	231550
ALACRIMA-ACHALASIA-ADRENAL INSUFFICIENCY NEUROLOGIC DISORDER	ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS	231550
GLUCOCORTICOID DEFICIENCY AND ACHALASIA	ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS	231550
ALLGROVE SYNDROME	ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS	231550
ADDISONIAN-ACHALASIA SYNDROME	ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS	231550
HYPOADRENALISM WITH ACHALASIA	ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS	231550
ALACRIMA-ACHALASIA-ADDISONIANISM	ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS	231550
ACTH-RESISTANT ADRENAL INSUFFICIENCY, ACHALASIA AND ALACRIMAACHALASIA-ALACRIMA SYNDROME, INCLUDED	ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS	231550
GLUTARIC ACIDEMIA I	GLUTARIC ACIDEMIA I	231670
GLUTARIC ACIDURIA I	GLUTARIC ACIDEMIA I	231670
GA I	GLUTARIC ACIDEMIA I	231670
GLUTARYL-CoA DEHYDROGENASE DEFICIENCY	GLUTARIC ACIDEMIA I	231670
MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	231680
GLUTARIC ACIDEMIA II	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	231680
GLUTARIC ACIDURIA II	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	231680
GA II	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	231680
ETHYLMALONIC-ADIPICACIDURIA; EMAGLUTARIC ACIDEMIA IIA, INCLUDED	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	231680
ETFA DEFICIENCY, INCLUDED	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	231680
GLUTARIC ACIDEMIA IIB, INCLUDED	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	231680
ETFB DEFICIENCY, INCLUDED	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	231680
GLUTARIC ACIDEMIA IIC, INCLUDED	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	231680
ETFDH DEFICIENCY, INCLUDED	MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD	231680
GLUTARIC ACIDURIA III	GLUTARIC ACIDURIA III	231690
GA III	GLUTARIC ACIDURIA III	231690
GLUTARYL-CoA OXIDASE DEFICIENCY	GLUTARIC ACIDURIA III	231690
GLUTATHIONE SYNTHETASE DEFICIENCY OF ERYTHROCYTES, HEMOLYTIC ANEMIADUE TO; GSSDE	GLUTATHIONE SYNTHETASE DEFICIENCY OF ERYTHROCYTES, HEMOLYTIC ANEMIADUE TO; GSSDE	231900
GLYCOGEN STORAGE DISEASE Ia; GSD1A	GLYCOGEN STORAGE DISEASE Ia; GSD1A	232200
GSD Ia	GLYCOGEN STORAGE DISEASE Ia; GSD1A	232200
GLYCOGEN STORAGE DISEASE I; GSD1	GLYCOGEN STORAGE DISEASE Ia; GSD1A	232200
VON GIERKE DISEASE	GLYCOGEN STORAGE DISEASE Ia; GSD1A	232200
HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE	GLYCOGEN STORAGE DISEASE Ia; GSD1A	232200
GLUCOSE-6-PHOSPHATASE DEFICIENCY	GLYCOGEN STORAGE DISEASE Ia; GSD1A	232200
HEPATORENAL GLYCOGENOSIS	GLYCOGEN STORAGE DISEASE Ia; GSD1A	232200
GLYCOGEN STORAGE DISEASE Ib; GSD1B	GLYCOGEN STORAGE DISEASE Ib; GSD1B	232220
GSD Ib	GLYCOGEN STORAGE DISEASE Ib; GSD1B	232220
GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT	GLYCOGEN STORAGE DISEASE Ib; GSD1B	232220
GLYCOGEN STORAGE DISEASE Ic	GLYCOGEN STORAGE DISEASE Ic	232240
GSD1CGLYCOGEN STORAGE DISEASE Id, INCLUDED; GSD1D, INCLUDED	GLYCOGEN STORAGE DISEASE Ic	232240
GLYCOGEN STORAGE DISEASE II; GSD2	GLYCOGEN STORAGE DISEASE II; GSD2	232300
GSD II; ACID ALPHA-GLUCOSIDASE DEFICIENCY	GLYCOGEN STORAGE DISEASE II; GSD2	232300
GAA DEFICIENCY	GLYCOGEN STORAGE DISEASE II; GSD2	232300
POMPE DISEASE	GLYCOGEN STORAGE DISEASE II; GSD2	232300
GLYCOGENOSIS, GENERALIZED, CARDIAC FORM	GLYCOGEN STORAGE DISEASE II; GSD2	232300
CARDIOMEGALIA GLYCOGENICA DIFFUSA	GLYCOGEN STORAGE DISEASE II; GSD2	232300
ACID MALTASE DEFICIENCY; AMD	GLYCOGEN STORAGE DISEASE II; GSD2	232300
ALPHA-1,4-GLUCOSIDASE DEFICIENCY	GLYCOGEN STORAGE DISEASE II; GSD2	232300
GLYCOGEN STORAGE DISEASE III; GSD3	GLYCOGEN STORAGE DISEASE III; GSD3	232400
FORBES DISEASE	GLYCOGEN STORAGE DISEASE III; GSD3	232400
CORI DISEASE	GLYCOGEN STORAGE DISEASE III; GSD3	232400
LIMIT DEXTRINOSIS	GLYCOGEN STORAGE DISEASE III; GSD3	232400
AMYLO-1,6-GLUCOSIDASE DEFICIENCY	GLYCOGEN STORAGE DISEASE III; GSD3	232400
AGL DEFICIENCY	GLYCOGEN STORAGE DISEASE III; GSD3	232400
GLYCOGEN DEBRANCHER DEFICIENCY	GLYCOGEN STORAGE DISEASE III; GSD3	232400
GDE DEFICIENCYGLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED	GLYCOGEN STORAGE DISEASE III; GSD3	232400
GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED	GLYCOGEN STORAGE DISEASE III; GSD3	232400
GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED	GLYCOGEN STORAGE DISEASE III; GSD3	232400
GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED	GLYCOGEN STORAGE DISEASE III; GSD3	232400
GLYCOGEN STORAGE DISEASE IV; GSD4	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
GSD IV	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
GLYCOGEN BRANCHING ENZYME DEFICIENCY	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
GBE1 DEFICIENCY	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
ANDERSEN DISEASE	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
BRANCHER DEFICIENCY	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
GLYCOGENOSIS IV	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
AMYLOPECTINOSIS	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
CIRRHOSIS, FAMILIAL, WITH DEPOSITION OF ABNORMAL GLYCOGENGSD IV, CLASSIC HEPATIC, INCLUDED	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
GSD IV, NONPROGRESSIVE HEPATIC, INCLUDED	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
GSD IV, NEUROMUSCULAR FORM, FATAL PERINATAL, INCLUDED	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
GSD IV, NEUROMUSCULAR FORM, CONGENITAL, INCLUDED	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
GSD IV, NEUROMUSCULAR FORM, CHILDHOOD, INCLUDED	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
GSD IV, NEUROMUSCULAR FORM, ADULT, WITH ISOLATED MYOPATHY, INCLUDED	GLYCOGEN STORAGE DISEASE IV; GSD4	232500
GLYCOGEN STORAGE DISEASE V; GSD5	GLYCOGEN STORAGE DISEASE V; GSD5	232600
GSD V	GLYCOGEN STORAGE DISEASE V; GSD5	232600
MCARDLE DISEASE	GLYCOGEN STORAGE DISEASE V; GSD5	232600
MYOPHOSPHORYLASE DEFICIENCY	GLYCOGEN STORAGE DISEASE V; GSD5	232600
MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY	GLYCOGEN STORAGE DISEASE V; GSD5	232600
PYGM DEFICIENCY	GLYCOGEN STORAGE DISEASE V; GSD5	232600
GLYCOGEN STORAGE DISEASE VI; GSD6	GLYCOGEN STORAGE DISEASE VI; GSD6	232700
GSD VI	GLYCOGEN STORAGE DISEASE VI; GSD6	232700
HERS DISEASE	GLYCOGEN STORAGE DISEASE VI; GSD6	232700
PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER	GLYCOGEN STORAGE DISEASE VI; GSD6	232700
GLYCOGEN STORAGE DISEASE VII; GSD7	GLYCOGEN STORAGE DISEASE VII; GSD7	232800
GSD VII	GLYCOGEN STORAGE DISEASE VII; GSD7	232800
MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY	GLYCOGEN STORAGE DISEASE VII; GSD7	232800
PFKM DEFICIENCY	GLYCOGEN STORAGE DISEASE VII; GSD7	232800
TARUI DISEASE	GLYCOGEN STORAGE DISEASE VII; GSD7	232800
RENAL GLUCOSURIA; GLYS	RENAL GLUCOSURIA; GLYS	233100
GLYS1	RENAL GLUCOSURIA; GLYS	233100
GLYCOSURIA, RENAL	RENAL GLUCOSURIA; GLYS	233100
OVARIAN DYSGENESIS 1; ODG1	OVARIAN DYSGENESIS 1; ODG1	233300
OVARIAN DYSGENESIS, HYPERGONADOTROPIC, AUTOSOMAL RECESSIVE	OVARIAN DYSGENESIS 1; ODG1	233300
OVARIAN DYSGENESIS, HYPERGONADOTROPIC, WITH NORMAL KARYOTYPE	OVARIAN DYSGENESIS 1; ODG1	233300
GONADAL DYSGENESIS, XX TYPE	OVARIAN DYSGENESIS 1; ODG1	233300
XX GONADAL DYSGENESIS; XXGD	OVARIAN DYSGENESIS 1; ODG1	233300
OVARIAN FAILURE, HYPERGONADOTROPIC	OVARIAN DYSGENESIS 1; ODG1	233300
PERRAULT SYNDROME 1; PRLTS1	PERRAULT SYNDROME 1; PRLTS1	233400
OVARIAN DYSGENESIS WITH SENSORINEURAL DEAFNESS	PERRAULT SYNDROME 1; PRLTS1	233400
GONADAL DYSGENESIS, XX TYPE, WITH DEAFNESS	PERRAULT SYNDROME 1; PRLTS1	233400
46,XY SEX REVERSAL 7; SRXY7	46,XY SEX REVERSAL 7; SRXY7	233420
46,XY SEX REVERSAL, PARTIAL OR COMPLETE, DHH-RELATED	46,XY SEX REVERSAL 7; SRXY7	233420
46,XY GONADAL DYSGENESIS, PARTIAL OR COMPLETE, DHH-RELATED	46,XY SEX REVERSAL 7; SRXY7	233420
GONADAL DYSGENESIS, XY, MALE-LIMITED; GDXYM	46,XY SEX REVERSAL 7; SRXY7	233420
GORLIN-CHAUDHRY-MOSS SYNDROME; GCMS	GORLIN-CHAUDHRY-MOSS SYNDROME; GCMS	233500
CRANIOFACIAL DYSOSTOSIS, HYPERTRICHOSIS, HYPOPLASIA OF LABIA MAJORA,	GORLIN-CHAUDHRY-MOSS SYNDROME; GCMS	233500
DENTAL AND EYE ANOMALIES, PATENT DUCTUS ARTERIOSUS, AND NORMAL INTELLIGENCE	GORLIN-CHAUDHRY-MOSS SYNDROME; GCMS	233500
COMBINED CELLULAR AND HUMORAL IMMUNE DEFECTS WITH GRANULOMAS; CCHIDG	COMBINED CELLULAR AND HUMORAL IMMUNE DEFECTS WITH GRANULOMAS; CCHIDG	233650
GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-NEGATIVE	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-NEGATIVE	233690
CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-NEGATIVE	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-NEGATIVE	233690
CGD DUE TO DEFICIENCY OF THE ALPHA SUBUNIT OF CYTOCHROME b	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-NEGATIVE	233690
CYBA DEFICIENCY	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-NEGATIVE	233690
GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE I	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE I	233700
CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE I	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE I	233700
GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF1 DEFICIENCY	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE I	233700
NEUTROPHIL CYTOSOL FACTOR 1, DEFICIENCY OF	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE I	233700
NCF1, DEFICIENCY OF	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE I	233700
SOLUBLE OXIDASE COMPONENT II, DEFICIENCY OF	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE I	233700
SOC2, DEFICIENCY OF	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE I	233700
p47-PHOX, DEFICIENCY OF	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE I	233700
GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE II	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE II	233710
CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE II	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE II	233710
GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF2 DEFICIENCY	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE II	233710
NEUTROPHIL CYTOSOL FACTOR 2, DEFICIENCY OF	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE II	233710
NCF2, DEFICIENCY OF	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE II	233710
p67-PHOX, DEFICIENCY OF	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE II	233710
HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B	233910
HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASEI DEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B	233910
GTP CYCLOHYDROLASE I DEFICIENCYDYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA,AUTOSOMAL RECESSIVE, INCLUDED	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B	233910
FACTOR XII DEFICIENCY	FACTOR XII DEFICIENCY	234000
F12 DEFICIENCY	FACTOR XII DEFICIENCY	234000
HAGEMAN FACTOR DEFICIENCY	FACTOR XII DEFICIENCY	234000
HAF DEFICIENCY	FACTOR XII DEFICIENCY	234000
TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE; TTD4	TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE; TTD4	234050
TRICHOTHIODYSTROPHY, NONPHOTOSENSITIVE 1; TTDN1	TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE; TTD4	234050
AMISH BRITTLE HAIR BRAIN SYNDROME; ABHS	TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE; TTD4	234050
HAIR-BRAIN SYNDROME	TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE; TTD4	234050
BIDS SYNDROME	TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE; TTD4	234050
POLLITT SYNDROME	TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE; TTD4	234050
TRICHOTHIODYSTROPHY-NEUROCUTANEOUS SYNDROME	TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE; TTD4	234050
HALLERMANN-STREIFF SYNDROME; HSS	HALLERMANN-STREIFF SYNDROME; HSS	234100
FRANCOIS DYSCEPHALIC SYNDROME	HALLERMANN-STREIFF SYNDROME; HSS	234100
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1	234200
PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION; PKAN	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1	234200
PKAN NEUROAXONAL DYSTROPHY, JUVENILE-ONSET	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1	234200
HALLERVORDEN-SPATZ DISEASE	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1	234200
HARTNUP DISORDER; HND	HARTNUP DISORDER; HND	234500
HARTNUP DISEASE	HARTNUP DISORDER; HND	234500
HEIMLER SYNDROME 1; HMLR1	HEIMLER SYNDROME 1; HMLR1	234580
HEARING LOSS, SENSORINEURAL, WITH ENAMEL HYPOPLASIA AND NAIL DEFECTS	HEIMLER SYNDROME 1; HMLR1	234580
PEROXISOME BIOGENESIS DISORDER 1C; PBD1C	HEIMLER SYNDROME 1; HMLR1	234580
PULMONARY VENOOCCLUSIVE DISEASE 2, AUTOSOMAL RECESSIVE; PVOD2	PULMONARY VENOOCCLUSIVE DISEASE 2, AUTOSOMAL RECESSIVE; PVOD2	234810
HEMANGIOMATOSIS, FAMILIAL PULMONARY CAPILLARY	PULMONARY VENOOCCLUSIVE DISEASE 2, AUTOSOMAL RECESSIVE; PVOD2	234810
HEMIHYPERPLASIA, ISOLATED; IH	HEMIHYPERPLASIA, ISOLATED; IH	235000
HEMIHYPERPLASIA; HHP	HEMIHYPERPLASIA, ISOLATED; IH	235000
HEMIHYPERTROPHY, ISOLATEDHEMI-3 SYNDROME, INCLUDED	HEMIHYPERPLASIA, ISOLATED; IH	235000
HEMOCHROMATOSIS, TYPE 1; HFE1	HEMOCHROMATOSIS, TYPE 1; HFE1	235200
HEMOCHROMATOSIS; HFE	HEMOCHROMATOSIS, TYPE 1; HFE1	235200
HEMOCHROMATOSIS, HEREDITARY; HH	HEMOCHROMATOSIS, TYPE 1; HFE1	235200
MULLERIAN DERIVATIVES, PERSISTENCE OF, WITH LYMPHANGIECTASIA AND POSTAXIALPOLYDACTYLY	MULLERIAN DERIVATIVES, PERSISTENCE OF, WITH LYMPHANGIECTASIA AND POSTAXIALPOLYDACTYLY	235255
URIOSTE SYNDROME	MULLERIAN DERIVATIVES, PERSISTENCE OF, WITH LYMPHANGIECTASIA AND POSTAXIALPOLYDACTYLY	235255
HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1; AHUS1	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1; AHUS1	235400
AHUS, SUSCEPTIBILITY TO, 1HEMOLYTIC UREMIC SYNDROME, TYPICAL, INCLUDED	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1; AHUS1	235400
HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 1; HKLLS1	HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 1; HKLLS1	235510
HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME	HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 1; HKLLS1	235510
LYMPHATIC DYSPLASIA, GENERALIZED	HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 1; HKLLS1	235510
HEPATIC VENOOCCLUSIVE DISEASE WITH IMMUNODEFICIENCY; VODI	HEPATIC VENOOCCLUSIVE DISEASE WITH IMMUNODEFICIENCY; VODI	235550
BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2	235555
CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2	235555
HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO HEXOKINASE DEFICIENCY	HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO HEXOKINASE DEFICIENCY	235700
MOWAT-WILSON SYNDROME; MOWS	MOWAT-WILSON SYNDROME; MOWS	235730
MICROCEPHALY, MENTAL RETARDATION, AND DISTINCT FACIAL FEATURES, WITHOR WITHOUT HIRSCHSPRUNG DISEASE	MOWAT-WILSON SYNDROME; MOWS	235730
HIRSCHSPRUNG DISEASE-MENTAL RETARDATION SYNDROME	MOWAT-WILSON SYNDROME; MOWS	235730
HISTIDINEMIA	HISTIDINEMIA	235800
HISTIDINE AMMONIA-LYASE DEFICIENCY	HISTIDINEMIA	235800
HAL DEFICIENCY	HISTIDINEMIA	235800
HISTIDASE DEFICIENCY	HISTIDINEMIA	235800
HIS DEFICIENCY	HISTIDINEMIA	235800
HISTIDINURIA DUE TO A RENAL TUBULAR DEFECT	HISTIDINURIA DUE TO A RENAL TUBULAR DEFECT	235830
HISTIOCYTOSIS, FAMILIAL LIPOCHROME	HISTIOCYTOSIS, FAMILIAL LIPOCHROME	235900
LYMPHOMA, HODGKIN, CLASSIC; CHL	LYMPHOMA, HODGKIN, CLASSIC; CHL	236000
HODGKIN DISEASE	LYMPHOMA, HODGKIN, CLASSIC; CHL	236000
HOLOPROSENCEPHALY 1; HPE1	HOLOPROSENCEPHALY 1; HPE1	236100
HOLOPROSENCEPHALY, FAMILIAL ALOBAR	HOLOPROSENCEPHALY 1; HPE1	236100
HPE, FAMILIAL; HPEC	HOLOPROSENCEPHALY 1; HPE1	236100
ARHINENCEPHALY	HOLOPROSENCEPHALY 1; HPE1	236100
CYCLOPIA	HOLOPROSENCEPHALY 1; HPE1	236100
DEMYER SEQUENCE	HOLOPROSENCEPHALY 1; HPE1	236100
HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY	HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY	236200
HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE	HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY	236200
CYSTATHIONINE BETA-SYNTHASE DEFICIENCY	HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY	236200
CBS DEFICIENCYHYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED	HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY	236200
HOMOCYSTINURIA DUE TO DEFICIENCY OF N(5,10)-METHYLENETETRAHYDROFOLATEREDUCTASE ACTIVITY	HOMOCYSTINURIA DUE TO DEFICIENCY OF N(5,10)-METHYLENETETRAHYDROFOLATEREDUCTASE ACTIVITY	236250
METHYLENETETRAHYDROFOLATE REDUCTASE DEFICIENCY	HOMOCYSTINURIA DUE TO DEFICIENCY OF N(5,10)-METHYLENETETRAHYDROFOLATEREDUCTASE ACTIVITY	236250
MTHFR DEFICIENCYMTHFR DEFICIENCY, THERMOLABILE TYPE, INCLUDED	HOMOCYSTINURIA DUE TO DEFICIENCY OF N(5,10)-METHYLENETETRAHYDROFOLATEREDUCTASE ACTIVITY	236250
HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE	236270
HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM,cblE COMPLEMENTATION TYPE	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE	236270
VITAMIN B12-RESPONSIVE HOMOCYSTINURIA, cblE TYPE	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE	236270
METHYLCOBALAMIN DEFICIENCY, cblE TYPE	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE	236270
HUMERORADIAL SYNOSTOSISHUMERORADIAL/MULTIPLE SYNOSTOSIS SYNDROME, INCLUDED	HUMERORADIAL SYNOSTOSISHUMERORADIAL/MULTIPLE SYNOSTOSIS SYNDROME, INCLUDED	236400
HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 1; HYC1	HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 1; HYC1	236600
HYDROCEPHALY	HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 1; HYC1	236600
VENTRICULOMEGALY	HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 1; HYC1	236600
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 1; MDDGA1	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 1; MDDGA1	236670
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMT1-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 1; MDDGA1	236670
HYDROCEPHALUS, AGYRIA, AND RETINAL DYSPLASIA	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 1; MDDGA1	236670
HARD SYNDROME	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 1; MDDGA1	236670
CEREBROOCULAR DYSPLASIA-MUSCULAR DYSTROPHY SYNDROME	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 1; MDDGA1	236670
COD-MD SYNDROME	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 1; MDDGA1	236670
HYDROLETHALUS SYNDROME 1; HLS1	HYDROLETHALUS SYNDROME 1; HLS1	236680
MCKUSICK-KAUFMAN SYNDROME; MKKS	MCKUSICK-KAUFMAN SYNDROME; MKKS	236700
HYDROMETROCOLPOS SYNDROME	MCKUSICK-KAUFMAN SYNDROME; MKKS	236700
HYDROMETROCOLPOS, POSTAXIAL POLYDACTYLY, AND CONGENITAL HEART MALFORMATION;HMCS	MCKUSICK-KAUFMAN SYNDROME; MKKS	236700
KAUFMAN-MCKUSICK SYNDROME	MCKUSICK-KAUFMAN SYNDROME; MKKS	236700
UROFACIAL SYNDROME 1; UFS1	UROFACIAL SYNDROME 1; UFS1	236730
UROFACIAL SYNDROME; UFS	UROFACIAL SYNDROME 1; UFS1	236730
OCHOA SYNDROME	UROFACIAL SYNDROME 1; UFS1	236730
HYDRONEPHROSIS WITH PECULIAR FACIAL EXPRESSION	UROFACIAL SYNDROME 1; UFS1	236730
INVERTED SMILE AND OCCULT NEUROPATHIC BLADDER	UROFACIAL SYNDROME 1; UFS1	236730
FACIAL PALSY, PARTIAL, WITH URINARY ABNORMALITIES	UROFACIAL SYNDROME 1; UFS1	236730
HYDROPS FETALIS, NONIMMUNE; NIHFHYDROPS FETALIS, ALPHA-THALASSEMIA-RELATED, INCLUDED	HYDROPS FETALIS, NONIMMUNE; NIHFHYDROPS FETALIS, ALPHA-THALASSEMIA-RELATED, INCLUDED	236750
HEMOGLOBIN H HYDROPS FETALIS SYNDROME, INCLUDED	HYDROPS FETALIS, NONIMMUNE; NIHFHYDROPS FETALIS, ALPHA-THALASSEMIA-RELATED, INCLUDED	236750
L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA	L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA	236792
L-2-HYDROXYGLUTARIC ACIDEMIA	L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA	236792
3-@HYDROXYISOBUTYRIC ACIDURIA	3-@HYDROXYISOBUTYRIC ACIDURIA	236795
HYDROXYKYNURENINURIA	HYDROXYKYNURENINURIA	236800
XANTHURENIC ACIDURIA	HYDROXYKYNURENINURIA	236800
KYNURENINASE DEFICIENCY	HYDROXYKYNURENINURIA	236800
HYDROXYLYSINURIA	HYDROXYLYSINURIA	236900
CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO	CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO	237300
CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY	CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO	237300
CPS I DEFICIENCY	CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO	237300
N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY; NAGSD	N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY; NAGSD	237310
HYPERAMMONEMIA DUE TO N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY	N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY; NAGSD	237310
N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY	N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY; NAGSD	237310
NAGS DEFICIENCY	N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY; NAGSD	237310
HYPERBILIRUBINEMIA, ROTOR TYPE; HBLRR	HYPERBILIRUBINEMIA, ROTOR TYPE; HBLRR	237450
ROTOR SYNDROME	HYPERBILIRUBINEMIA, ROTOR TYPE; HBLRR	237450
DUBIN-JOHNSON SYNDROME; DJS	DUBIN-JOHNSON SYNDROME; DJS	237500
HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ	DUBIN-JOHNSON SYNDROME; DJS	237500
HYPERBILIRUBINEMIA II	DUBIN-JOHNSON SYNDROME; DJS	237500
HYPERBILIRUBINEMIA, SHUNT, PRIMARY; PSHB	HYPERBILIRUBINEMIA, SHUNT, PRIMARY; PSHB	237800
HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL; HBLRTFN	HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL; HBLRTFN	237900
LUCEY-DRISCOLL SYNDROMEBREAST MILK JAUNDICE, INCLUDED	HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL; HBLRTFN	237900
LEYDIG CELL HYPOPLASIA, TYPE I	LEYDIG CELL HYPOPLASIA, TYPE I	238320
LEYDIG CELL HYPOPLASIA WITH MALE PSEUDOHERMAPHRODITISM	LEYDIG CELL HYPOPLASIA, TYPE I	238320
HYPERGONADOTROPIC HYPOGONADISM, MALE, DUE TO LHCGR DEFECT	LEYDIG CELL HYPOPLASIA, TYPE I	238320
LEYDIG CELL HYPOPLASIA, COMPLETE	LEYDIG CELL HYPOPLASIA, TYPE I	238320
LEYDIG CELL AGENESISLEYDIG CELL HYPOPLASIA, TYPE II, INCLUDED	LEYDIG CELL HYPOPLASIA, TYPE I	238320
LEYDIG CELL HYPOPLASIA, PARTIAL, INCLUDED	LEYDIG CELL HYPOPLASIA, TYPE I	238320
LUTEINIZING HORMONE RESISTANCE, FEMALE, INCLUDED	LEYDIG CELL HYPOPLASIA, TYPE I	238320
HYPERLIPOPROTEINEMIA, TYPE I	HYPERLIPOPROTEINEMIA, TYPE I	238600
LIPOPROTEIN LIPASE DEFICIENCY	HYPERLIPOPROTEINEMIA, TYPE I	238600
LPL DEFICIENCY	HYPERLIPOPROTEINEMIA, TYPE I	238600
HYPERCHYLOMICRONEMIA, FAMILIAL	HYPERLIPOPROTEINEMIA, TYPE I	238600
HYPERLIPEMIA, IDIOPATHIC, BURGER-GRUTZ TYPE	HYPERLIPOPROTEINEMIA, TYPE I	238600
HYPERLIPEMIA, ESSENTIAL FAMILIAL	HYPERLIPOPROTEINEMIA, TYPE I	238600
LIPASE D DEFICIENCY	HYPERLIPOPROTEINEMIA, TYPE I	238600
LIPD DEFICIENCY	HYPERLIPOPROTEINEMIA, TYPE I	238600
HYPERLIPOPROTEINEMIA, TYPE IA	HYPERLIPOPROTEINEMIA, TYPE I	238600
CHYLOMICRONEMIA, FAMILIAL	HYPERLIPOPROTEINEMIA, TYPE I	238600
HYPERLYSINEMIA, TYPE I	HYPERLYSINEMIA, TYPE I	238700
LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY	HYPERLYSINEMIA, TYPE I	238700
ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY	HYPERLYSINEMIA, TYPE I	238700
LYSINE INTOLERANCE	HYPERLYSINEMIA, TYPE I	238700
L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY	HYPERLYSINEMIA, TYPE I	238700
HYPERORNITHINEMIA-HYPERAMMONEMIA-HOMOCITRULLINURIA SYNDROME	HYPERORNITHINEMIA-HYPERAMMONEMIA-HOMOCITRULLINURIA SYNDROME	238970
HHH SYNDROME; HHHS; HHH	HYPERORNITHINEMIA-HYPERAMMONEMIA-HOMOCITRULLINURIA SYNDROME	238970
ORNITHINE TRANSLOCASE DEFICIENCY	HYPERORNITHINEMIA-HYPERAMMONEMIA-HOMOCITRULLINURIA SYNDROME	238970
PAGET DISEASE OF BONE 5, JUVENILE-ONSET; PDB5	PAGET DISEASE OF BONE 5, JUVENILE-ONSET; PDB5	239000
JUVENILE PAGET DISEASE; JPD	PAGET DISEASE OF BONE 5, JUVENILE-ONSET; PDB5	239000
HYPEROSTOSIS CORTICALIS DEFORMANS JUVENILIS	PAGET DISEASE OF BONE 5, JUVENILE-ONSET; PDB5	239000
HYPERPHOSPHATASIA, FAMILIAL IDIOPATHIC	PAGET DISEASE OF BONE 5, JUVENILE-ONSET; PDB5	239000
HYPERPHOSPHATASEMIA, CHRONIC CONGENITAL IDIOPATHIC	PAGET DISEASE OF BONE 5, JUVENILE-ONSET; PDB5	239000
OSTEOECTASIA, FAMILIAL	PAGET DISEASE OF BONE 5, JUVENILE-ONSET; PDB5	239000
HYPEROSTOSIS CORTICALIS GENERALISATA	HYPEROSTOSIS CORTICALIS GENERALISATA	239100
VAN BUCHEM DISEASE; VBCH	HYPEROSTOSIS CORTICALIS GENERALISATA	239100
HYPERPHOSPHATASEMIA TARDA	HYPEROSTOSIS CORTICALIS GENERALISATA	239100
ENDOSTEAL HYPEROSTOSIS, AUTOSOMAL RECESSIVE	HYPEROSTOSIS CORTICALIS GENERALISATA	239100
HYPERPARATHYROIDISM, NEONATAL SEVERE; NSHPT	HYPERPARATHYROIDISM, NEONATAL SEVERE; NSHPT	239200
NSPH; NHPT	HYPERPARATHYROIDISM, NEONATAL SEVERE; NSHPT	239200
HYPERPARATHYROIDISM, NEONATAL SEVERE PRIMARY	HYPERPARATHYROIDISM, NEONATAL SEVERE; NSHPT	239200
HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 1; HPMRS1	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 1; HPMRS1	239300
MABRY SYNDROME	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 1; HPMRS1	239300
HYPERPROLINEMIA, TYPE I; HYRPRO1	HYPERPROLINEMIA, TYPE I; HYRPRO1	239500
HPI	HYPERPROLINEMIA, TYPE I; HYRPRO1	239500
PROLINE OXIDASE DEFICIENCY	HYPERPROLINEMIA, TYPE I; HYRPRO1	239500
HYPERPROLINEMIA, TYPE II; HYRPRO2	HYPERPROLINEMIA, TYPE II; HYRPRO2	239510
HPII	HYPERPROLINEMIA, TYPE II; HYRPRO2	239510
1-@PYRROLINE-5-CARBOXYLATE DEHYDROGENASE DEFICIENCY	HYPERPROLINEMIA, TYPE II; HYRPRO2	239510
HYPERTELORISM, MICROTIA, FACIAL CLEFTING SYNDROME	HYPERTELORISM, MICROTIA, FACIAL CLEFTING SYNDROME	239800
HMC SYNDROME	HYPERTELORISM, MICROTIA, FACIAL CLEFTING SYNDROME	239800
CANTU SYNDROME	CANTU SYNDROME	239850
HYPERTRICHOTIC OSTEOCHONDRODYSPLASIA	CANTU SYNDROME	239850
HYPOADRENOCORTICISM, FAMILIAL	HYPOADRENOCORTICISM, FAMILIAL	240200
ADRENAL HYPOPLASIA	HYPOADRENOCORTICISM, FAMILIAL	240200
ADRENAL APLASIA	HYPOADRENOCORTICISM, FAMILIAL	240200
ADDISON DISEASE	HYPOADRENOCORTICISM, FAMILIAL	240200
AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLEMETAPHYSEAL DYSPLASIA; APS1	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLEMETAPHYSEAL DYSPLASIA; APS1	240300
APS I	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLEMETAPHYSEAL DYSPLASIA; APS1	240300
AUTOIMMUNE POLYENDOCRINOPATHY-CANDIDIASIS-ECTODERMAL DYSTROPHY; APECED	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLEMETAPHYSEAL DYSPLASIA; APS1	240300
AUTOIMMUNE POLYGLANDULAR SYNDROME, TYPE I	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLEMETAPHYSEAL DYSPLASIA; APS1	240300
POLYGLANDULAR AUTOIMMUNE SYNDROME, TYPE I	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLEMETAPHYSEAL DYSPLASIA; APS1	240300
PGA I	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLEMETAPHYSEAL DYSPLASIA; APS1	240300
HYPOADRENOCORTICISM WITH HYPOPARATHYROIDISM AND SUPERFICIAL MONILIASISAUTOIMMUNE POLYENDOCRINOPATHY SYNDROME, TYPE I, AUTOSOMAL DOMINANT,INCLUDED	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLEMETAPHYSEAL DYSPLASIA; APS1	240300
POLYGLANDULAR DEFICIENCY SYNDROME, PERSIAN-JEWISH TYPE, INCLUDED	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLEMETAPHYSEAL DYSPLASIA; APS1	240300
IMMUNODEFICIENCY, COMMON VARIABLE, 2; CVID2	IMMUNODEFICIENCY, COMMON VARIABLE, 2; CVID2	240500
ANTIBODY DEFICIENCY DUE TO TACI DEFECT	IMMUNODEFICIENCY, COMMON VARIABLE, 2; CVID2	240500
HYPOGAMMAGLOBULINEMIA DUE TO TACI DEFICIENCY	IMMUNODEFICIENCY, COMMON VARIABLE, 2; CVID2	240500
GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A	GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A	240600
GSD 0a	GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A	240600
HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER	GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A	240600
LIVER GLYCOGEN SYNTHASE DEFICIENCY	GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A	240600
LIVER GLYCOGEN STORAGE DISEASE 0	GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A	240600
HYPOGLYCEMIA, LEUCINE-INDUCED; LIH	HYPOGLYCEMIA, LEUCINE-INDUCED; LIH	240800
LEUCINE-SENSITIVE HYPOGLYCEMIA OF INFANCY	HYPOGLYCEMIA, LEUCINE-INDUCED; LIH	240800
HYPOINSULINEMIC HYPOGLYCEMIA WITH HEMIHYPERTROPHY; HIHGHH	HYPOINSULINEMIC HYPOGLYCEMIA WITH HEMIHYPERTROPHY; HIHGHH	240900
WOODHOUSE-SAKATI SYNDROME	WOODHOUSE-SAKATI SYNDROME	241080
HYPOGONADISM, ALOPECIA, DIABETES MELLITUS, MENTAL RETARDATION, DEAFNESS,AND EXTRAPYRAMIDAL SYNDROME	WOODHOUSE-SAKATI SYNDROME	241080
EXTRAPYRAMIDAL DISORDER, PROGRESSIVE, WITH PRIMARY HYPOGONADISM, MENTALRETARDATION, AND ALOPECIA	WOODHOUSE-SAKATI SYNDROME	241080
HYPERGONADOTROPIC HYPOGONADISM AND PARTIAL ALOPECIA	HYPERGONADOTROPIC HYPOGONADISM AND PARTIAL ALOPECIA	241090
HYPOKALEMIC ALKALOSIS, FAMILIAL, WITH SPECIFIC RENAL TUBULOPATHY	HYPOKALEMIC ALKALOSIS, FAMILIAL, WITH SPECIFIC RENAL TUBULOPATHY	241150
HYPOKALEMIA, FAMILIAL	HYPOKALEMIC ALKALOSIS, FAMILIAL, WITH SPECIFIC RENAL TUBULOPATHY	241150
GULLNER SYNDROME	HYPOKALEMIC ALKALOSIS, FAMILIAL, WITH SPECIFIC RENAL TUBULOPATHY	241150
BARTTER SYNDROME, ANTENATAL, TYPE 2	BARTTER SYNDROME, ANTENATAL, TYPE 2	241200
HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA, ANTENATAL, 2	BARTTER SYNDROME, ANTENATAL, TYPE 2	241200
HYPERPROSTAGLANDIN E SYNDROME 2	BARTTER SYNDROME, ANTENATAL, TYPE 2	241200
HYPOMANDIBULAR FACIOCRANIAL DYSOSTOSIS	HYPOMANDIBULAR FACIOCRANIAL DYSOSTOSIS	241310
HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM SYNDROME; HRD	HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM SYNDROME; HRD	241410
HYPOPARATHYROIDISM WITH SHORT STATURE, MENTAL RETARDATION, AND SEIZURES	HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM SYNDROME; HRD	241410
SANJAD-SAKATI SYNDROME	HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM SYNDROME; HRD	241410
HYPOPARATHYROIDISM, CONGENITAL, ASSOCIATED WITH DYSMORPHISM, GROWTHRETARDATION, AND DEVELOPMENTAL DELAY	HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM SYNDROME; HRD	241410
HYPOPHOSPHATASIA, INFANTILE	HYPOPHOSPHATASIA, INFANTILE	241500
HOPS	HYPOPHOSPHATASIA, INFANTILE	241500
PHOSPHOETHANOLAMINURIAHYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED	HYPOPHOSPHATASIA, INFANTILE	241500
HYPOPHOSPHATASIA, CHILDHOOD	HYPOPHOSPHATASIA, CHILDHOOD	241510
HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 1; ARHR1	HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 1; ARHR1	241520
ARHR	HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 1; ARHR1	241520
HYPOPHOSPHATEMIA, AUTOSOMAL RECESSIVE; ARHP	HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 1; ARHR1	241520
HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCIURIA, HEREDITARY; HHRH	HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCIURIA, HEREDITARY; HHRH	241530
HYPERCALCIURIC RICKETS	HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCIURIA, HEREDITARY; HHRH	241530
HYPOPLASTIC LEFT HEART SYNDROME 1; HLHS1	HYPOPLASTIC LEFT HEART SYNDROME 1; HLHS1	241550
HLHS	HYPOPLASTIC LEFT HEART SYNDROME 1; HLHS1	241550
IMMUNODEFICIENCY 43; IMD43	IMMUNODEFICIENCY 43; IMD43	241600
BETA-2-MICROGLOBULIN DEFICIENCY	IMMUNODEFICIENCY 43; IMD43	241600
B2M DEFICIENCY	IMMUNODEFICIENCY 43; IMD43	241600
HYPOPROTEINEMIA, HYPERCATABOLIC	IMMUNODEFICIENCY 43; IMD43	241600
HYPOTHYROIDISM, THYROIDAL OR ATHYROIDAL, WITH SPIKY HAIR AND CLEFTPALATE	HYPOTHYROIDISM, THYROIDAL OR ATHYROIDAL, WITH SPIKY HAIR AND CLEFTPALATE	241850
BAMFORTH-LAZARUS SYNDROME	HYPOTHYROIDISM, THYROIDAL OR ATHYROIDAL, WITH SPIKY HAIR AND CLEFTPALATE	241850
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 2; ARCI2	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 2; ARCI2	242100
COLLODION BABY, SELF-HEALING	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 2; ARCI2	242100
ICHTHYOSIFORM ERYTHRODERMA, NONBULLOUS CONGENITAL, 1, FORMERLY; NCIE1,FORMERLY	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 2; ARCI2	242100
ICHTHYOSIFORM ERYTHRODERMA, BROCQ CONGENITAL, NONBULLOUS FORM, FORMERLY	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 2; ARCI2	242100
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1	242300
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1, WITH BATHING SUIT DISTRIBUTION	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1	242300
COLLODION BABY, SELF-HEALING; SHCB	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1	242300
ICHTHYOSIS CONGENITA	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1	242300
LAMELLAR EXFOLIATION OF NEWBORN	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1	242300
DESQUAMATION OF NEWBORN	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1	242300
COLLODION FETUS	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1	242300
ICHTHYOSIS CONGENITA II; ICR2	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1	242300
ICHTHYOSIS, LAMELLAR, 1, FORMERLY; LI1, FORMERLY	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1	242300
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4B; ARCI4B	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4B; ARCI4B	242500
ICHTHYOSIS CONGENITA, HARLEQUIN FETUS TYPE	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4B; ARCI4B	242500
HARLEQUIN ICHTHYOSIS; HI	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4B; ARCI4B	242500
'HARLEQUIN FETUS'	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4B; ARCI4B	242500
IMINOGLYCINURIA	IMINOGLYCINURIA	242600
CILIARY DYSKINESIA WITH DEFECTIVE RADIAL SPOKES	CILIARY DYSKINESIA WITH DEFECTIVE RADIAL SPOKES	242670
IMMOTILE CILIA SYNDROME DUE TO DEFECTIVE RADIAL SPOKES	CILIARY DYSKINESIA WITH DEFECTIVE RADIAL SPOKES	242670
IMMUNE DEFECT DUE TO ABSENCE OF THYMUS	IMMUNE DEFECT DUE TO ABSENCE OF THYMUS	242700
T-LYMPHOCYTE DEFICIENCY	IMMUNE DEFECT DUE TO ABSENCE OF THYMUS	242700
NEZELOF SYNDROME	IMMUNE DEFECT DUE TO ABSENCE OF THYMUS	242700
THYMIC APLASIA	IMMUNE DEFECT DUE TO ABSENCE OF THYMUS	242700
VICI SYNDROME; VICIS	VICI SYNDROME; VICIS	242840
IMMUNODEFICIENCY WITH CLEFT LIP/PALATE, CATARACT, HYPOPIGMENTATION,AND ABSENT CORPUS CALLOSUM	VICI SYNDROME; VICIS	242840
IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME1; ICF1	IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME1; ICF1	242860
IMMUNE DEFICIENCY, VARIABLE, WITH CENTROMERIC INSTABILITY OF CHROMOSOMES1, 9, AND 16	IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME1; ICF1	242860
CENTROMERIC INSTABILITY, IMMUNODEFICIENCY SYNDROME; CIID	IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME1; ICF1	242860
IMMUNODEFICIENCY SYNDROME, VARIABLE	IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME1; ICF1	242860
IMMUNOOSSEOUS DYSPLASIA, SCHIMKE TYPE	IMMUNOOSSEOUS DYSPLASIA, SCHIMKE TYPE	242900
SCHIMKE IMMUNOOSSEOUS DYSPLASIA; SIOD	IMMUNOOSSEOUS DYSPLASIA, SCHIMKE TYPE	242900
INDIFFERENCE TO PAIN, CONGENITAL, AUTOSOMAL RECESSIVE; CIP	INDIFFERENCE TO PAIN, CONGENITAL, AUTOSOMAL RECESSIVE; CIP	243000
INSENSITIVITY TO PAIN, CHANNELOPATHY-ASSOCIATED	INDIFFERENCE TO PAIN, CONGENITAL, AUTOSOMAL RECESSIVE; CIP	243000
CONGENITAL ANALGESIA, AUTOSOMAL RECESSIVE	INDIFFERENCE TO PAIN, CONGENITAL, AUTOSOMAL RECESSIVE; CIP	243000
ASYMBOLIA FOR PAINNEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IID, INCLUDED;HSAN2D, INCLUDED	INDIFFERENCE TO PAIN, CONGENITAL, AUTOSOMAL RECESSIVE; CIP	243000
SPERMATOGENIC FAILURE 5; SPGF5	SPERMATOGENIC FAILURE 5; SPGF5	243060
MALE INFERTILITY WITH LARGE-HEADED, MULTIFLAGELLAR, POLYPLOID SPERMATOZOA	SPERMATOGENIC FAILURE 5; SPGF5	243060
INFERTILITY ASSOCIATED WITH MULTI-TAILED SPERMATOZOA AND EXCESSIVEDNA	SPERMATOGENIC FAILURE 5; SPGF5	243060
GASTROINTESTINAL DEFECTS AND IMMUNODEFICIENCY SYNDROME; GIDID	GASTROINTESTINAL DEFECTS AND IMMUNODEFICIENCY SYNDROME; GIDID	243150
INTESTINAL ATRESIA, MULTIPLE AND/OR INFLAMMATORY BOWEL DISEASE WITHOR WITHOUT IMMUNODEFICIENCY	GASTROINTESTINAL DEFECTS AND IMMUNODEFICIENCY SYNDROME; GIDID	243150
INTESTINAL ATRESIA, MULTIPLE; MINAT	GASTROINTESTINAL DEFECTS AND IMMUNODEFICIENCY SYNDROME; GIDID	243150
FAMILIAL INTESTINAL POLYATRESIA SYNDROME; FIPA	GASTROINTESTINAL DEFECTS AND IMMUNODEFICIENCY SYNDROME; GIDID	243150
VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL RECESSIVE	VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL RECESSIVE	243180
INTESTINAL PSEUDOOBSTRUCTION DUE TO NEURONAL DISEASE	VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL RECESSIVE	243180
ARGYROPHIL MYENTERIC PLEXUS, DEFICIENCY OF	VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL RECESSIVE	243180
PSEUDOOBSTRUCTION, CHRONIC IDIOPATHIC INTESTINAL, NEURONAL TYPENEURONAL INTESTINAL DYSPLASIA, TYPE A, INCLUDED	VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL RECESSIVE	243180
NID A, INCLUDED	VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL RECESSIVE	243180
CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 1; BRIC1	CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 1; BRIC1	243300
SUMMERSKILL SYNDROME	CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 1; BRIC1	243300
BARAITSER-WINTER SYNDROME 1; BRWS1	BARAITSER-WINTER SYNDROME 1; BRWS1	243310
IRIS COLOBOMA WITH PTOSIS, HYPERTELORISM, AND MENTAL RETARDATION	BARAITSER-WINTER SYNDROME 1; BRWS1	243310
FRYNS-AFTIMOS SYNDROME	BARAITSER-WINTER SYNDROME 1; BRWS1	243310
PACHYGYRIA, MENTAL RETARDATION, EPILEPSY, AND CHARACTERISTIC FACIES	BARAITSER-WINTER SYNDROME 1; BRWS1	243310
CEREBROOCULOFACIAL LYMPHATIC SYNDROME; COFLS	BARAITSER-WINTER SYNDROME 1; BRWS1	243310
MENTAL RETARDATION WITH EPILEPSY AND CHARACTERISTIC FACIES	BARAITSER-WINTER SYNDROME 1; BRWS1	243310
CEREBROFRONTOFACIAL SYNDROME	BARAITSER-WINTER SYNDROME 1; BRWS1	243310
ACETYLATION, SLOW	ACETYLATION, SLOW	243400
SLOW ACETYLATOR PHENOTYPE	ACETYLATION, SLOW	243400
ISONIAZID INACTIVATION, SLOW	ACETYLATION, SLOW	243400
INH INACTIVATION, SLOWACETYLATION, FAST, INCLUDED	ACETYLATION, SLOW	243400
FAST ACETYLATOR PHENOTYPE, INCLUDED	ACETYLATION, SLOW	243400
INH INACTIVATION, FAST, INCLUDED	ACETYLATION, SLOW	243400
ISOVALERIC ACIDEMIA; IVA	ISOVALERIC ACIDEMIA; IVA	243500
ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY	ISOVALERIC ACIDEMIA; IVA	243500
IVD DEFICIENCY	ISOVALERIC ACIDEMIA; IVA	243500
JEJUNAL ATRESIA	JEJUNAL ATRESIA	243600
APPLE PEEL SYNDROME	JEJUNAL ATRESIA	243600
APPLE PEEL SMALL BOWEL SYNDROME; APSB	JEJUNAL ATRESIA	243600
HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL RECESSIVE	HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL RECESSIVE	243700
HYPER-IgE SYNDROME, AUTOSOMAL RECESSIVE	HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL RECESSIVE	243700
HIES, AUTOSOMAL RECESSIVE	HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL RECESSIVE	243700
JOHANSON-BLIZZARD SYNDROME; JBS	JOHANSON-BLIZZARD SYNDROME; JBS	243800
NASAL ALAR HYPOPLASIA, HYPOTHYROIDISM, PANCREATIC ACHYLIA, AND CONGENITALDEAFNESS	JOHANSON-BLIZZARD SYNDROME; JBS	243800
ARIMA SYNDROME	ARIMA SYNDROME	243910
DEKABAN-ARIMA SYNDROME	ARIMA SYNDROME	243910
JOUBERT SYNDROME WITH BILATERAL CHORIORETINAL COLOBOMA	ARIMA SYNDROME	243910
COLOBOMA, CHORIORETINAL, WITH CEREBELLAR VERMIS APLASIA	ARIMA SYNDROME	243910
CEREBROOCULOHEPATORENAL SYNDROME	ARIMA SYNDROME	243910
HYPOGONADOTROPIC HYPOGONADISM 3 WITH OR WITHOUT ANOSMIA; HH3	HYPOGONADOTROPIC HYPOGONADISM 3 WITH OR WITHOUT ANOSMIA; HH3	244200
KAPUR-TORIELLO SYNDROME	KAPUR-TORIELLO SYNDROME	244300
LONG COLUMELLA WITH CLEFT LIP/PALATE AND EYE, HEART, AND INTESTINALANOMALIES	KAPUR-TORIELLO SYNDROME	244300
CILIARY DYSKINESIA, PRIMARY, 1; CILD1	CILIARY DYSKINESIA, PRIMARY, 1; CILD1	244400
PCD	CILIARY DYSKINESIA, PRIMARY, 1; CILD1	244400
CILIARY DYSKINESIA, PRIMARY, 1, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 1; CILD1	244400
IMMOTILE CILIA SYNDROME; ICS	CILIARY DYSKINESIA, PRIMARY, 1; CILD1	244400
POLYNESIAN BRONCHIECTASISKARTAGENER SYNDROME, INCLUDED	CILIARY DYSKINESIA, PRIMARY, 1; CILD1	244400
DEXTROCARDIA, BRONCHIECTASIS, AND SINUSITIS, INCLUDED	CILIARY DYSKINESIA, PRIMARY, 1; CILD1	244400
SIEWERT SYNDROME, INCLUDED	CILIARY DYSKINESIA, PRIMARY, 1; CILD1	244400
KAUFMAN OCULOCEREBROFACIAL SYNDROME; KOS	KAUFMAN OCULOCEREBROFACIAL SYNDROME; KOS	244450
BLEPHAROPHIMOSIS-PTOSIS-INTELLECTUAL DISABILITY SYNDROME; BPIDS	KAUFMAN OCULOCEREBROFACIAL SYNDROME; KOS	244450
KENNY-CAFFEY SYNDROME, TYPE 1; KCS1	KENNY-CAFFEY SYNDROME, TYPE 1; KCS1	244460
KCS	KENNY-CAFFEY SYNDROME, TYPE 1; KCS1	244460
KENNY-CAFFEY SYNDROME, AUTOSOMAL RECESSIVE	KENNY-CAFFEY SYNDROME, TYPE 1; KCS1	244460
PAPILLON-LEFEVRE SYNDROME; PALS	PAPILLON-LEFEVRE SYNDROME; PALS	245000
PLS	PAPILLON-LEFEVRE SYNDROME; PALS	245000
KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA	PAPILLON-LEFEVRE SYNDROME; PALS	245000
HAIM-MUNK SYNDROME; HMS	HAIM-MUNK SYNDROME; HMS	245010
KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS	HAIM-MUNK SYNDROME; HMS	245010
COCHIN JEWISH DISORDER	HAIM-MUNK SYNDROME; HMS	245010
SUCCINYL-CoA:3-OXOACID-CoA TRANSFERASE DEFICIENCY; SCOTD	SUCCINYL-CoA:3-OXOACID-CoA TRANSFERASE DEFICIENCY; SCOTD	245050
SCOT DEFICIENCY	SUCCINYL-CoA:3-OXOACID-CoA TRANSFERASE DEFICIENCY; SCOTD	245050
SUCCINYL-CoA:3-KETOACID CoA-TRANSFERASE DEFICIENCY	SUCCINYL-CoA:3-OXOACID-CoA TRANSFERASE DEFICIENCY; SCOTD	245050
SUCCINYL-CoA:ACETOACETATE TRANSFERASE DEFICIENCY	SUCCINYL-CoA:3-OXOACID-CoA TRANSFERASE DEFICIENCY; SCOTD	245050
KETOACIDOSIS DUE TO SCOT DEFICIENCY	SUCCINYL-CoA:3-OXOACID-CoA TRANSFERASE DEFICIENCY; SCOTD	245050
RICHARDS-RUNDLE SYNDROME; RRNS	RICHARDS-RUNDLE SYNDROME; RRNS	245100
ATAXIA-DEAFNESS-MENTAL RETARDATION SYNDROME	RICHARDS-RUNDLE SYNDROME; RRNS	245100
KEUTEL SYNDROME; KTLS	KEUTEL SYNDROME; KTLS	245150
PULMONIC STENOSIS, BRACHYTELEPHALANGISM, AND CALCIFICATION OF CARTILAGES	KEUTEL SYNDROME; KTLS	245150
KRABBE DISEASE	KRABBE DISEASE	245200
GLOBOID CELL LEUKODYSTROPHY; GLD; GCL	KRABBE DISEASE	245200
GLOBOID CELL LEUKOENCEPHALOPATHY	KRABBE DISEASE	245200
GALACTOSYLCERAMIDE BETA-GALACTOSIDASE DEFICIENCY	KRABBE DISEASE	245200
GALACTOCEREBROSIDASE DEFICIENCY	KRABBE DISEASE	245200
GALC DEFICIENCY	KRABBE DISEASE	245200
KURU, SUSCEPTIBILITY TO	KURU, SUSCEPTIBILITY TO	245300
ERYTHROCYTE LACTATE TRANSPORTER DEFECT	ERYTHROCYTE LACTATE TRANSPORTER DEFECT	245340
LACTATE TRANSPORTER DEFECT, MYOPATHY DUE TO	ERYTHROCYTE LACTATE TRANSPORTER DEFECT	245340
PYRUVATE DEHYDROGENASE E2 DEFICIENCY; PDHDD	PYRUVATE DEHYDROGENASE E2 DEFICIENCY; PDHDD	245348
LACTIC ACIDEMIA DUE TO DEFECT OF E2 LIPOYL TRANSACETYLASE OF THE PYRUVATEDEHYDROGENASE COMPLEX	PYRUVATE DEHYDROGENASE E2 DEFICIENCY; PDHDD	245348
PYRUVATE DEHYDROGENASE E3-BINDING PROTEIN DEFICIENCY; PDHXD	PYRUVATE DEHYDROGENASE E3-BINDING PROTEIN DEFICIENCY; PDHXD	245349
LACTIC ACIDEMIA DUE TO DEFECT IN LIPOYL-CONTAINING COMPONENT X OFTHE PYRUVATE DEHYDROGENASE COMPLEX	PYRUVATE DEHYDROGENASE E3-BINDING PROTEIN DEFICIENCY; PDHXD	245349
MITOCHONDRIAL DNA DEPLETION SYNDROME 9 (ENCEPHALOMYOPATHIC TYPE WITHMETHYLMALONIC ACIDURIA); MTDPS9	MITOCHONDRIAL DNA DEPLETION SYNDROME 9 (ENCEPHALOMYOPATHIC TYPE WITHMETHYLMALONIC ACIDURIA); MTDPS9	245400
LACTIC ACIDOSIS, FATAL INFANTILE, FORMERLY	MITOCHONDRIAL DNA DEPLETION SYNDROME 9 (ENCEPHALOMYOPATHIC TYPE WITHMETHYLMALONIC ACIDURIA); MTDPS9	245400
SPECIFIC GRANULE DEFICIENCY; SGD	SPECIFIC GRANULE DEFICIENCY; SGD	245480
LACTOFERRIN-DEFICIENT NEUTROPHILS	SPECIFIC GRANULE DEFICIENCY; SGD	245480
NEUTROPHIL LACTOFERRIN DEFICIENCY	SPECIFIC GRANULE DEFICIENCY; SGD	245480
EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION;FESD	EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION;FESD	245570
APHASIA, ACQUIRED, WITH EPILEPSYLANDAU-KLEFFNER SYNDROME, INCLUDED; LKS, INCLUDED	EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION;FESD	245570
CONTINUOUS SPIKE AND WAVES DURING SLOW-WAVE SLEEP SYNDROME, INCLUDED;CSWS, INCLUDED; CSWSS, INCLUDED	EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION;FESD	245570
ROLANDIC EPILEPSY, MENTAL RETARDATION, AND SPEECH DYSPRAXIA, AUTOSOMALDOMINANT, INCLUDED; RESDAD, INCLUDED; ADRESD, INCLUDED	EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION;FESD	245570
BENIGN EPILEPSY OF CHILDHOOD WITH CENTROTEMPORAL SPIKES, INCLUDED;BECTS, INCLUDED	EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION;FESD	245570
GROWTH HORMONE INSENSITIVITY WITH IMMUNODEFICIENCY	GROWTH HORMONE INSENSITIVITY WITH IMMUNODEFICIENCY	245590
LARON SYNDROME DUE TO POSTRECEPTOR DEFECT	GROWTH HORMONE INSENSITIVITY WITH IMMUNODEFICIENCY	245590
GROWTH HORMONE INSENSITIVITY DUE TO POSTRECEPTOR DEFECT	GROWTH HORMONE INSENSITIVITY WITH IMMUNODEFICIENCY	245590
MULTIPLE JOINT DISLOCATIONS, SHORT STATURE, CRANIOFACIAL DYSMORPHISM,AND CONGENITAL HEART DEFECTS	MULTIPLE JOINT DISLOCATIONS, SHORT STATURE, CRANIOFACIAL DYSMORPHISM,AND CONGENITAL HEART DEFECTS	245600
LARSEN SYNDROME, AUTOSOMAL RECESSIVE, FORMERLY	MULTIPLE JOINT DISLOCATIONS, SHORT STATURE, CRANIOFACIAL DYSMORPHISM,AND CONGENITAL HEART DEFECTS	245600
LARYNGOONYCHOCUTANEOUS SYNDROME; LOCS	LARYNGOONYCHOCUTANEOUS SYNDROME; LOCS	245660
LOGIC SYNDROME	LARYNGOONYCHOCUTANEOUS SYNDROME; LOCS	245660
LAURENCE-MOON SYNDROME; LNMS	LAURENCE-MOON SYNDROME; LNMS	245800
LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY	LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY	245900
LCAT DEFICIENCY	LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY	245900
NORUM DISEASE	LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY	245900
LEG, ABSENCE DEFORMITY OF, WITH CONGENITAL CATARACT	LEG, ABSENCE DEFORMITY OF, WITH CONGENITAL CATARACT	246000
DONOHUE SYNDROME	DONOHUE SYNDROME	246200
LEPRECHAUNISMINSULIN RECEPTOR, DEFECT IN, INCLUDED	DONOHUE SYNDROME	246200
LEPROSY, SUSCEPTIBILITY TO, 3; LPRS3	LEPROSY, SUSCEPTIBILITY TO, 3; LPRS3	246300
LETTERER-SIWE DISEASE	LETTERER-SIWE DISEASE	246400
L-S DISEASE; LESD	LETTERER-SIWE DISEASE	246400
HISTIOCYTOSIS X, ACUTE DISSEMINATED	LETTERER-SIWE DISEASE	246400
3-@HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD	3-@HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD	246450
HMG-CoA LYASE DEFICIENCY	3-@HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD	246450
HMGCL DEFICIENCY	3-@HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD	246450
HL DEFICIENCY	3-@HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD	246450
HYDROXYMETHYLGLUTARIC ACIDURIA	3-@HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD	246450
SPLIT-HAND/FOOT MALFORMATION 3; SHFM3	SPLIT-HAND/FOOT MALFORMATION 3; SHFM3	246560
SHSF3	SPLIT-HAND/FOOT MALFORMATION 3; SHFM3	246560
LIMB DEFICIENCIES, DISTAL, WITH MICROGNATHIA	SPLIT-HAND/FOOT MALFORMATION 3; SHFM3	246560
CHROMOSOME 10q24 DUPLICATION SYNDROME	SPLIT-HAND/FOOT MALFORMATION 3; SHFM3	246560
LIPASE DEFICIENCY, COMBINED	LIPASE DEFICIENCY, COMBINED	246650
LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY	LIPASE DEFICIENCY, COMBINED	246650
LPL AND HTGL DEFICIENCY	LIPASE DEFICIENCY, COMBINED	246650
LPL AND HL DEFICIENCY	LIPASE DEFICIENCY, COMBINED	246650
CHYLOMICRON RETENTION DISEASE; CMRD	CHYLOMICRON RETENTION DISEASE; CMRD	246700
ANDERSON DISEASE; ANDD	CHYLOMICRON RETENTION DISEASE; CMRD	246700
LIPID TRANSPORT DEFECT OF INTESTINE	CHYLOMICRON RETENTION DISEASE; CMRD	246700
HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKEPROTEIN IN INTESTINAL CELLS	CHYLOMICRON RETENTION DISEASE; CMRD	246700
DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD	DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD	246900
DLD DEFICIENCY	DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD	246900
E3 DEFICIENCY	DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD	246900
LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO	DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD	246900
MAPLE SYRUP URINE DISEASE, TYPE III	DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD	246900
LIPOID PROTEINOSIS OF URBACH AND WIETHE	LIPOID PROTEINOSIS OF URBACH AND WIETHE	247100
LIPOID PROTEINOSIS	LIPOID PROTEINOSIS OF URBACH AND WIETHE	247100
URBACH-WIETHE DISEASE	LIPOID PROTEINOSIS OF URBACH AND WIETHE	247100
HYALINOSIS CUTIS ET MUCOSAE	LIPOID PROTEINOSIS OF URBACH AND WIETHE	247100
MILLER-DIEKER LISSENCEPHALY SYNDROME; MDLS	MILLER-DIEKER LISSENCEPHALY SYNDROME; MDLS	247200
MDSCHROMOSOME 17p13.3 DELETION SYNDROME, INCLUDED	MILLER-DIEKER LISSENCEPHALY SYNDROME; MDLS	247200
MILLER-DIEKER SYNDROME CHROMOSOME REGION, INCLUDED; MDCR, INCLUDED	MILLER-DIEKER LISSENCEPHALY SYNDROME; MDLS	247200
LUTHERAN NULL	LUTHERAN NULL	247420
RECESSIVE LU (a-b-) PHENOTYPE	LUTHERAN NULL	247420
LYMPHOPENIC HYPERGAMMAGLOBULINEMIA, ANTIBODY DEFICIENCY, AUTOIMMUNEHEMOLYTIC ANEMIA, AND GLOMERULONEPHRITIS	LYMPHOPENIC HYPERGAMMAGLOBULINEMIA, ANTIBODY DEFICIENCY, AUTOIMMUNEHEMOLYTIC ANEMIA, AND GLOMERULONEPHRITIS	247800
MACROCEPHALY/MEGALENCEPHALY SYNDROME, AUTOSOMAL RECESSIVE; MGCPH	MACROCEPHALY/MEGALENCEPHALY SYNDROME, AUTOSOMAL RECESSIVE; MGCPH	248000
HYPOMAGNESEMIA 5, RENAL, WITH OCULAR INVOLVEMENT; HOMG5	HYPOMAGNESEMIA 5, RENAL, WITH OCULAR INVOLVEMENT; HOMG5	248190
HYPOMAGNESEMIA, RENAL, WITH OCULAR INVOLVEMENT	HYPOMAGNESEMIA 5, RENAL, WITH OCULAR INVOLVEMENT; HOMG5	248190
HYPOMAGNESEMIA, FAMILIAL, WITH HYPERCALCIURIA, NEPHROCALCINOSIS, ANDSEVERE OCULAR INVOLVEMENT	HYPOMAGNESEMIA 5, RENAL, WITH OCULAR INVOLVEMENT; HOMG5	248190
FHHNC WITH SEVERE OCULAR INVOLVEMENT	HYPOMAGNESEMIA 5, RENAL, WITH OCULAR INVOLVEMENT; HOMG5	248190
MACULAR COLOBOMA, BILATERAL, WITH HYPERCALCIURIA	HYPOMAGNESEMIA 5, RENAL, WITH OCULAR INVOLVEMENT; HOMG5	248190
STARGARDT DISEASE 1; STGD1	STARGARDT DISEASE 1; STGD1	248200
STGD	STARGARDT DISEASE 1; STGD1	248200
MACULAR DEGENERATION, JUVENILE	STARGARDT DISEASE 1; STGD1	248200
MACULAR DYSTROPHY WITH FLECKS, TYPE 1FUNDUS FLAVIMACULATUS, INCLUDED; FFM, INCLUDED	STARGARDT DISEASE 1; STGD1	248200
RETINAL DYSTROPHY, EARLY-ONSET SEVERE, INCLUDED	STARGARDT DISEASE 1; STGD1	248200
HYPOMAGNESEMIA 3, RENAL; HOMG3	HYPOMAGNESEMIA 3, RENAL; HOMG3	248250
HYPOMAGNESEMIA, PRIMARY, DUE TO DEFECT IN RENAL TUBULAR TRANSPORTOF MAGNESIUM	HYPOMAGNESEMIA 3, RENAL; HOMG3	248250
HYPOMAGNESEMIA, ISOLATED RENAL	HYPOMAGNESEMIA 3, RENAL; HOMG3	248250
HYPOMAGNESEMIA, FAMILIAL, WITH HYPERCALCIURIA AND NEPHROCALCINOSISHYPERCALCIURIA, CHILDHOOD, SELF-LIMITING, INCLUDED	HYPOMAGNESEMIA 3, RENAL; HOMG3	248250
MAL DE MELEDA; MDM	MAL DE MELEDA; MDM	248300
MELEDA DISEASE	MAL DE MELEDA; MDM	248300
KERATOSIS PALMOPLANTARIS TRANSGREDIENS OF SIEMENS	MAL DE MELEDA; MDM	248300
PLASMODIUM FALCIPARUM BLOOD INFECTION LEVEL	PLASMODIUM FALCIPARUM BLOOD INFECTION LEVEL	248310
PFBI	PLASMODIUM FALCIPARUM BLOOD INFECTION LEVEL	248310
PLASMODIUM FALCIPARUM PARASITEMIA	PLASMODIUM FALCIPARUM BLOOD INFECTION LEVEL	248310
MALONYL-CoA DECARBOXYLASE DEFICIENCY	MALONYL-CoA DECARBOXYLASE DEFICIENCY	248360
MANDIBULOACRAL DYSPLASIA WITH TYPE A LIPODYSTROPHY; MADA	MANDIBULOACRAL DYSPLASIA WITH TYPE A LIPODYSTROPHY; MADA	248370
LIPODYSTROPHY, TYPE A, ASSOCIATED WITH MANDIBULOACRAL DYSPLASIA	MANDIBULOACRAL DYSPLASIA WITH TYPE A LIPODYSTROPHY; MADA	248370
CRANIOMANDIBULAR DERMATODYSOSTOSISMANDIBULOACRAL DYSPLASIA WITH TYPE A LIPODYSTROPHY, ATYPICAL, INCLUDED	MANDIBULOACRAL DYSPLASIA WITH TYPE A LIPODYSTROPHY; MADA	248370
TREACHER COLLINS SYNDROME 3; TCS3	TREACHER COLLINS SYNDROME 3; TCS3	248390
MANDIBULOFACIAL DYSOSTOSIS, TREACHER COLLINS TYPE, AUTOSOMAL RECESSIVE	TREACHER COLLINS SYNDROME 3; TCS3	248390
MANITOBA OCULOTRICHOANAL SYNDROME; MOTA	MANITOBA OCULOTRICHOANAL SYNDROME; MOTA	248450
MARLES SYNDROME	MANITOBA OCULOTRICHOANAL SYNDROME; MOTA	248450
MANNOSIDOSIS, ALPHA B, LYSOSOMAL; MANSA	MANNOSIDOSIS, ALPHA B, LYSOSOMAL; MANSA	248500
ALPHA-MANNOSIDOSIS	MANNOSIDOSIS, ALPHA B, LYSOSOMAL; MANSA	248500
LYSOSOMAL ALPHA-D-MANNOSIDASE DEFICIENCY	MANNOSIDOSIS, ALPHA B, LYSOSOMAL; MANSA	248500
ALPHA-MANNOSIDASE B DEFICIENCY	MANNOSIDOSIS, ALPHA B, LYSOSOMAL; MANSA	248500
MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB	MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB	248510
BETA-MANNOSIDOSIS	MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB	248510
LYSOSOMAL BETA-MANNOSIDASE DEFICIENCY	MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB	248510
BETA-MANNOSIDASE DEFICIENCY	MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB	248510
MAPLE SYRUP URINE DISEASE; MSUD	MAPLE SYRUP URINE DISEASE; MSUD	248600
BRANCHED-CHAIN KETOACIDURIA	MAPLE SYRUP URINE DISEASE; MSUD	248600
BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY	MAPLE SYRUP URINE DISEASE; MSUD	248600
BCKD DEFICIENCY	MAPLE SYRUP URINE DISEASE; MSUD	248600
KETO ACID DECARBOXYLASE DEFICIENCYMAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED	MAPLE SYRUP URINE DISEASE; MSUD	248600
MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED	MAPLE SYRUP URINE DISEASE; MSUD	248600
MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED	MAPLE SYRUP URINE DISEASE; MSUD	248600
MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED	MAPLE SYRUP URINE DISEASE; MSUD	248600
MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED	MAPLE SYRUP URINE DISEASE; MSUD	248600
MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED	MAPLE SYRUP URINE DISEASE; MSUD	248600
MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED	MAPLE SYRUP URINE DISEASE; MSUD	248600
MARDEN-WALKER SYNDROME; MWKS	MARDEN-WALKER SYNDROME; MWKS	248700
MWS	MARDEN-WALKER SYNDROME; MWKS	248700
MARINESCO-SJOGREN SYNDROME; MSS	MARINESCO-SJOGREN SYNDROME; MSS	248800
MAST SYNDROME	MAST SYNDROME	248900
SPASTIC PARAPLEGIA 21, AUTOSOMAL RECESSIVE; SPG21	MAST SYNDROME	248900
MECKEL SYNDROME, TYPE 1; MKS1	MECKEL SYNDROME, TYPE 1; MKS1	249000
MECKEL-GRUBER SYNDROME, TYPE 1	MECKEL SYNDROME, TYPE 1; MKS1	249000
MECKEL SYNDROME; MKS	MECKEL SYNDROME, TYPE 1; MKS1	249000
MES	MECKEL SYNDROME, TYPE 1; MKS1	249000
DYSENCEPHALIA SPLANCHNOCYSTICA	MECKEL SYNDROME, TYPE 1; MKS1	249000
GRUBER SYNDROME	MECKEL SYNDROME, TYPE 1; MKS1	249000
MECKEL-GRUBER SYNDROME	MECKEL SYNDROME, TYPE 1; MKS1	249000
FAMILIAL MEDITERRANEAN FEVER; FMF	FAMILIAL MEDITERRANEAN FEVER; FMF	249100
FAMILIAL MEDITERRANEAN FEVER, AUTOSOMAL RECESSIVE	FAMILIAL MEDITERRANEAN FEVER; FMF	249100
POLYSEROSITIS, RECURRENT	FAMILIAL MEDITERRANEAN FEVER; FMF	249100
POLYSEROSITIS, FAMILIAL PAROXYSMAL	FAMILIAL MEDITERRANEAN FEVER; FMF	249100
THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME; TRMA	THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME; TRMA	249270
THIAMINE METABOLISM DYSFUNCTION SYNDROME 1 (MEGALOBLASTIC ANEMIA,DIABETES MELLITUS, AND DEAFNESS TYPE); THMD1	THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME; TRMA	249270
MEGALOBLASTIC ANEMIA, THIAMINE-RESPONSIVE, WITH DIABETES MELLITUSAND SENSORINEURAL DEAFNESS	THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME; TRMA	249270
ROGERS SYNDROME	THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME; TRMA	249270
THIAMINE-RESPONSIVE ANEMIA SYNDROME	THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME; TRMA	249270
THIAMINE-RESPONSIVE MYELODYSPLASIA	THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME; TRMA	249270
MEGALOCORNEA-MENTAL RETARDATION SYNDROME	MEGALOCORNEA-MENTAL RETARDATION SYNDROME	249310
MMR SYNDROME	MEGALOCORNEA-MENTAL RETARDATION SYNDROME	249310
NEUHAUSER SYNDROME	MEGALOCORNEA-MENTAL RETARDATION SYNDROME	249310
MELANOSIS, NEUROCUTANEOUS; NCMS	MELANOSIS, NEUROCUTANEOUS; NCMS	249400
NEUROMELANOSIS	MELANOSIS, NEUROCUTANEOUS; NCMS	249400
FRANK-TER HAAR SYNDROME; FTHS	FRANK-TER HAAR SYNDROME; FTHS	249420
TER HAAR SYNDROME	FRANK-TER HAAR SYNDROME; FTHS	249420
BORRONE DERMATOCARDIOSKELETAL SYNDROME	FRANK-TER HAAR SYNDROME; FTHS	249420
MELNICK-NEEDLES SYNDROME, AUTOSOMAL RECESSIVE, FORMERLY	FRANK-TER HAAR SYNDROME; FTHS	249420
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 1; MRT1	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 1; MRT1	249500
OHDO SYNDROME	OHDO SYNDROME	249620
OHDO BLEPHAROPHIMOSIS SYNDROME	OHDO SYNDROME	249620
MENTAL RETARDATION, CONGENITAL HEART DISEASE, BLEPHAROPHIMOSIS, BLEPHAROPTOSIS,AND HYPOPLASTIC TEETH	OHDO SYNDROME	249620
MERCAPTOLACTATE-CYSTEINE DISULFIDURIA; MCDU	MERCAPTOLACTATE-CYSTEINE DISULFIDURIA; MCDU	249650
DISULFIDURIA, MIXED	MERCAPTOLACTATE-CYSTEINE DISULFIDURIA; MCDU	249650
LANGER MESOMELIC DYSPLASIA; LMD	LANGER MESOMELIC DYSPLASIA; LMD	249700
DYSCHONDROSTEOSIS, HOMOZYGOUS	LANGER MESOMELIC DYSPLASIA; LMD	249700
MESOMELIC DWARFISM OF THE HYPOPLASTIC ULNA, FIBULA, AND MANDIBLE TYPE	LANGER MESOMELIC DYSPLASIA; LMD	249700
METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY	METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY	249900
METACHROMATIC LEUKODYSTROPHY DUE TO CEREBROSIDE SULFATASE ACTIVATORDEFICIENCY	METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY	249900
SAPOSIN B DEFICIENCY	METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY	249900
METACHROMATIC LEUKODYSTROPHY	METACHROMATIC LEUKODYSTROPHY	250100
MLD	METACHROMATIC LEUKODYSTROPHY	250100
METACHROMATIC LEUKOENCEPHALOPATHY	METACHROMATIC LEUKODYSTROPHY	250100
CEREBRAL SCLEROSIS, DIFFUSE, METACHROMATIC FORM	METACHROMATIC LEUKODYSTROPHY	250100
SULFATIDE LIPIDOSIS	METACHROMATIC LEUKODYSTROPHY	250100
ARYLSULFATASE A DEFICIENCY	METACHROMATIC LEUKODYSTROPHY	250100
ARSA DEFICIENCY	METACHROMATIC LEUKODYSTROPHY	250100
CEREBROSIDE SULFATASE DEFICIENCYPSEUDOARYLSULFATASE A DEFICIENCY, INCLUDED	METACHROMATIC LEUKODYSTROPHY	250100
METACHROMATIC LEUKODYSTROPHY, LATE INFANTILE, INCLUDED	METACHROMATIC LEUKODYSTROPHY	250100
METACHROMATIC LEUKODYSTROPHY, JUVENILE, INCLUDED	METACHROMATIC LEUKODYSTROPHY	250100
METACHROMATIC LEUKODYSTROPHY, ADULT, INCLUDED	METACHROMATIC LEUKODYSTROPHY	250100
METAPHYSEAL ACROSCYPHODYSPLASIA	METAPHYSEAL ACROSCYPHODYSPLASIA	250215
WEDGE-SHAPED EPIPHYSES OF KNEES	METAPHYSEAL ACROSCYPHODYSPLASIA	250215
CUPPED METAPHYSES AND CONE-SHAPED EPIPHYSES OF KNEES WITH BRACHYDACTYLY	METAPHYSEAL ACROSCYPHODYSPLASIA	250215
SPONDYLOMETAPHYSEAL DYSPLASIA, SEDAGHATIAN TYPE; SMDS	SPONDYLOMETAPHYSEAL DYSPLASIA, SEDAGHATIAN TYPE; SMDS	250220
SEDAGHATIAN CHONDRODYSPLASIA	SPONDYLOMETAPHYSEAL DYSPLASIA, SEDAGHATIAN TYPE; SMDS	250220
METAPHYSEAL CHONDRODYSPLASIA, CONGENITAL LETHAL	SPONDYLOMETAPHYSEAL DYSPLASIA, SEDAGHATIAN TYPE; SMDS	250220
CARTILAGE-HAIR HYPOPLASIA; CHH	CARTILAGE-HAIR HYPOPLASIA; CHH	250250
METAPHYSEAL CHONDRODYSPLASIA, MCKUSICK TYPE	CARTILAGE-HAIR HYPOPLASIA; CHH	250250
METAPHYSEAL DYSPLASIA, SPAHR TYPE; MDST	METAPHYSEAL DYSPLASIA, SPAHR TYPE; MDST	250400
METAPHYSEAL CHONDRODYSPLASIA, SPAHR TYPE	METAPHYSEAL DYSPLASIA, SPAHR TYPE; MDST	250400
METAPHYSEAL DYSPLASIA WITHOUT HYPOTRICHOSIS	METAPHYSEAL DYSPLASIA WITHOUT HYPOTRICHOSIS	250460
CARTILAGE-HAIR HYPOPLASIA-LIKE SKELETAL DYSPLASIA WITHOUT HYPOTRICHOSISOR IMMUNODEFICIENCY	METAPHYSEAL DYSPLASIA WITHOUT HYPOTRICHOSIS	250460
CARTILAGE-HAIR HYPOPLASIA VARIANT, SKELETAL MANIFESTATIONS ONLY; CHHV	METAPHYSEAL DYSPLASIA WITHOUT HYPOTRICHOSIS	250460
3-@HYDROXYISOBUTYRYL-CoA HYDROLASE DEFICIENCY; HIBCHD	3-@HYDROXYISOBUTYRYL-CoA HYDROLASE DEFICIENCY; HIBCHD	250620
BETA-HYDROXYISOBUTYRYL CoA DEACYLASE DEFICIENCY	3-@HYDROXYISOBUTYRYL-CoA HYDROLASE DEFICIENCY; HIBCHD	250620
HIBCH DEFICIENCY	3-@HYDROXYISOBUTYRYL-CoA HYDROLASE DEFICIENCY; HIBCHD	250620
METHACRYLIC ACIDURIA	3-@HYDROXYISOBUTYRYL-CoA HYDROLASE DEFICIENCY; HIBCHD	250620
METHACRYLIC ACID TOXICITY	3-@HYDROXYISOBUTYRYL-CoA HYDROLASE DEFICIENCY; HIBCHD	250620
VALINE METABOLIC DEFECT	3-@HYDROXYISOBUTYRYL-CoA HYDROLASE DEFICIENCY; HIBCHD	250620
METHEMOGLOBINEMIA TYPE IV	METHEMOGLOBINEMIA TYPE IV	250790
METHEMOGLOBINEMIA DUE TO DEFICIENCY OF CYTOCHROME b5	METHEMOGLOBINEMIA TYPE IV	250790
METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE	METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE	250800
NADH-DEPENDENT METHEMOGLOBIN REDUCTASE DEFICIENCY	METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE	250800
NADH-CYTOCHROME b5 REDUCTASE DEFICIENCY	METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE	250800
METHEMOGLOBINEMIA, CONGENITAL, AUTOSOMAL RECESSIVEMETHEMOGLOBINEMIA, TYPE I, INCLUDED	METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE	250800
METHEMOGLOBINEMIA, TYPE II, INCLUDED	METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE	250800
NADH-CYTOCHROME b5 REDUCTASE DEFICIENCY, TYPE I, INCLUDED	METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE	250800
NADH-CYTOCHROME b5 REDUCTASE DEFICIENCY, TYPE II, INCLUDED	METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE	250800
METHIONINE ADENOSYLTRANSFERASE DEFICIENCY	METHIONINE ADENOSYLTRANSFERASE DEFICIENCY	250850
MAT DEFICIENCY	METHIONINE ADENOSYLTRANSFERASE DEFICIENCY	250850
MAT I/III DEFICIENCY	METHIONINE ADENOSYLTRANSFERASE DEFICIENCY	250850
HYPERMETHIONINEMIA, ISOLATED PERSISTENT	METHIONINE ADENOSYLTRANSFERASE DEFICIENCY	250850
METHIONINE MALABSORPTION SYNDROME	METHIONINE MALABSORPTION SYNDROME	250900
SMITH-STRANG DISEASE	METHIONINE MALABSORPTION SYNDROME	250900
OASTHOUSE URINE DISEASE	METHIONINE MALABSORPTION SYNDROME	250900
HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG	250940
HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM,cblG COMPLEMENTATION TYPE	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG	250940
METHYLCOBALAMIN DEFICIENCY, cblG TYPE	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG	250940
METHIONINE SYNTHASE DEFICIENCY	HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG	250940
3-@METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1	3-@METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1	250950
MGA, TYPE I; MGA1	3-@METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1	250950
3-@METHYLGLUTACONYL-CoA HYDRATASE DEFICIENCY	3-@METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1	250950
3-@MG-CoA-HYDRATASE DEFICIENCY	3-@METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1	250950
METHYLMALONIC ACIDURIA DUE TO METHYLMALONYL-CoA MUTASE DEFICIENCY	METHYLMALONIC ACIDURIA DUE TO METHYLMALONYL-CoA MUTASE DEFICIENCY	251000
METHYLMALONIC ACIDEMIA DUE TO METHYLMALONYL-CoA MUTASE DEFICIENCYMMA DUE TO MCM DEFICIENCY	METHYLMALONIC ACIDURIA DUE TO METHYLMALONYL-CoA MUTASE DEFICIENCY	251000
METHYLMALONIC ACIDURIA, mut TYPEMETHYLMALONIC ACIDURIA, mut(0) TYPE, INCLUDED	METHYLMALONIC ACIDURIA DUE TO METHYLMALONYL-CoA MUTASE DEFICIENCY	251000
METHYLMALONIC ACIDURIA, mut(-) TYPE, INCLUDED	METHYLMALONIC ACIDURIA DUE TO METHYLMALONYL-CoA MUTASE DEFICIENCY	251000
METHYLMALONIC ACIDURIA, cblA TYPE	METHYLMALONIC ACIDURIA, cblA TYPE	251100
METHYLMALONIC ACIDEMIA, cblA TYPE	METHYLMALONIC ACIDURIA, cblA TYPE	251100
METHYLMALONIC ACIDURIA, VITAMIN B12-RESPONSIVE, DUE TO DEFECT IN SYNTHESISOF ADENOSYLCOBALAMIN, cblA TYPE	METHYLMALONIC ACIDURIA, cblA TYPE	251100
METHYLMALONIC ACIDURIA, cblB TYPE	METHYLMALONIC ACIDURIA, cblB TYPE	251110
METHYLMALONIC ACIDEMIA, cblB TYPE	METHYLMALONIC ACIDURIA, cblB TYPE	251110
METHYLMALONIC ACIDURIA, VITAMIN B12-RESPONSIVE, DUE TO DEFECT IN SYNTHESISOF ADENOSYLCOBALAMIN, cblB TYPE	METHYLMALONIC ACIDURIA, cblB TYPE	251110
METHYLMALONYL-CoA EPIMERASE DEFICIENCY	METHYLMALONYL-CoA EPIMERASE DEFICIENCY	251120
METHYLMALONYL-CoA RACEMASE DEFICIENCY	METHYLMALONYL-CoA EPIMERASE DEFICIENCY	251120
METHYLMALONIC ACIDURIA III, FORMERLYMETHYLMALONYL-CoA EPIMERASE DEFICIENCY WITH SEPIAPTERIN REDUCTASEDEFICIENCY, INCLUDED	METHYLMALONYL-CoA EPIMERASE DEFICIENCY	251120
MICROCEPHALY 1, PRIMARY, AUTOSOMAL RECESSIVE; MCPH1	MICROCEPHALY 1, PRIMARY, AUTOSOMAL RECESSIVE; MCPH1	251200
PREMATURE CHROMOSOME CONDENSATION WITH MICROCEPHALY AND MENTAL RETARDATION	MICROCEPHALY 1, PRIMARY, AUTOSOMAL RECESSIVE; MCPH1	251200
PREMATURE CHROMOSOME CONDENSATION SYNDROME	MICROCEPHALY 1, PRIMARY, AUTOSOMAL RECESSIVE; MCPH1	251200
PCC SYNDROME	MICROCEPHALY 1, PRIMARY, AUTOSOMAL RECESSIVE; MCPH1	251200
MICROCEPHALY-MICROMELIA SYNDROME	MICROCEPHALY-MICROMELIA SYNDROME	251230
JAWAD SYNDROME; JWDS	JAWAD SYNDROME; JWDS	251255
KELLY SYNDROME	JAWAD SYNDROME; JWDS	251255
MICROCEPHALY WITH MENTAL RETARDATION AND DIGITAL ANOMALIES	JAWAD SYNDROME; JWDS	251255
NIJMEGEN BREAKAGE SYNDROME	NIJMEGEN BREAKAGE SYNDROME	251260
NBS	NIJMEGEN BREAKAGE SYNDROME	251260
ATAXIA-TELANGIECTASIA VARIANT V1; AT-V1	NIJMEGEN BREAKAGE SYNDROME	251260
MICROCEPHALY WITH NORMAL INTELLIGENCE, IMMUNODEFICIENCY, AND LYMPHORETICULARMALIGNANCIES	NIJMEGEN BREAKAGE SYNDROME	251260
SEEMANOVA SYNDROME II	NIJMEGEN BREAKAGE SYNDROME	251260
NONSYNDROMAL MICROCEPHALY, AUTOSOMAL RECESSIVE, WITH NORMAL INTELLIGENCE	NIJMEGEN BREAKAGE SYNDROME	251260
IMMUNODEFICIENCY, MICROCEPHALY, AND CHROMOSOMAL INSTABILITYBERLIN BREAKAGE SYNDROME, INCLUDED; BBS, INCLUDED	NIJMEGEN BREAKAGE SYNDROME	251260
ATAXIA-TELANGIECTASIA VARIANT V2, INCLUDED; AT-V2, INCLUDED	NIJMEGEN BREAKAGE SYNDROME	251260
MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 1; MCCRP1	MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 1; MCCRP1	251270
BAND-LIKE CALCIFICATION WITH SIMPLIFIED GYRATION AND POLYMICROGYRIA;BLCPMG	BAND-LIKE CALCIFICATION WITH SIMPLIFIED GYRATION AND POLYMICROGYRIA;BLCPMG	251290
PSEUDO-TORCH SYNDROME	BAND-LIKE CALCIFICATION WITH SIMPLIFIED GYRATION AND POLYMICROGYRIA;BLCPMG	251290
GALLOWAY-MOWAT SYNDROME; GAMOS	GALLOWAY-MOWAT SYNDROME; GAMOS	251300
MICROCEPHALY, HIATAL HERNIA, AND NEPHROTIC SYNDROME	GALLOWAY-MOWAT SYNDROME; GAMOS	251300
GALLOWAY SYNDROME	GALLOWAY-MOWAT SYNDROME; GAMOS	251300
NEPHROSIS-NEURONAL DYSMIGRATION SYNDROME	GALLOWAY-MOWAT SYNDROME; GAMOS	251300
NEPHROSIS-MICROCEPHALY SYNDROME	GALLOWAY-MOWAT SYNDROME; GAMOS	251300
CEREBELLAR ATAXIA WITH MENTAL RETARDATION, OPTIC ATROPHY, AND SKINABNORMALITIES; CAMOS	GALLOWAY-MOWAT SYNDROME; GAMOS	251300
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 5, FORMERLY; SCAR5, FORMERLY	GALLOWAY-MOWAT SYNDROME; GAMOS	251300
DESBUQUOIS DYSPLASIA 1; DBQD1	DESBUQUOIS DYSPLASIA 1; DBQD1	251450
DESBUQUOIS SYNDROME	DESBUQUOIS DYSPLASIA 1; DBQD1	251450
MICROMELIC DWARFISM WITH VERTEBRAL AND METAPHYSEAL ABNORMALITIES ANDADVANCED CARPOTARSAL OSSIFICATIONDESBUQUOIS DYSPLASIA, KIM VARIANT, INCLUDED	DESBUQUOIS DYSPLASIA 1; DBQD1	251450
MICROPHTHALMIA, ISOLATED 1; MCOP1	MICROPHTHALMIA, ISOLATED 1; MCOP1	251600
MCOP	MICROPHTHALMIA, ISOLATED 1; MCOP1	251600
ANOPHTHALMIA, CLINICAL, ISOLATED	MICROPHTHALMIA, ISOLATED 1; MCOP1	251600
MICROPHTHALMOS, AUTOSOMAL RECESSIVE	MICROPHTHALMIA, ISOLATED 1; MCOP1	251600
MICROSPHEROPHAKIA AND/OR MEGALOCORNEA, WITH ECTOPIA LENTIS AND WITHOR WITHOUT SECONDARY GLAUCOMA; MSPKA	MICROSPHEROPHAKIA AND/OR MEGALOCORNEA, WITH ECTOPIA LENTIS AND WITHOR WITHOUT SECONDARY GLAUCOMA; MSPKA	251750
MICROTIA WITH MEATAL ATRESIA AND CONDUCTIVE DEAFNESS	MICROTIA WITH MEATAL ATRESIA AND CONDUCTIVE DEAFNESS	251800
DIARRHEA 2, WITH MICROVILLUS ATROPHY; DIAR2	DIARRHEA 2, WITH MICROVILLUS ATROPHY; DIAR2	251850
MICROVILLUS INCLUSION DISEASE; MVID	DIARRHEA 2, WITH MICROVILLUS ATROPHY; DIAR2	251850
MICROVILLUS ATROPHY, CONGENITAL	DIARRHEA 2, WITH MICROVILLUS ATROPHY; DIAR2	251850
DAVIDSON DISEASE	DIARRHEA 2, WITH MICROVILLUS ATROPHY; DIAR2	251850
CONGENITAL FAMILIAL PROTRACTED DIARRHEA WITH ENTEROCYTE BRUSH-BORDERABNORMALITIES	DIARRHEA 2, WITH MICROVILLUS ATROPHY; DIAR2	251850
INTRACTABLE DIARRHEA OF INFANCY	DIARRHEA 2, WITH MICROVILLUS ATROPHY; DIAR2	251850
MITOCHONDRIAL DNA DEPLETION SYNDROME 3 (HEPATOCEREBRAL TYPE); MTDPS3	MITOCHONDRIAL DNA DEPLETION SYNDROME 3 (HEPATOCEREBRAL TYPE); MTDPS3	251880
MITOCHONDRIAL MYOPATHY WITH LACTIC ACIDOSIS; MMLA	MITOCHONDRIAL MYOPATHY WITH LACTIC ACIDOSIS; MMLA	251950
MITOCHONDRIAL COMPLEX I DEFICIENCY	MITOCHONDRIAL COMPLEX I DEFICIENCY	252010
NADH:Q(1) OXIDOREDUCTASE DEFICIENCY	MITOCHONDRIAL COMPLEX I DEFICIENCY	252010
NADH-COENZYME Q REDUCTASE DEFICIENCY	MITOCHONDRIAL COMPLEX I DEFICIENCY	252010
MITOCHONDRIAL NADH DEHYDROGENASE COMPONENT OF COMPLEX I, DEFICIENCYOF	MITOCHONDRIAL COMPLEX I DEFICIENCY	252010
MITOCHONDRIAL COMPLEX II DEFICIENCY	MITOCHONDRIAL COMPLEX II DEFICIENCY	252011
SUCCINATE CoQ REDUCTASE DEFICIENCY	MITOCHONDRIAL COMPLEX II DEFICIENCY	252011
MOHR SYNDROME	MOHR SYNDROME	252100
OROFACIODIGITAL SYNDROME II; OFD2	MOHR SYNDROME	252100
OFDS II	MOHR SYNDROME	252100
ORAL-FACIAL-DIGITAL SYNDROME, TYPE II	MOHR SYNDROME	252100
MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP A; MOCODA	MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP A; MOCODA	252150
SULFITE OXIDASE, XANTHINE DEHYDROGENASE, AND ALDEHYDE OXIDASE, COMBINEDDEFICIENCY OF	MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP A; MOCODA	252150
MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP B; MOCODB	MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP B; MOCODB	252160
MONOSOMY 7 OF BONE MARROW	MONOSOMY 7 OF BONE MARROW	252270
MYELODYSPLASIA AND LEUKEMIA SYNDROME WITH MONOSOMY 7; MLSM7	MONOSOMY 7 OF BONE MARROW	252270
CHROMOSOME 7q DELETION	MONOSOMY 7 OF BONE MARROW	252270
MOYAMOYA DISEASE 1; MYMY1	MOYAMOYA DISEASE 1; MYMY1	252350
MOYAMOYA DISEASE; MYMY	MOYAMOYA DISEASE 1; MYMY1	252350
SPONTANEOUS OCCLUSION OF THE CIRCLE OF WILLIS	MOYAMOYA DISEASE 1; MYMY1	252350
MUCOLIPIDOSIS II ALPHA/BETA	MUCOLIPIDOSIS II ALPHA/BETA	252500
MUCOLIPIDOSIS II; ML II	MUCOLIPIDOSIS II ALPHA/BETA	252500
ML II ALPHA/BETA	MUCOLIPIDOSIS II ALPHA/BETA	252500
I-CELL DISEASE; ICD	MUCOLIPIDOSIS II ALPHA/BETA	252500
MUCOLIPIDOSIS III ALPHA/BETA	MUCOLIPIDOSIS III ALPHA/BETA	252600
ML III ALPHA/BETA	MUCOLIPIDOSIS III ALPHA/BETA	252600
MUCOLIPIDOSIS IIIA; ML IIIA	MUCOLIPIDOSIS III ALPHA/BETA	252600
MUCOLIPIDOSIS III	MUCOLIPIDOSIS III ALPHA/BETA	252600
ML III	MUCOLIPIDOSIS III ALPHA/BETA	252600
PSEUDO-HURLER POLYDYSTROPHYMUCOLIPIDOSIS III ALPHA/BETA, ATYPICAL, INCLUDED	MUCOLIPIDOSIS III ALPHA/BETA	252600
MUCOLIPIDOSIS III GAMMA	MUCOLIPIDOSIS III GAMMA	252605
ML III GAMMA	MUCOLIPIDOSIS III GAMMA	252605
MUCOLIPIDOSIS III, COMPLEMENTATION GROUP C	MUCOLIPIDOSIS III GAMMA	252605
MUCOLIPIDOSIS IIIC	MUCOLIPIDOSIS III GAMMA	252605
ML IIIC	MUCOLIPIDOSIS III GAMMA	252605
MUCOLIPIDOSIS III, IRANIAN VARIANT FORM	MUCOLIPIDOSIS III GAMMA	252605
MUCOLIPIDOSIS III, VARIANT FORM	MUCOLIPIDOSIS III GAMMA	252605
MUCOLIPIDOSIS IV; ML4	MUCOLIPIDOSIS IV; ML4	252650
ML IV	MUCOLIPIDOSIS IV; ML4	252650
SIALOLIPIDOSIS	MUCOLIPIDOSIS IV; ML4	252650
MUCOPOLYSACCHARIDOSES, UNCLASSIFIED TYPES	MUCOPOLYSACCHARIDOSES, UNCLASSIFIED TYPES	252700
MUCOPOLYSACCHARIDOSIS, TYPE IIIA; MPS3A	MUCOPOLYSACCHARIDOSIS, TYPE IIIA; MPS3A	252900
MPS IIIA	MUCOPOLYSACCHARIDOSIS, TYPE IIIA; MPS3A	252900
SANFILIPPO SYNDROME A	MUCOPOLYSACCHARIDOSIS, TYPE IIIA; MPS3A	252900
HEPARAN SULFATE SULFATASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE IIIA; MPS3A	252900
SULFAMIDASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE IIIA; MPS3A	252900
MUCOPOLYSACCHARIDOSIS, TYPE IIIB; MPS3B	MUCOPOLYSACCHARIDOSIS, TYPE IIIB; MPS3B	252920
MPS IIIB	MUCOPOLYSACCHARIDOSIS, TYPE IIIB; MPS3B	252920
SANFILIPPO SYNDROME B	MUCOPOLYSACCHARIDOSIS, TYPE IIIB; MPS3B	252920
N-ACETYL-ALPHA-D-GLUCOSAMINIDASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE IIIB; MPS3B	252920
NAGLU DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE IIIB; MPS3B	252920
MUCOPOLYSACCHARIDOSIS, TYPE IIIC; MPS3C	MUCOPOLYSACCHARIDOSIS, TYPE IIIC; MPS3C	252930
MPS IIIC	MUCOPOLYSACCHARIDOSIS, TYPE IIIC; MPS3C	252930
SANFILIPPO SYNDROME C	MUCOPOLYSACCHARIDOSIS, TYPE IIIC; MPS3C	252930
ACETYL-CoA:ALPHA-GLUCOSAMINIDE N-ACETYLTRANSFERASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE IIIC; MPS3C	252930
MUCOPOLYSACCHARIDOSIS, TYPE IIID; MPS3D	MUCOPOLYSACCHARIDOSIS, TYPE IIID; MPS3D	252940
MPS IIID	MUCOPOLYSACCHARIDOSIS, TYPE IIID; MPS3D	252940
SANFILIPPO SYNDROME D	MUCOPOLYSACCHARIDOSIS, TYPE IIID; MPS3D	252940
N-ACETYLGLUCOSAMINE-6-SULFATASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE IIID; MPS3D	252940
MUCOPOLYSACCHARIDOSIS, TYPE IVA; MPS4A	MUCOPOLYSACCHARIDOSIS, TYPE IVA; MPS4A	253000
MORQUIO SYNDROME A	MUCOPOLYSACCHARIDOSIS, TYPE IVA; MPS4A	253000
MPS IVA	MUCOPOLYSACCHARIDOSIS, TYPE IVA; MPS4A	253000
MORQUIO A DISEASE	MUCOPOLYSACCHARIDOSIS, TYPE IVA; MPS4A	253000
GALACTOSAMINE-6-SULFATASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE IVA; MPS4A	253000
GALNS DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE IVA; MPS4A	253000
MUCOPOLYSACCHARIDOSIS TYPE IVB	MUCOPOLYSACCHARIDOSIS TYPE IVB	253010
MORQUIO SYNDROME B	MUCOPOLYSACCHARIDOSIS TYPE IVB	253010
MPS IVB; MPS4B	MUCOPOLYSACCHARIDOSIS TYPE IVB	253010
MUCOPOLYSACCHARIDOSIS TYPE VI; MPS6	MUCOPOLYSACCHARIDOSIS TYPE VI; MPS6	253200
MPS VI	MUCOPOLYSACCHARIDOSIS TYPE VI; MPS6	253200
MAROTEAUX-LAMY SYNDROME	MUCOPOLYSACCHARIDOSIS TYPE VI; MPS6	253200
ARYLSULFATASE B DEFICIENCY	MUCOPOLYSACCHARIDOSIS TYPE VI; MPS6	253200
ARSB DEFICIENCY	MUCOPOLYSACCHARIDOSIS TYPE VI; MPS6	253200
N-ACETYLGALACTOSAMINE-4-SULFATASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS TYPE VI; MPS6	253200
MUCOPOLYSACCHARIDOSIS, TYPE VII; MPS7	MUCOPOLYSACCHARIDOSIS, TYPE VII; MPS7	253220
MPS VII	MUCOPOLYSACCHARIDOSIS, TYPE VII; MPS7	253220
SLY SYNDROME	MUCOPOLYSACCHARIDOSIS, TYPE VII; MPS7	253220
BETA-GLUCURONIDASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE VII; MPS7	253220
GUSB DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE VII; MPS7	253220
MUCUS INSPISSATION OF RESPIRATORY TRACT	MUCUS INSPISSATION OF RESPIRATORY TRACT	253240
MULIBREY NANISM	MULIBREY NANISM	253250
MUSCLE-LIVER-BRAIN-EYE NANISM	MULIBREY NANISM	253250
PERICARDIAL CONSTRICTION AND GROWTH FAILURE	MULIBREY NANISM	253250
PERHEENTUPA SYNDROME	MULIBREY NANISM	253250
BIOTINIDASE DEFICIENCYMULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET	BIOTINIDASE DEFICIENCYMULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET	253260
MULTIPLE CARBOXYLASE DEFICIENCY, JUVENILE-ONSET	BIOTINIDASE DEFICIENCYMULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET	253260
BTD DEFICIENCY	BIOTINIDASE DEFICIENCYMULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET	253260
HOLOCARBOXYLASE SYNTHETASE DEFICIENCY	HOLOCARBOXYLASE SYNTHETASE DEFICIENCY	253270
HLCS DEFICIENCY	HOLOCARBOXYLASE SYNTHETASE DEFICIENCY	253270
MULTIPLE CARBOXYLASE DEFICIENCY, NEONATAL FORM	HOLOCARBOXYLASE SYNTHETASE DEFICIENCY	253270
MULTIPLE CARBOXYLASE DEFICIENCY, EARLY ONSET	HOLOCARBOXYLASE SYNTHETASE DEFICIENCY	253270
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 3; MDDGA3	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 3; MDDGA3	253280
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMGNT1-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 3; MDDGA3	253280
MULTIPLE PTERYGIUM SYNDROME, LETHAL TYPE; LMPS	MULTIPLE PTERYGIUM SYNDROME, LETHAL TYPE; LMPS	253290
PTERYGIUM SYNDROME, MULTIPLE, LETHAL TYPE	MULTIPLE PTERYGIUM SYNDROME, LETHAL TYPE; LMPS	253290
SPINAL MUSCULAR ATROPHY, TYPE I; SMA1	SPINAL MUSCULAR ATROPHY, TYPE I; SMA1	253300
SMA I	SPINAL MUSCULAR ATROPHY, TYPE I; SMA1	253300
SMA, INFANTILE ACUTE FORM	SPINAL MUSCULAR ATROPHY, TYPE I; SMA1	253300
MUSCULAR ATROPHY, INFANTILE	SPINAL MUSCULAR ATROPHY, TYPE I; SMA1	253300
WERDNIG-HOFFMANN DISEASE	SPINAL MUSCULAR ATROPHY, TYPE I; SMA1	253300
LETHAL CONGENITAL CONTRACTURE SYNDROME 1; LCCS1	LETHAL CONGENITAL CONTRACTURE SYNDROME 1; LCCS1	253310
LCCS	LETHAL CONGENITAL CONTRACTURE SYNDROME 1; LCCS1	253310
MULTIPLE CONTRACTURE SYNDROME, FINNISH TYPE	LETHAL CONGENITAL CONTRACTURE SYNDROME 1; LCCS1	253310
SPINAL MUSCULAR ATROPHY, TYPE III; SMA3	SPINAL MUSCULAR ATROPHY, TYPE III; SMA3	253400
SMA III	SPINAL MUSCULAR ATROPHY, TYPE III; SMA3	253400
MUSCULAR ATROPHY, JUVENILE	SPINAL MUSCULAR ATROPHY, TYPE III; SMA3	253400
KUGELBERG-WELANDER SYNDROME; KWS	SPINAL MUSCULAR ATROPHY, TYPE III; SMA3	253400
SPINAL MUSCULAR ATROPHY, MILD CHILDHOOD AND ADOLESCENT FORM	SPINAL MUSCULAR ATROPHY, TYPE III; SMA3	253400
SPINAL MUSCULAR ATROPHY, TYPE II; SMA2	SPINAL MUSCULAR ATROPHY, TYPE II; SMA2	253550
SMA II	SPINAL MUSCULAR ATROPHY, TYPE II; SMA2	253550
MUSCULAR ATROPHY, SPINAL, INTERMEDIATE TYPE	SPINAL MUSCULAR ATROPHY, TYPE II; SMA2	253550
MUSCULAR ATROPHY, SPINAL, INFANTILE CHRONIC FORM	SPINAL MUSCULAR ATROPHY, TYPE II; SMA2	253550
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A	253600
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2; LGMD2	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A	253600
MUSCULAR DYSTROPHY, PELVOFEMORAL	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A	253600
LEYDEN-MOEBIUS MUSCULAR DYSTROPHY	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A	253600
CALPAINOPATHYMYOSITIS, EOSINOPHILIC, INCLUDED	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A	253600
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B	253601
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 3; LGMD3	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B	253601
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C	253700
MUSCULAR DYSTROPHY, DUCHENNE-LIKE	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C	253700
DUCHENNE-LIKE MUSCULAR DYSTROPHY, AUTOSOMAL RECESSIVE, TYPE 1; DMDA1	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C	253700
DMDA	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C	253700
ADHALIN DEFICIENCY, SECONDARY	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C	253700
SARCOGLYCAN, GAMMA, DEFICIENCY OF	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C	253700
SEVERE CHILDHOOD AUTOSOMAL RECESSIVE MUSCULAR DYSTROPHY, NORTH AFRICANTYPE; SCARMD	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C	253700
MAGHREBIAN MYOPATHY	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C	253700
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 4; MDDGA4	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 4; MDDGA4	253800
FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 4; MDDGA4	253800
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 4; MDDGA4	253800
MUSCULAR DYSTROPHY, CONGENITAL, PRODUCING ARTHROGRYPOSIS	MUSCULAR DYSTROPHY, CONGENITAL, PRODUCING ARTHROGRYPOSIS	253900
ULLRICH CONGENITAL MUSCULAR DYSTROPHY 1; UCMD1	ULLRICH CONGENITAL MUSCULAR DYSTROPHY 1; UCMD1	254090
ULLRICH CONGENITAL MUSCULAR DYSTROPHY; UCMD	ULLRICH CONGENITAL MUSCULAR DYSTROPHY 1; UCMD1	254090
MUSCULAR DYSTROPHY, SCLEROATONIC	ULLRICH CONGENITAL MUSCULAR DYSTROPHY 1; UCMD1	254090
ULLRICH DISEASE	ULLRICH CONGENITAL MUSCULAR DYSTROPHY 1; UCMD1	254090
ULLRICH SCLEROATONIC MUSCULAR DYSTROPHY	ULLRICH CONGENITAL MUSCULAR DYSTROPHY 1; UCMD1	254090
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2H; LGMD2H	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2H; LGMD2H	254110
MUSCULAR DYSTROPHY, HUTTERITE TYPE	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2H; LGMD2H	254110
SARCOTUBULAR MYOPATHY	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2H; LGMD2H	254110
MIYOSHI MUSCULAR DYSTROPHY 1; MMD1	MIYOSHI MUSCULAR DYSTROPHY 1; MMD1	254130
MIYOSHI MYOPATHY	MIYOSHI MUSCULAR DYSTROPHY 1; MMD1	254130
MUSCULAR DYSTROPHY, DISTAL, LATE-ONSET, AUTOSOMAL RECESSIVE	MIYOSHI MUSCULAR DYSTROPHY 1; MMD1	254130
MUSK, INABILITY TO SMELL	MUSK, INABILITY TO SMELL	254150
MYASTHENIC SYNDROME, CONGENITAL, 6, PRESYNAPTIC; CMS6	MYASTHENIC SYNDROME, CONGENITAL, 6, PRESYNAPTIC; CMS6	254210
MYASTHENIC SYNDROME, PRESYNAPTIC, CONGENITAL, ASSOCIATED WITH EPISODICAPNEA; CMSEA	MYASTHENIC SYNDROME, CONGENITAL, 6, PRESYNAPTIC; CMS6	254210
CONGENITAL MYASTHENIC SYNDROME TYPE Ia2, FORMERLY; CMS1A2, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 6, PRESYNAPTIC; CMS6	254210
CMS Ia2, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 6, PRESYNAPTIC; CMS6	254210
MYASTHENIA, FAMILIAL INFANTILE, FORMERLY; FIM, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 6, PRESYNAPTIC; CMS6	254210
MYASTHENIA GRAVIS, FAMILIAL INFANTILE, 2, FORMERLY; FIMG2, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 6, PRESYNAPTIC; CMS6	254210
MYASTHENIC SYNDROME, CONGENITAL, 10; CMS10	MYASTHENIC SYNDROME, CONGENITAL, 10; CMS10	254300
MYASTHENIA, LIMB-GIRDLE, FAMILIAL, FORMERLY; LGM, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 10; CMS10	254300
CONGENITAL MYASTHENIC SYNDROME TYPE Ib, FORMERLY; CMS1B, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 10; CMS10	254300
CMS Ib, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 10; CMS10	254300
MYASTHENIC MYOPATHY, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 10; CMS10	254300
MYELOFIBROSISMYELOFIBROSIS WITH MYELOID METAPLASIA, INCLUDED; MMM, INCLUDED	MYELOFIBROSISMYELOFIBROSIS WITH MYELOID METAPLASIA, INCLUDED; MMM, INCLUDED	254450
MYELOMA, MULTIPLEAMYLOIDOSIS, SYSTEMIC, INCLUDED; AL, INCLUDED	MYELOMA, MULTIPLEAMYLOIDOSIS, SYSTEMIC, INCLUDED; AL, INCLUDED	254500
AL AMYLOIDOSIS, INCLUDED	MYELOMA, MULTIPLEAMYLOIDOSIS, SYSTEMIC, INCLUDED; AL, INCLUDED	254500
MYELOPEROXIDASE DEFICIENCY; MPOD	MYELOPEROXIDASE DEFICIENCY; MPOD	254600
MPO DEFICIENCY	MYELOPEROXIDASE DEFICIENCY; MPOD	254600
EPILEPSY, MYOCLONIC JUVENILE; EJM	EPILEPSY, MYOCLONIC JUVENILE; EJM	254770
MYOCLONIC EPILEPSY, JUVENILE; JME	EPILEPSY, MYOCLONIC JUVENILE; EJM	254770
PETIT MAL, IMPULSIVE	EPILEPSY, MYOCLONIC JUVENILE; EJM	254770
JANZ SYNDROMEMYOCLONIC EPILEPSY, JUVENILE, SUSCEPTIBILITY TO, 1, INCLUDED; EJM1,INCLUDED	EPILEPSY, MYOCLONIC JUVENILE; EJM	254770
MYOCLONIC EPILEPSY OF LAFORA	MYOCLONIC EPILEPSY OF LAFORA	254780
MELF	MYOCLONIC EPILEPSY OF LAFORA	254780
LAFORA DISEASE	MYOCLONIC EPILEPSY OF LAFORA	254780
LAFORA BODY DISEASE; LBD	MYOCLONIC EPILEPSY OF LAFORA	254780
EPILEPSY, PROGRESSIVE MYOCLONIC, 2A; EPM2A	MYOCLONIC EPILEPSY OF LAFORA	254780
EPM2EPILEPSY, PROGRESSIVE MYOCLONIC, 2B, INCLUDED; EPM2B, INCLUDED	MYOCLONIC EPILEPSY OF LAFORA	254780
MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG	MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG	254800
ULD	MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG	254800
EPILEPSY, PROGRESSIVE MYOCLONIC, 1A; EPM1A	MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG	254800
EPILEPSY, PROGRESSIVE MYOCLONIC, 1; EPM1	MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG	254800
PROGRESSIVE MYOCLONIC EPILEPSY; PME	MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG	254800
BALTIC MYOCLONIC EPILEPSY	MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG	254800
EPILEPSY, PROGRESSIVE MYOCLONIC, 4, WITH OR WITHOUT RENAL FAILURE;EPM4	EPILEPSY, PROGRESSIVE MYOCLONIC, 4, WITH OR WITHOUT RENAL FAILURE;EPM4	254900
ACTION MYOCLONUS-RENAL FAILURE SYNDROME; AMRF	EPILEPSY, PROGRESSIVE MYOCLONIC, 4, WITH OR WITHOUT RENAL FAILURE;EPM4	254900
MYOCLONUS-NEPHROPATHY SYNDROME	EPILEPSY, PROGRESSIVE MYOCLONIC, 4, WITH OR WITHOUT RENAL FAILURE;EPM4	254900
CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LATE-ONSET	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LATE-ONSET	255110
CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, MYOPATHIC	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LATE-ONSET	255110
CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, ADULT-ONSET	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LATE-ONSET	255110
CPT II DEFICIENCY, MYOPATHIC	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LATE-ONSET	255110
CPT2 DEFICIENCY, LATE-ONSET	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LATE-ONSET	255110
CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY	CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY	255120
CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY	CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY	255120
CPT I DEFICIENCY	CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY	255120
CPT DEFICIENCY, HEPATIC, TYPE I	CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY	255120
MYOPATHY WITH LACTIC ACIDOSIS, HEREDITARY; HML	MYOPATHY WITH LACTIC ACIDOSIS, HEREDITARY; HML	255125
MYOPATHY WITH EXERCISE INTOLERANCE, SWEDISH TYPE	MYOPATHY WITH LACTIC ACIDOSIS, HEREDITARY; HML	255125
MYOPATHY WITH DEFICIENCY OF SUCCINATE DEHYDROGENASE AND ACONITASE	MYOPATHY WITH LACTIC ACIDOSIS, HEREDITARY; HML	255125
MYOGLOBINURIA DUE TO ABNORMAL GLYCOLYSIS	MYOPATHY WITH LACTIC ACIDOSIS, HEREDITARY; HML	255125
MYOPATHY, MYOSIN STORAGE, AUTOSOMAL RECESSIVE; MSMB	MYOPATHY, MYOSIN STORAGE, AUTOSOMAL RECESSIVE; MSMB	255160
MYOPATHY, HYALINE BODY, AUTOSOMAL RECESSIVE	MYOPATHY, MYOSIN STORAGE, AUTOSOMAL RECESSIVE; MSMB	255160
MYOPATHY, CENTRONUCLEAR, 2; CNM2	MYOPATHY, CENTRONUCLEAR, 2; CNM2	255200
MYOPATHY, CENTRONUCLEAR, AUTOSOMAL RECESSIVE	MYOPATHY, CENTRONUCLEAR, 2; CNM2	255200
MYOTUBULAR MYOPATHY, AUTOSOMAL RECESSIVE	MYOPATHY, CENTRONUCLEAR, 2; CNM2	255200
MYOPATHY, CONGENITAL	MYOPATHY, CONGENITAL	255300
BATTEN-TURNER CONGENITAL MYOPATHY	MYOPATHY, CONGENITAL	255300
MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION; CFTD	MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION; CFTD	255310
FIBER-TYPE DISPROPORTION MYOPATHY, CONGENITAL; CFTDM	MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION; CFTD	255310
MINICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA	MINICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA	255320
MINICORE MYOPATHY	MINICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA	255320
MULTICORE MYOPATHY	MINICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA	255320
MULTIMINICORE MYOPATHY MULTICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA	MINICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA	255320
MULTIMINICORE DISEASE WITH EXTERNAL OPHTHALMOPLEGIA	MINICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA	255320
MYOPIA 18, AUTOSOMAL RECESSIVE; MYP18	MYOPIA 18, AUTOSOMAL RECESSIVE; MYP18	255500
MYOSCLEROSIS, AUTOSOMAL RECESSIVE	MYOSCLEROSIS, AUTOSOMAL RECESSIVE	255600
MYOPATHY, MYOSCLEROTIC	MYOSCLEROSIS, AUTOSOMAL RECESSIVE	255600
MYOSCLEROSIS, CONGENITAL, OF LOWENTHAL	MYOSCLEROSIS, AUTOSOMAL RECESSIVE	255600
MYOTONIA CONGENITA, AUTOSOMAL RECESSIVE	MYOTONIA CONGENITA, AUTOSOMAL RECESSIVE	255700
BECKER DISEASE	MYOTONIA CONGENITA, AUTOSOMAL RECESSIVE	255700
MYOTONIA, GENERALIZED	MYOTONIA CONGENITA, AUTOSOMAL RECESSIVE	255700
SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1	SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1	255800
SCHWARTZ-JAMPEL SYNDROME; SJS	SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1	255800
MYOTONIC MYOPATHY, DWARFISM, CHONDRODYSTROPHY, AND OCULAR AND FACIALABNORMALITIES	SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1	255800
SCHWARTZ-JAMPEL-ABERFELD SYNDROME	SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1	255800
SJA SYNDROME	SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1	255800
CHONDRODYSTROPHIC MYOTONIA	SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1	255800
MYXOMA, INTRACARDIAC	MYXOMA, INTRACARDIAC	255960
ATRIAL MYXOMA, FAMILIAL	MYXOMA, INTRACARDIAC	255960
NASODIGITOACOUSTIC SYNDROME	NASODIGITOACOUSTIC SYNDROME	255980
KEIPERT SYNDROME	NASODIGITOACOUSTIC SYNDROME	255980
NATIVE AMERICAN MYOPATHY; NAM	NATIVE AMERICAN MYOPATHY; NAM	255995
MYOPATHY, CONGENITAL, WITH CLEFT PALATE AND MALIGNANT HYPERTHERMIA	NATIVE AMERICAN MYOPATHY; NAM	255995
LEIGH SYNDROME; LS	LEIGH SYNDROME; LS	256000
NECROTIZING ENCEPHALOPATHY, INFANTILE SUBACUTE, OF LEIGH; SNELEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX I DEFICIENCY, INCLUDED	LEIGH SYNDROME; LS	256000
LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX II DEFICIENCY, INCLUDED	LEIGH SYNDROME; LS	256000
LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX III DEFICIENCY, INCLUDED	LEIGH SYNDROME; LS	256000
LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX IV DEFICIENCY, INCLUDED	LEIGH SYNDROME; LS	256000
LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX V DEFICIENCY, INCLUDED	LEIGH SYNDROME; LS	256000
NEMALINE MYOPATHY 2; NEM2	NEMALINE MYOPATHY 2; NEM2	256030
AUTOINFLAMMATION, LIPODYSTROPHY, AND DERMATOSIS SYNDROME; ALDD	AUTOINFLAMMATION, LIPODYSTROPHY, AND DERMATOSIS SYNDROME; ALDD	256040
NAKAJO-NISHIMURA SYNDROME; NKJO	AUTOINFLAMMATION, LIPODYSTROPHY, AND DERMATOSIS SYNDROME; ALDD	256040
JOINT CONTRACTURES, MUSCULAR ATROPHY, MICROCYTIC ANEMIA, AND PANNICULITIS-INDUCEDLIPODYSTROPHY; JMP SYNDROME	AUTOINFLAMMATION, LIPODYSTROPHY, AND DERMATOSIS SYNDROME; ALDD	256040
CHRONIC ATYPICAL NEUTROPHILIC DERMATOSIS WITH LIPODYSTROPHY AND ELEVATEDTEMPERATURE SYNDROME; CANDLE	AUTOINFLAMMATION, LIPODYSTROPHY, AND DERMATOSIS SYNDROME; ALDD	256040
ATELOSTEOGENESIS, TYPE II; AO2	ATELOSTEOGENESIS, TYPE II; AO2	256050
AOII	ATELOSTEOGENESIS, TYPE II; AO2	256050
NEONATAL OSSEOUS DYSPLASIA IDE LA CHAPELLE DYSPLASIA, INCLUDED; DLCD, INCLUDED	ATELOSTEOGENESIS, TYPE II; AO2	256050
NEPHRONOPHTHISIS 1; NPHP1	NEPHRONOPHTHISIS 1; NPHP1	256100
NEPHRONOPHTHISIS, FAMILIAL JUVENILE	NEPHRONOPHTHISIS 1; NPHP1	256100
NPH1	NEPHRONOPHTHISIS 1; NPHP1	256100
NEPHROTIC SYNDROME, TYPE 1; NPHS1	NEPHROTIC SYNDROME, TYPE 1; NPHS1	256300
FINNISH CONGENITAL NEPHROSIS; CNF	NEPHROTIC SYNDROME, TYPE 1; NPHS1	256300
NEPHROTIC SYNDROME, CONGENITAL	NEPHROTIC SYNDROME, TYPE 1; NPHS1	256300
NEPHROTIC SYNDROME, TYPE 4; NPHS4	NEPHROTIC SYNDROME, TYPE 4; NPHS4	256370
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1	256450
PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PHHI	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1	256450
HYPOGLYCEMIA, HYPERINSULINEMIC, OF INFANCY	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1	256450
HYPERINSULINEMIC HYPOGLYCEMIA DUE TO FOCAL ADENOMATOUS HYPERPLASIA	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1	256450
NESIDIOBLASTOSIS OF PANCREAS	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1	256450
HYPERINSULINISM, FAMILIAL, WITH PANCREATIC NESIDIOBLASTOSIS	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1	256450
HYPERINSULINISM, CONGENITAL	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1	256450
NETHERTON SYNDROME; NETH	NETHERTON SYNDROME; NETH	256500
ERYTHRODERMA, ICHTHYOSIFORM, WITH HYPOTRICHOSIS AND HYPER-IgE	NETHERTON SYNDROME; NETH	256500
NS	NETHERTON SYNDROME; NETH	256500
NETHERTON DISEASE	NETHERTON SYNDROME; NETH	256500
COMEL-NETHERTON SYNDROME	NETHERTON SYNDROME; NETH	256500
NEU-LAXOVA SYNDROME 1; NLS1	NEU-LAXOVA SYNDROME 1; NLS1	256520
NEU-LAXOVA SYNDROME; NLS	NEU-LAXOVA SYNDROME 1; NLS1	256520
GALACTOSIALIDOSIS; GSL	GALACTOSIALIDOSIS; GSL	256540
GOLDBERG SYNDROME	GALACTOSIALIDOSIS; GSL	256540
NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY	GALACTOSIALIDOSIS; GSL	256540
NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE	GALACTOSIALIDOSIS; GSL	256540
LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY	GALACTOSIALIDOSIS; GSL	256540
CATHEPSIN A DEFICIENCY	GALACTOSIALIDOSIS; GSL	256540
PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY	GALACTOSIALIDOSIS; GSL	256540
PPCA DEFICIENCY	GALACTOSIALIDOSIS; GSL	256540
NEURAMINIDASE DEFICIENCY	NEURAMINIDASE DEFICIENCY	256550
SIALIDOSIS, TYPE II	NEURAMINIDASE DEFICIENCY	256550
MUCOLIPIDOSIS I	NEURAMINIDASE DEFICIENCY	256550
ML I	NEURAMINIDASE DEFICIENCY	256550
LIPOMUCOPOLYSACCHARIDOSIS	NEURAMINIDASE DEFICIENCY	256550
SIALIDASE DEFICIENCY	NEURAMINIDASE DEFICIENCY	256550
GLYCOPROTEIN NEURAMINIDASE DEFICIENCY	NEURAMINIDASE DEFICIENCY	256550
NEUG DEFICIENCY	NEURAMINIDASE DEFICIENCY	256550
NEURAMINIDASE 1 DEFICIENCY	NEURAMINIDASE DEFICIENCY	256550
NEU DEFICIENCY	NEURAMINIDASE DEFICIENCY	256550
NEU1 DEFICIENCYSIALIDOSIS, TYPE I, INCLUDED	NEURAMINIDASE DEFICIENCY	256550
CHERRY RED SPOT--MYOCLONUS SYNDROME, INCLUDED	NEURAMINIDASE DEFICIENCY	256550
MYOCLONUS--CHERRY RED SPOT SYNDROME, INCLUDED	NEURAMINIDASE DEFICIENCY	256550
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A	256600
NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A	256600
NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A	256600
SEITELBERGER DISEASE	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A	256600
NEUROBLASTOMA, SUSCEPTIBILITY TONEUROBLASTOMA, SUSCEPTIBILITY TO, 1, INCLUDED; NBLST1, INCLUDED	NEUROBLASTOMA, SUSCEPTIBILITY TONEUROBLASTOMA, SUSCEPTIBILITY TO, 1, INCLUDED; NBLST1, INCLUDED	256700
ELEJALDE DISEASE	ELEJALDE DISEASE	256710
NEUROECTODERMAL MELANOLYSOSOMAL DISEASE	ELEJALDE DISEASE	256710
CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1	CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1	256730
CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSETNEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED	CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1	256730
SANTAVUORI DISEASE, INCLUDED	CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1	256730
SANTAVUORI-HALTIA DISEASE, INCLUDED	CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1	256730
CEROID LIPOFUSCINOSIS, NEURONAL, 5; CLN5	CEROID LIPOFUSCINOSIS, NEURONAL, 5; CLN5	256731
CEROID LIPOFUSCINOSIS, NEURONAL, 5, VARIABLE AGE AT ONSETNEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, FINNISH VARIANT, INCLUDED	CEROID LIPOFUSCINOSIS, NEURONAL, 5; CLN5	256731
FINNISH vLINCL, INCLUDED	CEROID LIPOFUSCINOSIS, NEURONAL, 5; CLN5	256731
INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA	INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA	256800
NEUROPATHY, CONGENITAL SENSORY, WITH ANHIDROSIS	INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA	256800
HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY IV; HSAN4	INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA	256800
HSAN IV	INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA	256800
FAMILIAL DYSAUTONOMIA, TYPE II	INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA	256800
MITOCHONDRIAL DNA DEPLETION SYNDROME 6 (HEPATOCEREBRAL TYPE); MTDPS6	MITOCHONDRIAL DNA DEPLETION SYNDROME 6 (HEPATOCEREBRAL TYPE); MTDPS6	256810
NAVAJO NEUROHEPATOPATHY; NNH	MITOCHONDRIAL DNA DEPLETION SYNDROME 6 (HEPATOCEREBRAL TYPE); MTDPS6	256810
NAVAJO NEUROPATHY; NNNAVAJO FAMILIAL NEUROGENIC ARTHROPATHY, INCLUDED	MITOCHONDRIAL DNA DEPLETION SYNDROME 6 (HEPATOCEREBRAL TYPE); MTDPS6	256810
NEUROPATHY, HEREDITARY SENSORY, WITH SPASTIC PARAPLEGIA, AUTOSOMALRECESSIVE	NEUROPATHY, HEREDITARY SENSORY, WITH SPASTIC PARAPLEGIA, AUTOSOMALRECESSIVE	256840
GIANT AXONAL NEUROPATHY 1, AUTOSOMAL RECESSIVE; GAN1	GIANT AXONAL NEUROPATHY 1, AUTOSOMAL RECESSIVE; GAN1	256850
GAN	GIANT AXONAL NEUROPATHY 1, AUTOSOMAL RECESSIVE; GAN1	256850
NEUROPATHY, HEREDITARY MOTOR AND SENSORY, WITH EXCESSIVE MYELIN FOLDINGCOMPLEX, AUTOSOMAL RECESSIVE	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, WITH EXCESSIVE MYELIN FOLDINGCOMPLEX, AUTOSOMAL RECESSIVE	256855
HMSN WITH EXCESSIVE MYELIN OUTFOLDING, AUTOSOMAL RECESSIVE	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, WITH EXCESSIVE MYELIN FOLDINGCOMPLEX, AUTOSOMAL RECESSIVE	256855
CHARCOT-MARIE-TOOTH DISEASE WITH EXCESSIVE MYELIN FOLDING, AUTOSOMALRECESSIVE	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, WITH EXCESSIVE MYELIN FOLDINGCOMPLEX, AUTOSOMAL RECESSIVE	256855
NEUTROPHIL ACTIN DYSFUNCTION; NAD	NEUTROPHIL ACTIN DYSFUNCTION; NAD	257150
NIEMANN-PICK DISEASE, TYPE A	NIEMANN-PICK DISEASE, TYPE A	257200
SPHINGOMYELIN LIPIDOSIS	NIEMANN-PICK DISEASE, TYPE A	257200
SPHINGOMYELINASE DEFICIENCYNIEMANN-PICK DISEASE, INTERMEDIATE, PROTRACTED NEUROVISCERAL, INCLUDED	NIEMANN-PICK DISEASE, TYPE A	257200
NIEMANN-PICK DISEASE, TYPE C1; NPC1	NIEMANN-PICK DISEASE, TYPE C1; NPC1	257220
NIEMANN-PICK DISEASE, TYPE C; NPC	NIEMANN-PICK DISEASE, TYPE C1; NPC1	257220
NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK	NIEMANN-PICK DISEASE, TYPE C1; NPC1	257220
NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM	NIEMANN-PICK DISEASE, TYPE C1; NPC1	257220
NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM	NIEMANN-PICK DISEASE, TYPE C1; NPC1	257220
NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY	NIEMANN-PICK DISEASE, TYPE C1; NPC1	257220
NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIANIEMANN-PICK DISEASE, TYPE D, INCLUDED	NIEMANN-PICK DISEASE, TYPE C1; NPC1	257220
NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED	NIEMANN-PICK DISEASE, TYPE C1; NPC1	257220
NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1B; CSNB1B	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1B; CSNB1B	257270
NIGHT BLINDNESS, CONGENITAL STATIONARY, COMPLETE, AUTOSOMAL RECESSIVE	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1B; CSNB1B	257270
CSNB, COMPLETE, AUTOSOMAL RECESSIVE	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1B; CSNB1B	257270
MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1; MVA1	MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1; MVA1	257300
MVA SYNDROME	MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1; MVA1	257300
LISSENCEPHALY 2; LIS2	LISSENCEPHALY 2; LIS2	257320
LISSENCEPHALY SYNDROME, NORMAN-ROBERTS TYPE	LISSENCEPHALY 2; LIS2	257320
NORMAN-ROBERTS SYNDROME	LISSENCEPHALY 2; LIS2	257320
OCULAR MOTOR APRAXIA	OCULAR MOTOR APRAXIA	257550
OCULOMOTOR APRAXIA, COGAN TYPE; COMA	OCULAR MOTOR APRAXIA	257550
SACCADE INITIATION FAILURE, CONGENITAL	OCULAR MOTOR APRAXIA	257550
OCULAR MYOPATHY WITH CURARE SENSITIVITY	OCULAR MYOPATHY WITH CURARE SENSITIVITY	257600
OCULOCEREBRAL SYNDROME WITH HYPOPIGMENTATION	OCULOCEREBRAL SYNDROME WITH HYPOPIGMENTATION	257800
CROSS SYNDROME	OCULOCEREBRAL SYNDROME WITH HYPOPIGMENTATION	257800
KRAMER SYNDROME	OCULOCEREBRAL SYNDROME WITH HYPOPIGMENTATION	257800
OCULODENTODIGITAL DYSPLASIA, AUTOSOMAL RECESSIVE	OCULODENTODIGITAL DYSPLASIA, AUTOSOMAL RECESSIVE	257850
ODDD, AUTOSOMAL RECESSIVE	OCULODENTODIGITAL DYSPLASIA, AUTOSOMAL RECESSIVE	257850
OCULODENTOOSSEOUS DYSPLASIA, AUTOSOMAL RECESSIVE	OCULODENTODIGITAL DYSPLASIA, AUTOSOMAL RECESSIVE	257850
ODOD, AUTOSOMAL RECESSIVE	OCULODENTODIGITAL DYSPLASIA, AUTOSOMAL RECESSIVE	257850
OCULOPALATOCEREBRAL SYNDROME	OCULOPALATOCEREBRAL SYNDROME	257910
OCULOPALATOCEREBRAL DWARFISM	OCULOPALATOCEREBRAL SYNDROME	257910
OPC DWARFISM	OCULOPALATOCEREBRAL SYNDROME	257910
3MC SYNDROME 1; 3MC1	3MC SYNDROME 1; 3MC1	257920
OCULOPALATOSKELETAL SYNDROME	3MC SYNDROME 1; 3MC1	257920
CRANIOSYNOSTOSIS WITH LID ANOMALIES	3MC SYNDROME 1; 3MC1	257920
MICHELS SYNDROME, FORMERLY	3MC SYNDROME 1; 3MC1	257920
OCULORENOCEREBELLAR SYNDROME	OCULORENOCEREBELLAR SYNDROME	257970
ORC SYNDROME	OCULORENOCEREBELLAR SYNDROME	257970
ODONTOONYCHODERMAL DYSPLASIA; OODD	ODONTOONYCHODERMAL DYSPLASIA; OODD	257980
OGUCHI DISEASE 1	OGUCHI DISEASE 1	258100
NIGHT BLINDNESS, CONGENITAL STATIONARY, OGUCHI TYPE 1; CSNBO1	OGUCHI DISEASE 1	258100
SPERMATOGENIC FAILURE 1; SPGF1	SPERMATOGENIC FAILURE 1; SPGF1	258150
OLIGOSYNAPTIC INFERTILITY	SPERMATOGENIC FAILURE 1; SPGF1	258150
OLIGOCHIASMATIC INFERTILITY	SPERMATOGENIC FAILURE 1; SPGF1	258150
OLIVOPONTOCEREBELLAR ATROPHY II, AUTOSOMAL RECESSIVE	OLIVOPONTOCEREBELLAR ATROPHY II, AUTOSOMAL RECESSIVE	258300
OPCA II, FICKLER-WINKLER TYPE	OLIVOPONTOCEREBELLAR ATROPHY II, AUTOSOMAL RECESSIVE	258300
OMODYSPLASIA 1; OMOD1	OMODYSPLASIA 1; OMOD1	258315
OMODYSPLASIA, GENERALIZED FORM	OMODYSPLASIA 1; OMOD1	258315
OMODYSPLASIA, AUTOSOMAL RECESSIVE	OMODYSPLASIA 1; OMOD1	258315
MICROMELIC DYSPLASIA, CONGENITAL, WITH DISLOCATION OF RADIUS	OMODYSPLASIA 1; OMOD1	258315
ONYCHOTRICHODYSPLASIA AND NEUTROPENIA	ONYCHOTRICHODYSPLASIA AND NEUTROPENIA	258360
OPHTHALMOPLEGIA TOTALIS WITH PTOSIS AND MIOSIS	OPHTHALMOPLEGIA TOTALIS WITH PTOSIS AND MIOSIS	258400
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL RECESSIVE 1; PEOB1	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL RECESSIVE 1; PEOB1	258450
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 1	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL RECESSIVE 1; PEOB1	258450
OPSISMODYSPLASIA; OPSMD	OPSISMODYSPLASIA; OPSMD	258480
OPTIC ATROPHY 6; OPA6	OPTIC ATROPHY 6; OPA6	258500
OPTIC ATROPHY, CONGENITAL OR EARLY INFANTILE, AUTOSOMAL RECESSIVE	OPTIC ATROPHY 6; OPA6	258500
3-@METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3	3-@METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3	258501
MGA, TYPE III; MGA3	3-@METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3	258501
OPTIC ATROPHY PLUS SYNDROME	3-@METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3	258501
OPTIC ATROPHY, INFANTILE, WITH CHOREA AND SPASTIC PARAPLEGIA	3-@METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3	258501
IRAQI-JEWISH 'OPTIC ATROPHY PLUS'	3-@METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3	258501
COSTEFF SYNDROME	3-@METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3	258501
OPTIC ATROPHY 3, AUTOSOMAL RECESSIVE	3-@METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3	258501
OPA3, AUTOSOMAL RECESSIVE	3-@METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3	258501
NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY, SUSCEPTIBILITY TO	NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY, SUSCEPTIBILITY TO	258660
NAION, SUSCEPTIBILITY TO	NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY, SUSCEPTIBILITY TO	258660
OPTIC NEUROPATHY, ANTERIOR ISCHEMIC, SUSCEPTIBILITY TO	NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY, SUSCEPTIBILITY TO	258660
OPTICOCOCHLEODENTATE DEGENERATION	OPTICOCOCHLEODENTATE DEGENERATION	258700
OROFACIODIGITAL SYNDROME III; OFD3	OROFACIODIGITAL SYNDROME III; OFD3	258850
OFDS III	OROFACIODIGITAL SYNDROME III; OFD3	258850
ORAL-FACIAL-DIGITAL SYNDROME, TYPE III	OROFACIODIGITAL SYNDROME III; OFD3	258850
SUGARMAN SYNDROME	OROFACIODIGITAL SYNDROME III; OFD3	258850
OROFACIODIGITAL SYNDROME IV; OFD4	OROFACIODIGITAL SYNDROME IV; OFD4	258860
OFDS IV	OROFACIODIGITAL SYNDROME IV; OFD4	258860
ORAL-FACIAL-DIGITAL SYNDROME, TYPE IV	OROFACIODIGITAL SYNDROME IV; OFD4	258860
OFD SYNDROME WITH TIBIAL DEFECTS	OROFACIODIGITAL SYNDROME IV; OFD4	258860
MOHR-MAJEWSKI SYNDROME	OROFACIODIGITAL SYNDROME IV; OFD4	258860
OFD SYNDROME, BARAITSER-BURN TYPE	OROFACIODIGITAL SYNDROME IV; OFD4	258860
BARAITSER-BURN SYNDROME	OROFACIODIGITAL SYNDROME IV; OFD4	258860
OROFACIODIGITAL SYNDROME IX; OFD9	OROFACIODIGITAL SYNDROME IX; OFD9	258865
OFDS IX	OROFACIODIGITAL SYNDROME IX; OFD9	258865
ORAL-FACIAL-DIGITAL SYNDROME, TYPE IX	OROFACIODIGITAL SYNDROME IX; OFD9	258865
ORAL-FACIAL-DIGITAL SYNDROME WITH RETINAL ABNORMALITIES	OROFACIODIGITAL SYNDROME IX; OFD9	258865
OROFACIODIGITAL SYNDROME WITH RETINAL ABNORMALITIES	OROFACIODIGITAL SYNDROME IX; OFD9	258865
GYRATE ATROPHY OF CHOROID AND RETINA; GACR	GYRATE ATROPHY OF CHOROID AND RETINA; GACR	258870
HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA	GYRATE ATROPHY OF CHOROID AND RETINA; GACR	258870
GYRATE ATROPHY	GYRATE ATROPHY OF CHOROID AND RETINA; GACR	258870
ORNITHINE AMINOTRANSFERASE DEFICIENCY	GYRATE ATROPHY OF CHOROID AND RETINA; GACR	258870
OAT DEFICIENCY	GYRATE ATROPHY OF CHOROID AND RETINA; GACR	258870
ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY	GYRATE ATROPHY OF CHOROID AND RETINA; GACR	258870
OKT DEFICIENCY	GYRATE ATROPHY OF CHOROID AND RETINA; GACR	258870
ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY	GYRATE ATROPHY OF CHOROID AND RETINA; GACR	258870
OROTIC ACIDURIA	OROTIC ACIDURIA	258900
OROTIC ACIDURIA I	OROTIC ACIDURIA	258900
OROTATE PHOSPHORIBOSYLTRANSFERASE AND OROTIDYLIC DECARBOXYLASE DEFICIENCY	OROTIC ACIDURIA	258900
OPRT AND ODC DEFICIENCY	OROTIC ACIDURIA	258900
OROTIDYLIC PYROPHOSPHORYLASE AND OROTIDYLIC DECARBOXYLASE DEFICIENCY	OROTIC ACIDURIA	258900
URIDINE MONOPHOSPHATE SYNTHASE DEFICIENCY	OROTIC ACIDURIA	258900
UMP SYNTHASE DEFICIENCY	OROTIC ACIDURIA	258900
UMPS DEFICIENCYOROTIC ACIDURIA WITHOUT MEGALOBLASTIC ANEMIA, INCLUDED; OAWA, INCLUDED	OROTIC ACIDURIA	258900
OSSIFIED EAR CARTILAGES WITH MENTAL DEFICIENCY, MUSCLE WASTING, ANDBONY CHANGES	OSSIFIED EAR CARTILAGES WITH MENTAL DEFICIENCY, MUSCLE WASTING, ANDBONY CHANGES	259050
PRIMROSE SYNDROME; PRIMS	OSSIFIED EAR CARTILAGES WITH MENTAL DEFICIENCY, MUSCLE WASTING, ANDBONY CHANGES	259050
HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1; PHOAR1	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1; PHOAR1	259100
PHO, AUTOSOMAL RECESSIVE	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1; PHOAR1	259100
PACHYDERMOPERIOSTOSIS, AUTOSOMAL RECESSIVE	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1; PHOAR1	259100
PDP, AUTOSOMAL RECESSIVE	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1; PHOAR1	259100
TOURAINE-SOLENTE-GOLE SYNDROMECRANIOOSTEOARTHROPATHY, INCLUDED; COA, INCLUDED	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1; PHOAR1	259100
FAMILIAL IDIOPATHIC OSTEOARTHROPATHY OF CHILDHOOD, INCLUDED	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1; PHOAR1	259100
CURRARINO IDIOPATHIC OSTEOARTHROPATHY, INCLUDED; CIO, INCLUDED	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1; PHOAR1	259100
OSTEODYSPLASIA, FAMILIAL, ANDERSON TYPE	OSTEODYSPLASIA, FAMILIAL, ANDERSON TYPE	259250
OSTEOGENESIS IMPERFECTA, TYPE III; OI3	OSTEOGENESIS IMPERFECTA, TYPE III; OI3	259420
OI, TYPE III	OSTEOGENESIS IMPERFECTA, TYPE III; OI3	259420
OSTEOGENESIS IMPERFECTA, PROGRESSIVELY DEFORMING, WITH NORMAL SCLERAE	OSTEOGENESIS IMPERFECTA, TYPE III; OI3	259420
OSTEOGENESIS IMPERFECTA, TYPE IX; OI9	OSTEOGENESIS IMPERFECTA, TYPE IX; OI9	259440
OI, TYPE IX	OSTEOGENESIS IMPERFECTA, TYPE IX; OI9	259440
BRUCK SYNDROME 1; BRKS1	BRUCK SYNDROME 1; BRKS1	259450
KUSKOKWIM DISEASE	BRUCK SYNDROME 1; BRKS1	259450
ARTHROGRYPOSIS-LIKE DISORDER	BRUCK SYNDROME 1; BRKS1	259450
OSTEOGENIC SARCOMA	OSTEOGENIC SARCOMA	259500
OSTEOSARCOMA; OSRC	OSTEOGENIC SARCOMA	259500
MULTICENTRIC OSTEOLYSIS, NODULOSIS, AND ARTHROPATHY; MONA	MULTICENTRIC OSTEOLYSIS, NODULOSIS, AND ARTHROPATHY; MONA	259600
TORG SYNDROME	MULTICENTRIC OSTEOLYSIS, NODULOSIS, AND ARTHROPATHY; MONA	259600
NODULOSIS-ARTHROPATHY-OSTEOLYSIS SYNDROME	MULTICENTRIC OSTEOLYSIS, NODULOSIS, AND ARTHROPATHY; MONA	259600
NAO SYNDROME	MULTICENTRIC OSTEOLYSIS, NODULOSIS, AND ARTHROPATHY; MONA	259600
AL-AQEEL SEWAIRI SYNDROME	MULTICENTRIC OSTEOLYSIS, NODULOSIS, AND ARTHROPATHY; MONA	259600
OSTEOLYSIS, HEREDITARY MULTICENTRIC	MULTICENTRIC OSTEOLYSIS, NODULOSIS, AND ARTHROPATHY; MONA	259600
TORG-WINCHESTER SYNDROME, FORMERLY	MULTICENTRIC OSTEOLYSIS, NODULOSIS, AND ARTHROPATHY; MONA	259600
OSTEOPETROSIS, AUTOSOMAL RECESSIVE 1; OPTB1	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 1; OPTB1	259700
OSTEOPETROSIS, INFANTILE MALIGNANT 1	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 1; OPTB1	259700
MARBLE BONES, AUTOSOMAL RECESSIVE	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 1; OPTB1	259700
ALBERS-SCHONBERG DISEASE, AUTOSOMAL RECESSIVE	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 1; OPTB1	259700
OSTEOPETROSIS, AUTOSOMAL RECESSIVE 2; OPTB2	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 2; OPTB2	259710
OSTEOPETROSIS, OSTEOCLAST-POOR	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 2; OPTB2	259710
OSTEOPETROSIS, MILD AUTOSOMAL RECESSIVE FORM	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 2; OPTB2	259710
OSTEOPETROSIS, AUTOSOMAL RECESSIVE 5; OPTB5	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 5; OPTB5	259720
OSTEOPETROSIS, INFANTILE MALIGNANT 3	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 5; OPTB5	259720
OSTEOPETROSIS, AUTOSOMAL RECESSIVE 3; OPTB3	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 3; OPTB3	259730
OSTEOPETROSIS WITH RENAL TUBULAR ACIDOSIS	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 3; OPTB3	259730
CARBONIC ANHYDRASE II DEFICIENCY	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 3; OPTB3	259730
GUIBAUD-VAINSEL SYNDROME	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 3; OPTB3	259730
MARBLE BRAIN DISEASE	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 3; OPTB3	259730
OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; OPPG	OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; OPPG	259770
OPS	OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; OPPG	259770
OSTEOGENESIS IMPERFECTA, OCULAR FORM	OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; OPPG	259770
RAINE SYNDROME; RNS	RAINE SYNDROME; RNS	259775
OSTEOSCLEROTIC BONE DYSPLASIA, LETHAL	RAINE SYNDROME; RNS	259775
OTOONYCHOPERONEAL SYNDROME	OTOONYCHOPERONEAL SYNDROME	259780
HYPEROXALURIA, PRIMARY, TYPE I; HP1	HYPEROXALURIA, PRIMARY, TYPE I; HP1	259900
OXALOSIS I	HYPEROXALURIA, PRIMARY, TYPE I; HP1	259900
GLYCOLIC ACIDURIA	HYPEROXALURIA, PRIMARY, TYPE I; HP1	259900
ALANINE-GLYOXYLATE AMINOTRANSFERASE DEFICIENCY	HYPEROXALURIA, PRIMARY, TYPE I; HP1	259900
PEROXISOMAL ALANINE:GLYOXYLATE AMINOTRANSFERASE DEFICIENCY	HYPEROXALURIA, PRIMARY, TYPE I; HP1	259900
HEPATIC AGT DEFICIENCY	HYPEROXALURIA, PRIMARY, TYPE I; HP1	259900
SERINE:PYRUVATE AMINOTRANSFERASE DEFICIENCY	HYPEROXALURIA, PRIMARY, TYPE I; HP1	259900
HYPEROXALURIA, PRIMARY, TYPE II; HP2	HYPEROXALURIA, PRIMARY, TYPE II; HP2	260000
OXALOSIS II	HYPEROXALURIA, PRIMARY, TYPE II; HP2	260000
GLYCERIC ACIDURIA	HYPEROXALURIA, PRIMARY, TYPE II; HP2	260000
GLYOXYLATE REDUCTASE/HYDROXYPYRUVATE REDUCTASE DEFICIENCY	HYPEROXALURIA, PRIMARY, TYPE II; HP2	260000
D-GLYCERATE DEHYDROGENASE DEFICIENCY	HYPEROXALURIA, PRIMARY, TYPE II; HP2	260000
5-@OXOPROLINASE DEFICIENCY; OPLAHD	5-@OXOPROLINASE DEFICIENCY; OPLAHD	260005
OXOPROLINURIA DUE TO 5-OXOPROLINASE DEFICIENCY	5-@OXOPROLINASE DEFICIENCY; OPLAHD	260005
PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK15	PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK15	260300
PARKINSONIAN-PYRAMIDAL SYNDROME; PKPS	PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK15	260300
PALLIDOPYRAMIDAL SYNDROME	PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK15	260300
PALLIDO-PYRAMIDAL SYNDROME	PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK15	260300
PANCREATIC CANCER	PANCREATIC CANCER	260350
PANCREATIC CARCINOMA	PANCREATIC CANCER	260350
PANCREATIC ACINAR CARCINOMA	PANCREATIC CANCER	260350
PANCREATIC AGENESIS 1; PAGEN1	PANCREATIC AGENESIS 1; PAGEN1	260370
PAGEN	PANCREATIC AGENESIS 1; PAGEN1	260370
PANCREATIC HYPOPLASIA, CONGENITAL	PANCREATIC AGENESIS 1; PAGEN1	260370
SHWACHMAN-DIAMOND SYNDROME; SDS	SHWACHMAN-DIAMOND SYNDROME; SDS	260400
PANCREATIC INSUFFICIENCY AND BONE MARROW DYSFUNCTION	SHWACHMAN-DIAMOND SYNDROME; SDS	260400
SHWACHMAN-BODIAN SYNDROME	SHWACHMAN-DIAMOND SYNDROME; SDS	260400
LIPOMATOSIS OF PANCREAS, CONGENITAL	SHWACHMAN-DIAMOND SYNDROME; SDS	260400
PAPILLOMA OF CHOROID PLEXUS; CPP	PAPILLOMA OF CHOROID PLEXUS; CPP	260500
CHOROID PLEXUS PAPILLOMACHOROID PLEXUS CARCINOMA, INCLUDED; CPC, INCLUDED	PAPILLOMA OF CHOROID PLEXUS; CPP	260500
PARKINSON-DEMENTIA SYNDROMESUPRANUCLEAR PALSY, PROGRESSIVE, 1, ATYPICAL, INCLUDED	PARKINSON-DEMENTIA SYNDROMESUPRANUCLEAR PALSY, PROGRESSIVE, 1, ATYPICAL, INCLUDED	260540
STEELE-RICHARDSON-OLSZEWSKI SYNDROME, ATYPICAL, INCLUDED	PARKINSON-DEMENTIA SYNDROMESUPRANUCLEAR PALSY, PROGRESSIVE, 1, ATYPICAL, INCLUDED	260540
PEHO SYNDROME	PEHO SYNDROME	260565
PROGRESSIVE ENCEPHALOPATHY WITH EDEMA, HYPSARRHYTHMIA, AND OPTIC ATROPHY	PEHO SYNDROME	260565
INFANTILE CEREBELLOOPTIC ATROPHYPEHO-LIKE SYNDROME, INCLUDED	PEHO SYNDROME	260565
LEUKODYSTROPHY, HYPOMYELINATING, 3; HLD3	LEUKODYSTROPHY, HYPOMYELINATING, 3; HLD3	260600
COUSIN SYNDROME	COUSIN SYNDROME	260660
CRANIOFACIAL DYSMORPHISM, HYPOPLASIA OF SCAPULA AND PELVIS, AND SHORTSTATURE	COUSIN SYNDROME	260660
PELVISCAPULAR DYSPLASIA	COUSIN SYNDROME	260660
PENTOSURIA; PNTSU	PENTOSURIA; PNTSU	260800
L-XYLULOSURIA	PENTOSURIA; PNTSU	260800
XYLITOL DEHYDROGENASE DEFICIENCY	PENTOSURIA; PNTSU	260800
L-XYLULOSE REDUCTASE DEFICIENCY	PENTOSURIA; PNTSU	260800
HYPER-IgD SYNDROME; HIDS	HYPER-IgD SYNDROME; HIDS	260920
HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME	HYPER-IgD SYNDROME; HIDS	260920
PERIODIC FEVER, DUTCH TYPE	HYPER-IgD SYNDROME; HIDS	260920
INTRINSIC FACTOR DEFICIENCY; IFD	INTRINSIC FACTOR DEFICIENCY; IFD	261000
PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR	INTRINSIC FACTOR DEFICIENCY; IFD	261000
MEGALOBLASTIC ANEMIA 1	MEGALOBLASTIC ANEMIA 1	261100
MGA1	MEGALOBLASTIC ANEMIA 1	261100
IMERSLUND-GRASBECK SYNDROME; IGS	MEGALOBLASTIC ANEMIA 1	261100
PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTIONOF VITAMIN B12, WITH PROTEINURIA	MEGALOBLASTIC ANEMIA 1	261100
ENTEROCYTE COBALAMIN MALABSORPTION	MEGALOBLASTIC ANEMIA 1	261100
ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF	MEGALOBLASTIC ANEMIA 1	261100
EOSINOPHIL PEROXIDASE DEFICIENCY; EPXD	EOSINOPHIL PEROXIDASE DEFICIENCY; EPXD	261500
EOSINOPHIL PEROXIDASE DEFICIENCY, PARTIAL	EOSINOPHIL PEROXIDASE DEFICIENCY; EPXD	261500
PEROXIDASE AND PHOSPHOLIPID DEFICIENCY IN EOSINOPHILS	EOSINOPHIL PEROXIDASE DEFICIENCY; EPXD	261500
PRESENTEY ANOMALY	EOSINOPHIL PEROXIDASE DEFICIENCY; EPXD	261500
D-BIFUNCTIONAL PROTEIN DEFICIENCY	D-BIFUNCTIONAL PROTEIN DEFICIENCY	261515
17-@BETA-HYDROXYSTEROID DEHYDROGENASE IV DEFICIENCY	D-BIFUNCTIONAL PROTEIN DEFICIENCY	261515
DBP DEFICIENCY	D-BIFUNCTIONAL PROTEIN DEFICIENCY	261515
PEROXISOMAL BIFUNCTIONAL ENZYME DEFICIENCY	D-BIFUNCTIONAL PROTEIN DEFICIENCY	261515
PBFE DEFICIENCY	D-BIFUNCTIONAL PROTEIN DEFICIENCY	261515
PETERS-PLUS SYNDROME	PETERS-PLUS SYNDROME	261540
KRAUSE-KIVLIN SYNDROME	PETERS-PLUS SYNDROME	261540
PETERS ANOMALY WITH SHORT-LIMB DWARFISM	PETERS-PLUS SYNDROME	261540
PERSISTENT MULLERIAN DUCT SYNDROME, TYPES I AND II; PMDS	PERSISTENT MULLERIAN DUCT SYNDROME, TYPES I AND II; PMDS	261550
PSEUDOHERMAPHRODITISM, MALE INTERNAL	PERSISTENT MULLERIAN DUCT SYNDROME, TYPES I AND II; PMDS	261550
HERNIA UTERI INGUINALE	PERSISTENT MULLERIAN DUCT SYNDROME, TYPES I AND II; PMDS	261550
PERSISTENT OVIDUCT SYNDROME	PERSISTENT MULLERIAN DUCT SYNDROME, TYPES I AND II; PMDS	261550
FEMALE GENITAL DUCTS IN OTHERWISE NORMAL MALE	PERSISTENT MULLERIAN DUCT SYNDROME, TYPES I AND II; PMDS	261550
PHENYLKETONURIA; PKU	PHENYLKETONURIA; PKU	261600
PHENYLALANINE HYDROXYLASE DEFICIENCY	PHENYLKETONURIA; PKU	261600
PAH DEFICIENCY	PHENYLKETONURIA; PKU	261600
OLIGOPHRENIA PHENYLPYRUVICA	PHENYLKETONURIA; PKU	261600
FOLLING DISEASEHYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED	PHENYLKETONURIA; PKU	261600
HPA, NON-PKU MILD, INCLUDED	PHENYLKETONURIA; PKU	261600
PHENYLKETONURIA, MATERNAL, INCLUDED	PHENYLKETONURIA; PKU	261600
HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C	261630
HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPRDEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C	261630
DIHYDROPTERIDINE REDUCTASE DEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C	261630
DHPR DEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C	261630
QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C	261630
QDPR DEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C	261630
HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A	261640
HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A	261640
6-@PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A	261640
PTS DEFICIENCYHYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY,INCLUDED	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A	261640
PHOSPHOENOLPYRUVATE CARBOXYKINASE DEFICIENCY, MITOCHONDRIAL	PHOSPHOENOLPYRUVATE CARBOXYKINASE DEFICIENCY, MITOCHONDRIAL	261650
PCK2 DEFICIENCY	PHOSPHOENOLPYRUVATE CARBOXYKINASE DEFICIENCY, MITOCHONDRIAL	261650
PEPCK2 DEFICIENCY	PHOSPHOENOLPYRUVATE CARBOXYKINASE DEFICIENCY, MITOCHONDRIAL	261650
GLYCOGEN STORAGE DISEASE X; GSD10	GLYCOGEN STORAGE DISEASE X; GSD10	261670
GSD X	GLYCOGEN STORAGE DISEASE X; GSD10	261670
PHOSPHOGLYCERATE MUTASE, MUSCLE, DEFICIENCY OF	GLYCOGEN STORAGE DISEASE X; GSD10	261670
MYOPATHY DUE TO PHOSPHOGLYCERATE MUTASE DEFICIENCY	GLYCOGEN STORAGE DISEASE X; GSD10	261670
PGAMM DEFICIENCY	GLYCOGEN STORAGE DISEASE X; GSD10	261670
GLYCOGEN STORAGE DISEASE OF HEART, LETHAL CONGENITAL	GLYCOGEN STORAGE DISEASE OF HEART, LETHAL CONGENITAL	261740
PHOSPHORYLASE KINASE DEFICIENCY OF HEART	GLYCOGEN STORAGE DISEASE OF HEART, LETHAL CONGENITAL	261740
GLYCOGEN STORAGE DISEASE OF HEART	GLYCOGEN STORAGE DISEASE OF HEART, LETHAL CONGENITAL	261740
GLYCOGEN STORAGE DISEASE IXb; GSD9B	GLYCOGEN STORAGE DISEASE IXb; GSD9B	261750
GSD IXb	GLYCOGEN STORAGE DISEASE IXb; GSD9B	261750
GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE	GLYCOGEN STORAGE DISEASE IXb; GSD9B	261750
PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE	GLYCOGEN STORAGE DISEASE IXb; GSD9B	261750
PIERRE ROBIN SYNDROME; PRBNS	PIERRE ROBIN SYNDROME; PRBNS	261800
GLOSSOPTOSIS, MICROGNATHIA, AND CLEFT PALATE	PIERRE ROBIN SYNDROME; PRBNS	261800
PIERRE ROBIN SEQUENCE	PIERRE ROBIN SYNDROME; PRBNS	261800
PILI TORTI, EARLY-ONSET	PILI TORTI, EARLY-ONSET	261900
PILI TORTI, RONCHESE TYPE	PILI TORTI, EARLY-ONSET	261900
TWISTED HAIR	PILI TORTI, EARLY-ONSET	261900
BJORNSTAD SYNDROME; BJS	BJORNSTAD SYNDROME; BJS	262000
PILI TORTI AND NERVE DEAFNESS	BJORNSTAD SYNDROME; BJS	262000
PTD	BJORNSTAD SYNDROME; BJS	262000
PINEAL HYPERPLASIA, INSULIN-RESISTANT DIABETES MELLITUS, AND SOMATICABNORMALITIES	PINEAL HYPERPLASIA, INSULIN-RESISTANT DIABETES MELLITUS, AND SOMATICABNORMALITIES	262190
RABSON-MENDENHALL SYNDROME	PINEAL HYPERPLASIA, INSULIN-RESISTANT DIABETES MELLITUS, AND SOMATICABNORMALITIES	262190
MENDENHALL SYNDROME	PINEAL HYPERPLASIA, INSULIN-RESISTANT DIABETES MELLITUS, AND SOMATICABNORMALITIES	262190
ACHROMATOPSIA 3; ACHM3	ACHROMATOPSIA 3; ACHM3	262300
PINGELAPESE BLINDNESS	ACHROMATOPSIA 3; ACHM3	262300
TOTAL COLORBLINDNESS WITH MYOPIA	ACHROMATOPSIA 3; ACHM3	262300
ACHROMATOPSIA WITH MYOPIA	ACHROMATOPSIA 3; ACHM3	262300
ACHM1, FORMERLY	ACHROMATOPSIA 3; ACHM3	262300
ROD MONOCHROMATISM 1, FORMERLY	ACHROMATOPSIA 3; ACHM3	262300
ROD MONOCHROMACY 1, FORMERLY; RMCH1, FORMERLY	ACHROMATOPSIA 3; ACHM3	262300
ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IA; IGHD1A	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IA; IGHD1A	262400
IGHD IA	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IA; IGHD1A	262400
GROWTH HORMONE DEFICIENCY, ISOLATED, AUTOSOMAL RECESSIVE	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IA; IGHD1A	262400
ILLIG-TYPE GROWTH HORMONE DEFICIENCY	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IA; IGHD1A	262400
PRIMORDIAL DWARFISM	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IA; IGHD1A	262400
SEXUAL ATELEIOTIC DWARFISM	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IA; IGHD1A	262400
PITUITARY DWARFISM I	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IA; IGHD1A	262400
LARON SYNDROME	LARON SYNDROME	262500
GROWTH HORMONE INSENSITIVITY SYNDROME	LARON SYNDROME	262500
PITUITARY DWARFISM II	LARON SYNDROME	262500
GROWTH HORMONE RECEPTOR DEFICIENCY	LARON SYNDROME	262500
PITUITARY HORMONE DEFICIENCY, COMBINED, 2; CPHD2	PITUITARY HORMONE DEFICIENCY, COMBINED, 2; CPHD2	262600
PANHYPOPITUITARISM	PITUITARY HORMONE DEFICIENCY, COMBINED, 2; CPHD2	262600
ATELIOTIC DWARFISM WITH HYPOGONADISM	PITUITARY HORMONE DEFICIENCY, COMBINED, 2; CPHD2	262600
PITUITARY DWARFISM III	PITUITARY HORMONE DEFICIENCY, COMBINED, 2; CPHD2	262600
HANHART DWARFISM	PITUITARY HORMONE DEFICIENCY, COMBINED, 2; CPHD2	262600
KOWARSKI SYNDROME	KOWARSKI SYNDROME	262650
BIODEFECTIVE GROWTH HORMONE	KOWARSKI SYNDROME	262650
PITUITARY DWARFISM WITH NORMAL IMMUNOREACTIVE GROWTH HORMONE AND LOWSOMATOMEDIN	KOWARSKI SYNDROME	262650
PITUITARY HORMONE DEFICIENCY, COMBINED, 4; CPHD4	PITUITARY HORMONE DEFICIENCY, COMBINED, 4; CPHD4	262700
PITUITARY HORMONE DEFICIENCY, COMBINED, WITH OR WITHOUT CEREBELLARDEFECTS	PITUITARY HORMONE DEFICIENCY, COMBINED, 4; CPHD4	262700
SHORT STATURE, PITUITARY AND CEREBELLAR DEFECTS, AND SMALL SELLA TURCICA	PITUITARY HORMONE DEFICIENCY, COMBINED, 4; CPHD4	262700
ALPHA-2-PLASMIN INHIBITOR DEFICIENCY	ALPHA-2-PLASMIN INHIBITOR DEFICIENCY	262850
ANTIPLASMIN DEFICIENCY	ALPHA-2-PLASMIN INHIBITOR DEFICIENCY	262850
PLASMIN INHIBITOR DEFICIENCY	ALPHA-2-PLASMIN INHIBITOR DEFICIENCY	262850
SCOTT SYNDROME; SCTS	SCOTT SYNDROME; SCTS	262890
BLEEDING DISORDER, PLATELET-TYPE, 7; BDPLT7	SCOTT SYNDROME; SCTS	262890
BLEEDING ABNORMALITY DUE TO DEFICIENCY OF PLATELET BINDING OF FACTORX	SCOTT SYNDROME; SCTS	262890
PROTHROMBIN CONVERSION DEFECT, FAMILIAL	SCOTT SYNDROME; SCTS	262890
PROTHROMBIN CONSUMPTION DEFICIENCY	SCOTT SYNDROME; SCTS	262890
PROTHROMBIN CONSUMPTION INHIBITOR, FAMILIAL	SCOTT SYNDROME; SCTS	262890
INTERSTITIAL PNEUMONITIS, DESQUAMATIVE, FAMILIAL; DIP	INTERSTITIAL PNEUMONITIS, DESQUAMATIVE, FAMILIAL; DIP	263000
PNEUMONITIS, DESQUAMATIVE INTERSTITIAL, FAMILIAL	INTERSTITIAL PNEUMONITIS, DESQUAMATIVE, FAMILIAL; DIP	263000
PNEUMONIA, DESQUAMATIVE INTERSTITIAL, FAMILIAL	INTERSTITIAL PNEUMONITIS, DESQUAMATIVE, FAMILIAL; DIP	263000
INTERSTITIAL LUNG DISEASE, DESQUAMATIVE	INTERSTITIAL PNEUMONITIS, DESQUAMATIVE, FAMILIAL; DIP	263000
ILD, DESQUAMATIVE	INTERSTITIAL PNEUMONITIS, DESQUAMATIVE, FAMILIAL; DIP	263000
POLYCYSTIC KIDNEY DISEASE, AUTOSOMAL RECESSIVE; ARPKD	POLYCYSTIC KIDNEY DISEASE, AUTOSOMAL RECESSIVE; ARPKD	263200
POLYCYSTIC KIDNEY AND HEPATIC DISEASE 1; PKHD1	POLYCYSTIC KIDNEY DISEASE, AUTOSOMAL RECESSIVE; ARPKD	263200
POLYCYSTIC KIDNEY DISEASE, INFANTILE, TYPE I	POLYCYSTIC KIDNEY DISEASE, AUTOSOMAL RECESSIVE; ARPKD	263200
PKD3, FORMERLYHEPATIC FIBROSIS, CONGENITAL, INCLUDED	POLYCYSTIC KIDNEY DISEASE, AUTOSOMAL RECESSIVE; ARPKD	263200
POLYCYSTIC KIDNEY DISEASE, POTTER TYPE I, WITH MICROBRACHYCEPHALY,HYPERTELORISM, AND BRACHYMELIA	POLYCYSTIC KIDNEY DISEASE, POTTER TYPE I, WITH MICROBRACHYCEPHALY,HYPERTELORISM, AND BRACHYMELIA	263210
POLYCYTHEMIA VERA; PV	POLYCYTHEMIA VERA; PV	263300
POLYCYTHEMIA RUBRA VERA; PRV	POLYCYTHEMIA VERA; PV	263300
ERYTHROCYTOSIS, FAMILIAL, 2; ECYT2	ERYTHROCYTOSIS, FAMILIAL, 2; ECYT2	263400
ERYTHROCYTOSIS, AUTOSOMAL RECESSIVE BENIGN	ERYTHROCYTOSIS, FAMILIAL, 2; ECYT2	263400
POLYCYTHEMIA, VHL-DEPENDENT	ERYTHROCYTOSIS, FAMILIAL, 2; ECYT2	263400
POLYCYTHEMIA, CHUVASH TYPE	ERYTHROCYTOSIS, FAMILIAL, 2; ECYT2	263400
POLYDACTYLY, POSTAXIAL, TYPE A5; PAPA5	POLYDACTYLY, POSTAXIAL, TYPE A5; PAPA5	263450
SHORT-RIB THORACIC DYSPLASIA 6 WITH OR WITHOUT POLYDACTYLY; SRTD6	SHORT-RIB THORACIC DYSPLASIA 6 WITH OR WITHOUT POLYDACTYLY; SRTD6	263520
SHORT RIB-POLYDACTYLY SYNDROME, TYPE II	SHORT-RIB THORACIC DYSPLASIA 6 WITH OR WITHOUT POLYDACTYLY; SRTD6	263520
SRPS, TYPE II	SHORT-RIB THORACIC DYSPLASIA 6 WITH OR WITHOUT POLYDACTYLY; SRTD6	263520
MAJEWSKI SYNDROME	SHORT-RIB THORACIC DYSPLASIA 6 WITH OR WITHOUT POLYDACTYLY; SRTD6	263520
SHORT RIB-POLYDACTYLY SYNDROME, TYPE IIA; SRPS2A	SHORT-RIB THORACIC DYSPLASIA 6 WITH OR WITHOUT POLYDACTYLY; SRTD6	263520
POLYDACTYLY WITH NEONATAL CHONDRODYSTROPHY, TYPE II	SHORT-RIB THORACIC DYSPLASIA 6 WITH OR WITHOUT POLYDACTYLY; SRTD6	263520
POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN	POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN	263570
POLYGLUCOSAN BODY DISEASE, ADULT FORM; APBD	POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN	263570
POLYSYNDACTYLY WITH CARDIAC MALFORMATION	POLYSYNDACTYLY WITH CARDIAC MALFORMATION	263630
BONNEAU SYNDROME	POLYSYNDACTYLY WITH CARDIAC MALFORMATION	263630
POPLITEAL PTERYGIUM SYNDROME, LETHAL TYPE	POPLITEAL PTERYGIUM SYNDROME, LETHAL TYPE	263650
BARTSOCAS-PAPAS SYNDROME; BPS	POPLITEAL PTERYGIUM SYNDROME, LETHAL TYPE	263650
PTERYGIUM, POPLITEAL, LETHAL TYPE	POPLITEAL PTERYGIUM SYNDROME, LETHAL TYPE	263650
MULTIPLE PTERYGIUM SYNDROME, ASLAN TYPE	POPLITEAL PTERYGIUM SYNDROME, LETHAL TYPE	263650
PORPHYRIA, CONGENITAL ERYTHROPOIETIC	PORPHYRIA, CONGENITAL ERYTHROPOIETIC	263700
CEP	PORPHYRIA, CONGENITAL ERYTHROPOIETIC	263700
GUNTHER DISEASE	PORPHYRIA, CONGENITAL ERYTHROPOIETIC	263700
UROPORPHYRINOGEN III SYNTHASE DEFICIENCY	PORPHYRIA, CONGENITAL ERYTHROPOIETIC	263700
UROS DEFICIENCY	PORPHYRIA, CONGENITAL ERYTHROPOIETIC	263700
POSTAXIAL ACROFACIAL DYSOSTOSIS; POADS	POSTAXIAL ACROFACIAL DYSOSTOSIS; POADS	263750
MILLER SYNDROME	POSTAXIAL ACROFACIAL DYSOSTOSIS; POADS	263750
GENEE-WIEDEMANN SYNDROME	POSTAXIAL ACROFACIAL DYSOSTOSIS; POADS	263750
GITELMAN SYNDROME	GITELMAN SYNDROME	263800
HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA	GITELMAN SYNDROME	263800
POTASSIUM AND MAGNESIUM DEPLETION	GITELMAN SYNDROME	263800
HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D	264070
HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINEDEHYDRATASE DEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D	264070
HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D	264070
CADH DEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D	264070
PCBD DEFICIENCY	HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D	264070
PROGEROID SYNDROME, NEONATAL	PROGEROID SYNDROME, NEONATAL	264090
WIEDEMANN-RAUTENSTRAUCH SYNDROME	PROGEROID SYNDROME, NEONATAL	264090
PSEUDOHERMAPHRODITISM, FEMALE, WITH SKELETAL ANOMALIES	PSEUDOHERMAPHRODITISM, FEMALE, WITH SKELETAL ANOMALIES	264270
17-@BETA HYDROXYSTEROID DEHYDROGENASE III DEFICIENCY	17-@BETA HYDROXYSTEROID DEHYDROGENASE III DEFICIENCY	264300
17-@KETOSTEROID REDUCTASE DEFICIENCY OF TESTIS	17-@BETA HYDROXYSTEROID DEHYDROGENASE III DEFICIENCY	264300
17-@KSR DEFICIENCY	17-@BETA HYDROXYSTEROID DEHYDROGENASE III DEFICIENCY	264300
NEUTRAL 17-BETA-HYDROXYSTEROID OXIDOREDUCTASE DEFICIENCY	17-@BETA HYDROXYSTEROID DEHYDROGENASE III DEFICIENCY	264300
PSEUDOHERMAPHRODITISM, MALE, WITH GYNECOMASTIAPOLYCYSTIC OVARIAN DISEASE DUE TO 17-KETOSTEROID REDUCTASE DEFICIENCY,INCLUDED	17-@BETA HYDROXYSTEROID DEHYDROGENASE III DEFICIENCY	264300
PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL RECESSIVE; PHA1B	PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL RECESSIVE; PHA1B	264350
PHA I, AUTOSOMAL RECESSIVE	PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL RECESSIVE; PHA1B	264350
PEROXISOMAL ACYL-CoA OXIDASE DEFICIENCY	PEROXISOMAL ACYL-CoA OXIDASE DEFICIENCY	264470
STRAIGHT-CHAIN ACYL-CoA OXIDASE DEFICIENCY	PEROXISOMAL ACYL-CoA OXIDASE DEFICIENCY	264470
PSEUDONEONATAL ADRENOLEUKODYSTROPHY	PEROXISOMAL ACYL-CoA OXIDASE DEFICIENCY	264470
PSEUDOVAGINAL PERINEOSCROTAL HYPOSPADIAS; PPSH	PSEUDOVAGINAL PERINEOSCROTAL HYPOSPADIAS; PPSH	264600
MALE PSEUDOHERMAPHRODITISM DUE TO 5-ALPHA-REDUCTASE DEFICIENCY	PSEUDOVAGINAL PERINEOSCROTAL HYPOSPADIAS; PPSH	264600
FAMILIAL INCOMPLETE MALE PSEUDOHERMAPHRODITISM, TYPE 2	PSEUDOVAGINAL PERINEOSCROTAL HYPOSPADIAS; PPSH	264600
VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A	264700
VITAMIN D-DEPENDENT RICKETS, TYPE 1A	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A	264700
1@-ALPHA, 25-HYDROXYVITAMIN D3 DEFICIENCY, SELECTIVE	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A	264700
25-@HYDROXYCHOLECALCIFEROL-1-HYDROXYLASE DEFICIENCY	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A	264700
1-@ALPHA-HYDROXYLASE DEFICIENCY	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A	264700
VITAMIN D DEPENDENCY, TYPE 1; VDD1	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A	264700
PSEUDOVITAMIN D-DEFICIENCY RICKETS, TYPE IA; PDDR1A	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A	264700
PDDR IA	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A	264700
PSEUDOXANTHOMA ELASTICUM; PXE	PSEUDOXANTHOMA ELASTICUM; PXE	264800
GRONBLAD-STRANDBERG SYNDROMEPSEUDOXANTHOMA ELASTICUM, MODIFIER OF SEVERITY OF, INCLUDED	PSEUDOXANTHOMA ELASTICUM; PXE	264800
PXE, MODIFIER OF SEVERITY OF, INCLUDED	PSEUDOXANTHOMA ELASTICUM; PXE	264800
MULTIPLE PTERYGIUM SYNDROME, ESCOBAR VARIANT; EVMPS	MULTIPLE PTERYGIUM SYNDROME, ESCOBAR VARIANT; EVMPS	265000
ESCOBAR SYNDROME	MULTIPLE PTERYGIUM SYNDROME, ESCOBAR VARIANT; EVMPS	265000
MULTIPLE PTERYGIUM SYNDROME, NONLETHAL TYPE	MULTIPLE PTERYGIUM SYNDROME, ESCOBAR VARIANT; EVMPS	265000
PTERYGIUM SYNDROME	MULTIPLE PTERYGIUM SYNDROME, ESCOBAR VARIANT; EVMPS	265000
MULTIPLE PTERYGIUM SYNDROME	MULTIPLE PTERYGIUM SYNDROME, ESCOBAR VARIANT; EVMPS	265000
PTERYGIUM COLLI SYNDROME	MULTIPLE PTERYGIUM SYNDROME, ESCOBAR VARIANT; EVMPS	265000
PTERYGIUM UNIVERSALE	MULTIPLE PTERYGIUM SYNDROME, ESCOBAR VARIANT; EVMPS	265000
3MC SYNDROME 2; 3MC2	3MC SYNDROME 2; 3MC2	265050
PTOSIS OF EYELIDS WITH DIASTASIS RECTI AND HIP DYSPLASIA	3MC SYNDROME 2; 3MC2	265050
OCULO-SKELETAL-ABDOMINAL SYNDROME	3MC SYNDROME 2; 3MC2	265050
OSA SYNDROME	3MC SYNDROME 2; 3MC2	265050
CARNEVALE SYNDROME, FORMERLY	3MC SYNDROME 2; 3MC2	265050
PULMONARY ALVEOLAR MICROLITHIASIS	PULMONARY ALVEOLAR MICROLITHIASIS	265100
SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 1; SMDP1	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 1; SMDP1	265120
PULMONARY ALVEOLAR PROTEINOSIS, CONGENITAL, 1	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 1; SMDP1	265120
INTERSTITIAL LUNG DISEASE DUE TO SURFACTANT PROTEIN B DEFICIENCY	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 1; SMDP1	265120
INTERSTITIAL LUNG DISEASE, NONSPECIFIC, DUE TO SURFACTANT PROTEINB DEFICIENCY	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 1; SMDP1	265120
LYMPHANGIECTASIA, PULMONARY, CONGENITAL; CPL	LYMPHANGIECTASIA, PULMONARY, CONGENITAL; CPL	265300
LYMPHANGIOMATOSIS, PULMONARY	LYMPHANGIECTASIA, PULMONARY, CONGENITAL; CPL	265300
PULMONARY CYSTIC LYMPHANGIECTASIS	LYMPHANGIECTASIA, PULMONARY, CONGENITAL; CPL	265300
ALVEOLAR CAPILLARY DYSPLASIA WITH MISALIGNMENT OF PULMONARY VEINS;ACDMPV	ALVEOLAR CAPILLARY DYSPLASIA WITH MISALIGNMENT OF PULMONARY VEINS;ACDMPV	265380
ALVEOLAR CAPILLARY DYSPLASIA WITH MISALIGNMENT OF PULMONARY VEINSAND OTHER CONGENITAL ANOMALIES	ALVEOLAR CAPILLARY DYSPLASIA WITH MISALIGNMENT OF PULMONARY VEINS;ACDMPV	265380
PULMONARY VENOOCCLUSIVE DISEASE 1, AUTOSOMAL DOMINANT; PVOD1	PULMONARY VENOOCCLUSIVE DISEASE 1, AUTOSOMAL DOMINANT; PVOD1	265450
PVOD	PULMONARY VENOOCCLUSIVE DISEASE 1, AUTOSOMAL DOMINANT; PVOD1	265450
PYCNODYSOSTOSIS	PYCNODYSOSTOSIS	265800
PYKNODYSOSTOSIS; PKND	PYCNODYSOSTOSIS	265800
PYCD	PYCNODYSOSTOSIS	265800
PYGMY	PYGMY	265850
PYGMY, AFRICAN	PYGMY	265850
PYLE DISEASE	PYLE DISEASE	265900
METAPHYSEAL DYSPLASIA	PYLE DISEASE	265900
PYLORIC ATRESIA	PYLORIC ATRESIA	265950
EPILEPSY, PYRIDOXINE-DEPENDENT; EPD	EPILEPSY, PYRIDOXINE-DEPENDENT; EPD	266100
PYRIDOXINE-DEPENDENT EPILEPSY; PDE	EPILEPSY, PYRIDOXINE-DEPENDENT; EPD	266100
PYRIDOXINE DEPENDENCY WITH SEIZURES	EPILEPSY, PYRIDOXINE-DEPENDENT; EPD	266100
AASA DEHYDROGENASE DEFICIENCY	EPILEPSY, PYRIDOXINE-DEPENDENT; EPD	266100
URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE DEFICIENCY, HEMOLYTIC ANEMIADUE TO	URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE DEFICIENCY, HEMOLYTIC ANEMIADUE TO	266120
HEMOLYTIC ANEMIA DUE TO UMPH1 DEFICIENCY	URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE DEFICIENCY, HEMOLYTIC ANEMIADUE TO	266120
PYRIMIDINE 5-PRIME NUCLEOTIDASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO	URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE DEFICIENCY, HEMOLYTIC ANEMIADUE TO	266120
HEMOLYTIC ANEMIA DUE TO P5N DEFICIENCY	URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE DEFICIENCY, HEMOLYTIC ANEMIADUE TO	266120
P5N DEFICIENCY	URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE DEFICIENCY, HEMOLYTIC ANEMIADUE TO	266120
UMPH1 DEFICIENCY	URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE DEFICIENCY, HEMOLYTIC ANEMIADUE TO	266120
GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD	GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD	266130
5-@OXOPROLINURIA	GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD	266130
PYROGLUTAMIC ACIDURIA	GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD	266130
PYROPOIKILOCYTOSIS, HEREDITARY; HPP	PYROPOIKILOCYTOSIS, HEREDITARY; HPP	266140
PYRUVATE CARBOXYLASE DEFICIENCY	PYRUVATE CARBOXYLASE DEFICIENCY	266150
PC DEFICIENCY	PYRUVATE CARBOXYLASE DEFICIENCY	266150
ATAXIA WITH LACTIC ACIDOSIS II	PYRUVATE CARBOXYLASE DEFICIENCY	266150
LEIGH NECROTIZING ENCEPHALOPATHY DUE TO PYRUVATE CARBOXYLASE DEFICIENCY	PYRUVATE CARBOXYLASE DEFICIENCY	266150
LEIGH SYNDROME DUE TO PYRUVATE CARBOXYLASE DEFICIENCY	PYRUVATE CARBOXYLASE DEFICIENCY	266150
PYRUVATE KINASE DEFICIENCY OF RED CELLS	PYRUVATE KINASE DEFICIENCY OF RED CELLS	266200
PYRUVATE KINASE DEFICIENCY OF ERYTHROCYTE	PYRUVATE KINASE DEFICIENCY OF RED CELLS	266200
PK DEFICIENCY	PYRUVATE KINASE DEFICIENCY OF RED CELLS	266200
RADICULONEUROPATHY, FATAL NEONATAL	RADICULONEUROPATHY, FATAL NEONATAL	266250
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C	266265
CDG IIc; CDGIIc	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C	266265
LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C	266265
RAMBAM-HASHARON SYNDROME; RHS	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C	266265
RAPADILINO SYNDROME	RAPADILINO SYNDROME	266280
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 2; SHEP2	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 2; SHEP2	266300
RED HAIR COLOR; RHC	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 2; SHEP2	266300
BLOND HAIR/FAIR SKIN	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 2; SHEP2	266300
RHA	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 2; SHEP2	266300
HAIR COLOR 2; HCL2UV-INDUCED SKIN DAMAGE, SUSCEPTIBILITY TO, INCLUDED	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 2; SHEP2	266300
RED SKIN PIGMENT ANOMALY OF NEW GUINEA	RED SKIN PIGMENT ANOMALY OF NEW GUINEA	266350
REFSUM DISEASE, CLASSIC	REFSUM DISEASE, CLASSIC	266500
REFSUM DISEASE, ADULT, 1	REFSUM DISEASE, CLASSIC	266500
PHYTANIC ACID OXIDASE DEFICIENCY	REFSUM DISEASE, CLASSIC	266500
HEREDOPATHIA ATACTICA POLYNEURITIFORMIS	REFSUM DISEASE, CLASSIC	266500
HEREDITARY MOTOR AND SENSORY NEUROPATHY IV; HMSN4	REFSUM DISEASE, CLASSIC	266500
HMSN IV	REFSUM DISEASE, CLASSIC	266500
PEROXISOME BIOGENESIS DISORDER 3B; PBD3B	PEROXISOME BIOGENESIS DISORDER 3B; PBD3B	266510
INFLAMMATORY BOWEL DISEASE 1; IBD1REGIONAL ENTERITIS, INCLUDED	INFLAMMATORY BOWEL DISEASE 1; IBD1REGIONAL ENTERITIS, INCLUDED	266600
CROHN DISEASE, INCLUDED	INFLAMMATORY BOWEL DISEASE 1; IBD1REGIONAL ENTERITIS, INCLUDED	266600
ULCERATIVE COLITIS, INCLUDED	INFLAMMATORY BOWEL DISEASE 1; IBD1REGIONAL ENTERITIS, INCLUDED	266600
CROHN DISEASE-ASSOCIATED GROWTH FAILURE, SUSCEPTIBILITY TO, INCLUDED	INFLAMMATORY BOWEL DISEASE 1; IBD1REGIONAL ENTERITIS, INCLUDED	266600
SENIOR-LOKEN SYNDROME 1; SLSN1	SENIOR-LOKEN SYNDROME 1; SLSN1	266900
SENIOR-LOKEN SYNDROME	SENIOR-LOKEN SYNDROME 1; SLSN1	266900
LOKEN-SENIOR SYNDROME	SENIOR-LOKEN SYNDROME 1; SLSN1	266900
RENAL-RETINAL SYNDROME	SENIOR-LOKEN SYNDROME 1; SLSN1	266900
JUVENILE NEPHRONOPHTHISIS WITH LEBER AMAUROSIS	SENIOR-LOKEN SYNDROME 1; SLSN1	266900
RENAL DYSPLASIA AND RETINAL APLASIA	SENIOR-LOKEN SYNDROME 1; SLSN1	266900
SHORT-RIB THORACIC DYSPLASIA 9 WITH OR WITHOUT POLYDACTYLY; SRTD9	SHORT-RIB THORACIC DYSPLASIA 9 WITH OR WITHOUT POLYDACTYLY; SRTD9	266920
MAINZER-SALDINO SYNDROME; MZSDS	SHORT-RIB THORACIC DYSPLASIA 9 WITH OR WITHOUT POLYDACTYLY; SRTD9	266920
CONORENAL SYNDROME	SHORT-RIB THORACIC DYSPLASIA 9 WITH OR WITHOUT POLYDACTYLY; SRTD9	266920
RENAL DYSPLASIA, RETINAL PIGMENTARY DYSTROPHY, CEREBELLAR ATAXIA,AND SKELETAL DYSPLASIA	SHORT-RIB THORACIC DYSPLASIA 9 WITH OR WITHOUT POLYDACTYLY; SRTD9	266920
PERLMAN SYNDROME; PRLMNS	PERLMAN SYNDROME; PRLMNS	267000
RENAL HAMARTOMAS, NEPHROBLASTOMATOSIS, AND FETAL GIGANTISM	PERLMAN SYNDROME; PRLMNS	267000
NEPHROBLASTOMATOSIS, FETAL ASCITES, MACROSOMIA, AND WILMS TUMOR	PERLMAN SYNDROME; PRLMNS	267000
MECKEL SYNDROME, TYPE 7; MKS7	MECKEL SYNDROME, TYPE 7; MKS7	267010
RENAL-HEPATIC-PANCREATIC DYSPLASIA WITH DANDY-WALKER CYST	MECKEL SYNDROME, TYPE 7; MKS7	267010
GOLDSTON SYNDROME	MECKEL SYNDROME, TYPE 7; MKS7	267010
RENAL TUBULAR ACIDOSIS, DISTAL, WITH PROGRESSIVE NERVE DEAFNESS	RENAL TUBULAR ACIDOSIS, DISTAL, WITH PROGRESSIVE NERVE DEAFNESS	267300
RENAL TUBULAR ACIDOSIS, AUTOSOMAL RECESSIVE, WITH PROGRESSIVE NERVEDEAFNESS	RENAL TUBULAR ACIDOSIS, DISTAL, WITH PROGRESSIVE NERVE DEAFNESS	267300
RENAL TUBULAR ACIDOSIS WITH PROGRESSIVE NERVE DEAFNESS	RENAL TUBULAR ACIDOSIS, DISTAL, WITH PROGRESSIVE NERVE DEAFNESS	267300
RTA WITH PROGRESSIVE NERVE DEAFNESS	RENAL TUBULAR ACIDOSIS, DISTAL, WITH PROGRESSIVE NERVE DEAFNESS	267300
RENAL TUBULAR DYSGENESIS; RTD	RENAL TUBULAR DYSGENESIS; RTD	267430
PRIMITIVE RENAL TUBULE SYNDROMERENAL TUBULAR DYSGENESIS WITH CHOANAL ATRESIA AND ATHELIA, INCLUDED	RENAL TUBULAR DYSGENESIS; RTD	267430
RETICULAR DYSGENESIS	RETICULAR DYSGENESIS	267500
RETICULAR DYSGENESIA	RETICULAR DYSGENESIS	267500
CONGENITAL ALEUKIA	RETICULAR DYSGENESIS	267500
SEVERE COMBINED IMMUNODEFICIENCY WITH LEUKOPENIA	RETICULAR DYSGENESIS	267500
DE VAAL DISEASE	RETICULAR DYSGENESIS	267500
HEMATOPOIETIC HYPOPLASIA, GENERALIZED	RETICULAR DYSGENESIS	267500
ALEUKOCYTOSIS	RETICULAR DYSGENESIS	267500
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1	267700
HPLH1	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1	267700
HLH1	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1	267700
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL; FHL; FHLH; HPLH	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1	267700
RETICULOSIS, FAMILIAL HISTIOCYTIC	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1	267700
HEMOPHAGOCYTIC RETICULOSIS, FAMILIAL	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1	267700
ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL; FEL	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1	267700
KNOBLOCH SYNDROME 1; KNO1	KNOBLOCH SYNDROME 1; KNO1	267750
KNO	KNOBLOCH SYNDROME 1; KNO1	267750
RETINAL DETACHMENT AND OCCIPITAL ENCEPHALOCELE	KNOBLOCH SYNDROME 1; KNO1	267750
RETINITIS PIGMENTOSA; RP	RETINITIS PIGMENTOSA; RP	268000
RETINOSCHISIS OF FOVEA	RETINOSCHISIS OF FOVEA	268080
ENHANCED S-CONE SYNDROME; ESCSGOLDMANN-FAVRE SYNDROME, INCLUDED	ENHANCED S-CONE SYNDROME; ESCSGOLDMANN-FAVRE SYNDROME, INCLUDED	268100
RETINOSCHISIS WITH EARLY HEMERALOPIA, INCLUDED	ENHANCED S-CONE SYNDROME; ESCSGOLDMANN-FAVRE SYNDROME, INCLUDED	268100
FAVRE HYALOIDEORETINAL DEGENERATION, INCLUDED	ENHANCED S-CONE SYNDROME; ESCSGOLDMANN-FAVRE SYNDROME, INCLUDED	268100
REVESZ SYNDROME	REVESZ SYNDROME	268130
DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 5; DKCA5	REVESZ SYNDROME	268130
EXUDATIVE RETINOPATHY WITH BONE MARROW FAILURE	REVESZ SYNDROME	268130
RH-NULL, REGULATOR TYPE; RHNRH DEFICIENCY SYNDROME, INCLUDED	RH-NULL, REGULATOR TYPE; RHNRH DEFICIENCY SYNDROME, INCLUDED	268150
RH-NULL DISEASE, INCLUDED	RH-NULL, REGULATOR TYPE; RHNRH DEFICIENCY SYNDROME, INCLUDED	268150
MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE	MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE	268200
MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC	MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE	268200
RHABDOMYOLYSIS, ACUTE RECURRENT	MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE	268200
RHABDOMYOSARCOMA, EMBRYONAL, 1; RMSE1	RHABDOMYOSARCOMA, EMBRYONAL, 1; RMSE1	268210
RHABDOMYOSARCOMA 1; RMS1	RHABDOMYOSARCOMA, EMBRYONAL, 1; RMSE1	268210
RHABDOMYOSARCOMA CHROMOSOMAL REGION; RMSCR	RHABDOMYOSARCOMA, EMBRYONAL, 1; RMSE1	268210
RHABDOMYOSARCOMA 2; RMS2	RHABDOMYOSARCOMA 2; RMS2	268220
RHABDOMYOSARCOMA, ALVEOLAR; RMSA	RHABDOMYOSARCOMA 2; RMS2	268220
ROBERTS SYNDROME; RBS	ROBERTS SYNDROME; RBS	268300
LONG BONE DEFICIENCIES ASSOCIATED WITH CLEFT LIP-PALATE	ROBERTS SYNDROME; RBS	268300
ROBIN SEQUENCE WITH CLEFT MANDIBLE AND LIMB ANOMALIES	ROBIN SEQUENCE WITH CLEFT MANDIBLE AND LIMB ANOMALIES	268305
RICHIERI-COSTA-PEREIRA SYNDROME; RCPS	ROBIN SEQUENCE WITH CLEFT MANDIBLE AND LIMB ANOMALIES	268305
ROBINOW SYNDROME, AUTOSOMAL RECESSIVE; RRS	ROBINOW SYNDROME, AUTOSOMAL RECESSIVE; RRS	268310
COSTOVERTEBRAL SEGMENTATION DEFECT WITH MESOMELIA, FORMERLY	ROBINOW SYNDROME, AUTOSOMAL RECESSIVE; RRS	268310
COVESDEM SYNDROME, FORMERLYROBINOW SYNDROME, AUTOSOMAL RECESSIVE, WITH APLASIA/HYPOPLASIA OFPHALANGES AND METACARPALS/METATARSALS, INCLUDED	ROBINOW SYNDROME, AUTOSOMAL RECESSIVE; RRS	268310
ROBINOW SYNDROME, AUTOSOMAL RECESSIVE, WITH BRACHY-SYN-POLYDACTYLY,INCLUDED	ROBINOW SYNDROME, AUTOSOMAL RECESSIVE; RRS	268310
ROTHMUND-THOMSON SYNDROME; RTS	ROTHMUND-THOMSON SYNDROME; RTS	268400
POIKILODERMA ATROPHICANS AND CATARACT	ROTHMUND-THOMSON SYNDROME; RTS	268400
SACCHAROPINURIA	SACCHAROPINURIA	268700
HYPERLYSINEMIA, TYPE II	SACCHAROPINURIA	268700
SACCHAROPINE DEHYDROGENASE DEFICIENCY	SACCHAROPINURIA	268700
ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY	SACCHAROPINURIA	268700
SANDHOFF DISEASE	SANDHOFF DISEASE	268800
GM2-GANGLIOSIDOSIS, TYPE II	SANDHOFF DISEASE	268800
HEXOSAMINIDASES A AND B DEFICIENCYSANDHOFF DISEASE, ADULT TYPE, INCLUDED	SANDHOFF DISEASE	268800
SANDHOFF DISEASE, JUVENILE TYPE, INCLUDED	SANDHOFF DISEASE	268800
SANDHOFF DISEASE, INFANTILE TYPE, INCLUDED	SANDHOFF DISEASE	268800
RICHIERI-COSTA/GUION-ALMEIDA SYNDROME	RICHIERI-COSTA/GUION-ALMEIDA SYNDROME	268850
SHORT STATURE, MENTAL RETARDATION, EYE ANOMALIES, AND CLEFT LIP/PALATE	RICHIERI-COSTA/GUION-ALMEIDA SYNDROME	268850
SAO PAULO MCA/MR SYNDROME	RICHIERI-COSTA/GUION-ALMEIDA SYNDROME	268850
SARCOSINEMIA; SARCOS	SARCOSINEMIA; SARCOS	268900
HYPERSARCOSINEMIA	SARCOSINEMIA; SARCOS	268900
SARCOSINE DEHYDROGENASE COMPLEX DEFICIENCY	SARCOSINEMIA; SARCOS	268900
SARDH DEFICIENCY; SARDHD	SARCOSINEMIA; SARCOS	268900
SARD DEFICIENCY	SARCOSINEMIA; SARCOS	268900
SC PHOCOMELIA SYNDROME	SC PHOCOMELIA SYNDROME	269000
SC PSEUDOTHALIDOMIDE SYNDROME	SC PHOCOMELIA SYNDROME	269000
SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME	SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME	269150
SGS	SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME	269150
SCHIZENCEPHALY	SCHIZENCEPHALY	269160
AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II; APS2	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II; APS2	269200
SCHMIDT SYNDROME	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II; APS2	269200
DIABETES MELLITUS, ADDISON DISEASE, MYXEDEMA	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II; APS2	269200
POLYGLANDULAR AUTOIMMUNE SYNDROME, TYPE II	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II; APS2	269200
PGA II	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II; APS2	269200
POLYENDOCRINE AUTOIMMUNE SYNDROME, TYPE II	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II; APS2	269200
APS II	AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II; APS2	269200
SCHNECKENBECKEN DYSPLASIA	SCHNECKENBECKEN DYSPLASIA	269250
CHONDRODYSPLASIA, LETHAL NEONATAL, WITH SNAIL-LIKE PELVIS	SCHNECKENBECKEN DYSPLASIA	269250
CRANIOMETADIAPHYSEAL DYSPLASIA; CRMDD	CRANIOMETADIAPHYSEAL DYSPLASIA; CRMDD	269300
CORNEAL OPACIFICATION WITH OTHER OCULAR ANOMALIES; COPOA	CORNEAL OPACIFICATION WITH OTHER OCULAR ANOMALIES; COPOA	269400
SCLEROCORNEA WITH OTHER OCULAR ANOMALIES	CORNEAL OPACIFICATION WITH OTHER OCULAR ANOMALIES; COPOA	269400
SCLEROSTEOSIS 1; SOST1	SCLEROSTEOSIS 1; SOST1	269500
SOST	SCLEROSTEOSIS 1; SOST1	269500
CORTICAL HYPEROSTOSIS WITH SYNDACTYLY	SCLEROSTEOSIS 1; SOST1	269500
SEA-BLUE HISTIOCYTE DISEASE	SEA-BLUE HISTIOCYTE DISEASE	269600
SEA-BLUE HISTIOCYTOSIS	SEA-BLUE HISTIOCYTE DISEASE	269600
HISTIOCYTOSIS, SEA-BLUE	SEA-BLUE HISTIOCYTE DISEASE	269600
LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2	269700
BERARDINELLI-SEIP CONGENITAL LIPODYSTROPHY, TYPE 2	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2	269700
SEIP SYNDROME	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2	269700
BERARDINELLI SYNDROME	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2	269700
LIPODYSTROPHY, TOTAL, AND ACROMEGALOID GIGANTISM	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2	269700
LIPOATROPHIC DIABETES, CONGENITAL	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2	269700
LIPODYSTROPHY, BERARDINELLI-SEIP CONGENITAL, TYPE 2	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2	269700
BRUNZELL SYNDROME, BSCL2-RELATED	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2	269700
SELECTIVE T-CELL DEFECT; STCD	SELECTIVE T-CELL DEFECT; STCD	269840
SHORT-RIB THORACIC DYSPLASIA 12; SRTD12	SHORT-RIB THORACIC DYSPLASIA 12; SRTD12	269860
SHORT RIB-POLYDACTYLY SYNDROME, TYPE IV; SRPS4	SHORT-RIB THORACIC DYSPLASIA 12; SRTD12	269860
SRPS IV	SHORT-RIB THORACIC DYSPLASIA 12; SRTD12	269860
BEEMER-LANGER SYNDROME	SHORT-RIB THORACIC DYSPLASIA 12; SRTD12	269860
SHORT RIB SYNDROME, BEEMER TYPE	SHORT-RIB THORACIC DYSPLASIA 12; SRTD12	269860
SHORT SYNDROME	SHORT SYNDROME	269880
SHORT STATURE, HYPEREXTENSIBILITY, HERNIA, OCULAR DEPRESSION, RIEGERANOMALY, AND TEETHING DELAY	SHORT SYNDROME	269880
LIPODYSTROPHY, PARTIAL, WITH RIEGER ANOMALY AND SHORT STATURE	SHORT SYNDROME	269880
INFANTILE SIALIC ACID STORAGE DISEASE; ISSD	INFANTILE SIALIC ACID STORAGE DISEASE; ISSD	269920
SIALURIA, INFANTILE FORM	INFANTILE SIALIC ACID STORAGE DISEASE; ISSD	269920
N-ACETYLNEURAMINIC ACID STORAGE DISEASE	INFANTILE SIALIC ACID STORAGE DISEASE; ISSD	269920
NANA STORAGE DISEASE; NSD	INFANTILE SIALIC ACID STORAGE DISEASE; ISSD	269920
SIALURIA	SIALURIA	269921
SIALURIA, FRENCH TYPE	SIALURIA	269921
HETEROTAXY, VISCERAL, 5, AUTOSOMAL; HTX5	HETEROTAXY, VISCERAL, 5, AUTOSOMAL; HTX5	270100
SITUS INVERSUS VISCERUM; SIV	HETEROTAXY, VISCERAL, 5, AUTOSOMAL; HTX5	270100
SJOGREN SYNDROME	SJOGREN SYNDROME	270150
SICCA SYNDROME	SJOGREN SYNDROME	270150
SJOGREN-LARSSON SYNDROME; SLS	SJOGREN-LARSSON SYNDROME; SLS	270200
ICHTHYOSIS, SPASTIC NEUROLOGIC DISORDER, AND OLIGOPHRENIA	SJOGREN-LARSSON SYNDROME; SLS	270200
FATTY ALCOHOL:NAD+ OXIDOREDUCTASE DEFICIENCY	SJOGREN-LARSSON SYNDROME; SLS	270200
FATTY ALDEHYDE DEHYDROGENASE DEFICIENCY	SJOGREN-LARSSON SYNDROME; SLS	270200
FALDH DEFICIENCY	SJOGREN-LARSSON SYNDROME; SLS	270200
PEELING SKIN SYNDROME 1; PSS1	PEELING SKIN SYNDROME 1; PSS1	270300
PSS	PEELING SKIN SYNDROME 1; PSS1	270300
SKIN PEELING, FAMILIAL CONTINUOUS GENERALIZED	PEELING SKIN SYNDROME 1; PSS1	270300
KERATOLYSIS EXFOLIATIVA CONGENITA	PEELING SKIN SYNDROME 1; PSS1	270300
DECIDUOUS SKIN	PEELING SKIN SYNDROME 1; PSS1	270300
SMITH-LEMLI-OPITZ SYNDROME; SLOS	SMITH-LEMLI-OPITZ SYNDROME; SLOS	270400
SLO SYNDROME	SMITH-LEMLI-OPITZ SYNDROME; SLOS	270400
RSH SYNDROME	SMITH-LEMLI-OPITZ SYNDROME; SLOS	270400
RUTLEDGE LETHAL MULTIPLE CONGENITAL ANOMALY SYNDROME	SMITH-LEMLI-OPITZ SYNDROME; SLOS	270400
POLYDACTYLY, SEX REVERSAL, RENAL HYPOPLASIA, AND UNILOBAR LUNG	SMITH-LEMLI-OPITZ SYNDROME; SLOS	270400
LETHAL ACRODYSGENITAL SYNDROME	SMITH-LEMLI-OPITZ SYNDROME; SLOS	270400
DIARRHEA 3, SECRETORY SODIUM, CONGENITAL, WITH OR WITHOUT OTHER CONGENITALANOMALIES; DIAR3	DIARRHEA 3, SECRETORY SODIUM, CONGENITAL, WITH OR WITHOUT OTHER CONGENITALANOMALIES; DIAR3	270420
SODIUM DIARRHEA, CONGENITAL; CSD	DIARRHEA 3, SECRETORY SODIUM, CONGENITAL, WITH OR WITHOUT OTHER CONGENITALANOMALIES; DIAR3	270420
DIARRHEA 3, SECRETORY SODIUM, CONGENITAL, SYNDROMIC	DIARRHEA 3, SECRETORY SODIUM, CONGENITAL, WITH OR WITHOUT OTHER CONGENITALANOMALIES; DIAR3	270420
INSULIN-LIKE GROWTH FACTOR I, RESISTANCE TO	INSULIN-LIKE GROWTH FACTOR I, RESISTANCE TO	270450
SOMATOMEDIN, END-ORGAN INSENSITIVITY TO	INSULIN-LIKE GROWTH FACTOR I, RESISTANCE TO	270450
SOMATOMEDIN-C, RESISTANCE TO	INSULIN-LIKE GROWTH FACTOR I, RESISTANCE TO	270450
IGF-I RESISTANCEINSULIN-LIKE GROWTH FACTOR I, RESISTANCE TO, DUE TO INCREASED BINDINGPROTEIN, INCLUDED	INSULIN-LIKE GROWTH FACTOR I, RESISTANCE TO	270450
SPASTIC ATAXIA, CHARLEVOIX-SAGUENAY TYPE; SACS	SPASTIC ATAXIA, CHARLEVOIX-SAGUENAY TYPE; SACS	270550
SPASTIC ATAXIA 6, AUTOSOMAL RECESSIVE; SPAX6	SPASTIC ATAXIA, CHARLEVOIX-SAGUENAY TYPE; SACS	270550
CHARLEVOIX-SAGUENAY SPASTIC ATAXIA	SPASTIC ATAXIA, CHARLEVOIX-SAGUENAY TYPE; SACS	270550
AUTOSOMAL RECESSIVE SPASTIC ATAXIA OF CHARLEVOIX-SAGUENAY; ARSACS	SPASTIC ATAXIA, CHARLEVOIX-SAGUENAY TYPE; SACS	270550
SPASTIC DIPLEGIA AND MENTAL RETARDATION	SPASTIC DIPLEGIA AND MENTAL RETARDATION	270600
SPASTIC DIPLEGIA, INFANTILE TYPE	SPASTIC DIPLEGIA AND MENTAL RETARDATION	270600
SPASTIC PARAPLEGIA 17, AUTOSOMAL DOMINANT; SPG17	SPASTIC PARAPLEGIA 17, AUTOSOMAL DOMINANT; SPG17	270685
SPASTIC PARAPLEGIA WITH AMYOTROPHY OF HANDS AND FEET	SPASTIC PARAPLEGIA 17, AUTOSOMAL DOMINANT; SPG17	270685
SILVER SYNDROME	SPASTIC PARAPLEGIA 17, AUTOSOMAL DOMINANT; SPG17	270685
SILVER SPASTIC PARAPLEGIA SYNDROME	SPASTIC PARAPLEGIA 17, AUTOSOMAL DOMINANT; SPG17	270685
SPASTIC PARAPLEGIA 15, AUTOSOMAL RECESSIVE; SPG15	SPASTIC PARAPLEGIA 15, AUTOSOMAL RECESSIVE; SPG15	270700
SPASTIC PARAPLEGIA AND RETINAL DEGENERATION	SPASTIC PARAPLEGIA 15, AUTOSOMAL RECESSIVE; SPG15	270700
KJELLIN SYNDROME	SPASTIC PARAPLEGIA 15, AUTOSOMAL RECESSIVE; SPG15	270700
FITZSIMMONS-GUILBERT SYNDROME	FITZSIMMONS-GUILBERT SYNDROME	270710
SPASTIC PARAPLEGIA ASSOCIATED WITH BRACHYDACTYLY TYPE E	FITZSIMMONS-GUILBERT SYNDROME	270710
FITZSIMMONS SYNDROME	FITZSIMMONS-GUILBERT SYNDROME	270710
SPASTIC PARAPLEGIA 23; SPG23	SPASTIC PARAPLEGIA 23; SPG23	270750
SPASTIC PARAPLEGIA WITH PIGMENTARY ABNORMALITIES	SPASTIC PARAPLEGIA 23; SPG23	270750
SPASTIC PARAPARESIS, VITILIGO, PREMATURE GRAYING, CHARACTERISTIC FACIES	SPASTIC PARAPLEGIA 23; SPG23	270750
LISON SYNDROME	SPASTIC PARAPLEGIA 23; SPG23	270750
SPASTIC PARAPLEGIA 5A, AUTOSOMAL RECESSIVE; SPG5A	SPASTIC PARAPLEGIA 5A, AUTOSOMAL RECESSIVE; SPG5A	270800
SPERMATOGENIC FAILURE 4; SPGF4	SPERMATOGENIC FAILURE 4; SPGF4	270960
AZOOSPERMIA DUE TO PERTURBATIONS OF MEIOSIS	SPERMATOGENIC FAILURE 4; SPGF4	270960
AZOOSPERMIA WITH MATURATION ARREST	SPERMATOGENIC FAILURE 4; SPGF4	270960
SPERMATOGENESIS ARRESTPREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 4; RPRGL4	SPERMATOGENIC FAILURE 4; SPGF4	270960
SPHEROCYTOSIS, TYPE 3; SPH3	SPHEROCYTOSIS, TYPE 3; SPH3	270970
SPHEROCYTOSIS, HEREDITARY, 3; HS3	SPHEROCYTOSIS, TYPE 3; SPH3	270970
SPINAL MUSCULAR ATROPHY, TYPE IV; SMA4	SPINAL MUSCULAR ATROPHY, TYPE IV; SMA4	271150
SPINAL MUSCULAR ATROPHY, ADULT FORM	SPINAL MUSCULAR ATROPHY, TYPE IV; SMA4	271150
SPINAL MUSCULAR ATROPHY, PROXIMAL, ADULT, AUTOSOMAL RECESSIVE	SPINAL MUSCULAR ATROPHY, TYPE IV; SMA4	271150
MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7	MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7	271245
SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA	MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7	271245
OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS	MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7	271245
OHAHA SYNDROME	MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7	271245
SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY	MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7	271245
SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY	MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7	271245
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 3; SCAR3	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 3; SCAR3	271250
SPINOCEREBELLAR ATAXIA WITH BLINDNESS AND DEAFNESS; SCABD	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 3; SCAR3	271250
ASPLENIA, ISOLATED CONGENITAL; ICAS	ASPLENIA, ISOLATED CONGENITAL; ICAS	271400
HYPOSPLENIA, ISOLATED CONGENITAL	ASPLENIA, ISOLATED CONGENITAL; ICAS	271400
SPLENIC HYPOPLASIA	ASPLENIA, ISOLATED CONGENITAL; ICAS	271400
ASPLENIA, FAMILIAL	ASPLENIA, ISOLATED CONGENITAL; ICAS	271400
SPONDYLOEPIMETAPHYSEAL DYSPLASIA, SPONASTRIME TYPE	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, SPONASTRIME TYPE	271510
SPONDYLAR AND NASAL ALTERATIONS WITH STRIATED METAPHYSES	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, SPONASTRIME TYPE	271510
SPONASTRIME DYSPLASIA	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, SPONASTRIME TYPE	271510
SHORT-LIMB DWARFISM WITH SADDLE NOSE, SPINAL ALTERATIONS, AND METAPHYSEALSTRIATION	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, SPONASTRIME TYPE	271510
BRACHYOLMIA TYPE 1, HOBAEK TYPE; BCYM1A	BRACHYOLMIA TYPE 1, HOBAEK TYPE; BCYM1A	271530
BRACHYOLMIA, RECESSIVE TYPE OF HOBAEK	BRACHYOLMIA TYPE 1, HOBAEK TYPE; BCYM1A	271530
SPONDYLODYSPLASIA WITH PURE BRACHYOLMIA	BRACHYOLMIA TYPE 1, HOBAEK TYPE; BCYM1A	271530
SPONDYLOENCHONDRODYSPLASIA; SPENCD	SPONDYLOENCHONDRODYSPLASIA; SPENCD	271550
SPONDYLOMETAPHYSEAL DYSPLASIA WITH ENCHONDROMATOUS CHANGES	SPONDYLOENCHONDRODYSPLASIA; SPENCD	271550
SPONDYLOENCHONDROMATOSIS; SEM	SPONDYLOENCHONDRODYSPLASIA; SPENCD	271550
SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, AUTOSOMAL RECESSIVE	SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, AUTOSOMAL RECESSIVE	271600
BRACHYOLMIA TYPE 1, TOLEDO TYPE; BCYM1B	BRACHYOLMIA TYPE 1, TOLEDO TYPE; BCYM1B	271630
SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, TOLEDO TYPE	BRACHYOLMIA TYPE 1, TOLEDO TYPE; BCYM1B	271630
SED, CHONDROITIN SULFATE TYPE	BRACHYOLMIA TYPE 1, TOLEDO TYPE; BCYM1B	271630
PAPS-CHONDROITIN SULFATE SULFOTRANSFERASE DEFICIENCY	BRACHYOLMIA TYPE 1, TOLEDO TYPE; BCYM1B	271630
SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, TYPE 1, WITH ORWITHOUT FRACTURES; SEMDJL1	SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, TYPE 1, WITH ORWITHOUT FRACTURES; SEMDJL1	271640
SEMDJL	SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, TYPE 1, WITH ORWITHOUT FRACTURES; SEMDJL1	271640
SPONDYLOEPIMETAPHYSEAL DYSPLASIA, IRAPA TYPE; SEMDIT	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, IRAPA TYPE; SEMDIT	271650
SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE	SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE	271665
SMED-SL	SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE	271665
SMED, SHORT LIMB-HAND TYPE	SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE	271665
SMED, TYPE II	SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE	271665
SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-ABNORMAL CALCIFICATIONTYPE	SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE	271665
SMED, SHORT LIMB-ABNORMAL CALCIFICATION TYPE	SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE	271665
SMED-SL/AC	SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE	271665
SPONDYLOPERIPHERAL DYSPLASIA	SPONDYLOPERIPHERAL DYSPLASIA	271700
SPONDYLOPERIPHERAL DYSPLASIA WITH SHORT ULNA	SPONDYLOPERIPHERAL DYSPLASIA	271700
CANAVAN DISEASE	CANAVAN DISEASE	271900
CANAVAN-VAN BOGAERT-BERTRAND DISEASE	CANAVAN DISEASE	271900
SPONGY DEGENERATION OF CENTRAL NERVOUS SYSTEM	CANAVAN DISEASE	271900
ASPARTOACYLASE DEFICIENCY	CANAVAN DISEASE	271900
ASPA DEFICIENCY	CANAVAN DISEASE	271900
ASP DEFICIENCY	CANAVAN DISEASE	271900
AMINOACYLASE 2 DEFICIENCY	CANAVAN DISEASE	271900
ACY2 DEFICIENCY	CANAVAN DISEASE	271900
STRIATONIGRAL DEGENERATION, INFANTILE; SNDI	STRIATONIGRAL DEGENERATION, INFANTILE; SNDI	271930
INFANTILE BILATERAL STRIATAL NECROSIS; IBSN	STRIATONIGRAL DEGENERATION, INFANTILE; SNDI	271930
BILATERAL STRIATAL NECROSIS, INFANTILE	STRIATONIGRAL DEGENERATION, INFANTILE; SNDI	271930
STRIATAL DEGENERATION, FAMILIAL	STRIATONIGRAL DEGENERATION, INFANTILE; SNDI	271930
SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD	SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD	271980
SSADH DEFICIENCY	SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD	271980
4-@HYDROXYBUTYRIC ACIDURIA	SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD	271980
GABA METABOLIC DEFECT	SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD	271980
GAMMA-HYDROXYBUTYRIC ACIDURIA	SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD	271980
SUDDEN INFANT DEATH SYNDROME	SUDDEN INFANT DEATH SYNDROME	272120
SIDS	SUDDEN INFANT DEATH SYNDROME	272120
MULTIPLE SULFATASE DEFICIENCY; MSD	MULTIPLE SULFATASE DEFICIENCY; MSD	272200
MUCOSULFATIDOSIS	MULTIPLE SULFATASE DEFICIENCY; MSD	272200
SULFATIDOSIS, JUVENILE, AUSTIN TYPE	MULTIPLE SULFATASE DEFICIENCY; MSD	272200
SULFOCYSTEINURIA	SULFOCYSTEINURIA	272300
SULFITE OXIDASE DEFICIENCY	SULFOCYSTEINURIA	272300
SUSCEPTIBILITY TO LYSIS BY ALLOREACTIVE NATURAL KILLER CELLS; EC1	SUSCEPTIBILITY TO LYSIS BY ALLOREACTIVE NATURAL KILLER CELLS; EC1	272370
NATURAL KILLER CELL SUSCEPTIBILITY 1; NKS1	SUSCEPTIBILITY TO LYSIS BY ALLOREACTIVE NATURAL KILLER CELLS; EC1	272370
COLD-INDUCED SWEATING SYNDROME 1; CISS1	COLD-INDUCED SWEATING SYNDROME 1; CISS1	272430
CRISPONI SYNDROME	COLD-INDUCED SWEATING SYNDROME 1; CISS1	272430
SOHAR-CRISPONI SYNDROME	COLD-INDUCED SWEATING SYNDROME 1; CISS1	272430
MUSCLE CONTRACTIONS, TETANOFORM, WITH CHARACTERISTIC FACE, CAMPTODACTYLY,HYPERTHERMIA, AND SUDDEN DEATH	COLD-INDUCED SWEATING SYNDROME 1; CISS1	272430
FILIPPI SYNDROME; FLPIS	FILIPPI SYNDROME; FLPIS	272440
SYNDACTYLY, TYPE I, WITH MICROCEPHALY AND MENTAL RETARDATION	FILIPPI SYNDROME; FLPIS	272440
SCOTT CRANIODIGITAL SYNDROME WITH MENTAL RETARDATION	FILIPPI SYNDROME; FLPIS	272440
SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME; SCT	SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME; SCT	272460
SPONDYLOCARPOTARSAL SYNDROME	SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME; SCT	272460
SYNSPONDYLISM, CONGENITAL	SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME; SCT	272460
VERTEBRAL FUSION WITH CARPAL COALITION	SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME; SCT	272460
SCOLIOSIS, CONGENITAL, WITH UNILATERAL UNSEGMENTED BAR	SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME; SCT	272460
TATSUMI FACTOR DEFICIENCY	TATSUMI FACTOR DEFICIENCY	272650
GM2-GANGLIOSIDOSIS, AB VARIANT	GM2-GANGLIOSIDOSIS, AB VARIANT	272750
HEXOSAMINIDASE ACTIVATOR DEFICIENCY	GM2-GANGLIOSIDOSIS, AB VARIANT	272750
GM2 ACTIVATOR DEFICIENCY	GM2-GANGLIOSIDOSIS, AB VARIANT	272750
AB VARIANT GM2-GANGLIOSIDOSIS	GM2-GANGLIOSIDOSIS, AB VARIANT	272750
TAY-SACHS DISEASE, AB VARIANT	GM2-GANGLIOSIDOSIS, AB VARIANT	272750
TAY-SACHS DISEASE; TSD	TAY-SACHS DISEASE; TSD	272800
GM2-GANGLIOSIDOSIS, TYPE I	TAY-SACHS DISEASE; TSD	272800
B VARIANT GM2-GANGLIOSIDOSIS	TAY-SACHS DISEASE; TSD	272800
HEXOSAMINIDASE A DEFICIENCY	TAY-SACHS DISEASE; TSD	272800
HEXA DEFICIENCYTAY-SACHS DISEASE, JUVENILE, INCLUDED	TAY-SACHS DISEASE; TSD	272800
HEXOSAMINIDASE A DEFICIENCY, ADULT TYPE, INCLUDED	TAY-SACHS DISEASE; TSD	272800
GM2-GANGLIOSIDOSIS, ADULT CHRONIC TYPE, INCLUDED	TAY-SACHS DISEASE; TSD	272800
GM2-GANGLIOSIDOSIS, VARIANT B1, INCLUDED	TAY-SACHS DISEASE; TSD	272800
TAY-SACHS DISEASE, VARIANT B1, INCLUDED	TAY-SACHS DISEASE; TSD	272800
TAY-SACHS DISEASE, PSEUDO-AB VARIANT, INCLUDED	TAY-SACHS DISEASE; TSD	272800
TESTICULAR REGRESSION SYNDROME; TRS	TESTICULAR REGRESSION SYNDROME; TRS	273250
TESTICULAR REGRESSION, EMBRYONIC	TESTICULAR REGRESSION SYNDROME; TRS	273250
XY GONADAL AGENESIS SYNDROME	TESTICULAR REGRESSION SYNDROME; TRS	273250
ANORCHIA, FAMILIAL	TESTICULAR REGRESSION SYNDROME; TRS	273250
TESTICULAR GERM CELL TUMOR; TGCT	TESTICULAR GERM CELL TUMOR; TGCT	273300
MALE GERM CELL TUMOR; MGCTSEMINOMA, INCLUDED	TESTICULAR GERM CELL TUMOR; TGCT	273300
NONSEMINOMATOUS GERM CELL TUMORS, INCLUDED	TESTICULAR GERM CELL TUMOR; TGCT	273300
TERATOMA, TESTICULAR, INCLUDED	TESTICULAR GERM CELL TUMOR; TGCT	273300
EMBRYONAL CELL CARCINOMA, INCLUDED	TESTICULAR GERM CELL TUMOR; TGCT	273300
ENDODERMAL SINUS TUMOR, INCLUDED	TESTICULAR GERM CELL TUMOR; TGCT	273300
SPERMATOCYTIC SEMINOMA, INCLUDED	TESTICULAR GERM CELL TUMOR; TGCT	273300
TETRAAMELIA SYNDROME, AUTOSOMAL RECESSIVE; TETAMS	TETRAAMELIA SYNDROME, AUTOSOMAL RECESSIVE; TETAMS	273395
THREE M SYNDROME 1; 3M1	THREE M SYNDROME 1; 3M1	273750
3@M SYNDROME	THREE M SYNDROME 1; 3M1	273750
LE MERRER SYNDROME	THREE M SYNDROME 1; 3M1	273750
DOLICHOSPONDYLIC DYSPLASIA	THREE M SYNDROME 1; 3M1	273750
GLOOMY FACE SYNDROMEYAKUT SHORT STATURE SYNDROME, INCLUDED	THREE M SYNDROME 1; 3M1	273750
GLANZMANN THROMBASTHENIA; GT	GLANZMANN THROMBASTHENIA; GT	273800
BLEEDING DISORDER, PLATELET-TYPE, 2; BDPLT2	GLANZMANN THROMBASTHENIA; GT	273800
THROMBASTHENIA OF GLANZMANN AND NAEGELI	GLANZMANN THROMBASTHENIA; GT	273800
PLATELET GLYCOPROTEIN IIb-IIIa DEFICIENCY	GLANZMANN THROMBASTHENIA; GT	273800
GP IIb-IIIa COMPLEX, DEFICIENCY OF	GLANZMANN THROMBASTHENIA; GT	273800
PLATELET FIBRINOGEN RECEPTOR, DEFICIENCY OF	GLANZMANN THROMBASTHENIA; GT	273800
GLYCOPROTEIN COMPLEX IIb-IIIa, DEFICIENCY OF	GLANZMANN THROMBASTHENIA; GT	273800
THROMBOCYTOPENIA 3; THC3	THROMBOCYTOPENIA 3; THC3	273900
THROMBOCYTOPENIA, AUTOSOMAL RECESSIVE, 3	THROMBOCYTOPENIA 3; THC3	273900
THROMBOCYTOPENIA-ABSENT RADIUS SYNDROME; TAR	THROMBOCYTOPENIA-ABSENT RADIUS SYNDROME; TAR	274000
TAR SYNDROME	THROMBOCYTOPENIA-ABSENT RADIUS SYNDROME; TAR	274000
CHROMOSOME 1q21.1 DELETION SYNDROME, 200-KB	THROMBOCYTOPENIA-ABSENT RADIUS SYNDROME; TAR	274000
THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP	THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP	274150
MICROANGIOPATHIC HEMOLYTIC ANEMIA	THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP	274150
THROMBOTIC MICROANGIOPATHY, FAMILIAL	THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP	274150
UPSHAW-SCHULMAN SYNDROME; USS	THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP	274150
SCHULMAN-UPSHAW SYNDROME	THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP	274150
UPSHAW FACTOR, DEFICIENCY OF	THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP	274150
MICROANGIOPATHIC HEMOLYTIC ANEMIA, CONGENITAL	THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP	274150
THROMBOTIC THROMBOCYTOPENIC PURPURA, FAMILIAL	THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP	274150
THUMB AGENESIS, SHORT STATURE, AND IMMUNODEFICIENCY	THUMB AGENESIS, SHORT STATURE, AND IMMUNODEFICIENCY	274190
DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	274270
DPD DEFICIENCY	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	274270
DPYD DEFICIENCY	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	274270
THYMINE-URACILURIA, HEREDITARY	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	274270
PYRIMIDINEMIA, FAMILIAL5-@FLUOROURACIL TOXICITY, INCLUDED	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	274270
THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL RECESSIVE; GRTH	THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL RECESSIVE; GRTH	274300
GTHR	THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL RECESSIVE; GRTH	274300
THYROID HORMONE UNRESPONSIVENESS	THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL RECESSIVE; GRTH	274300
REFETOFF SYNDROME	THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL RECESSIVE; GRTH	274300
THYROID DYSHORMONOGENESIS 1; TDH1	THYROID DYSHORMONOGENESIS 1; TDH1	274400
THYROID HORMONOGENESIS, GENETIC DEFECT IN, 1	THYROID DYSHORMONOGENESIS 1; TDH1	274400
HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 1	THYROID DYSHORMONOGENESIS 1; TDH1	274400
IODINE ACCUMULATION, TRANSPORT, OR TRAPPING DEFECT	THYROID DYSHORMONOGENESIS 1; TDH1	274400
THYROID DYSHORMONOGENESIS 2A; TDH2A	THYROID DYSHORMONOGENESIS 2A; TDH2A	274500
THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2A	THYROID DYSHORMONOGENESIS 2A; TDH2A	274500
HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2A	THYROID DYSHORMONOGENESIS 2A; TDH2A	274500
IODIDE PEROXIDASE DEFICIENCY	THYROID DYSHORMONOGENESIS 2A; TDH2A	274500
THYROID PEROXIDASE DEFICIENCY	THYROID DYSHORMONOGENESIS 2A; TDH2A	274500
PENDRED SYNDROME; PDS	PENDRED SYNDROME; PDS	274600
DEAFNESS WITH GOITER	PENDRED SYNDROME; PDS	274600
GOITER-DEAFNESS SYNDROME	PENDRED SYNDROME; PDS	274600
THYROID DYSHORMONOGENESIS 2B; TDH2B	PENDRED SYNDROME; PDS	274600
THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B	PENDRED SYNDROME; PDS	274600
HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B	PENDRED SYNDROME; PDS	274600
THYROID DYSHORMONOGENESIS 3; TDH3	THYROID DYSHORMONOGENESIS 3; TDH3	274700
THYROID HORMONOGENESIS, GENETIC DEFECT IN, 3	THYROID DYSHORMONOGENESIS 3; TDH3	274700
HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 3	THYROID DYSHORMONOGENESIS 3; TDH3	274700
THYROID DYSHORMONOGENESIS 4; TDH4	THYROID DYSHORMONOGENESIS 4; TDH4	274800
THYROID HORMONOGENESIS, GENETIC DEFECT IN, 4	THYROID DYSHORMONOGENESIS 4; TDH4	274800
HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 4	THYROID DYSHORMONOGENESIS 4; TDH4	274800
IODOTYROSINE DEHALOGENASE DEFICIENCY	THYROID DYSHORMONOGENESIS 4; TDH4	274800
DEIODINASE DEFICIENCY	THYROID DYSHORMONOGENESIS 4; TDH4	274800
THYROID DYSHORMONOGENESIS 5; TDH5	THYROID DYSHORMONOGENESIS 5; TDH5	274900
THYROID HORMONOGENESIS, GENETIC DEFECT IN, 5	THYROID DYSHORMONOGENESIS 5; TDH5	274900
HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 5	THYROID DYSHORMONOGENESIS 5; TDH5	274900
GRAVES DISEASE, SUSCEPTIBILITY TO, 1; GRD1	GRAVES DISEASE, SUSCEPTIBILITY TO, 1; GRD1	275000
GRD	GRAVES DISEASE, SUSCEPTIBILITY TO, 1; GRD1	275000
THYROTOXICOSIS	GRAVES DISEASE, SUSCEPTIBILITY TO, 1; GRD1	275000
HYPERTHYROIDISM, AUTOIMMUNE	GRAVES DISEASE, SUSCEPTIBILITY TO, 1; GRD1	275000
HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 4; CHNG4	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 4; CHNG4	275100
THYROTROPIN DEFICIENCY, ISOLATED	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 4; CHNG4	275100
THYROID-STIMULATING HORMONE DEFICIENCY	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 4; CHNG4	275100
TSH DEFICIENCY	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 4; CHNG4	275100
PITUITARY CRETINISMTHYROTROPIN, BIOLOGICALLY INACTIVE, INCLUDED	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 4; CHNG4	275100
THYROTROPIN-RELEASING HORMONE DEFICIENCY	THYROTROPIN-RELEASING HORMONE DEFICIENCY	275120
TRH DEFICIENCY	THYROTROPIN-RELEASING HORMONE DEFICIENCY	275120
HYPOTHALAMIC HYPOTHYROIDISM	THYROTROPIN-RELEASING HORMONE DEFICIENCY	275120
HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1; CHNG1	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1; CHNG1	275200
THYROTROPIN RESISTANCE	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1; CHNG1	275200
THYROID-STIMULATING HORMONE, RESISTANCE TO; RTSH	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1; CHNG1	275200
TSH RESISTANCE	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1; CHNG1	275200
HYPOTHYROIDISM, NONAUTOIMMUNE	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1; CHNG1	275200
HYPOTHYROIDISM, CONGENITAL, DUE TO TSH RESISTANCE	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1; CHNG1	275200
HYPOTHYROIDISM DUE TO UNRESPONSIVENESS TO THYROTROPIN	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1; CHNG1	275200
RESTRICTIVE DERMOPATHY, LETHAL	RESTRICTIVE DERMOPATHY, LETHAL	275210
TIGHT SKIN CONTRACTURE SYNDROME, LETHAL	RESTRICTIVE DERMOPATHY, LETHAL	275210
HYPERKERATOSIS-CONTRACTURE SYNDROME	RESTRICTIVE DERMOPATHY, LETHAL	275210
FETAL HYPOKINESIA SEQUENCE DUE TO RESTRICTIVE DERMOPATHY	RESTRICTIVE DERMOPATHY, LETHAL	275210
TONGUE, PIGMENTED FUNGIFORM PAPILLAE OF	TONGUE, PIGMENTED FUNGIFORM PAPILLAE OF	275250
TRANSCOBALAMIN II DEFICIENCY	TRANSCOBALAMIN II DEFICIENCY	275350
TC II DEFICIENCY	TRANSCOBALAMIN II DEFICIENCY	275350
TCN2 DEFICIENCY	TRANSCOBALAMIN II DEFICIENCY	275350
SQUAMOUS CELL CARCINOMA, HEAD AND NECK; HNSCC	SQUAMOUS CELL CARCINOMA, HEAD AND NECK; HNSCC	275355
TRICARBOXYLIC ACID CYCLE, DEFECT OF	TRICARBOXYLIC ACID CYCLE, DEFECT OF	275370
OLIVER-MCFARLANE SYNDROME; OMCS	OLIVER-MCFARLANE SYNDROME; OMCS	275400
TRICHOMEGALY WITH MENTAL RETARDATION, DWARFISM, AND PIGMENTARY DEGENERATIONOF RETINA	OLIVER-MCFARLANE SYNDROME; OMCS	275400
EYELASHES, LONG, WITH MENTAL RETARDATION	OLIVER-MCFARLANE SYNDROME; OMCS	275400
CHANARIN-DORFMAN SYNDROME; CDS	CHANARIN-DORFMAN SYNDROME; CDS	275630
NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI	CHANARIN-DORFMAN SYNDROME; CDS	275630
TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION	CHANARIN-DORFMAN SYNDROME; CDS	275630
ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE	CHANARIN-DORFMAN SYNDROME; CDS	275630
DORFMAN-CHANARIN SYNDROME; DCS	CHANARIN-DORFMAN SYNDROME; CDS	275630
CHANARIN-DORFMAN DISEASE	CHANARIN-DORFMAN SYNDROME; CDS	275630
ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION	CHANARIN-DORFMAN SYNDROME; CDS	275630
SPASTIC PARAPLEGIA 20, AUTOSOMAL RECESSIVE; SPG20	SPASTIC PARAPLEGIA 20, AUTOSOMAL RECESSIVE; SPG20	275900
TROYER SYNDROME	SPASTIC PARAPLEGIA 20, AUTOSOMAL RECESSIVE; SPG20	275900
SPASTIC PARAPARESIS, CHILDHOOD-ONSET, WITH DISTAL MUSCLE WASTING	SPASTIC PARAPLEGIA 20, AUTOSOMAL RECESSIVE; SPG20	275900
SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE, TROYER TYPE	SPASTIC PARAPLEGIA 20, AUTOSOMAL RECESSIVE; SPG20	275900
TRYPTOPHANURIA WITH DWARFISM	TRYPTOPHANURIA WITH DWARFISM	276100
MISMATCH REPAIR CANCER SYNDROME; MMRCS	MISMATCH REPAIR CANCER SYNDROME; MMRCS	276300
MISMATCH REPAIR DEFICIENCY	MISMATCH REPAIR CANCER SYNDROME; MMRCS	276300
MMR DEFICIENCY	MISMATCH REPAIR CANCER SYNDROME; MMRCS	276300
CHILDHOOD CANCER SYNDROME	MISMATCH REPAIR CANCER SYNDROME; MMRCS	276300
BRAIN TUMOR-POLYPOSIS SYNDROME 1; BTPS1	MISMATCH REPAIR CANCER SYNDROME; MMRCS	276300
BTP1 SYNDROME	MISMATCH REPAIR CANCER SYNDROME; MMRCS	276300
TURCOT SYNDROME	MISMATCH REPAIR CANCER SYNDROME; MMRCS	276300
CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME; CMMRDS	MISMATCH REPAIR CANCER SYNDROME; MMRCS	276300
TWINNING, DIZYGOTICOVARIAN RESPONSE TO FSH STIMULATION, INCLUDED	TWINNING, DIZYGOTICOVARIAN RESPONSE TO FSH STIMULATION, INCLUDED	276400
TYROSINEMIA, TYPE II; TYRSN2	TYROSINEMIA, TYPE II; TYRSN2	276600
RICHNER-HANHART SYNDROME	TYROSINEMIA, TYPE II; TYRSN2	276600
TYROSINE AMINOTRANSFERASE DEFICIENCY	TYROSINEMIA, TYPE II; TYRSN2	276600
TAT DEFICIENCY	TYROSINEMIA, TYPE II; TYRSN2	276600
TYROSINE TRANSAMINASE DEFICIENCY	TYROSINEMIA, TYPE II; TYRSN2	276600
KERATOSIS PALMOPLANTARIS WITH CORNEAL DYSTROPHY	TYROSINEMIA, TYPE II; TYRSN2	276600
OREGON TYPE TYROSINEMIA	TYROSINEMIA, TYPE II; TYRSN2	276600
TYROSINOSIS, OCULOCUTANEOUS TYPE	TYROSINEMIA, TYPE II; TYRSN2	276600
TYROSINEMIA, TYPE I; TYRSN1	TYROSINEMIA, TYPE I; TYRSN1	276700
HEPATORENAL TYROSINEMIA	TYROSINEMIA, TYPE I; TYRSN1	276700
FUMARYLACETOACETASE DEFICIENCY	TYROSINEMIA, TYPE I; TYRSN1	276700
FAH DEFICIENCY	TYROSINEMIA, TYPE I; TYRSN1	276700
TYROSINEMIA, TYPE III; TYRSN3	TYROSINEMIA, TYPE III; TYRSN3	276710
4-@HYDROXYPHENYLPYRUVIC ACID OXIDASE DEFICIENCY	TYROSINEMIA, TYPE III; TYRSN3	276710
4-@HYDROXYPHENYLPYRUVATE DIOXYGENASE DEFICIENCY	TYROSINEMIA, TYPE III; TYRSN3	276710
ULNA AND FIBULA, ABSENCE OF, WITH SEVERE LIMB DEFICIENCY	ULNA AND FIBULA, ABSENCE OF, WITH SEVERE LIMB DEFICIENCY	276820
LIMB/PELVIS-HYPOPLASIA/APLASIA SYNDROME; LPHAS	ULNA AND FIBULA, ABSENCE OF, WITH SEVERE LIMB DEFICIENCY	276820
AL-AWADI/RAAS-ROTHSCHILD SYNDROME; AARRS	ULNA AND FIBULA, ABSENCE OF, WITH SEVERE LIMB DEFICIENCY	276820
SCHINZEL PHOCOMELIA SYNDROME	ULNA AND FIBULA, ABSENCE OF, WITH SEVERE LIMB DEFICIENCY	276820
UROCANASE DEFICIENCY; UROCD	UROCANASE DEFICIENCY; UROCD	276880
USHER SYNDROME, TYPE I; USH1	USHER SYNDROME, TYPE I; USH1	276900
US1	USHER SYNDROME, TYPE I; USH1	276900
RETINITIS PIGMENTOSA AND CONGENITAL DEAFNESSUSHER SYNDROME, TYPE IB, INCLUDED; USH1B, INCLUDED	USHER SYNDROME, TYPE I; USH1	276900
USHER SYNDROME, TYPE IA, FORMERLY, INCLUDED; USH1A, FORMERLY, INCLUDED	USHER SYNDROME, TYPE I; USH1	276900
USHER SYNDROME, TYPE I, FRENCH VARIETY, FORMERLY, INCLUDED	USHER SYNDROME, TYPE I; USH1	276900
USHER SYNDROME, TYPE IIA; USH2A	USHER SYNDROME, TYPE IIA; USH2A	276901
USHER SYNDROME, TYPE IIIA; USH3A	USHER SYNDROME, TYPE IIIA; USH3A	276902
USHER SYNDROME, TYPE III; USH3	USHER SYNDROME, TYPE IIIA; USH3A	276902
USHER SYNDROME, TYPE IC; USH1C	USHER SYNDROME, TYPE IC; USH1C	276904
USHER SYNDROME, TYPE I, ACADIAN VARIETY	USHER SYNDROME, TYPE IC; USH1C	276904
VACTERL ASSOCIATION WITH HYDROCEPHALUS	VACTERL ASSOCIATION WITH HYDROCEPHALUS	276950
VACTERL-HVATER ASSOCIATION WITH HYDROCEPHALUS, INCLUDED	VACTERL ASSOCIATION WITH HYDROCEPHALUS	276950
VATER ASSOCIATION WITH MACROCEPHALY AND VENTRICULOMEGALY, INCLUDED	VACTERL ASSOCIATION WITH HYDROCEPHALUS	276950
MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME	MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME	277000
MRKH SYNDROME	MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME	277000
MULLERIAN APLASIA/DYSGENESIS	MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME	277000
VON MAYER-ROKITANSKY-KUSTER ANOMALY	MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME	277000
MRKH ANOMALY	MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME	277000
MRK ANOMALY	MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME	277000
UTERUS BIPARTITUS SOLIDUS RUDIMENTARIUS CUM VAGINA SOLIDA	MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME	277000
CONGENITAL ABSENCE OF UTERUS AND VAGINA; CAUVUROGENITAL ADYSPLASIA, INCLUDED	MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME	277000
VALINEMIA	VALINEMIA	277100
VALINE TRANSAMINASE DEFICIENCY	VALINEMIA	277100
HYPERVALINEMIA	VALINEMIA	277100
VAN BOGAERT-HOZAY SYNDROME	VAN BOGAERT-HOZAY SYNDROME	277150
OROFACIODIGITAL SYNDROME VI; OFD6	OROFACIODIGITAL SYNDROME VI; OFD6	277170
ORAL-FACIAL-DIGITAL SYNDROME, TYPE VI	OROFACIODIGITAL SYNDROME VI; OFD6	277170
OFDS VI	OROFACIODIGITAL SYNDROME VI; OFD6	277170
VARADI-PAPP SYNDROME	OROFACIODIGITAL SYNDROME VI; OFD6	277170
VARADI SYNDROME	OROFACIODIGITAL SYNDROME VI; OFD6	277170
POLYDACTYLY, CLEFT LIP/PALATE OR LINGUAL LUMP, AND PSYCHOMOTOR RETARDATION	OROFACIODIGITAL SYNDROME VI; OFD6	277170
VAS DEFERENS, CONGENITAL BILATERAL APLASIA OF; CBAVD	VAS DEFERENS, CONGENITAL BILATERAL APLASIA OF; CBAVD	277180
CAVD	VAS DEFERENS, CONGENITAL BILATERAL APLASIA OF; CBAVD	277180
SPONDYLOCOSTAL DYSOSTOSIS 1, AUTOSOMAL RECESSIVE; SCDO1	SPONDYLOCOSTAL DYSOSTOSIS 1, AUTOSOMAL RECESSIVE; SCDO1	277300
VERTEBRAL ANOMALIES	SPONDYLOCOSTAL DYSOSTOSIS 1, AUTOSOMAL RECESSIVE; SCDO1	277300
JARCHO-LEVIN SYNDROME	SPONDYLOCOSTAL DYSOSTOSIS 1, AUTOSOMAL RECESSIVE; SCDO1	277300
SPONDYLOTHORACIC DYSPLASIA	SPONDYLOCOSTAL DYSOSTOSIS 1, AUTOSOMAL RECESSIVE; SCDO1	277300
COSTOVERTEBRAL DYSPLASIA	SPONDYLOCOSTAL DYSOSTOSIS 1, AUTOSOMAL RECESSIVE; SCDO1	277300
SPONDYLOTHORACIC DYSOSTOSIS	SPONDYLOCOSTAL DYSOSTOSIS 1, AUTOSOMAL RECESSIVE; SCDO1	277300
VISCERAL MYOPATHY, FAMILIAL, WITH EXTERNAL OPHTHALMOPLEGIA	VISCERAL MYOPATHY, FAMILIAL, WITH EXTERNAL OPHTHALMOPLEGIA	277320
INTESTINAL PSEUDOOBSTRUCTION WITH EXTERNAL OPHTHALMOPLEGIA	VISCERAL MYOPATHY, FAMILIAL, WITH EXTERNAL OPHTHALMOPLEGIA	277320
MUSCULAR DYSTROPHY, OCULOGASTROINTESTINAL	VISCERAL MYOPATHY, FAMILIAL, WITH EXTERNAL OPHTHALMOPLEGIA	277320
HYPERCAROTENEMIA AND VITAMIN A DEFICIENCY, AUTOSOMAL RECESSIVE	HYPERCAROTENEMIA AND VITAMIN A DEFICIENCY, AUTOSOMAL RECESSIVE	277350
METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblF TYPE	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblF TYPE	277380
METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblF TYPE	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblF TYPE	277380
METHYLMALONIC ACIDURIA DUE TO VITAMIN B12-RELEASE DEFECT	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblF TYPE	277380
VITAMIN B12 LYSOSOMAL RELEASE DEFECT	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblF TYPE	277380
COBALAMIN, DEFECT IN LYSOSOMAL RELEASE OF	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblF TYPE	277380
VITAMIN B12 STORAGE DISEASE	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblF TYPE	277380
COBALAMIN F DISEASE; cblF	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblF TYPE	277380
METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE	277400
METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE	277400
METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE	277400
VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoAMUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE	277400
METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE	277410
METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblD TYPEHOMOCYSTINURIA, cblD TYPE, VARIANT 1, INCLUDED	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE	277410
METHYLMALONIC ACIDURIA, cblD TYPE, VARIANT 2, INCLUDED	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE	277410
METHYLMALONIC ACIDURIA, cblH TYPE, FORMERLY	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE	277410
METHYLMALONIC ACIDEMIA, cblH TYPE, FORMERLY	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE	277410
VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A	VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A	277440
VITAMIN D-DEPENDENT RICKETS, TYPE 2A, WITH OR WITHOUT ALOPECIA	VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A	277440
RICKETS, HEREDITARY VITAMIN D-RESISTANT; HVDRR	VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A	277440
GENERALIZED RESISTANCE TO 1,25-DIHYDROXYVITAMIN D	VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A	277440
VITAMIN D-RESISTANT RICKETS WITH END-ORGAN UNRESPONSIVENESS TO 1,25-DIHYDROXYCHOLECALCIFEROL	VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A	277440
PSEUDOVITAMIN D-DEFICIENCY, TYPE IIA	VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A	277440
PDDR IIA	VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A	277440
HYPOCALCEMIC VITAMIN D-RESISTANT RICKETS; HVDRR	VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A	277440
RICKETS-ALOPECIA SYNDROME	VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A	277440
VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1	277450
VKCFD	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1	277450
VITAMIN K-DEPENDENT COAGULATION DEFECT	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1	277450
FAMILIAL MULTIPLE COAGULATION FACTOR DEFICIENCY III	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1	277450
FMFD III	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1	277450
MULTIPLE COAGULATION FACTOR DEFICIENCY III; MCFD3	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1	277450
FACTORS II, VII, IX, AND X, COMBINED DEFICIENCY OF	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1	277450
GLUTAMIC ACID, DEFICIENT GAMMA-CARBOXYLATION OF	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1	277450
VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED	VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED	277460
ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED	VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED	277460
FRIEDREICH-LIKE ATAXIA	VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED	277460
PONTOCEREBELLAR HYPOPLASIA, TYPE 2A; PCH2A	PONTOCEREBELLAR HYPOPLASIA, TYPE 2A; PCH2A	277470
PCH2	PONTOCEREBELLAR HYPOPLASIA, TYPE 2A; PCH2A	277470
PONTOCEREBELLAR HYPOPLASIA WITH PROGRESSIVE CEREBRAL ATROPHY	PONTOCEREBELLAR HYPOPLASIA, TYPE 2A; PCH2A	277470
VOLENDAM NEURODEGENERATIVE DISEASE	PONTOCEREBELLAR HYPOPLASIA, TYPE 2A; PCH2A	277470
VON WILLEBRAND DISEASE, TYPE 3; VWD3	VON WILLEBRAND DISEASE, TYPE 3; VWD3	277480
VON WILLEBRAND DISEASE, TYPE III	VON WILLEBRAND DISEASE, TYPE 3; VWD3	277480
VWD, TYPE 3	VON WILLEBRAND DISEASE, TYPE 3; VWD3	277480
WAARDENBURG SYNDROME, TYPE 4A; WS4A	WAARDENBURG SYNDROME, TYPE 4A; WS4A	277580
WAARDENBURG SYNDROME, TYPE IVA	WAARDENBURG SYNDROME, TYPE 4A; WS4A	277580
WAARDENBURG SYNDROME WITH HIRSCHSPRUNG DISEASE, TYPE 4A	WAARDENBURG SYNDROME, TYPE 4A; WS4A	277580
WAARDENBURG-SHAH SYNDROME	WAARDENBURG SYNDROME, TYPE 4A; WS4A	277580
SHAH-WAARDENBURG SYNDROME	WAARDENBURG SYNDROME, TYPE 4A; WS4A	277580
WS4	WAARDENBURG SYNDROME, TYPE 4A; WS4A	277580
WEAVER SYNDROME; WVS	WEAVER SYNDROME; WVS	277590
WEAVER-SMITH SYNDROME; WSSWEAVER-LIKE SYNDROME, INCLUDED	WEAVER SYNDROME; WVS	277590
WEILL-MARCHESANI SYNDROME 1; WMS1	WEILL-MARCHESANI SYNDROME 1; WMS1	277600
WEILL-MARCHESANI SYNDROME, AUTOSOMAL RECESSIVE	WEILL-MARCHESANI SYNDROME 1; WMS1	277600
SPHEROPHAKIA-BRACHYMORPHIA SYNDROME	WEILL-MARCHESANI SYNDROME 1; WMS1	277600
MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL	WEILL-MARCHESANI SYNDROME 1; WMS1	277600
WEISSENBACHER-ZWEYMULLER SYNDROME; WZS	WEISSENBACHER-ZWEYMULLER SYNDROME; WZS	277610
PIERRE ROBIN SYNDROME WITH FETAL CHONDRODYSPLASIA	WEISSENBACHER-ZWEYMULLER SYNDROME; WZS	277610
WERNER SYNDROME; WRN	WERNER SYNDROME; WRN	277700
WHISTLING FACE SYNDROME, RECESSIVE FORM	WHISTLING FACE SYNDROME, RECESSIVE FORM	277720
WERNICKE-KORSAKOFF SYNDROME	WERNICKE-KORSAKOFF SYNDROME	277730
TRANSKETOLASE DEFECT	WERNICKE-KORSAKOFF SYNDROME	277730
ALCOHOL-INDUCED ENCEPHALOPATHY	WERNICKE-KORSAKOFF SYNDROME	277730
WILSON DISEASE	WILSON DISEASE	277900
WND; WD	WILSON DISEASE	277900
HEPATOLENTICULAR DEGENERATION	WILSON DISEASE	277900
WINCHESTER SYNDROME; WNCHRS	WINCHESTER SYNDROME; WNCHRS	277950
LYSOSOMAL ACID LIPASE DEFICIENCY	LYSOSOMAL ACID LIPASE DEFICIENCY	278000
CHOLESTERYL ESTER STORAGE DISEASE; CESD	LYSOSOMAL ACID LIPASE DEFICIENCY	278000
LIPA DEFICIENCY	LYSOSOMAL ACID LIPASE DEFICIENCY	278000
LAL DEFICIENCY	LYSOSOMAL ACID LIPASE DEFICIENCY	278000
CHOLESTEROL ESTER HYDROLASE DEFICIENCYWOLMAN DISEASE, INCLUDED	LYSOSOMAL ACID LIPASE DEFICIENCY	278000
HYPOTRICHOSIS 8; HYPT8	HYPOTRICHOSIS 8; HYPT8	278150
HYPOTRICHOSIS, LOCALIZED, AUTOSOMAL RECESSIVE 3; LAH3WOOLLY HAIR, AUTOSOMAL RECESSIVE 1, WITH OR WITHOUT HYPOTRICHOSIS,INCLUDED; ARWH1, INCLUDED	HYPOTRICHOSIS 8; HYPT8	278150
WRINKLY SKIN SYNDROME; WSS	WRINKLY SKIN SYNDROME; WSS	278250
XANTHINURIA, TYPE I	XANTHINURIA, TYPE I	278300
XANTHINE DEHYDROGENASE DEFICIENCY	XANTHINURIA, TYPE I	278300
XDH DEFICIENCY	XANTHINURIA, TYPE I	278300
XANTHINE OXIDASE DEFICIENCY	XANTHINURIA, TYPE I	278300
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A; XPA	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A; XPA	278700
XP, GROUP A	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A; XPA	278700
XERODERMA PIGMENTOSUM I; XP1	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A; XPA	278700
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; XPC	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; XPC	278720
XPCC	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; XPC	278720
XP, GROUP C	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; XPC	278720
XERODERMA PIGMENTOSUM III; XP3	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; XPC	278720
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD	278730
XP, GROUP D; XPDC	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD	278730
XERODERMA PIGMENTOSUM IV	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD	278730
XP4 XERODERMA PIGMENTOSUM VIII, FORMERLY; XP8, FORMERLY	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD	278730
XP, GROUP H, FORMERLY; XPH, FORMERLY	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD	278730
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E	278740
XPE	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E	278740
XP, GROUP E	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E	278740
XERODERMA PIGMENTOSUM V; XP5	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E	278740
XERODERMA PIGMENTOSUM, VARIANT TYPE; XPV	XERODERMA PIGMENTOSUM, VARIANT TYPE; XPV	278750
XERODERMA PIGMENTOSUM WITH NORMAL DNA REPAIR RATES	XERODERMA PIGMENTOSUM, VARIANT TYPE; XPV	278750
PHOTOSENSITIVITY WITH DEFECTIVE DNA SYNTHESIS	XERODERMA PIGMENTOSUM, VARIANT TYPE; XPV	278750
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF	278760
XP, GROUP F	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF	278760
XERODERMA PIGMENTOSUM VI; XP6XERODERMA PIGMENTOSUM, TYPE F/COCKAYNE SYNDROME, INCLUDED; XPF/CS,INCLUDED	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF	278760
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP G; XPG	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP G; XPG	278780
XP, GROUP G; XPGC	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP G; XPG	278780
XERODERMA PIGMENTOSUM VII; XP7XERODERMA PIGMENTOSUM, TYPE G/COCKAYNE SYNDROME, INCLUDED; XPG/CS,INCLUDED	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP G; XPG	278780
DE SANCTIS-CACCHIONE SYNDROME	DE SANCTIS-CACCHIONE SYNDROME	278800
46,XX SEX REVERSAL 2; SRXX2	46,XX SEX REVERSAL 2; SRXX2	278850
CHROMOSOME 17q24 DUPLICATION SYNDROME	46,XX SEX REVERSAL 2; SRXX2	278850
YOUNG SYNDROME	YOUNG SYNDROME	279000
AZOOSPERMIA, OBSTRUCTIVE, AND CHRONIC SINOPULMONARY INFECTIONS	YOUNG SYNDROME	279000
SINUSITIS-INFERTILITY SYNDROME	YOUNG SYNDROME	279000
BARRY-PERKINS-YOUNG SYNDROME	YOUNG SYNDROME	279000
COLOBOMA, CONGENITAL HEART DISEASE, ICHTHYOSIFORM DERMATOSIS, MENTALRETARDATION, AND EAR ANOMALIES SYNDROME; CHIME	COLOBOMA, CONGENITAL HEART DISEASE, ICHTHYOSIFORM DERMATOSIS, MENTALRETARDATION, AND EAR ANOMALIES SYNDROME; CHIME	280000
CHIME SYNDROME	COLOBOMA, CONGENITAL HEART DISEASE, ICHTHYOSIFORM DERMATOSIS, MENTALRETARDATION, AND EAR ANOMALIES SYNDROME; CHIME	280000
ZUNICH NEUROECTODERMAL SYNDROME	COLOBOMA, CONGENITAL HEART DISEASE, ICHTHYOSIFORM DERMATOSIS, MENTALRETARDATION, AND EAR ANOMALIES SYNDROME; CHIME	280000
OPITZ GBBB SYNDROME, TYPE I; GBBB1	OPITZ GBBB SYNDROME, TYPE I; GBBB1	300000
OPITZ GBBB SYNDROME, X-LINKED	OPITZ GBBB SYNDROME, TYPE I; GBBB1	300000
OPITZ SYNDROME; OS	OPITZ GBBB SYNDROME, TYPE I; GBBB1	300000
OPITZ SYNDROME, X-LINKED; OSX	OPITZ GBBB SYNDROME, TYPE I; GBBB1	300000
OPITZ-G SYNDROME, TYPE I; OGS1	OPITZ GBBB SYNDROME, TYPE I; GBBB1	300000
OPITZ BBBG SYNDROME, TYPE I; BBBG1	OPITZ GBBB SYNDROME, TYPE I; GBBB1	300000
HYPERTELORISM WITH ESOPHAGEAL ABNORMALITY AND HYPOSPADIAS	OPITZ GBBB SYNDROME, TYPE I; GBBB1	300000
HYPERTELORISM-HYPOSPADIAS SYNDROME	OPITZ GBBB SYNDROME, TYPE I; GBBB1	300000
TELECANTHUS-HYPOSPADIAS SYNDROME	OPITZ GBBB SYNDROME, TYPE I; GBBB1	300000
ICHTHYOSIS, X-LINKED, WITHOUT STEROID SULFATASE DEFICIENCY	ICHTHYOSIS, X-LINKED, WITHOUT STEROID SULFATASE DEFICIENCY	300001
CORPUS CALLOSUM, AGENESIS OF, WITH ABNORMAL GENITALIA	CORPUS CALLOSUM, AGENESIS OF, WITH ABNORMAL GENITALIA	300004
ACC WITH ABNORMAL GENITALIA	CORPUS CALLOSUM, AGENESIS OF, WITH ABNORMAL GENITALIA	300004
PROUD SYNDROME	CORPUS CALLOSUM, AGENESIS OF, WITH ABNORMAL GENITALIA	300004
DENT DISEASE 1	DENT DISEASE 1	300009
NEPHROLITHIASIS, HYPERCALCIURIC, X-LINKED	DENT DISEASE 1	300009
UROLITHIASIS, HYPERCALCIURIC, X-LINKED	DENT DISEASE 1	300009
NEPHROLITHIASIS 2; NPHL2	DENT DISEASE 1	300009
46,XY SEX REVERSAL 2; SRXY2	46,XY SEX REVERSAL 2; SRXY2	300018
46,XY SEX REVERSAL, DAX1-RELATED	46,XY SEX REVERSAL 2; SRXY2	300018
DOSAGE-SENSITIVE SEX REVERSAL; DSS	46,XY SEX REVERSAL 2; SRXY2	300018
RETINITIS PIGMENTOSA 3; RP3	RETINITIS PIGMENTOSA 3; RP3	300029
RETINITIS PIGMENTOSA 15; RP15	RETINITIS PIGMENTOSA 3; RP3	300029
CONE-ROD DEGENERATION, X-LINKED	RETINITIS PIGMENTOSA 3; RP3	300029
CHOROIDORETINAL DEGENERATION WITH RETINAL REFLEX IN HETEROZYGOUS WOMEN	RETINITIS PIGMENTOSA 3; RP3	300029
DEAFNESS, X-LINKED 3; DFNX3	DEAFNESS, X-LINKED 3; DFNX3	300030
DEAFNESS, X-LINKED 4, CONGENITAL SENSORINEURAL; DFN4	DEAFNESS, X-LINKED 3; DFNX3	300030
MENTAL RETARDATION, X-LINKED 23; MRX23	MENTAL RETARDATION, X-LINKED 23; MRX23	300046
MENTAL RETARDATION, X-LINKED 20; MRX20	MENTAL RETARDATION, X-LINKED 20; MRX20	300047
INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED	INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED	300048
IPOX	INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED	300048
CONGENITAL IDIOPATHIC INTESTINAL PSEUDOOBSTRUCTION; CIIP	INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED	300048
CIIP, X-LINKED; CIIPX	INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED	300048
INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, WITH CENTRALNERVOUS SYSTEM INVOLVEMENTCONGENITAL SHORT BOWEL SYNDROME, X-LINKED, INCLUDED	INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED	300048
PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1	PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1	300049
HETEROTOPIA, PERIVENTRICULAR, X-LINKED DOMINANT	PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1	300049
HETEROTOPIA, FAMILIAL NODULAR	PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1	300049
NODULAR HETEROTOPIA, BILATERAL PERIVENTRICULAR; NHBP; BPNH	PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1	300049
HETEROTOPIA, PERIVENTRICULAR, EHLERS-DANLOS VARIANT	PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1	300049
PERIVENTRICULAR NODULAR HETEROTOPIA 4, FORMERLY; PVNH4, FORMERLYHETEROTOPIA, PERIVENTRICULAR NODULAR, WITH FRONTOMETAPHYSEAL DYSPLASIA,INCLUDED	PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1	300049
MENTAL RETARDATION, X-LINKED, SYNDROMIC 13; MRXS13MENTAL RETARDATION, X-LINKED 79; MRX79	MENTAL RETARDATION, X-LINKED, SYNDROMIC 13; MRXS13MENTAL RETARDATION, X-LINKED 79; MRX79	300055
MENTAL RETARDATION, X-LINKED 16; MRX16	MENTAL RETARDATION, X-LINKED, SYNDROMIC 13; MRXS13MENTAL RETARDATION, X-LINKED 79; MRX79	300055
MENTAL RETARDATION, X-LINKED, WITH SPASTICITY	MENTAL RETARDATION, X-LINKED, SYNDROMIC 13; MRXS13MENTAL RETARDATION, X-LINKED 79; MRX79	300055
MENTAL RETARDATION WITH PSYCHOSIS, PYRAMIDAL SIGNS, AND MACROORCHIDISM;PPMX	MENTAL RETARDATION, X-LINKED, SYNDROMIC 13; MRXS13MENTAL RETARDATION, X-LINKED 79; MRX79	300055
MENTAL RETARDATION, X-LINKED 14; MRX14	MENTAL RETARDATION, X-LINKED 14; MRX14	300062
DEAFNESS, X-LINKED 4; DFNX4	DEAFNESS, X-LINKED 4; DFNX4	300066
DEAFNESS, X-LINKED 6, PROGRESSIVE; DFN6	DEAFNESS, X-LINKED 4; DFNX4	300066
DEAFNESS, NONSYNDROMIC SENSORINEURAL PROGRESSIVE 6	DEAFNESS, X-LINKED 4; DFNX4	300066
LISSENCEPHALY, X-LINKED, 1; LISX1	LISSENCEPHALY, X-LINKED, 1; LISX1	300067
XLIS	LISSENCEPHALY, X-LINKED, 1; LISX1	300067
LISSENCEPHALY AND AGENESIS OF CORPUS CALLOSUMSUBCORTICAL LAMINAR HETEROTOPIA, X-LINKED, INCLUDED; SCLH, INCLUDED	LISSENCEPHALY, X-LINKED, 1; LISX1	300067
SUBCORTICAL BAND HETEROTOPIA, X-LINKED, INCLUDED; SBH, INCLUDED	LISSENCEPHALY, X-LINKED, 1; LISX1	300067
DOUBLE CORTEX SYNDROME, INCLUDED	LISSENCEPHALY, X-LINKED, 1; LISX1	300067
DC SYNDROME, INCLUDED	LISSENCEPHALY, X-LINKED, 1; LISX1	300067
ANDROGEN INSENSITIVITY SYNDROME; AIS	ANDROGEN INSENSITIVITY SYNDROME; AIS	300068
TESTICULAR FEMINIZATION SYNDROME; TFM	ANDROGEN INSENSITIVITY SYNDROME; AIS	300068
ANDROGEN RECEPTOR DEFICIENCY	ANDROGEN INSENSITIVITY SYNDROME; AIS	300068
AR DEFICIENCY	ANDROGEN INSENSITIVITY SYNDROME; AIS	300068
DIHYDROTESTOSTERONE RECEPTOR DEFICIENCY	ANDROGEN INSENSITIVITY SYNDROME; AIS	300068
DHTR DEFICIENCY	ANDROGEN INSENSITIVITY SYNDROME; AIS	300068
NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2A; CSNB2A	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2A; CSNB2A	300071
CSNB, INCOMPLETE, X-LINKED	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2A; CSNB2A	300071
NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2; CSNB2	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2A; CSNB2A	300071
IMMUNONEUROLOGIC DISORDER, X-LINKED	IMMUNONEUROLOGIC DISORDER, X-LINKED	300076
WOODS-BLACK-NORBURY SYNDROME	IMMUNONEUROLOGIC DISORDER, X-LINKED	300076
COGNITIVE FUNCTION 1, SOCIAL; CGF1	COGNITIVE FUNCTION 1, SOCIAL; CGF1	300082
SOCIAL COGNITION	COGNITIVE FUNCTION 1, SOCIAL; CGF1	300082
CONE-ROD DYSTROPHY, X-LINKED, 2; CORDX2	CONE-ROD DYSTROPHY, X-LINKED, 2; CORDX2	300085
CONE DYSTROPHY 2, X-LINKED; COD2	CONE-ROD DYSTROPHY, X-LINKED, 2; CORDX2	300085
X INACTIVATION, FAMILIAL SKEWED, 1; SXI1	X INACTIVATION, FAMILIAL SKEWED, 1; SXI1	300087
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 9; EIEE9	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 9; EIEE9	300088
EPILEPSY, FEMALE-RESTRICTED, WITH MENTAL RETARDATION; EFMR	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 9; EIEE9	300088
JUBERG-HELLMAN SYNDROME	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 9; EIEE9	300088
ADRENOLEUKODYSTROPHY; ALD	ADRENOLEUKODYSTROPHY; ALD	300100
ADDISON DISEASE AND CEREBRAL SCLEROSIS	ADRENOLEUKODYSTROPHY; ALD	300100
SIEMERLING-CREUTZFELDT DISEASE	ADRENOLEUKODYSTROPHY; ALD	300100
BRONZE SCHILDER DISEASE	ADRENOLEUKODYSTROPHY; ALD	300100
MELANODERMIC LEUKODYSTROPHYADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED	ADRENOLEUKODYSTROPHY; ALD	300100
MENTAL RETARDATION, X-LINKED 49; MRX49	MENTAL RETARDATION, X-LINKED 49; MRX49	300114
MENTAL RETARDATION, X-LINKED 50; MRX50	MENTAL RETARDATION, X-LINKED 50; MRX50	300115
MENTAL RETARDATION, X-LINKED, WITH PANHYPOPITUITARISMMENTAL RETARDATION, X-LINKED, WITH ISOLATED GROWTH HORMONE DEFICIENCY,INCLUDED; MRGH, INCLUDED	MENTAL RETARDATION, X-LINKED, WITH PANHYPOPITUITARISMMENTAL RETARDATION, X-LINKED, WITH ISOLATED GROWTH HORMONE DEFICIENCY,INCLUDED; MRGH, INCLUDED	300123
MIGRAINE, FAMILIAL TYPICAL, SUSCEPTIBILITY TO, 2	MIGRAINE, FAMILIAL TYPICAL, SUSCEPTIBILITY TO, 2	300125
MGR2	MIGRAINE, FAMILIAL TYPICAL, SUSCEPTIBILITY TO, 2	300125
MFTS	MIGRAINE, FAMILIAL TYPICAL, SUSCEPTIBILITY TO, 2	300125
DIABETES MELLITUS, INSULIN-DEPENDENT, X-LINKED, SUSCEPTIBILITY TO	DIABETES MELLITUS, INSULIN-DEPENDENT, X-LINKED, SUSCEPTIBILITY TO	300136
IDDMX	DIABETES MELLITUS, INSULIN-DEPENDENT, X-LINKED, SUSCEPTIBILITY TO	300136
INSULIN-DEPENDENT DIABETES MELLITUS, X-LINKED, SUSCEPTIBILITY TO	DIABETES MELLITUS, INSULIN-DEPENDENT, X-LINKED, SUSCEPTIBILITY TO	300136
MENTAL RETARDATION, X-LINKED 21; MRX21	MENTAL RETARDATION, X-LINKED 21; MRX21	300143
MENTAL RETARDATION, X-LINKED 34; MRX34	MENTAL RETARDATION, X-LINKED 21; MRX21	300143
PROSTATE CANCER, HEREDITARY, X-LINKED 1; HPCX1	PROSTATE CANCER, HEREDITARY, X-LINKED 1; HPCX1	300147
PROSTATE CANCER SUSCEPTIBILITY, X-LINKED; PCSX	PROSTATE CANCER, HEREDITARY, X-LINKED 1; HPCX1	300147
MENTAL RETARDATION, EPILEPTIC SEIZURES, HYPOGONADISM AND HYPOGENITALISM,MICROCEPHALY, AND OBESITY; MEHMO	MENTAL RETARDATION, EPILEPTIC SEIZURES, HYPOGONADISM AND HYPOGENITALISM,MICROCEPHALY, AND OBESITY; MEHMO	300148
MENTAL RETARDATION, X-LINKED, SYNDROMIC 20; MRXS20	MENTAL RETARDATION, EPILEPTIC SEIZURES, HYPOGONADISM AND HYPOGENITALISM,MICROCEPHALY, AND OBESITY; MEHMO	300148
MENTAL RETARDATION, X-LINKED, SYNDROMIC 25; MRXS25	MENTAL RETARDATION, EPILEPTIC SEIZURES, HYPOGONADISM AND HYPOGENITALISM,MICROCEPHALY, AND OBESITY; MEHMO	300148
RETINITIS PIGMENTOSA 24; RP24	RETINITIS PIGMENTOSA 24; RP24	300155
ARTHROGRYPOSIS, CONGENITAL, LOWER LIMB, X-LINKED; ACLLX	ARTHROGRYPOSIS, CONGENITAL, LOWER LIMB, X-LINKED; ACLLX	300158
ARTHROGRYPOSIS, X-LINKED, TYPE V, FORMERLY; AMCX5, FORMERLY	ARTHROGRYPOSIS, CONGENITAL, LOWER LIMB, X-LINKED; ACLLX	300158
MICROPHTHALMIA, SYNDROMIC 2; MCOPS2	MICROPHTHALMIA, SYNDROMIC 2; MCOPS2	300166
OCULOFACIOCARDIODENTAL SYNDROME	MICROPHTHALMIA, SYNDROMIC 2; MCOPS2	300166
OFCD SYNDROME	MICROPHTHALMIA, SYNDROMIC 2; MCOPS2	300166
MICROPHTHALMIA, CATARACTS, RADICULOMEGALY, AND SEPTAL HEART DEFECTS	MICROPHTHALMIA, SYNDROMIC 2; MCOPS2	300166
ANOP2, FORMERLY	MICROPHTHALMIA, SYNDROMIC 2; MCOPS2	300166
MAA2, FORMERLY	MICROPHTHALMIA, SYNDROMIC 2; MCOPS2	300166
X INACTIVATION, FAMILIAL SKEWED, 2; SXI2	X INACTIVATION, FAMILIAL SKEWED, 2; SXI2	300179
AMME COMPLEX	AMME COMPLEX	300194
ALPORT SYNDROME, MENTAL RETARDATION, MIDFACE HYPOPLASIA, AND ELLIPTOCYTOSIS	AMME COMPLEX	300194
ATS-MR	AMME COMPLEX	300194
CHROMOSOME Xq22.3 TELOMERIC DELETION SYNDROME	AMME COMPLEX	300194
ADRENAL HYPOPLASIA, CONGENITAL; AHC	ADRENAL HYPOPLASIA, CONGENITAL; AHC	300200
ADRENAL HYPOPLASIA, CONGENITAL, WITH HYPOGONADOTROPIC HYPOGONADISM;AHCH	ADRENAL HYPOPLASIA, CONGENITAL; AHC	300200
ADDISON DISEASE, X-LINKED; AHX	ADRENAL HYPOPLASIA, CONGENITAL; AHC	300200
AHC WITH HHG	ADRENAL HYPOPLASIA, CONGENITAL; AHC	300200
CYTOMEGALIC ADRENOCORTICAL HYPOPLASIA	ADRENAL HYPOPLASIA, CONGENITAL; AHC	300200
AHC WITH ISOLATED GONADOTROPIN DEFICIENCYADRENAL HYPOPLASIA, CONGENITAL, WITH PRECOCIOUS PUBERTY, INCLUDED	ADRENAL HYPOPLASIA, CONGENITAL; AHC	300200
ADRENAL INSUFFICIENCY, PROGRESSIVE, AND HYPOGONADOTROPIC HYPOGONADISM,INCLUDED	ADRENAL HYPOPLASIA, CONGENITAL; AHC	300200
MINERALOCORTICOID DEFICIENCY, ISOLATED, INCLUDED	ADRENAL HYPOPLASIA, CONGENITAL; AHC	300200
SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 2	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 2	300209
SGBS2	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 2	300209
MENTAL RETARDATION, X-LINKED 58; MRX58	MENTAL RETARDATION, X-LINKED 58; MRX58	300210
EPISODIC MUSCLE WEAKNESS, X-LINKED; EMWX	EPISODIC MUSCLE WEAKNESS, X-LINKED; EMWX	300211
LISSENCEPHALY, X-LINKED, 2; LISX2	LISSENCEPHALY, X-LINKED, 2; LISX2	300215
LISSENCEPHALY, X-LINKED, WITH AMBIGUOUS GENITALIA; XLAG	LISSENCEPHALY, X-LINKED, 2; LISX2	300215
XLISGHYDRANENCEPHALY AND ABNORMAL GENITALIA, INCLUDED	LISSENCEPHALY, X-LINKED, 2; LISX2	300215
MENTAL RETARDATION, X-LINKED, SYNDROMIC 7; MRXS7	MENTAL RETARDATION, X-LINKED, SYNDROMIC 7; MRXS7	300218
AHMAD X-LINKED MENTAL RETARDATION SYNDROME	MENTAL RETARDATION, X-LINKED, SYNDROMIC 7; MRXS7	300218
MYOTUBULAR MYOPATHY WITH ABNORMAL GENITAL DEVELOPMENT	MYOTUBULAR MYOPATHY WITH ABNORMAL GENITAL DEVELOPMENT	300219
MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10	MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10	300220
CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR	MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10	300220
MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR	MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10	300220
LYMPHOMA, HODGKIN, X-LINKED PSEUDOAUTOSOMAL	LYMPHOMA, HODGKIN, X-LINKED PSEUDOAUTOSOMAL	300221
HODGKIN DISEASE, X-LINKED PSEUDOAUTOSOMAL	LYMPHOMA, HODGKIN, X-LINKED PSEUDOAUTOSOMAL	300221
TESTICULAR GERM CELL TUMOR 1; TGCT1	TESTICULAR GERM CELL TUMOR 1; TGCT1	300228
MENTAL RETARDATION, X-LINKED, SYNDROMIC 11; MRXS11	MENTAL RETARDATION, X-LINKED, SYNDROMIC 11; MRXS11	300238
SHASHI X-LINKED MENTAL RETARDATION SYNDROME; SMRXS	MENTAL RETARDATION, X-LINKED, SYNDROMIC 11; MRXS11	300238
MENTAL RETARDATION, X-LINKED, SHASHI TYPE	MENTAL RETARDATION, X-LINKED, SYNDROMIC 11; MRXS11	300238
MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHRISTIANSON TYPE; MRXSCH	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHRISTIANSON TYPE; MRXSCH	300243
ANGELMAN-LIKE SYNDROME, X-LINKED	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHRISTIANSON TYPE; MRXSCH	300243
MENTAL RETARDATION, MICROCEPHALY, EPILEPSY, AND ATAXIA SYNDROME	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHRISTIANSON TYPE; MRXSCH	300243
TERMINAL OSSEOUS DYSPLASIA; TOD	TERMINAL OSSEOUS DYSPLASIA; TOD	300244
TERMINAL OSSEOUS DYSPLASIA AND PIGMENTARY DEFECTS; TODPD	TERMINAL OSSEOUS DYSPLASIA; TOD	300244
ODPD	TERMINAL OSSEOUS DYSPLASIA; TOD	300244
OSSEOUS DYSPLASIA, DIGITAL, WITH FACIAL PIGMENTARY DEFECTS AND MULTIPLEFRENULA; ODPF	TERMINAL OSSEOUS DYSPLASIA; TOD	300244
ODPF SYNDROME	TERMINAL OSSEOUS DYSPLASIA; TOD	300244
PTOSIS, HEREDITARY CONGENITAL 2	PTOSIS, HEREDITARY CONGENITAL 2	300245
PTOS2	PTOSIS, HEREDITARY CONGENITAL 2	300245
PTOSIS, X-LINKED; PTOSX	PTOSIS, HEREDITARY CONGENITAL 2	300245
DANON DISEASE	DANON DISEASE	300257
VACUOLAR CARDIOMYOPATHY AND MYOPATHY, X-LINKED	DANON DISEASE	300257
PSEUDOGLYCOGENOSIS II	DANON DISEASE	300257
ANTOPOL DISEASE	DANON DISEASE	300257
LYSOSOMAL GLYCOGEN STORAGE DISEASE WITHOUT ACID MALTASE DEFICIENCY,FORMERLY	DANON DISEASE	300257
GLYCOGEN STORAGE DISEASE IIb; GSD2B, FORMERLY	DANON DISEASE	300257
GSD IIb, FORMERLY	DANON DISEASE	300257
LUBS X-LINKED MENTAL RETARDATION SYNDROME; MRXSL	LUBS X-LINKED MENTAL RETARDATION SYNDROME; MRXSL	300260
MECP2 DUPLICATION SYNDROME	LUBS X-LINKED MENTAL RETARDATION SYNDROME; MRXSL	300260
MENTAL RETARDATION, X-LINKED, SYNDROMIC, LUBS TYPE	LUBS X-LINKED MENTAL RETARDATION SYNDROME; MRXSL	300260
MENTAL RETARDATION, X-LINKED, WITH RECURRENT RESPIRATORY INFECTIONS	LUBS X-LINKED MENTAL RETARDATION SYNDROME; MRXSL	300260
ARMFIELD X-LINKED MENTAL RETARDATION SYNDROME; MRXSA	ARMFIELD X-LINKED MENTAL RETARDATION SYNDROME; MRXSA	300261
MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARMFIELD TYPE	ARMFIELD X-LINKED MENTAL RETARDATION SYNDROME; MRXSA	300261
ABIDI X-LINKED MENTAL RETARDATION SYNDROME; MRXSAB	ABIDI X-LINKED MENTAL RETARDATION SYNDROME; MRXSAB	300262
MENTAL RETARDATION, X-LINKED, SYNDROMIC, ABIDI TYPE	ABIDI X-LINKED MENTAL RETARDATION SYNDROME; MRXSAB	300262
SIDERIUS X-LINKED MENTAL RETARDATION SYNDROME; MRXSSD	SIDERIUS X-LINKED MENTAL RETARDATION SYNDROME; MRXSSD	300263
MENTAL RETARDATION, X-LINKED, SYNDROMIC, SIDERIUS TYPE	SIDERIUS X-LINKED MENTAL RETARDATION SYNDROME; MRXSSD	300263
SIDERIUS-HAMEL SYNDROME	SIDERIUS X-LINKED MENTAL RETARDATION SYNDROME; MRXSSD	300263
SPASTIC PARAPLEGIA 16, X-LINKED; SPG16	SPASTIC PARAPLEGIA 16, X-LINKED; SPG16	300266
MENTAL RETARDATION, X-LINKED 72; MRX72	MENTAL RETARDATION, X-LINKED 72; MRX72	300271
GOITER, MULTINODULAR 2; MNG2	GOITER, MULTINODULAR 2; MNG2	300273
ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY	ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY	300291
HED-IDECTODERMAL DYSPLASIA, ANHIDROTIC, WITH IMMUNE DEFICIENCY, INCLUDED	ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY	300291
EDA-ID, INCLUDED	ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY	300291
HYPER-IgM IMMUNODEFICIENCY, X-LINKED, WITH HYPOHIDROTIC ECTODERMALDYSPLASIA, INCLUDED	ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY	300291
XHM-ED, INCLUDED	ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY	300291
NEUTROPENIA, SEVERE CONGENITAL, X-LINKED; SCNX	NEUTROPENIA, SEVERE CONGENITAL, X-LINKED; SCNX	300299
XLN	NEUTROPENIA, SEVERE CONGENITAL, X-LINKED; SCNX	300299
ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH IMMUNODEFICIENCY, OSTEOPETROSIS,AND LYMPHEDEMA; OLEDAID	ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH IMMUNODEFICIENCY, OSTEOPETROSIS,AND LYMPHEDEMA; OLEDAID	300301
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 11; BMIQ11	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 11; BMIQ11	300306
OBESITY, SUSCEPTIBILITY TO	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 11; BMIQ11	300306
AGAMMAGLOBULINEMIA, X-LINKED, TYPE 2; AGMX2	AGAMMAGLOBULINEMIA, X-LINKED, TYPE 2; AGMX2	300310
XLA2	AGAMMAGLOBULINEMIA, X-LINKED, TYPE 2; AGMX2	300310
FG SYNDROME 2; FGS2	FG SYNDROME 2; FGS2	300321
LESCH-NYHAN SYNDROME; LNS	LESCH-NYHAN SYNDROME; LNS	300322
HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY	LESCH-NYHAN SYNDROME; LNS	300322
HPRT1 DEFICIENCY	LESCH-NYHAN SYNDROME; LNS	300322
HPRT DEFICIENCY	LESCH-NYHAN SYNDROME; LNS	300322
HPRT DEFICIENCY, COMPLETEHPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED	LESCH-NYHAN SYNDROME; LNS	300322
LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED	LESCH-NYHAN SYNDROME; LNS	300322
KELLEY-SEEGMILLER SYNDROME	KELLEY-SEEGMILLER SYNDROME	300323
GOUT, HPRT-RELATED	KELLEY-SEEGMILLER SYNDROME	300323
HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY, PARTIAL	KELLEY-SEEGMILLER SYNDROME	300323
HPRT DEFICIENCY, PARTIAL	KELLEY-SEEGMILLER SYNDROME	300323
HPRT1 DEFICIENCY, PARTIAL	KELLEY-SEEGMILLER SYNDROME	300323
MENTAL RETARDATION, X-LINKED 53; MRX53	MENTAL RETARDATION, X-LINKED 53; MRX53	300324
THROMBOCYTHEMIA, X-LINKED; THCYTX	THROMBOCYTHEMIA, X-LINKED; THCYTX	300331
THROMBOCYTOSIS, X-LINKED	THROMBOCYTHEMIA, X-LINKED; THCYTX	300331
HYPOMELANOSIS OF ITO; HMI	HYPOMELANOSIS OF ITO; HMI	300337
INCONTINENTIA PIGMENTI ACHROMIANS; IPA	HYPOMELANOSIS OF ITO; HMI	300337
ITO HYPOMELANOSIS; ITO	HYPOMELANOSIS OF ITO; HMI	300337
INCONTINENTIA PIGMENTI, TYPE I, FORMERLY; IP1, FORMERLY	HYPOMELANOSIS OF ITO; HMI	300337
MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 1; MCOPCB1	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 1; MCOPCB1	300345
MICROPHTHALMIA, COLOBOMATOUS, ISOLATED 1	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 1; MCOPCB1	300345
GRAVES DISEASE, SUSCEPTIBILITY TO, X-LINKED 1	GRAVES DISEASE, SUSCEPTIBILITY TO, X-LINKED 1	300351
GRDX1GRAVES DISEASE, SUSCEPTIBILITY TO, X-LINKED 2, INCLUDED; GRDX2, INCLUDED	GRAVES DISEASE, SUSCEPTIBILITY TO, X-LINKED 1	300351
CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1	CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1	300352
CREATINE DEFICIENCY SYNDROME, X-LINKED	CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1	300352
CREATINE TRANSPORTER DEFECT	CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1	300352
MENTAL RETARDATION, X-LINKED, WITH SEIZURES, SHORT STATURE, AND MIDFACEHYPOPLASIA	CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1	300352
MENTAL RETARDATION, X-LINKED, WITH CREATINE TRANSPORT DEFICIENCY	CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1	300352
MENTAL RETARDATION, X-LINKED, SYNDROMIC, CABEZAS TYPE; MRXSC	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CABEZAS TYPE; MRXSC	300354
CABEZAS SYNDROME	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CABEZAS TYPE; MRXSC	300354
MENTAL RETARDATION, X-LINKED, SYNDROMIC 15; MRXS15	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CABEZAS TYPE; MRXSC	300354
MENTAL RETARDATION, X-LINKED, WITH SHORT STATURE, HYPOGONADISM, ANDABNORMAL GAIT	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CABEZAS TYPE; MRXSC	300354
MENTAL RETARDATION, X-LINKED, WITH SHORT STATURE; MRSS	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CABEZAS TYPE; MRXSC	300354
MENTAL RETARDATION, X-LINKED 73; MRX73	MENTAL RETARDATION, X-LINKED 73; MRX73	300355
THROMBOCYTOPENIA, X-LINKED, WITH OR WITHOUT DYSERYTHROPOIETIC ANEMIA;XLTDA	THROMBOCYTOPENIA, X-LINKED, WITH OR WITHOUT DYSERYTHROPOIETIC ANEMIA;XLTDA	300367
MENTAL RETARDATION, X-LINKED 42; MRX42	MENTAL RETARDATION, X-LINKED 42; MRX42	300372
OSTEOPATHIA STRIATA WITH CRANIAL SCLEROSIS; OSCS	OSTEOPATHIA STRIATA WITH CRANIAL SCLEROSIS; OSCS	300373
HYPEROSTOSIS GENERALISATA WITH STRIATIONS	OSTEOPATHIA STRIATA WITH CRANIAL SCLEROSIS; OSCS	300373
MUSCULAR DYSTROPHY, BECKER TYPE; BMD	MUSCULAR DYSTROPHY, BECKER TYPE; BMD	300376
BECKER MUSCULAR DYSTROPHY	MUSCULAR DYSTROPHY, BECKER TYPE; BMD	300376
MUSCULAR DYSTROPHY, PSEUDOHYPERTROPHIC PROGRESSIVE, BECKER TYPE	MUSCULAR DYSTROPHY, BECKER TYPE; BMD	300376
RADIAL RAY DEFICIENCY, X-LINKED	RADIAL RAY DEFICIENCY, X-LINKED	300378
RRDX	RADIAL RAY DEFICIENCY, X-LINKED	300378
MENTAL RETARDATION, X-LINKED 63; MRX63	MENTAL RETARDATION, X-LINKED 63; MRX63	300387
MENTAL RETARDATION, X-LINKED 68; MRX68	MENTAL RETARDATION, X-LINKED 63; MRX63	300387
POLYMICROGYRIA, BILATERAL PERISYLVIAN, X-LINKED; BPPX	POLYMICROGYRIA, BILATERAL PERISYLVIAN, X-LINKED; BPPX	300388
PMGX	POLYMICROGYRIA, BILATERAL PERISYLVIAN, X-LINKED; BPPX	300388
BPP	POLYMICROGYRIA, BILATERAL PERISYLVIAN, X-LINKED; BPPX	300388
PERISYLVIAN SYNDROME, CONGENITAL BILATERAL; CBPS	POLYMICROGYRIA, BILATERAL PERISYLVIAN, X-LINKED; BPPX	300388
SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED; SCIDX1	SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED; SCIDX1	300400
SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED, T CELL-NEGATIVE, B CELL-POSITIVE,NK CELL-NEGATIVE	SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED; SCIDX1	300400
SCIDX; XSCID	SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED; SCIDX1	300400
SCID, X-LINKED	SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED; SCIDX1	300400
IMMUNODEFICIENCY 4; IMD4	SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED; SCIDX1	300400
FG SYNDROME 3; FGS3	FG SYNDROME 3; FGS3	300406
MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED;MRXARX	MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED;MRXARX	300419
MENTAL RETARDATION, X-LINKED 29; MRX29	MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED;MRXARX	300419
MENTAL RETARDATION, X-LINKED 32; MRX32	MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED;MRXARX	300419
MENTAL RETARDATION, X-LINKED 33; MRX33	MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED;MRXARX	300419
MENTAL RETARDATION, X-LINKED 38; MRX38	MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED;MRXARX	300419
MENTAL RETARDATION, X-LINKED 43; MRX43	MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED;MRXARX	300419
MENTAL RETARDATION, X-LINKED 54; MRX54	MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED;MRXARX	300419
MENTAL RETARDATION, X-LINKED 76; MRX76	MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED;MRXARX	300419
MENTAL RETARDATION, X-LINKED 87; MRX87	MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED;MRXARX	300419
FG SYNDROME 4; FGS4MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT NYSTAGMUS, INCLUDED	FG SYNDROME 4; FGS4MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT NYSTAGMUS, INCLUDED	300422
MENTAL RETARDATION, X-LINKED, SYNDROMIC, HEDERA TYPE; MRXSH	MENTAL RETARDATION, X-LINKED, SYNDROMIC, HEDERA TYPE; MRXSH	300423
MENTAL RETARDATION, X-LINKED, WITH EPILEPSY; MRXE	MENTAL RETARDATION, X-LINKED, SYNDROMIC, HEDERA TYPE; MRXSH	300423
RETINITIS PIGMENTOSA 23; RP23	RETINITIS PIGMENTOSA 23; RP23	300424
AUTISM, SUSCEPTIBILITY TO, X-LINKED 1; AUTSX1	AUTISM, SUSCEPTIBILITY TO, X-LINKED 1; AUTSX1	300425
MENTAL RETARDATION, X-LINKED 2; MRX2	MENTAL RETARDATION, X-LINKED 2; MRX2	300428
MENTAL RETARDATION, X-LINKED 81; MRX81	MENTAL RETARDATION, X-LINKED 81; MRX81	300433
STOCCO DOS SANTOS X-LINKED MENTAL RETARDATION SYNDROME	STOCCO DOS SANTOS X-LINKED MENTAL RETARDATION SYNDROME	300434
SDSX	STOCCO DOS SANTOS X-LINKED MENTAL RETARDATION SYNDROME	300434
MENTAL RETARDATION, X-LINKED, STOCCO DOS SANTOS TYPE	STOCCO DOS SANTOS X-LINKED MENTAL RETARDATION SYNDROME	300434
MENTAL RETARDATION, X-LINKED 46; MRX46	MENTAL RETARDATION, X-LINKED 46; MRX46	300436
17-@BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY	17-@BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY	300438
HSD17B10 DEFICIENCY	17-@BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY	300438
HSD10 DEFICIENCY	17-@BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY	300438
3-@HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY	17-@BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY	300438
2-@METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	17-@BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY	300438
MHBD DEFICIENCY	17-@BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY	300438
ALPHA-THALASSEMIA MYELODYSPLASIA SYNDROME; ATMDS	ALPHA-THALASSEMIA MYELODYSPLASIA SYNDROME; ATMDS	300448
HEMOGLOBIN H DISEASE, ACQUIRED	ALPHA-THALASSEMIA MYELODYSPLASIA SYNDROME; ATMDS	300448
MENTAL RETARDATION, X-LINKED 77; MRX77	MENTAL RETARDATION, X-LINKED 77; MRX77	300454
RETINITIS PIGMENTOSA, X-LINKED, AND SINORESPIRATORY INFECTIONS, WITHOR WITHOUT DEAFNESS	RETINITIS PIGMENTOSA, X-LINKED, AND SINORESPIRATORY INFECTIONS, WITHOR WITHOUT DEAFNESS	300455
CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 3	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 3	300464
CHDS3	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 3	300464
CUBITUS VALGUS WITH MENTAL RETARDATION AND UNUSUAL FACIES	CUBITUS VALGUS WITH MENTAL RETARDATION AND UNUSUAL FACIES	300471
CORPUS CALLOSUM, AGENESIS OF, WITH MENTAL RETARDATION, OCULAR COLOBOMA,AND MICROGNATHIA	CORPUS CALLOSUM, AGENESIS OF, WITH MENTAL RETARDATION, OCULAR COLOBOMA,AND MICROGNATHIA	300472
MENTAL RETARDATION, X-LINKED, SYNDROMIC 28; MRXS28	CORPUS CALLOSUM, AGENESIS OF, WITH MENTAL RETARDATION, OCULAR COLOBOMA,AND MICROGNATHIA	300472
DEAFNESS, DYSTONIA, AND CEREBRAL HYPOMYELINATION; DDCHCONTIGUOUS ABCD1/DXS1375E DELETION SYNDROME, INCLUDED; CADDS, INCLUDED	DEAFNESS, DYSTONIA, AND CEREBRAL HYPOMYELINATION; DDCHCONTIGUOUS ABCD1/DXS1375E DELETION SYNDROME, INCLUDED; CADDS, INCLUDED	300475
CONE-ROD DYSTROPHY, X-LINKED, 3; CORDX3	CONE-ROD DYSTROPHY, X-LINKED, 3; CORDX3	300476
OROFACIODIGITAL SYNDROME VIII; OFD8	OROFACIODIGITAL SYNDROME VIII; OFD8	300484
OFDS VIII	OROFACIODIGITAL SYNDROME VIII; OFD8	300484
ORAL-FACIAL-DIGITAL SYNDROME, TYPE VIII	OROFACIODIGITAL SYNDROME VIII; OFD8	300484
ORAL-FACIAL-DIGITAL SYNDROME WITH HYPOPLASTIC EPIGLOTTIS	OROFACIODIGITAL SYNDROME VIII; OFD8	300484
EDWARDS SYNDROME	OROFACIODIGITAL SYNDROME VIII; OFD8	300484
MENTAL RETARDATION, X-LINKED, WITH CEREBELLAR HYPOPLASIA AND DISTINCTIVEFACIAL APPEARANCE	MENTAL RETARDATION, X-LINKED, WITH CEREBELLAR HYPOPLASIA AND DISTINCTIVEFACIAL APPEARANCE	300486
MENTAL RETARDATION, X-LINKED 60, FORMERLY; MRX60, FORMERLY	MENTAL RETARDATION, X-LINKED, WITH CEREBELLAR HYPOPLASIA AND DISTINCTIVEFACIAL APPEARANCE	300486
MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 1; MENOQ1	MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 1; MENOQ1	300488
SPINAL MUSCULAR ATROPHY, DISTAL, X-LINKED 3; SMAX3	SPINAL MUSCULAR ATROPHY, DISTAL, X-LINKED 3; SMAX3	300489
SPINAL MUSCULAR ATROPHY, DISTAL, X-LINKED RECESSIVE	SPINAL MUSCULAR ATROPHY, DISTAL, X-LINKED 3; SMAX3	300489
DSMAX	SPINAL MUSCULAR ATROPHY, DISTAL, X-LINKED 3; SMAX3	300489
EPILEPSY, X-LINKED, WITH VARIABLE LEARNING DISABILITIES AND BEHAVIORDISORDERS	EPILEPSY, X-LINKED, WITH VARIABLE LEARNING DISABILITIES AND BEHAVIORDISORDERS	300491
ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 1; ASPGX1	ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 1; ASPGX1	300494
AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2MENTAL RETARDATION, X-LINKED, INCLUDED	AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2MENTAL RETARDATION, X-LINKED, INCLUDED	300495
AUTISM, SUSCEPTIBILITY TO, X-LINKED 3; AUTSX3	AUTISM, SUSCEPTIBILITY TO, X-LINKED 3; AUTSX3	300496
ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 2; ASPGX2	ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 2; ASPGX2	300497
MENTAL RETARDATION, X-LINKED 45; MRX45	MENTAL RETARDATION, X-LINKED 45; MRX45	300498
ALBINISM, OCULAR, TYPE I; OA1	ALBINISM, OCULAR, TYPE I; OA1	300500
NETTLESHIP-FALLS TYPE OCULAR ALBINISM	ALBINISM, OCULAR, TYPE I; OA1	300500
MENTAL RETARDATION, X-LINKED 52; MRX52	MENTAL RETARDATION, X-LINKED 52; MRX52	300504
MENTAL RETARDATION, X-LINKED 84; MRX84	MENTAL RETARDATION, X-LINKED 84; MRX84	300505
DYSLEXIA, SUSCEPTIBILITY TO, 9; DYX9	DYSLEXIA, SUSCEPTIBILITY TO, 9; DYX9	300509
OVARIAN DYSGENESIS 2; ODG2	OVARIAN DYSGENESIS 2; ODG2	300510
OVARIAN DYSGENESIS, HYPERGONADOTROPIC, X-LINKED	OVARIAN DYSGENESIS 2; ODG2	300510
OVARIAN FAILURE, HYPERGONADOTROPIC, DUE TO OVARIAN DYSGENESISPREMATURE OVARIAN FAILURE 4, INCLUDED; POF4, INCLUDED	OVARIAN DYSGENESIS 2; ODG2	300510
PREMATURE OVARIAN FAILURE 2A; POF2A	PREMATURE OVARIAN FAILURE 2A; POF2A	300511
FANCONI ANEMIA, COMPLEMENTATION GROUP B; FANCB	FANCONI ANEMIA, COMPLEMENTATION GROUP B; FANCB	300514
FACB	FANCONI ANEMIA, COMPLEMENTATION GROUP B; FANCB	300514
FANCONI PANCYTOPENIA, TYPE 2; FA2	FANCONI ANEMIA, COMPLEMENTATION GROUP B; FANCB	300514
MENTAL RETARDATION, X-LINKED 82; MRX82	MENTAL RETARDATION, X-LINKED 82; MRX82	300518
MENTAL RETARDATION, X-LINKED, SYNDROMIC, MARTIN-PROBST TYPE; MRXSMP	MENTAL RETARDATION, X-LINKED, SYNDROMIC, MARTIN-PROBST TYPE; MRXSMP	300519
MARTIN-PROBST DEAFNESS-MENTAL RETARDATION SYNDROME	MENTAL RETARDATION, X-LINKED, SYNDROMIC, MARTIN-PROBST TYPE; MRXSMP	300519
ALLAN-HERNDON-DUDLEY SYNDROME; AHDS	ALLAN-HERNDON-DUDLEY SYNDROME; AHDS	300523
ALLAN-HERNDON SYNDROME	ALLAN-HERNDON-DUDLEY SYNDROME; AHDS	300523
MONOCARBOXYLATE TRANSPORTER 8 DEFICIENCY	ALLAN-HERNDON-DUDLEY SYNDROME; AHDS	300523
TRIIODOTHYRONINE RESISTANCE	ALLAN-HERNDON-DUDLEY SYNDROME; AHDS	300523
T3 RESISTANCE	ALLAN-HERNDON-DUDLEY SYNDROME; AHDS	300523
MENTAL RETARDATION, X-LINKED, WITH HYPOTONIA	ALLAN-HERNDON-DUDLEY SYNDROME; AHDS	300523
MENTAL RETARDATION AND MUSCULAR ATROPHY	ALLAN-HERNDON-DUDLEY SYNDROME; AHDS	300523
MENTAL RETARDATION, X-LINKED, SYNDROMIC, CLAES-JENSEN TYPE; MRXSCJ	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CLAES-JENSEN TYPE; MRXSCJ	300534
MENTAL RETARDATION, X-LINKED, SYNDROMIC, JARID1C-RELATED; MRXSJ	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CLAES-JENSEN TYPE; MRXSCJ	300534
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 4; BMND4	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 4; BMND4	300536
NEPHROGENIC SYNDROME OF INAPPROPRIATE ANTIDIURESIS; NSIAD	NEPHROGENIC SYNDROME OF INAPPROPRIATE ANTIDIURESIS; NSIAD	300539
MENTAL RETARDATION, X-LINKED 78; MRX78	MENTAL RETARDATION, X-LINKED 78; MRX78	300551
HYPOPHOSPHATEMIC RICKETS, X-LINKED RECESSIVE	HYPOPHOSPHATEMIC RICKETS, X-LINKED RECESSIVE	300554
DENT DISEASE 2	DENT DISEASE 2	300555
PARKINSON DISEASE 12; PARK12	PARKINSON DISEASE 12; PARK12	300557
PARKINSON DISEASE, X-LINKED	PARKINSON DISEASE 12; PARK12	300557
MENTAL RETARDATION, X-LINKED 30; MRX30	MENTAL RETARDATION, X-LINKED 30; MRX30	300558
MENTAL RETARDATION, X-LINKED 47; MRX47	MENTAL RETARDATION, X-LINKED 30; MRX30	300558
GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D	GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D	300559
GSD IXd	GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D	300559
MUSCLE PHOSPHORYLASE KINASE DEFICIENCY	GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D	300559
MUSCLE GLYCOGENOSIS, X-LINKED	GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D	300559
MENTAL RETARDATION, X-LINKED 91; MRX91	MENTAL RETARDATION, X-LINKED 91; MRX91	300577
CHROMOSOME Xp11.3 DELETION SYNDROME	CHROMOSOME Xp11.3 DELETION SYNDROME	300578
MENTAL RETARDATION, X-LINKED, WITH RETINITIS PIGMENTOSA	CHROMOSOME Xp11.3 DELETION SYNDROME	300578
MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION, X-LINKED; CFTDX	MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION, X-LINKED; CFTDX	300580
FG SYNDROME 5; FGS5	FG SYNDROME 5; FGS5	300581
SHORT STATURE, IDIOPATHIC, X-LINKED; ISS	SHORT STATURE, IDIOPATHIC, X-LINKED; ISS	300582
IMMUNODEFICIENCY WITHOUT ANHIDROTIC ECTODERMAL DYSPLASIA	IMMUNODEFICIENCY WITHOUT ANHIDROTIC ECTODERMAL DYSPLASIA	300584
IMMUNODEFICIENCY, ISOLATED	IMMUNODEFICIENCY WITHOUT ANHIDROTIC ECTODERMAL DYSPLASIA	300584
IMMUNODEFICIENCY, PURE	IMMUNODEFICIENCY WITHOUT ANHIDROTIC ECTODERMAL DYSPLASIA	300584
NYSTAGMUS 5, CONGENITAL, X-LINKED; NYS5	NYSTAGMUS 5, CONGENITAL, X-LINKED; NYS5	300589
CORNELIA DE LANGE SYNDROME 2; CDLS2	CORNELIA DE LANGE SYNDROME 2; CDLS2	300590
CORNELIA DE LANGE SYNDROME, X-LINKED	CORNELIA DE LANGE SYNDROME 2; CDLS2	300590
CDLS, X-LINKED	CORNELIA DE LANGE SYNDROME 2; CDLS2	300590
STATURE QUANTITATIVE TRAIT LOCUS 6; STQTL6	STATURE QUANTITATIVE TRAIT LOCUS 6; STQTL6	300591
ALAND ISLAND EYE DISEASE; AIED	ALAND ISLAND EYE DISEASE; AIED	300600
FORSIUS-ERIKSSON TYPE OCULAR ALBINISM	ALAND ISLAND EYE DISEASE; AIED	300600
PREMATURE OVARIAN FAILURE 2B; POF2B	PREMATURE OVARIAN FAILURE 2B; POF2B	300604
RETINITIS PIGMENTOSA 34; RP34	RETINITIS PIGMENTOSA 34; RP34	300605
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 8; EIEE8	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 8; EIEE8	300607
HYPEREKPLEXIA AND EPILEPSY	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 8; EIEE8	300607
BROOKS-WISNIEWSKI-BROWN SYNDROME	BROOKS-WISNIEWSKI-BROWN SYNDROME	300612
MENTAL RETARDATION, X-LINKED, SYNDROMIC, BROOKS-WISNIEWSKI-BROWN TYPE;MRXSBWB	BROOKS-WISNIEWSKI-BROWN SYNDROME	300612
MYOPIA 13, X-LINKED; MYP13	MYOPIA 13, X-LINKED; MYP13	300613
DEAFNESS, X-LINKED 5; DFNX5	DEAFNESS, X-LINKED 5; DFNX5	300614
AUDITORY NEUROPATHY, X-LINKED, 1, WITH PERIPHERAL SENSORY NEUROPATHY;AUNX1	DEAFNESS, X-LINKED 5; DFNX5	300614
BRUNNER SYNDROME	BRUNNER SYNDROME	300615
CATARACT, ATAXIA, SHORT STATURE, AND MENTAL RETARDATION	CATARACT, ATAXIA, SHORT STATURE, AND MENTAL RETARDATION	300619
CASM SYNDROME	CATARACT, ATAXIA, SHORT STATURE, AND MENTAL RETARDATION	300619
TN POLYAGGLUTINATION SYNDROME; TNPS	TN POLYAGGLUTINATION SYNDROME; TNPS	300622
GALACTOSYLTRANSFERASE DEFICIENCY	TN POLYAGGLUTINATION SYNDROME; TNPS	300622
FRAGILE X TREMOR/ATAXIA SYNDROME; FXTAS	FRAGILE X TREMOR/ATAXIA SYNDROME; FXTAS	300623
FRAGILE X MENTAL RETARDATION SYNDROME	FRAGILE X MENTAL RETARDATION SYNDROME	300624
FRAGILE X SYNDROME	FRAGILE X MENTAL RETARDATION SYNDROME	300624
MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH marXq28	FRAGILE X MENTAL RETARDATION SYNDROME	300624
X-LINKED MENTAL RETARDATION AND MACROORCHIDISM	FRAGILE X MENTAL RETARDATION SYNDROME	300624
MARKER X SYNDROME	FRAGILE X MENTAL RETARDATION SYNDROME	300624
MARTIN-BELL SYNDROMEPRIMARY OVARIAN INSUFFICIENCY, FRAGILE X-ASSOCIATED, INCLUDED	FRAGILE X MENTAL RETARDATION SYNDROME	300624
FRAGILE X PREMATURE OVARIAN FAILURE, INCLUDED	FRAGILE X MENTAL RETARDATION SYNDROME	300624
HYPOSPADIAS 1, X-LINKED; HYSP1	HYPOSPADIAS 1, X-LINKED; HYSP1	300633
LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 2; XLP2	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 2; XLP2	300635
XIAP DEFICIENCY	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 2; XLP2	300635
IMMUNODEFICIENCY 33; IMD33	IMMUNODEFICIENCY 33; IMD33	300636
IMMUNODEFICIENCY 33, MYCOBACTERIOSIS, X-LINKED	IMMUNODEFICIENCY 33; IMD33	300636
ATYPICAL MYCOBACTERIOSIS, FAMILIAL, X-LINKED 1; AMCBX1	IMMUNODEFICIENCY 33; IMD33	300636
INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED, 2; IPD2	INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED, 2; IPD2	300640
ROLANDIC EPILEPSY, MENTAL RETARDATION, AND SPEECH DYSPRAXIA, X-LINKED;RESDX	ROLANDIC EPILEPSY, MENTAL RETARDATION, AND SPEECH DYSPRAXIA, X-LINKED;RESDX	300643
IMMUNODEFICIENCY 34; IMD34	IMMUNODEFICIENCY 34; IMD34	300645
IMMUNODEFICIENCY 34, MYCOBACTERIOSIS, X-LINKED	IMMUNODEFICIENCY 34; IMD34	300645
ATYPICAL MYCOBACTERIOSIS, FAMILIAL, X-LINKED 2; AMCBX2	IMMUNODEFICIENCY 34; IMD34	300645
ANGIOMA SERPIGINOSUM, X-LINKED	ANGIOMA SERPIGINOSUM, X-LINKED	300652
PHOSPHOGLYCERATE KINASE 1 DEFICIENCY	PHOSPHOGLYCERATE KINASE 1 DEFICIENCY	300653
PGK1 DEFICIENCY	PHOSPHOGLYCERATE KINASE 1 DEFICIENCY	300653
MENTAL RETARDATION, X-LINKED 93; MRX93	MENTAL RETARDATION, X-LINKED 93; MRX93	300659
MENTAL RETARDATION, X-LINKED, WITH MACROCEPHALY	MENTAL RETARDATION, X-LINKED 93; MRX93	300659
LEUKOENCEPHALOPATHY WITH METAPHYSEAL CHONDRODYSPLASIA; LKMCD	LEUKOENCEPHALOPATHY WITH METAPHYSEAL CHONDRODYSPLASIA; LKMCD	300660
PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY	PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY	300661
PRPS1 SUPERACTIVITYGOUT, PRPS-RELATED, INCLUDED	PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY	300661
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2; EIEE2	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2; EIEE2	300672
INFANTILE SPASM SYNDROME, X-LINKED 2; ISSX2	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2; EIEE2	300672
ENCEPHALOPATHY, NEONATAL SEVERE, DUE TO MECP2 MUTATIONS	ENCEPHALOPATHY, NEONATAL SEVERE, DUE TO MECP2 MUTATIONS	300673
MENTAL RETARDATION, X-LINKED, SYNDROMIC 14; MRXS14	MENTAL RETARDATION, X-LINKED, SYNDROMIC 14; MRXS14	300676
CHROMOSOME Xp21 DELETION SYNDROME	CHROMOSOME Xp21 DELETION SYNDROME	300679
COMPLEX GLYCEROL KINASE DEFICIENCY	CHROMOSOME Xp21 DELETION SYNDROME	300679
SCAPULOPERONEAL MYOPATHY, X-LINKED DOMINANT; SPM	SCAPULOPERONEAL MYOPATHY, X-LINKED DOMINANT; SPM	300695
SCAPULOPERONEAL MYOPATHY, FHL1-RELATED	SCAPULOPERONEAL MYOPATHY, X-LINKED DOMINANT; SPM	300695
MYOPATHY, X-LINKED, WITH POSTURAL MUSCLE ATROPHY; XMPMAEMERY-DREIFUSS MUSCULAR DYSTROPHY 6, X-LINKED, INCLUDED; EDMD6, INCLUDED	MYOPATHY, X-LINKED, WITH POSTURAL MUSCLE ATROPHY; XMPMAEMERY-DREIFUSS MUSCULAR DYSTROPHY 6, X-LINKED, INCLUDED; EDMD6, INCLUDED	300696
MENTAL RETARDATION, X-LINKED, SYNDROMIC, WU TYPE; MRXSW	MENTAL RETARDATION, X-LINKED, SYNDROMIC, WU TYPE; MRXSW	300699
MENTAL RETARDATION, X-LINKED 94; MRX94	MENTAL RETARDATION, X-LINKED, SYNDROMIC, WU TYPE; MRXSW	300699
MENTAL RETARDATION, X-LINKED, SYNDROMIC 29; MRXS29	MENTAL RETARDATION, X-LINKED, SYNDROMIC, WU TYPE; MRXSW	300699
ALBINISM-DEAFNESS SYNDROME; ADFN	ALBINISM-DEAFNESS SYNDROME; ADFN	300700
ALDS	ALBINISM-DEAFNESS SYNDROME; ADFN	300700
SPINOCEREBELLAR ATAXIA, X-LINKED 5; SCAX5	SPINOCEREBELLAR ATAXIA, X-LINKED 5; SCAX5	300703
PROSTATE CANCER, HEREDITARY, X-LINKED 2; HPCX2	PROSTATE CANCER, HEREDITARY, X-LINKED 2; HPCX2	300704
CHROMOSOME Xp11.22 DUPLICATION SYNDROME	CHROMOSOME Xp11.22 DUPLICATION SYNDROME	300705
MENTAL RETARDATION, X-LINKED 17; MRX17	CHROMOSOME Xp11.22 DUPLICATION SYNDROME	300705
MENTAL RETARDATION, X-LINKED 31; MRX31	CHROMOSOME Xp11.22 DUPLICATION SYNDROME	300705
MENTAL RETARDATION, X-LINKED, SYNDROMIC, TURNER TYPE; MRXST	MENTAL RETARDATION, X-LINKED, SYNDROMIC, TURNER TYPE; MRXST	300706
MENTAL RETARDATION AND MACROCEPHALY SYNDROME	MENTAL RETARDATION, X-LINKED, SYNDROMIC, TURNER TYPE; MRXST	300706
TOE SYNDACTYLY, TELECANTHUS, AND ANOGENITAL AND RENAL MALFORMATIONS;STAR	TOE SYNDACTYLY, TELECANTHUS, AND ANOGENITAL AND RENAL MALFORMATIONS;STAR	300707
STAR SYNDROME	TOE SYNDACTYLY, TELECANTHUS, AND ANOGENITAL AND RENAL MALFORMATIONS;STAR	300707
SYNDACTYLY WITH RENAL AND ANOGENITAL MALFORMATIONS	TOE SYNDACTYLY, TELECANTHUS, AND ANOGENITAL AND RENAL MALFORMATIONS;STAR	300707
MENTAL RETARDATION, X-LINKED, SYNDROMIC 9; MRXS9	MENTAL RETARDATION, X-LINKED, SYNDROMIC 9; MRXS9	300709
ALOPECIA, ANDROGENETIC, 2; AGA2	ALOPECIA, ANDROGENETIC, 2; AGA2	300710
PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 4; IHPS4	PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 4; IHPS4	300711
CRANIOFACIOSKELETAL SYNDROME	CRANIOFACIOSKELETAL SYNDROME	300712
MENTAL RETARDATION, X-LINKED 95; MRX95	MENTAL RETARDATION, X-LINKED 95; MRX95	300716
REDUCING BODY MYOPATHY, X-LINKED 1A, SEVERE, WITH INFANTILE OR EARLYCHILDHOOD ONSET; RBMX1A	REDUCING BODY MYOPATHY, X-LINKED 1A, SEVERE, WITH INFANTILE OR EARLYCHILDHOOD ONSET; RBMX1A	300717
REDUCING BODY MYOPATHY, X-LINKED 1B, WITH LATE CHILDHOOD OR ADULTONSET; RBMX1B	REDUCING BODY MYOPATHY, X-LINKED 1B, WITH LATE CHILDHOOD OR ADULTONSET; RBMX1B	300718
DEAFNESS, CATARACT, RETINITIS PIGMENTOSA, AND SPERM ABNORMALITIES	DEAFNESS, CATARACT, RETINITIS PIGMENTOSA, AND SPERM ABNORMALITIES	300719
MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA;MICPCH	MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA;MICPCH	300749
MICPCH SYNDROME	MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA;MICPCH	300749
MENTAL RETARDATION, X-LINKED, SYNDROMIC, NAJM TYPE; MRXSNA	MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA;MICPCH	300749
SPASTIC PARAPLEGIA 34, X-LINKED; SPG34	SPASTIC PARAPLEGIA 34, X-LINKED; SPG34	300750
ANEMIA, SIDEROBLASTIC, X-LINKED; XLSA	ANEMIA, SIDEROBLASTIC, X-LINKED; XLSA	300751
ANEMIA, HYPOCHROMIC; ANH1	ANEMIA, SIDEROBLASTIC, X-LINKED; XLSA	300751
ANEMIA, HEREDITARY SIDEROBLASTIC	ANEMIA, SIDEROBLASTIC, X-LINKED; XLSA	300751
HEREDITARY IRON-LOADING ANEMIA	ANEMIA, SIDEROBLASTIC, X-LINKED; XLSA	300751
PROTOPORPHYRIA, ERYTHROPOIETIC, X-LINKED; XLEPP	PROTOPORPHYRIA, ERYTHROPOIETIC, X-LINKED; XLEPP	300752
PROTOPORPHYRIA, ERYTHROPOIETIC, X-LINKED DOMINANT; XLDPP	PROTOPORPHYRIA, ERYTHROPOIETIC, X-LINKED; XLEPP	300752
ERYTHROHEPATIC PROTOPORPHYRIA, X-LINKED	PROTOPORPHYRIA, ERYTHROPOIETIC, X-LINKED; XLEPP	300752
AGAMMAGLOBULINEMIA, X-LINKED; XLA	AGAMMAGLOBULINEMIA, X-LINKED; XLA	300755
BRUTON-TYPE AGAMMAGLOBULINEMIA	AGAMMAGLOBULINEMIA, X-LINKED; XLA	300755
AGAMMAGLOBULINEMIA, X-LINKED, TYPE 1; AGMX1	AGAMMAGLOBULINEMIA, X-LINKED; XLA	300755
IMMUNODEFICIENCY 1; IMD1HYPOGAMMAGLOBULINEMIA, X-LINKED, INCLUDED	AGAMMAGLOBULINEMIA, X-LINKED; XLA	300755
ALZHEIMER DISEASE 16; AD16	ALZHEIMER DISEASE 16; AD16	300756
HYPOSPADIAS 2, X-LINKED; HYSP2	HYPOSPADIAS 2, X-LINKED; HYSP2	300758
SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 4; SMDP4	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 4; SMDP4	300770
PULMONARY ALVEOLAR PROTEINOSIS, CONGENITAL, 4	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 4; SMDP4	300770
PAP DUE TO CSF2RA DEFICIENCY	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 4; SMDP4	300770
CSF2RA DEFICIENCY	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 4; SMDP4	300770
CORNEAL DYSTROPHY, LISCH EPITHELIAL; LECD	CORNEAL DYSTROPHY, LISCH EPITHELIAL; LECD	300778
LISCH EPITHELIAL CORNEAL DYSTROPHY	CORNEAL DYSTROPHY, LISCH EPITHELIAL; LECD	300778
BAND-SHAPED AND WHORLED MICROCYSTIC CORNEAL EPITHELIAL DYSTROPHY	CORNEAL DYSTROPHY, LISCH EPITHELIAL; LECD	300778
CORNEAL DYSTROPHY, ENDOTHELIAL, X-LINKED; XECD	CORNEAL DYSTROPHY, ENDOTHELIAL, X-LINKED; XECD	300779
ENDOTHELIAL CORNEAL DYSTROPHY, X-LINKED	CORNEAL DYSTROPHY, ENDOTHELIAL, X-LINKED; XECD	300779
MENTAL RETARDATION, X-LINKED, SYNDROMIC, RAYMOND TYPE; MRXSR	MENTAL RETARDATION, X-LINKED, SYNDROMIC, RAYMOND TYPE; MRXSR	300799
CHROMOSOME Xp11.23-p11.22 DUPLICATION SYNDROME	CHROMOSOME Xp11.23-p11.22 DUPLICATION SYNDROME	300801
MENTAL RETARDATION, X-LINKED 96; MRX96	MENTAL RETARDATION, X-LINKED 96; MRX96	300802
MENTAL RETARDATION, X-LINKED 97; MRX97	MENTAL RETARDATION, X-LINKED 97; MRX97	300803
MRXZ	MENTAL RETARDATION, X-LINKED 97; MRX97	300803
JOUBERT SYNDROME 10; JBTS10	JOUBERT SYNDROME 10; JBTS10	300804
THROMBOPHILIA, X-LINKED, DUE TO FACTOR IX DEFECT; THPH8DEEP VENOUS THROMBOSIS, PROTECTION AGAINST, INCLUDED	THROMBOPHILIA, X-LINKED, DUE TO FACTOR IX DEFECT; THPH8DEEP VENOUS THROMBOSIS, PROTECTION AGAINST, INCLUDED	300807
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 15; SLEB15	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 15; SLEB15	300809
NYSTAGMUS 6, CONGENITAL, X-LINKED; NYS6	NYSTAGMUS 6, CONGENITAL, X-LINKED; NYS6	300814
CHROMOSOME Xq28 DUPLICATION SYNDROME	CHROMOSOME Xq28 DUPLICATION SYNDROME	300815
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 6; COXPD6	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 6; COXPD6	300816
ENCEPHALOMYOPATHY, MITOCHONDRIAL, X-LINKED	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 6; COXPD6	300816
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1	300818
CARDIOMYOPATHY, FATAL FETAL, DUE TO MYOCARDIAL CALCIFICATION	CARDIOMYOPATHY, FATAL FETAL, DUE TO MYOCARDIAL CALCIFICATION	300829
AUTISM, SUSCEPTIBILITY TO, X-LINKED 4; AUTSX4	AUTISM, SUSCEPTIBILITY TO, X-LINKED 4; AUTSX4	300830
CHROMOSOME Xp22 DELETION SYNDROME	AUTISM, SUSCEPTIBILITY TO, X-LINKED 4; AUTSX4	300830
CK SYNDROME	CK SYNDROME	300831
MENTAL RETARDATION, X-LINKED, WITH THIN BODY HABITUS AND CORTICALMALFORMATION	CK SYNDROME	300831
46,XX SEX REVERSAL 3; SRXX3	46,XX SEX REVERSAL 3; SRXX3	300833
CHROMOSOME Xq26 DUPLICATION SYNDROME	46,XX SEX REVERSAL 3; SRXX3	300833
46,XX SEX REVERSAL, SOX3-RELATEDCHROMOSOME Xq26 DELETION SYNDROME, INCLUDED	46,XX SEX REVERSAL 3; SRXX3	300833
MACULAR DEGENERATION, X-LINKED ATROPHIC	MACULAR DEGENERATION, X-LINKED ATROPHIC	300834
ANEMIA, X-LINKED, WITH OR WITHOUT NEUTROPENIA AND/OR PLATELET ABNORMALITIES;XLANP	ANEMIA, X-LINKED, WITH OR WITHOUT NEUTROPENIA AND/OR PLATELET ABNORMALITIES;XLANP	300835
MCLEOD SYNDROME; MCLDS	MCLEOD SYNDROME; MCLDS	300842
MCLEOD PHENOTYPE	MCLEOD SYNDROME; MCLDS	300842
NEUROACANTHOCYTOSIS, MCLEOD TYPEMCLEOD SYNDROME WITH CHRONIC GRANULOMATOUS DISEASE, INCLUDED	MCLEOD SYNDROME; MCLDS	300842
BORNHOLM EYE DISEASE; BED	BORNHOLM EYE DISEASE; BED	300843
MYOPIA, HIGH, WITH NONPROGRESSIVE CONE DYSFUNCTION	BORNHOLM EYE DISEASE; BED	300843
MENTAL RETARDATION, X-LINKED 19; MRX19	MENTAL RETARDATION, X-LINKED 19; MRX19	300844
MOYAMOYA DISEASE 4 WITH SHORT STATURE, HYPERGONADOTROPIC HYPOGONADISM,AND FACIAL DYSMORPHISM; MYMY4	MOYAMOYA DISEASE 4 WITH SHORT STATURE, HYPERGONADOTROPIC HYPOGONADISM,AND FACIAL DYSMORPHISM; MYMY4	300845
CHROMOSOME Xq28 DELETION SYNDROME, 3.4-KB	MOYAMOYA DISEASE 4 WITH SHORT STATURE, HYPERGONADOTROPIC HYPOGONADISM,AND FACIAL DYSMORPHISM; MYMY4	300845
SYNDROMIC MOYAMOYA DISEASE	MOYAMOYA DISEASE 4 WITH SHORT STATURE, HYPERGONADOTROPIC HYPOGONADISM,AND FACIAL DYSMORPHISM; MYMY4	300845
AUTISM, SUSCEPTIBILITY TO, X-LINKED 5; AUTSX5	AUTISM, SUSCEPTIBILITY TO, X-LINKED 5; AUTSX5	300847
MENTAL RETARDATION, X-LINKED 89; MRX89	MENTAL RETARDATION, X-LINKED 89; MRX89	300848
MENTAL RETARDATION, X-LINKED 41; MRX41	MENTAL RETARDATION, X-LINKED 41; MRX41	300849
MENTAL RETARDATION, X-LINKED 48; MRX48	MENTAL RETARDATION, X-LINKED 41; MRX41	300849
MENTAL RETARDATION, X-LINKED 90; MRX90	MENTAL RETARDATION, X-LINKED 90; MRX90	300850
MENTAL RETARDATION, X-LINKED 92; MRX92	MENTAL RETARDATION, X-LINKED 92; MRX92	300851
MENTAL RETARDATION, X-LINKED 88; MRX88	MENTAL RETARDATION, X-LINKED 88; MRX88	300852
IMMUNODEFICIENCY, X-LINKED, WITH MAGNESIUM DEFECT, EPSTEIN-BARR VIRUSINFECTION, AND NEOPLASIA; XMEN	IMMUNODEFICIENCY, X-LINKED, WITH MAGNESIUM DEFECT, EPSTEIN-BARR VIRUSINFECTION, AND NEOPLASIA; XMEN	300853
RENAL CELL CARCINOMA, Xp11-ASSOCIATED; RCCX1	RENAL CELL CARCINOMA, Xp11-ASSOCIATED; RCCX1	300854
OGDEN SYNDROME; OGDNS	OGDEN SYNDROME; OGDNS	300855
N-TERMINAL ACETYLTRANSFERASE DEFICIENCY; NATD	OGDEN SYNDROME; OGDNS	300855
HYPOSPADIAS 4, X-LINKED, SUSCEPTIBILITY TO; HYSP4	HYPOSPADIAS 4, X-LINKED, SUSCEPTIBILITY TO; HYSP4	300856
AMYOTROPHIC LATERAL SCLEROSIS 15 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS15	AMYOTROPHIC LATERAL SCLEROSIS 15 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS15	300857
MENTAL RETARDATION, X-LINKED, SYNDROMIC 17; MRXS17	MENTAL RETARDATION, X-LINKED, SYNDROMIC 17; MRXS17	300858
MENTAL RETARDATION, X-LINKED, WITH ALACRIMA AND ACHALASIA	MENTAL RETARDATION, X-LINKED, SYNDROMIC 17; MRXS17	300858
MENTAL RETARDATION, X-LINKED, SYNDROMIC, NASCIMENTO TYPE; MRXSN	MENTAL RETARDATION, X-LINKED, SYNDROMIC, NASCIMENTO TYPE; MRXSN	300860
MENTAL RETARDATION, X-LINKED, SYNDROMIC 30; MRXS30	MENTAL RETARDATION, X-LINKED, SYNDROMIC, NASCIMENTO TYPE; MRXSN	300860
MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHUDLEY-SCHWARTZ TYPE; MRXSCS	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHUDLEY-SCHWARTZ TYPE; MRXSCS	300861
MENTAL RETARDATION, X-LINKED, WITH SEIZURES, HYPOGAMMAGLOBULINEMIA,AND GAIT DISTURBANCE	MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHUDLEY-SCHWARTZ TYPE; MRXSCS	300861
CHONDRODYSPLASIA WITH PLATYSPONDYLY, DISTINCTIVE BRACHYDACTYLY, HYDROCEPHALY,AND MICROPHTHALMIA	CHONDRODYSPLASIA WITH PLATYSPONDYLY, DISTINCTIVE BRACHYDACTYLY, HYDROCEPHALY,AND MICROPHTHALMIA	300863
KABUKI SYNDROME 2; KABUK2	KABUKI SYNDROME 2; KABUK2	300867
MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2	MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2	300868
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 20; EIEE20	MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2	300868
CHROMOSOME Xq27.3-q28 DUPLICATION SYNDROME	CHROMOSOME Xq27.3-q28 DUPLICATION SYNDROME	300869
ANEURYSM, INTRACRANIAL BERRY, 5; ANIB5	ANEURYSM, INTRACRANIAL BERRY, 5; ANIB5	300870
EPSILON-TRIMETHYLLYSINE HYDROXYLASE DEFICIENCY; TMLHED	EPSILON-TRIMETHYLLYSINE HYDROXYLASE DEFICIENCY; TMLHED	300872
AUTISM, SUSCEPTIBILITY TO, X-LINKED 6; AUTSX6	EPSILON-TRIMETHYLLYSINE HYDROXYLASE DEFICIENCY; TMLHED	300872
BARATELA-SCOTT SYNDROME	BARATELA-SCOTT SYNDROME	300881
CORNELIA DE LANGE SYNDROME 5; CDLS5	CORNELIA DE LANGE SYNDROME 5; CDLS5	300882
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Is; CDG1S	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Is; CDG1S	300884
CDG Is; CDGIs	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Is; CDG1S	300884
MENTAL RETARDATION, X-LINKED, SYNDROMIC 32; MRXS32	MENTAL RETARDATION, X-LINKED, SYNDROMIC 32; MRXS32	300886
LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 2; LSDMCA2	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 2; LSDMCA2	300887
APLASIA CUTIS CONGENITA, RETICULOLINEAR, WITH MICROCEPHALY, FACIALDYSMORPHISM, AND OTHER CONGENITAL ANOMALIES; APLCC	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 2; LSDMCA2	300887
HYPOTHYROIDISM, CENTRAL, AND TESTICULAR ENLARGEMENT; CHTE	HYPOTHYROIDISM, CENTRAL, AND TESTICULAR ENLARGEMENT; CHTE	300888
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 5; NBIA5	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 5; NBIA5	300894
BETA-PROPELLER PROTEIN-ASSOCIATED NEURODEGENERATION; BPAN	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 5; NBIA5	300894
STATIC ENCEPHALOPATHY OF CHILDHOOD WITH NEURODEGENERATION IN ADULTHOOD;SENDA	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 5; NBIA5	300894
OHDO SYNDROME, X-LINKED; OHDOX	OHDO SYNDROME, X-LINKED; OHDOX	300895
BLEPHAROPHIMOSIS-MENTAL RETARDATION SYNDROME, MAAT-KIEVIT-BRUNNERTYPE	OHDO SYNDROME, X-LINKED; OHDOX	300895
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm; CDG2M	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm; CDG2M	300896
CDG IIm; CDGIIm	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm; CDG2M	300896
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 22; EIEE22	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm; CDG2M	300896
CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 6; CMTX6	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 6; CMTX6	300905
CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED DOMINANT, 6	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 6; CMTX6	300905
ANEMIA, NONSPHEROCYTIC HEMOLYTIC, DUE TO G6PD DEFICIENCY	ANEMIA, NONSPHEROCYTIC HEMOLYTIC, DUE TO G6PD DEFICIENCY	300908
ANGIOEDEMA INDUCED BY ACE INHIBITORS, SUSCEPTIBILITY TO; AEACEI	ANGIOEDEMA INDUCED BY ACE INHIBITORS, SUSCEPTIBILITY TO; AEACEI	300909
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 18; BMND18	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 18; BMND18	300910
OSTEOPOROSIS AND OSTEOPOROTIC FRACTURES, SUSCEPTIBILITY TO	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 18; BMND18	300910
PARKINSONISM WITH SPASTICITY, X-LINKED; XPDS	PARKINSONISM WITH SPASTICITY, X-LINKED; XPDS	300911
MENTAL RETARDATION, X-LINKED 98; MRX98	MENTAL RETARDATION, X-LINKED 98; MRX98	300912
DEAFNESS, X-LINKED 6; DFNX6	DEAFNESS, X-LINKED 6; DFNX6	300914
MICROPHTHALMIA, SYNDROMIC 13; MCOPS13	MICROPHTHALMIA, SYNDROMIC 13; MCOPS13	300915
MAINE MICROPHTHALMOS	MICROPHTHALMIA, SYNDROMIC 13; MCOPS13	300915
COLOBOMATOUS MICROPHTHALMIA WITH MICROCEPHALY, SHORT STATURE, ANDPSYCHOMOTOR RETARDATION	MICROPHTHALMIA, SYNDROMIC 13; MCOPS13	300915
PALMOPLANTAR KERATODERMA, MUTILATING, WITH PERIORIFICIAL KERATOTICPLAQUES, X-LINKED	PALMOPLANTAR KERATODERMA, MUTILATING, WITH PERIORIFICIAL KERATOTICPLAQUES, X-LINKED	300918
OLMSTED SYNDROME, X-LINKED; OLMSX	PALMOPLANTAR KERATODERMA, MUTILATING, WITH PERIORIFICIAL KERATOTICPLAQUES, X-LINKED	300918
MENTAL RETARDATION, X-LINKED 99; MRX99	MENTAL RETARDATION, X-LINKED 99; MRX99	300919
MENTAL RETARDATION, X-LINKED 100; MRX100	MENTAL RETARDATION, X-LINKED 100; MRX100	300923
MENTAL RETARDATION, X-LINKED 101; MRX101	MENTAL RETARDATION, X-LINKED 101; MRX101	300928
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iy; CDG1Y	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iy; CDG1Y	300934
CDG IY; CDGIy	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iy; CDG1Y	300934
CHROMOSOME Xq26.3 DUPLICATION SYNDROME	CHROMOSOME Xq26.3 DUPLICATION SYNDROME	300942
CHROMOSOME Xq26 MICRODUPLICATION SYNDROME	CHROMOSOME Xq26.3 DUPLICATION SYNDROME	300942
X-LINKED ACROGIGANTISM; XLAG	CHROMOSOME Xq26.3 DUPLICATION SYNDROME	300942
PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 2; PAGH2	PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 2; PAGH2	300943
ACROMEGALY DUE TO PITUITARY ADENOMA 2	PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 2; PAGH2	300943
ACROMEGALY, X-LINKED	PITUITARY ADENOMA, GROWTH HORMONE-SECRETING, 2; PAGH2	300943
DIAMOND-BLACKFAN ANEMIA 14 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA14	DIAMOND-BLACKFAN ANEMIA 14 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA14	300946
LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 3; LSDMCA3	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 3; LSDMCA3	300952
LINEAR SKIN DEFECTS WITH CARDIOMYOPATHY AND OTHER CONGENITAL ANOMALIES	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 3; LSDMCA3	300952
TRICHOTHIODYSTROPHY 5, NONPHOTOSENSITIVE; TTD5	TRICHOTHIODYSTROPHY 5, NONPHOTOSENSITIVE; TTD5	300953
MENTAL RETARDATION, X-LINKED 12; MRX12	MENTAL RETARDATION, X-LINKED 12; MRX12	300957
MENTAL RETARDATION, X-LINKED 35; MRX35	MENTAL RETARDATION, X-LINKED 12; MRX12	300957
MENTAL RETARDATION, X-LINKED 102; MRX102	MENTAL RETARDATION, X-LINKED 102; MRX102	300958
MEND SYNDROME; MEND	MEND SYNDROME; MEND	300960
MALE EBP DISORDER WITH NEUROLOGIC DEFECTS	MEND SYNDROME; MEND	300960
RITSCHER-SCHINZEL SYNDROME 2; RTSC2	RITSCHER-SCHINZEL SYNDROME 2; RTSC2	300963
WISKOTT-ALDRICH SYNDROME; WAS	WISKOTT-ALDRICH SYNDROME; WAS	301000
WISKOTT-ALDRICH SYNDROME 1; WAS1	WISKOTT-ALDRICH SYNDROME; WAS	301000
ALDRICH SYNDROME	WISKOTT-ALDRICH SYNDROME; WAS	301000
ECZEMA-THROMBOCYTOPENIA-IMMUNODEFICIENCY SYNDROME	WISKOTT-ALDRICH SYNDROME; WAS	301000
IMMUNODEFICIENCY 2; IMD2	WISKOTT-ALDRICH SYNDROME; WAS	301000
ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED; ATRX	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED; ATRX	301040
ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, NONDELETION TYPE	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED; ATRX	301040
ATR-X SYNDROME	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED; ATRX	301040
ATR, NONDELETION TYPE	ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED; ATRX	301040
ALPORT SYNDROME, X-LINKED; ATS	ALPORT SYNDROME, X-LINKED; ATS	301050
NEPHROPATHY AND DEAFNESS, X-LINKED	ALPORT SYNDROME, X-LINKED; ATS	301050
AMELOGENESIS IMPERFECTA, TYPE IE; AI1E	AMELOGENESIS IMPERFECTA, TYPE IE; AI1E	301200
AMELOGENESIS IMPERFECTA, HYPOPLASTIC/HYPOMATURATION, X-LINKED 1	AMELOGENESIS IMPERFECTA, TYPE IE; AI1E	301200
AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, WITH SNOW-CAPPED TEETH	AMELOGENESIS IMPERFECTA, TYPE IE; AI1E	301200
AMELOGENESIS IMPERFECTA, X-LINKED 1; AIH1	AMELOGENESIS IMPERFECTA, TYPE IE; AI1E	301200
ENAMEL HYPOPLASIA, X-LINKED	AMELOGENESIS IMPERFECTA, TYPE IE; AI1E	301200
AMELOGENESIS IMPERFECTA, HYPOPLASTIC/HYPOMATURATION, X-LINKED 2	AMELOGENESIS IMPERFECTA, HYPOPLASTIC/HYPOMATURATION, X-LINKED 2	301201
AMELOGENESIS IMPERFECTA 3, HYPOPLASTIC TYPE, FORMERLY; AIH3, FORMERLY	AMELOGENESIS IMPERFECTA, HYPOPLASTIC/HYPOMATURATION, X-LINKED 2	301201
ENAMEL HYPOPLASIA, X-LINKED	AMELOGENESIS IMPERFECTA, HYPOPLASTIC/HYPOMATURATION, X-LINKED 2	301201
PIGMENTARY DISORDER, RETICULATE, WITH SYSTEMIC MANIFESTATIONS; PDR	PIGMENTARY DISORDER, RETICULATE, WITH SYSTEMIC MANIFESTATIONS; PDR	301220
AMYLOIDOSIS, FAMILIAL CUTANEOUS	PIGMENTARY DISORDER, RETICULATE, WITH SYSTEMIC MANIFESTATIONS; PDR	301220
ANEMIA, SIDEROBLASTIC, AND SPINOCEREBELLAR ATAXIA; ASAT	ANEMIA, SIDEROBLASTIC, AND SPINOCEREBELLAR ATAXIA; ASAT	301310
FABRY DISEASE	FABRY DISEASE	301500
ANGIOKERATOMA CORPORIS DIFFUSUM	FABRY DISEASE	301500
ANDERSON-FABRY DISEASE	FABRY DISEASE	301500
HEREDITARY DYSTOPIC LIPIDOSIS	FABRY DISEASE	301500
ALPHA-GALACTOSIDASE A DEFICIENCY	FABRY DISEASE	301500
GLA DEFICIENCY	FABRY DISEASE	301500
CERAMIDE TRIHEXOSIDASE DEFICIENCYFABRY DISEASE, CARDIAC VARIANT, INCLUDED	FABRY DISEASE	301500
MICROPHTHALMIA, SYNDROMIC 4; MCOPS4	MICROPHTHALMIA, SYNDROMIC 4; MCOPS4	301590
MICROPHTHALMIA WITH ANKYLOBLEPHARON AND MENTAL RETARDATION	MICROPHTHALMIA, SYNDROMIC 4; MCOPS4	301590
ANOP1, FORMERLY	MICROPHTHALMIA, SYNDROMIC 4; MCOPS4	301590
SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2	SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2	301830
SPINAL MUSCULAR ATROPHY, X-LINKED LETHAL INFANTILE	SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2	301830
SPINAL MUSCULAR ATROPHY, INFANTILE X-LINKED; XLSMA	SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2	301830
ARTHROGRYPOSIS MULTIPLEX CONGENITA, DISTAL, X-LINKED	SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2	301830
AMC, DISTAL, X-LINKED	SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2	301830
ARTHROGRYPOSIS, X-LINKED, TYPE I; AMCX1	SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2	301830
ARTS SYNDROME; ARTS	ARTS SYNDROME; ARTS	301835
MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS	ARTS SYNDROME; ARTS	301835
ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION	ARTS SYNDROME; ARTS	301835
MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18	ARTS SYNDROME; ARTS	301835
BAZEX SYNDROME; BZX	BAZEX SYNDROME; BZX	301845
BAZEX-DUPRE-CHRISTOL SYNDROME; BDCS	BAZEX SYNDROME; BZX	301845
FOLLICULAR ATROPHODERMA AND BASAL CELL CARCINOMAS	BAZEX SYNDROME; BZX	301845
BORJESON-FORSSMAN-LEHMANN SYNDROME; BFLS	BORJESON-FORSSMAN-LEHMANN SYNDROME; BFLS	301900
MENTAL RETARDATION, X-LINKED, SYNDROMIC, BORJESON-FORSSMAN-LEHMANNTYPE; MRXSBFL	BORJESON-FORSSMAN-LEHMANN SYNDROME; BFLS	301900
BORJESON SYNDROME; BORJ	BORJESON-FORSSMAN-LEHMANN SYNDROME; BFLS	301900
MENTAL RETARDATION, EPILEPSY, AND ENDOCRINE DISORDERS	BORJESON-FORSSMAN-LEHMANN SYNDROME; BFLS	301900
BULLOUS DYSTROPHY, HEREDITARY MACULAR TYPE	BULLOUS DYSTROPHY, HEREDITARY MACULAR TYPE	302000
EPIDERMOLYSIS BULLOSA, MACULAR TYPE; EBM	BULLOUS DYSTROPHY, HEREDITARY MACULAR TYPE	302000
CARDIOMYOPATHY, DILATED, 3B; CMD3B	CARDIOMYOPATHY, DILATED, 3B; CMD3B	302045
CARDIOMYOPATHY, DILATED, X-LINKED; XLCM	CARDIOMYOPATHY, DILATED, 3B; CMD3B	302045
BARTH SYNDROME; BTHS	BARTH SYNDROME; BTHS	302060
CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA	BARTH SYNDROME; BTHS	302060
3-@METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2	BARTH SYNDROME; BTHS	302060
MGA, TYPE II; MGA2	BARTH SYNDROME; BTHS	302060
CATARACT 40; CTRCT40	CATARACT 40; CTRCT40	302200
CATARACT 40 WITH OR WITHOUT MICROCORNEA	CATARACT 40; CTRCT40	302200
CATARACT, CONGENITAL, X-LINKED; CXN	CATARACT 40; CTRCT40	302200
CATARACT, CONGENITAL TOTAL, WITH POSTERIOR SUTURAL OPACITIES IN HETEROZYGOTES;CCT	CATARACT 40; CTRCT40	302200
NANCE-HORAN SYNDROME; NHS	NANCE-HORAN SYNDROME; NHS	302350
CATARACT-DENTAL SYNDROME	NANCE-HORAN SYNDROME; NHS	302350
CATARACT, X-LINKED, WITH HUTCHINSONIAN TEETH	NANCE-HORAN SYNDROME; NHS	302350
MESIODENS-CATARACT SYNDROME	NANCE-HORAN SYNDROME; NHS	302350
SPINOCEREBELLAR ATAXIA, X-LINKED 1; SCAX1	SPINOCEREBELLAR ATAXIA, X-LINKED 1; SCAX1	302500
OLIVOPONTOCEREBELLAR ATROPHY, X-LINKED	SPINOCEREBELLAR ATAXIA, X-LINKED 1; SCAX1	302500
OPCA, X-LINKED; OPCAX	SPINOCEREBELLAR ATAXIA, X-LINKED 1; SCAX1	302500
CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1	302800
CMTX	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1	302800
CHARCOT-MARIE-TOOTH PERONEAL MUSCULAR ATROPHY, X-LINKED	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1	302800
HEREDITARY MOTOR AND SENSORY NEUROPATHY, X-LINKED	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1	302800
HMSN, X-LINKED	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1	302800
CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED, 1	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1	302800
CMT2, FORMERLY	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1	302800
CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 2; CMTX2	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 2; CMTX2	302801
CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED RECESSIVE, 2	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 2; CMTX2	302801
CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 3; CMTX3	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 3; CMTX3	302802
CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED RECESSIVE, 3	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 3; CMTX3	302802
ABRUZZO-ERICKSON SYNDROME; ABERS	ABRUZZO-ERICKSON SYNDROME; ABERS	302905
CHARGE-LIKE SYNDROME, X-LINKED	ABRUZZO-ERICKSON SYNDROME; ABERS	302905
CHONDRODYSPLASIA PUNCTATA 1, X-LINKED RECESSIVE; CDPX1	CHONDRODYSPLASIA PUNCTATA 1, X-LINKED RECESSIVE; CDPX1	302950
CPXR	CHONDRODYSPLASIA PUNCTATA 1, X-LINKED RECESSIVE; CDPX1	302950
CHONDRODYSPLASIA PUNCTATA, BRACHYTELEPHALANGIC	CHONDRODYSPLASIA PUNCTATA 1, X-LINKED RECESSIVE; CDPX1	302950
CHONDRODYSPLASIA PUNCTATA 2, X-LINKED DOMINANT; CDPX2	CHONDRODYSPLASIA PUNCTATA 2, X-LINKED DOMINANT; CDPX2	302960
CDPXD; CPXD	CHONDRODYSPLASIA PUNCTATA 2, X-LINKED DOMINANT; CDPX2	302960
CONRADI-HUNERMANN SYNDROME	CHONDRODYSPLASIA PUNCTATA 2, X-LINKED DOMINANT; CDPX2	302960
HAPPLE SYNDROME	CHONDRODYSPLASIA PUNCTATA 2, X-LINKED DOMINANT; CDPX2	302960
CONRADI-HUNERMANN-HAPPLE SYNDROME	CHONDRODYSPLASIA PUNCTATA 2, X-LINKED DOMINANT; CDPX2	302960
CHOROIDEREMIA; CHM	CHOROIDEREMIA; CHM	303100
TAPETOCHOROIDAL DYSTROPHY, PROGRESSIVE; TCDCHOROIDAL SCLEROSIS, INCLUDED	CHOROIDEREMIA; CHM	303100
CHOROIDEREMIA, DEAFNESS, AND MENTAL RETARDATION	CHOROIDEREMIA, DEAFNESS, AND MENTAL RETARDATION	303110
CHROMOSOME Xq21 DELETION SYNDROME	CHOROIDEREMIA, DEAFNESS, AND MENTAL RETARDATION	303110
MASA SYNDROME	MASA SYNDROME	303350
MENTAL RETARDATION, APHASIA, SHUFFLING GAIT, AND ADDUCTED THUMBS	MASA SYNDROME	303350
SPASTIC PARAPLEGIA 1, X-LINKED; SPG1	MASA SYNDROME	303350
CLASPED THUMB AND MENTAL RETARDATION	MASA SYNDROME	303350
THUMB, CONGENITAL CLASPED, WITH MENTAL RETARDATION	MASA SYNDROME	303350
ADDUCTED THUMB WITH MENTAL RETARDATION	MASA SYNDROME	303350
GAREIS-MASON SYNDROME	MASA SYNDROME	303350
CRASH SYNDROME	MASA SYNDROME	303350
CLEFT PALATE WITH OR WITHOUT ANKYLOGLOSSIA, X-LINKED; CPX	CLEFT PALATE WITH OR WITHOUT ANKYLOGLOSSIA, X-LINKED; CPX	303400
COFFIN-LOWRY SYNDROME; CLS	COFFIN-LOWRY SYNDROME; CLS	303600
BLUE CONE MONOCHROMACY; BCM	BLUE CONE MONOCHROMACY; BCM	303700
BLUE CONE MONOCHROMATISM	BLUE CONE MONOCHROMACY; BCM	303700
COLORBLINDNESS, BLUE-MONO-CONE-MONOCHROMATIC TYPE; CBBMCONE DYSTROPHY 5, X-LINKED, INCLUDED; COD5, INCLUDED	BLUE CONE MONOCHROMACY; BCM	303700
COLORBLINDNESS, PARTIAL, DEUTAN SERIES; CBD	COLORBLINDNESS, PARTIAL, DEUTAN SERIES; CBD	303800
DEUTAN COLORBLINDNESS; DCB	COLORBLINDNESS, PARTIAL, DEUTAN SERIES; CBD	303800
DEUTERANOPIA	COLORBLINDNESS, PARTIAL, DEUTAN SERIES; CBD	303800
GREEN COLORBLINDNESSDEUTERANOMALY, INCLUDED	COLORBLINDNESS, PARTIAL, DEUTAN SERIES; CBD	303800
COLORBLINDNESS, PARTIAL, PROTAN SERIES; CBP	COLORBLINDNESS, PARTIAL, PROTAN SERIES; CBP	303900
PROTANOPIA	COLORBLINDNESS, PARTIAL, PROTAN SERIES; CBP	303900
RED COLORBLINDNESSPROTANOMALY, INCLUDED	COLORBLINDNESS, PARTIAL, PROTAN SERIES; CBP	303900
CONE-ROD DYSTROPHY, X-LINKED, 1; CORDX1	CONE-ROD DYSTROPHY, X-LINKED, 1; CORDX1	304020
CONE DYSTROPHY 1, X-LINKED; COD1	CONE-ROD DYSTROPHY, X-LINKED, 1; CORDX1	304020
AICARDI SYNDROME; AIC	AICARDI SYNDROME; AIC	304050
CORPUS CALLOSUM, AGENESIS OF, WITH CHORIORETINAL ABNORMALITY	AICARDI SYNDROME; AIC	304050
CORPUS CALLOSUM, PARTIAL AGENESIS OF, X-LINKED	CORPUS CALLOSUM, PARTIAL AGENESIS OF, X-LINKED	304100
CRANIOFRONTONASAL SYNDROME; CFNS	CRANIOFRONTONASAL SYNDROME; CFNS	304110
CRANIOFRONTONASAL DYSPLASIA; CFND	CRANIOFRONTONASAL SYNDROME; CFNS	304110
CRANIOFRONTONASAL DYSOSTOSIS	CRANIOFRONTONASAL SYNDROME; CFNS	304110
OTOPALATODIGITAL SYNDROME, TYPE II; OPD2	OTOPALATODIGITAL SYNDROME, TYPE II; OPD2	304120
OPD II SYNDROME	OTOPALATODIGITAL SYNDROME, TYPE II; OPD2	304120
OPD SYNDROME 2	OTOPALATODIGITAL SYNDROME, TYPE II; OPD2	304120
CRANIOORODIGITAL SYNDROME	OTOPALATODIGITAL SYNDROME, TYPE II; OPD2	304120
FACIOPALATOOSSEOUS SYNDROME; FPO	OTOPALATODIGITAL SYNDROME, TYPE II; OPD2	304120
OCCIPITAL HORN SYNDROME; OHS	OCCIPITAL HORN SYNDROME; OHS	304150
CUTIS LAXA, X-LINKED, FORMERLY	OCCIPITAL HORN SYNDROME; OHS	304150
EHLERS-DANLOS SYNDROME, OCCIPITAL HORN TYPE, FORMERLY	OCCIPITAL HORN SYNDROME; OHS	304150
EDS IX, FORMERLY	OCCIPITAL HORN SYNDROME; OHS	304150
EDS9, FORMERLY	OCCIPITAL HORN SYNDROME; OHS	304150
PETTIGREW SYNDROME; PGS	PETTIGREW SYNDROME; PGS	304340
MENTAL RETARDATION, X-LINKED, SYNDROMIC 5; MRXS5	PETTIGREW SYNDROME; PGS	304340
MENTAL RETARDATION, X-LINKED, WITH DANDY-WALKER MALFORMATION, BASALGANGLIA DISEASE, AND SEIZURES	PETTIGREW SYNDROME; PGS	304340
MENTAL RETARDATION, X-LINKED, SYNDROMIC, FRIED TYPE; MRXSF	PETTIGREW SYNDROME; PGS	304340
MENTAL RETARDATION, X-LINKED 59; MRX59	PETTIGREW SYNDROME; PGS	304340
MENTAL RETARDATION, X-LINKED, SYNDROMIC 21; MRXS21	PETTIGREW SYNDROME; PGS	304340
DEAFNESS, X-LINKED 2; DFNX2	DEAFNESS, X-LINKED 2; DFNX2	304400
DEAFNESS, CONDUCTIVE, WITH STAPES FIXATION	DEAFNESS, X-LINKED 2; DFNX2	304400
DEAFNESS 3, CONDUCTIVE, WITH STAPES FIXATION; DFN3	DEAFNESS, X-LINKED 2; DFNX2	304400
PERILYMPHATIC GUSHER-DEAFNESS SYNDROME	DEAFNESS, X-LINKED 2; DFNX2	304400
DEAFNESS, MIXED, WITH PERILYMPHATIC GUSHER	DEAFNESS, X-LINKED 2; DFNX2	304400
NANCE DEAFNESS	DEAFNESS, X-LINKED 2; DFNX2	304400
SENSORINEURAL DEAFNESS, PROFOUND, WITH OR WITHOUT A CONDUCTIVE COMPONENT,ASSOCIATED WITH A UNIQUE DEVELOPMENTAL ABNORMALITY OF THE EAR	DEAFNESS, X-LINKED 2; DFNX2	304400
DEAFNESS, X-LINKED 1; DFNX1	DEAFNESS, X-LINKED 1; DFNX1	304500
DEAFNESS, X-LINKED 2, SENSORINEURAL CONGENITAL; DFN2	DEAFNESS, X-LINKED 1; DFNX1	304500
MOHR-TRANEBJAERG SYNDROME; MTS	MOHR-TRANEBJAERG SYNDROME; MTS	304700
DYSTONIA-DEAFNESS SYNDROME; DDS	MOHR-TRANEBJAERG SYNDROME; MTS	304700
DEAFNESS-DYSTONIA-OPTIC ATROPHY SYNDROME; DDP	MOHR-TRANEBJAERG SYNDROME; MTS	304700
DEAFNESS SYNDROME, PROGRESSIVE, WITH BLINDNESS, DYSTONIA, FRACTURES,AND MENTAL DEFICIENCY	MOHR-TRANEBJAERG SYNDROME; MTS	304700
DERMOIDS OF CORNEA; CND	DERMOIDS OF CORNEA; CND	304730
IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;IPEX	IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;IPEX	304790
X-LINKED AUTOIMMUNITY-ALLERGIC DYSREGULATION SYNDROME; XLAAD	IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;IPEX	304790
IDDM-SECRETORY DIARRHEA SYNDROME; DMSD	IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;IPEX	304790
AUTOIMMUNITY-IMMUNODEFICIENCY SYNDROME, X-LINKED	IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;IPEX	304790
DIARRHEA, POLYENDOCRINOPATHY, FATAL INFECTION SYNDROME, X-LINKED	IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;IPEX	304790
ENTEROPATHY, AUTOIMMUNE, WITH HEMOLYTIC ANEMIA AND POLYENDOCRINOPATHY	IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;IPEX	304790
POLYENDOCRINOPATHY, IMMUNE DYSFUNCTION, AND DIARRHEA, X-LINKED; XPID	IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;IPEX	304790
DIABETES MELLITUS, CONGENITAL INSULIN-DEPENDENT, WITH FATAL SECRETORYDIARRHEA	IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;IPEX	304790
IMMUNODEFICIENCY, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED, FORMERLYISLETS OF LANGERHANS, ABSENCE OF, INCLUDED	IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;IPEX	304790
DIABETES INSIPIDUS, NEPHROGENIC, X-LINKED	DIABETES INSIPIDUS, NEPHROGENIC, X-LINKED	304800
NDI	DIABETES INSIPIDUS, NEPHROGENIC, X-LINKED	304800
DIABETES INSIPIDUS, NEPHROGENIC, TYPE I	DIABETES INSIPIDUS, NEPHROGENIC, X-LINKED	304800
DYSKERATOSIS CONGENITA, X-LINKED; DKCX	DYSKERATOSIS CONGENITA, X-LINKED; DKCX	305000
ZINSSER-COLE-ENGMAN SYNDROMEHOYERAAL-HREIDARSSON SYNDROME, INCLUDED; HHS, INCLUDED	DYSKERATOSIS CONGENITA, X-LINKED; DKCX	305000
CEREBELLAR HYPOPLASIA WITH PANCYTOPENIA, INCLUDED	DYSKERATOSIS CONGENITA, X-LINKED; DKCX	305000
GROWTH RETARDATION, PRENATAL, WITH PROGRESSIVE PANCYTOPENIA AND CEREBELLARHYPOPLASIA, INCLUDED	DYSKERATOSIS CONGENITA, X-LINKED; DKCX	305000
ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED	ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED	305100
ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC/HAIR/TOOTH TYPE, X-LINKED; ECTD1	ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED	305100
XLHED	ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED	305100
ECTODERMAL DYSPLASIA, ANHIDROTIC, X-LINKED; EDA	ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED	305100
EDA1	ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED	305100
ECTODERMAL DYSPLASIA, HYPOHIDROTIC, 1; HED1	ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED	305100
ECTODERMAL DYSPLASIA 1; ED1	ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED	305100
CHRIST-SIEMENS-TOURAINE SYNDROME	ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED	305100
CST SYNDROME	ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED	305100
EHLERS-DANLOS SYNDROME, TYPE V	EHLERS-DANLOS SYNDROME, TYPE V	305200
EDS5	EHLERS-DANLOS SYNDROME, TYPE V	305200
EDS V	EHLERS-DANLOS SYNDROME, TYPE V	305200
EXUDATIVE VITREORETINOPATHY 2, X-LINKED; EVR2	EXUDATIVE VITREORETINOPATHY 2, X-LINKED; EVR2	305390
EXUDATIVE VITREORETINOPATHY, FAMILIAL, 2	EXUDATIVE VITREORETINOPATHY 2, X-LINKED; EVR2	305390
EVRX	EXUDATIVE VITREORETINOPATHY 2, X-LINKED; EVR2	305390
FEVR, X-LINKED; FEVRX	EXUDATIVE VITREORETINOPATHY 2, X-LINKED; EVR2	305390
AARSKOG-SCOTT SYNDROME; AAS	AARSKOG-SCOTT SYNDROME; AAS	305400
FACIOGENITAL DYSPLASIA; FGDY	AARSKOG-SCOTT SYNDROME; AAS	305400
FACIODIGITOGENITAL SYNDROME	AARSKOG-SCOTT SYNDROME; AAS	305400
AARSKOG SYNDROME, X-LINKEDFACIOGENITAL DYSPLASIA WITH ATTENTION DEFICIT-HYPERACTIVITY DISORDER,INCLUDED	AARSKOG-SCOTT SYNDROME; AAS	305400
MENTAL RETARDATION, X-LINKED, SYNDROMIC 16, INCLUDED; MRXS16, INCLUDED	AARSKOG-SCOTT SYNDROME; AAS	305400
FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HBFQTL3	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HBFQTL3	305435
F-CELL PRODUCTION, X-LINKED; FCPX	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HBFQTL3	305435
HETEROCELLULAR HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN, SWISS TYPE	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HBFQTL3	305435
HPFH, SWISS TYPE	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HBFQTL3	305435
OPITZ-KAVEGGIA SYNDROME; OKS	OPITZ-KAVEGGIA SYNDROME; OKS	305450
FG SYNDROME 1; FGS1	OPITZ-KAVEGGIA SYNDROME; OKS	305450
FG SYNDROME; FGS	OPITZ-KAVEGGIA SYNDROME; OKS	305450
MENTAL RETARDATION, LARGE HEAD, IMPERFORATE ANUS, CONGENITAL HYPOTONIA,AND PARTIAL AGENESIS OF CORPUS CALLOSUM	OPITZ-KAVEGGIA SYNDROME; OKS	305450
KELLER SYNDROME	OPITZ-KAVEGGIA SYNDROME; OKS	305450
FOCAL DERMAL HYPOPLASIA; FDH	FOCAL DERMAL HYPOPLASIA; FDH	305600
FODH; DHOF	FOCAL DERMAL HYPOPLASIA; FDH	305600
GOLTZ SYNDROME	FOCAL DERMAL HYPOPLASIA; FDH	305600
GOLTZ-GORLIN SYNDROME	FOCAL DERMAL HYPOPLASIA; FDH	305600
FRONTOMETAPHYSEAL DYSPLASIA; FMD	FRONTOMETAPHYSEAL DYSPLASIA; FMD	305620
GLYCOGEN STORAGE DISEASE IXa1; GSD9A1	GLYCOGEN STORAGE DISEASE IXa1; GSD9A1	306000
LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1	GLYCOGEN STORAGE DISEASE IXa1; GSD9A1	306000
GLYCOGEN STORAGE DISEASE VIII, FORMERLY	GLYCOGEN STORAGE DISEASE IXa1; GSD9A1	306000
GSD VIII, FORMERLY; GSD8, FORMERLYGLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED	GLYCOGEN STORAGE DISEASE IXa1; GSD9A1	306000
GSD IXa2, INCLUDED	GLYCOGEN STORAGE DISEASE IXa1; GSD9A1	306000
LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED	GLYCOGEN STORAGE DISEASE IXa1; GSD9A1	306000
GRANULOMATOUS DISEASE, CHRONIC, X-LINKED; CGD	GRANULOMATOUS DISEASE, CHRONIC, X-LINKED; CGD	306400
CYTOCHROME b-NEGATIVE GRANULOMATOUS DISEASE, CHRONIC, X-LINKED	GRANULOMATOUS DISEASE, CHRONIC, X-LINKED; CGD	306400
CHRONIC GRANULOMATOUS DISEASE, X-LINKEDCYTOCHROME b-POSITIVE GRANULOMATOUS DISEASE, CHRONIC, X-LINKED, INCLUDED	GRANULOMATOUS DISEASE, CHRONIC, X-LINKED; CGD	306400
GRANULOMATOUS DISEASE, CHRONIC, X-LINKED, VARIANT, INCLUDED	GRANULOMATOUS DISEASE, CHRONIC, X-LINKED; CGD	306400
CHRONIC GRANULOMATOUS DISEASE, ATYPICAL, INCLUDED	GRANULOMATOUS DISEASE, CHRONIC, X-LINKED; CGD	306400
HEMOPHILIA A; HEMA	HEMOPHILIA A; HEMA	306700
HEMOPHILIA, CLASSIC	HEMOPHILIA A; HEMA	306700
HEMOPHILIA B; HEMB	HEMOPHILIA B; HEMB	306900
CHRISTMAS DISEASE	HEMOPHILIA B; HEMB	306900
FACTOR IX DEFICIENCY	HEMOPHILIA B; HEMB	306900
F9 DEFICIENCY	HEMOPHILIA B; HEMB	306900
PLASMA THROMBOPLASTIN COMPONENT DEFICIENCYHEMOPHILIA B(M), INCLUDED	HEMOPHILIA B; HEMB	306900
HEMOPHILIA B LEYDEN, INCLUDED	HEMOPHILIA B; HEMB	306900
HETEROTAXY, VISCERAL, 1, X-LINKED; HTX1	HETEROTAXY, VISCERAL, 1, X-LINKED; HTX1	306955
DEXTROCARDIA WITH OTHER CARDIAC MALFORMATIONS	HETEROTAXY, VISCERAL, 1, X-LINKED; HTX1	306955
LATERALITY, X-LINKED	HETEROTAXY, VISCERAL, 1, X-LINKED; HTX1	306955
SITUS INVERSUS, COMPLEX CARDIAC DEFECTS, AND SPLENIC DEFECTS, X-LINKEDCONGENITAL HEART DEFECTS, MULTIPLE TYPES, 1, X-LINKED, INCLUDED; CHTD1,INCLUDED	HETEROTAXY, VISCERAL, 1, X-LINKED; HTX1	306955
HHHH SYNDROME	HHHH SYNDROME	306960
HEREDITARY HEMIHYPOTROPHY HEMIPARESIS HEMIATHETOSIS SYNDROME	HHHH SYNDROME	306960
HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS	HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS	307000
HSAS1	HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS	307000
HYDROCEPHALUS, X-LINKED; HYCX	HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS	307000
AQUEDUCTAL STENOSIS, X-LINKED; XLASHYDROCEPHALUS, X-LINKED, WITH CONGENITAL IDIOPATHIC INTESTINAL PSEUDOOBSTRUCTION,INCLUDED	HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS	307000
GLYCEROL KINASE DEFICIENCY; GKD	GLYCEROL KINASE DEFICIENCY; GKD	307030
GK DEFICIENCY	GLYCEROL KINASE DEFICIENCY; GKD	307030
GK1 DEFICIENCY	GLYCEROL KINASE DEFICIENCY; GKD	307030
HYPERGLYCEROLEMIA	GLYCEROL KINASE DEFICIENCY; GKD	307030
HYPERTRICHOSIS, CONGENITAL GENERALIZED; HTC2	HYPERTRICHOSIS, CONGENITAL GENERALIZED; HTC2	307150
CHROMOSOME Xq27.1 INTERCHROMOSOMAL INSERTION SYNDROME	HYPERTRICHOSIS, CONGENITAL GENERALIZED; HTC2	307150
CGH	HYPERTRICHOSIS, CONGENITAL GENERALIZED; HTC2	307150
HCG	HYPERTRICHOSIS, CONGENITAL GENERALIZED; HTC2	307150
ISOLATED GROWTH HORMONE DEFICIENCY, TYPE III; IGHD3	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE III; IGHD3	307200
IGHD III	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE III; IGHD3	307200
GROWTH HORMONE DEFICIENCY WITH HYPOGAMMAGLOBULINEMIA	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE III; IGHD3	307200
HYPOGAMMAGLOBULINEMIA AND ISOLATED GROWTH HORMONE DEFICIENCY, X-LINKED	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE III; IGHD3	307200
AGAMMAGLOBULINEMIA AND ISOLATED GROWTH HORMONE DEFICIENCY, X-LINKED	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE III; IGHD3	307200
FLEISHER SYNDROME	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE III; IGHD3	307200
HYPOPARATHYROIDISM, X-LINKED; HYPX	HYPOPARATHYROIDISM, X-LINKED; HYPX	307700
PARATHYROID GLANDS, AGENESIS OF	HYPOPARATHYROIDISM, X-LINKED; HYPX	307700
HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR	HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR	307800
HYPOPHOSPHATEMIA, X-LINKED; XLH	HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR	307800
HYP	HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR	307800
VITAMIN D-RESISTANT RICKETS, X-LINKED	HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR	307800
HYPOPHOSPHATEMIC VITAMIN D-RESISTANT RICKETS; HPDR	HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR	307800
CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMBDEFECTS	CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMBDEFECTS	308050
CHILD SYNDROME	CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMBDEFECTS	308050
ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS,ESPECIALLY ABSENCE DEFORMITY OF LIMBS	CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMBDEFECTS	308050
ICHTHYOSIS, X-LINKED; XLI	ICHTHYOSIS, X-LINKED; XLI	308100
STEROID SULFATASE DEFICIENCY	ICHTHYOSIS, X-LINKED; XLI	308100
STS DEFICIENCY	ICHTHYOSIS, X-LINKED; XLI	308100
PLACENTAL STEROID SULFATASE DEFICIENCY	ICHTHYOSIS, X-LINKED; XLI	308100
STEROID SULFATASE DEFICIENCY DISEASE; SSDDICHTHYOSIS, X-LINKED, COMPLICATED, INCLUDED	ICHTHYOSIS, X-LINKED; XLI	308100
IFAP SYNDROME WITH OR WITHOUT BRESHECK SYNDROME	IFAP SYNDROME WITH OR WITHOUT BRESHECK SYNDROME	308205
ICHTHYOSIS FOLLICULARIS, ATRICHIA, AND PHOTOPHOBIA WITH OR WITHOUTBRAIN ANOMALIES, RETARDATION, ECTODERMAL DYSPLASIA, SKELETAL MALFORMATIONS,HIRSCHSPRUNG DISEASE, EAR/EYE ANOMALIES, CLEFT PALATE/CRYPTORCHIDISM,AND KIDNEY DYSPLASIA/HYPOPLASIA	IFAP SYNDROME WITH OR WITHOUT BRESHECK SYNDROME	308205
IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1; HIGM1	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1; HIGM1	308230
HYPER-IgM IMMUNODEFICIENCY, X-LINKED; XHIM	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1; HIGM1	308230
HYPER-IgM SYNDROME 1	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1; HIGM1	308230
HYPER-IgM SYNDROME; HIGM; IHIS	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1; HIGM1	308230
LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
XLP	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
LYMPHOPROLIFERATIVE DISEASE, X-LINKED; XLPD	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
LYP	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
DUNCAN DISEASE	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
EPSTEIN-BARR VIRUS INFECTION, FAMILIAL FATAL	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
EBV INFECTION, SEVERE, SUSCEPTIBILITY TO; EBVS	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
INFECTIOUS MONONUCLEOSIS, SEVERE, SUSCEPTIBILITY TO	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
IMMUNODEFICIENCY, X-LINKED PROGRESSIVE COMBINED VARIABLE	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
IMMUNODEFICIENCY 5; IMD5	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
PURTILO SYNDROME	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1	308240
IMMUNOGLOBULIN M, LEVEL OF	IMMUNOGLOBULIN M, LEVEL OF	308250
IMPACTED TEETH, MULTIPLE	IMPACTED TEETH, MULTIPLE	308280
INCONTINENTIA PIGMENTI; IP	INCONTINENTIA PIGMENTI; IP	308300
INCONTINENTIA PIGMENTI, FAMILIAL MALE-LETHAL TYPE	INCONTINENTIA PIGMENTI; IP	308300
BLOCH-SULZBERGER SYNDROME	INCONTINENTIA PIGMENTI; IP	308300
INCONTINENTIA PIGMENTI, TYPE II, FORMERLY; IP2, FORMERLY	INCONTINENTIA PIGMENTI; IP	308300
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1; EIEE1	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1; EIEE1	308350
INFANTILE SPASM SYNDROME, X-LINKED 1; ISSX1	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1; EIEE1	308350
WEST SYNDROME, X-LINKED	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1; EIEE1	308350
OHTAHARA SYNDROME, X-LINKED	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1; EIEE1	308350
INFANTILE EPILEPTIC-DYSKINETIC ENCEPHALOPATHY	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1; EIEE1	308350
XMESID	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1; EIEE1	308350
HYPOGONADOTROPIC HYPOGONADISM 1 WITH OR WITHOUT ANOSMIA; HH1	HYPOGONADOTROPIC HYPOGONADISM 1 WITH OR WITHOUT ANOSMIA; HH1	308700
KALLMANN SYNDROME 1; KAL1	HYPOGONADOTROPIC HYPOGONADISM 1 WITH OR WITHOUT ANOSMIA; HH1	308700
KMS	HYPOGONADOTROPIC HYPOGONADISM 1 WITH OR WITHOUT ANOSMIA; HH1	308700
HYPOGONADOTROPIC HYPOGONADISM AND ANOSMIA; HHA	HYPOGONADOTROPIC HYPOGONADISM 1 WITH OR WITHOUT ANOSMIA; HH1	308700
DYSPLASIA OLFACTOGENITALIS OF DE MORSIER	HYPOGONADOTROPIC HYPOGONADISM 1 WITH OR WITHOUT ANOSMIA; HH1	308700
ANOSMIC HYPOGONADISM	HYPOGONADOTROPIC HYPOGONADISM 1 WITH OR WITHOUT ANOSMIA; HH1	308700
KERATOSIS FOLLICULARIS SPINULOSA DECALVANS, X-LINKED; KFSDX	KERATOSIS FOLLICULARIS SPINULOSA DECALVANS, X-LINKED; KFSDX	308800
KERATOSIS FOLLICULARIS SPINULOSA DECALVANS CUM OPHIASI	KERATOSIS FOLLICULARIS SPINULOSA DECALVANS, X-LINKED; KFSDX	308800
LEBER OPTIC ATROPHY, SUSCEPTIBILITY TO	LEBER OPTIC ATROPHY, SUSCEPTIBILITY TO	308905
LOAS	LEBER OPTIC ATROPHY, SUSCEPTIBILITY TO	308905
LEBER HEREDITARY OPTIC NEUROPATHY, MODIFIER OF	LEBER OPTIC ATROPHY, SUSCEPTIBILITY TO	308905
LHON, MODIFIER OF	LEBER OPTIC ATROPHY, SUSCEPTIBILITY TO	308905
LEIOMYOMATOSIS, DIFFUSE, WITH ALPORT SYNDROME; DL-ATS	LEIOMYOMATOSIS, DIFFUSE, WITH ALPORT SYNDROME; DL-ATS	308940
LEIOMYOMATOSIS, ESOPHAGEAL AND VULVAL, WITH NEPHROPATHY	LEIOMYOMATOSIS, DIFFUSE, WITH ALPORT SYNDROME; DL-ATS	308940
ALPORT SYNDROME AND DIFFUSE LEIOMYOMATOSIS; ATS-DL	LEIOMYOMATOSIS, DIFFUSE, WITH ALPORT SYNDROME; DL-ATS	308940
CHROMOSOME Xq22.3 CENTROMERIC DELETION SYNDROME	LEIOMYOMATOSIS, DIFFUSE, WITH ALPORT SYNDROME; DL-ATS	308940
PROTEINURIA, LOW MOLECULAR WEIGHT, WITH HYPERCALCIURIA AND NEPHROCALCINOSIS	PROTEINURIA, LOW MOLECULAR WEIGHT, WITH HYPERCALCIURIA AND NEPHROCALCINOSIS	308990
LOWE OCULOCEREBRORENAL SYNDROME; OCRL	LOWE OCULOCEREBRORENAL SYNDROME; OCRL	309000
OCRL1	LOWE OCULOCEREBRORENAL SYNDROME; OCRL	309000
LOWE SYNDROME	LOWE OCULOCEREBRORENAL SYNDROME; OCRL	309000
PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY	LOWE OCULOCEREBRORENAL SYNDROME; OCRL	309000
MACULAR DYSTROPHY, X-LINKED	MACULAR DYSTROPHY, X-LINKED	309100
SPERMATOGENIC FAILURE, X-LINKED, 2; SPGFX2	SPERMATOGENIC FAILURE, X-LINKED, 2; SPGFX2	309120
MALE INFERTILITY FROM DEFECT IN MEIOSIS	SPERMATOGENIC FAILURE, X-LINKED, 2; SPGFX2	309120
MAJOR AFFECTIVE DISORDER 2; MAFD2	MAJOR AFFECTIVE DISORDER 2; MAFD2	309200
MANIC-DEPRESSIVE ILLNESS; MDI	MAJOR AFFECTIVE DISORDER 2; MAFD2	309200
MANIC-DEPRESSIVE PSYCHOSIS, X-LINKED; MDX	MAJOR AFFECTIVE DISORDER 2; MAFD2	309200
BIPOLAR AFFECTIVE DISORDER; BPAD	MAJOR AFFECTIVE DISORDER 2; MAFD2	309200
MEGALOCORNEA; MGC1	MEGALOCORNEA; MGC1	309300
MGCN	MEGALOCORNEA; MGC1	309300
MELNICK-NEEDLES SYNDROME; MNS	MELNICK-NEEDLES SYNDROME; MNS	309350
MELNICK-NEEDLES OSTEODYSPLASTY	MELNICK-NEEDLES SYNDROME; MNS	309350
OSTEODYSPLASTY OF MELNICK AND NEEDLES	MELNICK-NEEDLES SYNDROME; MNS	309350
MENKES DISEASE	MENKES DISEASE	309400
MK; MNK	MENKES DISEASE	309400
MENKES SYNDROME	MENKES DISEASE	309400
KINKY HAIR DISEASE	MENKES DISEASE	309400
STEELY HAIR DISEASE	MENKES DISEASE	309400
COPPER TRANSPORT DISEASE	MENKES DISEASE	309400
RENPENNING SYNDROME 1; RENS1	RENPENNING SYNDROME 1; RENS1	309500
MENTAL RETARDATION, X-LINKED, RENPENNING TYPE	RENPENNING SYNDROME 1; RENS1	309500
SUTHERLAND-HAAN X-LINKED MENTAL RETARDATION SYNDROME; SHS	RENPENNING SYNDROME 1; RENS1	309500
GOLABI-ITO-HALL SYNDROME	RENPENNING SYNDROME 1; RENS1	309500
MENTAL RETARDATION, X-LINKED, WITH SPASTIC DIPLEGIA	RENPENNING SYNDROME 1; RENS1	309500
MENTAL RETARDATION, X-LINKED, SYNDROMIC 3; MRXS3	RENPENNING SYNDROME 1; RENS1	309500
MENTAL RETARDATION, X-LINKED, SYNDROMIC 8; MRXS8	RENPENNING SYNDROME 1; RENS1	309500
MENTAL RETARDATION, X-LINKED 55; MRX55	RENPENNING SYNDROME 1; RENS1	309500
PARTINGTON X-LINKED MENTAL RETARDATION SYNDROME; PRTS	PARTINGTON X-LINKED MENTAL RETARDATION SYNDROME; PRTS	309510
PARTINGTON SYNDROME	PARTINGTON X-LINKED MENTAL RETARDATION SYNDROME; PRTS	309510
MENTAL RETARDATION, X-LINKED, SYNDROMIC 1; MRXS1	PARTINGTON X-LINKED MENTAL RETARDATION SYNDROME; PRTS	309510
MENTAL RETARDATION, X-LINKED, WITH DYSTONIC MOVEMENTS, ATAXIA, ANDSEIZURES	PARTINGTON X-LINKED MENTAL RETARDATION SYNDROME; PRTS	309510
MENTAL RETARDATION, X-LINKED 36; MRX36	PARTINGTON X-LINKED MENTAL RETARDATION SYNDROME; PRTS	309510
LUJAN-FRYNS SYNDROME	LUJAN-FRYNS SYNDROME	309520
MENTAL RETARDATION, X-LINKED, WITH MARFANOID HABITUS	LUJAN-FRYNS SYNDROME	309520
MENTAL RETARDATION, X-LINKED 1; MRX1	MENTAL RETARDATION, X-LINKED 1; MRX1	309530
MRXMENTAL RETARDATION, X-LINKED 18, INCLUDED; MRX18, INCLUDED	MENTAL RETARDATION, X-LINKED 1; MRX1	309530
METHYLMALONIC ACIDEMIA AND HOMOCYSTEINEMIA, cblX TYPE	METHYLMALONIC ACIDEMIA AND HOMOCYSTEINEMIA, cblX TYPE	309541
MENTAL RETARDATION, X-LINKED 3; MRX3	METHYLMALONIC ACIDEMIA AND HOMOCYSTEINEMIA, cblX TYPE	309541
MENTAL RETARDATION, X-LINKED, SYNDROMIC 12; MRXS12	MENTAL RETARDATION, X-LINKED, SYNDROMIC 12; MRXS12	309545
MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH FRAGILE SITE FRAXE	MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH FRAGILE SITE FRAXE	309548
FRAXE MENTAL RETARDATION SYNDROME	MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH FRAGILE SITE FRAXE	309548
MENTAL RETARDATION, X-LINKED 9; MRX9	MENTAL RETARDATION, X-LINKED 9; MRX9	309549
MENTAL RETARDATION, X-LINKED 44; MRX44	MENTAL RETARDATION, X-LINKED 9; MRX9	309549
MENTAL RETARDATION WITH OPTIC ATROPHY, DEAFNESS, AND SEIZURES	MENTAL RETARDATION WITH OPTIC ATROPHY, DEAFNESS, AND SEIZURES	309555
GUSTAVSON SYNDROME; GUST	MENTAL RETARDATION WITH OPTIC ATROPHY, DEAFNESS, AND SEIZURES	309555
MENTAL RETARDATION WITH SPASTIC PARAPLEGIA AND PALMOPLANTAR HYPERKERATOSIS	MENTAL RETARDATION WITH SPASTIC PARAPLEGIA AND PALMOPLANTAR HYPERKERATOSIS	309560
MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1	MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1	309580
SMITH-FINEMAN-MYERS SYNDROME 1; SFM1	MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1	309580
SFMS	MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1	309580
XLMR-HYPOTONIC FACIES SYNDROME	MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1	309580
CARPENTER-WAZIRI SYNDROME	MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1	309580
CHUDLEY-LOWRY SYNDROME	MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1	309580
JUBERG-MARSIDI SYNDROME; JMS	MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1	309580
HOLMES-GANG SYNDROME	MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1	309580
MENTAL RETARDATION, X-LINKED, WITH GROWTH RETARDATION, DEAFNESS, ANDMICROGENITALISM	MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1	309580
MENTAL RETARDATION, X-LINKED, SYNDROMIC, SNYDER-ROBINSON TYPE; MRXSSR	MENTAL RETARDATION, X-LINKED, SYNDROMIC, SNYDER-ROBINSON TYPE; MRXSSR	309583
SNYDER-ROBINSON MENTAL RETARDATION SYNDROME; SRS	MENTAL RETARDATION, X-LINKED, SYNDROMIC, SNYDER-ROBINSON TYPE; MRXSSR	309583
WILSON-TURNER X-LINKED MENTAL RETARDATION SYNDROME; WTS	WILSON-TURNER X-LINKED MENTAL RETARDATION SYNDROME; WTS	309585
MENTAL RETARDATION, X-LINKED, SYNDROMIC 6; MRXS6	WILSON-TURNER X-LINKED MENTAL RETARDATION SYNDROME; WTS	309585
MENTAL RETARDATION, X-LINKED, WITH GYNECOMASTIA AND OBESITY	WILSON-TURNER X-LINKED MENTAL RETARDATION SYNDROME; WTS	309585
MILES-CARPENTER X-LINKED MENTAL RETARDATION SYNDROME; MCS	MILES-CARPENTER X-LINKED MENTAL RETARDATION SYNDROME; MCS	309605
MENTAL RETARDATION, X-LINKED, SYNDROMIC 4; MRXS4	MILES-CARPENTER X-LINKED MENTAL RETARDATION SYNDROME; MCS	309605
MENTAL RETARDATION, X-LINKED, WITH CONGENITAL CONTRACTURES AND LOWFINGERTIP ARCHES	MILES-CARPENTER X-LINKED MENTAL RETARDATION SYNDROME; MCS	309605
PRIETO X-LINKED MENTAL RETARDATION SYNDROME; PRS	PRIETO X-LINKED MENTAL RETARDATION SYNDROME; PRS	309610
MENTAL RETARDATION, X-LINKED, SYNDROMIC 2; MRXS2	PRIETO X-LINKED MENTAL RETARDATION SYNDROME; PRS	309610
MENTAL RETARDATION, X-LINKED, WITH DYSMORPHISM AND CEREBRAL ATROPHY	PRIETO X-LINKED MENTAL RETARDATION SYNDROME; PRS	309610
MENTAL RETARDATION, SKELETAL DYSPLASIA, AND ABDUCENS PALSY; MRSD	MENTAL RETARDATION, SKELETAL DYSPLASIA, AND ABDUCENS PALSY; MRSD	309620
CHRISTIAN SYNDROME; CHRS	MENTAL RETARDATION, SKELETAL DYSPLASIA, AND ABDUCENS PALSY; MRSD	309620
METACARPAL 4-5 FUSION; MF4	METACARPAL 4-5 FUSION; MF4	309630
MICROPHTHALMIA, SYNDROMIC 1; MCOPS1	MICROPHTHALMIA, SYNDROMIC 1; MCOPS1	309800
LENZ MICROPHTHALMIA SYNDROME	MICROPHTHALMIA, SYNDROMIC 1; MCOPS1	309800
LENZ DYSPLASIA	MICROPHTHALMIA, SYNDROMIC 1; MCOPS1	309800
MAA, FORMERLY	MICROPHTHALMIA, SYNDROMIC 1; MCOPS1	309800
LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 1; LSDMCA1	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 1; LSDMCA1	309801
MICROPHTHALMIA, SYNDROMIC 7; MCOPS7	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 1; LSDMCA1	309801
MICROPHTHALMIA WITH LINEAR SKIN DEFECTS; MLS	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 1; LSDMCA1	309801
MICROPHTHALMIA, DERMAL APLASIA, AND SCLEROCORNEA	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 1; LSDMCA1	309801
MIDAS SYNDROME	LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 1; LSDMCA1	309801
MONOAMINE OXIDASE A; MAOA	MONOAMINE OXIDASE A; MAOA	309850
AMINE OXIDASE (FLAVIN-CONTAINING) AANTISOCIAL BEHAVIOR FOLLOWING CHILDHOOD MALTREATMENT, SUSCEPTIBILITYTO, INCLUDED	MONOAMINE OXIDASE A; MAOA	309850
MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2	MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2	309900
MPS II	MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2	309900
HUNTER SYNDROME	MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2	309900
IDURONATE 2-SULFATASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2	309900
IDS DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2	309900
SULFOIDURONATE SULFATASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2	309900
SIDS DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2	309900
MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD	MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD	310200
DUCHENNE MUSCULAR DYSTROPHY	MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD	310200
MUSCULAR DYSTROPHY, PSEUDOHYPERTROPHIC PROGRESSIVE, DUCHENNE TYPE	MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD	310200
EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1	EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1	310300
EMD1	EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1	310300
MUSCULAR DYSTROPHY, TARDIVE, DREIFUSS-EMERY TYPE, WITH CONTRACTURES	EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1	310300
SCAPULOPERONEAL SYNDROME, X-LINKED, FORMERLY	EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1	310300
HUMEROPERONEAL NEUROMUSCULAR DISEASE, FORMERLY	EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1	310300
MYOPATHY, CENTRONUCLEAR, X-LINKED; CNMX	MYOPATHY, CENTRONUCLEAR, X-LINKED; CNMX	310400
MYOTUBULAR MYOPATHY, X-LINKED; MTMX; XLMTM	MYOPATHY, CENTRONUCLEAR, X-LINKED; CNMX	310400
MYOTUBULAR MYOPATHY 1; MTM1	MYOPATHY, CENTRONUCLEAR, X-LINKED; CNMX	310400
MYOPATHY, X-LINKED, WITH EXCESSIVE AUTOPHAGY; MEAX	MYOPATHY, X-LINKED, WITH EXCESSIVE AUTOPHAGY; MEAX	310440
XMEA	MYOPATHY, X-LINKED, WITH EXCESSIVE AUTOPHAGY; MEAX	310440
MYOPIA 1, X-LINKED; MYP1	MYOPIA 1, X-LINKED; MYP1	310460
NEPHROLITHIASIS, X-LINKED RECESSIVE, WITH RENAL FAILURE; XRN	NEPHROLITHIASIS, X-LINKED RECESSIVE, WITH RENAL FAILURE; XRN	310468
NEPHROLITHIASIS, X-LINKED RECESSIVE, TYPE 1	NEPHROLITHIASIS, X-LINKED RECESSIVE, WITH RENAL FAILURE; XRN	310468
UROLITHIASIS, X-LINKED RECESSIVE, TYPE 1	NEPHROLITHIASIS, X-LINKED RECESSIVE, WITH RENAL FAILURE; XRN	310468
NEPHROLITHIASIS 1; NPHL1	NEPHROLITHIASIS, X-LINKED RECESSIVE, WITH RENAL FAILURE; XRN	310468
COWCHOCK SYNDROME; COWCK	COWCHOCK SYNDROME; COWCK	310490
CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 4; CMTX4	COWCHOCK SYNDROME; COWCK	310490
CHARCOT-MARIE-TOOTH DISEASE WITH DEAFNESS AND MENTAL RETARDATION	COWCHOCK SYNDROME; COWCK	310490
NEUROPATHY, AXONAL MOTOR-SENSORY, WITH DEAFNESS AND MENTAL RETARDATION;NAMSD	COWCHOCK SYNDROME; COWCK	310490
NADMR	COWCHOCK SYNDROME; COWCK	310490
NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1A; CSNB1A	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1A; CSNB1A	310500
CSNB, COMPLETE, X-LINKED	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1A; CSNB1A	310500
NIGHT BLINDNESS, CONGENITAL STATIONARY, WITH MYOPIA	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1A; CSNB1A	310500
HEMERALOPIA-MYOPIA	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1A; CSNB1A	310500
MYOPIA-NIGHT BLINDNESS; NBM1NYCTALOPIA, INCLUDED	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1A; CSNB1A	310500
NORRIE DISEASE; ND	NORRIE DISEASE; ND	310600
ATROPHIA BULBORUM HEREDITARIA	NORRIE DISEASE; ND	310600
EPISKOPI BLINDNESS	NORRIE DISEASE; ND	310600
NYSTAGMUS 1, CONGENITAL, X-LINKED; NYS1	NYSTAGMUS 1, CONGENITAL, X-LINKED; NYS1	310700
NYSTAGMUS, CONGENITAL MOTOR, 1	NYSTAGMUS 1, CONGENITAL, X-LINKED; NYS1	310700
NYSTAGMUS 1, INFANTILE, X-LINKED	NYSTAGMUS 1, CONGENITAL, X-LINKED; NYS1	310700
NYSTAGMUS, INFANTILE IDIOPATHIC, FORMERLY; IIN, FORMERLYNYSTAGMUS, INFANTILE PERIODIC ALTERNATING, X-LINKED, INCLUDED; XIPAN,INCLUDED	NYSTAGMUS 1, CONGENITAL, X-LINKED; NYS1	310700
XLPAN, INCLUDED	NYSTAGMUS 1, CONGENITAL, X-LINKED; NYS1	310700
OPHTHALMOPLEGIA, EXTERNAL, AND MYOPIA; OPEM	OPHTHALMOPLEGIA, EXTERNAL, AND MYOPIA; OPEM	311000
MYOPIA-OPHTHALMOPLEGIA SYNDROME	OPHTHALMOPLEGIA, EXTERNAL, AND MYOPIA; OPEM	311000
OPTIC ATROPHY 2; OPA2	OPTIC ATROPHY 2; OPA2	311050
OPTIC ATROPHY, X-LINKED	OPTIC ATROPHY 2; OPA2	311050
OPTIC ATROPHY, NON-LEBER TYPE, WITH EARLY ONSET	OPTIC ATROPHY 2; OPA2	311050
CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5	311070
OPTIC ATROPHY, POLYNEUROPATHY, AND DEAFNESS	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5	311070
ROSENBERG-CHUTORIAN SYNDROME	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5	311070
CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED RECESSIVE, 5	CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5	311070
OPTICOACOUSTIC NERVE ATROPHY WITH DEMENTIA	OPTICOACOUSTIC NERVE ATROPHY WITH DEMENTIA	311150
JENSEN SYNDROME	OPTICOACOUSTIC NERVE ATROPHY WITH DEMENTIA	311150
OROFACIODIGITAL SYNDROME I; OFD1	OROFACIODIGITAL SYNDROME I; OFD1	311200
ORAL-FACIAL-DIGITAL SYNDROME, TYPE I	OROFACIODIGITAL SYNDROME I; OFD1	311200
OFDS I	OROFACIODIGITAL SYNDROME I; OFD1	311200
PAPILLON-LEAGE AND PSAUME SYNDROME	OROFACIODIGITAL SYNDROME I; OFD1	311200
ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO	ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO	311250
ORNITHINE CARBAMOYLTRANSFERASE DEFICIENCY	ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO	311250
OTC DEFICIENCYVALPROATE SENSITIVITY, INCLUDED	ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO	311250
OTOPALATODIGITAL SYNDROME, TYPE I; OPD1	OTOPALATODIGITAL SYNDROME, TYPE I; OPD1	311300
OPD I SYNDROME	OTOPALATODIGITAL SYNDROME, TYPE I; OPD1	311300
OPD SYNDROME 1OTOPALATODIGITAL SPECTRUM DISORDER, INCLUDED	OTOPALATODIGITAL SYNDROME, TYPE I; OPD1	311300
FRONTOOTOPALATODIGITAL OSTEODYSPLASIA, INCLUDED	OTOPALATODIGITAL SYNDROME, TYPE I; OPD1	311300
PREMATURE OVARIAN FAILURE 1; POF1	PREMATURE OVARIAN FAILURE 1; POF1	311360
PREMATURE OVARIAN FAILURE, X-LINKED; POFX	PREMATURE OVARIAN FAILURE 1; POF1	311360
HYPERGONADOTROPIC OVARIAN FAILURE, X-LINKED	PREMATURE OVARIAN FAILURE 1; POF1	311360
OVARIAN FAILURE, PREMATURE; POF	PREMATURE OVARIAN FAILURE 1; POF1	311360
WAISMAN SYNDROME; WSMN	WAISMAN SYNDROME; WSMN	311510
PARKINSONISM, EARLY-ONSET, WITH MENTAL RETARDATION	WAISMAN SYNDROME; WSMN	311510
BASAL GANGLION DISORDER WITH MENTAL RETARDATION; BGMR	WAISMAN SYNDROME; WSMN	311510
WSN	WAISMAN SYNDROME; WSMN	311510
TARP SYNDROME; TARPS	TARP SYNDROME; TARPS	311900
TALIPES EQUINOVARUS, ATRIAL SEPTAL DEFECT, ROBIN SEQUENCE, AND PERSISTENCEOF LEFT SUPERIOR VENA CAVA	TARP SYNDROME; TARPS	311900
PIERRE ROBIN SYNDROME WITH CONGENITAL HEART MALFORMATION AND CLUBFOOT	TARP SYNDROME; TARPS	311900
PANHYPOPITUITARISM, X-LINKED; PHPX	PANHYPOPITUITARISM, X-LINKED; PHPX	312000
PITUITARY DWARFISM IV, FORMERLY	PANHYPOPITUITARISM, X-LINKED; PHPX	312000
PROPERDIN DEFICIENCY, X-LINKED; CFPD	PROPERDIN DEFICIENCY, X-LINKED; CFPD	312060
PROPERDIN P FACTOR DEFICIENCY; PFD	PROPERDIN DEFICIENCY, X-LINKED; CFPD	312060
COMPLEMENT FACTOR PROPERDIN DEFICIENCY	PROPERDIN DEFICIENCY, X-LINKED; CFPD	312060
PROPERDIN DEFICIENCY, TYPE IPROPERDIN DEFICIENCY, TYPE II, INCLUDED	PROPERDIN DEFICIENCY, X-LINKED; CFPD	312060
PROPERDIN DEFICIENCY, TYPE III, INCLUDED	PROPERDIN DEFICIENCY, X-LINKED; CFPD	312060
PELIZAEUS-MERZBACHER DISEASE; PMD	PELIZAEUS-MERZBACHER DISEASE; PMD	312080
LEUKODYSTROPHY, HYPOMYELINATING, 1; HLD1	PELIZAEUS-MERZBACHER DISEASE; PMD	312080
MULTIPLE PTERYGIUM SYNDROME, X-LINKED	MULTIPLE PTERYGIUM SYNDROME, X-LINKED	312150
PTERYGIUM SYNDROME, MULTIPLE, X-LINKED	MULTIPLE PTERYGIUM SYNDROME, X-LINKED	312150
PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD	PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD	312170
PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY	PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD	312170
PYRUVATE DECARBOXYLASE DEFICIENCY	PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD	312170
ATAXIA, INTERMITTENT, WITH ABNORMAL PYRUVATE METABOLISM	PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD	312170
PDH DEFICIENCY	PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD	312170
ATAXIA, INTERMITTENT, WITH PYRUVATE DEHYDROGENASE DEFICIENCY	PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD	312170
ATAXIA WITH LACTIC ACIDOSIS ILACTIC ACIDEMIA, THIAMINE-RESPONSIVE, INCLUDED	PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD	312170
ANDROGEN INSENSITIVITY, PARTIAL; PAIS	ANDROGEN INSENSITIVITY, PARTIAL; PAIS	312300
REIFENSTEIN SYNDROME	ANDROGEN INSENSITIVITY, PARTIAL; PAIS	312300
ANDROGEN INSENSITIVITY, PARTIAL, WITH OR WITHOUT BREAST CANCER	ANDROGEN INSENSITIVITY, PARTIAL; PAIS	312300
RETICULOENDOTHELIOSIS, X-LINKED	RETICULOENDOTHELIOSIS, X-LINKED	312500
RETINITIS PIGMENTOSA 2; RP2	RETINITIS PIGMENTOSA 2; RP2	312600
RETINITIS PIGMENTOSA 6; RP6	RETINITIS PIGMENTOSA 6; RP6	312612
RETINITIS PIGMENTOSA, X-LINKED RECESSIVE, 6	RETINITIS PIGMENTOSA 6; RP6	312612
RETINOSCHISIS 1, X-LINKED, JUVENILE; RS1	RETINOSCHISIS 1, X-LINKED, JUVENILE; RS1	312700
XLRS1	RETINOSCHISIS 1, X-LINKED, JUVENILE; RS1	312700
RS	RETINOSCHISIS 1, X-LINKED, JUVENILE; RS1	312700
RETT SYNDROME; RTT	RETT SYNDROME; RTT	312750
RTS	RETT SYNDROME; RTT	312750
AUTISM, DEMENTIA, ATAXIA, AND LOSS OF PURPOSEFUL HAND USERETT SYNDROME, ZAPPELLA VARIANT, INCLUDED	RETT SYNDROME; RTT	312750
RETT SYNDROME, PRESERVED SPEECH VARIANT, INCLUDED	RETT SYNDROME; RTT	312750
RETT SYNDROME, ATYPICAL, INCLUDED	RETT SYNDROME; RTT	312750
COMBINED IMMUNODEFICIENCY, X-LINKED; CIDX	COMBINED IMMUNODEFICIENCY, X-LINKED; CIDX	312863
XCID	COMBINED IMMUNODEFICIENCY, X-LINKED; CIDX	312863
IMMUNODEFICIENCY 6; IMD6	COMBINED IMMUNODEFICIENCY, X-LINKED; CIDX	312863
SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1	312870
SGBS	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1	312870
BULLDOG SYNDROME	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1	312870
DYSPLASIA GIGANTISM SYNDROME, X-LINKED; DGSX	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1	312870
GOLABI-ROSEN SYNDROME	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1	312870
SIMPSON DYSMORPHIA SYNDROME; SDYS	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1	312870
SPASTIC PARAPLEGIA 2, X-LINKED; SPG2	SPASTIC PARAPLEGIA 2, X-LINKED; SPG2	312920
SPPX2	SPASTIC PARAPLEGIA 2, X-LINKED; SPG2	312920
SPATIAL VISUALIZATION, APTITUDE FOR	SPATIAL VISUALIZATION, APTITUDE FOR	313000
VISUOSPATIAL/PERCEPTUAL ABILITIES; VSPATURNER SYNDROME-ASSOCIATED NEUROCOGNITIVE PHENOTYPE, INCLUDED	SPATIAL VISUALIZATION, APTITUDE FOR	313000
SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1	SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1	313200
SPINAL AND BULBAR MUSCULAR ATROPHY; SBMA	SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1	313200
KENNEDY DISEASE; KD	SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1	313200
KENNEDY SPINAL AND BULBAR MUSCULAR ATROPHY	SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1	313200
BULBOSPINAL MUSCULAR ATROPHY, X-LINKED	SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1	313200
BULBOSPINAL NEURONOPATHY, X-LINKED RECESSIVE; XBSN	SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1	313200
SPLIT-HAND/FOOT MALFORMATION 2; SHFM2	SPLIT-HAND/FOOT MALFORMATION 2; SHFM2	313350
SPLIT-HAND/SPLIT-FOOT ANOMALY, X-LINKED	SPLIT-HAND/FOOT MALFORMATION 2; SHFM2	313350
SPLIT-HAND/FOOT DEFORMITY 2; SHFD2	SPLIT-HAND/FOOT MALFORMATION 2; SHFM2	313350
SHSF2	SPLIT-HAND/FOOT MALFORMATION 2; SHFM2	313350
SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, X-LINKED; SEDT	SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, X-LINKED; SEDT	313400
SED TARDA, X-LINKED	SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, X-LINKED; SEDT	313400
SPONDYLOEPIPHYSEAL DYSPLASIA, LATE	SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, X-LINKED; SEDT	313400
SPONDYLOMETAPHYSEAL DYSPLASIA, X-LINKED	SPONDYLOMETAPHYSEAL DYSPLASIA, X-LINKED	313420
SPONDYLOMETAPHYSEAL DYSPLASIA, RICHMOND TYPE	SPONDYLOMETAPHYSEAL DYSPLASIA, X-LINKED	313420
TOOTH AGENESIS, SELECTIVE, X-LINKED, 1; STHAGX1	TOOTH AGENESIS, SELECTIVE, X-LINKED, 1; STHAGX1	313500
HYPODONTIA/OLIGODONTIA, X-LINKED, 1	TOOTH AGENESIS, SELECTIVE, X-LINKED, 1; STHAGX1	313500
THORACOABDOMINAL SYNDROME; THAS	THORACOABDOMINAL SYNDROME; THAS	313850
TASMIDLINE DEFECTS, X-LINKED, INCLUDED	THORACOABDOMINAL SYNDROME; THAS	313850
PENTALOGY OF CANTRELL, INCLUDED	THORACOABDOMINAL SYNDROME; THAS	313850
THROMBOCYTOPENIA 1; THC1	THROMBOCYTOPENIA 1; THC1	313900
THC	THROMBOCYTOPENIA 1; THC1	313900
THROMBOCYTOPENIA, X-LINKED; XLT	THROMBOCYTOPENIA 1; THC1	313900
THROMBOCYTOPENIA, X-LINKED, 1THROMBOCYTOPENIA, X-LINKED, INTERMITTENT, INCLUDED	THROMBOCYTOPENIA 1; THC1	313900
THROMBOCYTOPENIA WITH BETA-THALASSEMIA, X-LINKED; XLTT	THROMBOCYTOPENIA WITH BETA-THALASSEMIA, X-LINKED; XLTT	314050
THROMBOCYTOPENIA, PLATELET DYSFUNCTION, HEMOLYSIS, AND IMBALANCEDGLOBIN SYNTHESIS	THROMBOCYTOPENIA WITH BETA-THALASSEMIA, X-LINKED; XLTT	314050
THYROXINE-BINDING GLOBULIN OF SERUM; TBG	THYROXINE-BINDING GLOBULIN OF SERUM; TBG	314200
SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 7; SERPINA7	THYROXINE-BINDING GLOBULIN OF SERUM; TBG	314200
T4-BINDING GLOBULIN	THYROXINE-BINDING GLOBULIN OF SERUM; TBG	314200
TBG, SERUMTHYROXINE-BINDING GLOBULIN DEFICIENCY, INCLUDED	THYROXINE-BINDING GLOBULIN OF SERUM; TBG	314200
DYSTONIA 3, TORSION, X-LINKED; DYT3	DYSTONIA 3, TORSION, X-LINKED; DYT3	314250
DYSTONIA-PARKINSONISM, X-LINKED; XDP	DYSTONIA 3, TORSION, X-LINKED; DYT3	314250
TORSION DYSTONIA-PARKINSONISM, FILIPINO TYPE	DYSTONIA 3, TORSION, X-LINKED; DYT3	314250
TORTICOLLIS, KELOIDS, CRYPTORCHIDISM, AND RENAL DYSPLASIA; TKCR	TORTICOLLIS, KELOIDS, CRYPTORCHIDISM, AND RENAL DYSPLASIA; TKCR	314300
TKC	TORTICOLLIS, KELOIDS, CRYPTORCHIDISM, AND RENAL DYSPLASIA; TKCR	314300
TKCR SYNDROME	TORTICOLLIS, KELOIDS, CRYPTORCHIDISM, AND RENAL DYSPLASIA; TKCR	314300
GOEMINNE SYNDROME	TORTICOLLIS, KELOIDS, CRYPTORCHIDISM, AND RENAL DYSPLASIA; TKCR	314300
UNIQUE GREEN PHENOMENON	UNIQUE GREEN PHENOMENON	314380
VACTERL ASSOCIATION, X-LINKED, WITH OR WITHOUT HYDROCEPHALUS; VACTERLX	VACTERL ASSOCIATION, X-LINKED, WITH OR WITHOUT HYDROCEPHALUS; VACTERLX	314390
VACTERL-H, X-LINKED	VACTERL ASSOCIATION, X-LINKED, WITH OR WITHOUT HYDROCEPHALUS; VACTERLX	314390
CARDIAC VALVULAR DYSPLASIA, X-LINKED; CVD1	CARDIAC VALVULAR DYSPLASIA, X-LINKED; CVD1	314400
VALVULAR HEART DISEASE, CONGENITAL	CARDIAC VALVULAR DYSPLASIA, X-LINKED; CVD1	314400
MYXOMATOUS VALVULAR DYSTROPHY, X-LINKED; XMVD	CARDIAC VALVULAR DYSPLASIA, X-LINKED; CVD1	314400
VAN DEN BOSCH SYNDROME	VAN DEN BOSCH SYNDROME	314500
WIEACKER-WOLFF SYNDROME; WRWF	WIEACKER-WOLFF SYNDROME; WRWF	314580
WIEACKER SYNDROME	WIEACKER-WOLFF SYNDROME; WRWF	314580
CONTRACTURES OF FEET, MUSCLE ATROPHY, AND OCULOMOTOR APRAXIA	WIEACKER-WOLFF SYNDROME; WRWF	314580
APRAXIA, OCULOMOTOR, WITH CONGENITAL CONTRACTURES AND MUSCLE ATROPHY	WIEACKER-WOLFF SYNDROME; WRWF	314580
WILDERVANCK SYNDROME	WILDERVANCK SYNDROME	314600
CERVICOOCULOACOUSTIC SYNDROME	WILDERVANCK SYNDROME	314600
XG REGULATOR; XGR	XG REGULATOR; XGR	314705
XG AND MIC2 EXPRESSION ON ERYTHROCYTES	XG REGULATOR; XGR	314705
XM SYSTEM	XM SYSTEM	314900
RETINITIS PIGMENTOSA, Y-LINKED; RPY	RETINITIS PIGMENTOSA, Y-LINKED; RPY	400004
LYMPHOMA, HODGKIN, Y-LINKED PSEUDOAUTOSOMAL	LYMPHOMA, HODGKIN, Y-LINKED PSEUDOAUTOSOMAL	400021
HODGKIN DISEASE, Y-LINKED PSEUDOAUTOSOMAL	LYMPHOMA, HODGKIN, Y-LINKED PSEUDOAUTOSOMAL	400021
SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1	SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1	400042
SERTOLI CELL-ONLY SYNDROME, Y-LINKED	SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1	400042
SERTOLI CELL-ONLY SYNDROME, TYPE ISERTOLI CELL-ONLY SYNDROME, TYPE II, INCLUDED	SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1	400042
HYPOSPERMATOGENESIS, INCLUDED	SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1	400042
INCOMPLETE SERTOLI CELL-ONLY SYNDROME, INCLUDED	SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1	400042
DEAFNESS, Y-LINKED 1; DFNY1	DEAFNESS, Y-LINKED 1; DFNY1	400043
46,XY SEX REVERSAL 1; SRXY1	46,XY SEX REVERSAL 1; SRXY1	400044
46,XY SEX REVERSAL, SRY-RELATED	46,XY SEX REVERSAL 1; SRXY1	400044
46,XY GONADAL DYSGENESIS, COMPLETE, SRY-RELATED46,XY TRUE HERMAPHRODITISM, SRY-RELATED, INCLUDED	46,XY SEX REVERSAL 1; SRXY1	400044
TESTIS-DETERMINING FACTOR, X-CHROMOSOMAL, FORMERLY, INCLUDED; TDFX,FORMERLY, INCLUDED	46,XY SEX REVERSAL 1; SRXY1	400044
SEX-REVERSING LOCUS ON X, FORMERLY, INCLUDED; SRVX, FORMERLY, INCLUDED	46,XY SEX REVERSAL 1; SRXY1	400044
46,XX SEX REVERSAL 1; SRXX1	46,XX SEX REVERSAL 1; SRXX1	400045
46,XX SEX REVERSAL, SRY-POSITIVE	46,XX SEX REVERSAL 1; SRXX1	400045
XX MALE, SRY-POSITIVE	46,XX SEX REVERSAL 1; SRXX1	400045
46,XX TESTICULAR DISORDER OF SEX DEVELOPMENT46,XX GONADAL DYSGENESIS, COMPLETE, SRY-POSITIVE	46,XX SEX REVERSAL 1; SRXX1	400045
46,XX TRUE HERMAPHRODITISM, SRY-POSITIVE, INCLUDED	46,XX SEX REVERSAL 1; SRXX1	400045
OVOTESTICULAR DISORDER OF SEX DEVELOPMENT, INCLUDED	46,XX SEX REVERSAL 1; SRXX1	400045
OVOTESTICULAR DSD, INCLUDED	46,XX SEX REVERSAL 1; SRXX1	400045
SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2	SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2	415000
SPERMATOGENIC FAILURE, NONOBSTRUCTIVE, Y-LINKED	SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2	415000
AZOOSPERMIA, NONOBSTRUCTIVE, Y-LINKED	SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2	415000
OLIGOZOOSPERMIA, NONOBSTRUCTIVE, Y-LINKED	SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2	415000
OLIGOSPERMIA, NONOBSTRUCTIVE, Y-LINKED	SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2	415000
SPERMATOGENIC ARREST, Y-LINKEDAZOOSPERMIA FACTOR REGIONS, INCLUDED	SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2	415000
AZF REGIONS, INCLUDED	SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2	415000
GONADOBLASTOMA; GBY	GONADOBLASTOMA; GBY	424500
GROWTH CONTROL, Y-CHROMOSOME INFLUENCED; GCY	GROWTH CONTROL, Y-CHROMOSOME INFLUENCED; GCY	475000
STATURE; STA	GROWTH CONTROL, Y-CHROMOSOME INFLUENCED; GCY	475000
TOOTH SIZE; TS; TSY	GROWTH CONTROL, Y-CHROMOSOME INFLUENCED; GCY	475000
CARDIOMYOPATHY, INFANTILE HISTIOCYTOID	CARDIOMYOPATHY, INFANTILE HISTIOCYTOID	500000
CARDIOMYOPATHY, INFANTILE XANTHOMATOUS	CARDIOMYOPATHY, INFANTILE HISTIOCYTOID	500000
CARDIOMYOPATHY, FOCAL LIPID	CARDIOMYOPATHY, INFANTILE HISTIOCYTOID	500000
CARDIOMYOPATHY, ONCOCYTIC	CARDIOMYOPATHY, INFANTILE HISTIOCYTOID	500000
FOAMY MYOCARDIAL TRANSFORMATION OF INFANCY	CARDIOMYOPATHY, INFANTILE HISTIOCYTOID	500000
LEBER OPTIC ATROPHY AND DYSTONIA	LEBER OPTIC ATROPHY AND DYSTONIA	500001
LEBER HEREDITARY OPTIC NEUROPATHY WITH DYSTONIA; LDYT	LEBER OPTIC ATROPHY AND DYSTONIA	500001
DYSTONIA, FAMILIAL, WITH VISUAL FAILURE AND STRIATAL LUCENCIES	LEBER OPTIC ATROPHY AND DYSTONIA	500001
MARSDEN SYNDROME	LEBER OPTIC ATROPHY AND DYSTONIA	500001
MITOCHONDRIAL MYOPATHY WITH DIABETES	MITOCHONDRIAL MYOPATHY WITH DIABETES	500002
MITOCHONDRIAL MYOPATHY, LIPID TYPE	MITOCHONDRIAL MYOPATHY WITH DIABETES	500002
STRIATONIGRAL DEGENERATION, INFANTILE, MITOCHONDRIAL	STRIATONIGRAL DEGENERATION, INFANTILE, MITOCHONDRIAL	500003
BILATERAL STRIATAL NECROSIS, INFANTILE, MITOCHONDRIAL	STRIATONIGRAL DEGENERATION, INFANTILE, MITOCHONDRIAL	500003
INFANTILE BILATERAL STRIATAL NECROSIS, MITOCHONDRIAL	STRIATONIGRAL DEGENERATION, INFANTILE, MITOCHONDRIAL	500003
RETINITIS PIGMENTOSA-DEAFNESS SYNDROME	RETINITIS PIGMENTOSA-DEAFNESS SYNDROME	500004
RETINITIS PIGMENTOSA 8, FORMERLY; RP8, FORMERLY	RETINITIS PIGMENTOSA-DEAFNESS SYNDROME	500004
RETINITIS PIGMENTOSA 21, FORMERLY; RP21, FORMERLY	RETINITIS PIGMENTOSA-DEAFNESS SYNDROME	500004
HYPOMAGNESEMIA, HYPERTENSION, AND HYPERCHOLESTEROLEMIA, MITOCHONDRIAL	HYPOMAGNESEMIA, HYPERTENSION, AND HYPERCHOLESTEROLEMIA, MITOCHONDRIAL	500005
CYCLIC VOMITING SYNDROME; CVSCYCLIC VOMITING SYNDROME WITH NEUROMUSCULAR DISEASE, INCLUDED	CYCLIC VOMITING SYNDROME; CVSCYCLIC VOMITING SYNDROME WITH NEUROMUSCULAR DISEASE, INCLUDED	500007
CYCLIC VOMITING SYNDROME-PLUS, INCLUDED	CYCLIC VOMITING SYNDROME; CVSCYCLIC VOMITING SYNDROME WITH NEUROMUSCULAR DISEASE, INCLUDED	500007
CVS-PLUS, INCLUDED	CYCLIC VOMITING SYNDROME; CVSCYCLIC VOMITING SYNDROME WITH NEUROMUSCULAR DISEASE, INCLUDED	500007
DEAFNESS, NONSYNDROMIC SENSORINEURAL, MITOCHONDRIAL	DEAFNESS, NONSYNDROMIC SENSORINEURAL, MITOCHONDRIAL	500008
MITOCHONDRIAL MYOPATHY, INFANTILE, TRANSIENT; MMIT	MITOCHONDRIAL MYOPATHY, INFANTILE, TRANSIENT; MMIT	500009
MITOCHONDRIAL MYOPATHY, INFANTILE, TRANSIENT, DUE TO RESPIRATORY CHAINDEFICIENCY	MITOCHONDRIAL MYOPATHY, INFANTILE, TRANSIENT; MMIT	500009
COX DEFICIENCY MYOPATHY, INFANTILE, TRANSIENT	MITOCHONDRIAL MYOPATHY, INFANTILE, TRANSIENT; MMIT	500009
RESPIRATORY CHAIN DEFICIENCY, INFANTILE, TRANSIENT	MITOCHONDRIAL MYOPATHY, INFANTILE, TRANSIENT; MMIT	500009
MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 3; MLASA3	MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 3; MLASA3	500011
AGING	AGING	502000
ALZHEIMER DISEASE, SUSCEPTIBILITY TO, MITOCHONDRIAL	ALZHEIMER DISEASE, SUSCEPTIBILITY TO, MITOCHONDRIAL	502500
CHLORAMPHENICOL TOXICITY	CHLORAMPHENICOL TOXICITY	515000
ANEMIA, CHLORAMPHENICOL-INDUCEDCHLORAMPHENICOL RESISTANCE, INCLUDED	CHLORAMPHENICOL TOXICITY	515000
ATP SYNTHASE 6; MTATP6	ATP SYNTHASE 6; MTATP6	516060
COMPLEX V, ATP SYNTHASE, SUBUNIT ATPase 6; ATP6MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, MITOCHONDRIAL TYPE1, INCLUDED; MC5DM1, INCLUDED	ATP SYNTHASE 6; MTATP6	516060
ATAXIA AND POLYNEUROPATHY, ADULT-ONSET, INCLUDED	ATP SYNTHASE 6; MTATP6	516060
CARDIOMYOPATHY, INFANTILE HYPERTROPHIC, INCLUDED	ATP SYNTHASE 6; MTATP6	516060
ATP SYNTHASE 8; MTATP8	ATP SYNTHASE 8; MTATP8	516070
COMPLEX V, ATP SYNTHASE, SUBUNIT ATPase 8; ATP8MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, MITOCHONDRIAL TYPE2, INCLUDED; MC5DM2, INCLUDED	ATP SYNTHASE 8; MTATP8	516070
BRAIN PSEUDOATROPHY, REVERSIBLE, VALPROATE-INDUCED, SUSCEPTIBILITYTO, INCLUDED	ATP SYNTHASE 8; MTATP8	516070
CARDIOMYOPATHY, APICAL HYPERTROPHIC, AND NEUROPATHY, INCLUDED	ATP SYNTHASE 8; MTATP8	516070
CARDIOMYOPATHY, INFANTILE HYPERTROPHIC, INCLUDED	ATP SYNTHASE 8; MTATP8	516070
DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD	DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD	520000
DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED	DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD	520000
BALLINGER-WALLACE SYNDROME	DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD	520000
DIABETES MELLITUS, TYPE II, WITH DEAFNESS	DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD	520000
NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS	DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD	520000
NIDDM WITH DEAFNESS	DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD	520000
DIARRHEA, CHRONIC, WITH VILLOUS ATROPHY	DIARRHEA, CHRONIC, WITH VILLOUS ATROPHY	520100
KEARNS-SAYRE SYNDROME; KSS	KEARNS-SAYRE SYNDROME; KSS	530000
OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY	KEARNS-SAYRE SYNDROME; KSS	530000
OCULOCRANIOSOMATIC SYNDROME	KEARNS-SAYRE SYNDROME; KSS	530000
OPHTHALMOPLEGIA-PLUS SYNDROME	KEARNS-SAYRE SYNDROME; KSS	530000
MITOCHONDRIAL CYTOPATHY	KEARNS-SAYRE SYNDROME; KSS	530000
OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS	KEARNS-SAYRE SYNDROME; KSS	530000
CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY	KEARNS-SAYRE SYNDROME; KSS	530000
CPEO WITH MYOPATHY	KEARNS-SAYRE SYNDROME; KSS	530000
CPEO WITH RAGGED-RED FIBERS	KEARNS-SAYRE SYNDROME; KSS	530000
LEBER OPTIC ATROPHY	LEBER OPTIC ATROPHY	535000
LEBER HEREDITARY OPTIC NEUROPATHY; LHON	LEBER OPTIC ATROPHY	535000
MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKEEPISODES; MELAS	MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKEEPISODES; MELAS	540000
MELAS SYNDROME	MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKEEPISODES; MELAS	540000
MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF	MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF	545000
MERRF SYNDROME	MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF	545000
MYOGLOBINURIA, RECURRENT	MYOGLOBINURIA, RECURRENT	550500
MITOCHONDRIAL MYOPATHY, LETHAL, INFANTILE; LIMM	MITOCHONDRIAL MYOPATHY, LETHAL, INFANTILE; LIMM	551000
NEPHROPATHY, CHRONIC TUBULOINTERSTITIAL	NEPHROPATHY, CHRONIC TUBULOINTERSTITIAL	551200
NEUROPATHY, ATAXIA, AND RETINITIS PIGMENTOSA	NEUROPATHY, ATAXIA, AND RETINITIS PIGMENTOSA	551500
NARP SYNDROME	NEUROPATHY, ATAXIA, AND RETINITIS PIGMENTOSA	551500
ONCOCYTOMA	ONCOCYTOMA	553000
PARKINSON DISEASE, MITOCHONDRIAL	PARKINSON DISEASE, MITOCHONDRIAL	556500
PEARSON MARROW-PANCREAS SYNDROME	PEARSON MARROW-PANCREAS SYNDROME	557000
SIDEROBLASTIC ANEMIA WITH MARROW CELL VACUOLIZATION AND EXOCRINE PANCREATICDYSFUNCTION	PEARSON MARROW-PANCREAS SYNDROME	557000
RENAL TUBULOPATHY, DIABETES MELLITUS, AND CEREBELLAR ATAXIA	RENAL TUBULOPATHY, DIABETES MELLITUS, AND CEREBELLAR ATAXIA	560000
DEAFNESS, AMINOGLYCOSIDE-INDUCED	DEAFNESS, AMINOGLYCOSIDE-INDUCED	580000
DEAFNESS, STREPTOMYCIN-INDUCED	DEAFNESS, AMINOGLYCOSIDE-INDUCED	580000
STREPTOMYCIN OTOTOXICITY	DEAFNESS, AMINOGLYCOSIDE-INDUCED	580000
WOLFRAM SYNDROME, MITOCHONDRIAL FORM	WOLFRAM SYNDROME, MITOCHONDRIAL FORM	598500
DIABETES INSIPIDUS AND MELLITUS WITH OPTIC ATROPHY AND DEAFNESS, MITOCHONDRIALFORM	WOLFRAM SYNDROME, MITOCHONDRIAL FORM	598500
DIDMOAD SYNDROME, MITOCHONDRIAL FORM	WOLFRAM SYNDROME, MITOCHONDRIAL FORM	598500
HEART DEFECTS, CONGENITAL, AND OTHER CONGENITAL ANOMALIES; HDCA	HEART DEFECTS, CONGENITAL, AND OTHER CONGENITAL ANOMALIES; HDCA	600001
PANCREATIC HYPOPLASIA, CONGENITAL, WITH DIABETES MELLITUS AND CONGENITALHEART DISEASE	HEART DEFECTS, CONGENITAL, AND OTHER CONGENITAL ANOMALIES; HDCA	600001
PANCREATIC AGENESIS AND CONGENITAL HEART DEFECTS; PACHD	HEART DEFECTS, CONGENITAL, AND OTHER CONGENITAL ANOMALIES; HDCA	600001
EIKEN SYNDROME	EIKEN SYNDROME	600002
EIKEN SKELETAL DYSPLASIA	EIKEN SYNDROME	600002
BONE MODELING DEFECT OF HANDS AND FEET	EIKEN SYNDROME	600002
ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1; ABCA1	ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1; ABCA1	600046
ATP-BINDING CASSETTE 1; ABC1	ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1; ABCA1	600046
ATP-BINDING CASSETTE TRANSPORTER 1	ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1; ABCA1	600046
ABC TRANSPORTER 1	ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1; ABCA1	600046
CHOLESTEROL EFFLUX REGULATORY PROTEIN; CERPCORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA, PROTECTIONAGAINST, INCLUDED	ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1; ABCA1	600046
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS13, INCLUDED; HDLCQ13, INCLUDED	ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1; ABCA1	600046
BREAST CANCER, 11-22 TRANSLOCATION-ASSOCIATED; BRCATA	BREAST CANCER, 11-22 TRANSLOCATION-ASSOCIATED; BRCATA	600048
EXSTROPHY OF BLADDERBLADDER EXSTROPHY AND EPISPADIAS COMPLEX, INCLUDED; BEEC, INCLUDED	EXSTROPHY OF BLADDERBLADDER EXSTROPHY AND EPISPADIAS COMPLEX, INCLUDED; BEEC, INCLUDED	600057
RETINITIS PIGMENTOSA 13; RP13	RETINITIS PIGMENTOSA 13; RP13	600059
DEAFNESS, AUTOSOMAL RECESSIVE 2; DFNB2	DEAFNESS, AUTOSOMAL RECESSIVE 2; DFNB2	600060
NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 2; NSRD2	DEAFNESS, AUTOSOMAL RECESSIVE 2; DFNB2	600060
FATAL FAMILIAL INSOMNIA; FFI	FATAL FAMILIAL INSOMNIA; FFI	600072
INSOMNIA, FATAL FAMILIAL	FATAL FAMILIAL INSOMNIA; FFI	600072
VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1B; VDDR1B	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1B; VDDR1B	600081
VITAMIN D-DEPENDENT RICKETS, TYPE 1B	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1B; VDDR1B	600081
25-@HYDROXYVITAMIN D3 DEFICIENCY, SELECTIVE	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1B; VDDR1B	600081
PSEUDOVITAMIN D3 DEFICIENCY RICKETS DUE TO 25-HYDROXYLASE DEFICIENCY	VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1B; VDDR1B	600081
PROSTATIC HYPERPLASIA, BENIGN; BPH	PROSTATIC HYPERPLASIA, BENIGN; BPH	600082
DEAFNESS, AUTOSOMAL DOMINANT 2A; DFNA2A	DEAFNESS, AUTOSOMAL DOMINANT 2A; DFNA2A	600101
RETINITIS PIGMENTOSA 12; RP12	RETINITIS PIGMENTOSA 12; RP12	600105
RETINITIS PIGMENTOSA WITH OR WITHOUT PARAARTERIOLAR PRESERVATION OFRETINAL PIGMENT EPITHELIUM	RETINITIS PIGMENTOSA 12; RP12	600105
RP WITH OR WITHOUT PRESERVED PARAARTERIOLE RETINAL PIGMENT EPITHELIUM	RETINITIS PIGMENTOSA 12; RP12	600105
RP WITH OR WITHOUT PPRPE	RETINITIS PIGMENTOSA 12; RP12	600105
STARGARDT DISEASE 3; STGD3	STARGARDT DISEASE 3; STGD3	600110
MACULAR DYSTROPHY WITH FLECKS, TYPE 3	STARGARDT DISEASE 3; STGD3	600110
STARGARDT-LIKE MACULAR DYSTROPHY, AUTOSOMAL DOMINANT	STARGARDT DISEASE 3; STGD3	600110
PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE; PARK2	PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE; PARK2	600116
PARKINSON DISEASE, JUVENILE, AUTOSOMAL RECESSIVE; PDJ	PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE; PARK2	600116
PARKINSONISM, EARLY-ONSET, WITH DIURNAL FLUCTUATION; EPDF	PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE; PARK2	600116
WARBURG MICRO SYNDROME 1; WARBM1	WARBURG MICRO SYNDROME 1; WARBM1	600118
MICRO SYNDROME	WARBURG MICRO SYNDROME 1; WARBM1	600118
RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 3; RCDP3	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 3; RCDP3	600121
ALKYLDIHYDROXYACETONEPHOSPHATE SYNTHASE DEFICIENCY	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 3; RCDP3	600121
ALKYLGLYCERONE-PHOSPHATE SYNTHASE DEFICIENCY	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 3; RCDP3	600121
AGPS DEFICIENCY	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 3; RCDP3	600121
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 1; ECA1	EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 1; ECA1	600131
RETINITIS PIGMENTOSA 14; RP14	RETINITIS PIGMENTOSA 14; RP14	600132
RETINITIS PIGMENTOSA 11; RP11	RETINITIS PIGMENTOSA 11; RP11	600138
CEREBRAL ARTERIOPATHY, AUTOSOMAL RECESSIVE, WITH SUBCORTICAL INFARCTSAND LEUKOENCEPHALOPATHY; CARASIL	CEREBRAL ARTERIOPATHY, AUTOSOMAL RECESSIVE, WITH SUBCORTICAL INFARCTSAND LEUKOENCEPHALOPATHY; CARASIL	600142
MAEDA SYNDROME	CEREBRAL ARTERIOPATHY, AUTOSOMAL RECESSIVE, WITH SUBCORTICAL INFARCTSAND LEUKOENCEPHALOPATHY; CARASIL	600142
SUBCORTICAL VASCULAR ENCEPHALOPATHY, PROGRESSIVE	CEREBRAL ARTERIOPATHY, AUTOSOMAL RECESSIVE, WITH SUBCORTICAL INFARCTSAND LEUKOENCEPHALOPATHY; CARASIL	600142
CEREBROVASCULAR DISEASE WITH THIN SKIN, ALOPECIA, AND DISC DISEASE	CEREBRAL ARTERIOPATHY, AUTOSOMAL RECESSIVE, WITH SUBCORTICAL INFARCTSAND LEUKOENCEPHALOPATHY; CARASIL	600142
CEROID LIPOFUSCINOSIS, NEURONAL, 8; CLN8	CEROID LIPOFUSCINOSIS, NEURONAL, 8; CLN8	600143
SACRAL DEFECT WITH ANTERIOR MENINGOCELE	SACRAL DEFECT WITH ANTERIOR MENINGOCELE	600145
SDAMCAUDAL DYSGENESIS SYNDROME, INCLUDED	SACRAL DEFECT WITH ANTERIOR MENINGOCELE	600145
CAUDAL REGRESSION SYNDROME, INCLUDED	SACRAL DEFECT WITH ANTERIOR MENINGOCELE	600145
SACRAL AGENESIS, INCLUDED	SACRAL DEFECT WITH ANTERIOR MENINGOCELE	600145
SIRENOMELIA, INCLUDED	SACRAL DEFECT WITH ANTERIOR MENINGOCELE	600145
BARDET-BIEDL SYNDROME 3; BBS3	BARDET-BIEDL SYNDROME 3; BBS3	600151
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 2; HSCR2	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 2; HSCR2	600155
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 5; HSCR5	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 5; HSCR5	600156
NANOPHTHALMOS 1; NNO1	NANOPHTHALMOS 1; NNO1	600165
NANOPHTHALMIA 1	NANOPHTHALMOS 1; NNO1	600165
NANOPHTHALMOS, AUTOSOMAL DOMINANT	NANOPHTHALMOS 1; NNO1	600165
NANOPHTHALMOS WITH HIGH HYPEROPIA AND ANGLE-CLOSURE GLAUCOMA	NANOPHTHALMOS 1; NNO1	600165
MICROPHTHALMOS, SIMPLE, AUTOSOMAL DOMINANT	NANOPHTHALMOS 1; NNO1	600165
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIII; HMN8	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIII; HMN8	600175
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VIII; DHMN8	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIII; HMN8	600175
SPINAL MUSCULAR ATROPHY, DISTAL, CONGENITAL NONPROGRESSIVE	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIII; HMN8	600175
SPINAL MUSCULAR ATROPHY, CONGENITAL BENIGN, WITH CONTRACTURES	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIII; HMN8	600175
PACHYGYRIA WITH MENTAL RETARDATION, SEIZURES, AND ARACHNOID CYSTS	PACHYGYRIA WITH MENTAL RETARDATION, SEIZURES, AND ARACHNOID CYSTS	600176
PACHYGYRIA WITH MENTAL RETARDATION AND SEIZURES	PACHYGYRIA WITH MENTAL RETARDATION, SEIZURES, AND ARACHNOID CYSTS	600176
WAARDENBURG SYNDROME, TYPE 2B; WS2B	WAARDENBURG SYNDROME, TYPE 2B; WS2B	600193
WAARDENBURG SYNDROME, TYPE IIB	WAARDENBURG SYNDROME, TYPE 2B; WS2B	600193
VENOUS MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL; VMCM	VENOUS MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL; VMCM	600195
VMCM1	VENOUS MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL; VMCM	600195
DYSLEXIA, SUSCEPTIBILITY TO, 2; DYX2	DYSLEXIA, SUSCEPTIBILITY TO, 2; DYX2	600202
READING DISABILITY, SPECIFIC, 2	DYSLEXIA, SUSCEPTIBILITY TO, 2; DYX2	600202
EPIPHYSEAL DYSPLASIA, MULTIPLE, 2; EDM2	EPIPHYSEAL DYSPLASIA, MULTIPLE, 2; EDM2	600204
MACROTHROMBOCYTOPENIA AND PROGRESSIVE SENSORINEURAL DEAFNESS	MACROTHROMBOCYTOPENIA AND PROGRESSIVE SENSORINEURAL DEAFNESS	600208
EXOSTOSES, MULTIPLE, TYPE III; EXT3	EXOSTOSES, MULTIPLE, TYPE III; EXT3	600209
SPINOCEREBELLAR ATAXIA 4; SCA4	SPINOCEREBELLAR ATAXIA 4; SCA4	600223
SPINOCEREBELLAR ATAXIA, AUTOSOMAL DOMINANT, WITH SENSORY AXONAL NEUROPATHY	SPINOCEREBELLAR ATAXIA 4; SCA4	600223
SPINOCEREBELLAR ATAXIA 5; SCA5	SPINOCEREBELLAR ATAXIA 5; SCA5	600224
PALMOPLANTAR KERATODERMA, BOTHNIAN TYPE; PPKB	PALMOPLANTAR KERATODERMA, BOTHNIAN TYPE; PPKB	600231
FACIAL CLEFTING, OBLIQUE, 1; OBLFC1	FACIAL CLEFTING, OBLIQUE, 1; OBLFC1	600251
OCULOMAXILLOFACIAL DYSPLASIA WITH OBLIQUE FACIAL CLEFTS	FACIAL CLEFTING, OBLIQUE, 1; OBLFC1	600251
CHROMOSOME 8q12.1-q21.2 DELETION SYNDROME	CHROMOSOME 8q12.1-q21.2 DELETION SYNDROME	600257
BOR-DUANE HYDROCEPHALUS CONTIGUOUS GENE SYNDROME	CHROMOSOME 8q12.1-q21.2 DELETION SYNDROME	600257
HELICOBACTER PYLORI INFECTION, SUSCEPTIBILITY TO	HELICOBACTER PYLORI INFECTION, SUSCEPTIBILITY TO	600263
OCULOECTODERMAL SYNDROME; OES	OCULOECTODERMAL SYNDROME; OES	600268
APLASIA CUTIS CONGENITA WITH EPIBULBAR DERMOIDS	OCULOECTODERMAL SYNDROME; OES	600268
POLYCYSTIC KIDNEY DISEASE, INFANTILE SEVERE, WITH TUBEROUS SCLEROSIS;PKDTS	POLYCYSTIC KIDNEY DISEASE, INFANTILE SEVERE, WITH TUBEROUS SCLEROSIS;PKDTS	600273
CHROMOSOME 16p13.3 DELETION SYNDROME, DISTAL	POLYCYSTIC KIDNEY DISEASE, INFANTILE SEVERE, WITH TUBEROUS SCLEROSIS;PKDTS	600273
TUBEROUS SCLEROSIS/POLYCYSTIC KIDNEY DISEASE CONTIGUOUS GENE SYNDROME	POLYCYSTIC KIDNEY DISEASE, INFANTILE SEVERE, WITH TUBEROUS SCLEROSIS;PKDTS	600273
FRONTOTEMPORAL DEMENTIA; FTD	FRONTOTEMPORAL DEMENTIA; FTD	600274
FRONTOTEMPORAL LOBAR DEGENERATION WITH TAU INCLUSIONS	FRONTOTEMPORAL DEMENTIA; FTD	600274
FTLD WITH TAU INCLUSIONS	FRONTOTEMPORAL DEMENTIA; FTD	600274
DEMENTIA, FRONTOTEMPORAL, WITH PARKINSONISM	FRONTOTEMPORAL DEMENTIA; FTD	600274
FRONTOTEMPORAL DEMENTIA WITH PARKINSONISM	FRONTOTEMPORAL DEMENTIA; FTD	600274
FRONTOTEMPORAL LOBE DEMENTIA; FLDEM	FRONTOTEMPORAL DEMENTIA; FTD	600274
FTDP17	FRONTOTEMPORAL DEMENTIA; FTD	600274
MULTIPLE SYSTEM TAUOPATHY WITH PRESENILE DEMENTIA; MSTD	FRONTOTEMPORAL DEMENTIA; FTD	600274
DISINHIBITION-DEMENTIA-PARKINSONISM-AMYOTROPHY COMPLEX; DDPAC	FRONTOTEMPORAL DEMENTIA; FTD	600274
WILHELMSEN-LYNCH DISEASE; WLD	FRONTOTEMPORAL DEMENTIA; FTD	600274
PALLIDOPONTONIGRAL DEGENERATION; PPNDPICK COMPLEX, INCLUDED	FRONTOTEMPORAL DEMENTIA; FTD	600274
ATRIOVENTRICULAR SEPTAL DEFECT 3; AVSD3	ATRIOVENTRICULAR SEPTAL DEFECT 3; AVSD3	600309
DEAFNESS, AUTOSOMAL RECESSIVE 3; DFNB3	DEAFNESS, AUTOSOMAL RECESSIVE 3; DFNB3	600316
NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 3; NSRD3	DEAFNESS, AUTOSOMAL RECESSIVE 3; DFNB3	600316
DIABETES MELLITUS, INSULIN-DEPENDENT, 3; IDDM3	DIABETES MELLITUS, INSULIN-DEPENDENT, 3; IDDM3	600318
INSULIN-DEPENDENT DIABETES MELLITUS 3	DIABETES MELLITUS, INSULIN-DEPENDENT, 3; IDDM3	600318
DIABETES MELLITUS, INSULIN-DEPENDENT, 4; IDDM4	DIABETES MELLITUS, INSULIN-DEPENDENT, 4; IDDM4	600319
INSULIN-DEPENDENT DIABETES MELLITUS 4	DIABETES MELLITUS, INSULIN-DEPENDENT, 4; IDDM4	600319
DIABETES MELLITUS, INSULIN-DEPENDENT, 5; IDDM5	DIABETES MELLITUS, INSULIN-DEPENDENT, 5; IDDM5	600320
INSULIN-DEPENDENT DIABETES MELLITUS 5	DIABETES MELLITUS, INSULIN-DEPENDENT, 5; IDDM5	600320
DIABETES MELLITUS, INSULIN-DEPENDENT, 7; IDDM7	DIABETES MELLITUS, INSULIN-DEPENDENT, 7; IDDM7	600321
INSULIN-DEPENDENT DIABETES MELLITUS 7	DIABETES MELLITUS, INSULIN-DEPENDENT, 7; IDDM7	600321
AMINOPTERIN SYNDROME SINE AMINOPTERIN; ASSA	AMINOPTERIN SYNDROME SINE AMINOPTERIN; ASSA	600325
PSEUDOAMINOPTERIN SYNDROME	AMINOPTERIN SYNDROME SINE AMINOPTERIN; ASSA	600325
RIPPLING MUSCLE DISEASE 1; RMD1	RIPPLING MUSCLE DISEASE 1; RMD1	600332
TIBIAL MUSCULAR DYSTROPHY, TARDIVE	TIBIAL MUSCULAR DYSTROPHY, TARDIVE	600334
TMD	TIBIAL MUSCULAR DYSTROPHY, TARDIVE	600334
TARDIVE TIBIAL MUSCULAR DYSTROPHY	TIBIAL MUSCULAR DYSTROPHY, TARDIVE	600334
UDD MYOPATHY	TIBIAL MUSCULAR DYSTROPHY, TARDIVE	600334
PAROTID SALIVARY GLANDS, POLYCYSTIC DYSGENETIC DISEASE OF; PDDP	PAROTID SALIVARY GLANDS, POLYCYSTIC DYSGENETIC DISEASE OF; PDDP	600343
APLASIA CUTIS CONGENITA OF LIMBS, AUTOSOMAL RECESSIVE	APLASIA CUTIS CONGENITA OF LIMBS, AUTOSOMAL RECESSIVE	600360
HEREDITARY MOTOR AND SENSORY NEUROPATHY V	HEREDITARY MOTOR AND SENSORY NEUROPATHY V	600361
HMSN V	HEREDITARY MOTOR AND SENSORY NEUROPATHY V	600361
HMSN5	HEREDITARY MOTOR AND SENSORY NEUROPATHY V	600361
PERONEAL MUSCULAR ATROPHY WITH PYRAMIDAL FEATURES, AUTOSOMAL DOMINANT	HEREDITARY MOTOR AND SENSORY NEUROPATHY V	600361
CHARCOT-MARIE-TOOTH DISEASE WITH PYRAMIDAL FEATURES, AUTOSOMAL DOMINANT	HEREDITARY MOTOR AND SENSORY NEUROPATHY V	600361
CHARCOT-MARIE-TOOTH NEUROPATHY WITH PYRAMIDAL FEATURES, AUTOSOMALDOMINANT	HEREDITARY MOTOR AND SENSORY NEUROPATHY V	600361
CMT WITH PYRAMIDAL FEATURES	HEREDITARY MOTOR AND SENSORY NEUROPATHY V	600361
SPASTIC PARAPLEGIA 6, AUTOSOMAL DOMINANT; SPG6	SPASTIC PARAPLEGIA 6, AUTOSOMAL DOMINANT; SPG6	600363
FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 3; FSP3	SPASTIC PARAPLEGIA 6, AUTOSOMAL DOMINANT; SPG6	600363
CODAS SYNDROME	CODAS SYNDROME	600373
CEREBRAL, OCULAR, DENTAL, AURICULAR, AND SKELETAL ANOMALIES SYNDROME	CODAS SYNDROME	600373
TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 2; HHT2PULMONARY ARTERIAL HYPERTENSION, HEREDITARY HEMORRHAGIC TELANGIECTASIA-RELATED,INCLUDED	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 2; HHT2PULMONARY ARTERIAL HYPERTENSION, HEREDITARY HEMORRHAGIC TELANGIECTASIA-RELATED,INCLUDED	600376
MESOMELIA-SYNOSTOSES SYNDROME	MESOMELIA-SYNOSTOSES SYNDROME	600383
CHROMOSOME 8q13 DELETION SYNDROME	MESOMELIA-SYNOSTOSES SYNDROME	600383
MESOMELIC DYSPLASIA WITH ACRAL SYNOSTOSES, VERLOES-DAVID-PFEIFFERTYPE	MESOMELIA-SYNOSTOSES SYNDROME	600383
MESOMELIC DYSPLASIA, SYNDROMIC	MESOMELIA-SYNOSTOSES SYNDROME	600383
APHALANGIA, PARTIAL, WITH SYNDACTYLY AND DUPLICATION OF METATARSALIV	APHALANGIA, PARTIAL, WITH SYNDACTYLY AND DUPLICATION OF METATARSALIV	600384
PECTUS EXCAVATUM, MACROCEPHALY, SHORT STATURE, AND DYSPLASTIC NAILS	PECTUS EXCAVATUM, MACROCEPHALY, SHORT STATURE, AND DYSPLASTIC NAILS	600399
CHROMOSOME 2q37 DELETION SYNDROME	CHROMOSOME 2q37 DELETION SYNDROME	600430
ALBRIGHT HEREDITARY OSTEODYSTROPHY-LIKE SYNDROME	CHROMOSOME 2q37 DELETION SYNDROME	600430
BRACHYDACTYLY-MENTAL RETARDATION SYNDROME; BDMR	CHROMOSOME 2q37 DELETION SYNDROME	600430
MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 1; MLASA1	MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 1; MLASA1	600462
MITOCHONDRIAL MYOPATHY AND SIDEROBLASTIC ANEMIA	MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 1; MLASA1	600462
MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 4	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 4	600467
MHS4	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 4	600467
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 3; MODY3	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 3; MODY3	600496
MODY, TYPE 3	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 3; MODY3	600496
ABCD SYNDROME; ABCDS	ABCD SYNDROME; ABCDS	600501
ALBINISM, BLACK LOCK, CELL MIGRATION DISORDER OF THE NEUROCYTES OFTHE GUT, AND DEAFNESS	ABCD SYNDROME; ABCDS	600501
GLAUCOMA-RELATED PIGMENT DISPERSION SYNDROME; GPDS1	GLAUCOMA-RELATED PIGMENT DISPERSION SYNDROME; GPDS1	600510
GLAUCOMA, PIGMENT-DISPERSION TYPE	GLAUCOMA-RELATED PIGMENT DISPERSION SYNDROME; GPDS1	600510
PIGMENT DISPERSION SYNDROME; PDS	GLAUCOMA-RELATED PIGMENT DISPERSION SYNDROME; GPDS1	600510
SCHIZOPHRENIA 3; SCZD3	SCHIZOPHRENIA 3; SCZD3	600511
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 6-RELATED	SCHIZOPHRENIA 3; SCZD3	600511
EPILEPSY, FAMILIAL TEMPORAL LOBE, 1; ETL1	EPILEPSY, FAMILIAL TEMPORAL LOBE, 1; ETL1	600512
EPILEPSY, LATERAL TEMPORAL LOBE, AUTOSOMAL DOMINANT; ADLTE	EPILEPSY, FAMILIAL TEMPORAL LOBE, 1; ETL1	600512
EPILEPSY, PARTIAL, WITH AUDITORY FEATURES; ADPEAF	EPILEPSY, FAMILIAL TEMPORAL LOBE, 1; ETL1	600512
EPILEPSY, NOCTURNAL FRONTAL LOBE, 1; ENFL1	EPILEPSY, NOCTURNAL FRONTAL LOBE, 1; ENFL1	600513
PHOSPHOLIPASE A2, GROUP IVA; PLA2G4A	PHOSPHOLIPASE A2, GROUP IVA; PLA2G4A	600522
PHOSPHOLIPASE A2, CYTOSOLIC, CALCIUM-DEPENDENT, ALPHA	PHOSPHOLIPASE A2, GROUP IVA; PLA2G4A	600522
CPLA2-ALPHAPHOSPHOLIPASE A2, GROUP IVA, DEFICIENCY OF, INCLUDED	PHOSPHOLIPASE A2, GROUP IVA; PLA2G4A	600522
CRANIOSYNOSTOSIS, ADELAIDE TYPE; CRSA	CRANIOSYNOSTOSIS, ADELAIDE TYPE; CRSA	600593
CONE-ROD DYSTROPHY 1; CORD1	CONE-ROD DYSTROPHY 1; CORD1	600624
CRD1	CONE-ROD DYSTROPHY 1; CORD1	600624
OROFACIAL CLEFT 11; OFC11	OROFACIAL CLEFT 11; OFC11	600625
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 11CLEFT LIP, CONGENITAL HEALED, INCLUDED	OROFACIAL CLEFT 11; OFC11	600625
CONGENITAL HEALED CLEFT LIP, INCLUDED; CHCL, INCLUDED	OROFACIAL CLEFT 11; OFC11	600625
UV-SENSITIVE SYNDROME 1; UVSS1	UV-SENSITIVE SYNDROME 1; UVSS1	600630
ENURESIS, NOCTURNAL, 1; ENUR1	ENURESIS, NOCTURNAL, 1; ENUR1	600631
BEDWETTING	ENURESIS, NOCTURNAL, 1; ENUR1	600631
PITUITARY ADENOMA, PROLACTIN-SECRETING	PITUITARY ADENOMA, PROLACTIN-SECRETING	600634
PROLACTINOMA, FAMILIAL	PITUITARY ADENOMA, PROLACTIN-SECRETING	600634
FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3A, WITH OR WITHOUT EXTRAOCULARINVOLVEMENT; CFEOM3A	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3A, WITH OR WITHOUT EXTRAOCULARINVOLVEMENT; CFEOM3A	600638
FEOM3 LOCUS	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3A, WITH OR WITHOUT EXTRAOCULARINVOLVEMENT; CFEOM3A	600638
CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE	600649
CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY WITH HYPOKETOTIC HYPOGLYCEMIA	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE	600649
CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, HEPATOCARDIOMUSCULAR	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE	600649
CPT II DEFICIENCY, HEPATIC	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE	600649
CPT2 DEFICIENCY, INFANTILE	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE	600649
FRAGILE SITE 11B; FRA11B	FRAGILE SITE 11B; FRA11B	600651
DEAFNESS, AUTOSOMAL DOMINANT 4A; DFNA4A	DEAFNESS, AUTOSOMAL DOMINANT 4A; DFNA4A	600652
DEAFNESS, AUTOSOMAL DOMINANT 4; DFNA4	DEAFNESS, AUTOSOMAL DOMINANT 4A; DFNA4A	600652
CHONDROCALCINOSIS 1; CCAL1	CHONDROCALCINOSIS 1; CCAL1	600668
CHONDROCALCINOSIS WITH EARLY-ONSET OSTEOARTHRITIS	CHONDROCALCINOSIS 1; CCAL1	600668
EPILEPSY, IDIOPATHIC GENERALIZED; EIG	EPILEPSY, IDIOPATHIC GENERALIZED; EIG	600669
IDIOPATHIC GENERALIZED EPILEPSY; IGEEPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 1, INCLUDED;EIG1, INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED; EIG	600669
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME8, INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED; EIG	600669
MICROTIA-ANOTIA	MICROTIA-ANOTIA	600674
D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1	D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1	600721
D2HGA	D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1	600721
HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3	600740
FAMILIAL BENIGN HYPERCALCEMIA, TYPE III; FBH3	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3	600740
HYPERCALCEMIA, FAMILIAL BENIGN, TYPE III	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3	600740
HYPERCALCEMIA, FAMILIAL BENIGN, OKLAHOMA TYPE	HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3	600740
OROFACIAL CLEFT 3; OFC3	OROFACIAL CLEFT 3; OFC3	600757
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 3	OROFACIAL CLEFT 3; OFC3	600757
DWARFISM, FAMILIAL, WITH MUSCLE SPASMS	DWARFISM, FAMILIAL, WITH MUSCLE SPASMS	600771
CRANIOSYNOSTOSIS 4; CRS4	CRANIOSYNOSTOSIS 4; CRS4	600775
VITAMIN D-DEPENDENT RICKETS, TYPE 2B, WITH NORMAL VITAMIN D RECEPTOR;VDDR2B	VITAMIN D-DEPENDENT RICKETS, TYPE 2B, WITH NORMAL VITAMIN D RECEPTOR;VDDR2B	600785
CHORIORETINAL ATROPHY, PROGRESSIVE BIFOCAL	CHORIORETINAL ATROPHY, PROGRESSIVE BIFOCAL	600790
CRAPB	CHORIORETINAL ATROPHY, PROGRESSIVE BIFOCAL	600790
PROGRESSIVE BIFOCAL CHORIORETINAL ATROPHY; PBCRA	CHORIORETINAL ATROPHY, PROGRESSIVE BIFOCAL	600790
DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT;DFNB4	DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT;DFNB4	600791
NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 4; NSRD4	DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT;DFNB4	600791
DILATED VESTIBULAR AQUEDUCT; DVA	DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT;DFNB4	600791
DEAFNESS, AUTOSOMAL RECESSIVE 5; DFNB5	DEAFNESS, AUTOSOMAL RECESSIVE 5; DFNB5	600792
NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 5; NSRD5	DEAFNESS, AUTOSOMAL RECESSIVE 5; DFNB5	600792
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A	600794
HMN VA	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A	600794
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE V; HMN5	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A	600794
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; DHMN5A	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A	600794
DHMN VA	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A	600794
SPINAL MUSCULAR ATROPHY, DISTAL, TYPE VA; DSMAVA	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A	600794
SPINAL MUSCULAR ATROPHY, DISTAL, TYPE V; DSMAV	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A	600794
SPINAL MUSCULAR ATROPHY, DISTAL, WITH UPPER LIMB PREDOMINANCE	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A	600794
FRONTOTEMPORAL DEMENTIA, CHROMOSOME 3-LINKED; FTD3	FRONTOTEMPORAL DEMENTIA, CHROMOSOME 3-LINKED; FTD3	600795
DMT1; DEM	FRONTOTEMPORAL DEMENTIA, CHROMOSOME 3-LINKED; FTD3	600795
DEMENTIA, FAMILIAL NONSPECIFIC	FRONTOTEMPORAL DEMENTIA, CHROMOSOME 3-LINKED; FTD3	600795
SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-POSITIVE, NK CELL-NEGATIVE	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-POSITIVE, NK CELL-NEGATIVE	600802
SCID, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-NEGATIVE	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-POSITIVE, NK CELL-NEGATIVE	600802
GALLBLADDER DISEASE 1; GBD1	GALLBLADDER DISEASE 1; GBD1	600803
CHOLELITHIASIS, LOW PHOSPHOLIPID-ASSOCIATED; LPAC	GALLBLADDER DISEASE 1; GBD1	600803
ASTHMA, SUSCEPTIBILITY TO	ASTHMA, SUSCEPTIBILITY TO	600807
ASTHMA, BRONCHIAL	ASTHMA, SUSCEPTIBILITY TO	600807
ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TOASTHMA, PROTECTION AGAINST, INCLUDED	ASTHMA, SUSCEPTIBILITY TO	600807
ASTHMA, DIMINISHED RESPONSE TO ANTILEUKOTRIENE TREATMENT IN, INCLUDED	ASTHMA, SUSCEPTIBILITY TO	600807
ENURESIS, NOCTURNAL, 2; ENUR2	ENURESIS, NOCTURNAL, 2; ENUR2	600808
SCHIZOPHRENIA 4; SCZD4	SCHIZOPHRENIA 4; SCZD4	600850
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 22q11-RELATED	SCHIZOPHRENIA 4; SCZD4	600850
RETINITIS PIGMENTOSA 17; RP17	RETINITIS PIGMENTOSA 17; RP17	600852
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 6; CMH6	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 6; CMH6	600858
BUDD-CHIARI SYNDROME; BDCHSMEMBRANOUS OBSTRUCTION OF INFERIOR VENA CAVA, INCLUDED; MOVC, INCLUDED	BUDD-CHIARI SYNDROME; BDCHSMEMBRANOUS OBSTRUCTION OF INFERIOR VENA CAVA, INCLUDED; MOVC, INCLUDED	600880
CATARACT 10, MULTIPLE TYPES; CTRCT10	CATARACT 10, MULTIPLE TYPES; CTRCT10	600881
CATARACT, CONGENITAL ZONULAR, WITH SUTURAL OPACITIES; CCZS	CATARACT 10, MULTIPLE TYPES; CTRCT10	600881
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B	600882
CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2B	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B	600882
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2B	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B	600882
HEREDITARY MOTOR AND SENSORY NEUROPATHY IIB; HMSN IIB	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B	600882
HMSN2B	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B	600882
DIABETES MELLITUS, INSULIN-DEPENDENT, 8; IDDM8	DIABETES MELLITUS, INSULIN-DEPENDENT, 8; IDDM8	600883
INSULIN-DEPENDENT DIABETES MELLITUS 8	DIABETES MELLITUS, INSULIN-DEPENDENT, 8; IDDM8	600883
CARDIOMYOPATHY, DILATED, 1B; CMD1B	CARDIOMYOPATHY, DILATED, 1B; CMD1B	600884
CARDIOMYOPATHY, FAMILIAL DILATED, 1; CMPD1	CARDIOMYOPATHY, DILATED, 1B; CMD1B	600884
CARDIOMYOPATHY, FAMILIAL DILATED; FDC	CARDIOMYOPATHY, DILATED, 1B; CMD1B	600884
HYPERFERRITINEMIA WITH OR WITHOUT CATARACT	HYPERFERRITINEMIA WITH OR WITHOUT CATARACT	600886
HYPERFERRITINEMIA-CATARACT SYNDROME	HYPERFERRITINEMIA WITH OR WITHOUT CATARACT	600886
HYPERFERRITINEMIA, HEREDITARY, WITH CONGENITAL CATARACTS; HHCS	HYPERFERRITINEMIA WITH OR WITHOUT CATARACT	600886
FANCONI ANEMIA, COMPLEMENTATION GROUP E; FANCE	FANCONI ANEMIA, COMPLEMENTATION GROUP E; FANCE	600901
FACE	FANCONI ANEMIA, COMPLEMENTATION GROUP E; FANCE	600901
CARDIAC ARRHYTHMIA, ANKYRIN-B-RELATED	CARDIAC ARRHYTHMIA, ANKYRIN-B-RELATED	600919
ANKYRIN-B SYNDROMELONG QT SYNDROME 4, INCLUDED; LQT4, INCLUDED	CARDIAC ARRHYTHMIA, ANKYRIN-B-RELATED	600919
VAN DEN ENDE-GUPTA SYNDROME; VDEGS	VAN DEN ENDE-GUPTA SYNDROME; VDEGS	600920
MARDEN-WALKER-LIKE SYNDROME WITHOUT PSYCHOMOTOR RETARDATION	VAN DEN ENDE-GUPTA SYNDROME; VDEGS	600920
BLEPHAROPHIMOSIS, ARACHNODACTYLY, AND CONGENITAL CONTRACTURES	VAN DEN ENDE-GUPTA SYNDROME; VDEGS	600920
GROWTH HORMONE RECEPTOR; GHRGROWTH HORMONE-BINDING PROTEIN, INCLUDED; GHBP, INCLUDED	GROWTH HORMONE RECEPTOR; GHRGROWTH HORMONE-BINDING PROTEIN, INCLUDED; GHBP, INCLUDED	600946
INCREASED RESPONSIVENESS TO GROWTH HORMONE, INCLUDED	GROWTH HORMONE RECEPTOR; GHRGROWTH HORMONE-BINDING PROTEIN, INCLUDED; GHBP, INCLUDED	600946
PROPROTEIN CONVERTASE 1/3 DEFICIENCY	PROPROTEIN CONVERTASE 1/3 DEFICIENCY	600955
OBESITY AND ENDOCRINOPATHY DUE TO IMPAIRED PROCESSING OF PROHORMONES	PROPROTEIN CONVERTASE 1/3 DEFICIENCY	600955
PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC; NEPPK	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC; NEPPK	600962
PPKNE	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC; NEPPK	600962
NONEPIDERMOLYTIC PALMOPLANTAR KERATODERMA	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC; NEPPK	600962
KERATODERMA, NONEPIDERMOLYTIC PALMOPLANTAR	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC; NEPPK	600962
TYLOSIS	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC; NEPPK	600962
DEAFNESS, AUTOSOMAL DOMINANT 6; DFNA6	DEAFNESS, AUTOSOMAL DOMINANT 6; DFNA6	600965
DEAFNESS, AUTOSOMAL DOMINANT 14; DFNA14	DEAFNESS, AUTOSOMAL DOMINANT 6; DFNA6	600965
DEAFNESS, AUTOSOMAL DOMINANT 38; DFNA38	DEAFNESS, AUTOSOMAL DOMINANT 6; DFNA6	600965
EPIPHYSEAL DYSPLASIA, MULTIPLE, 3; EDM3EPIPHYSEAL DYSPLASIA, MULTIPLE, 3, WITH MYOPATHY, INCLUDED	EPIPHYSEAL DYSPLASIA, MULTIPLE, 3; EDM3EPIPHYSEAL DYSPLASIA, MULTIPLE, 3, WITH MYOPATHY, INCLUDED	600969
DEAFNESS, AUTOSOMAL RECESSIVE 6; DFNB6	DEAFNESS, AUTOSOMAL RECESSIVE 6; DFNB6	600971
NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 6; NSRD6	DEAFNESS, AUTOSOMAL RECESSIVE 6; DFNB6	600971
ACHONDROGENESIS, TYPE IB; ACG1B	ACHONDROGENESIS, TYPE IB; ACG1B	600972
ACHONDROGENESIS, FRACCARO TYPE	ACHONDROGENESIS, TYPE IB; ACG1B	600972
DEAFNESS, AUTOSOMAL RECESSIVE 7; DFNB7	DEAFNESS, AUTOSOMAL RECESSIVE 7; DFNB7	600974
DEAFNESS, AUTOSOMAL RECESSIVE 11; DFNB11	DEAFNESS, AUTOSOMAL RECESSIVE 7; DFNB7	600974
GLAUCOMA 3, PRIMARY INFANTILE, B; GLC3B	GLAUCOMA 3, PRIMARY INFANTILE, B; GLC3B	600975
GLAUCOMA, PRIMARY CONGENITAL, TYPE B	GLAUCOMA 3, PRIMARY INFANTILE, B; GLC3B	600975
GLC3, TYPE B	GLAUCOMA 3, PRIMARY INFANTILE, B; GLC3B	600975
CONE-ROD DYSTROPHY 5; CORD5	CONE-ROD DYSTROPHY 5; CORD5	600977
DEAFNESS, AUTOSOMAL DOMINANT 5; DFNA5	DEAFNESS, AUTOSOMAL DOMINANT 5; DFNA5	600994
NEPHROTIC SYNDROME, TYPE 2; NPHS2	NEPHROTIC SYNDROME, TYPE 2; NPHS2	600995
NEPHROTIC SYNDROME, STEROID-RESISTANT, AUTOSOMAL RECESSIVE; SRN1	NEPHROTIC SYNDROME, TYPE 2; NPHS2	600995
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 2; ARVD2	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 2; ARVD2	600996
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 2; ARVC2	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 2; ARVD2	600996
EPIDERMOLYSIS BULLOSA SIMPLEX, AUTOSOMAL RECESSIVE 1; EBSB1	EPIDERMOLYSIS BULLOSA SIMPLEX, AUTOSOMAL RECESSIVE 1; EBSB1	601001
BRODY MYOPATHY	BRODY MYOPATHY	601003
TIMOTHY SYNDROME; TS	TIMOTHY SYNDROME; TS	601005
LONG QT SYNDROME WITH SYNDACTYLY	TIMOTHY SYNDROME; TS	601005
LONG QT SYNDROME 8; LQT8	TIMOTHY SYNDROME; TS	601005
DYSTONIA 9; DYT9	DYSTONIA 9; DYT9	601042
CHOREOATHETOSIS/SPASTICITY, EPISODIC	DYSTONIA 9; DYT9	601042
CSE CHOREOATHETOSIS, PAROXYSMAL, WITH EPISODIC ATAXIA	DYSTONIA 9; DYT9	601042
CHOREOATHETOSIS, KINESIGENIC, WITH EPISODIC ATAXIA AND SPASTICITY	DYSTONIA 9; DYT9	601042
USHER SYNDROME, TYPE ID; USH1DUSHER SYNDROME, TYPE ID/F, CDH23/PCDH15, DIGENIC, INCLUDED	USHER SYNDROME, TYPE ID; USH1DUSHER SYNDROME, TYPE ID/F, CDH23/PCDH15, DIGENIC, INCLUDED	601067
USH1D/F, CDH23/PCDH15, DIGENIC, INCLUDED	USHER SYNDROME, TYPE ID; USH1DUSHER SYNDROME, TYPE ID/F, CDH23/PCDH15, DIGENIC, INCLUDED	601067
EPILEPSY, FAMILIAL ADULT MYOCLONIC, 1; FAME1	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 1; FAME1	601068
BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY 1; BAFME1	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 1; FAME1	601068
CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 1; FCMTE1	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 1; FAME1	601068
DEAFNESS, AUTOSOMAL RECESSIVE 9; DFNB9	DEAFNESS, AUTOSOMAL RECESSIVE 9; DFNB9	601071
NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 9; NSRD9AUDITORY NEUROPATHY, AUTOSOMAL RECESSIVE, 1, INCLUDED; AUNB1, INCLUDED	DEAFNESS, AUTOSOMAL RECESSIVE 9; DFNB9	601071
AUDITORY NEUROPATHY, NONSYNDROMIC RECESSIVE, INCLUDED; NSRAN, INCLUDED	DEAFNESS, AUTOSOMAL RECESSIVE 9; DFNB9	601071
DEAFNESS, AUTOSOMAL RECESSIVE 8; DFNB8	DEAFNESS, AUTOSOMAL RECESSIVE 8; DFNB8	601072
DEAFNESS, AUTOSOMAL RECESSIVE 10; DFNB10	DEAFNESS, AUTOSOMAL RECESSIVE 8; DFNB8	601072
DEAFNESS, CHILDHOOD-ONSET NEUROSENSORY, AUTOSOMAL RECESSIVE 8; DFNB8	DEAFNESS, AUTOSOMAL RECESSIVE 8; DFNB8	601072
NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 8; NSRD8	DEAFNESS, AUTOSOMAL RECESSIVE 8; DFNB8	601072
MULLERIAN DUCT APLASIA, UNILATERAL RENAL AGENESIS, AND CERVICOTHORACICSOMITE ANOMALIES; MURCS	MULLERIAN DUCT APLASIA, UNILATERAL RENAL AGENESIS, AND CERVICOTHORACICSOMITE ANOMALIES; MURCS	601076
MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME, TYPE II	MULLERIAN DUCT APLASIA, UNILATERAL RENAL AGENESIS, AND CERVICOTHORACICSOMITE ANOMALIES; MURCS	601076
MRKH, TYPE II	MULLERIAN DUCT APLASIA, UNILATERAL RENAL AGENESIS, AND CERVICOTHORACICSOMITE ANOMALIES; MURCS	601076
KLIPPEL-FEIL DEFORMITY, CONDUCTIVE DEAFNESS, AND ABSENT VAGINA	MULLERIAN DUCT APLASIA, UNILATERAL RENAL AGENESIS, AND CERVICOTHORACICSOMITE ANOMALIES; MURCS	601076
LATERALITY DEFECTS, AUTOSOMAL DOMINANT	LATERALITY DEFECTS, AUTOSOMAL DOMINANT	601086
AYME-GRIPP SYNDROME; AYGRP	AYME-GRIPP SYNDROME; AYGRP	601088
CATARACTS, CONGENITAL, WITH SENSORINEURAL DEAFNESS, DOWN SYNDROME-LIKEFACIAL APPEARANCE, SHORT STATURE, AND MENTAL RETARDATION	AYME-GRIPP SYNDROME; AYGRP	601088
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1C; CMT1C	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1C; CMT1C	601098
CMT, SLOW NERVE CONDUCTION TYPE C	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1C; CMT1C	601098
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1C	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1C; CMT1C	601098
NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE IC; HMSN1C	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1C; CMT1C	601098
HMSN IC	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1C; CMT1C	601098
TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 3; HHT3	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 3; HHT3	601101
SUPRANUCLEAR PALSY, PROGRESSIVE, 1; PSNP1	SUPRANUCLEAR PALSY, PROGRESSIVE, 1; PSNP1	601104
PSP	SUPRANUCLEAR PALSY, PROGRESSIVE, 1; PSNP1	601104
STEELE-RICHARDSON-OLSZEWSKI SYNDROME	SUPRANUCLEAR PALSY, PROGRESSIVE, 1; PSNP1	601104
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Id; CDG1D	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Id; CDG1D	601110
CDG Id; CDGId	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Id; CDG1D	601110
CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE IV, FORMERLY; CDGS4,FORMERLY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Id; CDG1D	601110
CDGS, TYPE IV, FORMERLY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Id; CDG1D	601110
CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 8; CYP2C8RHABDOMYOLYSIS, CERIVASTATIN-INDUCED, INCLUDED	CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 8; CYP2C8RHABDOMYOLYSIS, CERIVASTATIN-INDUCED, INCLUDED	601129
BRUGADA SYNDROME 1; BRGDA1	BRUGADA SYNDROME 1; BRGDA1	601144
RIGHT BUNDLE BRANCH BLOCK, ST SEGMENT ELEVATION, AND SUDDEN DEATHSYNDROME	BRUGADA SYNDROME 1; BRGDA1	601144
SUDDEN UNEXPLAINED NOCTURNAL DEATH SYNDROME; SUNDSCARDIAC CONDUCTION DEFECT, NONSPECIFIC, INCLUDED	BRUGADA SYNDROME 1; BRGDA1	601144
NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA; HMSN6A	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA; HMSN6A	601152
HMSN VIA	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA; HMSN6A	601152
NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VI; HMSN6	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA; HMSN6A	601152
PERIPHERAL NEUROPATHY AND OPTIC ATROPHY	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA; HMSN6A	601152
CHARCOT-MARIE-TOOTH DISEASE, TYPE 6A; CMT6A	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA; HMSN6A	601152
CHARCOT-MARIE-TOOTH DISEASE, TYPE 6; CMT6	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA; HMSN6A	601152
CARDIOMYOPATHY, DILATED, 1E; CMD1E	CARDIOMYOPATHY, DILATED, 1E; CMD1E	601154
CARDIOMYOPATHY, DILATED, WITH CONDUCTION DISORDER AND ARRHYTHMIA	CARDIOMYOPATHY, DILATED, 1E; CMD1E	601154
CARDIOMYOPATHY, DILATED, WITH CONDUCTION DEFECT 2; CDCD2	CARDIOMYOPATHY, DILATED, 1E; CMD1E	601154
SPASTIC PARAPLEGIA 9A, AUTOSOMAL DOMINANT; SPG9A	SPASTIC PARAPLEGIA 9A, AUTOSOMAL DOMINANT; SPG9A	601162
CATARACTS WITH MOTOR NEURONOPATHY, SHORT STATURE, AND SKELETAL ABNORMALITIES	SPASTIC PARAPLEGIA 9A, AUTOSOMAL DOMINANT; SPG9A	601162
SPASTIC PARAPARESIS WITH AMYOPATHY, CATARACTS, AND GASTROESOPHAGEALREFLUX	SPASTIC PARAPLEGIA 9A, AUTOSOMAL DOMINANT; SPG9A	601162
DIAPHRAGMATIC DEFECTS, LIMB DEFICIENCIES, AND OSSIFICATION DEFECTSOF SKULL	DIAPHRAGMATIC DEFECTS, LIMB DEFICIENCIES, AND OSSIFICATION DEFECTSOF SKULL	601163
FROSTER SYNDROME	DIAPHRAGMATIC DEFECTS, LIMB DEFICIENCIES, AND OSSIFICATION DEFECTSOF SKULL	601163
MICROPHTHALMIA, SYNDROMIC 9; MCOPS9	MICROPHTHALMIA, SYNDROMIC 9; MCOPS9	601186
ANOPHTHALMIA, CLINICAL, WITH MILD FACIAL DYSMORPHISM AND VARIABLEMALFORMATIONS OF THE LUNG, HEART, AND DIAPHRAGM	MICROPHTHALMIA, SYNDROMIC 9; MCOPS9	601186
ANOPHTHALMIA/MICROPHTHALMIA AND PULMONARY HYPOPLASIA	MICROPHTHALMIA, SYNDROMIC 9; MCOPS9	601186
SPEAR SYNDROME	MICROPHTHALMIA, SYNDROMIC 9; MCOPS9	601186
MATTHEW-WOOD SYNDROME	MICROPHTHALMIA, SYNDROMIC 9; MCOPS9	601186
PULMONARY AGENESIS, MICROPHTHALMIA, AND DIAPHRAGMATIC DEFECT; PMDMICROPHTHALMIA, ISOLATED, WITH COLOBOMA 8, INCLUDED; MCOPCB8, INCLUDED	MICROPHTHALMIA, SYNDROMIC 9; MCOPS9	601186
HYPOCALCEMIA, AUTOSOMAL DOMINANT 1; HYPOC1	HYPOCALCEMIA, AUTOSOMAL DOMINANT 1; HYPOC1	601198
HYPERCALCIURIC HYPOCALCEMIA	HYPOCALCEMIA, AUTOSOMAL DOMINANT 1; HYPOC1	601198
HYPOCALCEMIA, FAMILIALHYPOCALCEMIA, AUTOSOMAL DOMINANT 1, WITH BARTTER SYNDROME, INCLUDED	HYPOCALCEMIA, AUTOSOMAL DOMINANT 1; HYPOC1	601198
CALCIUM-SENSING RECEPTOR; CASR	CALCIUM-SENSING RECEPTOR; CASR	601199
PARATHYROID CA(2+)-SENSING RECEPTOR 1; PCAR1HYPERCALCIURIC HYPERCALCEMIA, INCLUDED	CALCIUM-SENSING RECEPTOR; CASR	601199
CALCIUM, SERUM LEVEL OF, INCLUDED	CALCIUM-SENSING RECEPTOR; CASR	601199
PLEUROPULMONARY BLASTOMA; PPB	PLEUROPULMONARY BLASTOMA; PPB	601200
PPB FAMILIAL TUMOR AND DYSPLASIA SYNDROME; PPBFTDS	PLEUROPULMONARY BLASTOMA; PPB	601200
CATARACT 24; CTRCT24	CATARACT 24; CTRCT24	601202
CATARACT 24, ANTERIOR POLAR	CATARACT 24; CTRCT24	601202
CATARACT, ANTERIOR POLAR, 2; CTAA2	CATARACT 24; CTRCT24	601202
DIABETES MELLITUS, INSULIN-DEPENDENT, 11; IDDM11	DIABETES MELLITUS, INSULIN-DEPENDENT, 11; IDDM11	601208
INSULIN-DEPENDENT DIABETES MELLITUS 11	DIABETES MELLITUS, INSULIN-DEPENDENT, 11; IDDM11	601208
NAXOS DISEASE; NXD	NAXOS DISEASE; NXD	601214
CARDIOMYOPATHY, ARRHYTHMOGENIC RIGHT VENTRICULAR, WITH SKIN, HAIR,AND NAIL ABNORMALITIES	NAXOS DISEASE; NXD	601214
MAL DE NAXOS	NAXOS DISEASE; NXD	601214
KERATOSIS PALMOPLANTARIS WITH ARRHYTHMOGENIC CARDIOMYOPATHY	NAXOS DISEASE; NXD	601214
WOOLLY HAIR, PALMOPLANTAR KERATODERMA, AND CARDIAC ABNORMALITIES	NAXOS DISEASE; NXD	601214
PALMOPLANTAR KERATODERMA WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHYAND WOOLLY HAIR	NAXOS DISEASE; NXD	601214
DENTAL ANOMALIES AND SHORT STATURE; DASS	DENTAL ANOMALIES AND SHORT STATURE; DASS	601216
PLATYSPONDYLY WITH AMELOGENESIS IMPERFECTA	DENTAL ANOMALIES AND SHORT STATURE; DASS	601216
TOOTH AGENESIS, SELECTIVE, 6, FORMERLY; STHAG6, FORMERLY	DENTAL ANOMALIES AND SHORT STATURE; DASS	601216
POTOCKI-SHAFFER SYNDROME	POTOCKI-SHAFFER SYNDROME	601224
PSS	POTOCKI-SHAFFER SYNDROME	601224
CHROMOSOME 11p11.2 DELETION SYNDROME	POTOCKI-SHAFFER SYNDROME	601224
PROXIMAL 11p DELETION SYNDROME; P11pDS	POTOCKI-SHAFFER SYNDROME	601224
DEFECT11 SYNDROME	POTOCKI-SHAFFER SYNDROME	601224
POLYPOSIS SYNDROME, HEREDITARY MIXED, 1; HMPS1	POLYPOSIS SYNDROME, HEREDITARY MIXED, 1; HMPS1	601228
CHROMOSOME 15q13-q14 DUPLICATION SYNDROME, 40-KB	POLYPOSIS SYNDROME, HEREDITARY MIXED, 1; HMPS1	601228
COLORECTAL ADENOMA AND CARCINOMA 1; CRAC1COLORECTAL CANCER, SUSCEPTIBILITY TO, 4, INCLUDED; CRCS4, INCLUDED	POLYPOSIS SYNDROME, HEREDITARY MIXED, 1; HMPS1	601228
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 15, INCLUDED	POLYPOSIS SYNDROME, HEREDITARY MIXED, 1; HMPS1	601228
CEREBELLAR ATAXIA, CAYMAN TYPE; ATCAY	CEREBELLAR ATAXIA, CAYMAN TYPE; ATCAY	601238
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4A; ARCI4A	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4A; ARCI4A	601277
ICHTHYOSIS CONGENITA IIB; ICR2B	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4A; ARCI4A	601277
ICHTHYOSIS, LAMELLAR, 2, FORMERLY; LI2, FORMERLY	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4A; ARCI4A	601277
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 1; NIDDM1	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 1; NIDDM1	601283
NONINSULIN-DEPENDENT DIABETES MELLITUS 1	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 1; NIDDM1	601283
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2F; LGMD2F	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2F; LGMD2F	601287
MYELOID TUMOR SUPPRESSOR	MYELOID TUMOR SUPPRESSOR	601308
MYELOID LEUKEMIA-RELATED LOCUS; MLRL	MYELOID TUMOR SUPPRESSOR	601308
DEAFNESS, AUTOSOMAL DOMINANT 10; DFNA10	DEAFNESS, AUTOSOMAL DOMINANT 10; DFNA10	601316
DEAFNESS, AUTOSOMAL DOMINANT 11; DFNA11	DEAFNESS, AUTOSOMAL DOMINANT 11; DFNA11	601317
DIABETES MELLITUS, INSULIN-DEPENDENT, 13; IDDM13	DIABETES MELLITUS, INSULIN-DEPENDENT, 13; IDDM13	601318
INSULIN-DEPENDENT DIABETES MELLITUS 13	DIABETES MELLITUS, INSULIN-DEPENDENT, 13; IDDM13	601318
NEUROFIBROMATOSIS-NOONAN SYNDROME; NFNS	NEUROFIBROMATOSIS-NOONAN SYNDROME; NFNS	601321
NOONAN-NEUROFIBROMATOSIS SYNDROME	NEUROFIBROMATOSIS-NOONAN SYNDROME; NFNS	601321
NEUROFIBROMATOSIS WITH NOONAN PHENOTYPE	NEUROFIBROMATOSIS-NOONAN SYNDROME; NFNS	601321
RENAL DYSPLASIA, CYSTIC, SUSCEPTIBILITY TO; CYSRD	RENAL DYSPLASIA, CYSTIC, SUSCEPTIBILITY TO; CYSRD	601331
CEREBELLAR ATAXIA, AREFLEXIA, PES CAVUS, OPTIC ATROPHY, AND SENSORINEURALHEARING LOSS; CAPOS	CEREBELLAR ATAXIA, AREFLEXIA, PES CAVUS, OPTIC ATROPHY, AND SENSORINEURALHEARING LOSS; CAPOS	601338
MARTINEZ-FRIAS SYNDROME	MARTINEZ-FRIAS SYNDROME	601346
PANCREATIC HYPOPLASIA, INTESTINAL ATRESIA, AND GALLBLADDER APLASIAOR HYPOPLASIA, WITH OR WITHOUT TRACHEOESOPHAGEAL FISTULA	MARTINEZ-FRIAS SYNDROME	601346
MICROPHTHALMIA, SYNDROMIC 8; MCOPS8	MICROPHTHALMIA, SYNDROMIC 8; MCOPS8	601349
MICROCEPHALY, MICROPHTHALMIA, ECTRODACTYLY OF LOWER LIMBS, AND PROGNATHISM;MMEP	MICROPHTHALMIA, SYNDROMIC 8; MCOPS8	601349
BRACHYCEPHALY, DEAFNESS, CATARACT, MICROSTOMIA, AND MENTAL RETARDATION	BRACHYCEPHALY, DEAFNESS, CATARACT, MICROSTOMIA, AND MENTAL RETARDATION	601353
FINE-LUBINSKY SYNDROME	BRACHYCEPHALY, DEAFNESS, CATARACT, MICROSTOMIA, AND MENTAL RETARDATION	601353
LETHAL SHORT-LIMB SKELETAL DYSPLASIA, AL GAZALI TYPE	LETHAL SHORT-LIMB SKELETAL DYSPLASIA, AL GAZALI TYPE	601356
BRACHIAL AMELIA, CLEFT LIP, AND HOLOPROSENCEPHALY; ACLH	BRACHIAL AMELIA, CLEFT LIP, AND HOLOPROSENCEPHALY; ACLH	601357
BRACHIAL AMELIA, FOREBRAIN DEFECTS, AND FACIAL CLEFTS	BRACHIAL AMELIA, CLEFT LIP, AND HOLOPROSENCEPHALY; ACLH	601357
NICOLAIDES-BARAITSER SYNDROME; NCBRS	NICOLAIDES-BARAITSER SYNDROME; NCBRS	601358
SPARSE HAIR AND MENTAL RETARDATION	NICOLAIDES-BARAITSER SYNDROME; NCBRS	601358
NBS	NICOLAIDES-BARAITSER SYNDROME; NCBRS	601358
DIGEORGE SYNDROME/VELOCARDIOFACIAL SYNDROME COMPLEX 2	DIGEORGE SYNDROME/VELOCARDIOFACIAL SYNDROME COMPLEX 2	601362
DGS2	DIGEORGE SYNDROME/VELOCARDIOFACIAL SYNDROME COMPLEX 2	601362
WILMS TUMOR 4	WILMS TUMOR 4	601363
WT4	WILMS TUMOR 4	601363
FAMILIAL WILMS TUMOR 1; FWT1	WILMS TUMOR 4	601363
STROKE, ISCHEMIC	STROKE, ISCHEMIC	601367
CEREBROVASCULAR ACCIDENT	STROKE, ISCHEMIC	601367
CEREBRAL INFARCTION	STROKE, ISCHEMIC	601367
DEAFNESS, AUTOSOMAL DOMINANT 9; DFNA9	DEAFNESS, AUTOSOMAL DOMINANT 9; DFNA9	601369
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B1; CMT4B1	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B1; CMT4B1	601382
CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, WITH FOCALLY FOLDEDMYELIN SHEATHS, AUTOSOMAL RECESSIVE, TYPE 4B1	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B1; CMT4B1	601382
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4B1	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B1; CMT4B1	601382
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B; CMT4B	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B1; CMT4B1	601382
DEAFNESS, AUTOSOMAL RECESSIVE 12; DFNB12	DEAFNESS, AUTOSOMAL RECESSIVE 12; DFNB12	601386
DIABETES MELLITUS, INSULIN-DEPENDENT, 12; IDDM12	DIABETES MELLITUS, INSULIN-DEPENDENT, 12; IDDM12	601388
INSULIN-DEPENDENT DIABETES MELLITUS 12	DIABETES MELLITUS, INSULIN-DEPENDENT, 12; IDDM12	601388
VAN MALDERGEM SYNDROME 1; VMLDS1	VAN MALDERGEM SYNDROME 1; VMLDS1	601390
CEREBROFACIOARTICULAR SYNDROME	VAN MALDERGEM SYNDROME 1; VMLDS1	601390
PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY; FPDMM	PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY; FPDMM	601399
PLATELET DISORDER, ASPIRIN-LIKE	PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY; FPDMM	601399
THROMBOCYTOPENIA, FAMILIAL, WITH PROPENSITY TO ACUTE MYELOGENOUS LEUKEMIA;FPD/AML	PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY; FPDMM	601399
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2; NIDDM2	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2; NIDDM2	601407
NONINSULIN-DEPENDENT DIABETES MELLITUS 2	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2; NIDDM2	601407
DIABETES MELLITUS, TRANSIENT NEONATAL, 1	DIABETES MELLITUS, TRANSIENT NEONATAL, 1	601410
TNDM1	DIABETES MELLITUS, TRANSIENT NEONATAL, 1	601410
TNDM	DIABETES MELLITUS, TRANSIENT NEONATAL, 1	601410
DMTN	DIABETES MELLITUS, TRANSIENT NEONATAL, 1	601410
DEAFNESS, AUTOSOMAL DOMINANT 7; DFNA7	DEAFNESS, AUTOSOMAL DOMINANT 7; DFNA7	601412
RETINITIS PIGMENTOSA 18; RP18	RETINITIS PIGMENTOSA 18; RP18	601414
MYOPATHY, MYOFIBRILLAR, 1; MFM1	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
MYOPATHY, MYOFIBRILLAR, DESMIN-RELATED	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
DESMINOPATHY, PRIMARY	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
DESMIN-RELATED MYOPATHY; DRM	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
MYOFIBRILLAR MYOPATHY WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
DESMIN-RELATED MYOPATHY WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 7, FORMERLY;ARVD7, FORMERLY	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 7, FORMERLY; ARVC7,FORMERLY	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
INCLUSION BODY MYOPATHY 1, AUTOSOMAL DOMINANT, FORMERLY; IBM1, FORMERLY	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
CARDIOMYOPATHY, DILATED, 1F AND LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE1D, FORMERLY	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
CMD1F AND LGMD1D, FORMERLY	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
CARDIOMYOPATHY, DILATED, WITH CONDUCTION DEFECT AND MUSCULAR DYSTROPHY;CDCD3, FORMERLY	MYOPATHY, MYOFIBRILLAR, 1; MFM1	601419
OCULOAURICULOFRONTONASAL SYNDROME; OAFNS	OCULOAURICULOFRONTONASAL SYNDROME; OAFNS	601452
OCULOAURICULOFRONTONASAL DYSPLASIA	OCULOAURICULOFRONTONASAL SYNDROME; OAFNS	601452
PSORIASIS 3, SUSCEPTIBILITY TO; PSORS3	PSORIASIS 3, SUSCEPTIBILITY TO; PSORS3	601454
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4D; CMT4D	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4D; CMT4D	601455
NEUROPATHY, HEREDITARY MOTOR AND SENSORY, LOM TYPE; HMSNL	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4D; CMT4D	601455
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE4D	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4D; CMT4D	601455
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4D	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4D; CMT4D	601455
HMSN4D	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4D; CMT4D	601455
SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-POSITIVE	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-POSITIVE	601457
SCID, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-NEGATIVE, NK CELL-POSITIVE	601457
INFLAMMATORY BOWEL DISEASE 2; IBD2	INFLAMMATORY BOWEL DISEASE 2; IBD2	601458
MYASTHENIC SYNDROME, CONGENITAL, 1A, SLOW-CHANNEL; CMS1A	MYASTHENIC SYNDROME, CONGENITAL, 1A, SLOW-CHANNEL; CMS1A	601462
MYASTHENIC SYNDROME, CONGENITAL, TYPE IIa, FORMERLY; CMS2A, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 1A, SLOW-CHANNEL; CMS1A	601462
CMS IIa, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 1A, SLOW-CHANNEL; CMS1A	601462
FACIAL PARESIS, HEREDITARY CONGENITAL, 1; HCFP1	FACIAL PARESIS, HEREDITARY CONGENITAL, 1; HCFP1	601471
FACIAL PALSY, CONGENITAL, UNILATERAL OR BILATERAL	FACIAL PARESIS, HEREDITARY CONGENITAL, 1; HCFP1	601471
MOEBIUS SYNDROME 2, FORMERLY; MBS2, FORMERLY	FACIAL PARESIS, HEREDITARY CONGENITAL, 1; HCFP1	601471
MOBIUS SYNDROME 2, FORMERLY	FACIAL PARESIS, HEREDITARY CONGENITAL, 1; HCFP1	601471
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D; CMT2D	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D; CMT2D	601472
CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2D	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D; CMT2D	601472
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2D	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D; CMT2D	601472
MUCOPOLYSACCHARIDOSIS, TYPE IX; MPS9	MUCOPOLYSACCHARIDOSIS, TYPE IX; MPS9	601492
MPS IX	MUCOPOLYSACCHARIDOSIS, TYPE IX; MPS9	601492
HYALURONIDASE DEFICIENCY	MUCOPOLYSACCHARIDOSIS, TYPE IX; MPS9	601492
CARDIOMYOPATHY, DILATED, 1C, WITH OR WITHOUT LEFT VENTRICULAR NONCOMPACTION;CMD1CLEFT VENTRICULAR NONCOMPACTION 3, INCLUDED; LVNC3, INCLUDED	CARDIOMYOPATHY, DILATED, 1C, WITH OR WITHOUT LEFT VENTRICULAR NONCOMPACTION;CMD1CLEFT VENTRICULAR NONCOMPACTION 3, INCLUDED; LVNC3, INCLUDED	601493
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 24, INCLUDED; CMH24, INCLUDED	CARDIOMYOPATHY, DILATED, 1C, WITH OR WITHOUT LEFT VENTRICULAR NONCOMPACTION;CMD1CLEFT VENTRICULAR NONCOMPACTION 3, INCLUDED; LVNC3, INCLUDED	601493
CARDIOMYOPATHY, DILATED, 1D; CMD1D	CARDIOMYOPATHY, DILATED, 1D; CMD1D	601494
LEFT VENTRICULAR NONCOMPACTION 6, INCLUDED; LVNC6, INCLUDED	CARDIOMYOPATHY, DILATED, 1D; CMD1D	601494
AGAMMAGLOBULINEMIA 1, AUTOSOMAL RECESSIVE; AGM1	AGAMMAGLOBULINEMIA 1, AUTOSOMAL RECESSIVE; AGM1	601495
AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO IGHM DEFECT	AGAMMAGLOBULINEMIA 1, AUTOSOMAL RECESSIVE; AGM1	601495
AXENFELD-RIEGER SYNDROME, TYPE 2; RIEG2	AXENFELD-RIEGER SYNDROME, TYPE 2; RIEG2	601499
RIEGER SYNDROME, TYPE 2	AXENFELD-RIEGER SYNDROME, TYPE 2; RIEG2	601499
PROSTATE CANCER, HEREDITARY, 1; HPC1	PROSTATE CANCER, HEREDITARY, 1; HPC1	601518
PRCA1	PROSTATE CANCER, HEREDITARY, 1; HPC1	601518
ATHABASKAN BRAINSTEM DYSGENESIS SYNDROME; ABDS	ATHABASKAN BRAINSTEM DYSGENESIS SYNDROME; ABDS	601536
NAVAJO BRAINSTEM SYNDROMEBOSLEY-SALIH-ALORAINY SYNDROME, INCLUDED; BSAS, INCLUDED	ATHABASKAN BRAINSTEM DYSGENESIS SYNDROME; ABDS	601536
MICROCEPHALY, RETINITIS PIGMENTOSA, AND SUTURAL CATARACT	MICROCEPHALY, RETINITIS PIGMENTOSA, AND SUTURAL CATARACT	601537
PEROXISOME BIOGENESIS DISORDER 1B; PBD1B	PEROXISOME BIOGENESIS DISORDER 1B; PBD1B	601539
PEROXISOME BIOGENESIS DISORDER (NEONATAL ADRENOLEUKODYSTROPHY/INFANTILEREFSUM DISEASE)	PEROXISOME BIOGENESIS DISORDER 1B; PBD1B	601539
PEROXISOME BIOGENESIS DISORDER (NALD/IRD)	PEROXISOME BIOGENESIS DISORDER 1B; PBD1B	601539
ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL	PEROXISOME BIOGENESIS DISORDER 1B; PBD1B	601539
REFSUM DISEASE, INFANTILE	PEROXISOME BIOGENESIS DISORDER 1B; PBD1B	601539
INFANTILE PHYTANIC ACID STORAGE DISEASE	PEROXISOME BIOGENESIS DISORDER 1B; PBD1B	601539
DEAFNESS, AUTOSOMAL DOMINANT 12; DFNA12	DEAFNESS, AUTOSOMAL DOMINANT 12; DFNA12	601543
DEAFNESS, AUTOSOMAL DOMINANT 8; DFNA8	DEAFNESS, AUTOSOMAL DOMINANT 12; DFNA12	601543
DEAFNESS, AUTOSOMAL DOMINANT 3A; DFNA3A	DEAFNESS, AUTOSOMAL DOMINANT 3A; DFNA3A	601544
CATARACT 3, MULTIPLE TYPES; CTRCT3	CATARACT 3, MULTIPLE TYPES; CTRCT3	601547
CATARACT 3, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA	CATARACT 3, MULTIPLE TYPES; CTRCT3	601547
CATARACT, CONGENITAL, CERULEAN TYPE, 2; CCA2	CATARACT 3, MULTIPLE TYPES; CTRCT3	601547
ALACRIMA, CONGENITAL, AUTOSOMAL RECESSIVE	ALACRIMA, CONGENITAL, AUTOSOMAL RECESSIVE	601549
BLOOD GROUP--SWANN SYSTEM; SW	BLOOD GROUP--SWANN SYSTEM; SW	601550
SWANN BLOOD GROUP	BLOOD GROUP--SWANN SYSTEM; SW	601550
BLOOD GROUP--FROESE	BLOOD GROUP--FROESE	601551
FR	BLOOD GROUP--FROESE	601551
FROESE BLOOD GROUP ANTIGEN	BLOOD GROUP--FROESE	601551
FACIAL DYSMORPHISM, LENS DISLOCATION, ANTERIOR SEGMENT ABNORMALITIES,AND SPONTANEOUS FILTERING BLEBS; FDLAB	FACIAL DYSMORPHISM, LENS DISLOCATION, ANTERIOR SEGMENT ABNORMALITIES,AND SPONTANEOUS FILTERING BLEBS; FDLAB	601552
TRABOULSI SYNDROME	FACIAL DYSMORPHISM, LENS DISLOCATION, ANTERIOR SEGMENT ABNORMALITIES,AND SPONTANEOUS FILTERING BLEBS; FDLAB	601552
ECTOPIA LENTIS, SPONTANEOUS FILTERING BLEBS, AND CRANIOFACIAL DYSMORPHISM	FACIAL DYSMORPHISM, LENS DISLOCATION, ANTERIOR SEGMENT ABNORMALITIES,AND SPONTANEOUS FILTERING BLEBS; FDLAB	601552
HYPOTRICHOSIS, CONGENITAL, WITH JUVENILE MACULAR DYSTROPHY; HJMD	HYPOTRICHOSIS, CONGENITAL, WITH JUVENILE MACULAR DYSTROPHY; HJMD	601553
HYPOTRICHOSIS WITH CONE-ROD DYSTROPHY	HYPOTRICHOSIS, CONGENITAL, WITH JUVENILE MACULAR DYSTROPHY; HJMD	601553
STUVE-WIEDEMANN SYNDROME	STUVE-WIEDEMANN SYNDROME	601559
STWS; SWS	STUVE-WIEDEMANN SYNDROME	601559
SCHWARTZ-JAMPEL SYNDROME, TYPE 2; SJS2	STUVE-WIEDEMANN SYNDROME	601559
SCHWARTZ-JAMPEL SYNDROME, NEONATAL	STUVE-WIEDEMANN SYNDROME	601559
STUVE-WIEDEMANN/SCHWARTZ-JAMPEL TYPE 2 SYNDROME	STUVE-WIEDEMANN SYNDROME	601559
WILMS TUMOR 5; WT5	WILMS TUMOR 5; WT5	601583
WILMS TUMOR, SUSCEPTIBILITY TO; WTSL	WILMS TUMOR 5; WT5	601583
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4C; CMT4C	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4C; CMT4C	601596
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE4C	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4C; CMT4C	601596
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4C	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4C; CMT4C	601596
TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1	TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1	601606
MFT1	TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1	601606
EPITHELIOMA ADENOIDES CYSTICUM OF BROOKE; EAC	TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1	601606
EPITHELIOMA, HEREDITARY MULTIPLE BENIGN CYSTIC	TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1	601606
BROOKE-FORDYCE TRICHOEPITHELIOMAS	TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1	601606
LUNG AGENESIS, CONGENITAL HEART DEFECTS, AND THUMB ANOMALIES SYNDROME;LACHT	LUNG AGENESIS, CONGENITAL HEART DEFECTS, AND THUMB ANOMALIES SYNDROME;LACHT	601612
MARDINI-NYHAN ASSOCIATION	LUNG AGENESIS, CONGENITAL HEART DEFECTS, AND THUMB ANOMALIES SYNDROME;LACHT	601612
IRIS PIGMENT EPITHELIUM ANOMALIES	IRIS PIGMENT EPITHELIUM ANOMALIES	601616
RUFFLES AND CYSTS OF IRIS PIGMENT EPITHELIUM	IRIS PIGMENT EPITHELIUM ANOMALIES	601616
CYSTS OF IRIS PIGMENT EPITHELIUM	IRIS PIGMENT EPITHELIUM ANOMALIES	601616
LEUKEMIA, ACUTE MYELOID; AML	LEUKEMIA, ACUTE MYELOID; AML	601626
LEUKEMIA, ACUTE MYELOGENOUSLEUKEMIA, ACUTE MYELOID, SUSCEPTIBILITY TO, INCLUDED	LEUKEMIA, ACUTE MYELOID; AML	601626
IRIDOGONIODYSGENESIS, TYPE 1; IRID1	IRIDOGONIODYSGENESIS, TYPE 1; IRID1	601631
IRIDOGONIODYSGENESIS ANOMALY, AUTOSOMAL DOMINANT; IGDAIRIS HYPOPLASIA WITH GLAUCOMA, INCLUDED	IRIDOGONIODYSGENESIS, TYPE 1; IRID1	601631
GLAUCOMA IRIDOGONIODYSPLASIA, FAMILIAL, INCLUDED	IRIDOGONIODYSGENESIS, TYPE 1; IRID1	601631
NEURAL TUBE DEFECTS, FOLATE-SENSITIVE; NTDFS	NEURAL TUBE DEFECTS, FOLATE-SENSITIVE; NTDFS	601634
NTD, FOLATE-SENSITIVESPINA BIFIDA, FOLATE-SENSITIVE, INCLUDED	NEURAL TUBE DEFECTS, FOLATE-SENSITIVE; NTDFS	601634
PARAGANGLIOMAS 2; PGL2	PARAGANGLIOMAS 2; PGL2	601650
GLOMUS TUMORS, FAMILIAL, 2	PARAGANGLIOMAS 2; PGL2	601650
OBESITYLEANNESS, INCLUDED	OBESITYLEANNESS, INCLUDED	601665
DIABETES MELLITUS, INSULIN-DEPENDENT, 15; IDDM15	DIABETES MELLITUS, INSULIN-DEPENDENT, 15; IDDM15	601666
INSULIN-DEPENDENT DIABETES MELLITUS 15	DIABETES MELLITUS, INSULIN-DEPENDENT, 15; IDDM15	601666
TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE; TTD1	TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE; TTD1	601675
TRICHOTHIODYSTROPHY, PHOTOSENSITIVE; TTDP	TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE; TTD1	601675
ICHTHYOSIFORM ERYTHRODERMA WITH HAIR ABNORMALITY AND MENTAL AND GROWTHRETARDATION	TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE; TTD1	601675
TAY SYNDROME	TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE; TTD1	601675
TRICHOTHIODYSTROPHY WITH CONGENITAL ICHTHYOSIS; ICHTHYOSIS, CONGENITAL,WITH TRICHOTHIODYSTROPHY	TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE; TTD1	601675
PIBIDS SYNDROME	TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE; TTD1	601675
ACUTE INSULIN RESPONSE	ACUTE INSULIN RESPONSE	601676
AIR	ACUTE INSULIN RESPONSE	601676
BARTTER SYNDROME, ANTENATAL, TYPE 1	BARTTER SYNDROME, ANTENATAL, TYPE 1	601678
HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA, ANTENATAL, 1	BARTTER SYNDROME, ANTENATAL, TYPE 1	601678
HYPERPROSTAGLANDIN E SYNDROME 1	BARTTER SYNDROME, ANTENATAL, TYPE 1	601678
ARTHROGRYPOSIS, DISTAL, TYPE 2B; DA2B	ARTHROGRYPOSIS, DISTAL, TYPE 2B; DA2B	601680
ARTHROGRYPOSIS MULTIPLEX CONGENITA, DISTAL, TYPE 2B	ARTHROGRYPOSIS, DISTAL, TYPE 2B; DA2B	601680
SHELDON-HALL SYNDROME; SHS	ARTHROGRYPOSIS, DISTAL, TYPE 2B; DA2B	601680
FREEMAN-SHELDON SYNDROME VARIANT; FSSV	ARTHROGRYPOSIS, DISTAL, TYPE 2B; DA2B	601680
ARTHROGRYPOSIS MULTIPLEX CONGENITA, DISTAL, TYPE II, WITH CRANIOFACIALABNORMALITIES	ARTHROGRYPOSIS, DISTAL, TYPE 2B; DA2B	601680
GLAUCOMA 1, PRIMARY OPEN ANGLE, C; GLC1C	GLAUCOMA 1, PRIMARY OPEN ANGLE, C; GLC1C	601682
LEPTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; LEPQTL1	LEPTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; LEPQTL1	601694
LSL	LEPTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; LEPQTL1	601694
SEBACEOUS GLAND HYPERPLASIA, FAMILIAL PRESENILE	SEBACEOUS GLAND HYPERPLASIA, FAMILIAL PRESENILE	601700
T-CELL IMMUNODEFICIENCY, CONGENITAL ALOPECIA, AND NAIL DYSTROPHY	T-CELL IMMUNODEFICIENCY, CONGENITAL ALOPECIA, AND NAIL DYSTROPHY	601705
QUEBEC PLATELET DISORDER; QPD	QUEBEC PLATELET DISORDER; QPD	601709
BLEEDING DISORDER, PLATELET-TYPE, 5; BDPLT5	QUEBEC PLATELET DISORDER; QPD	601709
FACTOR V QUEBEC	QUEBEC PLATELET DISORDER; QPD	601709
RETINITIS PIGMENTOSA 19; RP19	RETINITIS PIGMENTOSA 19; RP19	601718
PHOSPHATASE AND TENSIN HOMOLOG; PTEN	PHOSPHATASE AND TENSIN HOMOLOG; PTEN	601728
PTEN1	PHOSPHATASE AND TENSIN HOMOLOG; PTEN	601728
MUTATED IN MULTIPLE ADVANCED CANCERS 1; MMAC1	PHOSPHATASE AND TENSIN HOMOLOG; PTEN	601728
PHOSPHATASE AND TENSIN HOMOLOG DELETED ON CHROMOSOME 10PTEN HAMARTOMA TUMOR SYNDROME, INCLUDED; PHTS, INCLUDED	PHOSPHATASE AND TENSIN HOMOLOG; PTEN	601728
PTEN HAMARTOMA TUMOR SYNDROME WITH GRANULAR CELL TUMOR, INCLUDED	PHOSPHATASE AND TENSIN HOMOLOG; PTEN	601728
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 1; SLEB1SYSTEMIC LUPUS ERYTHEMATOSUS, RESISTANCE TO, 1, INCLUDED	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 1; SLEB1SYSTEMIC LUPUS ERYTHEMATOSUS, RESISTANCE TO, 1, INCLUDED	601744
SEIZURES, BENIGN FAMILIAL INFANTILE, 1; BFIS1	SEIZURES, BENIGN FAMILIAL INFANTILE, 1; BFIS1	601764
CONVULSIONS, BENIGN FAMILIAL INFANTILE, 1; BFIC1	SEIZURES, BENIGN FAMILIAL INFANTILE, 1; BFIS1	601764
EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE 1; EDSMC1	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE 1; EDSMC1	601776
EDSMC	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE 1; EDSMC1	601776
ADDUCTED THUMB, CLUBFOOT, AND PROGRESSIVE JOINT AND SKIN LAXITY SYNDROME	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE 1; EDSMC1	601776
EHLERS-DANLOS SYNDROME, TYPE VIB, FORMERLY; EDS6B, FORMERLY	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE 1; EDSMC1	601776
ADDUCTED THUMB-CLUBFOOT SYNDROME; ATCS	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE 1; EDSMC1	601776
DUNDAR SYNDROME	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE 1; EDSMC1	601776
ARTHROGRYPOSIS, DISTAL, WITH PECULIAR FACIES AND HYDRONEPHROSIS	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE 1; EDSMC1	601776
CONE-ROD DYSTROPHY 6; CORD6	CONE-ROD DYSTROPHY 6; CORD6	601777
RETINAL CONE DYSTROPHY 2; RCD2	CONE-ROD DYSTROPHY 6; CORD6	601777
CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6	CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6	601780
CEROID LIPOFUSCINOSIS, NEURONAL, 6, VARIABLE AGE AT ONSETNEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, VARIANT, INCLUDED;vLINCL, INCLUDED	CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6	601780
COLOBOMA-OBESITY-HYPOGENITALISM-MENTAL RETARDATION SYNDROME	COLOBOMA-OBESITY-HYPOGENITALISM-MENTAL RETARDATION SYNDROME	601794
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3	601800
SKIN/HAIR/EYE PIGMENTATION 3, LIGHT/DARK SKIN	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3	601800
SKIN/HAIR/EYE PIGMENTATION 3, FRECKLING	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3	601800
SKIN/HAIR/EYE PIGMENTATION 3, BLUE/GREEN EYE COLOR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3	601800
EYE COLOR 1; EYCL1	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3	601800
EYE COLOR, GREEN/BLUE; GEYMELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8, INCLUDED	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3	601800
PALLISTER-KILLIAN SYNDROME; PKS	PALLISTER-KILLIAN SYNDROME; PKS	601803
TETRASOMY 12p, MOSAIC	PALLISTER-KILLIAN SYNDROME; PKS	601803
ISOCHROMOSOME 12p SYNDROMEHEXASOMY 12p, MOSAIC, INCLUDED	PALLISTER-KILLIAN SYNDROME; PKS	601803
CHROMOSOME 18q DELETION SYNDROME	CHROMOSOME 18q DELETION SYNDROME	601808
CHROMOSOME 18q- SYNDROME	CHROMOSOME 18q DELETION SYNDROME	601808
18q- SYNDROME	CHROMOSOME 18q DELETION SYNDROME	601808
PREMATURE AGING SYNDROME, PENTTINEN TYPE; PENTT	PREMATURE AGING SYNDROME, PENTTINEN TYPE; PENTT	601812
EXUDATIVE VITREORETINOPATHY 4; EVR4	EXUDATIVE VITREORETINOPATHY 4; EVR4	601813
PHOSPHOGLYCERATE DEHYDROGENASE DEFICIENCY; PHGDHD	PHOSPHOGLYCERATE DEHYDROGENASE DEFICIENCY; PHGDHD	601815
PHGDH DEFICIENCY	PHOSPHOGLYCERATE DEHYDROGENASE DEFICIENCY; PHGDHD	601815
BILIRUBIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; BILIQTL1	BILIRUBIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; BILIQTL1	601816
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2	601820
PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PHHI	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2	601820
HYPERINSULINEMIC HYPOGLYCEMIA, PERSISTENT	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2	601820
HYPERINSULINEMIC HYPOGLYCEMIA DUE TO FOCAL ADENOMATOUS HYPERPLASIA	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2	601820
HYPERINSULINISM, NEONATAL	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2	601820
HYPERINSULINISM, CONGENITAL	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2	601820
HYPERINSULINISM, FAMILIAL	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2	601820
NESIDIOBLASTOSIS	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2	601820
VACUOLAR NEUROMYOPATHY	VACUOLAR NEUROMYOPATHY	601846
MUSCULAR DYSTROPHY, AUTOSOMAL DOMINANT, WITH RIMMED VACUOLES; MDRV	VACUOLAR NEUROMYOPATHY	601846
CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 2; PFIC2	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 2; PFIC2	601847
GOMEZ-LOPEZ-HERNANDEZ SYNDROME; GLHS	GOMEZ-LOPEZ-HERNANDEZ SYNDROME; GLHS	601853
CEREBELLOTRIGEMINAL DERMAL DYSPLASIA CEREBELLO-TRIGEMINAL-DERMAL DYSPLASIA	GOMEZ-LOPEZ-HERNANDEZ SYNDROME; GLHS	601853
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS	601859
CANALE-SMITH SYNDROME	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS	601859
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE I, AUTOSOMAL DOMINANTAUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, INCLUDED; ALPS1A,INCLUDED	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS	601859
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, INCLUDED; ALPS1B,INCLUDED	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS	601859
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE I, AUTOSOMAL RECESSIVE,INCLUDED	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS	601859
DEAFNESS, AUTOSOMAL DOMINANT 13; DFNA13	DEAFNESS, AUTOSOMAL DOMINANT 13; DFNA13	601868
DEAFNESS, AUTOSOMAL RECESSIVE 15; DFNB15	DEAFNESS, AUTOSOMAL RECESSIVE 15; DFNB15	601869
DEAFNESS, AUTOSOMAL RECESSIVE 72; DFNB72	DEAFNESS, AUTOSOMAL RECESSIVE 15; DFNB15	601869
DEAFNESS, AUTOSOMAL RECESSIVE 95; DFNB95	DEAFNESS, AUTOSOMAL RECESSIVE 15; DFNB15	601869
LEFT-RIGHT DETERMINATION FACTOR 2; LEFTY2	LEFT-RIGHT DETERMINATION FACTOR 2; LEFTY2	601877
ENDOMETRIAL BLEEDING-ASSOCIATED FACTOR; EBAF	LEFT-RIGHT DETERMINATION FACTOR 2; LEFTY2	601877
LEFT-RIGHT DETERMINATION, FACTOR A; LEFTA	LEFT-RIGHT DETERMINATION FACTOR 2; LEFTY2	601877
LEFTY A	LEFT-RIGHT DETERMINATION FACTOR 2; LEFTY2	601877
LEFTY2, MOUSE, HOMOLOG OF	LEFT-RIGHT DETERMINATION FACTOR 2; LEFTY2	601877
LEFTY2 TRANSFORMING GROWTH FACTOR, BETA-4; TGFB4LEFT-RIGHT AXIS MALFORMATIONS, INCLUDED	LEFT-RIGHT DETERMINATION FACTOR 2; LEFTY2	601877
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 1; BMND1HIGH BONE MASS, INCLUDED; HBM, INCLUDED	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 1; BMND1HIGH BONE MASS, INCLUDED; HBM, INCLUDED	601884
OSTEOPOROSIS, SUSCEPTIBILITY TO, INCLUDED	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 1; BMND1HIGH BONE MASS, INCLUDED; HBM, INCLUDED	601884
CATARACT 14, MULTIPLE TYPES; CTRCT14	CATARACT 14, MULTIPLE TYPES; CTRCT14	601885
CATARACT, ZONULAR PULVERULENT 3; CZP3	CATARACT 14, MULTIPLE TYPES; CTRCT14	601885
CAE3	CATARACT 14, MULTIPLE TYPES; CTRCT14	601885
MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 5	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 5	601887
MHS5	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 5	601887
MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 6	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 6	601888
MHS6	MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 6	601888
GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 2; GFND2	GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 2; GFND2	601894
GLOMERULAR NEPHRITIS, FAMILIAL, WITH FIBRONECTIN DEPOSITS	GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 2; GFND2	601894
FIBRONECTIN GLOMERULOPATHY	GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 2; GFND2	601894
JAGGED 1; JAG1	JAGGED 1; JAG1	601920
JAGL1DEAFNESS, CONGENITAL HEART DEFECTS, AND POSTERIOR EMBRYOTOXON, INCLUDED	JAGGED 1; JAG1	601920
LYMPHEDEMA, CARDIAC SEPTAL DEFECTS, AND CHARACTERISTIC FACIES	LYMPHEDEMA, CARDIAC SEPTAL DEFECTS, AND CHARACTERISTIC FACIES	601927
IRONS-BIANCHI SYNDROME	LYMPHEDEMA, CARDIAC SEPTAL DEFECTS, AND CHARACTERISTIC FACIES	601927
LYMPHEDEMA, ATRIAL SEPTAL DEFECT, AND CHARACTERISTIC FACIES	LYMPHEDEMA, CARDIAC SEPTAL DEFECTS, AND CHARACTERISTIC FACIES	601927
DIABETES MELLITUS, INSULIN-DEPENDENT, 6; IDDM6	DIABETES MELLITUS, INSULIN-DEPENDENT, 6; IDDM6	601941
INSULIN-DEPENDENT DIABETES MELLITUS 6AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 5, INCLUDED; AITD5,INCLUDED	DIABETES MELLITUS, INSULIN-DEPENDENT, 6; IDDM6	601941
DIABETES MELLITUS, INSULIN-DEPENDENT, 10; IDDM10	DIABETES MELLITUS, INSULIN-DEPENDENT, 10; IDDM10	601942
INSULIN-DEPENDENT DIABETES MELLITUS 10	DIABETES MELLITUS, INSULIN-DEPENDENT, 10; IDDM10	601942
KERATOSIS LINEARIS WITH ICHTHYOSIS CONGENITA AND SCLEROSING KERATODERMA	KERATOSIS LINEARIS WITH ICHTHYOSIS CONGENITA AND SCLEROSING KERATODERMA	601952
KLICK SYNDROME	KERATOSIS LINEARIS WITH ICHTHYOSIS CONGENITA AND SCLEROSING KERATODERMA	601952
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2G; LGMD2G	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2G; LGMD2G	601954
THROMBOCYTHEMIA 2; THCYT2	THROMBOCYTHEMIA 2; THCYT2	601977
FRIEDREICH ATAXIA 2; FRDA2	FRIEDREICH ATAXIA 2; FRDA2	601992
HYPOMAGNESEMIA 1, INTESTINAL; HOMG1	HYPOMAGNESEMIA 1, INTESTINAL; HOMG1	602014
HOMG	HYPOMAGNESEMIA 1, INTESTINAL; HOMG1	602014
HYPOMAGNESEMIA WITH SECONDARY HYPOCALCEMIA; HSH	HYPOMAGNESEMIA 1, INTESTINAL; HOMG1	602014
HYPOMAGNESEMIC TETANY	HYPOMAGNESEMIA 1, INTESTINAL; HOMG1	602014
HYPOMAGNESEMIA, INTESTINAL, WITH SECONDARY HYPOCALCEMIA	HYPOMAGNESEMIA 1, INTESTINAL; HOMG1	602014
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 9; BMIQ9	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 9; BMIQ9	602025
OBESITY, SUSCEPTIBILITY TO	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 9; BMIQ9	602025
ECTODERMAL DYSPLASIA 4, HAIR/NAIL TYPE; ECTD4	ECTODERMAL DYSPLASIA 4, HAIR/NAIL TYPE; ECTD4	602032
ECTODERMAL DYSPLASIA, 'PURE' HAIR/NAIL TYPE	ECTODERMAL DYSPLASIA 4, HAIR/NAIL TYPE; ECTD4	602032
CONVULSIONS, FAMILIAL INFANTILE, WITH PAROXYSMAL CHOREOATHETOSIS;ICCA	CONVULSIONS, FAMILIAL INFANTILE, WITH PAROXYSMAL CHOREOATHETOSIS;ICCA	602066
INFANTILE CONVULSIONS AND PAROXYSMAL CHOREOATHETOSIS, FAMILIAL	CONVULSIONS, FAMILIAL INFANTILE, WITH PAROXYSMAL CHOREOATHETOSIS;ICCA	602066
ICCA SYNDROME	CONVULSIONS, FAMILIAL INFANTILE, WITH PAROXYSMAL CHOREOATHETOSIS;ICCA	602066
PAROXYSMAL KINESIGENIC DYSKINESIA WITH INFANTILE CONVULSIONS; PKD/IC	CONVULSIONS, FAMILIAL INFANTILE, WITH PAROXYSMAL CHOREOATHETOSIS;ICCA	602066
BROAD TERMINAL PHALANGES, FAMILIAL	BROAD TERMINAL PHALANGES, FAMILIAL	602071
FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 2; CFEOM2	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 2; CFEOM2	602078
FEOM2 LOCUS	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 2; CFEOM2	602078
FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, AUTOSOMAL RECESSIVE	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 2; CFEOM2	602078
TRIMETHYLAMINURIA; TMAU	TRIMETHYLAMINURIA; TMAU	602079
FISH-ODOR SYNDROME	TRIMETHYLAMINURIA; TMAU	602079
PAGET DISEASE OF BONE 2, EARLY-ONSET; PDB2	PAGET DISEASE OF BONE 2, EARLY-ONSET; PDB2	602080
SPEECH-LANGUAGE DISORDER 1; SPCH1	SPEECH-LANGUAGE DISORDER 1; SPCH1	602081
CHILDHOOD APRAXIA OF SPEECH; CAS	SPEECH-LANGUAGE DISORDER 1; SPCH1	602081
DEVELOPMENTAL VERBAL DYSPRAXIA; DVD	SPEECH-LANGUAGE DISORDER 1; SPCH1	602081
SPEECH AND LANGUAGE DISORDER WITH OROFACIAL DYSPRAXIA	SPEECH-LANGUAGE DISORDER 1; SPCH1	602081
CORNEAL DYSTROPHY, THIEL-BEHNKE TYPE; CDTB	CORNEAL DYSTROPHY, THIEL-BEHNKE TYPE; CDTB	602082
THIEL-BEHNKE CORNEAL DYSTROPHY; TBCD	CORNEAL DYSTROPHY, THIEL-BEHNKE TYPE; CDTB	602082
CORNEAL DYSTROPHY OF BOWMAN LAYER, TYPE II; CDB2	CORNEAL DYSTROPHY, THIEL-BEHNKE TYPE; CDTB	602082
CORNEAL DYSTROPHY, HONEYCOMB-SHAPED	CORNEAL DYSTROPHY, THIEL-BEHNKE TYPE; CDTB	602082
USHER SYNDROME, TYPE IF; USH1F	USHER SYNDROME, TYPE IF; USH1F	602083
POLYDACTYLY, POSTAXIAL, TYPE A2; PAPA2	POLYDACTYLY, POSTAXIAL, TYPE A2; PAPA2	602085
POSTAXIAL POLYDACTYLY, TYPE A2	POLYDACTYLY, POSTAXIAL, TYPE A2; PAPA2	602085
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 3; ARVD3	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 3; ARVD3	602086
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 3; ARVC3	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 3; ARVD3	602086
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 4; ARVD4	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 4; ARVD4	602087
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 4; ARVC4	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 4; ARVD4	602087
NEPHRONOPHTHISIS 2; NPHP2	NEPHRONOPHTHISIS 2; NPHP2	602088
NPH2	NEPHRONOPHTHISIS 2; NPHP2	602088
HEMANGIOMA, CAPILLARY INFANTILE	HEMANGIOMA, CAPILLARY INFANTILE	602089
HCI	HEMANGIOMA, CAPILLARY INFANTILE	602089
HEMANGIOMA, HEREDITARY CAPILLARY	HEMANGIOMA, CAPILLARY INFANTILE	602089
DEAFNESS, AUTOSOMAL RECESSIVE 18A; DFNB18A	DEAFNESS, AUTOSOMAL RECESSIVE 18A; DFNB18A	602092
DEAFNESS, AUTOSOMAL RECESSIVE 18; DFNB18	DEAFNESS, AUTOSOMAL RECESSIVE 18A; DFNB18A	602092
CONE DYSTROPHY 3; COD3	CONE DYSTROPHY 3; COD3	602093
RETINAL CONE DYSTROPHYCONE-ROD DYSTROPHY 14, INCLUDED; CORD14, INCLUDED	CONE DYSTROPHY 3; COD3	602093
ALZHEIMER DISEASE 5	ALZHEIMER DISEASE 5	602096
AD5	ALZHEIMER DISEASE 5	602096
ALZHEIMER DISEASE, FAMILIAL, 5	ALZHEIMER DISEASE 5	602096
USHER SYNDROME, TYPE IE; USH1E	USHER SYNDROME, TYPE IE; USH1E	602097
AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE; ALS5	AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE; ALS5	602099
SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MISSOURI TYPE	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MISSOURI TYPE	602111
SEMD, MISSOURI TYPEMETAPHYSEAL ANADYSPLASIA 1, INCLUDED; MANDP1, INCLUDED	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MISSOURI TYPE	602111
DYSTONIA 7, TORSION; DYT7	DYSTONIA 7, TORSION; DYT7	602124
TORSION DYSTONIA, FOCAL ADULT-ONSETCERVICAL DYSTONIA, PRIMARY, INCLUDED	DYSTONIA 7, TORSION; DYT7	602124
TREMOR, HEREDITARY ESSENTIAL, 2; ETM2	TREMOR, HEREDITARY ESSENTIAL, 2; ETM2	602134
PIERRE ROBIN SEQUENCE WITH PECTUS EXCAVATUM AND RIB AND SCAPULAR ANOMALIES	PIERRE ROBIN SEQUENCE WITH PECTUS EXCAVATUM AND RIB AND SCAPULAR ANOMALIES	602196
SKELETAL DYSPLASIA RELATED TO CAMPOMELIC DYSPLASIA	PIERRE ROBIN SEQUENCE WITH PECTUS EXCAVATUM AND RIB AND SCAPULAR ANOMALIES	602196
CAMPOMELIC DYSPLASIA, MILD	PIERRE ROBIN SEQUENCE WITH PECTUS EXCAVATUM AND RIB AND SCAPULAR ANOMALIES	602196
MEDIUM CHAIN 3-KETOACYL-CoA THIOLASE DEFICIENCY	MEDIUM CHAIN 3-KETOACYL-CoA THIOLASE DEFICIENCY	602199
MCKAT DEFICIENCY	MEDIUM CHAIN 3-KETOACYL-CoA THIOLASE DEFICIENCY	602199
VENTRICULOMEGALY WITH DEFECTS OF THE RADIUS AND KIDNEY	VENTRICULOMEGALY WITH DEFECTS OF THE RADIUS AND KIDNEY	602200
XANTHOMATOSIS, SUSCEPTIBILITY TO	XANTHOMATOSIS, SUSCEPTIBILITY TO	602247
MALIGNANT ATROPHIC PAPULOSIS	MALIGNANT ATROPHIC PAPULOSIS	602248
DEGOS DISEASE	MALIGNANT ATROPHIC PAPULOSIS	602248
PAPULOSIS, MALIGNANT ATROPHIC	MALIGNANT ATROPHIC PAPULOSIS	602248
PLANTAR LIPOMATOSIS, UNUSUAL FACIES, AND DEVELOPMENTAL DELAY	PLANTAR LIPOMATOSIS, UNUSUAL FACIES, AND DEVELOPMENTAL DELAY	602342
PIERPONT SYNDROME	PLANTAR LIPOMATOSIS, UNUSUAL FACIES, AND DEVELOPMENTAL DELAY	602342
CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 3; PFIC3	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 3; PFIC3	602347
MDR3 DEFICIENCY	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 3; PFIC3	602347
CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, WITH ELEVATED SERUMGAMMA-GLUTAMYLTRANSFERASE	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 3; PFIC3	602347
GRACILE BONE DYSPLASIA; GCLEB	GRACILE BONE DYSPLASIA; GCLEB	602361
SKELETAL DYSPLASIA, LETHAL, WITH GRACILE BONES	GRACILE BONE DYSPLASIA; GCLEB	602361
OSTEOCRANIOSPLENIC SYNDROME	GRACILE BONE DYSPLASIA; GCLEB	602361
OSTEOCRANIOSTENOSIS	GRACILE BONE DYSPLASIA; GCLEB	602361
HABRODYSPLASIA	GRACILE BONE DYSPLASIA; GCLEB	602361
HEMOCHROMATOSIS, TYPE 2A; HFE2AHEMOCHROMATOSIS, TYPE 2, INCLUDED; HFE2, INCLUDED	HEMOCHROMATOSIS, TYPE 2A; HFE2AHEMOCHROMATOSIS, TYPE 2, INCLUDED; HFE2, INCLUDED	602390
HEMOCHROMATOSIS, JUVENILE, INCLUDED; JH, INCLUDED	HEMOCHROMATOSIS, TYPE 2A; HFE2AHEMOCHROMATOSIS, TYPE 2, INCLUDED; HFE2, INCLUDED	602390
DESMOSTEROLOSIS	DESMOSTEROLOSIS	602398
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 11; ARCI11	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 11; ARCI11	602400
ICHTHYOSIS WITH HYPOTRICHOSIS, AUTOSOMAL RECESSIVE; ARIH	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 11; ARCI11	602400
ICHTHYOSIS AND FOLLICULAR ATROPHODERMA WITH HYPOTRICHOSIS AND HYPOHIDROSIS;IFAH	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 11; ARCI11	602400
ECTODERMAL DYSPLASIA 8, HAIR/TOOTH/NAIL TYPE; ECTD8	ECTODERMAL DYSPLASIA 8, HAIR/TOOTH/NAIL TYPE; ECTD8	602401
PARKINSON DISEASE 3, AUTOSOMAL DOMINANT; PARK3	PARKINSON DISEASE 3, AUTOSOMAL DOMINANT; PARK3	602404
PARKINSON DISEASE 3, AUTOSOMAL DOMINANT LEWY BODY	PARKINSON DISEASE 3, AUTOSOMAL DOMINANT; PARK3	602404
GLAUCOMA 1, OPEN ANGLE, D; GLC1D	GLAUCOMA 1, OPEN ANGLE, D; GLC1D	602429
GLAUCOMA, PRIMARY OPEN ANGLE, ADULT-ONSET	GLAUCOMA 1, OPEN ANGLE, D; GLC1D	602429
AMYOTROPHIC LATERAL SCLEROSIS 4, JUVENILE; ALS4	AMYOTROPHIC LATERAL SCLEROSIS 4, JUVENILE; ALS4	602433
NEURONOPATHY, DISTAL HEREDITARY MOTOR, WITH PYRAMIDAL FEATURES	AMYOTROPHIC LATERAL SCLEROSIS 4, JUVENILE; ALS4	602433
AMYOTROPHY, MONOMELIC	AMYOTROPHY, MONOMELIC	602440
HIRAYAMA DISEASE	AMYOTROPHY, MONOMELIC	602440
SPINAL MUSCULAR ATROPHY, JUVENILE, NONPROGRESSIVE	AMYOTROPHY, MONOMELIC	602440
SEVERE COMBINED IMMUNODEFICIENCY WITH SENSITIVITY TO IONIZING RADIATION	SEVERE COMBINED IMMUNODEFICIENCY WITH SENSITIVITY TO IONIZING RADIATION	602450
RS-SCID	SEVERE COMBINED IMMUNODEFICIENCY WITH SENSITIVITY TO IONIZING RADIATION	602450
SCID, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE,WITH SENSITIVITY TO IONIZING RADIATIONSEVERE COMBINED IMMUNODEFICIENCY, ATHABASKAN-TYPE, INCLUDED; SCIDA,INCLUDED	SEVERE COMBINED IMMUNODEFICIENCY WITH SENSITIVITY TO IONIZING RADIATION	602450
ATHABASKAN SEVERE COMBINED IMMUNODEFICIENCY, INCLUDED	SEVERE COMBINED IMMUNODEFICIENCY WITH SENSITIVITY TO IONIZING RADIATION	602450
SEVERE COMBINED IMMUNODEFICIENCY, PARTIAL, INCLUDED	SEVERE COMBINED IMMUNODEFICIENCY WITH SENSITIVITY TO IONIZING RADIATION	602450
DEAFNESS, AUTOSOMAL DOMINANT 15; DFNA15	DEAFNESS, AUTOSOMAL DOMINANT 15; DFNA15	602459
SHORT STATURE, AUDITORY CANAL ATRESIA, MANDIBULAR HYPOPLASIA, ANDSKELETAL ABNORMALITIES; SAMS	SHORT STATURE, AUDITORY CANAL ATRESIA, MANDIBULAR HYPOPLASIA, ANDSKELETAL ABNORMALITIES; SAMS	602471
ENCEPHALOPATHY, ETHYLMALONIC; EE	ENCEPHALOPATHY, ETHYLMALONIC; EE	602473
OSSIFICATION OF THE POSTERIOR LONGITUDINAL LIGAMENT OF SPINE; OPLL	OSSIFICATION OF THE POSTERIOR LONGITUDINAL LIGAMENT OF SPINE; OPLL	602475
FEBRILE SEIZURES, FAMILIAL, 2; FEB2	FEBRILE SEIZURES, FAMILIAL, 2; FEB2	602477
CONVULSIONS, FAMILIAL FEBRILE, 2	FEBRILE SEIZURES, FAMILIAL, 2; FEB2	602477
MIGRAINE, FAMILIAL HEMIPLEGIC, 2; FHM2	MIGRAINE, FAMILIAL HEMIPLEGIC, 2; FHM2	602481
MHP2MIGRAINE, FAMILIAL BASILAR, INCLUDED	MIGRAINE, FAMILIAL HEMIPLEGIC, 2; FHM2	602481
AXENFELD-RIEGER SYNDROME, TYPE 3; RIEG3	AXENFELD-RIEGER SYNDROME, TYPE 3; RIEG3	602482
AXENFELD-RIEGER ANOMALY WITH OR WITHOUT CARDIAC DEFECTS AND/OR SENSORINEURALHEARING LOSS	AXENFELD-RIEGER SYNDROME, TYPE 3; RIEG3	602482
ANTERIOR SEGMENT MESENCHYMAL DYSGENESIS	AXENFELD-RIEGER SYNDROME, TYPE 3; RIEG3	602482
ANTERIOR CHAMBER CLEAVAGE SYNDROME	AXENFELD-RIEGER SYNDROME, TYPE 3; RIEG3	602482
RIEGER SYNDROME, TYPE 3AXENFELD ANOMALY, INCLUDED	AXENFELD-RIEGER SYNDROME, TYPE 3; RIEG3	602482
RIEGER ANOMALY, INCLUDED	AXENFELD-RIEGER SYNDROME, TYPE 3; RIEG3	602482
AXENFELD-RIEGER ANOMALY, INCLUDED	AXENFELD-RIEGER SYNDROME, TYPE 3; RIEG3	602482
AURICULOCONDYLAR SYNDROME 1; ARCND1	AURICULOCONDYLAR SYNDROME 1; ARCND1	602483
QUESTION MARK EARS SYNDROME	AURICULOCONDYLAR SYNDROME 1; ARCND1	602483
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3	602485
HYPERLIPIDEMIA, COMBINED, 1	HYPERLIPIDEMIA, COMBINED, 1	602491
HYPLIP1	HYPERLIPIDEMIA, COMBINED, 1	602491
HYPERLIPIDEMIA, FAMILIAL COMBINED, 1; FCHL1	HYPERLIPIDEMIA, COMBINED, 1	602491
MACROPHTHALMIA, COLOBOMATOUS, WITH MICROCORNEA; MACOM	MACROPHTHALMIA, COLOBOMATOUS, WITH MICROCORNEA; MACOM	602499
MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME; MCAP	MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME; MCAP	602501
MACROCEPHALY-CAPILLARY MALFORMATION; MCM	MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME; MCAP	602501
MEGALENCEPHALY-CAPILLARY MALFORMATION SYNDROME	MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME; MCAP	602501
MACROCEPHALY-CUTIS MARMORATA TELANGIECTATICA CONGENITA; MCMTC	MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME; MCAP	602501
MEGALENCEPHALY-CUTIS MARMORATA TELANGIECTATICA CONGENITA	MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME; MCAP	602501
BARTTER SYNDROME, TYPE 4A	BARTTER SYNDROME, TYPE 4A	602522
BARTTER SYNDROME, INFANTILE, WITH SENSORINEURAL DEAFNESS; BSNDSENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED	BARTTER SYNDROME, TYPE 4A	602522
MARSHALL-SMITH SYNDROME; MRSHSS	MARSHALL-SMITH SYNDROME; MRSHSS	602535
ICHTHYOSIS, HYSTRIX-LIKE, WITH DEAFNESS	ICHTHYOSIS, HYSTRIX-LIKE, WITH DEAFNESS	602540
HID SYNDROME	ICHTHYOSIS, HYSTRIX-LIKE, WITH DEAFNESS	602540
MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC	MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC	602541
MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES	MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC	602541
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B	602579
CDG Ib; CDGIb	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B	602579
CDG, GASTROINTESTINAL TYPE	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B	602579
MANNOSEPHOSPHATE ISOMERASE DEFICIENCY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B	602579
MPI DEFICIENCY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B	602579
PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B	602579
SAGUENAY-LAC SAINT-JEAN SYNDROME; SLSJ SYNDROME	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B	602579
BRANCHIOOTIC SYNDROME 1; BOS1	BRANCHIOOTIC SYNDROME 1; BOS1	602588
BO SYNDROME 1	BRANCHIOOTIC SYNDROME 1; BOS1	602588
BRANCHIOOTIC DYSPLASIAANTERIOR SEGMENT ANOMALIES WITH OR WITHOUT CATARACT, INCLUDED	BRANCHIOOTIC SYNDROME 1; BOS1	602588
RETINITIS PIGMENTOSA 22; RP22	RETINITIS PIGMENTOSA 22; RP22	602594
DYSTONIA 6, TORSION; DYT6	DYSTONIA 6, TORSION; DYT6	602629
TORSION DYSTONIA, ADULT-ONSET, MIXED TYPE	DYSTONIA 6, TORSION; DYT6	602629
TOOTH AGENESIS, SELECTIVE, 2; STHAG2	TOOTH AGENESIS, SELECTIVE, 2; STHAG2	602639
HYPODONTIA/OLIGODONTIA 2; HYD2	TOOTH AGENESIS, SELECTIVE, 2; STHAG2	602639
MYOTONIC DYSTROPHY 2; DM2	MYOTONIC DYSTROPHY 2; DM2	602668
DYSTROPHIA MYOTONICA 2	MYOTONIC DYSTROPHY 2; DM2	602668
PROXIMAL MYOTONIC MYOPATHY; PROMM	MYOTONIC DYSTROPHY 2; DM2	602668
MYOTONIC MYOPATHY, PROXIMAL	MYOTONIC DYSTROPHY 2; DM2	602668
RICKER SYNDROME	MYOTONIC DYSTROPHY 2; DM2	602668
MENTAL RETARDATION, SEVERE, WITH SPASTICITY AND PIGMENTARY TAPETORETINALDEGENERATION	MENTAL RETARDATION, SEVERE, WITH SPASTICITY AND PIGMENTARY TAPETORETINALDEGENERATION	602685
MRST	MENTAL RETARDATION, SEVERE, WITH SPASTICITY AND PIGMENTARY TAPETORETINALDEGENERATION	602685
RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL RECESSIVE; RTADR	RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL RECESSIVE; RTADR	602722
RTA, DISTAL, AUTOSOMAL RECESSIVE	RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL RECESSIVE; RTADR	602722
RENAL TUBULAR ACIDOSIS, AUTOSOMAL RECESSIVE, WITH PRESERVED HEARINGRENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL RECESSIVE, WITH LATE-ONSETSENSORINEURAL HEARING LOSS, INCLUDED	RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL RECESSIVE; RTADR	602722
PSORIASIS 2; PSORS2	PSORIASIS 2; PSORS2	602723
PROSTATE CANCER, HEREDITARY, 8	PROSTATE CANCER, HEREDITARY, 8	602759
HPC8	PROSTATE CANCER, HEREDITARY, 8	602759
PREDISPOSING FOR PROSTATE CANCER; PCAP	PROSTATE CANCER, HEREDITARY, 8	602759
RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	602771
RIGID SPINE SYNDROME; RSS	RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	602771
MYOPATHY, SEPN1-RELATED	RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	602771
MUSCULAR DYSTROPHY, CONGENITAL, MEROSIN-POSITIVE, WITH EARLY SPINERIGIDITY; MDRS1	RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	602771
MULTICORE MYOPATHY, SEVERE CLASSIC FORM	RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	602771
MINICORE MYOPATHY, SEVERE CLASSIC FORM	RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	602771
MULTIMINICORE DISEASE, SEVERE CLASSIC FORM	RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	602771
DESMIN-RELATED MYOPATHY WITH MALLORY BODIES	RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	602771
MUSCULAR DYSTROPHY, CONGENITAL, EICHSFELD TYPE	RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	602771
RETINITIS PIGMENTOSA 25; RP25	RETINITIS PIGMENTOSA 25; RP25	602772
HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME	HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME	602782
HISTIOCYTOSIS AND LYMPHADENOPATHY WITH OR WITHOUT CUTANEOUS, CARDIAC,AND/OR ENDOCRINE FEATURES, JOINT CONTRACTURES, AND/OR DEAFNESS	HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME	602782
HYPERPIGMENTATION, CUTANEOUS, WITH HYPERTRICHOSIS, HEPATOSPLENOMEGALY,HEART ANOMALIES, AND HYPOGONADISM WITH OR WITHOUT HEARING LOSS	HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME	602782
H SYNDROME	HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME	602782
PIGMENTED HYPERTRICHOSIS WITH INSULIN-DEPENDENT DIABETES MELLITUS;PHID	HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME	602782
HISTIOCYTOSIS WITH JOINT CONTRACTURES AND SENSORINEURAL DEAFNESS;HJCD	HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME	602782
FAISALABAD HISTIOCYTOSIS	HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME	602782
ROSAI-DORFMAN DISEASE, FAMILIAL	HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME	602782
SINUS HISTIOCYTOSIS AND MASSIVE LYMPHADENOPATHY; SHML	HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME	602782
MUENKE SYNDROME; MNKES	MUENKE SYNDROME; MNKES	602849
MUENKE NONSYNDROMIC CORONAL CRANIOSYNOSTOSIS	MUENKE SYNDROME; MNKES	602849
ACROMESOMELIC DYSPLASIA, MAROTEAUX TYPE; AMDM	ACROMESOMELIC DYSPLASIA, MAROTEAUX TYPE; AMDM	602875
ST. HELENA DYSPLASIA	ACROMESOMELIC DYSPLASIA, MAROTEAUX TYPE; AMDM	602875
OROFACIAL CLEFT 2; OFC2	OROFACIAL CLEFT 2; OFC2	602966
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 2	OROFACIAL CLEFT 2; OFC2	602966
BILE DUCT CYSTS	BILE DUCT CYSTS	603003
CHOLEDOCHAL CYSTS	BILE DUCT CYSTS	603003
CHOLEDOCHOCELE	BILE DUCT CYSTS	603003
DEAFNESS, AUTOSOMAL RECESSIVE 17; DFNB17	DEAFNESS, AUTOSOMAL RECESSIVE 17; DFNB17	603010
SCHIZOPHRENIA 6; SCZD6	SCHIZOPHRENIA 6; SCZD6	603013
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 8p-RELATED	SCHIZOPHRENIA 6; SCZD6	603013
TOLL-LIKE RECEPTOR 4; TLR4	TOLL-LIKE RECEPTOR 4; TLR4	603030
TOLL, DROSOPHILA, HOMOLOG OF; TOLLENDOTOXIN HYPORESPONSIVENESS, INCLUDED	TOLL-LIKE RECEPTOR 4; TLR4	603030
MYASTHENIC SYNDROME, CONGENITAL, 5; CMS5	MYASTHENIC SYNDROME, CONGENITAL, 5; CMS5	603034
ENDPLATE ACETYLCHOLINESTERASE DEFICIENCY; EAD	MYASTHENIC SYNDROME, CONGENITAL, 5; CMS5	603034
ENGEL CONGENITAL MYASTHENIC SYNDROME	MYASTHENIC SYNDROME, CONGENITAL, 5; CMS5	603034
MYASTHENIC SYNDROME, CONGENITAL, ENGEL TYPE	MYASTHENIC SYNDROME, CONGENITAL, 5; CMS5	603034
CONGENITAL MYASTHENIC SYNDROME TYPE Ic, FORMERLY; CMS1C, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 5; CMS5	603034
CMS Ic, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 5; CMS5	603034
TUMOR SUPPRESSOR GENE ON CHROMOSOME 11	TUMOR SUPPRESSOR GENE ON CHROMOSOME 11	603040
TSG11	TUMOR SUPPRESSOR GENE ON CHROMOSOME 11	603040
NONSMALL CELL LUNG CANCER SUPPRESSOR	TUMOR SUPPRESSOR GENE ON CHROMOSOME 11	603040
MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1	MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1	603041
MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME, TYMP-RELATED	MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1	603041
MNGIE, TYMP-RELATED	MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1	603041
MYONEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME	MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1	603041
POLYNEUROPATHY, OPHTHALMOPLEGIA, LEUKOENCEPHALOPATHY, AND INTESTINALPSEUDOOBSTRUCTION	MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1	603041
POLIP SYNDROME	MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1	603041
ASTIGMATISM	ASTIGMATISM	603047
MACULAR DEGENERATION, AGE-RELATED, 1; ARMD1	MACULAR DEGENERATION, AGE-RELATED, 1; ARMD1	603075
MACULOPATHY, AGE-RELATED, 1	MACULAR DEGENERATION, AGE-RELATED, 1; ARMD1	603075
DEAFNESS, AUTOSOMAL RECESSIVE 13; DFNB13	DEAFNESS, AUTOSOMAL RECESSIVE 13; DFNB13	603098
CDAGS SYNDROME	CDAGS SYNDROME	603116
CRANIOSYNOSTOSIS, ANAL ANOMALIES, AND POROKERATOSIS	CDAGS SYNDROME	603116
CAP SYNDROME	CDAGS SYNDROME	603116
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C	603147
CDG Ic; CDGIc	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C	603147
CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE I, WITH DEFICIENTGLYCOSYLATION OF DOLICHOL-LINKED OLIGOSACCHARIDE, FORMERLY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C	603147
CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE V, FORMERLY; CDGS5,FORMERLY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C	603147
DERMATITIS, ATOPIC	DERMATITIS, ATOPIC	603165
ATOD	DERMATITIS, ATOPIC	603165
ECZEMA, ATOPICDERMATITIS, ATOPIC, 1, INCLUDED; ATOD1, INCLUDED	DERMATITIS, ATOPIC	603165
SCHIZOPHRENIA 5; SCZD5	SCHIZOPHRENIA 5; SCZD5	603175
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 6q-RELATED	SCHIZOPHRENIA 5; SCZD5	603175
SCHIZOPHRENIA 7; SCZD7	SCHIZOPHRENIA 7; SCZD7	603176
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 13q-RELATED	SCHIZOPHRENIA 7; SCZD7	603176
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 8; BMIQ8	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 8; BMIQ8	603188
OBESITY, SUSCEPTIBILITY TO	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 8; BMIQ8	603188
MECKEL SYNDROME, TYPE 2; MKS2	MECKEL SYNDROME, TYPE 2; MKS2	603194
MECKEL-GRUBER SYNDROME, TYPE 2	MECKEL SYNDROME, TYPE 2; MKS2	603194
EPILEPSY, NOCTURNAL FRONTAL LOBE, 2; ENFL2	EPILEPSY, NOCTURNAL FRONTAL LOBE, 2; ENFL2	603204
SCHIZOPHRENIA 8; SCZD8	SCHIZOPHRENIA 8; SCZD8	603206
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 18-RELATED	SCHIZOPHRENIA 8; SCZD8	603206
HUNTINGTON DISEASE-LIKE 1; HDL1	HUNTINGTON DISEASE-LIKE 1; HDL1	603218
HUNTINGTON-LIKE NEURODEGENERATIVE DISORDER 1; HLN1	HUNTINGTON DISEASE-LIKE 1; HDL1	603218
HUNTINGTON-LIKE NEURODEGENERATIVE DISORDER, AUTOSOMAL DOMINANT	HUNTINGTON DISEASE-LIKE 1; HDL1	603218
PRION DISEASE, EARLY-ONSET, WITH PROMINENT PSYCHIATRIC FEATURES	HUNTINGTON DISEASE-LIKE 1; HDL1	603218
MYOPIA 3, AUTOSOMAL DOMINANT; MYP3	MYOPIA 3, AUTOSOMAL DOMINANT; MYP3	603221
PSEUDOHYPOPARATHYROIDISM, TYPE IB; PHP1B	PSEUDOHYPOPARATHYROIDISM, TYPE IB; PHP1B	603233
PHP IB	PSEUDOHYPOPARATHYROIDISM, TYPE IB; PHP1B	603233
DIABETES MELLITUS, INSULIN-DEPENDENT, 17; IDDM17	DIABETES MELLITUS, INSULIN-DEPENDENT, 17; IDDM17	603266
INSULIN-DEPENDENT DIABETES MELLITUS 17	DIABETES MELLITUS, INSULIN-DEPENDENT, 17; IDDM17	603266
FOCAL SEGMENTAL GLOMERULOSCLEROSIS 1; FSGS1	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 1; FSGS1	603278
GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 1	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 1; FSGS1	603278
CEREBRAL CAVERNOUS MALFORMATIONS 2; CCM2	CEREBRAL CAVERNOUS MALFORMATIONS 2; CCM2	603284
CEREBRAL CAVERNOUS MALFORMATIONS 3; CCM3	CEREBRAL CAVERNOUS MALFORMATIONS 3; CCM3	603285
GAP JUNCTION PROTEIN, BETA-3; GJB3	GAP JUNCTION PROTEIN, BETA-3; GJB3	603324
GAP JUNCTION PROTEIN, 31-KD	GAP JUNCTION PROTEIN, BETA-3; GJB3	603324
CONNEXIN 31; CX31DEAFNESS, AUTOSOMAL RECESSIVE, INCLUDED	GAP JUNCTION PROTEIN, BETA-3; GJB3	603324
DEAFNESS, AUTOSOMAL DOMINANT, WITH PERIPHERAL NEUROPATHY, INCLUDED	GAP JUNCTION PROTEIN, BETA-3; GJB3	603324
SCHIZOPHRENIA 2; SCZD2	SCHIZOPHRENIA 2; SCZD2	603342
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 11q-RELATED	SCHIZOPHRENIA 2; SCZD2	603342
GRACILE SYNDROME	GRACILE SYNDROME	603358
GROWTH RETARDATION, AMINO ACIDURIA, CHOLESTASIS, IRON OVERLOAD, LACTICACIDOSIS, AND EARLY DEATH	GRACILE SYNDROME	603358
FINNISH LETHAL NEONATAL METABOLIC SYNDROME; FLNMS	GRACILE SYNDROME	603358
LACTIC ACIDOSIS, FINNISH, WITH HEPATIC HEMOSIDEROSIS	GRACILE SYNDROME	603358
FELLMAN SYNDROME	GRACILE SYNDROME	603358
THYROID-STIMULATING HORMONE RECEPTOR; TSHR	THYROID-STIMULATING HORMONE RECEPTOR; TSHR	603372
THYROTROPIN RECEPTOR	THYROID-STIMULATING HORMONE RECEPTOR; TSHR	603372
LGR3THYROID ADENOMA, HYPERFUNCTIONING, INCLUDED	THYROID-STIMULATING HORMONE RECEPTOR; TSHR	603372
THYROID CARCINOMA WITH THYROTOXICOSIS, INCLUDED	THYROID-STIMULATING HORMONE RECEPTOR; TSHR	603372
HYPERTHYROIDISM, FAMILIAL GESTATIONAL	HYPERTHYROIDISM, FAMILIAL GESTATIONAL	603373
GLAUCOMA 1, OPEN ANGLE, F; GLC1F	GLAUCOMA 1, OPEN ANGLE, F; GLC1F	603383
GLAUCOMA, PRIMARY OPEN ANGLE, ADULT-ONSET	GLAUCOMA 1, OPEN ANGLE, F; GLC1F	603383
THYROID CARCINOMA, NONMEDULLARY, WITH OR WITHOUT CELL OXYPHILIA	THYROID CARCINOMA, NONMEDULLARY, WITH OR WITHOUT CELL OXYPHILIA	603386
TCO	THYROID CARCINOMA, NONMEDULLARY, WITH OR WITHOUT CELL OXYPHILIA	603386
TCO1	THYROID CARCINOMA, NONMEDULLARY, WITH OR WITHOUT CELL OXYPHILIA	603386
MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1;MPPH1	MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1;MPPH1	603387
MEGALENCEPHALY, POLYMICROGYRIA, MEGA CORPUS CALLOSUM SYNDROME; MPPH	MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1;MPPH1	603387
MEG-PMG-MEGACC SYNDROME	MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1;MPPH1	603387
MEGALENCEPHALY, MEGA CORPUS CALLOSUM, AND COMPLETE LACK OF MOTOR DEVELOPMENT	MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1;MPPH1	603387
GRAVES DISEASE, SUSCEPTIBILITY TO, 2	GRAVES DISEASE, SUSCEPTIBILITY TO, 2	603388
GRD2	GRAVES DISEASE, SUSCEPTIBILITY TO, 2	603388
FANCONI ANEMIA, COMPLEMENTATION GROUP F; FANCF	FANCONI ANEMIA, COMPLEMENTATION GROUP F; FANCF	603467
CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2	CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2	603471
CITRIN DEFICIENCY	CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2	603471
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1E; LGMD1E	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1E; LGMD1E	603511
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1D, FORMERLY; LGMD1D, FORMERLY	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1E; LGMD1E	603511
CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 1; CPSQ1	CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 1; CPSQ1	603513
SPINOCEREBELLAR ATAXIA 10; SCA10	SPINOCEREBELLAR ATAXIA 10; SCA10	603516
LIMB-MAMMARY SYNDROME; LMS	LIMB-MAMMARY SYNDROME; LMS	603543
SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY TYPE 2; SEMDJL2	SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY TYPE 2; SEMDJL2	603546
SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, HALL TYPE	SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY TYPE 2; SEMDJL2	603546
SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, LEPTODACTYLICTYPE	SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY TYPE 2; SEMDJL2	603546
SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH MULTIPLE DISLOCATIONS, HALLTYPE	SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY TYPE 2; SEMDJL2	603546
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4; FHL4	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4; FHL4	603552
HPLH4	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4; FHL4	603552
HLH4	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4; FHL4	603552
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 2; FHL2	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 2; FHL2	603553
HPLH2	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 2; FHL2	603553
HLH2	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 2; FHL2	603553
OMENN SYNDROME	OMENN SYNDROME	603554
RETICULOENDOTHELIOSIS, FAMILIAL, WITH EOSINOPHILIA	OMENN SYNDROME	603554
SEVERE COMBINED IMMUNODEFICIENCY WITH HYPEREOSINOPHILIA	OMENN SYNDROME	603554
SPASTIC PARAPLEGIA 8, AUTOSOMAL DOMINANT; SPG8	SPASTIC PARAPLEGIA 8, AUTOSOMAL DOMINANT; SPG8	603563
VANIN 1; VNN1HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS8, INCLUDED; HDLCQ8, INCLUDED	VANIN 1; VNN1HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS8, INCLUDED; HDLCQ8, INCLUDED	603570
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIf; CDG2F	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIf; CDG2F	603585
CDG IIf; CDGIIf	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIf; CDG2F	603585
POLYDACTYLY	POLYDACTYLY	603596
DEAFNESS, AUTOSOMAL DOMINANT 17; DFNA17COCHLEOSACCULAR DEGENERATION, INCLUDED	DEAFNESS, AUTOSOMAL DOMINANT 17; DFNA17COCHLEOSACCULAR DEGENERATION, INCLUDED	603622
DEAFNESS, AUTOSOMAL RECESSIVE 21; DFNB21	DEAFNESS, AUTOSOMAL RECESSIVE 21; DFNB21	603629
CONE-ROD DYSTROPHY 7; CORD7	CONE-ROD DYSTROPHY 7; CORD7	603649
MENTAL HEALTH WELLNESS 1	MENTAL HEALTH WELLNESS 1	603663
MHW1	MENTAL HEALTH WELLNESS 1	603663
ACROMELIC FRONTONASAL DYSOSTOSIS; AFND	ACROMELIC FRONTONASAL DYSOSTOSIS; AFND	603671
DEAFNESS, AUTOSOMAL RECESSIVE 14; DFNB14	DEAFNESS, AUTOSOMAL RECESSIVE 14; DFNB14	603678
PROSTATE CANCER/BRAIN CANCER SUSCEPTIBILITY	PROSTATE CANCER/BRAIN CANCER SUSCEPTIBILITY	603688
PCBC	PROSTATE CANCER/BRAIN CANCER SUSCEPTIBILITY	603688
CAPB	PROSTATE CANCER/BRAIN CANCER SUSCEPTIBILITY	603688
HEREDITARY MYOPATHY WITH EARLY RESPIRATORY FAILURE; HMERF	HEREDITARY MYOPATHY WITH EARLY RESPIRATORY FAILURE; HMERF	603689
MYOPATHY, PROXIMAL, WITH EARLY RESPIRATORY MUSCLE INVOLVEMENT; MPRM	HEREDITARY MYOPATHY WITH EARLY RESPIRATORY FAILURE; HMERF	603689
EDSTROM MYOPATHY	HEREDITARY MYOPATHY WITH EARLY RESPIRATORY FAILURE; HMERF	603689
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 3	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 3	603694
NIDDM3	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 3	603694
NONINSULIN-DEPENDENT DIABETES MELLITUS 3	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 3	603694
DEAFNESS, AUTOSOMAL RECESSIVE 16; DFNB16	DEAFNESS, AUTOSOMAL RECESSIVE 16; DFNB16	603720
OHDO SYNDROME, SBBYS VARIANT; SBBYSS	OHDO SYNDROME, SBBYS VARIANT; SBBYSS	603736
SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME	OHDO SYNDROME, SBBYS VARIANT; SBBYSS	603736
YOUNG-SIMPSON SYNDROME; YSS	OHDO SYNDROME, SBBYS VARIANT; SBBYSS	603736
HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, 3; HCHOLA3	HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, 3; HCHOLA3	603776
FH3LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS1, INCLUDED; LDLCQ1, INCLUDED	HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, 3; HCHOLA3	603776
INTELLIGENCE QUANTITATIVE TRAIT LOCUS 1	INTELLIGENCE QUANTITATIVE TRAIT LOCUS 1	603783
INTLQ1	INTELLIGENCE QUANTITATIVE TRAIT LOCUS 1	603783
COGNITIVE ABILITY, GENERALSELF-PERCEIVED ABILITY, INCLUDED	INTELLIGENCE QUANTITATIVE TRAIT LOCUS 1	603783
STARGARDT DISEASE 4; STGD4	STARGARDT DISEASE 4; STGD4	603786
MICROCEPHALY WITH SIMPLIFIED GYRAL PATTERN	MICROCEPHALY WITH SIMPLIFIED GYRAL PATTERN	603802
HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE; ARH	HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE; ARH	603813
HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE, 1, FORMERLY; ARH1, FORMERLY	HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE; ARH	603813
FHCB1, FORMERLY	HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE; ARH	603813
HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE, 2, FORMERLY; ARH2, FORMERLY	HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE; ARH	603813
FHCB2, FORMERLY	HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE; ARH	603813
VENTRICULAR FIBRILLATION, PAROXYSMAL FAMILIAL, 1; VF1VENTRICULAR FIBRILLATION DURING MYOCARDIAL INFARCTION, SUSCEPTIBILITYTO, INCLUDED	VENTRICULAR FIBRILLATION, PAROXYSMAL FAMILIAL, 1; VF1VENTRICULAR FIBRILLATION DURING MYOCARDIAL INFARCTION, SUSCEPTIBILITYTO, INCLUDED	603829
LONG QT SYNDROME 3; LQT3LONG QT SYNDROME 3, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	LONG QT SYNDROME 3; LQT3LONG QT SYNDROME 3, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	603830
LONG QT SYNDROME 2/3, DIGENIC, INCLUDED; LQT2/3, DIGENIC, INCLUDED	LONG QT SYNDROME 3; LQT3LONG QT SYNDROME 3, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	603830
LONG QT SYNDROME 3/6, DIGENIC, INCLUDED; LQT3/6, DIGENIC, INCLUDED	LONG QT SYNDROME 3; LQT3LONG QT SYNDROME 3, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	603830
CYSTIC FIBROSIS, MODIFIER OF, 1; CFM1MECONIUM ILEUS IN CYSTIC FIBROSIS, SUSCEPTIBILITY TO, INCLUDED	CYSTIC FIBROSIS, MODIFIER OF, 1; CFM1MECONIUM ILEUS IN CYSTIC FIBROSIS, SUSCEPTIBILITY TO, INCLUDED	603855
MEDULLARY CYSTIC KIDNEY DISEASE 2; MCKD2	MEDULLARY CYSTIC KIDNEY DISEASE 2; MCKD2	603860
MEDULLARY CYSTIC KIDNEY DISEASE 2, AUTOSOMAL DOMINANT; ADMCKD2	MEDULLARY CYSTIC KIDNEY DISEASE 2; MCKD2	603860
LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM	LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM	603896
CHILDHOOD ATAXIA WITH CENTRAL NERVOUS SYSTEM HYPOMYELINIZATION; CACH	LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM	603896
VANISHING WHITE MATTER LEUKODYSTROPHY	LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM	603896
CREE LEUKOENCEPHALOPATHY; CLEVANISHING WHITE MATTER LEUKODYSTROPHY WITH OVARIAN FAILURE, INCLUDED	LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM	603896
OVARIOLEUKODYSTROPHY, INCLUDED	LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM	603896
BETA-THALASSEMIA, DOMINANT INCLUSION BODY TYPE	BETA-THALASSEMIA, DOMINANT INCLUSION BODY TYPE	603902
DYSERYTHROPOIETIC ANEMIA, CONGENITAL, IRISH OR WEATHERALL TYPE	BETA-THALASSEMIA, DOMINANT INCLUSION BODY TYPE	603902
SICKLE CELL ANEMIA	SICKLE CELL ANEMIA	603903
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IIA; ALPS2A	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IIA; ALPS2A	603909
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE II; ALPS2	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IIA; ALPS2A	603909
HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 1	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 1	603918
HYT1	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 1	603918
INTERVERTEBRAL DISC DISEASE; IDDLUMBAR DISC DISEASE, INCLUDED; LDD, INCLUDED	INTERVERTEBRAL DISC DISEASE; IDDLUMBAR DISC DISEASE, INCLUDED; LDD, INCLUDED	603932
LUMBAR DISC HERNIATION, SUSCEPTIBILITY TO, INCLUDED	INTERVERTEBRAL DISC DISEASE; IDDLUMBAR DISC DISEASE, INCLUDED; LDD, INCLUDED	603932
LUMBAR DISC DEGENERATION, SUSCEPTIBILITY TO, INCLUDED	INTERVERTEBRAL DISC DISEASE; IDDLUMBAR DISC DISEASE, INCLUDED; LDD, INCLUDED	603932
MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1	603933
PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1	603933
NONPROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TOMICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, INCLUDED	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1	603933
MICROVASCULAR COMPLICATIONS OF DIABETES, PROTECTION AGAINST, INCLUDED	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1	603933
NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO, INCLUDED	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1	603933
END-STAGE RENAL DISEASE, DIABETIC, SUSCEPTIBILITY TO, INCLUDED	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1	603933
PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO, INCLUDED	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1	603933
NONPROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO, INCLUDED	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1	603933
NEUROPATHY, DIABETIC, SUSCEPTIBILITY TO, INCLUDED	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1	603933
PSORIASIS 4, SUSCEPTIBILITY TO; PSORS4	PSORIASIS 4, SUSCEPTIBILITY TO; PSORS4	603935
CERVICAL CANCER	CERVICAL CANCER	603956
DEAFNESS, AUTOSOMAL DOMINANT 16; DFNA16	DEAFNESS, AUTOSOMAL DOMINANT 16; DFNA16	603964
FOCAL SEGMENTAL GLOMERULOSCLEROSIS 2; FSGS2	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 2; FSGS2	603965
GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 2	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 2; FSGS2	603965
MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 1; MLC1	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 1; MLC1	604004
VACUOLATING MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 1; MLC1	604004
LVM	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 1; MLC1	604004
VL	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 1; MLC1	604004
LEUKOENCEPHALOPATHY WITH SWELLING AND CYSTS	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 1; MLC1	604004
VAN DER KNAAP DISEASE	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 1; MLC1	604004
UNC119, C. ELEGANS, HOMOLOG OF; UNC119	UNC119, C. ELEGANS, HOMOLOG OF; UNC119	604011
HUMAN RETINAL GENE 4; HRG4CONE-ROD DYSTROPHY, INCLUDED	UNC119, C. ELEGANS, HOMOLOG OF; UNC119	604011
DEAFNESS, AUTOSOMAL RECESSIVE 20; DFNB20	DEAFNESS, AUTOSOMAL RECESSIVE 20; DFNB20	604060
HYPOALPHALIPOPROTEINEMIA, PRIMARY	HYPOALPHALIPOPROTEINEMIA, PRIMARY	604091
HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA	HYPOALPHALIPOPROTEINEMIA, PRIMARY	604091
HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD	HYPOALPHALIPOPROTEINEMIA, PRIMARY	604091
FAMILIAL HDL DEFICIENCY; FHD	HYPOALPHALIPOPROTEINEMIA, PRIMARY	604091
HDL CHOLESTEROL, LOW SERUM; HDLC	HYPOALPHALIPOPROTEINEMIA, PRIMARY	604091
CONE-ROD DYSTROPHY 3; CORD3	CONE-ROD DYSTROPHY 3; CORD3	604116
VOHWINKEL SYNDROME, VARIANT FORM	VOHWINKEL SYNDROME, VARIANT FORM	604117
VOHWINKEL SYNDROME WITH ICHTHYOSIS	VOHWINKEL SYNDROME, VARIANT FORM	604117
MUTILATING KERATODERMA WITH ICHTHYOSIS	VOHWINKEL SYNDROME, VARIANT FORM	604117
LORICRIN KERATODERMA	VOHWINKEL SYNDROME, VARIANT FORM	604117
CEREBELLAR ATAXIA, DEAFNESS, AND NARCOLEPSY, AUTOSOMAL DOMINANT; ADCADN	CEREBELLAR ATAXIA, DEAFNESS, AND NARCOLEPSY, AUTOSOMAL DOMINANT; ADCADN	604121
EPIDERMOLYSIS BULLOSA PRURIGINOSA	EPIDERMOLYSIS BULLOSA PRURIGINOSA	604129
DYSTROPHIC EPIDERMOLYSIS BULLOSA PRURIGINOSA	EPIDERMOLYSIS BULLOSA PRURIGINOSA	604129
DEB, PRURIGINOSA	EPIDERMOLYSIS BULLOSA PRURIGINOSA	604129
ALPHA-THALASSEMIA	ALPHA-THALASSEMIA	604131
CARDIOMYOPATHY, DILATED, 1G; CMD1G	CARDIOMYOPATHY, DILATED, 1G; CMD1G	604145
CONGENITAL CATARACTS, FACIAL DYSMORPHISM, AND NEUROPATHY; CCFDN	CONGENITAL CATARACTS, FACIAL DYSMORPHISM, AND NEUROPATHY; CCFDN	604168
CATARACT, CONGENITAL, WITH FACIAL DYSMORPHISM AND NEUROPATHY	CONGENITAL CATARACTS, FACIAL DYSMORPHISM, AND NEUROPATHY; CCFDN	604168
LEFT VENTRICULAR NONCOMPACTION 1; LVNC1	LEFT VENTRICULAR NONCOMPACTION 1; LVNC1	604169
LEFT VENTRICULAR NONCOMPACTION 1 WITH OR WITHOUT CONGENITAL HEARTDEFECTS	LEFT VENTRICULAR NONCOMPACTION 1; LVNC1	604169
POIKILODERMA WITH NEUTROPENIA; PN	POIKILODERMA WITH NEUTROPENIA; PN	604173
POIKILODERMA WITH NEUTROPENIA, CLERICUZIO-TYPE	POIKILODERMA WITH NEUTROPENIA; PN	604173
FACIAL PARESIS, HEREDITARY CONGENITAL, 2; HCFP2	FACIAL PARESIS, HEREDITARY CONGENITAL, 2; HCFP2	604185
MOEBIUS SYNDROME 3, FORMERLY; MBS3, FORMERLY	FACIAL PARESIS, HEREDITARY CONGENITAL, 2; HCFP2	604185
MOBIUS SYNDROME 3, FORMERLY	FACIAL PARESIS, HEREDITARY CONGENITAL, 2; HCFP2	604185
SPASTIC PARAPLEGIA 10, AUTOSOMAL DOMINANT; SPG10	SPASTIC PARAPLEGIA 10, AUTOSOMAL DOMINANT; SPG10	604187
SPASTIC PARAPLEGIA 10 WITH OR WITHOUT PERIPHERAL NEUROPATHY	SPASTIC PARAPLEGIA 10, AUTOSOMAL DOMINANT; SPG10	604187
HEPATIC FIBROSIS, SEVERE, SUSCEPTIBILITY TO, DUE TO SCHISTOSOMA MANSONIINFECTION	HEPATIC FIBROSIS, SEVERE, SUSCEPTIBILITY TO, DUE TO SCHISTOSOMA MANSONIINFECTION	604201
SM2HEPATIC FIBROSIS, SEVERE, SUSCEPTIBILITY TO, DUE TO SCHISTOSOMA JAPONICUMINFECTION, INCLUDED	HEPATIC FIBROSIS, SEVERE, SUSCEPTIBILITY TO, DUE TO SCHISTOSOMA MANSONIINFECTION	604201
CHUDLEY-MCCULLOUGH SYNDROME; CMCS	CHUDLEY-MCCULLOUGH SYNDROME; CMCS	604213
DEAFNESS, SENSORINEURAL, WITH PARTIAL AGENESIS OF THE CORPUS CALLOSUMAND ARACHNOID CYSTS	CHUDLEY-MCCULLOUGH SYNDROME; CMCS	604213
DEAFNESS, AUTOSOMAL RECESSIVE 82, FORMERLY; DFNB82, FORMERLY	CHUDLEY-MCCULLOUGH SYNDROME; CMCS	604213
ENCEPHALOPATHY, FAMILIAL, WITH NEUROSERPIN INCLUSION BODIES; FENIB	ENCEPHALOPATHY, FAMILIAL, WITH NEUROSERPIN INCLUSION BODIES; FENIB	604218
ENCEPHALOPATHY, FAMILIAL, WITH COLLINS BODIES	ENCEPHALOPATHY, FAMILIAL, WITH NEUROSERPIN INCLUSION BODIES; FENIB	604218
CATARACT 9, MULTIPLE TYPES; CTRCT9	CATARACT 9, MULTIPLE TYPES; CTRCT9	604219
CATARACT 9, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA	CATARACT 9, MULTIPLE TYPES; CTRCT9	604219
CATARACT, AUTOSOMAL DOMINANT	CATARACT 9, MULTIPLE TYPES; CTRCT9	604219
CATARACT, AUTOSOMAL RECESSIVE CONGENITAL 1; CATC1	CATARACT 9, MULTIPLE TYPES; CTRCT9	604219
PETERS ANOMALY	PETERS ANOMALY	604229
LEBER CONGENITAL AMAUROSIS 3; LCA3RETINITIS PIGMENTOSA, JUVENILE, SPATA7-RELATED, INCLUDED	LEBER CONGENITAL AMAUROSIS 3; LCA3RETINITIS PIGMENTOSA, JUVENILE, SPATA7-RELATED, INCLUDED	604232
GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 1; GEFSP1	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 1; GEFSP1	604233
GEFS+, TYPE 1; GEFS+1	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 1; GEFSP1	604233
HEMOCHROMATOSIS, TYPE 3; HFE3	HEMOCHROMATOSIS, TYPE 3; HFE3	604250
HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2	HEMOCHROMATOSIS, TYPE 3; HFE3	604250
DYSLEXIA, SUSCEPTIBILITY TO, 3; DYX3	DYSLEXIA, SUSCEPTIBILITY TO, 3; DYX3	604254
GROWTH HORMONE INSENSITIVITY, PARTIAL; GHIP	GROWTH HORMONE INSENSITIVITY, PARTIAL; GHIP	604271
MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 1;MC5DN1MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, ATPAF2 TYPE	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 1;MC5DN1MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, ATPAF2 TYPE	604273
RENAL TUBULAR ACIDOSIS, PROXIMAL, WITH OCULAR ABNORMALITIES AND MENTALRETARDATION	RENAL TUBULAR ACIDOSIS, PROXIMAL, WITH OCULAR ABNORMALITIES AND MENTALRETARDATION	604278
RTA, PROXIMAL, AUTOSOMAL RECESSIVE	RENAL TUBULAR ACIDOSIS, PROXIMAL, WITH OCULAR ABNORMALITIES AND MENTALRETARDATION	604278
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2E; LGMD2E	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2E; LGMD2E	604286
CARDIOMYOPATHY, DILATED, 1H; CMD1H	CARDIOMYOPATHY, DILATED, 1H; CMD1H	604288
CARDIOMYOPATHY, DILATED, WITH CONDUCTION DEFECT	CARDIOMYOPATHY, DILATED, 1H; CMD1H	604288
ACERULOPLASMINEMIAHYPOCERULOPLASMINEMIA, INCLUDED	ACERULOPLASMINEMIAHYPOCERULOPLASMINEMIA, INCLUDED	604290
CERULOPLASMIN DEFICIENCY, INCLUDED	ACERULOPLASMINEMIAHYPOCERULOPLASMINEMIA, INCLUDED	604290
HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED	ACERULOPLASMINEMIAHYPOCERULOPLASMINEMIA, INCLUDED	604290
ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME3; EEC3	ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME3; EEC3	604292
EEC SYNDROME 3	ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME3; EEC3	604292
RHEUMATOID ARTHRITIS, SYSTEMIC JUVENILE	RHEUMATOID ARTHRITIS, SYSTEMIC JUVENILE	604302
SYSTEMIC JUVENILE RHEUMATOID ARTHRITIS	RHEUMATOID ARTHRITIS, SYSTEMIC JUVENILE	604302
CATARACT 2, MULTIPLE TYPES; CTRCT2	CATARACT 2, MULTIPLE TYPES; CTRCT2	604307
CATARACT 2, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA	CATARACT 2, MULTIPLE TYPES; CTRCT2	604307
CATARACT, COPPOCK-LIKE; CCL	CATARACT 2, MULTIPLE TYPES; CTRCT2	604307
MASS SYNDROME	MASS SYNDROME	604308
MASS PHENOTYPE	MASS SYNDROME	604308
OVERLAP CONNECTIVE TISSUE DISEASE; OCTD	MASS SYNDROME	604308
BLEPHAROPHIMOSIS WITH FACIAL AND GENITAL ANOMALIES AND MENTAL RETARDATION	BLEPHAROPHIMOSIS WITH FACIAL AND GENITAL ANOMALIES AND MENTAL RETARDATION	604314
BLEPHAROPHIMOSIS-MENTAL RETARDATION SYNDROME, VERLOES TYPE	BLEPHAROPHIMOSIS WITH FACIAL AND GENITAL ANOMALIES AND MENTAL RETARDATION	604314
PSORIASIS 5, SUSCEPTIBILITY TO; PSORS5	PSORIASIS 5, SUSCEPTIBILITY TO; PSORS5	604316
MICROCEPHALY 2, PRIMARY, AUTOSOMAL RECESSIVE, WITH OR WITHOUT CORTICALMALFORMATIONS; MCPH2	MICROCEPHALY 2, PRIMARY, AUTOSOMAL RECESSIVE, WITH OR WITHOUT CORTICALMALFORMATIONS; MCPH2	604317
SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1	604320
SPINAL MUSCULAR ATROPHY WITH RESPIRATORY DISTRESS 1; SMARD1	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1	604320
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VI; DHMN6	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1	604320
HMN6	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1	604320
HMN VI	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1	604320
SEVERE INFANTILE AXONAL NEUROPATHY WITH RESPIRATORY FAILURE; SIANRF	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1	604320
NEURONOPATHY, SEVERE INFANTILE AXONAL, WITH RESPIRATORY FAILURE	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1	604320
SPINAL MUSCULAR ATROPHY, DIAPHRAGMATIC	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1	604320
MICROCEPHALY 4, PRIMARY, AUTOSOMAL RECESSIVE; MCPH4	MICROCEPHALY 4, PRIMARY, AUTOSOMAL RECESSIVE; MCPH4	604321
SPINOCEREBELLAR ATAXIA 12; SCA12	SPINOCEREBELLAR ATAXIA 12; SCA12	604326
HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 2	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 2	604329
HYT2	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 2	604329
ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 1; FASPS1	ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 1; FASPS1	604348
FEBRILE SEIZURES, FAMILIAL, 4; FEB4	FEBRILE SEIZURES, FAMILIAL, 4; FEB4	604352
CONVULSIONS, FAMILIAL FEBRILE, 4	FEBRILE SEIZURES, FAMILIAL, 4; FEB4	604352
DUANE RETRACTION SYNDROME 2; DURS2	DUANE RETRACTION SYNDROME 2; DURS2	604356
SPASTIC PARAPLEGIA 11, AUTOSOMAL RECESSIVE; SPG11	SPASTIC PARAPLEGIA 11, AUTOSOMAL RECESSIVE; SPG11	604360
SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE, WITH MENTAL IMPAIRMENT ANDTHIN CORPUS CALLOSUM	SPASTIC PARAPLEGIA 11, AUTOSOMAL RECESSIVE; SPG11	604360
SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE, COMPLICATED, WITH THIN CORPUSCALLOSUM	SPASTIC PARAPLEGIA 11, AUTOSOMAL RECESSIVE; SPG11	604360
HSP-TCC	SPASTIC PARAPLEGIA 11, AUTOSOMAL RECESSIVE; SPG11	604360
EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI; FFEVF	EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI; FFEVF	604364
EPILEPSY, PARTIAL, WITH VARIABLE FOCI; FPEVF	EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI; FFEVF	604364
LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 3; FPLD3	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 3; FPLD3	604367
LIPODYSTROPHY, FAMILIAL PARTIAL, ASSOCIATED WITH PPARG MUTATIONS	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 3; FPLD3	604367
SALLA DISEASE; SD	SALLA DISEASE; SD	604369
SIALURIA, FINNISH TYPE	SALLA DISEASE; SD	604369
BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1; BROVCA1BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1, INCLUDED	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1; BROVCA1BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1, INCLUDED	604370
OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1, INCLUDED	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1; BROVCA1BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1, INCLUDED	604370
CHECKPOINT KINASE 2, S. POMBE, HOMOLOG OF; CHEK2	CHECKPOINT KINASE 2, S. POMBE, HOMOLOG OF; CHEK2	604373
CHK2	CHECKPOINT KINASE 2, S. POMBE, HOMOLOG OF; CHEK2	604373
RAD53, S. CEREVISIAE, HOMOLOG OF; RAD53	CHECKPOINT KINASE 2, S. POMBE, HOMOLOG OF; CHEK2	604373
CDS1, S. POMBE, HOMOLOG OFBREAST AND COLORECTAL CANCER, SUSCEPTIBILITY TO, INCLUDED	CHECKPOINT KINASE 2, S. POMBE, HOMOLOG OF; CHEK2	604373
HBCC, SUSCEPTIBILITY TO, INCLUDED	CHECKPOINT KINASE 2, S. POMBE, HOMOLOG OF; CHEK2	604373
CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASEDEFICIENCY 1; CEMCOX1	CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASEDEFICIENCY 1; CEMCOX1	604377
CYTOCHROME c OXIDASE DEFICIENCY, FATAL INFANTILE, WITH CARDIOENCEPHALOMYOPATHY	CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASEDEFICIENCY 1; CEMCOX1	604377
HYPOTRICHOSIS 7; HYPT7	HYPOTRICHOSIS 7; HYPT7	604379
HYPOTRICHOSIS, LOCALIZED, AUTOSOMAL RECESSIVE 2; LAH2	HYPOTRICHOSIS 7; HYPT7	604379
HYPOTRICHOSIS, AUTOSOMAL RECESSIVE; AH	HYPOTRICHOSIS 7; HYPT7	604379
HYPOTRICHOSIS, TOTAL, MARI TYPEWOOLLY HAIR, AUTOSOMAL RECESSIVE 2, WITH OR WITHOUT HYPOTRICHOSIS,INCLUDED; ARWH2, INCLUDED	HYPOTRICHOSIS 7; HYPT7	604379
WH/HT, INCLUDED	HYPOTRICHOSIS 7; HYPT7	604379
NEPHRONOPHTHISIS 3; NPHP3	NEPHRONOPHTHISIS 3; NPHP3	604387
NPH3	NEPHRONOPHTHISIS 3; NPHP3	604387
ATAXIA-TELANGIECTASIA-LIKE DISORDER 1; ATLD1	ATAXIA-TELANGIECTASIA-LIKE DISORDER 1; ATLD1	604391
ATLD	ATAXIA-TELANGIECTASIA-LIKE DISORDER 1; ATLD1	604391
LEBER CONGENITAL AMAUROSIS 4; LCA4RETINITIS PIGMENTOSA, JUVENILE, AIPL1-RELATED, INCLUDED	LEBER CONGENITAL AMAUROSIS 4; LCA4RETINITIS PIGMENTOSA, JUVENILE, AIPL1-RELATED, INCLUDED	604393
CONE-ROD DYSTROPHY, AIPL1-RELATED, INCLUDED	LEBER CONGENITAL AMAUROSIS 4; LCA4RETINITIS PIGMENTOSA, JUVENILE, AIPL1-RELATED, INCLUDED	604393
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 5; ARVD5	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 5; ARVD5	604400
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 5; ARVC5	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 5; ARVD5	604400
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 6; ARVD6	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 6; ARVD6	604401
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 6; ARVC6	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 6; ARVD6	604401
GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 2; GEFSP2	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 2; GEFSP2	604403
GEFS+, TYPE 2; GEFS+2FEBRILE SEIZURES, FAMILIAL, 3A, INCLUDED; FEB3A, INCLUDED	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 2; GEFSP2	604403
PYOGENIC STERILE ARTHRITIS, PYODERMA GANGRENOSUM, AND ACNE	PYOGENIC STERILE ARTHRITIS, PYODERMA GANGRENOSUM, AND ACNE	604416
PAPA SYNDROME; PAPAS	PYOGENIC STERILE ARTHRITIS, PYODERMA GANGRENOSUM, AND ACNE	604416
FAMILIAL RECURRENT ARTHRITIS; FRA	PYOGENIC STERILE ARTHRITIS, PYODERMA GANGRENOSUM, AND ACNE	604416
POLYNEUROPATHY, LETHAL NEONATAL, AXONAL SENSORIMOTOR, AUTOSOMAL RECESSIVE	POLYNEUROPATHY, LETHAL NEONATAL, AXONAL SENSORIMOTOR, AUTOSOMAL RECESSIVE	604431
SPINOCEREBELLAR ATAXIA 11; SCA11	SPINOCEREBELLAR ATAXIA 11; SCA11	604432
WELANDER DISTAL MYOPATHY; WDM	WELANDER DISTAL MYOPATHY; WDM	604454
MUSCULAR DYSTROPHY, DISTAL, LATE-ONSET, AUTOSOMAL DOMINANT	WELANDER DISTAL MYOPATHY; WDM	604454
MYOPATHY, DISTAL, SWEDISH	WELANDER DISTAL MYOPATHY; WDM	604454
NEUROPATHY, HEREDITARY MOTOR AND SENSORY, OKINAWA TYPE; HMSNO	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, OKINAWA TYPE; HMSNO	604484
HEREDITARY MOTOR AND SENSORY NEUROPATHY, PROXIMAL TYPE, FORMERLY;HMSNP, FORMERLY	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, OKINAWA TYPE; HMSNO	604484
AMEGAKARYOCYTIC THROMBOCYTOPENIA, CONGENITAL; CAMT	AMEGAKARYOCYTIC THROMBOCYTOPENIA, CONGENITAL; CAMT	604498
HYPERLIPIDEMIA, COMBINED, 2	HYPERLIPIDEMIA, COMBINED, 2	604499
HYPLIP2	HYPERLIPIDEMIA, COMBINED, 2	604499
HYPERLIPIDEMIA, FAMILIAL COMBINED, 2; FCHL2	HYPERLIPIDEMIA, COMBINED, 2	604499
INFLAMMATORY BOWEL DISEASE 3; IBD3	INFLAMMATORY BOWEL DISEASE 3; IBD3	604519
ECTODERMAL DYSPLASIA/SKIN FRAGILITY SYNDROME	ECTODERMAL DYSPLASIA/SKIN FRAGILITY SYNDROME	604536
MCGRATH SYNDROME	ECTODERMAL DYSPLASIA/SKIN FRAGILITY SYNDROME	604536
LEBER CONGENITAL AMAUROSIS 5; LCA5	LEBER CONGENITAL AMAUROSIS 5; LCA5	604537
VAN DER WOUDE SYNDROME 1, MODIFIER OF	VAN DER WOUDE SYNDROME 1, MODIFIER OF	604547
VWSM	VAN DER WOUDE SYNDROME 1, MODIFIER OF	604547
PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IB; PFHB1B	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IB; PFHB1B	604559
PFHBIB	PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IB; PFHB1B	604559
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B2; CMT4B2	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B2; CMT4B2	604563
CHARCOT-MARIE-TOOTH DISEASE, WITH FOCALLY FOLDED MYELIN SHEATHS, AUTOSOMALRECESSIVE, TYPE 4B2	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B2; CMT4B2	604563
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4B2CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B2, WITH EARLY-ONSET GLAUCOMA,INCLUDED	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B2; CMT4B2	604563
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4B2, WITH EARLY-ONSET GLAUCOMA,INCLUDED	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B2; CMT4B2	604563
BARE LYMPHOCYTE SYNDROME, TYPE I	BARE LYMPHOCYTE SYNDROME, TYPE I	604571
BLS, TYPE I	BARE LYMPHOCYTE SYNDROME, TYPE I	604571
HLA CLASS I DEFICIENCY	BARE LYMPHOCYTE SYNDROME, TYPE I	604571
CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 1	CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 1	604595
CLQTL1	CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 1	604595
CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 13	CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 1	604595
CHOLESTEROL-LOWERING FACTOR; CLF	CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 1	604595
TOOTH AGENESIS, SELECTIVE, 3; STHAG3	TOOTH AGENESIS, SELECTIVE, 3; STHAG3	604625
HYPODONTIA/OLIGODONTIA 3	TOOTH AGENESIS, SELECTIVE, 3; STHAG3	604625
ORTHOSTATIC INTOLERANCE	ORTHOSTATIC INTOLERANCE	604715
NEUROCIRCULATORY ASTHENIA	ORTHOSTATIC INTOLERANCE	604715
MITRAL VALVE PROLAPSE SYNDROME	ORTHOSTATIC INTOLERANCE	604715
IRRITABLE HEART	ORTHOSTATIC INTOLERANCE	604715
SOLDIERS HEART	ORTHOSTATIC INTOLERANCE	604715
DEAFNESS, AUTOSOMAL DOMINANT 20; DFNA20	DEAFNESS, AUTOSOMAL DOMINANT 20; DFNA20	604717
DFNA26	DEAFNESS, AUTOSOMAL DOMINANT 20; DFNA20	604717
CRANIOSYNOSTOSIS 2; CRS2	CRANIOSYNOSTOSIS 2; CRS2	604757
CRANIOSYNOSTOSIS, BOSTON-TYPE; CSB	CRANIOSYNOSTOSIS 2; CRS2	604757
CARDIOMYOPATHY, DILATED, 1I; CMD1I	CARDIOMYOPATHY, DILATED, 1I; CMD1I	604765
VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH ORWITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH ORWITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1	604772
VENTRICULAR TACHYCARDIA, STRESS-INDUCED POLYMORPHIC; VTSIP	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH ORWITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1	604772
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 5; ARCI5	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 5; ARCI5	604777
ICHTHYOSIS, NONLAMELLAR AND NONERYTHRODERMIC, CONGENITAL, AUTOSOMALRECESSIVE; NNCI	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 5; ARCI5	604777
ICHTHYOSIS CONGENITA III	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 5; ARCI5	604777
ICHTHYOSIS, LAMELLAR, 3, FORMERLY; LI3, FORMERLY	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 5; ARCI5	604777
MUSCULAR DYSTROPHY, CONGENITAL, 1B; MDC1B	MUSCULAR DYSTROPHY, CONGENITAL, 1B; MDC1B	604801
HUNTINGTON DISEASE-LIKE 3; HDL3	HUNTINGTON DISEASE-LIKE 3; HDL3	604802
HUNTINGTON DISEASE-LIKE NEURODEGENERATIVE DISORDER, AUTOSOMAL RECESSIVE	HUNTINGTON DISEASE-LIKE 3; HDL3	604802
MICROCEPHALY 3, PRIMARY, AUTOSOMAL RECESSIVE; MCPH3	MICROCEPHALY 3, PRIMARY, AUTOSOMAL RECESSIVE; MCPH3	604804
SPASTIC PARAPLEGIA 12, AUTOSOMAL DOMINANT; SPG12	SPASTIC PARAPLEGIA 12, AUTOSOMAL DOMINANT; SPG12	604805
PANBRONCHIOLITIS, DIFFUSE	PANBRONCHIOLITIS, DIFFUSE	604809
DPB	PANBRONCHIOLITIS, DIFFUSE	604809
PBLT	PANBRONCHIOLITIS, DIFFUSE	604809
KLOTHO; KL	KLOTHO; KL	604824
ALPHA-KLOTHOCORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED	KLOTHO; KL	604824
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 7; EIG7MYOCLONIC EPILEPSY, JUVENILE, 2, INCLUDED; EJM2, INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 7; EIG7MYOCLONIC EPILEPSY, JUVENILE, 2, INCLUDED; EJM2, INCLUDED	604827
STICKLER SYNDROME, TYPE II; STL2	STICKLER SYNDROME, TYPE II; STL2	604841
STICKLER SYNDROME, VITREOUS TYPE 2	STICKLER SYNDROME, TYPE II; STL2	604841
STICKLER SYNDROME, BEADED VITREOUS TYPE	STICKLER SYNDROME, TYPE II; STL2	604841
OSTEOARTHRITIS WITH MILD CHONDRODYSPLASIA; OSCDPNAMAQUALAND HIP DYSPLASIA; NHD	OSTEOARTHRITIS WITH MILD CHONDRODYSPLASIA; OSCDPNAMAQUALAND HIP DYSPLASIA; NHD	604864
TASTE RECEPTOR, TYPE 2, MEMBER 16; TAS2R16	TASTE RECEPTOR, TYPE 2, MEMBER 16; TAS2R16	604867
T2R16BETA-GLYCOPYRANOSIDE TASTING, INCLUDED	TASTE RECEPTOR, TYPE 2, MEMBER 16; TAS2R16	604867
NORTH AMERICAN INDIAN CHILDHOOD CIRRHOSIS; NAIC	NORTH AMERICAN INDIAN CHILDHOOD CIRRHOSIS; NAIC	604901
SCHIZOPHRENIA 9; SCZD9	SCHIZOPHRENIA 9; SCZD9	604906
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 1q42-RELATED	SCHIZOPHRENIA 9; SCZD9	604906
WOLFRAM SYNDROME 2; WFS2	WOLFRAM SYNDROME 2; WFS2	604928
CORTISONE REDUCTASE DEFICIENCY 1; CORTRD1	CORTISONE REDUCTASE DEFICIENCY 1; CORTRD1	604931
PROTOCADHERIN-ALPHA GENE CLUSTER; PCDHA@	PROTOCADHERIN-ALPHA GENE CLUSTER; PCDHA@	604966
PCDH-ALPHA GENE CLUSTER; PCDHA	PROTOCADHERIN-ALPHA GENE CLUSTER; PCDHA@	604966
PROTOCADHERIN-BETA GENE CLUSTER; PCDHB@	PROTOCADHERIN-BETA GENE CLUSTER; PCDHB@	604967
PCDH-BETA GENE CLUSTER; PCDHB	PROTOCADHERIN-BETA GENE CLUSTER; PCDHB@	604967
PROTOCADHERIN-GAMMA GENE CLUSTER; PCDHG@	PROTOCADHERIN-GAMMA GENE CLUSTER; PCDHG@	604968
PCDH-GAMMA GENE CLUSTER; PCDHG	PROTOCADHERIN-GAMMA GENE CLUSTER; PCDHG@	604968
PROTEIN KINASE, AMP-ACTIVATED, NONCATALYTIC, GAMMA-3; PRKAG3GLYCOGEN CONTENT IN SKELETAL MUSCLE, INCREASED, INCLUDED	PROTEIN KINASE, AMP-ACTIVATED, NONCATALYTIC, GAMMA-3; PRKAG3GLYCOGEN CONTENT IN SKELETAL MUSCLE, INCREASED, INCLUDED	604976
MICROHYDRANENCEPHALY; MHAC	MICROHYDRANENCEPHALY; MHAC	605013
HYDRANENCEPHALY AND MICROCEPHALY	MICROHYDRANENCEPHALY; MHAC	605013
HYPOBETALIPOPROTEINEMIA, FAMILIAL, 2; FHBL2	HYPOBETALIPOPROTEINEMIA, FAMILIAL, 2; FHBL2	605019
HYPOLIPIDEMIA, FAMILIAL, COMBINED	HYPOBETALIPOPROTEINEMIA, FAMILIAL, 2; FHBL2	605019
MYOCLONIC EPILEPSY, FAMILIAL INFANTILE; FIME	MYOCLONIC EPILEPSY, FAMILIAL INFANTILE; FIME	605021
EIM	MYOCLONIC EPILEPSY, FAMILIAL INFANTILE; FIME	605021
LYMPHOMA, NON-HODGKIN, FAMILIAL	LYMPHOMA, NON-HODGKIN, FAMILIAL	605027
NON-HODGKIN LYMPHOMA; NHL	LYMPHOMA, NON-HODGKIN, FAMILIAL	605027
BOHRING-OPITZ SYNDROME; BOPS	BOHRING-OPITZ SYNDROME; BOPS	605039
C-LIKE SYNDROME	BOHRING-OPITZ SYNDROME; BOPS	605039
OPITZ TRIGONOCEPHALY-LIKE SYNDROME	BOHRING-OPITZ SYNDROME; BOPS	605039
BOHRING SYNDROME	BOHRING-OPITZ SYNDROME; BOPS	605039
BROOKE-SPIEGLER SYNDROME; BRSS	BROOKE-SPIEGLER SYNDROME; BRSS	605041
BSS	BROOKE-SPIEGLER SYNDROME; BRSS	605041
SPIEGLER-BROOKE SYNDROME; SBS	BROOKE-SPIEGLER SYNDROME; BRSS	605041
ALZHEIMER DISEASE, FAMILIAL EARLY-ONSET, WITH COEXISTING AMYLOID ANDPRION PATHOLOGY	ALZHEIMER DISEASE, FAMILIAL EARLY-ONSET, WITH COEXISTING AMYLOID ANDPRION PATHOLOGY	605055
RENAL CELL CARCINOMA, PAPILLARY, 1; RCCP1	RENAL CELL CARCINOMA, PAPILLARY, 1; RCCP1	605074
HYPERTENSION, EARLY-ONSET, AUTOSOMAL DOMINANT, WITH SEVERE EXACERBATIONIN PREGNANCY	HYPERTENSION, EARLY-ONSET, AUTOSOMAL DOMINANT, WITH SEVERE EXACERBATIONIN PREGNANCY	605115
WIEDEMANN-STEINER SYNDROME; WDSTS	WIEDEMANN-STEINER SYNDROME; WDSTS	605130
HAIRY ELBOWS, SHORT STATURE, FACIAL DYSMORPHISM, AND DEVELOPMENTALDELAY	WIEDEMANN-STEINER SYNDROME; WDSTS	605130
DEAFNESS, AUTOSOMAL DOMINANT 23; DFNA23	DEAFNESS, AUTOSOMAL DOMINANT 23; DFNA23	605192
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS14; HDLCQ14	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS14; HDLCQ14	605201
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 2; SLEB2	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 2; SLEB2	605218
INFLAMMATORY BOWEL DISEASE 7; IBD7	INFLAMMATORY BOWEL DISEASE 7; IBD7	605225
SPASTIC PARAPLEGIA 14, AUTOSOMAL RECESSIVE; SPG14	SPASTIC PARAPLEGIA 14, AUTOSOMAL RECESSIVE; SPG14	605229
BARDET-BIEDL SYNDROME 6; BBS6	BARDET-BIEDL SYNDROME 6; BBS6	605231
DIANZANI AUTOIMMUNE LYMPHOPROLIFERATIVE DISEASE	DIANZANI AUTOIMMUNE LYMPHOPROLIFERATIVE DISEASE	605233
DALD	DIANZANI AUTOIMMUNE LYMPHOPROLIFERATIVE DISEASE	605233
CARNEY COMPLEX, TYPE 2; CNC2	CARNEY COMPLEX, TYPE 2; CNC2	605244
CARNEY MYXOMA-ENDOCRINE COMPLEX, TYPE 2	CARNEY COMPLEX, TYPE 2; CNC2	605244
SEBASTIAN SYNDROME; SBS	SEBASTIAN SYNDROME; SBS	605249
SEBASTIAN PLATELET SYNDROME	SEBASTIAN SYNDROME; SBS	605249
MACROTHROMBOCYTOPENIA WITH DISPERSED LEUKOCYTIC INCLUSIONS	SEBASTIAN SYNDROME; SBS	605249
NEUROPATHY, CONGENITAL HYPOMYELINATING OR AMYELINATING, AUTOSOMALRECESSIVE; CHN	NEUROPATHY, CONGENITAL HYPOMYELINATING OR AMYELINATING, AUTOSOMALRECESSIVE; CHN	605253
HYPOMYELINATION, SEVERE CONGENITAL	NEUROPATHY, CONGENITAL HYPOMYELINATING OR AMYELINATING, AUTOSOMALRECESSIVE; CHN	605253
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4E; CMT4E	NEUROPATHY, CONGENITAL HYPOMYELINATING OR AMYELINATING, AUTOSOMALRECESSIVE; CHN	605253
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4ENEUROPATHY, CONGENITAL HYPOMYELINATING, AUTOSOMAL DOMINANT, INCLUDED	NEUROPATHY, CONGENITAL HYPOMYELINATING OR AMYELINATING, AUTOSOMALRECESSIVE; CHN	605253
IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 2; HIGM2	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 2; HIGM2	605258
HYPER-IgM SYNDROME 2	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 2; HIGM2	605258
SPINOCEREBELLAR ATAXIA 13; SCA13	SPINOCEREBELLAR ATAXIA 13; SCA13	605259
SPASTIC PARAPLEGIA 13, AUTOSOMAL DOMINANT; SPG13	SPASTIC PARAPLEGIA 13, AUTOSOMAL DOMINANT; SPG13	605280
TEMTAMY PREAXIAL BRACHYDACTYLY SYNDROME; TPBS	TEMTAMY PREAXIAL BRACHYDACTYLY SYNDROME; TPBS	605282
PREAXIAL BRACHYDACTYLY SYNDROME, TEMTAMY TYPE	TEMTAMY PREAXIAL BRACHYDACTYLY SYNDROME; TPBS	605282
NEUROPATHY, HEREDITARY MOTOR AND SENSORY, RUSSE TYPE; HMSNR	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, RUSSE TYPE; HMSNR	605285
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4G; CMT4G	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, RUSSE TYPE; HMSNR	605285
CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, TYPE 4G	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, RUSSE TYPE; HMSNR	605285
HEREDITARY MOTOR AND SENSORY NEUROPATHY, RUSSE TYPE	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, RUSSE TYPE; HMSNR	605285
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4G	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, RUSSE TYPE; HMSNR	605285
SPLIT-HAND/FOOT MALFORMATION 4; SHFM4	SPLIT-HAND/FOOT MALFORMATION 4; SHFM4	605289
OPTIC ATROPHY 4; OPA4	OPTIC ATROPHY 4; OPA4	605293
MACROCEPHALY/AUTISM SYNDROME	MACROCEPHALY/AUTISM SYNDROME	605309
NEMALINE MYOPATHY 5; NEM5	NEMALINE MYOPATHY 5; NEM5	605355
NEMALINE MYOPATHY, AMISH TYPE; ANM	NEMALINE MYOPATHY 5; NEM5	605355
AMISH NEMALINE MYOPATHY	NEMALINE MYOPATHY 5; NEM5	605355
SPINOCEREBELLAR ATAXIA 14; SCA14	SPINOCEREBELLAR ATAXIA 14; SCA14	605361
CARDIOMYOPATHY, DILATED, 1J; CMD1J	CARDIOMYOPATHY, DILATED, 1J; CMD1J	605362
CARDIOMYOPATHY, DILATED, WITH SENSORINEURAL HEARING LOSS, AUTOSOMALDOMINANT	CARDIOMYOPATHY, DILATED, 1J; CMD1J	605362
PSORIASIS 6, SUSCEPTIBILITY TO; PSORS6	PSORIASIS 6, SUSCEPTIBILITY TO; PSORS6	605364
BREAST CANCER 3; BRCA3	BREAST CANCER 3; BRCA3	605365
BRCAX	BREAST CANCER 3; BRCA3	605365
PARAGANGLIOMAS 3; PGL3	PARAGANGLIOMAS 3; PGL3	605373
GLOMUS TUMORS, FAMILIAL, 3	PARAGANGLIOMAS 3; PGL3	605373
EPILEPSY, NOCTURNAL FRONTAL LOBE, 3; ENFL3	EPILEPSY, NOCTURNAL FRONTAL LOBE, 3; ENFL3	605375
HETEROTAXY, VISCERAL, 2, AUTOSOMAL; HTX2	HETEROTAXY, VISCERAL, 2, AUTOSOMAL; HTX2	605376
HTX	HETEROTAXY, VISCERAL, 2, AUTOSOMAL; HTX2	605376
CATARACT 31, MULTIPLE TYPES; CTRCT31	CATARACT 31, MULTIPLE TYPES; CTRCT31	605387
CATARACT, POSTERIOR POLAR, 3; CTPP3; CPP3	CATARACT 31, MULTIPLE TYPES; CTRCT31	605387
CEREBRAL PALSY, ATAXIC, AUTOSOMAL RECESSIVE	CEREBRAL PALSY, ATAXIC, AUTOSOMAL RECESSIVE	605388
ACP	CEREBRAL PALSY, ATAXIC, AUTOSOMAL RECESSIVE	605388
ATAXIC CEREBRAL PALSY	CEREBRAL PALSY, ATAXIC, AUTOSOMAL RECESSIVE	605388
HYPOTRICHOSIS 1; HYPT1	HYPOTRICHOSIS 1; HYPT1	605389
HYPOTRICHOSIS SIMPLEX, GENERALIZED, HEREDITARY; HHS	HYPOTRICHOSIS 1; HYPT1	605389
HTS	HYPOTRICHOSIS 1; HYPT1	605389
SEGAWA SYNDROME, AUTOSOMAL RECESSIVE	SEGAWA SYNDROME, AUTOSOMAL RECESSIVE	605407
PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE	SEGAWA SYNDROME, AUTOSOMAL RECESSIVE	605407
DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE	SEGAWA SYNDROME, AUTOSOMAL RECESSIVE	605407
DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE	SEGAWA SYNDROME, AUTOSOMAL RECESSIVE	605407
TYROSINE HYDROXYLASE DEFICIENCY	SEGAWA SYNDROME, AUTOSOMAL RECESSIVE	605407
SCHIZOPHRENIA 10; SCZD10	SCHIZOPHRENIA 10; SCZD10	605419
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 15q15-RELATED	SCHIZOPHRENIA 10; SCZD10	605419
CATATONIA, PERIODIC	SCHIZOPHRENIA 10; SCZD10	605419
DEAFNESS, AUTOSOMAL RECESSIVE 26; DFNB26	DEAFNESS, AUTOSOMAL RECESSIVE 26; DFNB26	605428
DEAFNESS, NONSYNDROMIC, MODIFIER 1; DFNM1	DEAFNESS, NONSYNDROMIC, MODIFIER 1; DFNM1	605429
RADIOULNAR SYNOSTOSIS WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA; RUSAT	RADIOULNAR SYNOSTOSIS WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA; RUSAT	605432
THROMBOCYTOPENIA, CONGENITAL, WITH RADIOULNAR SYNOSTOSIS; CTRUS	RADIOULNAR SYNOSTOSIS WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA; RUSAT	605432
BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 1; BCC1BASAL CELL CARCINOMA, NONSYNDROMIC, INCLUDED	BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 1; BCC1BASAL CELL CARCINOMA, NONSYNDROMIC, INCLUDED	605462
BASAL CELL CARCINOMA, MULTIPLE, INCLUDED	BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 1; BCC1BASAL CELL CARCINOMA, NONSYNDROMIC, INCLUDED	605462
USHER SYNDROME, TYPE IIC; USH2CUSHER SYNDROME, TYPE IIC, GPR98/PDZD7, DIGENIC, INCLUDED	USHER SYNDROME, TYPE IIC; USH2CUSHER SYNDROME, TYPE IIC, GPR98/PDZD7, DIGENIC, INCLUDED	605472
USHER SYNDROME, TYPE IIB, FORMERLY, INCLUDED; USH2B, FORMERLY, INCLUDED	USHER SYNDROME, TYPE IIC; USH2CUSHER SYNDROME, TYPE IIC, GPR98/PDZD7, DIGENIC, INCLUDED	605472
CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 2; BRIC2	CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 2; BRIC2	605479
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 3; SLEB3	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 3; SLEB3	605480
ALZHEIMER DISEASE 6	ALZHEIMER DISEASE 6	605526
AD6	ALZHEIMER DISEASE 6	605526
ALZHEIMER DISEASE 6, LATE-ONSETPLASMA BETA-AMYLOID-42 LEVEL QUANTITATIVE TRAIT LOCUS, INCLUDED	ALZHEIMER DISEASE 6	605526
PARKINSON DISEASE 4, AUTOSOMAL DOMINANT; PARK4	PARKINSON DISEASE 4, AUTOSOMAL DOMINANT; PARK4	605543
PARKINSON DISEASE 4, AUTOSOMAL DOMINANT LEWY BODY	PARKINSON DISEASE 4, AUTOSOMAL DOMINANT; PARK4	605543
FIBROMATOSIS, GINGIVAL, 2; GINGF2	FIBROMATOSIS, GINGIVAL, 2; GINGF2	605544
GGF2	FIBROMATOSIS, GINGIVAL, 2; GINGF2	605544
FIBROMATOSIS, GINGIVAL, HEREDITARY, 2; HGF2	FIBROMATOSIS, GINGIVAL, 2; GINGF2	605544
CONE-ROD DYSTROPHY 8; CORD8	CONE-ROD DYSTROPHY 8; CORD8	605549
ABDOMINAL OBESITY-METABOLIC SYNDROME 1; AOMS1	ABDOMINAL OBESITY-METABOLIC SYNDROME 1; AOMS1	605552
METABOLIC SYNDROME XABDOMINAL OBESITY-METABOLIC SYNDROME QUANTITATIVE TRAIT LOCUS 1, INCLUDED	ABDOMINAL OBESITY-METABOLIC SYNDROME 1; AOMS1	605552
METABOLIC SYNDROME, PROTECTION AGAINST, INCLUDED	ABDOMINAL OBESITY-METABOLIC SYNDROME 1; AOMS1	605552
ABDOMINAL OBESITY-METABOLIC SYNDROME QUANTITATIVE TRAIT LOCUS 2	ABDOMINAL OBESITY-METABOLIC SYNDROME QUANTITATIVE TRAIT LOCUS 2	605572
AOMS2	ABDOMINAL OBESITY-METABOLIC SYNDROME QUANTITATIVE TRAIT LOCUS 2	605572
CARDIOMYOPATHY, DILATED, 1K; CMD1K	CARDIOMYOPATHY, DILATED, 1K; CMD1K	605582
DEAFNESS, AUTOSOMAL DOMINANT 25; DFNA25	DEAFNESS, AUTOSOMAL DOMINANT 25; DFNA25	605583
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B1; CMT2B1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B1; CMT2B1	605588
CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2B1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B1; CMT2B1	605588
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, 2B1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B1; CMT2B1	605588
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2B1	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B1; CMT2B1	605588
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B2; CMT2B2	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B2; CMT2B2	605589
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2B2	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B2; CMT2B2	605589
CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2B2	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B2; CMT2B2	605589
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2B2	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B2; CMT2B2	605589
ARCMT2B	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B2; CMT2B2	605589
DEAFNESS, AUTOSOMAL DOMINANT 39, WITH DENTINOGENESIS IMPERFECTA 1	DEAFNESS, AUTOSOMAL DOMINANT 39, WITH DENTINOGENESIS IMPERFECTA 1	605594
DFNA39/DENTINOGENESIS IMPERFECTA 1 SYNDROME	DEAFNESS, AUTOSOMAL DOMINANT 39, WITH DENTINOGENESIS IMPERFECTA 1	605594
DFNA39/DGI1 SYNDROME	DEAFNESS, AUTOSOMAL DOMINANT 39, WITH DENTINOGENESIS IMPERFECTA 1	605594
DGI1/DFNA39 SYNDROME	DEAFNESS, AUTOSOMAL DOMINANT 39, WITH DENTINOGENESIS IMPERFECTA 1	605594
DIABETES MELLITUS, INSULIN-DEPENDENT, 18; IDDM18	DIABETES MELLITUS, INSULIN-DEPENDENT, 18; IDDM18	605598
INSULIN-DEPENDENT DIABETES MELLITUS 18	DIABETES MELLITUS, INSULIN-DEPENDENT, 18; IDDM18	605598
PSORIASIS 7, SUSCEPTIBILITY TO; PSORS7	PSORIASIS 7, SUSCEPTIBILITY TO; PSORS7	605606
CEREBROOCULONASAL SYNDROME	CEREBROOCULONASAL SYNDROME	605627
HYPERALDOSTERONISM, FAMILIAL, TYPE II	HYPERALDOSTERONISM, FAMILIAL, TYPE II	605635
FH II	HYPERALDOSTERONISM, FAMILIAL, TYPE II	605635
MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA; MYPOP	MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA; MYPOP	605637
MYOPATHY WITH CONGENITAL JOINT CONTRACTURES, OPHTHALMOPLEGIA, ANDRIMMED VACUOLES	MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA; MYPOP	605637
INCLUSION BODY MYOPATHY 3, AUTOSOMAL DOMINANT, FORMERLY; IBM3, FORMERLY	MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA; MYPOP	605637
THYROID CARCINOMA, PAPILLARY, WITH PAPILLARY RENAL NEOPLASIA	THYROID CARCINOMA, PAPILLARY, WITH PAPILLARY RENAL NEOPLASIA	605642
PTCPRN	THYROID CARCINOMA, PAPILLARY, WITH PAPILLARY RENAL NEOPLASIA	605642
PRN1	THYROID CARCINOMA, PAPILLARY, WITH PAPILLARY RENAL NEOPLASIA	605642
LATE-ONSET RETINAL DEGENERATION; LORD	LATE-ONSET RETINAL DEGENERATION; LORD	605670
RETINAL DEGENERATION, LATE-ONSET, AUTOSOMAL DOMINANT	LATE-ONSET RETINAL DEGENERATION; LORD	605670
CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR AND KERATODERMA; DCWHK	CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR AND KERATODERMA; DCWHK	605676
CARVAJAL SYNDROME	CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR AND KERATODERMA; DCWHK	605676
PALMOPLANTAR KERATODERMA WITH LEFT VENTRICULAR CARDIOMYOPATHY ANDWOOLLY HAIR	CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR AND KERATODERMA; DCWHK	605676
MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 1; MMDS1	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 1; MMDS1	605711
MMDS	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 1; MMDS1	605711
CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED	CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED	605714
AMYLOIDOSIS, CEREBROARTERIAL, APP-RELATED	CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED	605714
AMYLOIDOSIS, HEREDITARY, WITH CEREBRAL HEMORRHAGE, DUTCH VARIANT;HCHWAD	CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED	605714
CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, DUTCH VARIANT	CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED	605714
CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, IOWA VARIANT	CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED	605714
CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, ITALIAN VARIANT	CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED	605714
CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, FLEMISH VARIANT	CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED	605714
CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, ARCTIC VARIANT	CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED	605714
FANCONI ANEMIA, COMPLEMENTATION GROUP D1; FANCD1	FANCONI ANEMIA, COMPLEMENTATION GROUP D1; FANCD1	605724
FAD1	FANCONI ANEMIA, COMPLEMENTATION GROUP D1; FANCD1	605724
SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 2; DSMA2	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 2; DSMA2	605726
NEURONOPATHY, DISTAL HEREDITARY MOTOR, JERASH TYPE	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 2; DSMA2	605726
NEUROPATHY, DISTAL HEREDITARY MOTOR, JERASH TYPE; HMNJ	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 2; DSMA2	605726
SPINAL MUSCULAR ATROPHY, JERASH TYPE	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 2; DSMA2	605726
OTOSCLEROSIS 2; OTSC2	OTOSCLEROSIS 2; OTSC2	605727
CATARACT 25; CTRCT25	CATARACT 25; CTRCT25	605728
CATARACT, CENTRAL SACCULAR, WITH SUTURAL OPACITIES; CCSSO	CATARACT 25; CTRCT25	605728
CATARACT, CENTRAL POUCH-LIKE, WITH SUTURAL OPACITIES	CATARACT 25; CTRCT25	605728
BLEEDING DISORDER, PLATELET-TYPE, 12; BDPLT12	BLEEDING DISORDER, PLATELET-TYPE, 12; BDPLT12	605735
PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 1 DEFICIENCY, PLATELET	BLEEDING DISORDER, PLATELET-TYPE, 12; BDPLT12	605735
PGHS1 DEFICIENCY	BLEEDING DISORDER, PLATELET-TYPE, 12; BDPLT12	605735
PLATELET CYCLOOXYGENASE 1 DEFICIENCY	BLEEDING DISORDER, PLATELET-TYPE, 12; BDPLT12	605735
PLATELET COX1 DEFICIENCY	BLEEDING DISORDER, PLATELET-TYPE, 12; BDPLT12	605735
MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 2; MCOPCB2	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 2; MCOPCB2	605738
MICROPHTHALMIA, COLOBOMATOUS, ISOLATED 2; MCOPCB2	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 2; MCOPCB2	605738
ANISOMASTIA	ANISOMASTIA	605746
CATARACT 26, MULTIPLE TYPES; CTRCT26	CATARACT 26, MULTIPLE TYPES; CTRCT26	605749
CATARACT, AUTOSOMAL RECESSIVE, EARLY-ONSET, PULVERULENT; CAAR	CATARACT 26, MULTIPLE TYPES; CTRCT26	605749
EXUDATIVE VITREORETINOPATHY 3; EVR3	EXUDATIVE VITREORETINOPATHY 3; EVR3	605750
SEIZURES, BENIGN FAMILIAL INFANTILE, 2; BFIS2	SEIZURES, BENIGN FAMILIAL INFANTILE, 2; BFIS2	605751
CONVULSIONS, BENIGN FAMILIAL INFANTILE, 2; BFIC2	SEIZURES, BENIGN FAMILIAL INFANTILE, 2; BFIS2	605751
NAIL DISORDER, NONSYNDROMIC CONGENITAL, 7; NDNC7	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 7; NDNC7	605779
ONYCHODYSPLASIA, ISOLATED CONGENITAL	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 7; NDNC7	605779
DERMATITIS, ATOPIC, 2; ATOD2	DERMATITIS, ATOPIC, 2; ATOD2	605803
DERMATITIS, ATOPIC, 3; ATOD3	DERMATITIS, ATOPIC, 3; ATOD3	605804
DERMATITIS, ATOPIC, WITH ASTHMA	DERMATITIS, ATOPIC, 3; ATOD3	605804
DERMATITIS, ATOPIC, 4; ATOD4	DERMATITIS, ATOPIC, 4; ATOD4	605805
MYASTHENIC SYNDROME, CONGENITAL, 4A, SLOW-CHANNEL; CMS4A	MYASTHENIC SYNDROME, CONGENITAL, 4A, SLOW-CHANNEL; CMS4A	605809
CONGENITAL MYASTHENIC SYNDROME TYPE Ia1, FORMERLY; CMS1A1, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 4A, SLOW-CHANNEL; CMS4A	605809
CMS Ia1, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 4A, SLOW-CHANNEL; CMS4A	605809
CITRULLINEMIA, TYPE II, NEONATAL-ONSET	CITRULLINEMIA, TYPE II, NEONATAL-ONSET	605814
CHOLESTASIS, NEONATAL INTRAHEPATIC, CAUSED BY CITRIN DEFICIENCY; NICCD	CITRULLINEMIA, TYPE II, NEONATAL-ONSET	605814
DEAFNESS, AUTOSOMAL RECESSIVE 27; DFNB27	DEAFNESS, AUTOSOMAL RECESSIVE 27; DFNB27	605818
NONAKA MYOPATHY; NM	NONAKA MYOPATHY; NM	605820
NONAKA DISTAL MYOPATHY	NONAKA MYOPATHY; NM	605820
MYOPATHY, DISTAL, WITH RIMMED VACUOLES; DMRV	NONAKA MYOPATHY; NM	605820
INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM	NONAKA MYOPATHY; NM	605820
INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM	NONAKA MYOPATHY; NM	605820
GNE MYOPATHY	NONAKA MYOPATHY; NM	605820
INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY	NONAKA MYOPATHY; NM	605820
SPONDYLOOCULAR SYNDROME; SOS	SPONDYLOOCULAR SYNDROME; SOS	605822
BASALOID FOLLICULAR HAMARTOMA SYNDROME, GENERALIZED, AUTOSOMAL DOMINANT;GBFHS	BASALOID FOLLICULAR HAMARTOMA SYNDROME, GENERALIZED, AUTOSOMAL DOMINANT;GBFHS	605827
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 2; BMND2	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 2; BMND2	605833
NARCOLEPSY 2, SUSCEPTIBILITY TO; NRCLP2	NARCOLEPSY 2, SUSCEPTIBILITY TO; NRCLP2	605841
DERMATITIS, ATOPIC, 5; ATOD5	DERMATITIS, ATOPIC, 5; ATOD5	605844
DERMATITIS, ATOPIC, 6; ATOD6	DERMATITIS, ATOPIC, 6; ATOD6	605845
DIMETHYLGLYCINE DEHYDROGENASE DEFICIENCY; DMGDHD	DIMETHYLGLYCINE DEHYDROGENASE DEFICIENCY; DMGDHD	605850
DMGDH DEFICIENCY	DIMETHYLGLYCINE DEHYDROGENASE DEFICIENCY; DMGDHD	605850
SHORT STATURE, MENTAL RETARDATION, CALLOSAL AGENESIS, HEMINASAL HYPOPLASIA,MICROPHTHALMIA, AND ATYPICAL CLEFTING	SHORT STATURE, MENTAL RETARDATION, CALLOSAL AGENESIS, HEMINASAL HYPOPLASIA,MICROPHTHALMIA, AND ATYPICAL CLEFTING	605856
GLYCINE ENCEPHALOPATHY; GCE	GLYCINE ENCEPHALOPATHY; GCE	605899
HYPERGLYCINEMIA, NONKETOTIC; NKHHYPERGLYCINEMIA, TRANSIENT NEONATAL, INCLUDED; TNH, INCLUDED	GLYCINE ENCEPHALOPATHY; GCE	605899
PARKINSON DISEASE 6, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK6	PARKINSON DISEASE 6, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK6	605909
PARKINSON DISEASE 6, EARLY-ONSET; PARK6PARKINSON DISEASE 6, LATE-ONSET, SUSCEPTIBILITY TO, INCLUDED	PARKINSON DISEASE 6, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK6	605909
PARKINSON DISEASE, AUTOSOMAL RECESSIVE EARLY-ONSET, DIGENIC, PINK1/DJ1,INCLUDED	PARKINSON DISEASE 6, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK6	605909
3-@HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE-2 DEFICIENCY; HMGCS2D	3-@HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE-2 DEFICIENCY; HMGCS2D	605911
MITOCHONDRIAL HMG-CoA SYNTHASE DEFICIENCY	3-@HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE-2 DEFICIENCY; HMGCS2D	605911
HMGCS2 DEFICIENCY	3-@HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE-2 DEFICIENCY; HMGCS2D	605911
BLEEDING DISORDER, EAST TEXAS TYPE	BLEEDING DISORDER, EAST TEXAS TYPE	605913
BDET	BLEEDING DISORDER, EAST TEXAS TYPE	605913
HOLOPROSENCEPHALY 6; HPE6	HOLOPROSENCEPHALY 6; HPE6	605934
METAPHYSEAL DYSPLASIA, BRAUN-TINSCHERT TYPE	METAPHYSEAL DYSPLASIA, BRAUN-TINSCHERT TYPE	605946
ACROPECTORAL SYNDROME; ACRPS	ACROPECTORAL SYNDROME; ACRPS	605967
ACRP SYNDROME	ACROPECTORAL SYNDROME; ACRPS	605967
SYNDACTYLY, PREAXIAL POLYDACTYLY, AND STERNAL DEFORMITY	ACROPECTORAL SYNDROME; ACRPS	605967
NEPHROLITHIASIS, URIC ACID, SUSCEPTIBILITY TO	NEPHROLITHIASIS, URIC ACID, SUSCEPTIBILITY TO	605990
UAN	NEPHROLITHIASIS, URIC ACID, SUSCEPTIBILITY TO	605990
UROLITHIASIS, URIC ACID, SUSCEPTIBILITY TO	NEPHROLITHIASIS, URIC ACID, SUSCEPTIBILITY TO	605990
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 1; SCAR1	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 1; SCAR1	606002
ATAXIA-OCULOMOTOR APRAXIA 2; AOA2	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 1; SCAR1	606002
ATAXIA-OCULAR APRAXIA 2	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 1; SCAR1	606002
TRANSALDOLASE DEFICIENCY	TRANSALDOLASE DEFICIENCY	606003
EYAID SYNDROME	TRANSALDOLASE DEFICIENCY	606003
TALDO DEFICIENCY	TRANSALDOLASE DEFICIENCY	606003
DEAFNESS, AUTOSOMAL DOMINANT 18; DFNA18	DEAFNESS, AUTOSOMAL DOMINANT 18; DFNA18	606012
FASTING INSULIN LEVEL QUANTITATIVE TRAIT LOCUS 1; FIQTL1	FASTING INSULIN LEVEL QUANTITATIVE TRAIT LOCUS 1; FIQTL1	606035
ACROMEGALOID FEATURES, OVERGROWTH, CLEFT PALATE, AND HERNIA	ACROMEGALOID FEATURES, OVERGROWTH, CLEFT PALATE, AND HERNIA	606049
AOCH	ACROMEGALOID FEATURES, OVERGROWTH, CLEFT PALATE, AND HERNIA	606049
AUTISM, SUSCEPTIBILITY TO, 5; AUTS5	AUTISM, SUSCEPTIBILITY TO, 5; AUTS5	606053
PHRASE SPEECH DELAY, AUTISM-RELATED	AUTISM, SUSCEPTIBILITY TO, 5; AUTS5	606053
AUTISM-RELATED SPEECH DELAY	AUTISM, SUSCEPTIBILITY TO, 5; AUTS5	606053
PROPIONIC ACIDEMIA	PROPIONIC ACIDEMIA	606054
PROPIONYL-CoA CARBOXYLASE DEFICIENCY	PROPIONIC ACIDEMIA	606054
PCC DEFICIENCY	PROPIONIC ACIDEMIA	606054
GLYCINEMIA, KETOTIC	PROPIONIC ACIDEMIA	606054
HYPERGLYCINEMIA WITH KETOACIDOSIS AND LEUKOPENIA	PROPIONIC ACIDEMIA	606054
KETOTIC HYPERGLYCINEMIA	PROPIONIC ACIDEMIA	606054
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIb; CDG2B	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIb; CDG2B	606056
CDG IIb; CDGIIb	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIb; CDG2B	606056
GLUCOSIDASE I DEFICIENCY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIb; CDG2B	606056
RETINITIS PIGMENTOSA 28; RP28	RETINITIS PIGMENTOSA 28; RP28	606068
HEMOCHROMATOSIS, TYPE 4; HFE4	HEMOCHROMATOSIS, TYPE 4; HFE4	606069
HEMOCHROMATOSIS, AUTOSOMAL DOMINANT	HEMOCHROMATOSIS, TYPE 4; HFE4	606069
HEMOCHROMATOSIS DUE TO DEFECT IN FERROPORTIN	HEMOCHROMATOSIS, TYPE 4; HFE4	606069
AMYOTROPHIC LATERAL SCLEROSIS 21; ALS21	AMYOTROPHIC LATERAL SCLEROSIS 21; ALS21	606070
MYOPATHY, DISTAL, 2, FORMERLY; MPD2, FORMERLY	AMYOTROPHIC LATERAL SCLEROSIS 21; ALS21	606070
VOCAL CORD AND PHARYNGEAL DYSFUNCTION WITH DISTAL MYOPATHY, FORMERLY;VCPDM, FORMERLY	AMYOTROPHIC LATERAL SCLEROSIS 21; ALS21	606070
HEREDITARY MOTOR AND SENSORY NEUROPATHY, TYPE IIC; HMSN2C	HEREDITARY MOTOR AND SENSORY NEUROPATHY, TYPE IIC; HMSN2C	606071
HMSN IIC	HEREDITARY MOTOR AND SENSORY NEUROPATHY, TYPE IIC; HMSN2C	606071
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2C;CMT2C	HEREDITARY MOTOR AND SENSORY NEUROPATHY, TYPE IIC; HMSN2C	606071
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2C	HEREDITARY MOTOR AND SENSORY NEUROPATHY, TYPE IIC; HMSN2C	606071
RIPPLING MUSCLE DISEASE; RMDRIPPLING MUSCLE DISEASE 2, INCLUDED; RMD2, INCLUDED	RIPPLING MUSCLE DISEASE; RMDRIPPLING MUSCLE DISEASE 2, INCLUDED; RMD2, INCLUDED	606072
GOITER, MULTINODULAR 3; MNG3	GOITER, MULTINODULAR 3; MNG3	606082
DIAMOND-BLACKFAN ANEMIA 2; DBA2	DIAMOND-BLACKFAN ANEMIA 2; DBA2	606129
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 3; NBIA3	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 3; NBIA3	606159
NEUROFERRITINOPATHY	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 3; NBIA3	606159
BASAL GANGLIA DISEASE, ADULT-ONSET	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 3; NBIA3	606159
DIAMOND-BLACKFAN ANEMIA 15 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA15	DIAMOND-BLACKFAN ANEMIA 15 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA15	606164
GENITOPATELLAR SYNDROME; GTPTS	GENITOPATELLAR SYNDROME; GTPTS	606170
ABSENT PATELLAE, SCROTAL HYPOPLASIA, RENAL ANOMALIES, FACIAL DYSMORPHISM,AND MENTAL RETARDATION	GENITOPATELLAR SYNDROME; GTPTS	606170
DIABETES MELLITUS, PERMANENT NEONATAL; PNDM	DIABETES MELLITUS, PERMANENT NEONATAL; PNDM	606176
DIABETES MELLITUS, PERMANENT, OF INFANCY; PDMIDIABETES MELLITUS, PERMANENT NEONATAL, WITH NEUROLOGIC FEATURES, INCLUDED	DIABETES MELLITUS, PERMANENT NEONATAL; PNDM	606176
DEVELOPMENTAL DELAY, EPILEPSY, AND NEONATAL DIABETES, INCLUDED; DEND,INCLUDED	DIABETES MELLITUS, PERMANENT NEONATAL; PNDM	606176
ALZHEIMER DISEASE 7	ALZHEIMER DISEASE 7	606187
ALZHEIMER DISEASE, FAMILIAL, 7	ALZHEIMER DISEASE 7	606187
AD7	ALZHEIMER DISEASE 7	606187
ATRIOVENTRICULAR SEPTAL DEFECT; AVSD	ATRIOVENTRICULAR SEPTAL DEFECT; AVSD	606215
ATRIOVENTRICULAR CANAL DEFECT; AVCD	ATRIOVENTRICULAR SEPTAL DEFECT; AVSD	606215
AVC DEFECT	ATRIOVENTRICULAR SEPTAL DEFECT; AVSD	606215
ENDOCARDIAL CUSHION DEFECT; ECDATRIOVENTRICULAR SEPTAL DEFECT, SUSCEPTIBILITY TO, 1, INCLUDED; AVSD1,INCLUDED	ATRIOVENTRICULAR SEPTAL DEFECT; AVSD	606215
ATRIOVENTRICULAR SEPTAL DEFECT, SUSCEPTIBILITY TO, 2; AVSD2ATRIOVENTRICULAR SEPTAL DEFECT, PARTIAL, WITH HETEROTAXY SYNDROME,INCLUDED	ATRIOVENTRICULAR SEPTAL DEFECT, SUSCEPTIBILITY TO, 2; AVSD2ATRIOVENTRICULAR SEPTAL DEFECT, PARTIAL, WITH HETEROTAXY SYNDROME,INCLUDED	606217
PHELAN-MCDERMID SYNDROME; PHMDS	PHELAN-MCDERMID SYNDROME; PHMDS	606232
CHROMOSOME 22q13.3 DELETION SYNDROME	PHELAN-MCDERMID SYNDROME; PHMDS	606232
TELOMERIC 22q13 MONOSOMY SYNDROME	PHELAN-MCDERMID SYNDROME; PHMDS	606232
THYROID CANCER, NONMEDULLARY, 3; NMTC3	THYROID CANCER, NONMEDULLARY, 3; NMTC3	606240
THYROID CANCER, NONMEDULLARY, 1, FORMERLY; NMTC1, FORMERLY	THYROID CANCER, NONMEDULLARY, 3; NMTC3	606240
MENTAL RETARDATION, MICROCEPHALY, GROWTH RETARDATION, JOINT CONTRACTURES,AND FACIAL DYSMORPHISM	MENTAL RETARDATION, MICROCEPHALY, GROWTH RETARDATION, JOINT CONTRACTURES,AND FACIAL DYSMORPHISM	606242
KONDOH SYNDROME	MENTAL RETARDATION, MICROCEPHALY, GROWTH RETARDATION, JOINT CONTRACTURES,AND FACIAL DYSMORPHISM	606242
ALVEOLAR SOFT PART SARCOMA; ASPS	ALVEOLAR SOFT PART SARCOMA; ASPS	606243
STATURE AS A QUANTITATIVE TRAITSTATURE QUANTITATIVE TRAIT LOCUS 1, INCLUDED; STQTL1, INCLUDED	STATURE AS A QUANTITATIVE TRAITSTATURE QUANTITATIVE TRAIT LOCUS 1, INCLUDED; STQTL1, INCLUDED	606255
STATURE QUANTITATIVE TRAIT LOCUS 2; STQTL2	STATURE QUANTITATIVE TRAIT LOCUS 2; STQTL2	606256
STATURE QUANTITATIVE TRAIT LOCUS 3; STQTL3	STATURE QUANTITATIVE TRAIT LOCUS 3; STQTL3	606257
STATURE QUANTITATIVE TRAIT LOCUS 4; STQTL4	STATURE QUANTITATIVE TRAIT LOCUS 4; STQTL4	606258
PAGET DISEASE OF BONE 4; PDB4	PAGET DISEASE OF BONE 4; PDB4	606263
DEAFNESS, AUTOSOMAL DOMINANT 24; DFNA24	DEAFNESS, AUTOSOMAL DOMINANT 24; DFNA24	606282
PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK7	PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK7	606324
HETEROTAXY, VISCERAL, 3, AUTOSOMAL; HTX3	HETEROTAXY, VISCERAL, 3, AUTOSOMAL; HTX3	606325
DEAFNESS, AUTOSOMAL DOMINANT 22; DFNA22DEAFNESS, AUTOSOMAL DOMINANT 22, WITH HYPERTROPHIC CARDIOMYOPATHY,INCLUDED	DEAFNESS, AUTOSOMAL DOMINANT 22; DFNA22DEAFNESS, AUTOSOMAL DOMINANT 22, WITH HYPERTROPHIC CARDIOMYOPATHY,INCLUDED	606346
INFLAMMATORY BOWEL DISEASE 5; IBD5	INFLAMMATORY BOWEL DISEASE 5; IBD5	606348
PRIMARY LATERAL SCLEROSIS, JUVENILE; PLSJ	PRIMARY LATERAL SCLEROSIS, JUVENILE; PLSJ	606353
PLS, JUVENILE	PRIMARY LATERAL SCLEROSIS, JUVENILE; PLSJ	606353
IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY; IMD41	IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY; IMD41	606367
INTERLEUKIN 2 RECEPTOR, ALPHA, DEFICIENCY OF	IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY; IMD41	606367
IL2RA DEFICIENCY	IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY; IMD41	606367
CD25 DEFICIENCY	IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY; IMD41	606367
MATURITY-ONSET DIABETES OF THE YOUNG; MODY	MATURITY-ONSET DIABETES OF THE YOUNG; MODY	606391
MASON-TYPE DIABETES	MATURITY-ONSET DIABETES OF THE YOUNG; MODY	606391
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 4; MODY4	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 4; MODY4	606392
MODY, TYPE 4	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 4; MODY4	606392
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 6; MODY6	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 6; MODY6	606394
MODY, TYPE 6	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 6; MODY6	606394
HYPOTONIA-CYSTINURIA SYNDROME	HYPOTONIA-CYSTINURIA SYNDROME	606407
CYSTINURIA WITH MITOCHONDRIAL DISEASE	HYPOTONIA-CYSTINURIA SYNDROME	606407
HOMOZYGOUS 2p16 DELETION SYNDROME, FORMERLYHOMOZYGOUS 2p21 DELETION SYNDROME, INCLUDED	HYPOTONIA-CYSTINURIA SYNDROME	606407
EHLERS-DANLOS SYNDROME DUE TO TENASCIN-X DEFICIENCY	EHLERS-DANLOS SYNDROME DUE TO TENASCIN-X DEFICIENCY	606408
EDS DUE TO TNX DEFICIENCY	EHLERS-DANLOS SYNDROME DUE TO TENASCIN-X DEFICIENCY	606408
TNX DEFICIENCY	EHLERS-DANLOS SYNDROME DUE TO TENASCIN-X DEFICIENCY	606408
HUNTINGTON DISEASE-LIKE 2; HDL2	HUNTINGTON DISEASE-LIKE 2; HDL2	606438
DEAFNESS, AUTOSOMAL DOMINANT 30; DFNA30	DEAFNESS, AUTOSOMAL DOMINANT 30; DFNA30	606451
LONGEVITY 2	LONGEVITY 2	606460
LGV2	LONGEVITY 2	606460
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB	606482
CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE B	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB	606482
DI-CMTB	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB	606482
CMTDI1CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2M, INCLUDED; CMT2M, INCLUDED	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB	606482
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2M,INCLUDED	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB	606482
CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2M, INCLUDED	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB	606482
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B, WITH NEUTROPENIA,INCLUDED	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB	606482
CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE B, WITH NEUTROPENIA,INCLUDED	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB	606482
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE A; CMTDIA	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE A; CMTDIA	606483
CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE A	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE A; CMTDIA	606483
DI-CMTA	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE A; CMTDIA	606483
HOMOZYGOUS 11p15-p14 DELETION SYNDROME	HOMOZYGOUS 11p15-p14 DELETION SYNDROME	606528
HYPERINSULINISM, INFANTILE, WITH ENTEROPATHY AND DEAFNESS	HOMOZYGOUS 11p15-p14 DELETION SYNDROME	606528
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 3; ARCI3	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 3; ARCI3	606545
COLLODION BABY, SELF-HEALING	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 3; ARCI3	606545
ICHTHYOSIS, LAMELLAR, 5, FORMERLY; LI5, FORMERLY	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 3; ARCI3	606545
EPISODIC ATAXIA, TYPE 4; EA4	EPISODIC ATAXIA, TYPE 4; EA4	606552
PERIODIC VESTIBULOCEREBELLAR ATAXIA; PATX	EPISODIC ATAXIA, TYPE 4; EA4	606552
ATAXIA, PERIODIC VESTIBULOCEREBELLAR	EPISODIC ATAXIA, TYPE 4; EA4	606552
EPISODIC ATAXIA, TYPE 3; EA3	EPISODIC ATAXIA, TYPE 3; EA3	606554
ATAXIA, EPISODIC, WITH VERTIGO AND TINNITUS	EPISODIC ATAXIA, TYPE 3; EA3	606554
ALBINISM, OCULOCUTANEOUS, TYPE IV; OCA4	ALBINISM, OCULOCUTANEOUS, TYPE IV; OCA4	606574
OCULOCUTANEOUS ALBINISM, TYPE IV	ALBINISM, OCULOCUTANEOUS, TYPE IV; OCA4	606574
VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1;VAMAS1	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1;VAMAS1	606579
VITILIGO; VTLG	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1;VAMAS1	606579
SYSTEMIC LUPUS ERYTHEMATOSUS, VITILIGO-RELATED; SLEV1	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1;VAMAS1	606579
POLYSUBSTANCE ABUSE, SUSCEPTIBILITY TO; PSAB	POLYSUBSTANCE ABUSE, SUSCEPTIBILITY TO; PSAB	606581
DRUG ADDICTION, SUSCEPTIBILITY TO	POLYSUBSTANCE ABUSE, SUSCEPTIBILITY TO; PSAB	606581
LIG4 SYNDROME	LIG4 SYNDROME	606593
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2F; CMT2F	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2F; CMT2F	606595
CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2F	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2F; CMT2F	606595
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2F	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2F; CMT2F	606595
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUTMENTAL RETARDATION), TYPE B, 5; MDDGB5	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUTMENTAL RETARDATION), TYPE B, 5; MDDGB5	606612
MUSCULAR DYSTROPHY, CONGENITAL, 1C; MDC1C	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUTMENTAL RETARDATION), TYPE B, 5; MDDGB5	606612
MUSCULAR DYSTROPHY, CONGENITAL, FKRP-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUTMENTAL RETARDATION), TYPE B, 5; MDDGB5	606612
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS1; HDLCQ1	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS1; HDLCQ1	606613
HDLC1	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS1; HDLCQ1	606613
DYSLEXIA, SUSCEPTIBILITY TO, 6; DYX6	DYSLEXIA, SUSCEPTIBILITY TO, 6; DYX6	606616
CAMURATI-ENGELMANN DISEASE, TYPE 2	CAMURATI-ENGELMANN DISEASE, TYPE 2	606631
CAEND2	CAMURATI-ENGELMANN DISEASE, TYPE 2	606631
AMYOTROPHIC LATERAL SCLEROSIS 3; ALS3	AMYOTROPHIC LATERAL SCLEROSIS 3; ALS3	606640
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 1; BMIQ1	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 1; BMIQ1	606641
BODY MASS INDEX; BMI	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 1; BMIQ1	606641
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 2; BMIQ2	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 2; BMIQ2	606643
BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 2; IBGC2	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 2; IBGC2	606656
GLAUCOMA, NORMAL TENSION, SUSCEPTIBILITY TO	GLAUCOMA, NORMAL TENSION, SUSCEPTIBILITY TO	606657
NTG	GLAUCOMA, NORMAL TENSION, SUSCEPTIBILITY TO	606657
GLAUCOMA, NORMAL PRESSURE, SUSCEPTIBILITY TO; NPG	GLAUCOMA, NORMAL TENSION, SUSCEPTIBILITY TO	606657
SPINOCEREBELLAR ATAXIA 15; SCA15SPINOCEREBELLAR ATAXIA 16, FORMERLY; SCA16, FORMERLY	SPINOCEREBELLAR ATAXIA 15; SCA15SPINOCEREBELLAR ATAXIA 16, FORMERLY; SCA16, FORMERLY	606658
MELANOMA, UVEAL, SUSCEPTIBILITY TO, 1	MELANOMA, UVEAL, SUSCEPTIBILITY TO, 1	606660
UVM1	MELANOMA, UVEAL, SUSCEPTIBILITY TO, 1	606660
MELANOMA, UVEAL, SUSCEPTIBILITY TO, 2	MELANOMA, UVEAL, SUSCEPTIBILITY TO, 2	606661
UVM2	MELANOMA, UVEAL, SUSCEPTIBILITY TO, 2	606661
WAARDENBURG SYNDROME, TYPE 2C; WS2C	WAARDENBURG SYNDROME, TYPE 2C; WS2C	606662
WAARDENBURG SYNDROME, TYPE IIC	WAARDENBURG SYNDROME, TYPE 2C; WS2C	606662
GLYCINE N-METHYLTRANSFERASE DEFICIENCY	GLYCINE N-METHYLTRANSFERASE DEFICIENCY	606664
GNMT DEFICIENCY	GLYCINE N-METHYLTRANSFERASE DEFICIENCY	606664
INFLAMMATORY BOWEL DISEASE 8; IBD8	INFLAMMATORY BOWEL DISEASE 8; IBD8	606668
INFLAMMATORY BOWEL DISEASE 6; IBD6	INFLAMMATORY BOWEL DISEASE 6; IBD6	606674
INFLAMMATORY BOWEL DISEASE 4; IBD4	INFLAMMATORY BOWEL DISEASE 4; IBD4	606675
CARDIOMYOPATHY, DILATED, 1L; CMD1L	CARDIOMYOPATHY, DILATED, 1L; CMD1L	606685
SPONGIFORM ENCEPHALOPATHY WITH NEUROPSYCHIATRIC FEATURES	SPONGIFORM ENCEPHALOPATHY WITH NEUROPSYCHIATRIC FEATURES	606688
GLAUCOMA 1, OPEN ANGLE, B; GLC1B	GLAUCOMA 1, OPEN ANGLE, B; GLC1B	606689
LYMPHANGIOLEIOMYOMATOSIS; LAM	LYMPHANGIOLEIOMYOMATOSIS; LAM	606690
LYMPHANGIOMYOMATOSIS	LYMPHANGIOLEIOMYOMATOSIS; LAM	606690
KUFOR-RAKEB SYNDROME; KRS	KUFOR-RAKEB SYNDROME; KRS	606693
PARKINSON DISEASE 9, AUTOSOMAL RECESSIVE; PARK9	KUFOR-RAKEB SYNDROME; KRS	606693
PALLIDOPYRAMIDAL DEGENERATION WITH SUPRANUCLEAR UPGAZE PARESIS ANDDEMENTIA; KRPPDCEROID LIPOFUSCINOSIS, NEURONAL, 12, INCLUDED; CLN12, INCLUDED	KUFOR-RAKEB SYNDROME; KRS	606693
DYSKINESIA, FAMILIAL, WITH FACIAL MYOKYMIA; FDFM	DYSKINESIA, FAMILIAL, WITH FACIAL MYOKYMIA; FDFM	606703
DEAFNESS, AUTOSOMAL DOMINANT 36; DFNA36	DEAFNESS, AUTOSOMAL DOMINANT 36; DFNA36	606705
SPLIT-HAND/FOOT MALFORMATION 5; SHFM5	SPLIT-HAND/FOOT MALFORMATION 5; SHFM5	606708
SPECIFIC LANGUAGE IMPAIRMENT 1; SLI1	SPECIFIC LANGUAGE IMPAIRMENT 1; SLI1	606711
SPECIFIC LANGUAGE IMPAIRMENT QUANTITATIVE TRAIT LOCUS ON CHROMOSOME16	SPECIFIC LANGUAGE IMPAIRMENT 1; SLI1	606711
SPECIFIC LANGUAGE IMPAIRMENT 2; SLI2	SPECIFIC LANGUAGE IMPAIRMENT 2; SLI2	606712
SPECIFIC LANGUAGE IMPAIRMENT QUANTITATIVE TRAIT LOCUS ON CHROMOSOME19	SPECIFIC LANGUAGE IMPAIRMENT 2; SLI2	606712
VAN DER WOUDE SYNDROME 2; VWS2	VAN DER WOUDE SYNDROME 2; VWS2	606713
MELANOMA-PANCREATIC CANCER SYNDROME	MELANOMA-PANCREATIC CANCER SYNDROME	606719
FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA-PANCREATIC CARCINOMA SYNDROME;FAMMMPC	MELANOMA-PANCREATIC CANCER SYNDROME	606719
PARTIAL LIPODYSTROPHY, CONGENITAL CATARACTS, AND NEURODEGENERATIONSYNDROME; LCCNS	PARTIAL LIPODYSTROPHY, CONGENITAL CATARACTS, AND NEURODEGENERATIONSYNDROME; LCCNS	606721
LIPODYSTROPHY, PARTIAL, WITH CONGENITAL CATARACTS AND NEURODEGENERATION	PARTIAL LIPODYSTROPHY, CONGENITAL CATARACTS, AND NEURODEGENERATIONSYNDROME; LCCNS	606721
SECKEL SYNDROME 2; SCKL2	SECKEL SYNDROME 2; SCKL2	606744
SECKEL-TYPE DWARFISM 2	SECKEL SYNDROME 2; SCKL2	606744
MICROCEPHALIC PRIMORDIAL DWARFISM 2	SECKEL SYNDROME 2; SCKL2	606744
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6	606762
HYPERINSULINISM-HYPERAMMONEMIA SYNDROME	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6	606762
CILIARY DYSKINESIA, PRIMARY, 2; CILD2	CILIARY DYSKINESIA, PRIMARY, 2; CILD2	606763
CILIARY DYSKINESIA, PRIMARY, 2, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 2; CILD2	606763
GASTROINTESTINAL STROMAL TUMOR; GIST	GASTROINTESTINAL STROMAL TUMOR; GIST	606764
SPERMATOGENIC FAILURE 3; SPGF3	SPERMATOGENIC FAILURE 3; SPGF3	606766
MYOPATHY, DISTAL, WITH ANTERIOR TIBIAL ONSET; DMAT	MYOPATHY, DISTAL, WITH ANTERIOR TIBIAL ONSET; DMAT	606768
ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 2; ADIPQTL2	ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 2; ADIPQTL2	606770
CIRCULATING ADIPONECTIN QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 5;CAQ5	ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 2; ADIPQTL2	606770
ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 3; ADIPQTL3	ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 3; ADIPQTL3	606771
CIRCULATING ADIPONECTIN QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 14;CAQ14	ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 3; ADIPQTL3	606771
MENTAL RETARDATION, OBESITY, MANDIBULAR PROGNATHISM, AND EYE AND SKINANOMALIES	MENTAL RETARDATION, OBESITY, MANDIBULAR PROGNATHISM, AND EYE AND SKINANOMALIES	606772
MOMES SYNDROME	MENTAL RETARDATION, OBESITY, MANDIBULAR PROGNATHISM, AND EYE AND SKINANOMALIES	606772
GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1	GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1	606777
GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIERGLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED	GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1	606777
CRIGLER-NAJJAR SYNDROME, TYPE II	CRIGLER-NAJJAR SYNDROME, TYPE II	606785
HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2	CRIGLER-NAJJAR SYNDROME, TYPE II	606785
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE 1	PERIPHERAL ARTERIAL OCCLUSIVE DISEASE 1	606787
PAOD1	PERIPHERAL ARTERIAL OCCLUSIVE DISEASE 1	606787
ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 1; ANON1	ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 1; ANON1	606788
AN	ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 1; ANON1	606788
FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 4; HBFQTL4	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 4; HBFQTL4	606789
BLEPHAROSPASM, BENIGN ESSENTIAL	BLEPHAROSPASM, BENIGN ESSENTIAL	606798
STROKE, SUSCEPTIBILITY TO, 1	STROKE, SUSCEPTIBILITY TO, 1	606799
STRK1	STROKE, SUSCEPTIBILITY TO, 1	606799
FUMARASE DEFICIENCY; FMRD	FUMARASE DEFICIENCY; FMRD	606812
FUMARIC ACIDURIA	FUMARASE DEFICIENCY; FMRD	606812
GLUCOSE/GALACTOSE MALABSORPTION; GGM	GLUCOSE/GALACTOSE MALABSORPTION; GGM	606824
MONOSACCHARIDE MALABSORPTION; GM	GLUCOSE/GALACTOSE MALABSORPTION; GGM	606824
DIGITAL ARTHROPATHY-BRACHYDACTYLY, FAMILIAL; FDAB	DIGITAL ARTHROPATHY-BRACHYDACTYLY, FAMILIAL; FDAB	606835
PARASOMNIA, SLEEP BRUXISM TYPE; PSMNSB	PARASOMNIA, SLEEP BRUXISM TYPE; PSMNSB	606840
FACIOMANDIBULAR MYOCLONUS, NOCTURNALPARASOMNIA, SLEEPTALKING TYPE, INCLUDED; PSMNST, INCLUDED	PARASOMNIA, SLEEP BRUXISM TYPE; PSMNSB	606840
CARDIONEUROMYOPATHY WITH HYALINE MASSES AND NEMALINE RODS	CARDIONEUROMYOPATHY WITH HYALINE MASSES AND NEMALINE RODS	606842
IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 3; HIGM3	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 3; HIGM3	606843
HYPER-IgM SYNDROME 3	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 3; HIGM3	606843
PARKINSON DISEASE 10; PARK10	PARKINSON DISEASE 10; PARK10	606852
PARKINSON DISEASE, AGE AT ONSET OF; AAOPD	PARKINSON DISEASE 10; PARK10	606852
POLYMICROGYRIA, BILATERAL FRONTOPARIETAL; BFPP	POLYMICROGYRIA, BILATERAL FRONTOPARIETAL; BFPP	606854
CEREBELLAR ATAXIA WITH NEURONAL MIGRATION DEFECT	POLYMICROGYRIA, BILATERAL FRONTOPARIETAL; BFPP	606854
PANCREATIC CANCER, SUSCEPTIBILITY TO, 1	PANCREATIC CANCER, SUSCEPTIBILITY TO, 1	606856
PNCA1	PANCREATIC CANCER, SUSCEPTIBILITY TO, 1	606856
PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA	PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA	606864
CARNEY-STRATAKIS SYNDROME	PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA	606864
PARAGANGLIOMA AND GASTROINTESTINAL STROMAL TUMOR; GIST	PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA	606864
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 6; HSCR6	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 6; HSCR6	606874
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 7; HSCR7	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 7; HSCR7	606875
ALZHEIMER DISEASE 4	ALZHEIMER DISEASE 4	606889
AD4	ALZHEIMER DISEASE 4	606889
ALZHEIMER DISEASE, FAMILIAL, 4	ALZHEIMER DISEASE 4	606889
DYSLEXIA, SUSCEPTIBILITY TO, 5; DYX5	DYSLEXIA, SUSCEPTIBILITY TO, 5; DYX5	606896
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 3; BMND3	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 3; BMND3	606928
BONE MINERAL DENSITY, LOW, SUSCEPTIBILITY TO	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 3; BMND3	606928
USHER SYNDROME, TYPE IG; USH1G	USHER SYNDROME, TYPE IG; USH1G	606943
ALBINISM, OCULOCUTANEOUS, TYPE IB; OCA1B	ALBINISM, OCULOCUTANEOUS, TYPE IB; OCA1B	606952
OCULOCUTANEOUS ALBINISM, TYPE IB	ALBINISM, OCULOCUTANEOUS, TYPE IB; OCA1B	606952
ALBINISM, YELLOW MUTANT TYPE	ALBINISM, OCULOCUTANEOUS, TYPE IB; OCA1B	606952
YELLOW ALBINISMALBINISM, OCULOCUTANEOUS, TYPE I, TEMPERATURE-SENSITIVE, INCLUDED	ALBINISM, OCULOCUTANEOUS, TYPE IB; OCA1B	606952
OCA1-TS, INCLUDED	ALBINISM, OCULOCUTANEOUS, TYPE IB; OCA1B	606952
INSULINOMA TUMOR SUPPRESSOR GENE LOCUS	INSULINOMA TUMOR SUPPRESSOR GENE LOCUS	606960
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; COPDPULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SEVERE EARLY-ONSET, INCLUDED	PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; COPDPULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SEVERE EARLY-ONSET, INCLUDED	606963
COPD, SEVERE EARLY-ONSET, INCLUDED	PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; COPDPULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SEVERE EARLY-ONSET, INCLUDED	606963
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, RATE OF DECLINE OF LUNG FUNCTIONIN, INCLUDED	PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; COPDPULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SEVERE EARLY-ONSET, INCLUDED	606963
NEPHRONOPHTHISIS 4; NPHP4	NEPHRONOPHTHISIS 4; NPHP4	606966
NEPHRONOPHTHISIS 4, JUVENILE	NEPHRONOPHTHISIS 4; NPHP4	606966
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 2; EIG2	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 2; EIG2	606972
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME14	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 2; EIG2	606972
HYPERRENINEMIC HYPOALDOSTERONISM, FAMILIAL, 2	HYPERRENINEMIC HYPOALDOSTERONISM, FAMILIAL, 2	606984
FHHA2	HYPERRENINEMIC HYPOALDOSTERONISM, FAMILIAL, 2	606984
SENIOR-LOKEN SYNDROME 3; SLSN3	SENIOR-LOKEN SYNDROME 3; SLSN3	606995
SENIOR-LOKEN SYNDROME 4; SLSN4	SENIOR-LOKEN SYNDROME 4; SLSN4	606996
BRACHYDACTYLY, TYPE A1, B; BDA1B	BRACHYDACTYLY, TYPE A1, B; BDA1B	607004
HURLER SYNDROME	HURLER SYNDROME	607014
MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H	HURLER SYNDROME	607014
HURLER-SCHEIE SYNDROME	HURLER-SCHEIE SYNDROME	607015
MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS	HURLER-SCHEIE SYNDROME	607015
SCHEIE SYNDROME	SCHEIE SYNDROME	607016
MUCOPOLYSACCHARIDOSIS TYPE IS; MPS1-S	SCHEIE SYNDROME	607016
MUCOPOLYSACCHARIDOSIS TYPE V, FORMERLY	SCHEIE SYNDROME	607016
MPS V, FORMERLY; MPS5, FORMERLY	SCHEIE SYNDROME	607016
DEAFNESS, AUTOSOMAL DOMINANT 21; DFNA21	DEAFNESS, AUTOSOMAL DOMINANT 21; DFNA21	607017
DEAFNESS, AUTOSOMAL RECESSIVE 22; DFNB22	DEAFNESS, AUTOSOMAL RECESSIVE 22; DFNB22	607039
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS2; HDLCQ2	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS2; HDLCQ2	607053
PARKINSON DISEASE 8, AUTOSOMAL DOMINANT; PARK8	PARKINSON DISEASE 8, AUTOSOMAL DOMINANT; PARK8	607060
EPIPHYSEAL DYSPLASIA, MULTIPLE, 5; EDM5	EPIPHYSEAL DYSPLASIA, MULTIPLE, 5; EDM5	607078
MULTIPLE EPIPHYSEAL DYSPLASIA, MATN3-RELATED	EPIPHYSEAL DYSPLASIA, MULTIPLE, 5; EDM5	607078
MICROEPIPHYSEAL DYSPLASIA, BILATERAL HEREDITARY; BHMED	EPIPHYSEAL DYSPLASIA, MULTIPLE, 5; EDM5	607078
46,XY GONADAL DYSGENESIS, PARTIAL, WITH MINIFASCICULAR NEUROPATHY	46,XY GONADAL DYSGENESIS, PARTIAL, WITH MINIFASCICULAR NEUROPATHY	607080
DEAFNESS, AUTOSOMAL RECESSIVE 31; DFNB31	DEAFNESS, AUTOSOMAL RECESSIVE 31; DFNB31	607084
WHIRLER, MOUSE, HOMOLOG OF	DEAFNESS, AUTOSOMAL RECESSIVE 31; DFNB31	607084
MYASTHENIA GRAVIS WITH THYMUS HYPERPLASIA	MYASTHENIA GRAVIS WITH THYMUS HYPERPLASIA	607085
MYAS1	MYASTHENIA GRAVIS WITH THYMUS HYPERPLASIA	607085
AORTIC ANEURYSM, FAMILIAL THORACIC 1; AAT1	AORTIC ANEURYSM, FAMILIAL THORACIC 1; AAT1	607086
FAA1	AORTIC ANEURYSM, FAMILIAL THORACIC 1; AAT1	607086
ANNULOAORTIC ECTASIA	AORTIC ANEURYSM, FAMILIAL THORACIC 1; AAT1	607086
AORTIC DISSECTION, FAMILIAL	AORTIC ANEURYSM, FAMILIAL THORACIC 1; AAT1	607086
AORTIC ANEURYSM, FAMILIAL THORACIC	AORTIC ANEURYSM, FAMILIAL THORACIC 1; AAT1	607086
ANEURYSM, THORACIC AORTICERDHEIM CYSTIC MEDIAL NECROSIS OF AORTA, INCLUDED	AORTIC ANEURYSM, FAMILIAL THORACIC 1; AAT1	607086
AORTIC ANEURYSM, FAMILIAL THORACIC 2; AAT2	AORTIC ANEURYSM, FAMILIAL THORACIC 2; AAT2	607087
FAA2	AORTIC ANEURYSM, FAMILIAL THORACIC 2; AAT2	607087
SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3	607088
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IV; HMN4	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3	607088
DHMN4	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3	607088
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IV	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3	607088
HMN IV	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3	607088
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE III; HMN3	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3	607088
DHMN3	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3	607088
HMN III	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3	607088
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D	607091
CDG IId; CDGIId	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D	607091
ANAUXETIC DYSPLASIA	ANAUXETIC DYSPLASIA	607095
SPONDYLOMETAEPIPHYSEAL DYSPLASIA, ANAUXETIC TYPE	ANAUXETIC DYSPLASIA	607095
SPONDYLOMETAEPIPHYSEAL DYSPLASIA, MENGER TYPE	ANAUXETIC DYSPLASIA	607095
DEAFNESS, AUTOSOMAL RECESSIVE 30; DFNB30	DEAFNESS, AUTOSOMAL RECESSIVE 30; DFNB30	607101
NASOPHARYNGEAL CARCINOMA	NASOPHARYNGEAL CARCINOMA	607107
NPCA	NASOPHARYNGEAL CARCINOMA	607107
NPC	NASOPHARYNGEAL CARCINOMA	607107
NASOPHARYNGEAL CANCERNASOPHARYNGEAL CARCINOMA, SUSCEPTIBILITY TO, 1, INCLUDED; NPCA1, INCLUDED	NASOPHARYNGEAL CARCINOMA	607107
CINCA SYNDROME; CINCA	CINCA SYNDROME; CINCA	607115
CHRONIC NEUROLOGIC CUTANEOUS AND ARTICULAR SYNDROME	CINCA SYNDROME; CINCA	607115
MULTISYSTEM INFLAMMATORY DISEASE, NEONATAL-ONSET; NOMID	CINCA SYNDROME; CINCA	607115
CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME 3; CAPS3	CINCA SYNDROME; CINCA	607115
ALZHEIMER DISEASE 8	ALZHEIMER DISEASE 8	607116
ALZHEIMER DISEASE, FAMILIAL, 8	ALZHEIMER DISEASE 8	607116
AD8	ALZHEIMER DISEASE 8	607116
MACROCEPHALY WITH MULTIPLE EPIPHYSEAL DYSPLASIA AND DISTINCTIVE FACIES	MACROCEPHALY WITH MULTIPLE EPIPHYSEAL DYSPLASIA AND DISTINCTIVE FACIES	607131
MMEDF	MACROCEPHALY WITH MULTIPLE EPIPHYSEAL DYSPLASIA AND DISTINCTIVE FACIES	607131
SPECIFIC LANGUAGE IMPAIRMENT 3; SLI3	SPECIFIC LANGUAGE IMPAIRMENT 3; SLI3	607134
SPECIFIC LANGUAGE IMPAIRMENT QUANTITATIVE TRAIT LOCUS ON CHROMOSOME13	SPECIFIC LANGUAGE IMPAIRMENT 3; SLI3	607134
CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS	CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS	607135
CRCL	CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS	607135
SPINOCEREBELLAR ATAXIA 17; SCA17	SPINOCEREBELLAR ATAXIA 17; SCA17	607136
HUNTINGTON DISEASE-LIKE 4; HDL4	SPINOCEREBELLAR ATAXIA 17; SCA17	607136
ANGIOID STREAKS	ANGIOID STREAKS	607140
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ig; CDG1G	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ig; CDG1G	607143
CDG Ig; CDGIg	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ig; CDG1G	607143
MOYAMOYA DISEASE 2; MYMY2	MOYAMOYA DISEASE 2; MYMY2	607151
SPASTIC PARAPLEGIA 19, AUTOSOMAL DOMINANT; SPG19	SPASTIC PARAPLEGIA 19, AUTOSOMAL DOMINANT; SPG19	607152
ALLERGIC RHINITIS	ALLERGIC RHINITIS	607154
ALRH	ALLERGIC RHINITIS	607154
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5	607155
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5	607155
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5	607155
MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO	MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO	607174
MICROCEPHALY, AMISH TYPE; MCPHA	MICROCEPHALY, AMISH TYPE; MCPHA	607196
AMISH LETHAL MICROCEPHALY	MICROCEPHALY, AMISH TYPE; MCPHA	607196
THIAMINE METABOLISM DYSFUNCTION SYNDROME 3 (MICROCEPHALY TYPE); THMD3	MICROCEPHALY, AMISH TYPE; MCPHA	607196
THYROID DYSHORMONOGENESIS 6; TDH6	THYROID DYSHORMONOGENESIS 6; TDH6	607200
THYROID HORMONOGENESIS, GENETIC DEFECT IN, 6	THYROID DYSHORMONOGENESIS 6; TDH6	607200
HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 6	THYROID DYSHORMONOGENESIS 6; TDH6	607200
CELIAC DISEASE, SUSCEPTIBILITY TO, 5; CELIAC5	CELIAC DISEASE, SUSCEPTIBILITY TO, 5; CELIAC5	607202
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 5	CELIAC DISEASE, SUSCEPTIBILITY TO, 5; CELIAC5	607202
GSES	CELIAC DISEASE, SUSCEPTIBILITY TO, 5; CELIAC5	607202
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 6; EIEE6	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 6; EIEE6	607208
DRAVET SYNDROME	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 6; EIEE6	607208
SEVERE MYOCLONIC EPILEPSY OF INFANCY; SMEI	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 6; EIEE6	607208
EPILEPSY, PARTIAL, WITH PERICENTRAL SPIKES; PEPS	EPILEPSY, PARTIAL, WITH PERICENTRAL SPIKES; PEPS	607221
EPPS	EPILEPSY, PARTIAL, WITH PERICENTRAL SPIKES; PEPS	607221
SPASTIC PARALYSIS, INFANTILE-ONSET ASCENDING; IAHSP	SPASTIC PARALYSIS, INFANTILE-ONSET ASCENDING; IAHSP	607225
HYPOPREBETALIPOPROTEINEMIA, ACANTHOCYTOSIS, RETINITIS PIGMENTOSA,AND PALLIDAL DEGENERATION	HYPOPREBETALIPOPROTEINEMIA, ACANTHOCYTOSIS, RETINITIS PIGMENTOSA,AND PALLIDAL DEGENERATION	607236
HARP SYNDROME	HYPOPREBETALIPOPROTEINEMIA, ACANTHOCYTOSIS, RETINITIS PIGMENTOSA,AND PALLIDAL DEGENERATION	607236
DEAFNESS, AUTOSOMAL RECESSIVE 33; DFNB33	DEAFNESS, AUTOSOMAL RECESSIVE 33; DFNB33	607239
GLIOMA SUSCEPTIBILITY 4; GLM4	GLIOMA SUSCEPTIBILITY 4; GLM4	607248
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, WITH AXONAL NEUROPATHY;SCAN1	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, WITH AXONAL NEUROPATHY;SCAN1	607250
HYPERCALCIURIA, ABSORPTIVE, 1	HYPERCALCIURIA, ABSORPTIVE, 1	607258
HCA1	HYPERCALCIURIA, ABSORPTIVE, 1	607258
SPASTIC PARAPLEGIA 7, AUTOSOMAL RECESSIVE; SPG7	SPASTIC PARAPLEGIA 7, AUTOSOMAL RECESSIVE; SPG7	607259
CASPASE 8 DEFICIENCY	CASPASE 8 DEFICIENCY	607271
CEDS	CASPASE 8 DEFICIENCY	607271
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IIB; ALPS2B	CASPASE 8 DEFICIENCY	607271
RESTING HEART RATE, VARIATION IN	RESTING HEART RATE, VARIATION IN	607276
RHR	RESTING HEART RATE, VARIATION IN	607276
ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 1	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 1	607277
ASRT1	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 1	607277
AS1	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 1	607277
SYSTEMIC LUPUS ERYTHEMATOSUS WITH HEMOLYTIC ANEMIA, SUSCEPTIBILITYTO, 1; SLEH1	SYSTEMIC LUPUS ERYTHEMATOSUS WITH HEMOLYTIC ANEMIA, SUSCEPTIBILITYTO, 1; SLEH1	607279
SYSTEMIC LUPUS ERYTHEMATOSUS, HEMOLYTIC ANEMIA-RELATED	SYSTEMIC LUPUS ERYTHEMATOSUS WITH HEMOLYTIC ANEMIA, SUSCEPTIBILITYTO, 1; SLEH1	607279
CATARACT 27; CTRCT27	CATARACT 27; CTRCT27	607304
CATARACT 27, NUCLEAR PROGRESSIVE	CATARACT 27; CTRCT27	607304
CCNP	CATARACT 27; CTRCT27	607304
STEROID 5-ALPHA-REDUCTASE 2; SRD5A2MICROPENIS, INCLUDED	STEROID 5-ALPHA-REDUCTASE 2; SRD5A2MICROPENIS, INCLUDED	607306
MAMMOGRAPHIC DENSITY	MAMMOGRAPHIC DENSITY	607308
GAZE PALSY, FAMILIAL HORIZONTAL, WITH PROGRESSIVE SCOLIOSIS; HGPPSOPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, AND SCOLIOSIS, INCLUDED	GAZE PALSY, FAMILIAL HORIZONTAL, WITH PROGRESSIVE SCOLIOSIS; HGPPSOPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, AND SCOLIOSIS, INCLUDED	607313
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 4; SCAR4	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 4; SCAR4	607317
SPINOCEREBELLAR ATAXIA WITH SACCADIC INTRUSIONS; SCASI	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 4; SCAR4	607317
SPINOCEREBELLAR ATAXIA 24, FORMERLY; SCA24, FORMERLY	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 4; SCAR4	607317
DUANE-RADIAL RAY SYNDROME; DRRS	DUANE-RADIAL RAY SYNDROME; DRRS	607323
OKIHIRO SYNDROME	DUANE-RADIAL RAY SYNDROME; DRRS	607323
DUANE ANOMALY WITH RADIAL RAY ABNORMALITIES AND DEAFNESS	DUANE-RADIAL RAY SYNDROME; DRRS	607323
DR SYNDROME	DUANE-RADIAL RAY SYNDROME; DRRS	607323
ACRORENOOCULAR SYNDROME	DUANE-RADIAL RAY SYNDROME; DRRS	607323
POLYDACTYLY, POSTAXIAL, TYPE A3	POLYDACTYLY, POSTAXIAL, TYPE A3	607324
PAPA3	POLYDACTYLY, POSTAXIAL, TYPE A3	607324
POSTAXIAL POLYDACTYLY, TYPE A3	POLYDACTYLY, POSTAXIAL, TYPE A3	607324
SMITH-MCCORT DYSPLASIA 1; SMC1	SMITH-MCCORT DYSPLASIA 1; SMC1	607326
SMC	SMITH-MCCORT DYSPLASIA 1; SMC1	607326
HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 3	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 3	607329
HYT3	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 3	607329
LATHOSTEROLOSIS	LATHOSTEROLOSIS	607330
STEROL C5-DESATURASE DEFICIENCY	LATHOSTEROLOSIS	607330
SC5D DEFICIENCY	LATHOSTEROLOSIS	607330
CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 1	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 1	607339
CHDS1	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 1	607339
FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT	FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT	607341
CORTICAL DYSPLASIA OF TAYLOR; CDT	FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT	607341
FOCAL CORTICAL DYSPLASIA, TYPE IIFOCAL CORTICAL DYSPLASIA OF TAYLOR, TYPE IIA, INCLUDED	FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT	607341
CORTICAL DYSPLASIA OF TAYLOR WITHOUT BALLOON CELLS, INCLUDED	FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT	607341
CORTICAL DYSPLASIA OF TAYLOR, DYSPLASIA ONLY, INCLUDED; CDTD, INCLUDED	FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT	607341
FOCAL CORTICAL DYSPLASIA OF TAYLOR, TYPE IIB, INCLUDED	FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT	607341
CORTICAL DYSPLASIA OF TAYLOR WITH BALLOON CELLS, INCLUDED; CDTBC,INCLUDED	FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT	607341
SPINOCEREBELLAR ATAXIA 19; SCA19	SPINOCEREBELLAR ATAXIA 19; SCA19	607346
SPINOCEREBELLAR ATAXIA 22; SCA22	SPINOCEREBELLAR ATAXIA 19; SCA19	607346
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 2; IS2	SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 2; IS2	607354
MECKEL SYNDROME, TYPE 3; MKS3	MECKEL SYNDROME, TYPE 3; MKS3	607361
MECKEL-GRUBER SYNDROME, TYPE 3	MECKEL SYNDROME, TYPE 3; MKS3	607361
BARTTER SYNDROME, TYPE 3	BARTTER SYNDROME, TYPE 3	607364
BARTTER SYNDROME, CLASSICBARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED	BARTTER SYNDROME, TYPE 3	607364
DYSTONIA, JUVENILE-ONSET; DJO	DYSTONIA, JUVENILE-ONSET; DJO	607371
AUTISM, SUSCEPTIBILITY TO, 8; AUTS8	AUTISM, SUSCEPTIBILITY TO, 8; AUTS8	607373
AUTS2, FORMERLY	AUTISM, SUSCEPTIBILITY TO, 8; AUTS8	607373
GLUCOCORTICOID DEFICIENCY 2; GCCD2	GLUCOCORTICOID DEFICIENCY 2; GCCD2	607398
FAMILIAL GLUCOCORTICOID DEFICIENCY 2; FGD2	GLUCOCORTICOID DEFICIENCY 2; GCCD2	607398
PATENT DUCTUS ARTERIOSUS	PATENT DUCTUS ARTERIOSUS	607411
PDA	PATENT DUCTUS ARTERIOSUS	607411
PDA1	PATENT DUCTUS ARTERIOSUS	607411
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 2; MRT2	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 2; MRT2	607417
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 2A; MRT2A	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 2; MRT2	607417
COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1	COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1	607426
CoQ10 DEFICIENCY, PRIMARY, 1	COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1	607426
UBIQUINONE DEFICIENCY 1	COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1	607426
COENZYME Q DEFICIENCY 1	COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1	607426
CoQ DEFICIENCY 1	COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1	607426
LISSENCEPHALY 1; LIS1	LISSENCEPHALY 1; LIS1	607432
LISSENCEPHALY SEQUENCE, ISOLATED; ILS	LISSENCEPHALY 1; LIS1	607432
LISSENCEPHALY, CLASSICSUBCORTICAL LAMINAR HETEROTOPIA, INCLUDED; SCLH, INCLUDED	LISSENCEPHALY 1; LIS1	607432
SUBCORTICAL BAND HETEROTOPIA, INCLUDED; SBH, INCLUDED	LISSENCEPHALY 1; LIS1	607432
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 3; BMIQ3	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 3; BMIQ3	607446
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 4; BMIQ4	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 4; BMIQ4	607447
OBESITY, SUSCEPTIBILITY TO	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 4; BMIQ4	607447
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 8; ARVD8	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 8; ARVD8	607450
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 8; ARVC8	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 8; ARVD8	607450
DEAFNESS, AUTOSOMAL DOMINANT 44; DFNA44	DEAFNESS, AUTOSOMAL DOMINANT 44; DFNA44	607453
SPINOCEREBELLAR ATAXIA 21; SCA21	SPINOCEREBELLAR ATAXIA 21; SCA21	607454
GIL BLOOD GROUP	GIL BLOOD GROUP	607457
SPINOCEREBELLAR ATAXIA 18; SCA18	SPINOCEREBELLAR ATAXIA 18; SCA18	607458
SENSORIMOTOR NEUROPATHY WITH ATAXIA, AUTOSOMAL DOMINANT; SMNA	SPINOCEREBELLAR ATAXIA 18; SCA18	607458
SENSORY ATAXIC NEUROPATHY, DYSARTHRIA, AND OPHTHALMOPARESIS; SANDO	SENSORY ATAXIC NEUROPATHY, DYSARTHRIA, AND OPHTHALMOPARESIS; SANDO	607459
SENSORY ATAXIC NEUROPATHY WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMALRECESSIVESPINOCEREBELLAR ATAXIA WITH EPILEPSY, INCLUDED; SCAE, INCLUDED	SENSORY ATAXIC NEUROPATHY, DYSARTHRIA, AND OPHTHALMOPARESIS; SANDO	607459
THYROID CARCINOMA, HURTHLE CELL	THYROID CARCINOMA, HURTHLE CELL	607464
HURTHLE CELL THYROID NEOPLASIA	THYROID CARCINOMA, HURTHLE CELL	607464
VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 2; VKCFD2	VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 2; VKCFD2	607473
BOTHNIA RETINAL DYSTROPHY	BOTHNIA RETINAL DYSTROPHY	607475
VASTERBOTTEN DYSTROPHY	BOTHNIA RETINAL DYSTROPHY	607475
NEWFOUNDLAND ROD-CONE DYSTROPHY; NFRCD	NEWFOUNDLAND ROD-CONE DYSTROPHY; NFRCD	607476
CARDIOMYOPATHY, DILATED, 1M; CMD1M	CARDIOMYOPATHY, DILATED, 1M; CMD1M	607482
THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVETYPE); THMD2	THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVETYPE); THMD2	607483
BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD	THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVETYPE); THMD2	607483
ENCEPHALOPATHY, THIAMINE-RESPONSIVE	THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVETYPE); THMD2	607483
FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED	FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED	607485
FTLD-TDP, GRN-RELATED	FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED	607485
FRONTOTEMPORAL DEMENTIA WITH TDP43 INCLUSIONS, GRN-RELATED	FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED	607485
FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS;FTLDU	FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED	607485
FRONTOTEMPORAL DEMENTIA, UBIQUITIN-POSITIVE; FTDU	FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED	607485
DEMENTIA, HEREDITARY DYSPHASIC DISINHIBITION; HDDDAPHASIA, PRIMARY PROGRESSIVE, INCLUDED; PPA, INCLUDED	FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED	607485
KNOPS BLOOD GROUP SYSTEM; KN	KNOPS BLOOD GROUP SYSTEM; KN	607486
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 25; CMH25	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 25; CMH25	607487
DYSTONIA 15, MYOCLONIC; DYT15	DYSTONIA 15, MYOCLONIC; DYT15	607488
MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 3	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 3	607498
MGR3	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 3	607498
BULIMIA NERVOSA, SUSCEPTIBILITY TO, 1; BULN1	BULIMIA NERVOSA, SUSCEPTIBILITY TO, 1; BULN1	607499
BN	BULIMIA NERVOSA, SUSCEPTIBILITY TO, 1; BULN1	607499
MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO, 4	MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO, 4	607501
MGR4	MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO, 4	607501
MGOA	MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO, 4	607501
PSORIATIC ARTHRITIS, SUSCEPTIBILITY TOPSORIATIC ARTHRITIS, SUSCEPTIBILITY TO, 1; PSORAS1	PSORIATIC ARTHRITIS, SUSCEPTIBILITY TOPSORIATIC ARTHRITIS, SUSCEPTIBILITY TO, 1; PSORAS1	607507
MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 5	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 5	607508
MGR5	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 5	607508
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 10; BMIQ10	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 10; BMIQ10	607514
OBESITY, SUSCEPTIBILITY TO	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 10; BMIQ10	607514
MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 6	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 6	607516
MGR6MIGRAINE, FAMILIAL HEMIPLEGIC, 4, INCLUDED; FHM4, INCLUDED	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 6	607516
NAIL DISORDER, NONSYNDROMIC CONGENITAL, 8; NDNC8	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 8; NDNC8	607523
TOENAIL DYSTROPHY, ISOLATED	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 8; NDNC8	607523
CAMPTOSYNPOLYDACTYLY, COMPLEX	CAMPTOSYNPOLYDACTYLY, COMPLEX	607539
CAMPTOPOLYDACTYLY, DISORGANIZATION TYPE	CAMPTOSYNPOLYDACTYLY, COMPLEX	607539
CORNEAL DYSTROPHY, AVELLINO TYPE; CDA	CORNEAL DYSTROPHY, AVELLINO TYPE; CDA	607541
ACD	CORNEAL DYSTROPHY, AVELLINO TYPE; CDA	607541
AVELLINO CORNEAL DYSTROPHY	CORNEAL DYSTROPHY, AVELLINO TYPE; CDA	607541
COMBINED GRANULAR-LATTICE CORNEAL DYSTROPHY	CORNEAL DYSTROPHY, AVELLINO TYPE; CDA	607541
GRANULAR CORNEAL DYSTROPHY, TYPE II; CGD2	CORNEAL DYSTROPHY, AVELLINO TYPE; CDA	607541
ATRIAL FIBRILLATION, FAMILIAL, 3; ATFB3	ATRIAL FIBRILLATION, FAMILIAL, 3; ATFB3	607554
LEPROSY, SUSCEPTIBILITY TO, 2; LPRS2	LEPROSY, SUSCEPTIBILITY TO, 2; LPRS2	607572
SPASTIC PARAPLEGIA 24, AUTOSOMAL RECESSIVE; SPG24	SPASTIC PARAPLEGIA 24, AUTOSOMAL RECESSIVE; SPG24	607584
PROSTATE CANCER AGGRESSIVENESS QUANTITATIVE TRAIT LOCUS ON CHROMOSOME19	PROSTATE CANCER AGGRESSIVENESS QUANTITATIVE TRAIT LOCUS ON CHROMOSOME19	607592
HPCQTL19	PROSTATE CANCER AGGRESSIVENESS QUANTITATIVE TRAIT LOCUS ON CHROMOSOME19	607592
IMMUNODEFICIENCY, COMMON VARIABLE, 1; CVID1	IMMUNODEFICIENCY, COMMON VARIABLE, 1; CVID1	607594
ANTIBODY DEFICIENCY DUE TO ICOS DEFECTIMMUNODEFICIENCY, COMMON VARIABLE, INCLUDED; CVID, INCLUDED	IMMUNODEFICIENCY, COMMON VARIABLE, 1; CVID1	607594
BRAIN SMALL VESSEL DISEASE WITH OR WITHOUT OCULAR ANOMALIES; BSVD	BRAIN SMALL VESSEL DISEASE WITH OR WITHOUT OCULAR ANOMALIES; BSVD	607595
BRAIN SMALL VESSEL DISEASE WITH HEMORRHAGE	BRAIN SMALL VESSEL DISEASE WITH OR WITHOUT OCULAR ANOMALIES; BSVD	607595
INFANTILE HEMIPARESIS	BRAIN SMALL VESSEL DISEASE WITH OR WITHOUT OCULAR ANOMALIES; BSVD	607595
RETINAL ARTERIOLAR TORTUOSITY, INFANTILE HEMIPARESIS, AND LEUKOENCEPHALOPATHY,AUTOSOMAL DOMINANT	BRAIN SMALL VESSEL DISEASE WITH OR WITHOUT OCULAR ANOMALIES; BSVD	607595
BRAIN SMALL VESSEL DISEASE WITH AXENFELD-RIEGER ANOMALY	BRAIN SMALL VESSEL DISEASE WITH OR WITHOUT OCULAR ANOMALIES; BSVD	607595
LEUKOENCEPHALOPATHY WITH AXENFELD-RIEGER ANOMALY	BRAIN SMALL VESSEL DISEASE WITH OR WITHOUT OCULAR ANOMALIES; BSVD	607595
PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A	PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A	607596
PCH1	PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A	607596
PONTOCEREBELLAR HYPOPLASIA WITH INFANTILE SPINAL MUSCULAR ATROPHY	PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A	607596
PONTOCEREBELLAR HYPOPLASIA WITH ANTERIOR HORN CELL DISEASE	PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A	607596
LETHAL CONGENITAL CONTRACTURE SYNDROME 2; LCCS2	LETHAL CONGENITAL CONTRACTURE SYNDROME 2; LCCS2	607598
MULTIPLE CONTRACTURE SYNDROME, ISRAELI BEDOUIN TYPE A	LETHAL CONGENITAL CONTRACTURE SYNDROME 2; LCCS2	607598
EPIDERMOLYSIS BULLOSA SIMPLEX SUPERFICIALIS; EBSS	EPIDERMOLYSIS BULLOSA SIMPLEX SUPERFICIALIS; EBSS	607600
ICHTHYOSIS, CYCLIC, WITH EPIDERMOLYTIC HYPERKERATOSIS	ICHTHYOSIS, CYCLIC, WITH EPIDERMOLYTIC HYPERKERATOSIS	607602
CIEHK	ICHTHYOSIS, CYCLIC, WITH EPIDERMOLYTIC HYPERKERATOSIS	607602
EPIDERMOLYTIC ICHTHYOSIS, ANNULAR; AEI	ICHTHYOSIS, CYCLIC, WITH EPIDERMOLYTIC HYPERKERATOSIS	607602
NIEMANN-PICK DISEASE, TYPE BNIEMANN-PICK DISEASE, TYPE E, INCLUDED	NIEMANN-PICK DISEASE, TYPE BNIEMANN-PICK DISEASE, TYPE E, INCLUDED	607616
NIEMANN-PICK DISEASE, TYPE F, INCLUDED	NIEMANN-PICK DISEASE, TYPE BNIEMANN-PICK DISEASE, TYPE E, INCLUDED	607616
NIEMANN-PICK DISEASE, INTERMEDIATE, WITH VISCERAL INVOLVEMENT ANDRAPID PROGRESSION, INCLUDED	NIEMANN-PICK DISEASE, TYPE BNIEMANN-PICK DISEASE, TYPE E, INCLUDED	607616
GRISCELLI SYNDROME, TYPE 2; GS2	GRISCELLI SYNDROME, TYPE 2; GS2	607624
GRISCELLI SYNDROME WITH HEMOPHAGOCYTIC SYNDROME	GRISCELLI SYNDROME, TYPE 2; GS2	607624
PARTIAL ALBINISM AND IMMUNODEFICIENCY SYNDROME	GRISCELLI SYNDROME, TYPE 2; GS2	607624
PAID SYNDROME	GRISCELLI SYNDROME, TYPE 2; GS2	607624
NIEMANN-PICK DISEASE, TYPE C2; NPC2	NIEMANN-PICK DISEASE, TYPE C2; NPC2	607625
ICHTHYOSIS, LEUKOCYTE VACUOLES, ALOPECIA, AND SCLEROSING CHOLANGITIS;ILVASC	ICHTHYOSIS, LEUKOCYTE VACUOLES, ALOPECIA, AND SCLEROSING CHOLANGITIS;ILVASC	607626
ICHTHYOSIS-SCLEROSING CHOLANGITIS SYNDROME	ICHTHYOSIS, LEUKOCYTE VACUOLES, ALOPECIA, AND SCLEROSING CHOLANGITIS;ILVASC	607626
NEONATAL ICHTHYOSIS-SCLEROSING CHOLANGITIS SYNDROME	ICHTHYOSIS, LEUKOCYTE VACUOLES, ALOPECIA, AND SCLEROSING CHOLANGITIS;ILVASC	607626
NISCH SYNDROME	ICHTHYOSIS, LEUKOCYTE VACUOLES, ALOPECIA, AND SCLEROSING CHOLANGITIS;ILVASC	607626
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 11; EIG11EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 8, INCLUDED; EJM8,INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 11; EIG11EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 8, INCLUDED; EJM8,INCLUDED	607628
EPILEPSY, JUVENILE ABSENCE, SUSCEPTIBILITY TO, 2, INCLUDED; EJA2,INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 11; EIG11EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 8, INCLUDED; EJM8,INCLUDED	607628
EPILEPSY, JUVENILE ABSENCE, SUSCEPTIBILITY TO, 1; EJA1	EPILEPSY, JUVENILE ABSENCE, SUSCEPTIBILITY TO, 1; EJA1	607631
JAE1	EPILEPSY, JUVENILE ABSENCE, SUSCEPTIBILITY TO, 1; EJA1	607631
OSTEOPETROSIS, AUTOSOMAL DOMINANT 1; OPTA1	OSTEOPETROSIS, AUTOSOMAL DOMINANT 1; OPTA1	607634
OSTEOPETROSIS, AUTOSOMAL DOMINANT, TYPE I	OSTEOPETROSIS, AUTOSOMAL DOMINANT 1; OPTA1	607634
VAN BUCHEM DISEASE, TYPE 2	VAN BUCHEM DISEASE, TYPE 2	607636
VBCH2	VAN BUCHEM DISEASE, TYPE 2	607636
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB; HMN7B	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB; HMN7B	607641
HMN VIIB	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB; HMN7B	607641
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB; HMN7B	607641
DHMN7B	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB; HMN7B	607641
NEUROPATHY, DISTAL HEREDITARY MOTOR, WITH VOCAL CORD PARALYSIS, TYPEVIIB	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB; HMN7B	607641
LOWER MOTOR NEURON DISEASE, DYNACTIN TYPE	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB; HMN7B	607641
CANDIDIASIS, FAMILIAL, 3; CANDF3	CANDIDIASIS, FAMILIAL, 3; CANDF3	607644
CANDIDIASIS, FAMILIAL CHRONIC NAIL, WITH ICAM1 DEFICIENCY; CANDN1	CANDIDIASIS, FAMILIAL, 3; CANDF3	607644
FCNC	CANDIDIASIS, FAMILIAL, 3; CANDF3	607644
KERATOSIS PALMOPLANTARIS STRIATA III; PPKS3	KERATOSIS PALMOPLANTARIS STRIATA III; PPKS3	607654
STRIATE PALMOPLANTAR KERATODERMA III; SPPK3	KERATOSIS PALMOPLANTARIS STRIATA III; PPKS3	607654
KERATODERMA, PALMOPLANTAR, STRIATE FORM III; KPPS3	KERATOSIS PALMOPLANTARIS STRIATA III; PPKS3	607654
SKIN FRAGILITY-WOOLLY HAIR SYNDROME; SFWHS	SKIN FRAGILITY-WOOLLY HAIR SYNDROME; SFWHS	607655
CURLY HAIR-ACRAL KERATODERMA-CARIES SYNDROME	CURLY HAIR-ACRAL KERATODERMA-CARIES SYNDROME	607656
CHACS	CURLY HAIR-ACRAL KERATODERMA-CARIES SYNDROME	607656
HYPOTRICHOSIS-OSTEOLYSIS-PERIODONTITIS-PALMOPLANTAR KERATODERMA SYNDROME	HYPOTRICHOSIS-OSTEOLYSIS-PERIODONTITIS-PALMOPLANTAR KERATODERMA SYNDROME	607658
HOPP SYNDROME	HYPOTRICHOSIS-OSTEOLYSIS-PERIODONTITIS-PALMOPLANTAR KERATODERMA SYNDROME	607658
DYSTONIA 13, TORSION, AUTOSOMAL DOMINANT; DYT13	DYSTONIA 13, TORSION, AUTOSOMAL DOMINANT; DYT13	607671
CATARACT, CONGENITAL, WITH MENTAL IMPAIRMENT AND DENTATE GYRUS ATROPHY	CATARACT, CONGENITAL, WITH MENTAL IMPAIRMENT AND DENTATE GYRUS ATROPHY	607674
IRAK4 DEFICIENCY	IRAK4 DEFICIENCY	607676
IRAK4D	IRAK4 DEFICIENCY	607676
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2I; CMT2I	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2I; CMT2I	607677
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2I	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2I; CMT2I	607677
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1D; CMT1D	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1D; CMT1D	607678
HEREDITARY MOTOR AND SENSORY NEUROPATHY 1D	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1D; CMT1D	607678
HMSN ID	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1D; CMT1D	607678
HMSN1D	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1D; CMT1D	607678
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1D	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1D; CMT1D	607678
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2; ECA2	EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2; ECA2	607681
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 9; EIG9EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 6, INCLUDED; EJM6,INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 9; EIG9EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 6, INCLUDED; EJM6,INCLUDED	607682
DEAFNESS, AUTOSOMAL DOMINANT 52; DFNA52	DEAFNESS, AUTOSOMAL DOMINANT 52; DFNA52	607683
DEAFNESS, AUTOSOMAL DOMINANT 42; DFNA42	DEAFNESS, AUTOSOMAL DOMINANT 52; DFNA52	607683
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2E; CMT2E	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2E; CMT2E	607684
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2E	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2E; CMT2E	607684
HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC; HES	HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC; HES	607685
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS3	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS3	607687
HDLCQ3	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS3	607687
PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK11	PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK11	607688
LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/ORHYPOGONADOTROPIC HYPOGONADISM; HLD7	LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/ORHYPOGONADOTROPIC HYPOGONADISM; HLD7	607694
LEUKOENCEPHALOPATHY, HYPOMYELINATING, WITH ATAXIA AND DELAYED DENTITION	LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/ORHYPOGONADOTROPIC HYPOGONADISM; HLD7	607694
ATAXIA, DELAYED DENTITION, AND HYPOMYELINATION; ADDH	LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/ORHYPOGONADOTROPIC HYPOGONADISM; HLD7	607694
LEUKODYSTROPHY, HYPOMYELINATING, WITH HYPODONTIA AND HYPOGONADOTROPICHYPOGONADISM	LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/ORHYPOGONADOTROPIC HYPOGONADISM; HLD7	607694
4H SYNDROME	LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/ORHYPOGONADOTROPIC HYPOGONADISM; HLD7	607694
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMALRECESSIVE	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMALRECESSIVE	607706
CMT2 WITH VOCAL CORD PARESIS, AUTOSOMAL RECESSIVE	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMALRECESSIVE	607706
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4A, AXONAL FORM	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMALRECESSIVE	607706
CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMALRECESSIVE	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMALRECESSIVE	607706
NOONAN SYNDROME-LIKE DISORDER WITH LOOSE ANAGEN HAIR; NSLH	NOONAN SYNDROME-LIKE DISORDER WITH LOOSE ANAGEN HAIR; NSLH	607721
TOSTI SYNDROME	NOONAN SYNDROME-LIKE DISORDER WITH LOOSE ANAGEN HAIR; NSLH	607721
POROKERATOSIS 4, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK4	POROKERATOSIS 4, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK4	607728
POROKERATOSIS, DISSEMINATED SUPERFICIAL ACTINIC, 2; DSAP2	POROKERATOSIS 4, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK4	607728
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2H; CMT2H	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2H; CMT2H	607731
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, WITH PYRAMIDAL FEATURES, AUTOSOMALRECESSIVE	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2H; CMT2H	607731
CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, WITH PYRAMIDAL FEATURES, AUTOSOMALRECESSIVE	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2H; CMT2H	607731
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1F; CMT1F	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1F; CMT1F	607734
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1F	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1F; CMT1F	607734
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2J; CMT2J	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2J; CMT2J	607736
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2J	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2J; CMT2J	607736
CHARCOT-MARIE-TOOTH DISEASE, TYPE 2, WITH HEARING LOSS AND PUPILLARYABNORMALITIES	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2J; CMT2J	607736
SEIZURES, BENIGN FAMILIAL INFANTILE, 3; BFIS3	SEIZURES, BENIGN FAMILIAL INFANTILE, 3; BFIS3	607745
CONVULSIONS, BENIGN FAMILIAL INFANTILE, 3; BFIC3	SEIZURES, BENIGN FAMILIAL INFANTILE, 3; BFIS3	607745
SEIZURES, BENIGN FAMILIAL NEONATAL-INFANTILE; BFNIS	SEIZURES, BENIGN FAMILIAL INFANTILE, 3; BFIS3	607745
HYPERCHOLANEMIA, FAMILIAL; FHCA	HYPERCHOLANEMIA, FAMILIAL; FHCA	607748
BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1	607765
3-@BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1	607765
ACROCAPITOFEMORAL DYSPLASIA; ACFD	ACROCAPITOFEMORAL DYSPLASIA; ACFD	607778
JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML	JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML	607785
LEUKEMIA, JUVENILE MYELOMONOCYTICLEUKEMIA, CHRONIC MYELOMONOCYTIC, INCLUDED; CMML, INCLUDED	JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML	607785
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE D; CMTDID	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE D; CMTDID	607791
CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE D	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE D; CMTDID	607791
DI-CMTD	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE D; CMTDID	607791
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1C; LGMD1C	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1C; LGMD1C	607801
CRANIOLENTICULOSUTURAL DYSPLASIA; CLSD	CRANIOLENTICULOSUTURAL DYSPLASIA; CLSD	607812
BOYADJIEV-JABS SYNDROME	CRANIOLENTICULOSUTURAL DYSPLASIA; CLSD	607812
DEAFNESS, AUTOSOMAL RECESSIVE 37; DFNB37	DEAFNESS, AUTOSOMAL RECESSIVE 37; DFNB37	607821
ALZHEIMER DISEASE 3	ALZHEIMER DISEASE 3	607822
AD3	ALZHEIMER DISEASE 3	607822
ALZHEIMER DISEASE 3, EARLY-ONSET	ALZHEIMER DISEASE 3	607822
ALZHEIMER DISEASE, FAMILIAL, 3ALZHEIMER DISEASE, FAMILIAL, 3, WITH SPASTIC PARAPARESIS AND UNUSUALPLAQUES, INCLUDED	ALZHEIMER DISEASE 3	607822
ALZHEIMER DISEASE, FAMILIAL, 3, WITH SPASTIC PARAPARESIS AND APRAXIA,INCLUDED	ALZHEIMER DISEASE 3	607822
HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA SYNDROME; HLTS	HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA SYNDROME; HLTS	607823
MITRAL VALVE PROLAPSE 2; MVP2	MITRAL VALVE PROLAPSE 2; MVP2	607829
MITRAL VALVE PROLAPSE, MYXOMATOUS 2; MMVP2	MITRAL VALVE PROLAPSE 2; MVP2	607829
MYXOMATOUS MITRAL VALVE PROLAPSE 2	MITRAL VALVE PROLAPSE 2; MVP2	607829
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2K; CMT2K	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2K; CMT2K	607831
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2K	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2K; CMT2K	607831
CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2KCHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2K, INCLUDED	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2K; CMT2K	607831
FOCAL SEGMENTAL GLOMERULOSCLEROSIS 3, SUSCEPTIBILITY TO; FSGS3	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 3, SUSCEPTIBILITY TO; FSGS3	607832
GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 3, SUSCEPTIBILITY TO	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 3, SUSCEPTIBILITY TO; FSGS3	607832
ANXIETYHARM AVOIDANCE, INCLUDED	ANXIETYHARM AVOIDANCE, INCLUDED	607834
AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 1; AIS1	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 1; AIS1	607836
VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 2;VAMAS2	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 1; AIS1	607836
AUTOIMMUNE DISEASE SUSCEPTIBILITY LOCUS, CHROMOSOME 1p-RELATED	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 1; AIS1	607836
DEAFNESS, AUTOSOMAL DOMINANT 48; DFNA48	DEAFNESS, AUTOSOMAL DOMINANT 48; DFNA48	607841
AURAL ATRESIA, CONGENITAL; CAA	AURAL ATRESIA, CONGENITAL; CAA	607842
AURAL ATRESIA, CONGENITAL, WITH HYPOSMIA	AURAL ATRESIA, CONGENITAL; CAA	607842
NEUTROPENIA, NONIMMUNE CHRONIC IDIOPATHIC, OF ADULTS	NEUTROPENIA, NONIMMUNE CHRONIC IDIOPATHIC, OF ADULTS	607847
NONIMMUNE CHRONIC IDIOPATHIC NEUTROPENIA OF ADULTS	NEUTROPENIA, NONIMMUNE CHRONIC IDIOPATHIC, OF ADULTS	607847
NI-CINA	NEUTROPENIA, NONIMMUNE CHRONIC IDIOPATHIC, OF ADULTS	607847
OSTEOARTHRITIS SUSCEPTIBILITY 3; OS3	OSTEOARTHRITIS SUSCEPTIBILITY 3; OS3	607850
OSTEOARTHRITIS OF KNEE/HIP	OSTEOARTHRITIS SUSCEPTIBILITY 3; OS3	607850
PANIC DISORDER 2	PANIC DISORDER 2	607853
PAND2	PANIC DISORDER 2	607853
PANIC DISORDER SUSCEPTIBILITY LOCUS, CHROMOSOME 9q-RELATED	PANIC DISORDER 2	607853
MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT, 1A; MDC1A	MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT, 1A; MDC1A	607855
MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENTMUSCULAR DYSTROPHY, CONGENITAL, DUE TO PARTIAL LAMA2 DEFICIENCY, INCLUDED	MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT, 1A; MDC1A	607855
PSORIASIS 9, SUSCEPTIBILITY TO; PSORS9	PSORIASIS 9, SUSCEPTIBILITY TO; PSORS9	607857
CAUDAL DUPLICATION ANOMALY	CAUDAL DUPLICATION ANOMALY	607864
CHROMOSOME 1p36 DELETION SYNDROME	CHROMOSOME 1p36 DELETION SYNDROME	607872
MONOSOMY 1p36 SYNDROME	CHROMOSOME 1p36 DELETION SYNDROME	607872
EPILEPSY, FAMILIAL ADULT MYOCLONIC, 2; FAME2	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 2; FAME2	607876
BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY 2; BAFME2	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 2; FAME2	607876
CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 2; FCMTE2	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 2; FAME2	607876
CORTICAL MYOCLONUS AND EPILEPSY, AUTOSOMAL DOMINANT; ADCME	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 2; FAME2	607876
OVARIAN CANCER, SUSCEPTIBILITY TO, 1; OVCAS1	OVARIAN CANCER, SUSCEPTIBILITY TO, 1; OVCAS1	607893
HYPOTRICHOSIS 6; HYPT6	HYPOTRICHOSIS 6; HYPT6	607903
HYPOTRICHOSIS, LOCALIZED, AUTOSOMAL RECESSIVE 1; LAH1	HYPOTRICHOSIS 6; HYPT6	607903
HYPOTRICHOSIS, LOCALIZED, AUTOSOMAL RECESSIVE; LAH	HYPOTRICHOSIS 6; HYPT6	607903
HTL	HYPOTRICHOSIS 6; HYPT6	607903
MONILETHRIX-LIKE HYPOTRICHOSIS	HYPOTRICHOSIS 6; HYPT6	607903
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ii; CDG1I	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ii; CDG1I	607906
CDG Ii; CDGIi	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ii; CDG1I	607906
DERMATOFIBROSARCOMA PROTUBERANS; DFSP	DERMATOFIBROSARCOMA PROTUBERANS; DFSP	607907
GIANT CELL FIBROBLASTOMA	DERMATOFIBROSARCOMA PROTUBERANS; DFSP	607907
RETINITIS PIGMENTOSA 30; RP30MACULAR DEGENERATION, INCLUDED	RETINITIS PIGMENTOSA 30; RP30MACULAR DEGENERATION, INCLUDED	607921
MICROPHTHALMIA, SYNDROMIC 6; MCOPS6	MICROPHTHALMIA, SYNDROMIC 6; MCOPS6	607932
MICROPHTHALMIA AND PITUITARY ANOMALIES	MICROPHTHALMIA, SYNDROMIC 6; MCOPS6	607932
MICROPHTHALMIA WITH BRAIN AND DIGIT DEVELOPMENTAL ANOMALIES	MICROPHTHALMIA, SYNDROMIC 6; MCOPS6	607932
ANOPHTHALMIA, CLINICAL, WITH MICROGNATHIA, MALFORMED EARS, DIGITALANOMALIES, AND ABNORMAL EXTERNAL GENITALIA	MICROPHTHALMIA, SYNDROMIC 6; MCOPS6	607932
PEELING SKIN SYNDROME 4; PSS4	PEELING SKIN SYNDROME 4; PSS4	607936
ICHTHYOSIS BULLOSA OF SIEMENS-LIKE	PEELING SKIN SYNDROME 4; PSS4	607936
ICHTHYOSIS, EXFOLIATIVE, AUTOSOMAL RECESSIVE; AREI	PEELING SKIN SYNDROME 4; PSS4	607936
ATRIAL SEPTAL DEFECT 2; ASD2	ATRIAL SEPTAL DEFECT 2; ASD2	607941
SPONDYLOENCHONDRODYSPLASIA WITH IMMUNE DYSREGULATION; SPENCDI	SPONDYLOENCHONDRODYSPLASIA WITH IMMUNE DYSREGULATION; SPENCDI	607944
ROIFMAN IMMUNOSKELETAL SYNDROME	SPONDYLOENCHONDRODYSPLASIA WITH IMMUNE DYSREGULATION; SPENCDI	607944
COMBINED IMMUNODEFICIENCY WITH AUTOIMMUNITY AND SPONDYLOMETAPHYSEALDYSPLASIA	SPONDYLOENCHONDRODYSPLASIA WITH IMMUNE DYSREGULATION; SPENCDI	607944
MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TOMYCOBACTERIUM TUBERCULOSIS, PROTECTION AGAINST, INCLUDED	MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TOMYCOBACTERIUM TUBERCULOSIS, PROTECTION AGAINST, INCLUDED	607948
MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 1	MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 1	607949
MTBS1	MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 1	607949
SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 1;SLEN1	SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 1;SLEN1	607965
SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 2;SLEN2	SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 2;SLEN2	607966
SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 3;SLEN3	SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 3;SLEN3	607967
NPC1-LIKE 1; NPC1L1EZETIMIBE, NONRESPONSE TO, INCLUDED	NPC1-LIKE 1; NPC1L1EZETIMIBE, NONRESPONSE TO, INCLUDED	608010
GAUCHER DISEASE, PERINATAL LETHAL	GAUCHER DISEASE, PERINATAL LETHAL	608013
GAUCHER DISEASE, COLLODION TYPE	GAUCHER DISEASE, PERINATAL LETHAL	608013
DIAPHANOSPONDYLODYSOSTOSIS	DIAPHANOSPONDYLODYSOSTOSIS	608022
VERTEBRAL OSSIFICATION, DEFECT IN, WITH NEPHROGENIC RESTS	DIAPHANOSPONDYLODYSOSTOSIS	608022
HYPERTENSIVE NEPHROPATHY; HNP1	HYPERTENSIVE NEPHROPATHY; HNP1	608026
PONTOCEREBELLAR HYPOPLASIA, TYPE 3; PCH3	PONTOCEREBELLAR HYPOPLASIA, TYPE 3; PCH3	608027
CEREBELLAR ATROPHY WITH PROGRESSIVE MICROCEPHALY; CLAM	PONTOCEREBELLAR HYPOPLASIA, TYPE 3; PCH3	608027
PCH WITH OPTIC ATROPHY	PONTOCEREBELLAR HYPOPLASIA, TYPE 3; PCH3	608027
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 6; SCAR6	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 6; SCAR6	608029
CEREBELLAR ATAXIA, INFANTILE NONPROGRESSIVE, AUTOSOMAL RECESSIVE	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 6; SCAR6	608029
NORWEGIAN INFANTILE ONSET ATAXIA	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 6; SCAR6	608029
AMYOTROPHIC LATERAL SCLEROSIS 6 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS6	AMYOTROPHIC LATERAL SCLEROSIS 6 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS6	608030
AMYOTROPHIC LATERAL SCLEROSIS 7; ALS7	AMYOTROPHIC LATERAL SCLEROSIS 7; ALS7	608031
ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 3; IIAE3	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 3; IIAE3	608033
ENCEPHALOPATHY, ACUTE NECROTIZING, SUSCEPTIBILITY TO; ANE	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 3; IIAE3	608033
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 4; CMM4	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 4; CMM4	608035
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 4	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 4	608036
NIDDM4	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 4	608036
NONINSULIN-DEPENDENT DIABETES MELLITUS 4	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 4	608036
REPRESSOR OF TELOMERASE EXPRESSION 1	REPRESSOR OF TELOMERASE EXPRESSION 1	608045
RTE1	REPRESSOR OF TELOMERASE EXPRESSION 1	608045
AUTISM, SUSCEPTIBILITY TO, 3; AUTS3	AUTISM, SUSCEPTIBILITY TO, 3; AUTS3	608049
MACULAR DYSTROPHY, RETINAL, 2; MCDR2	MACULAR DYSTROPHY, RETINAL, 2; MCDR2	608051
NEUTROPHILIC DERMATOSIS, ACUTE FEBRILE	NEUTROPHILIC DERMATOSIS, ACUTE FEBRILE	608068
AFND	NEUTROPHILIC DERMATOSIS, ACUTE FEBRILE	608068
SWEET SYNDROME; SS	NEUTROPHILIC DERMATOSIS, ACUTE FEBRILE	608068
GOMM-BUTTON DISEASE	NEUTROPHILIC DERMATOSIS, ACUTE FEBRILE	608068
SCHIZOPHRENIA 11	SCHIZOPHRENIA 11	608078
SCZD11	SCHIZOPHRENIA 11	608078
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 10q-RELATED	SCHIZOPHRENIA 11	608078
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE I, WITH COUGH ANDGASTROESOPHAGEAL REFLUX	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE I, WITH COUGH ANDGASTROESOPHAGEAL REFLUX	608088
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IB; HSAN1B	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE I, WITH COUGH ANDGASTROESOPHAGEAL REFLUX	608088
NEUROPATHY, HEREDITARY SENSORY, TYPE IB; HSN1B	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE I, WITH COUGH ANDGASTROESOPHAGEAL REFLUX	608088
ENDOMETRIAL CANCER	ENDOMETRIAL CANCER	608089
JOUBERT SYNDROME 2; JBTS2	JOUBERT SYNDROME 2; JBTS2	608091
CEREBELLOOCULORENAL SYNDROME 2; CORS2	JOUBERT SYNDROME 2; JBTS2	608091
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ij; CDG1J	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ij; CDG1J	608093
CDG Ij; CDGIj	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ij; CDG1J	608093
EPILEPSY, FAMILIAL TEMPORAL LOBE, 2; ETL2	EPILEPSY, FAMILIAL TEMPORAL LOBE, 2; ETL2	608096
FTLE	EPILEPSY, FAMILIAL TEMPORAL LOBE, 2; ETL2	608096
PERIVENTRICULAR HETEROTOPIA WITH MICROCEPHALY, AUTOSOMAL RECESSIVE;ARPHM	PERIVENTRICULAR HETEROTOPIA WITH MICROCEPHALY, AUTOSOMAL RECESSIVE;ARPHM	608097
PERIVENTRICULAR NODULAR HETEROTOPIA 2; PVNH2	PERIVENTRICULAR HETEROTOPIA WITH MICROCEPHALY, AUTOSOMAL RECESSIVE;ARPHM	608097
HETEROTOPIA, PERIVENTRICULAR, AUTOSOMAL RECESSIVE	PERIVENTRICULAR HETEROTOPIA WITH MICROCEPHALY, AUTOSOMAL RECESSIVE;ARPHM	608097
HETEROTOPIA, PERIVENTRICULAR, ASSOCIATED WITH CHROMOSOME 5p ANOMALIES	HETEROTOPIA, PERIVENTRICULAR, ASSOCIATED WITH CHROMOSOME 5p ANOMALIES	608098
PERIVENTRICULAR NODULAR HETEROTOPIA 3; PVNH3	HETEROTOPIA, PERIVENTRICULAR, ASSOCIATED WITH CHROMOSOME 5p ANOMALIES	608098
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D	608099
DUCHENNE-LIKE AUTOSOMAL RECESSIVE MUSCULAR DYSTROPHY, TYPE 2; DMDA2	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D	608099
ADHALINOPATHY, PRIMARY	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D	608099
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ih; CDG1H	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ih; CDG1H	608104
CDG Ih; CDGIh	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ih; CDG1H	608104
EPILEPSY, ROLANDIC, WITH PAROXYSMAL EXERCISE-INDUCED DYSTONIA ANDWRITER'S CRAMP; EPRPDC	EPILEPSY, ROLANDIC, WITH PAROXYSMAL EXERCISE-INDUCED DYSTONIA ANDWRITER'S CRAMP; EPRPDC	608105
RE-PED-WC	EPILEPSY, ROLANDIC, WITH PAROXYSMAL EXERCISE-INDUCED DYSTONIA ANDWRITER'S CRAMP; EPRPDC	608105
IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 5; HIGM5	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 5; HIGM5	608106
HYPER-IgM SYNDROME 5	IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 5; HIGM5	608106
OVARIAN HYPERSTIMULATION SYNDROME; OHSS	OVARIAN HYPERSTIMULATION SYNDROME; OHSS	608115
OVARIAN HYPERSTIMULATION SYNDROME, FAMILIAL GESTATIONAL SPONTANEOUS	OVARIAN HYPERSTIMULATION SYNDROME; OHSS	608115
ZINC DEFICIENCY, TRANSIENT NEONATAL; TNZD	ZINC DEFICIENCY, TRANSIENT NEONATAL; TNZD	608118
ZINC DEFICIENCY, NEONATAL, DUE TO LOW BREAST MILK ZINCZINC IN BREAST MILK, REDUCED, INCLUDED	ZINC DEFICIENCY, TRANSIENT NEONATAL; TNZD	608118
RETINITIS PIGMENTOSA 7; RP7RETINITIS PIGMENTOSA 7, DIGENIC, INCLUDED	RETINITIS PIGMENTOSA 7; RP7RETINITIS PIGMENTOSA 7, DIGENIC, INCLUDED	608133
LEBER CONGENITAL AMAUROSIS 18, INCLUDED; LCA18, INCLUDED	RETINITIS PIGMENTOSA 7; RP7RETINITIS PIGMENTOSA 7, DIGENIC, INCLUDED	608133
KAGAMI-OGATA SYNDROME	KAGAMI-OGATA SYNDROME	608149
UNIPARENTAL DISOMY, PATERNAL, CHROMOSOME 14	KAGAMI-OGATA SYNDROME	608149
LIPODYSTROPHY, GENERALIZED, WITH MENTAL RETARDATION, DEAFNESS, SHORTSTATURE, AND SLENDER BONES	LIPODYSTROPHY, GENERALIZED, WITH MENTAL RETARDATION, DEAFNESS, SHORTSTATURE, AND SLENDER BONES	608154
NABLUS MASK-LIKE FACIAL SYNDROME; NMLFS	NABLUS MASK-LIKE FACIAL SYNDROME; NMLFS	608156
CHROMOSOME 8q22.1 DELETION SYNDROME	NABLUS MASK-LIKE FACIAL SYNDROME; NMLFS	608156
CoQ-RESPONSIVE OXPHOS DEFICIENCY	CoQ-RESPONSIVE OXPHOS DEFICIENCY	608158
MACULAR DYSTROPHY, VITELLIFORM, 3; VMD3	MACULAR DYSTROPHY, VITELLIFORM, 3; VMD3	608161
VITELLIFORM MACULAR DYSTROPHY, ADULT-ONSET; AVMD	MACULAR DYSTROPHY, VITELLIFORM, 3; VMD3	608161
FOVEOMACULAR DYSTROPHY, ADULT-ONSET; AOFMD	MACULAR DYSTROPHY, VITELLIFORM, 3; VMD3	608161
FOVEOMACULAR DYSTROPHY, ADULT-ONSET, WITH OR WITHOUT CHOROIDAL NEOVASCULARIZATION	MACULAR DYSTROPHY, VITELLIFORM, 3; VMD3	608161
AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 1	AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 1	608173
AITD1	AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 1	608173
AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 2	AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 2	608174
AITD2	AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 2	608174
AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3; AITD3	AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3; AITD3	608175
AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 4	AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 4	608176
AITD4	AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 4	608176
SYNPOLYDACTYLY 2; SPD2	SYNPOLYDACTYLY 2; SPD2	608180
SYNPOLYDACTYLY, 3/3-PRIME/4, ASSOCIATED WITH METACARPAL AND METATARSALSYNOSTOSES	SYNPOLYDACTYLY 2; SPD2	608180
TROPICAL CALCIFIC PANCREATITIS	TROPICAL CALCIFIC PANCREATITIS	608189
TCP	TROPICAL CALCIFIC PANCREATITIS	608189
CONE-ROD DYSTROPHY 13; CORD13	CONE-ROD DYSTROPHY 13; CORD13	608194
NEUTROPHIL IMMUNODEFICIENCY SYNDROME	NEUTROPHIL IMMUNODEFICIENCY SYNDROME	608203
KALA-AZAR, SUSCEPTIBILITY TO, 1; KAZA1	KALA-AZAR, SUSCEPTIBILITY TO, 1; KAZA1	608207
LEISHMANIASIS, VISCERAL, SUSCEPTIBILITY TO, 1	KALA-AZAR, SUSCEPTIBILITY TO, 1; KAZA1	608207
SEIZURES, BENIGN FAMILIAL NEONATAL, 3; BFNS3	SEIZURES, BENIGN FAMILIAL NEONATAL, 3; BFNS3	608217
CONVULSIONS, BENIGN FAMILIAL NEONATAL, 3; BFNC3	SEIZURES, BENIGN FAMILIAL NEONATAL, 3; BFNS3	608217
DEAFNESS, AUTOSOMAL RECESSIVE 38; DFNB38	DEAFNESS, AUTOSOMAL RECESSIVE 38; DFNB38	608219
SPASTIC PARAPLEGIA 25, AUTOSOMAL RECESSIVE; SPG25	SPASTIC PARAPLEGIA 25, AUTOSOMAL RECESSIVE; SPG25	608220
DISC HERNIATION WITH SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE	SPASTIC PARAPLEGIA 25, AUTOSOMAL RECESSIVE; SPG25	608220
DEAFNESS, AUTOSOMAL DOMINANT 41; DFNA41	DEAFNESS, AUTOSOMAL DOMINANT 41; DFNA41	608224
LEUKEMIA, CHRONIC MYELOID; CML	LEUKEMIA, CHRONIC MYELOID; CML	608232
LEUKEMIA, CHRONIC MYELOGENOUSLEUKEMIA, CHRONIC MYELOID, ATYPICAL, INCLUDED; ACML, INCLUDED	LEUKEMIA, CHRONIC MYELOID; CML	608232
HERMANSKY-PUDLAK SYNDROME 2; HPS2	HERMANSKY-PUDLAK SYNDROME 2; HPS2	608233
SLOWED NERVE CONDUCTION VELOCITY, AUTOSOMAL DOMINANT; SNCV	SLOWED NERVE CONDUCTION VELOCITY, AUTOSOMAL DOMINANT; SNCV	608236
OTOSCLEROSIS 3; OTSC3	OTOSCLEROSIS 3; OTSC3	608244
PHOBIA, SPECIFIC	PHOBIA, SPECIFIC	608251
PHOBIA, SIMPLE	PHOBIA, SPECIFIC	608251
DEAFNESS, AUTOSOMAL RECESSIVE 40; DFNB40	DEAFNESS, AUTOSOMAL RECESSIVE 40; DFNB40	608264
DEAFNESS, AUTOSOMAL RECESSIVE 39; DFNB39	DEAFNESS, AUTOSOMAL RECESSIVE 39; DFNB39	608265
PARATHYROID CARCINOMA	PARATHYROID CARCINOMA	608266
PRTC	PARATHYROID CARCINOMA	608266
LELIS SYNDROME	LELIS SYNDROME	608290
ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH ACANTHOSIS NIGRICANS	LELIS SYNDROME	608290
CARBAMOYL PHOSPHATE SYNTHETASE I; CPS1VENOOCCLUSIVE DISEASE AFTER BONE MARROW TRANSPLANTATION, SUSCEPTIBILITYTO, INCLUDED	CARBAMOYL PHOSPHATE SYNTHETASE I; CPS1VENOOCCLUSIVE DISEASE AFTER BONE MARROW TRANSPLANTATION, SUSCEPTIBILITYTO, INCLUDED	608307
CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 2	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 2	608316
CHDS2	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 2	608316
CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 4	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 4	608318
CHDS4	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 4	608318
CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT, 1; ADCAD1	CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT, 1; ADCAD1	608320
CORONARY ARTERY DISEASE WITH MYOCARDIAL INFARCTION	CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT, 1; ADCAD1	608320
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE C; CMTDIC	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE C; CMTDIC	608323
CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE C	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE C; CMTDIC	608323
DI-CMTC	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE C; CMTDIC	608323
WEILL-MARCHESANI SYNDROME 2; WMS2	WEILL-MARCHESANI SYNDROME 2; WMS2	608328
WEILL-MARCHESANI SYNDROME, AUTOSOMAL DOMINANT	WEILL-MARCHESANI SYNDROME 2; WMS2	608328
SPHEROPHAKIA-BRACHYMORPHIA SYNDROME	WEILL-MARCHESANI SYNDROME 2; WMS2	608328
MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL	WEILL-MARCHESANI SYNDROME 2; WMS2	608328
GLAUCOMA-LENS ECTOPIA-MICROSPHEROPHAKIA-STIFFNESS-SHORTNESS SYNDROME;GEMSS	WEILL-MARCHESANI SYNDROME 2; WMS2	608328
CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE A; CMTRIA	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE A; CMTRIA	608340
CHARCOT-MARIE-TOOTH NEUROPATHY, RECESSIVE INTERMEDIATE A	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE A; CMTRIA	608340
RI-CMTA	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE A; CMTRIA	608340
NYSTAGMUS 3, CONGENITAL, AUTOSOMAL DOMINANT; NYS3	NYSTAGMUS 3, CONGENITAL, AUTOSOMAL DOMINANT; NYS3	608345
CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION; CMAVMCAPILLARY MALFORMATION WITHOUT ARTERIOVENOUS MALFORMATION, INCLUDED	CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION; CMAVMCAPILLARY MALFORMATION WITHOUT ARTERIOVENOUS MALFORMATION, INCLUDED	608354
PARKES WEBER SYNDROME	PARKES WEBER SYNDROME	608355
PKWS	PARKES WEBER SYNDROME	608355
MYOPATHY, MYOSIN STORAGE, AUTOSOMAL DOMINANT; MSMA	MYOPATHY, MYOSIN STORAGE, AUTOSOMAL DOMINANT; MSMA	608358
MYOPATHY, HYALINE BODY, AUTOSOMAL DOMINANT	MYOPATHY, MYOSIN STORAGE, AUTOSOMAL DOMINANT; MSMA	608358
MYOPATHY WITH LYSIS OF TYPE I MYOFIBRILS	MYOPATHY, MYOSIN STORAGE, AUTOSOMAL DOMINANT; MSMA	608358
SPONDYLOEPIPHYSEAL DYSPLASIA, KIMBERLEY TYPE	SPONDYLOEPIPHYSEAL DYSPLASIA, KIMBERLEY TYPE	608361
SEDK	SPONDYLOEPIPHYSEAL DYSPLASIA, KIMBERLEY TYPE	608361
CHROMOSOME 22q11.2 DUPLICATION SYNDROME	CHROMOSOME 22q11.2 DUPLICATION SYNDROME	608363
CHROMOSOME 22q11.2 MICRODUPLICATION SYNDROME	CHROMOSOME 22q11.2 DUPLICATION SYNDROME	608363
MYOPIA 17, AUTOSOMAL DOMINANT; MYP17	MYOPIA 17, AUTOSOMAL DOMINANT; MYP17	608367
MYOPIA 4, FORMERLY; MYP4, FORMERLY	MYOPIA 17, AUTOSOMAL DOMINANT; MYP17	608367
OROFACIAL CLEFT 4; OFC4	OROFACIAL CLEFT 4; OFC4	608371
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 4	OROFACIAL CLEFT 4; OFC4	608371
DEAFNESS, AUTOSOMAL DOMINANT 49; DFNA49	DEAFNESS, AUTOSOMAL DOMINANT 49; DFNA49	608372
RETINITIS PIGMENTOSA 26; RP26	RETINITIS PIGMENTOSA 26; RP26	608380
BRANCHIOOTIC SYNDROME 3; BOS3	BRANCHIOOTIC SYNDROME 3; BOS3	608389
BO SYNDROME 3	BRANCHIOOTIC SYNDROME 3; BOS3	608389
MYOTONIA, POTASSIUM-AGGRAVATED	MYOTONIA, POTASSIUM-AGGRAVATED	608390
MYOTONIA FLUCTUANS	MYOTONIA, POTASSIUM-AGGRAVATED	608390
MYOTONIA PERMANENS	MYOTONIA, POTASSIUM-AGGRAVATED	608390
SODIUM CHANNEL MUSCLE DISEASE	MYOTONIA, POTASSIUM-AGGRAVATED	608390
MYOTONIA CONGENITA, ACETAZOLAMIDE-RESPONSIVE	MYOTONIA, POTASSIUM-AGGRAVATED	608390
MYOTONIA CONGENITA, ATYPICALLARYNGOSPASM, SEVERE NEONATAL EPISODIC, INCLUDED; SNEL, INCLUDED	MYOTONIA, POTASSIUM-AGGRAVATED	608390
AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 2; AIS2	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 2; AIS2	608391
VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 3;VAMAS3	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 2; AIS2	608391
AUTOIMMUNE DISEASE SUSCEPTIBILITY LOCUS, CHROMOSOME 7-RELATED	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 2; AIS2	608391
AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 3; AIS3	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 3; AIS3	608392
VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 4;VAMAS4	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 3; AIS3	608392
AUTOIMMUNE DISEASE SUSCEPTIBILITY LOCUS, CHROMOSOME 8-RELATED	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 3; AIS3	608392
MICROCEPHALY 6, PRIMARY, AUTOSOMAL RECESSIVE; MCPH6	MICROCEPHALY 6, PRIMARY, AUTOSOMAL RECESSIVE; MCPH6	608393
DEAFNESS, AUTOSOMAL DOMINANT 43; DFNA43	DEAFNESS, AUTOSOMAL DOMINANT 43; DFNA43	608394
PLATELET GLYCOPROTEIN IV DEFICIENCY	PLATELET GLYCOPROTEIN IV DEFICIENCY	608404
BLEEDING DISORDER, PLATELET-TYPE, 10; BDPLT10	PLATELET GLYCOPROTEIN IV DEFICIENCY	608404
CD36 DEFICIENCY	PLATELET GLYCOPROTEIN IV DEFICIENCY	608404
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 7; BMIQ7	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 7; BMIQ7	608410
OBESITY, SUSCEPTIBILITY TO	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 7; BMIQ7	608410
PROLONGED ELECTRORETINAL RESPONSE SUPPRESSION; PERRS	PROLONGED ELECTRORETINAL RESPONSE SUPPRESSION; PERRS	608415
BRADYOPSIA	PROLONGED ELECTRORETINAL RESPONSE SUPPRESSION; PERRS	608415
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1F; LGMD1F	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1F; LGMD1F	608423
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 4; SLEB4	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 4; SLEB4	608437
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 3; MRT3	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 3; MRT3	608443
SPEECH-SOUND DISORDER	SPEECH-SOUND DISORDER	608445
SSD	SPEECH-SOUND DISORDER	608445
MYOCARDIAL INFARCTION, SUSCEPTIBILITY TOMYOCARDIAL INFARCTION, SUSCEPTIBILITY TO, 1, INCLUDED; MCI1, INCLUDED	MYOCARDIAL INFARCTION, SUSCEPTIBILITY TOMYOCARDIAL INFARCTION, SUSCEPTIBILITY TO, 1, INCLUDED; MCI1, INCLUDED	608446
MYOCARDIAL INFARCTION, PROTECTION AGAINST, INCLUDED	MYOCARDIAL INFARCTION, SUSCEPTIBILITY TOMYOCARDIAL INFARCTION, SUSCEPTIBILITY TO, 1, INCLUDED; MCI1, INCLUDED	608446
CAROTID INTIMAL MEDIAL THICKNESS 2	CAROTID INTIMAL MEDIAL THICKNESS 2	608447
CIMT2	CAROTID INTIMAL MEDIAL THICKNESS 2	608447
CAROTID INTIMAL MEDIAL THICKNESS QUANTITATIVE TRAIT LOCUS ON CHROMOSOME12	CAROTID INTIMAL MEDIAL THICKNESS 2	608447
INFLAMMATORY BOWEL DISEASE 9; IBD9	INFLAMMATORY BOWEL DISEASE 9; IBD9	608448
FAMILIAL ADENOMATOUS POLYPOSIS, 2; FAP2	FAMILIAL ADENOMATOUS POLYPOSIS, 2; FAP2	608456
COLORECTAL ADENOMATOUS POLYPOSIS, AUTOSOMAL RECESSIVE	FAMILIAL ADENOMATOUS POLYPOSIS, 2; FAP2	608456
ADENOMAS, MULTIPLE COLORECTAL, AUTOSOMAL RECESSIVE	FAMILIAL ADENOMATOUS POLYPOSIS, 2; FAP2	608456
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 8; HSCR8	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 8; HSCR8	608462
CORNEAL DYSTROPHY, REIS-BUCKLERS TYPE; CDRB	CORNEAL DYSTROPHY, REIS-BUCKLERS TYPE; CDRB	608470
REIS-BUCKLERS CORNEAL DYSTROPHY; RBCD	CORNEAL DYSTROPHY, REIS-BUCKLERS TYPE; CDRB	608470
CORNEAL DYSTROPHY OF BOWMAN LAYER, TYPE I; CDB1	CORNEAL DYSTROPHY, REIS-BUCKLERS TYPE; CDRB	608470
CORNEAL DYSTROPHY, GEOGRAPHIC	CORNEAL DYSTROPHY, REIS-BUCKLERS TYPE; CDRB	608470
GRANULAR CORNEAL DYSTROPHY, TYPE III	CORNEAL DYSTROPHY, REIS-BUCKLERS TYPE; CDRB	608470
CORNEAL DYSTROPHY, LATTICE TYPE IIIA; CDL3A	CORNEAL DYSTROPHY, LATTICE TYPE IIIA; CDL3A	608471
LATTICE CORNEAL DYSTROPHY, TYPE IIIA	CORNEAL DYSTROPHY, LATTICE TYPE IIIA; CDL3A	608471
MYOPIA 5, AUTOSOMAL DOMINANT; MYP5	MYOPIA 5, AUTOSOMAL DOMINANT; MYP5	608474
CYTOCHROME b(-245), ALPHA SUBUNIT; CYBA	CYTOCHROME b(-245), ALPHA SUBUNIT; CYBA	608508
CYTOCHROME b(558), ALPHA SUBUNIT	CYTOCHROME b(-245), ALPHA SUBUNIT; CYBA	608508
p22-PHOX	CYTOCHROME b(-245), ALPHA SUBUNIT; CYBA	608508
CYTOCHROME b LIGHT CHAINREACTIVE OXYGEN SPECIES GENERATION, DECREASED, INCLUDED	CYTOCHROME b(-245), ALPHA SUBUNIT; CYBA	608508
MAJOR DEPRESSIVE DISORDER; MDD	MAJOR DEPRESSIVE DISORDER; MDD	608516
UNIPOLAR DEPRESSIONSEASONAL AFFECTIVE DISORDER, INCLUDED; SAD, INCLUDED	MAJOR DEPRESSIVE DISORDER; MDD	608516
MAJOR DEPRESSIVE DISORDER 1	MAJOR DEPRESSIVE DISORDER 1	608520
MDD1	MAJOR DEPRESSIVE DISORDER 1	608520
UNIPOLAR DEPRESSION 1	MAJOR DEPRESSIVE DISORDER 1	608520
PERIODONTITIS, AGGRESSIVE, 2	PERIODONTITIS, AGGRESSIVE, 2	608526
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K	608540
CDG Ik; CDGIk	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K	608540
ANEURYSM, INTRACRANIAL BERRY, 2; ANIB2	ANEURYSM, INTRACRANIAL BERRY, 2; ANIB2	608542
SCHIZOPHRENIA 12	SCHIZOPHRENIA 12	608543
SCZD12	SCHIZOPHRENIA 12	608543
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 1p-RELATED	SCHIZOPHRENIA 12	608543
LARSEN-LIKE SYNDROME	LARSEN-LIKE SYNDROME	608545
LRSL	LARSEN-LIKE SYNDROME	608545
LEBER CONGENITAL AMAUROSIS 9; LCA9	LEBER CONGENITAL AMAUROSIS 9; LCA9	608553
LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO	LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO	608556
MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO, 2	MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO, 2	608557
MCI2	MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO, 2	608557
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 5; BMIQ5	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 5; BMIQ5	608558
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 6; BMIQ6	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 6; BMIQ6	608559
POLYDACTYLY, POSTAXIAL, TYPE A4	POLYDACTYLY, POSTAXIAL, TYPE A4	608562
PAPA4	POLYDACTYLY, POSTAXIAL, TYPE A4	608562
POSTAXIAL POLYDACTYLY, TYPE A4	POLYDACTYLY, POSTAXIAL, TYPE A4	608562
DEAFNESS, AUTOSOMAL RECESSIVE 35; DFNB35	DEAFNESS, AUTOSOMAL RECESSIVE 35; DFNB35	608565
SICK SINUS SYNDROME 1, AUTOSOMAL RECESSIVE; SSS1	SICK SINUS SYNDROME 1, AUTOSOMAL RECESSIVE; SSS1	608567
SINUS RHYTHM, CONGENITAL ABSENCE OF	SICK SINUS SYNDROME 1, AUTOSOMAL RECESSIVE; SSS1	608567
SINUS NODE DISEASE, FAMILIAL, AUTOSOMAL RECESSIVE	SICK SINUS SYNDROME 1, AUTOSOMAL RECESSIVE; SSS1	608567
SICK SINUS SYNDROME, CONGENITAL	SICK SINUS SYNDROME 1, AUTOSOMAL RECESSIVE; SSS1	608567
SINUS BRADYCARDIA SYNDROME, FAMILIAL	SICK SINUS SYNDROME 1, AUTOSOMAL RECESSIVE; SSS1	608567
CARDIOMYOPATHY, DILATED, 1O; CMD1O	CARDIOMYOPATHY, DILATED, 1O; CMD1O	608569
CARDIOMYOPATHY, DILATED, WITH VENTRICULAR TACHYCARDIA	CARDIOMYOPATHY, DILATED, 1O; CMD1O	608569
BURN-MCKEOWN SYNDROME; BMKS	BURN-MCKEOWN SYNDROME; BMKS	608572
OCULOOTOFACIAL DYSPLASIA; OOFD	BURN-MCKEOWN SYNDROME; BMKS	608572
SEVERE CUTANEOUS ADVERSE REACTION, SUSCEPTIBILITY TOTOXIC EPIDERMAL NECROLYSIS, SUSCEPTIBILITY TO, INCLUDED	SEVERE CUTANEOUS ADVERSE REACTION, SUSCEPTIBILITY TOTOXIC EPIDERMAL NECROLYSIS, SUSCEPTIBILITY TO, INCLUDED	608579
STEVENS-JOHNSON SYNDROME, SUSCEPTIBILITY TO, INCLUDED	SEVERE CUTANEOUS ADVERSE REACTION, SUSCEPTIBILITY TOTOXIC EPIDERMAL NECROLYSIS, SUSCEPTIBILITY TO, INCLUDED	608579
HYPERSENSITIVITY SYNDROME, CARBAMAZEPINE-INDUCED, SUSCEPTIBILITY TO,INCLUDED	SEVERE CUTANEOUS ADVERSE REACTION, SUSCEPTIBILITY TOTOXIC EPIDERMAL NECROLYSIS, SUSCEPTIBILITY TO, INCLUDED	608579
ATRIAL FIBRILLATION, FAMILIAL, 1; ATFB1	ATRIAL FIBRILLATION, FAMILIAL, 1; ATFB1	608583
ATRIAL FIBRILLATION, AUTOSOMAL DOMINANT	ATRIAL FIBRILLATION, FAMILIAL, 1; ATFB1	608583
ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 2	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 2	608584
ASRT2	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 2	608584
BRACHIAL PALSY, FAMILIAL CONGENITAL	BRACHIAL PALSY, FAMILIAL CONGENITAL	608585
KERATOCONUS 3; KTCN3	KERATOCONUS 3; KTCN3	608586
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2G; CMT2G	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2G; CMT2G	608591
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2G	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2G; CMT2G	608591
LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1; CGL1	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1; CGL1	608594
BERARDINELLI-SEIP CONGENITAL LIPODYSTROPHY, TYPE 1; BSCL1	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1; CGL1	608594
LIPODYSTROPHY, BERARDINELLI-SEIP CONGENITAL, TYPE 1	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1; CGL1	608594
BRUNZELL SYNDROME, AGPAT2-RELATED	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1; CGL1	608594
LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 1; FPLD1	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 1; FPLD1	608600
LIPODYSTROPHY, FAMILIAL PARTIAL, KOBBERLING TYPE	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 1; FPLD1	608600
RIBOSE 5-PHOSPHATE ISOMERASE DEFICIENCY	RIBOSE 5-PHOSPHATE ISOMERASE DEFICIENCY	608611
MANDIBULOACRAL DYSPLASIA WITH TYPE B LIPODYSTROPHY; MADB	MANDIBULOACRAL DYSPLASIA WITH TYPE B LIPODYSTROPHY; MADB	608612
LIPODYSTROPHY, TYPE B, ASSOCIATED WITH MANDIBULOACRAL DYSPLASIA	MANDIBULOACRAL DYSPLASIA WITH TYPE B LIPODYSTROPHY; MADB	608612
OLIGODONTIA-COLORECTAL CANCER SYNDROME; ODCRCS	OLIGODONTIA-COLORECTAL CANCER SYNDROME; ODCRCS	608615
TOOTH AGENESIS-COLORECTAL CANCER SYNDROME	OLIGODONTIA-COLORECTAL CANCER SYNDROME; ODCRCS	608615
HYPERTENSION, DIASTOLIC, RESISTANCE TO	HYPERTENSION, DIASTOLIC, RESISTANCE TO	608622
AMYOTROPHIC LATERAL SCLEROSIS 8; ALS8	AMYOTROPHIC LATERAL SCLEROSIS 8; ALS8	608627
JOUBERT SYNDROME 3; JBTS3	JOUBERT SYNDROME 3; JBTS3	608629
ASPERGER SYNDROME, SUSCEPTIBILITY TO, 2; ASPG2	ASPERGER SYNDROME, SUSCEPTIBILITY TO, 2; ASPG2	608631
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIB; HMN2B	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIB; HMN2B	608634
HMN IIB	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIB; HMN2B	608634
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IIB; DHMN2B	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIB; HMN2B	608634
CHROMOSOME 15q11-q13 DUPLICATION SYNDROME	CHROMOSOME 15q11-q13 DUPLICATION SYNDROME	608636
DUPLICATION 15q11-q13 SYNDROMEAUTISM, SUSCEPTIBILITY TO, 4, INCLUDED; AUTS4, INCLUDED	CHROMOSOME 15q11-q13 DUPLICATION SYNDROME	608636
CHROMOSOME 15q11.2 DUPLICATION SYNDROME, INCLUDED	CHROMOSOME 15q11-q13 DUPLICATION SYNDROME	608636
ASPERGER SYNDROME, SUSCEPTIBILITY TO, 1; ASPG1	ASPERGER SYNDROME, SUSCEPTIBILITY TO, 1; ASPG1	608638
DEAFNESS, AUTOSOMAL DOMINANT 28; DFNA28	DEAFNESS, AUTOSOMAL DOMINANT 28; DFNA28	608641
AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY	AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY	608643
AADC DEFICIENCY	AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY	608643
DOPA DECARBOXYLASE DEFICIENCY	AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY	608643
DDC DEFICIENCY	AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY	608643
CILIARY DYSKINESIA, PRIMARY, 3; CILD3	CILIARY DYSKINESIA, PRIMARY, 3; CILD3	608644
CILIARY DYSKINESIA, PRIMARY, 3, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 3; CILD3	608644
DEAFNESS, AUTOSOMAL DOMINANT 31; DFNA31	DEAFNESS, AUTOSOMAL DOMINANT 31; DFNA31	608645
CILIARY DYSKINESIA, PRIMARY, 4; CILD4	CILIARY DYSKINESIA, PRIMARY, 4; CILD4	608646
CILIARY DYSKINESIA, PRIMARY, 4, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 4; CILD4	608646
CILIARY DYSKINESIA, PRIMARY, 5; CILD5	CILIARY DYSKINESIA, PRIMARY, 5; CILD5	608647
CILIARY DYSKINESIA, PRIMARY, 5, WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 5; CILD5	608647
ICHTHYOSIS PREMATURITY SYNDROME; IPS	ICHTHYOSIS PREMATURITY SYNDROME; IPS	608649
ICHTHYOSIS CONGENITA IV	ICHTHYOSIS PREMATURITY SYNDROME; IPS	608649
DEAFNESS, AUTOSOMAL DOMINANT 47; DFNA47	DEAFNESS, AUTOSOMAL DOMINANT 47; DFNA47	608652
DEAFNESS, AUTOSOMAL RECESSIVE 32; DFNB32	DEAFNESS, AUTOSOMAL RECESSIVE 32; DFNB32	608653
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE V; HSAN5	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE V; HSAN5	608654
HSAN V	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE V; HSAN5	608654
INSENSITIVITY TO PAIN, CONGENITAL	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE V; HSAN5	608654
PROSTATE CANCER, HEREDITARY, 3	PROSTATE CANCER, HEREDITARY, 3	608656
HPC3	PROSTATE CANCER, HEREDITARY, 3	608656
PROSTATE CANCER, HEREDITARY, 4	PROSTATE CANCER, HEREDITARY, 4	608658
HPC4	PROSTATE CANCER, HEREDITARY, 4	608658
PROSTATE CANCER, HEREDITARY, ON CHROMOSOME 7	PROSTATE CANCER, HEREDITARY, 4	608658
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2L; CMT2L	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2L; CMT2L	608673
CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2L	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2L; CMT2L	608673
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2L	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2L; CMT2L	608673
SPONDYLOCOSTAL DYSOSTOSIS 2, AUTOSOMAL RECESSIVE; SCDO2	SPONDYLOCOSTAL DYSOSTOSIS 2, AUTOSOMAL RECESSIVE; SCDO2	608681
SPINOCEREBELLAR ATAXIA 20; SCA20	SPINOCEREBELLAR ATAXIA 20; SCA20	608687
CHROMOSOME 11q12 DUPLICATION SYNDROME, 260-KB	SPINOCEREBELLAR ATAXIA 20; SCA20	608687
SPINOCEREBELLAR ATAXIA WITH DYSPHONIA	SPINOCEREBELLAR ATAXIA 20; SCA20	608687
SPINOCEREBELLAR ATAXIA WITH SPASMODIC COUGH	SPINOCEREBELLAR ATAXIA 20; SCA20	608687
AICAR TRANSFORMYLASE/IMP CYCLOHYDROLASE DEFICIENCY	AICAR TRANSFORMYLASE/IMP CYCLOHYDROLASE DEFICIENCY	608688
ATIC DEFICIENCY	AICAR TRANSFORMYLASE/IMP CYCLOHYDROLASE DEFICIENCY	608688
AICA-RIBOSURIA DUE TO ATIC DEFICIENCY	AICAR TRANSFORMYLASE/IMP CYCLOHYDROLASE DEFICIENCY	608688
MAJOR DEPRESSIVE DISORDER 2	MAJOR DEPRESSIVE DISORDER 2	608691
MDD2	MAJOR DEPRESSIVE DISORDER 2	608691
UNIPOLAR DEPRESSION 2	MAJOR DEPRESSIVE DISORDER 2	608691
GLAUCOMA 1, OPEN ANGLE, J; GLC1J	GLAUCOMA 1, OPEN ANGLE, J; GLC1J	608695
GLAUCOMA, PRIMARY OPEN ANGLE, JUVENILE-ONSET, 2; JOAG2	GLAUCOMA 1, OPEN ANGLE, J; GLC1J	608695
GLAUCOMA 1, OPEN ANGLE, K; GLC1K	GLAUCOMA 1, OPEN ANGLE, K; GLC1K	608696
GLAUCOMA, PRIMARY OPEN ANGLE, JUVENILE-ONSET, 3; JOAG3	GLAUCOMA 1, OPEN ANGLE, K; GLC1K	608696
SPINOCEREBELLAR ATAXIA 25; SCA25	SPINOCEREBELLAR ATAXIA 25; SCA25	608703
LIPODYSTROPHY, PARTIAL, ACQUIRED, SUSCEPTIBILITY TO; APLD	LIPODYSTROPHY, PARTIAL, ACQUIRED, SUSCEPTIBILITY TO; APLD	608709
APLD, SUSCEPTIBILITY TO	LIPODYSTROPHY, PARTIAL, ACQUIRED, SUSCEPTIBILITY TO; APLD	608709
BARRAQUER-SIMONS SYNDROME	LIPODYSTROPHY, PARTIAL, ACQUIRED, SUSCEPTIBILITY TO; APLD	608709
LIPODYSTROPHY, CEPHALOTHORACIC TYPE	LIPODYSTROPHY, PARTIAL, ACQUIRED, SUSCEPTIBILITY TO; APLD	608709
LIPODYSTROPHY, PARTIAL, PROGRESSIVE	LIPODYSTROPHY, PARTIAL, ACQUIRED, SUSCEPTIBILITY TO; APLD	608709
WEGENER GRANULOMATOSIS	WEGENER GRANULOMATOSIS	608710
WG	WEGENER GRANULOMATOSIS	608710
GRANULOMATOSIS WITH POLYANGIITIS	WEGENER GRANULOMATOSIS	608710
MICROCEPHALY 5, PRIMARY, AUTOSOMAL RECESSIVE; MCPH5	MICROCEPHALY 5, PRIMARY, AUTOSOMAL RECESSIVE; MCPH5	608716
SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MATRILIN-3 RELATED	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MATRILIN-3 RELATED	608728
SEMD, MATN3-RELATED	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MATRILIN-3 RELATED	608728
HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 4	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 4	608742
HYT4	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 4	608742
INSULIN-LIKE GROWTH FACTOR I DEFICIENCY	INSULIN-LIKE GROWTH FACTOR I DEFICIENCY	608747
IGF1 DEFICIENCY	INSULIN-LIKE GROWTH FACTOR I DEFICIENCY	608747
GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION	INSULIN-LIKE GROWTH FACTOR I DEFICIENCY	608747
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 8; CMH8	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 8; CMH8	608751
CARDIOMYOPATHY, HYPERTROPHIC, MID-LEFT VENTRICULAR CHAMBER TYPE, 1	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 8; CMH8	608751
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 10; CMH10	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 10; CMH10	608758
CARDIOMYOPATHY, HYPERTROPHIC, MID-LEFT VENTRICULAR CHAMBER TYPE, 2	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 10; CMH10	608758
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 3; EIG3	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 3; EIG3	608762
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME9	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 3; EIG3	608762
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3; IS3	SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3; IS3	608765
SPINOCEREBELLAR ATAXIA 8; SCA8	SPINOCEREBELLAR ATAXIA 8; SCA8	608768
ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1; ANKK1DOPAMINE RECEPTOR D2, REDUCED BRAIN DENSITY OF, INCLUDED	ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1; ANKK1DOPAMINE RECEPTOR D2, REDUCED BRAIN DENSITY OF, INCLUDED	608774
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Il; CDG1L	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Il; CDG1L	608776
CDG Il; CDGIl	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Il; CDG1L	608776
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIe; CDG2E	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIe; CDG2E	608779
CDG IIe; CDGIIe	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIe; CDG2E	608779
ASPERGER SYNDROME, SUSCEPTIBILITY TO, 3; ASPG3	ASPERGER SYNDROME, SUSCEPTIBILITY TO, 3; ASPG3	608781
PYRUVATE DEHYDROGENASE PHOSPHATASE DEFICIENCY; PDHPD	PYRUVATE DEHYDROGENASE PHOSPHATASE DEFICIENCY; PDHPD	608782
LACTIC ACIDEMIA WITH PYRUVATE DEHYDROGENASE PHOSPHATASE DEFICIENCY	PYRUVATE DEHYDROGENASE PHOSPHATASE DEFICIENCY; PDHPD	608782
OTOSCLEROSIS 5; OTSC5	OTOSCLEROSIS 5; OTSC5	608787
MOYAMOYA DISEASE 3; MYMY3	MOYAMOYA DISEASE 3; MYMY3	608796
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E	608799
CDG Ie; CDGIe	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E	608799
SUDDEN INFANT DEATH WITH DYSGENESIS OF THE TESTES SYNDROME; SIDDT	SUDDEN INFANT DEATH WITH DYSGENESIS OF THE TESTES SYNDROME; SIDDT	608800
LEUKODYSTROPHY, HYPOMYELINATING, 2; HLD2	LEUKODYSTROPHY, HYPOMYELINATING, 2; HLD2	608804
PELIZAEUS-MERZBACHER-LIKE DISEASE, 1; PMLD1	LEUKODYSTROPHY, HYPOMYELINATING, 2; HLD2	608804
AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY; ANFH	AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY; ANFH	608805
FEMORAL HEAD, AVASCULAR NECROSIS OF	AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY; ANFH	608805
FEMORAL HEAD, ASEPTIC NECROSIS OF	AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY; ANFH	608805
ISCHEMIC NECROSIS OF FEMORAL HEAD	AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY; ANFH	608805
OSTEONECROSIS OF FEMORAL HEAD	AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY; ANFH	608805
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2J; LGMD2J	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2J; LGMD2J	608807
TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 1; DTGA1	TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 1; DTGA1	608808
D-TGA	TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 1; DTGA1	608808
MYOPATHY, MYOFIBRILLAR, 2; MFM2	MYOPATHY, MYOFIBRILLAR, 2; MFM2	608810
MYOPATHY, MYOFIBRILLAR, ALPHA-B CRYSTALLIN-RELATED	MYOPATHY, MYOFIBRILLAR, 2; MFM2	608810
MYOPATHY, DESMIN-RELATED, ASSOCIATED WITH MUTATION IN THE CRYAB GENE	MYOPATHY, MYOFIBRILLAR, 2; MFM2	608810
ALPHA-B CRYSTALLINOPATHY	MYOPATHY, MYOFIBRILLAR, 2; MFM2	608810
MYOPATHY, MYOFIBRILLAR, WITH OR WITHOUT CATARACT AND/OR CARDIOMYOPATHY	MYOPATHY, MYOFIBRILLAR, 2; MFM2	608810
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1; CRCS1	COLORECTAL CANCER, SUSCEPTIBILITY TO, 1; CRCS1	608812
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 9	COLORECTAL CANCER, SUSCEPTIBILITY TO, 1; CRCS1	608812
COLORECTAL ADENOMA AND CANCER, SUSCEPTIBILITY TO	COLORECTAL CANCER, SUSCEPTIBILITY TO, 1; CRCS1	608812
MYOCLONIC EPILEPSY, JUVENILE, SUSCEPTIBILITY TO, 3; EJM3	MYOCLONIC EPILEPSY, JUVENILE, SUSCEPTIBILITY TO, 3; EJM3	608816
RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 2; RLS2	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 2; RLS2	608831
CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL	608836
CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, NEONATAL	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL	608836
CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, ANTENATAL	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL	608836
CPT II DEFICIENCY, LETHAL NEONATAL	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL	608836
CPT2 DEFICIENCY, LETHAL NEONATAL	CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL	608836
CARNEY COMPLEX VARIANT	CARNEY COMPLEX VARIANT	608837
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 6; MDDGB6	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 6; MDDGB6	608840
MUSCULAR DYSTROPHY, CONGENITAL, LARGE-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 6; MDDGB6	608840
MUSCULAR DYSTROPHY, CONGENITAL, TYPE 1D; MDC1D	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 6; MDDGB6	608840
MACULAR DYSTROPHY, RETINAL, 3	MACULAR DYSTROPHY, RETINAL, 3	608850
MCDR3	MACULAR DYSTROPHY, RETINAL, 3	608850
PULMONARY FUNCTION	PULMONARY FUNCTION	608852
PLF	PULMONARY FUNCTION	608852
LUNG FUNCTION, ACCELERATED RATE OF DECLINE IN, SMOKING-RELATED	PULMONARY FUNCTION	608852
OROFACIAL CLEFT 6, SUSCEPTIBILITY TO; OFC6	OROFACIAL CLEFT 6, SUSCEPTIBILITY TO; OFC6	608864
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 6	OROFACIAL CLEFT 6, SUSCEPTIBILITY TO; OFC6	608864
OROFACIAL CLEFT 5; OFC5	OROFACIAL CLEFT 5; OFC5	608874
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 5	OROFACIAL CLEFT 5; OFC5	608874
GENE EXPRESSION, VARIATION IN, QUANTITATIVE TRAIT LOCUS ON CHROMOSOME14	GENE EXPRESSION, VARIATION IN, QUANTITATIVE TRAIT LOCUS ON CHROMOSOME14	608875
GEVQ1	GENE EXPRESSION, VARIATION IN, QUANTITATIVE TRAIT LOCUS ON CHROMOSOME14	608875
GENE EXPRESSION, VARIATION IN, QUANTITATIVE TRAIT LOCUS ON CHROMOSOME20	GENE EXPRESSION, VARIATION IN, QUANTITATIVE TRAIT LOCUS ON CHROMOSOME20	608878
GEVQ2	GENE EXPRESSION, VARIATION IN, QUANTITATIVE TRAIT LOCUS ON CHROMOSOME20	608878
STOMATIN-DEFICIENT CRYOHYDROCYTOSIS WITH NEUROLOGIC DEFECTS; SDCHCN	STOMATIN-DEFICIENT CRYOHYDROCYTOSIS WITH NEUROLOGIC DEFECTS; SDCHCN	608885
GLUT1 DEFICIENCY SYNDROME WITH PSEUDOHYPERKALEMIA AND HEMOLYSIS	STOMATIN-DEFICIENT CRYOHYDROCYTOSIS WITH NEUROLOGIC DEFECTS; SDCHCN	608885
CRYOHYDROCYTOSIS, STOMATIN-DEFICIENT, WITH MENTAL RETARDATION, SEIZURES,CATARACTS, AND MASSIVE HEPATOSPLENOMEGALY	STOMATIN-DEFICIENT CRYOHYDROCYTOSIS WITH NEUROLOGIC DEFECTS; SDCHCN	608885
WAARDENBURG SYNDROME, TYPE 2D; WS2D	WAARDENBURG SYNDROME, TYPE 2D; WS2D	608890
WAARDENBURG SYNDROME, TYPE IID	WAARDENBURG SYNDROME, TYPE 2D; WS2D	608890
NEUROPATHY, HEREDITARY, WITH OR WITHOUT AGE-RELATED MACULAR DEGENERATION;HNARMDMACULAR DEGENERATION, AGE-RELATED, 3, INCLUDED; ARMD3, INCLUDED	NEUROPATHY, HEREDITARY, WITH OR WITHOUT AGE-RELATED MACULAR DEGENERATION;HNARMDMACULAR DEGENERATION, AGE-RELATED, 3, INCLUDED; ARMD3, INCLUDED	608895
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 3; FHL3	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 3; FHL3	608898
HPLH3	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 3; FHL3	608898
HLH3	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 3; FHL3	608898
CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 5	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 5	608901
CHDS5	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 5	608901
CORONARY ARTERY DISEASE, EARLY-ONSET	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 5	608901
DRUG METABOLISM, POOR, CYP2D6-RELATEDDRUG METABOLISM, ULTRARAPID, CYP2D6-RELATED, INCLUDED	DRUG METABOLISM, POOR, CYP2D6-RELATEDDRUG METABOLISM, ULTRARAPID, CYP2D6-RELATED, INCLUDED	608902
DEBRISOQUINE, POOR METABOLISM OF, INCLUDED	DRUG METABOLISM, POOR, CYP2D6-RELATEDDRUG METABOLISM, ULTRARAPID, CYP2D6-RELATED, INCLUDED	608902
DEBRISOQUINE, ULTRARAPID METABOLISM OF, INCLUDED	DRUG METABOLISM, POOR, CYP2D6-RELATEDDRUG METABOLISM, ULTRARAPID, CYP2D6-RELATED, INCLUDED	608902
SPARTEINE, POOR METABOLISM OF, INCLUDED	DRUG METABOLISM, POOR, CYP2D6-RELATEDDRUG METABOLISM, ULTRARAPID, CYP2D6-RELATED, INCLUDED	608902
NORTRIPTYLINE, POOR METABOLISM OF, INCLUDED	DRUG METABOLISM, POOR, CYP2D6-RELATEDDRUG METABOLISM, ULTRARAPID, CYP2D6-RELATED, INCLUDED	608902
CODEINE, ULTRARAPID METABOLISM OF, INCLUDED	DRUG METABOLISM, POOR, CYP2D6-RELATEDDRUG METABOLISM, ULTRARAPID, CYP2D6-RELATED, INCLUDED	608902
ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 1	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 1	608903
ADHD1	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 1	608903
ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 2	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 2	608904
ADHD2	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 2	608904
ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 3	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 3	608905
ADHD3	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 3	608905
ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 4	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 4	608906
ADHD4	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 4	608906
ALZHEIMER DISEASE 9; AD9	ALZHEIMER DISEASE 9; AD9	608907
ALZHEIMER DISEASE 9, LATE-ONSET	ALZHEIMER DISEASE 9; AD9	608907
MYOPIA 6; MYP6	MYOPIA 6; MYP6	608908
CHOANAL ATRESIA, POSTERIOR; PCA	CHOANAL ATRESIA, POSTERIOR; PCA	608911
MYASTHENIC SYNDROME, CONGENITAL, 1B, FAST-CHANNEL; CMS1B	MYASTHENIC SYNDROME, CONGENITAL, 1B, FAST-CHANNEL; CMS1B	608930
MYASTHENIC SYNDROME, CONGENITAL, 4C, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS4C	MYASTHENIC SYNDROME, CONGENITAL, 4C, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS4C	608931
MYASTHENIC SYNDROME, CONGENITAL, TYPE Id; CMS1D, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 4C, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS4C	608931
CMS Id, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 4C, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS4C	608931
MYASTHENIA, FAMILIAL INFANTILE, 1, FORMERLY; FIM1, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 4C, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS4C	608931
KERATOCONUS 2; KTCN2	KERATOCONUS 2; KTCN2	608932
LUNG CANCER SUSCEPTIBILITY 1; LNCR1	LUNG CANCER SUSCEPTIBILITY 1; LNCR1	608935
SPONDYLOMETAPHYSEAL DYSPLASIA WITH CONE-ROD DYSTROPHY; SMDCRD	SPONDYLOMETAPHYSEAL DYSPLASIA WITH CONE-ROD DYSTROPHY; SMDCRD	608940
CD8 DEFICIENCY, FAMILIAL	CD8 DEFICIENCY, FAMILIAL	608957
MACULAR DYSTROPHY, PATTERNED, 2	MACULAR DYSTROPHY, PATTERNED, 2	608970
MACULAR DYSTROPHY, BUTTERFLY-SHAPED PIGMENTARY, 2	MACULAR DYSTROPHY, PATTERNED, 2	608970
SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-POSITIVE, NK CELL-POSITIVE	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-POSITIVE, NK CELL-POSITIVE	608971
SCID, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE	SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,B CELL-POSITIVE, NK CELL-POSITIVE	608971
MEACHAM SYNDROME	MEACHAM SYNDROME	608978
BIFID NOSE WITH OR WITHOUT ANORECTAL AND RENAL ANOMALIES; BNAR	BIFID NOSE WITH OR WITHOUT ANORECTAL AND RENAL ANOMALIES; BNAR	608980
STATURE QUANTITATIVE TRAIT LOCUS 5; STQTL5	STATURE QUANTITATIVE TRAIT LOCUS 5; STQTL5	608982
ATAXIA, SENSORY, 1, AUTOSOMAL DOMINANT; SNAX1	ATAXIA, SENSORY, 1, AUTOSOMAL DOMINANT; SNAX1	608984
ADSA	ATAXIA, SENSORY, 1, AUTOSOMAL DOMINANT; SNAX1	608984
ATRIAL FIBRILLATION, FAMILIAL, 2; ATFB2	ATRIAL FIBRILLATION, FAMILIAL, 2; ATFB2	608988
DYSLEXIA, SUSCEPTIBILITY TO, 8; DYX8	DYSLEXIA, SUSCEPTIBILITY TO, 8; DYX8	608995
PREMATURE OVARIAN FAILURE 3; POF3	PREMATURE OVARIAN FAILURE 3; POF3	608996
DEAFNESS, AUTOSOMAL RECESSIVE 36, WITH OR WITHOUT VESTIBULAR INVOLVEMENT;DFNB36DEAFNESS, AUTOSOMAL DOMINANT, WITHOUT VESTIBULAR INVOLVEMENT, INCLUDED	DEAFNESS, AUTOSOMAL RECESSIVE 36, WITH OR WITHOUT VESTIBULAR INVOLVEMENT;DFNB36DEAFNESS, AUTOSOMAL DOMINANT, WITHOUT VESTIBULAR INVOLVEMENT, INCLUDED	609006
MITOCHONDRIAL TRIFUNCTIONAL PROTEIN DEFICIENCY; MTPD	MITOCHONDRIAL TRIFUNCTIONAL PROTEIN DEFICIENCY; MTPD	609015
TRIFUNCTIONAL PROTEIN DEFICIENCYTRIFUNCTIONAL PROTEIN DEFICIENCY WITH MYOPATHY AND NEUROPATHY, INCLUDED	MITOCHONDRIAL TRIFUNCTIONAL PROTEIN DEFICIENCY; MTPD	609015
LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY	LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY	609016
LCHAD DEFICIENCY	LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY	609016
PERIPHERAL CONE DYSTROPHY	PERIPHERAL CONE DYSTROPHY	609021
CATARACT 28; CTRCT28	CATARACT 28; CTRCT28	609026
CATARACT, AGE-RELATED CORTICAL, 1; ARCC1	CATARACT 28; CTRCT28	609026
BLOOD GROUP, INDIAN SYSTEM; IN	BLOOD GROUP, INDIAN SYSTEM; IN	609027
INDIAN BLOOD GROUP SYSTEM; IN	BLOOD GROUP, INDIAN SYSTEM; IN	609027
EMANUEL SYNDROME	EMANUEL SYNDROME	609029
SUPERNUMERARY DER(22)t(11;22) SYNDROME	EMANUEL SYNDROME	609029
POSTERIOR COLUMN ATAXIA WITH RETINITIS PIGMENTOSA; AXPC1	POSTERIOR COLUMN ATAXIA WITH RETINITIS PIGMENTOSA; AXPC1	609033
PCARP	POSTERIOR COLUMN ATAXIA WITH RETINITIS PIGMENTOSA; AXPC1	609033
NARCOLEPSY 3; NRCLP3	NARCOLEPSY 3; NRCLP3	609039
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9; ARVD9	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9; ARVD9	609040
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 9; ARVC9	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9; ARVD9	609040
SPASTIC PARAPLEGIA 27, AUTOSOMAL RECESSIVE; SPG27	SPASTIC PARAPLEGIA 27, AUTOSOMAL RECESSIVE; SPG27	609041
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 3; CMM3	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 3; CMM3	609048
PIERSON SYNDROME	PIERSON SYNDROME	609049
MICROCORIA-CONGENITAL NEPHROTIC SYNDROME	PIERSON SYNDROME	609049
SPONDYLOMETAPHYSEAL DYSPLASIA, TYPE A4	SPONDYLOMETAPHYSEAL DYSPLASIA, TYPE A4	609052
FANCONI ANEMIA, COMPLEMENTATION GROUP I; FANCI	FANCONI ANEMIA, COMPLEMENTATION GROUP I; FANCI	609053
FANCONI ANEMIA, COMPLEMENTATION GROUP J; FANCJ	FANCONI ANEMIA, COMPLEMENTATION GROUP J; FANCJ	609054
CEROID LIPOFUSCINOSIS, NEURONAL, 9; CLN9	CEROID LIPOFUSCINOSIS, NEURONAL, 9; CLN9	609055
AMISH INFANTILE EPILEPSY SYNDROME	AMISH INFANTILE EPILEPSY SYNDROME	609056
EPILEPSY SYNDROME, INFANTILE-ONSET SYMPTOMATIC	AMISH INFANTILE EPILEPSY SYNDROME	609056
GM3 SYNTHASE DEFICIENCY	AMISH INFANTILE EPILEPSY SYNDROME	609056
SALT AND PEPPER MENTAL RETARDATION SYNDROME	AMISH INFANTILE EPILEPSY SYNDROME	609056
NEPHROPATHY WITH PRETIBIAL EPIDERMOLYSIS BULLOSA AND DEAFNESS	NEPHROPATHY WITH PRETIBIAL EPIDERMOLYSIS BULLOSA AND DEAFNESS	609057
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1; COXPD1	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1; COXPD1	609060
HEPATOENCEPHALOPATHY, EARLY FATAL PROGRESSIVE	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1; COXPD1	609060
PANCREATIC AND CEREBELLAR AGENESIS; PACA	PANCREATIC AND CEREBELLAR AGENESIS; PACA	609069
DIABETES MELLITUS, PERMANENT NEONATAL, WITH CEREBELLAR AGENESIS	PANCREATIC AND CEREBELLAR AGENESIS; PACA	609069
HEMOGLOBIN, HIGH ALTITUDE ADAPTATION; HALAH	HEMOGLOBIN, HIGH ALTITUDE ADAPTATION; HALAH	609070
HEMOGLOBIN, HIGH OXYGEN SATURATION OF	HEMOGLOBIN, HIGH ALTITUDE ADAPTATION; HALAH	609070
TELOMERE LENGTH, MEAN LEUKOCYTE; LTL	TELOMERE LENGTH, MEAN LEUKOCYTE; LTL	609113
TELM	TELOMERE LENGTH, MEAN LEUKOCYTE; LTL	609113
LIMB-GIRDLE MUSCULAR DYSTROPHY, TYPE 1G; LGMD1G	LIMB-GIRDLE MUSCULAR DYSTROPHY, TYPE 1G; LGMD1G	609115
RESPIRATORY RHYTHMICITY IN SLEEP	RESPIRATORY RHYTHMICITY IN SLEEP	609116
RRIS	RESPIRATORY RHYTHMICITY IN SLEEP	609116
ANEURYSM, INTRACRANIAL BERRY, 3; ANIB3	ANEURYSM, INTRACRANIAL BERRY, 3; ANIB3	609122
ARTHROGRYPOSIS, DISTAL, TYPE 4; DA4	ARTHROGRYPOSIS, DISTAL, TYPE 4; DA4	609128
ARTHROGRYPOSIS WITH SEVERE SCOLIOSIS	ARTHROGRYPOSIS, DISTAL, TYPE 4; DA4	609128
ARTHROGRYPOSIS, DISTAL, TYPE IID; DAIID	ARTHROGRYPOSIS, DISTAL, TYPE 4; DA4	609128
AUDITORY NEUROPATHY, AUTOSOMAL DOMINANT, 1; AUNA1	AUDITORY NEUROPATHY, AUTOSOMAL DOMINANT, 1; AUNA1	609129
AUDITORY NEUROPATHY, NONSYNDROMIC DOMINANT; NSDAN	AUDITORY NEUROPATHY, AUTOSOMAL DOMINANT, 1; AUNA1	609129
APLASTIC ANEMIAAPLASTIC ANEMIA, SUSCEPTIBILITY TO, INCLUDED	APLASTIC ANEMIAAPLASTIC ANEMIA, SUSCEPTIBILITY TO, INCLUDED	609135
PERIPHERAL DEMYELINATING NEUROPATHY, CENTRAL DYSMYELINATION, WAARDENBURGSYNDROME, AND HIRSCHSPRUNG DISEASE; PCWH	PERIPHERAL DEMYELINATING NEUROPATHY, CENTRAL DYSMYELINATION, WAARDENBURGSYNDROME, AND HIRSCHSPRUNG DISEASE; PCWH	609136
WAARDENBURG-SHAH SYNDROME, NEUROLOGIC VARIANT	PERIPHERAL DEMYELINATING NEUROPATHY, CENTRAL DYSMYELINATION, WAARDENBURGSYNDROME, AND HIRSCHSPRUNG DISEASE; PCWH	609136
CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 2; PPCD2	CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 2; PPCD2	609140
CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 3; PPCD3	CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 3; PPCD3	609141
TIBIA, BOWING OF, WITH PSEUDARTHROSIS AND PECTUS EXCAVATUM	TIBIA, BOWING OF, WITH PSEUDARTHROSIS AND PECTUS EXCAVATUM	609143
MALARIA, MILD, SUSCEPTIBILITY TO	MALARIA, MILD, SUSCEPTIBILITY TO	609148
MALS	MALARIA, MILD, SUSCEPTIBILITY TO	609148
HYPERTHYROIDISM, NONAUTOIMMUNE	HYPERTHYROIDISM, NONAUTOIMMUNE	609152
HYPERTHYROIDISM, CONGENITAL NONAUTOIMMUNE	HYPERTHYROIDISM, NONAUTOIMMUNE	609152
HYPERTHYROIDISM, NONAUTOIMMUNE, AUTOSOMAL DOMINANT	HYPERTHYROIDISM, NONAUTOIMMUNE	609152
TOXIC THYROID HYPERPLASIA, AUTOSOMAL DOMINANT	HYPERTHYROIDISM, NONAUTOIMMUNE	609152
PSEUDOHYPERKALEMIA, FAMILIAL, 2, DUE TO RED CELL LEAK; PSHK2	PSEUDOHYPERKALEMIA, FAMILIAL, 2, DUE TO RED CELL LEAK; PSHK2	609153
PSEUDOHYPERKALEMIA LILLE	PSEUDOHYPERKALEMIA, FAMILIAL, 2, DUE TO RED CELL LEAK; PSHK2	609153
PSEUDOHYPERKALEMIA FALKIRK	PSEUDOHYPERKALEMIA, FAMILIAL, 2, DUE TO RED CELL LEAK; PSHK2	609153
PSEUDOHYPERKALEMIA CHISWICK	PSEUDOHYPERKALEMIA, FAMILIAL, 2, DUE TO RED CELL LEAK; PSHK2	609153
PSEUDOHYPERKALEMIA CARDIFF	PSEUDOHYPERKALEMIA, FAMILIAL, 2, DUE TO RED CELL LEAK; PSHK2	609153
PSEUDOHYPERKALEMIA EAST LONDON	PSEUDOHYPERKALEMIA, FAMILIAL, 2, DUE TO RED CELL LEAK; PSHK2	609153
CRYOHYDROCYTOSIS, MILD	PSEUDOHYPERKALEMIA, FAMILIAL, 2, DUE TO RED CELL LEAK; PSHK2	609153
STRIATAL DEGENERATION, AUTOSOMAL DOMINANT; ADSD	STRIATAL DEGENERATION, AUTOSOMAL DOMINANT; ADSD	609161
CZECH DYSPLASIA	CZECH DYSPLASIA	609162
CZECH DYSPLASIA, METATARSAL TYPE	CZECH DYSPLASIA	609162
PSEUDORHEUMATOID DYSPLASIA, PROGRESSIVE, WITH HYPOPLASTIC TOES	CZECH DYSPLASIA	609162
SPONDYLOEPIPHYSEAL DYSPLASIA WITH PRECOCIOUS OSTEOARTHRITIS	CZECH DYSPLASIA	609162
UMBILICUS, FAMILIAL FLAT	UMBILICUS, FAMILIAL FLAT	609164
FLAT UMBILICUS, AUTOSOMAL DOMINANT	UMBILICUS, FAMILIAL FLAT	609164
ERYTHRODERMA, ICHTHYOSIFORM, CONGENITAL RETICULAR; CRIE	ERYTHRODERMA, ICHTHYOSIFORM, CONGENITAL RETICULAR; CRIE	609165
ICHTHYOSIS WITH CONFETTI; IWC	ERYTHRODERMA, ICHTHYOSIFORM, CONGENITAL RETICULAR; CRIE	609165
ICHTHYOSIS VARIEGATAERYTHROKERATODERMA, RETICULAR, INCLUDED	ERYTHRODERMA, ICHTHYOSIFORM, CONGENITAL RETICULAR; CRIE	609165
AARAU DISEASE, INCLUDED	ERYTHRODERMA, ICHTHYOSIFORM, CONGENITAL RETICULAR; CRIE	609165
BRANCHIOGENIC-DEAFNESS SYNDROME	BRANCHIOGENIC-DEAFNESS SYNDROME	609166
MIGRAINE WITH AURA, SUSCEPTIBILITY TO, 7	MIGRAINE WITH AURA, SUSCEPTIBILITY TO, 7	609179
MGR7	MIGRAINE WITH AURA, SUSCEPTIBILITY TO, 7	609179
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE If; CDG1F	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE If; CDG1F	609180
CDG If; CDGIf	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE If; CDG1F	609180
LOEYS-DIETZ SYNDROME 1; LDS1	LOEYS-DIETZ SYNDROME 1; LDS1	609192
FURLONG SYNDROME	LOEYS-DIETZ SYNDROME 1; LDS1	609192
LOEYS-DIETZ AORTIC ANEURYSM SYNDROME	LOEYS-DIETZ SYNDROME 1; LDS1	609192
AORTIC ANEURYSM, FAMILIAL THORACIC 5; AAT5	LOEYS-DIETZ SYNDROME 1; LDS1	609192
SPASTIC PARAPLEGIA 26, AUTOSOMAL RECESSIVE; SPG26	SPASTIC PARAPLEGIA 26, AUTOSOMAL RECESSIVE; SPG26	609195
GLUCOCORTICOID DEFICIENCY 3; GCCD3	GLUCOCORTICOID DEFICIENCY 3; GCCD3	609197
FAMILIAL GLUCOCORTICOID DEFICIENCY 3; FGD3	GLUCOCORTICOID DEFICIENCY 3; GCCD3	609197
GLUCOCORTICOID DEFICIENCY 2, FORMERLY; GCCD2, FORMERLY	GLUCOCORTICOID DEFICIENCY 3; GCCD3	609197
MYOPATHY, MYOFIBRILLAR, 3; MFM3	MYOPATHY, MYOFIBRILLAR, 3; MFM3	609200
MYOTILINOPATHY	MYOPATHY, MYOFIBRILLAR, 3; MFM3	609200
MYOPATHY, MYOFIBRILLAR, MYOTILIN-RELATED	MYOPATHY, MYOFIBRILLAR, 3; MFM3	609200
FOVEAL HYPOPLASIA 2; FVH2	FOVEAL HYPOPLASIA 2; FVH2	609218
FOVEAL HYPOPLASIA 2 WITH OR WITHOUT OPTIC NERVE MISROUTING AND/ORANTERIOR SEGMENT DYSGENESIS	FOVEAL HYPOPLASIA 2; FVH2	609218
FOVEAL HYPOPLASIA 2 WITH OPTIC NERVE DECUSSATION DEFECTS AND ANTERIORSEGMENT DYSGENESIS WITHOUT ALBINISM; FHONDA	FOVEAL HYPOPLASIA 2; FVH2	609218
BRUCK SYNDROME 2; BRKS2	BRUCK SYNDROME 2; BRKS2	609220
OSTEOGENESIS IMPERFECTA WITH CONGENITAL JOINT CONTRACTURES	BRUCK SYNDROME 2; BRKS2	609220
DANDY-WALKER MALFORMATION WITH OCCIPITAL CEPHALOCELE, AUTOSOMAL DOMINANT;ADDWOC	DANDY-WALKER MALFORMATION WITH OCCIPITAL CEPHALOCELE, AUTOSOMAL DOMINANT;ADDWOC	609222
SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, AUTOSOMAL RECESSIVE, LEROY-SPRANGERTYPE	SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, AUTOSOMAL RECESSIVE, LEROY-SPRANGERTYPE	609223
GRISCELLI SYNDROME, TYPE 3; GS3	GRISCELLI SYNDROME, TYPE 3; GS3	609227
SCHINDLER DISEASE, TYPE I	SCHINDLER DISEASE, TYPE I	609241
NEUROAXONAL DYSTROPHY, SCHINDLER TYPE	SCHINDLER DISEASE, TYPE I	609241
ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE I	SCHINDLER DISEASE, TYPE I	609241
NAGA DEFICIENCY, TYPE IALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE III, INCLUDED	SCHINDLER DISEASE, TYPE I	609241
NAGA DEFICIENCY, TYPE III, INCLUDED	SCHINDLER DISEASE, TYPE I	609241
SCHINDLER DISEASE, TYPE III, INCLUDED	SCHINDLER DISEASE, TYPE I	609241
KANZAKI DISEASE	KANZAKI DISEASE	609242
ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE II	KANZAKI DISEASE	609242
ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, ADULT-ONSET	KANZAKI DISEASE	609242
NAGA DEFICIENCY, TYPE II	KANZAKI DISEASE	609242
SCHINDLER DISEASE, TYPE II	KANZAKI DISEASE	609242
FEBRILE SEIZURES, FAMILIAL, 6; FEB6	FEBRILE SEIZURES, FAMILIAL, 6; FEB6	609253
CONVULSIONS, FAMILIAL FEBRILE, 6	FEBRILE SEIZURES, FAMILIAL, 6; FEB6	609253
SENIOR-LOKEN SYNDROME 5; SLSN5	SENIOR-LOKEN SYNDROME 5; SLSN5	609254
FEBRILE SEIZURES, FAMILIAL, 5; FEB5	FEBRILE SEIZURES, FAMILIAL, 5; FEB5	609255
CONVULSIONS, FAMILIAL FEBRILE, 5	FEBRILE SEIZURES, FAMILIAL, 5; FEB5	609255
MYOPIA 7; MYP7	MYOPIA 7; MYP7	609256
MYOPIA 8; MYP8	MYOPIA 8; MYP8	609257
MYOPIA 9; MYP9	MYOPIA 9; MYP9	609258
MYOPIA 10; MYP10	MYOPIA 10; MYP10	609259
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2; CMT2A2	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2; CMT2A2	609260
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2A2	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2; CMT2A2	609260
CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2A2	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2; CMT2A2	609260
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2A2	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2; CMT2A2	609260
HEREDITARY MOTOR AND SENSORY NEUROPATHY IIA2; HMSN2A2	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2; CMT2A2	609260
HMSN IIA2	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2; CMT2A2	609260
STUTTERING, FAMILIAL PERSISTENT, 2; STUT2	STUTTERING, FAMILIAL PERSISTENT, 2; STUT2	609261
LI-FRAUMENI SYNDROME 2; LFS2	LI-FRAUMENI SYNDROME 2; LFS2	609265
LI-FRAUMENI SYNDROME 3; LFS3	LI-FRAUMENI SYNDROME 3; LFS3	609266
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 7; SCAR7	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 7; SCAR7	609270
KERATOCONUS 4; KTCN4	KERATOCONUS 4; KTCN4	609271
NEMALINE MYOPATHY 6; NEM6	NEMALINE MYOPATHY 6; NEM6	609273
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 2; PEOA2	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 2; PEOA2	609283
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 2	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 2; PEOA2	609283
NEMALINE MYOPATHY 1; NEM1CAP MYOPATHY 1, INCLUDED; CAPM1, INCLUDED	NEMALINE MYOPATHY 1; NEM1CAP MYOPATHY 1, INCLUDED; CAPM1, INCLUDED	609284
NEMALINE MYOPATHY 4; NEM4CAP MYOPATHY 2, INCLUDED; CAPM2, INCLUDED	NEMALINE MYOPATHY 4; NEM4CAP MYOPATHY 2, INCLUDED; CAPM2, INCLUDED	609285
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 3; PEOA3	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 3; PEOA3	609286
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 3	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 3; PEOA3	609286
SYNCOPE, FAMILIAL VASOVAGAL; VVS	SYNCOPE, FAMILIAL VASOVAGAL; VVS	609289
SYNCOPE, FAMILIAL NEUROCARDIOGENIC	SYNCOPE, FAMILIAL VASOVAGAL; VVS	609289
B-CELL IMMUNODEFICIENCY, DISTAL LIMB ANOMALIES, AND UROGENITAL MALFORMATIONS	B-CELL IMMUNODEFICIENCY, DISTAL LIMB ANOMALIES, AND UROGENITAL MALFORMATIONS	609296
BILU SYNDROME	B-CELL IMMUNODEFICIENCY, DISTAL LIMB ANOMALIES, AND UROGENITAL MALFORMATIONS	609296
HOFFMAN SYNDROME	B-CELL IMMUNODEFICIENCY, DISTAL LIMB ANOMALIES, AND UROGENITAL MALFORMATIONS	609296
PROSTATE CANCER, HEREDITARY, 5	PROSTATE CANCER, HEREDITARY, 5	609299
HPC5	PROSTATE CANCER, HEREDITARY, 5	609299
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 3; EIEE3	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 3; EIEE3	609304
SPINOCEREBELLAR ATAXIA 26; SCA26	SPINOCEREBELLAR ATAXIA 26; SCA26	609306
SPINOCEREBELLAR ATAXIA 27; SCA27	SPINOCEREBELLAR ATAXIA 27; SCA27	609307
CEREBELLAR ATAXIA, AUTOSOMAL DOMINANT, FGF14-RELATED	SPINOCEREBELLAR ATAXIA 27; SCA27	609307
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1	609308
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2K; LGMD2K	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1	609308
COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2	609310
COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 2; FCC2	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2	609310
COCA2	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2	609310
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4H; CMT4H	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4H; CMT4H	609311
CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, TYPE 4H	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4H; CMT4H	609311
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE4H	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4H; CMT4H	609311
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4H	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4H; CMT4H	609311
MENTAL RETARDATION, ENTEROPATHY, DEAFNESS, PERIPHERAL NEUROPATHY,ICHTHYOSIS, AND KERATODERMA; MEDNIK	MENTAL RETARDATION, ENTEROPATHY, DEAFNESS, PERIPHERAL NEUROPATHY,ICHTHYOSIS, AND KERATODERMA; MEDNIK	609313
ERYTHROKERATODERMIA VARIABILIS 3; EKV3	MENTAL RETARDATION, ENTEROPATHY, DEAFNESS, PERIPHERAL NEUROPATHY,ICHTHYOSIS, AND KERATODERMA; MEDNIK	609313
ERYTHROKERATODERMIA VARIABILIS, KAMOURASKA TYPE	MENTAL RETARDATION, ENTEROPATHY, DEAFNESS, PERIPHERAL NEUROPATHY,ICHTHYOSIS, AND KERATODERMA; MEDNIK	609313
HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HCHGQ1	HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HCHGQ1	609319
HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 6	HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HCHGQ1	609319
HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 2; HCHGQ2	HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 2; HCHGQ2	609320
HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 9	HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 2; HCHGQ2	609320
RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1	RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1	609322
BRAIN TUMOR, POSTERIOR FOSSA, OF INFANCY, FAMILIALMALIGNANT RHABDOID TUMOR, SOMATIC, INCLUDED	RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1	609322
RHABDOID TUMOR, INCLUDED; RDT, INCLUDED	RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1	609322
TERATOID TUMOR, ATYPICAL, INCLUDED	RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1	609322
AT/RT, INCLUDED	RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1	609322
EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH SEVERE PROXIMAL FEMORAL DYSPLASIA	EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH SEVERE PROXIMAL FEMORAL DYSPLASIA	609324
EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH MINIEPIPHYSES	EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH MINIEPIPHYSES	609325
CHROMOSOME 18 PERICENTRIC INVERSION	CHROMOSOME 18 PERICENTRIC INVERSION	609334
CAROTID INTIMAL MEDIAL THICKNESS 1	CAROTID INTIMAL MEDIAL THICKNESS 1	609338
CIMT1	CAROTID INTIMAL MEDIAL THICKNESS 1	609338
INTIMAL MEDIAL THICKNESS OF INTERNAL CAROTID ARTERY	CAROTID INTIMAL MEDIAL THICKNESS 1	609338
SPASTIC PARAPLEGIA 28, AUTOSOMAL RECESSIVE; SPG28	SPASTIC PARAPLEGIA 28, AUTOSOMAL RECESSIVE; SPG28	609340
EPIDERMOLYSIS BULLOSA SIMPLEX WITH MIGRATORY CIRCINATE ERYTHEMA	EPIDERMOLYSIS BULLOSA SIMPLEX WITH MIGRATORY CIRCINATE ERYTHEMA	609352
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 5; BMND5	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 5; BMND5	609354
CATARACT 35; CTRCT35	CATARACT 35; CTRCT35	609376
CATARACT, CONGENITAL NUCLEAR, AUTOSOMAL RECESSIVE 1; CATCN1	CATARACT 35; CTRCT35	609376
AUTISM, SUSCEPTIBILITY TO, 6; AUTS6	AUTISM, SUSCEPTIBILITY TO, 6; AUTS6	609378
FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3C; CFEOM3C	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3C; CFEOM3C	609384
FEOM4 LOCUS	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3C; CFEOM3C	609384
AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 4; AIS4	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 4; AIS4	609400
VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 5;VAMAS5	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 4; AIS4	609400
AUTOIMMUNE DISEASE SUSCEPTIBILITY LOCUS, CHROMOSOME 4-RELATED	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 4; AIS4	609400
PREECLAMPSIA/ECLAMPSIA 2; PEE2	PREECLAMPSIA/ECLAMPSIA 2; PEE2	609402
PREECLAMPSIA/ECLAMPSIA 3; PEE3	PREECLAMPSIA/ECLAMPSIA 3; PEE3	609403
PREECLAMPSIA/ECLAMPSIA 4; PEE4	PREECLAMPSIA/ECLAMPSIA 4; PEE4	609404
HOLOPROSENCEPHALY 8; HPE8	HOLOPROSENCEPHALY 8; HPE8	609408
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO	609423
HIV-1, SUSCEPTIBILITY TOHUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO, INCLUDED	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO	609423
HIV-1, RESISTANCE TO, INCLUDED	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO	609423
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO, INCLUDED	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO	609423
AIDS, PROGRESSION TO, INCLUDED	HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO	609423
CHROMOSOME 3q29 DELETION SYNDROME	CHROMOSOME 3q29 DELETION SYNDROME	609425
MICRODELETION 3q29 SYNDROME	CHROMOSOME 3q29 DELETION SYNDROME	609425
TUKEL SYNDROME	TUKEL SYNDROME	609428
FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, WITH ULNAR HAND ANOMALIES	TUKEL SYNDROME	609428
CFEOM-U	TUKEL SYNDROME	609428
FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 4; CFEOM4	TUKEL SYNDROME	609428
SYNDACTYLY, MESOAXIAL SYNOSTOTIC, WITH PHALANGEAL REDUCTION; MSSD	SYNDACTYLY, MESOAXIAL SYNOSTOTIC, WITH PHALANGEAL REDUCTION; MSSD	609432
SYNDACTYLY, MALIK-PERCIN TYPE	SYNDACTYLY, MESOAXIAL SYNOSTOTIC, WITH PHALANGEAL REDUCTION; MSSD	609432
SYNDACTYLY, TYPE IX	SYNDACTYLY, MESOAXIAL SYNOSTOTIC, WITH PHALANGEAL REDUCTION; MSSD	609432
DEAFNESS, AUTOSOMAL RECESSIVE 48; DFNB48	DEAFNESS, AUTOSOMAL RECESSIVE 48; DFNB48	609439
ACROMESOMELIC DYSPLASIA, DEMIRHAN TYPE; AMDD	ACROMESOMELIC DYSPLASIA, DEMIRHAN TYPE; AMDD	609441
CHONDRODYSPLASIA, ACROMESOMELIC, WITH OR WITHOUT GENITAL ANOMALIES	ACROMESOMELIC DYSPLASIA, DEMIRHAN TYPE; AMDD	609441
GENERALIZED EPILEPSY AND PAROXYSMAL DYSKINESIA; GEPD	GENERALIZED EPILEPSY AND PAROXYSMAL DYSKINESIA; GEPD	609446
EPILEPSY, GENERALIZED, WITH PAROXYSMAL DYSKINESIA	GENERALIZED EPILEPSY AND PAROXYSMAL DYSKINESIA; GEPD	609446
MYOPATHY, MYOFIBRILLAR, 4; MFM4	MYOPATHY, MYOFIBRILLAR, 4; MFM4	609452
SUPRANUCLEAR PALSY, PROGRESSIVE, 2; PSNP2	SUPRANUCLEAR PALSY, PROGRESSIVE, 2; PSNP2	609454
MUSCULAR DYSTROPHY, CONGENITAL, MEROSIN-POSITIVE	MUSCULAR DYSTROPHY, CONGENITAL, MEROSIN-POSITIVE	609456
GOLDBERG-SHPRINTZEN SYNDROME; GOSHS	GOLDBERG-SHPRINTZEN SYNDROME; GOSHS	609460
GOLDBERG-SHPRINTZEN MEGACOLON SYNDROME	GOLDBERG-SHPRINTZEN SYNDROME; GOSHS	609460
SARCOIDOSIS, EARLY-ONSET	SARCOIDOSIS, EARLY-ONSET	609464
EOS	SARCOIDOSIS, EARLY-ONSET	609464
NEPHROPATHY, PROGRESSIVE, WITH DEAFNESS	NEPHROPATHY, PROGRESSIVE, WITH DEAFNESS	609469
NEDE	NEPHROPATHY, PROGRESSIVE, WITH DEAFNESS	609469
ALPORT/FOCAL SEGMENTAL GLOMERULOSCLEROSIS-LIKE SYNDROME	NEPHROPATHY, PROGRESSIVE, WITH DEAFNESS	609469
LEFT VENTRICULAR NONCOMPACTION 2; LVNC2	LEFT VENTRICULAR NONCOMPACTION 2; LVNC2	609470
MYOPATHY, AUTOPHAGIC VACUOLAR, INFANTILE-ONSET	MYOPATHY, AUTOPHAGIC VACUOLAR, INFANTILE-ONSET	609500
STICKLER SYNDROME, TYPE I, NONSYNDROMIC OCULAR	STICKLER SYNDROME, TYPE I, NONSYNDROMIC OCULAR	609508
STICKLER SYNDROME, TYPE I, PREDOMINANTLY OCULAR	STICKLER SYNDROME, TYPE I, NONSYNDROMIC OCULAR	609508
STICKLER SYNDROME, ATYPICALRHEGMATOGENOUS RETINAL DETACHMENT, AUTOSOMAL DOMINANT, INCLUDED; DRRD,INCLUDED	STICKLER SYNDROME, TYPE I, NONSYNDROMIC OCULAR	609508
MYOPATHY, MYOFIBRILLAR, 5; MFM5	MYOPATHY, MYOFIBRILLAR, 5; MFM5	609524
MYOPATHY, MYOFIBRILLAR, FILAMIN C-RELATED	MYOPATHY, MYOFIBRILLAR, 5; MFM5	609524
FILAMINOPATHY, AUTOSOMAL DOMINANT	MYOPATHY, MYOFIBRILLAR, 5; MFM5	609524
CEREBRAL DYSGENESIS, NEUROPATHY, ICHTHYOSIS, AND PALMOPLANTAR KERATODERMASYNDROME	CEREBRAL DYSGENESIS, NEUROPATHY, ICHTHYOSIS, AND PALMOPLANTAR KERATODERMASYNDROME	609528
CEDNIK SYNDROME	CEREBRAL DYSGENESIS, NEUROPATHY, ICHTHYOSIS, AND PALMOPLANTAR KERATODERMASYNDROME	609528
IMMUNOGLOBULIN A DEFICIENCY 2; IGAD2	IMMUNOGLOBULIN A DEFICIENCY 2; IGAD2	609529
IMMUNOGLOBULIN A, SELECTIVE DEFICIENCY OF, TACI-RELATED	IMMUNOGLOBULIN A DEFICIENCY 2; IGAD2	609529
IgA, SELECTIVE DEFICIENCY OF, TACI-RELATED	IMMUNOGLOBULIN A DEFICIENCY 2; IGAD2	609529
HEPATITIS C VIRUS, SUSCEPTIBILITY TO	HEPATITIS C VIRUS, SUSCEPTIBILITY TO	609532
HCV, SUSCEPTIBILITY TOHEPATITIS C VIRUS, RESISTANCE TO, INCLUDED	HEPATITIS C VIRUS, SUSCEPTIBILITY TO	609532
HCV, RESISTANCE TO, INCLUDED	HEPATITIS C VIRUS, SUSCEPTIBILITY TO	609532
HEPATITIS C VIRUS INFECTION, RESPONSE TO THERAPY OF, INCLUDED	HEPATITIS C VIRUS, SUSCEPTIBILITY TO	609532
DEAFNESS, AUTOSOMAL RECESSIVE 23; DFNB23	DEAFNESS, AUTOSOMAL RECESSIVE 23; DFNB23	609533
DRUG METABOLISM, POOR, CYP2C19-RELATEDMEPHENYTOIN, POOR METABOLISM OF, INCLUDED	DRUG METABOLISM, POOR, CYP2C19-RELATEDMEPHENYTOIN, POOR METABOLISM OF, INCLUDED	609535
OMEPRAZOLE, POOR METABOLISM OF, INCLUDED	DRUG METABOLISM, POOR, CYP2C19-RELATEDMEPHENYTOIN, POOR METABOLISM OF, INCLUDED	609535
PROGUANIL, POOR METABOLISM OF, INCLUDED	DRUG METABOLISM, POOR, CYP2C19-RELATEDMEPHENYTOIN, POOR METABOLISM OF, INCLUDED	609535
CLOPIDOGREL, POOR METABOLISM OF, INCLUDED	DRUG METABOLISM, POOR, CYP2C19-RELATEDMEPHENYTOIN, POOR METABOLISM OF, INCLUDED	609535
COMPLEMENT COMPONENT 5 DEFICIENCY; C5D	COMPLEMENT COMPONENT 5 DEFICIENCY; C5D	609536
C5 DEFICIENCY	COMPLEMENT COMPONENT 5 DEFICIENCY; C5D	609536
SPASTIC PARAPLEGIA, OPTIC ATROPHY, AND NEUROPATHY; SPOAN	SPASTIC PARAPLEGIA, OPTIC ATROPHY, AND NEUROPATHY; SPOAN	609541
NANOPHTHALMOS 2; NNO2	NANOPHTHALMOS 2; NNO2	609549
NANOPHTHALMIA 2	NANOPHTHALMOS 2; NNO2	609549
NANOPHTHALMOS, AUTOSOMAL RECESSIVE	NANOPHTHALMOS 2; NNO2	609549
PROSTATE CANCER, HEREDITARY, 6	PROSTATE CANCER, HEREDITARY, 6	609558
HPC6	PROSTATE CANCER, HEREDITARY, 6	609558
MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE); MTDPS2	MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE); MTDPS2	609560
MITOCHONDRIAL DNA DEPLETION MYOPATHY, TK2-RELATED	MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE); MTDPS2	609560
PARIETAL FORAMINA 3; PFM3	PARIETAL FORAMINA 3; PFM3	609566
MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 8	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 8	609570
MGR8	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 8	609570
PHOTOPAROXYSMAL RESPONSE 2; PPR2	PHOTOPAROXYSMAL RESPONSE 2; PPR2	609572
PHOTOPAROXYSMAL RESPONSE WITH OR WITHOUT IDIOPATHIC GENERALIZED EPILEPSY	PHOTOPAROXYSMAL RESPONSE 2; PPR2	609572
PHOTOPAROXYSMAL RESPONSE 3; PPR3	PHOTOPAROXYSMAL RESPONSE 3; PPR3	609573
PHOTOPAROXYSMAL RESPONSE WITH OR WITHOUT MYOCLONIC EPILEPSY	PHOTOPAROXYSMAL RESPONSE 3; PPR3	609573
CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 2; RCM2	CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 2; RCM2	609578
SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION	SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION	609579
JOUBERT SYNDROME 4; JBTS4	JOUBERT SYNDROME 4; JBTS4	609583
PARIETAL FORAMINA 2; PFM2	PARIETAL FORAMINA 2; PFM2	609597
SHORT QT SYNDROME 1; SQT1	SHORT QT SYNDROME 1; SQT1	609620
SHORT QT SYNDROME 2; SQT2	SHORT QT SYNDROME 2; SQT2	609621
SHORT QT SYNDROME 3; SQT3	SHORT QT SYNDROME 3; SQT3	609622
CHROMOSOME 10q26 DELETION SYNDROME	CHROMOSOME 10q26 DELETION SYNDROME	609625
TERMINAL CHROMOSOME 10q26 DELETION SYNDROME	CHROMOSOME 10q26 DELETION SYNDROME	609625
MAJEED SYNDROME	MAJEED SYNDROME	609628
CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS, CONGENITAL DYSERYTHROPOIETICANEMIA, AND NEUTROPHILIC DERMATOSIS	MAJEED SYNDROME	609628
VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL DOMINANT	VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL DOMINANT	609629
ENTERIC NEUROPATHY, FAMILIAL	VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL DOMINANT	609629
PSEUDOOBSTRUCTION, CHRONIC INTESTINAL, NEUROPATHIC	VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL DOMINANT	609629
PSEUDOOBSTRUCTION, IDIOPATHIC INTESTINAL	VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL DOMINANT	609629
LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 1	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 1	609630
CLLS1	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 1	609630
MAJOR AFFECTIVE DISORDER 3; MAFD3	MAJOR AFFECTIVE DISORDER 3; MAFD3	609633
BIPOLAR AFFECTIVE DISORDER, EARLY-ONSET; BPEO	MAJOR AFFECTIVE DISORDER 3; MAFD3	609633
MIGRAINE, FAMILIAL HEMIPLEGIC, 3; FHM3	MIGRAINE, FAMILIAL HEMIPLEGIC, 3; FHM3	609634
ALZHEIMER DISEASE 10	ALZHEIMER DISEASE 10	609636
ALZHEIMER DISEASE, FAMILIAL, 10	ALZHEIMER DISEASE 10	609636
AD10	ALZHEIMER DISEASE 10	609636
HOLOPROSENCEPHALY 5; HPE5	HOLOPROSENCEPHALY 5; HPE5	609637
EPIDERMOLYSIS BULLOSA, LETHAL ACANTHOLYTIC; EBLA	EPIDERMOLYSIS BULLOSA, LETHAL ACANTHOLYTIC; EBLA	609638
LETHAL ACANTHOLYTIC EPIDERMOLYSIS BULLOSA; LAEB	EPIDERMOLYSIS BULLOSA, LETHAL ACANTHOLYTIC; EBLA	609638
FRIAS SYNDROME	FRIAS SYNDROME	609640
CHROMOSOME 14q22 DELETION SYNDROME	FRIAS SYNDROME	609640
GROWTH DEFICIENCY, FACIAL ANOMALIES, AND BRACHYDACTYLY	FRIAS SYNDROME	609640
NGUYEN SYNDROME	NGUYEN SYNDROME	609643
MCA/MR WITH HYPOCHOLESTEROLEMIA DUE TO FAMILIAL HYPOBETALIPOPROTEINEMIA	NGUYEN SYNDROME	609643
DEAFNESS, AUTOSOMAL RECESSIVE 42; DFNB42	DEAFNESS, AUTOSOMAL RECESSIVE 42; DFNB42	609646
DEAFNESS, AUTOSOMAL RECESSIVE 46; DFNB46	DEAFNESS, AUTOSOMAL RECESSIVE 46; DFNB46	609647
TRICHILEMMAL CYST 1; TRICY1	TRICHILEMMAL CYST 1; TRICY1	609649
TRICHOLEMMAL CYST	TRICHILEMMAL CYST 1; TRICY1	609649
PILAR CYST	TRICHILEMMAL CYST 1; TRICY1	609649
BONE SIZE QUANTITATIVE TRAIT LOCUS 1	BONE SIZE QUANTITATIVE TRAIT LOCUS 1	609656
BSZQTL1	BONE SIZE QUANTITATIVE TRAIT LOCUS 1	609656
BONE SIZE QUANTITATIVE TRAIT LOCUS 2	BONE SIZE QUANTITATIVE TRAIT LOCUS 2	609657
BSZQTL2	BONE SIZE QUANTITATIVE TRAIT LOCUS 2	609657
MIGRAINE WITH AURA, SUSCEPTIBILITY TO, 9	MIGRAINE WITH AURA, SUSCEPTIBILITY TO, 9	609670
MGR9	MIGRAINE WITH AURA, SUSCEPTIBILITY TO, 9	609670
THYROID HORMONE METABOLISM, ABNORMAL	THYROID HORMONE METABOLISM, ABNORMAL	609698
DEAFNESS, AUTOSOMAL RECESSIVE 53; DFNB53	DEAFNESS, AUTOSOMAL RECESSIVE 53; DFNB53	609706
LIPOPROTEIN LIPASE; LPLHIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS11, INCLUDED; HDLCQ11, INCLUDED	LIPOPROTEIN LIPASE; LPLHIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS11, INCLUDED; HDLCQ11, INCLUDED	609708
SPASTIC PARAPLEGIA 29, AUTOSOMAL DOMINANT; SPG29	SPASTIC PARAPLEGIA 29, AUTOSOMAL DOMINANT; SPG29	609727
PROOPIOMELANOCORTIN DEFICIENCY	PROOPIOMELANOCORTIN DEFICIENCY	609734
OBESITY, EARLY-ONSET, ADRENAL INSUFFICIENCY, AND RED HAIR	PROOPIOMELANOCORTIN DEFICIENCY	609734
CATARACT 22, MULTIPLE TYPES; CTRCT22	CATARACT 22, MULTIPLE TYPES; CTRCT22	609741
CATARACT, CONGENITAL NUCLEAR, AUTOSOMAL RECESSIVE 2; CATCN2	CATARACT 22, MULTIPLE TYPES; CTRCT22	609741
GLAUCOMA 1, OPEN ANGLE, I; GLC1I	GLAUCOMA 1, OPEN ANGLE, I; GLC1I	609745
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 4; EIG4	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 4; EIG4	609750
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME10	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 4; EIG4	609750
CELIAC DISEASE, SUSCEPTIBILITY TO, 4; CELIAC4	CELIAC DISEASE, SUSCEPTIBILITY TO, 4; CELIAC4	609753
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 4	CELIAC DISEASE, SUSCEPTIBILITY TO, 4; CELIAC4	609753
CELIAC DISEASE, SUSCEPTIBILITY TO, 2; CELIAC2	CELIAC DISEASE, SUSCEPTIBILITY TO, 2; CELIAC2	609754
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 2	CELIAC DISEASE, SUSCEPTIBILITY TO, 2; CELIAC2	609754
CELIAC DISEASE, SUSCEPTIBILITY TO, 3; CELIAC3	CELIAC DISEASE, SUSCEPTIBILITY TO, 3; CELIAC3	609755
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 3	CELIAC DISEASE, SUSCEPTIBILITY TO, 3; CELIAC3	609755
WILLIAMS-BEUREN REGION DUPLICATION SYNDROME	WILLIAMS-BEUREN REGION DUPLICATION SYNDROME	609757
WBS DUPLICATION SYNDROME	WILLIAMS-BEUREN REGION DUPLICATION SYNDROME	609757
CHROMOSOME 7q11.23 DUPLICATION SYNDROME	WILLIAMS-BEUREN REGION DUPLICATION SYNDROME	609757
SOMERVILLE-VAN DER AA SYNDROMEWBS TRIPLICATION SYNDROME, INCLUDED	WILLIAMS-BEUREN REGION DUPLICATION SYNDROME	609757
CHROMOSOME 7q11.23 TRIPLICATION SYNDROME, INCLUDED	WILLIAMS-BEUREN REGION DUPLICATION SYNDROME	609757
AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 2; AAA2	AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 2; AAA2	609782
ALZHEIMER DISEASE 11	ALZHEIMER DISEASE 11	609790
ALZHEIMER DISEASE, FAMILIAL, 11	ALZHEIMER DISEASE 11	609790
AD11	ALZHEIMER DISEASE 11	609790
PEELING SKIN SYNDROME 2; PSS2	PEELING SKIN SYNDROME 2; PSS2	609796
ACRAL PEELING SKIN SYNDROME; APSS	PEELING SKIN SYNDROME 2; PSS2	609796
PEELING SKIN SYNDROME, ACRAL TYPE	PEELING SKIN SYNDROME 2; PSS2	609796
GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 4; GEFSP4	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 4; GEFSP4	609800
GEFS+, TYPE 4; GEFS+4	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 4; GEFSP4	609800
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 8, WITH EXOCRINE DYSFUNCTION;MODY8	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 8, WITH EXOCRINE DYSFUNCTION;MODY8	609812
DIABETES AND PANCREATIC EXOCRINE DYSFUNCTION; DPED	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 8, WITH EXOCRINE DYSFUNCTION;MODY8	609812
DIABETES-PANCREATIC EXOCRINE DYSFUNCTION SYNDROME	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 8, WITH EXOCRINE DYSFUNCTION;MODY8	609812
SPONDYLOCOSTAL DYSOSTOSIS 3, AUTOSOMAL RECESSIVE; SCDO3	SPONDYLOCOSTAL DYSOSTOSIS 3, AUTOSOMAL RECESSIVE; SCDO3	609813
COMPLEMENT FACTOR H DEFICIENCY; CFHD	COMPLEMENT FACTOR H DEFICIENCY; CFHD	609814
FACTOR H DEFICIENCY	COMPLEMENT FACTOR H DEFICIENCY; CFHD	609814
CFH DEFICIENCY	COMPLEMENT FACTOR H DEFICIENCY; CFHD	609814
ZYGODACTYLY 1	ZYGODACTYLY 1	609815
ZD1	ZYGODACTYLY 1	609815
VASCULITIS, LYMPHOCYTIC, CUTANEOUS SMALL VESSEL	VASCULITIS, LYMPHOCYTIC, CUTANEOUS SMALL VESSEL	609817
ERYTHROCYTOSIS, FAMILIAL, 3; ECYT3	ERYTHROCYTOSIS, FAMILIAL, 3; ECYT3	609820
BLEEDING DISORDER, PLATELET-TYPE, 8; BDPLT8	BLEEDING DISORDER, PLATELET-TYPE, 8; BDPLT8	609821
BLEEDING DISORDER DUE TO P2RY12 DEFECTBLEEDING DISORDER DUE TO P2RX1 DEFECT, SOMATIC, INCLUDED	BLEEDING DISORDER, PLATELET-TYPE, 8; BDPLT8	609821
STATURE QUANTITATIVE TRAIT LOCUS 7; STQTL7	STATURE QUANTITATIVE TRAIT LOCUS 7; STQTL7	609822
DEAFNESS, AUTOSOMAL RECESSIVE 28; DFNB28	DEAFNESS, AUTOSOMAL RECESSIVE 28; DFNB28	609823
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 6; BMND6	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 6; BMND6	609876
GLOMERULOCYSTIC KIDNEY DISEASE WITH HYPERURICEMIA AND ISOSTHENURIA	GLOMERULOCYSTIC KIDNEY DISEASE WITH HYPERURICEMIA AND ISOSTHENURIA	609886
GLAUCOMA 1, OPEN ANGLE, G; GLC1G	GLAUCOMA 1, OPEN ANGLE, G; GLC1G	609887
LEPROSY, SUSCEPTIBILITY TO, 1; LPRS1	LEPROSY, SUSCEPTIBILITY TO, 1; LPRS1	609888
LEPROSY, PAUCIBACILLARY TYPE, SUSCEPTIBILITY TO, 1	LEPROSY, SUSCEPTIBILITY TO, 1; LPRS1	609888
ALPHA/BETA T-CELL LYMPHOPENIA WITH GAMMA/DELTA T-CELL EXPANSION, SEVERECYTOMEGALOVIRUS INFECTION, AND AUTOIMMUNITY	ALPHA/BETA T-CELL LYMPHOPENIA WITH GAMMA/DELTA T-CELL EXPANSION, SEVERECYTOMEGALOVIRUS INFECTION, AND AUTOIMMUNITY	609889
HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 3; CHNG3	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 3; CHNG3	609893
RESISTANCE TO THYROTROPIN; RTSH	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 3; CHNG3	609893
THYROTROPIN RESISTANCE	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 3; CHNG3	609893
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 5; SLEB5	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 5; SLEB5	609903
CARDIOMYOPATHY, DILATED, 1P; CMD1P	CARDIOMYOPATHY, DILATED, 1P; CMD1P	609909
RETINITIS PIGMENTOSA 32; RP32	RETINITIS PIGMENTOSA 32; RP32	609913
CARDIOMYOPATHY, DILATED, 1Q; CMD1Q	CARDIOMYOPATHY, DILATED, 1Q; CMD1Q	609915
GALLBLADDER DISEASE 2; GBD2	GALLBLADDER DISEASE 2; GBD2	609918
GALLBLADDER DISEASE 3; GBD3	GALLBLADDER DISEASE 3; GBD3	609919
RETINITIS PIGMENTOSA 31; RP31	RETINITIS PIGMENTOSA 31; RP31	609923
AMINOACYLASE 1 DEFICIENCY; ACY1D	AMINOACYLASE 1 DEFICIENCY; ACY1D	609924
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 6; SLEB6	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 6; SLEB6	609939
DEAFNESS, AUTOSOMAL RECESSIVE 51; DFNB51	DEAFNESS, AUTOSOMAL RECESSIVE 51; DFNB51	609941
NOONAN SYNDROME 3; NS3	NOONAN SYNDROME 3; NS3	609942
DEAFNESS, AUTOSOMAL RECESSIVE 47; DFNB47	DEAFNESS, AUTOSOMAL RECESSIVE 47; DFNB47	609946
DEAFNESS, AUTOSOMAL RECESSIVE 55; DFNB55	DEAFNESS, AUTOSOMAL RECESSIVE 55; DFNB55	609952
ASPERGER SYNDROME, SUSCEPTIBILITY TO, 4; ASPG4	ASPERGER SYNDROME, SUSCEPTIBILITY TO, 4; ASPG4	609954
FIBROMATOSIS, GINGIVAL, 3; GINGF3	FIBROMATOSIS, GINGIVAL, 3; GINGF3	609955
GGF3	FIBROMATOSIS, GINGIVAL, 3; GINGF3	609955
FIBROMATOSIS, GINGIVAL, HEREDITARY, 3; HGF3	FIBROMATOSIS, GINGIVAL, 3; GINGF3	609955
ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 3	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 3	609958
ASRT3	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 3	609958
DEAFNESS, AUTOSOMAL DOMINANT 53; DFNA53	DEAFNESS, AUTOSOMAL DOMINANT 53; DFNA53	609965
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 5; HHF5	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 5; HHF5	609968
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 4; HHF4	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 4; HHF4	609975
NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIRDEFECT; NKGCD	NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIRDEFECT; NKGCD	609981
NATURAL KILLER CELL DEFICIENCY, FAMILIAL ISOLATED; NKCD	NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIRDEFECT; NKGCD	609981
PANIC DISORDER 3	PANIC DISORDER 3	609985
PAND3	PANIC DISORDER 3	609985
PANIC DISORDER SUSCEPTIBILITY LOCUS, CHROMOSOME 4q-RELATED	PANIC DISORDER 3	609985
METAPHYSEAL CHONDRODYSPLASIA WITH CONE-SHAPED EPIPHYSES, NORMAL HAIR,AND NORMAL HANDS	METAPHYSEAL CHONDRODYSPLASIA WITH CONE-SHAPED EPIPHYSES, NORMAL HAIR,AND NORMAL HANDS	609989
CUPPED METAPHYSES AND CONE-SHAPED EPIPHYSES WITHOUT ALOPECIA OR BRACHYDACTYLY	METAPHYSEAL CHONDRODYSPLASIA WITH CONE-SHAPED EPIPHYSES, NORMAL HAIR,AND NORMAL HANDS	609989
TRICHOSCYPHODYSPLASIA	TRICHOSCYPHODYSPLASIA	609990
METAPHYSEAL CHONDRODYSPLASIA WITH CONE-SHAPED EPIPHYSES AND ALOPECIA	TRICHOSCYPHODYSPLASIA	609990
METAPHYSEAL CHONDRODYSPLASIA WITH ECTODERMAL DYSPLASIA	TRICHOSCYPHODYSPLASIA	609990
CUPPED METAPHYSES AND CONE-SHAPED EPIPHYSES WITH ALOPECIA	TRICHOSCYPHODYSPLASIA	609990
OSTEOSCLEROSIS WITH ICHTHYOSIS AND PREMATURE OVARIAN FAILURE	OSTEOSCLEROSIS WITH ICHTHYOSIS AND PREMATURE OVARIAN FAILURE	609993
SCLEROSING DYSPLASIA OF BONE WITH ICHTHYOSIS AND PREMATURE OVARIANFAILURE	OSTEOSCLEROSIS WITH ICHTHYOSIS AND PREMATURE OVARIAN FAILURE	609993
MYOPIA 11, AUTOSOMAL DOMINANT; MYP11	MYOPIA 11, AUTOSOMAL DOMINANT; MYP11	609994
MYOPIA 12, AUTOSOMAL DOMINANT; MYP12	MYOPIA 12, AUTOSOMAL DOMINANT; MYP12	609995
CEROID LIPOFUSCINOSIS, NEURONAL, 8, NORTHERN EPILEPSY VARIANT	CEROID LIPOFUSCINOSIS, NEURONAL, 8, NORTHERN EPILEPSY VARIANT	610003
NORTHERN EPILEPSY	CEROID LIPOFUSCINOSIS, NEURONAL, 8, NORTHERN EPILEPSY VARIANT	610003
EPILEPSY, PROGRESSIVE, WITH MENTAL RETARDATION; EPMR	CEROID LIPOFUSCINOSIS, NEURONAL, 8, NORTHERN EPILEPSY VARIANT	610003
2-@METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	2-@METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	610006
2-@METHYLBUTYRYL GLYCINURIA	2-@METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	610006
SHORT/BRANCHED-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY; SBCADD	2-@METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	610006
GLUTAMINE DEFICIENCY, CONGENITAL	GLUTAMINE DEFICIENCY, CONGENITAL	610015
GLUTAMINE SYNTHASE DEFICIENCY, CONGENITAL SYSTEMIC	GLUTAMINE DEFICIENCY, CONGENITAL	610015
MULTIPLE SYNOSTOSES SYNDROME 2; SYNS2	MULTIPLE SYNOSTOSES SYNDROME 2; SYNS2	610017
CATARACT 18; CTRCT18	CATARACT 18; CTRCT18	610019
CATARACT, AUTOSOMAL RECESSIVE CONGENITAL 2; CATC2	CATARACT 18; CTRCT18	610019
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 7; HHF7	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 7; HHF7	610021
HYPERINSULINEMIC HYPOGLYCEMIA, EXERCISE-INDUCED	HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 7; HHF7	610021
RETINAL CONE DYSTROPHY 3A; RCD3A	RETINAL CONE DYSTROPHY 3A; RCD3A	610024
CONE DYSTROPHY WITH NIGHT BLINDNESS AND SUPERNORMAL ROD RESPONSES,PDE6H-RELATEDACHROMATOPSIA 6, INCLUDED; ACHM6, INCLUDED	RETINAL CONE DYSTROPHY 3A; RCD3A	610024
POLYMICROGYRIA, SYMMETRIC OR ASYMMETRIC; PMGYSA	POLYMICROGYRIA, SYMMETRIC OR ASYMMETRIC; PMGYSA	610031
CORTICAL DYSPLASIA-FOCAL EPILEPSY SYNDROME; CDFES	CORTICAL DYSPLASIA-FOCAL EPILEPSY SYNDROME; CDFES	610042
CDFE SYNDROMEPITT-HOPKINS-LIKE SYNDROME 1, INCLUDED; PTHSL1, INCLUDED	CORTICAL DYSPLASIA-FOCAL EPILEPSY SYNDROME; CDFES	610042
CORNEAL DYSTROPHY, CONGENITAL STROMAL; CSCD	CORNEAL DYSTROPHY, CONGENITAL STROMAL; CSCD	610048
CONGENITAL STROMAL CORNEAL DYSTROPHY	CORNEAL DYSTROPHY, CONGENITAL STROMAL; CSCD	610048
OPIOID DEPENDENCE, SUSCEPTIBILITY TO, 1	OPIOID DEPENDENCE, SUSCEPTIBILITY TO, 1	610064
ODS1	OPIOID DEPENDENCE, SUSCEPTIBILITY TO, 1	610064
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 7; SLEB7	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 7; SLEB7	610065
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 8; SLEB8	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 8; SLEB8	610066
POLYPOSIS SYNDROME, HEREDITARY MIXED, 2; HMPS2	POLYPOSIS SYNDROME, HEREDITARY MIXED, 2; HMPS2	610069
HYPERPARATHYROIDISM 3; HRPT3	HYPERPARATHYROIDISM 3; HRPT3	610071
HYPERPARATHYROIDISM, FAMILIAL ISOLATED	HYPERPARATHYROIDISM 3; HRPT3	610071
PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY	PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY	610090
PNPO DEFICIENCY	PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY	610090
SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE	PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY	610090
EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED	PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY	610090
MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 3; MCOPCB3	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 3; MCOPCB3	610092
MICROPHTHALMIA, COLOBOMATOUS, ISOLATED 3MICROPHTHALMIA, CATARACTS, AND IRIS ABNORMALITIES, INCLUDED	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 3; MCOPCB3	610092
MICROPHTHALMIA, ISOLATED 2; MCOP2	MICROPHTHALMIA, ISOLATED 2; MCOP2	610093
ANOPHTHALMIA, CLINICAL, ISOLATED	MICROPHTHALMIA, ISOLATED 2; MCOP2	610093
MYOPATHY, DISTAL, 3; MPD3	MYOPATHY, DISTAL, 3; MPD3	610099
GIANT AXONAL NEUROPATHY 2, AUTOSOMAL DOMINANT; GAN2	GIANT AXONAL NEUROPATHY 2, AUTOSOMAL DOMINANT; GAN2	610100
COMPLEMENT COMPONENT 7 DEFICIENCY; C7D	COMPLEMENT COMPONENT 7 DEFICIENCY; C7D	610102
C7 DEFICIENCY	COMPLEMENT COMPONENT 7 DEFICIENCY; C7D	610102
STATURE QUANTITATIVE TRAIT LOCUS 8; STQTL8	STATURE QUANTITATIVE TRAIT LOCUS 8; STQTL8	610114
MICROPHTHALMIA, SYNDROMIC 5; MCOPS5RETINAL DYSTROPHY, EARLY-ONSET, WITH OR WITHOUT PITUITARY DYSFUNCTION,INCLUDED	MICROPHTHALMIA, SYNDROMIC 5; MCOPS5RETINAL DYSTROPHY, EARLY-ONSET, WITH OR WITHOUT PITUITARY DYSFUNCTION,INCLUDED	610125
CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10	CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10	610127
CEROID LIPOFUSCINOSIS, NEURONAL, CATHEPSIN D-DEFICIENT	CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10	610127
NEURONAL CEROID LIPOFUSCINOSIS DUE TO CATHEPSIN D DEFICIENCYNEURONAL CEROID LIPOFUSCINOSIS, CONGENITAL, INCLUDED	CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10	610127
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 4; PEOA4	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 4; PEOA4	610131
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 4; PEOA4	610131
HEART-HAND SYNDROME, SLOVENIAN TYPE	HEART-HAND SYNDROME, SLOVENIAN TYPE	610140
QT INTERVAL, VARIATION IN	QT INTERVAL, VARIATION IN	610141
DEAFNESS, AUTOSOMAL RECESSIVE 62; DFNB62	DEAFNESS, AUTOSOMAL RECESSIVE 62; DFNB62	610143
MACULAR DEGENERATION, AGE-RELATED, 7; ARMD7MACULAR DEGENERATION, AGE-RELATED, NEOVASCULAR TYPE, SUSCEPTIBILITYTO, INCLUDED	MACULAR DEGENERATION, AGE-RELATED, 7; ARMD7MACULAR DEGENERATION, AGE-RELATED, NEOVASCULAR TYPE, SUSCEPTIBILITYTO, INCLUDED	610149
MACULAR DEGENERATION, AGE-RELATED, WET TYPE, SUSCEPTIBILITY TO, INCLUDED	MACULAR DEGENERATION, AGE-RELATED, 7; ARMD7MACULAR DEGENERATION, AGE-RELATED, NEOVASCULAR TYPE, SUSCEPTIBILITYTO, INCLUDED	610149
DEAFNESS, AUTOSOMAL RECESSIVE 49; DFNB49	DEAFNESS, AUTOSOMAL RECESSIVE 49; DFNB49	610153
DEAFNESS, AUTOSOMAL RECESSIVE 44; DFNB44	DEAFNESS, AUTOSOMAL RECESSIVE 44; DFNB44	610154
DIABETES MELLITUS, INSULIN-DEPENDENT, 19; IDDM19	DIABETES MELLITUS, INSULIN-DEPENDENT, 19; IDDM19	610155
MENTAL RETARDATION, TRUNCAL OBESITY, RETINAL DYSTROPHY, AND MICROPENISSYNDROME; MORMS	MENTAL RETARDATION, TRUNCAL OBESITY, RETINAL DYSTROPHY, AND MICROPENISSYNDROME; MORMS	610156
MORM SYNDROME	MENTAL RETARDATION, TRUNCAL OBESITY, RETINAL DYSTROPHY, AND MICROPENISSYNDROME; MORMS	610156
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 2; FECD2	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 2; FECD2	610158
FCD1 LOCUS	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 2; FECD2	610158
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 2; FECD2	610158
IMMUNODEFICIENCY 25; IMD25	IMMUNODEFICIENCY 25; IMD25	610163
IMMUNODEFICIENCY DUE TO DEFECT IN CD3-ZETA	IMMUNODEFICIENCY 25; IMD25	610163
LOEYS-DIETZ SYNDROME 2; LDS2	LOEYS-DIETZ SYNDROME 2; LDS2	610168
AORTIC ANEURYSM, FAMILIAL THORACIC 3; AAT3	LOEYS-DIETZ SYNDROME 2; LDS2	610168
MARFAN SYNDROME, TYPE II, FORMERLY	LOEYS-DIETZ SYNDROME 2; LDS2	610168
KYPHOSCOLIOSIS 1; KYPSC1	KYPHOSCOLIOSIS 1; KYPSC1	610170
AICARDI-GOUTIERES SYNDROME 2; AGS2	AICARDI-GOUTIERES SYNDROME 2; AGS2	610181
CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME2; CAMRQ2	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME2; CAMRQ2	610185
CEREBELLAR ATAXIA AND MENTAL RETARDATION WITH OR WITHOUT QUADRUPEDALLOCOMOTION 2	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME2; CAMRQ2	610185
DIAPHRAGMATIC HERNIA 3; DIH3	DIAPHRAGMATIC HERNIA 3; DIH3	610187
JOUBERT SYNDROME 5; JBTS5	JOUBERT SYNDROME 5; JBTS5	610188
SENIOR-LOKEN SYNDROME 6; SLSN6	SENIOR-LOKEN SYNDROME 6; SLSN6	610189
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 10; ARVD10	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 10; ARVD10	610193
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 10; ARVC10	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 10; ARVD10	610193
3-@METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5	3-@METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5	610198
CARDIOMYOPATHY, DILATED, WITH ATAXIA; DCMA	3-@METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5	610198
MGA, TYPE V; MGA5	3-@METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5	610198
DIABETES MELLITUS, NEONATAL, WITH CONGENITAL HYPOTHYROIDISM	DIABETES MELLITUS, NEONATAL, WITH CONGENITAL HYPOTHYROIDISM	610199
NDH SYNDROME	DIABETES MELLITUS, NEONATAL, WITH CONGENITAL HYPOTHYROIDISM	610199
CATARACT 21, MULTIPLE TYPES; CTRCT21	CATARACT 21, MULTIPLE TYPES; CTRCT21	610202
CATARACT 21, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA	CATARACT 21, MULTIPLE TYPES; CTRCT21	610202
CATARACT, CONGENITAL, CERULEAN TYPE, 4; CCA4	CATARACT 21, MULTIPLE TYPES; CTRCT21	610202
CATARACT, PULVERULENT, JUVENILE-ONSET	CATARACT 21, MULTIPLE TYPES; CTRCT21	610202
PONTOCEREBELLAR HYPOPLASIA, TYPE 5; PCH5	PONTOCEREBELLAR HYPOPLASIA, TYPE 5; PCH5	610204
OLIVOPONTOCEREBELLAR HYPOPLASIA, FETAL-ONSET	PONTOCEREBELLAR HYPOPLASIA, TYPE 5; PCH5	610204
ALAGILLE SYNDROME 2; ALGS2	ALAGILLE SYNDROME 2; ALGS2	610205
MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 10	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 10	610208
MGR10	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 10	610208
MIGRAINE WITH PULSATION	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 10	610208
MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 11	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 11	610209
MGR11	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 11	610209
DEAFNESS, AUTOSOMAL RECESSIVE 66; DFNB66	DEAFNESS, AUTOSOMAL RECESSIVE 66; DFNB66	610212
ANEURYSM, INTRACRANIAL BERRY, 4; ANIB4	ANEURYSM, INTRACRANIAL BERRY, 4; ANIB4	610213
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B; NBIA2B	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B; NBIA2B	610217
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION, PLA2G6-RELATED	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B; NBIA2B	610217
NEUROAXONAL DYSTROPHY, ATYPICALKARAK SYNDROME, INCLUDED	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B; NBIA2B	610217
DEAFNESS, AUTOSOMAL RECESSIVE 59; DFNB59	DEAFNESS, AUTOSOMAL RECESSIVE 59; DFNB59	610220
SEBORRHEA-LIKE DERMATITIS WITH PSORIASIFORM ELEMENTS	SEBORRHEA-LIKE DERMATITIS WITH PSORIASIFORM ELEMENTS	610227
SYNPOLYDACTYLY 3; SPD3	SYNPOLYDACTYLY 3; SPD3	610234
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS4	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS4	610239
HDLCQ4	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS4	610239
SPASTIC PARAPLEGIA 33, AUTOSOMAL DOMINANT; SPG33	SPASTIC PARAPLEGIA 33, AUTOSOMAL DOMINANT; SPG33	610244
SPINOCEREBELLAR ATAXIA 23; SCA23	SPINOCEREBELLAR ATAXIA 23; SCA23	610245
SPINOCEREBELLAR ATAXIA 28; SCA28	SPINOCEREBELLAR ATAXIA 28; SCA28	610246
ESOPHAGITIS, EOSINOPHILIC, 1; EOE1	ESOPHAGITIS, EOSINOPHILIC, 1; EOE1	610247
ESOPHAGITIS, EOSINOPHILIC; EE	ESOPHAGITIS, EOSINOPHILIC, 1; EOE1	610247
DEAFNESS, AUTOSOMAL RECESSIVE 65; DFNB65	DEAFNESS, AUTOSOMAL RECESSIVE 65; DFNB65	610248
SPASTIC PARAPLEGIA 31, AUTOSOMAL DOMINANT; SPG31	SPASTIC PARAPLEGIA 31, AUTOSOMAL DOMINANT; SPG31	610250
ALCOHOL SENSITIVITY, ACUTEHANGOVER, SUSCEPTIBILITY TO, INCLUDED	ALCOHOL SENSITIVITY, ACUTEHANGOVER, SUSCEPTIBILITY TO, INCLUDED	610251
KLEEFSTRA SYNDROME	KLEEFSTRA SYNDROME	610253
CHROMOSOME 9q34.3 DELETION SYNDROME	KLEEFSTRA SYNDROME	610253
9q- SYNDROME	KLEEFSTRA SYNDROME	610253
9q SUBTELOMERIC DELETION SYNDROME	KLEEFSTRA SYNDROME	610253
APHAKIA, CONGENITAL PRIMARY	APHAKIA, CONGENITAL PRIMARY	610256
PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 2; IHPS2	PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 2; IHPS2	610260
HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 5	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 5	610261
HYT5	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 5	610261
HYPERTENSION, ESSENTIAL, BODY MASS-RELATED	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 5	610261
HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 6	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 6	610262
HYT6	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 6	610262
HYPERTENSION, ESSENTIAL, KIDNEY FUNCTION-RELATED	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 6	610262
DEAFNESS, AUTOSOMAL RECESSIVE 67; DFNB67	DEAFNESS, AUTOSOMAL RECESSIVE 67; DFNB67	610265
BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2; BULN2ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED; ANON2, INCLUDED	BULIMIA NERVOSA, SUSCEPTIBILITY TO, 2; BULN2ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 2, INCLUDED; ANON2, INCLUDED	610269
PACHYGYRIA, FRONTOTEMPORAL	PACHYGYRIA, FRONTOTEMPORAL	610279
RETINITIS PIGMENTOSA 35; RP35	RETINITIS PIGMENTOSA 35; RP35	610282
CONE-ROD DYSTROPHY 10; CORD10	CONE-ROD DYSTROPHY 10; CORD10	610283
GLYCOSYLPHOSPHATIDYLINOSITOL DEFICIENCY	GLYCOSYLPHOSPHATIDYLINOSITOL DEFICIENCY	610293
GPI DEFICIENCY	GLYCOSYLPHOSPHATIDYLINOSITOL DEFICIENCY	610293
INTELLIGENCE QUANTITATIVE TRAIT LOCUS 2	INTELLIGENCE QUANTITATIVE TRAIT LOCUS 2	610294
INTLQ2	INTELLIGENCE QUANTITATIVE TRAIT LOCUS 2	610294
INTELLIGENCE QUANTITATIVE TRAIT LOCUS 3	INTELLIGENCE QUANTITATIVE TRAIT LOCUS 3	610295
INTLQ3	INTELLIGENCE QUANTITATIVE TRAIT LOCUS 3	610295
PARKINSON DISEASE 13, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK13	PARKINSON DISEASE 13, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK13	610297
COLD-INDUCED SWEATING SYNDROME 2; CISS2	COLD-INDUCED SWEATING SYNDROME 2; CISS2	610313
MYOPIA 14; MYP14	MYOPIA 14; MYP14	610320
PROSTATE CANCER, HEREDITARY, 7; HPC7	PROSTATE CANCER, HEREDITARY, 7; HPC7	610321
PROSTATE CANCER AGGRESSIVENESS	PROSTATE CANCER, HEREDITARY, 7; HPC7	610321
AICARDI-GOUTIERES SYNDROME 3; AGS3	AICARDI-GOUTIERES SYNDROME 3; AGS3	610329
AICARDI-GOUTIERES SYNDROME 4; AGS4	AICARDI-GOUTIERES SYNDROME 4; AGS4	610333
EPILEPSY, NOCTURNAL FRONTAL LOBE, 4; ENFL4	EPILEPSY, NOCTURNAL FRONTAL LOBE, 4; ENFL4	610353
EPILEPSY, FAMILIAL, WITH NOCTURNAL WANDERING AND ICTAL FEAR	EPILEPSY, NOCTURNAL FRONTAL LOBE, 4; ENFL4	610353
RETINAL CONE DYSTROPHY 3B; RCD3B	RETINAL CONE DYSTROPHY 3B; RCD3B	610356
CONE DYSTROPHY WITH SUPERNORMAL ROD RESPONSES; CDSRR	RETINAL CONE DYSTROPHY 3B; RCD3B	610356
CONE DYSTROPHY WITH NIGHT BLINDNESS AND SUPERNORMAL ROD RESPONSES,KCNV2-RELATED	RETINAL CONE DYSTROPHY 3B; RCD3B	610356
SPASTIC PARAPLEGIA 30, AUTOSOMAL RECESSIVE; SPG30	SPASTIC PARAPLEGIA 30, AUTOSOMAL RECESSIVE; SPG30	610357
RETINITIS PIGMENTOSA 33; RP33	RETINITIS PIGMENTOSA 33; RP33	610359
OROFACIAL CLEFT 9; OFC9	OROFACIAL CLEFT 9; OFC9	610361
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 9	OROFACIAL CLEFT 9; OFC9	610361
DIARRHEA 4, MALABSORPTIVE, CONGENITAL; DIAR4	DIARRHEA 4, MALABSORPTIVE, CONGENITAL; DIAR4	610370
ENTERIC ANENDOCRINOSIS	DIARRHEA 4, MALABSORPTIVE, CONGENITAL; DIAR4	610370
DIABETES MELLITUS, TRANSIENT NEONATAL, 2	DIABETES MELLITUS, TRANSIENT NEONATAL, 2	610374
TNDM2	DIABETES MELLITUS, TRANSIENT NEONATAL, 2	610374
MEVALONIC ACIDURIA; MEVA	MEVALONIC ACIDURIA; MEVA	610377
WEST NILE VIRUS, SUSCEPTIBILITY TO	WEST NILE VIRUS, SUSCEPTIBILITY TO	610379
WNV, SUSCEPTIBILITY TO	WEST NILE VIRUS, SUSCEPTIBILITY TO	610379
CONE-ROD DYSTROPHY 11; CORD11	CONE-ROD DYSTROPHY 11; CORD11	610381
PROSOPAGNOSIA, HEREDITARY	PROSOPAGNOSIA, HEREDITARY	610382
FACE BLINDNESS	PROSOPAGNOSIA, HEREDITARY	610382
PROSOPAGNOSIA, DEVELOPMENTAL	PROSOPAGNOSIA, HEREDITARY	610382
PROSOPAGNOSIA, CONGENITAL	PROSOPAGNOSIA, HEREDITARY	610382
DEAFNESS, AUTOSOMAL RECESSIVE 68; DFNB68	DEAFNESS, AUTOSOMAL RECESSIVE 68; DFNB68	610419
PREAURICULAR TAG, ISOLATED, AUTOSOMAL DOMINANT, 1	PREAURICULAR TAG, ISOLATED, AUTOSOMAL DOMINANT, 1	610420
ALOPECIA-MENTAL RETARDATION SYNDROME 2; APMR2	ALOPECIA-MENTAL RETARDATION SYNDROME 2; APMR2	610422
HEPATITIS B VIRUS, SUSCEPTIBILITY TO	HEPATITIS B VIRUS, SUSCEPTIBILITY TO	610424
HBV, SUSCEPTIBILITY TOHEPATITIS B VIRUS, RESISTANCE TO, INCLUDED	HEPATITIS B VIRUS, SUSCEPTIBILITY TO	610424
HBV, RESISTANCE TO, INCLUDED	HEPATITIS B VIRUS, SUSCEPTIBILITY TO	610424
CATARACT 23; CTRCT23	CATARACT 23; CTRCT23	610425
CATARACT 23, LAMELLAR	CATARACT 23; CTRCT23	610425
CONE-ROD SYNAPTIC DISORDER, CONGENITAL NONPROGRESSIVE; CRSD	CONE-ROD SYNAPTIC DISORDER, CONGENITAL NONPROGRESSIVE; CRSD	610427
NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2B, FORMERLY; CSNB2B,FORMERLY	CONE-ROD SYNAPTIC DISORDER, CONGENITAL NONPROGRESSIVE; CRSD	610427
NIGHT BLINDNESS, CONGENITAL STATIONARY, INCOMPLETE, AUTOSOMAL RECESSIVE,FORMERLY	CONE-ROD SYNAPTIC DISORDER, CONGENITAL NONPROGRESSIVE; CRSD	610427
MACROGLOBULINEMIA, WALDENSTROM, SUSCEPTIBILITY TO, 2; WM2	MACROGLOBULINEMIA, WALDENSTROM, SUSCEPTIBILITY TO, 2; WM2	610430
RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 3; RLS3	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 3; RLS3	610438
RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 4; RLS4	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 4; RLS4	610439
TESTICULAR MICROLITHIASIS	TESTICULAR MICROLITHIASIS	610441
KOOLEN-DE VRIES SYNDROME; KDVS	KOOLEN-DE VRIES SYNDROME; KDVS	610443
CHROMOSOME 17q21.31 DELETION SYNDROME	KOOLEN-DE VRIES SYNDROME; KDVS	610443
MICRODELETION 17q21.31 SYNDROME	KOOLEN-DE VRIES SYNDROME; KDVS	610443
NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 3; CSNBAD3	NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 3; CSNBAD3	610444
NIGHT BLINDNESS, CONGENITAL STATIONARY, NOUGARET TYPE	NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 3; CSNBAD3	610444
NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 1; CSNBAD1	NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 1; CSNBAD1	610445
NIGHT BLINDNESS, CONGENITAL STATIONARY, RHODOPSIN-RELATED	NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 1; CSNBAD1	610445
BURULI ULCER, SUSCEPTIBILITY TO	BURULI ULCER, SUSCEPTIBILITY TO	610446
MYCOBACTERIUM ULCERANS, SUSCEPTIBILITY TO	BURULI ULCER, SUSCEPTIBILITY TO	610446
CHILBLAIN LUPUS 1; CHBL1	CHILBLAIN LUPUS 1; CHBL1	610448
MUTAGEN SENSITIVITY	MUTAGEN SENSITIVITY	610452
TUMORAL CALCINOSIS, NORMOPHOSPHATEMIC, FAMILIAL; NFTC	TUMORAL CALCINOSIS, NORMOPHOSPHATEMIC, FAMILIAL; NFTC	610455
CALCINOSIS, TUMORAL, WITH NORMOPHOSPHATEMIA	TUMORAL CALCINOSIS, NORMOPHOSPHATEMIC, FAMILIAL; NFTC	610455
THIOPURINE S-METHYLTRANSFERASE DEFICIENCY	THIOPURINE S-METHYLTRANSFERASE DEFICIENCY	610460
TPMT DEFICIENCY	THIOPURINE S-METHYLTRANSFERASE DEFICIENCY	610460
THIOPURINES, POOR METABOLISM OF	THIOPURINE S-METHYLTRANSFERASE DEFICIENCY	610460
CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME	CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME	610474
CATSHL SYNDROME	CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME	610474
PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 2; PPNAD2	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 2; PPNAD2	610475
PIGMENTED MICRONODULAR ADRENOCORTICAL DISEASE, PRIMARY, 2	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 2; PPNAD2	610475
CUSHING SYNDROME, ADRENAL, DUE TO PPNAD2	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 2; PPNAD2	610475
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11; ARVD11	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11; ARVD11	610476
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 11; ARVC11ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11, WITH MILDPALMOPLANTAR KERATODERMA AND WOOLLY HAIR, INCLUDED	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11; ARVD11	610476
RETINAL CONE DYSTROPHY 4; RCD4	RETINAL CONE DYSTROPHY 4; RCD4	610478
AGAMMAGLOBULINEMIA, MICROCEPHALY, AND SEVERE DERMATITIS	AGAMMAGLOBULINEMIA, MICROCEPHALY, AND SEVERE DERMATITIS	610483
PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1; PPNAD1	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1; PPNAD1	610489
PIGMENTED MICRONODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1; PPNAD1	610489
CUSHING SYNDROME, ADRENAL, DUE TO PPNAD1	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1; PPNAD1	610489
ADRENOCORTICAL NODULAR DYSPLASIA, PRIMARY	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1; PPNAD1	610489
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 2; COXPD2	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 2; COXPD2	610498
CORPUS CALLOSUM, AGENESIS OF, WITH DYSMORPHISM AND FATAL LACTIC ACIDOSIS	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 2; COXPD2	610498
PRETERM PREMATURE RUPTURE OF THE MEMBRANES; PPROM	PRETERM PREMATURE RUPTURE OF THE MEMBRANES; PPROM	610504
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 3; COXPD3	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 3; COXPD3	610505
ENCEPHALOMYOPATHY, RESPIRATORY FAILURE, AND LACTIC ACIDOSIS	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 3; COXPD3	610505
CONCENTRIC CARDIOMYOPATHY, HYPOTONIA, AND LACTIC ACIDOSIS	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 3; COXPD3	610505
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 7; MODY7	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 7; MODY7	610508
LEUKODYSTROPHY, HYPOMYELINATING, 5; HLD5	LEUKODYSTROPHY, HYPOMYELINATING, 5; HLD5	610532
HYPOMYELINATION AND CONGENITAL CATARACT: HCC	LEUKODYSTROPHY, HYPOMYELINATING, 5; HLD5	610532
GLAUCOMA 1, OPEN ANGLE, M; GLC1M	GLAUCOMA 1, OPEN ANGLE, M; GLC1M	610535
MANDIBULOFACIAL DYSOSTOSIS, GUION-ALMEIDA TYPE; MFDGA	MANDIBULOFACIAL DYSOSTOSIS, GUION-ALMEIDA TYPE; MFDGA	610536
MANDIBULOFACIAL DYSOSTOSIS WITH MICROCEPHALY; MFDM	MANDIBULOFACIAL DYSOSTOSIS, GUION-ALMEIDA TYPE; MFDGA	610536
GROWTH AND MENTAL RETARDATION, MANDIBULOFACIAL DYSOSTOSIS, MICROCEPHALY,AND CLEFT PALATE	MANDIBULOFACIAL DYSOSTOSIS, GUION-ALMEIDA TYPE; MFDGA	610536
GAUCHER DISEASE, ATYPICAL, DUE TO SAPOSIN C DEFICIENCY	GAUCHER DISEASE, ATYPICAL, DUE TO SAPOSIN C DEFICIENCY	610539
MYASTHENIC SYNDROME, CONGENITAL, 12; CMS12	MYASTHENIC SYNDROME, CONGENITAL, 12; CMS12	610542
MYASTHENIC SYNDROME, CONGENITAL, WITH TUBULAR AGGREGATES 1; CMSTA1	MYASTHENIC SYNDROME, CONGENITAL, 12; CMS12	610542
CHROMOSOME 16p13.3 DELETION SYNDROME, PROXIMAL	CHROMOSOME 16p13.3 DELETION SYNDROME, PROXIMAL	610543
RUBINSTEIN-TAYBI DELETION SYNDROME	CHROMOSOME 16p13.3 DELETION SYNDROME, PROXIMAL	610543
RSTS DELETION SYNDROME	CHROMOSOME 16p13.3 DELETION SYNDROME, PROXIMAL	610543
DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS	DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS	610549
INSULIN RECEPTOR, DEFECT IN, WITH INSULIN-RESISTANT DIABETES MELLITUSAND ACANTHOSIS NIGRICANS	DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS	610549
DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS, TYPEA	DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS	610549
IRAN, TYPE A	DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS	610549
HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 1	HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 1	610551
ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 1; IIAE1	HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 1	610551
DIABETES MELLITUS, TRANSIENT NEONATAL, 3	DIABETES MELLITUS, TRANSIENT NEONATAL, 3	610582
TNDM3DIABETES MELLITUS, TYPE II, AUTOSOMAL DOMINANT, INCLUDED	DIABETES MELLITUS, TRANSIENT NEONATAL, 3	610582
RETINITIS PIGMENTOSA 36; RP36	RETINITIS PIGMENTOSA 36; RP36	610599
CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY	CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY	610600
CMO II DEFICIENCY	CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY	610600
ALDOSTERONE DEFICIENCY II	CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY	610600
HYPERRENINEMIC HYPOALDOSTERONISM, FAMILIAL, 1; FHHA1B	CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY	610600
ALDOSTERONE DEFICIENCY DUE TO DEFICIENCY OF STEROID 18-OXIDASE	CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY	610600
STEROID 18-OXIDASE DEFICIENCY	CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY	610600
18-@OXIDASE DEFICIENCY	CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY	610600
LEBER CONGENITAL AMAUROSIS 12; LCA12	LEBER CONGENITAL AMAUROSIS 12; LCA12	610612
ANGIOEDEMA, HEREDITARY, TYPE III; HAE3	ANGIOEDEMA, HEREDITARY, TYPE III; HAE3	610618
HAE III	ANGIOEDEMA, HEREDITARY, TYPE III; HAE3	610618
ESTROGEN-RELATED HAE	ANGIOEDEMA, HEREDITARY, TYPE III; HAE3	610618
ESTROGEN-SENSITIVE HAE	ANGIOEDEMA, HEREDITARY, TYPE III; HAE3	610618
ANGIONEUROTIC EDEMA, HEREDITARY, WITH NORMAL C1 INHIBITOR CONCENTRATIONAND FUNCTION	ANGIOEDEMA, HEREDITARY, TYPE III; HAE3	610618
HAE WITH NORMAL C1 INHIBITOR CONCENTRATION AND FUNCTION	ANGIOEDEMA, HEREDITARY, TYPE III; HAE3	610618
HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR ACTIVITY	ANGIOEDEMA, HEREDITARY, TYPE III; HAE3	610618
CATARACT 11, MULTIPLE TYPES; CTRCT11	CATARACT 11, MULTIPLE TYPES; CTRCT11	610623
CATARACT, POSTERIOR POLAR, 4; CTPP4	CATARACT 11, MULTIPLE TYPES; CTRCT11	610623
CPP4CATARACT 11 WITH MICROPHTHALMIA AND NEURODEVELOPMENTAL ABNORMALITIES,INCLUDED	CATARACT 11, MULTIPLE TYPES; CTRCT11	610623
HYPOGONADOTROPIC HYPOGONADISM 4 WITH OR WITHOUT ANOSMIA; HH4	HYPOGONADOTROPIC HYPOGONADISM 4 WITH OR WITHOUT ANOSMIA; HH4	610628
DIAMOND-BLACKFAN ANEMIA 3; DBA3	DIAMOND-BLACKFAN ANEMIA 3; DBA3	610629
PALMOPLANTAR HYPERKERATOSIS WITH SQUAMOUS CELL CARCINOMA OF SKIN AND46,XX SEX REVERSALPALMOPLANTAR HYPERKERATOSIS AND TRUE HERMAPHRODITISM, INCLUDED	PALMOPLANTAR HYPERKERATOSIS WITH SQUAMOUS CELL CARCINOMA OF SKIN AND46,XX SEX REVERSALPALMOPLANTAR HYPERKERATOSIS AND TRUE HERMAPHRODITISM, INCLUDED	610644
BONE SIZE QUANTITATIVE TRAIT LOCUS 3	BONE SIZE QUANTITATIVE TRAIT LOCUS 3	610649
BSZQTL3	BONE SIZE QUANTITATIVE TRAIT LOCUS 3	610649
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP B; XPB	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP B; XPB	610651
XP, GROUP B; XPBCXERODERMA PIGMENTOSUM B/COCKAYNE SYNDROME, INCLUDED	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP B; XPB	610651
XPB/CS, INCLUDED	XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP B; XPB	610651
TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 4; HHT4	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 4; HHT4	610655
AUTISM, SUSCEPTIBILITY TO, 7; AUTS7	AUTISM, SUSCEPTIBILITY TO, 7; AUTS7	610676
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4; COXPD4	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4; COXPD4	610678
OSTEOGENESIS IMPERFECTA, TYPE VII; OI7	OSTEOGENESIS IMPERFECTA, TYPE VII; OI7	610682
OI, TYPE VII	OSTEOGENESIS IMPERFECTA, TYPE VII; OI7	610682
OSTEOGENESIS IMPERFECTA, TYPE IIB, FORMERLY; OI2B, FORMERLY	OSTEOGENESIS IMPERFECTA, TYPE VII; OI7	610682
SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 2; SHFLD2	SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 2; SHFLD2	610685
NEMALINE MYOPATHY 7; NEM7	NEMALINE MYOPATHY 7; NEM7	610687
JOUBERT SYNDROME 6; JBTS6	JOUBERT SYNDROME 6; JBTS6	610688
MACULAR DEGENERATION, AGE-RELATED, 4; ARMD4	MACULAR DEGENERATION, AGE-RELATED, 4; ARMD4	610698
DEAFNESS, CONGENITAL, WITH INNER EAR AGENESIS, MICROTIA, AND MICRODONTIA	DEAFNESS, CONGENITAL, WITH INNER EAR AGENESIS, MICROTIA, AND MICRODONTIA	610706
DEAFNESS, CONGENITAL, WITH LABYRINTHINE APLASIA, MICROTIA, AND MICRODONTIA	DEAFNESS, CONGENITAL, WITH INNER EAR AGENESIS, MICROTIA, AND MICRODONTIA	610706
DEAFNESS WITH LAMM	DEAFNESS, CONGENITAL, WITH INNER EAR AGENESIS, MICROTIA, AND MICRODONTIA	610706
PSORIASIS 8, SUSCEPTIBILITY TO; PSORS8	PSORIASIS 8, SUSCEPTIBILITY TO; PSORS8	610707
OPTIC ATROPHY 5; OPA5	OPTIC ATROPHY 5; OPA5	610708
BRACHYDACTYLY-SYNDACTYLY SYNDROME	BRACHYDACTYLY-SYNDACTYLY SYNDROME	610713
BDSD	BRACHYDACTYLY-SYNDACTYLY SYNDROME	610713
NEUTRAL LIPID STORAGE DISEASE WITH MYOPATHY; NLSDM	NEUTRAL LIPID STORAGE DISEASE WITH MYOPATHY; NLSDM	610717
NEUTRAL LIPID STORAGE DISEASE WITHOUT ICHTHYOSIS	NEUTRAL LIPID STORAGE DISEASE WITH MYOPATHY; NLSDM	610717
NEPHROTIC SYNDROME, TYPE 3; NPHS3	NEPHROTIC SYNDROME, TYPE 3; NPHS3	610725
NEPHROTIC SYNDROME, EARLY-ONSET, TYPE 3	NEPHROTIC SYNDROME, TYPE 3; NPHS3	610725
NOONAN SYNDROME 4; NS4	NOONAN SYNDROME 4; NS4	610733
NEUTROPENIA, SEVERE CONGENITAL, 3, AUTOSOMAL RECESSIVE; SCN3	NEUTROPENIA, SEVERE CONGENITAL, 3, AUTOSOMAL RECESSIVE; SCN3	610738
KOSTMANN DISEASE	NEUTROPENIA, SEVERE CONGENITAL, 3, AUTOSOMAL RECESSIVE; SCN3	610738
AGRANULOCYTOSIS, INFANTILE	NEUTROPENIA, SEVERE CONGENITAL, 3, AUTOSOMAL RECESSIVE; SCN3	610738
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 8; SCAR8	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 8; SCAR8	610743
ATAXIA, RECESSIVE, OF BEAUCE	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 8; SCAR8	610743
CEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, TYPE 1; ARCA1	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 8; SCAR8	610743
IRIS PATTERN	IRIS PATTERN	610744
ALOPECIA AREATA 2; AA2	ALOPECIA AREATA 2; AA2	610753
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV; MEN4	MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV; MEN4	610755
CEREBROOCULOFACIOSKELETAL SYNDROME 2; COFS2	CEREBROOCULOFACIOSKELETAL SYNDROME 2; COFS2	610756
CEREBROOCULOFACIOSKELETAL SYNDROME 4; COFS4	CEREBROOCULOFACIOSKELETAL SYNDROME 4; COFS4	610758
CORNELIA DE LANGE SYNDROME 3; CDLS3	CORNELIA DE LANGE SYNDROME 3; CDLS3	610759
CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 2	CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 2	610760
CLQTL2	CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 2	610760
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS5	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS5	610761
HDLCQ5	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS5	610761
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS6; HDLCQ6	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS6; HDLCQ6	610762
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M	610768
CDG Im; CDGIm	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M	610768
DOLICHOL KINASE DEFICIENCY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M	610768
DK1 DEFICIENCY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M	610768
MITOCHONDRIAL PHOSPHATE CARRIER DEFICIENCY	MITOCHONDRIAL PHOSPHATE CARRIER DEFICIENCY	610773
MPCD	MITOCHONDRIAL PHOSPHATE CARRIER DEFICIENCY	610773
IMMUNODEFICIENCY DUE TO DEFECT IN MAPBP-INTERACTING PROTEIN	IMMUNODEFICIENCY DUE TO DEFECT IN MAPBP-INTERACTING PROTEIN	610798
INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED, 1; IPD1INVASIVE PNEUMOCOCCAL DISEASE, PROTECTION AGAINST, INCLUDED	INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED, 1; IPD1INVASIVE PNEUMOCOCCAL DISEASE, PROTECTION AGAINST, INCLUDED	610799
CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 1, SUSCEPTIBILITYTO; CAKUT1	CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 1, SUSCEPTIBILITYTO; CAKUT1	610805
RENAL HYPODYSPLASIA, NONSYNDROMIC, 1; RHDNS1	CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 1, SUSCEPTIBILITYTO; CAKUT1	610805
HOLOPROSENCEPHALY 7; HPE7	HOLOPROSENCEPHALY 7; HPE7	610828
HOLOPROSENCEPHALY 9; HPE9	HOLOPROSENCEPHALY 9; HPE9	610829
PITUITARY ANOMALIES WITH HOLOPROSENCEPHALY-LIKE FEATURES	HOLOPROSENCEPHALY 9; HPE9	610829
HOLOPROSENCEPHALY WITH MICROPHTHALMIA AND FIRST BRANCHIAL ARCH ANOMALIES	HOLOPROSENCEPHALY 9; HPE9	610829
FANCONI ANEMIA, COMPLEMENTATION GROUP N; FANCN	FANCONI ANEMIA, COMPLEMENTATION GROUP N; FANCN	610832
AUTISM, SUSCEPTIBILITY TO, 11; AUTS11	AUTISM, SUSCEPTIBILITY TO, 11; AUTS11	610836
AUTISM, SUSCEPTIBILITY TO, 12; AUTS12	AUTISM, SUSCEPTIBILITY TO, 12; AUTS12	610838
OSTEOARTHRITIS SUSCEPTIBILITY 4; OS4	OSTEOARTHRITIS SUSCEPTIBILITY 4; OS4	610839
OSTEOARTHRITIS, GENERALIZED, WITHOUT DYSPLASIA; GOA1	OSTEOARTHRITIS SUSCEPTIBILITY 4; OS4	610839
MITRAL VALVE PROLAPSE 3; MVP3	MITRAL VALVE PROLAPSE 3; MVP3	610840
MITRAL VALVE PROLAPSE, MYXOMATOUS 3; MMVP3	MITRAL VALVE PROLAPSE 3; MVP3	610840
MYXOMATOUS MITRAL VALVE PROLAPSE 3	MITRAL VALVE PROLAPSE 3; MVP3	610840
PSEUDOXANTHOMA ELASTICUM-LIKE DISORDER WITH MULTIPLE COAGULATION FACTORDEFICIENCY	PSEUDOXANTHOMA ELASTICUM-LIKE DISORDER WITH MULTIPLE COAGULATION FACTORDEFICIENCY	610842
PXE-LIKE DISORDER WITH MULTIPLE COAGULATION FACTOR DEFICIENCY	PSEUDOXANTHOMA ELASTICUM-LIKE DISORDER WITH MULTIPLE COAGULATION FACTORDEFICIENCY	610842
CILIARY DYSKINESIA, PRIMARY, 6; CILD6	CILIARY DYSKINESIA, PRIMARY, 6; CILD6	610852
MENARCHE, AGE AT, QUANTITATIVE TRAIT LOCUS 1; MENAQ1	MENARCHE, AGE AT, QUANTITATIVE TRAIT LOCUS 1; MENAQ1	610873
VESICOURETERAL REFLUX 2; VUR2	VESICOURETERAL REFLUX 2; VUR2	610878
POTOCKI-LUPSKI SYNDROME; PTLS	POTOCKI-LUPSKI SYNDROME; PTLS	610883
CHROMOSOME 17p11.2 DUPLICATION SYNDROME	POTOCKI-LUPSKI SYNDROME; PTLS	610883
BRANCHIOOTORENAL SYNDROME 2; BOR2	BRANCHIOOTORENAL SYNDROME 2; BOR2	610896
SUPRANUCLEAR PALSY, PROGRESSIVE, 3; PSNP3	SUPRANUCLEAR PALSY, PROGRESSIVE, 3; PSNP3	610898
ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 4	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 4	610906
ASRT4	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 4	610906
ASTHMA AND ALLERGIC RHINITIS, SUSCEPTIBILITY TO	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 4	610906
AUTISM, SUSCEPTIBILITY TO, 13; AUTS13	AUTISM, SUSCEPTIBILITY TO, 13; AUTS13	610908
PULMONARY ALVEOLAR PROTEINOSIS, ACQUIRED	PULMONARY ALVEOLAR PROTEINOSIS, ACQUIRED	610910
PAP, ACQUIRED	PULMONARY ALVEOLAR PROTEINOSIS, ACQUIRED	610910
PULMONARY ALVEOLAR LIPOPROTEINOSIS, ACQUIRED	PULMONARY ALVEOLAR PROTEINOSIS, ACQUIRED	610910
PULMONARY ALVEOLAR PROTEINOSIS, AUTOIMMUNE	PULMONARY ALVEOLAR PROTEINOSIS, ACQUIRED	610910
SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 2; SMDP2	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 2; SMDP2	610913
INTERSTITIAL LUNG DISEASE DUE TO SURFACTANT PROTEIN C DEFICIENCY	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 2; SMDP2	610913
DESQUAMATIVE INTERSTITIAL PNEUMONITIS DUE TO SURFACTANT PROTEIN CDEFICIENCY	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 2; SMDP2	610913
PULMONARY ALVEOLAR PROTEINOSIS, CONGENITAL, 2	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 2; SMDP2	610913
OSTEOGENESIS IMPERFECTA, TYPE VIII; OI8	OSTEOGENESIS IMPERFECTA, TYPE VIII; OI8	610915
OI, TYPE VIII	OSTEOGENESIS IMPERFECTA, TYPE VIII; OI8	610915
SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 3; SMDP3	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 3; SMDP3	610921
PULMONARY ALVEOLAR PROTEINOSIS, CONGENITAL, 3	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 3; SMDP3	610921
INTERSTITIAL LUNG DISEASE DUE TO ABCA3 DEFICIENCY	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 3; SMDP3	610921
TOOTH AGENESIS, SELECTIVE, 5; STHAG5	TOOTH AGENESIS, SELECTIVE, 5; STHAG5	610926
HYPODONTIA/OLIGODONTIA 5	TOOTH AGENESIS, SELECTIVE, 5; STHAG5	610926
HE-ZHAO DEFICIENCY	TOOTH AGENESIS, SELECTIVE, 5; STHAG5	610926
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 9; SLEB9	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 9; SLEB9	610927
CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 7; CHDS7	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 7; CHDS7	610938
CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT 2; ADCAD2	CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT 2; ADCAD2	610947
HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 7	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 7	610948
HYT7	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 7	610948
CEROID LIPOFUSCINOSIS, NEURONAL, 7; CLN7	CEROID LIPOFUSCINOSIS, NEURONAL, 7; CLN7	610951
PITT-HOPKINS SYNDROME; PTHS	PITT-HOPKINS SYNDROME; PTHS	610954
ENCEPHALOPATHY, SEVERE EPILEPTIC, WITH AUTONOMIC DYSFUNCTION	PITT-HOPKINS SYNDROME; PTHS	610954
MENTAL RETARDATION, SYNDROMAL, WITH INTERMITTENT HYPERVENTILATION	PITT-HOPKINS SYNDROME; PTHS	610954
XFE PROGEROID SYNDROME; XFEPS	XFE PROGEROID SYNDROME; XFEPS	610965
XPF-ERCC1 PROGEROID SYNDROME	XFE PROGEROID SYNDROME; XFEPS	610965
OSTEOGENESIS IMPERFECTA, TYPE V; OI5	OSTEOGENESIS IMPERFECTA, TYPE V; OI5	610967
OI, TYPE V	OSTEOGENESIS IMPERFECTA, TYPE V; OI5	610967
OSTEOGENESIS IMPERFECTA, TYPE XI; OI11	OSTEOGENESIS IMPERFECTA, TYPE XI; OI11	610968
OI, TYPE XI	OSTEOGENESIS IMPERFECTA, TYPE XI; OI11	610968
CHOREOATHETOSIS AND CONGENITAL HYPOTHYROIDISM WITH OR WITHOUT PULMONARYDYSFUNCTION; CAHTP	CHOREOATHETOSIS AND CONGENITAL HYPOTHYROIDISM WITH OR WITHOUT PULMONARYDYSFUNCTION; CAHTP	610978
BRAIN-LUNG-THYROID SYNDROME	CHOREOATHETOSIS AND CONGENITAL HYPOTHYROIDISM WITH OR WITHOUT PULMONARYDYSFUNCTION; CAHTP	610978
COMPLEMENT FACTOR I DEFICIENCY; CFID	COMPLEMENT FACTOR I DEFICIENCY; CFID	610984
COMPLEMENT COMPONENT 3 INACTIVATOR DEFICIENCY	COMPLEMENT FACTOR I DEFICIENCY; CFID	610984
C3 INACTIVATOR DEFICIENCY	COMPLEMENT FACTOR I DEFICIENCY; CFID	610984
LEPROSY, SUSCEPTIBILITY TO, 4; LPRS4LEPROSY, EARLY-ONSET, SUSCEPTIBILITY TO, INCLUDED	LEPROSY, SUSCEPTIBILITY TO, 4; LPRS4LEPROSY, EARLY-ONSET, SUSCEPTIBILITY TO, INCLUDED	610988
PHOSPHOSERINE AMINOTRANSFERASE DEFICIENCY; PSATD	PHOSPHOSERINE AMINOTRANSFERASE DEFICIENCY; PSATD	610992
PSAT DEFICIENCY	PHOSPHOSERINE AMINOTRANSFERASE DEFICIENCY; PSATD	610992
PROSTATE CANCER, HEREDITARY, 9	PROSTATE CANCER, HEREDITARY, 9	610997
HPC9	PROSTATE CANCER, HEREDITARY, 9	610997
SMOKING AS A QUANTITATIVE TRAIT LOCUS 1; SQTL1	SMOKING AS A QUANTITATIVE TRAIT LOCUS 1; SQTL1	611003
SMOKING AS A QUANTITATIVE TRAIT LOCUS 2; SQTL2	SMOKING AS A QUANTITATIVE TRAIT LOCUS 2; SQTL2	611004
FIBROMATOSIS, GINGIVAL, 4; GINGF4	FIBROMATOSIS, GINGIVAL, 4; GINGF4	611010
GGF4	FIBROMATOSIS, GINGIVAL, 4; GINGF4	611010
FIBROMATOSIS, GINGIVAL, HEREDITARY, 4; HGF4	FIBROMATOSIS, GINGIVAL, 4; GINGF4	611010
HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 8; HYT8	HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 8; HYT8	611014
AUTISM, SUSCEPTIBILITY TO, 9; AUTS9	AUTISM, SUSCEPTIBILITY TO, 9; AUTS9	611015
AUTISM, SUSCEPTIBILITY TO, 10; AUTS10	AUTISM, SUSCEPTIBILITY TO, 10; AUTS10	611016
DEAFNESS, AUTOSOMAL RECESSIVE 24; DFNB24	DEAFNESS, AUTOSOMAL RECESSIVE 24; DFNB24	611022
EPISODIC KINESIGENIC DYSKINESIA 2; EKD2	EPISODIC KINESIGENIC DYSKINESIA 2; EKD2	611031
DYSTONIA 19; DYT19	EPISODIC KINESIGENIC DYSKINESIA 2; EKD2	611031
MICROPHTHALMIA, ISOLATED 3; MCOP3	MICROPHTHALMIA, ISOLATED 3; MCOP3	611038
MICROPHTHALMIA, ISOLATED 5; MCOP5	MICROPHTHALMIA, ISOLATED 5; MCOP5	611040
MICROPHTHALMIA, POSTERIOR, WITH RETINITIS PIGMENTOSA, FOVEOSCHISIS,AND OPTIC DISC DRUSEN	MICROPHTHALMIA, ISOLATED 5; MCOP5	611040
MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 2	MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 2	611046
MTBS2	MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 2	611046
ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 5	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 5	611064
ASRT5	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 5	611064
SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 4; DSMA4	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 4; DSMA4	611067
ALZHEIMER DISEASE 12	ALZHEIMER DISEASE 12	611073
AD12	ALZHEIMER DISEASE 12	611073
ALZHEIMER DISEASE, FAMILIAL, 12	ALZHEIMER DISEASE 12	611073
INFLAMMATORY BOWEL DISEASE 10; IBD10	INFLAMMATORY BOWEL DISEASE 10; IBD10	611081
POLYHYDRAMNIOS, MEGALENCEPHALY, AND SYMPTOMATIC EPILEPSY; PMSE	POLYHYDRAMNIOS, MEGALENCEPHALY, AND SYMPTOMATIC EPILEPSY; PMSE	611087
PMSE SYNDROME	POLYHYDRAMNIOS, MEGALENCEPHALY, AND SYMPTOMATIC EPILEPSY; PMSE	611087
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 12; MRT12	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 12; MRT12	611090
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 5; MRT5	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 5; MRT5	611091
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 6; MRT6	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 6; MRT6	611092
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 7; MRT7	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 7; MRT7	611093
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 22; MRT22	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 7; MRT7	611093
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 8; MRT8	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 8; MRT8	611094
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 9; MRT9	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 9; MRT9	611095
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 26; MRT26	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 9; MRT9	611095
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 10; MRT10	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 10; MRT10	611096
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 20; MRT20	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 10; MRT10	611096
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 11; MRT11	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 11; MRT11	611097
PROSTATE CANCER, HEREDITARY, 10; HPC10	PROSTATE CANCER, HEREDITARY, 10; HPC10	611100
DEAFNESS-INFERTILITY SYNDROME; DIS	DEAFNESS-INFERTILITY SYNDROME; DIS	611102
DEAFNESS, SENSORINEURAL, AND MALE INFERTILITY	DEAFNESS-INFERTILITY SYNDROME; DIS	611102
CHROMOSOME 15q15.3 DELETION SYNDROME	DEAFNESS-INFERTILITY SYNDROME; DIS	611102
LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT ANDLACTATE ELEVATION; LBSL	LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT ANDLACTATE ELEVATION; LBSL	611105
MITOCHONDRIAL ASPARTYL-tRNA SYNTHETASE DEFICIENCY	LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT ANDLACTATE ELEVATION; LBSL	611105
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 4; MRT4	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 4; MRT4	611107
CINNAMON ODOR, PLEASANTNESS OF	CINNAMON ODOR, PLEASANTNESS OF	611109
CINN	CINNAMON ODOR, PLEASANTNESS OF	611109
MITOCHONDRIAL COMPLEX I DEFICIENCY DUE TO ACAD9 DEFICIENCY	MITOCHONDRIAL COMPLEX I DEFICIENCY DUE TO ACAD9 DEFICIENCY	611126
ACYL-CoA DEHYDROGENASE 9 DEFICIENCY	MITOCHONDRIAL COMPLEX I DEFICIENCY DUE TO ACAD9 DEFICIENCY	611126
ACAD9 DEFICIENCY	MITOCHONDRIAL COMPLEX I DEFICIENCY DUE TO ACAD9 DEFICIENCY	611126
RETINITIS PIGMENTOSA 37; RP37	RETINITIS PIGMENTOSA 37; RP37	611131
MECKEL SYNDROME, TYPE 4; MKS4	MECKEL SYNDROME, TYPE 4; MKS4	611134
MECKEL-GRUBER SYNDROME, TYPE 4MECKEL-LIKE CEREBRORENODIGITAL SYNDROME, INCLUDED	MECKEL SYNDROME, TYPE 4; MKS4	611134
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 13; EIG13EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 5, INCLUDED; EJM5,INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 13; EIG13EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 5, INCLUDED; EJM5,INCLUDED	611136
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 4, INCLUDED; ECA4,INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 13; EIG13EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 5, INCLUDED; EJM5,INCLUDED	611136
CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 8; CHDS8	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 8; CHDS8	611139
PAROXYSMAL NONKINESIGENIC DYSKINESIA 2; PNKD2	PAROXYSMAL NONKINESIGENIC DYSKINESIA 2; PNKD2	611147
DYSTONIA 20; DYT20	PAROXYSMAL NONKINESIGENIC DYSKINESIA 2; PNKD2	611147
ALZHEIMER DISEASE 13; AD13	ALZHEIMER DISEASE 13; AD13	611152
ALZHEIMER DISEASE 14; AD14	ALZHEIMER DISEASE 14; AD14	611154
ALZHEIMER DISEASE 15; AD15	ALZHEIMER DISEASE 15; AD15	611155
MALARIA, SUSCEPTIBILITY TOMALARIA, RESISTANCE TO, INCLUDED	MALARIA, SUSCEPTIBILITY TOMALARIA, RESISTANCE TO, INCLUDED	611162
MALARIA, SEVERE, SUSCEPTIBILITY TO, INCLUDED	MALARIA, SUSCEPTIBILITY TOMALARIA, RESISTANCE TO, INCLUDED	611162
MALARIA, SEVERE, RESISTANCE TO, INCLUDED	MALARIA, SUSCEPTIBILITY TOMALARIA, RESISTANCE TO, INCLUDED	611162
MALARIA, CEREBRAL, SUSCEPTIBILITY TO, INCLUDED	MALARIA, SUSCEPTIBILITY TOMALARIA, RESISTANCE TO, INCLUDED	611162
MALARIA, CEREBRAL, RESISTANCE TO, INCLUDED	MALARIA, SUSCEPTIBILITY TOMALARIA, RESISTANCE TO, INCLUDED	611162
HAMAMY SYNDROME; HMMS	HAMAMY SYNDROME; HMMS	611174
HYPERTELORISM, SEVERE, WITH MIDFACE PROMINENCE, MYOPIA, MENTAL RETARDATION,AND BONE FRAGILITY	HAMAMY SYNDROME; HMMS	611174
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIh; CDG2H	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIh; CDG2H	611182
CDG IIh; CDGIIh	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIh; CDG2H	611182
RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 6; RLS6	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 6; RLS6	611185
PERIODIC LIMB MOVEMENTS IN SLEEP	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 6; RLS6	611185
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G	611209
CDG IIg; CDGIIg	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G	611209
CDGII/COG1 CEREBROCOSTOMANDIBULAR-LIKE SYNDROME	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G	611209
MICROPHTHALMIA, SYNDROMIC 10; MCOPS10	MICROPHTHALMIA, SYNDROMIC 10; MCOPS10	611222
MICROPHTHALMIA AND BRAIN ATROPHY; MOBA	MICROPHTHALMIA, SYNDROMIC 10; MCOPS10	611222
SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE; SPG18	SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE; SPG18	611225
INTELLECTUAL DISABILITY, MOTOR DYSFUNCTION, AND JOINT CONTRACTURES;IDMDC	SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE; SPG18	611225
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4J; CMT4J	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4J; CMT4J	611228
CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, TYPE 4J	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4J; CMT4J	611228
RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 5; RLS5	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 5; RLS5	611242
MAJOR AFFECTIVE DISORDER 4; MAFD4	MAJOR AFFECTIVE DISORDER 4; MAFD4	611247
BIPOLAR AFFECTIVE DISORDER; BPAD	MAJOR AFFECTIVE DISORDER 4; MAFD4	611247
SPASTIC PARAPLEGIA 32, AUTOSOMAL RECESSIVE; SPG32	SPASTIC PARAPLEGIA 32, AUTOSOMAL RECESSIVE; SPG32	611252
SHORT-RIB THORACIC DYSPLASIA 2 WITH OR WITHOUT POLYDACTYLY; SRTD2	SHORT-RIB THORACIC DYSPLASIA 2 WITH OR WITHOUT POLYDACTYLY; SRTD2	611263
ASPHYXIATING THORACIC DYSTROPHY 2; ATD2	SHORT-RIB THORACIC DYSPLASIA 2 WITH OR WITHOUT POLYDACTYLY; SRTD2	611263
GLAUCOMA 1, OPEN ANGLE, N; GLC1N	GLAUCOMA 1, OPEN ANGLE, N; GLC1N	611274
GLAUCOMA 1, OPEN ANGLE, H; GLC1H	GLAUCOMA 1, OPEN ANGLE, H; GLC1H	611276
GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 3; GEFSP3	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 3; GEFSP3	611277
GEFS+, TYPE 3; GEFS+3FEBRILE SEIZURES, FAMILIAL, 8, INCLUDED; FEB8, INCLUDED	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 3; GEFSP3	611277
ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	611283
IBD DEFICIENCY	ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	611283
ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 8, DEFICIENCY OF	ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	611283
ACAD8 DEFICIENCY	ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY	611283
DYSTONIA, FOCAL, TASK-SPECIFIC; FTSDMUSICIAN'S DYSTONIA, INCLUDED	DYSTONIA, FOCAL, TASK-SPECIFIC; FTSDMUSICIAN'S DYSTONIA, INCLUDED	611284
SEVERE COMBINED IMMUNODEFICIENCY WITH MICROCEPHALY, GROWTH RETARDATION,AND SENSITIVITY TO IONIZING RADIATION	SEVERE COMBINED IMMUNODEFICIENCY WITH MICROCEPHALY, GROWTH RETARDATION,AND SENSITIVITY TO IONIZING RADIATION	611291
SCID, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE,WITH MICROCEPHALY, GROWTH RETARDATION, AND SENSITIVITY TO IONIZINGRADIATION	SEVERE COMBINED IMMUNODEFICIENCY WITH MICROCEPHALY, GROWTH RETARDATION,AND SENSITIVITY TO IONIZING RADIATION	611291
NHEJ1 SYNDROMESEVERE COMBINED IMMUNODEFICIENCY WITH SENSITIVITY TO IONIZING RADIATIONDUE TO NHEJ1 DEFICIENCY, INCLUDED	SEVERE COMBINED IMMUNODEFICIENCY WITH MICROCEPHALY, GROWTH RETARDATION,AND SENSITIVITY TO IONIZING RADIATION	611291
SCID, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE,AND SENSITIVITY TO IONIZING RADIATION DUE TO NHEJ1 DEFICIENCY, INCLUDED	SEVERE COMBINED IMMUNODEFICIENCY WITH MICROCEPHALY, GROWTH RETARDATION,AND SENSITIVITY TO IONIZING RADIATION	611291
SPASTIC ATAXIA 2, AUTOSOMAL RECESSIVE; SPAX2	SPASTIC ATAXIA 2, AUTOSOMAL RECESSIVE; SPAX2	611302
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2L; LGMD2L	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2L; LGMD2L	611307
PERSISTENT HYPERPLASTIC PRIMARY VITREOUS, AUTOSOMAL DOMINANT; PHPVAD	PERSISTENT HYPERPLASTIC PRIMARY VITREOUS, AUTOSOMAL DOMINANT; PHPVAD	611308
ATRIAL SEPTAL DEFECT 4; ASD4	ATRIAL SEPTAL DEFECT 4; ASD4	611363
MYOCLONIC EPILEPSY, JUVENILE, SUSCEPTIBILITY TO, 4; EJM4	MYOCLONIC EPILEPSY, JUVENILE, SUSCEPTIBILITY TO, 4; EJM4	611364
LETHAL CONGENITAL CONTRACTURE SYNDROME 3; LCCS3	LETHAL CONGENITAL CONTRACTURE SYNDROME 3; LCCS3	611369
MULTIPLE CONTRACTURE SYNDROME, ISRAELI BEDOUIN TYPE B	LETHAL CONGENITAL CONTRACTURE SYNDROME 3; LCCS3	611369
MUNGAN SYNDROME; MGS	MUNGAN SYNDROME; MGS	611376
VISCERAL NEUROMYOPATHY, FAMILIAL, WITH PSEUDOOBSTRUCTION, MEGADUODENUM,BARRETT ESOPHAGUS, AND CARDIAC ABNORMALITIES	MUNGAN SYNDROME; MGS	611376
PSEUDOOBSTRUCTION, CHRONIC IDIOPATHIC INTESTINAL, WITH BARRETT ESOPHAGUSAND CARDIAC ABNORMALITIES	MUNGAN SYNDROME; MGS	611376
BRACHYDACTYLY, TYPE B2; BDB2	BRACHYDACTYLY, TYPE B2; BDB2	611377
MACULAR DEGENERATION, AGE-RELATED, 9; ARMD9	MACULAR DEGENERATION, AGE-RELATED, 9; ARMD9	611378
KALA-AZAR, SUSCEPTIBILITY TO, 2; KAZA2	KALA-AZAR, SUSCEPTIBILITY TO, 2; KAZA2	611381
LEISHMANIASIS, VISCERAL, SUSCEPTIBILITY TO, 2	KALA-AZAR, SUSCEPTIBILITY TO, 2; KAZA2	611381
KALA-AZAR, SUSCEPTIBILITY TO, 3; KAZA3	KALA-AZAR, SUSCEPTIBILITY TO, 3; KAZA3	611382
LEISHMANIASIS, VISCERAL, SUSCEPTIBILITY TO, 3	KALA-AZAR, SUSCEPTIBILITY TO, 3; KAZA3	611382
USHER SYNDROME, TYPE IID; USH2D	USHER SYNDROME, TYPE IID; USH2D	611383
PLASMODIUM FALCIPARUM FEVER EPISODES QUANTITATIVE TRAIT LOCUS 1	PLASMODIUM FALCIPARUM FEVER EPISODES QUANTITATIVE TRAIT LOCUS 1	611384
PFFE1	PLASMODIUM FALCIPARUM FEVER EPISODES QUANTITATIVE TRAIT LOCUS 1	611384
MALARIA FEVER EPISODES QUANTITATIVE TRAIT LOCUS 1	PLASMODIUM FALCIPARUM FEVER EPISODES QUANTITATIVE TRAIT LOCUS 1	611384
SPASTIC ATAXIA 3, AUTOSOMAL RECESSIVE; SPAX3	SPASTIC ATAXIA 3, AUTOSOMAL RECESSIVE; SPAX3	611390
AUTOSOMAL RECESSIVE SPASTIC ATAXIA WITH LEUKOENCEPHALOPATHY; ARSAL	SPASTIC ATAXIA 3, AUTOSOMAL RECESSIVE; SPAX3	611390
CATARACT 33; CTRCT33	CATARACT 33; CTRCT33	611391
CATARACT 33, CORTICAL	CATARACT 33; CTRCT33	611391
ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 6	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 6	611403
ASRT6	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 6	611403
CARDIOMYOPATHY, DILATED, 1W; CMD1W	CARDIOMYOPATHY, DILATED, 1W; CMD1W	611407
LEGIUS SYNDROME	LEGIUS SYNDROME	611431
NEUROFIBROMATOSIS TYPE 1-LIKE SYNDROME; NFLS	LEGIUS SYNDROME	611431
DEAFNESS, AUTOSOMAL RECESSIVE 63; DFNB63	DEAFNESS, AUTOSOMAL RECESSIVE 63; DFNB63	611451
TREMOR, HEREDITARY ESSENTIAL, 3; ETM3	TREMOR, HEREDITARY ESSENTIAL, 3; ETM3	611456
GALLBLADDER DISEASE 4; GBD4	GALLBLADDER DISEASE 4; GBD4	611465
COLORECTAL CANCER, SUSCEPTIBILITY TO, 2; CRCS2	COLORECTAL CANCER, SUSCEPTIBILITY TO, 2; CRCS2	611469
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 8q24	COLORECTAL CANCER, SUSCEPTIBILITY TO, 2; CRCS2	611469
MACULAR DEGENERATION, AGE-RELATED, 10; ARMD10	MACULAR DEGENERATION, AGE-RELATED, 10; ARMD10	611488
CORTICOSTEROID-BINDING GLOBULIN DEFICIENCY	CORTICOSTEROID-BINDING GLOBULIN DEFICIENCY	611489
CBG DEFICIENCY	CORTICOSTEROID-BINDING GLOBULIN DEFICIENCY	611489
TRANSCORTIN DEFICIENCYCORTICOSTEROID-BINDING GLOBULIN, ELEVATED, INCLUDED	CORTICOSTEROID-BINDING GLOBULIN DEFICIENCY	611489
OSTEOPETROSIS,  AUTOSOMAL RECESSIVE 4; OPTB4	OSTEOPETROSIS,  AUTOSOMAL RECESSIVE 4; OPTB4	611490
OSTEOPETROSIS, INFANTILE MALIGNANT 2	OSTEOPETROSIS,  AUTOSOMAL RECESSIVE 4; OPTB4	611490
ATRIAL FIBRILLATION, FAMILIAL, 4; ATFB4	ATRIAL FIBRILLATION, FAMILIAL, 4; ATFB4	611493
ATRIAL FIBRILLATION, FAMILIAL, 5; ATFB5	ATRIAL FIBRILLATION, FAMILIAL, 5; ATFB5	611494
OSTEOPETROSIS, AUTOSOMAL RECESSIVE 6; OPTB6	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 6; OPTB6	611497
OSTEOPETROSIS, AUTOSOMAL RECESSIVE, INTERMEDIATE FORM	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 6; OPTB6	611497
NEPHRONOPHTHISIS 7; NPHP7	NEPHRONOPHTHISIS 7; NPHP7	611498
FEBRILE SEIZURES, FAMILIAL, 7; FEB7	FEBRILE SEIZURES, FAMILIAL, 7; FEB7	611515
FEBRILE CONVULSIONS, FAMILIAL, 7; FEB7	FEBRILE SEIZURES, FAMILIAL, 7; FEB7	611515
IMMUNODEFICIENCY 35; IMD35	IMMUNODEFICIENCY 35; IMD35	611521
TYROSINE KINASE 2 DEFICIENCY	IMMUNODEFICIENCY 35; IMD35	611521
TYK2 DEFICIENCY	IMMUNODEFICIENCY 35; IMD35	611521
HYPER-IgE SYNDROME WITH ATYPICAL MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE	IMMUNODEFICIENCY 35; IMD35	611521
HIES WITH ATYPICAL MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE	IMMUNODEFICIENCY 35; IMD35	611521
INTRAOCULAR PRESSURE QUANTITATIVE TRAIT LOCUS; IOPQTL	INTRAOCULAR PRESSURE QUANTITATIVE TRAIT LOCUS; IOPQTL	611522
GLAUCOMA, SUSCEPTIBILITY TO	INTRAOCULAR PRESSURE QUANTITATIVE TRAIT LOCUS; IOPQTL	611522
PONTOCEREBELLAR HYPOPLASIA, TYPE 6; PCH6	PONTOCEREBELLAR HYPOPLASIA, TYPE 6; PCH6	611523
ENCEPHALOPATHY, FATAL INFANTILE, WITH MITOCHONDRIAL RESPIRATORY CHAINDEFECTS	PONTOCEREBELLAR HYPOPLASIA, TYPE 6; PCH6	611523
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 12; ARVD12	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 12; ARVD12	611528
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 12; ARVC12	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 12; ARVD12	611528
MAJOR AFFECTIVE DISORDER 5; MAFD5	MAJOR AFFECTIVE DISORDER 5; MAFD5	611535
BIPOLAR AFFECTIVE DISORDER; BPAD	MAJOR AFFECTIVE DISORDER 5; MAFD5	611535
MAJOR AFFECTIVE DISORDER 6; MAFD6	MAJOR AFFECTIVE DISORDER 6; MAFD6	611536
BIPOLAR AFFECTIVE DISORDER; BPAD	MAJOR AFFECTIVE DISORDER 6; MAFD6	611536
CAVITARY OPTIC DISC ANOMALIES; CODA	CAVITARY OPTIC DISC ANOMALIES; CODA	611543
CATARACT 17, MULTIPLE TYPES; CTRCT17	CATARACT 17, MULTIPLE TYPES; CTRCT17	611544
CATARACT, CONGENITAL NUCLEAR, AUTOSOMAL RECESSIVE 3; CATCN3	CATARACT 17, MULTIPLE TYPES; CTRCT17	611544
STATURE QUANTITATIVE TRAIT LOCUS 9; STQTL9	STATURE QUANTITATIVE TRAIT LOCUS 9; STQTL9	611547
PREMATURE OVARIAN FAILURE 5; POF5	PREMATURE OVARIAN FAILURE 5; POF5	611548
NOONAN SYNDROME 5; NS5	NOONAN SYNDROME 5; NS5	611553
LEOPARD SYNDROME 2; LPRD2	LEOPARD SYNDROME 2; LPRD2	611554
GLYCOGEN STORAGE DISEASE 0, MUSCLE; GSD0B	GLYCOGEN STORAGE DISEASE 0, MUSCLE; GSD0B	611556
GSD 0b	GLYCOGEN STORAGE DISEASE 0, MUSCLE; GSD0B	611556
; MUSCLE GLYCOGEN STORAGE DISEASE 0	GLYCOGEN STORAGE DISEASE 0, MUSCLE; GSD0B	611556
MUSCLE GLYCOGEN SYNTHASE DEFICIENCY	GLYCOGEN STORAGE DISEASE 0, MUSCLE; GSD0B	611556
JOUBERT SYNDROME 7; JBTS7	JOUBERT SYNDROME 7; JBTS7	611560
MECKEL SYNDROME, TYPE 5; MKS5	MECKEL SYNDROME, TYPE 5; MKS5	611561
OTOSCLEROSIS 4; OTSC4	OTOSCLEROSIS 4; OTSC4	611571
OTOSCLEROSIS 7; OTSC7	OTOSCLEROSIS 7; OTSC7	611572
WAARDENBURG SYNDROME, TYPE 2E; WS2E	WAARDENBURG SYNDROME, TYPE 2E; WS2E	611584
HYPOGONADOTROPIC HYPOGONADISM WITH ANOSMIA AND DEAFNESS, WITH OR WITHOUTHYPOPIGMENTATION	WAARDENBURG SYNDROME, TYPE 2E; WS2E	611584
WAARDENBURG SYNDROME, TYPE 2E, WITH OR WITHOUT NEUROLOGIC INVOLVEMENT	WAARDENBURG SYNDROME, TYPE 2E; WS2E	611584
WS2E, WITH OR WITHOUT NEUROLOGIC INVOLVEMENT	WAARDENBURG SYNDROME, TYPE 2E; WS2E	611584
WAARDENBURG SYNDROME, TYPE IIE	WAARDENBURG SYNDROME, TYPE 2E; WS2E	611584
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 4; MDDGC4	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 4; MDDGC4	611588
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2M; LGMD2M	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 4; MDDGC4	611588
RENAL TUBULAR ACIDOSIS, DISTAL, WITH HEMOLYTIC ANEMIA	RENAL TUBULAR ACIDOSIS, DISTAL, WITH HEMOLYTIC ANEMIA	611590
RTA, DISTAL, AUTOSOMAL RECESSIVE, WITH HEMOLYTIC ANEMIARENAL TUBULAR ACIDOSIS, DISTAL, WITH NORMAL RED CELL MORPHOLOGY, INCLUDED	RENAL TUBULAR ACIDOSIS, DISTAL, WITH HEMOLYTIC ANEMIA	611590
CATARACT 12, MULTIPLE TYPES; CTRCT12	CATARACT 12, MULTIPLE TYPES; CTRCT12	611597
CELIAC DISEASE, SUSCEPTIBILITY TO, 6; CELIAC6	CELIAC DISEASE, SUSCEPTIBILITY TO, 6; CELIAC6	611598
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 6AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 5, INCLUDED; AIS5, INCLUDED	CELIAC DISEASE, SUSCEPTIBILITY TO, 6; CELIAC6	611598
LISSENCEPHALY 3; LIS3	LISSENCEPHALY 3; LIS3	611603
CARDIOMYOPATHY, DILATED, 1X; CMD1X	CARDIOMYOPATHY, DILATED, 1X; CMD1X	611615
CARDIOMYOPATHY, DILATED, WITH MILD OR NO PROXIMAL MUSCLE WEAKNESS	CARDIOMYOPATHY, DILATED, 1X; CMD1X	611615
EPILEPSY, FAMILIAL TEMPORAL LOBE, 3; ETL3	EPILEPSY, FAMILIAL TEMPORAL LOBE, 3; ETL3	611630
EPILEPSY, FAMILIAL MESIAL TEMPORAL LOBE; FMTLE	EPILEPSY, FAMILIAL TEMPORAL LOBE, 3; ETL3	611630
EPILEPSY, FAMILIAL TEMPORAL LOBE, 4; ETL4	EPILEPSY, FAMILIAL TEMPORAL LOBE, 4; ETL4	611631
EPILEPSY, OCCIPITOTEMPORAL LOBE, AND MIGRAINE WITH AURA; EPOLM	EPILEPSY, FAMILIAL TEMPORAL LOBE, 4; ETL4	611631
FEBRILE SEIZURES, FAMILIAL, 9; FEB9	FEBRILE SEIZURES, FAMILIAL, 9; FEB9	611634
FEBRILE CONVULSIONS, FAMILIAL, 9; FEB9	FEBRILE SEIZURES, FAMILIAL, 9; FEB9	611634
PRIMARY LATERAL SCLEROSIS, ADULT, 1; PLSA1	PRIMARY LATERAL SCLEROSIS, ADULT, 1; PLSA1	611637
PLS, ADULT; PLSA	PRIMARY LATERAL SCLEROSIS, ADULT, 1; PLSA1	611637
MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 5; MCOPCB5	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 5; MCOPCB5	611638
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 9; HSCR9	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 9; HSCR9	611644
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 7; SHEP7	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 7; SHEP7	611664
SKIN/HAIR/EYE PIGMENTATION 7, BLOND/BROWN HAIR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 7; SHEP7	611664
SKIN/HAIR/EYE PIGMENTATION 7, DARK/LIGHT SKIN	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 7; SHEP7	611664
DYSTONIA WITH CEREBELLAR ATROPHY; DYTCA	DYSTONIA WITH CEREBELLAR ATROPHY; DYTCA	611694
MYOPATHY, EARLY-ONSET, WITH FATAL CARDIOMYOPATHY	MYOPATHY, EARLY-ONSET, WITH FATAL CARDIOMYOPATHY	611705
EOMFC	MYOPATHY, EARLY-ONSET, WITH FATAL CARDIOMYOPATHY	611705
MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 12; MGR12	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 12; MGR12	611706
SPONDYLOEPIPHYSEAL DYSPLASIA-BRACHYDACTYLY AND DISTINCTIVE SPEECH	SPONDYLOEPIPHYSEAL DYSPLASIA-BRACHYDACTYLY AND DISTINCTIVE SPEECH	611717
SED-BDS	SPONDYLOEPIPHYSEAL DYSPLASIA-BRACHYDACTYLY AND DISTINCTIVE SPEECH	611717
FANTASY ISLAND SYNDROME	SPONDYLOEPIPHYSEAL DYSPLASIA-BRACHYDACTYLY AND DISTINCTIVE SPEECH	611717
TATOO DYSPLASIA	SPONDYLOEPIPHYSEAL DYSPLASIA-BRACHYDACTYLY AND DISTINCTIVE SPEECH	611717
HYPOMAGNESEMIA 4, RENAL; HOMG4	HYPOMAGNESEMIA 4, RENAL; HOMG4	611718
HYPOMAGNESEMIA, RENAL, NORMOCALCIURIC	HYPOMAGNESEMIA 4, RENAL; HOMG4	611718
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 5; COXPD5	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 5; COXPD5	611719
COMBINED SAPOSIN DEFICIENCY	COMBINED SAPOSIN DEFICIENCY	611721
PROSAPOSIN DEFICIENCY; PSAPD	COMBINED SAPOSIN DEFICIENCY	611721
COMBINED SAP DEFICIENCY	COMBINED SAPOSIN DEFICIENCY	611721
KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY	KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY	611722
SAPOSIN A DEFICIENCY	KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY	611722
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 8; SHEP8	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 8; SHEP8	611724
SKIN/HAIR/EYE PIGMENTATION 8, BROWN HAIR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 8; SHEP8	611724
SKIN/HAIR/EYE PIGMENTATION 8, FAIR SKIN	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 8; SHEP8	611724
SKIN/HAIR/EYE PIGMENTATION 8, BLUE/LIGHT EYE COLOR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 8; SHEP8	611724
SKIN/HAIR/EYE PIGMENTATION 8, FRECKLING/SUNBURN	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 8; SHEP8	611724
EPILEPSY, PROGRESSIVE MYOCLONIC, 3, WITH OR WITHOUT INTRACELLULARINCLUSIONS; EPM3	EPILEPSY, PROGRESSIVE MYOCLONIC, 3, WITH OR WITHOUT INTRACELLULARINCLUSIONS; EPM3	611726
CEROID LIPOFUSCINOSIS, NEURONAL, 14; CLN14	EPILEPSY, PROGRESSIVE MYOCLONIC, 3, WITH OR WITHOUT INTRACELLULARINCLUSIONS; EPM3	611726
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 7; BMND7	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 7; BMND7	611738
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 8; BMND8	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 8; BMND8	611739
OSTEOPOROSIS, SUSCEPTIBILITY TO	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 8; BMND8	611739
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 9; SHEP9	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 9; SHEP9	611742
SKIN/HAIR/EYE PIGMENTATION 9, DARK/LIGHT HAIR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 9; SHEP9	611742
SKIN/HAIR/EYE PIGMENTATION 9, BROWN/NONBROWN EYES	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 9; SHEP9	611742
SKIN/HAIR/EYE PIGMENTATION 9, RED/NONRED HAIR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 9; SHEP9	611742
SKIN/HAIR/EYE PIGMENTATION 9, FRECKLING/SUNBURN	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 9; SHEP9	611742
LEBER CONGENITAL AMAUROSIS 10; LCA10	LEBER CONGENITAL AMAUROSIS 10; LCA10	611755
FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 2; FCAS2	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 2; FCAS2	611762
LIPOPROTEIN GLOMERULOPATHY; LPG	LIPOPROTEIN GLOMERULOPATHY; LPG	611771
ANGIOPATHY, HEREDITARY, WITH NEPHROPATHY, ANEURYSMS, AND MUSCLE CRAMPS;HANAC	ANGIOPATHY, HEREDITARY, WITH NEPHROPATHY, ANEURYSMS, AND MUSCLE CRAMPS;HANAC	611773
KAWASAKI DISEASE	KAWASAKI DISEASE	611775
KD	KAWASAKI DISEASE	611775
MUCOCUTANEOUS LYMPH NODE SYNDROME	KAWASAKI DISEASE	611775
INFANTILE POLYARTERITIS	KAWASAKI DISEASE	611775
BRUGADA SYNDROME 2; BRGDA2	BRUGADA SYNDROME 2; BRGDA2	611777
ERYTHROCYTOSIS, FAMILIAL, 4; ECYT4	ERYTHROCYTOSIS, FAMILIAL, 4; ECYT4	611783
AORTIC ANEURYSM, FAMILIAL THORACIC 6; AAT6	AORTIC ANEURYSM, FAMILIAL THORACIC 6; AAT6	611788
FAMILIAL THORACIC AORTIC ANEURYSM WITH LIVEDO RETICULARIS AND IRISFLOCCULI	AORTIC ANEURYSM, FAMILIAL THORACIC 6; AAT6	611788
ELLIPTOCYTOSIS 1; EL1	ELLIPTOCYTOSIS 1; EL1	611804
ELLIPTOCYTOSIS, RHESUS-LINKED TYPE	ELLIPTOCYTOSIS 1; EL1	611804
PROTEIN 4.1 OF ERYTHROCYTE MEMBRANE, DEFECT OF	ELLIPTOCYTOSIS 1; EL1	611804
4.1-MINUS TRAIT	ELLIPTOCYTOSIS 1; EL1	611804
4.1- TRAIT	ELLIPTOCYTOSIS 1; EL1	611804
BESTROPHINOPATHY, AUTOSOMAL RECESSIVE; ARB	BESTROPHINOPATHY, AUTOSOMAL RECESSIVE; ARB	611809
46,XX SEX REVERSAL WITH DYSGENESIS OF KIDNEYS, ADRENALS, AND LUNGS;SERKAL	46,XX SEX REVERSAL WITH DYSGENESIS OF KIDNEYS, ADRENALS, AND LUNGS;SERKAL	611812
SERKAL SYNDROME	46,XX SEX REVERSAL WITH DYSGENESIS OF KIDNEYS, ADRENALS, AND LUNGS;SERKAL	611812
TEMPLE-BARAITSER SYNDROME; TMBTS	TEMPLE-BARAITSER SYNDROME; TMBTS	611816
MENTAL RETARDATION, SEVERE, AND ABSENT NAILS OF HALLUX AND POLLEX	TEMPLE-BARAITSER SYNDROME; TMBTS	611816
LONG QT SYNDROME 9; LQT9	LONG QT SYNDROME 9; LQT9	611818
LONG QT SYNDROME 9, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	LONG QT SYNDROME 9; LQT9	611818
LONG QT SYNDROME 2/9, DIGENIC, INCLUDED; LQT2/9, DIGENIC, INCLUDED	LONG QT SYNDROME 9; LQT9	611818
LONG QT SYNDROME 10; LQT10ATRIAL FIBRILLATION, FAMILIAL, 17, INCLUDED; ATFB17, INCLUDED	LONG QT SYNDROME 10; LQT10ATRIAL FIBRILLATION, FAMILIAL, 17, INCLUDED; ATFB17, INCLUDED	611819
LONG QT SYNDROME 11; LQT11	LONG QT SYNDROME 11; LQT11	611820
WHITE BLOOD CELL COUNT QUANTITATIVE TRAIT LOCUS 1; WBCQ1	WHITE BLOOD CELL COUNT QUANTITATIVE TRAIT LOCUS 1; WBCQ1	611862
MICROTIA WITH NASOLACRIMAL DUCT IMPERFORATION AND EYE COLOBOMA	MICROTIA WITH NASOLACRIMAL DUCT IMPERFORATION AND EYE COLOBOMA	611863
CHROMOSOME 22q11.2 DELETION SYNDROME, DISTAL	CHROMOSOME 22q11.2 DELETION SYNDROME, DISTAL	611867
DISTAL CHROMOSOME 22q11.2 DELETION SYNDROME	CHROMOSOME 22q11.2 DELETION SYNDROME, DISTAL	611867
PROSTATE CANCER, HEREDITARY, 12; HPC12	PROSTATE CANCER, HEREDITARY, 12; HPC12	611868
BRUGADA SYNDROME 3; BRGDA3	BRUGADA SYNDROME 3; BRGDA3	611875
BRUGADA SYNDROME 4; BRGDA4	BRUGADA SYNDROME 4; BRGDA4	611876
CARDIOMYOPATHY, DILATED, 1Y; CMD1YLEFT VENTRICULAR NONCOMPACTION 9, INCLUDED; LVNC9, INCLUDED	CARDIOMYOPATHY, DILATED, 1Y; CMD1YLEFT VENTRICULAR NONCOMPACTION 9, INCLUDED; LVNC9, INCLUDED	611878
CARDIOMYOPATHY, DILATED, 1Z; CMD1Z	CARDIOMYOPATHY, DILATED, 1Z; CMD1Z	611879
CARDIOMYOPATHY, DILATED, 2A; CMD2A	CARDIOMYOPATHY, DILATED, 2A; CMD2A	611880
CARDIOMYOPATHY, DILATED, AUTOSOMAL RECESSIVE	CARDIOMYOPATHY, DILATED, 2A; CMD2A	611880
CARDIOMYOPATHY, CONGESTIVE, AUTOSOMAL RECESSIVE	CARDIOMYOPATHY, DILATED, 2A; CMD2A	611880
GLYCOGEN STORAGE DISEASE XII; GSD12	GLYCOGEN STORAGE DISEASE XII; GSD12	611881
GSD XII	GLYCOGEN STORAGE DISEASE XII; GSD12	611881
ALDOLASE A DEFICIENCY	GLYCOGEN STORAGE DISEASE XII; GSD12	611881
ALDOA DEFICIENCY	GLYCOGEN STORAGE DISEASE XII; GSD12	611881
ALDOLASE DEFICIENCY, RED CELL	GLYCOGEN STORAGE DISEASE XII; GSD12	611881
RED CELL ALDOLASE DEFICIENCY	GLYCOGEN STORAGE DISEASE XII; GSD12	611881
CILIARY DYSKINESIA, PRIMARY, 7; CILD7	CILIARY DYSKINESIA, PRIMARY, 7; CILD7	611884
CILIARY DYSKINESIA, PRIMARY, 7, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 7; CILD7	611884
LETHAL ARTHROGRYPOSIS WITH ANTERIOR HORN CELL DISEASE; LAAHD	LETHAL ARTHROGRYPOSIS WITH ANTERIOR HORN CELL DISEASE; LAAHD	611890
AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 3; AAA3	AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 3; AAA3	611891
ANEURYSM, INTRACRANIAL BERRY, 6; ANIB6	ANEURYSM, INTRACRANIAL BERRY, 6; ANIB6	611892
AMYOTROPHIC LATERAL SCLEROSIS 9; ALS9	AMYOTROPHIC LATERAL SCLEROSIS 9; ALS9	611895
NANOPHTHALMOS 3; NNO3	NANOPHTHALMOS 3; NNO3	611897
NANOPHTHALMIA 3	NANOPHTHALMOS 3; NNO3	611897
EPISODIC ATAXIA, TYPE 7; EA7	EPISODIC ATAXIA, TYPE 7; EA7	611907
CHROMOSOME 16p11.2 DELETION SYNDROME, 593-KBAUTISM, SUSCEPTIBILITY TO, 14A, INCLUDED; AUTS14A, INCLUDED	CHROMOSOME 16p11.2 DELETION SYNDROME, 593-KBAUTISM, SUSCEPTIBILITY TO, 14A, INCLUDED; AUTS14A, INCLUDED	611913
C-REACTIVE PROTEIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; CRPQTL1	C-REACTIVE PROTEIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; CRPQTL1	611920
IMMUNODEFICIENCY, OVARIAN DYSGENESIS, AND PULMONARY FIBROSIS	IMMUNODEFICIENCY, OVARIAN DYSGENESIS, AND PULMONARY FIBROSIS	611926
PROSTATE CANCER, HEREDITARY, 13; HPC13	PROSTATE CANCER, HEREDITARY, 13; HPC13	611928
CAMPTODACTYLY SYNDROME, GUADALAJARA, TYPE III	CAMPTODACTYLY SYNDROME, GUADALAJARA, TYPE III	611929
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 5; EIG5	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 5; EIG5	611934
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME10	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 5; EIG5	611934
CHROMOSOME 3q29 DUPLICATION SYNDROME	CHROMOSOME 3q29 DUPLICATION SYNDROME	611936
MICRODUPLICATION 3q29 SYNDROME	CHROMOSOME 3q29 DUPLICATION SYNDROME	611936
VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2	611938
VENTRICULAR TACHYCARDIA, STRESS-INDUCED POLYMORPHIC; VTSIP	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2	611938
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 6; ECA6EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 6, INCLUDED;EIG6, INCLUDED	EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 6; ECA6EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 6, INCLUDED;EIG6, INCLUDED	611942
RIDDLE SYNDROME	RIDDLE SYNDROME	611943
RADIOSENSITIVITY, IMMUNODEFICIENCY, DYSMORPHIC FEATURES, AND LEARNINGDIFFICULTIES	RIDDLE SYNDROME	611943
LYMPHEDEMA, HEREDITARY, IB; LMPH1B	LYMPHEDEMA, HEREDITARY, IB; LMPH1B	611944
SPASTIC PARAPLEGIA 37, AUTOSOMAL DOMINANT; SPG37	SPASTIC PARAPLEGIA 37, AUTOSOMAL DOMINANT; SPG37	611945
MACULAR DEGENERATION, AGE-RELATED, 11; ARMD11	MACULAR DEGENERATION, AGE-RELATED, 11; ARMD11	611953
PROSTATE CANCER, HEREDITARY, 11; HPC11	PROSTATE CANCER, HEREDITARY, 11; HPC11	611955
PROSTATE CANCER, HEREDITARY, 14; HPC14	PROSTATE CANCER, HEREDITARY, 14; HPC14	611958
PROSTATE CANCER, HEREDITARY, 15; HPC15	PROSTATE CANCER, HEREDITARY, 15; HPC15	611959
ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 7; ASRT7	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 7; ASRT7	611960
HUNTER-MACDONALD SYNDROME	HUNTER-MACDONALD SYNDROME	611962
CHROMOSOME 15q13.3 DELETION SYNDROME	CHROMOSOME 15q13.3 DELETION SYNDROME	612001
CHROMOSOME 15q13.3 MICRODELETION SYNDROME	CHROMOSOME 15q13.3 DELETION SYNDROME	612001
THROMBOCYTOPENIA 4; THC4	THROMBOCYTOPENIA 4; THC4	612004
THROMBOCYTOPENIA, AUTOSOMAL DOMINANT, 4	THROMBOCYTOPENIA 4; THC4	612004
CELIAC DISEASE, SUSCEPTIBILITY TO, 7; CELIAC7	CELIAC DISEASE, SUSCEPTIBILITY TO, 7; CELIAC7	612005
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 7	CELIAC DISEASE, SUSCEPTIBILITY TO, 7; CELIAC7	612005
CELIAC DISEASE, SUSCEPTIBILITY TO, 8; CELIAC8	CELIAC DISEASE, SUSCEPTIBILITY TO, 8; CELIAC8	612006
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 8	CELIAC DISEASE, SUSCEPTIBILITY TO, 8; CELIAC8	612006
CELIAC DISEASE, SUSCEPTIBILITY TO, 9; CELIAC9	CELIAC DISEASE, SUSCEPTIBILITY TO, 9; CELIAC9	612007
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 9	CELIAC DISEASE, SUSCEPTIBILITY TO, 9; CELIAC9	612007
CELIAC DISEASE, SUSCEPTIBILITY TO, 10; CELIAC10	CELIAC DISEASE, SUSCEPTIBILITY TO, 10; CELIAC10	612008
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 10	CELIAC DISEASE, SUSCEPTIBILITY TO, 10; CELIAC10	612008
CELIAC DISEASE, SUSCEPTIBILITY TO, 11; CELIAC11	CELIAC DISEASE, SUSCEPTIBILITY TO, 11; CELIAC11	612009
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 11	CELIAC DISEASE, SUSCEPTIBILITY TO, 11; CELIAC11	612009
CELIAC DISEASE, SUSCEPTIBILITY TO, 12; CELIAC12	CELIAC DISEASE, SUSCEPTIBILITY TO, 12; CELIAC12	612010
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 12	CELIAC DISEASE, SUSCEPTIBILITY TO, 12; CELIAC12	612010
CELIAC DISEASE, SUSCEPTIBILITY TO, 13; CELIAC13	CELIAC DISEASE, SUSCEPTIBILITY TO, 13; CELIAC13	612011
GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 13	CELIAC DISEASE, SUSCEPTIBILITY TO, 13; CELIAC13	612011
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE In; CDG1N	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE In; CDG1N	612015
CDG In; CDGIn	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE In; CDG1N	612015
COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4	COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4	612016
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9	COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4	612016
PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 3; IHPS3	PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 3; IHPS3	612017
CATARACT, JUVENILE, WITH MICROCORNEA AND GLUCOSURIA; CJMG	CATARACT, JUVENILE, WITH MICROCORNEA AND GLUCOSURIA; CJMG	612018
SPASTIC PARAPLEGIA 39, AUTOSOMAL RECESSIVE; SPG39	SPASTIC PARAPLEGIA 39, AUTOSOMAL RECESSIVE; SPG39	612020
NTE-RELATED MOTOR NEURON DISORDER; NTEMND	SPASTIC PARAPLEGIA 39, AUTOSOMAL RECESSIVE; SPG39	612020
CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 9; CHDS9	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 9; CHDS9	612030
RECOMBINATION RATE QUANTITATIVE TRAIT LOCUS 1; RRQTL1	RECOMBINATION RATE QUANTITATIVE TRAIT LOCUS 1; RRQTL1	612042
SMOKING AS A QUANTITATIVE TRAIT LOCUS 3; SQTL3	SMOKING AS A QUANTITATIVE TRAIT LOCUS 3; SQTL3	612052
NICOTINE DEPENDENCE, SUSCEPTIBILITY TOLUNG CANCER SUSCEPTIBILITY 2, INCLUDED; LNCR2, INCLUDED	SMOKING AS A QUANTITATIVE TRAIT LOCUS 3; SQTL3	612052
DYSTONIA 16; DYT16	DYSTONIA 16; DYT16	612067
AMYOTROPHIC LATERAL SCLEROSIS 10 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS10FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, TARDBP-RELATED,INCLUDED	AMYOTROPHIC LATERAL SCLEROSIS 10 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS10FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, TARDBP-RELATED,INCLUDED	612069
FRONTOTEMPORAL DEMENTIA WITH TDP43 INCLUSIONS, TARDBP-RELATED, INCLUDED	AMYOTROPHIC LATERAL SCLEROSIS 10 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS10FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, TARDBP-RELATED,INCLUDED	612069
FTLD-TDP, TARDBP-RELATED, INCLUDED	AMYOTROPHIC LATERAL SCLEROSIS 10 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS10FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, TARDBP-RELATED,INCLUDED	612069
MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH ORWITHOUT METHYLMALONIC ACIDURIA); MTDPS5	MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH ORWITHOUT METHYLMALONIC ACIDURIA); MTDPS5	612073
MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC FORM, WITHOR WITHOUT METHYLMALONIC ACIDURIA, AUTOSOMAL RECESSIVE, SUCLA2-RELATED	MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH ORWITHOUT METHYLMALONIC ACIDURIA); MTDPS5	612073
MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITHRENAL TUBULOPATHY); MTDPS8A	MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITHRENAL TUBULOPATHY); MTDPS8A	612075
MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC, WITH RENALTUBULOPATHY, AUTOSOMAL RECESSIVEMITOCHONDRIAL DNA DEPLETION SYNDROME 8B (MNGIE TYPE), INCLUDED; MTDPS8B,INCLUDED	MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITHRENAL TUBULOPATHY); MTDPS8A	612075
MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME, RRM2B-RELATED,INCLUDED	MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITHRENAL TUBULOPATHY); MTDPS8A	612075
MNGIE, RRM2B-RELATED, INCLUDED	MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITHRENAL TUBULOPATHY); MTDPS8A	612075
HYPOURICEMIA, RENAL, 2; RHUC2URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 2, INCLUDED;UAQTL2, INCLUDED	HYPOURICEMIA, RENAL, 2; RHUC2URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 2, INCLUDED;UAQTL2, INCLUDED	612076
GOUT SUSCEPTIBILITY 2, INCLUDED; GOUT2, INCLUDED	HYPOURICEMIA, RENAL, 2; RHUC2URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 2, INCLUDED;UAQTL2, INCLUDED	612076
ALOPECIA, NEUROLOGIC DEFECTS, AND ENDOCRINOPATHY SYNDROME; ANES	ALOPECIA, NEUROLOGIC DEFECTS, AND ENDOCRINOPATHY SYNDROME; ANES	612079
ANE SYNDROME	ALOPECIA, NEUROLOGIC DEFECTS, AND ENDOCRINOPATHY SYNDROME; ANES	612079
MUSCLE STRENGTH QUANTITATIVE TRAIT LOCUS 1	MUSCLE STRENGTH QUANTITATIVE TRAIT LOCUS 1	612083
MUSTQTL1	MUSCLE STRENGTH QUANTITATIVE TRAIT LOCUS 1	612083
HYPOPHOSPHATEMIC RICKETS AND HYPERPARATHYROIDISM	HYPOPHOSPHATEMIC RICKETS AND HYPERPARATHYROIDISM	612089
RETINITIS PIGMENTOSA 41; RP41	RETINITIS PIGMENTOSA 41; RP41	612095
RETINAL DEGENERATION, AUTOSOMAL RECESSIVE, PROMININ-RELATED	RETINITIS PIGMENTOSA 41; RP41	612095
OTOSCLEROSIS 8; OTSC8	OTOSCLEROSIS 8; OTSC8	612096
DEAFNESS, UNILATERAL, WITH DELAYED ENDOLYMPHATIC HYDROPS	DEAFNESS, UNILATERAL, WITH DELAYED ENDOLYMPHATIC HYDROPS	612097
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 11; CMH11	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 11; CMH11	612098
TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 2	TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 2	612099
MFT2	TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 2	612099
AUTISM, SUSCEPTIBILITY TO, 15; AUTS15	AUTISM, SUSCEPTIBILITY TO, 15; AUTS15	612100
FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 1; FGQTL1	FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 1; FGQTL1	612108
OCULOAURICULAR SYNDROME; OCACS	OCULOAURICULAR SYNDROME; OCACS	612109
MICROPHTHALMIA, MICROCORNEA, ANTERIOR SEGMENT DYSGENESIS, CATARACT,OCULAR COLOBOMA, RETINAL PIGMENT EPITHELIUM ABNORMALITIES, ROD-CONEDYSTROPHY, AND ANOMALIES OF THE EXTERNAL EAR	OCULOAURICULAR SYNDROME; OCACS	612109
SCHORDERET-MUNIER-FRANCESCHETTI SYNDROME	OCULOAURICULAR SYNDROME; OCACS	612109
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 9; BMND9	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 9; BMND9	612110
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 10; BMND10	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 10; BMND10	612113
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 11; BMND11	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 11; BMND11	612114
TREHALASE DEFICIENCY	TREHALASE DEFICIENCY	612119
TREHALOSE INTOLERANCE	TREHALASE DEFICIENCY	612119
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 12; CMH12	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 12; CMH12	612124
GLUT1 DEFICIENCY SYNDROME 2; GLUT1DS2	GLUT1 DEFICIENCY SYNDROME 2; GLUT1DS2	612126
PAROXYSMAL EXERCISE-INDUCED DYSKINESIA WITH OR WITHOUT EPILEPSY AND/ORHEMOLYTIC ANEMIA	GLUT1 DEFICIENCY SYNDROME 2; GLUT1DS2	612126
PED WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA	GLUT1 DEFICIENCY SYNDROME 2; GLUT1DS2	612126
PAROXYSMAL EXERTION-INDUCED DYSTONIA WITH OR WITHOUT EPILEPSY AND/ORHEMOLYTIC ANEMIA	GLUT1 DEFICIENCY SYNDROME 2; GLUT1DS2	612126
DYSTONIA 18; DYT18	GLUT1 DEFICIENCY SYNDROME 2; GLUT1DS2	612126
ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH T-CELL IMMUNODEFICIENCY, AUTOSOMALDOMINANT	ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH T-CELL IMMUNODEFICIENCY, AUTOSOMALDOMINANT	612132
EPIDERMOLYSIS BULLOSA SIMPLEX WITH PYLORIC ATRESIA; EBSPA	EPIDERMOLYSIS BULLOSA SIMPLEX WITH PYLORIC ATRESIA; EBSPA	612138
EBS WITH PYLORIC ATRESIA	EPIDERMOLYSIS BULLOSA SIMPLEX WITH PYLORIC ATRESIA; EBSPA	612138
CARDIOMYOPATHY, DILATED, 1AA, WITH OR WITHOUT LEFT VENTRICULAR NONCOMPACTION;CMD1AACARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 23, WITH OR WITHOUT VENTRICULARNONCOMPACTION, INCLUDED; CMH23, INCLUDED	CARDIOMYOPATHY, DILATED, 1AA, WITH OR WITHOUT LEFT VENTRICULAR NONCOMPACTION;CMD1AACARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 23, WITH OR WITHOUT VENTRICULARNONCOMPACTION, INCLUDED; CMH23, INCLUDED	612158
HISTIOCYTOMA, ANGIOMATOID FIBROUS	HISTIOCYTOMA, ANGIOMATOID FIBROUS	612160
ANEURYSM, INTRACRANIAL BERRY, 7; ANIB7	ANEURYSM, INTRACRANIAL BERRY, 7; ANIB7	612161
ANEURYSM, INTRACRANIAL BERRY, 8; ANIB8	ANEURYSM, INTRACRANIAL BERRY, 8; ANIB8	612162
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 4; EIEE4	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 4; EIEE4	612164
RETINITIS PIGMENTOSA 29; RP29	RETINITIS PIGMENTOSA 29; RP29	612165
DIASTASIS RECTI AND WEAKNESS OF THE LINEA ALBA	DIASTASIS RECTI AND WEAKNESS OF THE LINEA ALBA	612198
CEREBRORETINAL MICROANGIOPATHY WITH CALCIFICATIONS AND CYSTS; CRMCC	CEREBRORETINAL MICROANGIOPATHY WITH CALCIFICATIONS AND CYSTS; CRMCC	612199
COATS PLUS SYNDROME	CEREBRORETINAL MICROANGIOPATHY WITH CALCIFICATIONS AND CYSTS; CRMCC	612199
ATRIAL FIBRILLATION, FAMILIAL, 6; ATFB6	ATRIAL FIBRILLATION, FAMILIAL, 6; ATFB6	612201
EWING SARCOMA; ESNEUROEPITHELIOMA, PERIPHERAL, INCLUDED; PNE, INCLUDED	EWING SARCOMA; ESNEUROEPITHELIOMA, PERIPHERAL, INCLUDED; PNE, INCLUDED	612219
ASKIN TUMOR, INCLUDED	EWING SARCOMA; ESNEUROEPITHELIOMA, PERIPHERAL, INCLUDED; PNE, INCLUDED	612219
STATURE QUANTITATIVE TRAIT LOCUS 10; STQTL10	STATURE QUANTITATIVE TRAIT LOCUS 10; STQTL10	612221
STATURE QUANTITATIVE TRAIT LOCUS 11; STQTL11	STATURE QUANTITATIVE TRAIT LOCUS 11; STQTL11	612223
STATURE QUANTITATIVE TRAIT LOCUS 12; STQTL12	STATURE QUANTITATIVE TRAIT LOCUS 12; STQTL12	612224
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 9; MODY9	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 9; MODY9	612225
STATURE QUANTITATIVE TRAIT LOCUS 13; STQTL13	STATURE QUANTITATIVE TRAIT LOCUS 13; STQTL13	612226
DIABETES MELLITUS, KETOSIS-PRONE; KPD	DIABETES MELLITUS, KETOSIS-PRONE; KPD	612227
STATURE QUANTITATIVE TRAIT LOCUS 14; STQTL14	STATURE QUANTITATIVE TRAIT LOCUS 14; STQTL14	612228
COLORECTAL CANCER, SUSCEPTIBILITY TO, 3; CRCS3	COLORECTAL CANCER, SUSCEPTIBILITY TO, 3; CRCS3	612229
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 18	COLORECTAL CANCER, SUSCEPTIBILITY TO, 3; CRCS3	612229
COLORECTAL CANCER, SUSCEPTIBILITY TO, 5; CRCS5	COLORECTAL CANCER, SUSCEPTIBILITY TO, 5; CRCS5	612230
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 10	COLORECTAL CANCER, SUSCEPTIBILITY TO, 5; CRCS5	612230
COLORECTAL CANCER, SUSCEPTIBILITY TO, 6; CRCS6	COLORECTAL CANCER, SUSCEPTIBILITY TO, 6; CRCS6	612231
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 8q23	COLORECTAL CANCER, SUSCEPTIBILITY TO, 6; CRCS6	612231
COLORECTAL CANCER, SUSCEPTIBILITY TO, 7; CRCS7	COLORECTAL CANCER, SUSCEPTIBILITY TO, 7; CRCS7	612232
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 11	COLORECTAL CANCER, SUSCEPTIBILITY TO, 7; CRCS7	612232
LEUKODYSTROPHY, HYPOMYELINATING, 4; HLD4	LEUKODYSTROPHY, HYPOMYELINATING, 4; HLD4	612233
MITOCHONDRIAL HSP60 CHAPERONOPATHY	LEUKODYSTROPHY, HYPOMYELINATING, 4; HLD4	612233
MITCHAP60 DISEASE	LEUKODYSTROPHY, HYPOMYELINATING, 4; HLD4	612233
CHONDROSARCOMA, EXTRASKELETAL MYXOID	CHONDROSARCOMA, EXTRASKELETAL MYXOID	612237
EMC	CHONDROSARCOMA, EXTRASKELETAL MYXOID	612237
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 4; IS4	SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 4; IS4	612238
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 5; IS5	SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 5; IS5	612239
ATRIAL FIBRILLATION, FAMILIAL, 7; ATFB7	ATRIAL FIBRILLATION, FAMILIAL, 7; ATFB7	612240
INFLAMMATORY BOWEL DISEASE 12; IBD12	INFLAMMATORY BOWEL DISEASE 12; IBD12	612241
CHROMOSOME 10q23 DELETION SYNDROMEJUVENILE POLYPOSIS OF INFANCY, INCLUDED	CHROMOSOME 10q23 DELETION SYNDROMEJUVENILE POLYPOSIS OF INFANCY, INCLUDED	612242
JUVENILE POLYPOSIS, INFANTILE, INCLUDED	CHROMOSOME 10q23 DELETION SYNDROMEJUVENILE POLYPOSIS OF INFANCY, INCLUDED	612242
INFLAMMATORY BOWEL DISEASE 13; IBD13	INFLAMMATORY BOWEL DISEASE 13; IBD13	612244
INFLAMMATORY BOWEL DISEASE 14; IBD14	INFLAMMATORY BOWEL DISEASE 14; IBD14	612245
CROUZON SYNDROME WITH ACANTHOSIS NIGRICANS; CAN	CROUZON SYNDROME WITH ACANTHOSIS NIGRICANS; CAN	612247
CROUZONODERMOSKELETAL SYNDROME	CROUZON SYNDROME WITH ACANTHOSIS NIGRICANS; CAN	612247
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 10; SLEB10	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 10; SLEB10	612251
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 11; SLEB11	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 11; SLEB11	612253
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 12; SLEB12	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 12; SLEB12	612254
INFLAMMATORY BOWEL DISEASE 15; IBD15	INFLAMMATORY BOWEL DISEASE 15; IBD15	612255
INFLAMMATORY BOWEL DISEASE 16; IBD16	INFLAMMATORY BOWEL DISEASE 16; IBD16	612259
MYD88 DEFICIENCY; MYD88D	MYD88 DEFICIENCY; MYD88D	612260
PYOGENIC BACTERIAL INFECTIONS, RECURRENT, DUE TO MYD88 DEFICIENCY	MYD88 DEFICIENCY; MYD88D	612260
RECURRENT PYOGENIC BACTERIAL INFECTIONS DUE TO MYD88 DEFICIENCY	MYD88 DEFICIENCY; MYD88D	612260
INFLAMMATORY BOWEL DISEASE 17; IBD17	INFLAMMATORY BOWEL DISEASE 17; IBD17	612261
INFLAMMATORY BOWEL DISEASE 18; IBD18	INFLAMMATORY BOWEL DISEASE 18; IBD18	612262
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 7; CMM7	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 7; CMM7	612263
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 10; SHEP10	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 10; SHEP10	612267
SKIN/HAIR/EYE PIGMENTATION 10, BLOND/BROWN HAIR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 10; SHEP10	612267
EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 5; ECA5	EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 5; ECA5	612269
SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 11; SHEP11	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 11; SHEP11	612271
MELANESIAN BLOND HAIR	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 11; SHEP11	612271
SKIN/HAIR/EYE PIGMENTATION 11, BLUE/NONBLUE EYES	SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 11; SHEP11	612271
CILIARY DYSKINESIA, PRIMARY, 8; CILD8	CILIARY DYSKINESIA, PRIMARY, 8; CILD8	612274
CILIARY DYSKINESIA, PRIMARY, 8, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 8; CILD8	612274
INFLAMMATORY BOWEL DISEASE 19; IBD19	INFLAMMATORY BOWEL DISEASE 19; IBD19	612278
GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 6; GEFSP6	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 6; GEFSP6	612279
GEFS+, TYPE 6; GEFS+6	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 6; GEFSP6	612279
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 6; ARCI6	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 6; ARCI6	612281
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE, NIPAL4-RELATED	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 6; ARCI6	612281
MECKEL SYNDROME, TYPE 6; MKS6	MECKEL SYNDROME, TYPE 6; MKS6	612284
JOUBERT SYNDROME 9; JBTS9JOUBERT SYNDROME 9/15, DIGENIC, INCLUDED	JOUBERT SYNDROME 9; JBTS9JOUBERT SYNDROME 9/15, DIGENIC, INCLUDED	612285
NEPHROLITHIASIS/OSTEOPOROSIS, HYPOPHOSPHATEMIC, 1; NPHLOP1	NEPHROLITHIASIS/OSTEOPOROSIS, HYPOPHOSPHATEMIC, 1; NPHLOP1	612286
NEPHROLITHIASIS/OSTEOPOROSIS, HYPOPHOSPHATEMIC, 2; NPHLOP2	NEPHROLITHIASIS/OSTEOPOROSIS, HYPOPHOSPHATEMIC, 2; NPHLOP2	612287
INFLAMMATORY BOWEL DISEASE 20; IBD20	INFLAMMATORY BOWEL DISEASE 20; IBD20	612288
MICROTIA, HEARING IMPAIRMENT, AND CLEFT PALATEMICROTIA WITH OR WITHOUT HEARING IMPAIRMENT, INCLUDED	MICROTIA, HEARING IMPAIRMENT, AND CLEFT PALATEMICROTIA WITH OR WITHOUT HEARING IMPAIRMENT, INCLUDED	612290
JOUBERT SYNDROME 8; JBTS8	JOUBERT SYNDROME 8; JBTS8	612291
BIRK-BAREL MENTAL RETARDATION DYSMORPHISM SYNDROME	BIRK-BAREL MENTAL RETARDATION DYSMORPHISM SYNDROME	612292
BIRK-BAREL SYNDROME	BIRK-BAREL MENTAL RETARDATION DYSMORPHISM SYNDROME	612292
MENTAL RETARDATION WITH HYPOTONIA AND FACIAL DYSMORPHISM	BIRK-BAREL MENTAL RETARDATION DYSMORPHISM SYNDROME	612292
POROKERATOSIS 5, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK5	POROKERATOSIS 5, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK5	612293
POROKERATOSIS, DISSEMINATED SUPERFICIAL ACTINIC, 3; DSAP3	POROKERATOSIS 5, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK5	612293
HEMOLYTIC ANEMIA, CD59-MEDIATED, WITH OR WITHOUT IMMUNE-MEDIATED POLYNEUROPATHY;HACD59	HEMOLYTIC ANEMIA, CD59-MEDIATED, WITH OR WITHOUT IMMUNE-MEDIATED POLYNEUROPATHY;HACD59	612300
CD59 DEFICIENCY	HEMOLYTIC ANEMIA, CD59-MEDIATED, WITH OR WITHOUT IMMUNE-MEDIATED POLYNEUROPATHY;HACD59	612300
OSTEOPETROSIS, AUTOSOMAL RECESSIVE 7; OPTB7	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 7; OPTB7	612301
OSTEOPETROSIS, OSTEOCLAST-POOR, WITH HYPOGAMMAGLOBULINEMIA	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 7; OPTB7	612301
THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL RECESSIVE; THPH4	THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL RECESSIVE; THPH4	612304
PROTEIN C DEFICIENCY, AUTOSOMAL RECESSIVE	THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL RECESSIVE; THPH4	612304
PROC DEFICIENCY, AUTOSOMAL RECESSIVE	THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL RECESSIVE; THPH4	612304
THYROID-STIMULATING HORMONE LEVEL QUANTITATIVE TRAIT LOCUS 1; TSHQTL1	THYROID-STIMULATING HORMONE LEVEL QUANTITATIVE TRAIT LOCUS 1; TSHQTL1	612306
THYROTROPIN QUANTITATIVE TRAIT LOCUS 1	THYROID-STIMULATING HORMONE LEVEL QUANTITATIVE TRAIT LOCUS 1; TSHQTL1	612306
PREMATURE OVARIAN FAILURE 6; POF6	PREMATURE OVARIAN FAILURE 6; POF6	612310
ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 5	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 5	612311
ADHD5	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 5	612311
MOTOR TIMING QUANTITATIVE TRAIT LOCUS	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 5	612311
ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 6	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 6	612312
ADHD6	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 6	612312
DIGIT SPAN QUANTITATIVE TRAIT LOCUS	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 6	612312
GLASS SYNDROME; GLASS	GLASS SYNDROME; GLASS	612313
CHROMOSOME 2q32-q33 DELETION SYNDROME	GLASS SYNDROME; GLASS	612313
PSEUDOFOLLICULITIS BARBAE	PSEUDOFOLLICULITIS BARBAE	612318
PFB	PSEUDOFOLLICULITIS BARBAE	612318
PILI INCARNATI	PSEUDOFOLLICULITIS BARBAE	612318
INGROWN HAIRS	PSEUDOFOLLICULITIS BARBAE	612318
SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35	SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35	612319
FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION; FAHN	SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35	612319
LEUKODYSTROPHY, DYSMYELINATING, AND SPASTIC PARAPARESIS WITH OR WITHOUTDYSTONIA	SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35	612319
SPASTIC PARAPLEGIA 38, AUTOSOMAL DOMINANT; SPG38	SPASTIC PARAPLEGIA 38, AUTOSOMAL DOMINANT; SPG38	612335
THROMBOPHILIA DUE TO PROTEIN S DEFICIENCY, AUTOSOMAL DOMINANT; THPH5	THROMBOPHILIA DUE TO PROTEIN S DEFICIENCY, AUTOSOMAL DOMINANT; THPH5	612336
MENTAL RETARDATION, AUTOSOMAL DOMINANT 22; MRD22CHROMOSOME 1q43-q44 DELETION SYNDROME, INCLUDED	MENTAL RETARDATION, AUTOSOMAL DOMINANT 22; MRD22CHROMOSOME 1q43-q44 DELETION SYNDROME, INCLUDED	612337
CHROMOSOME 1qter DELETION SYNDROME, INCLUDED	MENTAL RETARDATION, AUTOSOMAL DOMINANT 22; MRD22CHROMOSOME 1q43-q44 DELETION SYNDROME, INCLUDED	612337
MUSICAL APTITUDE QUANTITATIVE TRAIT LOCUS	MUSICAL APTITUDE QUANTITATIVE TRAIT LOCUS	612343
CHROMOSOME 2q31.2 DELETION SYNDROME	CHROMOSOME 2q31.2 DELETION SYNDROME	612345
JERVELL AND LANGE-NIELSEN SYNDROME 2; JLNS2	JERVELL AND LANGE-NIELSEN SYNDROME 2; JLNS2	612347
THROMBOPHILIA, FAMILIAL, DUE TO DECREASED RELEASE OF TISSUE PLASMINOGENACTIVATOR; THPH9HYPERFIBRINOLYSIS, FAMILIAL, DUE TO INCREASED RELEASE OF TISSUE PLASMINOGENACTIVATOR, INCLUDED	THROMBOPHILIA, FAMILIAL, DUE TO DECREASED RELEASE OF TISSUE PLASMINOGENACTIVATOR; THPH9HYPERFIBRINOLYSIS, FAMILIAL, DUE TO INCREASED RELEASE OF TISSUE PLASMINOGENACTIVATOR, INCLUDED	612348
SPONDYLOCHEIRODYSPLASIA, EHLERS-DANLOS SYNDROME-LIKE	SPONDYLOCHEIRODYSPLASIA, EHLERS-DANLOS SYNDROME-LIKE	612350
SCD-EDS	SPONDYLOCHEIRODYSPLASIA, EHLERS-DANLOS SYNDROME-LIKE	612350
POROKERATOSIS 6, MULTIPLE TYPES; POROK6	POROKERATOSIS 6, MULTIPLE TYPES; POROK6	612353
POROKERATOSIS 6, DISSEMINATED SUPERFICIAL	POROKERATOSIS 6, MULTIPLE TYPES; POROK6	612353
POROKERATOSIS, DISSEMINATED SUPERFICIAL ACTINIC, 4; DSAP4	POROKERATOSIS 6, MULTIPLE TYPES; POROK6	612353
INFLAMMATORY BOWEL DISEASE 21; IBD21	INFLAMMATORY BOWEL DISEASE 21; IBD21	612354
HEPARIN COFACTOR II DEFICIENCY	HEPARIN COFACTOR II DEFICIENCY	612356
THROMBOPHILIA DUE TO HEPARIN COFACTOR II DEFICIENCY; THPH10	HEPARIN COFACTOR II DEFICIENCY	612356
HCF II DEFICIENCY	HEPARIN COFACTOR II DEFICIENCY	612356
HCF2 DEFICIENCY	HEPARIN COFACTOR II DEFICIENCY	612356
MAJOR AFFECTIVE DISORDER 8; MAFD8	MAJOR AFFECTIVE DISORDER 8; MAFD8	612357
BIPOLAR AFFECTIVE DISORDER	MAJOR AFFECTIVE DISORDER 8; MAFD8	612357
COWDEN SYNDROME 2; CWS2	COWDEN SYNDROME 2; CWS2	612359
SCHIZOPHRENIA 14	SCHIZOPHRENIA 14	612361
SCZD14	SCHIZOPHRENIA 14	612361
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 2q32-RELATED	SCHIZOPHRENIA 14	612361
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 12; BMIQ12	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 12; BMIQ12	612362
OBESITY, SUSCEPTIBILITY TO	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 12; BMIQ12	612362
ALANINE AMINOTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS1	ALANINE AMINOTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS1	612363
ALTQTL1	ALANINE AMINOTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS1	612363
ALANINE AMINOTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS2	ALANINE AMINOTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS2	612364
ALTQTL2	ALANINE AMINOTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS2	612364
GAMMA GLUTAMYLTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS1	GAMMA GLUTAMYLTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS1	612365
GGTQTL1	GAMMA GLUTAMYLTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS1	612365
GAMMA GLUTAMYLTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS2	GAMMA GLUTAMYLTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS2	612366
GGTQTL2	GAMMA GLUTAMYLTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS2	612366
ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 2	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 2	612367
ALPQTL2	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 2	612367
ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 3	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 3	612368
ALPQTL3	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 3	612368
ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 4	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 4	612369
ALPQTL4	ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 4	612369
HYPOGONADOTROPIC HYPOGONADISM 5 WITH OR WITHOUT ANOSMIA; HH5	HYPOGONADOTROPIC HYPOGONADISM 5 WITH OR WITHOUT ANOSMIA; HH5	612370
MAJOR AFFECTIVE DISORDER 7; MAFD7	MAJOR AFFECTIVE DISORDER 7; MAFD7	612371
BIPOLAR AFFECTIVE DISORDER	MAJOR AFFECTIVE DISORDER 7; MAFD7	612371
MAJOR AFFECTIVE DISORDER 9; MAFD9	MAJOR AFFECTIVE DISORDER 9; MAFD9	612372
BIPOLAR AFFECTIVE DISORDER	MAJOR AFFECTIVE DISORDER 9; MAFD9	612372
ACUTE PROMYELOCYTIC LEUKEMIA; APL	ACUTE PROMYELOCYTIC LEUKEMIA; APL	612376
LEUKEMIA, ACUTE PROMYELOCYTIC	ACUTE PROMYELOCYTIC LEUKEMIA; APL	612376
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 13; SLEB13	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 13; SLEB13	612378
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iq; CDG1Q	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iq; CDG1Q	612379
COLOBOMA, OCULAR, WITH ICHTHYOSIS, BRAIN MALFORMATIONS, AND ENDOCRINEABNORMALITIES	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iq; CDG1Q	612379
CDG Iq; CDGIq	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iq; CDG1Q	612379
INFLAMMATORY BOWEL DISEASE 22; IBD22	INFLAMMATORY BOWEL DISEASE 22; IBD22	612380
INFLAMMATORY BOWEL DISEASE 23; IBD23	INFLAMMATORY BOWEL DISEASE 23; IBD23	612381
SARCOIDOSIS, SUSCEPTIBILITY TO, 2; SS2	SARCOIDOSIS, SUSCEPTIBILITY TO, 2; SS2	612387
SARCOIDOSIS, SUSCEPTIBILITY TO, 3; SS3	SARCOIDOSIS, SUSCEPTIBILITY TO, 3; SS3	612388
PONTOCEREBELLAR HYPOPLASIA, TYPE 2B; PCH2B	PONTOCEREBELLAR HYPOPLASIA, TYPE 2B; PCH2B	612389
PONTOCEREBELLAR HYPOPLASIA, TYPE 2C; PCH2C	PONTOCEREBELLAR HYPOPLASIA, TYPE 2C; PCH2C	612390
BONE FRAGILITY WITH CONTRACTURES, ARTERIAL RUPTURE, AND DEAFNESS	BONE FRAGILITY WITH CONTRACTURES, ARTERIAL RUPTURE, AND DEAFNESS	612394
LYSYL HYDROXYLASE 3 DEFICIENCY	BONE FRAGILITY WITH CONTRACTURES, ARTERIAL RUPTURE, AND DEAFNESS	612394
LH3 DEFICIENCY	BONE FRAGILITY WITH CONTRACTURES, ARTERIAL RUPTURE, AND DEAFNESS	612394
OSTEOARTHRITIS SUSCEPTIBILITY 5; OS5	OSTEOARTHRITIS SUSCEPTIBILITY 5; OS5	612400
OSTEOARTHRITIS OF HIP	OSTEOARTHRITIS SUSCEPTIBILITY 5; OS5	612400
OSTEOARTHRITIS SUSCEPTIBILITY 6; OS6	OSTEOARTHRITIS SUSCEPTIBILITY 6; OS6	612401
OSTEOARTHRITIS OF KNEE	OSTEOARTHRITIS SUSCEPTIBILITY 6; OS6	612401
DYSTONIA 17, TORSION, AUTOSOMAL RECESSIVE; DYT17	DYSTONIA 17, TORSION, AUTOSOMAL RECESSIVE; DYT17	612406
PSORIASIS 10, SUSCEPTIBILITY TO; PSORS10	PSORIASIS 10, SUSCEPTIBILITY TO; PSORS10	612410
FACTOR XI DEFICIENCY	FACTOR XI DEFICIENCY	612416
F11 DEFICIENCY	FACTOR XI DEFICIENCY	612416
PLASMA THROMBOPLASTIN ANTECEDENT DEFICIENCY	FACTOR XI DEFICIENCY	612416
PTA DEFICIENCY	FACTOR XI DEFICIENCY	612416
ROSENTHAL SYNDROME	FACTOR XI DEFICIENCY	612416
NARCOLEPSY 4, SUSCEPTIBILITY TO; NRCLP4	NARCOLEPSY 4, SUSCEPTIBILITY TO; NRCLP4	612417
ALOPECIA, ANDROGENETIC, 3; AGA3	ALOPECIA, ANDROGENETIC, 3; AGA3	612421
CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 3; RCM3	CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 3; RCM3	612422
PREKALLIKREIN DEFICIENCY	PREKALLIKREIN DEFICIENCY	612423
PKK DEFICIENCY	PREKALLIKREIN DEFICIENCY	612423
FLETCHER FACTOR DEFICIENCY	PREKALLIKREIN DEFICIENCY	612423
DEAFNESS, AUTOSOMAL DOMINANT 27; DFNA27	DEAFNESS, AUTOSOMAL DOMINANT 27; DFNA27	612431
DEAFNESS, AUTOSOMAL RECESSIVE 45; DFNB45	DEAFNESS, AUTOSOMAL RECESSIVE 45; DFNB45	612433
EPILEPSY, PROGRESSIVE MYOCLONIC, 1B; EPM1B	EPILEPSY, PROGRESSIVE MYOCLONIC, 1B; EPM1B	612437
LEUKODYSTROPHY, HYPOMYELINATING, 6; HLD6	LEUKODYSTROPHY, HYPOMYELINATING, 6; HLD6	612438
LEUKODYSTROPHY, HYPOMYELINATING, WITH ATROPHY OF THE BASAL GANGLIAAND CEREBELLUM; HABC	LEUKODYSTROPHY, HYPOMYELINATING, 6; HLD6	612438
CILIARY DYSKINESIA, PRIMARY, 9; CILD9	CILIARY DYSKINESIA, PRIMARY, 9; CILD9	612444
CILIARY DYSKINESIA, PRIMARY, 9, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 9; CILD9	612444
COMPLEMENT COMPONENT 6 DEFICIENCY; C6D	COMPLEMENT COMPONENT 6 DEFICIENCY; C6D	612446
C6 DEFICIENCYCOMPLEMENT COMPONENT 6 DEFICIENCY, SUBTOTAL, INCLUDED	COMPLEMENT COMPONENT 6 DEFICIENCY; C6D	612446
C6 DEFICIENCY, SUBTOTAL, INCLUDED	COMPLEMENT COMPONENT 6 DEFICIENCY; C6D	612446
SKELETAL DEFECTS, GENITAL HYPOPLASIA, AND MENTAL RETARDATION	SKELETAL DEFECTS, GENITAL HYPOPLASIA, AND MENTAL RETARDATION	612447
AGE-RELATED HEARING IMPAIRMENT 1; ARHI1	AGE-RELATED HEARING IMPAIRMENT 1; ARHI1	612448
PRESBYCUSIS 1	AGE-RELATED HEARING IMPAIRMENT 1; ARHI1	612448
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 13; BMIQ13	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 13; BMIQ13	612459
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 14; BMIQ14	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 14; BMIQ14	612460
PSEUDOHYPOPARATHYROIDISM, TYPE IC; PHP1C	PSEUDOHYPOPARATHYROIDISM, TYPE IC; PHP1C	612462
PHP IC	PSEUDOHYPOPARATHYROIDISM, TYPE IC; PHP1C	612462
PSEUDOPSEUDOHYPOPARATHYROIDISM; PPHP	PSEUDOPSEUDOHYPOPARATHYROIDISM; PPHP	612463
ALBRIGHT HEREDITARY OSTEODYSTROPHY WITHOUT MULTIPLE HORMONE RESISTANCE	PSEUDOPSEUDOHYPOPARATHYROIDISM; PPHP	612463
WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, MENTAL RETARDATION,AND OBESITY SYNDROME; WAGRO	WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, MENTAL RETARDATION,AND OBESITY SYNDROME; WAGRO	612469
WAGRO SYNDROME	WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, MENTAL RETARDATION,AND OBESITY SYNDROME; WAGRO	612469
WAGR SYNDROME WITH OBESITY	WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, MENTAL RETARDATION,AND OBESITY SYNDROME; WAGRO	612469
CHROMOSOME 11p13-p12 DELETION SYNDROME	WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, MENTAL RETARDATION,AND OBESITY SYNDROME; WAGRO	612469
CHROMOSOME 1q21.1 DELETION SYNDROME, 1.35-MB	CHROMOSOME 1q21.1 DELETION SYNDROME, 1.35-MB	612474
CHROMOSOME 1q21.1 DUPLICATION SYNDROME	CHROMOSOME 1q21.1 DUPLICATION SYNDROME	612475
CHROMOSOME 2p16.1-p15 DELETION SYNDROME	CHROMOSOME 2p16.1-p15 DELETION SYNDROME	612513
SPECIFIC LANGUAGE IMPAIRMENT 4; SLI4	SPECIFIC LANGUAGE IMPAIRMENT 4; SLI4	612514
CILIARY DYSKINESIA, PRIMARY, 10; CILD10	CILIARY DYSKINESIA, PRIMARY, 10; CILD10	612518
CILIARY DYSKINESIA, PRIMARY, 10, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 10; CILD10	612518
DIABETES MELLITUS, INSULIN-DEPENDENT, 20; IDDM20	DIABETES MELLITUS, INSULIN-DEPENDENT, 20; IDDM20	612520
DIABETES MELLITUS, INSULIN-DEPENDENT, 21; IDDM21	DIABETES MELLITUS, INSULIN-DEPENDENT, 21; IDDM21	612521
DIABETES MELLITUS, INSULIN-DEPENDENT, 22; IDDM22	DIABETES MELLITUS, INSULIN-DEPENDENT, 22; IDDM22	612522
PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 5; IHPS5	PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 5; IHPS5	612525
LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 3; CGL3	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 3; CGL3	612526
BERARDINELLI-SEIP CONGENITAL LIPODYSTROPHY, TYPE 3; BSCL3	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 3; CGL3	612526
LIPODYSTROPHY, BERARDINELLI-SEIP CONGENITAL, TYPE 3	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 3; CGL3	612526
DIAMOND-BLACKFAN ANEMIA 4; DBA4	DIAMOND-BLACKFAN ANEMIA 4; DBA4	612527
DIAMOND-BLACKFAN ANEMIA 5; DBA5	DIAMOND-BLACKFAN ANEMIA 5; DBA5	612528
AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA2; AI2A2	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA2; AI2A2	612529
AMELOGENESIS IMPERFECTA, PIGMENTED HYPOMATURATION TYPE, 2	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA2; AI2A2	612529
CHROMOSOME 1q41-q42 DELETION SYNDROME	CHROMOSOME 1q41-q42 DELETION SYNDROME	612530
HOLOPROSENCEPHALY 10, INCLUDED; HPE10, INCLUDED	CHROMOSOME 1q41-q42 DELETION SYNDROME	612530
SPASTIC PARAPLEGIA 42, AUTOSOMAL DOMINANT; SPG42	SPASTIC PARAPLEGIA 42, AUTOSOMAL DOMINANT; SPG42	612539
MYOPATHY, CONGENITAL, COMPTON-NORTH; MYPCN	MYOPATHY, CONGENITAL, COMPTON-NORTH; MYPCN	612540
NEUTROPENIA, SEVERE CONGENITAL, 4, AUTOSOMAL RECESSIVE; SCN4DURSUN SYNDROME, INCLUDED	NEUTROPENIA, SEVERE CONGENITAL, 4, AUTOSOMAL RECESSIVE; SCN4DURSUN SYNDROME, INCLUDED	612541
PULMONARY ARTERIAL HYPERTENSION, LEUKOPENIA, AND ATRIAL SEPTAL DEFECT,INCLUDED	NEUTROPENIA, SEVERE CONGENITAL, 4, AUTOSOMAL RECESSIVE; SCN4DURSUN SYNDROME, INCLUDED	612541
VITAMIN B12 PLASMA LEVEL QUANTITATIVE TRAIT LOCUS 1; B12QTL1	VITAMIN B12 PLASMA LEVEL QUANTITATIVE TRAIT LOCUS 1; B12QTL1	612542
FOCAL SEGMENTAL GLOMERULOSCLEROSIS 4, SUSCEPTIBILITY TO; FSGS4	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 4, SUSCEPTIBILITY TO; FSGS4	612551
END-STAGE RENAL DISEASE, NONDIABETIC, SUSCEPTIBILITY TO, INCLUDED	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 4, SUSCEPTIBILITY TO; FSGS4	612551
MYOPIA 16, AUTOSOMAL DOMINANT; MYP16	MYOPIA 16, AUTOSOMAL DOMINANT; MYP16	612554
BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2; BROVCA2BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2, INCLUDED	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2; BROVCA2BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2, INCLUDED	612555
OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2, INCLUDED	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2; BROVCA2BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2, INCLUDED	612555
ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; ADIPQTL1ADIPONECTIN DEFICIENCY, INCLUDED	ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; ADIPQTL1ADIPONECTIN DEFICIENCY, INCLUDED	612556
HYPOADIPONECTINEMIA, INCLUDED	ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; ADIPQTL1ADIPONECTIN DEFICIENCY, INCLUDED	612556
LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 3	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 3	612557
CLLS3	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 3	612557
LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 4	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 4	612558
CLLS4	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 4	612558
LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 5	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 5	612559
CLLS5	LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 5	612559
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 12; BMND12	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 12; BMND12	612560
DIAMOND-BLACKFAN ANEMIA 6; DBA6	DIAMOND-BLACKFAN ANEMIA 6; DBA6	612561
AASE-SMITH SYNDROME II	DIAMOND-BLACKFAN ANEMIA 6; DBA6	612561
DIAMOND-BLACKFAN ANEMIA 7; DBA7	DIAMOND-BLACKFAN ANEMIA 7; DBA7	612562
DIAMOND-BLACKFAN ANEMIA 8; DBA8	DIAMOND-BLACKFAN ANEMIA 8; DBA8	612563
INFLAMMATORY BOWEL DISEASE 24; IBD24	INFLAMMATORY BOWEL DISEASE 24; IBD24	612566
INFLAMMATORY BOWEL DISEASE 25, AUTOSOMAL RECESSIVE; IBD25	INFLAMMATORY BOWEL DISEASE 25, AUTOSOMAL RECESSIVE; IBD25	612567
INFLAMMATORY BOWEL DISEASE, EARLY-ONSET, AUTOSOMAL RECESSIVE	INFLAMMATORY BOWEL DISEASE 25, AUTOSOMAL RECESSIVE; IBD25	612567
LUNG CANCER SUSCEPTIBILITY 3; LNCR3	LUNG CANCER SUSCEPTIBILITY 3; LNCR3	612571
ADENOCARCINOMA OF LUNG, SUSCEPTIBILITY TO	LUNG CANCER SUSCEPTIBILITY 3; LNCR3	612571
RETINITIS PIGMENTOSA 46; RP46	RETINITIS PIGMENTOSA 46; RP46	612572
RETINITIS PIGMENTOSA, AUTOSOMAL RECESSIVE, IDH3B-RELATED	RETINITIS PIGMENTOSA 46; RP46	612572
MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 1; MPVQTL1	MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 1; MPVQTL1	612573
MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 2; MPVQTL2	MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 2; MPVQTL2	612574
PLATELET COUNT QUANTITATIVE TRAIT LOCUS 1	MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 2; MPVQTL2	612574
MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 3; MPVQTL3	MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 3; MPVQTL3	612575
CHROMOSOME 17p13.3, TELOMERIC, DUPLICATION SYNDROME	CHROMOSOME 17p13.3, TELOMERIC, DUPLICATION SYNDROME	612576
SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 3; SHFLD3	CHROMOSOME 17p13.3, TELOMERIC, DUPLICATION SYNDROME	612576
AMYOTROPHIC LATERAL SCLEROSIS 11; ALS11	AMYOTROPHIC LATERAL SCLEROSIS 11; ALS11	612577
STATURE QUANTITATIVE TRAIT LOCUS 15; STQTL15	STATURE QUANTITATIVE TRAIT LOCUS 15; STQTL15	612578
STATURE QUANTITATIVE TRAIT LOCUS 16; STQTL16	STATURE QUANTITATIVE TRAIT LOCUS 16; STQTL16	612579
MENTAL RETARDATION, AUTOSOMAL DOMINANT 3; MRD3	MENTAL RETARDATION, AUTOSOMAL DOMINANT 3; MRD3	612580
MENTAL RETARDATION, AUTOSOMAL DOMINANT 4; MRD4	MENTAL RETARDATION, AUTOSOMAL DOMINANT 4; MRD4	612581
CHROMOSOME 6pter-p24 DELETION SYNDROME	CHROMOSOME 6pter-p24 DELETION SYNDROME	612582
ANEURYSM, INTRACRANIAL BERRY, 9; ANIB9	ANEURYSM, INTRACRANIAL BERRY, 9; ANIB9	612586
ANEURYSM, INTRACRANIAL BERRY, 10; ANIB10	ANEURYSM, INTRACRANIAL BERRY, 10; ANIB10	612587
COLORECTAL CANCER, SUSCEPTIBILITY TO, 8; CRCS8	COLORECTAL CANCER, SUSCEPTIBILITY TO, 8; CRCS8	612589
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 14q	COLORECTAL CANCER, SUSCEPTIBILITY TO, 8; CRCS8	612589
COLORECTAL CANCER, SUSCEPTIBILITY TO, 9; CRCS9	COLORECTAL CANCER, SUSCEPTIBILITY TO, 9; CRCS9	612590
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 16q	COLORECTAL CANCER, SUSCEPTIBILITY TO, 9; CRCS9	612590
COLORECTAL CANCER, SUSCEPTIBILITY TO, 10; CRCS10	COLORECTAL CANCER, SUSCEPTIBILITY TO, 10; CRCS10	612591
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 19q	COLORECTAL CANCER, SUSCEPTIBILITY TO, 10; CRCS10	612591
COLORECTAL CANCER, SUSCEPTIBILITY TO, 11; CRCS11	COLORECTAL CANCER, SUSCEPTIBILITY TO, 11; CRCS11	612592
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 20p	COLORECTAL CANCER, SUSCEPTIBILITY TO, 11; CRCS11	612592
LUNG CANCER SUSCEPTIBILITY 4; LNCR4	LUNG CANCER SUSCEPTIBILITY 4; LNCR4	612593
MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 2; MS2	MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 2; MS2	612594
MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 3; MS3	MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 3; MS3	612595
MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 4; MS4	MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 4; MS4	612596
PSORIASIS 11, SUSCEPTIBILITY TO; PSORS11	PSORIASIS 11, SUSCEPTIBILITY TO; PSORS11	612599
MENTAL RETARDATION, AUTOSOMAL DOMINANT 5; MRD5	MENTAL RETARDATION, AUTOSOMAL DOMINANT 5; MRD5	612621
DIABETES MELLITUS, INSULIN-DEPENDENT, 23; IDDM23	DIABETES MELLITUS, INSULIN-DEPENDENT, 23; IDDM23	612622
MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 2; MVCD2	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 2; MVCD2	612623
PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 2; MVCD2	612623
END-STAGE RENAL DISEASE, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 2; MVCD2	612623
MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3; MVCD3	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3; MVCD3	612624
NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3; MVCD3	612624
END-STAGE RENAL DISEASE, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3; MVCD3	612624
CHROMOSOME 15q26-qter DELETION SYNDROME	CHROMOSOME 15q26-qter DELETION SYNDROME	612626
DRAYER SYNDROME	CHROMOSOME 15q26-qter DELETION SYNDROME	612626
SEIZURES, BENIGN FAMILIAL INFANTILE, 4; BFIS4	SEIZURES, BENIGN FAMILIAL INFANTILE, 4; BFIS4	612627
CONVULSIONS, BENIGN FAMILIAL INFANTILE, 4; BFIC4	SEIZURES, BENIGN FAMILIAL INFANTILE, 4; BFIS4	612627
MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 4; MVCD4	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 4; MVCD4	612628
NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 4; MVCD4	612628
ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 4; ADIPQTL4	ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 4; ADIPQTL4	612629
HAIR MORPHOLOGY 1; HRM1	HAIR MORPHOLOGY 1; HRM1	612630
HAIR THICKNESS, VARIATION IN	HAIR MORPHOLOGY 1; HRM1	612630
ADENYLATE KINASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO	ADENYLATE KINASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO	612631
USHER SYNDROME, TYPE IH; USH1H	USHER SYNDROME, TYPE IH; USH1H	612632
MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5; MVCD5	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5; MVCD5	612633
RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5; MVCD5	612633
MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 6; MVCD6	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 6; MVCD6	612634
NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 6; MVCD6	612634
MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7; MVCD7	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7; MVCD7	612635
PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7; MVCD7	612635
NONPROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7; MVCD7	612635
NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO	MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7; MVCD7	612635
FEBRILE SEIZURES, FAMILIAL, 10; FEB10	FEBRILE SEIZURES, FAMILIAL, 10; FEB10	612637
CONVULSIONS, FAMILIAL FEBRILE, 10	FEBRILE SEIZURES, FAMILIAL, 10; FEB10	612637
INFLAMMATORY BOWEL DISEASE 26; IBD26	INFLAMMATORY BOWEL DISEASE 26; IBD26	612639
DEAFNESS, AUTOSOMAL DOMINANT 59; DFNA59	DEAFNESS, AUTOSOMAL DOMINANT 59; DFNA59	612642
DEAFNESS, AUTOSOMAL DOMINANT 3B; DFNA3B	DEAFNESS, AUTOSOMAL DOMINANT 3B; DFNA3B	612643
DEAFNESS, AUTOSOMAL DOMINANT 2B; DFNA2B	DEAFNESS, AUTOSOMAL DOMINANT 2B; DFNA2B	612644
DEAFNESS, AUTOSOMAL RECESSIVE 1B; DFNB1B	DEAFNESS, AUTOSOMAL RECESSIVE 1B; DFNB1B	612645
CILIARY DYSKINESIA, PRIMARY, 11; CILD11	CILIARY DYSKINESIA, PRIMARY, 11; CILD11	612649
CILIARY DYSKINESIA, PRIMARY, 11, WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 11; CILD11	612649
CILIARY DYSKINESIA, PRIMARY, 12; CILD12	CILIARY DYSKINESIA, PRIMARY, 12; CILD12	612650
CILIARY DYSKINESIA, PRIMARY, 12, WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 12; CILD12	612650
ENDOCRINE-CEREBROOSTEODYSPLASIA; ECO	ENDOCRINE-CEREBROOSTEODYSPLASIA; ECO	612651
SPHEROCYTOSIS, TYPE 4; SPH4	SPHEROCYTOSIS, TYPE 4; SPH4	612653
SPHEROCYTOSIS, HEREDITARY, 4; HS4	SPHEROCYTOSIS, TYPE 4; SPH4	612653
EPISODIC ATAXIA, TYPE 6; EA6	EPISODIC ATAXIA, TYPE 6; EA6	612656
CONE-ROD DYSTROPHY 12; CORD12	CONE-ROD DYSTROPHY 12; CORD12	612657
URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 4; UAQTL4	URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 4; UAQTL4	612671
GOUT SUSCEPTIBILITY 4; GOUT4	URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 4; UAQTL4	612671
POLYNEUROPATHY, HEARING LOSS, ATAXIA, RETINITIS PIGMENTOSA, AND CATARACT;PHARC	POLYNEUROPATHY, HEARING LOSS, ATAXIA, RETINITIS PIGMENTOSA, AND CATARACT;PHARC	612674
SPHEROCYTOSIS, TYPE 5; SPH5	SPHEROCYTOSIS, TYPE 5; SPH5	612690
SPHEROCYTOSIS, HEREDITARY, 5; HS5	SPHEROCYTOSIS, TYPE 5; SPH5	612690
POLYMICROGYRIA, BILATERAL TEMPOROOCCIPITAL; BTOP	POLYMICROGYRIA, BILATERAL TEMPOROOCCIPITAL; BTOP	612691
AGAMMAGLOBULINEMIA 6, AUTOSOMAL RECESSIVE; AGM6	AGAMMAGLOBULINEMIA 6, AUTOSOMAL RECESSIVE; AGM6	612692
AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO CD79B DEFECT	AGAMMAGLOBULINEMIA 6, AUTOSOMAL RECESSIVE; AGM6	612692
HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA; HH6	HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA; HH6	612702
MICROCEPHALY 7, PRIMARY, AUTOSOMAL RECESSIVE; MCPH7	MICROCEPHALY 7, PRIMARY, AUTOSOMAL RECESSIVE; MCPH7	612703
LEBER CONGENITAL AMAUROSIS 13; LCA13RETINITIS PIGMENTOSA 53, INCLUDED; RP53, INCLUDED	LEBER CONGENITAL AMAUROSIS 13; LCA13RETINITIS PIGMENTOSA 53, INCLUDED; RP53, INCLUDED	612712
KAHRIZI SYNDROME; KHRZ	KAHRIZI SYNDROME; KHRZ	612713
MENTAL RETARDATION, CATARACT, COLOBOMA, AND KYPHOSIS, AUTOSOMAL RECESSIVE	KAHRIZI SYNDROME; KHRZ	612713
EXOCRINE PANCREATIC INSUFFICIENCY, DYSERYTHROPOIETIC ANEMIA, AND CALVARIALHYPEROSTOSIS	EXOCRINE PANCREATIC INSUFFICIENCY, DYSERYTHROPOIETIC ANEMIA, AND CALVARIALHYPEROSTOSIS	612714
DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 2; DUH2	DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 2; DUH2	612715
DYSTONIA, DOPA-RESPONSIVE, DUE TO SEPIAPTERIN REDUCTASE DEFICIENCY	DYSTONIA, DOPA-RESPONSIVE, DUE TO SEPIAPTERIN REDUCTASE DEFICIENCY	612716
SEPIAPTERIN REDUCTASE DEFICIENCY; SRD	DYSTONIA, DOPA-RESPONSIVE, DUE TO SEPIAPTERIN REDUCTASE DEFICIENCY	612716
SPR DEFICIENCY	DYSTONIA, DOPA-RESPONSIVE, DUE TO SEPIAPTERIN REDUCTASE DEFICIENCY	612716
MYOPIA 15, AUTOSOMAL DOMINANT; MYP15	MYOPIA 15, AUTOSOMAL DOMINANT; MYP15	612717
CEREBRAL CREATINE DEFICIENCY SYNDROME 3; CCDS3	CEREBRAL CREATINE DEFICIENCY SYNDROME 3; CCDS3	612718
ARGININE:GLYCINE AMIDINOTRANSFERASE DEFICIENCY	CEREBRAL CREATINE DEFICIENCY SYNDROME 3; CCDS3	612718
AGAT DEFICIENCY	CEREBRAL CREATINE DEFICIENCY SYNDROME 3; CCDS3	612718
GATM DEFICIENCY	CEREBRAL CREATINE DEFICIENCY SYNDROME 3; CCDS3	612718
CREATINE DEFICIENCY SYNDROME DUE TO AGAT DEFICIENCY	CEREBRAL CREATINE DEFICIENCY SYNDROME 3; CCDS3	612718
HARDIKAR SYNDROME	HARDIKAR SYNDROME	612726
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 13; BMND13	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 13; BMND13	612727
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 14; BMND14	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 14; BMND14	612728
LEAN BODY MASS QUANTITATIVE TRAIT LOCUS 1; LBMQTL1	LEAN BODY MASS QUANTITATIVE TRAIT LOCUS 1; LBMQTL1	612729
FACIOCARDIOMELIC SYNDROME	FACIOCARDIOMELIC SYNDROME	612731
CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2	CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2	612736
GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY	CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2	612736
GAMT DEFICIENCY	CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2	612736
CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY	CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2	612736
STATURE QUANTITATIVE TRAIT LOCUS 17; STQTL17	STATURE QUANTITATIVE TRAIT LOCUS 17; STQTL17	612737
PORPHYRIA, ACUTE HEPATIC	PORPHYRIA, ACUTE HEPATIC	612740
DELTA-AMINOLEVULINATE DEHYDRATASE DEFICIENCY	PORPHYRIA, ACUTE HEPATIC	612740
ALAD DEFICIENCY	PORPHYRIA, ACUTE HEPATIC	612740
PORPHYRIA, ALAD	PORPHYRIA, ACUTE HEPATIC	612740
PORPHOBILINOGEN SYNTHASE DEFICIENCY	PORPHYRIA, ACUTE HEPATIC	612740
DOSS PORPHYRIALEAD POISONING, SUSCEPTIBILITY TO, INCLUDED	PORPHYRIA, ACUTE HEPATIC	612740
SYNESTHESIA	SYNESTHESIA	612759
SYNSTH	SYNESTHESIA	612759
CONE-ROD DYSTROPHY 9; CORD9	CONE-ROD DYSTROPHY 9; CORD9	612775
HYPOGLOSSIA WITH SITUS INVERSUSHYPOGLOSSIA, ISOLATED, INCLUDED	HYPOGLOSSIA WITH SITUS INVERSUSHYPOGLOSSIA, ISOLATED, INCLUDED	612776
SEIZURES, SENSORINEURAL DEAFNESS, ATAXIA, MENTAL RETARDATION, ANDELECTROLYTE IMBALANCE; SESAMES	SEIZURES, SENSORINEURAL DEAFNESS, ATAXIA, MENTAL RETARDATION, ANDELECTROLYTE IMBALANCE; SESAMES	612780
SESAME SYNDROME	SEIZURES, SENSORINEURAL DEAFNESS, ATAXIA, MENTAL RETARDATION, ANDELECTROLYTE IMBALANCE; SESAMES	612780
EPILEPSY, ATAXIA, SENSORINEURAL DEAFNESS, AND TUBULOPATHY	SEIZURES, SENSORINEURAL DEAFNESS, ATAXIA, MENTAL RETARDATION, ANDELECTROLYTE IMBALANCE; SESAMES	612780
EAST SYNDROME	SEIZURES, SENSORINEURAL DEAFNESS, ATAXIA, MENTAL RETARDATION, ANDELECTROLYTE IMBALANCE; SESAMES	612780
ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IB; IGHD1B	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IB; IGHD1B	612781
IGHD IB	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IB; IGHD1B	612781
DWARFISM OF SINDH	ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IB; IGHD1B	612781
IMMUNODEFICIENCY 9; IMD9	IMMUNODEFICIENCY 9; IMD9	612782
IMMUNE DYSFUNCTION WITH T-CELL INACTIVATION DUE TO CALCIUM ENTRY DEFECT1	IMMUNODEFICIENCY 9; IMD9	612782
IMMUNODEFICIENCY 10; IMD10	IMMUNODEFICIENCY 10; IMD10	612783
IMMUNE DYSFUNCTION WITH T-CELL INACTIVATION DUE TO CALCIUM ENTRY DEFECT2	IMMUNODEFICIENCY 10; IMD10	612783
STIM1 DEFICIENCY	IMMUNODEFICIENCY 10; IMD10	612783
DEAFNESS, AUTOSOMAL RECESSIVE 71; DFNB71	DEAFNESS, AUTOSOMAL RECESSIVE 71; DFNB71	612789
ATRIAL SEPTAL DEFECT 5; ASD5	ATRIAL SEPTAL DEFECT 5; ASD5	612794
POLYUNSATURATED FATTY ACIDS PLASMA LEVEL QUANTITATIVE TRAIT LOCUS1; PUFAQTL1	POLYUNSATURATED FATTY ACIDS PLASMA LEVEL QUANTITATIVE TRAIT LOCUS1; PUFAQTL1	612795
INFLAMMATORY BOWEL DISEASE 27; IBD27	INFLAMMATORY BOWEL DISEASE 27; IBD27	612796
HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS12; HDLCQ12	HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS12; HDLCQ12	612797
QUESTION MARK EARS, ISOLATED; QME	QUESTION MARK EARS, ISOLATED; QME	612798
EARS, PROMINENT AND CONSTRICTED	QUESTION MARK EARS, ISOLATED; QME	612798
COSMAN DEFORMITY OF THE AURICLE	QUESTION MARK EARS, ISOLATED; QME	612798
AURICULAR CLEFT, CONGENITAL	QUESTION MARK EARS, ISOLATED; QME	612798
SPONDYLOEPIMETAPHYSEAL DYSPLASIA, AGGRECAN TYPE	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, AGGRECAN TYPE	612813
SEMD, AGGRECAN TYPE	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, AGGRECAN TYPE	612813
BRUGADA SYNDROME 5; BRGDA5CARDIAC CONDUCTION DEFECT, NONSPECIFIC, INCLUDED	BRUGADA SYNDROME 5; BRGDA5CARDIAC CONDUCTION DEFECT, NONSPECIFIC, INCLUDED	612838
LEUKOCYTE ADHESION DEFICIENCY, TYPE III; LAD3	LEUKOCYTE ADHESION DEFICIENCY, TYPE III; LAD3	612840
LEUKOCYTE ADHESION DEFICIENCY 3	LEUKOCYTE ADHESION DEFICIENCY, TYPE III; LAD3	612840
LEUKOCYTE ADHESION DEFICIENCY 1 VARIANT; LAD1V	LEUKOCYTE ADHESION DEFICIENCY, TYPE III; LAD3	612840
INTEGRIN ACTIVATION DEFICIENCY DISEASE; IADD	LEUKOCYTE ADHESION DEFICIENCY, TYPE III; LAD3	612840
HYPOTRICHOSIS 5; HYPT5	HYPOTRICHOSIS 5; HYPT5	612841
MARIE UNNA HEREDITARY HYPOTRICHOSIS 2; MUHH2	HYPOTRICHOSIS 5; HYPT5	612841
KERATOSIS FOLLICULARIS SPINULOSA DECALVANS, AUTOSOMAL DOMINANT; KFSD	KERATOSIS FOLLICULARIS SPINULOSA DECALVANS, AUTOSOMAL DOMINANT; KFSD	612843
BRACHYOLMIA TYPE 4 WITH MILD EPIPHYSEAL AND METAPHYSEAL CHANGES; BCYM4	BRACHYOLMIA TYPE 4 WITH MILD EPIPHYSEAL AND METAPHYSEAL CHANGES; BCYM4	612847
SPONDYLOEPIMETAPHYSEAL DYSPLASIA, PAKISTANI TYPE	BRACHYOLMIA TYPE 4 WITH MILD EPIPHYSEAL AND METAPHYSEAL CHANGES; BCYM4	612847
SEMD, PAKISTANI TYPE	BRACHYOLMIA TYPE 4 WITH MILD EPIPHYSEAL AND METAPHYSEAL CHANGES; BCYM4	612847
SPONDYLODYSPLASIA AND PREMATURE PUBARCHE	BRACHYOLMIA TYPE 4 WITH MILD EPIPHYSEAL AND METAPHYSEAL CHANGES; BCYM4	612847
NARCOLEPSY 5, SUSCEPTIBILITY TO; NRCLP5	NARCOLEPSY 5, SUSCEPTIBILITY TO; NRCLP5	612851
OSTEOMYELITIS, STERILE MULTIFOCAL, WITH PERIOSTITIS AND PUSTULOSIS;OMPP	OSTEOMYELITIS, STERILE MULTIFOCAL, WITH PERIOSTITIS AND PUSTULOSIS;OMPP	612852
INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY; DIRA	OSTEOMYELITIS, STERILE MULTIFOCAL, WITH PERIOSTITIS AND PUSTULOSIS;OMPP	612852
RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 7; RLS7	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 7; RLS7	612853
OROFACIAL CLEFT 12; OFC12	OROFACIAL CLEFT 12; OFC12	612858
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 12	OROFACIAL CLEFT 12; OFC12	612858
PULMONARY HYPERTENSION, CHRONIC THROMBOEMBOLIC, WITHOUT DEEP VEINTHROMBOSIS, SUSCEPTIBILITY TO	PULMONARY HYPERTENSION, CHRONIC THROMBOEMBOLIC, WITHOUT DEEP VEINTHROMBOSIS, SUSCEPTIBILITY TO	612862
CTEPH, DVT-NEGATIVE, SUSCEPTIBILITY TO	PULMONARY HYPERTENSION, CHRONIC THROMBOEMBOLIC, WITHOUT DEEP VEINTHROMBOSIS, SUSCEPTIBILITY TO	612862
CHROMOSOME 6q24-q25 DELETION SYNDROME	CHROMOSOME 6q24-q25 DELETION SYNDROME	612863
CORNEAL DYSTROPHY, POSTERIOR AMORPHOUS; PACD	CORNEAL DYSTROPHY, POSTERIOR AMORPHOUS; PACD	612868
POSTERIOR AMORPHOUS CORNEAL DYSTROPHY	CORNEAL DYSTROPHY, POSTERIOR AMORPHOUS; PACD	612868
ERYTHROCYTE AMP DEAMINASE DEFICIENCY	ERYTHROCYTE AMP DEAMINASE DEFICIENCY	612874
SPINOCEREBELLAR ATAXIA 9; SCA9	SPINOCEREBELLAR ATAXIA 9; SCA9	612876
CARDIOMYOPATHY, DILATED, 1BB; CMD1BB	CARDIOMYOPATHY, DILATED, 1BB; CMD1BB	612877
CHROMOSOME 5q14.3 DELETION SYNDROME, DISTAL	CHROMOSOME 5q14.3 DELETION SYNDROME, DISTAL	612881
HETEROTOPIA, PERIVENTRICULAR, ASSOCIATED WITH CHROMOSOME 5q DELETION	CHROMOSOME 5q14.3 DELETION SYNDROME, DISTAL	612881
PERIVENTRICULAR NODULAR HETEROTOPIA 5; PVNH5	CHROMOSOME 5q14.3 DELETION SYNDROME, DISTAL	612881
MENARCHE, AGE AT, QUANTITATIVE TRAIT LOCUS 2; MENAQ2	MENARCHE, AGE AT, QUANTITATIVE TRAIT LOCUS 2; MENAQ2	612882
MENARCHE, AGE AT, QUANTITATIVE TRAIT LOCUS 3; MENAQ3	MENARCHE, AGE AT, QUANTITATIVE TRAIT LOCUS 3; MENAQ3	612883
MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 2; MENOQ2	MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 2; MENOQ2	612884
PREMATURE OVARIAN FAILURE 10; POF10MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 3, INCLUDED;MENOQ3, INCLUDED	PREMATURE OVARIAN FAILURE 10; POF10MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 3, INCLUDED;MENOQ3, INCLUDED	612885
MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 4; MENOQ4	MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 4; MENOQ4	612886
STATURE QUANTITATIVE TRAIT LOCUS 18; STQTL18	STATURE QUANTITATIVE TRAIT LOCUS 18; STQTL18	612892
STATURE QUANTITATIVE TRAIT LOCUS 19; STQTL19	STATURE QUANTITATIVE TRAIT LOCUS 19; STQTL19	612893
STATURE QUANTITATIVE TRAIT LOCUS 20; STQTL20	STATURE QUANTITATIVE TRAIT LOCUS 20; STQTL20	612894
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 8; EIG8	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 8; EIG8	612899
CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 2; CPSQ2	CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 2; CPSQ2	612900
KERATOSIS PALMOPLANTARIS STRIATA II; PPKS2	KERATOSIS PALMOPLANTARIS STRIATA II; PPKS2	612908
KERATODERMA, PALMOPLANTAR, STRIATE FORM II; KPPS2	KERATOSIS PALMOPLANTARIS STRIATA II; PPKS2	612908
STRIATE PALMOPLANTAR KERATODERMA II; SPPK2	KERATOSIS PALMOPLANTARIS STRIATA II; PPKS2	612908
OROFACIODIGITAL SYNDROME XI; OFD11	OROFACIODIGITAL SYNDROME XI; OFD11	612913
OFDS XI	OROFACIODIGITAL SYNDROME XI; OFD11	612913
ORAL-FACIAL-DIGITAL SYNDROME, TYPE XI	OROFACIODIGITAL SYNDROME XI; OFD11	612913
ORAL-FACIAL-DIGITAL SYNDROME WITH SKELETAL ANOMALIES	OROFACIODIGITAL SYNDROME XI; OFD11	612913
GABRIELLI SYNDROME	OROFACIODIGITAL SYNDROME XI; OFD11	612913
CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMALNEVI	CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMALNEVI	612918
CLOVE SYNDROME	CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMALNEVI	612918
CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, EPIDERMALNEVI, AND SKELETAL/SPINAL ABNORMALITIES	CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMALNEVI	612918
CLOVES SYNDROME	CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMALNEVI	612918
THREE M SYNDROME 2; 3M2	THREE M SYNDROME 2; 3M2	612921
3@M SYNDROME 2	THREE M SYNDROME 2; 3M2	612921
HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 2; AHUS2	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 2; AHUS2	612922
AHUS, SUSCEPTIBILITY TO, 2	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 2; AHUS2	612922
HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3; AHUS3	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3; AHUS3	612923
AHUS, SUSCEPTIBILITY TO, 3	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3; AHUS3	612923
HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 4; AHUS4	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 4; AHUS4	612924
AHUS, SUSCEPTIBILITY TO, 4	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 4; AHUS4	612924
HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 5; AHUS5	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 5; AHUS5	612925
AHUS, SUSCEPTIBILITY TO, 5	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 5; AHUS5	612925
HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 6; AHUS6	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 6; AHUS6	612926
AHUS, SUSCEPTIBILITY TO, 6	HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 6; AHUS6	612926
MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 3	MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 3	612929
MTBS3	MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 3	612929
GLYCOGEN STORAGE DISEASE XIII; GSD13	GLYCOGEN STORAGE DISEASE XIII; GSD13	612932
GSD XIII	GLYCOGEN STORAGE DISEASE XIII; GSD13	612932
ENOLASE 3 DEFICIENCY	GLYCOGEN STORAGE DISEASE XIII; GSD13	612932
ENOLASE-BETA DEFICIENCY	GLYCOGEN STORAGE DISEASE XIII; GSD13	612932
GLYCOGEN STORAGE DISEASE XI; GSD11	GLYCOGEN STORAGE DISEASE XI; GSD11	612933
GSD XI	GLYCOGEN STORAGE DISEASE XI; GSD11	612933
LACTATE DEHYDROGENASE A DEFICIENCY	GLYCOGEN STORAGE DISEASE XI; GSD11	612933
SPASTIC PARAPLEGIA 50, AUTOSOMAL RECESSIVE; SPG50	SPASTIC PARAPLEGIA 50, AUTOSOMAL RECESSIVE; SPG50	612936
CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 3, FORMERLY; CPSQ3, FORMERLY	SPASTIC PARAPLEGIA 50, AUTOSOMAL RECESSIVE; SPG50	612936
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Io; CDG1O	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Io; CDG1O	612937
CDG Io; CDGIo	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Io; CDG1O	612937
CDG1(DPM3)	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Io; CDG1O	612937
GROWTH RETARDATION, DEVELOPMENTAL DELAY, AND FACIAL DYSMORPHISM; GDFD	GROWTH RETARDATION, DEVELOPMENTAL DELAY, AND FACIAL DYSMORPHISM; GDFD	612938
CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB; ARCL2B	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB; ARCL2B	612940
CUTIS LAXA WITH PROGEROID FEATURES	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB; ARCL2B	612940
RETINITIS PIGMENTOSA 42; RP42	RETINITIS PIGMENTOSA 42; RP42	612943
HADZISELIMOVIC SYNDROME	HADZISELIMOVIC SYNDROME	612946
MICROCEPHALY-FACIOCARDIOSKELETAL SYNDROME	HADZISELIMOVIC SYNDROME	612946
HYPOMYELINATION, GLOBAL CEREBRAL	HYPOMYELINATION, GLOBAL CEREBRAL	612949
ASPARTATE-GLUTAMATE CARRIER 1 DEFICIENCY	HYPOMYELINATION, GLOBAL CEREBRAL	612949
AGC1 DEFICIENCY	HYPOMYELINATION, GLOBAL CEREBRAL	612949
PSORIASIS 12, SUSCEPTIBILITY TO; PSORS12	PSORIASIS 12, SUSCEPTIBILITY TO; PSORS12	612950
LEUKOENCEPHALOPATHY, CYSTIC, WITHOUT MEGALENCEPHALY	LEUKOENCEPHALOPATHY, CYSTIC, WITHOUT MEGALENCEPHALY	612951
AICARDI-GOUTIERES SYNDROME 5; AGS5	AICARDI-GOUTIERES SYNDROME 5; AGS5	612952
PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14	PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14	612953
DYSTONIA-PARKINSONISM, ADULT-ONSET	PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14	612953
MYOPATHY, MYOFIBRILLAR, 6; MFM6	MYOPATHY, MYOFIBRILLAR, 6; MFM6	612954
MYOPATHY, MYOFIBRILLAR, BAG3-RELATED	MYOPATHY, MYOFIBRILLAR, 6; MFM6	612954
LONG QT SYNDROME 12; LQT12	LONG QT SYNDROME 12; LQT12	612955
VENTRICULAR FIBRILLATION, PAROXYSMAL FAMILIAL, 2; VF2	VENTRICULAR FIBRILLATION, PAROXYSMAL FAMILIAL, 2; VF2	612956
VITAMIN B6 PLASMA LEVEL QUANTITATIVE TRAIT LOCUS 1; B6QTL1	VITAMIN B6 PLASMA LEVEL QUANTITATIVE TRAIT LOCUS 1; B6QTL1	612957
MULTIPLE SYNOSTOSES SYNDROME 3; SYNS3	MULTIPLE SYNOSTOSES SYNDROME 3; SYNS3	612961
PREMATURE OVARIAN FAILURE 7; POF7	PREMATURE OVARIAN FAILURE 7; POF7	612964
46,XY SEX REVERSAL 3; SRXY3	46,XY SEX REVERSAL 3; SRXY3	612965
46,XY SEX REVERSAL, PARTIAL OR COMPLETE, NR5A1-RELATED	46,XY SEX REVERSAL 3; SRXY3	612965
46,XY GONADAL DYSGENESIS, PARTIAL OR COMPLETE, WITH OR WITHOUT ADRENALFAILURE	46,XY SEX REVERSAL 3; SRXY3	612965
SEX REVERSAL, XY, WITH OR WITHOUT ADRENAL FAILURE	46,XY SEX REVERSAL 3; SRXY3	612965
DISORDER OF SEX DEVELOPMENT, 46,XY, NR5A1-RELATED	46,XY SEX REVERSAL 3; SRXY3	612965
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 15; BMIQ15	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 15; BMIQ15	612967
CATARACT 34, MULTIPLE TYPES; CTRCT34	CATARACT 34, MULTIPLE TYPES; CTRCT34	612968
CATARACT 34, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA	CATARACT 34, MULTIPLE TYPES; CTRCT34	612968
CATARACT, AUTOSOMAL RECESSIVE CONGENITAL 3; CATC3	CATARACT 34, MULTIPLE TYPES; CTRCT34	612968
SHORT SLEEPER	SHORT SLEEPER	612975
SHORT SLEEP PHENOTYPE	SHORT SLEEPER	612975
AGE-RELATED HEARING IMPAIRMENT 2; ARHI2	AGE-RELATED HEARING IMPAIRMENT 2; ARHI2	612976
PRESBYCUSIS 2	AGE-RELATED HEARING IMPAIRMENT 2; ARHI2	612976
OPTIC ATROPHY 7 WITH OR WITHOUT AUDITORY NEUROPATHY; OPA7	OPTIC ATROPHY 7 WITH OR WITHOUT AUDITORY NEUROPATHY; OPA7	612989
SPERMATOGENIC FAILURE 7; SPGF7	SPERMATOGENIC FAILURE 7; SPGF7	612997
MALE INFERTILITY, NONSYNDROMIC, AUTOSOMAL RECESSIVE; MIAR	SPERMATOGENIC FAILURE 7; SPGF7	612997
EMERY-DREIFUSS MUSCULAR DYSTROPHY 4, AUTOSOMAL DOMINANT; EDMD4	EMERY-DREIFUSS MUSCULAR DYSTROPHY 4, AUTOSOMAL DOMINANT; EDMD4	612998
EMERY-DREIFUSS MUSCULAR DYSTROPHY 4 WITH VARIABLE FEATURES	EMERY-DREIFUSS MUSCULAR DYSTROPHY 4, AUTOSOMAL DOMINANT; EDMD4	612998
EMERY-DREIFUSS MUSCULAR DYSTROPHY 5, AUTOSOMAL DOMINANT; EDMD5	EMERY-DREIFUSS MUSCULAR DYSTROPHY 5, AUTOSOMAL DOMINANT; EDMD5	612999
PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 1; FNEPPK1	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 1; FNEPPK1	613000
PPKFNE	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 1; FNEPPK1	613000
FOCAL NONEPIDERMOLYTIC PALMOPLANTAR KERATODERMA	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 1; FNEPPK1	613000
KERATODERMA, FOCAL NONEPIDERMOLYTIC PALMOPLANTAR	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 1; FNEPPK1	613000
ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS; ECCL	ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS; ECCL	613001
HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 2	HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 2	613002
ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 2; IIAE2	HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 2	613002
ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 7	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 7	613003
ADHD7	ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 7	613003
DIABETES MELLITUS, INSULIN-DEPENDENT, 24; IDDM24	DIABETES MELLITUS, INSULIN-DEPENDENT, 24; IDDM24	613006
BILIARY CIRRHOSIS, PRIMARY, 2; PBC2	BILIARY CIRRHOSIS, PRIMARY, 2; PBC2	613007
BILIARY CIRRHOSIS, PRIMARY, 3; PBC3	BILIARY CIRRHOSIS, PRIMARY, 3; PBC3	613008
LYMPHOPROLIFERATIVE SYNDROME 1; LPFS1	LYMPHOPROLIFERATIVE SYNDROME 1; LPFS1	613011
NEUROBLASTOMA, SUSCEPTIBILITY TO, 2; NBLST2NEUROBLASTOMA WITH HIRSCHSPRUNG DISEASE, INCLUDED	NEUROBLASTOMA, SUSCEPTIBILITY TO, 2; NBLST2NEUROBLASTOMA WITH HIRSCHSPRUNG DISEASE, INCLUDED	613013
NEUROBLASTOMA, SUSCEPTIBILITY TO, 3; NBLST3	NEUROBLASTOMA, SUSCEPTIBILITY TO, 3; NBLST3	613014
NEUROBLASTOMA, SUSCEPTIBILITY TO, 4; NBLST4	NEUROBLASTOMA, SUSCEPTIBILITY TO, 4; NBLST4	613015
NEUROBLASTOMA, SUSCEPTIBILITY TO, 5; NBLST5	NEUROBLASTOMA, SUSCEPTIBILITY TO, 5; NBLST5	613016
NEUROBLASTOMA, SUSCEPTIBILITY TO, 6; NBLST6	NEUROBLASTOMA, SUSCEPTIBILITY TO, 6; NBLST6	613017
BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 2; BESC2	BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 2; BESC2	613021
CYSTIC FIBROSIS-LIKE SYNDROME	BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 2; BESC2	613021
FOLLICULAR LYMPHOMA, SUSCEPTIBILITY TO, 1; FL1	FOLLICULAR LYMPHOMA, SUSCEPTIBILITY TO, 1; FL1	613024
SCHIZOPHRENIA 13; SCZD13	SCHIZOPHRENIA 13; SCZD13	613025
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 15q13-q14-RELATEDSCHIZOPHRENIA, NEUROPHYSIOLOGIC DEFECT IN, INCLUDED	SCHIZOPHRENIA 13; SCZD13	613025
CHROMOSOME 19q13.11 DELETION SYNDROME	CHROMOSOME 19q13.11 DELETION SYNDROME	613026
GLYCOGEN STORAGE DISEASE IXc; GSD9C	GLYCOGEN STORAGE DISEASE IXc; GSD9C	613027
GSD IXc	GLYCOGEN STORAGE DISEASE IXc; GSD9C	613027
GLIOMA SUSCEPTIBILITY 2; GLM2	GLIOMA SUSCEPTIBILITY 2; GLM2	613028
GLIOMA SUSCEPTIBILITY 3; GLM3	GLIOMA SUSCEPTIBILITY 3; GLM3	613029
GLIOMA SUSCEPTIBILITY 5; GLM5	GLIOMA SUSCEPTIBILITY 5; GLM5	613030
GLIOMA SUSCEPTIBILITY 6; GLM6	GLIOMA SUSCEPTIBILITY 6; GLM6	613031
GLIOMA SUSCEPTIBILITY 7; GLM7	GLIOMA SUSCEPTIBILITY 7; GLM7	613032
GLIOMA SUSCEPTIBILITY 8; GLM8	GLIOMA SUSCEPTIBILITY 8; GLM8	613033
HEARING LOSS, NOISE-INDUCED, SUSCEPTIBILITY TO; NIHL	HEARING LOSS, NOISE-INDUCED, SUSCEPTIBILITY TO; NIHL	613035
PITUITARY HORMONE DEFICIENCY, COMBINED, 1; CPHD1	PITUITARY HORMONE DEFICIENCY, COMBINED, 1; CPHD1	613038
ATRIAL FIBRILLATION, FAMILIAL, 8; ATFB8	ATRIAL FIBRILLATION, FAMILIAL, 8; ATFB8	613055
BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 2; BCC2	BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 2; BCC2	613058
BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 3; BCC3	BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 3; BCC3	613059
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 10; EIG10GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 5, SUSCEPTIBILITYTO, INCLUDED; GEFS5, INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 10; EIG10GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 5, SUSCEPTIBILITYTO, INCLUDED; GEFS5, INCLUDED	613060
GEFS+, TYPE 5, SUSCEPTIBILITY TO, INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 10; EIG10GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 5, SUSCEPTIBILITYTO, INCLUDED; GEFS5, INCLUDED	613060
GEFS+5, SUSCEPTIBILITY TO, INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 10; EIG10GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 5, SUSCEPTIBILITYTO, INCLUDED; GEFS5, INCLUDED	613060
GEFSP5, SUSCEPTIBILITY TO, INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 10; EIG10GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 5, SUSCEPTIBILITYTO, INCLUDED; GEFS5, INCLUDED	613060
EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 7, INCLUDED; EJM7,INCLUDED	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 10; EIG10GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 5, SUSCEPTIBILITYTO, INCLUDED; GEFS5, INCLUDED	613060
BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 4; BCC4	BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 4; BCC4	613061
BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 5; BCC5	BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 5; BCC5	613062
BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 6; BCC6	BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 6; BCC6	613063
DERMATITIS, ATOPIC, 7; ATOD7	DERMATITIS, ATOPIC, 7; ATOD7	613064
LEUKEMIA, ACUTE LYMPHOBLASTIC; ALLLEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 1, INCLUDED	LEUKEMIA, ACUTE LYMPHOBLASTIC; ALLLEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 1, INCLUDED	613065
ALL1, INCLUDED	LEUKEMIA, ACUTE LYMPHOBLASTIC; ALLLEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 1, INCLUDED	613065
LEUKEMIA, ACUTE LYMPHOCYTIC, SUSCEPTIBILITY TO, 1, INCLUDED	LEUKEMIA, ACUTE LYMPHOBLASTIC; ALLLEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 1, INCLUDED	613065
LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, INCLUDED	LEUKEMIA, ACUTE LYMPHOBLASTIC; ALLLEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 1, INCLUDED	613065
LEUKEMIA, T-CELL ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, INCLUDED	LEUKEMIA, ACUTE LYMPHOBLASTIC; ALLLEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 1, INCLUDED	613065
LEUKEMIA, ACUTE LYMPHOBLASTIC, B-HYPERDIPLOID, SUSCEPTIBILITY TO,INCLUDED	LEUKEMIA, ACUTE LYMPHOBLASTIC; ALLLEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 1, INCLUDED	613065
LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 2; ALL2	LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 2; ALL2	613067
LEUKEMIA, ACUTE LYMPHOCYTIC, SUSCEPTIBILITY TO, 2	LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 2; ALL2	613067
NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY	NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY	613068
LIVER FAILURE, INFANTILE, TRANSIENT; LFIT	LIVER FAILURE, INFANTILE, TRANSIENT; LFIT	613070
BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 3; BESC3	BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 3; BESC3	613071
CYSTIC FIBROSIS-LIKE SYNDROME	BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 3; BESC3	613071
METAPHYSEAL ANADYSPLASIA 2; MANDP2	METAPHYSEAL ANADYSPLASIA 2; MANDP2	613073
DEAFNESS, AUTOSOMAL DOMINANT 50; DFNA50	DEAFNESS, AUTOSOMAL DOMINANT 50; DFNA50	613074
MACS SYNDROME	MACS SYNDROME	613075
MACROCEPHALY, ALOPECIA, CUTIS LAXA, AND SCOLIOSIS	MACS SYNDROME	613075
TALL FOREHEAD, SPARSE HAIR, SKIN HYPEREXTENSIBILITY, AND SCOLIOSIS	MACS SYNDROME	613075
MYOPATHY, MITOCHONDRIAL PROGRESSIVE, WITH CONGENITAL CATARACT, HEARINGLOSS, AND DEVELOPMENTAL DELAY	MYOPATHY, MITOCHONDRIAL PROGRESSIVE, WITH CONGENITAL CATARACT, HEARINGLOSS, AND DEVELOPMENTAL DELAY	613076
MYOPATHY WITH CATARACT AND COMBINED RESPIRATORY CHAIN DEFICIENCY	MYOPATHY, MITOCHONDRIAL PROGRESSIVE, WITH CONGENITAL CATARACT, HEARINGLOSS, AND DEVELOPMENTAL DELAY	613076
MITOCHONDRIAL COMPLEX DEFICIENCY, COMBINED	MYOPATHY, MITOCHONDRIAL PROGRESSIVE, WITH CONGENITAL CATARACT, HEARINGLOSS, AND DEVELOPMENTAL DELAY	613076
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 5; PEOA5	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 5; PEOA5	613077
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 5	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 5; PEOA5	613077
NIJMEGEN BREAKAGE SYNDROME-LIKE DISORDER; NBSLD	NIJMEGEN BREAKAGE SYNDROME-LIKE DISORDER; NBSLD	613078
NBS-LIKE DISORDER	NIJMEGEN BREAKAGE SYNDROME-LIKE DISORDER; NBSLD	613078
RAD50 DEFICIENCY	NIJMEGEN BREAKAGE SYNDROME-LIKE DISORDER; NBSLD	613078
MICROCEPHALY AND SPONTANEOUS CHROMOSOME INSTABILITY WITHOUT IMMUNODEFICIENCY	NIJMEGEN BREAKAGE SYNDROME-LIKE DISORDER; NBSLD	613078
DEAFNESS, AUTOSOMAL RECESSIVE 77; DFNB77	DEAFNESS, AUTOSOMAL RECESSIVE 77; DFNB77	613079
46,XY SEX REVERSAL 5; SRXY5	46,XY SEX REVERSAL 5; SRXY5	613080
46,XY SEX REVERSAL, CBX2-RELATED	46,XY SEX REVERSAL 5; SRXY5	613080
46,XY GONADAL DYSGENESIS, COMPLETE, CBX2-RELATED	46,XY SEX REVERSAL 5; SRXY5	613080
SEX REVERSAL, XY, CBX2-RELATED	46,XY SEX REVERSAL 5; SRXY5	613080
DISORDER OF SEX DEVELOPMENT, 46,XY, CBX2-RELATED	46,XY SEX REVERSAL 5; SRXY5	613080
GLAUCOMA 3, PRIMARY CONGENITAL, C; GLC3C	GLAUCOMA 3, PRIMARY CONGENITAL, C; GLC3C	613085
GLAUCOMA 3, PRIMARY CONGENITAL, D; GLC3D	GLAUCOMA 3, PRIMARY CONGENITAL, D; GLC3D	613086
ATRIAL SEPTAL DEFECT 6; ASD6	ATRIAL SEPTAL DEFECT 6; ASD6	613087
PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO, 2	PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO, 2	613088
PVOP2	PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO, 2	613088
BARTTER SYNDROME, TYPE 4B	BARTTER SYNDROME, TYPE 4B	613090
BARTTER SYNDROME, INFANTILE, WITH SENSORINEURAL DEAFNESS	BARTTER SYNDROME, TYPE 4B	613090
SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3	SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3	613091
ASPHYXIATING THORACIC DYSTROPHY 3; ATD3	SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3	613091
SHORT RIB-POLYDACTYLY SYNDROME, TYPE I; SRPS1	SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3	613091
SALDINO-NOONAN SYNDROME	SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3	613091
POLYDACTYLY WITH NEONATAL CHONDRODYSTROPHY, TYPE I	SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3	613091
SHORT RIB-POLYDACTYLY SYNDROME, TYPE III; SRPS3	SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3	613091
VERMA-NAUMOFF SYNDROME	SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3	613091
POLYDACTYLY WITH NEONATAL CHONDRODYSTROPHY, TYPE III	SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3	613091
SHORT RIB-POLYDACTYLY SYNDROME, TYPE IIB; SRPS2B	SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3	613091
HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 2; HNFJ2	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 2; HNFJ2	613092
EARLY-ONSET HYPERURICEMIA, ANEMIA, AND PROGRESSIVE KIDNEY FAILURE	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 2; HNFJ2	613092
CONE DYSTROPHY 4; COD4ACHROMATOPSIA 5, INCLUDED; ACHM5, INCLUDED	CONE DYSTROPHY 4; COD4ACHROMATOPSIA 5, INCLUDED; ACHM5, INCLUDED	613093
MICROPHTHALMIA, ISOLATED 4; MCOP4	MICROPHTHALMIA, ISOLATED 4; MCOP4	613094
POLYCYSTIC KIDNEY DISEASE 2; PKD2	POLYCYSTIC KIDNEY DISEASE 2; PKD2	613095
POLYCYSTIC KIDNEY DISEASE, ADULT, TYPE II; APKD2	POLYCYSTIC KIDNEY DISEASE 2; PKD2	613095
SPASTIC PARAPLEGIA 36, AUTOSOMAL DOMINANT; SPG36	SPASTIC PARAPLEGIA 36, AUTOSOMAL DOMINANT; SPG36	613096
INCREASED ANALGESIA FROM KAPPA-OPIOID RECEPTOR AGONIST, FEMALE-SPECIFIC	INCREASED ANALGESIA FROM KAPPA-OPIOID RECEPTOR AGONIST, FEMALE-SPECIFIC	613098
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 5; CMM5	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 5; CMM5	613099
GLAUCOMA 1, OPEN ANGLE, O; GLC1O	GLAUCOMA 1, OPEN ANGLE, O; GLC1O	613100
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 5; FHL5	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 5; FHL5	613101
HYPOTRICHOSIS AND RECURRENT SKIN VESICLES	HYPOTRICHOSIS AND RECURRENT SKIN VESICLES	613102
CHOROIDAL DYSTROPHY, CENTRAL AREOLAR 2; CACD2	CHOROIDAL DYSTROPHY, CENTRAL AREOLAR 2; CACD2	613105
MACULAR DYSTROPHY, PROGRESSIVE	CHOROIDAL DYSTROPHY, CENTRAL AREOLAR 2; CACD2	613105
VERTIGO, BENIGN RECURRENT, 2; BRV2	VERTIGO, BENIGN RECURRENT, 2; BRV2	613106
NEUTROPENIA, SEVERE CONGENITAL, 2, AUTOSOMAL DOMINANT; SCN2	NEUTROPENIA, SEVERE CONGENITAL, 2, AUTOSOMAL DOMINANT; SCN2	613107
CANDIDIASIS, FAMILIAL, 4; CANDF4	CANDIDIASIS, FAMILIAL, 4; CANDF4	613108
CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS	CANDIDIASIS, FAMILIAL, 4; CANDF4	613108
MACROTHROMBOCYTOPENIA, AUTOSOMAL DOMINANT, TUBB1-RELATED	MACROTHROMBOCYTOPENIA, AUTOSOMAL DOMINANT, TUBB1-RELATED	613112
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIB; HSAN2B	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIB; HSAN2B	613115
THROMBOPHILIA DUE TO HISTIDINE-RICH GLYCOPROTEIN DEFICIENCY; THPH11THROMBOPHILIA DUE TO ELEVATED HISTIDINE-RICH GLYCOPROTEIN, INCLUDED	THROMBOPHILIA DUE TO HISTIDINE-RICH GLYCOPROTEIN DEFICIENCY; THPH11THROMBOPHILIA DUE TO ELEVATED HISTIDINE-RICH GLYCOPROTEIN, INCLUDED	613116
ANTITHROMBIN III DEFICIENCY; AT3D	ANTITHROMBIN III DEFICIENCY; AT3D	613118
THROMBOPHILIA DUE TO ANTITHROMBIN III DEFICIENCY; THPH7	ANTITHROMBIN III DEFICIENCY; AT3D	613118
BRUGADA SYNDROME 6; BRGDA6	BRUGADA SYNDROME 6; BRGDA6	613119
BRUGADA SYNDROME 7; BRGDA7ATRIAL FIBRILLATION, FAMILIAL, 16, INCLUDED; ATFB16, INCLUDED	BRUGADA SYNDROME 7; BRGDA7ATRIAL FIBRILLATION, FAMILIAL, 16, INCLUDED; ATFB16, INCLUDED	613120
CARDIOMYOPATHY, DILATED, 1CC; CMD1CC	CARDIOMYOPATHY, DILATED, 1CC; CMD1CC	613122
BRUGADA SYNDROME 8; BRGDA8	BRUGADA SYNDROME 8; BRGDA8	613123
PARKINSONISM-DYSTONIA, INFANTILE; PKDYS	PARKINSONISM-DYSTONIA, INFANTILE; PKDYS	613135
DOPAMINE TRANSPORTER DEFICIENCY SYNDROME; DTDS	PARKINSONISM-DYSTONIA, INFANTILE; PKDYS	613135
CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, 3; CACD3	CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, 3; CACD3	613144
CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, WITH OR WITHOUT DRUSEN	CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, 3; CACD3	613144
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 14; SLEB14	SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 14; SLEB14	613145
INFLAMMATORY BOWEL DISEASE 28, AUTOSOMAL RECESSIVE; IBD28	INFLAMMATORY BOWEL DISEASE 28, AUTOSOMAL RECESSIVE; IBD28	613148
INFLAMMATORY BOWEL DISEASE, EARLY-ONSET, AUTOSOMAL RECESSIVE	INFLAMMATORY BOWEL DISEASE 28, AUTOSOMAL RECESSIVE; IBD28	613148
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 2; MDDGA2	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 2; MDDGA2	613150
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMT2-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 2; MDDGA2	613150
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 3; MDDGB3	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 3; MDDGB3	613151
MUSCULAR DYSTROPHY, CONGENITAL, POMGNT1-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 3; MDDGB3	613151
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITHOUT MENTAL RETARDATION),TYPE B, 4; MDDGB4	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITHOUT MENTAL RETARDATION),TYPE B, 4; MDDGB4	613152
MUSCULAR DYSTROPHY, CONGENITAL, FKTN-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITHOUT MENTAL RETARDATION),TYPE B, 4; MDDGB4	613152
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 5; MDDGA5	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 5; MDDGA5	613153
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKRP-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 5; MDDGA5	613153
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 6; MDDGA6	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 6; MDDGA6	613154
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, LARGE-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 6; MDDGA6	613154
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 1; MDDGB1	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 1; MDDGB1	613155
MUSCULAR DYSTROPHY, CONGENITAL, POMT1-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 1; MDDGB1	613155
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 2; MDDGB2	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 2; MDDGB2	613156
MUSCULAR DYSTROPHY, CONGENITAL, POMT2-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 2; MDDGB2	613156
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 3; MDDGC3	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 3; MDDGC3	613157
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2O; LGMD2O	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 3; MDDGC3	613157
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, POMGNT1-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 3; MDDGC3	613157
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 2; MDDGC2	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 2; MDDGC2	613158
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2N; LGMD2N	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 2; MDDGC2	613158
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, POMT2-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 2; MDDGC2	613158
NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1; NPHPL1	NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1; NPHPL1	613159
BETA-UREIDOPROPIONASE DEFICIENCY	BETA-UREIDOPROPIONASE DEFICIENCY	613161
SPASTIC PARAPLEGIA 45, AUTOSOMAL RECESSIVE; SPG45	SPASTIC PARAPLEGIA 45, AUTOSOMAL RECESSIVE; SPG45	613162
GABA-TRANSAMINASE DEFICIENCY	GABA-TRANSAMINASE DEFICIENCY	613163
PARKINSON DISEASE 16; PARK16	PARKINSON DISEASE 16; PARK16	613164
CARDIOMYOPATHY, DILATED, 1DD; CMD1DD	CARDIOMYOPATHY, DILATED, 1DD; CMD1DD	613172
CHROMOSOME 5p13 DUPLICATION SYNDROME	CHROMOSOME 5p13 DUPLICATION SYNDROME	613174
CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IC; ARCL1C	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IC; ARCL1C	613177
CUTIS LAXA WITH SEVERE PULMONARY, GASTROINTESTINAL, AND URINARY ABNORMALITIES	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IC; ARCL1C	613177
URBAN-RIFKIN-DAVIS SYNDROME; URDS	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IC; ARCL1C	613177
PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY	PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY	613179
NUCLEOSIDE PHOSPHORYLASE DEFICIENCY	PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY	613179
POLYMICROGYRIA WITH OPTIC NERVE HYPOPLASIA	POLYMICROGYRIA WITH OPTIC NERVE HYPOPLASIA	613180
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 13; MRT13	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 13; MRT13	613192
CILIARY DYSKINESIA, PRIMARY, 13; CILD13	CILIARY DYSKINESIA, PRIMARY, 13; CILD13	613193
CILIARY DYSKINESIA, PRIMARY, 13, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 13; CILD13	613193
RETINITIS PIGMENTOSA 50; RP50RETINITIS PIGMENTOSA, CONCENTRIC, INCLUDED	RETINITIS PIGMENTOSA 50; RP50RETINITIS PIGMENTOSA, CONCENTRIC, INCLUDED	613194
WEILL-MARCHESANI-LIKE SYNDROME	WEILL-MARCHESANI-LIKE SYNDROME	613195
MUSCULAR DYSTROPHY, CONGENITAL, DUE TO INTEGRIN ALPHA-7 DEFICIENCY	MUSCULAR DYSTROPHY, CONGENITAL, DUE TO INTEGRIN ALPHA-7 DEFICIENCY	613204
MYOPATHY, CONGENITAL, DUE TO INTEGRIN ALPHA-7 DEFICIENCY	MUSCULAR DYSTROPHY, CONGENITAL, DUE TO INTEGRIN ALPHA-7 DEFICIENCY	613204
MUSCULAR DYSTROPHY, CONGENITAL, LMNA-RELATED	MUSCULAR DYSTROPHY, CONGENITAL, LMNA-RELATED	613205
MDCL	MUSCULAR DYSTROPHY, CONGENITAL, LMNA-RELATED	613205
SPASTIC PARAPLEGIA 44, AUTOSOMAL RECESSIVE; SPG44	SPASTIC PARAPLEGIA 44, AUTOSOMAL RECESSIVE; SPG44	613206
ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 8; ASRT8RHINOCONJUNCTIVITIS, SUSCEPTIBILITY TO, INCLUDED	ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 8; ASRT8RHINOCONJUNCTIVITIS, SUSCEPTIBILITY TO, INCLUDED	613207
AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA3; AI2A3	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA3; AI2A3	613211
CHROMOSOME 17p13.3, CENTROMERIC, DUPLICATION SYNDROME	CHROMOSOME 17p13.3, CENTROMERIC, DUPLICATION SYNDROME	613215
NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1C; CSNB1C	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1C; CSNB1C	613216
CSNB, COMPLETE, AUTOSOMAL RECESSIVE	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1C; CSNB1C	613216
DIARRHEA 5, WITH TUFTING ENTEROPATHY, CONGENITAL; DIAR5	DIARRHEA 5, WITH TUFTING ENTEROPATHY, CONGENITAL; DIAR5	613217
ENTEROPATHY, CONGENITAL TUFTING; CTE	DIARRHEA 5, WITH TUFTING ENTEROPATHY, CONGENITAL; DIAR5	613217
INTESTINAL EPITHELIAL CELL DYSPLASIA	DIARRHEA 5, WITH TUFTING ENTEROPATHY, CONGENITAL; DIAR5	613217
FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 2; FGQTL2BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 1, INCLUDED; BWQTL1, INCLUDED	FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 2; FGQTL2BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 1, INCLUDED; BWQTL1, INCLUDED	613219
LEPROSY, SUSCEPTIBILITY TO, 5; LPRS5LEPROSY, PROTECTION AGAINST, INCLUDED	LEPROSY, SUSCEPTIBILITY TO, 5; LPRS5LEPROSY, PROTECTION AGAINST, INCLUDED	613223
NOONAN SYNDROME 6; NS6	NOONAN SYNDROME 6; NS6	613224
FACTOR XIII, A SUBUNIT, DEFICIENCY OF	FACTOR XIII, A SUBUNIT, DEFICIENCY OF	613225
CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME3; CAMRQ3	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME3; CAMRQ3	613227
CEREBELLAR ATAXIA AND MENTAL RETARDATION WITH OR WITHOUT QUADRUPEDALLOCOMOTION 3	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME3; CAMRQ3	613227
TRICHOTILLOMANIA; TTM	TRICHOTILLOMANIA; TTM	613229
FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 3; FGQTL3	FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 3; FGQTL3	613233
FACTOR XIII, B SUBUNIT, DEFICIENCY OF	FACTOR XIII, B SUBUNIT, DEFICIENCY OF	613235
FOCAL SEGMENTAL GLOMERULOSCLEROSIS 5; FSGS5	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 5; FSGS5	613237
GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 5	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 5; FSGS5	613237
SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 3; SPDA3	SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 3; SPDA3	613238
THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 2; TTPP2	THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 2; TTPP2	613239
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 13; CMH13	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 13; CMH13	613243
COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 8; HNPCC8	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 8; HNPCC8	613244
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 14; CMH14	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 14; CMH14	613251
CARDIOMYOPATHY, DILATED, 1EE; CMD1EE	CARDIOMYOPATHY, DILATED, 1EE; CMD1EE	613252
TUBEROUS SCLEROSIS 2; TSC2TSC2 ANGIOMYOLIPOMAS, RENAL, MODIFIER OF, INCLUDED	TUBEROUS SCLEROSIS 2; TSC2TSC2 ANGIOMYOLIPOMAS, RENAL, MODIFIER OF, INCLUDED	613254
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 15; CMH15	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 15; CMH15	613255
WAARDENBURG SYNDROME, TYPE 4B; WS4B	WAARDENBURG SYNDROME, TYPE 4B; WS4B	613265
WAARDENBURG SYNDROME, TYPE 4B, WITH HIRSCHSPRUNG DISEASE	WAARDENBURG SYNDROME, TYPE 4B; WS4B	613265
WAARDENBURG SYNDROME, TYPE IVB	WAARDENBURG SYNDROME, TYPE 4B; WS4B	613265
WAARDENBURG SYNDROME, TYPE 4C; WS4C	WAARDENBURG SYNDROME, TYPE 4C; WS4C	613266
WAARDENBURG SYNDROME WITH HIRSCHSPRUNG DISEASE, TYPE 4C	WAARDENBURG SYNDROME, TYPE 4C; WS4C	613266
WAARDENBURG SYNDROME, TYPE IVC	WAARDENBURG SYNDROME, TYPE 4C; WS4C	613266
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 3; FECD3	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 3; FECD3	613267
FCD2 LOCUS	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 3; FECD3	613267
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 3; FECD3	613267
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 4; FECD4	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 4; FECD4	613268
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 4; FECD4	613268
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 5; FECD5	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 5; FECD5	613269
FCD3 LOCUS	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 5; FECD5	613269
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 5; FECD5	613269
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 6; FECD6	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 6; FECD6	613270
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 6; FECD6	613270
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 7; FECD7	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 7; FECD7	613271
FCD4 LOCUS	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 7; FECD7	613271
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 7; FECD7	613271
HYPERMANGANESEMIA WITH DYSTONIA, POLYCYTHEMIA, AND CIRRHOSIS; HMDPC	HYPERMANGANESEMIA WITH DYSTONIA, POLYCYTHEMIA, AND CIRRHOSIS; HMDPC	613280
FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 1; NAFLD1LIVER DISEASE, ALCOHOLIC, SUSCEPTIBILITY TO, 1, INCLUDED	FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 1; NAFLD1LIVER DISEASE, ALCOHOLIC, SUSCEPTIBILITY TO, 1, INCLUDED	613282
HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HCHGQ3	HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HCHGQ3	613284
HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 22	HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HCHGQ3	613284
DEAFNESS, AUTOSOMAL RECESSIVE 25; DFNB25	DEAFNESS, AUTOSOMAL RECESSIVE 25; DFNB25	613285
CARDIOMYOPATHY, DILATED, 1FF; CMD1FF	CARDIOMYOPATHY, DILATED, 1FF; CMD1FF	613286
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2N; CMT2N	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2N; CMT2N	613287
CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2N	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2N; CMT2N	613287
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2N	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2N; CMT2N	613287
HEARING LOSS, CISPLATIN-INDUCED, SUSCEPTIBILITY TO; CIHL	HEARING LOSS, CISPLATIN-INDUCED, SUSCEPTIBILITY TO; CIHL	613290
BILE ACID MALABSORPTION, PRIMARY; PBAM	BILE ACID MALABSORPTION, PRIMARY; PBAM	613291
DEAFNESS, AUTOSOMAL RECESSIVE 79; DFNB79	DEAFNESS, AUTOSOMAL RECESSIVE 79; DFNB79	613307
DIAMOND-BLACKFAN ANEMIA 9; DBA9	DIAMOND-BLACKFAN ANEMIA 9; DBA9	613308
DIAMOND-BLACKFAN ANEMIA 10; DBA10	DIAMOND-BLACKFAN ANEMIA 10; DBA10	613309
EXUDATIVE VITREORETINOPATHY 5; EVR5	EXUDATIVE VITREORETINOPATHY 5; EVR5	613310
HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 2; ARHR2	HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 2; ARHR2	613312
HEMOCHROMATOSIS, TYPE 2B; HFE2B	HEMOCHROMATOSIS, TYPE 2B; HFE2B	613313
MIYOSHI MUSCULAR DYSTROPHY 2; MMD2	MIYOSHI MUSCULAR DYSTROPHY 2; MMD2	613318
MIYOSHI MYOPATHY 2	MIYOSHI MUSCULAR DYSTROPHY 2; MMD2	613318
MIYOSHI MUSCULAR DYSTROPHY 3; MMD3	MIYOSHI MUSCULAR DYSTROPHY 3; MMD3	613319
MIYOSHI MYOPATHY 3	MIYOSHI MUSCULAR DYSTROPHY 3; MMD3	613319
SPONDYLOMETAPHYSEAL DYSPLASIA, MEGARBANE-DAGHER-MELKI TYPE; SMDMDM	SPONDYLOMETAPHYSEAL DYSPLASIA, MEGARBANE-DAGHER-MELKI TYPE; SMDMDM	613320
CHONDRODYSPLASIA, MEGARBANE-DAGHER-MELKI TYPE	SPONDYLOMETAPHYSEAL DYSPLASIA, MEGARBANE-DAGHER-MELKI TYPE; SMDMDM	613320
RHABDOID TUMOR PREDISPOSITION SYNDROME 2; RTPS2	RHABDOID TUMOR PREDISPOSITION SYNDROME 2; RTPS2	613325
LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 4; CGL4	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 4; CGL4	613327
BERARDINELLI-SEIP CONGENITAL LIPODYSTROPHY, TYPE 4, WITH MUSCULARDYSTROPHY	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 4; CGL4	613327
LIPODYSTROPHY, BERARDINELLI-SEIP CONGENITAL, TYPE 4, WITH MUSCULARDYSTROPHY	LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 4; CGL4	613327
PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCY	PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCY	613329
HYPERFIBRINOLYSIS DUE TO PAI1 DEFICIENCY	PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCY	613329
SPONDYLO-MEGAEPIPHYSEAL-METAPHYSEAL DYSPLASIA; SMMD	SPONDYLO-MEGAEPIPHYSEAL-METAPHYSEAL DYSPLASIA; SMMD	613330
EPILEPSY, HOT WATER, 1; HWE1	EPILEPSY, HOT WATER, 1; HWE1	613339
BATHING EPILEPSY	EPILEPSY, HOT WATER, 1; HWE1	613339
WATER IMMERSION EPILEPSY	EPILEPSY, HOT WATER, 1; HWE1	613339
EPILEPSY, HOT WATER, 2; HWE2	EPILEPSY, HOT WATER, 2; HWE2	613340
LEBER CONGENITAL AMAUROSIS 14; LCA14RETINAL DYSTROPHY, EARLY-ONSET SEVERE, LRAT-RELATED, INCLUDED	LEBER CONGENITAL AMAUROSIS 14; LCA14RETINAL DYSTROPHY, EARLY-ONSET SEVERE, LRAT-RELATED, INCLUDED	613341
RETINITIS PIGMENTOSA, JUVENILE, LRAT-RELATED, INCLUDED	LEBER CONGENITAL AMAUROSIS 14; LCA14RETINAL DYSTROPHY, EARLY-ONSET SEVERE, LRAT-RELATED, INCLUDED	613341
HANDIGODU JOINT DISEASE	HANDIGODU JOINT DISEASE	613343
HJD	HANDIGODU JOINT DISEASE	613343
SPONDYLOEPIMETAPHYSEAL DYSPLASIA, HANDIGODU TYPE	HANDIGODU JOINT DISEASE	613343
HYPOKALEMIC PERIODIC PARALYSIS, TYPE 2; HOKPP2	HYPOKALEMIC PERIODIC PARALYSIS, TYPE 2; HOKPP2	613345
PANCREATIC CANCER, SUSCEPTIBILITY TO, 2	PANCREATIC CANCER, SUSCEPTIBILITY TO, 2	613347
PNCA2	PANCREATIC CANCER, SUSCEPTIBILITY TO, 2	613347
PANCREATIC CANCER, SUSCEPTIBILITY TO, 3	PANCREATIC CANCER, SUSCEPTIBILITY TO, 3	613348
PNCA3	PANCREATIC CANCER, SUSCEPTIBILITY TO, 3	613348
MONONEUROPATHY OF THE MEDIAN NERVE, MILD; MNMN	MONONEUROPATHY OF THE MEDIAN NERVE, MILD; MNMN	613353
CARPAL TUNNEL SYNDROME, SUSCEPTIBILITY TO	MONONEUROPATHY OF THE MEDIAN NERVE, MILD; MNMN	613353
CHROMOSOME 17q23.1-q23.2 DELETION SYNDROME	CHROMOSOME 17q23.1-q23.2 DELETION SYNDROME	613355
SPASTIC PARAPLEGIA 41, AUTOSOMAL DOMINANT; SPG41	SPASTIC PARAPLEGIA 41, AUTOSOMAL DOMINANT; SPG41	613364
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 10; MODY10	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 10; MODY10	613370
SPINOCEREBELLAR ATAXIA 30; SCA30	SPINOCEREBELLAR ATAXIA 30; SCA30	613371
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 11; MODY11	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 11; MODY11	613375
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIC; HMN2C	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIC; HMN2C	613376
HMN IIC	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIC; HMN2C	613376
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IIC; DHMN2C	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIC; HMN2C	613376
BRACHYDACTYLY, TYPE E2; BDE2	BRACHYDACTYLY, TYPE E2; BDE2	613382
AUTOIMMUNE DISEASE, MULTISYSTEM, WITH FACIAL DYSMORPHISM; ADMFD	AUTOIMMUNE DISEASE, MULTISYSTEM, WITH FACIAL DYSMORPHISM; ADMFD	613385
FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 2; NAFLD2	FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 2; NAFLD2	613387
FANCONI RENOTUBULAR SYNDROME 2; FRTS2	FANCONI RENOTUBULAR SYNDROME 2; FRTS2	613388
FANCONI ANEMIA, COMPLEMENTATION GROUP O; FANCO	FANCONI ANEMIA, COMPLEMENTATION GROUP O; FANCO	613390
DEAFNESS, AUTOSOMAL RECESSIVE 84A; DFNB84A	DEAFNESS, AUTOSOMAL RECESSIVE 84A; DFNB84A	613391
DEAFNESS, AUTOSOMAL RECESSIVE 84; DFNB84	DEAFNESS, AUTOSOMAL RECESSIVE 84A; DFNB84A	613391
DEAFNESS, AUTOSOMAL RECESSIVE 84A, WITH VESTIBULAR DYSFUNCTION	DEAFNESS, AUTOSOMAL RECESSIVE 84A; DFNB84A	613391
DEAFNESS, AUTOSOMAL RECESSIVE 85; DFNB85	DEAFNESS, AUTOSOMAL RECESSIVE 85; DFNB85	613392
BIRBECK GRANULE DEFICIENCY	BIRBECK GRANULE DEFICIENCY	613393
BIRBECK GRANULES, ABSENCE OF	BIRBECK GRANULE DEFICIENCY	613393
WARSAW BREAKAGE SYNDROME; WABS	WARSAW BREAKAGE SYNDROME; WABS	613398
BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3; BROVCA3BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3, INCLUDED	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3; BROVCA3BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3, INCLUDED	613399
OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3, INCLUDED	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3; BROVCA3BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3, INCLUDED	613399
MICROCEPHALY, SEIZURES, AND DEVELOPMENTAL DELAY; MCSZ	MICROCEPHALY, SEIZURES, AND DEVELOPMENTAL DELAY; MCSZ	613402
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 10; EIEE10	MICROCEPHALY, SEIZURES, AND DEVELOPMENTAL DELAY; MCSZ	613402
ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS 2; ARCS2	ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS 2; ARCS2	613404
CHROMOSOME 15q24 DELETION SYNDROMECHROMOSOME 15q24 DUPLICATION SYNDROME, INCLUDED	CHROMOSOME 15q24 DELETION SYNDROMECHROMOSOME 15q24 DUPLICATION SYNDROME, INCLUDED	613406
LEPROSY, SUSCEPTIBILITY TO, 6; LPRS6	LEPROSY, SUSCEPTIBILITY TO, 6; LPRS6	613407
AUTISM, SUSCEPTIBILITY TO, 16; AUTS16	AUTISM, SUSCEPTIBILITY TO, 16; AUTS16	613410
AUTISM WITH OR WITHOUT SEIZURES	AUTISM, SUSCEPTIBILITY TO, 16; AUTS16	613410
OGUCHI DISEASE 2	OGUCHI DISEASE 2	613411
NIGHT BLINDNESS, CONGENITAL STATIONARY, OGUCHI TYPE 2; CSNBO2	OGUCHI DISEASE 2	613411
ESOPHAGITIS, EOSINOPHILIC, 2; EOE2	ESOPHAGITIS, EOSINOPHILIC, 2; EOE2	613412
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 15; BMND15	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 15; BMND15	613418
OSTEOPOROSIS, SUSCEPTIBILITY TO	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 15; BMND15	613418
METAPHYSEAL FRACTURE, SUSCEPTIBILITY TO	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 15; BMND15	613418
COMPRESSION FRACTURE, SUSCEPTIBILITY TO	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 15; BMND15	613418
CARDIOMYOPATHY, DILATED, 1R; CMD1RLEFT VENTRICULAR NONCOMPACTION 4, INCLUDED; LVNC4, INCLUDED	CARDIOMYOPATHY, DILATED, 1R; CMD1RLEFT VENTRICULAR NONCOMPACTION 4, INCLUDED; LVNC4, INCLUDED	613424
CARDIOMYOPATHY, DILATED, 1S; CMD1SLEFT VENTRICULAR NONCOMPACTION 5, INCLUDED; LVNC5, INCLUDED	CARDIOMYOPATHY, DILATED, 1S; CMD1SLEFT VENTRICULAR NONCOMPACTION 5, INCLUDED; LVNC5, INCLUDED	613426
RETINITIS PIGMENTOSA 54; RP54	RETINITIS PIGMENTOSA 54; RP54	613428
AMYOTROPHIC LATERAL SCLEROSIS 12; ALS12	AMYOTROPHIC LATERAL SCLEROSIS 12; ALS12	613435
AUTISM, SUSCEPTIBILITY TO, 17; AUTS17	AUTISM, SUSCEPTIBILITY TO, 17; AUTS17	613436
STATURE QUANTITATIVE TRAIT LOCUS 21; STQTL21	STATURE QUANTITATIVE TRAIT LOCUS 21; STQTL21	613440
MENTAL RETARDATION, AUTOSOMAL DOMINANT 20; MRD20	MENTAL RETARDATION, AUTOSOMAL DOMINANT 20; MRD20	613443
MENTAL RETARDATION, STEREOTYPIC MOVEMENTS, EPILEPSY, AND/OR CEREBRALMALFORMATIONSCHROMOSOME 5q14.3 DELETION SYNDROME, PROXIMAL, INCLUDED	MENTAL RETARDATION, AUTOSOMAL DOMINANT 20; MRD20	613443
CHROMOSOME 16p11.2 DELETION SYNDROME, 220-KBBODY MASS INDEX QUANTITATIVE TRAIT LOCUS 16, INCLUDED; BMIQ16, INCLUDED	CHROMOSOME 16p11.2 DELETION SYNDROME, 220-KBBODY MASS INDEX QUANTITATIVE TRAIT LOCUS 16, INCLUDED; BMIQ16, INCLUDED	613444
OBESITY, SUSCEPTIBILITY TO, INCLUDED	CHROMOSOME 16p11.2 DELETION SYNDROME, 220-KBBODY MASS INDEX QUANTITATIVE TRAIT LOCUS 16, INCLUDED; BMIQ16, INCLUDED	613444
FRONTONASAL DYSPLASIA 2; FND2	FRONTONASAL DYSPLASIA 2; FND2	613451
DEAFNESS, AUTOSOMAL RECESSIVE 91; DFNB91	DEAFNESS, AUTOSOMAL RECESSIVE 91; DFNB91	613453
RETT SYNDROME, CONGENITAL VARIANT	RETT SYNDROME, CONGENITAL VARIANT	613454
FRONTONASAL DYSPLASIA 3; FND3	FRONTONASAL DYSPLASIA 3; FND3	613456
CHROMOSOME 14q11-q22 DELETION SYNDROME	CHROMOSOME 14q11-q22 DELETION SYNDROME	613457
CHROMOSOME 16p13.3 DUPLICATION SYNDROME	CHROMOSOME 16p13.3 DUPLICATION SYNDROME	613458
BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 2; BWQTL2	BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 2; BWQTL2	613459
FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 6; FGQTL6BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 3, INCLUDED; BWQTL3, INCLUDED	FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 6; FGQTL6BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 3, INCLUDED; BWQTL3, INCLUDED	613460
PLASMA GLUCOSE, 2-HOUR, QUANTITATIVE TRAIT LOCUS 1, INCLUDED; PGQTL1,INCLUDED	FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 6; FGQTL6BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 3, INCLUDED; BWQTL3, INCLUDED	613460
FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 4; FGQTL4	FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 4; FGQTL4	613462
FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 5; FGQTL5	FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 5; FGQTL5	613463
RETINITIS PIGMENTOSA 51; RP51	RETINITIS PIGMENTOSA 51; RP51	613464
HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO GLUCOSE PHOSPHATE ISOMERASEDEFICIENCY	HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO GLUCOSE PHOSPHATE ISOMERASEDEFICIENCY	613470
REYNOLDS SYNDROME	REYNOLDS SYNDROME	613471
PRIMARY BILIARY CIRRHOSIS, SCLERODERMA, RAYNAUD DISEASE, AND TELANGIECTASIA	REYNOLDS SYNDROME	613471
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 5; EIEE5	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 5; EIEE5	613477
LYMPHEDEMA, HEREDITARY, IC; LMPH1C	LYMPHEDEMA, HEREDITARY, IC; LMPH1C	613480
LONG QT SYNDROME 13; LQT13	LONG QT SYNDROME 13; LQT13	613485
MYXOID LIPOSARCOMA	MYXOID LIPOSARCOMA	613488
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIj; CDG2J	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIj; CDG2J	613489
CDG IIj; CDGIIj	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIj; CDG2J	613489
ALPHA-1-ANTITRYPSIN DEFICIENCY	ALPHA-1-ANTITRYPSIN DEFICIENCY	613490
IMMUNODEFICIENCY, COMMON VARIABLE, 3; CVID3	IMMUNODEFICIENCY, COMMON VARIABLE, 3; CVID3	613493
ANTIBODY DEFICIENCY DUE TO CD19 DEFECT	IMMUNODEFICIENCY, COMMON VARIABLE, 3; CVID3	613493
IMMUNODEFICIENCY, COMMON VARIABLE, 4; CVID4	IMMUNODEFICIENCY, COMMON VARIABLE, 4; CVID4	613494
ANTIBODY DEFICIENCY DUE TO BAFFR DEFECT	IMMUNODEFICIENCY, COMMON VARIABLE, 4; CVID4	613494
IMMUNODEFICIENCY, COMMON VARIABLE, 5; CVID5	IMMUNODEFICIENCY, COMMON VARIABLE, 5; CVID5	613495
ANTIBODY DEFICIENCY DUE TO CD20 DEFECT	IMMUNODEFICIENCY, COMMON VARIABLE, 5; CVID5	613495
IMMUNODEFICIENCY, COMMON VARIABLE, 6; CVID6	IMMUNODEFICIENCY, COMMON VARIABLE, 6; CVID6	613496
ANTIBODY DEFICIENCY DUE TO CD81 DEFECT	IMMUNODEFICIENCY, COMMON VARIABLE, 6; CVID6	613496
SEX HORMONE-BINDING GLOBULIN CIRCULATING LEVEL QUANTITATIVE TRAITLOCUS; SXGQTL1TESTOSTERONE CIRCULATING LEVEL QUANTITATIVE TRAIT LOCUS, DUE TO SEXHORMONE-BINDING GLOBULIN	SEX HORMONE-BINDING GLOBULIN CIRCULATING LEVEL QUANTITATIVE TRAITLOCUS; SXGQTL1TESTOSTERONE CIRCULATING LEVEL QUANTITATIVE TRAIT LOCUS, DUE TO SEXHORMONE-BINDING GLOBULIN	613498
AGAMMAGLOBULINEMIA 2, AUTOSOMAL RECESSIVE; AGM2	AGAMMAGLOBULINEMIA 2, AUTOSOMAL RECESSIVE; AGM2	613500
AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO IGLL1 DEFECT	AGAMMAGLOBULINEMIA 2, AUTOSOMAL RECESSIVE; AGM2	613500
AGAMMAGLOBULINEMIA 3, AUTOSOMAL RECESSIVE; AGM3	AGAMMAGLOBULINEMIA 3, AUTOSOMAL RECESSIVE; AGM3	613501
AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO CD79A DEFECT	AGAMMAGLOBULINEMIA 3, AUTOSOMAL RECESSIVE; AGM3	613501
AGAMMAGLOBULINEMIA 4, AUTOSOMAL RECESSIVE; AGM4	AGAMMAGLOBULINEMIA 4, AUTOSOMAL RECESSIVE; AGM4	613502
AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO BLNK DEFECT	AGAMMAGLOBULINEMIA 4, AUTOSOMAL RECESSIVE; AGM4	613502
AGAMMAGLOBULINEMIA 5, AUTOSOMAL DOMINANT; AGM5	AGAMMAGLOBULINEMIA 5, AUTOSOMAL DOMINANT; AGM5	613506
AGAMMAGLOBULINEMIA, AUTOSOMAL DOMINANT, DUE TO LRRC8A DEFECT	AGAMMAGLOBULINEMIA 5, AUTOSOMAL DOMINANT; AGM5	613506
GLYCOGEN STORAGE DISEASE XV; GSD15	GLYCOGEN STORAGE DISEASE XV; GSD15	613507
GSD XV	GLYCOGEN STORAGE DISEASE XV; GSD15	613507
GLYCOGENIN DEFICIENCY	GLYCOGEN STORAGE DISEASE XV; GSD15	613507
GYG1 DEFICIENCY	GLYCOGEN STORAGE DISEASE XV; GSD15	613507
SODIUM SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1; SSQTL1HYPONATREMIA, INCLUDED	SODIUM SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1; SSQTL1HYPONATREMIA, INCLUDED	613508
CHROMOSOME 4q21 DELETION SYNDROME	CHROMOSOME 4q21 DELETION SYNDROME	613509
MICROPHTHALMIA, ISOLATED 6; MCOP6	MICROPHTHALMIA, ISOLATED 6; MCOP6	613517
MICROPHTHALMIA, POSTERIOR NONSYNDROMIC	MICROPHTHALMIA, ISOLATED 6; MCOP6	613517
DERMATITIS, ATOPIC, 8; ATOD8	DERMATITIS, ATOPIC, 8; ATOD8	613518
DERMATITIS, ATOPIC, SEVERITY OF	DERMATITIS, ATOPIC, 8; ATOD8	613518
DERMATITIS, ATOPIC, 9; ATOD9	DERMATITIS, ATOPIC, 9; ATOD9	613519
CHROMOSOME 8p11 MYELOPROLIFERATIVE SYNDROME	CHROMOSOME 8p11 MYELOPROLIFERATIVE SYNDROME	613523
STEM CELL LEUKEMIA/LYMPHOMA; SCLL	CHROMOSOME 8p11 MYELOPROLIFERATIVE SYNDROME	613523
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1H; LGMD1H	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1H; LGMD1H	613530
CHROMOSOME 17q21.31 DUPLICATION SYNDROME	CHROMOSOME 17q21.31 DUPLICATION SYNDROME	613533
CHROMOSOME 6q11-q14 DELETION SYNDROMECHROMOSOME 6q13-q14 DELETION SYNDROME, INCLUDED	CHROMOSOME 6q11-q14 DELETION SYNDROMECHROMOSOME 6q13-q14 DELETION SYNDROME, INCLUDED	613544
MACROSTOMIA, ISOLATED	MACROSTOMIA, ISOLATED	613545
LATERAL CLEFT, ISOLATED	MACROSTOMIA, ISOLATED	613545
COMMISSURAL CLEFT, ISOLATED	MACROSTOMIA, ISOLATED	613545
TRANSVERSE CLEFT, ISOLATED	MACROSTOMIA, ISOLATED	613545
AROMATASE DEFICIENCY	AROMATASE DEFICIENCY	613546
PSEUDOHERMAPHRODITISM, FEMALE, DUE TO PLACENTAL AROMATASE DEFICIENCY	AROMATASE DEFICIENCY	613546
STATURE QUANTITATIVE TRAIT LOCUS 22; STQTL22	STATURE QUANTITATIVE TRAIT LOCUS 22; STQTL22	613547
STATURE QUANTITATIVE TRAIT LOCUS 23; STQTL23	STATURE QUANTITATIVE TRAIT LOCUS 23; STQTL23	613548
STATURE QUANTITATIVE TRAIT LOCUS 24; STQTL24	STATURE QUANTITATIVE TRAIT LOCUS 24; STQTL24	613549
NEPHRONOPHTHISIS 11; NPHP11	NEPHRONOPHTHISIS 11; NPHP11	613550
AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 6; AIS6	AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 6; AIS6	613551
VON WILLEBRAND DISEASE, TYPE 2; VWD2	VON WILLEBRAND DISEASE, TYPE 2; VWD2	613554
VON WILLEBRAND DISEASE, TYPE II	VON WILLEBRAND DISEASE, TYPE 2; VWD2	613554
VWD, TYPE 2VON WILLEBRAND DISEASE, TYPE 2A, INCLUDED; VWD2A, INCLUDED	VON WILLEBRAND DISEASE, TYPE 2; VWD2	613554
VON WILLEBRAND DISEASE, TYPE 2B, INCLUDED; VWD2B, INCLUDED	VON WILLEBRAND DISEASE, TYPE 2; VWD2	613554
VON WILLEBRAND DISEASE, TYPE 2M, INCLUDED; VWD2M, INCLUDED	VON WILLEBRAND DISEASE, TYPE 2; VWD2	613554
VON WILLEBRAND DISEASE, TYPE 2N, INCLUDED; VWD2N, INCLUDED	VON WILLEBRAND DISEASE, TYPE 2; VWD2	613554
DEAFNESS, AUTOSOMAL DOMINANT 51; DFNA51	DEAFNESS, AUTOSOMAL DOMINANT 51; DFNA51	613558
CHROMOSOME 9q21.11 DUPLICATION SYNDROME	DEAFNESS, AUTOSOMAL DOMINANT 51; DFNA51	613558
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 7; COXPD7	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 7; COXPD7	613559
MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 2; MLASA2	MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 2; MLASA2	613561
NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTICLEUKEMIA; NSLL	NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTICLEUKEMIA; NSLL	613563
CBL SYNDROME	NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTICLEUKEMIA; NSLL	613563
CBL MUTATION-ASSOCIATED SYNDROME	NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTICLEUKEMIA; NSLL	613563
CHROMOSOME 2p12-p11.2 DELETION SYNDROME	CHROMOSOME 2p12-p11.2 DELETION SYNDROME	613564
FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 6; HBFQTL6	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 6; HBFQTL6	613566
HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN, KLF1-RELATED	FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 6; HBFQTL6	613566
DISORDERED STEROIDOGENESIS DUE TO CYTOCHROME P450 OXIDOREDUCTASE DEFICIENCY	DISORDERED STEROIDOGENESIS DUE TO CYTOCHROME P450 OXIDOREDUCTASE DEFICIENCY	613571
ADRENAL HYPERPLASIA, CONGENITAL, DUE TO CYTOCHROME P450 OXIDOREDUCTASEDEFICIENCY	DISORDERED STEROIDOGENESIS DUE TO CYTOCHROME P450 OXIDOREDUCTASE DEFICIENCY	613571
DISORDERED STEROIDOGENESIS DUE TO POR DEFICIENCY	DISORDERED STEROIDOGENESIS DUE TO CYTOCHROME P450 OXIDOREDUCTASE DEFICIENCY	613571
ECTODERMAL DYSPLASIA-SYNDACTYLY SYNDROME 1; EDSS1	ECTODERMAL DYSPLASIA-SYNDACTYLY SYNDROME 1; EDSS1	613573
RETINITIS PIGMENTOSA 55; RP55	RETINITIS PIGMENTOSA 55; RP55	613575
ECTODERMAL DYSPLASIA-SYNDACTYLY SYNDROME 2; EDSS2	ECTODERMAL DYSPLASIA-SYNDACTYLY SYNDROME 2; EDSS2	613576
RETINITIS PIGMENTOSA 56; RP56MACULOPATHY, IMPG2-RELATED, INCLUDED	RETINITIS PIGMENTOSA 56; RP56MACULOPATHY, IMPG2-RELATED, INCLUDED	613581
RETINITIS PIGMENTOSA 57; RP57	RETINITIS PIGMENTOSA 57; RP57	613582
OCCULT MACULAR DYSTROPHY; OCMD	OCCULT MACULAR DYSTROPHY; OCMD	613587
OMD	OCCULT MACULAR DYSTROPHY; OCMD	613587
LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS6; LDLCQ6	LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS6; LDLCQ6	613589
CHROMOSOME 4q32.1-q32.2 TRIPLICATION SYNDROME	CHROMOSOME 4q32.1-q32.2 TRIPLICATION SYNDROME	613603
CHROMOSOME 16p12.2-p11.2 DELETION SYNDROME, 7.1- TO 8.7-MB	CHROMOSOME 16p12.2-p11.2 DELETION SYNDROME, 7.1- TO 8.7-MB	613604
FORSYTHE-WAKELING SYNDROME; FWS	FORSYTHE-WAKELING SYNDROME; FWS	613606
MICROCEPHALY AND GROWTH RETARDATION WITH CHILDHOOD-ONSET NEPHROTICSYNDROME AND THROMBOCYTOPENIA	FORSYTHE-WAKELING SYNDROME; FWS	613606
EPILEPSY, FAMILIAL ADULT MYOCLONIC, 3; FAME3	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 3; FAME3	613608
CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 3; FCMTE3	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 3; FAME3	613608
CRANIOECTODERMAL DYSPLASIA 2; CED2	CRANIOECTODERMAL DYSPLASIA 2; CED2	613610
CHOANAL ATRESIA AND LYMPHEDEMA	CHOANAL ATRESIA AND LYMPHEDEMA	613611
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi; CDG2I	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi; CDG2I	613612
CDG IIi; CDGIIi	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi; CDG2I	613612
SENIOR-LOKEN SYNDROME 7; SLSN7	SENIOR-LOKEN SYNDROME 7; SLSN7	613615
HYPEROXALURIA, PRIMARY, TYPE III; HP3	HYPEROXALURIA, PRIMARY, TYPE III; HP3	613616
RETINITIS PIGMENTOSA 58; RP58	RETINITIS PIGMENTOSA 58; RP58	613617
CHROMOSOME 17q23.1-q23.2 DUPLICATION SYNDROME	CHROMOSOME 17q23.1-q23.2 DUPLICATION SYNDROME	613618
FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 2; F5F8D2	FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 2; F5F8D2	613625
ODONTOID HYPOPLASIA	ODONTOID HYPOPLASIA	613628
COCOON SYNDROME	COCOON SYNDROME	613630
FETAL ENCASEMENT SYNDROME	COCOON SYNDROME	613630
TUBERCULIN SKIN TEST REACTIVITY, ABSENCE OF	TUBERCULIN SKIN TEST REACTIVITY, ABSENCE OF	613636
TST REACTIVITY, ABSENCE OF	TUBERCULIN SKIN TEST REACTIVITY, ABSENCE OF	613636
TST1	TUBERCULIN SKIN TEST REACTIVITY, ABSENCE OF	613636
TUBERCULIN SKIN TEST REACTIVITY QUANTITATIVE TRAIT LOCUS	TUBERCULIN SKIN TEST REACTIVITY QUANTITATIVE TRAIT LOCUS	613637
TST REACTIVITY QUANTITATIVE TRAIT LOCUS	TUBERCULIN SKIN TEST REACTIVITY QUANTITATIVE TRAIT LOCUS	613637
TST2	TUBERCULIN SKIN TEST REACTIVITY QUANTITATIVE TRAIT LOCUS	613637
CHROMOSOME 19p13.13 DELETION SYNDROMECHROMOSOME 19p13.13 DUPLICATION SYNDROME, INCLUDED	CHROMOSOME 19p13.13 DELETION SYNDROMECHROMOSOME 19p13.13 DUPLICATION SYNDROME, INCLUDED	613638
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IC; HSAN1C	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IC; HSAN1C	613640
HSAN IC	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IC; HSAN1C	613640
NEUROPATHY, HEREDITARY SENSORY, TYPE IC; HSN1C	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IC; HSAN1C	613640
HSN IC	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IC; HSAN1C	613640
CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE B; CMTRIB	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE B; CMTRIB	613641
CHARCOT-MARIE-TOOTH NEUROPATHY, RECESSIVE INTERMEDIATE B; RI-CMTB	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE B; CMTRIB	613641
CARDIOMYOPATHY, DILATED, 1GG; CMD1GG	CARDIOMYOPATHY, DILATED, 1GG; CMD1GG	613642
PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK5	PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK5	613643
METHYLMALONIC ACIDURIA DUE TO TRANSCOBALAMIN RECEPTOR DEFECT	METHYLMALONIC ACIDURIA DUE TO TRANSCOBALAMIN RECEPTOR DEFECT	613646
METHYLMALONIC ACIDEMIA, TCblR TYPE	METHYLMALONIC ACIDURIA DUE TO TRANSCOBALAMIN RECEPTOR DEFECT	613646
SPASTIC PARAPLEGIA 48, AUTOSOMAL RECESSIVE; SPG48	SPASTIC PARAPLEGIA 48, AUTOSOMAL RECESSIVE; SPG48	613647
C1q DEFICIENCY; C1QD	C1q DEFICIENCY; C1QD	613652
MIGRAINE, WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 13; MGR13	MIGRAINE, WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 13; MGR13	613656
D-2-HYDROXYGLUTARIC ACIDURIA 2; D2HGA2	D-2-HYDROXYGLUTARIC ACIDURIA 2; D2HGA2	613657
RAJAB SYNDROME	RAJAB SYNDROME	613658
DEVELOPMENTAL DELAY, SMALL STATURE, MICROCEPHALY, AND BRAIN CALCIFICATIONS	RAJAB SYNDROME	613658
GASTRIC CANCERGASTRIC CANCER, INTESTINAL, INCLUDED	GASTRIC CANCERGASTRIC CANCER, INTESTINAL, INCLUDED	613659
CONE-ROD DYSTROPHY 15; CORD15RETINITIS PIGMENTOSA 65, INCLUDED; RP65, INCLUDED	CONE-ROD DYSTROPHY 15; CORD15RETINITIS PIGMENTOSA 65, INCLUDED; RP65, INCLUDED	613660
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip; CDG1P	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip; CDG1P	613661
MITOCHONDRIAL DNA DEPLETION SYNDROME 4B (MNGIE TYPE); MTDPS4B	MITOCHONDRIAL DNA DEPLETION SYNDROME 4B (MNGIE TYPE); MTDPS4B	613662
MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME, POLG-RELATED	MITOCHONDRIAL DNA DEPLETION SYNDROME 4B (MNGIE TYPE); MTDPS4B	613662
MNGIE, POLG-RELATED	MITOCHONDRIAL DNA DEPLETION SYNDROME 4B (MNGIE TYPE); MTDPS4B	613662
MICROCEPHALY, POSTNATAL PROGRESSIVE, WITH SEIZURES AND BRAIN ATROPHY	MICROCEPHALY, POSTNATAL PROGRESSIVE, WITH SEIZURES AND BRAIN ATROPHY	613668
MENTAL RETARDATION WITH LANGUAGE IMPAIRMENT AND WITH OR WITHOUT AUTISTICFEATURES	MENTAL RETARDATION WITH LANGUAGE IMPAIRMENT AND WITH OR WITHOUT AUTISTICFEATURES	613670
MENTAL RETARDATION, ANTERIOR MAXILLARY PROTRUSION, AND STRABISMUS;MRAMS	MENTAL RETARDATION, ANTERIOR MAXILLARY PROTRUSION, AND STRABISMUS;MRAMS	613671
SPASTIC ATAXIA 4, AUTOSOMAL RECESSIVE; SPAX4	SPASTIC ATAXIA 4, AUTOSOMAL RECESSIVE; SPAX4	613672
ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE IV; CDAN4	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE IV; CDAN4	613673
CDA, TYPE IV	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE IV; CDAN4	613673
VESICOURETERAL REFLUX 3; VUR3	VESICOURETERAL REFLUX 3; VUR3	613674
CHROMOSOME 17q11.2 DELETION SYNDROME, 1.4-MB	CHROMOSOME 17q11.2 DELETION SYNDROME, 1.4-MB	613675
NEUROFIBROMATOSIS 1 MICRODELETION SYNDROME	CHROMOSOME 17q11.2 DELETION SYNDROME, 1.4-MB	613675
NF1 MICRODELETION SYNDROME	CHROMOSOME 17q11.2 DELETION SYNDROME, 1.4-MB	613675
VAN ASPEREN SYNDROMENF1 MICRODUPLICATION SYNDROME, INCLUDED	CHROMOSOME 17q11.2 DELETION SYNDROME, 1.4-MB	613675
SECKEL SYNDROME 4; SCKL4	SECKEL SYNDROME 4; SCKL4	613676
HYPERALDOSTERONISM, FAMILIAL, TYPE III	HYPERALDOSTERONISM, FAMILIAL, TYPE III	613677
FH III	HYPERALDOSTERONISM, FAMILIAL, TYPE III	613677
BRACHYOLMIA TYPE 2; BCYM2	BRACHYOLMIA TYPE 2; BCYM2	613678
BRACHYOLMIA, MAROTEAUX TYPE	BRACHYOLMIA TYPE 2; BCYM2	613678
PROTHROMBIN DEFICIENCY, CONGENITAL	PROTHROMBIN DEFICIENCY, CONGENITAL	613679
HYPOPROTHROMBINEMIADYSPROTHROMBINEMIA, INCLUDED	PROTHROMBIN DEFICIENCY, CONGENITAL	613679
BEAULIEU-BOYCOTT-INNES SYNDROME; BBIS	BEAULIEU-BOYCOTT-INNES SYNDROME; BBIS	613680
MICROCEPHALY, MENTAL RETARDATION, AND DISTINCTIVE FACIES, WITH CARDIACAND GENITOURINARY MALFORMATIONS	BEAULIEU-BOYCOTT-INNES SYNDROME; BBIS	613680
CHROMOSOME 2q31.1 DUPLICATION SYNDROME	CHROMOSOME 2q31.1 DUPLICATION SYNDROME	613681
MESOMELIC DYSPLASIA, 2q31.1 DUPLICATION-RELATED	CHROMOSOME 2q31.1 DUPLICATION SYNDROME	613681
RUBINSTEIN-TAYBI SYNDROME 2; RSTS2	RUBINSTEIN-TAYBI SYNDROME 2; RSTS2	613684
DEAFNESS, AUTOSOMAL RECESSIVE 83; DFNB83	DEAFNESS, AUTOSOMAL RECESSIVE 83; DFNB83	613685
SPONDYLOCOSTAL DYSOSTOSIS 4, AUTOSOMAL RECESSIVE; SCDO4	SPONDYLOCOSTAL DYSOSTOSIS 4, AUTOSOMAL RECESSIVE; SCDO4	613686
LONG QT SYNDROME 2; LQT2LONG QT SYNDROME 2, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	LONG QT SYNDROME 2; LQT2LONG QT SYNDROME 2, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	613688
LONG QT SYNDROME 1/2, DIGENIC, INCLUDED; LQT1/2, DIGENIC, INCLUDED	LONG QT SYNDROME 2; LQT2LONG QT SYNDROME 2, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	613688
LONG QT SYNDROME 2/3, DIGENIC, INCLUDED; LQT2/3, DIGENIC, INCLUDED	LONG QT SYNDROME 2; LQT2LONG QT SYNDROME 2, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	613688
LONG QT SYNDROME 2/5, DIGENIC, INCLUDED; LQT2/5, DIGENIC, INCLUDED	LONG QT SYNDROME 2; LQT2LONG QT SYNDROME 2, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	613688
LONG QT SYNDROME 2/9, DIGENIC, INCLUDED; LQT2/9, DIGENIC, INCLUDED	LONG QT SYNDROME 2; LQT2LONG QT SYNDROME 2, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	613688
MAMMARY-DIGITAL-NAIL SYNDROME; MDNS	MAMMARY-DIGITAL-NAIL SYNDROME; MDNS	613689
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 7; CMH7	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 7; CMH7	613690
LONG QT SYNDROME 6; LQT6LONG QT SYNDROME 6, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	LONG QT SYNDROME 6; LQT6LONG QT SYNDROME 6, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	613693
LONG QT SYNDROME 3/6, DIGENIC, INCLUDED; LQT3/6, DIGENIC, INCLUDED	LONG QT SYNDROME 6; LQT6LONG QT SYNDROME 6, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	613693
CARDIOMYOPATHY, DILATED, 1U; CMD1U	CARDIOMYOPATHY, DILATED, 1U; CMD1U	613694
LONG QT SYNDROME 5; LQT5LONG QT SYNDROME 5, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	LONG QT SYNDROME 5; LQT5LONG QT SYNDROME 5, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	613695
LONG QT SYNDROME 2/5, DIGENIC, INCLUDED; LQT2/5, DIGENIC, INCLUDED	LONG QT SYNDROME 5; LQT5LONG QT SYNDROME 5, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED	613695
CARDIOMYOPATHY, DILATED, 1V; CMD1V	CARDIOMYOPATHY, DILATED, 1V; CMD1V	613697
SUPERNUMERARY DER(22)t(8;22) SYNDROME	SUPERNUMERARY DER(22)t(8;22) SYNDROME	613700
KLIPPEL-FEIL SYNDROME 3, AUTOSOMAL DOMINANT; KFS3	KLIPPEL-FEIL SYNDROME 3, AUTOSOMAL DOMINANT; KFS3	613702
MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 6; MCOPCB6	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 6; MCOPCB6	613703
MICROPHTHALMIA, ISOLATED 7; MCOP7	MICROPHTHALMIA, ISOLATED 7; MCOP7	613704
OROFACIAL CLEFT 10; OFC10	OROFACIAL CLEFT 10; OFC10	613705
CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 10	OROFACIAL CLEFT 10; OFC10	613705
NOONAN SYNDROME 7; NS7	NOONAN SYNDROME 7; NS7	613706
LEOPARD SYNDROME 3; LPRD3	LEOPARD SYNDROME 3; LPRD3	613707
NEUROPATHY, HEREDITARY SENSORY, TYPE ID; HSN1D	NEUROPATHY, HEREDITARY SENSORY, TYPE ID; HSN1D	613708
THIAMINE METABOLISM DYSFUNCTION SYNDROME 4 (BILATERAL STRIATAL DEGENERATIONAND PROGRESSIVE POLYNEUROPATHY TYPE); THMD4	THIAMINE METABOLISM DYSFUNCTION SYNDROME 4 (BILATERAL STRIATAL DEGENERATIONAND PROGRESSIVE POLYNEUROPATHY TYPE); THMD4	613710
BILATERAL STRIATAL DEGENERATION AND PROGRESSIVE POLYNEUROPATHY	THIAMINE METABOLISM DYSFUNCTION SYNDROME 4 (BILATERAL STRIATAL DEGENERATIONAND PROGRESSIVE POLYNEUROPATHY TYPE); THMD4	613710
STRIATAL NECROSIS, BILATERAL, AND PROGRESSIVE POLYNEUROPATHY	THIAMINE METABOLISM DYSFUNCTION SYNDROME 4 (BILATERAL STRIATAL DEGENERATIONAND PROGRESSIVE POLYNEUROPATHY TYPE); THMD4	613710
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 3; HSCR3	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 3; HSCR3	613711
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 4; HSCR4	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 4; HSCR4	613712
TREACHER COLLINS SYNDROME 2; TCS2	TREACHER COLLINS SYNDROME 2; TCS2	613717
DEAFNESS, AUTOSOMAL RECESSIVE 74; DFNB74	DEAFNESS, AUTOSOMAL RECESSIVE 74; DFNB74	613718
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 7; EIEE7	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 7; EIEE7	613720
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 11; EIEE11	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 11; EIEE11	613721
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 12; EIEE12	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 12; EIEE12	613722
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2Q; LGMD2Q	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2Q; LGMD2Q	613723
LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY	LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY	613724
STEROL CARRIER PROTEIN 2 DEFICIENCY	LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY	613724
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 10; SCAR10	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 10; SCAR10	613728
CHROMOSOME 7q11.23 DELETION SYNDROME, DISTAL, 1.2-MB	CHROMOSOME 7q11.23 DELETION SYNDROME, DISTAL, 1.2-MB	613729
DISTAL CHROMOSOME 7q11.23 DELETION SYNDROME	CHROMOSOME 7q11.23 DELETION SYNDROME, DISTAL, 1.2-MB	613729
HEMORRHAGIC DESTRUCTION OF THE BRAIN, SUBEPENDYMAL CALCIFICATION,AND CATARACTS; HDBSCC	HEMORRHAGIC DESTRUCTION OF THE BRAIN, SUBEPENDYMAL CALCIFICATION,AND CATARACTS; HDBSCC	613730
RETINITIS PIGMENTOSA 4; RP4	RETINITIS PIGMENTOSA 4; RP4	613731
RETINITIS PIGMENTOSA, RHODOPSIN-RELATED	RETINITIS PIGMENTOSA 4; RP4	613731
CHROMOSOME 1p32-p31 DELETION SYNDROME	CHROMOSOME 1p32-p31 DELETION SYNDROME	613735
ACNE INVERSA, FAMILIAL, 2; ACNINV2	ACNE INVERSA, FAMILIAL, 2; ACNINV2	613736
ACNE INVERSA, FAMILIAL, 3; ACNINV3	ACNE INVERSA, FAMILIAL, 3; ACNINV3	613737
CARDIOMYOPATHY, DILATED, 1T; CMD1T	CARDIOMYOPATHY, DILATED, 1T; CMD1T	613740
ADRENAL INSUFFICIENCY, CONGENITAL, WITH 46,XY SEX REVERSAL, PARTIALOR COMPLETE	ADRENAL INSUFFICIENCY, CONGENITAL, WITH 46,XY SEX REVERSAL, PARTIALOR COMPLETE	613743
P450scc DEFICIENCY	ADRENAL INSUFFICIENCY, CONGENITAL, WITH 46,XY SEX REVERSAL, PARTIALOR COMPLETE	613743
SPASTIC PARAPLEGIA 51, AUTOSOMAL RECESSIVE; SPG51	SPASTIC PARAPLEGIA 51, AUTOSOMAL RECESSIVE; SPG51	613744
CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 4, FORMERLY; CPSQ4, FORMERLY	SPASTIC PARAPLEGIA 51, AUTOSOMAL RECESSIVE; SPG51	613744
RETINITIS PIGMENTOSA 27; RP27	RETINITIS PIGMENTOSA 27; RP27	613750
HETEROTAXY, VISCERAL, 4, AUTOSOMAL; HTX4	HETEROTAXY, VISCERAL, 4, AUTOSOMAL; HTX4	613751
HYPERMETHIONINEMIA WITH S-ADENOSYLHOMOCYSTEINE HYDROLASE DEFICIENCY	HYPERMETHIONINEMIA WITH S-ADENOSYLHOMOCYSTEINE HYDROLASE DEFICIENCY	613752
RETINITIS PIGMENTOSA 49; RP49	RETINITIS PIGMENTOSA 49; RP49	613756
MACULAR DEGENERATION, AGE-RELATED, 6; ARMD6	MACULAR DEGENERATION, AGE-RELATED, 6; ARMD6	613757
RETINITIS PIGMENTOSA 47; RP47	RETINITIS PIGMENTOSA 47; RP47	613758
INFECTIONS, RECURRENT, WITH ENCEPHALOPATHY, HEPATIC DYSFUNCTION, ANDCARDIOVASCULAR MALFORMATIONS	INFECTIONS, RECURRENT, WITH ENCEPHALOPATHY, HEPATIC DYSFUNCTION, ANDCARDIOVASCULAR MALFORMATIONS	613759
FADD DEFICIENCY	INFECTIONS, RECURRENT, WITH ENCEPHALOPATHY, HEPATIC DYSFUNCTION, ANDCARDIOVASCULAR MALFORMATIONS	613759
MACULAR DEGENERATION, AGE-RELATED, 5; ARMD5	MACULAR DEGENERATION, AGE-RELATED, 5; ARMD5	613761
46,XY SEX REVERSAL 6; SRXY6	46,XY SEX REVERSAL 6; SRXY6	613762
46,XY SEX REVERSAL, PARTIAL OR COMPLETE, MAP3K1-RELATED	46,XY SEX REVERSAL 6; SRXY6	613762
46,XY GONADAL DYSGENESIS, PARTIAL OR COMPLETE, MAP3K1-RELATED	46,XY SEX REVERSAL 6; SRXY6	613762
CATARACT 16, MULTIPLE TYPES; CTRCT16CATARACT, POSTERIOR POLAR, 2; CTPP2	CATARACT 16, MULTIPLE TYPES; CTRCT16CATARACT, POSTERIOR POLAR, 2; CTPP2	613763
CATARACT, CONGENITAL LAMELLAR	CATARACT 16, MULTIPLE TYPES; CTRCT16CATARACT, POSTERIOR POLAR, 2; CTPP2	613763
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 9; CMH9	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 9; CMH9	613765
RETINITIS PIGMENTOSA 45; RP45	RETINITIS PIGMENTOSA 45; RP45	613767
RETINITIS PIGMENTOSA 44; RP44	RETINITIS PIGMENTOSA 44; RP44	613769
CHROMOSOME 17p13.1 DELETION SYNDROME	CHROMOSOME 17p13.1 DELETION SYNDROME	613776
MACULAR DEGENERATION, AGE-RELATED, 8; ARMD8	MACULAR DEGENERATION, AGE-RELATED, 8; ARMD8	613778
COMPLEMENT COMPONENT 3 DEFICIENCY, AUTOSOMAL RECESSIVE; C3D	COMPLEMENT COMPONENT 3 DEFICIENCY, AUTOSOMAL RECESSIVE; C3D	613779
C3 DEFICIENCY, AUTOSOMAL RECESSIVE	COMPLEMENT COMPONENT 3 DEFICIENCY, AUTOSOMAL RECESSIVE; C3D	613779
AORTIC ANEURYSM, FAMILIAL THORACIC 7; AAT7	AORTIC ANEURYSM, FAMILIAL THORACIC 7; AAT7	613780
AORTIC DISSECTION, FAMILIAL, WITH OR WITHOUT AORTIC ANEURYSM	AORTIC ANEURYSM, FAMILIAL THORACIC 7; AAT7	613780
COMPLEMENT COMPONENT C1s DEFICIENCY; C1SD	COMPLEMENT COMPONENT C1s DEFICIENCY; C1SD	613783
C1s DEFICIENCY	COMPLEMENT COMPONENT C1s DEFICIENCY; C1SD	613783
MACULAR DEGENERATION, AGE-RELATED, 12; ARMD12	MACULAR DEGENERATION, AGE-RELATED, 12; ARMD12	613784
COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE II; C8D2	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE II; C8D2	613789
C8 DEFICIENCY, TYPE II	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE II; C8D2	613789
COMPLEMENT COMPONENT 8B DEFICIENCY	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE II; C8D2	613789
C8 BETA DEFICIENCY	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE II; C8D2	613789
C8B DEFICIENCY	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE II; C8D2	613789
COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE I; C8D1	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE I; C8D1	613790
C8 DEFICIENCY, TYPE I	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE I; C8D1	613790
C8 ALPHA-GAMMA DEFICIENCY	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE I; C8D1	613790
C8AG DEFICIENCY	COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE I; C8D1	613790
MASP2 DEFICIENCY	MASP2 DEFICIENCY	613791
CHROMOSOME 3pter-p25 DELETION SYNDROME	CHROMOSOME 3pter-p25 DELETION SYNDROME	613792
3p- SYNDROME	CHROMOSOME 3pter-p25 DELETION SYNDROME	613792
BLOOD GROUP, CROMER SYSTEM; CROM	BLOOD GROUP, CROMER SYSTEM; CROM	613793
CROMER BLOOD GROUP SYSTEM	BLOOD GROUP, CROMER SYSTEM; CROM	613793
RETINITIS PIGMENTOSA 20; RP20	RETINITIS PIGMENTOSA 20; RP20	613794
LOEYS-DIETZ SYNDROME 3; LDS3	LOEYS-DIETZ SYNDROME 3; LDS3	613795
ANEURYSMS-OSTEOARTHRITIS SYNDROME	LOEYS-DIETZ SYNDROME 3; LDS3	613795
LOEYS-DIETZ SYNDROME WITH OSTEOARTHRITIS	LOEYS-DIETZ SYNDROME 3; LDS3	613795
LOEYS-DIETZ SYNDROME, TYPE 1C, FORMERLY; LDS1C, FORMERLY	LOEYS-DIETZ SYNDROME 3; LDS3	613795
IMMUNODEFICIENCY 31B; IMD31B	IMMUNODEFICIENCY 31B; IMD31B	613796
IMMUNODEFICIENCY 31B, MYCOBACTERIAL AND VIRAL INFECTIONS, AUTOSOMALRECESSIVE	IMMUNODEFICIENCY 31B; IMD31B	613796
STAT1 DEFICIENCY, AUTOSOMAL RECESSIVE	IMMUNODEFICIENCY 31B; IMD31B	613796
MEIER-GORLIN SYNDROME 2; MGORS2	MEIER-GORLIN SYNDROME 2; MGORS2	613800
RETINITIS PIGMENTOSA 40; RP40	RETINITIS PIGMENTOSA 40; RP40	613801
MEIER-GORLIN SYNDROME 3; MGORS3	MEIER-GORLIN SYNDROME 3; MGORS3	613803
MEIER-GORLIN SYNDROME 4; MGORS4	MEIER-GORLIN SYNDROME 4; MGORS4	613804
MEIER-GORLIN SYNDROME 5; MGORS5	MEIER-GORLIN SYNDROME 5; MGORS5	613805
CHOLANGITIS, PRIMARY SCLEROSING; PSC	CHOLANGITIS, PRIMARY SCLEROSING; PSC	613806
CILIARY DYSKINESIA, PRIMARY, 14; CILD14	CILIARY DYSKINESIA, PRIMARY, 14; CILD14	613807
CILIARY DYSKINESIA, PRIMARY, 14, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 14; CILD14	613807
CILIARY DYSKINESIA, PRIMARY, 15; CILD15	CILIARY DYSKINESIA, PRIMARY, 15; CILD15	613808
CILIARY DYSKINESIA, PRIMARY, 15, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 15; CILD15	613808
RETINITIS PIGMENTOSA 39; RP39	RETINITIS PIGMENTOSA 39; RP39	613809
RETINITIS PIGMENTOSA 43; RP43	RETINITIS PIGMENTOSA 43; RP43	613810
PONTOCEREBELLAR HYPOPLASIA, TYPE 2D; PCH2D	PONTOCEREBELLAR HYPOPLASIA, TYPE 2D; PCH2D	613811
CEREBELLOCEREBRAL ATROPHY, PROGRESSIVE; PCCA	PONTOCEREBELLAR HYPOPLASIA, TYPE 2D; PCH2D	613811
CEREBELLO-CEREBRAL ATROPHY, PROGRESSIVE	PONTOCEREBELLAR HYPOPLASIA, TYPE 2D; PCH2D	613811
BILE ACID SYNTHESIS DEFECT, CONGENITAL, 3; CBAS3	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 3; CBAS3	613812
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 9; MDDGC9	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 9; MDDGC9	613818
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2P; LGMD2P	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 9; MDDGC9	613818
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, DAG1-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 9; MDDGC9	613818
SHORT-RIB THORACIC DYSPLASIA 4 WITH OR WITHOUT POLYDACTYLY; SRTD4	SHORT-RIB THORACIC DYSPLASIA 4 WITH OR WITHOUT POLYDACTYLY; SRTD4	613819
ASPHYXIATING THORACIC DYSTROPHY 4; ATD4	SHORT-RIB THORACIC DYSPLASIA 4 WITH OR WITHOUT POLYDACTYLY; SRTD4	613819
NEPHRONOPHTHISIS 12; NPHP12JOUBERT SYNDROME 11, INCLUDED; JBTS11, INCLUDED	NEPHRONOPHTHISIS 12; NPHP12JOUBERT SYNDROME 11, INCLUDED; JBTS11, INCLUDED	613820
SECKEL SYNDROME 5; SCKL5	SECKEL SYNDROME 5; SCKL5	613823
NEPHRONOPHTHISIS 9; NPHP9	NEPHRONOPHTHISIS 9; NPHP9	613824
COMPLEMENT COMPONENT 9 DEFICIENCY; C9D	COMPLEMENT COMPONENT 9 DEFICIENCY; C9D	613825
C9 DEFICIENCY	COMPLEMENT COMPONENT 9 DEFICIENCY; C9D	613825
LEBER CONGENITAL AMAUROSIS 6; LCA6	LEBER CONGENITAL AMAUROSIS 6; LCA6	613826
RETINITIS PIGMENTOSA 48; RP48	RETINITIS PIGMENTOSA 48; RP48	613827
GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 8; GEFSP8	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 8; GEFSP8	613828
GEFS+, TYPE 8; GEFS+8	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 8; GEFSP8	613828
LEBER CONGENITAL AMAUROSIS 7; LCA7	LEBER CONGENITAL AMAUROSIS 7; LCA7	613829
NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1D; CSNB1D	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1D; CSNB1D	613830
CSNB, COMPLETE, AUTOSOMAL RECESSIVE	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1D; CSNB1D	613830
EPILEPSY, PROGRESSIVE MYOCLONIC, 5; EPM5	EPILEPSY, PROGRESSIVE MYOCLONIC, 5; EPM5	613832
MULTISYSTEMIC SMOOTH MUSCLE DYSFUNCTION SYNDROME	MULTISYSTEMIC SMOOTH MUSCLE DYSFUNCTION SYNDROME	613834
MYDRIASIS, CONGENITAL, WITH PATENT DUCTUS ARTERIOSUS, THORACIC AORTICANEURYSM, AND VASCULOPATHY	MULTISYSTEMIC SMOOTH MUSCLE DYSFUNCTION SYNDROME	613834
LEBER CONGENITAL AMAUROSIS 8; LCA8	LEBER CONGENITAL AMAUROSIS 8; LCA8	613835
ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 5; ADIPQTL5	ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 5; ADIPQTL5	613836
LEBER CONGENITAL AMAUROSIS 11; LCA11	LEBER CONGENITAL AMAUROSIS 11; LCA11	613837
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 16; CMH16	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 16; CMH16	613838
MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY	MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY	613839
DHFR DEFICIENCY	MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY	613839
LEBER CONGENITAL AMAUROSIS 15; LCA15RETINITIS PIGMENTOSA, JUVENILE, TULP1-RELATED, INCLUDED	LEBER CONGENITAL AMAUROSIS 15; LCA15RETINITIS PIGMENTOSA, JUVENILE, TULP1-RELATED, INCLUDED	613843
HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSISSYNDROME; HUPRAS	HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSISSYNDROME; HUPRAS	613845
HUPRA SYNDROME	HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSISSYNDROME; HUPRAS	613845
OSTEOGENESIS IMPERFECTA, TYPE X; OI10	OSTEOGENESIS IMPERFECTA, TYPE X; OI10	613848
OI, TYPE X	OSTEOGENESIS IMPERFECTA, TYPE X; OI10	613848
OSTEOGENESIS IMPERFECTA, TYPE XII; OI12	OSTEOGENESIS IMPERFECTA, TYPE XII; OI12	613849
OI, TYPE XII	OSTEOGENESIS IMPERFECTA, TYPE XII; OI12	613849
INOSINE TRIPHOSPHATASE DEFICIENCY	INOSINE TRIPHOSPHATASE DEFICIENCY	613850
INOSINE TRIPHOSPHATE PYROPHOSPHOHYDROLASE DEFICIENCY	INOSINE TRIPHOSPHATASE DEFICIENCY	613850
FUCOSYLTRANSFERASE 6 DEFICIENCY	FUCOSYLTRANSFERASE 6 DEFICIENCY	613852
TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 3; DTGA3	TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 3; DTGA3	613854
EPISODIC ATAXIA, TYPE 5; EA5	EPISODIC ATAXIA, TYPE 5; EA5	613855
ACHROMATOPSIA 4; ACHM4	ACHROMATOPSIA 4; ACHM4	613856
OROFACIAL CLEFT 13; OFC13	OROFACIAL CLEFT 13; OFC13	613857
IMMUNODEFICIENCY DUE TO FICOLIN 3 DEFICIENCY	IMMUNODEFICIENCY DUE TO FICOLIN 3 DEFICIENCY	613860
FICOLIN 3 DEFICIENCY	IMMUNODEFICIENCY DUE TO FICOLIN 3 DEFICIENCY	613860
FCN3 DEFICIENCY	IMMUNODEFICIENCY DUE TO FICOLIN 3 DEFICIENCY	613860
RETINITIS PIGMENTOSA 59; RP59	RETINITIS PIGMENTOSA 59; RP59	613861
RETINITIS PIGMENTOSA 38; RP38	RETINITIS PIGMENTOSA 38; RP38	613862
ROD-CONE DYSTROPHY, CHILDHOOD-ONSET	RETINITIS PIGMENTOSA 38; RP38	613862
GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 7; GEFSP7	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 7; GEFSP7	613863
GEFS+, TYPE 7; GEFS+7FEBRILE SEIZURES, FAMILIAL, 3B, INCLUDED; FEB3B, INCLUDED	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 7; GEFSP7	613863
DEAFNESS, AUTOSOMAL RECESSIVE 61; DFNB61	DEAFNESS, AUTOSOMAL RECESSIVE 61; DFNB61	613865
MYOPATHY, MYOFIBRILLAR, FATAL INFANTILE HYPERTONIC, ALPHA-B CRYSTALLIN-RELATED	MYOPATHY, MYOFIBRILLAR, FATAL INFANTILE HYPERTONIC, ALPHA-B CRYSTALLIN-RELATED	613869
MFM, FATAL INFANTILE HYPERTONIC, ALPHA-B CRYSTALLIN-RELATED	MYOPATHY, MYOFIBRILLAR, FATAL INFANTILE HYPERTONIC, ALPHA-B CRYSTALLIN-RELATED	613869
HIRSCHSPRUNG DISEASE, CARDIAC DEFECTS, AND AUTONOMIC DYSFUNCTION	HIRSCHSPRUNG DISEASE, CARDIAC DEFECTS, AND AUTONOMIC DYSFUNCTION	613870
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 17; CMH17	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 17; CMH17	613873
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 18; CMH18	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 18; CMH18	613874
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 19; CMH19	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 19; CMH19	613875
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 20; CMH20	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 20; CMH20	613876
LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 4; FPLD4	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 4; FPLD4	613877
LIPODYSTROPHY, FAMILIAL PARTIAL, ASSOCIATED WITH PLIN1 MUTATIONS	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 4; FPLD4	613877
CARDIOMYOPATHY, DILATED, 1HH; CMD1HH	CARDIOMYOPATHY, DILATED, 1HH; CMD1HH	613881
HYPOMAGNESEMIA 6, RENAL; HOMG6	HYPOMAGNESEMIA 6, RENAL; HOMG6	613882
CHROMOSOME 13q14 DELETION SYNDROME	CHROMOSOME 13q14 DELETION SYNDROME	613884
CHROMOSOME 13q DELETION SYNDROME	CHROMOSOME 13q14 DELETION SYNDROME	613884
MECKEL SYNDROME, TYPE 8; MKS8	MECKEL SYNDROME, TYPE 8; MKS8	613885
OBESITY, HYPERPHAGIA, AND DEVELOPMENTAL DELAY; OBHD	OBESITY, HYPERPHAGIA, AND DEVELOPMENTAL DELAY; OBHD	613886
CATARACT 36; CTRCT36	CATARACT 36; CTRCT36	613887
CATARACT, AUTOSOMAL RECESSIVE CONGENITAL 4; CATC4	CATARACT 36; CTRCT36	613887
SPINOCEREBELLAR ATAXIA 35; SCA35	SPINOCEREBELLAR ATAXIA 35; SCA35	613908
SPINOCEREBELLAR ATAXIA 32; SCA32	SPINOCEREBELLAR ATAXIA 32; SCA32	613909
COMPLEMENT FACTOR D DEFICIENCY; CFDD	COMPLEMENT FACTOR D DEFICIENCY; CFDD	613912
FACTOR D DEFICIENCY	COMPLEMENT FACTOR D DEFICIENCY; CFDD	613912
LIPODYSTROPHY, PARTIAL, ACQUIRED, WITH LOW COMPLEMENT COMPONENT C3,WITH OR WITHOUT GLOMERULONEPHRITIS; APLDC3	LIPODYSTROPHY, PARTIAL, ACQUIRED, WITH LOW COMPLEMENT COMPONENT C3,WITH OR WITHOUT GLOMERULONEPHRITIS; APLDC3	613913
LIPODYSTROPHY, PARTIAL, ACQUIRED, ASSOCIATED WITH C3 NEPHRITIC FACTOR	LIPODYSTROPHY, PARTIAL, ACQUIRED, WITH LOW COMPLEMENT COMPONENT C3,WITH OR WITHOUT GLOMERULONEPHRITIS; APLDC3	613913
DEAFNESS, AUTOSOMAL RECESSIVE 89; DFNB89	DEAFNESS, AUTOSOMAL RECESSIVE 89; DFNB89	613916
MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 2A; MLC2A	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 2A; MLC2A	613925
MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 2B, REMITTING,WITH OR WITHOUT MENTAL RETARDATION; MLC2B	MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 2B, REMITTING,WITH OR WITHOUT MENTAL RETARDATION; MLC2B	613926
ALOPECIA-MENTAL RETARDATION SYNDROME 3; APMR3	ALOPECIA-MENTAL RETARDATION SYNDROME 3; APMR3	613930
ACETYL-CoA CARBOXYLASE DEFICIENCY; ACACAD	ACETYL-CoA CARBOXYLASE DEFICIENCY; ACACAD	613933
ACACA DEFICIENCY	ACETYL-CoA CARBOXYLASE DEFICIENCY; ACACAD	613933
ACC1 DEFICIENCY	ACETYL-CoA CARBOXYLASE DEFICIENCY; ACACAD	613933
PARASOMNIA, SLEEPWALKING TYPE; PSMNSWPARASOMNIA, SLEEP TERRORS TYPE, INCLUDED; PSMNST, INCLUDED	PARASOMNIA, SLEEPWALKING TYPE; PSMNSWPARASOMNIA, SLEEP TERRORS TYPE, INCLUDED; PSMNST, INCLUDED	613938
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 8; ARCI8	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 8; ARCI8	613943
LAMELLAR ICHTHYOSIS, LATE-ONSET	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 8; ARCI8	613943
ICHTHYOSIS, LAMELLAR, 4, FORMERLY; LI4, FORMERLY	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 8; ARCI8	613943
IgA NEPHROPATHY, SUSCEPTIBILITY TO, 2; IGAN2	IgA NEPHROPATHY, SUSCEPTIBILITY TO, 2; IGAN2	613944
OKT4 EPITOPE DEFICIENCY	OKT4 EPITOPE DEFICIENCY	613949
T4 EPITOPE DEFICIENCY	OKT4 EPITOPE DEFICIENCY	613949
SCHIZOPHRENIA 15; SCZD15	SCHIZOPHRENIA 15; SCZD15	613950
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 22q13-RELATED	SCHIZOPHRENIA 15; SCZD15	613950
FANCONI ANEMIA, COMPLEMENTATION GROUP P; FANCP	FANCONI ANEMIA, COMPLEMENTATION GROUP P; FANCP	613951
CANDIDIASIS, FAMILIAL, 5; CANDF5	CANDIDIASIS, FAMILIAL, 5; CANDF5	613953
CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL RECESSIVE	CANDIDIASIS, FAMILIAL, 5; CANDF5	613953
AMYOTROPHIC LATERAL SCLEROSIS 14 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS14	AMYOTROPHIC LATERAL SCLEROSIS 14 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS14	613954
AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 2; PLCA2	AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 2; PLCA2	613955
CANDIDIASIS, FAMILIAL, 6; CANDF6	CANDIDIASIS, FAMILIAL, 6; CANDF6	613956
CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL DOMINANT	CANDIDIASIS, FAMILIAL, 6; CANDF6	613956
SPERMATOGENIC FAILURE 8; SPGF8	SPERMATOGENIC FAILURE 8; SPGF8	613957
SPERMATOGENIC FAILURE 9; SPGF9	SPERMATOGENIC FAILURE 9; SPGF9	613958
GLOBOZOOSPERMIA, COMPLETE	SPERMATOGENIC FAILURE 9; SPGF9	613958
GLOBOZOOSPERMIA, TOTAL	SPERMATOGENIC FAILURE 9; SPGF9	613958
SCHIZOPHRENIA 16; SCZD16	SCHIZOPHRENIA 16; SCZD16	613959
SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 7q36.3-RELATED	SCHIZOPHRENIA 16; SCZD16	613959
CHROMOSOME 7q36.3 DUPLICATION SYNDROME, 362-KB	SCHIZOPHRENIA 16; SCZD16	613959
GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE III	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE III	613960
CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE III	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE III	613960
GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF4 DEFICIENCY	GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE,TYPE III	613960
MYOPIA 19, AUTOSOMAL DOMINANT; MYP19	MYOPIA 19, AUTOSOMAL DOMINANT; MYP19	613969
MENTAL RETARDATION, AUTOSOMAL DOMINANT 6; MRD6	MENTAL RETARDATION, AUTOSOMAL DOMINANT 6; MRD6	613970
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 6; CMM6	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 6; CMM6	613972
CYANOSIS, TRANSIENT NEONATAL; TNCY	CYANOSIS, TRANSIENT NEONATAL; TNCY	613977
HEMOGLOBIN H DISEASE; HBH	HEMOGLOBIN H DISEASE; HBH	613978
ALPHA-THALASSEMIA, HEMOGLOBIN H TYPE	HEMOGLOBIN H DISEASE; HBH	613978
HEMOGLOBIN H DISEASE, DELETIONALHEMOGLOBIN H DISEASE, NONDELETIONAL, INCLUDED	HEMOGLOBIN H DISEASE; HBH	613978
ATRIAL FIBRILLATION, FAMILIAL, 9; ATFB9	ATRIAL FIBRILLATION, FAMILIAL, 9; ATFB9	613980
HYPOTRICHOSIS 3; HYPT3	HYPOTRICHOSIS 3; HYPT3	613981
HYPOTRICHOSIS SIMPLEX OF THE SCALP 2; HTSS2	HYPOTRICHOSIS 3; HYPT3	613981
OSTEOGENESIS IMPERFECTA, TYPE VI; OI6	OSTEOGENESIS IMPERFECTA, TYPE VI; OI6	613982
RETINITIS PIGMENTOSA 60; RP60	RETINITIS PIGMENTOSA 60; RP60	613983
BETA-THALASSEMIA	BETA-THALASSEMIA	613985
PITUITARY HORMONE DEFICIENCY, COMBINED, 6; CPHD6	PITUITARY HORMONE DEFICIENCY, COMBINED, 6; CPHD6	613986
DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 2; DKCB2	DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 2; DKCB2	613987
DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 3; DKCB3	DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 3; DKCB3	613988
DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 2; DKCA2DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 4, INCLUDED; DKCB4, INCLUDED	DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 2; DKCA2DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 4, INCLUDED; DKCB4, INCLUDED	613989
DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3; DKCA3	DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3; DKCA3	613990
NESTOR-GUILLERMO PROGERIA SYNDROME; NGPS	NESTOR-GUILLERMO PROGERIA SYNDROME; NGPS	614008
PROGERIA SYNDROME, CHILDHOOD-ONSET, WITH OSTEOLYSIS; PSCOO	NESTOR-GUILLERMO PROGERIA SYNDROME; NGPS	614008
BLEEDING DISORDER, PLATELET-TYPE, 13, SUSCEPTIBILITY TO; BDPLT13	BLEEDING DISORDER, PLATELET-TYPE, 13, SUSCEPTIBILITY TO; BDPLT13	614009
BLEEDING DISORDER, SUSCEPTIBILITY TO, DUE TO DEFECTIVE PLATELET THROMBOXANEA2 RECEPTOR	BLEEDING DISORDER, PLATELET-TYPE, 13, SUSCEPTIBILITY TO; BDPLT13	614009
CILIARY DYSKINESIA, PRIMARY, 16; CILD16	CILIARY DYSKINESIA, PRIMARY, 16; CILD16	614017
CILIARY DYSKINESIA, PRIMARY, 16, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 16; CILD16	614017
EPILEPSY, PROGRESSIVE MYOCLONIC, 6; EPM6	EPILEPSY, PROGRESSIVE MYOCLONIC, 6; EPM6	614018
LISSENCEPHALY 4; LIS4	LISSENCEPHALY 4; LIS4	614019
LISSENCEPHALY 4, WITH MICROCEPHALY	LISSENCEPHALY 4; LIS4	614019
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 14; MRT14	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 14; MRT14	614020
VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 3; CPVT3	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 3; CPVT3	614021
ATRIAL FIBRILLATION, FAMILIAL, 10; ATFB10	ATRIAL FIBRILLATION, FAMILIAL, 10; ATFB10	614022
PHOSPHOSERINE PHOSPHATASE DEFICIENCY; PSPHD	PHOSPHOSERINE PHOSPHATASE DEFICIENCY; PSPHD	614023
PROTEIN Z DEFICIENCY	PROTEIN Z DEFICIENCY	614024
HEPATIC LIPASE DEFICIENCY	HEPATIC LIPASE DEFICIENCY	614025
LIPC DEFICIENCY	HEPATIC LIPASE DEFICIENCY	614025
HL DEFICIENCY	HEPATIC LIPASE DEFICIENCY	614025
APOLIPOPROTEIN C-III DEFICIENCY	APOLIPOPROTEIN C-III DEFICIENCY	614028
HYPERALPHALIPOPROTEINEMIA 2; HALP2	APOLIPOPROTEIN C-III DEFICIENCY	614028
HEME OXYGENASE 1 DEFICIENCY; HMOX1D	HEME OXYGENASE 1 DEFICIENCY; HMOX1D	614034
DEAFNESS, AUTOSOMAL RECESSIVE 29; DFNB29	DEAFNESS, AUTOSOMAL RECESSIVE 29; DFNB29	614035
LYMPHEDEMA, PRIMARY, WITH MYELODYSPLASIA	LYMPHEDEMA, PRIMARY, WITH MYELODYSPLASIA	614038
EMBERGER SYNDROME	LYMPHEDEMA, PRIMARY, WITH MYELODYSPLASIA	614038
CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 1; CDCBM1	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 1; CDCBM1	614039
MOYAMOYA DISEASE 5; MYMY5	MOYAMOYA DISEASE 5; MYMY5	614042
ATRIAL FIBRILLATION, FAMILIAL, 11; ATFB11	ATRIAL FIBRILLATION, FAMILIAL, 11; ATFB11	614049
ATRIAL FIBRILLATION, FAMILIAL, 12; ATFB12	ATRIAL FIBRILLATION, FAMILIAL, 12; ATFB12	614050
MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 2;MC5DN2	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 2;MC5DN2	614052
MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, TMEM70 TYPE	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 2;MC5DN2	614052
ENCEPHALOCARDIOMYOPATHY, MITOCHONDRIAL, NEONATAL, DUE TO ATP SYNTHASEDEFICIENCY	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 2;MC5DN2	614052
MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 3;MC5DN3	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 3;MC5DN3	614053
MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, ATP5E TYPE	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 3;MC5DN3	614053
N-ACETYLASPARTATE DEFICIENCY; NACED	N-ACETYLASPARTATE DEFICIENCY; NACED	614063
NAA DEFICIENCY	N-ACETYLASPARTATE DEFICIENCY; NACED	614063
HYPOACETYLASPARTIA	N-ACETYLASPARTATE DEFICIENCY; NACED	614063
MYOPATHY, DISTAL, 4; MPD4	MYOPATHY, DISTAL, 4; MPD4	614065
WILLIAMS DISTAL MYOPATHY	MYOPATHY, DISTAL, 4; MPD4	614065
SPASTIC PARAPLEGIA 47, AUTOSOMAL RECESSIVE; SPG47	SPASTIC PARAPLEGIA 47, AUTOSOMAL RECESSIVE; SPG47	614066
CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 5, FORMERLY; CPSQ5, FORMERLY	SPASTIC PARAPLEGIA 47, AUTOSOMAL RECESSIVE; SPG47	614066
SPASTIC PARAPLEGIA 52, AUTOSOMAL RECESSIVE; SPG52	SPASTIC PARAPLEGIA 52, AUTOSOMAL RECESSIVE; SPG52	614067
CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 6, FORMERLY; CPSQ6, FORMERLY	SPASTIC PARAPLEGIA 52, AUTOSOMAL RECESSIVE; SPG52	614067
IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME2; ICF2	IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME2; ICF2	614069
PSORIASIS 13, SUSCEPTIBILITY TO; PSORS13	PSORIASIS 13, SUSCEPTIBILITY TO; PSORS13	614070
HERMANSKY-PUDLAK SYNDROME 3; HPS3	HERMANSKY-PUDLAK SYNDROME 3; HPS3	614072
HERMANSKY-PUDLAK SYNDROME 4; HPS4	HERMANSKY-PUDLAK SYNDROME 4; HPS4	614073
HERMANSKY-PUDLAK SYNDROME 5; HPS5	HERMANSKY-PUDLAK SYNDROME 5; HPS5	614074
HERMANSKY-PUDLAK SYNDROME 6; HPS6	HERMANSKY-PUDLAK SYNDROME 6; HPS6	614075
HERMANSKY-PUDLAK SYNDROME 7; HPS7	HERMANSKY-PUDLAK SYNDROME 7; HPS7	614076
HERMANSKY-PUDLAK SYNDROME 8; HPS8	HERMANSKY-PUDLAK SYNDROME 8; HPS8	614077
CHONDRODYSPLASIA WITH JOINT DISLOCATIONS, GPAPP TYPE	CHONDRODYSPLASIA WITH JOINT DISLOCATIONS, GPAPP TYPE	614078
GPAPP DEFICIENCY	CHONDRODYSPLASIA WITH JOINT DISLOCATIONS, GPAPP TYPE	614078
ASPERGILLOSIS, SUSCEPTIBILITY TO	ASPERGILLOSIS, SUSCEPTIBILITY TO	614079
MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1	MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1	614080
ANHAPTOGLOBINEMIA; AHP	ANHAPTOGLOBINEMIA; AHP	614081
AHAPTOGLOBINEMIAHYPOHAPTOGLOBINEMIA, INCLUDED	ANHAPTOGLOBINEMIA; AHP	614081
FANCONI ANEMIA, COMPLEMENTATION GROUP G; FANCG	FANCONI ANEMIA, COMPLEMENTATION GROUP G; FANCG	614082
FANCONI ANEMIA, COMPLEMENTATION GROUP L; FANCL	FANCONI ANEMIA, COMPLEMENTATION GROUP L; FANCL	614083
ATRIAL SEPTAL DEFECT 3; ASD3	ATRIAL SEPTAL DEFECT 3; ASD3	614089
SICK SINUS SYNDROME 3, SUSCEPTIBILITY TO; SSS3	SICK SINUS SYNDROME 3, SUSCEPTIBILITY TO; SSS3	614090
SHORT-RIB THORACIC DYSPLASIA 7 WITH OR WITHOUT POLYDACTYLY; SRTD7	SHORT-RIB THORACIC DYSPLASIA 7 WITH OR WITHOUT POLYDACTYLY; SRTD7	614091
SHORT RIB-POLYDACTYLY SYNDROME, TYPE V; SRPS5	SHORT-RIB THORACIC DYSPLASIA 7 WITH OR WITHOUT POLYDACTYLY; SRTD7	614091
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 8; COXPD8	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 8; COXPD8	614096
CARDIOMYOPATHY, HYPERTROPHIC MITOCHONDRIAL, FATAL INFANTILE	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 8; COXPD8	614096
ACATALASEMIA	ACATALASEMIA	614097
ACATALASIA	ACATALASEMIA	614097
CATALASE DEFICIENCY	ACATALASEMIA	614097
KEPPEN-LUBINSKY SYNDROME; KPLBS	KEPPEN-LUBINSKY SYNDROME; KPLBS	614098
CRANIOECTODERMAL DYSPLASIA 3; CED3	CRANIOECTODERMAL DYSPLASIA 3; CED3	614099
CUTIS LAXA, NEONATAL, WITH MARFANOID PHENOTYPE	CUTIS LAXA, NEONATAL, WITH MARFANOID PHENOTYPE	614100
CUTIS LAXA-MARFANOID SYNDROME	CUTIS LAXA, NEONATAL, WITH MARFANOID PHENOTYPE	614100
PLASMA FIBRONECTIN DEFICIENCY	PLASMA FIBRONECTIN DEFICIENCY	614101
IMMUNOGLOBULIN KAPPA LIGHT CHAIN DEFICIENCY; IGKCD	IMMUNOGLOBULIN KAPPA LIGHT CHAIN DEFICIENCY; IGKCD	614102
KAPPA CHAIN DEFICIENCY	IMMUNOGLOBULIN KAPPA LIGHT CHAIN DEFICIENCY; IGKCD	614102
LIPEDEMA	LIPEDEMA	614103
MENTAL RETARDATION, AUTOSOMAL DOMINANT 7; MRD7	MENTAL RETARDATION, AUTOSOMAL DOMINANT 7; MRD7	614104
METHYLMALONATE SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; MMSDHD	METHYLMALONATE SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; MMSDHD	614105
MMSDH DEFICIENCY	METHYLMALONATE SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; MMSDHD	614105
PYRUVATE DEHYDROGENASE E1-BETA DEFICIENCY; PDHBD	PYRUVATE DEHYDROGENASE E1-BETA DEFICIENCY; PDHBD	614111
MENTAL RETARDATION, AUTOSOMAL DOMINANT 2; MRD2	MENTAL RETARDATION, AUTOSOMAL DOMINANT 2; MRD2	614113
MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 2; MVA2	MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 2; MVA2	614114
CORTICAL MALFORMATIONS, OCCIPITAL; OCCM	CORTICAL MALFORMATIONS, OCCIPITAL; OCCM	614115
NEUROPATHY, HEREDITARY SENSORY, TYPE IE; HSN1E	NEUROPATHY, HEREDITARY SENSORY, TYPE IE; HSN1E	614116
HSN IE	NEUROPATHY, HEREDITARY SENSORY, TYPE IE; HSN1E	614116
NEUROPATHY, HEREDITARY SENSORY, WITH HEARING LOSS AND DEMENTIA	NEUROPATHY, HEREDITARY SENSORY, TYPE IE; HSN1E	614116
HYDROLETHALUS SYNDROME 2; HLS2	HYDROLETHALUS SYNDROME 2; HLS2	614120
CHITOTRIOSIDASE DEFICIENCY; CHITD	CHITOTRIOSIDASE DEFICIENCY; CHITD	614122
LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD	LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD	614128
PERRAULT SYNDROME 3; PRLTS3	PERRAULT SYNDROME 3; PRLTS3	614129
DEAFNESS, AUTOSOMAL RECESSIVE 81, FORMERLY; DFNB81, FORMERLY	PERRAULT SYNDROME 3; PRLTS3	614129
FOCAL SEGMENTAL GLOMERULOSCLEROSIS 6; FSGS6	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 6; FSGS6	614131
GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 6	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 6; FSGS6	614131
STICKLER SYNDROME, TYPE IV; STL4	STICKLER SYNDROME, TYPE IV; STL4	614134
EPIPHYSEAL DYSPLASIA, MULTIPLE, 6; EDM6	EPIPHYSEAL DYSPLASIA, MULTIPLE, 6; EDM6	614135
NAIL DISORDER, NONSYNDROMIC CONGENITAL, 9; NDNC9	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 9; NDNC9	614149
ANONYCHIA-ONYCHOLYSIS, ISOLATED	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 9; NDNC9	614149
ONYCHODYSTROPHY	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 9; NDNC9	614149
NAIL DYSPLASIA	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 9; NDNC9	614149
DEAFNESS, AUTOSOMAL DOMINANT 64; DFNA64	DEAFNESS, AUTOSOMAL DOMINANT 64; DFNA64	614152
SPINOCEREBELLAR ATAXIA 36; SCA36	SPINOCEREBELLAR ATAXIA 36; SCA36	614153
HYPERBILIVERDINEMIA; HBLVD	HYPERBILIVERDINEMIA; HBLVD	614156
GREEN JAUNDICE	HYPERBILIVERDINEMIA; HBLVD	614156
NAIL DISORDER, NONSYNDROMIC CONGENITAL, 10; NDNC10	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 10; NDNC10	614157
CLAW-SHAPED NAILS	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 10; NDNC10	614157
ONYCHAUXIS, HYPONYCHIA, AND ONYCHOLYSIS	NAIL DISORDER, NONSYNDROMIC CONGENITAL, 10; NDNC10	614157
MUSCLE HYPERTROPHY; MSLHP	MUSCLE HYPERTROPHY; MSLHP	614160
IMMUNODEFICIENCY 31C; IMD31C	IMMUNODEFICIENCY 31C; IMD31C	614162
CANDIDIASIS, FAMILIAL, 7; CANDF7	IMMUNODEFICIENCY 31C; IMD31C	614162
CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL DOMINANT	IMMUNODEFICIENCY 31C; IMD31C	614162
DELAYED SLEEP PHASE SYNDROME, SUSCEPTIBILITY TO; DSPS	DELAYED SLEEP PHASE SYNDROME, SUSCEPTIBILITY TO; DSPS	614163
GLUTATHIONE PEROXIDASE DEFICIENCY; GPXD	GLUTATHIONE PEROXIDASE DEFICIENCY; GPXD	614164
PARAGANGLIOMAS 5; PGL5	PARAGANGLIOMAS 5; PGL5	614165
MYOPIA 20, AUTOSOMAL DOMINANT; MYP20	MYOPIA 20, AUTOSOMAL DOMINANT; MYP20	614166
MYOPIA 21, AUTOSOMAL DOMINANT; MYP21	MYOPIA 21, AUTOSOMAL DOMINANT; MYP21	614167
BRITTLE CORNEA SYNDROME 2; BCS2	BRITTLE CORNEA SYNDROME 2; BCS2	614170
HERMANSKY-PUDLAK SYNDROME 9; HPS9	HERMANSKY-PUDLAK SYNDROME 9; HPS9	614171
IMMUNODEFICIENCY 21; IMD21	IMMUNODEFICIENCY 21; IMD21	614172
DENDRITIC CELL, MONOCYTE, B LYMPHOCYTE, AND NATURAL KILLER LYMPHOCYTEDEFICIENCY; DCML	IMMUNODEFICIENCY 21; IMD21	614172
MONOCYTOPENIA AND MYCOBACTERIAL INFECTION SYNDROME; MONOMAC	IMMUNODEFICIENCY 21; IMD21	614172
MONOCYTOPENIA WITH SUSCEPTIBILITY TO MYCOBACTERIAL, FUNGAL, AND PAPILLOMAVIRUSINFECTIONS AND MYELODYSPLASIA	IMMUNODEFICIENCY 21; IMD21	614172
COMBINED IMMUNODEFICIENCY WITH SUSCEPTIBILITY TO MYCOBACTERIAL, VIRAL,AND FUNGAL INFECTIONS	IMMUNODEFICIENCY 21; IMD21	614172
GATA2 DEFICIENCY	IMMUNODEFICIENCY 21; IMD21	614172
JOUBERT SYNDROME 13; JBTS13	JOUBERT SYNDROME 13; JBTS13	614173
MECKEL SYNDROME, TYPE 10; MKS10	MECKEL SYNDROME, TYPE 10; MKS10	614175
RETINITIS PIGMENTOSA 61; RP61	RETINITIS PIGMENTOSA 61; RP61	614180
RETINITIS PIGMENTOSA 62; RP62	RETINITIS PIGMENTOSA 62; RP62	614181
GELEOPHYSIC DYSPLASIA 2; GPHYSD2	GELEOPHYSIC DYSPLASIA 2; GPHYSD2	614185
LEBER CONGENITAL AMAUROSIS 16; LCA16	LEBER CONGENITAL AMAUROSIS 16; LCA16	614186
HYPERTELORISM, PREAURICULAR SINUS, PUNCTAL PITS, AND DEAFNESS; HPPD	HYPERTELORISM, PREAURICULAR SINUS, PUNCTAL PITS, AND DEAFNESS; HPPD	614187
CRANIOSYNOSTOSIS AND DENTAL ANOMALIES; CRSDA	CRANIOSYNOSTOSIS AND DENTAL ANOMALIES; CRSDA	614188
KREIBORG-PAKISTANI SYNDROME	CRANIOSYNOSTOSIS AND DENTAL ANOMALIES; CRSDA	614188
PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 3; PPNAD3	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 3; PPNAD3	614190
CUSHING SYNDROME, ADRENAL, DUE TO PPNAD3	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 3; PPNAD3	614190
MACROCEPHALY, MACROSOMIA, AND FACIAL DYSMORPHISM SYNDROME; MMFD	MACROCEPHALY, MACROSOMIA, AND FACIAL DYSMORPHISM SYNDROME; MMFD	614192
TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 2; TFQTL2	TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 2; TFQTL2	614193
CRANIOFACIAL ANOMALIES AND ANTERIOR SEGMENT DYSGENESIS SYNDROME; CAASDS	CRANIOFACIAL ANOMALIES AND ANTERIOR SEGMENT DYSGENESIS SYNDROME; CAASDS	614195
NEPHROTIC SYNDROME, TYPE 6; NPHS6	NEPHROTIC SYNDROME, TYPE 6; NPHS6	614196
MYASTHENIC SYNDROME, CONGENITAL, 16; CMS16	MYASTHENIC SYNDROME, CONGENITAL, 16; CMS16	614198
MYASTHENIC SYNDROME, CONGENITAL, ACETAZOLAMIDE-RESPONSIVE	MYASTHENIC SYNDROME, CONGENITAL, 16; CMS16	614198
NEPHROTIC SYNDROME, TYPE 5, WITH OR WITHOUT OCULAR ABNORMALITIES;NPHS5	NEPHROTIC SYNDROME, TYPE 5, WITH OR WITHOUT OCULAR ABNORMALITIES;NPHS5	614199
BLEEDING DISORDER, PLATELET-TYPE, 9; BDPLT9	BLEEDING DISORDER, PLATELET-TYPE, 9; BDPLT9	614200
GLYCOPROTEIN Ia DEFICIENCY	BLEEDING DISORDER, PLATELET-TYPE, 9; BDPLT9	614200
GP Ia DEFICIENCY	BLEEDING DISORDER, PLATELET-TYPE, 9; BDPLT9	614200
COLLAGEN PLATELET RECEPTOR DEFICIENCY	BLEEDING DISORDER, PLATELET-TYPE, 9; BDPLT9	614200
BLEEDING DISORDER, PLATELET-TYPE, 11; BDPLT11	BLEEDING DISORDER, PLATELET-TYPE, 11; BDPLT11	614201
GLYCOPROTEIN VI DEFICIENCY	BLEEDING DISORDER, PLATELET-TYPE, 11; BDPLT11	614201
GP VI DEFICIENCY	BLEEDING DISORDER, PLATELET-TYPE, 11; BDPLT11	614201
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15	614202
PARKINSON DISEASE 17; PARK17	PARKINSON DISEASE 17; PARK17	614203
PSORIASIS 14, PUSTULAR; PSORS14	PSORIASIS 14, PUSTULAR; PSORS14	614204
INTERLEUKIN 36 RECEPTOR ANTAGONIST DEFICIENCY; DITRA	PSORIASIS 14, PUSTULAR; PSORS14	614204
GENERALIZED PUSTULAR PSORIASIS; GPP	PSORIASIS 14, PUSTULAR; PSORS14	614204
PSORP	PSORIASIS 14, PUSTULAR; PSORS14	614204
ACRODERMATITIS CONTINUA OF HALLOPEAU	PSORIASIS 14, PUSTULAR; PSORS14	614204
PALMOPLANTAR PUSTULOSIS	PSORIASIS 14, PUSTULAR; PSORS14	614204
THREE M SYNDROME 3; 3M3	THREE M SYNDROME 3; 3M3	614205
3@M SYNDROME 3	THREE M SYNDROME 3; 3M3	614205
HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 3; HPMRS3	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 3; HPMRS3	614207
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 17; MRT17	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 3; HPMRS3	614207
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 21; MRT21	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 3; HPMRS3	614207
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 16; MRT16	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 16; MRT16	614208
MECKEL SYNDROME, TYPE 9; MKS9	MECKEL SYNDROME, TYPE 9; MKS9	614209
LUNG CANCER SUSCEPTIBILITY 5; LNCR5	LUNG CANCER SUSCEPTIBILITY 5; LNCR5	614210
DEAFNESS, AUTOSOMAL DOMINANT 33; DFNA33	DEAFNESS, AUTOSOMAL DOMINANT 33; DFNA33	614211
ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 4; IIAE4	ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 4; IIAE4	614212
NEUROPATHY, HEREDITARY SENSORY, TYPE IIC; HSN2C	NEUROPATHY, HEREDITARY SENSORY, TYPE IIC; HSN2C	614213
ADAMS-OLIVER SYNDROME 2; AOS2	ADAMS-OLIVER SYNDROME 2; AOS2	614219
BILIARY CIRRHOSIS, PRIMARY, 4; PBC4	BILIARY CIRRHOSIS, PRIMARY, 4; PBC4	614220
BILIARY CIRRHOSIS, PRIMARY, 5; PBC5	BILIARY CIRRHOSIS, PRIMARY, 5; PBC5	614221
WARBURG MICRO SYNDROME 3; WARBM3	WARBURG MICRO SYNDROME 3; WARBM3	614222
MICRO SYNDROME 3	WARBURG MICRO SYNDROME 3; WARBM3	614222
NARCOLEPSY 6, SUSCEPTIBILITY TO; NRCLP6	NARCOLEPSY 6, SUSCEPTIBILITY TO; NRCLP6	614223
RETINAL ARTERIAL MACROANEURYSM WITH SUPRAVALVULAR PULMONIC STENOSIS;RAMSVPS	RETINAL ARTERIAL MACROANEURYSM WITH SUPRAVALVULAR PULMONIC STENOSIS;RAMSVPS	614224
WARBURG MICRO SYNDROME 2; WARBM2	WARBURG MICRO SYNDROME 2; WARBM2	614225
MICRO SYNDROME 2	WARBURG MICRO SYNDROME 2; WARBM2	614225
HOLOPROSENCEPHALY 11; HPE11	HOLOPROSENCEPHALY 11; HPE11	614226
HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 3; HNFJ3	HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 3; HNFJ3	614227
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2O; CMT2O	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2O; CMT2O	614228
CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2O	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2O; CMT2O	614228
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2O	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2O; CMT2O	614228
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 11; SCAR11	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 11; SCAR11	614229
CHROMOSOME 8q21.11 DELETION SYNDROME	CHROMOSOME 8q21.11 DELETION SYNDROME	614230
MICROCEPHALY, EPILEPSY, AND DIABETES SYNDROME; MEDS	MICROCEPHALY, EPILEPSY, AND DIABETES SYNDROME; MEDS	614231
HYPERPIGMENTATION, FAMILIAL PROGRESSIVE, 1; FPH1	HYPERPIGMENTATION, FAMILIAL PROGRESSIVE, 1; FPH1	614233
FPH	HYPERPIGMENTATION, FAMILIAL PROGRESSIVE, 1; FPH1	614233
HYPOTRICHOSIS 9; HYPT9	HYPOTRICHOSIS 9; HYPT9	614237
HYPOTRICHOSIS 10; HYPT10	HYPOTRICHOSIS 10; HYPT10	614238
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 18; MRT18	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 18; MRT18	614249
NARCOLEPSY 7; NRCLP7	NARCOLEPSY 7; NRCLP7	614250
PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK18	PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK18	614251
ANEURYSM, INTRACRANIAL BERRY, 11; ANIB11	ANEURYSM, INTRACRANIAL BERRY, 11; ANIB11	614252
MENTAL RETARDATION, AUTOSOMAL DOMINANT 8; MRD8	MENTAL RETARDATION, AUTOSOMAL DOMINANT 8; MRD8	614254
MENTAL RETARDATION, AUTOSOMAL DOMINANT 9; MRD9	MENTAL RETARDATION, AUTOSOMAL DOMINANT 9; MRD9	614255
MENTAL RETARDATION, AUTOSOMAL DOMINANT 10; MRD10	MENTAL RETARDATION, AUTOSOMAL DOMINANT 10; MRD10	614256
MENTAL RETARDATION, AUTOSOMAL DOMINANT 11; MRD11	MENTAL RETARDATION, AUTOSOMAL DOMINANT 11; MRD11	614257
MICROCEPHALY-CAPILLARY MALFORMATION SYNDROME; MICCAP	MICROCEPHALY-CAPILLARY MALFORMATION SYNDROME; MICCAP	614261
COMBINED MALONIC AND METHYLMALONIC ACIDURIA; CMAMMA	COMBINED MALONIC AND METHYLMALONIC ACIDURIA; CMAMMA	614265
BARRETT ESOPHAGUS	BARRETT ESOPHAGUS	614266
BARRETT METAPLASIAADENOCARCINOMA OF ESOPHAGUS, INCLUDED	BARRETT ESOPHAGUS	614266
PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE DEFICIENCY; PAFAD	PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE DEFICIENCY; PAFAD	614278
46,XY SEX REVERSAL 8; SRXY8	46,XY SEX REVERSAL 8; SRXY8	614279
MALE PSEUDOHERMAPHRODITISM DUE TO DEFICIENCY OF TESTICULAR 17,20-DESMOLASE;TDD	46,XY SEX REVERSAL 8; SRXY8	614279
EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 9; EJM9	EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 9; EJM9	614280
STICKLER SYNDROME, TYPE V; STL5	STICKLER SYNDROME, TYPE V; STL5	614284
MYELODYSPLASTIC SYNDROME; MDS	MYELODYSPLASTIC SYNDROME; MDS	614286
MYELODYSPLASTIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED	MYELODYSPLASTIC SYNDROME; MDS	614286
TETRASOMY 18p	TETRASOMY 18p	614290
ISOCHROMOSOME 18p SYNDROME	TETRASOMY 18p	614290
BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 4; BROVCA4	BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 4; BROVCA4	614291
MYOPIA, HIGH, WITH CATARACT AND VITREORETINAL DEGENERATION; MCVD	MYOPIA, HIGH, WITH CATARACT AND VITREORETINAL DEGENERATION; MCVD	614292
HYDATIDIFORM MOLE, RECURRENT, 2; HYDM2	HYDATIDIFORM MOLE, RECURRENT, 2; HYDM2	614293
HYDATIDIFORM MOLE, COMPLETE	HYDATIDIFORM MOLE, RECURRENT, 2; HYDM2	614293
CHROMOSOME 15q25 DELETION SYNDROME	CHROMOSOME 15q25 DELETION SYNDROME	614294
WOLFRAM-LIKE SYNDROME, AUTOSOMAL DOMINANT; WFSL	WOLFRAM-LIKE SYNDROME, AUTOSOMAL DOMINANT; WFSL	614296
HEARING LOSS, PROGRESSIVE, WITH OPTIC ATROPHY AND/OR IMPAIRED GLUCOSEREGULATION	WOLFRAM-LIKE SYNDROME, AUTOSOMAL DOMINANT; WFSL	614296
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 4; NBIA4	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 4; NBIA4	614298
MITOCHONDRIAL PROTEIN-ASSOCIATED NEURODEGENERATION; MPAN	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 4; NBIA4	614298
MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 2; MMDS2	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 2; MMDS2	614299
HYPERMETHIONINEMIA DUE TO ADENOSINE KINASE DEFICIENCY	HYPERMETHIONINEMIA DUE TO ADENOSINE KINASE DEFICIENCY	614300
EMERY-DREIFUSS MUSCULAR DYSTROPHY 7, AUTOSOMAL DOMINANT; EDMD7	EMERY-DREIFUSS MUSCULAR DYSTROPHY 7, AUTOSOMAL DOMINANT; EDMD7	614302
EDICT SYNDROME; EDICT	EDICT SYNDROME; EDICT	614303
ENDOTHELIAL DYSTROPHY, IRIS HYPOPLASIA, CONGENITAL CATARACT, AND STROMALTHINNING SYNDROME	EDICT SYNDROME; EDICT	614303
KERATOCONUS WITH CATARACT; KTCNCT	EDICT SYNDROME; EDICT	614303
KERATOCONUS, FAMILIAL, WITH EARLY-ONSET ANTERIOR POLAR CATARACT	EDICT SYNDROME; EDICT	614303
SCLEROSTEOSIS 2; SOST2	SCLEROSTEOSIS 2; SOST2	614305
COGNITIVE IMPAIRMENT WITH OR WITHOUT CEREBELLAR ATAXIA; CIAT	COGNITIVE IMPAIRMENT WITH OR WITHOUT CEREBELLAR ATAXIA; CIAT	614306
ALPHA-METHYLACYL-CoA RACEMASE DEFICIENCY; AMACRD	ALPHA-METHYLACYL-CoA RACEMASE DEFICIENCY; AMACRD	614307
AMACR DEFICIENCY	ALPHA-METHYLACYL-CoA RACEMASE DEFICIENCY; AMACRD	614307
VESICOURETERAL REFLUX 4; VUR4	VESICOURETERAL REFLUX 4; VUR4	614317
VESICOURETERAL REFLUX 5; VUR5	VESICOURETERAL REFLUX 5; VUR5	614318
VESICOURETERAL REFLUX 6; VUR6	VESICOURETERAL REFLUX 6; VUR6	614319
PANCREATIC CANCER, SUSCEPTIBILITY TO, 4; PNCA4	PANCREATIC CANCER, SUSCEPTIBILITY TO, 4; PNCA4	614320
MYOPATHY, DISTAL, TATEYAMA TYPE; MPDT	MYOPATHY, DISTAL, TATEYAMA TYPE; MPDT	614321
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 12; SCAR12	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 12; SCAR12	614322
SPINOCEREBELLAR ATAXIA WITH MENTAL RETARDATION AND EPILEPSY	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 12; SCAR12	614322
NEVOID HYPERMELANOSIS, LINEAR AND WHORLED; LWNHHYPERPIGMENTATION, PROGRESSIVE CRIBRIFORM AND ZOSTERIFORM, INCLUDED;PCZH, INCLUDED	NEVOID HYPERMELANOSIS, LINEAR AND WHORLED; LWNHHYPERPIGMENTATION, PROGRESSIVE CRIBRIFORM AND ZOSTERIFORM, INCLUDED;PCZH, INCLUDED	614323
OVARIAN DYSGENESIS 3; ODG3	OVARIAN DYSGENESIS 3; ODG3	614324
PITT-HOPKINS-LIKE SYNDROME 2; PTHSL2	PITT-HOPKINS-LIKE SYNDROME 2; PTHSL2	614325
FEINGOLD SYNDROME 2; FGLDS2	FEINGOLD SYNDROME 2; FGLDS2	614326
BRACHYDACTYLY WITH SHORT STATURE AND MICROCEPHALY	FEINGOLD SYNDROME 2; FGLDS2	614326
TUMOR PREDISPOSITION SYNDROME; TPDS	TUMOR PREDISPOSITION SYNDROME; TPDS	614327
INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 1; NISBD1	INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 1; NISBD1	614328
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 31; MRT31	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 31; MRT31	614329
COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 6; HNPCC6	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 6; HNPCC6	614331
COLON CANCER, HEREDITARY NONPOLYPOSIS, TYPE 6	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 6; HNPCC6	614331
CHROMOSOME 2p16.3 DELETION SYNDROMESCHIZOPHRENIA 17, INCLUDED; SCZD17, INCLUDED	CHROMOSOME 2p16.3 DELETION SYNDROMESCHIZOPHRENIA 17, INCLUDED; SCZD17, INCLUDED	614332
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 29; MRT29	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 29; MRT29	614333
ARTHROGRYPOSIS, DISTAL, TYPE 1B; DA1B	ARTHROGRYPOSIS, DISTAL, TYPE 1B; DA1B	614335
COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 4; HNPCC4	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 4; HNPCC4	614337
PANCREATIC LIPASE DEFICIENCY; PNLIPD	PANCREATIC LIPASE DEFICIENCY; PNLIPD	614338
LIPASE, CONGENITAL ABSENCE OF PANCREATIC	PANCREATIC LIPASE DEFICIENCY; PNLIPD	614338
PL DEFICIENCYPANCREATIC COLIPASE DEFICIENCY, INCLUDED	PANCREATIC LIPASE DEFICIENCY; PNLIPD	614338
COLIPASE, CONGENITAL ABSENCE OF PANCREATIC, INCLUDED	PANCREATIC LIPASE DEFICIENCY; PNLIPD	614338
LIPASE AND COLIPASE, DEFICIENCY OF, INCLUDED	PANCREATIC LIPASE DEFICIENCY; PNLIPD	614338
LIPASE AND COLIPASE, CONGENITAL ABSENCE OF PANCREATIC, INCLUDED	PANCREATIC LIPASE DEFICIENCY; PNLIPD	614338
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 32; MRT32	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 32; MRT32	614339
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 27; MRT27	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 27; MRT27	614340
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 33; MRT33	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 33; MRT33	614341
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 30; MRT30	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 30; MRT30	614342
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 19; MRT19	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 19; MRT19	614343
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 23; MRT23	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 23; MRT23	614344
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 24; MRT24	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 24; MRT24	614345
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 25; MRT25	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 25; MRT25	614346
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 28; MRT28	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 28; MRT28	614347
COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5; HNPCC5	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5; HNPCC5	614350
PERIPHERAL NEUROPATHY, MYOPATHY, HOARSENESS, AND HEARING LOSS; PNMHH	PERIPHERAL NEUROPATHY, MYOPATHY, HOARSENESS, AND HEARING LOSS; PNMHH	614369
SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 5; SMDP5	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 5; SMDP5	614370
PULMONARY ALVEOLAR PROTEINOSIS 5	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 5; SMDP5	614370
PAP DUE TO CSF2RB DEFICIENCY	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 5; SMDP5	614370
CSF2RB DEFICIENCY	SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 5; SMDP5	614370
DENGUE VIRUS, SUSCEPTIBILITY TODENGUE FEVER, SUSCEPTIBILITY TO, INCLUDED	DENGUE VIRUS, SUSCEPTIBILITY TODENGUE FEVER, SUSCEPTIBILITY TO, INCLUDED	614371
DENGUE FEVER, PROTECTION AGAINST, INCLUDED	DENGUE VIRUS, SUSCEPTIBILITY TODENGUE FEVER, SUSCEPTIBILITY TO, INCLUDED	614371
DENGUE HEMORRHAGIC FEVER, SUSCEPTIBILITY TO, INCLUDED	DENGUE VIRUS, SUSCEPTIBILITY TODENGUE FEVER, SUSCEPTIBILITY TO, INCLUDED	614371
DENGUE SHOCK SYNDROME, SUSCEPTIBILITY TO, INCLUDED	DENGUE VIRUS, SUSCEPTIBILITY TODENGUE FEVER, SUSCEPTIBILITY TO, INCLUDED	614371
MANNOSE-BINDING PROTEIN DEFICIENCY	MANNOSE-BINDING PROTEIN DEFICIENCY	614372
MBP DEFICIENCY	MANNOSE-BINDING PROTEIN DEFICIENCY	614372
MANNOSE-BINDING LECTIN DEFICIENCY	MANNOSE-BINDING PROTEIN DEFICIENCY	614372
MBL DEFICIENCY	MANNOSE-BINDING PROTEIN DEFICIENCY	614372
MBL2 DEFICIENCY	MANNOSE-BINDING PROTEIN DEFICIENCY	614372
AMYOTROPHIC LATERAL SCLEROSIS 16, JUVENILE; ALS16	AMYOTROPHIC LATERAL SCLEROSIS 16, JUVENILE; ALS16	614373
BLOOD GROUP, CHIDO/RODGERS SYSTEM	BLOOD GROUP, CHIDO/RODGERS SYSTEM	614374
CHIDO/RODGERS BLOOD GROUP SYSTEM	BLOOD GROUP, CHIDO/RODGERS SYSTEM	614374
AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 4; AAA4	AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 4; AAA4	614375
SHORT-RIB THORACIC DYSPLASIA 5 WITH OR WITHOUT POLYDACTYLY; SRTD5	SHORT-RIB THORACIC DYSPLASIA 5 WITH OR WITHOUT POLYDACTYLY; SRTD5	614376
ASPHYXIATING THORACIC DYSTROPHY 5; ATD5	SHORT-RIB THORACIC DYSPLASIA 5 WITH OR WITHOUT POLYDACTYLY; SRTD5	614376
NEPHRONOPHTHISIS 13; NPHP13	NEPHRONOPHTHISIS 13; NPHP13	614377
CRANIOECTODERMAL DYSPLASIA 4; CED4	CRANIOECTODERMAL DYSPLASIA 4; CED4	614378
COMPLEMENT COMPONENT 4B DEFICIENCY; C4BD	COMPLEMENT COMPONENT 4B DEFICIENCY; C4BD	614379
C4B DEFICIENCY	COMPLEMENT COMPONENT 4B DEFICIENCY; C4BD	614379
COMPLEMENT COMPONENT 4A DEFICIENCY; C4AD	COMPLEMENT COMPONENT 4A DEFICIENCY; C4AD	614380
C4A DEFICIENCY	COMPLEMENT COMPONENT 4A DEFICIENCY; C4AD	614380
LEUKODYSTROPHY, HYPOMYELINATING, 8, WITH OR WITHOUT OLIGODONTIA AND/ORHYPOGONADOTROPIC HYPOGONADISM; HLD8	LEUKODYSTROPHY, HYPOMYELINATING, 8, WITH OR WITHOUT OLIGODONTIA AND/ORHYPOGONADOTROPIC HYPOGONADISM; HLD8	614381
BACTEREMIA, SUSCEPTIBILITY TO, 1; BACTS1BACTEREMIA, RESISTANCE TO, INCLUDED	BACTEREMIA, SUSCEPTIBILITY TO, 1; BACTS1BACTEREMIA, RESISTANCE TO, INCLUDED	614382
BACTEREMIA, SUSCEPTIBILITY TO, 2; BACTS2	BACTEREMIA, SUSCEPTIBILITY TO, 2; BACTS2	614383
COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 7; HNPCC7	COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 7; HNPCC7	614385
ENCEPHALOPATHY, LETHAL, DUE TO DEFECTIVE MITOCHONDRIAL AND PEROXISOMALFISSION; EMPF	ENCEPHALOPATHY, LETHAL, DUE TO DEFECTIVE MITOCHONDRIAL AND PEROXISOMALFISSION; EMPF	614388
PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1	614389
RPRGL	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1	614389
RPL	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1	614389
ABORTION, SPONTANEOUS, RECURRENT	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1	614389
FETAL LOSS, RECURRENT, SUSCEPTIBILITY TO	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1	614389
MISCARRIAGE, RECURRENT	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1	614389
EMBRYONIC LOSS, RECURRENT	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1	614389
STILLBIRTH, RECURRENT	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1	614389
PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 2; RPRGL2	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 2; RPRGL2	614390
PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 3; RPRGL3	PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 3; RPRGL3	614391
GRAFT-VERSUS-HOST DISEASE, SUSCEPTIBILITY TO; GVHDSGRAFT-VERSUS-HOST DISEASE, RESISTANCE TO, INCLUDED	GRAFT-VERSUS-HOST DISEASE, SUSCEPTIBILITY TO; GVHDSGRAFT-VERSUS-HOST DISEASE, RESISTANCE TO, INCLUDED	614395
MYOPATHY, AREFLEXIA, RESPIRATORY DISTRESS, AND DYSPHAGIA, EARLY-ONSET;EMARDDMYOPATHY, AREFLEXIA, RESPIRATORY DISTRESS, AND DYSPHAGIA, EARLY-ONSET,MILD VARIANT, INCLUDED	MYOPATHY, AREFLEXIA, RESPIRATORY DISTRESS, AND DYSPHAGIA, EARLY-ONSET;EMARDDMYOPATHY, AREFLEXIA, RESPIRATORY DISTRESS, AND DYSPHAGIA, EARLY-ONSET,MILD VARIANT, INCLUDED	614399
GLUCOCORTICOID THERAPY, RESPONSE TO; GCTR	GLUCOCORTICOID THERAPY, RESPONSE TO; GCTR	614400
ACCELERATED TUMOR FORMATION, SUSCEPTIBILITY TO; ACTFS	ACCELERATED TUMOR FORMATION, SUSCEPTIBILITY TO; ACTFS	614401
MICROPHTHALMIA, SYNDROMIC 11; MCOPS11	MICROPHTHALMIA, SYNDROMIC 11; MCOPS11	614402
MICROCEPHALY, CEREBELLAR HYPOPLASIA, AND CARDIAC CONDUCTION DEFECTSYNDROME; MCHCCD	MICROCEPHALY, CEREBELLAR HYPOPLASIA, AND CARDIAC CONDUCTION DEFECTSYNDROME; MCHCCD	614407
ZAKI-GLEESON SYNDROME	MICROCEPHALY, CEREBELLAR HYPOPLASIA, AND CARDIAC CONDUCTION DEFECTSYNDROME; MCHCCD	614407
MYOPATHY, CENTRONUCLEAR, 3; CNM3	MYOPATHY, CENTRONUCLEAR, 3; CNM3	614408
SPASTIC PARAPLEGIA 46, AUTOSOMAL RECESSIVE; SPG46	SPASTIC PARAPLEGIA 46, AUTOSOMAL RECESSIVE; SPG46	614409
GLYCEROL QUANTITATIVE TRAIT LOCUS; GLYCQTL	GLYCEROL QUANTITATIVE TRAIT LOCUS; GLYCQTL	614411
GLYCEROL RELEASE DURING EXERCISE, DEFECTIVEBODY MASS INDEX QUANTITATIVE TRAIT LOCUS 17, INCLUDED; BMIQ17, INCLUDED	GLYCEROL QUANTITATIVE TRAIT LOCUS; GLYCQTL	614411
DEAFNESS, AUTOSOMAL RECESSIVE 96; DFNB96	DEAFNESS, AUTOSOMAL RECESSIVE 96; DFNB96	614414
CHILBLAIN LUPUS 2; CHBL2	CHILBLAIN LUPUS 2; CHBL2	614415
RADIOHUMERAL FUSIONS WITH OTHER SKELETAL AND CRANIOFACIAL ANOMALIES;RHFCA	RADIOHUMERAL FUSIONS WITH OTHER SKELETAL AND CRANIOFACIAL ANOMALIES;RHFCA	614416
EPILEPSY, FAMILIAL TEMPORAL LOBE, 5; ETL5	EPILEPSY, FAMILIAL TEMPORAL LOBE, 5; ETL5	614417
FEBRILE SEIZURES, FAMILIAL, 11; FEB11	FEBRILE SEIZURES, FAMILIAL, 11; FEB11	614418
CONVULSIONS, FAMILIAL FEBRILE, 11	FEBRILE SEIZURES, FAMILIAL, 11; FEB11	614418
ASPARTATE AMINOTRANSFERASE, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS1	ASPARTATE AMINOTRANSFERASE, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS1	614419
ASTQTL1	ASPARTATE AMINOTRANSFERASE, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS1	614419
SYSTEMIC LUPUS ERYTHEMATOSUS 16; SLEB16	SYSTEMIC LUPUS ERYTHEMATOSUS 16; SLEB16	614420
CATARACT 37; CTRCT37	CATARACT 37; CTRCT37	614422
CATARACT, CONGENITAL, CERULEAN TYPE, 5; CCA5	CATARACT 37; CTRCT37	614422
JOUBERT SYNDROME 14; JBTS14	JOUBERT SYNDROME 14; JBTS14	614424
VENTRICULAR SEPTAL DEFECT 1; VSD1	VENTRICULAR SEPTAL DEFECT 1; VSD1	614429
ATRIOVENTRICULAR SEPTAL DEFECT 4; AVSD4	ATRIOVENTRICULAR SEPTAL DEFECT 4; AVSD4	614430
VENTRICULAR SEPTAL DEFECT 2; VSD2	VENTRICULAR SEPTAL DEFECT 2; VSD2	614431
VENTRICULAR SEPTAL DEFECT 3; VSD3	VENTRICULAR SEPTAL DEFECT 3; VSD3	614432
ATRIAL SEPTAL DEFECT 8; ASD8	ATRIAL SEPTAL DEFECT 8; ASD8	614433
CUTIS LAXA, AUTOSOMAL DOMINANT 2; ADCL2	CUTIS LAXA, AUTOSOMAL DOMINANT 2; ADCL2	614434
HYPOPLASTIC LEFT HEART SYNDROME 2; HLHS2	HYPOPLASTIC LEFT HEART SYNDROME 2; HLHS2	614435
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2P; CMT2P	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2P; CMT2P	614436
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2P	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2P; CMT2P	614436
CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IB; ARCL1B	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IB; ARCL1B	614437
CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIB; ARCL3B	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIB; ARCL3B	614438
DE BARSY SYNDROME B	CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIB; ARCL3B	614438
HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 2; PHOAR2	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 2; PHOAR2	614441
PACHYDERMOPERIOSTOSIS, AUTOSOMAL RECESSIVE	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 2; PHOAR2	614441
PDP, AUTOSOMAL RECESSIVE	HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 2; PHOAR2	614441
HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 6; CHNG6	HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 6; CHNG6	614450
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE E; CMTDIE	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE E; CMTDIE	614455
CHARCOT-MARIE-TOOTH NEUROPATHY WITH FOCAL SEGMENTAL GLOMERULONEPHRITIS	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE E; CMTDIE	614455
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8; CMM8	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8; CMM8	614456
MELANOMA AND RENAL CELL CARCINOMA, SUSCEPTIBILITY TO	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8; CMM8	614456
ICHTHYOSIS, SPASTIC QUADRIPLEGIA, AND MENTAL RETARDATION; ISQMR	ICHTHYOSIS, SPASTIC QUADRIPLEGIA, AND MENTAL RETARDATION; ISQMR	614457
THIAMINE METABOLISM DYSFUNCTION SYNDROME 5 (EPISODIC ENCEPHALOPATHYTYPE); THMD5	THIAMINE METABOLISM DYSFUNCTION SYNDROME 5 (EPISODIC ENCEPHALOPATHYTYPE); THMD5	614458
ENCEPHALOPATHY, EPISODIC, DUE TO THIAMINE PYROPHOSPHOKINASE DEFICIENCY	THIAMINE METABOLISM DYSFUNCTION SYNDROME 5 (EPISODIC ENCEPHALOPATHYTYPE); THMD5	614458
PYRUVATE DEHYDROGENASE LIPOIC ACID SYNTHETASE DEFICIENCY; PDHLD	PYRUVATE DEHYDROGENASE LIPOIC ACID SYNTHETASE DEFICIENCY; PDHLD	614462
JOUBERT SYNDROME 15; JBTS15JOUBERT SYNDROME 9/15, DIGENIC, INCLUDED	JOUBERT SYNDROME 15; JBTS15JOUBERT SYNDROME 9/15, DIGENIC, INCLUDED	614464
JOUBERT SYNDROME 12/15, DIGENIC, INCLUDED	JOUBERT SYNDROME 15; JBTS15JOUBERT SYNDROME 9/15, DIGENIC, INCLUDED	614464
JOUBERT SYNDROME 16; JBTS16	JOUBERT SYNDROME 16; JBTS16	614465
CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 6; CHDS6	CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 6; CHDS6	614466
FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 3; FCAS3	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 3; FCAS3	614468
ANTIBODY DEFICIENCY AND IMMUNE DYSREGULATION, PLCG2-ASSOCIATED; PLAID	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 3; FCAS3	614468
FAMILIAL ATYPICAL COLD URTICARIA; FACU	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 3; FCAS3	614468
RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER; RALD	RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER; RALD	614470
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IV; ALPS4	RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER; RALD	614470
ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 2; GACI2	ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 2; GACI2	614473
ATRIOVENTRICULAR SEPTAL DEFECT 5; AVSD5	ATRIOVENTRICULAR SEPTAL DEFECT 5; AVSD5	614474
ATRIAL SEPTAL DEFECT 9; ASD9	ATRIAL SEPTAL DEFECT 9; ASD9	614475
HYPERTRIGLYCERIDEMIA, TRANSIENT INFANTILE; HTGTI	HYPERTRIGLYCERIDEMIA, TRANSIENT INFANTILE; HTGTI	614480
CONGENITAL CATARACTS, HEARING LOSS, AND NEURODEGENERATION; CCHLND	CONGENITAL CATARACTS, HEARING LOSS, AND NEURODEGENERATION; CCHLND	614482
PORENCEPHALY 2; POREN2	PORENCEPHALY 2; POREN2	614483
TRIGONOCEPHALY 2; TRIGNO2	TRIGONOCEPHALY 2; TRIGNO2	614485
CRANIOSYNOSTOSIS, METOPIC	TRIGONOCEPHALY 2; TRIGNO2	614485
THROMBOPHILIA DUE TO THROMBOMODULIN DEFECT; THPH12	THROMBOPHILIA DUE TO THROMBOMODULIN DEFECT; THPH12	614486
SPASTIC ATAXIA 5, AUTOSOMAL RECESSIVE; SPAX5	SPASTIC ATAXIA 5, AUTOSOMAL RECESSIVE; SPAX5	614487
BLOOD GROUP, JUNIOR SYSTEM; JR	BLOOD GROUP, JUNIOR SYSTEM; JR	614490
PSEUDOHYPOALDOSTERONISM, TYPE IIB; PHA2B	PSEUDOHYPOALDOSTERONISM, TYPE IIB; PHA2B	614491
PSEUDOHYPOALDOSTERONISM, TYPE IIC; PHA2C	PSEUDOHYPOALDOSTERONISM, TYPE IIC; PHA2C	614492
WISKOTT-ALDRICH SYNDROME 2; WAS2	WISKOTT-ALDRICH SYNDROME 2; WAS2	614493
WIPF1 DEFICIENCY	WISKOTT-ALDRICH SYNDROME 2; WAS2	614493
RETINITIS PIGMENTOSA 63; RP63	RETINITIS PIGMENTOSA 63; RP63	614494
PSEUDOHYPOALDOSTERONISM, TYPE IID; PHA2D	PSEUDOHYPOALDOSTERONISM, TYPE IID; PHA2D	614495
FAMILIAL HYPERKALEMIC HYPERTENSION; FHHT	PSEUDOHYPOALDOSTERONISM, TYPE IID; PHA2D	614495
PSEUDOHYPOALDOSTERONISM, TYPE IIE; PHA2E	PSEUDOHYPOALDOSTERONISM, TYPE IIE; PHA2E	614496
MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 7; MCOPCB7	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 7; MCOPCB7	614497
RIGIDITY AND MULTIFOCAL SEIZURE SYNDROME, LETHAL NEONATAL; RMFSL	RIGIDITY AND MULTIFOCAL SEIZURE SYNDROME, LETHAL NEONATAL; RMFSL	614498
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 34; MRT34	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 34; MRT34	614499
CONE-ROD DYSTROPHY 16; CORD16	CONE-ROD DYSTROPHY 16; CORD16	614500
RETINAL DYSTROPHY WITH EARLY MACULAR INVOLVEMENTRETINITIS PIGMENTOSA 64, INCLUDED; RP64, INCLUDED	CONE-ROD DYSTROPHY 16; CORD16	614500
PSYCHOMOTOR RETARDATION, EPILEPSY, AND CRANIOFACIAL DYSMORPHISM;PMRED	PSYCHOMOTOR RETARDATION, EPILEPSY, AND CRANIOFACIAL DYSMORPHISM;PMRED	614501
USHER SYNDROME, TYPE IIIB; USH3B	USHER SYNDROME, TYPE IIIB; USH3B	614504
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ir; CDG1R	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ir; CDG1R	614507
MIRROR MOVEMENTS 2; MRMV2	MIRROR MOVEMENTS 2; MRMV2	614508
THROMBOPHILIA DUE TO PROTEIN S DEFICIENCY, AUTOSOMAL RECESSIVE; THPH6	THROMBOPHILIA DUE TO PROTEIN S DEFICIENCY, AUTOSOMAL RECESSIVE; THPH6	614514
HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO; ICH	HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO; ICH	614519
STROKE, HEMORRHAGIC, SUSCEPTIBILITY TO	HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO; ICH	614519
THROMBOCYTHEMIA 3; THCYT3	THROMBOCYTHEMIA 3; THCYT3	614521
THROMBOCYTOSIS 3	THROMBOCYTHEMIA 3; THCYT3	614521
FIBROCHONDROGENESIS 2; FBCG2	FIBROCHONDROGENESIS 2; FBCG2	614524
CHROMOSOME 17q12 DUPLICATION SYNDROME	CHROMOSOME 17q12 DUPLICATION SYNDROME	614526
CHROMOSOME 17q12 DELETION SYNDROME	CHROMOSOME 17q12 DELETION SYNDROME	614527
CHROMOSOME 16q22 DELETION SYNDROME	CHROMOSOME 16q22 DELETION SYNDROME	614541
EFAVIRENZ, POOR METABOLISM OFEFAVIRENZ CENTRAL NERVOUS SYSTEM TOXICITY, SUSCEPTIBILITY TO, INCLUDED	EFAVIRENZ, POOR METABOLISM OFEFAVIRENZ CENTRAL NERVOUS SYSTEM TOXICITY, SUSCEPTIBILITY TO, INCLUDED	614546
EHLERS-DANLOS SYNDROME WITH PROGRESSIVE KYPHOSCOLIOSIS, MYOPATHY,AND HEARING LOSS; EDSKMH	EHLERS-DANLOS SYNDROME WITH PROGRESSIVE KYPHOSCOLIOSIS, MYOPATHY,AND HEARING LOSS; EDSKMH	614557
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 13; EIEE13	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 13; EIEE13	614558
INFANTILE CEREBELLAR-RETINAL DEGENERATION; ICRD	INFANTILE CEREBELLAR-RETINAL DEGENERATION; ICRD	614559
LEUKOENCEPHALOPATHY, BRAIN CALCIFICATIONS, AND CYSTS; LCC	LEUKOENCEPHALOPATHY, BRAIN CALCIFICATIONS, AND CYSTS; LCC	614561
LABRUNE SYNDROME	LEUKOENCEPHALOPATHY, BRAIN CALCIFICATIONS, AND CYSTS; LCC	614561
MENTAL RETARDATION, AUTOSOMAL DOMINANT 12; MRD12	MENTAL RETARDATION, AUTOSOMAL DOMINANT 12; MRD12	614562
MENTAL RETARDATION, AUTOSOMAL DOMINANT 13; MRD13	MENTAL RETARDATION, AUTOSOMAL DOMINANT 13; MRD13	614563
MENTAL RETARDATION, AUTOSOMAL DOMINANT, 13, WITH NEURONAL MIGRATIONDEFECTS	MENTAL RETARDATION, AUTOSOMAL DOMINANT 13; MRD13	614563
CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL; FCTCS	CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL; FCTCS	614564
TELANGIECTASIA, CUTANEOUS, AND CANCER SYNDROME, FAMILIAL	CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL; FCTCS	614564
NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1E; CSNB1E	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1E; CSNB1E	614565
CSNB, COMPLETE, AUTOSOMAL RECESSIVE	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1E; CSNB1E	614565
MULTIPLE ENCHONDROMATOSIS, MAFFUCCI TYPE	MULTIPLE ENCHONDROMATOSIS, MAFFUCCI TYPE	614569
MAFFUCCI SYNDROME	MULTIPLE ENCHONDROMATOSIS, MAFFUCCI TYPE	614569
CEREBELLAR ATAXIA, NEUROPATHY, AND VESTIBULAR AREFLEXIA SYNDROME;CANVAS	CEREBELLAR ATAXIA, NEUROPATHY, AND VESTIBULAR AREFLEXIA SYNDROME;CANVAS	614575
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIl; CDG2L	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIl; CDG2L	614576
CDG IIl; CDGIIl	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIl; CDG2L	614576
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 9; COXPD9	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 9; COXPD9	614582
BARAITSER-WINTER SYNDROME 2; BRWS2	BARAITSER-WINTER SYNDROME 2; BRWS2	614583
DYSTONIA 21; DYT21	DYSTONIA 21; DYT21	614588
PODOCONIOSIS, SUSCEPTIBILITY TO; PDCOS	PODOCONIOSIS, SUSCEPTIBILITY TO; PDCOS	614590
NONFILARIAL ELEPHANTIASIS OF LOWER LEGS, SUSCEPTIBILITY TO	PODOCONIOSIS, SUSCEPTIBILITY TO; PDCOS	614590
ENDEMIC NONFILARIAL ELEPHANTIASIS, SUSCEPTIBILITY TO	PODOCONIOSIS, SUSCEPTIBILITY TO; PDCOS	614590
LYMPHOSTATIC VERRUCOSIS, SUSCEPTIBILITY TO	PODOCONIOSIS, SUSCEPTIBILITY TO; PDCOS	614590
BENT BONE DYSPLASIA SYNDROME; BBDS	BENT BONE DYSPLASIA SYNDROME; BBDS	614592
PALMOPLANTAR KERATODERMA, MUTILATING, WITH PERIORIFICIAL KERATOTICPLAQUES	PALMOPLANTAR KERATODERMA, MUTILATING, WITH PERIORIFICIAL KERATOTICPLAQUES	614594
OLMSTED SYNDROME; OLMS	PALMOPLANTAR KERATODERMA, MUTILATING, WITH PERIORIFICIAL KERATOTICPLAQUES	614594
PREECLAMPSIA/ECLAMPSIA 5; PEE5	PREECLAMPSIA/ECLAMPSIA 5; PEE5	614595
TRICHOHEPATOENTERIC SYNDROME 2; THES2	TRICHOHEPATOENTERIC SYNDROME 2; THES2	614602
MENTAL RETARDATION, AUTOSOMAL DOMINANT 14; MRD14	MENTAL RETARDATION, AUTOSOMAL DOMINANT 14; MRD14	614607
MENTAL RETARDATION, AUTOSOMAL DOMINANT 15; MRD15	MENTAL RETARDATION, AUTOSOMAL DOMINANT 15; MRD15	614608
MENTAL RETARDATION, AUTOSOMAL DOMINANT 16; MRD16	MENTAL RETARDATION, AUTOSOMAL DOMINANT 16; MRD16	614609
ACRODYSOSTOSIS 2 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS2	ACRODYSOSTOSIS 2 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS2	614613
DEAFNESS, AUTOSOMAL DOMINANT 4B; DFNA4B	DEAFNESS, AUTOSOMAL DOMINANT 4B; DFNA4B	614614
JOUBERT SYNDROME 17; JBTS17	JOUBERT SYNDROME 17; JBTS17	614615
DIARRHEA 6; DIAR6	DIARRHEA 6; DIAR6	614616
DEAFNESS, AUTOSOMAL RECESSIVE 86; DFNB86	DEAFNESS, AUTOSOMAL RECESSIVE 86; DFNB86	614617
HYPEREKPLEXIA 3; HKPX3	HYPEREKPLEXIA 3; HKPX3	614618
HYPEREKPLEXIA 2; HKPX2	HYPEREKPLEXIA 2; HKPX2	614619
UV-SENSITIVE SYNDROME 2; UVSS2	UV-SENSITIVE SYNDROME 2; UVSS2	614621
KERATOCONUS 5; KTCN5	KERATOCONUS 5; KTCN5	614622
KERATOCONUS 6; KTCN6	KERATOCONUS 6; KTCN6	614623
KERATOCONUS 8; KTCN8	KERATOCONUS 8; KTCN8	614628
KERATOCONUS 7; KTCN7	KERATOCONUS 7; KTCN7	614629
UV-SENSITIVE SYNDROME 3; UVSS3	UV-SENSITIVE SYNDROME 3; UVSS3	614640
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 7; MDDGA7	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 7; MDDGA7	614643
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, ISPD-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 7; MDDGA7	614643
MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 4; MPVQTL4	MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 4; MPVQTL4	614644
MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 5; MPVQTL5	MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 5; MPVQTL5	614645
MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 6; MPVQTL6	MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 6; MPVQTL6	614646
COENZYME Q10 DEFICIENCY, PRIMARY, 6; COQ10D6	COENZYME Q10 DEFICIENCY, PRIMARY, 6; COQ10D6	614650
COENZYME Q10 DEFICIENCY, PRIMARY, 2; COQ10D2	COENZYME Q10 DEFICIENCY, PRIMARY, 2; COQ10D2	614651
COENZYME Q10 DEFICIENCY, PRIMARY, 3; COQ10D3	COENZYME Q10 DEFICIENCY, PRIMARY, 3; COQ10D3	614652
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VI; HSAN6	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VI; HSAN6	614653
HSAN VI	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VI; HSAN6	614653
COENZYME Q10 DEFICIENCY, PRIMARY, 5; COQ10D5	COENZYME Q10 DEFICIENCY, PRIMARY, 5; COQ10D5	614654
STUTTERING, FAMILIAL PERSISTENT, 3; STUT3	STUTTERING, FAMILIAL PERSISTENT, 3; STUT3	614655
CORTISONE REDUCTASE DEFICIENCY 2; CORTRD2	CORTISONE REDUCTASE DEFICIENCY 2; CORTRD2	614662
MECONIUM ILEUS	MECONIUM ILEUS	614665
STUTTERING, FAMILIAL PERSISTENT, 4; STUT4	STUTTERING, FAMILIAL PERSISTENT, 4; STUT4	614668
AURICULOCONDYLAR SYNDROME 2; ARCND2	AURICULOCONDYLAR SYNDROME 2; ARCND2	614669
PERIPARTUM CARDIOMYOPATHY, SUSCEPTIBILITY TO	PERIPARTUM CARDIOMYOPATHY, SUSCEPTIBILITY TO	614670
PPCM, SUSCEPTIBILITY TO	PERIPARTUM CARDIOMYOPATHY, SUSCEPTIBILITY TO	614670
CHROMOSOME 16p11.2 DUPLICATION SYNDROMEAUTISM, SUSCEPTIBILITY TO, 14B, INCLUDED; AUTS14B, INCLUDED	CHROMOSOME 16p11.2 DUPLICATION SYNDROMEAUTISM, SUSCEPTIBILITY TO, 14B, INCLUDED; AUTS14B, INCLUDED	614671
CARDIOMYOPATHY, DILATED, 2B; CMD2B	CARDIOMYOPATHY, DILATED, 2B; CMD2B	614672
MICROCEPHALY 8, PRIMARY, AUTOSOMAL RECESSIVE; MCPH8	MICROCEPHALY 8, PRIMARY, AUTOSOMAL RECESSIVE; MCPH8	614673
PERIODIC FEVER, MENSTRUAL CYCLE-DEPENDENT	PERIODIC FEVER, MENSTRUAL CYCLE-DEPENDENT	614674
BONE MARROW FAILURE SYNDROME 1; BMFS1	BONE MARROW FAILURE SYNDROME 1; BMFS1	614675
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 21; CMH21	CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 21; CMH21	614676
PONTOCEREBELLAR HYPOPLASIA, TYPE 1B; PCH1B	PONTOCEREBELLAR HYPOPLASIA, TYPE 1B; PCH1B	614678
CILIARY DYSKINESIA, PRIMARY, 17; CILD17	CILIARY DYSKINESIA, PRIMARY, 17; CILD17	614679
CILIARY DYSKINESIA, PRIMARY, 17, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 17; CILD17	614679
INFLUENZA, SEVERE, SUSCEPTIBILITY TO	INFLUENZA, SEVERE, SUSCEPTIBILITY TO	614680
HYPERTELORISM AND OTHER FACIAL DYSMORPHISM, BRACHYDACTYLY, GENITALABNORMALITIES, MENTAL RETARDATION, AND RECURRENT INFLAMMATORY EPISODES	HYPERTELORISM AND OTHER FACIAL DYSMORPHISM, BRACHYDACTYLY, GENITALABNORMALITIES, MENTAL RETARDATION, AND RECURRENT INFLAMMATORY EPISODES	614684
SOLUBLE INTERLEUKIN-6 RECEPTOR, SERUM LEVEL OF, QUANTITATIVE TRAITLOCUS	SOLUBLE INTERLEUKIN-6 RECEPTOR, SERUM LEVEL OF, QUANTITATIVE TRAITLOCUS	614689
SOLUBLE IL6R, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS	SOLUBLE INTERLEUKIN-6 RECEPTOR, SERUM LEVEL OF, QUANTITATIVE TRAITLOCUS	614689
CATARACT 38; CTRCT38	CATARACT 38; CTRCT38	614691
CATARACT, AUTOSOMAL RECESSIVE CONGENITAL 5; CATC5	CATARACT 38; CTRCT38	614691
MEMBRANOUS NEPHROPATHY, SUSCEPTIBILITY TO; MBNP	MEMBRANOUS NEPHROPATHY, SUSCEPTIBILITY TO; MBNP	614692
AMYOTROPHIC LATERAL SCLEROSIS 17; ALS17	AMYOTROPHIC LATERAL SCLEROSIS 17; ALS17	614696
AMYOTROPHIC LATERAL SCLEROSIS, CHMP2B-RELATED	AMYOTROPHIC LATERAL SCLEROSIS 17; ALS17	614696
IMMUNODEFICIENCY, COMMON VARIABLE, 7; CVID7	IMMUNODEFICIENCY, COMMON VARIABLE, 7; CVID7	614699
IMMUNODEFICIENCY, COMMON VARIABLE, 8, WITH AUTOIMMUNITY; CVID8	IMMUNODEFICIENCY, COMMON VARIABLE, 8, WITH AUTOIMMUNITY; CVID8	614700
CORNELIA DE LANGE SYNDROME 4; CDLS4	CORNELIA DE LANGE SYNDROME 4; CDLS4	614701
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 10; COXPD10	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 10; COXPD10	614702
CARDIOMYOPATHY, INFANTILE HYPERTROPHIC MITOCHONDRIAL, AND LACTIC ACIDOSIS	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 10; COXPD10	614702
CEROID LIPOFUSCINOSIS, NEURONAL, 11; CLN11	CEROID LIPOFUSCINOSIS, NEURONAL, 11; CLN11	614706
BROWN-VIALETTO-VAN LAERE SYNDROME 2; BVVLS2	BROWN-VIALETTO-VAN LAERE SYNDROME 2; BVVLS2	614707
POROKERATOSIS 7, MULTIPLE TYPES; POROK7	POROKERATOSIS 7, MULTIPLE TYPES; POROK7	614714
ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD	ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD	614723
APRT DEFICIENCY	ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD	614723
UROLITHIASIS, 2,8-@DIHYDROXYADENINE	ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD	614723
UROLITHIASIS, DHA	ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD	614723
NEPHROLITHIASIS, DHA	ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD	614723
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIk; CDG2K	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIk; CDG2K	614727
CDG IIk; CDGIIk	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIk; CDG2K	614727
SECKEL SYNDROME 6; SCKL6	SECKEL SYNDROME 6; SCKL6	614728
PROSTATE CANCER, HEREDITARY, 2; HPC2	PROSTATE CANCER, HEREDITARY, 2; HPC2	614731
INTRAUTERINE GROWTH RETARDATION, METAPHYSEAL DYSPLASIA, ADRENAL HYPOPLASIACONGENITA, AND GENITAL ANOMALIES	INTRAUTERINE GROWTH RETARDATION, METAPHYSEAL DYSPLASIA, ADRENAL HYPOPLASIACONGENITA, AND GENITAL ANOMALIES	614732
IMAGE SYNDROME	INTRAUTERINE GROWTH RETARDATION, METAPHYSEAL DYSPLASIA, ADRENAL HYPOPLASIACONGENITA, AND GENITAL ANOMALIES	614732
GLUCOCORTICOID DEFICIENCY 4; GCCD4	GLUCOCORTICOID DEFICIENCY 4; GCCD4	614736
3-@METHYLGLUTACONIC ACIDURIA WITH DEAFNESS, ENCEPHALOPATHY, AND LEIGH-LIKESYNDROME; MEGDEL	3-@METHYLGLUTACONIC ACIDURIA WITH DEAFNESS, ENCEPHALOPATHY, AND LEIGH-LIKESYNDROME; MEGDEL	614739
3-@METHYLGLUTACONIC ACIDURIA, TYPE VI; MGCA6	3-@METHYLGLUTACONIC ACIDURIA WITH DEAFNESS, ENCEPHALOPATHY, AND LEIGH-LIKESYNDROME; MEGDEL	614739
BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 7; BCC7	BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 7; BCC7	614740
MITOCHONDRIAL PYRUVATE CARRIER DEFICIENCY; MPYCD	MITOCHONDRIAL PYRUVATE CARRIER DEFICIENCY; MPYCD	614741
PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1;PFBMFT1	PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1;PFBMFT1	614742
PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 2;PFBMFT2	PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 2;PFBMFT2	614743
FACIAL PARESIS, HEREDITARY CONGENITAL, 3; HCFP3	FACIAL PARESIS, HEREDITARY CONGENITAL, 3; HCFP3	614744
BLOOD GROUP, JOHN MILTON HAGEN SYSTEM	BLOOD GROUP, JOHN MILTON HAGEN SYSTEM	614745
JOHN MILTON HAGEN BLOOD GROUP SYSTEM	BLOOD GROUP, JOHN MILTON HAGEN SYSTEM	614745
JMH BLOOD GROUP SYSTEM	BLOOD GROUP, JOHN MILTON HAGEN SYSTEM	614745
URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 5; UAQTL5	URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 5; UAQTL5	614746
URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 6; UAQTL6	URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 6; UAQTL6	614747
INTERSTITIAL LUNG DISEASE, NEPHROTIC SYNDROME, AND EPIDERMOLYSIS BULLOSA,CONGENITAL; ILNEB	INTERSTITIAL LUNG DISEASE, NEPHROTIC SYNDROME, AND EPIDERMOLYSIS BULLOSA,CONGENITAL; ILNEB	614748
HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 2; HPMRS2	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 2; HPMRS2	614749
MYASTHENIC SYNDROME, CONGENITAL, 13; CMS13	MYASTHENIC SYNDROME, CONGENITAL, 13; CMS13	614750
MYASTHENIC SYNDROME, CONGENITAL, WITH TUBULAR AGGREGATES 2; CMSTA2	MYASTHENIC SYNDROME, CONGENITAL, 13; CMS13	614750
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VB; HMN5B	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VB; HMN5B	614751
HMN VB	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VB; HMN5B	614751
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VB; DHMN5B	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VB; HMN5B	614751
DHMN VB	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VB; HMN5B	614751
SPINAL MUSCULAR ATROPHY, DISTAL, TYPE VB; DSMAVB	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VB; HMN5B	614751
INTERLEUKIN 6, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS	INTERLEUKIN 6, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS	614752
IL6, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS	INTERLEUKIN 6, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS	614752
SOTOS SYNDROME 2; SOTOS2	SOTOS SYNDROME 2; SOTOS2	614753
CEREBELLAR ATAXIA, NONPROGRESSIVE, WITH MENTAL RETARDATION; CANPMR	CEREBELLAR ATAXIA, NONPROGRESSIVE, WITH MENTAL RETARDATION; CANPMR	614756
HETEROTAXY, VISCERAL, 6, AUTOSOMAL; HTX6	HETEROTAXY, VISCERAL, 6, AUTOSOMAL; HTX6	614779
TREMOR, HEREDITARY ESSENTIAL, 4; ETM4	TREMOR, HEREDITARY ESSENTIAL, 4; ETM4	614782
SHORT STATURE, OPTIC NERVE ATROPHY, AND PELGER-HUET ANOMALY; SOPH	SHORT STATURE, OPTIC NERVE ATROPHY, AND PELGER-HUET ANOMALY; SOPH	614800
MYOPATHY, CENTRONUCLEAR, 4; CNM4	MYOPATHY, CENTRONUCLEAR, 4; CNM4	614807
AMYOTROPHIC LATERAL SCLEROSIS 18; ALS18	AMYOTROPHIC LATERAL SCLEROSIS 18; ALS18	614808
CFHR5 DEFICIENCY	CFHR5 DEFICIENCY	614809
MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 5; MS5	MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 5; MS5	614810
SHORT STATURE, ONYCHODYSPLASIA, FACIAL DYSMORPHISM, AND HYPOTRICHOSIS;SOFT	SHORT STATURE, ONYCHODYSPLASIA, FACIAL DYSMORPHISM, AND HYPOTRICHOSIS;SOFT	614813
SOFT SYNDROME	SHORT STATURE, ONYCHODYSPLASIA, FACIAL DYSMORPHISM, AND HYPOTRICHOSIS;SOFT	614813
ADAMS-OLIVER SYNDROME 3; AOS3	ADAMS-OLIVER SYNDROME 3; AOS3	614814
JOUBERT SYNDROME 18; JBTS18	JOUBERT SYNDROME 18; JBTS18	614815
LOEYS-DIETZ SYNDROME 4; LDS4	LOEYS-DIETZ SYNDROME 4; LDS4	614816
ANEURYSM, AORTIC AND CEREBRAL, WITH ARTERIAL TORTUOSITY AND SKELETALMANIFESTATIONS	LOEYS-DIETZ SYNDROME 4; LDS4	614816
INTERSTITIAL NEPHRITIS, KARYOMEGALIC; KMIN	INTERSTITIAL NEPHRITIS, KARYOMEGALIC; KMIN	614817
WEILL-MARCHESANI SYNDROME 3; WMS3	WEILL-MARCHESANI SYNDROME 3; WMS3	614819
ALTERNATING HEMIPLEGIA OF CHILDHOOD 2; AHC2	ALTERNATING HEMIPLEGIA OF CHILDHOOD 2; AHC2	614820
SPERMATOGENIC FAILURE 10; SPGF10	SPERMATOGENIC FAILURE 10; SPGF10	614822
SPERMATOGENIC FAILURE WITH DEFECTIVE SPERM ANNULUS	SPERMATOGENIC FAILURE 10; SPGF10	614822
AORTIC VALVE DISEASE 2; AOVD2	AORTIC VALVE DISEASE 2; AOVD2	614823
BICUSPID AORTIC VALVE	AORTIC VALVE DISEASE 2; AOVD2	614823
AORTIC VALVE STENOSIS	AORTIC VALVE DISEASE 2; AOVD2	614823
NYSTAGMUS 7, CONGENITAL, AUTOSOMAL DOMINANT; NYS7	NYSTAGMUS 7, CONGENITAL, AUTOSOMAL DOMINANT; NYS7	614826
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 8; MDDGA8	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 8; MDDGA8	614830
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, GTDC2-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 8; MDDGA8	614830
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 13; SCAR13	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 13; SCAR13	614831
AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA4; AI2A4	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA4; AI2A4	614832
POLYMICROGYRIA WITH SEIZURES; PMGYS	POLYMICROGYRIA WITH SEIZURES; PMGYS	614833
THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 3; TTPP3	THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 3; TTPP3	614834
HUMAN HERPESVIRUS 8, SUSCEPTIBILITY TO; HHV8S	HUMAN HERPESVIRUS 8, SUSCEPTIBILITY TO; HHV8S	614836
HHV-8, SUSCEPTIBILITY TO	HUMAN HERPESVIRUS 8, SUSCEPTIBILITY TO; HHV8S	614836
HYPOGONADOTROPIC HYPOGONADISM 8 WITH OR WITHOUT ANOSMIA; HH8	HYPOGONADOTROPIC HYPOGONADISM 8 WITH OR WITHOUT ANOSMIA; HH8	614837
HYPOGONADOTROPIC HYPOGONADISM 9 WITH OR WITHOUT ANOSMIA; HH9	HYPOGONADOTROPIC HYPOGONADISM 9 WITH OR WITHOUT ANOSMIA; HH9	614838
HYPOGONADOTROPIC HYPOGONADISM 10 WITH OR WITHOUT ANOSMIA; HH10	HYPOGONADOTROPIC HYPOGONADISM 10 WITH OR WITHOUT ANOSMIA; HH10	614839
HYPOGONADOTROPIC HYPOGONADISM 11 WITH OR WITHOUT ANOSMIA; HH11	HYPOGONADOTROPIC HYPOGONADISM 11 WITH OR WITHOUT ANOSMIA; HH11	614840
HYPOGONADOTROPIC HYPOGONADISM 12 WITH OR WITHOUT ANOSMIA; HH12	HYPOGONADOTROPIC HYPOGONADISM 12 WITH OR WITHOUT ANOSMIA; HH12	614841
EUNUCHOIDISM, FAMILIAL HYPOGONADOTROPIC	HYPOGONADOTROPIC HYPOGONADISM 12 WITH OR WITHOUT ANOSMIA; HH12	614841
GONADOTROPIN DEFICIENCY, FAMILIAL IDIOPATHIC; FIGD	HYPOGONADOTROPIC HYPOGONADISM 12 WITH OR WITHOUT ANOSMIA; HH12	614841
HYPOGONADOTROPIC HYPOGONADISM 13 WITH OR WITHOUT ANOSMIA; HH13	HYPOGONADOTROPIC HYPOGONADISM 13 WITH OR WITHOUT ANOSMIA; HH13	614842
NEPHRONOPHTHISIS 14; NPHP14JOUBERT SYNDROME 19, INCLUDED; JBTS19, INCLUDED	NEPHRONOPHTHISIS 14; NPHP14JOUBERT SYNDROME 19, INCLUDED; JBTS19, INCLUDED	614844
NEPHRONOPHTHISIS 15; NPHP15	NEPHRONOPHTHISIS 15; NPHP15	614845
TETRASOMY 15q26	TETRASOMY 15q26	614846
LEVY-SHANSKE SYNDROME	TETRASOMY 15q26	614846
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 12; EIG12	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 12; EIG12	614847
HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 3	HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 3	614849
ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 5; IIAE5	HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 3	614849
HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 4	HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 4	614850
ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 6; IIAE6	HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 4	614850
SECKEL SYNDROME 7; SCKL7	SECKEL SYNDROME 7; SCKL7	614851
MICROCEPHALY 9, PRIMARY, AUTOSOMAL RECESSIVE; MCPH9	MICROCEPHALY 9, PRIMARY, AUTOSOMAL RECESSIVE; MCPH9	614852
OSTEOGENESIS IMPERFECTA, TYPE XIII; OI13	OSTEOGENESIS IMPERFECTA, TYPE XIII; OI13	614856
OI, TYPE XIII	OSTEOGENESIS IMPERFECTA, TYPE XIII; OI13	614856
METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblJ TYPE; MAHCJ	METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblJ TYPE; MAHCJ	614857
HYPOGONADOTROPIC HYPOGONADISM 14 WITH OR WITHOUT ANOSMIA; HH14	HYPOGONADOTROPIC HYPOGONADISM 14 WITH OR WITHOUT ANOSMIA; HH14	614858
PEROXISOME BIOGENESIS DISORDER 3A (ZELLWEGER); PBD3APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 3, INCLUDED;CG3, INCLUDED	PEROXISOME BIOGENESIS DISORDER 3A (ZELLWEGER); PBD3APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 3, INCLUDED;CG3, INCLUDED	614859
DYSTONIA 23; DYT23	DYSTONIA 23; DYT23	614860
DEAFNESS, AUTOSOMAL RECESSIVE 98; DFNB98	DEAFNESS, AUTOSOMAL RECESSIVE 98; DFNB98	614861
PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER); PBD4APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 4, INCLUDED;CG4, INCLUDED	PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER); PBD4APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 4, INCLUDED;CG4, INCLUDED	614862
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 6, INCLUDED;CG6, INCLUDED	PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER); PBD4APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 4, INCLUDED;CG4, INCLUDED	614862
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP C, INCLUDED;CGC, INCLUDED	PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER); PBD4APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 4, INCLUDED;CG4, INCLUDED	614862
PEROXISOME BIOGENESIS DISORDER 4B; PBD4B	PEROXISOME BIOGENESIS DISORDER 4B; PBD4B	614863
PEROXISOME BIOGENESIS DISORDER 5A (ZELLWEGER); PBD5APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 5, INCLUDED;CG5, INCLUDED	PEROXISOME BIOGENESIS DISORDER 5A (ZELLWEGER); PBD5APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 5, INCLUDED;CG5, INCLUDED	614866
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 10, INCLUDED;CG10, INCLUDED	PEROXISOME BIOGENESIS DISORDER 5A (ZELLWEGER); PBD5APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 5, INCLUDED;CG5, INCLUDED	614866
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP F, INCLUDED;CGF, INCLUDED	PEROXISOME BIOGENESIS DISORDER 5A (ZELLWEGER); PBD5APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 5, INCLUDED;CG5, INCLUDED	614866
PEROXISOME BIOGENESIS DISORDER 5B; PBD5B	PEROXISOME BIOGENESIS DISORDER 5B; PBD5B	614867
T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AND AUTOIMMUNITY WITHOR WITHOUT CARDIAC MALFORMATIONS; TIIAC	T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AND AUTOIMMUNITY WITHOR WITHOUT CARDIAC MALFORMATIONS; TIIAC	614868
STK4 DEFICIENCY	T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AND AUTOIMMUNITY WITHOR WITHOUT CARDIAC MALFORMATIONS; TIIAC	614868
MST1 DEFICIENCY	T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AND AUTOIMMUNITY WITHOR WITHOUT CARDIAC MALFORMATIONS; TIIAC	614868
USHER SYNDROME, TYPE IJ; USH1J	USHER SYNDROME, TYPE IJ; USH1J	614869
PEROXISOME BIOGENESIS DISORDER 6A (ZELLWEGER); PBD6APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 7, INCLUDED;CG7, INCLUDED	PEROXISOME BIOGENESIS DISORDER 6A (ZELLWEGER); PBD6APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 7, INCLUDED;CG7, INCLUDED	614870
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP B, INCLUDED;CGB, INCLUDED	PEROXISOME BIOGENESIS DISORDER 6A (ZELLWEGER); PBD6APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 7, INCLUDED;CG7, INCLUDED	614870
PEROXISOME BIOGENESIS DISORDER 6B; PBD6B	PEROXISOME BIOGENESIS DISORDER 6B; PBD6B	614871
PEROXISOME BIOGENESIS DISORDER 7A (ZELLWEGER); PBD7APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 8, INCLUDED;CG8, INCLUDED	PEROXISOME BIOGENESIS DISORDER 7A (ZELLWEGER); PBD7APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 8, INCLUDED;CG8, INCLUDED	614872
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP A, INCLUDED;CGA, INCLUDED	PEROXISOME BIOGENESIS DISORDER 7A (ZELLWEGER); PBD7APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 8, INCLUDED;CG8, INCLUDED	614872
PEROXISOME BIOGENESIS DISORDER 7B; PBD7B	PEROXISOME BIOGENESIS DISORDER 7B; PBD7B	614873
CILIARY DYSKINESIA, PRIMARY, 18; CILD18	CILIARY DYSKINESIA, PRIMARY, 18; CILD18	614874
CILIARY DYSKINESIA, PRIMARY, 18, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 18; CILD18	614874
METAPHYSEAL ENCHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA	METAPHYSEAL ENCHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA	614875
SPONDYLOENCHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA	METAPHYSEAL ENCHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA	614875
METAPHYSEAL ENCHONDRODYSPLASIA WITH 2-HYDROXYGLUTARIC ACIDURIA	METAPHYSEAL ENCHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA	614875
METAPHYSEAL CHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA	METAPHYSEAL ENCHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA	614875
PEROXISOME BIOGENESIS DISORDER 8A (ZELLWEGER); PBD8APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 9, INCLUDED;CG9, INCLUDED	PEROXISOME BIOGENESIS DISORDER 8A (ZELLWEGER); PBD8APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 9, INCLUDED;CG9, INCLUDED	614876
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP D, INCLUDED;CGD, INCLUDED	PEROXISOME BIOGENESIS DISORDER 8A (ZELLWEGER); PBD8APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 9, INCLUDED;CG9, INCLUDED	614876
PEROXISOME BIOGENESIS DISORDER 8B; PBD8B	PEROXISOME BIOGENESIS DISORDER 8B; PBD8B	614877
AUTOINFLAMMATION, ANTIBODY DEFICIENCY, AND IMMUNE DYSREGULATION, PLCG2-ASSOCIATED;APLAID	AUTOINFLAMMATION, ANTIBODY DEFICIENCY, AND IMMUNE DYSREGULATION, PLCG2-ASSOCIATED;APLAID	614878
PEROXISOME BIOGENESIS DISORDER 9B; PBD9B	PEROXISOME BIOGENESIS DISORDER 9B; PBD9B	614879
REFSUM DISEASE, ADULT, 2	PEROXISOME BIOGENESIS DISORDER 9B; PBD9B	614879
PEROXISOME BIOGENESIS DISORDER, PEX7-RELATED, ATYPICALPEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 11, INCLUDED;CG11, INCLUDED	PEROXISOME BIOGENESIS DISORDER 9B; PBD9B	614879
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP R, INCLUDED;CGR, INCLUDED	PEROXISOME BIOGENESIS DISORDER 9B; PBD9B	614879
HYPOGONADOTROPIC HYPOGONADISM 15 WITH OR WITHOUT ANOSMIA; HH15	HYPOGONADOTROPIC HYPOGONADISM 15 WITH OR WITHOUT ANOSMIA; HH15	614880
SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 5; DSMA5	SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 5; DSMA5	614881
PEROXISOME BIOGENESIS DISORDER 10A (ZELLWEGER); PBD10APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 12, INCLUDED;CG12, INCLUDED	PEROXISOME BIOGENESIS DISORDER 10A (ZELLWEGER); PBD10APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 12, INCLUDED;CG12, INCLUDED	614882
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP G, INCLUDED;CGG, INCLUDED	PEROXISOME BIOGENESIS DISORDER 10A (ZELLWEGER); PBD10APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 12, INCLUDED;CG12, INCLUDED	614882
PEROXISOME BIOGENESIS DISORDER 11A (ZELLWEGER); PBD11APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 13, INCLUDED;CG13, INCLUDED	PEROXISOME BIOGENESIS DISORDER 11A (ZELLWEGER); PBD11APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 13, INCLUDED;CG13, INCLUDED	614883
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP H, INCLUDED;CGH, INCLUDED	PEROXISOME BIOGENESIS DISORDER 11A (ZELLWEGER); PBD11APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 13, INCLUDED;CG13, INCLUDED	614883
PEROXISOME BIOGENESIS DISORDER 11B; PBD11B	PEROXISOME BIOGENESIS DISORDER 11B; PBD11B	614885
PEROXISOME BIOGENESIS DISORDER 12A (ZELLWEGER); PBD12APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 14, INCLUDED	PEROXISOME BIOGENESIS DISORDER 12A (ZELLWEGER); PBD12APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 14, INCLUDED	614886
CG14, INCLUDED	PEROXISOME BIOGENESIS DISORDER 12A (ZELLWEGER); PBD12APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 14, INCLUDED	614886
PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP J, INCLUDED	PEROXISOME BIOGENESIS DISORDER 12A (ZELLWEGER); PBD12APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 14, INCLUDED	614886
CGJ, INCLUDED	PEROXISOME BIOGENESIS DISORDER 12A (ZELLWEGER); PBD12APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 14, INCLUDED	614886
PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER); PBD13APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP K, INCLUDED;CGK, INCLUDED	PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER); PBD13APEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP K, INCLUDED;CGK, INCLUDED	614887
IMMUNODEFICIENCY 28; IMD28	IMMUNODEFICIENCY 28; IMD28	614889
IMMUNODEFICIENCY 28, MYCOBACTERIOSIS	IMMUNODEFICIENCY 28; IMD28	614889
IFNGR2 DEFICIENCY	IMMUNODEFICIENCY 28; IMD28	614889
IMMUNODEFICIENCY 29; IMD29	IMMUNODEFICIENCY 29; IMD29	614890
IL12B DEFICIENCY	IMMUNODEFICIENCY 29; IMD29	614890
IMMUNODEFICIENCY 30; IMD30	IMMUNODEFICIENCY 30; IMD30	614891
IL12RB1 DEFICIENCY	IMMUNODEFICIENCY 30; IMD30	614891
IMMUNODEFICIENCY 31A; IMD31A	IMMUNODEFICIENCY 31A; IMD31A	614892
IMMUNODEFICIENCY 31A, MYCOBACTERIOSIS, AUTOSOMAL DOMINANT	IMMUNODEFICIENCY 31A; IMD31A	614892
STAT1 DEFICIENCY, AUTOSOMAL DOMINANT	IMMUNODEFICIENCY 31A; IMD31A	614892
IMMUNODEFICIENCY 32A; IMD32A	IMMUNODEFICIENCY 32A; IMD32A	614893
IMMUNODEFICIENCY 32A, MYCOBACTERIOSIS, AUTOSOMAL DOMINANT	IMMUNODEFICIENCY 32A; IMD32A	614893
IRF8 DEFICIENCY, AUTOSOMAL DOMINANT	IMMUNODEFICIENCY 32A; IMD32A	614893
CD11C-POSITIVE/CD1C-POSITIVE DENDRITIC CELL DEFICIENCY, AUTOSOMALDOMINANT	IMMUNODEFICIENCY 32A; IMD32A	614893
MONOCYTE AND DENDRITIC CELL DEFICIENCY, AUTOSOMAL RECESSIVE	MONOCYTE AND DENDRITIC CELL DEFICIENCY, AUTOSOMAL RECESSIVE	614894
IRF8 DEFICIENCY, AUTOSOMAL RECESSIVE	MONOCYTE AND DENDRITIC CELL DEFICIENCY, AUTOSOMAL RECESSIVE	614894
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 4F; CMT4F	CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 4F; CMT4F	614895
SINOATRIAL NODE DYSFUNCTION AND DEAFNESS; SANDD	SINOATRIAL NODE DYSFUNCTION AND DEAFNESS; SANDD	614896
HYPOGONADOTROPIC HYPOGONADISM 16 WITH OR WITHOUT ANOSMIA; HH16	HYPOGONADOTROPIC HYPOGONADISM 16 WITH OR WITHOUT ANOSMIA; HH16	614897
SPASTIC PARAPLEGIA 53, AUTOSOMAL RECESSIVE; SPG53	SPASTIC PARAPLEGIA 53, AUTOSOMAL RECESSIVE; SPG53	614898
DEAFNESS, AUTOSOMAL RECESSIVE 93; DFNB93	DEAFNESS, AUTOSOMAL RECESSIVE 93; DFNB93	614899
DIAMOND-BLACKFAN ANEMIA 11; DBA11	DIAMOND-BLACKFAN ANEMIA 11; DBA11	614900
LETHAL CONGENITAL CONTRACTURE SYNDROME 4; LCCS4	LETHAL CONGENITAL CONTRACTURE SYNDROME 4; LCCS4	614915
VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 4; CPVT4	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 4; CPVT4	614916
PEROXISOME BIOGENESIS DISORDER 14B; PEX14B	PEROXISOME BIOGENESIS DISORDER 14B; PEX14B	614920
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T	614921
CDG It; CDGIt	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T	614921
PHOSPHOGLUCOMUTASE 1 DEFICIENCY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T	614921
PGM1 DEFICIENCY	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T	614921
GLYCOGEN STORAGE DISEASE XIV; GSD14	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T	614921
GSD XIV	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T	614921
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 11; COXPD11	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 11; COXPD11	614922
ENCEPHALONEUROMYOPATHY, INFANTILE, DUE TO MITOCHONDRIAL TRANSLATIONDEFECT	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 11; COXPD11	614922
BRANCHED-CHAIN KETO ACID DEHYDROGENASE KINASE DEFICIENCY; BCKDKD	BRANCHED-CHAIN KETO ACID DEHYDROGENASE KINASE DEFICIENCY; BCKDKD	614923
BCKDK DEFICIENCY	BRANCHED-CHAIN KETO ACID DEHYDROGENASE KINASE DEFICIENCY; BCKDKD	614923
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 12; COXPD12	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 12; COXPD12	614924
LEUKOENCEPHALOPATHY WITH THALAMUS AND BRAINSTEM INVOLVEMENT AND HIGHLACTATE; LTBL	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 12; COXPD12	614924
PERRAULT SYNDROME 2; PRLTS2	PERRAULT SYNDROME 2; PRLTS2	614926
ECTODERMAL DYSPLASIA 5, HAIR/NAIL TYPE; ECTD5	ECTODERMAL DYSPLASIA 5, HAIR/NAIL TYPE; ECTD5	614927
ECTODERMAL DYSPLASIA 6, HAIR/NAIL TYPE; ECTD6	ECTODERMAL DYSPLASIA 6, HAIR/NAIL TYPE; ECTD6	614928
ECTODERMAL DYSPLASIA 7, HAIR/NAIL TYPE; ECTD7	ECTODERMAL DYSPLASIA 7, HAIR/NAIL TYPE; ECTD7	614929
ECTODERMAL DYSPLASIA 9, HAIR/NAIL TYPE; ECTD9	ECTODERMAL DYSPLASIA 9, HAIR/NAIL TYPE; ECTD9	614931
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 13; COXPD13	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 13; COXPD13	614932
DEAFNESS, AUTOSOMAL RECESSIVE 70; DFNB70	DEAFNESS, AUTOSOMAL RECESSIVE 70; DFNB70	614934
CILIARY DYSKINESIA, PRIMARY, 19; CILD19	CILIARY DYSKINESIA, PRIMARY, 19; CILD19	614935
CILIARY DYSKINESIA, PRIMARY, 19, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 19; CILD19	614935
PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IB; PPKP1B	PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IB; PPKP1B	614936
MYOCLONUS, FAMILIAL CORTICAL; FCM	MYOCLONUS, FAMILIAL CORTICAL; FCM	614937
ECTODERMAL DYSPLASIA 11A, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALDOMINANT; ECTD11A	ECTODERMAL DYSPLASIA 11A, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALDOMINANT; ECTD11A	614940
ECTODERMAL DYSPLASIA, HYPOHIDROTIC, AUTOSOMAL DOMINANT; HED	ECTODERMAL DYSPLASIA 11A, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALDOMINANT; ECTD11A	614940
ECTODERMAL DYSPLASIA 11B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALRECESSIVE; ECTD11B	ECTODERMAL DYSPLASIA 11B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALRECESSIVE; ECTD11B	614941
ECTODERMAL DYSPLASIA, HYPOHIDROTIC; HED	ECTODERMAL DYSPLASIA 11B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALRECESSIVE; ECTD11B	614941
ECTODERMAL DYSPLASIA, ANHIDROTIC; EDA	ECTODERMAL DYSPLASIA 11B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMALRECESSIVE; ECTD11B	614941
DEAFNESS, AUTOSOMAL RECESSIVE 84B; DFNB84B	DEAFNESS, AUTOSOMAL RECESSIVE 84B; DFNB84B	614944
DEAFNESS, AUTOSOMAL RECESSIVE 18B; DFNB18B	DEAFNESS, AUTOSOMAL RECESSIVE 18B; DFNB18B	614945
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 14; COXPD14	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 14; COXPD14	614946
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 15; COXPD15	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 15; COXPD15	614947
CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 3; CHTD3	CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 3; CHTD3	614954
CONGENITAL HEART DEFECTS, MULTIPLE TYPES, WITH CARDIAC RHYTHM ANDCONDUCTION DISTURBANCES	CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 3; CHTD3	614954
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 14; EIEE14	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 14; EIEE14	614959
PONTOCEREBELLAR HYPOPLASIA, TYPE 8; PCH8	PONTOCEREBELLAR HYPOPLASIA, TYPE 8; PCH8	614961
LEPTIN DEFICIENCY OR DYSFUNCTION; LEPD	LEPTIN DEFICIENCY OR DYSFUNCTION; LEPD	614962
OBESITY, MORBID, NONSYNDROMIC 1	LEPTIN DEFICIENCY OR DYSFUNCTION; LEPD	614962
LEPTIN RECEPTOR DEFICIENCY	LEPTIN RECEPTOR DEFICIENCY	614963
OBESITY, MORBID, NONSYNDROMIC 2	LEPTIN RECEPTOR DEFICIENCY	614963
PONTOCEREBELLAR HYPOPLASIA, TYPE 7; PCH7	PONTOCEREBELLAR HYPOPLASIA, TYPE 7; PCH7	614969
JOUBERT SYNDROME 20; JBTS20	JOUBERT SYNDROME 20; JBTS20	614970
CHOLESTASIS, INTRAHEPATIC, OF PREGNANCY 3; ICP3	CHOLESTASIS, INTRAHEPATIC, OF PREGNANCY 3; ICP3	614972
FOCAL FACIAL DERMAL DYSPLASIA 2, BRAUER-SETLEIS TYPE; FFDD2	FOCAL FACIAL DERMAL DYSPLASIA 2, BRAUER-SETLEIS TYPE; FFDD2	614973
BRAUER-SETLEIS SYNDROME	FOCAL FACIAL DERMAL DYSPLASIA 2, BRAUER-SETLEIS TYPE; FFDD2	614973
FOCAL FACIAL DERMAL DYSPLASIA 4; FFDD4	FOCAL FACIAL DERMAL DYSPLASIA 4; FFDD4	614974
CARPENTER SYNDROME 2; CRPT2	CARPENTER SYNDROME 2; CRPT2	614976
SPLENOMEGALY, CYTOPENIA, AND VISION LOSS	SPLENOMEGALY, CYTOPENIA, AND VISION LOSS	614979
CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 2; CHTD2	CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 2; CHTD2	614980
USHER SYNDROME, TYPE IK; USH1K	USHER SYNDROME, TYPE IK; USH1K	614990
EPILEPSY, NOCTURNAL FRONTAL LOBE, 5; ENFL5	EPILEPSY, NOCTURNAL FRONTAL LOBE, 5; ENFL5	615005
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 15; EIEE15	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 15; EIEE15	615006
BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 4; IBGC4	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 4; IBGC4	615007
NEPHROTIC SYNDROME, TYPE 7; NPHS7	NEPHROTIC SYNDROME, TYPE 7; NPHS7	615008
NEPHROTIC SYNDROME, TYPE 7, WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRITISHEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 7, INCLUDED;AHUS7, INCLUDED	NEPHROTIC SYNDROME, TYPE 7; NPHS7	615008
AHUS, SUSCEPTIBILITY TO, 7, INCLUDED	NEPHROTIC SYNDROME, TYPE 7; NPHS7	615008
MENTAL RETARDATION, AUTOSOMAL DOMINANT 17; MRD17	MENTAL RETARDATION, AUTOSOMAL DOMINANT 17; MRD17	615009
AICARDI-GOUTIERES SYNDROME 6; AGS6	AICARDI-GOUTIERES SYNDROME 6; AGS6	615010
PHOSPHOHYDROXYLYSINURIA; PHLU	PHOSPHOHYDROXYLYSINURIA; PHLU	615011
BLOOD GROUP, GLOBOSIDE SYSTEM; GLOB	BLOOD GROUP, GLOBOSIDE SYSTEM; GLOB	615021
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 7; ARCI7	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 7; ARCI7	615022
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 9; ARCI9	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 9; ARCI9	615023
ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 10; ARCI10	ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 10; ARCI10	615024
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Q; CMT2Q	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Q; CMT2Q	615025
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2Q	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Q; CMT2Q	615025
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2Q	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Q; CMT2Q	615025
RIBOFLAVIN DEFICIENCY; RBFVD	RIBOFLAVIN DEFICIENCY; RBFVD	615026
EPIDERMOLYSIS BULLOSA, NONSPECIFIC, AUTOSOMAL RECESSIVE; EBNS	EPIDERMOLYSIS BULLOSA, NONSPECIFIC, AUTOSOMAL RECESSIVE; EBNS	615028
SPASTIC PARAPLEGIA 56, AUTOSOMAL RECESSIVE; SPG56	SPASTIC PARAPLEGIA 56, AUTOSOMAL RECESSIVE; SPG56	615030
SPASTIC PARAPLEGIA 49, AUTOSOMAL RECESSIVE; SPG49	SPASTIC PARAPLEGIA 49, AUTOSOMAL RECESSIVE; SPG49	615031
AUTISM, SUSCEPTIBILITY TO, 18; AUTS18	AUTISM, SUSCEPTIBILITY TO, 18; AUTS18	615032
SPASTIC PARAPLEGIA 54, AUTOSOMAL RECESSIVE; SPG54	SPASTIC PARAPLEGIA 54, AUTOSOMAL RECESSIVE; SPG54	615033
DYSTONIA 24; DYT24	DYSTONIA 24; DYT24	615034
SPASTIC PARAPLEGIA 55, AUTOSOMAL RECESSIVE; SPG55	SPASTIC PARAPLEGIA 55, AUTOSOMAL RECESSIVE; SPG55	615035
EPISODIC PAIN SYNDROME, FAMILIAL, 1; FEPS1	EPISODIC PAIN SYNDROME, FAMILIAL, 1; FEPS1	615040
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 10; MDDGA10	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 10; MDDGA10	615041
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, TMEM5-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 10; MDDGA10	615041
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U	615042
CDG Iu; CDGIu	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U	615042
SPASTIC PARAPLEGIA 43, AUTOSOMAL RECESSIVE; SPG43	SPASTIC PARAPLEGIA 43, AUTOSOMAL RECESSIVE; SPG43	615043
SPINAL MUSCULAR ATROPHY, JOKELA TYPE; SMAJ	SPINAL MUSCULAR ATROPHY, JOKELA TYPE; SMAJ	615048
NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1F; CSNB1F	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1F; CSNB1F	615058
HYPOTRICHOSIS 11; HYPT11	HYPOTRICHOSIS 11; HYPT11	615059
ARTHROGRYPOSIS, DISTAL, TYPE 5D; DA5D	ARTHROGRYPOSIS, DISTAL, TYPE 5D; DA5D	615065
OSTEOGENESIS IMPERFECTA, TYPE XIV; OI14	OSTEOGENESIS IMPERFECTA, TYPE XIV; OI14	615066
OI, TYPE XIV	OSTEOGENESIS IMPERFECTA, TYPE XIV; OI14	615066
CILIARY DYSKINESIA, PRIMARY, 20; CILD20	CILIARY DYSKINESIA, PRIMARY, 20; CILD20	615067
CILIARY DYSKINESIA, PRIMARY, 20, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 20; CILD20	615067
ALAZAMI SYNDROME; ALAZS	ALAZAMI SYNDROME; ALAZS	615071
FACIAL DYSMORPHISM, INTELLECTUAL DISABILITY, AND PRIMORDIAL DWARFISM	ALAZAMI SYNDROME; ALAZS	615071
BRACHYDACTYLY, TYPE A1, C; BDA1C	BRACHYDACTYLY, TYPE A1, C; BDA1C	615072
DYSTONIA 25; DYT25	DYSTONIA 25; DYT25	615073
MENTAL RETARDATION, AUTOSOMAL DOMINANT 18; MRD18	MENTAL RETARDATION, AUTOSOMAL DOMINANT 18; MRD18	615074
MENTAL RETARDATION, AUTOSOMAL DOMINANT 19; MRD19	MENTAL RETARDATION, AUTOSOMAL DOMINANT 19; MRD19	615075
ALZHEIMER DISEASE 17; AD17	ALZHEIMER DISEASE 17; AD17	615080
ALZHEIMER DISEASE 17, LATE-ONSET	ALZHEIMER DISEASE 17; AD17	615080
SPERMATOGENIC FAILURE 11; SPGF11	SPERMATOGENIC FAILURE 11; SPGF11	615081
C3HEX, ABILITY TO SMELL	C3HEX, ABILITY TO SMELL	615082
COLORECTAL CANCER, SUSCEPTIBILITY TO, 12; CRCS12	COLORECTAL CANCER, SUSCEPTIBILITY TO, 12; CRCS12	615083
COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 12q24	COLORECTAL CANCER, SUSCEPTIBILITY TO, 12; CRCS12	615083
MITOCHONDRIAL DNA DEPLETION SYNDROME 11; MTDPS11	MITOCHONDRIAL DNA DEPLETION SYNDROME 11; MTDPS11	615084
OSTEOPETROSIS, AUTOSOMAL RECESSIVE 8; OPTB8	OSTEOPETROSIS, AUTOSOMAL RECESSIVE 8; OPTB8	615085
AUTISM, SUSCEPTIBILITY TO, 19; AUTS19	AUTISM, SUSCEPTIBILITY TO, 19; AUTS19	615091
LEFT VENTRICULAR NONCOMPACTION 7; LVNC7	LEFT VENTRICULAR NONCOMPACTION 7; LVNC7	615092
MICROCEPHALY 10, PRIMARY, AUTOSOMAL RECESSIVE; MCPH10	MICROCEPHALY 10, PRIMARY, AUTOSOMAL RECESSIVE; MCPH10	615095
TYSHCHENKO SYNDROME	TYSHCHENKO SYNDROME	615102
COWDEN SYNDROME 3; CWS3	COWDEN SYNDROME 3; CWS3	615106
COWDEN SYNDROME 4; CWS4	COWDEN SYNDROME 4; CWS4	615107
COWDEN SYNDROME 5; CWS5	COWDEN SYNDROME 5; CWS5	615108
COWDEN SYNDROME 6; CWS6	COWDEN SYNDROME 6; CWS6	615109
UROFACIAL SYNDROME 2; UFS2	UROFACIAL SYNDROME 2; UFS2	615112
MICROPHTHALMIA, ISOLATED 8; MCOP8	MICROPHTHALMIA, ISOLATED 8; MCOP8	615113
CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASEDEFICIENCY 2; CEMCOX2	CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASEDEFICIENCY 2; CEMCOX2	615119
MYASTHENIC SYNDROME, CONGENITAL, 8; CMS8	MYASTHENIC SYNDROME, CONGENITAL, 8; CMS8	615120
MYASTHENIC SYNDROME, CONGENITAL, WITH PRE- AND POSTSYNAPTIC DEFECTS;CMSPPD	MYASTHENIC SYNDROME, CONGENITAL, 8; CMS8	615120
MYASTHENIC SYNDROME, CONGENITAL, DUE TO AGRIN DEFICIENCY	MYASTHENIC SYNDROME, CONGENITAL, 8; CMS8	615120
STOMATIN-LIKE PROTEIN-2, HYPERPHOSPHORYLATION OF	STOMATIN-LIKE PROTEIN-2, HYPERPHOSPHORYLATION OF	615121
HYPERPHOSPHORYLATED PARATARG-7	STOMATIN-LIKE PROTEIN-2, HYPERPHOSPHORYLATION OF	615121
LYMPHOPROLIFERATIVE SYNDROME 2; LPFS2	LYMPHOPROLIFERATIVE SYNDROME 2; LPFS2	615122
CD27 DEFICIENCY	LYMPHOPROLIFERATIVE SYNDROME 2; LPFS2	615122
EPILEPSY, FAMILIAL ADULT MYOCLONIC, 4; FAME4	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 4; FAME4	615127
CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 4; FCMTE4	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 4; FAME4	615127
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 9; CMM9	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 9; CMM9	615134
MAPLE SYRUP URINE DISEASE, MILD VARIANT; MSUDMV	MAPLE SYRUP URINE DISEASE, MILD VARIANT; MSUDMV	615135
FACIAL DYSMORPHISM, IMMUNODEFICIENCY, LIVEDO, AND SHORT STATURE; FILS	FACIAL DYSMORPHISM, IMMUNODEFICIENCY, LIVEDO, AND SHORT STATURE; FILS	615139
MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 9; MCOPCB9	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 9; MCOPCB9	615145
RETINAL DYSTROPHY, IRIS COLOBOMA, AND COMEDOGENIC ACNE SYNDROME; RDCCAS	RETINAL DYSTROPHY, IRIS COLOBOMA, AND COMEDOGENIC ACNE SYNDROME; RDCCAS	615147
STEEL SYNDROME; STLS	STEEL SYNDROME; STLS	615155
DISLOCATED HIPS AND RADIAL HEADS, CARPAL COALITION, SCOLIOSIS, ANDSHORT STATURE	STEEL SYNDROME; STLS	615155
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 6; PEOA6	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 6; PEOA6	615156
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 6	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL DOMINANT 6; PEOA6	615156
MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 2; MC3DN2	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 2; MC3DN2	615157
MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 3; MC3DN3	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 3; MC3DN3	615158
MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 4; MC3DN4	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 4; MC3DN4	615159
MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 5; MC3DN5	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 5; MC3DN5	615160
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 35; MRT35	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 35; MRT35	615162
CONE-ROD DYSTROPHY 17; CORD17	CONE-ROD DYSTROPHY 17; CORD17	615163
WAHAB SYNDROME	WAHAB SYNDROME	615170
CAMPTODACTYLY, CLINODACTYLY, SYNDACTYLY, AND BIFID TOE SYNDROME	WAHAB SYNDROME	615170
ALBINISM, OCULOCUTANEOUS, TYPE VII; OCA7	ALBINISM, OCULOCUTANEOUS, TYPE VII; OCA7	615179
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 11; MDDGA11	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 11; MDDGA11	615181
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, B3GALNT2-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 11; MDDGA11	615181
COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD	COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD	615182
CARDIOMYOPATHY, DILATED, 1II; CMD1II	CARDIOMYOPATHY, DILATED, 1II; CMD1II	615184
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE F; CMTDIF	CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE F; CMTDIF	615185
CATARACT 39, MULTIPLE TYPES; CTRCT39	CATARACT 39, MULTIPLE TYPES; CTRCT39	615188
DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 5; DKCB5DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 4, INCLUDED; DKCA4, INCLUDED	DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 5; DKCB5DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 4, INCLUDED; DKCA4, INCLUDED	615190
LISSENCEPHALY 5; LIS5	LISSENCEPHALY 5; LIS5	615191
BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 4; BWQTL4	BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 4; BWQTL4	615192
BLEEDING DISORDER, PLATELET-TYPE, 15; BDPLT15	BLEEDING DISORDER, PLATELET-TYPE, 15; BDPLT15	615193
MACROTHROMBOCYTOPENIA, AUTOSOMAL DOMINANT, ACTN1-RELATED	BLEEDING DISORDER, PLATELET-TYPE, 15; BDPLT15	615193
RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 8; RLS8	RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 8; RLS8	615197
OSTEOSCLEROTIC METAPHYSEAL DYSPLASIA; OSMD	OSTEOSCLEROTIC METAPHYSEAL DYSPLASIA; OSMD	615198
IMMUNODEFICIENCY 11; IMD11	IMMUNODEFICIENCY 11; IMD11	615206
CARD11 IMMUNODEFICIENCY	IMMUNODEFICIENCY 11; IMD11	615206
IL21R IMMUNODEFICIENCY	IL21R IMMUNODEFICIENCY	615207
AGAMMAGLOBULINEMIA 7, AUTOSOMAL RECESSIVE; AGM7	AGAMMAGLOBULINEMIA 7, AUTOSOMAL RECESSIVE; AGM7	615214
AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO PIK3R1 DEFECT	AGAMMAGLOBULINEMIA 7, AUTOSOMAL RECESSIVE; AGM7	615214
ATAXIA-OCULOMOTOR APRAXIA 3; AOA3	ATAXIA-OCULOMOTOR APRAXIA 3; AOA3	615217
HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 2; HYC2	HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 2; HYC2	615219
OSTEOGENESIS IMPERFECTA, TYPE XV; OI15	OSTEOGENESIS IMPERFECTA, TYPE XV; OI15	615220
OI, TYPE XV	OSTEOGENESIS IMPERFECTA, TYPE XV; OI15	615220
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 16; BMND16	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 16; BMND16	615221
OSTEOPOROSIS, EARLY-ONSET, SUSCEPTIBILITY TO	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 16; BMND16	615221
SMITH-MCCORT DYSPLASIA 2; SMC2	SMITH-MCCORT DYSPLASIA 2; SMC2	615222
ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 2; FASPS2	ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 2; FASPS2	615224
CORNEAL INTRAEPITHELIAL DYSKERATOSIS AND ECTODERMAL DYSPLASIA; CIDED	CORNEAL INTRAEPITHELIAL DYSKERATOSIS AND ECTODERMAL DYSPLASIA; CIDED	615225
POLYDACTYLY, POSTAXIAL, TYPE A6; PAPA6	POLYDACTYLY, POSTAXIAL, TYPE A6; PAPA6	615226
MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 4;MC5DN4	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 4;MC5DN4	615228
MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, ATP5A1 TYPE	MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 4;MC5DN4	615228
SCHIZOPHRENIA 18; SCZD18SCHIZOAFFECTIVE DISORDER, INCLUDED	SCHIZOPHRENIA 18; SCZD18SCHIZOAFFECTIVE DISORDER, INCLUDED	615232
RETINITIS PIGMENTOSA 66; RP66	RETINITIS PIGMENTOSA 66; RP66	615233
ANEMIA, HYPOCHROMIC MICROCYTIC, WITH IRON OVERLOAD 2; AHMIO2	ANEMIA, HYPOCHROMIC MICROCYTIC, WITH IRON OVERLOAD 2; AHMIO2	615234
CARDIOMYOPATHY, DILATED, 1JJ; CMD1JJ	CARDIOMYOPATHY, DILATED, 1JJ; CMD1JJ	615235
CONGENITAL SHORT BOWEL SYNDROME; CSBS	CONGENITAL SHORT BOWEL SYNDROME; CSBS	615237
LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5; FPLD5	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5; FPLD5	615238
LIPODYSTROPHY, FAMILIAL PARTIAL, ASSOCIATED WITH CIDEC MUTATIONS	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5; FPLD5	615238
NEPHROTIC SYNDROME, TYPE 8; NPHS8	NEPHROTIC SYNDROME, TYPE 8; NPHS8	615244
CARDIOMYOPATHY, DILATED, 1KK; CMD1KKCARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 22, INCLUDED; CMH22, INCLUDED	CARDIOMYOPATHY, DILATED, 1KK; CMD1KKCARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 22, INCLUDED; CMH22, INCLUDED	615248
CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 4, INCLUDED; RCM4, INCLUDED	CARDIOMYOPATHY, DILATED, 1KK; CMD1KKCARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 22, INCLUDED; CMH22, INCLUDED	615248
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 12; MDDGA12	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 12; MDDGA12	615249
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMK-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 12; MDDGA12	615249
BLOOD GROUP, VEL SYSTEM; VELVEL-NULL PHENOTYPE, INCLUDED	BLOOD GROUP, VEL SYSTEM; VELVEL-NULL PHENOTYPE, INCLUDED	615264
HYPOGONADOTROPIC HYPOGONADISM 17 WITH OR WITHOUT ANOSMIA; HH17	HYPOGONADOTROPIC HYPOGONADISM 17 WITH OR WITHOUT ANOSMIA; HH17	615266
HYPOGONADOTROPIC HYPOGONADISM 18 WITH OR WITHOUT ANOSMIA; HH18	HYPOGONADOTROPIC HYPOGONADISM 18 WITH OR WITHOUT ANOSMIA; HH18	615267
CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME4; CAMRQ4	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME4; CAMRQ4	615268
CEREBELLAR ATAXIA AND MENTAL RETARDATION WITH OR WITHOUT QUADRUPEDALLOCOMOTION 4	CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME4; CAMRQ4	615268
HYPOGONADOTROPIC HYPOGONADISM 19 WITH OR WITHOUT ANOSMIA; HH19	HYPOGONADOTROPIC HYPOGONADISM 19 WITH OR WITHOUT ANOSMIA; HH19	615269
HYPOGONADOTROPIC HYPOGONADISM 20 WITH OR WITHOUT ANOSMIA; HH20	HYPOGONADOTROPIC HYPOGONADISM 20 WITH OR WITHOUT ANOSMIA; HH20	615270
HYPOGONADOTROPIC HYPOGONADISM 21 WITH OR WITHOUT ANOSMIA; HH21	HYPOGONADOTROPIC HYPOGONADISM 21 WITH OR WITHOUT ANOSMIA; HH21	615271
FANCONI ANEMIA, COMPLEMENTATION GROUP Q; FANCQ	FANCONI ANEMIA, COMPLEMENTATION GROUP Q; FANCQ	615272
CONGENITAL DISORDER OF DEGLYCOSYLATION; CDDG	CONGENITAL DISORDER OF DEGLYCOSYLATION; CDDG	615273
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iv, FORMERLY; CDG1V, FORMERLY	CONGENITAL DISORDER OF DEGLYCOSYLATION; CDDG	615273
CDG Iv, FORMERLY; CDGIv, FORMERLY	CONGENITAL DISORDER OF DEGLYCOSYLATION; CDDG	615273
CATARACT 15, MULTIPLE TYPES; CTRCT15	CATARACT 15, MULTIPLE TYPES; CTRCT15	615274
CATARACT 19; CTRCT19	CATARACT 19; CTRCT19	615277
CARDIOFACIOCUTANEOUS SYNDROME 2; CFC2	CARDIOFACIOCUTANEOUS SYNDROME 2; CFC2	615278
CARDIOFACIOCUTANEOUS SYNDROME 3; CFC3	CARDIOFACIOCUTANEOUS SYNDROME 3; CFC3	615279
CARDIOFACIOCUTANEOUS SYNDROME 4; CFC4	CARDIOFACIOCUTANEOUS SYNDROME 4; CFC4	615280
HYPOMYELINATION WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LEGSPASTICITY; HBSL	HYPOMYELINATION WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LEGSPASTICITY; HBSL	615281
ASPARTYL-tRNA SYNTHETASE DEFICIENCY	HYPOMYELINATION WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LEGSPASTICITY; HBSL	615281
CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 2; CDCBM2	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 2; CDCBM2	615282
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B3; CMT4B3	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B3; CMT4B3	615284
NEUTROPENIA, SEVERE CONGENITAL, 5, AUTOSOMAL RECESSIVE; SCN5	NEUTROPENIA, SEVERE CONGENITAL, 5, AUTOSOMAL RECESSIVE; SCN5	615285
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 36; MRT36	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 36; MRT36	615286
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 13; MDDGA13	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 13; MDDGA13	615287
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, B3GNT1-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 13; MDDGA13	615287
SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2, AUTOSOMALDOMINANT; SMALED2	SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2, AUTOSOMALDOMINANT; SMALED2	615290
MYOFIBROMATOSIS, INFANTILE, 2; IMF2	MYOFIBROMATOSIS, INFANTILE, 2; IMF2	615293
CILIARY DYSKINESIA, PRIMARY, 21; CILD21	CILIARY DYSKINESIA, PRIMARY, 21; CILD21	615294
CILIARY DYSKINESIA, PRIMARY, 21, WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 21; CILD21	615294
ADAMS-OLIVER SYNDROME 4; AOS4	ADAMS-OLIVER SYNDROME 4; AOS4	615297
SYMPHALANGISM, PROXIMAL, 1B; SYM1B	SYMPHALANGISM, PROXIMAL, 1B; SYM1B	615298
PERRAULT SYNDROME 4; PRLTS4	PERRAULT SYNDROME 4; PRLTS4	615300
BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 17; BMND17	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 17; BMND17	615311
BONE MINERAL DENSITY, LOW, SUSCEPTIBILITY TO	BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 17; BMND17	615311
ALBINISM, OCULOCUTANEOUS, TYPE V; OCA5	ALBINISM, OCULOCUTANEOUS, TYPE V; OCA5	615312
CRANIOSYNOSTOSIS 3; CRS3	CRANIOSYNOSTOSIS 3; CRS3	615314
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2R; LGMD2R	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2R; LGMD2R	615325
DOWLING-DEGOS DISEASE 2; DDD2	DOWLING-DEGOS DISEASE 2; DDD2	615327
SHAHEEN SYNDROME; SHNS	SHAHEEN SYNDROME; SHNS	615328
MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 3; MMDS3	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 3; MMDS3	615330
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 16; EIEE16	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 16; EIEE16	615338
PULMONARY HYPERTENSION, PRIMARY, 2; PPH2	PULMONARY HYPERTENSION, PRIMARY, 2; PPH2	615342
PULMONARY HYPERTENSION, PRIMARY, 3; PPH3	PULMONARY HYPERTENSION, PRIMARY, 3; PPH3	615343
PULMONARY HYPERTENSION, PRIMARY, 4; PPH4	PULMONARY HYPERTENSION, PRIMARY, 4; PPH4	615344
PRECOCIOUS PUBERTY, CENTRAL, 2; CPPB2	PRECOCIOUS PUBERTY, CENTRAL, 2; CPPB2	615346
NEMALINE MYOPATHY 8; NEM8	NEMALINE MYOPATHY 8; NEM8	615348
EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 2; EDSP2	EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 2; EDSP2	615349
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 14; MDDGA14	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 14; MDDGA14	615350
WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, GMPPB-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 14; MDDGA14	615350
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 14; MDDGB14	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 14; MDDGB14	615351
MUSCULAR DYSTROPHY, CONGENITAL, GMPPB-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION),TYPE B, 14; MDDGB14	615351
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 14; MDDGC14	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 14; MDDGC14	615352
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, GMPPB-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 14; MDDGC14	615352
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2T; LGMD2T	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 14; MDDGC14	615352
NOONAN SYNDROME 8; NS8	NOONAN SYNDROME 8; NS8	615355
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2S; LGMD2S	MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2S; LGMD2S	615356
LEBER CONGENITAL AMAUROSIS 17; LCA17	LEBER CONGENITAL AMAUROSIS 17; LCA17	615360
HYPOCALCEMIA, AUTOSOMAL DOMINANT 2; HYPOC2	HYPOCALCEMIA, AUTOSOMAL DOMINANT 2; HYPOC2	615361
CEROID LIPOFUSCINOSIS, NEURONAL, 13; CLN13	CEROID LIPOFUSCINOSIS, NEURONAL, 13; CLN13	615362
CEROID LIPOFUSCINOSIS, NEURONAL, 13, KUFS TYPE	CEROID LIPOFUSCINOSIS, NEURONAL, 13; CLN13	615362
ESTROGEN RESISTANCE; ESTRR	ESTROGEN RESISTANCE; ESTRR	615363
ESTROGEN INSENSITIVITY	ESTROGEN RESISTANCE; ESTRR	615363
LETHAL CONGENITAL CONTRACTURE SYNDROME 5; LCCS5	LETHAL CONGENITAL CONTRACTURE SYNDROME 5; LCCS5	615368
MYOPATHY, CENTRONUCLEAR, LETHAL, AUTOSOMAL RECESSIVE	LETHAL CONGENITAL CONTRACTURE SYNDROME 5; LCCS5	615368
EPILEPTIC ENCEPHALOPATHY, CHILDHOOD-ONSET; EEOC	EPILEPTIC ENCEPHALOPATHY, CHILDHOOD-ONSET; EEOC	615369
PULMONARY HYPERTENSION, NEONATAL, SUSCEPTIBILITY TO; PHN	PULMONARY HYPERTENSION, NEONATAL, SUSCEPTIBILITY TO; PHN	615371
LEFT VENTRICULAR NONCOMPACTION 8; LVNC8CARDIOMYOPATHY, DILATED, 1LL, INCLUDED; CMD1LL, INCLUDED	LEFT VENTRICULAR NONCOMPACTION 8; LVNC8CARDIOMYOPATHY, DILATED, 1LL, INCLUDED; CMD1LL, INCLUDED	615373
CONE-ROD DYSTROPHY 18; CORD18	CONE-ROD DYSTROPHY 18; CORD18	615374
CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE C; CMTRIC	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE C; CMTRIC	615376
CHARCOT-MARIE-TOOTH NEUROPATHY, RECESSIVE INTERMEDIATE C; RI-CMTC	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE C; CMTRIC	615376
ATRIAL FIBRILLATION, FAMILIAL, 13; ATFB13	ATRIAL FIBRILLATION, FAMILIAL, 13; ATFB13	615377
ATRIAL FIBRILLATION, FAMILIAL, 14; ATFB14	ATRIAL FIBRILLATION, FAMILIAL, 14; ATFB14	615378
MANDIBULAR HYPOPLASIA, DEAFNESS, PROGEROID FEATURES, AND LIPODYSTROPHYSYNDROME; MDPL	MANDIBULAR HYPOPLASIA, DEAFNESS, PROGEROID FEATURES, AND LIPODYSTROPHYSYNDROME; MDPL	615381
NEPHRONOPHTHISIS 16; NPHP16	NEPHRONOPHTHISIS 16; NPHP16	615382
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 14; SCAR14	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 14; SCAR14	615386
CEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, SPECTRIN-ASSOCIATED, 1; SPARCA1	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 14; SCAR14	615386
T-CELL RECEPTOR-ALPHA/BETA DEFICIENCY	T-CELL RECEPTOR-ALPHA/BETA DEFICIENCY	615387
TCR-ALPHA/BETA DEFICIENCY	T-CELL RECEPTOR-ALPHA/BETA DEFICIENCY	615387
IMMUNODEFICIENCY 7; IMD7	T-CELL RECEPTOR-ALPHA/BETA DEFICIENCY	615387
VESICOURETERAL REFLUX 7; VUR7	VESICOURETERAL REFLUX 7; VUR7	615390
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16	615395
LEFT VENTRICULAR NONCOMPACTION 10; LVNC10CARDIOMYOPATHY, DILATED, 1MM, INCLUDED; CMD1MM, INCLUDED	LEFT VENTRICULAR NONCOMPACTION 10; LVNC10CARDIOMYOPATHY, DILATED, 1MM, INCLUDED; CMD1MM, INCLUDED	615396
MECKEL SYNDROME, TYPE 11; MKS11	MECKEL SYNDROME, TYPE 11; MKS11	615397
MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3	MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3	615398
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 2; PNH2	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 2; PNH2	615399
EPILEPSY, FAMILIAL ADULT MYOCLONIC, 5; FAME5	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 5; FAME5	615400
CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 5; FCMTE5	EPILEPSY, FAMILIAL ADULT MYOCLONIC, 5; FAME5	615400
IMMUNODEFICIENCY 8; IMD8	IMMUNODEFICIENCY 8; IMD8	615401
DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 3; DUH3	DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 3; DUH3	615402
CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 3; CDCBM3	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 3; CDCBM3	615411
CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 4; CDCBM4	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 4; CDCBM4	615412
SPERMATOGENIC FAILURE 12; SPGF12	SPERMATOGENIC FAILURE 12; SPGF12	615413
MICROCEPHALY 11, PRIMARY, AUTOSOMAL RECESSIVE; MCPH11	MICROCEPHALY 11, PRIMARY, AUTOSOMAL RECESSIVE; MCPH11	615414
RENAL-HEPATIC-PANCREATIC DYSPLASIA 2; RHPD2	RENAL-HEPATIC-PANCREATIC DYSPLASIA 2; RHPD2	615415
MITOCHONDRIAL DNA DEPLETION SYNDROME 12 (CARDIOMYOPATHIC TYPE); MTDPS12	MITOCHONDRIAL DNA DEPLETION SYNDROME 12 (CARDIOMYOPATHIC TYPE); MTDPS12	615418
HYPOTONIA, INFANTILE, WITH PSYCHOMOTOR RETARDATION AND CHARACTERISTICFACIES; IHPRF	HYPOTONIA, INFANTILE, WITH PSYCHOMOTOR RETARDATION AND CHARACTERISTICFACIES; IHPRF	615419
MYOPIA 22, AUTOSOMAL DOMINANT; MYP22	MYOPIA 22, AUTOSOMAL DOMINANT; MYP22	615420
INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 2; IBMPFD2	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 2; IBMPFD2	615422
MULTISYSTEM PROTEINOPATHY 2; MSP2	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 2; IBMPFD2	615422
INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 3; IBMPFD3	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 3; IBMPFD3	615424
MULTISYSTEM PROTEINOPATHY 3; MSP3	INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUTFRONTOTEMPORAL DEMENTIA 3; IBMPFD3	615424
EPIDERMOLYSIS BULLOSA SIMPLEX, AUTOSOMAL RECESSIVE 2; EBSB2	EPIDERMOLYSIS BULLOSA SIMPLEX, AUTOSOMAL RECESSIVE 2; EBSB2	615425
AMYOTROPHIC LATERAL SCLEROSIS 20; ALS20	AMYOTROPHIC LATERAL SCLEROSIS 20; ALS20	615426
DEAFNESS, AUTOSOMAL RECESSIVE 88; DFNB88	DEAFNESS, AUTOSOMAL RECESSIVE 88; DFNB88	615429
MYOPIA 23, AUTOSOMAL RECESSIVE; MYP23	MYOPIA 23, AUTOSOMAL RECESSIVE; MYP23	615431
SPECIFIC LANGUAGE IMPAIRMENT 5; SLI5	SPECIFIC LANGUAGE IMPAIRMENT 5; SLI5	615432
CHROMOSOME 3q13.31 DELETION SYNDROME	CHROMOSOME 3q13.31 DELETION SYNDROME	615433
RETINITIS PIGMENTOSA WITH OR WITHOUT SITUS INVERSUS	RETINITIS PIGMENTOSA WITH OR WITHOUT SITUS INVERSUS	615434
AORTIC ANEURYSM, FAMILIAL THORACIC 8; AAT8	AORTIC ANEURYSM, FAMILIAL THORACIC 8; AAT8	615436
INFANTILE LIVER FAILURE SYNDROME 1; ILFS1	INFANTILE LIVER FAILURE SYNDROME 1; ILFS1	615438
MACULAR DEGENERATION, AGE-RELATED, 13; ARMD13	MACULAR DEGENERATION, AGE-RELATED, 13; ARMD13	615439
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 17; COXPD17	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 17; COXPD17	615440
VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 5, WITH ORWITHOUT MUSCLE WEAKNESS; CPVT5	VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 5, WITH ORWITHOUT MUSCLE WEAKNESS; CPVT5	615441
CILIARY DYSKINESIA, PRIMARY, 22; CILD22	CILIARY DYSKINESIA, PRIMARY, 22; CILD22	615444
CILIARY DYSKINESIA, PRIMARY, 22, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 22; CILD22	615444
CILIARY DYSKINESIA, PRIMARY, 23; CILD23	CILIARY DYSKINESIA, PRIMARY, 23; CILD23	615451
CILIARY DYSKINESIA, PRIMARY, 23, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 23; CILD23	615451
MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 6; MC3DN6	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 6; MC3DN6	615453
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 18; BMIQ18	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 18; BMIQ18	615457
OBESITY, SUSCEPTIBILITY TO	BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 18; BMIQ18	615457
MICROCORNEA, MYOPIC CHORIORETINAL ATROPHY, AND TELECANTHUS; MMCAT	MICROCORNEA, MYOPIC CHORIORETINAL ATROPHY, AND TELECANTHUS; MMCAT	615458
HARTSFIELD SYNDROME; HRTFDS	HARTSFIELD SYNDROME; HRTFDS	615465
HOLOPROSENCEPHALY, ECTRODACTYLY, AND BILATERAL CLEFT LIP/PALATE	HARTSFIELD SYNDROME; HRTFDS	615465
IMMUNODEFICIENCY 12; IMD12	IMMUNODEFICIENCY 12; IMD12	615468
MITOCHONDRIAL DNA DEPLETION SYNDROME 13 (ENCEPHALOMYOPATHIC TYPE);MTDPS13	MITOCHONDRIAL DNA DEPLETION SYNDROME 13 (ENCEPHALOMYOPATHIC TYPE);MTDPS13	615471
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 17; EIEE17	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 17; EIEE17	615473
PRIMARY ALDOSTERONISM, SEIZURES, AND NEUROLOGIC ABNORMALITIES; PASNA	PRIMARY ALDOSTERONISM, SEIZURES, AND NEUROLOGIC ABNORMALITIES; PASNA	615474
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 18; EIEE18	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 18; EIEE18	615476
CILIARY DYSKINESIA, PRIMARY, 24; CILD24	CILIARY DYSKINESIA, PRIMARY, 24; CILD24	615481
CILIARY DYSKINESIA, PRIMARY, 24, WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 24; CILD24	615481
CILIARY DYSKINESIA, PRIMARY, 25; CILD25	CILIARY DYSKINESIA, PRIMARY, 25; CILD25	615482
CILIARY DYSKINESIA, PRIMARY, 25, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 25; CILD25	615482
BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 5; IBGC5	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 5; IBGC5	615483
BAINBRIDGE-ROPERS SYNDROME; BRPS	BAINBRIDGE-ROPERS SYNDROME; BRPS	615485
INTERSTITIAL LUNG AND LIVER DISEASE; ILLD	INTERSTITIAL LUNG AND LIVER DISEASE; ILLD	615486
PULMONARY ALVEOLAR PROTEINOSIS, REUNION ISLAND	INTERSTITIAL LUNG AND LIVER DISEASE; ILLD	615486
INFANTILE LIVER FAILURE SYNDROME 2, FORMERLY; ILFS2, FORMERLY	INTERSTITIAL LUNG AND LIVER DISEASE; ILLD	615486
MACULAR DEGENERATION, AGE-RELATED, 14; ARMD14MACULAR DEGENERATION, AGE-RELATED, REDUCED RISK OF, INCLUDED	MACULAR DEGENERATION, AGE-RELATED, 14; ARMD14MACULAR DEGENERATION, AGE-RELATED, REDUCED RISK OF, INCLUDED	615489
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2R; CMT2R	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2R; CMT2R	615490
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2R	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2R; CMT2R	615490
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2R	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2R; CMT2R	615490
NEURODEGENERATION WITH OPTIC ATROPHY, CHILDHOOD-ONSET; NDGOA	NEURODEGENERATION WITH OPTIC ATROPHY, CHILDHOOD-ONSET; NDGOA	615491
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 37; MRT37	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 37; MRT37	615493
CILIARY DYSKINESIA, PRIMARY, 26; CILD26	CILIARY DYSKINESIA, PRIMARY, 26; CILD26	615500
CILIARY DYSKINESIA, PRIMARY, 26, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 26; CILD26	615500
MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP C; MOCODC	MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP C; MOCODC	615501
MENTAL RETARDATION, AUTOSOMAL DOMINANT 21; MRD21	MENTAL RETARDATION, AUTOSOMAL DOMINANT 21; MRD21	615502
SHORT-RIB THORACIC DYSPLASIA 8 WITH OR WITHOUT POLYDACTYLY; SRTD8	SHORT-RIB THORACIC DYSPLASIA 8 WITH OR WITHOUT POLYDACTYLY; SRTD8	615503
SHORT RIB-POLYDACTYLY SYNDROME, TYPE VI; SRPS6	SHORT-RIB THORACIC DYSPLASIA 8 WITH OR WITHOUT POLYDACTYLY; SRTD8	615503
CILIARY DYSKINESIA, PRIMARY, 27; CILD27	CILIARY DYSKINESIA, PRIMARY, 27; CILD27	615504
CILIARY DYSKINESIA, PRIMARY, 27, WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 27; CILD27	615504
CILIARY DYSKINESIA, PRIMARY, 28; CILD28	CILIARY DYSKINESIA, PRIMARY, 28; CILD28	615505
CILIARY DYSKINESIA, PRIMARY, 28, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 28; CILD28	615505
TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 5; HHT5	TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 5; HHT5	615506
ERYTHRODERMA, CONGENITAL, WITH PALMOPLANTAR KERATODERMA, HYPOTRICHOSIS,AND HYPER-IgE; EPKHE	ERYTHRODERMA, CONGENITAL, WITH PALMOPLANTAR KERATODERMA, HYPOTRICHOSIS,AND HYPER-IgE; EPKHE	615508
SEVERE DERMATITIS, MULTIPLE ALLERGIES, AND METABOLIC WASTING SYNDROME	ERYTHRODERMA, CONGENITAL, WITH PALMOPLANTAR KERATODERMA, HYPOTRICHOSIS,AND HYPER-IgE; EPKHE	615508
SAM SYNDROME	ERYTHRODERMA, CONGENITAL, WITH PALMOPLANTAR KERATODERMA, HYPOTRICHOSIS,AND HYPER-IgE; EPKHE	615508
ALACRIMA, ACHALASIA, AND MENTAL RETARDATION SYNDROME; AAMR	ALACRIMA, ACHALASIA, AND MENTAL RETARDATION SYNDROME; AAMR	615510
MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD	MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD	615511
ADENOSINE MONOPHOSPHATE DEAMINASE-1 DEFICIENCY, MYOPATHY DUE TO	MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD	615511
AMPD1 DEFICIENCY	MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD	615511
MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO	MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD	615511
TRIOSEPHOSPHATE ISOMERASE DEFICIENCY; TPID	TRIOSEPHOSPHATE ISOMERASE DEFICIENCY; TPID	615512
IMMUNODEFICIENCY 14; IMD14	IMMUNODEFICIENCY 14; IMD14	615513
ACTIVATED PI3K-DELTA SYNDROME; APDS	IMMUNODEFICIENCY 14; IMD14	615513
p110-DELTA-ACTIVATING MUTATION CAUSING SENESCENT T CELLS, LYMPHADENOPATHY,AND IMMUNODEFICIENCY; PASLI	IMMUNODEFICIENCY 14; IMD14	615513
AMYOTROPHIC LATERAL SCLEROSIS 19; ALS19	AMYOTROPHIC LATERAL SCLEROSIS 19; ALS19	615515
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 38; MRT38	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 38; MRT38	615516
HEMOCHROMATOSIS, TYPE 5; HFE5	HEMOCHROMATOSIS, TYPE 5; HFE5	615517
IRON OVERLOAD, AUTOSOMAL DOMINANT	HEMOCHROMATOSIS, TYPE 5; HFE5	615517
IMMUNODEFICIENCY 13; IMD13	IMMUNODEFICIENCY 13; IMD13	615518
IDIOPATHIC CD4 LYMPHOPENIA; ICL	IMMUNODEFICIENCY 13; IMD13	615518
COLE DISEASE; COLED	COLE DISEASE; COLED	615522
GUTTATE HYPOPIGMENTATION AND PUNCTATE PALMOPLANTAR KERATODERMA WITHOR WITHOUT ECTOPIC CALCIFICATION	COLE DISEASE; COLED	615522
CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 8; FECD8	CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 8; FECD8	615523
MICROPHTHALMIA, SYNDROMIC 12; MCOPS12	MICROPHTHALMIA, SYNDROMIC 12; MCOPS12	615524
MICROPHTHALMIA WITH OR WITHOUT PULMONARY HYPOPLASIA, DIAPHRAGMATICHERNIA, AND/OR CARDIAC DEFECTS	MICROPHTHALMIA, SYNDROMIC 12; MCOPS12	615524
CANDIDIASIS, FAMILIAL, 8; CANDF8	CANDIDIASIS, FAMILIAL, 8; CANDF8	615527
CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL RECESSIVE	CANDIDIASIS, FAMILIAL, 8; CANDF8	615527
PARKINSON DISEASE 19, JUVENILE-ONSET; PARK19	PARKINSON DISEASE 19, JUVENILE-ONSET; PARK19	615528
CRANIOSYNOSTOSIS 5, SUSCEPTIBILITY TO; CRS5	CRANIOSYNOSTOSIS 5, SUSCEPTIBILITY TO; CRS5	615529
PARKINSON DISEASE 20, EARLY-ONSET; PARK20	PARKINSON DISEASE 20, EARLY-ONSET; PARK20	615530
RETICULATE ACROPIGMENTATION OF KITAMURA; RAK	RETICULATE ACROPIGMENTATION OF KITAMURA; RAK	615537
ACROPIGMENTATIO RETICULARIS	RETICULATE ACROPIGMENTATION OF KITAMURA; RAK	615537
RETICULATE PIGMENTATION OF KITAMURA; RPK	RETICULATE ACROPIGMENTATION OF KITAMURA; RAK	615537
KITAMURA RETICULATE ACROPIGMENTATION	RETICULATE ACROPIGMENTATION OF KITAMURA; RAK	615537
CHROMOSOME 22q13 DUPLICATION SYNDROME	CHROMOSOME 22q13 DUPLICATION SYNDROME	615538
EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE 2; EDSMC2	EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE 2; EDSMC2	615539
DEAFNESS, AUTOSOMAL RECESSIVE 76; DFNB76	DEAFNESS, AUTOSOMAL RECESSIVE 76; DFNB76	615540
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 39; MRT39	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 39; MRT39	615541
TESTICULAR ANOMALIES WITH OR WITHOUT CONGENITAL HEART DISEASE; TACHD	TESTICULAR ANOMALIES WITH OR WITHOUT CONGENITAL HEART DISEASE; TACHD	615542
PERIVENTRICULAR NODULAR HETEROTOPIA 6; PVNH6	PERIVENTRICULAR NODULAR HETEROTOPIA 6; PVNH6	615544
LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 3; ALL3	LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 3; ALL3	615545
VAN MALDERGEM SYNDROME 2; VMLDS2	VAN MALDERGEM SYNDROME 2; VMLDS2	615546
SCHAAF-YANG SYNDROME; SHFYNG	SCHAAF-YANG SYNDROME; SHFYNG	615547
PRADER-WILLI-LIKE SYNDROME; PWLS	SCHAAF-YANG SYNDROME; SHFYNG	615547
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VII; HSAN7	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VII; HSAN7	615548
HSAN VII	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VII; HSAN7	615548
INSENSITIVITY TO PAIN, CONGENITAL, WITH GASTROINTESTINAL DYSFUNCTIONAND HYPERHIDROSIS	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VII; HSAN7	615548
DIAMOND-BLACKFAN ANEMIA 12; DBA12	DIAMOND-BLACKFAN ANEMIA 12; DBA12	615550
EPISODIC PAIN SYNDROME, FAMILIAL, 2; FEPS2	EPISODIC PAIN SYNDROME, FAMILIAL, 2; FEPS2	615551
EPISODIC PAIN SYNDROME, FAMILIAL, 3; FEPS3	EPISODIC PAIN SYNDROME, FAMILIAL, 3; FEPS3	615552
ARTHROGRYPOSIS, MENTAL RETARDATION, AND SEIZURES; AMRS	ARTHROGRYPOSIS, MENTAL RETARDATION, AND SEIZURES; AMRS	615553
MULTIPLE FIBROADENOMAS OF THE BREAST; MFAB	MULTIPLE FIBROADENOMAS OF THE BREAST; MFAB	615554
HYPERPROLACTINEMIA; HPRL	HYPERPROLACTINEMIA; HPRL	615555
MELIOIDOSIS, SUSCEPTIBILITY TOMELIOIDOSIS, RESISTANCE TO, INCLUDED	MELIOIDOSIS, SUSCEPTIBILITY TOMELIOIDOSIS, RESISTANCE TO, INCLUDED	615557
HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1	HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1	615558
HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL	HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1	615558
ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA	HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1	615558
HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC	HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1	615558
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III; ALPS3	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III; ALPS3	615559
IMMUNODEFICIENCY, COMMON VARIABLE, 9, FORMERLY; CVID9, FORMERLY	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III; ALPS3	615559
OTOFACIOCERVICAL SYNDROME 2; OFC2	OTOFACIOCERVICAL SYNDROME 2; OFC2	615560
COMPLEMENT FACTOR B DEFICIENCY; CFBD	COMPLEMENT FACTOR B DEFICIENCY; CFBD	615561
RETINITIS PIGMENTOSA 67; RP67	RETINITIS PIGMENTOSA 67; RP67	615565
NEPHROTIC SYNDROME, TYPE 9; NPHS9	NEPHROTIC SYNDROME, TYPE 9; NPHS9	615573
ASPARAGINE SYNTHETASE DEFICIENCY; ASNSD	ASPARAGINE SYNTHETASE DEFICIENCY; ASNSD	615574
ASNS DEFICIENCY	ASPARAGINE SYNTHETASE DEFICIENCY; ASNSD	615574
NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IID; HMN2D	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IID; HMN2D	615575
HMN IID	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IID; HMN2D	615575
NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IID; DHMN2D	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IID; HMN2D	615575
SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL DOMINANT, CALF-PREDOMINANT	NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IID; HMN2D	615575
IMMUNODEFICIENCY, COMMON VARIABLE, 10; CVID10	IMMUNODEFICIENCY, COMMON VARIABLE, 10; CVID10	615577
IMMUNODEFICIENCY, COMMON VARIABLE, WITH CENTRAL ADRENAL INSUFFICIENCY	IMMUNODEFICIENCY, COMMON VARIABLE, 10; CVID10	615577
DEFICIT IN ANTERIOR PITUITARY FUNCTION AND VARIABLE IMMUNODEFICIENCY;DAVID	IMMUNODEFICIENCY, COMMON VARIABLE, 10; CVID10	615577
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 18; COXPD18	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 18; COXPD18	615578
LOEYS-DIETZ SYNDROME 5; LDS5	LOEYS-DIETZ SYNDROME 5; LDS5	615582
RIENHOFF SYNDROME; RNHF	LOEYS-DIETZ SYNDROME 5; LDS5	615582
VERHEIJ SYNDROME; VRJS	VERHEIJ SYNDROME; VRJS	615583
CHROMOSOME 8q24.3 DELETION SYNDROME	VERHEIJ SYNDROME; VRJS	615583
OTOSCLEROSIS 10; OTSC10	OTOSCLEROSIS 10; OTSC10	615589
ALZHEIMER DISEASE 18; AD18	ALZHEIMER DISEASE 18; AD18	615590
ALZHEIMER DISEASE 18, LATE-ONSET	ALZHEIMER DISEASE 18; AD18	615590
MACULAR DEGENERATION, AGE-RELATED, 15; ARMD15	MACULAR DEGENERATION, AGE-RELATED, 15; ARMD15	615591
IMMUNODEFICIENCY 15; IMD15	IMMUNODEFICIENCY 15; IMD15	615592
IMMUNODEFICIENCY 16; IMD16	IMMUNODEFICIENCY 16; IMD16	615593
OX40 DEFICIENCY	IMMUNODEFICIENCY 16; IMD16	615593
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 19; COXPD19	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 19; COXPD19	615595
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iw; CDG1W	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iw; CDG1W	615596
CDG Iw; CDGIw	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iw; CDG1W	615596
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ix; CDG1X	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ix; CDG1X	615597
CDG Ix; CDGIx	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ix; CDG1X	615597
PALMOPLANTAR KERATODERMA, NAGASHIMA TYPE; PPKN	PALMOPLANTAR KERATODERMA, NAGASHIMA TYPE; PPKN	615598
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 40; MRT40	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 40; MRT40	615599
MEMORY QUANTITATIVE TRAIT LOCUS; MEMRYQTL	MEMORY QUANTITATIVE TRAIT LOCUS; MEMRYQTL	615602
L-FERRITIN DEFICIENCY; LFTD	L-FERRITIN DEFICIENCY; LFTD	615604
FANCONI RENOTUBULAR SYNDROME 3; FRTS3	FANCONI RENOTUBULAR SYNDROME 3; FRTS3	615605
IMMUNODEFICIENCY 17; IMD17	IMMUNODEFICIENCY 17; IMD17	615607
CD3-GAMMA DEFICIENCY	IMMUNODEFICIENCY 17; IMD17	615607
SCID-LIKE IMMUNODEFICIENCY, T CELL-PARTIAL, B CELL-POSITIVE, NK CELL-POSITIVE	IMMUNODEFICIENCY 17; IMD17	615607
DEVELOPMENTAL DYSPLASIA OF THE HIP 2; DDH2	DEVELOPMENTAL DYSPLASIA OF THE HIP 2; DDH2	615612
IMMUNODEFICIENCY 18; IMD18	IMMUNODEFICIENCY 18; IMD18	615615
CD3-EPSILON DEFICIENCYIMMUNODEFICIENCY 18, SEVERE COMBINED IMMUNODEFICIENCY VARIANT, INCLUDED	IMMUNODEFICIENCY 18; IMD18	615615
IMMUNODEFICIENCY 18, SCID VARIANT, INCLUDED	IMMUNODEFICIENCY 18; IMD18	615615
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 13; ARVD13	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 13; ARVD13	615616
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 13; ARVC13	ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 13; ARVD13	615616
IMMUNODEFICIENCY 19; IMD19	IMMUNODEFICIENCY 19; IMD19	615617
CD3-DELTA DEFICIENCY	IMMUNODEFICIENCY 19; IMD19	615617
SEVERE COMBINED IMMUNODEFICIENCY, T CELL-NEGATIVE, B CELL-POSITIVE,NK CELL-POSITIVE	IMMUNODEFICIENCY 19; IMD19	615617
SCID, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE	IMMUNODEFICIENCY 19; IMD19	615617
SPASTIC PARAPLEGIA 72, AUTOSOMAL RECESSIVE; SPG72SPASTIC PARAPLEGIA 72, AUTOSOMAL DOMINANT, INCLUDED	SPASTIC PARAPLEGIA 72, AUTOSOMAL RECESSIVE; SPG72SPASTIC PARAPLEGIA 72, AUTOSOMAL DOMINANT, INCLUDED	615625
DEAFNESS, AUTOSOMAL DOMINANT 56; DFNA56	DEAFNESS, AUTOSOMAL DOMINANT 56; DFNA56	615629
SHORT-RIB THORACIC DYSPLASIA 10 WITH OR WITHOUT POLYDACTYLY; SRTD10	SHORT-RIB THORACIC DYSPLASIA 10 WITH OR WITHOUT POLYDACTYLY; SRTD10	615630
ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ib; CDAN1B	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ib; CDAN1B	615631
CDA, TYPE Ib	ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ib; CDAN1B	615631
NEUROPATHY, HEREDITARY SENSORY, TYPE IF; HSN1F	NEUROPATHY, HEREDITARY SENSORY, TYPE IF; HSN1F	615632
HSN IF	NEUROPATHY, HEREDITARY SENSORY, TYPE IF; HSN1F	615632
SHORT-RIB THORACIC DYSPLASIA 11 WITH OR WITHOUT POLYDACTYLY; SRTD11	SHORT-RIB THORACIC DYSPLASIA 11 WITH OR WITHOUT POLYDACTYLY; SRTD11	615633
JOUBERT SYNDROME 21; JBTS21	JOUBERT SYNDROME 21; JBTS21	615636
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 41; MRT41	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 41; MRT41	615637
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 6; NBIA6	NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 6; NBIA6	615643
DEAFNESS, AUTOSOMAL DOMINANT 54; DFNA54	DEAFNESS, AUTOSOMAL DOMINANT 54; DFNA54	615649
LEUKOENCEPHALOPATHY WITH ATAXIA; LKPAT	LEUKOENCEPHALOPATHY WITH ATAXIA; LKPAT	615651
DEAFNESS, AUTOSOMAL DOMINANT 58; DFNA58	DEAFNESS, AUTOSOMAL DOMINANT 58; DFNA58	615654
CHROMOSOME 15q11.2 DELETION SYNDROME	CHROMOSOME 15q11.2 DELETION SYNDROME	615656
SPASTIC PARAPLEGIA 57, AUTOSOMAL RECESSIVE; SPG57	SPASTIC PARAPLEGIA 57, AUTOSOMAL RECESSIVE; SPG57	615658
WARBURG MICRO SYNDROME 4; WARBM4	WARBURG MICRO SYNDROME 4; WARBM4	615663
JOUBERT SYNDROME 22; JBTS22	JOUBERT SYNDROME 22; JBTS22	615665
CHROMOSOME 5q12 DELETION SYNDROME	CHROMOSOME 5q12 DELETION SYNDROME	615668
SCHWANNOMATOSIS 2; SWNTS2	SCHWANNOMATOSIS 2; SWNTS2	615670
MYOPATHY WITH EXTRAPYRAMIDAL SIGNS; MPXPS	MYOPATHY WITH EXTRAPYRAMIDAL SIGNS; MPXPS	615673
DOWLING-DEGOS DISEASE 3; DDD3	DOWLING-DEGOS DISEASE 3; DDD3	615674
SPASTIC PARAPLEGIA 64, AUTOSOMAL RECESSIVE; SPG64	SPASTIC PARAPLEGIA 64, AUTOSOMAL RECESSIVE; SPG64	615683
SPASTIC PARAPLEGIA 61, AUTOSOMAL RECESSIVE; SPG61	SPASTIC PARAPLEGIA 61, AUTOSOMAL RECESSIVE; SPG61	615685
SPASTIC PARAPLEGIA 63, AUTOSOMAL RECESSIVE; SPG63	SPASTIC PARAPLEGIA 63, AUTOSOMAL RECESSIVE; SPG63	615686
POLYARTERITIS NODOSA, CHILDHOOD-ONSET; PAN	POLYARTERITIS NODOSA, CHILDHOOD-ONSET; PAN	615688
ADA2 DEFICIENCY	POLYARTERITIS NODOSA, CHILDHOOD-ONSET; PAN	615688
DOWLING-DEGOS DISEASE 4; DDD4	DOWLING-DEGOS DISEASE 4; DDD4	615696
EPILEPSY, FAMILIAL TEMPORAL LOBE, 6; ETL6	EPILEPSY, FAMILIAL TEMPORAL LOBE, 6; ETL6	615697
MORBID OBESITY AND SPERMATOGENIC FAILURE; MOSPGF	MORBID OBESITY AND SPERMATOGENIC FAILURE; MOSPGF	615703
POIKILODERMA, HEREDITARY FIBROSING, WITH TENDON CONTRACTURES, MYOPATHY,AND PULMONARY FIBROSIS; POIKTMP	POIKILODERMA, HEREDITARY FIBROSING, WITH TENDON CONTRACTURES, MYOPATHY,AND PULMONARY FIBROSIS; POIKTMP	615704
POIKILODERMA, HEREDITARY SCLEROSING, WITH TENDON AND PULMONARY INVOLVEMENT	POIKILODERMA, HEREDITARY FIBROSING, WITH TENDON CONTRACTURES, MYOPATHY,AND PULMONARY FIBROSIS; POIKTMP	615704
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 15; SCAR15	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 15; SCAR15	615705
SALIH ATAXIA	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 15; SCAR15	615705
AURICULOCONDYLAR SYNDROME 3; ARCND3	AURICULOCONDYLAR SYNDROME 3; ARCND3	615706
IMMUNODEFICIENCY 20; IMD20	IMMUNODEFICIENCY 20; IMD20	615707
SACRAL AGENESIS WITH VERTEBRAL ANOMALIES; SAVA	SACRAL AGENESIS WITH VERTEBRAL ANOMALIES; SAVA	615709
MITCHELL-RILEY SYNDROME; MTCHRS	MITCHELL-RILEY SYNDROME; MTCHRS	615710
DIABETES, NEONATAL, WITH PANCREATIC HYPOPLASIA, INTESTINAL ATRESIA,AND GALLBLADDER APLASIA OR HYPOPLASIA	MITCHELL-RILEY SYNDROME; MTCHRS	615710
ALZHEIMER DISEASE 19; AD19	ALZHEIMER DISEASE 19; AD19	615711
ALZHEIMER DISEASE 19, LATE-ONSET	ALZHEIMER DISEASE 19; AD19	615711
BONE MARROW FAILURE SYNDROME 2; BMFS2	BONE MARROW FAILURE SYNDROME 2; BMFS2	615715
HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 4; HPMRS4	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 4; HPMRS4	615716
RENAL HYPODYSPLASIA/APLASIA 2; RHDA2	RENAL HYPODYSPLASIA/APLASIA 2; RHDA2	615721
BOSCH-BOONSTRA-SCHAAF OPTIC ATROPHY SYNDROME; BBSOAS	BOSCH-BOONSTRA-SCHAAF OPTIC ATROPHY SYNDROME; BBSOAS	615722
PREMATURE OVARIAN FAILURE 8; POF8	PREMATURE OVARIAN FAILURE 8; POF8	615723
PREMATURE OVARIAN FAILURE 9; POF9	PREMATURE OVARIAN FAILURE 9; POF9	615724
RETINITIS PIGMENTOSA 68; RP68	RETINITIS PIGMENTOSA 68; RP68	615725
PACHYONYCHIA CONGENITA 3; PC3	PACHYONYCHIA CONGENITA 3; PC3	615726
PACHYONYCHIA CONGENITA 4; PC4	PACHYONYCHIA CONGENITA 4; PC4	615728
NEMALINE MYOPATHY 9; NEM9	NEMALINE MYOPATHY 9; NEM9	615731
PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL OR DIFFUSE; PPKNEFD	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL OR DIFFUSE; PPKNEFD	615735
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 19; EIEE19	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 19; EIEE19	615744
ATRIAL STANDSTILL 2; ATRST2	ATRIAL STANDSTILL 2; ATRST2	615745
ATRIAL DILATION AND STANDSTILL	ATRIAL STANDSTILL 2; ATRST2	615745
CARDIOMYOPATHY, ATRIAL DILATED, WITH ATRIAL STANDSTILL	ATRIAL STANDSTILL 2; ATRST2	615745
ECULIZUMAB, POOR RESPONSE TO	ECULIZUMAB, POOR RESPONSE TO	615749
MOYAMOYA DISEASE 6 WITH ACHALASIA; MYMY6	MOYAMOYA DISEASE 6 WITH ACHALASIA; MYMY6	615750
CARBONIC ANHYDRASE VA DEFICIENCY, HYPERAMMONEMIA DUE TO; CA5AD	CARBONIC ANHYDRASE VA DEFICIENCY, HYPERAMMONEMIA DUE TO; CA5AD	615751
POLYMICROGYRIA, BILATERAL PERISYLVIAN, AUTOSOMAL RECESSIVE; BPPR	POLYMICROGYRIA, BILATERAL PERISYLVIAN, AUTOSOMAL RECESSIVE; BPPR	615752
PMGR	POLYMICROGYRIA, BILATERAL PERISYLVIAN, AUTOSOMAL RECESSIVE; BPPR	615752
IMMUNODEFICIENCY 22; IMD22	IMMUNODEFICIENCY 22; IMD22	615758
MICROCEPHALY, PROGRESSIVE, WITH SEIZURES AND CEREBRAL AND CEREBELLARATROPHY; MSCCA	MICROCEPHALY, PROGRESSIVE, WITH SEIZURES AND CEREBRAL AND CEREBELLARATROPHY; MSCCA	615760
MENTAL RETARDATION, AUTOSOMAL DOMINANT 23; MRD23	MENTAL RETARDATION, AUTOSOMAL DOMINANT 23; MRD23	615761
CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 5; CDCBM5	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 5; CDCBM5	615763
IMMUNODEFICIENCY, COMMON VARIABLE, 11; CVID11	IMMUNODEFICIENCY, COMMON VARIABLE, 11; CVID11	615767
IL21 DEFICIENCY	IMMUNODEFICIENCY, COMMON VARIABLE, 11; CVID11	615767
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 16; SCAR16	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 16; SCAR16	615768
ATRIAL FIBRILLATION, FAMILIAL, 15; ATFB15	ATRIAL FIBRILLATION, FAMILIAL, 15; ATFB15	615770
CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 6; CDCBM6	CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 6; CDCBM6	615771
OOCYTE MATURATION DEFECT; OOMD	OOCYTE MATURATION DEFECT; OOMD	615774
DESBUQUOIS DYSPLASIA 2; DBQD2	DESBUQUOIS DYSPLASIA 2; DBQD2	615777
CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 4; CHTD4	CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 4; CHTD4	615779
RETINITIS PIGMENTOSA 69; RP69	RETINITIS PIGMENTOSA 69; RP69	615780
WHITE SPONGE NEVUS 2; WSN2	WHITE SPONGE NEVUS 2; WSN2	615785
SHORT STATURE WITH MICROCEPHALY AND DISTINCTIVE FACIES	SHORT STATURE WITH MICROCEPHALY AND DISTINCTIVE FACIES	615789
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 42; MRT42	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 42; MRT42	615802
PONTOCEREBELLAR HYPOPLASIA, TYPE 10; PCH10	PONTOCEREBELLAR HYPOPLASIA, TYPE 10; PCH10	615803
SECKEL SYNDROME 8; SCKL8	SECKEL SYNDROME 8; SCKL8	615807
PONTOCEREBELLAR HYPOPLASIA, TYPE 9; PCH9	PONTOCEREBELLAR HYPOPLASIA, TYPE 9; PCH9	615809
ABDOMINAL OBESITY-METABOLIC SYNDROME 3; AOMS3	ABDOMINAL OBESITY-METABOLIC SYNDROME 3; AOMS3	615812
CENTRAL OBESITY, TYPE 2 DIABETES, HYPERTENSION, AND EARLY-ONSET CORONARYARTERY DISEASE	ABDOMINAL OBESITY-METABOLIC SYNDROME 3; AOMS3	615812
IMMUNODEFICIENCY 23; IMD23	IMMUNODEFICIENCY 23; IMD23	615816
IMMUNODEFICIENCY WITH HYPER IgE AND COGNITIVE IMPAIRMENT	IMMUNODEFICIENCY 23; IMD23	615816
IMMUNODEFICIENCY-VASCULITIS-MYOCLONUS SYNDROME; IVMS	IMMUNODEFICIENCY 23; IMD23	615816
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 43; MRT43	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 43; MRT43	615817
CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR, KERATODERMA, AND TOOTHAGENESIS; DCWHKTA	CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR, KERATODERMA, AND TOOTHAGENESIS; DCWHKTA	615821
MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 7; MC3DN7	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 7; MC3DN7	615824
MENTAL RETARDATION, AUTOSOMAL DOMINANT 24; MRD24	MENTAL RETARDATION, AUTOSOMAL DOMINANT 24; MRD24	615828
XIA-GIBBS SYNDROME	XIA-GIBBS SYNDROME	615829
MENTAL RETARDATION, AUTOSOMAL DOMINANT 25; MRD25	XIA-GIBBS SYNDROME	615829
PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 4; PPNAD4	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 4; PPNAD4	615830
CUSHING SYNDROME, ADRENAL, DUE TO PPNAD4	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 4; PPNAD4	615830
CHROMOSOME 19p13 DUPLICATION SYNDROMEACTH-INDEPENDENT ADRENAL CUSHING SYNDROME, SOMATIC, INCLUDED	PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 4; PPNAD4	615830
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 21; EIEE21	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 21; EIEE21	615833
MENTAL RETARDATION, AUTOSOMAL DOMINANT 26; MRD26	MENTAL RETARDATION, AUTOSOMAL DOMINANT 26; MRD26	615834
CHROMOSOME 16 INVERSION, 0.45-MB	CHROMOSOME 16 INVERSION, 0.45-MB	615835
DEAFNESS, AUTOSOMAL RECESSIVE 101; DFNB101	DEAFNESS, AUTOSOMAL RECESSIVE 101; DFNB101	615837
MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 8; MC3DN8	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 8; MC3DN8	615838
SPERMATOGENIC FAILURE 13; SPGF13	SPERMATOGENIC FAILURE 13; SPGF13	615841
SPERMATOGENIC FAILURE 14; SPGF14	SPERMATOGENIC FAILURE 14; SPGF14	615842
AICARDI-GOUTIERES SYNDROME 7; AGS7	AICARDI-GOUTIERES SYNDROME 7; AGS7	615846
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10; CMM10	MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10; CMM10	615848
CULLER-JONES SYNDROME; CJS	CULLER-JONES SYNDROME; CJS	615849
PALLISTER-HALL SYNDROME 2, FORMERLY; PHS2, FORMERLY	CULLER-JONES SYNDROME; CJS	615849
PONTOCEREBELLAR HYPOPLASIA, TYPE 2E; PCH2E	PONTOCEREBELLAR HYPOPLASIA, TYPE 2E; PCH2E	615851
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 23; EIEE23	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 23; EIEE23	615859
CONE-ROD DYSTROPHY 19; CORD19	CONE-ROD DYSTROPHY 19; CORD19	615860
NEPHROTIC SYNDROME, TYPE 10; NPHS10	NEPHROTIC SYNDROME, TYPE 10; NPHS10	615861
NEPHRONOPHTHISIS 18; NPHP18	NEPHRONOPHTHISIS 18; NPHP18	615862
DIARRHEA 7; DIAR7	DIARRHEA 7; DIAR7	615863
MENTAL RETARDATION, AUTOSOMAL DOMINANT 27; MRD27	MENTAL RETARDATION, AUTOSOMAL DOMINANT 27; MRD27	615866
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 24; EIEE24	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 24; EIEE24	615871
CILIARY DYSKINESIA, PRIMARY, 29; CILD29	CILIARY DYSKINESIA, PRIMARY, 29; CILD29	615872
CILIARY DYSKINESIA, PRIMARY, 29, WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 29; CILD29	615872
HELSMOORTEL-VAN DER AA SYNDROME; HVDAS	HELSMOORTEL-VAN DER AA SYNDROME; HVDAS	615873
MENTAL RETARDATION, AUTOSOMAL DOMINANT 28; MRD28	HELSMOORTEL-VAN DER AA SYNDROME; HVDAS	615873
MICROPHTHALMIA, SYNDROMIC 14; MCOPS14	MICROPHTHALMIA, SYNDROMIC 14; MCOPS14	615877
MICROPHTHALMIA AND COLOBOMA, WITH OR WITHOUT RHIZOMELIC SKELETAL DYSPLASIA	MICROPHTHALMIA, SYNDROMIC 14; MCOPS14	615877
CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 4; PFIC4	CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 4; PFIC4	615878
TATTON-BROWN-RAHMAN SYNDROME; TBRS	TATTON-BROWN-RAHMAN SYNDROME; TBRS	615879
PLASMA TRIGLYCERIDE LEVEL QUANTITATIVE TRAIT LOCUS; TGQTL	PLASMA TRIGLYCERIDE LEVEL QUANTITATIVE TRAIT LOCUS; TGQTL	615881
MYOPATHY, TUBULAR AGGREGATE, 2; TAM2	MYOPATHY, TUBULAR AGGREGATE, 2; TAM2	615883
HYPOTRICHOSIS 12; HYPT12	HYPOTRICHOSIS 12; HYPT12	615885
AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA5; AI2A5	AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA5; AI2A5	615887
BLEEDING DISORDER, PLATELET-TYPE, 18; BDPLT18	BLEEDING DISORDER, PLATELET-TYPE, 18; BDPLT18	615888
LEUKOENCEPHALOPATHY, PROGRESSIVE, WITH OVARIAN FAILURE; LKENP	LEUKOENCEPHALOPATHY, PROGRESSIVE, WITH OVARIAN FAILURE; LKENP	615889
OROFACIAL CLEFT 14; OFC14	OROFACIAL CLEFT 14; OFC14	615892
POLYGLUCOSAN BODY MYOPATHY 1 WITH OR WITHOUT IMMUNODEFICIENCY; PGBM1	POLYGLUCOSAN BODY MYOPATHY 1 WITH OR WITHOUT IMMUNODEFICIENCY; PGBM1	615895
POLYGLUCOSAN BODY MYOPATHY, EARLY-ONSET, WITH OR WITHOUT IMMUNODEFICIENCY;PBMEI	POLYGLUCOSAN BODY MYOPATHY 1 WITH OR WITHOUT IMMUNODEFICIENCY; PGBM1	615895
HYPOTRICHOSIS 13; HYPT13	HYPOTRICHOSIS 13; HYPT13	615896
HYPOTRICHOSIS WITH WOOLLY HAIR	HYPOTRICHOSIS 13; HYPT13	615896
IMMUNODEFICIENCY 24; IMD24	IMMUNODEFICIENCY 24; IMD24	615897
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 25; EIEE25	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 25; EIEE25	615905
LYMPHEDEMA, HEREDITARY, ID; LMPH1D	LYMPHEDEMA, HEREDITARY, ID; LMPH1D	615907
DIAMOND-BLACKFAN ANEMIA 13; DBA13	DIAMOND-BLACKFAN ANEMIA 13; DBA13	615909
FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 2; FTDALS2	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 2; FTDALS2	615911
CARDIOMYOPATHY, DILATED, 1NN; CMD1NN	CARDIOMYOPATHY, DILATED, 1NN; CMD1NN	615916
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 20; COXPD20	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 20; COXPD20	615917
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 21; COXPD21	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 21; COXPD21	615918
ATAXIA-TELANGIECTASIA-LIKE DISORDER 2; ATLD2	ATAXIA-TELANGIECTASIA-LIKE DISORDER 2; ATLD2	615919
RETINITIS PIGMENTOSA 70; RP70	RETINITIS PIGMENTOSA 70; RP70	615922
EPIPHYSEAL CHONDRODYSPLASIA, MIURA TYPE; ECDM	EPIPHYSEAL CHONDRODYSPLASIA, MIURA TYPE; ECDM	615923
ENCEPHALOPATHY, PROGRESSIVE, WITH OR WITHOUT LIPODYSTROPHY; PELD	ENCEPHALOPATHY, PROGRESSIVE, WITH OR WITHOUT LIPODYSTROPHY; PELD	615924
GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL; GHDP	GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL; GHDP	615925
WEBB-DATTANI SYNDROME; WEDAS	WEBB-DATTANI SYNDROME; WEDAS	615926
HYPOTHALAMO-PITUITARY-FRONTOTEMPORAL HYPOPLASIA WITH VISUAL AND RENALANOMALIES	WEBB-DATTANI SYNDROME; WEDAS	615926
STING-ASSOCIATED VASCULOPATHY, INFANTILE-ONSET; SAVI	STING-ASSOCIATED VASCULOPATHY, INFANTILE-ONSET; SAVI	615934
PANCREATIC AGENESIS 2; PAGEN2	PANCREATIC AGENESIS 2; PAGEN2	615935
PANCREATIC HYPOPLASIA, CONGENITAL 2	PANCREATIC AGENESIS 2; PAGEN2	615935
MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 2;MPPH2	MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 2;MPPH2	615937
MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 3;MPPH3	MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 3;MPPH3	615938
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 44; MRT44	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 44; MRT44	615942
SPINOCEREBELLAR ATAXIA 37; SCA37	SPINOCEREBELLAR ATAXIA 37; SCA37	615945
MYOPIA 24, AUTOSOMAL DOMINANT; MYP24	MYOPIA 24, AUTOSOMAL DOMINANT; MYP24	615946
HYPERLIPOPROTEINEMIA, TYPE ID	HYPERLIPOPROTEINEMIA, TYPE ID	615947
OROFACIODIGITAL SYNDROME XIV; OFD14	OROFACIODIGITAL SYNDROME XIV; OFD14	615948
AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET; ADMIO	AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET; ADMIO	615952
KALLIKREIN, DECREASED URINARY ACTIVITY OF	KALLIKREIN, DECREASED URINARY ACTIVITY OF	615953
ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA 2; AIMAH2	ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA 2; AIMAH2	615954
PRIMARY MACRONODULAR ADRENAL HYPERPLASIA	ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA 2; AIMAH2	615954
SPINOCEREBELLAR ATAXIA 38; SCA38	SPINOCEREBELLAR ATAXIA 38; SCA38	615957
MYOPATHY, CENTRONUCLEAR, 5; CNM5	MYOPATHY, CENTRONUCLEAR, 5; CNM5	615959
PORETTI-BOLTSHAUSER SYNDROME; PTBHS	PORETTI-BOLTSHAUSER SYNDROME; PTBHS	615960
ACID-LABILE SUBUNIT DEFICIENCY; ACLSD	ACID-LABILE SUBUNIT DEFICIENCY; ACLSD	615961
GLUCOCORTICOID RESISTANCE, GENERALIZED; GCCR	GLUCOCORTICOID RESISTANCE, GENERALIZED; GCCR	615962
GLUCOCORTICOID RECEPTOR DEFICIENCY	GLUCOCORTICOID RESISTANCE, GENERALIZED; GCCR	615962
GCCR DEFICIENCY	GLUCOCORTICOID RESISTANCE, GENERALIZED; GCCR	615962
GCR DEFICIENCY	GLUCOCORTICOID RESISTANCE, GENERALIZED; GCCR	615962
GRL DEFICIENCY	GLUCOCORTICOID RESISTANCE, GENERALIZED; GCCR	615962
CORTISOL RESISTANCE FROM GLUCOCORTICOID RECEPTOR DEFECT	GLUCOCORTICOID RESISTANCE, GENERALIZED; GCCR	615962
VESICOURETERAL REFLUX 8; VUR8	VESICOURETERAL REFLUX 8; VUR8	615963
IMMUNODEFICIENCY 26 WITH OR WITHOUT NEUROLOGIC ABNORMALITIES; IMD26	IMMUNODEFICIENCY 26 WITH OR WITHOUT NEUROLOGIC ABNORMALITIES; IMD26	615966
ALPHA-FETOPROTEIN DEFICIENCY; AFPD	ALPHA-FETOPROTEIN DEFICIENCY; AFPD	615969
ALPHA-FETOPROTEIN, HEREDITARY PERSISTENCE OF; HPAFP	ALPHA-FETOPROTEIN, HEREDITARY PERSISTENCE OF; HPAFP	615970
NANOPHTHALMOS 4; NNO4	NANOPHTHALMOS 4; NNO4	615972
NANOPHTHALMIA 4	NANOPHTHALMOS 4; NNO4	615972
CONE-ROD DYSTROPHY 20; CORD20	CONE-ROD DYSTROPHY 20; CORD20	615973
DEAFNESS, AUTOSOMAL RECESSIVE 102; DFNB102	DEAFNESS, AUTOSOMAL RECESSIVE 102; DFNB102	615974
IMMUNODEFICIENCY 27B; IMD27B	IMMUNODEFICIENCY 27B; IMD27B	615978
IMMUNODEFICIENCY 27B, MYCOBACTERIOSIS, AUTOSOMAL DOMINANT	IMMUNODEFICIENCY 27B; IMD27B	615978
IFNGR1 DEFICIENCY, AUTOSOMAL DOMINANT	IMMUNODEFICIENCY 27B; IMD27B	615978
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 45; MRT45	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 45; MRT45	615979
LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 6; FPLD6	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 6; FPLD6	615980
LIPODYSTROPHY, FAMILIAL PARTIAL, ASSOCIATED WITH LIPE MUTATIONS	LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 6; FPLD6	615980
BARDET-BIEDL SYNDROME 2; BBS2	BARDET-BIEDL SYNDROME 2; BBS2	615981
BARDET-BIEDL SYNDROME 4; BBS4	BARDET-BIEDL SYNDROME 4; BBS4	615982
BARDET-BIEDL SYNDROME 5; BBS5	BARDET-BIEDL SYNDROME 5; BBS5	615983
BARDET-BIEDL SYNDROME 7; BBS7	BARDET-BIEDL SYNDROME 7; BBS7	615984
BARDET-BIEDL SYNDROME 8; BBS8	BARDET-BIEDL SYNDROME 8; BBS8	615985
BARDET-BIEDL SYNDROME 9; BBS9	BARDET-BIEDL SYNDROME 9; BBS9	615986
BARDET-BIEDL SYNDROME 10; BBS10	BARDET-BIEDL SYNDROME 10; BBS10	615987
BARDET-BIEDL SYNDROME 11; BBS11	BARDET-BIEDL SYNDROME 11; BBS11	615988
BARDET-BIEDL SYNDROME 12; BBS12	BARDET-BIEDL SYNDROME 12; BBS12	615989
BARDET-BIEDL SYNDROME 13; BBS13	BARDET-BIEDL SYNDROME 13; BBS13	615990
BARDET-BIEDL SYNDROME 14; BBS14	BARDET-BIEDL SYNDROME 14; BBS14	615991
BARDET-BIEDL SYNDROME 15; BBS15	BARDET-BIEDL SYNDROME 15; BBS15	615992
BARDET-BIEDL SYNDROME 16; BBS16	BARDET-BIEDL SYNDROME 16; BBS16	615993
BARDET-BIEDL SYNDROME 17; BBS17	BARDET-BIEDL SYNDROME 17; BBS17	615994
BARDET-BIEDL SYNDROME 18; BBS18	BARDET-BIEDL SYNDROME 18; BBS18	615995
BARDET-BIEDL SYNDROME 19; BBS19	BARDET-BIEDL SYNDROME 19; BBS19	615996
HYPERTHYROXINEMIA, FAMILIAL DYSALBUMINEMIC; FDAH	HYPERTHYROXINEMIA, FAMILIAL DYSALBUMINEMIC; FDAH	615999
FDH	HYPERTHYROXINEMIA, FAMILIAL DYSALBUMINEMIC; FDAH	615999
EUTHYROID HYPERTHYROXINEMIA 1	HYPERTHYROXINEMIA, FAMILIAL DYSALBUMINEMIC; FDAH	615999
ANALBUMINEMIA; ANALBA	ANALBUMINEMIA; ANALBA	616000
BREASTS AND/OR NIPPLES, APLASIA OR HYPOPLASIA OF, 2; BNAH2	BREASTS AND/OR NIPPLES, APLASIA OR HYPOPLASIA OF, 2; BNAH2	616001
FOCAL SEGMENTAL GLOMERULOSCLEROSIS 7; FSGS7	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 7; FSGS7	616002
GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 7	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 7; FSGS7	616002
DYSFIBRINOGENEMIA, CONGENITALHYPODYSFIBRINOGENEMIA, CONGENITAL, INCLUDED	DYSFIBRINOGENEMIA, CONGENITALHYPODYSFIBRINOGENEMIA, CONGENITAL, INCLUDED	616004
IMMUNODEFICIENCY 36; IMD36	IMMUNODEFICIENCY 36; IMD36	616005
HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 2; HKLLS2	HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 2; HKLLS2	616006
CATARACTS, GROWTH HORMONE DEFICIENCY, SENSORY NEUROPATHY, SENSORINEURALHEARING LOSS, AND SKELETAL DYSPLASIA; CAGSSS	CATARACTS, GROWTH HORMONE DEFICIENCY, SENSORY NEUROPATHY, SENSORINEURALHEARING LOSS, AND SKELETAL DYSPLASIA; CAGSSS	616007
NEUTROPENIA, SEVERE CONGENITAL, 6, AUTOSOMAL RECESSIVE; SCN6	NEUTROPENIA, SEVERE CONGENITAL, 6, AUTOSOMAL RECESSIVE; SCN6	616022
HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 5; HPMRS5	HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 5; HPMRS5	616025
FANCONI RENOTUBULAR SYNDROME 4 WITH MATURITY-ONSET DIABETES OF THEYOUNG; FRTS4	FANCONI RENOTUBULAR SYNDROME 4 WITH MATURITY-ONSET DIABETES OF THEYOUNG; FRTS4	616026
FRTS4 WITH MODY	FANCONI RENOTUBULAR SYNDROME 4 WITH MATURITY-ONSET DIABETES OF THEYOUNG; FRTS4	616026
ADAMS-OLIVER SYNDROME 5; AOS5	ADAMS-OLIVER SYNDROME 5; AOS5	616028
ECTODERMAL DYSPLASIA/SHORT STATURE SYNDROME; ECTDS	ECTODERMAL DYSPLASIA/SHORT STATURE SYNDROME; ECTDS	616029
HYPOGONADOTROPIC HYPOGONADISM 22 WITH OR WITHOUT ANOSMIA; HH22	HYPOGONADOTROPIC HYPOGONADISM 22 WITH OR WITHOUT ANOSMIA; HH22	616030
FOCAL SEGMENTAL GLOMERULOSCLEROSIS 8; FSGS8	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 8; FSGS8	616032
GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 8	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 8; FSGS8	616032
MICROCEPHALY, SHORT STATURE, AND IMPAIRED GLUCOSE METABOLISM; MSSGM	MICROCEPHALY, SHORT STATURE, AND IMPAIRED GLUCOSE METABOLISM; MSSGM	616033
2,4-@DIENOYL-CoA REDUCTASE DEFICIENCY; DECRD	2,4-@DIENOYL-CoA REDUCTASE DEFICIENCY; DECRD	616034
CILIARY DYSKINESIA, PRIMARY, 30; CILD30	CILIARY DYSKINESIA, PRIMARY, 30; CILD30	616037
CILIARY DYSKINESIA, PRIMARY, 30, WITH OR WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 30; CILD30	616037
NEU-LAXOVA SYNDROME 2; NLS2	NEU-LAXOVA SYNDROME 2; NLS2	616038
CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE D; CMTRID	CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE D; CMTRID	616039
MYASTHENIC SYNDROME, CONGENITAL, 7, PRESYNAPTIC; CMS7	MYASTHENIC SYNDROME, CONGENITAL, 7, PRESYNAPTIC; CMS7	616040
MYASTHENIC SYNDROME, PRESYNAPTIC, CONGENITAL, WITH OR WITHOUT MOTORNEUROPATHY; MYSPC	MYASTHENIC SYNDROME, CONGENITAL, 7, PRESYNAPTIC; CMS7	616040
DEAFNESS, AUTOSOMAL RECESSIVE 103; DFNB103	DEAFNESS, AUTOSOMAL RECESSIVE 103; DFNB103	616042
DEAFNESS, AUTOSOMAL DOMINANT 65; DFNA65	DEAFNESS, AUTOSOMAL DOMINANT 65; DFNA65	616044
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 22; COXPD22	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 22; COXPD22	616045
AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS; AIFEC	AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS; AIFEC	616050
MICROCEPHALY 13, PRIMARY, AUTOSOMAL RECESSIVE; MCPH13	MICROCEPHALY 13, PRIMARY, AUTOSOMAL RECESSIVE; MCPH13	616051
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 7; MDDGC7	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 7; MDDGC7	616052
SPINOCEREBELLAR ATAXIA 40; SCA40	SPINOCEREBELLAR ATAXIA 40; SCA40	616053
EPISODIC ATAXIA, TYPE 8; EA8	EPISODIC ATAXIA, TYPE 8; EA8	616055
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 26; EIEE26	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 26; EIEE26	616056
MIRROR MOVEMENTS 3; MRMV3	MIRROR MOVEMENTS 3; MRMV3	616059
BLOOD GROUP, DOMBROCK SYSTEM; DO	BLOOD GROUP, DOMBROCK SYSTEM; DO	616060
DOMBROCK BLOOD GROUP SYSTEM	BLOOD GROUP, DOMBROCK SYSTEM; DO	616060
POROKERATOSIS 8, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK8	POROKERATOSIS 8, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK8	616063
46,XY SEX REVERSAL 9; SRXY9	46,XY SEX REVERSAL 9; SRXY9	616067
46,XY SEX REVERSAL, ZFPM2-RELATED	46,XY SEX REVERSAL 9; SRXY9	616067
INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 2; NISBD2	INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 2; NISBD2	616069
MENTAL RETARDATION, AUTOSOMAL DOMINANT 29; MRD29	MENTAL RETARDATION, AUTOSOMAL DOMINANT 29; MRD29	616078
RETINAL DYSTROPHY WITH INNER RETINAL DYSFUNCTION AND GANGLION CELLABNORMALITIES; RDGCA	RETINAL DYSTROPHY WITH INNER RETINAL DYSFUNCTION AND GANGLION CELLABNORMALITIES; RDGCA	616079
MICROCEPHALY 12, PRIMARY, AUTOSOMAL RECESSIVE; MCPH12	MICROCEPHALY 12, PRIMARY, AUTOSOMAL RECESSIVE; MCPH12	616080
PONTOCEREBELLAR HYPOPLASIA, TYPE 1C; PCH1C	PONTOCEREBELLAR HYPOPLASIA, TYPE 1C; PCH1C	616081
HYPOMYELINATION WITH SPINAL MUSCULAR ATROPHY AND CEREBELLAR HYPOPLASIA	PONTOCEREBELLAR HYPOPLASIA, TYPE 1C; PCH1C	616081
MENTAL RETARDATION, AUTOSOMAL DOMINANT 30; MRD30	MENTAL RETARDATION, AUTOSOMAL DOMINANT 30; MRD30	616083
SIDEROBLASTIC ANEMIA WITH B-CELL IMMUNODEFICIENCY, PERIODIC FEVERS,AND DEVELOPMENTAL DELAY; SIFD	SIDEROBLASTIC ANEMIA WITH B-CELL IMMUNODEFICIENCY, PERIODIC FEVERS,AND DEVELOPMENTAL DELAY; SIFD	616084
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 5; NIDDM5	DIABETES MELLITUS, NONINSULIN-DEPENDENT, 5; NIDDM5	616087
BLOOD GROUP, GERBICH SYSTEM; GE	BLOOD GROUP, GERBICH SYSTEM; GE	616089
GERBICH BLOOD GROUP SYSTEM	BLOOD GROUP, GERBICH SYSTEM; GE	616089
BLOOD GROUP, ABO SYSTEM	BLOOD GROUP, ABO SYSTEM	616093
ABO BLOOD GROUP SYSTEM	BLOOD GROUP, ABO SYSTEM	616093
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 12; MDDGC12	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 12; MDDGC12	616094
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, POMK-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 12; MDDGC12	616094
MONOCARBOXYLATE TRANSPORTER 1 DEFICIENCY; MCT1D	MONOCARBOXYLATE TRANSPORTER 1 DEFICIENCY; MCT1D	616095
IMMUNODEFICIENCY 37; IMD37	IMMUNODEFICIENCY 37; IMD37	616098
PALMOPLANTAR KERATODERMA AND WOOLLY HAIR; PPKWH	PALMOPLANTAR KERATODERMA AND WOOLLY HAIR; PPKWH	616099
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE V; ALPS5	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE V; ALPS5	616100
CTLA4 HAPLOINSUFFICIENCY WITH AUTOIMMUNE INFILTRATION; CHAI	AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE V; ALPS5	616100
PSORIASIS 15, PUSTULAR, SUSCEPTIBILITY TO; PSORS15	PSORIASIS 15, PUSTULAR, SUSCEPTIBILITY TO; PSORS15	616106
RETINAL DYSTROPHY, JUVENILE CATARACTS, AND SHORT STATURE SYNDROME;RDJCSS	RETINAL DYSTROPHY, JUVENILE CATARACTS, AND SHORT STATURE SYNDROME;RDJCSS	616108
MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 9; MC3DN9	MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 9; MC3DN9	616111
POLYENDOCRINE-POLYNEUROPATHY SYNDROME; PEPNS	POLYENDOCRINE-POLYNEUROPATHY SYNDROME; PEPNS	616113
FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 4; FCAS4	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 4; FCAS4	616115
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 46; MRT46	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 46; MRT46	616116
CARDIAC CONDUCTION DISEASE WITH OR WITHOUT DILATED CARDIOMYOPATHY;CCDD	CARDIAC CONDUCTION DISEASE WITH OR WITHOUT DILATED CARDIOMYOPATHY;CCDD	616117
MACULAR DEGENERATION, EARLY-ONSET; EOMD	MACULAR DEGENERATION, EARLY-ONSET; EOMD	616118
IMMUNODEFICIENCY 38 WITH BASAL GANGLIA CALCIFICATION; IMD38	IMMUNODEFICIENCY 38 WITH BASAL GANGLIA CALCIFICATION; IMD38	616126
IMMUNODEFICIENCY 38, MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE	IMMUNODEFICIENCY 38 WITH BASAL GANGLIA CALCIFICATION; IMD38	616126
ISG15 DEFICIENCY, AUTOSOMAL RECESSIVE	IMMUNODEFICIENCY 38 WITH BASAL GANGLIA CALCIFICATION; IMD38	616126
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 17; SCAR17	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 17; SCAR17	616127
PERRAULT SYNDROME 5; PRLTS5	PERRAULT SYNDROME 5; PRLTS5	616138
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 27; EIEE27	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 27; EIEE27	616139
LEUKODYSTROPHY, HYPOMYELINATING, 9; HLD9	LEUKODYSTROPHY, HYPOMYELINATING, 9; HLD9	616140
CATEL-MANZKE SYNDROME; CATMANS	CATEL-MANZKE SYNDROME; CATMANS	616145
HYPERPHALANGY-CLINODACTYLY OF INDEX FINGER WITH PIERRE ROBIN SYNDROME	CATEL-MANZKE SYNDROME; CATMANS	616145
PIERRE ROBIN SYNDROME WITH HYPERPHALANGY AND CLINODACTYLY	CATEL-MANZKE SYNDROME; CATMANS	616145
INDEX FINGER ANOMALY WITH PIERRE ROBIN SYNDROME	CATEL-MANZKE SYNDROME; CATMANS	616145
PALATODIGITAL SYNDROME, CATEL-MANZKE TYPE	CATEL-MANZKE SYNDROME; CATMANS	616145
MICROGNATHIA DIGITAL SYNDROME	CATEL-MANZKE SYNDROME; CATMANS	616145
MACULAR DYSTROPHY, VITELLIFORM, 4; VMD4	MACULAR DYSTROPHY, VITELLIFORM, 4; VMD4	616151
MACULAR DYSTROPHY, VITELLIFORM, 5; VMD5	MACULAR DYSTROPHY, VITELLIFORM, 5; VMD5	616152
PEROXISOMAL FATTY ACYL-CoA REDUCTASE 1 DISORDER; PFCRD	PEROXISOMAL FATTY ACYL-CoA REDUCTASE 1 DISORDER; PFCRD	616154
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2S; CMT2S	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2S; CMT2S	616155
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2S	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2S; CMT2S	616155
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2S	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2S; CMT2S	616155
MENTAL RETARDATION, AUTOSOMAL DOMINANT 31; MRD31	MENTAL RETARDATION, AUTOSOMAL DOMINANT 31; MRD31	616158
NEMALINE MYOPATHY 10; NEM10	NEMALINE MYOPATHY 10; NEM10	616165
AORTIC ANEURYSM, FAMILIAL THORACIC 9; AAT9	AORTIC ANEURYSM, FAMILIAL THORACIC 9; AAT9	616166
AORTIC ANEURYSM, THORACIC, WITH OR WITHOUT AORTIC DISSECTION	AORTIC ANEURYSM, FAMILIAL THORACIC 9; AAT9	616166
MACULAR DYSTROPHY WITH CENTRAL CONE INVOLVEMENT; CCMD	MACULAR DYSTROPHY WITH CENTRAL CONE INVOLVEMENT; CCMD	616170
MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 2; MCCRP2	MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 2; MCCRP2	616171
GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 9; GEFSP9	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 9; GEFSP9	616172
GEFS+, TYPE 9; GEFS+9	GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 9; GEFSP9	616172
BLEEDING DISORDER, PLATELET-TYPE, 19; BDPLT19	BLEEDING DISORDER, PLATELET-TYPE, 19; BDPLT19	616176
CHRONIC MOUNTAIN SICKNESS, SUSCEPTIBILITY TO	CHRONIC MOUNTAIN SICKNESS, SUSCEPTIBILITY TO	616182
MONGE DISEASE	CHRONIC MOUNTAIN SICKNESS, SUSCEPTIBILITY TO	616182
OVARIAN DYSGENESIS 4; ODG4	OVARIAN DYSGENESIS 4; ODG4	616185
EPILEPSY, PROGRESSIVE MYOCLONIC 7; EPM7	EPILEPSY, PROGRESSIVE MYOCLONIC 7; EPM7	616187
RETINAL DYSTROPHY AND OBESITY; RDOB	RETINAL DYSTROPHY AND OBESITY; RDOB	616188
ATAXIA, COMBINED CEREBELLAR AND PERIPHERAL, WITH HEARING LOSS ANDDIABETES MELLITUS; ACPHD	ATAXIA, COMBINED CEREBELLAR AND PERIPHERAL, WITH HEARING LOSS ANDDIABETES MELLITUS; ACPHD	616192
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 47; MRT47	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 47; MRT47	616193
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 23; COXPD23	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 23; COXPD23	616198
POLYGLUCOSAN BODY MYOPATHY 2; PGBM2	POLYGLUCOSAN BODY MYOPATHY 2; PGBM2	616199
RUIJS-AALFS SYNDROME; RJALS	RUIJS-AALFS SYNDROME; RJALS	616200
CHRONIC ATRIAL AND INTESTINAL DYSRHYTHMIA; CAID	CHRONIC ATRIAL AND INTESTINAL DYSRHYTHMIA; CAID	616201
CEREBELLOFACIODENTAL SYNDROME; CFDS	CEREBELLOFACIODENTAL SYNDROME; CFDS	616202
CEREBELLAR-FACIAL-DENTAL SYNDROME	CEREBELLOFACIODENTAL SYNDROME; CFDS	616202
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 18; SCAR18	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 18; SCAR18	616204
AMYOTROPHIC LATERAL SCLEROSIS 22 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS22	AMYOTROPHIC LATERAL SCLEROSIS 22 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA;ALS22	616208
MYOPATHY, ISOLATED MITOCHONDRIAL, AUTOSOMAL DOMINANT; IMMD	MYOPATHY, ISOLATED MITOCHONDRIAL, AUTOSOMAL DOMINANT; IMMD	616209
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 28; EIEE28	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 28; EIEE28	616211
LISSENCEPHALY 6 WITH MICROCEPHALY; LIS6	LISSENCEPHALY 6 WITH MICROCEPHALY; LIS6	616212
HYPERPROINSULINEMIA	HYPERPROINSULINEMIA	616214
THROMBOCYTOPENIA 5; THC5	THROMBOCYTOPENIA 5; THC5	616216
THROMBOCYTOPENIA 5 WITH INCREASED SUSCEPTIBILITY TO MALIGNANCY	THROMBOCYTOPENIA 5; THC5	616216
THROMBOCYTOPENIA, AUTOSOMAL DOMINANT, 5	THROMBOCYTOPENIA 5; THC5	616216
NEPHRONOPHTHISIS 19; NPHP19	NEPHRONOPHTHISIS 19; NPHP19	616217
FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 5; CFEOM5	FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 5; CFEOM5	616219
FOCAL SEGMENTAL GLOMERULOSCLEROSIS 9; FSGS9	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 9; FSGS9	616220
GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 9	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 9; FSGS9	616220
AMELOGENESIS IMPERFECTA, TYPE IH; AI1H	AMELOGENESIS IMPERFECTA, TYPE IH; AI1H	616221
TEMPLE SYNDROME	TEMPLE SYNDROME	616222
UNIPARENTAL DISOMY, MATERNAL, CHROMOSOME 14	TEMPLE SYNDROME	616222
MYASTHENIC SYNDROME, CONGENITAL, 15; CMS15	MYASTHENIC SYNDROME, CONGENITAL, 15; CMS15	616227
MYASTHENIC SYNDROME, CONGENITAL, WITHOUT TUBULAR AGGREGATES; CMSWTA	MYASTHENIC SYNDROME, CONGENITAL, 15; CMS15	616227
MYASTHENIC SYNDROME, CONGENITAL, 14; CMS14	MYASTHENIC SYNDROME, CONGENITAL, 14; CMS14	616228
MYASTHENIC SYNDROME, CONGENITAL, WITH TUBULAR AGGREGATES 3; CMSTA3	MYASTHENIC SYNDROME, CONGENITAL, 14; CMS14	616228
OSTEOGENESIS IMPERFECTA, TYPE XVI; OI16	OSTEOGENESIS IMPERFECTA, TYPE XVI; OI16	616229
OI, TYPE XVI	OSTEOGENESIS IMPERFECTA, TYPE XVI; OI16	616229
CHROMOSOME 11p11.2 DELETION SYNDROME, 91.3-KB	OSTEOGENESIS IMPERFECTA, TYPE XVI; OI16	616229
EPILEPSY, PROGRESSIVE MYOCLONIC, 8; EPM8	EPILEPSY, PROGRESSIVE MYOCLONIC, 8; EPM8	616230
MYOPATHY, VACUOLAR, WITH CASQ1 AGGREGATES; VMCQA	MYOPATHY, VACUOLAR, WITH CASQ1 AGGREGATES; VMCQA	616231
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2T; CMT2T	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2T; CMT2T	616233
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2T	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2T; CMT2T	616233
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2T	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2T; CMT2T	616233
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 24; COXPD24	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 24; COXPD24	616239
LONG QT SYNDROME 14; LQT14	LONG QT SYNDROME 14; LQT14	616247
LETHAL CONGENITAL CONTRACTURE SYNDROME 6; LCCS6	LETHAL CONGENITAL CONTRACTURE SYNDROME 6; LCCS6	616248
LONG QT SYNDROME 15; LQT15	LONG QT SYNDROME 15; LQT15	616249
SHORT STATURE WITH NONSPECIFIC SKELETAL ABNORMALITIES; SNSK	SHORT STATURE WITH NONSPECIFIC SKELETAL ABNORMALITIES; SNSK	616255
MECKEL SYNDROME 12; MKS12	MECKEL SYNDROME 12; MKS12	616258
TENORIO SYNDROME; TNORS	TENORIO SYNDROME; TNORS	616260
OVERGROWTH, MACROCEPHALY, AND INTELLECTUAL DISABILITY SYNDROME	TENORIO SYNDROME; TNORS	616260
NEUROLOGIC, ENDOCRINE, AND PANCREATIC DISEASE, MULTISYSTEM, INFANTILE-ONSET;IMNEPD	NEUROLOGIC, ENDOCRINE, AND PANCREATIC DISEASE, MULTISYSTEM, INFANTILE-ONSET;IMNEPD	616263
PEELING SKIN SYNDROME 3; PSS3	PEELING SKIN SYNDROME 3; PSS3	616265
CONGENITAL CONTRACTURES OF THE LIMBS AND FACE, HYPOTONIA, AND DEVELOPMENTALDELAY; CLIFAHDD	CONGENITAL CONTRACTURES OF THE LIMBS AND FACE, HYPOTONIA, AND DEVELOPMENTALDELAY; CLIFAHDD	616266
ATAXIA-OCULOMOTOR APRAXIA 4; AOA4	ATAXIA-OCULOMOTOR APRAXIA 4; AOA4	616267
MENTAL RETARDATION, AUTOSOMAL DOMINANT 32; MRD32	MENTAL RETARDATION, AUTOSOMAL DOMINANT 32; MRD32	616268
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 48; MRT48	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 48; MRT48	616269
AMELOGENESIS IMPERFECTA, TYPE IF; AI1F	AMELOGENESIS IMPERFECTA, TYPE IF; AI1F	616270
AMELOGENESIS IMPERFECTA, HYPOPLASTIC TYPE IF; AI1F	AMELOGENESIS IMPERFECTA, TYPE IF; AI1F	616270
3-@METHYLGLUTACONIC ACIDURIA WITH CATARACTS, NEUROLOGIC INVOLVEMENT,AND NEUTROPENIA; MEGCANN	3-@METHYLGLUTACONIC ACIDURIA WITH CATARACTS, NEUROLOGIC INVOLVEMENT,AND NEUTROPENIA; MEGCANN	616271
3-@METHYLGLUTACONIC ACIDURIA, TYPE VII; MGCA7	3-@METHYLGLUTACONIC ACIDURIA WITH CATARACTS, NEUROLOGIC INVOLVEMENT,AND NEUTROPENIA; MEGCANN	616271
COENZYME Q10 DEFICIENCY, PRIMARY, 7; COQ10D7	COENZYME Q10 DEFICIENCY, PRIMARY, 7; COQ10D7	616276
MITOCHONDRIAL SHORT-CHAIN ENOYL-CoA HYDRATASE 1 DEFICIENCY; ECHS1D	MITOCHONDRIAL SHORT-CHAIN ENOYL-CoA HYDRATASE 1 DEFICIENCY; ECHS1D	616277
BILE ACID SYNTHESIS DEFECT, CONGENITAL, 5; CBAS5	BILE ACID SYNTHESIS DEFECT, CONGENITAL, 5; CBAS5	616278
CATARACT 43; CTRCT43	CATARACT 43; CTRCT43	616279
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2U; CMT2U	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2U; CMT2U	616280
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2U	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2U; CMT2U	616280
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2U	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2U; CMT2U	616280
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 49; MRT49	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 49; MRT49	616281
SPASTIC PARAPLEGIA 73, AUTOSOMAL DOMINANT; SPG73	SPASTIC PARAPLEGIA 73, AUTOSOMAL DOMINANT; SPG73	616282
LETHAL CONGENITAL CONTRACTURE SYNDROME 7; LCCS7	LETHAL CONGENITAL CONTRACTURE SYNDROME 7; LCCS7	616286
LETHAL CONGENITAL CONTRACTURE SYNDROME 8; LCCS8	LETHAL CONGENITAL CONTRACTURE SYNDROME 8; LCCS8	616287
OPTIC ATROPHY 9; OPA9	OPTIC ATROPHY 9; OPA9	616289
LICHTENSTEIN-KNORR SYNDROME; LIKNS	LICHTENSTEIN-KNORR SYNDROME; LIKNS	616291
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 19; SCAR19	LICHTENSTEIN-KNORR SYNDROME; LIKNS	616291
COLE-CARPENTER SYNDROME 2; CLCRP2	COLE-CARPENTER SYNDROME 2; CLCRP2	616294
PEELING SKIN WITH LEUKONYCHIA, ACRAL PUNCTATE KERATOSES, CHEILITIS,AND KNUCKLE PADS; PLACK	PEELING SKIN WITH LEUKONYCHIA, ACRAL PUNCTATE KERATOSES, CHEILITIS,AND KNUCKLE PADS; PLACK	616295
SINGLETON-MERTEN SYNDROME 2; SGMRT2	SINGLETON-MERTEN SYNDROME 2; SGMRT2	616298
LIPOYLTRANSFERASE 1 DEFICIENCY; LIPT1D	LIPOYLTRANSFERASE 1 DEFICIENCY; LIPT1D	616299
SHORT-RIB THORACIC DYSPLASIA 13 WITH OR WITHOUT POLYDACTYLY; SRTD13	SHORT-RIB THORACIC DYSPLASIA 13 WITH OR WITHOUT POLYDACTYLY; SRTD13	616300
MYASTHENIC SYNDROME, CONGENITAL, 17; CMS17	MYASTHENIC SYNDROME, CONGENITAL, 17; CMS17	616304
SENIOR-LOKEN SYNDROME 8; SLSN8	SENIOR-LOKEN SYNDROME 8; SLSN8	616307
MENTAL RETARDATION, AUTOSOMAL DOMINANT 33; MRD33	MENTAL RETARDATION, AUTOSOMAL DOMINANT 33; MRD33	616311
MYASTHENIC SYNDROME, CONGENITAL, 2A, SLOW-CHANNEL; CMS2A	MYASTHENIC SYNDROME, CONGENITAL, 2A, SLOW-CHANNEL; CMS2A	616313
MYASTHENIC SYNDROME, CONGENITAL, 2C, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS2C	MYASTHENIC SYNDROME, CONGENITAL, 2C, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS2C	616314
MYASTHENIC SYNDROME, CONGENITAL, 3A, SLOW-CHANNEL; CMS3A	MYASTHENIC SYNDROME, CONGENITAL, 3A, SLOW-CHANNEL; CMS3A	616321
MYASTHENIC SYNDROME, CONGENITAL, 3B, FAST-CHANNEL; CMS3B	MYASTHENIC SYNDROME, CONGENITAL, 3B, FAST-CHANNEL; CMS3B	616322
MYASTHENIC SYNDROME, CONGENITAL, 3C, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS3C	MYASTHENIC SYNDROME, CONGENITAL, 3C, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS3C	616323
MYASTHENIC SYNDROME, CONGENITAL, 4B, FAST-CHANNEL; CMS4B	MYASTHENIC SYNDROME, CONGENITAL, 4B, FAST-CHANNEL; CMS4B	616324
MYASTHENIC SYNDROME, CONGENITAL, 9, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS9	MYASTHENIC SYNDROME, CONGENITAL, 9, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS9	616325
MYASTHENIC SYNDROME, CONGENITAL, 11, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS11	MYASTHENIC SYNDROME, CONGENITAL, 11, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS11	616326
MYASTHENIC SYNDROME, CONGENITAL, Ie, FORMERLY; CMS1E, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 11, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS11	616326
CMS Ie, FORMERLY	MYASTHENIC SYNDROME, CONGENITAL, 11, ASSOCIATED WITH ACETYLCHOLINERECEPTOR DEFICIENCY; CMS11	616326
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 13; MODY13	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 13; MODY13	616329
MODY, TYPE 13	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 13; MODY13	616329
MYASTHENIC SYNDROME, CONGENITAL, 18; CMS18	MYASTHENIC SYNDROME, CONGENITAL, 18; CMS18	616330
MYASTHENIC SYNDROME, CONGENITAL, 18, WITH INTELLECTUAL DISABILITYAND ATAXIA	MYASTHENIC SYNDROME, CONGENITAL, 18; CMS18	616330
ROBINOW SYNDROME, AUTOSOMAL DOMINANT 2; DRS2	ROBINOW SYNDROME, AUTOSOMAL DOMINANT 2; DRS2	616331
MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 3; MCCRP3	MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 3; MCCRP3	616335
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 29; EIEE29	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 29; EIEE29	616339
DEAFNESS, AUTOSOMAL DOMINANT 67; DFNA67	DEAFNESS, AUTOSOMAL DOMINANT 67; DFNA67	616340
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 30; EIEE30	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 30; EIEE30	616341
LISSENCEPHALY 7 WITH CEREBELLAR HYPOPLASIA; LIS7	LISSENCEPHALY 7 WITH CEREBELLAR HYPOPLASIA; LIS7	616342
IMMUNODEFICIENCY 39; IMD39	IMMUNODEFICIENCY 39; IMD39	616345
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 31; EIEE31	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 31; EIEE31	616346
MENTAL RETARDATION, AUTOSOMAL DOMINANT 34; MRD34	MENTAL RETARDATION, AUTOSOMAL DOMINANT 34; MRD34	616351
DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 6; DKCB6	DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 6; DKCB6	616353
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 20; SCAR20	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 20; SCAR20	616354
MENTAL RETARDATION, AUTOSOMAL DOMINANT 35; MRD35	MENTAL RETARDATION, AUTOSOMAL DOMINANT 35; MRD35	616355
DEAFNESS, AUTOSOMAL DOMINANT 40; DFNA40	DEAFNESS, AUTOSOMAL DOMINANT 40; DFNA40	616357
PARKINSON DISEASE 21; PARK21	PARKINSON DISEASE 21; PARK21	616361
MENTAL RETARDATION, AUTOSOMAL DOMINANT 36; MRD36	MENTAL RETARDATION, AUTOSOMAL DOMINANT 36; MRD36	616362
MENTAL RETARDATION, AUTOSOMAL DOMINANT 37; MRD37	MENTAL RETARDATION, AUTOSOMAL DOMINANT 37; MRD37	616364
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 32; EIEE32	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 32; EIEE32	616366
MANDIBULOFACIAL DYSOSTOSIS WITH ALOPECIA; MFDA	MANDIBULOFACIAL DYSOSTOSIS WITH ALOPECIA; MFDA	616367
CHOPS SYNDROME; CHOPS	CHOPS SYNDROME; CHOPS	616368
COGNITIVE IMPAIRMENT, COARSE FACIES, HEART DEFECTS, OBESITY, PULMONARYINVOLVEMENT, SHORT STATURE, AND SKELETAL DYSPLASIA	CHOPS SYNDROME; CHOPS	616368
CILIARY DYSKINESIA, PRIMARY, 31; CILD31	CILIARY DYSKINESIA, PRIMARY, 31; CILD31	616369
MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 4; MMDS4	MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 4; MMDS4	616370
PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 4;PFBMFT4	PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 4;PFBMFT4	616371
PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 3;PFBMFT3	PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 3;PFBMFT3	616373
NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1G; CSNB1G	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1G; CSNB1G	616389
TRICHOTHIODYSTROPHY 2, PHOTOSENSITIVE; TTD2	TRICHOTHIODYSTROPHY 2, PHOTOSENSITIVE; TTD2	616390
MENTAL RETARDATION, AUTOSOMAL DOMINANT 38; MRD38	MENTAL RETARDATION, AUTOSOMAL DOMINANT 38; MRD38	616393
PSYCHOMOTOR RETARDATION, EPILEPSY, AND LANGUAGE DISABILITY SYNDROME;PRELDS	MENTAL RETARDATION, AUTOSOMAL DOMINANT 38; MRD38	616393
RETINITIS PIGMENTOSA 71; RP71	RETINITIS PIGMENTOSA 71; RP71	616394
TRICHOTHIODYSTROPHY 3, PHOTOSENSITIVE; TTD3	TRICHOTHIODYSTROPHY 3, PHOTOSENSITIVE; TTD3	616395
TRICHOTHIODYSTROPHY, COMPLEMENTATION GROUP A; TTDA	TRICHOTHIODYSTROPHY 3, PHOTOSENSITIVE; TTD3	616395
DYSTONIA 26, MYOCLONIC; DYT26	DYSTONIA 26, MYOCLONIC; DYT26	616398
BRUGADA SYNDROME 9; BRGDA9	BRUGADA SYNDROME 9; BRGDA9	616399
PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 2; FNEPPK2	PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 2; FNEPPK2	616400
MICROCEPHALY 14, PRIMARY, AUTOSOMAL RECESSIVE; MCPH14	MICROCEPHALY 14, PRIMARY, AUTOSOMAL RECESSIVE; MCPH14	616402
BROWN SYNDROME; BRWNS	BROWN SYNDROME; BRWNS	616407
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 33; EIEE33	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 33; EIEE33	616409
SPINOCEREBELLAR ATAXIA 41; SCA41	SPINOCEREBELLAR ATAXIA 41; SCA41	616410
DYSTONIA 27; DYT27	DYSTONIA 27; DYT27	616411
BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 6; IBGC6	BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 6; IBGC6	616413
AUTOIMMUNE INTERSTITIAL LUNG, JOINT, AND KIDNEY DISEASE; AILJK	AUTOIMMUNE INTERSTITIAL LUNG, JOINT, AND KIDNEY DISEASE; AILJK	616414
FAMILIAL ADENOMATOUS POLYPOSIS 3; FAP3	FAMILIAL ADENOMATOUS POLYPOSIS 3; FAP3	616415
HYPOMAGNESEMIA, SEIZURES, AND MENTAL RETARDATION; HOMGSMR	HYPOMAGNESEMIA, SEIZURES, AND MENTAL RETARDATION; HOMGSMR	616418
LEUKODYSTROPHY, HYPOMYELINATING, 10; HLD10	LEUKODYSTROPHY, HYPOMYELINATING, 10; HLD10	616420
MYOCLONIC-ATONIC EPILEPSY; MAE	MYOCLONIC-ATONIC EPILEPSY; MAE	616421
46,XY SEX REVERSAL 10; SRXY10	46,XY SEX REVERSAL 10; SRXY10	616425
CHROMOSOME 17q24 DELETION SYNDROME	46,XY SEX REVERSAL 10; SRXY10	616425
MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 10; MCOPCB10	MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 10; MCOPCB10	616428
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 25; COXPD25	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 25; COXPD25	616430
IMMUNODEFICIENCY 40; IMD40	IMMUNODEFICIENCY 40; IMD40	616433
FANCONI ANEMIA, COMPLEMENTATION GROUP T; FANCT	FANCONI ANEMIA, COMPLEMENTATION GROUP T; FANCT	616435
EPILEPSY, FAMILIAL TEMPORAL LOBE, 7; ETL7	EPILEPSY, FAMILIAL TEMPORAL LOBE, 7; ETL7	616436
FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 3; FTDALS3	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 3; FTDALS3	616437
FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 4; FTDALS4	FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 4; FTDALS4	616439
CANDIDIASIS, FAMILIAL, 9; CANDF9	CANDIDIASIS, FAMILIAL, 9; CANDF9	616445
BASEL-VANAGAITE-SMIRIN-YOSEF SYNDROME; BVSYS	BASEL-VANAGAITE-SMIRIN-YOSEF SYNDROME; BVSYS	616449
SPASTIC PARAPLEGIA 74, AUTOSOMAL RECESSIVE; SPG74	SPASTIC PARAPLEGIA 74, AUTOSOMAL RECESSIVE; SPG74	616451
B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY; BENTA	B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY; BENTA	616452
ZIMMERMANN-LABAND SYNDROME 2; ZLS2	ZIMMERMANN-LABAND SYNDROME 2; ZLS2	616455
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iz; CDG1Z	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iz; CDG1Z	616457
AL-RAQAD SYNDROME; ARS	AL-RAQAD SYNDROME; ARS	616459
MENTAL RETARDATION, AUTOSOMAL RECESSIVE 50; MRT50	MENTAL RETARDATION, AUTOSOMAL RECESSIVE 50; MRT50	616460
EPILEPSY, FAMILIAL TEMPORAL LOBE, 8; ETL8	EPILEPSY, FAMILIAL TEMPORAL LOBE, 8; ETL8	616461
ACROFACIAL DYSOSTOSIS, CINCINNATI TYPE; AFDCIN	ACROFACIAL DYSOSTOSIS, CINCINNATI TYPE; AFDCIN	616462
EXUDATIVE VITREORETINOPATHY 6; EVR6	EXUDATIVE VITREORETINOPATHY 6; EVR6	616468
RETINITIS PIGMENTOSA 72; RP72	RETINITIS PIGMENTOSA 72; RP72	616469
ULLRICH CONGENITAL MUSCULAR DYSTROPHY 2; UCMD2	ULLRICH CONGENITAL MUSCULAR DYSTROPHY 2; UCMD2	616470
BETHLEM MYOPATHY 2; BTHLM2	BETHLEM MYOPATHY 2; BTHLM2	616471
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL RECESSIVE 2; PEOB2	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL RECESSIVE 2; PEOB2	616479
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 2	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS,AUTOSOMAL RECESSIVE 2; PEOB2	616479
CILIARY DYSKINESIA, PRIMARY, 32; CILD32	CILIARY DYSKINESIA, PRIMARY, 32; CILD32	616481
CILIARY DYSKINESIA, PRIMARY, 32, WITHOUT SITUS INVERSUS	CILIARY DYSKINESIA, PRIMARY, 32; CILD32	616481
ACHONDROPLASIA, SEVERE, WITH DEVELOPMENTAL DELAY AND ACANTHOSIS NIGRICANS;SADDAN	ACHONDROPLASIA, SEVERE, WITH DEVELOPMENTAL DELAY AND ACANTHOSIS NIGRICANS;SADDAN	616482
SADDAN DYSPLASIA	ACHONDROPLASIA, SEVERE, WITH DEVELOPMENTAL DELAY AND ACANTHOSIS NIGRICANS;SADDAN	616482
INFANTILE LIVER FAILURE SYNDROME 2; ILFS2	INFANTILE LIVER FAILURE SYNDROME 2; ILFS2	616483
MICROCEPHALY 15, PRIMARY, AUTOSOMAL RECESSIVE; MCPH15	MICROCEPHALY 15, PRIMARY, AUTOSOMAL RECESSIVE; MCPH15	616486
EPIDERMOLYSIS BULLOSA SIMPLEX WITH NAIL DYSTROPHY; EBSND	EPIDERMOLYSIS BULLOSA SIMPLEX WITH NAIL DYSTROPHY; EBSND	616487
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VIII; HSAN8	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VIII; HSAN8	616488
HSAN VIII	NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VIII; HSAN8	616488
GROWTH RESTRICTION, SEVERE, WITH DISTINCTIVE FACIES; GRDF	GROWTH RESTRICTION, SEVERE, WITH DISTINCTIVE FACIES; GRDF	616489
JOUBERT SYNDROME 23; JBTS23	JOUBERT SYNDROME 23; JBTS23	616490
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2V; CMT2V	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2V; CMT2V	616491
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2V	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2V; CMT2V	616491
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2V	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2V; CMT2V	616491
LEUKODYSTROPHY, HYPOMYELINATING, 11; HLD11	LEUKODYSTROPHY, HYPOMYELINATING, 11; HLD11	616494
CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASEDEFICIENCY 3; CEMCOX3	CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASEDEFICIENCY 3; CEMCOX3	616500
CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASEDEFICIENCY 4; CEMCOX4	CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASEDEFICIENCY 4; CEMCOX4	616501
CONE-ROD DYSTROPHY 21; CORD21	CONE-ROD DYSTROPHY 21; CORD21	616502
RETINAL DYSTROPHY WITH EARLY MACULAR INVOLVEMENT	CONE-ROD DYSTROPHY 21; CORD21	616502
LETHAL CONGENITAL CONTRACTURE SYNDROME 9; LCCS9	LETHAL CONGENITAL CONTRACTURE SYNDROME 9; LCCS9	616503
NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB; HMSN6B	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB; HMSN6B	616505
HMSN VIB	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB; HMSN6B	616505
CHARCOT-MARIE-TOOTH DISEASE, TYPE 6B; CMT6B	NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB; HMSN6B	616505
OSTEOGENESIS IMPERFECTA, TYPE XVII; OI17	OSTEOGENESIS IMPERFECTA, TYPE XVII; OI17	616507
CATARACT 44; CTRCT44	CATARACT 44; CTRCT44	616509
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 14; MODY14	MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 14; MODY14	616511
DEAFNESS, AUTOSOMAL RECESSIVE 104; DFNB104	DEAFNESS, AUTOSOMAL RECESSIVE 104; DFNB104	616515
EMERY-DREIFUSS MUSCULAR DYSTROPHY 3, AUTOSOMAL RECESSIVE; EDMD3	EMERY-DREIFUSS MUSCULAR DYSTROPHY 3, AUTOSOMAL RECESSIVE; EDMD3	616516
ACHROMATOPSIA 7; ACHM7	ACHROMATOPSIA 7; ACHM7	616517
MENTAL RETARDATION, AUTOSOMAL DOMINANT 39; MRD39CHROMOSOME 2p25.3 DELETION SYNDROME, INCLUDED	MENTAL RETARDATION, AUTOSOMAL DOMINANT 39; MRD39CHROMOSOME 2p25.3 DELETION SYNDROME, INCLUDED	616521
CHROMOSOME 2p25.3 DUPLICATION SYNDROME, INCLUDED	MENTAL RETARDATION, AUTOSOMAL DOMINANT 39; MRD39CHROMOSOME 2p25.3 DELETION SYNDROME, INCLUDED	616521
POLYMICROGYRIA, PERISYLVIAN, WITH CEREBELLAR HYPOPLASIA AND ARTHROGRYPOSIS;PMGYCHA	POLYMICROGYRIA, PERISYLVIAN, WITH CEREBELLAR HYPOPLASIA AND ARTHROGRYPOSIS;PMGYCHA	616531
HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 7	HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 7	616532
ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 7; IIAE7	HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 7	616532
THYROID CANCER, NONMEDULLARY, 4; NMTC4	THYROID CANCER, NONMEDULLARY, 4; NMTC4	616534
THYROID CANCER, NONMEDULLARY, 5; NMTC5	THYROID CANCER, NONMEDULLARY, 5; NMTC5	616535
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 9; MDDGA9	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 9; MDDGA9	616538
WALKER-WARBURG SYNDROME OR MUSCLE-EYE BRAIN DISEASE, DAG1-RELATED	MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYEANOMALIES), TYPE A, 9; MDDGA9	616538
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 26; COXPD26	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 26; COXPD26	616539
EPILEPSY, PROGRESSIVE MYOCLONIC, 9; EPM9	EPILEPSY, PROGRESSIVE MYOCLONIC, 9; EPM9	616540
SHORT STATURE, MICROCEPHALY, AND ENDOCRINE DYSFUNCTION; SSMED	SHORT STATURE, MICROCEPHALY, AND ENDOCRINE DYSFUNCTION; SSMED	616541
RETINITIS PIGMENTOSA 73; RP73	RETINITIS PIGMENTOSA 73; RP73	616544
SHORT-RIB THORACIC DYSPLASIA 14 WITH POLYDACTYLY; SRTD14	SHORT-RIB THORACIC DYSPLASIA 14 WITH POLYDACTYLY; SRTD14	616546
KLIPPEL-FEIL SYNDROME 4, AUTOSOMAL RECESSIVE, WITH MYOPATHY AND FACIALDYSMORPHISM; KFS4	KLIPPEL-FEIL SYNDROME 4, AUTOSOMAL RECESSIVE, WITH MYOPATHY AND FACIALDYSMORPHISM; KFS4	616549
DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6; DKCA6DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, INCLUDED; DKCB7, INCLUDED	DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6; DKCA6DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, INCLUDED; DKCB7, INCLUDED	616553
NOONAN SYNDROME 9; NS9	NOONAN SYNDROME 9; NS9	616559
RETINITIS PIGMENTOSA 74; RP74	RETINITIS PIGMENTOSA 74; RP74	616562
NOONAN SYNDROME 10; NS10	NOONAN SYNDROME 10; NS10	616564
SPONDYLOCOSTAL DYSOSTOSIS 6, AUTOSOMAL RECESSIVE; SCDO6	SPONDYLOCOSTAL DYSOSTOSIS 6, AUTOSOMAL RECESSIVE; SCDO6	616566
GLIOMA SUSCEPTIBILITY 9; GLM9	GLIOMA SUSCEPTIBILITY 9; GLM9	616568
CEREBROOCULOFACIOSKELETAL SYNDROME 3; COFS3	CEREBROOCULOFACIOSKELETAL SYNDROME 3; COFS3	616570
IMMUNODEFICIENCY, COMMON VARIABLE, 12; CVID12	IMMUNODEFICIENCY, COMMON VARIABLE, 12; CVID12	616576
NFKB1 DEFICIENCY	IMMUNODEFICIENCY, COMMON VARIABLE, 12; CVID12	616576
EPILEPSY, HEARING LOSS, AND MENTAL RETARDATION SYNDROME; EHLMRS	EPILEPSY, HEARING LOSS, AND MENTAL RETARDATION SYNDROME; EHLMRS	616577
MENTAL RETARDATION, AUTOSOMAL DOMINANT 40; MRD40	MENTAL RETARDATION, AUTOSOMAL DOMINANT 40; MRD40	616579
AU-KLINE SYNDROME; AUKS	AU-KLINE SYNDROME; AUKS	616580
SPONDYLOEPIPHYSEAL DYSPLASIA, STANESCU TYPE; SEDSTN	SPONDYLOEPIPHYSEAL DYSPLASIA, STANESCU TYPE; SEDSTN	616583
SED, STANESCU TYPE	SPONDYLOEPIPHYSEAL DYSPLASIA, STANESCU TYPE; SEDSTN	616583
SPASTIC PARAPLEGIA 9B, AUTOSOMAL RECESSIVE; SPG9B	SPASTIC PARAPLEGIA 9B, AUTOSOMAL RECESSIVE; SPG9B	616586
ADAMS-OLIVER SYNDROME 6; AOS6	ADAMS-OLIVER SYNDROME 6; AOS6	616589
KOSAKI OVERGROWTH SYNDROME; KOGS	KOSAKI OVERGROWTH SYNDROME; KOGS	616592
SKELETAL OVERGROWTH WITH FACIAL DYSMORPHISM, HYPERELASTIC SKIN, WHITEMATTER LESIONS, AND NEUROLOGIC DETERIORATION	KOSAKI OVERGROWTH SYNDROME; KOGS	616592
CRANIOSYNOSTOSIS 6; CRS6	CRANIOSYNOSTOSIS 6; CRS6	616602
CUTIS LAXA, AUTOSOMAL DOMINANT 3; ADCL3	CUTIS LAXA, AUTOSOMAL DOMINANT 3; ADCL3	616603
CHROMOSOME 14q32 DUPLICATION SYNDROME, 700-KB	CHROMOSOME 14q32 DUPLICATION SYNDROME, 700-KB	616604
MYELOPROLIFERATIVE NEOPLASMS, FAMILIAL, SUSCEPTIBILITY TO	CHROMOSOME 14q32 DUPLICATION SYNDROME, 700-KB	616604
RING CHROMOSOME 14 SYNDROME	RING CHROMOSOME 14 SYNDROME	616606
HEIMLER SYNDROME 2; HMLR2	HEIMLER SYNDROME 2; HMLR2	616617
PEROXISOME BIOGENESIS DISORDER 4C; PBD4C	HEIMLER SYNDROME 2; HMLR2	616617
IMMUNODEFICIENCY 42; IMD42	IMMUNODEFICIENCY 42; IMD42	616622
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2W; CMT2W	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2W; CMT2W	616625
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2W	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2W; CMT2W	616625
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2W	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2W; CMT2W	616625
SENIOR-LOKEN SYNDROME 9; SLSN9	SENIOR-LOKEN SYNDROME 9; SLSN9	616629
POROKERATOSIS 9, MULTIPLE TYPES; POROK9	POROKERATOSIS 9, MULTIPLE TYPES; POROK9	616631
SEIZURES, CORTICAL BLINDNESS, MICROCEPHALY SYNDROME; SCBMS	SEIZURES, CORTICAL BLINDNESS, MICROCEPHALY SYNDROME; SCBMS	616632
IMMUNODEFICIENCY 44; IMD44	IMMUNODEFICIENCY 44; IMD44	616636
SMITH-KINGSMORE SYNDROME; SKS	SMITH-KINGSMORE SYNDROME; SKS	616638
MACROCEPHALY, SEIZURES, MENTAL RETARDATION, UMBILICAL HERNIA, ANDFACIAL DYSMORPHISM	SMITH-KINGSMORE SYNDROME; SKS	616638
EPILEPSY, PROGRESSIVE MYOCLONIC, 10; EPM10	EPILEPSY, PROGRESSIVE MYOCLONIC, 10; EPM10	616640
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 34; EIEE34	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 34; EIEE34	616645
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 35; EIEE35	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 35; EIEE35	616647
OPTIC ATROPHY 8; OPA8	OPTIC ATROPHY 8; OPA8	616648
SPHEROCYTOSIS, TYPE 2; SPH2	SPHEROCYTOSIS, TYPE 2; SPH2	616649
SPHEROCYTOSIS, HEREDITARY, 2; HS2	SPHEROCYTOSIS, TYPE 2; SPH2	616649
ROIFMAN SYNDROME; RFMN	ROIFMAN SYNDROME; RFMN	616651
SPONDYLOEPIPHYSEAL DYSPLASIA, RETINAL DYSTROPHY, AND ANTIBODY DEFICIENCY	ROIFMAN SYNDROME; RFMN	616651
YUAN-HAREL-LUPSKI SYNDROME; YUHAL	YUAN-HAREL-LUPSKI SYNDROME; YUHAL	616652
JOUBERT SYNDROME 24; JBTS24	JOUBERT SYNDROME 24; JBTS24	616654
SPASTIC TETRAPLEGIA, THIN CORPUS CALLOSUM, AND PROGRESSIVE MICROCEPHALY;SPATCCM	SPASTIC TETRAPLEGIA, THIN CORPUS CALLOSUM, AND PROGRESSIVE MICROCEPHALY;SPATCCM	616657
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2X; CMT2X	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2X; CMT2X	616668
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2X	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2X; CMT2X	616668
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2X	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2X; CMT2X	616668
IMMUNODEFICIENCY 45; IMD45	IMMUNODEFICIENCY 45; IMD45	616669
COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 27; COXPD27	COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 27; COXPD27	616672
SPASTIC PARAPLEGIA 75, AUTOSOMAL RECESSIVE; SPG75	SPASTIC PARAPLEGIA 75, AUTOSOMAL RECESSIVE; SPG75	616680
MICROCEPHALY 16, PRIMARY, AUTOSOMAL RECESSIVE; MCPH16	MICROCEPHALY 16, PRIMARY, AUTOSOMAL RECESSIVE; MCPH16	616681
SEIZURES, SCOLIOSIS, AND MACROCEPHALY SYNDROME; SSMS	SEIZURES, SCOLIOSIS, AND MACROCEPHALY SYNDROME; SSMS	616682
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4K; CMT4K	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4K; CMT4K	616684
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE4K	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4K; CMT4K	616684
CHARCOT-MARIE-TOOTH NEUROPATHY, DEMYELINATING, AUTOSOMAL RECESSIVE,TYPE 4K	CHARCOT-MARIE-TOOTH DISEASE, TYPE 4K; CMT4K	616684
EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 14; EIG14	EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 14; EIG14	616685
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Y; CMT2Y	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Y; CMT2Y	616687
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2Y	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Y; CMT2Y	616687
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2Y	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Y; CMT2Y	616687
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Z; CMT2Z	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Z; CMT2Z	616688
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2Z	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Z; CMT2Z	616688
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2Z	CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Z; CMT2Z	616688
DEHYDRATED HEREDITARY STOMATOCYTOSIS 2; DHS2	DEHYDRATED HEREDITARY STOMATOCYTOSIS 2; DHS2	616689
XEROCYTOSIS GARDOS	DEHYDRATED HEREDITARY STOMATOCYTOSIS 2; DHS2	616689
DESICCYTOSIS GARDOS	DEHYDRATED HEREDITARY STOMATOCYTOSIS 2; DHS2	616689
DEAFNESS, CONGENITAL, UNILATERAL OR ASYMMETRIC; DCUA	DEAFNESS, CONGENITAL, UNILATERAL OR ASYMMETRIC; DCUA	616697
DEAFNESS, AUTOSOMAL RECESSIVE 97; DFNB97	DEAFNESS, AUTOSOMAL RECESSIVE 97; DFNB97	616705
DEAFNESS, AUTOSOMAL DOMINANT 68; DFNA68	DEAFNESS, AUTOSOMAL DOMINANT 68; DFNA68	616707
PARKINSON DISEASE 22, AUTOSOMAL DOMINANT; PARK22	PARKINSON DISEASE 22, AUTOSOMAL DOMINANT; PARK22	616710
RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 5; RCDP5	RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 5; RCDP5	616716
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 21; SCAR21	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 21; SCAR21	616719
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 21, WITH HEPATOPATHY	SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 21; SCAR21	616719
MYASTHENIC SYNDROME, CONGENITAL, 19; CMS19	MYASTHENIC SYNDROME, CONGENITAL, 19; CMS19	616720
CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIn; CDG2N	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIn; CDG2N	616721
CDG IIn; CDGIIn	CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIn; CDG2N	616721
RETINAL DYSTROPHY AND IRIS COLOBOMA WITH OR WITHOUT CONGENITAL CATARACT;RDICC	RETINAL DYSTROPHY AND IRIS COLOBOMA WITH OR WITHOUT CONGENITAL CATARACT;RDICC	616722
SPONDYLOEPIMETAPHYSEAL DYSPLASIA, FADEN-ALKURAYA TYPE; SEMDFA	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, FADEN-ALKURAYA TYPE; SEMDFA	616723
SPONDYLOEPIMETAPHYSEAL DYSPLASIA, PROGRESSIVE, WITH SHORT STATURE,FACIAL DYSMORPHISM, SHORT FOURTH METATARSALS, AND MENTAL RETARDATION,WITH OR WITHOUT CRANIOSYNOSTOSIS	SPONDYLOEPIMETAPHYSEAL DYSPLASIA, FADEN-ALKURAYA TYPE; SEMDFA	616723
TOOTH AGENESIS, SELECTIVE, 7; STHAG7	TOOTH AGENESIS, SELECTIVE, 7; STHAG7	616724
